"Authors","Author full names","Author(s) ID","Title","Year","Source title","Volume","Issue","Art. No.","Page start","Page end","Page count","Cited by","DOI","Link","Affiliations","Authors with affiliations","Abstract","Author Keywords","Index Keywords","Molecular Sequence Numbers","Chemicals/CAS","Tradenames","Manufacturers","Funding Details","Funding Texts","References","Correspondence Address","Editors","Publisher","Sponsors","Conference name","Conference date","Conference location","Conference code","ISSN","ISBN","CODEN","PubMed ID","Language of Original Document","Abbreviated Source Title","Document Type","Publication Stage","Open Access","Source","EID"
"Djukic T.; Stevanovic G.; Coric V.; Bukumiric Z.; Pljesa-Ercegovac M.; Matic M.; Jerotic D.; Todorovic N.; Asanin M.; Ercegovac M.; Ranin J.; Milosevic I.; Savic-Radojevic A.; Simic T.","Djukic, Tatjana (36193753800); Stevanovic, Goran (15059280200); Coric, Vesna (55584570400); Bukumiric, Zoran (36600111200); Pljesa-Ercegovac, Marija (16644038900); Matic, Marija (58618962300); Jerotic, Djurdja (57209718540); Todorovic, Nevena (58688792000); Asanin, Milika (8603366900); Ercegovac, Marko (7006226257); Ranin, Jovan (6603091043); Milosevic, Ivana (58456808200); Savic-Radojevic, Ana (16246037100); Simic, Tatjana (6602094386)","36193753800; 15059280200; 55584570400; 36600111200; 16644038900; 58618962300; 57209718540; 58688792000; 8603366900; 7006226257; 6603091043; 58456808200; 16246037100; 6602094386","GSTO1, GSTO2 and ACE2 Polymorphisms Modify Susceptibility to Developing COVID-19","2022","Journal of Personalized Medicine","12","3","458","","","","14","10.3390/jpm12030458","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127381936&doi=10.3390%2fjpm12030458&partnerID=40&md5=0f0fa50032c1848a40cf49aee02434b0","Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia; Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Institute of Medical Statistics and Informatics, Belgrade, 11000, Serbia; Clinic of Neurology, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Clinic of Cardiology, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Department of Medical Sciences, Serbian Academy of Sciences and Arts, Belgrade, 11000, Serbia","Djukic T., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Stevanovic G., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Coric V., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Bukumiric Z., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical Statistics and Informatics, Belgrade, 11000, Serbia; Pljesa-Ercegovac M., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Matic M., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Jerotic D., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Todorovic N., Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Asanin M., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Clinic of Neurology, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Ercegovac M., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Clinic of Cardiology, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Ranin J., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Milosevic I., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Clinic of Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, 11000, Serbia; Savic-Radojevic A., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia; Simic T., Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia, Institute of Medical and Clinical Biochemistry, Belgrade, 11000, Serbia, Department of Medical Sciences, Serbian Academy of Sciences and Arts, Belgrade, 11000, Serbia","Based on the close relationship between dysregulation of redox homeostasis and immune response in SARS-CoV-2 infection, we proposed a possible modifying role of ACE2 and glutathione transferase omega (GSTO) polymorphisms in the individual propensity towards the development of clinical manifestations in COVID-19. The distribution of polymorphisms in ACE2 (rs4646116), GSTO1 (rs4925) and GSTO2 (rs156697) were assessed in 255 COVID-19 patients and 236 matched healthy individuals, emphasizing their individual and haplotype effects on disease development and severity. Polymorphisms were determined by the appropriate qPCR method. The data obtained showed that individuals carrying variant GSTO1*AA and variant GSTO2*GG genotypes exhibit higher odds of COVID-19 development, contrary to ones carrying referent alleles (p = 0.044, p = 0.002, respectively). These findings are confirmed by haplotype analysis. Carriers of H2 haplotype, comprising GSTO1*A and GSTO2*G variant alleles were at 2-fold increased risk of COVID-19 development (p = 0.002). Although ACE2 (rs4646116) polymorphism did not exhibit a statistically significant effect on COVID19 risk (p = 0.100), the risk of COVID-19 development gradually increased with the presence of each additional risk-associated genotype. Further studies are needed to clarify the specific roles of glutathione transferases omega in innate immune response and vitamin C homeostasis once the SARS-CoV-2 infection is initiated in the host cell. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.","ACE2; COVID-19; glutathione transferase omega; oxidative distress; polymorphisms","angiotensin converting enzyme 2; glutathione transferase; adult; Article; case control study; controlled study; coronavirus disease 2019; disease severity; DNA extraction; female; gene frequency; genetic association; genetic polymorphism; genetic susceptibility; genotype; haplotype; homeostasis; human; hypertension; immune response; innate immunity; major clinical study; male; middle aged; obesity; oxidation reduction potential; questionnaire; real time polymerase chain reaction; single nucleotide polymorphism","","glutathione transferase, 50812-37-8","Mastercycler ep realplex, Eppendorf, Germany","Eppendorf, Germany","","","Lavillette D., Barbouche R., Yao Y., Boson B., Cosset F.-L., Jones I.M., Fenouillet E., Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein, J. Biol. Chem, 281, pp. 9200-9204, (2006); Board P.G., Coggan M., Chelvanayagam G., Easteal S., Jermiin L.S., Schulte G.K., Danley D.E., Hoth L.R., Griffor M.C., Kamath A.V., Et al., Identification, characterization, and crystal structure of the omega class glutathione transferases, J. Biol. Chem, 275, pp. 24798-24806, (2000); Board P.G., The omega-class glutathione transferases: Structure, function, and genetics, Drug Metab. Rev, 43, pp. 226-235, (2011); Whitbread A.K., Tetlow N., Eyre H.J., Sutherland G.R., Board P.G., Characterization of the human omega class glutathione transferase genes and associated polymorphisms, Pharmacogenetics, 13, pp. 131-144, (2003); Harju T.H., Peltoniemi M.J., Rytila P.H., Soini Y., Salmenkivi K.M., Board P.G., Ruddock L.W., Kinnula V.L., Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients, Respir. Res, 8, (2007); Menon D., Coll R., O'Neill L.A.J., Board P.G., GSTO1-1 modulates metabolism in macrophages activated through the LPS and TLR4 pathway, J. Cell Sci, 128, pp. 1982-1990, (2015); Menon D., Innes A., Oakley A.J., Dahlstrom J.E., Jensen L.M., Brustle A., Tummala P., Rooke M., Casarotto M.G., Baell J.B., Et al., GSTO1-1 plays a pro-inflammatory role in models of inflammation, colitis and obesity, Sci. Rep, 7, (2017); Majidi N., Rabbani F., Gholami S., Gholamalizadeh M., BourBour F., Rastgoo S., Hajipour A., Shadnoosh M., Akbari M.E., Bahar B., Et al., The effect of Vitamin C on pathological parameters and survival duration of critically ill coronavirus disease 2019 patients: A randomized clinical trial, Front. Immunol, 12, (2021); Wilk J.B., Walter R.E., Laramie J.M., Gottlieb D.J., O'Connor G.T., Framingham heart study genome-wide association: Results for pulmonary function measures, BMC Med. Genet, 8, (2007); Wang Y.-H., Yeh S.-D., Shen K.-H., Shen C.-H., Juang G.-D., Hsu L.-I., Chiou H.-Y., Chen C.-J., A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma, Toxicol. Appl. Pharmacol, 241, pp. 111-118, (2009); Board P.G., Menon D., Glutathione transferases, regulators of cellular metabolism and physiology, Biochim. Biophys. Acta (BBA)-Gen. Subj, 1830, pp. 3267-3288, (2013); Tanaka-Kagawa T., Jinno H., Hasegawa T., Makino Y., Seko Y., Hanioka N., Ando M., Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn), Biochem. Biophys. Res. Commun, 301, pp. 516-520, (2003); Menon D., Board P.G., A role for glutathione transferase Omega 1 (GSTO1-1) in the glutathionylation cycle, J. Biol. Chem, 288, pp. 25769-25779, (2013); Allen M., Zou F., Chai H.S., Younkin C.S., Miles R., Nair A.A., Crook J.E., Pankratz V.S., Carrasquillo M.M., Rowley C.N., Et al., Glutathione S-transferase omega genes in alzheimer and parkinson disease risk, age-at-diagnosis and brain gene expression: An Association Study with Mechanistic Implications, Mol. Neurodegener, 7, (2012); Mukherjee B., Salavaggione O.E., Pelleymounter L.L., Moon I., Eckloff B.W., Schaid D.J., Wieben E.D., Weinshilboum R.M., Glutathione S-transferase omega 1 and omega 2 pharmacogenomics, Drug Metab. Dispos, 34, pp. 1237-1246, (2006); Parmar M.S., TMPRSS2: An equally important protease as ACE2 in the pathogenicity of SARS-CoV-2 infection, Mayo Clin. Proc, 96, pp. 2748-2752, (2021); Ren W., Zhu Y., Lan J., Chen H., Wang Y., Shi H., Feng F., Chen D.-Y., Close B., Zhao X., Et al., Susceptibilities of human ACE2 genetic variants in coronavirus infection, J. Virol, 96, pp. e01492-21, (2022); Lu G., Wang Q., Gao G.F., Bat-to-human: Spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond, Trends Microbiol, 23, pp. 468-478, (2015); Wang J., Xu X., Zhou X., Chen P., Liang H., Li X., Zhong W., Hao P., Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection, J. Gen. Virol, 101, pp. 921-924, (2020); Gibson W.T., Evans D.M., An J., Jones S.J.M., ACE 2 coding variants: A potential X-linked risk factor for COVID-19 disease, bioRxiv, (2020); Miljanovic D., Milicevic O., Loncar A., Abazovic D., Despot D., Banko A., The first molecular characterization of Serbian SARS-CoV-2 isolates from a unique early second wave in Europe, Front. Microbiol, 12, (2021); Musaogullari A., Chai Y.-C., Redox regulation by protein S-glutathionylation: From molecular mechanisms to implications in health and disease, Int. J. Mol. Sci, 21, (2020); Hughes M.M., Hooftman A., Angiari S., Tummala P., Zaslona Z., Runtsch M.C., McGettrick A.F., Sutton C.E., Diskin C., Rooke M., Et al., Glutathione transferase omega-1 regulates NLRP3 inflammasome activation through NEK7 deglutathionylation, Cell Rep, 29, pp. 151-161, (2019); Zhao N., Di B., Xu L., The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies, Cytokine Growth Factor Rev, 61, pp. 2-15, (2021); McKee C.M., Coll R.C., NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma, J. Leukoc. Biol, 108, pp. 937-952, (2020); Rodrigues T.S., de Sa K.S.G., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Goncalves A.V., Perucello D.B., Andrade W.A., Castro R., Et al., Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J. Exp. Med, 218, (2021); Piaggi S., Marchi E., Carnicelli V., Zucchi R., Griese M., Hector A., Sorio C., Pompella A., Corti A., Airways glutathione S-transferase omega-1 and its A140D polymorphism are associated with severity of inflammation and respiratory dysfunction in cystic fibrosis, J. Cyst. Fibros, 20, pp. 1053-1061, (2021); Mehdi A., Riazalhosseini Y., Epigenome aberrations: Emerging driving factors of the clear cell renal cell carcinoma, Int. J. Mol. Sci, 18, (2017); Li Y., Schellhorn H.E., New developments and novel therapeutic perspectives for Vitamin C, J. Nutr, 137, pp. 2171-2184, (2007); Badraoui R., Adnan M., Bardakci F., Alreshidi M.M., Chloroquine and hydroxychloroquine interact differently with ACE2 domains reported to bind with the coronavirus spike protein: Mediation by ACE2 polymorphism, Molecules, 26, (2021); Yi M.C., Khosla C., Thiol–disulfide exchange reactions in the mammalian extracellular environment, Annu. Rev. Chem. Biomol. Eng, 7, pp. 197-222, (2016); Hati S., Bhattacharyya S., Impact of thiol–disulfide balance on the binding of COVID-19 spike protein with angiotensin-converting enzyme 2 receptor, ACS Omega, 5, pp. 16292-16298, (2020)","A. Savic-Radojevic; Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia; email: ana.savic-radojevic@med.bg.ac.rs; T. Simic; Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia; email: tatjana.simic@med.bg.ac.rs","","MDPI","","","","","","20754426","","","","English","J. Pers. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85127381936"
"Vydyam P.; Choi J.-Y.; Gihaz S.; Chand M.; Gewirtz M.; Thekkiniath J.; Lonardi S.; Gennaro J.C.; Ben Mamoun C.","Vydyam, Pratap (57208924808); Choi, Jae-Yeon (7501395712); Gihaz, Shalev (56664504500); Chand, Meenal (57899037300); Gewirtz, Meital (58741878100); Thekkiniath, Jose (36158765600); Lonardi, Stefano (7003773948); Gennaro, Joseph C. (58686470200); Ben Mamoun, Choukri (55663541500)","57208924808; 7501395712; 56664504500; 57899037300; 58741878100; 36158765600; 7003773948; 58686470200; 55663541500","Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril","2023","Journal of Biological Chemistry","299","11","105313","","","","3","10.1016/j.jbc.2023.105313","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176130526&doi=10.1016%2fj.jbc.2023.105313&partnerID=40&md5=2592bed082ddc8e39873feaeb4b9bc40","Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Department of Computer Science and Engineering, University of California, Riverside, CA, United States","Vydyam P., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Choi J.-Y., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Gihaz S., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Chand M., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Gewirtz M., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Thekkiniath J., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Lonardi S., Department of Computer Science and Engineering, University of California, Riverside, CA, United States; Gennaro J.C., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Ben Mamoun C., Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States","Effective and safe therapies for the treatment of diseases caused by intraerythrocytic parasites are impeded by the rapid emergence of drug resistance and the lack of novel drug targets. One such disease is human babesiosis, which is a rapidly emerging tick-borne illness caused by Babesia parasites. In this study, we identified fosinopril, a phosphonate-containing, FDA-approved angiotensin converting enzyme (ACE) inhibitor commonly used as a prodrug for hypertension and heart failure, as a potent inhibitor of Babesia duncani parasite development within human erythrocytes. Cell biological and mass spectrometry analyses revealed that the conversion of fosinopril to its active diacid molecule, fosinoprilat, is essential for its antiparasitic activity. We show that this conversion is mediated by a parasite-encoded esterase, BdFE1, which is highly conserved among apicomplexan parasites. Parasites carrying the L238H mutation in the active site of BdFE1 failed to convert the prodrug to its active moiety and became resistant to the drug. Our data set the stage for the development of this class of drugs for the therapy of vector-borne parasitic diseases. © 2023 The Authors","babesia; Babesia duncani; BdFE1; FDA-approved drugs; fosinopril; fosinoprilat; human babesiosis; parasite","Angiotensin-Converting Enzyme Inhibitors; Animals; Babesia; Fosinopril; Humans; Parasites; Prodrugs; Disease control; Enzymes; Esters; Mass spectrometry; 4,6 diamino 1,2 dihydro 2,2 dimethyl 1 [3 (2,4,5 trichlorophenoxy)propoxy] 1,3,5 triazine; bdfe1 esterase; captopril; carbromal; enalapril; enalaprilat; esterase; fosinopril; fosinoprilat; lisinopril; quinapril; ramipril; unclassified drug; dipeptidyl carboxypeptidase inhibitor; fosinopril; prodrug; Angiotensin converting enzyme inhibitors; Babesia; Babesia duncani; BdFE1; FDA-approved drug; Fosinopril; Fosinoprilat; Human babesiosis; Parasite-; Parasitics; animal experiment; animal model; antiparasitic activity; Apicomplexa; Article; Babesia; Babesia duncani; C3H/He mouse; controlled study; cytology; dose response; drug efficacy; drug mechanism; drug sensitivity; drug structure; erythrocyte; HCT 116 cell line; HEK293 cell line; HeLa cell line; Hep-G2 cell line; human; human cell; IC50; in vitro study; mass spectrometry; mouse; mutation; nonhuman; single nucleotide polymorphism; whole genome sequencing; animal; parasite; Diseases","","4,6 diamino 1,2 dihydro 2,2 dimethyl 1 [3 (2,4,5 trichlorophenoxy)propoxy] 1,3,5 triazine, 30711-93-4, 30737-44-1; captopril, 62571-86-2; carbromal, 77-65-6; CRISPR associated endonuclease Cas9, ; enalapril, 75847-73-3; enalaprilat, 76420-72-9; esterase, 9013-79-0; fosinopril, 88889-14-9, 98048-97-6; fosinoprilat, 95399-71-6; lisinopril, 76547-98-3, 83915-83-7; quinapril, 82586-55-8, 85441-61-8; ramipril, 87333-19-5; Angiotensin-Converting Enzyme Inhibitors, ; Fosinopril, ; Prodrugs, ","","","NBIA Foundations; National Institutes of Health, NIH, (AI123321, AI136118, AI138139, AI152220); National Institutes of Health, NIH; Steven and Alexandra Cohen Foundation","Research in the CBM Lab is supported by the National Institutes of Health grants ( AI123321 , AI138139 , AI152220 , and AI136118 ), the Steven and Alexandra Cohen Foundation (Lyme 62 2020) and the NBIA Foundations . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ","Renard I., Ben Mamoun C., Treatment of human babesiosis: then and now, Pathogens, 10, (2021); Karshima S.N., Karshima M.N., Ahmed M.I., Global meta-analysis on Babesia infections in human population: prevalence, distribution and species diversity, Pathog. Glob. Health, 116, pp. 220-235, (2022); Werden L., Lindsay L.R., Barker I.K., Bowman J., Gonzales E.K., Jardine C.M., Prevalence of anaplasma phagocytophilum and Babesia microti in Ixodes scapularis from a newly established Lyme disease endemic area, the Thousand Islands region of Ontario, Canada, Vector Borne Zoonotic Dis., 15, pp. 627-629, (2015); Madison-Antenucci S., Kramer L.D., Gebhardt L.L., Kauffman E., Emerging tick-borne diseases, Clin. Microbiol. Rev., 33, (2020); Swanson M., Pickrel A., Williamson J., Montgomery S., Trends in reported babesiosis cases United States, 2011–2019, MMWR Morb Mortal Wkly Rep, 72, pp. 273-277, (2023); Wormser G.P., Prasad A., Neuhaus E., Joshi S., Nowakowski J., Nelson J., Et al., Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection, Clin. Infect. Dis., 50, pp. 381-386, (2010); Simon M.S., Westblade L.F., Dziedziech A., Visone J.E., Furman R.R., Jenkins S.G., Et al., Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia, Clin. Infect. Dis., 65, pp. 1222-1225, (2017); Abraham A., Brasov I., Thekkiniath J., Kilian N., Lawres L., Gao R., Et al., Establishment of a continuous in vitro culture of Babesia duncani in human erythrocytes reveals unusually high tolerance to recommended therapies, J. Biol. Chem., 293, pp. 19974-19981, (2018); Dao A.H., Eberhard M.L., Pathology of acute fatal babesiosis in hamsters experimentally infected with the WA-1 strain of Babesia, Lab. Invest., 74, pp. 853-859, (1996); Pal A.C., Renard I., Singh P., Vydyam P., Chiu J.E., Pou S., Et al., Babesia duncani as a model organism to study the development, virulence and drug susceptibility of intraerythrocytic parasites in vitro and in vivo, J. Infect. Dis., 226, pp. 1267-1275, (2022); Warner N.J., Rush J.E., Safety profiles of the angiotensin-converting enzyme inhibitors, Drugs, 35 Suppl 5, pp. 89-97, (1988); Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, Lancet, 398, pp. 957-980, (2021); Williams B., Zhang Y., Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19, Lancet, 395, pp. 1671-1673, (2020); Bernstein K.E., Ong F.S., Blackwell W.L., Shah K.H., Giani J.F., Gonzalez-Villalobos R.A., Et al., A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme, Pharmacol. Rev., 65, pp. 1-46, (2013); Skeggs L.T., Kahn J.R., Shumway N.P., The preparation and function of the hypertensin-converting enzyme, J. Exp. Med., 103, pp. 295-299, (1956); Zheng W., Tian E., Liu Z., Zhou C., Yang P., Tian K., Et al., Small molecule angiotensin converting enzyme inhibitors: a medicinal chemistry perspective, Front. Pharmacol., 13, (2022); Duchin K.L., Waclawski A.P., Tu J.I., Manning J., Frantz M., Willard D.A., Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects, J. Clin. Pharmacol., 31, pp. 58-64, (1991); Singh P., Pal A.C., Mamoun C.B., An alternative culture medium for continuous in vitro propagation of the human pathogen Babesia duncani in human erythrocytes pathogens, 11, (2022); Kumari V., Pal A.C., Singh P., Mamoun C.B., Babesia duncani in culture and in mouse (ICIM) model for the advancement of Babesia biology, pathogenesis, and therapy, Bio Protoc., 12, (2022); Ranadive S.A., Chen A.X., Serajuddin A.T.M., Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors, Pharm. Res., 9, pp. 1480-1486, (1992); Ng C.L., Fidock D.A., Plasmodium falciparum in vitro drug resistance selections and gene editing methods, Mol. Biol., 2013, pp. 123-140, (2019); Istvan E.S., Mallari J.P., Corey V.C., Dharia N.V., Marshall G.R., Winzeler E.A., Et al., Esterase mutation is a mechanism of resistance to antimalarial compounds, Nat. Commun., 8, (2017); Murdoch D., McTavish D., Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension, Drugs, 43, pp. 123-140, (1992); Shionoiri H., Naruse M., Minamisawa K., Ueda S., Himeno H., Hiroto S., Et al., Fosinopril. Clinical pharmacokinetics and clinical potential, Clin. Pharmacokinet., 32, pp. 460-480, (1997); Davis R., Coukell A., McTavish D., Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure, Drugs, 54, pp. 103-116, (1997); Singh P., Lonardi S., Liang Q., Vydyam P., Khabirova E., Fang T., Et al., Babesia duncani multi-omics identifies virulence factors and drug targets, Nat. Microbiol., 8, pp. 845-859, (2023); Butler J.H., Baptista R.P., Valenciano A.L., Zhou B., Kissinger J.C., Tumwebaze P.K., Et al., Resistance to some but not other dimeric lindenane sesquiterpenoid esters is mediated by mutations in a Plasmodium falciparum esterase, ACS Infect. Dis., 6, pp. 2994-3003, (2020); Sindhe K.M.V., Wu W., Legac J., Zhang Y.-K., Easom E.E., Cooper R.A., Et al., Plasmodium falciparum resistance to a lead benzoxaborole due to blocked compound activation and altered ubiquitination or sumoylation, mBio, 11, (2020); Cornillot E., Hadj-Kaddour K., Dassouli A., Noel B., Ranwez V., Vacherie B., Et al., Sequencing of the smallest Apicomplexan genome from the human pathogen Babesia microti, Nucleic Acids Res., 40, pp. 9102-9114, (2012); Wang J., Chen K., Yang J., Zhang S., Li Y., Liu G., Et al., Comparative genomic analysis of Babesia duncani responsible for human babesiosis, BMC Biol., 20, (2022); Krause P.J., Gewurz B.E., Hill D., Marty F.M., Vannier E., Foppa I.M., Et al., Persistent and relapsing babesiosis in immunocompromised patients, Clin. Infect. Dis., 46, pp. 370-376, (2008); Chiu J.E., Renard I., Pal A.C., Singh P., Vydyam P., Thekkiniath J., Et al., Effective therapy targeting cytochrome bc(1) prevents Babesia erythrocytic development and protects from lethal infection, Antimicrob. Agents Chemother., 65, (2021); Lawres L.A., Garg A., Kumar V., Bruzual I., Forquer I.P., Renard I., Et al., Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone, J. Exp. Med., 213, pp. 1307-1318, (2016); Vydyam P., Pal A.C., Renards I., Chand M., Kumari V., Gennaro J.C., Et al., Tafenoquine-atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human Babesiosis, J. Infect. Dis., (2023)","C. Ben Mamoun; Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, United States; email: choukri.benmamoun@yale.edu","","American Society for Biochemistry and Molecular Biology Inc.","","","","","","00219258","","JBCHA","37797695","English","J. Biol. Chem.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85176130526"
"Citterio L.; Carpini S.D.; Lupoli S.; Brioni E.; Simonini M.; Fontana S.; Zagato L.; Messaggio E.; Barlassina C.; Cusi D.; Manunta P.; Lanzani C.","Citterio, Lorena (6603243638); Carpini, Simona Delli (57192311258); Lupoli, Sara (26433631200); Brioni, Elena (24597744200); Simonini, Marco (24598271800); Fontana, Simone (57205415443); Zagato, Laura (6603443045); Messaggio, Elisabetta (8068925100); Barlassina, Cristina (57195494058); Cusi, Daniele (57198162951); Manunta, Paolo (7004391832); Lanzani, Chiara (6507327902)","6603243638; 57192311258; 26433631200; 24597744200; 24598271800; 57205415443; 6603443045; 8068925100; 57195494058; 57198162951; 7004391832; 6507327902","Klotho gene in human salt-sensitive hypertension","2020","Clinical Journal of the American Society of Nephrology","15","3","","375","383","8","34","10.2215/CJN.08620719","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081945119&doi=10.2215%2fCJN.08620719&partnerID=40&md5=accadb55601b14ecba3e7801283627d6","Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Department of Health Sciences, University of Milan, Filarete Foundation, Milan, Italy; Institute of Biomedical Technologies, National Research Council of Italy (Consiglio Nazionale delle Ricerche, CNR), Milan, Italy; Bio4Dreams Scientific Unit, Bio4Dreams—Business Nursery for, Life Sciences, Milan, Italy","Citterio L., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Carpini S.D., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Lupoli S., Department of Health Sciences, University of Milan, Filarete Foundation, Milan, Italy; Brioni E., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Simonini M., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Fontana S., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Zagato L., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Messaggio E., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Barlassina C., Department of Health Sciences, University of Milan, Filarete Foundation, Milan, Italy; Cusi D., Institute of Biomedical Technologies, National Research Council of Italy (Consiglio Nazionale delle Ricerche, CNR), Milan, Italy, Bio4Dreams Scientific Unit, Bio4Dreams—Business Nursery for, Life Sciences, Milan, Italy; Manunta P., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Lanzani C., Genomics of Renal Diseases and Hypertension Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy","Background and objectives Hypertension is a common aging-related disorder. Salt intake is one of the main environmental factors contributing to the development of hypertension. Transgenic mice with one-half Klotho deficiency displayed a spontaneous BP increase and salt-sensitive hypertension in response to high sodium intake. Usually circulating levels of a-Klotho decrease with age, and this reduction may be stronger in patients with several aging-related diseases. This study aimed at exploring the association of Klotho with salt sensitivity in humans. Design, setting, participants, & measurements The role of Klotho polymorphisms and a-Klotho serum levels was evaluated in patients with hypertension who were treatment naive and underwent an acute salt-sensitivity test (discovery n5673, intravenous 2 L of 0.9% saline in 2 hours). Salt sensitivity was defined as a mean BP increase of.4 mm Hg at the end of the infusion. A total of 32 single nucleotide polymorphisms in the Klotho gene (KL), previously identified with a genome-wide association study, were used in the genetic analysis and studied for a pressure-natriuresis relationship. Results Of the patients with hypertension, 35% were classified as salt sensitive. The most relevant polymorphism associated with pressure natriuresis was the common missense single nucleotide polymorphism rs9536314, and the GG and GT genotypes were more represented among patients who were salt sensitive (P50.001). Those carrying the G allele showed a less steep pressure-natriuresis relationship, meaning that a significant increase in mean BP was needed to excrete the same quantity of salt compared with patients who were salt resistant. KL rs9536314 also replicated the pressure-natriuresis association in an independent replication cohort (n5193) and in the combined analysis (n5866). There was an inverse relationship between circulating Klotho and mean BP changes after the saline infusion (r520.14, P50.03). Moreover, circulating a-Klotho was directly related to kidney function at baseline eGFR (r50.22, P,0.001). Conclusions KL rs9536314 is associated with salt-sensitive hypertension in patients with hypertension who are treatment naive. Moreover, circulating a-Klotho levels were mainly related to diastolic BP changes at the end of a salt load and to eGFR as an expression of kidney aging. © 2020, American Society of Nephrology. All rights reserved.","","Adult; Biomarkers; Blood Pressure; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Glomerular Filtration Rate; Glucuronidase; Humans; Hypertension; Infusions, Intravenous; Kidney; Male; Middle Aged; Polymorphism, Single Nucleotide; Saline Solution; Time Factors; aldosterone; angiotensin; creatinine; electrolyte; Klotho protein; potassium; renin; sodium; sodium chloride; beta glucuronidase; biological marker; Klotho protein; adult; aldosterone blood level; Article; blood pressure; body mass; chemoluminescence; cohort analysis; computer model; controlled study; creatinine urine level; DNA extraction; enzyme chemistry; estimated glomerular filtration rate; female; flame photometry; gene; gene frequency; genetic analysis; genetic variability; heterozygote detection; homozygote; human; hypertension; Klotho gene; major clinical study; male; middle aged; natriuresis; phenotype; plasma renin activity; potassium blood level; potassium urine level; protein blood level; renin angiotensin aldosterone system; salt intake; single nucleotide polymorphism; sodium blood level; sodium intake; sodium urine level; administration and dosage; adverse event; blood; comparative study; genetic predisposition; genetics; genome-wide association study; glomerulus filtration rate; hypertension; intravenous drug administration; kidney; pathophysiology; single nucleotide polymorphism; time factor","","aldosterone, 52-39-1, 6251-69-0; angiotensin, 1407-47-2; creatinine, 19230-81-0, 60-27-5; potassium, 7440-09-7; renin, 61506-93-2, 9015-94-5; sodium, 7440-23-5; sodium chloride, 7647-14-5; beta glucuronidase, 9001-45-0; Biomarkers, ; Glucuronidase, ; klotho protein, ; Saline Solution, ","","","","","Kelly T.N., He J., Genomic epidemiology of blood pressure salt sensitivity, J Hypertens, 30, pp. 861-873, (2012); Alghatrif M., Wang M., Fedorova O.V., Bagrov A.Y., Lakatta E.G., The pressure of aging, Med Clin North Am, 101, pp. 81-101, (2017); Lin H., Lunetta K.L., Zhao Q., Mandaviya P.R., Rong J., Benjamin E.J., Joehanes R., Levy D., van Meurs J.B.J., Larson M.G., Murabito J.M., Whole blood gene expression associated with clinical biological age, J Gerontol a Biol Sci Med Sci, 74, pp. 81-88, (2019); Arnett D.K., Claas S.A., Omics of blood pressure and hypertension, Circ Res, 122, pp. 1409-1419, (2018); Zhou X., Chen K., Lei H., Sun Z., Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation, J am Soc Nephrol, 26, pp. 121-132, (2015); Kuro-O M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y.I., Mutation of the mouse klotho gene leads to a syndrome resembling ageing, Nature, 390, pp. 45-51, (1997); Xu Y., Sun Z., Molecular basis of Klotho: From gene to function in aging, Endocr Rev, 36, pp. 174-193, (2015); Yamazaki Y., Imura A., Urakawa I., Shimada T., Murakami J., Aono Y., Hasegawa H., Yamashita T., Nakatani K., Saito Y., Okamoto N., Kurumatani N., Namba N., Kitaoka T., Ozono K., Sakai T., Hataya H., Ichikawa S., Imel E.A., Econs M.J., Nabeshima Y., Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects, Biochem Biophys Res Commun, 398, pp. 513-518, (2010); Zhou X., Wang X., Klotho: A novel biomarker for cancer, J Cancer Res Clin Oncol, 141, pp. 961-969, (2015); Takenaka T., Inoue T., Miyazaki T., Kobori H., Nishiyama A., Ishii N., Hayashi M., Suzuki H., Klotho ameliorates medullary fibrosis and pressure natriuresis in hypertensive rat kidneys, Hypertension, 72, pp. 1151-1159, (2018); Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T., Klotho converts canonical FGF receptor into a specific receptor for FGF23, Nature, 444, pp. 770-774, (2006); Wang H.L., Xu Q., Wang Z., Zhang Y.H., Si L.Y., Li X.J., Yang Q.H., Xiao H., A potential regulatory single nucleotide polymorphism in the promoter of the Klotho gene may be associated with essential hypertension in the Chinese Han population, Clin Chim Acta, 411, pp. 386-390, (2010); Nzietchueng R., El Shamieh S., Benachour H., Labat C., Herbeth B., Ndiaye N.C., Masson C., Visvikis-Siest S., Benetos A., Klotho KL-VS genotype is involved in blood pressure regulation, Clin Chim Acta, 412, pp. 1773-1777, (2011); Gao L.L., Ding X., Xie D.M., Yang M., Dong B.R., G-395A polymorphism in the promoter region of the KLOTHO gene and hypertension among elderly (90 years and older) Chinese individuals, Genet Mol Res, 14, pp. 15444-15452, (2015); Haruna Y., Kashihara N., Satoh M., Tomita N., Namikoshi T., Sasaki T., Fujimori T., Xie P., Kanwar Y.S., Amelioration of progressive renal injury by genetic manipulation of Klotho gene, Proc Natl Acad Sci U S A, 104, pp. 2331-2336, (2007); Rhee E.J., Oh K.W., Yun E.J., Jung C.H., Lee W.Y., Kim S.W., Baek K.H., Kang M.I., Park S.W., Relationship between polymorphisms G395A in promoter and C1818T in exon 4 of the KLOTHO gene with glucose metabolism and cardiovascular risk factors in Korean women, J Endocrinol Invest, 29, pp. 613-618, (2006); Arking D.E., Becker D.M., Yanek L.R., Fallin D., Judge D.P., Moy T.F., Becker L.C., Dietz H.C., KLOTHO allele status and the risk of early-onset occult coronary artery disease, Am J Hum Genet, 72, pp. 1154-1161, (2003); Qian J., Zhong J., Yan M., Cheng P., Shi H., Hao C., Gu Y., Lai L., Circulating a-Klotho is related to plasma aldosterone and its follow-up change predicts CKD progression, Kidney Blood Press Res, 43, pp. 836-846, (2018); Elijovich F., Weinberger M.H., Anderson C.A.M., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L., American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Functional Genomics and Translational Biology; Stroke Council: Salt sensitivity of blood pressure: A scientific statement from the American heart association [published correction appears in Hypertension 68: E62, 2016], Hypertension, 68, pp. e7-e46, (2016); Wijmenga C., Zhernakova A., The importance of cohort studies in the post-GWAS era, Nat Genet, 50, pp. 322-328, (2018); Arcidiacono T., Simonini M., Lanzani C., Citterio L., Salvi E., Barlassina C., Spotti D., Cusi D., Manunta P., Vezzoli G., Claudin-14 gene polymorphisms and urine calcium excretion, Clin J am Soc Nephrol, 13, pp. 1542-1549, (2018); Citterio L., Lanzani C., Manunta P., Bianchi G., Genetics of primary hypertension: The clinical impact of adducin polymorphisms, Biochim Biophys Acta, 1802, pp. 1285-1298, (2010); Citterio L., Simonini M., Zagato L., Salvi E., Delli Carpini S., Lanzani C., Messaggio E., Casamassima N., Frau F., D'Avila F., Cusi D., Barlassina C., Manunta P., Genes involved in vasoconstriction and vasodilation system affect salt-sensitive hypertension, Plos One, 6, (2011); Manunta P., Cusi D., Barlassina C., Righetti M., Lanzani C., D'Amico M., Buzzi L., Citterio L., Stella P., Rivera R., Bianchi G., Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients, Kidney Int, 53, pp. 1471-1478, (1998); Manunta P., Burnier M., D'Amico M., Buzzi L., Maillard M., Barlassina C., Lanella G., Cusi D., Bianchi G., Adducin polymorphism affects renal proximal tubule reabsorption in hypertension, Hypertension, 33, pp. 694-697, (1999); Manunta P., Lavery G., Lanzani C., Braund P.S., Simonini M., Bodycote C., Zagato L., Delli Carpini S., Tantardini C., Brioni E., Bianchi G., Samani N.J., Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation, Hypertension, 52, pp. 366-372, (2008); Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., Kusek J.W., Eggers P., Lente F., Greene T., Coresh J., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011], Ann Intern Med, 150, pp. 604-612, (2009); Salvi E., Kutalik Z., Glorioso N., Benaglio P., Frau F., Kuznetsova T., Arima H., Hoggart C., Tichet J., Nikitin Y.P., Conti C., Seidlerova J., Tikhonoff V., Stolarz-Skrzypek K., Johnson T., Devos N., Zagato L., Guarrera S., Zaninello R., Calabria A., Stancanelli B., Troffa C., Thijs L., Rizzi F., Simonova G., Lupoli S., Argiolas G., Braga D., D'Alessio M.C., Ortu M.F., Ricceri F., Mercurio M., Descombes P., Marconi M., Chalmers J., Harrap S., Filipovsky J., Bochud M., Iacoviello L., Ellis J., Stanton A.V., Laan M., Padmanabhan S., Dominiczak A.F., Samani N.J., Melander O., Jeunemaitre X., Manunta P., Shabo A., Vineis P., Cappuccio F.P., Caulfield M.J., Matullo G., Rivolta C., Munroe P.B., Barlassina C., Staessen J.A., Beckmann J.S., Cusi D., Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase, Hypertension, 59, pp. 248-255, (2012); Arking D.E., Krebsova A., Macek M., Macek M., Arking A., Mian I.S., Fried L., Hamosh A., Dey S., McIntosh I., Dietz H.C., Association of human aging with a functional variant of klotho, Proc Natl Acad Sci U S A, 99, pp. 856-861, (2002); Aizawa H., Saito Y., Nakamura T., Inoue M., Imanari T., Ohyama Y., Matsumura Y., Masuda H., Oba S., Mise N., Kimura K., Hasegawa A., Kurabayashi M., Kuro-O M., Nabeshima Y., Nagai R., Down-regulation of the Klotho gene in the kidney under sustained circulatory stress in rats, Biochem Biophys Res Commun, 249, pp. 865-871, (1998); Eren M., Boe A.E., Murphy S.B., Place A.T., Nagpal V., Morales-Nebreda L., Urich D., Quaggin S.E., Budinger G.R.S., Mutlu G.M., Miyata T., Vaughan D.E., PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice, Proc Natl Acad Sci U S A, 111, pp. 7090-7095, (2014); Lee J.W., Chou C.L., Knepper M.A., Deep sequencing in micro-dissected renal tubules identifies nephron segment-specific transcriptomes, J am Soc Nephrol, 26, pp. 2669-2677, (2015); Hu M.C., Shi M., Zhang J., Pastor J., Nakatani T., Lanske B., Razzaque M.S., Rosenblatt K.P., Baum M.G., Kuro-O M., Moe O.W., Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule, FASEB J, 24, pp. 3438-3450, (2010); Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-O M., Mohammadi M., Sirkis R., Naveh-Many T., Silver J., The parathyroidis a target organ for FGF23in rats, J Clin Invest, 117, pp. 4003-4008, (2007); Ritter C.S., Zhang S., Delmez J., Finch J.L., Slatopolsky E., Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats, Kidney Int, 87, pp. 1141-1152, (2015); Matsumura Y., Aizawa H., Shiraki-Iida T., Nagai R., Kuro-O M., Nabeshima Y., Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein, Biochem Biophys Res Commun, 242, pp. 626-630, (1998); Kuro-O M., The Klotho proteins in health and disease, Nat Rev Nephrol, 15, pp. 27-44, (2019); Aucella F., Corsonello A., Leosco D., Brunori G., Gesualdo L., Antonelli-Incalzi R., Beyond chronic kidney disease: The diagnosis of Renal Disease in the Elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG), J Nephrol, 32, pp. 165-176, (2019); Sugiura H., Yoshida T., Shiohira S., Kohei J., Mitobe M., Kurosu H., Kuro-O M., Nitta K., Tsuchiya K., Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis, Am J Physiol Renal Physiol, 302, pp. F1252-F1264, (2012); Doi S., Zou Y., Togao O., Pastor J.V., John G.B., Wang L., Shiizaki K., Gotschall R., Schiavi S., Yorioka N., Takahashi M., Boothman D.A., Kuro-O M., Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice, J Biol Chem, 286, pp. 8655-8665, (2011); Zhou L., Li Y., Zhou D., Tan R.J., Liu Y., Loss of Klotho contributes to kidney injury by derepression of Wnt/b-catenin signaling, J am Soc Nephrol, 24, pp. 771-785, (2013); Li Y., Chen F., Wei A., Bi F., Zhu X., Yin S., Lin W., Cao W., Klotho recovery by genistein via promoter histone acetylation and DNA demethylation mitigates renal fibrosis in mice, J Mol Med (Berl), 97, pp. 541-552, (2019); Luft F.C., Miller J.Z., Grim C.E., Fineberg N.S., Christian J.C., Daugherty S.A., Weinberger M.H., Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses, Hypertension, 17, pp. I102-I108, (1991); Weinberger M.H., Salt sensitivity of blood pressure in humans, Hypertension, 27, pp. 481-490, (1996); Sun Z., Aging, arterial stiffness, and hypertension, Hypertension, 65, pp. 252-256, (2015); Arking D.E., Atzmon G., Arking A., Barzilai N., Dietz H.C., Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity, Circ Res, 96, pp. 412-418, (2005); Zhou L., Mo H., Miao J., Zhou D., Tan R.J., Hou F.F., Liu Y., Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system, Am J Pathol, 185, pp. 3211-3223, (2015); Lim S.C., Liu J.J., Subramaniam T., Sum C.F., Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients, J Renin Angiotensin Aldosterone Syst, 15, pp. 487-490, (2014)","C. Lanzani; Genomics of Renal Diseases and Hypertension Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Via Olgettina 60, 20132, Italy; email: lanzani.chiara@hsr.it","","American Society of Nephrology","","","","","","15559041","","","31992575","English","Clin. J. Am. Soc. Nephrol.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-85081945119"
"Kanakan A.; Mishra N.; Vasudevan J.S.; Sahni S.; Khan A.; Sharma S.; Pandey R.","Kanakan, Akshay (57219901443); Mishra, Neha (57208861785); Vasudevan, Janani Srinivasa (57219901148); Sahni, Shweta (57219904363); Khan, Azka (57219906625); Sharma, Sachin (57219902057); Pandey, Rajesh (57226265331)","57219901443; 57208861785; 57219901148; 57219904363; 57219906625; 57219902057; 57226265331","Threading the pieces together: Integrative perspective on sars-cov-2","2020","Pathogens","9","11","912","1","32","31","7","10.3390/pathogens9110912","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096024853&doi=10.3390%2fpathogens9110912&partnerID=40&md5=e08dd9c6557df4eb06ebad1aa8dbfc61","INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India","Kanakan A., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; Mishra N., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; Vasudevan J.S., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; Sahni S., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; Khan A., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; Sharma S., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; Pandey R., INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged the research community globally to innovate, interact, and integrate findings across hierarchies. Research on SARS-CoV-2 has produced an abundance of data spanning multiple parallels, including clinical data, SARS-CoV-2 genome architecture, host response captured through transcriptome and genetic variants, microbial co-infections (metagenome), and comorbidities. Disease phenotypes in the case of COVID-19 present an intriguing complexity that includes a broad range of symptomatic to asymptomatic individuals, further compounded by a vast heterogeneity within the spectrum of clinical symptoms displayed by the symptomatic individuals. The clinical outcome is further modulated by the presence of comorbid conditions at the point of infection. The COVID-19 pandemic has produced an expansive wealth of literature touching many aspects of SARS-CoV-2 ranging from causal to outcome, predisposition to protective (possible), co-infection to comorbidity, and differential mortality globally. As challenges provide opportunities, the current pandemic’s challenge has underscored the need and opportunity to work for an integrative approach that may be able to thread together the multiple variables. Through this review, we have made an effort towards bringing together information spanning across different domains to facilitate researchers globally in pursuit of their response to SARS-CoV-2. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","Co-infection; Comorbidity; Drugs; Host response; Integrative genomics; SARS-CoV-2; Therapeutics; Vaccines","angiotensin converting enzyme 2; HLA antigen; interleukin 6; transmembrane protease serine 2; adaptive immunity; asthma; bioinformatics; cardiovascular disease; chronic kidney failure; chronic obstructive lung disease; clustered regularly interspaced short palindromic repeat; coinfection; coronavirus disease 2019; CRISPR-CAS9 system; cytokine release syndrome; cytokine storm; diabetes mellitus; genetic marker; genetic susceptibility; genetic transcription; genetic variability; genome-wide association study; geographic distribution; host pathogen interaction; hypertension; immune response; incubation time; Influenza A virus (H1N1); innate immunity; Middle East respiratory syndrome coronavirus; mortality; nonhuman; protein expression; protein protein interaction; proteomics; receptor binding; Review; RNA editing; Severe acute respiratory syndrome coronavirus 2; single cell RNA seq; single nucleotide polymorphism; structural genomics; transcriptomics; virus replication; whole exome sequencing","","","","","Council of Scientific & Industrial Research, (INGEN-CoV-2, MLP-2005); Fondation Botnar, (CLP-0031); Fondation Botnar","This research was funded by the Council of Scientific & Industrial Research project, INtegrative GENomics of SARS-CoV-2 [INGEN-CoV-2], project code [MLP-2005], and Fondation Botnar, project Technology Tools for COVID-19 Response, project code [CLP-0031].","The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2, Nat. Microbiol, 5, pp. 536-544, (2020); Chan J.F.-W., Yuan S., Kok K.-H., To K.K.-W., Chu H., Yang J., Xing F., Liu J., Yip C.C.-Y., Poon R.W.-S., Et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster, Lancet, 395, pp. 514-523, (2020); Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S.C., Et al., China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med, 382, pp. 1708-1720, (2020); Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet, 395, pp. 507-513, (2020); Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), (2020); Van Doremalen N., Bushmaker T., Morris D.H., Holbrook M.G., Gamble A., Williamson B.N., Tamin A., Harcourt J.L., Thornburg N.J., Gerber S.I., Et al., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1, N. Engl. J. Med, 382, pp. 1564-1567, (2020); Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Et al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, N. Engl. J. Med, 382, pp. 1199-1207, (2020); Du Z., Xu X., Wu Y., Wang L., Cowling B.J., Meyers L.A., Serial Interval of COVID-19 among Publicly Reported Confirmed Cases, Emerg. Infect. Dis, 26, pp. 1341-1343, (2020); He X., Lau E.H.Y., Wu P., Deng X., Wang J., Hao X., Lau Y.C., Wong J.Y., Guan Y., Tan X., Et al., Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat. Med, 26, pp. 672-675, (2020); Tindale L., Coombe M., Stockdale J.E., Garlock E., Lau W.Y.V., Saraswat M., Lee Y.-H.B., Zhang L., Chen D., Wallinga J., Et al., Transmission interval estimates suggest pre-symptomatic spread of COVID-19, medRxiv, (2020); Zhang S., Diao M., Yu W., Pei L., Lin Z., Chen D., Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis, Int. J. Infect. Dis, 93, pp. 201-204, (2020); Sanche S., Lin Y.T., Xu C., Romero-Severson E., Hengartner N., Ke R., High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2, Emerg. Infect. Dis, 26, pp. 1470-1477, (2020); Zhang X., Epidemiology of Covid-19, N. Engl. J. Med, 382, (2020); Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., Et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, pp. 270-273, (2020); Tang X., Wu C., Li X., Song Y., Yao X., Wu X., Duan Y., Zhang H., Wang Y., Qian Z., Et al., On the origin and continuing evolution of SARS-CoV-2, Natl. Sci. Rev, 7, pp. 1012-1023, (2020); Zhang T., Wu Q., Zhang Z., Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak, Curr. Biol, 30, pp. 1346-1351, (2020); Sawicki S.G., Sawicki D.L., A new model for coronavirus transcription, Adv. Exp. Med. Biol, 440, pp. 215-219, (1998); Jia W., Karaca K., Parrish C.R., Naqi S.A., A novel variant of avian infectious bronchitis virus resulting from recombination among three different strains, Arch. Virol, 140, pp. 259-271, (1995); Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J., Et al., Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China, Cell Host Microbe, 27, pp. 325-328, (2020); Rehman S.U., Shafique L., Ihsan A., Liu Q., Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2, Pathogens, 9, (2020); Snijder E.J., Decroly E., Ziebuhr J., The nonstructural proteins directing coronavirus RNA synthesis and processing, Adv. Virus Res, 96, pp. 59-126, (2016); Kim D., Lee J.-Y., Yang J.-S., Kim J.W., Kim V.N., Chang H., The Architecture of SARS-CoV-2 Transcriptome, Cell, 181, pp. 914-921, (2020); Sola I., Almazan F., Zuniga S., Enjuanes L., Continuous and discontinuous RNA synthesis in coronaviruses, Annu. Rev. Virol, 2, pp. 265-288, (2015); Li F., Structure, function, and evolution of coronavirus spike proteins, Annu. Rev. Virol, 3, pp. 237-261, (2016); Wu K., Li W., Peng G., Li F., Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor, Proc. Natl. Acad. Sci. USA, 106, pp. 19970-19974, (2009); Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china, JAMA Intern. Med, 180, pp. 934-943, (2020); Raj V.S., Mou H., Smits S.L., Dekkers D.H.W., Muller M.A., Dijkman R., Muth D., Demmers J.A.A., Zaki A., Fouchier R.A.M., Et al., Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature, 495, pp. 251-254, (2013); Wang K., Chen W., Zhou Y.-S., Lian J.-Q., Zhang Z., Du P., Gong L., Zhang Y., Cui H.-Y., Geng J.-J., Et al., SARS-CoV-2 invades host cells via a novel route: CD147-spike protein, bioRxiv, (2020); Bian H., Zheng Z.-H., Wei D., Zhang Z., Kang W.-Z., Hao C.-Q., Dong K., Kang W., Xia J.-L., Miao J.-L., Et al., Meplazumab treats COVID-19 pneumonia: An open-labelled, concurrent controlled add-on clinical trial, medRxiv, (2020); Pushkarsky T., Zybarth G., Dubrovsky L., Yurchenko V., Tang H., Guo H., Toole B., Sherry B., Bukrinsky M., CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A, Proc. Natl. Acad. Sci. USA, 98, pp. 6360-6365, (2001); Tian X., Zhao C., Zhu H., She W., Zhang J., Liu J., Li L., Zheng S., Wen Y.-M., Xie Y., Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: Possible link to pathogenesis of HBV infection, J. Virol, 84, pp. 3373-3381, (2010); Ulrich H., Pillat M.M., CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, Stem Cell Rev. Rep, 16, pp. 434-440, (2020); Chan C.-P., Siu K.-L., Chin K.-T., Yuen K.-Y., Zheng B., Jin D.-Y., Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein, J. Virol, 80, pp. 9279-9287, (2006); Chan S.-W., Unfolded protein response in hepatitis C virus infection, Front. Microbiol, 5, (2014); Romero-Brey I., Bartenschlager R., Endoplasmic reticulum: The favorite intracellular niche for viral replication and assembly, Viruses, 8, (2016); Reid C.R., Airo A.M., Hobman T.C., The Virus-Host Interplay: Biogenesis of +RNA Replication Complexes, Viruses, 7, pp. 4385-4413, (2015); Hagemeijer M.C., Monastyrska I., Griffith J., van der Sluijs P., Voortman J., van Bergen en Henegouwen P.M., Vonk A.M., Rottier P.J.M., Reggiori F., de Haan C.A.M., Membrane rearrangements mediated by coronavirus nonstructural proteins 3 and 4, Virology, pp. 125-135, (2014); Knoops K., Kikkert M., van den Worm S.H.E., Zevenhoven-Dobbe J.C., van der Meer Y., Koster A.J., Mommaas A.M., Snijder E.J., SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum, PLoS Biol, 6, (2008); Snijder E.J., van der Meer Y., Zevenhoven-Dobbe J., Onderwater J.J.M., van der Meulen J., Koerten H.K., Mommaas A.M., Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex, J. Virol, 80, pp. 5927-5940, (2006); Verheije M.H., Raaben M., Mari M., Te Lintelo E.G., Reggiori F., van Kuppeveld F.J.M., Rottier P.J.M., de Haan C.A.M., Mouse hepatitis coronavirus RNA replication depends on GBF1-mediated ARF1 activation, PLoS Pathog, 4, (2008); Oostra M., te Lintelo E.G., Deijs M., Verheije M.H., Rottier P.J.M., de Haan C.A.M., Localization and membrane topology of coronavirus nonstructural protein 4: Involvement of the early secretory pathway in replication, J. Virol, 81, pp. 12323-12336, (2007); Knoops K., Swett-Tapia C., van den Worm S.H.E., Te Velthuis A.J.W., Koster A.J., Mommaas A.M., Snijder E.J., Kikkert M., Integrity of the early secretory pathway promotes, but is not required for, severe acute respiratory syndrome coronavirus RNA synthesis and virus-induced remodeling of endoplasmic reticulum membranes, J. Virol, 84, pp. 833-846, (2010); De Wilde A.H., Wannee K.F., Scholte F.E.M., Goeman J.J., Ten Dijke P., Snijder E.J., Kikkert M., van Hemert M.J., A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins, J. Virol, 89, pp. 8318-8333, (2015); Prentice E., Jerome W.G., Yoshimori T., Mizushima N., Denison M.R., Coronavirus replication complex formation utilizes components of cellular autophagy, J. Biol. Chem, 279, pp. 10136-10141, (2004); Zhao Z., Thackray L.B., Miller B.C., Lynn T.M., Becker M.M., Ward E., Mizushima N.N., Denison M.R., Virgin H.W., Coronavirus replication does not require the autophagy gene ATG5, Autophagy, 3, pp. 581-585, (2007); De Wilde A.H., Snijder E.J., Kikkert M., van Hemert M.J., Host factors in coronavirus replication, Curr. Top. Microbiol. Immunol, 419, pp. 1-42, (2018); Kwak H., Park M.W., Jeong S., Annexin A2 binds RNA and reduces the frameshifting efficiency of infectious bronchitis virus, PLoS ONE, 6, (2011); Tan Y.W., Hong W., Liu D.X., Binding of the 5<sup>′</sup>-untranslated region of coronavirus RNA to zinc finger CCHC-type and RNA-binding motif 1 enhances viral replication and transcription, Nucleic Acids Res, 40, pp. 5065-5077, (2012); Emmott E., Munday D., Bickerton E., Britton P., Rodgers M.A., Whitehouse A., Zhou E.-M., Hiscox J.A., The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology, J. Virol, 87, pp. 9486-9500, (2013); Shen X., Masters P.S., Evaluation of the role of heterogeneous nuclear ribonucleoprotein A1 as a host factor in murine coronavirus discontinuous transcription and genome replication, Proc. Natl. Acad. Sci. USA, 98, pp. 2717-2722, (2001); Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., Et al., Coronavirus infections and immune responses, J. Med. Virol, 92, pp. 424-432, (2020); Tumpey T.M., Garcia-Sastre A., Taubenberger J.K., Palese P., Swayne D.E., Pantin-Jackwood M.J., Schultz-Cherry S., Solorzano A., Van Rooijen N., Katz J.M., Et al., Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: Functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice, J. Virol, 79, pp. 14933-14944, (2005); Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, pp. 281-292, (2020); Guruprasad L., Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition, ChemRxiv, (2020); Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., Et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, pp. 271-280, (2020); Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T., Katoh H., Kato F., Et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc. Natl. Acad. Sci. USA, 117, pp. 7001-7003, (2020); Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, pp. 1444-1448, (2020); Bojkova D., Klann K., Koch B., Widera M., Krause D., Ciesek S., Cinatl J., Munch C., Proteomics of SARS-CoV-2-infected host cells reveals therapy targets, Nature, 583, pp. 469-472, (2020); Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O'Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., Et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, 583, pp. 459-468, (2020); Srinivasan S., Cui H., Gao Z., Liu M., Lu S., Mkandawire W., Narykov O., Sun M., Korkin D., Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins, Viruses, 12, (2020); Messina F., Giombini E., Agrati C., Vairo F., Ascoli Bartoli T., Al Moghazi S., Piacentini M., Locatelli F., Kobinger G., Maeurer M., Et al., COVID 19 INMI Network Medicine for IDs Study Group COVID-19: Viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection, J. Transl. Med, 18, (2020); Ellinghaus D., Degenhardt F., Bujanda L., Buti M., Albillos A., Invernizzi P., Fernandez J., Prati D., Baselli G., Asselta R., Et al., Genomewide Association Study of Severe Covid-19 with Respiratory Failure, N. Engl. J. Med, 383, pp. 1522-1534, (2020); Zhang X., Tan Y., Ling Y., Lu G., Liu F., Yi Z., Jia X., Wu M., Shi B., Xu S., Et al., Viral and host factors related to the clinical outcome of COVID-19, Nature, 583, pp. 437-440, (2020); Saha P., Banerjee A.K., Tripathi P.P., Srivastava A.K., Ray U., A virus that has gone viral: Amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity, Biosci. Rep, 40, (2020); Qi F., Qian S., Zhang S., Zhang Z., Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses, Biochem. Biophys. Res. Commun, 526, pp. 135-140, (2020); Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., Cao Y., Yousif A.S., Bals J., Hauser B.M., Et al., SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues, Cell, 181, pp. 1016-1035, (2020); Lee J.J., Kopetz S., Vilar E., Shen J.P., Chen K., Maitra A., Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract, Genes, 11, (2020); Zang R., Gomez Castro M.F., McCune B.T., Zeng Q., Rothlauf P.W., Sonnek N.M., Liu Z., Brulois K.F., Wang X., Greenberg H.B., Et al., TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes, Sci. Immunol, 5, (2020); Collin J., Queen R., Zerti D., Dorgau B., Georgiou M., Djidrovski I., Hussain R., Coxhead J.M., Joseph A., Rooney P., Et al., Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface, Ocul. Surf, (2020); Sungnak W., Huang N., Becavin C., Berg M., Queen R., Litvinukova M., Talavera-Lopez C., Maatz H., Reichart D., Sampaziotis F., Et al., HCA Lung Biological Network SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat. Med, 26, pp. 681-687, (2020); Ma D., Chen C.-B., Jhanji V., Xu C., Yuan X.-L., Liang J.-J., Huang Y., Cen L.-P., Ng T.K., Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea, Eye, 34, pp. 1212-1219, (2020); Lamers M.M., Beumer J., van der Vaart J., Knoops K., Puschhof J., Breugem T.I., Ravelli R.B.G., Paul van Schayck J., Mykytyn A.Z., Duimel H.Q., Et al., SARS-CoV-2 productively infects human gut enterocytes, Science, 369, pp. 50-54, (2020); Bilinska K., Jakubowska P., Von Bartheld C.S., Butowt R., Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age, ACS Chem. Neurosci, 11, pp. 1555-1562, (2020); Zhou J., Li C., Liu X., Chiu M.C., Zhao X., Wang D., Wei Y., Lee A., Zhang A.J., Chu H., Et al., Infection of bat and human intestinal organoids by SARS-CoV-2, Nat. Med, 26, pp. 1077-1083, (2020); Elbadawi M., Efferth T., Organoids of human airways to study infectivity and cytopathy of SARS-CoV-2, Lancet Respir. Med, 8, pp. e55-e56, (2020); Allison S.J., SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2, Nat. Rev. Nephrol, 16, (2020); Su H., Yang M., Wan C., Yi L.-X., Tang F., Zhu H.-Y., Yi F., Yang H.-C., Fogo A.B., Nie X., Et al., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China, Kidney Int, 98, pp. 219-227, (2020); Xu J., Chu M., Zhong F., Tan X., Tang G., Mai J., Lai N., Guan C., Liang Y., Liao G., Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs, Cell Death Discov, 6, (2020); Fang Z., Yi F., Wu K., Lai K., Sun X., Zhong N., Liu Z., Clinical Characteristics of Coronavirus Pneumonia 2019 (COVID-19): An Updated Systematic Review; Knisbacher B.A., Levanon E.Y., DNA and RNA editing of retrotransposons accelerate mammalian genome evolution, Ann. N. Y. Acad. Sci, 1341, pp. 115-125, (2015); Dong X., Wang X., Zhang F., Tian W., Genome-Wide Identification of Regulatory Sequences Undergoing Accelerated Evolution in the Human Genome, Mol. Biol. Evol, 33, pp. 2565-2575, (2016); Cattaneo R., Schmid A., Eschle D., Baczko K., ter Meulen V., Billeter M.A., Biased hypermutation and other genetic changes in defective measles viruses in human brain infections, Cell, 55, pp. 255-265, (1988); Cao Y., Cao R., Huang Y., Zhou H., Liu Y., Li X., Zhong W., Hao P., A comprehensive study on cellular RNA editing activity in response to infections with different subtypes of influenza a viruses, BMC Genom, 19, (2018); Piontkivska H., Frederick M., Miyamoto M.M., Wayne M.L., RNA editing by the host ADAR system affects the molecular evolution of the Zika virus, Ecol. Evol, 7, pp. 4475-4485, (2017); Sharma S., Wang J., Alqassim E., Portwood S., Cortes Gomez E., Maguire O., Basse P.H., Wang E.S., Segal B.H., Baysal B.E., Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells, Genome Biol, 20, (2019); Westermann A.J., Gorski S.A., Vogel J., Dual RNA-seq of pathogen and host, Nat. Rev. Microbiol, 10, pp. 618-630, (2012); Bost P., Giladi A., Liu Y., Bendjelal Y., Xu G., David E., Blecher-Gonen R., Cohen M., Medaglia C., Li H., Et al., Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients, Cell, 181, pp. 1475-1488, (2020); Di Giorgio S., Martignano F., Torcia M.G., Mattiuz G., Conticello S.G., Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2, Sci. Adv, 6, (2020); Simmonds P., Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short-and Long-Term Evolutionary Trajectories, mSphere, 5, (2020); Wang P., Yu S., Liu J., Zhang D., Kang X., Seven novel mutations of ADAR in multi-ethnic pedigrees with dyschromatosis symmetrica hereditaria in China, Mol. Genet. Genom. Med, 7, (2019); Crow Y.J., Chase D.S., Lowenstein Schmidt J., Szynkiewicz M., Forte G.M.A., Gornall H.L., Oojageer A., Anderson B., Pizzino A., Helman G., Et al., Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1, Am. J. Med. Genet. A, 167, pp. 296-312, (2015); Pauli E.-K., Schmolke M., Hofmann H., Ehrhardt C., Flory E., Munk C., Ludwig S., High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity, Retrovirology, 6, (2009); Nair S., Miller B., Barends M., Jaidee A., Patel J., Mayxay M., Newton P., Nosten F., Ferdig M.T., Anderson T.J.C., Adaptive copy number evolution in malaria parasites, PLoS Genet, 4, (2008); Jern P., Stoye J.P., Coffin J.M., Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses, PLoS Genet, 3, pp. 2014-2022, (2007); Chang S., Dolganiuc A., Szabo G., Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins, J. Leukoc. Biol, 82, pp. 479-487, (2007); Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T., The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses, Nat. Immunol, 5, pp. 730-737, (2004); Delaloye J., Roger T., Steiner-Tardivel Q.-G., Le Roy D., Knaup Reymond M., Akira S., Petrilli V., Gomez C.E., Perdiguero B., Tschopp J., Et al., Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome, PLoS Pathog, 5, (2009); Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA, Science, 303, pp. 1529-1531, (2004); Iwanaszko M., Kimmel M., NF-κB and IRF pathways: Cross-regulation on target genes promoter level, BMC Genom, 16, (2015); Lazear H.M., Schoggins J.W., Diamond M.S., Shared and distinct functions of type I and type III interferons, Immunity, 50, pp. 907-923, (2019); Sokol C.L., Luster A.D., The chemokine system in innate immunity, Cold Spring Harb. Perspect. Biol, 7, (2015); Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA, 323, pp. 1061-1069, (2020); Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin. Infect. Dis, 71, pp. 762-768, (2020); Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.-E., Katsaounou P., Et al., Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure, Cell Host Microbe, 27, pp. 992-1000, (2020); Wang F., Nie J., Wang H., Zhao Q., Xiong Y., Deng L., Song S., Ma Z., Mo P., Zhang Y., Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia, J. Infect. Dis, 221, pp. 1762-1769, (2020); Lee J.S., Park S., Jeong H.W., Ahn J.Y., Choi S.J., Lee H., Choi B., Nam S.K., Sa M., Kwon J.-S., Et al., Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19, Sci. Immunol, 5, (2020); Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, pp. 497-506, (2020); Mazzoni A., Salvati L., Maggi L., Capone M., Vanni A., Spinicci M., Mencarini J., Caporale R., Peruzzi B., Antonelli A., Et al., Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent, J. Clin. Investig, 130, pp. 4694-4703, (2020); Wang J., Jiang M., Chen X., Montaner L.J., Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts, J. Leukoc. Biol, 108, pp. 17-41, (2020); Kim G.U., Kim M.J., Ra S.H., Lee J., Bae S., Jung J., Kim S.H., Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19, Clin. Microbiol. Infect, 26, pp. e1-948, (2020); Jin X., Lian J.-S., Hu J.-H., Gao J., Zheng L., Zhang Y.-M., Hao S.-R., Jia H.-Y., Cai H., Zhang X.-L., Et al., Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms, Gut, 69, pp. 1002-1009, (2020); Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T., Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J., Et al., Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2, bioRxiv, (2020); Zhang B., Zhou X., Qiu Y., Song Y., Feng F., Feng J., Song Q., Jia Q., Wang J., Clinical characteristics of 82 cases of death from COVID-19, PLoS ONE, 15, (2020); Mauvais-Jarvis F., Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19, Diabetes, 69, pp. 1857-1863, (2020); Zheng Z., Peng F., Xu B., Zhao J., Liu H., Peng J., Li Q., Jiang C., Zhou Y., Liu S., Et al., Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis, J. Infect, 81, pp. e16-e25, (2020); The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic, Eur. J. Hum. Genet, 28, pp. 715-718, (2020); Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet, 395, pp. 1054-1062, (2020); Zhang J.-J., Dong X., Cao Y.-Y., Yuan Y.-D., Yang Y.-B., Yan Y.-Q., Akdis C.A., Gao Y.-D., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, 75, pp. 1730-1741, (2020); Liu K., Fang Y.-Y., Deng Y., Liu W., Wang M.-F., Ma J.-P., Xiao W., Wang Y.-N., Zhong M.-H., Li C.-H., Et al., Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin. Med. J, 133, pp. 1025-1031, (2020); Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W., the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area, JAMA, 323, pp. 2052-2059, (2020); Khan F.A., The role of selectivity of the SARS-CoV-2 virus for human genetic profiles in susceptibility and resistance to COVID-19, New Microbes New Infect, 36, (2020); Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, pp. 450-454, (2003); Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., Zhong W., Hao P., Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci. China Life Sci, 63, pp. 457-460, (2020); Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W., Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov, bioRxiv, (2020); Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X., Wen F., Huang X., Ning G., Wang W., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov, 6, (2020); Chen J., Jiang Q., Xia X., Liu K., Yu Z., Tao W., Gong W., Han J.-D.J., Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation, Aging Cell, 19, (2020); Leung J.M., Yang C.X., Tam A., Shaipanich T., Hackett T.-L., Singhera G.K., Dorscheid D.R., Sin D.D., ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19, Eur. Respir. J, 55, (2020); Yilin Z., Yandong N., Faguang J., Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome, Burns, 41, pp. 1468-1477, (2015); Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., van Goor H., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol, 203, pp. 631-637, (2004); Tian C., Hromatka B.S., Kiefer A.K., Eriksson N., Noble S.M., Tung J.Y., Hinds D.A., Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections, Nat. Commun, 8, (2017); Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I.W., Walker B.D., Ripke S., Brumme C.J., Pulit S.L., Et al., The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Science, 330, pp. 1551-1557, (2010); Nguyen A., David J.K., Maden S.K., Wood M.A., Weeder B.R., Nellore A., Thompson R.F., Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2, J. Virol, 94, (2020); Cheng Y., Cheng G., Chui C.H., Lau F.Y., Chan P.K.S., Ng M.H.L., Sung J.J.Y., Wong R.S.M., ABO blood group and susceptibility to severe acute respiratory syndrome, JAMA, 293, pp. 1450-1451, (2005); Zhao J., Yang Y., Huang H.-P., Li D., Gu D.-F., Lu X.-F., Zhang Z., Liu L., Liu T., Liu Y.-K., Et al., Relationship between the ABO Blood Group and the COVID-19 Susceptibility, medRxiv, (2020); Li J., Wang X., Chen J., Cai Y., Deng A., Yang M., Association between ABO blood groups and risk of SARS-CoV-2 pneumonia, Br. J. Haematol, 190, pp. 24-27, (2020); Hou Y., Zhao J., Martin W., Kallianpur A., Chung M.K., Jehi L., Sharifi N., Erzurum S., Eng C., Cheng F., New insights into genetic susceptibility of COVID-19: An ACE2 and TMPRSS2 polymorphism analysis, BMC Med, 18, (2020); Itoyama S., Keicho N., Quy T., Phi N.C., Long H.T., Ha L.D., Ban V.V., Ohashi J., Hijikata M., Matsushita I., Et al., ACE1 polymorphism and progression of SARS, Biochem. Biophys. Res. Commun, 323, pp. 1124-1129, (2004); Lin M., Tseng H.-K., Trejaut J.A., Lee H.-L., Loo J.-H., Chu C.-C., Chen P.-J., Su Y.-W., Lim K.H., Tsai Z.-U., Et al., Association of HLA class I with severe acute respiratory syndrome coronavirus infection, BMC Med. Genet, 4, (2003); Ulhaq Z.S., Soraya G.V., Anti-IL-6 Receptor Antibody Treatment for Severe COVID-19 and the Potential Implication of IL-6 Gene Polymorphisms in Novel Coronavirus Pneumonia, Med. Clin, (2020); Hamano E., Hijikata M., Itoyama S., Quy T., Phi N.C., Long H.T., Ha L.D., Ban V.V., Matsushita I., Yanai H., Et al., Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population, Biochem. Biophys. Res. Commun, 329, pp. 1234-1239, (2005); He J., Feng D., de Vlas S.J., Wang H., Fontanet A., Zhang P., Plancoulaine S., Tang F., Zhan L., Yang H., Et al., Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: A case-control study, BMC Infect. Dis, 6, (2006); Zhang H., Zhou G., Zhi L., Yang H., Zhai Y., Dong X., Zhang X., Gao X., Zhu Y., He F., Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection, J. Infect. Dis, 192, pp. 1355-1361, (2005); Ip W.K.E., Chan K.H., Law H.K.W., Tso G.H.W., Kong E.K.P., Wong W.H.S., To Y.F., Yung R.W.H., Chow E.Y., Au K.L., Et al., Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection, J. Infect. Dis, 191, pp. 1697-1704, (2005); Tu X., Chong W.P., Zhai Y., Zhang H., Zhang F., Wang S., Liu W., Wei M., Siu N.H.O., Yang H., Et al., Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection, J. Infect, 71, pp. 101-109, (2015); Yuan F.F., Tanner J., Chan P.K.S., Biffin S., Dyer W.B., Geczy A.F., Tang J.W., Hui D.S.C., Sung J.J.Y., Sullivan J.S., Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome, Tissue Antigens, 66, pp. 291-296, (2005); Chan K.Y.K., Ching J.C.Y., Xu M.S., Cheung A.N.Y., Yip S.-P., Yam L.Y.C., Lai S.-T., Chu C.-M., Wong A.T.Y., Song Y.-Q., Et al., Association of ICAM3 genetic variant with severe acute respiratory syndrome, J. Infect. Dis, 196, pp. 271-280, (2007); Ching J.C.-Y., Chan K.Y.K., Lee E.H.L., Xu M.-S., Ting C.K.P., So T.M.K., Sham P.C., Leung G.M., Peiris J.S.M., Khoo U.-S., Significance of the myxovirus resistance A (MxA) gene-123C>a single-nucleotide polymorphism in suppressed interferon beta induction of severe acute respiratory syndrome coronavirus infection, J. Infect. Dis, 201, pp. 1899-1908, (2010); Martinez A., Soldevila N., Romero-Tamarit A., Torner N., Godoy P., Rius C., Jane M., Dominguez A., Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype, PLoS ONE, 14, (2019); Werneck G.L., Macias A.E., Mascarenas C., Coudeville L., Morley D., Recamier V., Guergova-Kuras M., Puentes-Rosas E., Baurin N., Toh M.-L., Comorbidities increase in-hospital mortality in dengue patients in Brazil, Mem. Inst. Oswaldo Cruz, 113, (2018)","R. Pandey; INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, 110007, India; email: rajeshp@igib.in","","MDPI AG","","","","","","20760817","","","","English","Pathogens","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85096024853"
"Bernstein K.E.; Ong F.S.; Blackwell W.-L.B.; Shah K.H.; Giani J.F.; Gonzalez-Villalobos R.A.; Shen X.Z.; Fuchs S.","Bernstein, Kenneth E. (7101917030); Ong, Frank S. (36542902400); Blackwell, Wendell-Lamar B. (54792617800); Shah, Kandarp H. (7402959209); Giani, Jorge F. (18633971000); Gonzalez-Villalobos, Romer A. (6504037823); Shen, Xiao Z. (9733518900); Fuchs, Sebastien (56831657200)","7101917030; 36542902400; 54792617800; 7402959209; 18633971000; 6504037823; 9733518900; 56831657200","A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme","2013","Pharmacological Reviews","65","1","","1","46","45","240","10.1124/pr.112.006809","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871542698&doi=10.1124%2fpr.112.006809&partnerID=40&md5=953cfe0a66d0b4a4021ed1dfe74461e0","Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States","Bernstein K.E., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Ong F.S., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Blackwell W.-L.B., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Shah K.H., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Giani J.F., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Gonzalez-Villalobos R.A., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Shen X.Z., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Fuchs S., Department of Biomedical Sciences, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States","Angiotensin-converting enzyme (ACE) is a zinc-dependent peptidase responsible for converting angiotensin I into the vasoconstrictor angiotensin II. However, ACE is a relatively nonspecific peptidase that is capable of cleaving a wide range of substrates. Because of this, ACE and its peptide substrates and products affect many physiologic processes, including blood pressure control, hematopoiesis, reproduction, renal development, renal function, and the immune response. The defining feature of ACE is that it is composed of two homologous and independently catalytic domains, the result of an ancient gene duplication, and ACE-like genes are widely distributed in nature. The two ACE catalytic domains contribute to the wide substrate diversity of ACE and, by extension, the physiologic impact of the enzyme. Several studies suggest that the two catalytic domains have different biologic functions. Recently, the X-ray crystal structure of ACE has elucidated some of the structural differences between the two ACE domains. This is important now that ACE domain-specific inhibitors have been synthesized and characterized. Once widely available, these reagents will undoubtedly be powerful tools for probing the physiologic actions of each ACE domain. In turn, this knowledge should allow clinicians to envision new therapies for diseases not currently treated with ACE inhibitors. © 2013 by The American Society for Pharmacology and Experimental Therapeutics.","","Angiotensin-Converting Enzyme Inhibitors; Animals; History, 20th Century; Humans; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Protein Structure, Tertiary; Renin; angiotensin I; angiotensin II; angiotensin receptor antagonist; angiotensin[1-7]; bradykinin; captopril; carboxypeptidase A inhibitor; chimeric protein; chloride; cytokine; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; enalapril; enalaprilat; gonadorelin; lisinopril; major histocompatibility antigen class 1; n acetylisoleucyltyrosyl[1 amino 2 (4 hydroxyphenyl)ethanephosphonic acid]; natural product; peptide hydrolase inhibitor; reactive oxygen metabolite; renin; rxp 407; rxp a 380; snake venom; sq 13297; teprotide; unclassified drug; adrenergic system; Alzheimer disease; amino acid sequence; amino terminal sequence; anemia; antigen presentation; antigen presenting cell; antihypertensive activity; apoptosis; article; behavior; blood clotting; blood pressure regulation; carboxy terminal sequence; cell lineage; cell proliferation; central nervous system; chemotaxis; cholinergic system; coronary artery disease; crystal structure; cytokine production; development; digestion; drug protein binding; drug structure; electrolyte balance; enzyme activation; enzyme active site; enzyme blood level; enzyme purification; enzyme specificity; enzyme stability; enzyme structure; enzyme substrate; erythropoiesis; essential hypertension; extracellular matrix; fertility; fibrinolysis; fibrosis; genetic polymorphism; genital system; glomerulus filtration rate; heart infarction; hematocrit; hematopoiesis; hematopoietic stem cell; hepatitis; human; hypertension; hypertrophy; IC 50; immune response; indel mutation; infection; inflammation; inotropism; kidney development; kidney tubule absorption; liver blood flow; liver metabolism; male fertility; melanoma; metabolism; molecular evolution; myelopoiesis; nervous system development; nonhuman; nucleotide sequence; oxidative stress; phylogenetic tree; pressor response; priority journal; protein domain; protein expression; protein function; renin angiotensin aldosterone system; renovascular hypertension; side effect; signal transduction; species difference; T lymphocyte; testis; thrombocyte aggregation; thrombosis; tumor immunity; vasoconstriction; vasodilatation; visual system; water retention","GENBANK: AAR85358, AAS57725, ABL73884, ABW34729, AEV53960, BAD98304, CAG04404, CAX48990, CBN81253, EFR22959, EFX86779, EGI64832, EHB07361, NP_000780, NP_036676, NP_477046, NP_926089, NP_997507, XP_313865, XP_393561, XP_694336, YP465231, YP631771, YP826088","angiotensin I, 9041-90-1; angiotensin II, 11128-99-7; angiotensin[1-7], 39386-80-6; bradykinin, 58-82-2, 5979-11-3; captopril, 62571-86-2; chloride, 16887-00-6; dipeptidyl carboxypeptidase, 9015-82-1; enalapril, 75847-73-3; enalaprilat, 76420-72-9; gonadorelin, 33515-09-2, 9034-40-6; lisinopril, 76547-98-3, 83915-83-7; renin, 61506-93-2, 9015-94-5; snake venom, 55230-69-8; teprotide, 35115-60-7; Angiotensin-Converting Enzyme Inhibitors, ; Peptidyl-Dipeptidase A, 3.4.15.1; Renin, 3.4.23.15","k 26; rxp 407; rxp a 380; sq 13297; sq 14225; sq 20881","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R00DK083455)","","Abdalla S., Lother H., Langer A., El Faramawy Y., Quitterer U., Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis, Cell, 119, pp. 343-354, (2004); Acharya K.R., Sturrock E.D., Riordan J.F., Ehlers M.R., Ace revisited: A new target for structure-based drug design, Nat Rev Drug Discov, 2, pp. 891-902, (2003); Agerholm-Larsen B., Nordestgaard B.G., Tybjaerg-Hansen A., ACE gene polymorphism in cardiovascular disease: Meta-analyses of small and large studies in whites, Arterioscler Thromb Vasc Biol, 20, pp. 484-492, (2000); Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Sorensen T.I., Jensen G., Tybjaerg-Hansen A., ACE gene polymorphism: Ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study, Circulation, 95, pp. 2358-2367, (1997); Ahmed A., Fonarow G.C., Zhang Y., Sanders P.W., Allman R.M., Arnett D.K., Feller M.A., Love T.E., Aban I.B., Levesque R., Et al., Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease, Am J Med, 125, pp. 399-410, (2012); Ainscough J.F., Drinkhill M.J., Sedo A., Turner N.A., Brooke D.A., Balmforth A.J., Ball S.G., Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction, Cardiovasc Res, 81, pp. 592-600, (2009); Albitar S., Genin R., Fen-Chong M., Serveaux M.O., Bourgeon B., High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients, Nephrol Dial Transplant, 13, pp. 1206-1210, (1998); Allinson T.M., Parkin E.T., Condon T.P., Schwager S.L., Sturrock E.D., Turner A.J., Hooper N.M., The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein, Eur J Biochem, 271, pp. 2539-2547, (2004); Anthony C.S., Corradi H.R., Schwager S.L., Redelinghuys P., Georgiadis D., Dive V., Acharya K.R., Sturrock E.D., The N domain of human angiotensin-Iconverting enzyme: The role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407, J Biol Chem, 285, pp. 35685-35693, (2010); Anthony C.S., Masuyer G., Sturrock E.D., Acharya K.R., Structure based drug design of angiotensin-I converting enzyme inhibitors, Curr Med Chem, 19, pp. 845-855, (2012); Araujo M.C., Melo R.L., Cesari M.H., Juliano M.A., Juliano L., Carmona A.K., Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme, Biochemistry, 39, pp. 8519-8525, (2000); Arendshorst W.J., Brannstrom K., Ruan X., Actions of angiotensin II on the renal microvasculature, J Am Soc Nephrol, 10, 11 SUPPL., (1999); Arndt J.W., Hao B., Ramakrishnan V., Cheng T., Chan S.I., Chan M.K., Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus, Structure, 10, pp. 215-224, (2002); Arnett D.K., Borecki I.B., Ludwig E.H., Pankow J.S., Myers R., Evans G., Folsom A.R., Heiss G., Higgins M., Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: The atherosclerosis risk in communities and the NHLBI family heart studies, Atherosclerosis, 138, pp. 111-116, (1998); Ashizawa N., Graf K., Do Y.S., Nunohiro T., Giachelli C.M., Meehan W.P., Tuan T.L., Hsueh W.A., Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction, J Clin Invest, 98, pp. 2218-2227, (1996); Azizi M., Ezan E., Nicolet L., Grognet J.M., Menard J., High plasma level of Nacetyl-seryl-aspartyl-lysyl-proline: A new marker of chronic angiotensin-converting enzyme inhibition, Hypertension, 30, pp. 1015-1019, (1997); Azizi M., Ezan E., Reny J.L., Wdzieczak-Bakala J., Gerineau V., Menard J., Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans, Hypertension, 33, pp. 879-886, (1999); Azizi M., Rousseau A., Ezan E., Guyene T.T., Michelet S., Grognet J.M., Lenfant M., Corvol P., Menard J., Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysylproline, J Clin Invest, 97, pp. 839-844, (1996); Bakhle Y.S., Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung, Nature, 220, pp. 919-921, (1968); Bakhle Y.S., Converting enzyme in vitro measurement and properties, Angiotensin (Handbook of Experimental Pharmacology), pp. 41-80, (1974); Bakhle Y.S., Reynard A.M., Vane J.R., Metabolism of the angiotensins in isolated perfused tissues, Nature, 222, pp. 956-959, (1969); Ball B.A., Gravance C.G., Wessel M.T., Sabeur K., Activity of angiotensinconverting enzyme (ACE) in reproductive tissues of the stallion and effects of angiotensin II on sperm motility, Theriogenology, 59, pp. 901-914, (2003); Barley J., Blackwood A., Miller M., Markandu N.D., Carter N.D., Jeffery S., Cappuccio F.P., Macgregor G.A., Sagnella G.A., Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin-angiotensin system in Caucasian and Afro-Caribbean peoples, J Hum Hypertens, 10, pp. 31-35, (1996); Barreto-Chaves M.L., Mello-Aires M., Effect of luminal angiotensin II and ANP on early and late cortical distal tubule HCO3- reabsorption, Am J Physiol, 271, (1996); Baylis C., Brenner B.M., Modulation by prostaglandin synthesis inhibitors of the action of exogenous angiotensin II on glomerular ultrafiltration in the rat, Circ Res, 43, pp. 889-898, (1978); Baudin B., Alves N., Pilon A., Beneteau-Burnat B., Giboudeau J., Structural and biological roles of glycosylations in pulmonary angiotensin I-converting enzyme, Glycobiology, 7, pp. 565-570, (1997); Becker J.C., Houben R., Schrama D., Voigt H., Ugurel S., Reisfeld R.A., Mouse models for melanoma: A personal perspective, Exp Dermatol, 19, pp. 157-164, (2010); Belcheva I., Ternianov A., Georgiev V., Lateralized learning and memory effects of angiotensin II microinjected into the rat CA1 hippocampal area, Peptides, 21, pp. 407-411, (2000); Beldent V., Michaud A., Bonnefoy C., Chauvet M.T., Corvol P., Cell surface localization of proteolysis of human endothelial angiotensin I-converting enzyme. Effect of the amino-terminal domain in the solubilization process, J Biol Chem, 270, pp. 28962-28969, (1995); Beneteau-Burnat B., Baudin B., Morgant G., Baumann F.C., Giboudeau J., Serum angiotensin-converting enzyme in healthy and sarcoidotic children: Comparison with the reference interval for adults, Clin Chem, 36, pp. 344-346, (1990); Benohr P., Harsch S., Proksch B., Gleiter C.H., Does angiotensin II modulate erythropoietin production in HepG2 cells? Nephron, Exp Nephrol, 98, (2004); Berg T., Sulner J., Lai C.Y., Soffer R.L., Immunohistochemical localization of two angiotensin I-converting isoenzymes in the reproductive tract of the male rabbit, J Histochem Cytochem, 34, pp. 753-760, (1986); Bernstein K.E., Martin B.M., Bernstein E.A., Linton J., Striker L., Striker G., The isolation of angiotensin-converting enzyme cDNA, J Biol Chem, 263, pp. 11021-11024, (1988); Bernstein K.E., Martin B.M., Edwards A.S., Bernstein E.A., Mouse angiotensin-converting enzyme is a protein composed of two homologous domains, J Biol Chem, 264, pp. 11945-11951, (1989); Bernstein K.E., Martin B.M., Striker L., Striker G., Partial protein sequence of mouse and bovine kidney angiotensin converting enzyme, Kidney Int, 33, pp. 652-655, (1988); Bernstein K.E., Shen X.Z., Gonzalez-Villalobos R.A., Billet S., Okwan-Duodu D., Ong F.S., Fuchs S., Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE), Curr Opin Pharmacol, 11, pp. 105-111, (2011); Bernstein K.E., Welsh S.L., Inman J.K., A deeply recessed active site in angiotensin-converting enzyme is indicated from the binding characteristics of biotin-spacer-inhibitor reagents, Biochem Biophys Res Commun, 167, pp. 310-316, (1990); Bersanetti P.A., Andrade M.C., Casarini D.E., Juliano M.A., Nchinda A.T., Sturrock E.D., Juliano L., Carmona A.K., Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates, Biochemistry, 43, pp. 15729-15736, (2004); Binevski P.V., Sizova E.A., Pozdnev V.F., Kost O.A., Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme, FEBS Lett, 550, pp. 84-88, (2003); Bingel A., Strauss E., Uber die blutdrucksteigernde Substanz der Niere, Dtsch Arch Klin Med, 96, pp. 476-492, (1909); Blantz R.C., Konnen K.S., Tucker B.J., Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat, J Clin Invest, 57, pp. 419-434, (1976); Bloem L.J., Manatunga A.K., Pratt J.H., Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin Iconverting enzyme activity, Hypertension, 27, pp. 62-66, (1996); Bonnet D., Lemoine F.M., Pontvert-Delucq S., Baillou C., Najman A., Guigon M., Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors, Blood, 82, pp. 3307-3314, (1993); Braun-Menendez E., Fasciolo J.C., Leloir L.F., Munoz J.M., The substance causing renal hypertension, J Physiol, 98, pp. 283-298, (1940); Braun-Menendez E., Page I.H., Suggested Revision of Nomenclature-Angiotensin, Science, 127, (1958); Brentjens J.R., Matsuo S., Andres G.A., Caldwell P.R., Zamboni L., Gametes contain angiotensin converting enzyme (kininase II), Experientia, 42, pp. 399-402, (1986); Brice E.A., Friedlander W., Bateman E.D., Kirsch R.E., Serum angiotensinconverting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD, Chest, 107, pp. 706-710, (1995); Brooks D.R., Appleford P.J., Murray L., Isaac R.E., An essential role in molting and morphogenesis of Caenorhabditis elegans for ACN-1, a novel member of the angiotensin-converting enzyme family that lacks a metallopeptidase active site, J Biol Chem, 278, pp. 52340-52346, (2003); Brown C.K., Madauss K., Lian W., Beck M.R., Tolbert W.D., Rodgers D.W., Structure of neurolysin reveals a deep channel that limits substrate access, Proc Natl Acad Sci USA, 98, pp. 3127-3132, (2001); Bruneval P., Hinglais N., Alhenc-Gelas F., Tricottet V., Corvol P., Menard J., Camilleri J.P., Bariety J., Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization, Histochemistry, 85, pp. 73-80, (1986); Bull H.G., Thornberry N.A., Cordes E.H., Purification of angiotensinconverting enzyme from rabbit lung and human plasma by affinity chromatography, J Biol Chem, 260, pp. 2963-2972, (1985); Bull H.G., Thornberry N.A., Cordes M.H., Patchett A.A., Cordes E.H., Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]Llysyl-L-proline, J Biol Chem, 260, pp. 2952-2962, (1985); Bumpus F.M., Schwarz H., Page I.H., Synthesis and pharmacology of the octapeptide angiotonin, Science, 125, pp. 886-887, (1957); Bumpus F.M., Schwarz H., Page I.H., Partial separation of an oxytocic principle from preparations of angiotonin, Circ Res, 4, pp. 488-492, (1956); Bunning P., Riordan J.F., Activation of angiotensin converting enzyme by monovalent anions, Biochemistry, 22, pp. 110-116, (1983); Bunning P., Riordan J.F., The functional role of zinc in angiotensin converting enzyme: Implications for the enzyme mechanism, J Inorg Biochem, 24, pp. 183-198, (1985); Bunting M., Bernstein K.E., Greer J.M., Capecchi M.R., Thomas K.R., Targeting genes for self-excision in the germ line, Genes Dev, 13, pp. 1524-1528, (1999); Byers L.D., Wolfenden R., Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A, Biochemistry, 12, pp. 2070-2078, (1973); Caldwell P.R., Seegal B.C., Hsu K.C., Das M., Soffer R.L., Angiotensinconverting enzyme: Vascular endothelial localization, Science, 191, pp. 1050-1051, (1976); Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.P., Arveiler D., Luc G., Bard J.M., Bara L., Ricard S., Et al., Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction, Nature, 359, pp. 641-644, (1992); Campbell D.J., Alexiou T., Xiao H.D., Fuchs S., McKinley M.J., Corvol P., Bernstein K.E., Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice, Hypertension, 43, pp. 854-859, (2004); Casselbrant A., Edebo A., Wennerblom J., Lonroth H., Helander H.F., Vieth M., Lundell L., Fandriks L., Actions by angiotensin II on esophageal contractility in humans, Gastroenterology, 132, pp. 249-260, (2007); Castro-Chaves P., Fontes-Carvalho R., Pintalhao M., Pimentel-Nunes P., Leite-Moreira A.F., Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart, Exp Physiol, 94, pp. 665-674, (2009); Cavasin M.A., Rhaleb N.E., Yang X.P., Carretero O.A., Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP, Hypertension, 43, pp. 1140-1145, (2004); Chao J., Zhang J.J., Lin K.F., Chao L., Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl saltsensitive rats, Hum Gene Ther, 9, pp. 21-31, (1998); Charrier S., Michaud A., Badaoui S., Giroux S., Ezan E., Sainteny F., Corvol P., Vainchenker W., Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells, Blood, 104, pp. 978-985, (2004); Charytan C., Goldfarb-Rumyantzev A., Wang Y.F., Schwenk M.H., Spinowitz B.S., Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients, Am J Nephrol, 18, pp. 498-503, (1998); Chen H.L., Lunsdorf H., Hecht H.J., Tsai H., Porcine pulmonary angiotensin Iconverting enzyme-biochemical characterization and spatial arrangement of the N-and C-domains by three-dimensional electron microscopic reconstruction, Micron, 41, pp. 674-685, (2010); Chew C.G., Weise M.D., Disney A.P., The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients, Nephrol Dial Transplant, 14, pp. 2047-2049, (1999); Chisi J.E., Briscoe C.V., Ezan E., Genet R., Riches A.C., Wdzieczak-Bakala J., Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation, Br J Haematol, 109, pp. 563-570, (2000); Cigola E., Kajstura J., Li B., Meggs L.G., Anversa P., Angiotensin II activates programmed myocyte cell death in vitro, Exp Cell Res, 231, pp. 363-371, (1997); Cingolani H.E., Perez N.G., Aiello E.A., de Hurtado M.C., Intracellular signaling following myocardial stretch: An autocrine/paracrine loop, Regul Pept, 128, pp. 211-220, (2005); Cochran G., Harpending H., The 10,000 Year Explosion: How Civilization Accelerated Human Evolution, (2009); Colbourne J.K., Pfrender M.E., Gilbert D., Thomas W.K., Tucker A., Oakley T.H., Tokishita S., Aerts A., Arnold G.J., Basu M.K., Et al., The ecoresponsive genome of Daphnia pulex, Science, 331, pp. 555-561, (2011); Cole J., Ertoy D., Lin H., Sutliff R.L., Ezan E., Guyene T.T., Capecchi M., Corvol P., Bernstein K.E., Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice, J Clin Invest, 106, pp. 1391-1398, (2000); Cole J.M., Khokhlova N., Sutliff R.L., Adams J.W., Disher K.M., Zhao H., Capecchi M.R., Corvol P., Bernstein K.E., Mice lacking endothelial ACE: Normal blood pressure with elevated angiotensin II, Hypertension, 41, pp. 313-321, (2003); Cole J., Quach D.L., Sundaram K., Corvol P., Capecchi M.R., Bernstein K.E., Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure, Circ Res, 90, pp. 87-92, (2002); Collier J.G., Robinson B.F., Vane J.R., Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme, Lancet, 1, pp. 72-74, (1973); Cornell M.J., Williams T.A., Lamango N.S., Coates D., Corvol P., Soubrier F., Hoheisel J., Lehrach H., Isaac R.E., Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from Drosophila melanogaster, J Biol Chem, 270, pp. 13613-13619, (1995); Corradi H.R., Chitapi I., Sewell B.T., Georgiadis D., Dive V., Sturrock E.D., Acharya K.R., The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380, Biochemistry, 46, pp. 5473-5478, (2007); Corradi H.R., Schwager S.L., Nchinda A.T., Sturrock E.D., Acharya K.R., Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design, J Mol Biol, 357, pp. 964-974, (2006); Corvol P., Eyries M., Soubrier F., Peptidyl-dipeptidase A/Angiotensin Iconverting enzyme, Handbook of Proteolytic Enzymes, pp. 332-349, (2004); Cote F., Do T.H., Laflamme L., Gallo J.M., Gallo-Payet N., Activation of the AT (2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum, J Biol Chem, 274, pp. 31686-31692, (1999); Cotton J., Hayashi M.A., Cuniasse P., Vazeux G., Ianzer D., de Camargo A.C., Dive V., Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides, Biochemistry, 41, pp. 6065-6071, (2002); Coude G., Marois A., Casanova C., Effects of angiotensin II on visual evoked potentials in the superior colliculus of juvenile rats, Neuropeptides, 34, pp. 203-210, (2000); Craiu A., Akopian T., Goldberg A., Rock K.L., Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide, Proc Natl Acad Sci USA, 94, pp. 10850-10855, (1997); Crowley S.D., Gurley S.B., Herrera M.J., Ruiz P., Griffiths R., Kumar A.P., Kim H.S., Smithies O., Le T.H., Coffman T.M., Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney, Proc Natl Acad Sci USA, 103, pp. 17985-17990, (2006); Cumano A., Ferraz J.C., Klaine M., Di Santo J.P., Godin I., Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide longterm multilineage reconstitution, Immunity, 15, pp. 477-485, (2001); Cumin F., Vellaud V., Corvol P., Alhenc-Gelas F., Evidence for a single active site in the human angiotensin I-converting enzyme from inhibitor binding studies with [3H] RU 44 403: Role of chloride, Biochem Biophys Res Commun, 163, pp. 718-725, (1989); Cushman D.W., Cheung H.S., A simple substrate for the assay of dog lung angiotensin converting enzyme, Fed Proc, 28, (1969); Cushman D.W., Cheung H.S., Concentrations of angiotensin-converting enzyme in tissues of the rat, Biochim Biophys Acta, 250, pp. 261-265, (1971); Cushman D.W., Cheung H.S., Sabo E.F., Ondetti M.A., Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids, Biochemistry, 16, pp. 5484-5491, (1977); Cushman D.W., Ondetti M.A., Design of angiotensin converting enzyme inhibitors, Nat Med, 5, pp. 1110-1113, (1999); Dalbeth N., Edwards J., Fairchild S., Callan M., Hall F.C., The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis, Rheumatology (Oxford), 44, pp. 24-31, (2005); Danilov S.M., Faerman A.I., Printseva O., Martynov A.V., Sakharov I., Trakht I.N., Immunohistochemical study of angiotensin-converting enzyme in human tissues using monoclonal antibodies, Histochemistry, 87, pp. 487-490, (1987); Danilov S.M., Gordon K., Nesterovitch A.B., Lunsdorf H., Chen Z., Castellon M., Popova I.A., Kalinin S., Mendonca E., Petukhov P.A., Schwartz D.E., Minshall R.D., Sturrock E.D., An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding, PLoS One, 6, (2011); Das M., Soffer R.L., Pulmonary angiotensin-converting enzyme. Structural and catalytic properties, J Biol Chem, 250, pp. 6762-6768, (1975); Das M., Soffer R.L., Pulmonary angiotensin-converting enzyme antienzyme antibody, Biochemistry, 15, pp. 5088-5094, (1976); Das M., Hartley J.L., Soffers R.L., Serum angiotensin-converting enzyme. Isolation and relationship to the pulmonary enzyme, J Biol Chem, 252, pp. 1316-1319, (1977); Davis T.A., Landauer M.R., Mog S.R., Barshishat-Kupper M., Zins S.R., Amare M.F., Day R.M., Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation, Exp Hematol, 38, pp. 270-281, (2010); de Kloet A.D., Krause E.G., Scott K.A., Foster M.T., Herman J.P., Sakai R.R., Seeley R.J., Woods S.C., Central angiotensin II has catabolic action at white and brown adipose tissue, Am J Physiol Endocrinol Metab, 301, (2011); de los Rios A.D., Labajos M., Manteca A., Morell M., Souviron A., Stimulatory action of angiotensin II on water and electrolyte transport by the proximal colon of the rat, J Endocrinol, 86, pp. 35-43, (1980); Deddish P.A., Jackman H.L., Skidgel R.A., Erdos E.G., Differences in the hydrolysis of enkephalin congeners by the two domains of angiotensin converting enzyme, Biochem Pharmacol, 53, pp. 1459-1463, (1997); Deddish P.A., Marcic B., Jackman H.L., Wang H.Z., Skidgel R.A., Erdos E.G., Ndomain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: Angiotensin-(1-7) and keto-ACE, Hypertension, 31, pp. 912-917, (1998); Defendini R., Zimmerman E.A., Weare J.A., Alhenc-Gelas F., Edros E.G., Hydrolysis of enkephalins by human converting enzyme and localization of the enzyme in neuronal components of the brain, Adv Biochem Psychopharmacol, 33, pp. 271-280, (1982); Defendini R., Zimmerman E.A., Weare J.A., Alhenc-Gelas F., Erdos E.G., Angiotensin-converting enzyme in epithelial and neuroepithelial cells, Neuroendocrinology, 37, pp. 32-40, (1983); Del Vecchio P.J., Smith J.R., Expression of angiotensin-converting enzyme activity in cultured pulmonary artery endothelial cells, J Cell Physiol, 108, pp. 337-345, (1981); Dempsey P.J., McCallum Z.T., Kent K.M., Cooper T., Direct myocardial effects of angiotensin II, Am J Physiol, 220, pp. 477-481, (1971); Di Zhang A., Nguyen D.C.A., Soukaseum C., Escoubet B., Cherfa A., Messaoudi S., Delcayre C., Samuel J.L., Jaisser F., Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling, Hypertension, 52, pp. 1060-1067, (2008); Diaz-Torga G., Gonzalez I.A., Achaval-Zaia R., Libertun C., Becu-Villalobos D., Angiotensin II-induced Ca2+ mobilization and prolactin release in normal and hyperplastic pituitary cells, Am J Physiol, 274, (1998); Dicpinigaitis P.V., Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines, Chest 129, 1 SUPPL., (2006); Dive V., Georgiadis D., Matziari M., Makaritis A., Beau F., Cuniasse P., Yiotakis A., Phosphinic peptides as zinc metalloproteinase inhibitors, Cell Mol Life Sci, 61, pp. 2010-2019, (2004); Domenighetti A.A., Wang Q., Egger M., Richards S.M., Pedrazzini T., Delbridge L.M., Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to agedependent cardiac dysfunction and failure, Hypertension, 46, pp. 426-432, (2005); Dorer F.E., Kahn J.R., Lentz K.E., Levine M., Skeggs L.T., Purification and properties of angiotensin-converting enzyme from hog lung, Circ Res, 31, pp. 356-366, (1972); Dostal D.E., Baker K.M., Angiotensin and endothelin: Messengers that couple ventricular stretch to the Na+/H+ exchanger and cardiac hypertrophy, Circ Res, 83, pp. 870-873, (1998); Doughan A.K., Harrison D.G., Dikalov S.I., Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: Linking mitochondrial oxidative damage and vascular endothelial dysfunction, Circ Res, 102, pp. 488-496, (2008); Dubreuil P., Fulcrand P., Rodriguez M., Fulcrand H., Laur J., Martinez J., Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide, Biochem J, 262, pp. 125-130, (1989); Duncan A.M., Kladis A., Jennings G.L., Dart A.M., Esler M., Campbell D.J., Kinins in humans, Am J Physiol Regul Integr Comp Physiol, 278, (2000); Dux S., Aron N., Boner G., Carmel A., Yaron A., Rosenfeld J.B., Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension, Isr J Med Sci, 20, pp. 1138-1142, (1984); Eckman E.A., Adams S.K., Troendle F.J., Stodola B.A., Kahn M.A., Fauq A.H., Xiao H.D., Bernstein K.E., Eckman C.B., Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme, J Biol Chem, 281, pp. 30471-30478, (2006); Ehlers M.R., Riordan J.F., Angiotensin-converting enzyme: Zincand inhibitor-binding stoichiometries of the somatic and testis isozymes, Biochemistry, 30, pp. 7118-7126, (1991); Ehlers M.R., Chen Y.N., Riordan J.F., Spontaneous solubilization of membrane-bound human testis angiotensin-converting enzyme expressed in Chinese hamster ovary cells, Proc Natl Acad Sci USA, 88, pp. 1009-1013, (1991); Ehlers M.R., Chen Y.N., Riordan J.F., The unique N-terminal sequence of testis angiotensin-converting enzyme is heavily O-glycosylated and unessential for activity or stability, Biochem Biophys Res Commun, 183, pp. 199-205, (1992); Ehlers M.R., Fox E.A., Strydom D.J., Riordan J.F., Molecular cloning of human testicular angiotensin-converting enzyme: The testis isozyme is identical to the Cterminal half of endothelial angiotensin-converting enzyme, Proc Natl Acad Sci USA, 86, pp. 7741-7745, (1989); Ehlers M.R., Schwager S.L., Scholle R.R., Manji G.A., Brandt W.F., Riordan J.F., Proteolytic release of membrane-bound angiotensin-converting enzyme: Role of the juxtamembrane stalk sequence, Biochemistry, 35, pp. 9549-9559, (1996); Eisenlohr L.C., Bacik I., Bennink J.R., Bernstein K., Yewdell J.W., Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes, Cell, 71, pp. 963-972, (1992); Ekbote U., Coates D., Isaac R.E., A mosquito (Anopheles stephensi) angiotensin I-converting enzyme (ACE) is induced by a blood meal and accumulates in the developing ovary, FEBS Lett, 455, pp. 219-222, (1999); Ekbote U., Looker M., Isaac R.E., ACE inhibitors reduce fecundity in the mosquito, Anopheles stephensi, Comp Biochem Physiol B Biochem Mol Biol, 134, pp. 593-598, (2003); El-Dorry H.A., Bull H.G., Iwata K., Thornberry N.A., Cordes E.H., Soffer R.L., Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase, J Biol Chem, 257, pp. 14128-14133, (1982); El-Dorry H.A., Macgregor J.S., Soffer R.L., Dipeptidyl carboxypeptidase from seminal fluid resembles the pulmonary rather than the testicular isoenzyme, Biochem Biophys Res Commun, 115, pp. 1096-1100, (1983); El-Dorry H.A., Pickett C.B., Macgregor J.S., Soffer R.L., Tissue-specific expression of mRNAs for dipeptidyl carboxypeptidase isoenzymes, Proc Natl Acad Sci USA, 79, pp. 4295-4297, (1982); Elliott D.F., Peart W.S., Amino-acid sequence in a hypertensin, Nature, 177, pp. 527-528, (1956); English W.R., Corvol P., Murphy G., LPS activates ADAM9 dependent shedding of ACE from endothelial cells, Biochem Biophys Res Commun, 421, pp. 70-75, (2012); Epstein A.N., Fitzsimons J.T., Rolls B.J., Drinking induced by injection of angiotensin into the rain of the rat, J Physiol, 210, pp. 457-474, (1970); Erdos E.G., Angiotensin I converting enzyme, Circ Res, 36, pp. 247-255, (1975); Erdos E.G., The ACE and I: How ACE inhibitors came to be, FASEB J, 20, pp. 1034-1038, (2006); Erdoes E.G., Wohler J.R., Inhibition in vivo of the enzymatic inactivation of bradykinin and kallidin, Biochem Pharmacol, 12, pp. 1193-1199, (1963); Erdos E.G., Yang H.Y.T., An enzyme in microsomal fraction of kidney that inactivates bradykinin, Life Sci, 6, pp. 569-574, (1967); Ertoy D., Bernstein K.E., Targeted interruption of the renin-angiotensin system, Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery, pp. 205-223, (2000); Esther Jr. C.R., Howard T.E., Marino E.M., Goddard J.M., Capecchi M.R., Bernstein K.E., Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility, Lab Invest, 74, pp. 953-965, (1996); Esther Jr. C.R., Semeniuk D., Marino E.M., Zhou Y., Overbeek P.A., Bernstein K.E., Expression of testis angiotensin-converting enzyme is mediated by a cyclic AMP responsive element, Lab Invest, 77, pp. 483-488, (1997); Esther Jr. C.R., Thomas K.E., Bernstein K.E., Chicken lacks the testis specific isozyme of angiotensin converting enzyme found in mammals, Biochem Biophys Res Commun, 205, pp. 1916-1921, (1994); Eyries M., Michaud A., Deinum J., Agrapart M., Chomilier J., Kramers C., Soubrier F., Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region, J Biol Chem, 276, pp. 5525-5532, (2001); Farmer J.A., Renin angiotensin system and ASCVD, Curr Opin Cardiol, 15, pp. 141-150, (2000); Ferreira S.H., A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca, Br J Pharmacol Chemother, 24, pp. 163-169, (1965); Ferreira S.H., Rocha E., Silva M., Potentiation of bradykinin by dimercaptopropanol (bal) and other inhibitors of its destroying enzyme in plasma, Biochem Pharmacol, 11, pp. 1123-1128, (1962); Ferreira S.H., Vane J.R., The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat, Br Pharmacol Chemother, 30, pp. 417-424, (1967); Ferreira S.H., Bartelt D.C., Greene L.J., Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom, Biochemistry, 9, pp. 2583-2593, (1970); Fishlock D.J., Gunn A., The action of angiotensin on the human colon in vitro, Br J Pharmacol, 39, pp. 34-39, (1970); Fleming I., Signaling by the angiotensin-converting enzyme, Circ Res, 98, pp. 887-896, (2006); Forslund T., Fyhrquist F., Gronhagen-Riska C., Tikkanen I., Induction of angiotensin-converting enzyme with the ACE inhibitory compound MK-421 in rat lung, Eur J Pharmacol, 80, pp. 121-125, (1982); Foy C.A., McCormack L.J., Knowler W.C., Barrett J.H., Catto A., Grant P.J., The angiotensin-I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians, J Med Genet, 33, pp. 336-337, (1996); Friberg P., Sundelin B., Bohman S.O., Bobik A., Nilsson H., Wickman A., Gustafsson H., Petersen J., Adams M.A., Renin-angiotensin system in neonatal rats: Induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism, Kidney Int, 45, pp. 485-492, (1994); Friedl W., Krempler F., Paulweber B., Pichler M., Sandhofer F., A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population, Atherosclerosis, 112, pp. 137-143, (1995); Friedland J., Setton C., Silverstein E., Induction of angiotensin converting enzyme in human monocytes in culture, Biochem Biophys Res Commun, 83, pp. 843-849, (1978); Fuchs S., Frenzel K., Hubert C., Lyng R., Muller L., Michaud A., Xiao H.D., Adams J.W., Capecchi M.R., Corvol P., Et al., Male fertility is dependent on dipeptidase activity of testis ACE, Nat Med, 11, pp. 1140-1142, (2005); Fuchs S., Xiao H.D., Cole J.M., Adams J.W., Frenzel K., Michaud A., Zhao H., Keshelava G., Capecchi M.R., Corvol P., Et al., Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice, J Biol Chem, 279, pp. 15946-15953, (2004); Fuchs S., Xiao H.D., Hubert C., Michaud A., Campbell D.J., Adams J.W., Capecchi M.R., Corvol P., Bernstein K.E., Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo, Hypertension, 51, pp. 267-274, (2008)","K. E. Bernstein; Cedars-Sinai Medical Center, Los Angeles, CA 90048, 8700 Beverly Boulevard, Davis 2021, United States; email: kbernst@cshs.org","","","","","","","","15210081","","PAREA","23257181","English","Pharmacol. Rev.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84871542698"
"Rodriguez J.A.; Gonzalez J.; Arboleda-Bustos C.E.; Mendoza N.; Martinez C.; Pinzon A.","Rodriguez, J.A. (58706678300); Gonzalez, J. (24435661900); Arboleda-Bustos, C.E. (57188623481); Mendoza, N. (57962510900); Martinez, C. (59090612000); Pinzon, A. (8426880400)","58706678300; 24435661900; 57188623481; 57962510900; 59090612000; 8426880400","Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation","2022","Chemico-Biological Interactions","368","","110244","","","","4","10.1016/j.cbi.2022.110244","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141745126&doi=10.1016%2fj.cbi.2022.110244&partnerID=40&md5=8289573dee6c58c086c71785ea5157ac","Bioinformatics and Systems Biology Laboratory (GIBBS). Instituto de Genética, Universidad Nacional de Colombia, Colombia; Neurosciences Group. Instituto de Genética, Universidad Nacional de Colombia, Colombia; Departamento de Nutrición y Bioquímica. Pontificia Universidad Javeriana Bogotá, Colombia","Rodriguez J.A., Bioinformatics and Systems Biology Laboratory (GIBBS). Instituto de Genética, Universidad Nacional de Colombia, Colombia; Gonzalez J., Departamento de Nutrición y Bioquímica. Pontificia Universidad Javeriana Bogotá, Colombia; Arboleda-Bustos C.E., Neurosciences Group. Instituto de Genética, Universidad Nacional de Colombia, Colombia; Mendoza N., Bioinformatics and Systems Biology Laboratory (GIBBS). Instituto de Genética, Universidad Nacional de Colombia, Colombia; Martinez C., Neurosciences Group. Instituto de Genética, Universidad Nacional de Colombia, Colombia; Pinzon A., Bioinformatics and Systems Biology Laboratory (GIBBS). Instituto de Genética, Universidad Nacional de Colombia, Colombia","Interactions between the human angiotensin-converting enzyme 2 (ACE2) and the RBD region of the SARS-CoV-2 Spike protein are critical for virus entry into the host cell. The objective of this work was to identify some of the most relevant SARS-CoV-2 Spike variants that emerged during the pandemic and evaluate their binding affinity with human variants of ACE2 since some ACE2 variants can enhance or reduce the affinity of the interaction between the ACE2 and S proteins. However, no information has been sought to extrapolate to different variants of SARS-CoV-2. Therefore, to understand the impact on the affinity of the interaction between ACE2 protein variants and SARS-CoV-2 protein S variants, molecular docking was used in this study to predict the effects of five mutations of ACE2 when they interact with Alpha, Beta, Delta, Omicron variants and a hypothetical variant, which present mutations in the RBD region of the SARS-CoV-2 Spike protein. Our results suggest that these variants could alter the interaction of the Spike and the human ACE2 protein, losing or creating new inter-protein contacts, enhancing viral fitness by improving binding affinity, and leading to an increase in infectivity, virulence, and transmission. This investigation highlighted that the S19P mutation of ACE2 decreases the binding affinity between the ACE2 and Spike proteins in the presence of the Beta variant and the wild-type variant of SARS-CoV-2 isolated in Wuhan-2019. The R115Q mutation of ACE2 lowers the binding affinity of these two proteins in the presence of the Beta and Delta variants. Similarly, the K26R mutation lowers the affinity of the interaction between the ACE2 and Spike proteins in the presence of the Alpha variant. This decrease in binding affinity is probably due to the lack of interaction between some of the key residues of the interaction complex between the ACE2 protein and the RBD region of the SARS-CoV-2 Spike protein. Therefore, ACE2 mutations appear in the presence of these variants, they could suggest an intrinsic resistance to COVID-19 disease. On the other hand, our results suggested that the K26R, M332L, and K341R mutations of ACE2 expressively showed the affinity between the ACE2 and Spike proteins in the Alpha, Beta, and Delta variants. Consequently, these ACE2 mutations in the presence of the Alpha, Beta, and delta variants of SARS-CoV-2 could be more infectious and virulent in human cells compared to the SARS-CoV-2 isolated in Wuhan-2019 and it could have a negative prognosis of the disease. Finally, the Omicron variant in interaction with ACE2 WT, S19P, R115Q, M332L, and K341R mutations of ACE2 showed a significant decrease in binding affinity. This could be consistent that the Omicron variant causes less severe symptoms than previous variants. On the other hand, our results suggested Omicron in the complex with K26R, the binding affinity is increased between ACE2/RBD, which could indicate a negative prognosis of the disease in people with these allelic conditions. © 2022 The Authors","ACE2-SARS-CoV-2; Alpha; Beta; Binding affinity; Delta; Omicron","Angiotensin-Converting Enzyme 2; COVID-19; Humans; Molecular Docking Simulation; Mutation; Peptidyl-Dipeptidase A; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Viral Envelope Proteins; Virulence; angiotensin converting enzyme 2; protein S; protein variant; coronavirus spike glycoprotein; dipeptidyl carboxypeptidase; protein binding; spike protein, SARS-CoV-2; virus envelope protein; article; Article; base pairing; binding affinity; calf (bovine); computer model; conformational transition; coronavirus disease 2019; crystal structure; disease severity; enzyme active site; Escherichia coli; genetic polymorphism; genetic variability; high throughput screening; human; human cell; hydrogen bond; hypertension; immune response; missense mutation; molecular docking; molecular dynamics; mutation; pandemic; protein interaction; protein secondary structure; protein structure; SARS coronavirus; SARS-CoV-2 Beta; SARS-CoV-2 Delta; SARS-CoV-2 Omicron; scientific literature; Severe acute respiratory syndrome coronavirus 2; single nucleotide polymorphism; static electricity; vaccination; virus replication; virus transmission; wild type; chemistry; genetics; metabolism; mutation; virulence","","dipeptidyl carboxypeptidase, 9015-82-1; Angiotensin-Converting Enzyme 2, ; Peptidyl-Dipeptidase A, ; Spike Glycoprotein, Coronavirus, ; spike protein, SARS-CoV-2, ; Viral Envelope Proteins, ","","","","","Fratev V.O.P., The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human-derived antibody: a Free energy of perturbation study, bioRxiv : The Preprint Server for Biology, pp. 4-5, (2020); Tanaka S., Nelson G., Olson C.A., Buzko O., Higashide W., Shin A., Gonzalez M., Taft J., Patel R., Buta S., Richardson A., Bogunovic D., Spilman P., Niazi K., Rabizadeh S., Soon-Shiong P., An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants, Sci. Rep., 11, 1, pp. 1-12, (2021); Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C.C., Muecksch F., Rutkowska M., Hoffmann H.H., Michailidis E., Gaebler C., Agudelo M., Cho A., Wang Z., Gazumyan A., Cipolla M., Luchsinger L., Hillyer C.D., Caskey M., Bieniasz P.D., Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants, Elife, 9, (2020); Deng X., Et al., Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant, Ann. Oncol., pp. 19-21, (2020); Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J.A., Oliveira T.Y., Yang Z., Abernathy M.E., Huey-Tubman K.E., Hurley A., Turroja M., West K.A., Gordon K., Millard K.G., Nussenzweig M.C., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants, Nature, 592, 7855, pp. 616-622, (2021); SARS-CoV-2 variant classifications and definitions. Centers for disease control and prevention; Riemersma K.K., Grogan B.E., Kita-yarbro A., Halfmann P., Kocharian A., Florek K.R., Westergaard R., Bateman A., Jeppson G.E., Kawaoka Y., Connor D.H.O., Friedrich T.C., Grande K.M., Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant Is Prevalent - Wisconsin, (2021); Salleh M.Z., Derrick J.P., Deris Z.Z., Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion, Int. J. Mol. Sci., 22, 14, (2021); Supasa P., Zhou D., Dejnirattisai W., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Nutalai R., Tuekprakhon A., Wang B., Paesen G.C., Slon-Campos J., Lopez-Camacho C., Hallis B., Coombes N., Bewley K.R., Charlton S., Walter T.S., Screaton G.R., Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera, Cell, 184, 8, pp. 2201-2211, (2021); Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V., Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K., von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J., Engelbrecht S., van Zyl G., de Oliveira T., Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa, medRxiv, 2, (2020); Kemp S.A., Meng B., Ferriera I.A.T.M., Datir R., Harvey W.T., Collier D.A., Lytras S., Papa G., Carabelli A., Kenyon J., Lever A., James L.C., Robertson D., Gupta R.K., Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70, SSRN Electron. J., (2021); Lauring A.S., Malani P.N., Variants of SARS-CoV-2, JAMA, (2021); Starr T.N., Greaney A.J., Hilton S.K., Ellis D., Crawford K.H.D., Dingens A.S., Navarro M.J., Bowen J.E., Tortorici M.A., Walls A.C., King N.P., Veesler D., Bloom J.D., Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding, Cell, 182, 5, pp. 1295-1310, (2020); Yi C., Sun X., Ye J., Ding L., Liu M., Yang Z., Lu X., Zhang Y., Ma L., Gu W., Qu A., Xu J., Shi Z., Ling Z., Sun B., Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies, Cell. Mol. Immunol., 17, 6, pp. 621-630, (2020); Zahradnik J., Marciano S., Shemesh M., Zoler E., Harari D., Chiaravalli J., Meyer B., Rudich Y., Li C., Marton I., Dym O., Elad N., Lewis M.G., Andersen H., Gagne M., Seder R.A., Douek D.C., Schreiber G., SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution, Nature Microbiology, 6, 9, pp. 1188-1198, (2021); Davies N.G., Jarvis C.I., CMMID COVID-19 Working Group. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7, Nature, 593, pp. 270-274, (2021); Sheikh A., Jim McMenamin, Taylor B., Robertson C., SARS-CoV-2 delta VOC in scotland: demographics, risk of hospital admission, and vaccine effectiveness, Lancet, 397, pp. 2461-2462, (2021); Bernal L., Jamie, Andrews N., Gower C., Gallagher E., Simmons R., Simon T., Julia Stowe, Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant, N. Engl. J. Med., 385, 7, pp. 585-594, (2021); Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W., Li Q., Wang P., An R., Wang J., Wang Y., Niu X., Yang S., Liang H., Sun H., Li T., Yu Y., Cui Q., Liu S., Yang X., Du S., Zhang Z., Hao X., Shao F., Jin R., Wang X., Xiao J., Wang Y., Xie X.S., Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, Nature, 602, 7898, pp. 657-663, (2022); Ren S.Y., Wang W.B., Gao R.D., Zhou A.M., Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance, World J. Clin. Cases, (2022); Guang W.J., Risikofaktor Komorbiditäten bei COVID-19- Erkrankung, Pneumologie, 74, 10, (2020); Yang J., Zheng Y., Gou X., Pu K., Chen Z., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int. J. Infect. Dis., 94, March, pp. 91-95, (2020); Debnath M., Banerjee M., Berk M., Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes, FASEB (Fed. Am. Soc. Exp. Biol.) J., 34, 7, pp. 8787-8795, (2020); Renhong Y., Yuanyuan Z., Yaning L., Lu X., Yingying G., Qiang Z., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 6485, pp. 1444-1448, (2020); Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Muller M.A., Drosten C., Pohlmann S., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 2, pp. 271-280, (2020); Taka E., Yilmaz S.Z., Golcuk M., Kilinc C., Aktas U., Yildiz A., Gur M., Critical interactions between the SARS-CoV-2 spike glycoprotein and the human ACE2 receptor, J. Phys. Chem. B, 125, Issue 21, pp. 5537-5548, (2021); Benetti E., Tita R., Spiga O., Ciolfi A., Birolo G., Bruselles A., Doddato G., Giliberti A., Marconi C., Musacchia F., Pippucci T., Torella A., Trezza A., Valentino F., Baldassarri M., Brusco A., Asselta R., Bruttini M., Furini S., Pinto A.M., ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population, Eur. J. Hum. Genet., 28, 11, pp. 1602-1614, (2020); Calcagnile M., Forgez P., Iannelli A., Bucci C., Alifano M., Alifano P., Molecular Docking Simulation Reveals ACE2 Polymorphisms that May Increase the Affinity of ACE2 with the SARS-CoV-2 Spike Protein, (2020); Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X., Wen F., Huang X., Ning G., Wang W., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discovery, 6, 1, pp. 4-7, (2020); Hussain M., Jabeen N., Raza F., Shabbir S., Baig A.A., Amanullah A., Aziz B., Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein, J. Med. Virol., 92, 9, pp. 1580-1586, (2020); Elbe S., Buckland-merrett G., Data, Disease, and Diplomacy : GISAID's Innovative Contribution to Global Health, pp. 33-46, (2017); Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., Wang X., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature, 581, 7807, pp. 215-220, (2020); Jawad B., Adhikari P., Podgornik R., Ching W., Key Interacting Residues between RBD of SARS-CoV - 2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation, (2021); Low-Gan J., Huang R., Kelley A., Jenkins G.W., McGregor D., Smider V.V., Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain, Biochem. J., 478, 19, pp. 3671-3684, (2021); Crackower M.A., Sarao R., Oliveira-dos-Santos A.J., Da Costa J., Zhang L., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, 417, 6891, pp. 822-828, (2002); Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alfoldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P., Gauthier L.D., Brand H., Solomonson M., Watts N.A., Rhodes D., Singer-Berk M., England E.M., Seaby E.G., Kosmicki J.A., MacArthur D.G., The mutational constraint spectrum quantified from variation in 141,456 humans, Nature, 581, 7809, pp. 434-443, (2020); Chen C.W., Lin J., Chu Y.W., iStable: off-the-shelf predictor integration for predicting protein stability changes, BMC Bioinf., 14, (2013); Parthiban V., Gromiha M.M., Schomburg D., CUPSAT: prediction of protein stability upon point mutations, Nucleic Acids Res., 34, pp. 239-242, (2006); Krieger E., Koraimann G., Vriend G., Increasing the precision of comparative models with YASARA NOVA - a self-parameterizing force field, Proteins Struct. Funct. Genet., 47, 3, pp. 393-402, (2002); Schrodinger L., The PyMOL Molecular Graphics System, (2015); Yan Y., Tao H., He J., Huang S.Y., The HDOCK server for integrated protein–protein docking, Nat. Protoc., 15, 5, pp. 1829-1852, (2020); Studer G., Rempfer C., Waterhouse A.M., Gumienny R., Haas J., Schwede T., QMEANDisCo—distance constraints applied on model quality estimation, Bioinformatics, 36, 6, pp. 1765-1771, (2020); Xue L.C., Rodrigues J.P., Kastritis P.L., Bonvin A.M., Vangone A., PRODIGY: a web server for predicting the binding affinity of protein-protein complexes, Bioinformatics, 32, 23, pp. 3676-3678, (2016); Vangone A., Bonvin A.M.J.J., Contacts-based prediction of binding affinity in protein–protein complexes, Elife, 4, JULY2015, pp. 1-15, (2015); Masso M., Vaisman I.I., Accurate prediction of stability changes in protein mutants by combining machine learning with structure based computational mutagenesis, Bioinformatics, 24, 18, pp. 2002-2009, (2008); Li F., Receptor Recognition Mechanisms of Coronaviruses : a Decade of, 89, pp. 1954-1964, (2015); Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.K., Huang I.C., Xu K., Vasilieva N., Murakami A., He Y., Marasco W.A., Guan Y., Choe H., Farzan M., Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2, EMBO J., 24, 8, pp. 1634-1643, (2005); Chellasamy G., Arumugasamy S.K., Govindaraju S., Evolutionary and Structural Analysis Elucidates Mutations on SARS-CoV2 Spike Protein with Altered Human ACE2 Binding Affinity, (2020); Shah M., Ahmad B., Choi S., Woo H.G., Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization, Comput. Struct. Biotechnol. J., 18, pp. 3402-3414, (2020); Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 6483, pp. 1260-1263, (2020); Yesudhas D., Srivastava A., Gromiha M.M., COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics, Infection, 49, 2, pp. 199-213, (2021); Wu L., Zhou L., Mo M., Liu T., Wu C., Gong C., Lu K., Gong L., Zhu W., Xu Z., SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2, Signal Transduct. Targeted Ther., (2022); Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y., Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S., Guo Y., Zhao G., Wang X., Zhou Y., Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy, Science, 369, 6511, pp. 1603-1607, (2020); Dejnirattisai W., Zhou D., Supasa P., Ren J., Stuart D.I., Screaton G.R., Antibody Evasion by the P. 1 Strain of SARS-CoV-2, pp. 2939-2954, (2021); Liu H., Wei P., Zhang Q., Aviszus K., Linderberger J., Yang J., Liu J., Chen Z., Waheed H., Reynoso L., Downey G.P., Frankel S.K., Kappler J., Marrack P., Z G., The Lambda Variant of SARS-CoV-2 Has a Better Chance than the Delta Variant to Escape Vaccines, pp. 1-26, (2021); Hajj-Hassan H., Hamze K., Abdel Sater F., Kizilbash N., Khachfe H.M., Probing the increased virulence of severe acute respiratory syndrome coronavirus 2 B.1.617 (Indian variant) from predicted spike protein structure, Cureus, 617, 8, pp. 1-8, (2021); Li Q., Wu J., Jianhui Nie, Li X., Weijin Huang Y.W., The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity, (2020); Motozono C., Toyoda M., Tan T.S., Hamana H., Goto Y., Aritsu Y., Miyashita Y., Oshiumi H., Nakamura K., Okada S., Udaka K., Kitamatsu M., Kishi H., Ueno T., The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition, Nat. Commun., 13, 1, (2022); Liu Z., VanBlargan L.A., Bloyet L.M., Rothlauf P.W., Chen R.E., Stumpf S., Zhao H., Errico J.M., Theel E.S., Liebeskind M.J., Alford B., Buchser W.J., Ellebedy A.H., Fremont D.H., Diamond M.S., Whelan S.P.J., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization, Cell Host Microbe, 29, 3, pp. 477-488, (2021); Khan A., Randhawa A.W., Balouch A.R., Mukhtar N., Sayaf A.M., Suleman M., Khan T., Ali S., Ali S.S., Wang Y., Mohammad A., Wei D.Q., Blocking key mutated hotspot residues in the RBD of the omicron variant (B.1.1.529) with medicinal compounds to disrupt the RBD-hACE2 complex using molecular screening and simulation approaches, RSC Adv., 12, 12, pp. 7318-7327, (2022); Saifi S., Ravi V., Sharma S., Swaminathan A., Chauhan N.S., Pandey R., SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: are they modulating drug efficacy by altered binding strength?, Genomics, 114, 5, (2022); He X., Hong W., Pan X., Lu G., Wei X., SARS-CoV-2 Omicron variant: characteristics and prevention, MedComm, 2, 4, pp. 838-845, (2020); Chan K.K., Dorosky D., Sharma P., Abbasi S.A., Dye J.M., Kranz D.M., Herbert A.S., Procko E., Engineering Human ACE2 to optimize binding to the spike protein of SARS coronavirus 2, Science, 369, 6508, pp. 1261-1265, (2020); Suryamohan K., Diwanji D., Stawiski E.W., Gupta R., Miersch S., Liu J., Chen C., Jiang Y.P., Fellouse F.A., Sathirapongsasuti J.F., Albers P.K., Deepak T., Saberianfar R., Ratan A., Washburn G., Mis M., Santhosh D., Somasekar S., Hiranjith G.H., Seshagiri S., Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2, Communications Biology, 4, 1, (2021); Stawiski E.W., Diwanji D., Suryamohan K., Gupta R., Fellouse F.A., Sathirapongsasuti J.F., Liu J., Jiang Y.P., Ratan A., Mis M., Santhosh D., Somasekar S., Mohan S., Phalke S., Kuriakose B., Antony A., Junutula J.R., Schuster S.C., Jura N., Seshagiri S., Human ACE2 Receptor Polymorphisms Predict SARS-CoV-2 Susceptibility, (2020); Al-Mulla F., Mohammad A., Al Madhoun A., Haddad D., Ali H., Eaaswarkhanth M., John S.E., Nizam R., Channanath A., Abu-Farha M., Ahmad R., Abubaker J., Thanaraj T.A., ACE2 and FURIN variants are potential predictors of SARS-CoV-2 outcome: a time to implement precision medicine against COVID-19, Heliyon, 7, 2, (2021); Abd El-Aziz T.M., Al-Sabi A., Stockand J.D., Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19, Signal Transduct. Targeted Ther., 5, 1, pp. 3-4, (2020)","J.A. Rodriguez; Bioinformatics and Systems Biology Laboratory (GIBBS). Instituto de Genética, Universidad Nacional de Colombia, Colombia; email: jearodriguezos@unal.edu.co","","Elsevier Ireland Ltd","","","","","","00092797","","CBINA","36336003","English","Chem.-Biol. Interact.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85141745126"
"Anthony E.G.; Richard E.; Lipkowitz M.S.; Bhatnagar V.","Anthony, Ericha G. (56008713100); Richard, Erin (13005685400); Lipkowitz, Michael S. (7003636843); Bhatnagar, Vibha (57203082784)","56008713100; 13005685400; 7003636843; 57203082784","Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension","2015","Pharmacogenetics and Genomics","25","9","","444","449","5","10","10.1097/FPC.0000000000000154","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939501378&doi=10.1097%2fFPC.0000000000000154&partnerID=40&md5=ac9b65f4bcbbfb17eb0633f03c801d84","Graduate School of Public Health, San Diego State University, United States; Department of Family Medicine and Public Health, University of California San Diego, MC 0725, 9500 Gilman Drive, San Diego, 92093, CA, United States; Department of Veterans Affairs, Health Services Research and Development, San Diego, CA, United States; Department of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC, United States","Anthony E.G., Graduate School of Public Health, San Diego State University, United States, Department of Family Medicine and Public Health, University of California San Diego, MC 0725, 9500 Gilman Drive, San Diego, 92093, CA, United States, Department of Veterans Affairs, Health Services Research and Development, San Diego, CA, United States; Richard E., Department of Family Medicine and Public Health, University of California San Diego, MC 0725, 9500 Gilman Drive, San Diego, 92093, CA, United States, Department of Veterans Affairs, Health Services Research and Development, San Diego, CA, United States; Lipkowitz M.S., Department of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC, United States; Bhatnagar V., Department of Family Medicine and Public Health, University of California San Diego, MC 0725, 9500 Gilman Drive, San Diego, 92093, CA, United States, Department of Veterans Affairs, Health Services Research and Development, San Diego, CA, United States","Aim/objectives/background Hypertension is a risk factor for cardiovascular and kidney disease and is most prevalent in African-American adults. The renin-angiotensin-aldosterone system is integral in blood pressure regulation; angiotensinconverting enzyme inhibitors such as ramipril are first-line treatment options. As decreases in angiotensin result in catecholamine release, β-adrenergic receptor (ADRB) polymorphisms may influence blood pressure response to ramipril. Methods Associations between ADRB polymorphisms and blood pressure response to ramipril were analyzed in the African American Study of Kidney Disease and Hypertension, a randomized clinical trial. A total of 336 participants were included in this analysis. Six polymorphisms were analyzed here: (a) ADRB1 rs1801252 (Ser49Gly) and rs1801253 (Gly389Arg); and (b) ADRB2 rs2053044, rs1042711, rs1042713 (Arg16Gly), and rs1042714 (Gln27Glu). Time to reach a mean arterial pressure (MAP) of 107 mmHg within the first 60 days after randomization was studied using Kaplan-Meier and Cox proportional hazards modeling for univariate and adjusted analyses. Results Genotypes at rs2053044, upstream from the ADRB2 5¡ä untranslated region, were associated with time to reach target MAP among those randomized to the usual treatment group. Participants with the GG genotype achieved target MAP on average 12.2 days (38.1%) later than in comparison with those with the A allele (P=0.01). After adjusting for covariates, those with the AA/AG genotype had 2.09 greater odds of reaching MAP of 107 mmHg or less within 60 days of treatment in comparison with those with a GG genotype (hazard ratio=2.09, 95% confidence interval=1.21-3.60). Conclusion Results suggest that ADRB2 rs2053044 genotypes may be a determinant of blood pressure response to ramipril. Additional studies are needed to clarify the effect of rs2053044 and other 5 untranslated region polymorphisms on gene expression and blood pressure response to angiotensin-converting enzyme inhibitors. © 2015 Wolters Kluwer Health, Inc. All rights reserved.","ADRB2; adrenergic-â-receptors; African American Study of Kidney Disease and Hypertension; angiotensin-converting enzyme inhibitor; blood pressure; hypertension; rs2053044","5' Untranslated Regions; African Americans; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Female; Humans; Hypertension; Male; Metoprolol; Ramipril; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; ramipril; 5' untranslated region; ADRB1 protein, human; ADRB2 protein, human; amlodipine; beta 1 adrenergic receptor; beta 2 adrenergic receptor; dipeptidyl carboxypeptidase inhibitor; metoprolol; ramipril; 5' untranslated region; ADRB1 gene; ADRB2 gene; African American; Article; blood pressure; blood pressure regulation; female; gene; gene frequency; genotype; human; hypertension; kidney disease; major clinical study; male; mean arterial pressure; priority journal; randomized controlled trial (topic); single nucleotide polymorphism; controlled study; drug effects; ethnology; genetics; hypertension; randomized controlled trial","","ramipril, 87333-19-5; amlodipine, 88150-42-9, 103129-82-4, 736178-83-9; metoprolol, 37350-58-6; 5' Untranslated Regions, ; ADRB1 protein, human, ; ADRB2 protein, human, ; Amlodipine, ; Angiotensin-Converting Enzyme Inhibitors, ; Metoprolol, ; Ramipril, ; Receptors, Adrenergic, beta-1, ; Receptors, Adrenergic, beta-2, ","","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (U01DK048689); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","","Who Is at Risk for High Blood Pressure?, (2012); Wright J.T., Bakris G., Greene T., Agodoa L.Y., Appel L.J., Charleston J., Et al., African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial, JAMA, 288, pp. 2421-2431, (2002); Atlas S.A., The renin-angiotensin-aldosterone system: Pathophysiological role and pharmacologic inhibition, J Manag Care Pharm, 13, pp. 9-20, (2007); Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S., Et al., Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects, Am J Hypertens, 12, pp. 451-459, (1999); Atlas S.A., Sealey J.E., Laragh J.H., Moon C., Atlas S.A., Sealey J.E., Et al., Plasma renin and 'prorenin' in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure, Lancet, 2, pp. 785-789, (1977); Iwamoto Y., Ohishi M., Yuan M., Tatara Y., Kato N., Takeya Y., Et al., B-Adrenergic receptor gene polymorphism is a genetic risk factor for cardiovascular disease: A cohort study with hypertensive patients, Hypertens Res, 34, pp. 573-577, (2011); Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., Et al., Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, 92, pp. 414-417, (2012); Weeke P., Roden D.M., Pharmacogenomics and cardiovascular disease, Curr Cardiol Rep, 15, (2013); Lee J., Aziz H., Liu L., Lipkowitz M., O'Connor D., Richard E., Et al., FS1-Adrenergic receptor polymorphisms and response to fi-blockade in the African-American Study of Kidney Disease and Hypertension (AASK), Am J Hypertens, 24, pp. 694-700, (2011); Jin B., Ge-Shang Q.Z., Li Y., Shen W., Shi H.M., Ni H.C., A meta-analysis of fS1-adrenergic receptor gene polymorphisms in idiopathic dilated cardiomyopathy, Mol Biol Rep, 39, pp. 563-567, (2012); Peng Y., Xue H., Luo L., Yao W., Li R., Polymorphisms of the beta1-adrenergic receptor gene are associated with essential hypertension in Chinese, Clin Chem Lab Med, 47, pp. 1227-1231, (2009); Estrada-Velasco B.I., Cruz M., Madrid-Marina V., Martinez-Nava G.A., Gomez-Zamudio J., Burguete-Garcia A.I., IRS1, TCF7L2, ADRB1, PPARG, and HHEX polymorphisms associated with atherogenic risk in Mexican population, Biomed Res Int, 2013, (2013); Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., Liggett S.B., Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure, N Engl J Med, 347, pp. 1135-1142, (2002); Svetkey L.P., Harris E.L., Martin E., Vollmer W.M., Meltesen G.T., Ricchiuti V., Et al., Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system, Am J Hypertens, 24, pp. 209-217, (2011); Pojoga L., Kolatkar N.S., Williams J.S., Perlstein T.S., Jeunemaitre X., Brown N.J., Et al., Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension, Hypertension, 48, pp. 892-900, (2006); Kelsey R.M., Alpert B.S., Dahmer M.K., Krushkal J., Quasney M.W., Beta-adrenergic receptor gene polymorphisms and cardiovascular reactivity to stress in Black adolescents and young adults, Psychophysiology, 47, pp. 863-873, (2010); Poole J.C., Snieder H., Davis H.C., Treiber F.A., Anger suppression and adiposity modulate association between ADRB2 haplotype and cardiovascular stress reactivity, Psychosom Med, 68, pp. 207-212, (2006); Iaccarino G., Izzo R., Trimarco V., Cipolletta E., Lanni F., Sorriento D., Et al., Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension, Clin Pharmacol Ther, 80, pp. 633-645, (2006); Iaccarino G., Trimarco V., Lanni F., Cipolletta E., Izzo R., Arcucci O., Et al., Beta-blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene, Pharmacogenomics J, 5, pp. 292-297, (2005); Hawkins G.A., Tantisira K., Meyers D.A., Ampleford E.J., Moore W.C., Klanderman B., Et al., Sequence, haplotype, and association analysis of ADRB2 in a Multiethnic Asthma Case-Control Study, Am J Respir Crit Care Med, 174, pp. 1101-1106, (2006); Bhatnagar V., O'Connor D.T., Schork N.J., Salem R.M., Nievergelt C.M., Rana B.K., Et al., Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial, J Hypertens, 25, pp. 2082-2092, (2007); Panebra A., Wang W.C., Malone M.M., Pitter D.R., Weiss S.T., Hawkins G.A., Liggett S.B., Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes, PLoS One, 5, (2010); Naka I., Hikami K., Nakayama K., Koga M., Nishida N., Kimura R., Et al., A functional SNP upstream of the beta-2 adrenergic receptor gene (ADRB2) is associated with obesity in Oceanic populations, Int J Obes (Lond), 37, pp. 1204-1210, (2013); Naka I., Ohashi J., Kimura R., Inaoka T., Matsumura Y., Association of ADRB2 polymorphism with triglyceride levels in Tongans, Lipids Health Dis, 12, (2013)","V. Bhatnagar; Department of Family Medicine and Public Health, University of California San Diego, MC 0725, San Diego, 9500 Gilman Drive, 92093, United States; email: vbhatnag@ucsd.edu","","Lippincott Williams and Wilkins","","","","","","17446872","","","26111150","English","Pharmacogenet. Genomics","Article","Final","","Scopus","2-s2.0-84939501378"
"Yu L.; Wang T.; Bai H.; Zhu W.; Li Y.; Wu J.; Liu W.; Sun L.; Yu A.; Li H.","Yu, Luhai (57217172344); Wang, Tingting (57217172126); Bai, Huidong (57226693588); Zhu, Weijiang (57226687364); Li, Yanju (57226701336); Wu, Jianhua (57226689050); Liu, Wenli (57217171836); Sun, Li (57217172053); Yu, Aiping (57218262610); Li, Hongjian (57196365971)","57217172344; 57217172126; 57226693588; 57226687364; 57226701336; 57226689050; 57217171836; 57217172053; 57218262610; 57196365971","Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study","2021","BMC Cardiovascular Disorders","21","1","391","","","","7","10.1186/s12872-021-02201-4","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112358461&doi=10.1186%2fs12872-021-02201-4&partnerID=40&md5=fab7279d6c569c208957351ed94f3a48","Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Dean’s Office, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China","Yu L., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Wang T., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Bai H., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Zhu W., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Li Y., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Wu J., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Liu W., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Sun L., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Yu A., Dean’s Office, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China; Li H., Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No, 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China, Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, No. 91 Tianchi Road, Tianshan District, Urumqi, 830001, Xinjiang, China","Background: Acute coronary syndrome (ACS) has become a vital disease with high mortality in the Uygur populations. Clopidogrel plays an important role in reducing the risk of recurrent cardiovascular events after ACS; however, it is a prodrug that requires biotransformation by cytochrome P450 (CYP450). Objectives: To determine the effect of genetic polymorphisms in CYP2C19*2, *3, and *17, and along with clinical, demographic factors, on variation in response to clinical outcomes in Uygur patients. Methods: A total of 351 patients with ACS were treated with clopidogrel and aspirin for at least 12 months; we recorded major adverse cardiovascular events (MACE) or bleeding within 1 year. Multivariable logistic regression analyses were carried out to identify factors associated with MACE or bleeding. Results: We analyze risk factors include age, BMI (body mass index), smoking, alcohol intake, NSTEMI (non-ST-segment elevation myocardial infarction), hypertension, dyslipidemia, concomitant medication, CYP2C19*2 carriers, CYP2C19*17 carriers and metabolizer phenotype. CYP2C19*2 carriers had an odds of having MACE of 2.51 (95% CI: 1.534–4.09) compared with noncarriers (P <.001). However, no factors were significantly associated with bleeding (P > 0.05). Conclusion: The CYP2C19*2 gene polymorphism contributes to the risk of MACE in dual clopidogrel—treated Uygur population with ACS with or without PCI (percutaneous coronary intervention). These data may provide valuable insights into the genetic polymorphisms affecting clopidogrel metabolism among minority groups in China. © 2021, The Author(s).","Acute coronary syndrome; Bleeding; Clopidogrel; CYP2C19; Major adverse cardiovascular events; Uygur","Acute Coronary Syndrome; Adult; Aged; Aspirin; Body Mass Index; Case-Control Studies; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prodrugs; Retrospective Studies; Risk Factors; Treatment Outcome; acetylsalicylic acid; angiotensin antagonist; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; calcium channel blocking agent; clopidogrel; cytochrome P450 2C19; diuretic agent; hydroxymethylglutaryl coenzyme A reductase inhibitor; acetylsalicylic acid; antithrombocytic agent; clopidogrel; CYP2C19 protein, human; cytochrome P450 2C19; prodrug; acute coronary syndrome; adult; age; alcohol consumption; Article; bleeding; body mass; cardiovascular disease; case control study; controlled study; CYP2C19 gene; dyslipidemia; female; gene; genetic association; genetic polymorphism; human; hypertension; loading drug dose; major clinical study; male; non ST segment elevation myocardial infarction; observational study; percutaneous coronary intervention; population research; retrospective study; smoking; Uygur (people); acute coronary syndrome; aged; China; ethnology; genetics; metabolism; middle aged; risk factor; single nucleotide polymorphism; statistical model; treatment outcome","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8, 120202-65-5, 120202-67-7, 894353-16-3; Aspirin, ; Clopidogrel, ; CYP2C19 protein, human, ; Cytochrome P-450 CYP2C19, ; Platelet Aggregation Inhibitors, ; Prodrugs, ","","","Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China","We thank the Internal Medicine-Cardiovascular Department, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China for their support.","Timmis A., Acute coronary syndromes, BMJ, 20, 351, (2015); Levine G.N., Bates E.R., Bittl J.A., Brindis R.G., Fihn S.D., Fleisher L.A., Et al., 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery, Circulation, 134, pp. e123-e155, (2016); Pereira N.L., Rihal C.S., So D.Y.F., Rosenberg Y., Lennon R.J., Clopidogrel pharmacogenetics, Circ Cardiovasc Interv, 12, 4, (2019); Yin T., Miyata T., Pharmacogenomics of clopidogrel: evidence and perspectives, Thromb Res, 128, pp. 307-316, (2011); Buzoianu A.D., Trifa A.P., Popp R.A., Militaru M.S., Militaru C.F., Bocsan C.I., Farcas M.F., Pop I.V., Screening for CYP2C19*2,*3 and *4 gene variants in a Romanian population study group, Farmacia, 58, pp. 806-818, (2010); Dehbozorg M., Kamalidehghan B., Hosseini I., Dehghanfard Z., Sangtarash M.H., Et al., Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities, Mol Med Rep, 17, 3, pp. 4195-4202, (2018); Scott S.A., Sangkuhl K., Stein C.M., Hulot J.-S., Mega J.L., Et al., Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update, Clin Pharmacol Ther, 94, 3, pp. 317-323, (2013); Sofi F., Giusti B., Marcucci R., Gori A.M., Abbate R., Gensini G.F., Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis, Pharmacogenomics J, 11, pp. 199-206, (2011); Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., Ingelman-Sundberg M., A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther, 79, pp. 103-113, (2006); Wang Y., Zhao X., Lin J., Li H., Johnston S.C., Lin Y., Et al., Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack, JAMA, 316, 1, pp. 70-78, (2016); Simon T., Verstuyft C., Mary-Krause M., Et al., Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, (2009); Wang T.T., Zhao T., Bao S.C., Jia L., Feng J., Et al., CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019, Medicine (Baltimore), 99, 29, (2020); Chen Q.J., Lai H.M., Chen B.D., Et al., Appropriate LDL-C-to-HDL-C ratio cutoffs for categorization of cardiovascular disease risk factorsamong uygur adults in Xinjiang, China, Int J Environ Res Public Health, 13, (2016); Fathy S., Shahin M.H., Langaee T., Khalil B.M., Saleh A., Et al., Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians, Pharmacogenet Genomics, 28, 9, pp. 207-213, (2018); Li X.Y., Wang Z., Wang Q.B., Xu Q., Lv Q.Z., Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients, Basic Clin Pharmacol Toxicol, 124, 1, pp. 84-93, (2019); Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., Et al., Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study, Lancet, 366, 9497, pp. 1640-1649, (2005); Dhingra R., Vasan R.S., Age as a risk factor, Med Clin NorthAm, 96, 1, pp. 87-91, (2012); Crimi G., Somaschini A., Cattaneo M., Angiolillo D.J., Piscione F., Et al., Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes, Platelets, 29, 3, pp. 309-311, (2018); Bucerius J., Duivenvoorden R., Mani V., Et al., Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study, JACC Cardiovasc Imaging, 4, 11, pp. 1195-1205, (2011); Nguyen H.N., Fujiyoshi A., Abbott R.D., Miura K., Epidemiology of cardiovascular risk factors in Asian countries, Circ J, 77, 12, pp. 2851-2859, (2013); Lin R., Zhang L., Zhang P., Et al., Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China, J Clin Pharm Ther, 40, pp. 308-314, (2015); Tang X.F., Han Y.L., Zhang J.H., Wang J., Yao Y., Et al., CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention, Thromb Res, 147, pp. 108-114, (2016); Ellis K.J., Stouffer G.A., McLeod H.L., Lee C.R., Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations, Pharmacogenomics, 10, pp. 1799-1817, (2009); Lewis J.P., Stephens S.H., Horenstein R.B., Et al., The CYP2C19 ∗ 17variantis not independently associated with clopidogrel response, J Thromb Haemost, 11, pp. 1640-1646, (2013); Park J.J., Park K.W., Kang J., Et al., Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents, Int J Cardiol, 163, pp. 79-86, (2013); Swen J.J., Nijenhuis M., de Boer A., Et al., Pharmacogenetics: from bench to byte-an update of guidelines, Clin Pharmacol Ther, 89, pp. 662-673, (2011); Shuldiner A.R., O'Connell J.R., Bliden K.P., Et al., Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, 302, pp. 849-857, (2009); Fricke-Galindo I., Cespedes-Garro C., Rodrigues-Soares F., Naranjo M.E., Delgado A., de Andres F., Lopez-Lopez M., Penas-Lledo E., Llerena A., Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations, Pharmacogenomics J, 16, pp. 113-123, (2016); Sorich M.J., Rowland A., McKinnon R.A., Wiese M.D., CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis, Circ Cardiovasc Genet, 7, pp. 895-902, (2014); Klein M.D., Williams A.K., Lee C.R., Stouffer G.A., Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention, Arterioscler Thromb Vasc Biol, 39, 4, pp. 647-652, (2019); Sibbing D., Koch W., Gebhard D., Et al., Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement, Circulation, 121, pp. 512-518, (2010); Park D.W., Kwon O., Jang J.S., Yun S.C., Park H., Et al., Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management a randomized clinical trial, Circulation, 140, 23, pp. 1865-1877, (2019); Grenfell R.D., Guidelines for the management of absolute cardiovasculardisease risk, Med J Aust, 199, (2013)","H. Li; Institute of Clinical Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, No. 91 Tianchi Road, Tianshan District, 830001, China; email: 331689583@qq.com; A. Yu; Dean’s Office, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, No. 91 Tianchi Road, Tianshan District, 830001, China; email: yuaiping_xj@sina.com","","BioMed Central Ltd","","","","","","14712261","","BCDMB","34384383","English","BMC Cardiovasc. Disord.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85112358461"
"Amraei R.; Moreira J.D.; Wainford R.D.","Amraei, Razie (56003276000); Moreira, Jesse D. (57204034102); Wainford, Richard D. (16403836700)","56003276000; 57204034102; 16403836700","Central Gαi2 Protein Mediated Neuro-Hormonal Control of Blood Pressure and Salt Sensitivity","2022","Frontiers in Endocrinology","13","","895466","","","","0","10.3389/fendo.2022.895466","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133921197&doi=10.3389%2ffendo.2022.895466&partnerID=40&md5=38abb998da048793309188f70eaff312","Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, United States; Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States; Department of Medicine, Boston University School of Medicine, Boston, MA, United States; Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, United States","Amraei R., Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, United States; Moreira J.D., Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States, Department of Medicine, Boston University School of Medicine, Boston, MA, United States; Wainford R.D., Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, United States","Hypertension, a major public health issue, is estimated to contribute to 10% of all deaths worldwide. Further, the salt sensitivity of blood pressure is a critical risk factor for the development of hypertension. The hypothalamic paraventricular nucleus (PVN) coordinates neuro-hormonal responses to alterations in plasma sodium and osmolality and multiple G Protein-Coupled Receptors (GPCRs) are involved in fluid and electrolyte homeostasis. In acute animal studies, our laboratory has shown that central Gαi/o subunit protein signal transduction mediates hypotensive and bradycardic responses and that Gz/q, proteins mediate the release of arginine vasopressin (AVP) and subsequent aquaretic responses to acute pharmacological stimuli. Extending these studies, our laboratory has shown that central Gαi2 proteins selectively mediate the hypotensive, sympathoinhibitory and natriuretic responses to acute pharmacological activation of GPCRs and in response to acute physiological challenges to fluid and electrolyte balance. In addition, following chronically elevated dietary sodium intake, salt resistant rats demonstrate site-specific and subunit-specific upregulation of Gαi2 proteins in the PVN, resulting in sympathoinhibition and normotension. In contrast, chronic dietary sodium intake in salt sensitive animals, which fail to upregulate PVN Gαi2 proteins, results in the absence of dietary sodium-evoked sympathoinhibition and salt sensitive hypertension. Using in situ hybridization, we observed that Gαi2 expressing neurons in parvocellular division of the PVN strongly (85%) colocalize with GABAergic neurons. Our data suggest that central Gαi2 protein-dependent responses to an acute isotonic volume expansion (VE) and elevated dietary sodium intake are mediated by the peripheral sensory afferent renal nerves and do not depend on the anteroventral third ventricle (AV3V) sodium sensitive region or the actions of central angiotensin II type 1 receptors. Our translational human genomic studies have identified three G protein subunit alpha I2 (GNAI2) single nucleotide polymorphisms (SNPs) as potential biomarkers in individuals with salt sensitivity and essential hypertension. Collectively, PVN Gαi2 proteins-gated pathways appear to be highly conserved in salt resistance to counter the effects of acute and chronic challenges to fluid and electrolyte homeostasis on blood pressure via a renal sympathetic nerve-dependent mechanism. Copyright © 2022 Amraei, Moreira and Wainford.","Gαi<sub>2</sub> proteins; hypertension; paraventricular nucleus; renal nerves; salt sensitivity","acetylcholine; adenosine phosphate; alpha adrenergic receptor; angiotensin 1 receptor; angiotensin II; argipressin; beta adrenergic receptor; endothelin; G alpha i subunit protein; G alpha i1 protein; G alpha i2 protein; G protein coupled receptor; G protein coupled receptor kinase 2; G protein coupled receptor kinase 5; G protein subunit alpha I2; G q protein; G z protein; guanine diphosphate; guanine triphosphate; inositol trisphosphate; interleukin 1beta; interleukin 6; membrane receptor; neurohormone; nociceptin; nociceptin receptor; oligodeoxynucleotide; phospholipase C; sodium; sodium chloride cotransporter; tumor necrosis factor; unclassified drug; anteroventral third ventricle; blood pressure monitoring; bradycardia; calcium cell level; deoxycorticosterone-salt-induced hypertension; diuresis; downstream processing; electrolyte balance; electrolyte blood level; gene frequency; hormonal regulation; human; hypertension; hypothalamic paraventricular nucleus; isotonic volume expansion; lateral parvocellular; mean arterial pressure; medial parvocellular; natriuretic response; nervous system inflammation; nonhuman; noradrenalin brain level; osmolality; peripheral sensory afferent renal nerve; plasma renin activity; protein expression; receptor upregulation; Review; salt resistance; salt sensitivity; signal transduction; single nucleotide polymorphism; sodium intake; sympathetic nerve; sympathoexcitation; sympathoinhibitory; urinary excretion; ventrolateral parvocellular","","acetylcholine, 51-84-3, 60-31-1, 66-23-9; adenosine phosphate, 61-19-8, 8063-98-7; angiotensin II, 11128-99-7, 68521-88-0; argipressin, 113-79-1; inositol trisphosphate, 27121-73-9; nociceptin, 170713-75-4; phospholipase C, 9001-86-9; sodium, 7440-23-5","","","National Institutes of Health, NIH; National Institute on Aging, NIA, (R01AG062515, R01AG075963); National Institute on Aging, NIA; National Heart, Lung, and Blood Institute, NHLBI, (R01HL139867, R01HL141406); National Heart, Lung, and Blood Institute, NHLBI; Center for Information Technology, CIT; Center for Scientific Review, CSR; Office of Extramural Research, National Institutes of Health, OER; Office of Research Infrastructure Programs, National Institutes of Health, ORIP, NIH, NIH-ORIP, ORIP","These studies were supported by National Heart, Lung, and Blood Institute (NHLBI) R01HL141406, R01HL139867, and National Institute on Aging (NIA) R01AG062515 and R01AG075963 to RW. ","Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., Et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Hypertension, 71, 6, (2018); He F.J., Li J., Macgregor G.A., Effect of Longer Term Modest Salt Reduction on Blood Pressure: Cochrane Systematic Review and Meta-Analysis of Randomised Trials, BMJ, 346, (2013); Cook N.R., Appel L.J., Whelton P.K., Lower Levels of Sodium Intake and Reduced Cardiovascular Risk, Circulation, 129, 9, (2014); Lloyd-Jones D.M., Hong Y., Labarthe D., Mozaffarian D., Appel L.J., Van Horn L., Et al., Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond, Circulation, 121, 4, pp. 586-613, (2010); Stocker S.D., Monahan K.D., Browning K.N., Neurogenic and Sympathoexcitatory Actions of NaCl in Hypertension, Curr Hypertens Rep, 15, 6, (2013); Fujita M., Fujita T., The Role of CNS in the Effects of Salt on Blood Pressure, Curr Hypertens Rep, 18, 2, (2016); Hiyama T.Y., Noda M., Sodium Sensing in the Subfornical Organ and Body-Fluid Homeostasis, Neurosci Res, 113, pp. 1-11, (2016); Franco V., Oparil S., Salt Sensitivity, a Determinant of Blood Pressure, Cardiovascular Disease and Survival, J Am Coll Nutr, 25, (2006); Puleo F., Kim K., Frame A.A., Walsh K.R., Ferdaus M.Z., Moreira J.D., Et al., Sympathetic Regulation of the NCC (Sodium Chloride Cotransporter) in Dahl Salt-Sensitive Hypertension, Hypertension, 76, 5, (2020); Frame A.A., Wainford R.D., Mechanisms of Altered Renal Sodium Handling in Age-Related Hypertension, Am J Physiol Renal Physiol, 315, 1, (2018); Frame A.A., Puleo F., Kim K., Walsh K.R., Faudoa E., Hoover R.S., Et al., Sympathetic Regulation of NCC in Norepinephrine-Evoked Salt-Sensitive Hypertension in Sprague-Dawley Rats, Am J Physiol Renal Physiol, 317, 6, (2019); Walsh K.R., Kuwabara J.T., Shim J.W., Wainford R.D., Norepinephrine-Evoked Salt-Sensitive Hypertension Requires Impaired Renal Sodium Chloride Cotransporter Activity in Sprague-Dawley Rats, Am J Physiol Regul Integr Comp Physiol, 310, 2, (2016); Fujita M., Fujita T., The Role of CNS in Salt-Sensitive Hypertension, Curr Hypertens Rep, 15, 4, (2013); DiBona G.F., Physiology in Perspective: The Wisdom of the Body. Neural Control of the Kidney, Am J Physiol Regul Integr Comp Physiol, 289, 3, (2005); Guyenet P.G., The Sympathetic Control of Blood Pressure, Nat Rev Neurosci, 7, 5, (2006); Gao J., Denys I., Shahien A., Sutphen J., Kapusta D.R., Et al., Downregulation of Brain Galpha12 Attenuates Angiotensin II-Dependent Hypertension, Am J Hypertens, 33, 2, pp. 198-204, (2020); Thibault C., Anand-Srivastava M.B., Altered Expression of G-Protein mRNA in Spontaneously Hypertensive Rats, FEBS Lett, 313, 2, (1992); Anand-Srivastava M.B., de Champlain J., Thibault C., DOCA-Salt Hypertensive Rat Hearts Exhibit Altered Expression of G-Proteins, Am J Hypertens, 6, 1, (1993); Hercule H.C., Tank J., Plehm R., Wellner M., da CostaGoncalves C.A., Gollasch M., Et al., Regulator of G Protein Signalling 2 Ameliorates Angiotensin II-Induced Hypertension in Mice, Exp Physiol, 92, 6, (2007); Divorty N., Milligan G., Graham D., Nicklin S.A., The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice, Am J Hypertens, 31, 9, (2018); Brinks H.L., Eckhart A.D., Regulation of GPCR Signaling in Hypertension, Biochim Biophys Acta, 1802, 12, (2010); Feldman R.D., Tan C.M., Chorazyczewski J., G Protein Alterations in Hypertension and Aging, Hypertension, 26, 5, (1995); Hilger D., Masureel M., Kobilka B.K., Structure and Dynamics of GPCR Signaling Complexes, Nat Struct Mol Biol, 25, 1, pp. 4-12, (2018); Nasman J., Kukkonen J.P., Ammoun S., Akerman K.E., Role of G-Protein Availability in Differential Signaling by Alpha 2-Adrenoceptors, Biochem Pharmacol, 62, 7, (2001); Regard J.B., Sato I.T., Coughlin S.R., Anatomical Profiling of G Protein-Coupled Receptor Expression, Cell, 135, 3, (2008); Cotecchia S., Stanasila L., Diviani D., Protein-Protein Interactions at the Adrenergic Receptors, Curr Drug Targets, 13, 1, pp. 15-27, (2012); Wang J., Gareri C., Rockman H.A., G-Protein-Coupled Receptors in Heart Disease, Circ Res, 123, 6, (2018); Wu Y., Zeng L., Zhao S., Ligands of Adrenergic Receptors: A Structural Point of View, Biomolecules, 11, 7, (2021); Wingler L.M., Skiba M.A., McMahon C., Staus D.P., Kleinhenz A.L.W., Suomivuori C.-M., Et al., Angiotensin and Biased Analogs Induce Structurally Distinct Active Conformations Within a GPCR, Science, 367, 6480, (2020); Lymperopoulos A., Cora N., Maning J., Brill A.R., Sizova A., Signaling and Function of Cardiac Autonomic Nervous System Receptors: Insights From the GPCR Signalling Universe, FEBS J, 288, 8, (2021); Kang M., Chung K.Y., Walker J.W., G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart, Physiol (Bethesda), 22, (2007); Harris D.M., Cohn H.I., Pesant S., Eckhart A.D., GPCR Signalling in Hypertension: Role of GRKs, Clin Sci (Lond), 115, 3, pp. 79-89, (2008); Wainford R.D., Kurtz K., Kapusta D.R., Central G-Alpha Subunit Protein-Mediated Control of Cardiovascular Function, Urine Output, and Vasopressin Secretion in Conscious Sprague-Dawley Rats, Am J Physiol Regul Integr Comp Physiol, 295, 2, (2008); Wainford R.D., Kapusta D.R., Chronic High-NaCl Intake Prolongs the Cardiorenal Responses to Central N/OFQ and Produces Regional Changes in the Endogenous Brain NOP Receptor System, Am J Physiol Regul Integr Comp Physiol, 296, 2, (2009); Wainford R.D., Kapusta D.R., Hypothalamic Paraventricular Nucleus G Alpha Q Subunit Protein Pathways Mediate Vasopressin Dysregulation and Fluid Retention in Salt-Sensitive Rats, Endocrinology, 151, 11, (2010); Wainford R.D., Kapusta D.R., Functional Selectivity of Central Galpha-Subunit Proteins in Mediating the Cardiovascular and Renal Excretory Responses Evoked by Central Alpha(2) -Adrenoceptor Activation In Vivo, Br J Pharmacol, 166, 1, (2012); Kapusta D.R., Pascale C.L., Wainford R.D., Brain Heterotrimeric Galphai(2)-Subunit Protein-Gated Pathways Mediate Central Sympathoinhibition to Maintain Fluid and Electrolyte Homeostasis During Stress, FASEB J, 26, 7, (2012); Carmichael C.Y., Kuwabara J.T., Pascale C.L., Moreira J.D., Mahne S.E., Kapusta D.R., Et al., Hypothalamic Paraventricular Nucleus Galphai2 (Guanine Nucleotide-Binding Protein Alpha Inhibiting Activity Polypeptide 2) Protein-Mediated Neural Control of the Kidney and the Salt Sensitivity of Blood Pressure, Hypertension, 75, 4, (2020); Frame A.A., Carmichael C.Y., Kuwabara J.T., Cunningham J.T., Wainford R.D., Role of the Afferent Renal Nerves in Sodium Homeostasis and Blood Pressure Regulation in Rats, Exp Physiol, 104, 8, (2019); Moreira J.D., Nist K.M., Carmichael C.Y., Kuwabara J.T., Wainford R.D., Sensory Afferent Renal Nerve Activated Galphai2 Subunit Proteins Mediate the Natriuretic, Sympathoinhibitory and Normotensive Responses to Peripheral Sodium Challenges, Front Physiol, 12, (2021); Wainford R.D., Pascale C.L., Kuwabara J.T., Brain Galphai2-Subunit Protein-Gated Pathways are Required to Mediate the Centrally Evoked Sympathoinhibitory Mechanisms Activated to Maintain Sodium Homeostasis, J Hypertens, 31, 4, (2013); Carmichael C.Y., Carmichael A.C.T., Kuwabara J.T., Cunningham J.T., Wainford R.D., Impaired Sodium-Evoked Paraventricular Nucleus Neuronal Activation and Blood Pressure Regulation in Conscious Sprague-Dawley Rats Lacking Central Galphai2 Proteins, Acta Physiol (Oxf), 216, 3, (2016); Kapusta D.R., Pascale C.L., Kuwabara J.T., Wainford R.D., Central Nervous System Galphai2-Subunit Proteins Maintain Salt Resistance via a Renal Nerve-Dependent Sympathoinhibitory Pathway, Hypertension, 61, 2, (2013); Wainford R.D., Carmichael C.Y., Pascale C.L., Kuwabara J.T., Galphai2-Protein-Mediated Signal Transduction: Central Nervous System Molecular Mechanism Countering the Development of Sodium-Dependent Hypertension, Hypertension, 65, 1, (2015); Mattson D.L., Dwinell M.R., Greene A.S., Kwitek A.E., Roman R.J., Jacob H.I., Et al., Chromosome Substitution Reveals the Genetic Basis of Dahl Salt-Sensitive Hypertension and Renal Disease, Am J Physiol Renal Physiol, 295, 3, (2008); Frame A.A., Carmichael C.Y., Wainford R.D., Renal Afferents, Curr Hypertens Rep, 18, 9, (2016); Jiang E., Chapp A.D., Fan Y., Larson R.A., Hahka T., Huber M.J., Et al., Expression of Proinflammatory Cytokines Is Upregulated in the Hypothalamic Paraventricular Nucleus of Dahl Salt-Sensitive Hypertensive Rats, Front Physiol, 9, (2018); Galic M.A., Riazi K., Pittman Q.J., Cytokines and Brain Excitability, Front Neuroendocrinol, 33, 1, (2012); Shi Z., Gan X.-B., Fan Z.-D., Zhang F., Zhou Y.-B., Gao X.-Y., Et al., Inflammatory Cytokines in Paraventricular Nucleus Modulate Sympathetic Activity and Cardiac Sympathetic Afferent Reflex in Rats, Acta Physiol (Oxf), 203, 2, (2011); Vezzani A., Viviani B., Neuromodulatory Properties of Inflammatory Cytokines and Their Impact on Neuronal Excitability, Neuropharmacology, 96, pp. 70-82, (2015); Moreira J.D., Chaudhary P., Frame A.A., Puleo F., Nist K.M., Abkin E.A., Et al., Inhibition of Microglial Activation in Rats Attenuates Paraventricular Nucleus Inflammation in Galphai2 Protein-Dependent, Salt-Sensitive Hypertension, Exp Physiol, 104, 12, (2019); Ferguson A.V., Latchford K.J., Samson W.K., The Paraventricular Nucleus of the Hypothalamus - a Potential Target for Integrative Treatment of Autonomic Dysfunction, Expert Opin Ther Targets, 12, 6, (2008); Antunes-Rodrigues J., de Castro M., Elias L.L.K., Valenca M.M., McCann S.M., Et al., Neuroendocrine Control of Body Fluid Metabolism, Physiol Rev, 84, 1, pp. 169-208, (2004); Chaudhary P., Wainford R.D., Neuroanatomical Characterization of Galphai2-Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Male and Female Sprague-Dawley Rats, Physiol Genomics, 53, 1, pp. 12-21, (2021); Li P., Zou A.P., al-Kayed N.J., Rusch N.J., Harder D.R., Guanine Nucleotide-Binding Proteins in Aortic Smooth Muscle From Hypertensive Rats, Hypertension, 23, (1994); Hashim S., Anand-Srivastava M.B., Losartan-Induced Attenuation of Blood Pressure in L-NAME Hypertensive Rats is Associated With Reversal of the Enhanced Expression of Gi Alpha Proteins, J Hypertens, 22, 1, (2004); Marcil J., Schiffrin E.L., Anand-Srivastava M.B., Aberrant Adenylyl Cyclase/cAMP Signal Transduction and G Protein Levels in Platelets From Hypertensive Patients Improve With Antihypertensive Drug Therapy, Hypertension, 28, 1, pp. 83-90, (1996); Watanabe Y., Metoki H., Ohkubo T., Katsuya T., Tabara Y., Kikuya M., Et al., Accumulation of Common Polymorphisms is Associated With Development of Hypertension: A 12-Year Follow-Up From the Ohasama Study, Hypertens Res, 33, 2, (2010); Menzaghi C., Paroni G., De Bonis C., Soccio T., Marucci A., Bacci S., Et al., The -318 C>G Single-Nucleotide Polymorphism in GNAI2 Gene Promoter Region Impairs Transcriptional Activity Through Specific Binding of Sp1 Transcription Factor and is Associated With High Blood Pressure in Caucasians From Italy, J Am Soc Nephrol, 17, (2006); Zhang X., Frame A.A., Williams J.S., Wainford R.D., GNAI2 Polymorphic Variance Associates With Salt Sensitivity of Blood Pressure in the Genetic Epidemiology Network of Salt Sensitivity Study, Physiol Genomics, 50, 9, (2018)","R.D. Wainford; Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, United States; email: rwainf@bu.edu","","Frontiers Media S.A.","","","","","","16642392","","","","English","Front. Endocrinol.","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85133921197"
"Loganathan L.; Gopinath K.; Sankaranarayanan V.M.; Kukreti R.; Rajendran K.; Lee J.-K.; Muthusamy K.","Loganathan, Lakshmanan (57197815965); Gopinath, Krishnasamy (42961574800); Sankaranarayanan, Vadivel Murugan (57212801505); Kukreti, Ritushree (8974579200); Rajendran, Kannan (57191522764); Lee, Jung-Kul (27172120200); Muthusamy, Karthikeyan (35275598100)","57197815965; 42961574800; 57212801505; 8974579200; 57191522764; 27172120200; 35275598100","Computational and pharmacogenomic insights on hypertension treatment: Rational drug design and optimization strategies","2020","Current Drug Targets","21","1","","18","33","15","9","10.2174/1389450120666190808101356","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076082571&doi=10.2174%2f1389450120666190808101356&partnerID=40&md5=c4eec3b4b60f1ba0a117d2ccd71bce83","Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India; Department of Chemical Engineering, Konkuk University, 1 Hwayang-Dong, Gwangjin-Gu, Seoul, South Korea; Department of General Medicine, Velammal Medical College Hospital and Research Institute, Madurai, Tamil Nadu, India; Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, New Delhi, India; Department of General Medicine, Saveetha Medical College and Hospital, Chennai, Tamil Nadu, India","Loganathan L., Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India, Department of Chemical Engineering, Konkuk University, 1 Hwayang-Dong, Gwangjin-Gu, Seoul, South Korea; Gopinath K., Department of Chemical Engineering, Konkuk University, 1 Hwayang-Dong, Gwangjin-Gu, Seoul, South Korea; Sankaranarayanan V.M., Department of General Medicine, Velammal Medical College Hospital and Research Institute, Madurai, Tamil Nadu, India; Kukreti R., Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, New Delhi, India; Rajendran K., Department of General Medicine, Saveetha Medical College and Hospital, Chennai, Tamil Nadu, India; Lee J.-K., Department of Chemical Engineering, Konkuk University, 1 Hwayang-Dong, Gwangjin-Gu, Seoul, South Korea; Muthusamy K., Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India","Background: Hypertension is a prevalent cardiovascular complication caused by genetic and nongenetic factors. Blood pressure (BP) management is difficult because most patients become resistant to monotherapy soon after treatment initiation. Although many antihypertensive drugs are available, some patients do not respond to multiple drugs. Identification of personalized antihypertensive treatments is a key for better BP management. Objective: This review aimed to elucidate aspects of rational drug design and other methods to develop better hypertension management. Results: Among hypertension-related signaling mechanisms, the renin-angiotensin-aldosterone system is the leading genetic target for hypertension treatment. Identifying a single drug that acts on multiple targets is an emerging strategy for hypertension treatment, and could be achieved by discovering new drug targets with less mutated and highly conserved regions. Extending pharmacogenomics research to include patients with hypertension receiving multiple antihypertensive drugs could help identify the genetic markers of hypertension. However, available evidence on the role of pharmacogenomics in hypertension is limited and primarily focused on candidate genes. Studies on hypertension pharmacogenomics aim to identify the genetic causes of response variations to antihypertensive drugs. Genetic association studies have identified single nucleotide polymorphisms affecting drug responses. To understand how genetic traits alter drug responses, computational screening of mutagenesis can be utilized to observe drug response variations at the protein level, which can help identify new inhibitors and drug targets to manage hypertension. Conclusion: Rational drug design facilitates the discovery and design of potent inhibitors. However, further research and clinical validation are required before novel inhibitors can be clinically used as antihypertensive therapies. © 2020 Bentham Science Publishers.","Blood pressure; Computational mutagenesis; Drug discovery; Hypertension; Pharmacogenomics; RAAS; SNPs","Antihypertensive Agents; Blood Pressure; Computational Biology; Drug Design; Drug Therapy, Combination; Genotype; Humans; Hypertension; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Renin-Angiotensin System; aldosterone synthase; aliskiren; amlodipine; angiotensin 2 receptor 1; angiotensin receptor antagonist; angiotensinogen; atenolol; benazepril; chlorothiazide; cytochrome P450; cytochrome P450 2D6; cytochrome P450 3A4; enalapril; felodipine; fosinopril; hydrochlorothiazide; irbesartan; lisinopril; losartan; metoprolol; nicardipine; peptides and proteins; remikiren; unclassified drug; valsartan; antihypertensive agent; adverse event; amino acid sequence; antihypertensive therapy; binding affinity; computer model; conformational transition; drug binding; drug design; drug response; drug structure; gene expression; gene frequency; genetic association; genetic variability; genotype; haplotype; healthy lifestyle; hypertension; lifestyle modification; molecular docking; molecular dynamics; pharmacogenomics; pharmacophore; plasma half life; quantitative structure activity relation; renin angiotensin aldosterone system; Review; signal transduction; single nucleotide polymorphism; training; vasodilatation; biology; blood pressure; combination drug therapy; drug design; drug effect; genetic polymorphism; genetics; human; hypertension; personalized medicine; pharmacogenetics","","aldosterone synthase, 122933-89-5; aliskiren, 173334-57-1, 173334-58-2, 173399-03-6; amlodipine, 88150-42-9, 103129-82-4, 736178-83-9; angiotensinogen, 11002-13-4, 64315-16-8; atenolol, 29122-68-7, 93379-54-5; benazepril, 86541-75-5; chlorothiazide, 58-94-6, 7085-44-1; cytochrome P450, 9035-51-2; cytochrome P450 3A4, 329736-03-0; enalapril, 75847-73-3; felodipine, 72509-76-3; fosinopril, 88889-14-9, 98048-97-6; hydrochlorothiazide, 58-93-5; irbesartan, 138402-11-6; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; metoprolol, 37350-58-6; nicardipine, 54527-84-3, 55985-32-5; remikiren, 126222-34-2; valsartan, 137862-53-4; Antihypertensive Agents, ","","","MHRD-RUSA, (2.0-F.24/51/2014-U); TNMulti-Gen; Konkuk University, KU, (2013M3A6A 8073184, 2017R1A2B3011676, 2017R1A4A1014806); Ministry of Science, ICT and Future Planning, MSIP; National Research Foundation of Korea, NRF; Wuhan Textile University, WTU","Funding text 1: This work was supported by the WTU joint research grants from the Konkuk University. This research was supported by the Basic Science Research Program (2017R1A2B3011676, 2017R1A4A1014806, 2013M3A6A 8073184) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning. LL and KM are grateful to the MHRD-RUSA 2.0-F.24/51/2014-U, Policy (TNMulti-Gen), Dept. of Edn. Govt. of India for the support.; Funding text 2: This work was supported by the WTU joint research grants from the Konkuk University. This research was supported by the Basic Science Research Program (2017R1A2B3011676, 2017R1A4A1014806, 2013M3A6A 8073184) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning. LL and KM are grateful to the MHRD-RUSA 2.0 - F.24/51/2014-U, Policy (TNMulti-Gen), Dept. of Edn. Govt. of India for the support.","Global Health Observatory (GHO) Data; Benjamin E.J., Virani S.S., Callaway C.W., Et al., American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke sta-tistics-2018 update: A report from the american heart association, Circulation, 137, 12, pp. e67-e492, (2018); Arwood M.J., Cavallari L.H., Duarte J.D., Pharmacogenomics of hypertension and heart disease, Curr Hypertens Rep, 17, 9, (2015); Williams B., Cockcroft J.R., Kario K., Et al., Effects of sacubi-tril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The parameter study, Hypertension, 69, 3, pp. 411-420, (2017); Toto R.D., Treatment of hypertension in chronic kidney disease, Semin Nephrol, 25, 6, pp. 435-439, (2005); Tabassum N., Ahmad F., Role of natural herbs in the treatment of hypertension, Pharmacogn Rev, 5, 9, pp. 30-40, (2011); Vm M., Kak L., Pm F., Bassett K., Jm W., Blood pressure lowering efficacy of renin inhibitors for primary hypertension ( Review ) Summary of Findings for the Main Comparison Cochrane, Database Syst Rev, 4, (2017); Shrout T., Rudy D.W., Piascik M.T., Hypertension Update, JNC8 and beyond Current Opinion in Pharmacology, pp. 41-46, (2017); Rose R., Balakrishnan A., Muthusamy K., Arumugam P., Shan-Mugam S., Gopalswamy J., Myocilin mutations among POAG patients from two populations of Tamil Nadu, South India, a comparative analysis, Mol Vis, 17, pp. 3243-3253, (2011); Gupta R., Trends in Hypertension Epidemiology in India, pp. 73-78, (2004); Cover Story _ the 2017 High Blood Pressure Guideline_ Risk Reduction through Better Management-, (2017); Kario K., Tomitani N., Buranakitjaroen P., Et al., HOPE Asia Network. Rationale and design for the Asia BP@Home study on home blood pressure control status in 12 Asian countries and regions, J Clin Hypertens (Greenwich), 20, 1, pp. 33-38, (2018); Dymond J.N., Rarities C., Bird Report 1972, Systematic List, 39, (1976); Kim T.J., Lee J.W., Kang H.T., Et al., Trends in Blood Pressure and Prevalence of Hypertension in Korean Adults Based on the 1998-2014 KNHANES, Yonsei Med J, 59, 3, pp. 356-365, (2018); Ohno Y., Sone M., Inagaki N., Et al., Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in japan, Hypertension, 71, 3, pp. 530-537, (2018); Franklin S.S., Hypertension in older people: Part 2, J Clin Hypertens (Greenwich), 8, 7, pp. 521-525, (2006); Staessen J.A., Byttebier G., Buntinx F., Celis H., O'Brien E.T., Fagard R., Ambulatory blood pressure monitoring and treatment of hypertension investigators. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial, JAMA, 278, 13, pp. 1065-1072, (1997); Baker M.D., Bell L.M.A.J., The new england journal of medicine downloaded from Nejm.Org at GEORGE WASHINGTON UNIVERSITY on March 4, 2012. For personal use only. No other uses without permission. Copyright<sup>©</sup> 1993 Massachusetts medical society. All Rights Reserved, N Engl J Med, 329, 20, pp. 1437-1441, (1993); Lupoli S., Salvi E., Barcella M., Barlassina C., Pharmacogenomics considerations in the control of hypertension, Pharmacogenomics, 16, 17, pp. 1951-1964, (2015); Fox L.S., Schooley W.R., Nichols R.L., Webb W.R., Open cardiac operations in patients with abnormalities of white blood cell number or function, South Med J, 81, 8, pp. 1065-1066, (1988); Wassertheil-Smoller S., Fann C., Allman R.M., Et al., The SHEP Cooperative Research Group. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program, Arch Intern Med, 160, 4, pp. 494-500, (2000); Alderman M.H., Cohen H.W., Sealey J.E., Laragh J.H., Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients, Am J Hypertens, 17, 1, pp. 1-7, (2004); Banic A., Benkovic V., Knezevic A., Effectiveness of hypertension therapy by using fixed combinations and monocomponent drugs-A prospective study from croatia, J Pharm Pharmacol, 6, pp. 333-339, (2018); Mehanna M., Gong Y., McDonough C.W., Et al., Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension, J Clin Hypertens (Greenwich), 19, 12, pp. 1301-1308, (2017); Gong Y., Wang Z., Beitelshees A.L., Et al., Pharmacogenomic genome-wide meta-analysis of blood pressure response to β-blockers in hypertensive african americans, Hypertension, 67, 3, pp. 556-563, (2016); Baker J.H., Meditation for Reducing CVD Risk, Integrative Medicine Alert, pp. 57-60, (2018); Kaufman A.L., Spitz J., Jacobs M., Et al., Evidence for clinical implementation of pharmacogenomics in cardiac drugs, Mayo Clin Proc, 90, 6, pp. 716-729, (2015); Feldman R.D., Hussain Y., Kuyper L.M., McAlister F.A., Padwal R.S., Tobe S.W., Intraclass differences among antihypertensive drugs, Annu Rev Pharmacol Toxicol, 55, 1, pp. 333-352, (2015); Guasti L., Gaudio G., Lupi A., Et al., Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients, Drug Des Devel Ther, 11, pp. 2293-2300, (2017); Menni C., Blood pressure pharmacogenomics: Gazing into a misty crystal ball, J Hypertens, 33, 6, pp. 1142-1143, (2015); Cooper-Dehoff R.M., Johnson J.A., Hypertension pharmacogenomics: In search of personalized treatment approaches, Nat Rev Nephrol, 12, 2, pp. 110-122, (2016); Barton Laws M., Beach M.C., Lee Y., Et al., The pharmacogenomics research network translational pharmacogenetics program: Overcoming challenges of real-world implementation NIH public, Access, 17, 1, pp. 148-159, (2013); Singh K.D., Jajodia A., Kaur H., Kukreti R., Karthikeyan M., Renin angiotensin system gene polymorphisms in response to antihypertensive drugs and visit-to-visit blood pressure variability in essential hypertensive patients, Curr Pharmacogenomics Person Med, 12, 4, pp. 227-235, (2015); Wang J., Shi X., Ma C., Et al., Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: A systematic review and meta-analysis, J Hypertens, 35, 1, pp. 10-17, (2017); Wu C., Shlipak M.G., Stawski R.S., Et al., Visit-to-visit blood pressure variability and mortality and cardiovascular outcomes among older adults: The health, aging, and body composition study, Am J Hypertens, 30, 2, pp. 151-158, (2017); Dumitrescu L., Ritchie M.D., Denny J.C., Et al., Genome-wide study of resistant hypertension identified from electronic health records, Plos One, 12, 2, (2017); Chern T.H., Chiang F.T., Molecular genetic study of hypertension, Acta Cardiol Sin, 20, 3, pp. 129-138, (2004); Hackenthal E., Paul M., Ganten D., Taugner R., Morphology, physiology and molecular biology of renin secretion, Physiol Rev, 70, 4, pp. 1067-1116, (1990); Fyhrquist F., Saijonmaa O., Renin-angiotensin system revisited, J Intern Med, 264, 3, pp. 224-236, (2008); Lee W.K., Padmanabhan S., Dominiczak A.F., Genetics of hypertension: From experimental models to clinical applications, J Hum Hypertens, 14, 10-11, pp. 631-647, (2000); Gautam N., Kaur S., Kaur S., Kumar S., Computational Study of ACE and AGT Gene of RAAS Pathway, World News Nat Sci, 19, June, pp. 65-77, (2018); Alanazi A.M., Abdelhameed A.S., Bakheit A.H., Et al., Spectroscopic and Molecular Docking Studies of the Binding of the Angiotensin II Receptor Blockers (ARBs) Azilsartan, Eprosartan and Olmesartan to Bovine Serum Albumin, J Lumin, 203, pp. 616-628, (2018); Karthikeyan M., Rose R., Shridevi V., Et al., Core promoter variants (A-20C, T-18C and G-6A) of the angiotensinogen (AGT) gene are not significantly associated with hypertension in patients of tamil-nadu, India, Int J Hum Genet, 9, 1, pp. 13-19, (2009); Rae K.M., Grimson S., Pringle K.G., Personalised medicine: A new approach to improving health in indigenous australian populations, Public Health Genomics, 20, 1, pp. 58-62, (2017); Zhang H., Jin L., Mu T., Et al., Associations of CYP4A11 gene-gene and gene-smoking interactions with essential hypertension in the male eastern Chinese Han population, Clin Exp Hypertens, 39, 5, pp. 448-453, (2017); Sanoski C.A., Aliskiren: An oral direct renin inhibitor for the treatment of hypertension, Pharmacotherapy, 29, 2, pp. 193-212, (2009); Matsubara H., Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases, Circ Res, 83, 12, pp. 1182-1191, (1998); Zisaki A., Miskovic L., Hatzimanikatis V., Antihypertensive drugs metabolism: An update to pharmacokinetic profiles and computational approaches, Curr Pharm Des, 21, 6, pp. 806-822, (2015); Durdagi S., Erol I., Salmas R.E., Aksoydan B., Kantarcioglu I., Oligomerization and Cooperativity in GPCRs from the Perspective of the Angiotensin AT1 and Dopamine D2 Receptors, Neurosci Lett, (2018); Feldman R.D., Gros R., Impaired vasodilator function in hypertension: The role of alterations in receptor-G protein coupling, Trends Cardiovasc Med, 8, 7, pp. 297-305, (1998); Brinks H.L., Eckhart A.D., Regulation of GPCR Signaling in Hypertension, Biochim Biophys Acta, 6, 9, pp. 790-795, (2015); Majzunova M., Dovinova I., Barancik M., Chan J.Y.H., Redox signaling in pathophysiology of hypertension, J Biomed Sci, 20, 69, (2013); Paravicini T.M., Touyz R.M., Redox signaling in hypertension, Cardiovasc Res, 71, 2, pp. 247-258, (2006); Giorgini P., Sahebkar A., Stamerra C.A., Et al., Comparison of clinical outcomes between genders following antihypertensive therapy: A meta-analysis, Curr Med Chem, 24, 24, pp. 2639-2649, (2017); Divac N., Naumovic R., Stojanovic R., Prostran M., The role of im-munosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients, Curr Med Chem, 23, 19, pp. 1941-1952, (2016); Cruz J.N., Oliveira M.S., Vogado J.H., Silva S.G., Costa W.A., Fernanda W.F.B., Renato A.C., Junior R.N., Neto A.M., Molecular insights on the interactions of nitrosamines from cigarette smoking with CYP2A13 using molecular docking and molecular dynamics simulation HSOA, J Pulm Med Respir Res, 4, (2018); Wen H., Wang L., Reducing effect of aerobic exercise on blood pressure of essential hypertensive patients, Medicine (United States), 96, 11, (2017); Turnbull F., Neal B., Algert C., Et al., Blood pressure lowering treatment trialists’ collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of pro-spectively-designed overviews of randomised trials, Lancet, 362, 9395, pp. 1527-1535, (2003); Cushman W.C., Ford C.E., Cutler J.A., Et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), J Clin Hypertens (Greenwich), 4, 6, pp. 393-404, (2002); Law M.R., Wald N.J., Morris J.K., Jordan R.E., Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials, BMJ, 326, 7404, pp. 1427-1430, (2003); Davison K.K., Birch L.L., Oral direct renin inhibition: Premise, promise, and potential limitations of a new class of antihypertensive drug, Am J Med, 64, 12, pp. 2391-2404, (2008); Pool J.L., Direct renin inhibition: Focus on aliskiren, J Manag Care Pharm, 13, 8, pp. 21-33, (2007); Pich J., The efficacy of renin inhibitors in primary hypertension, Am J Nurs, 118, 4, (2018); Desjarlais M., Dussault S., Dhahri W., Mathieu R., Rivard A., Direct renin inhibition with aliskiren improves ischemia-induced neovas-cularization: Blood pressure-independent effect, Atherosclerosis, 242, 2, pp. 450-460, (2015); Hsu C.N., Lee C.T., Huang L.T., Tain Y.L., Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylargin-ine in offspring exposed to maternal caloric restriction, J Renin Angiotensin Aldosterone Syst, 16, 3, pp. 506-513, (2015); Buczko W., Hermanowicz J.M., Pharmacokinetics and pharmacody-namics of aliskiren, an oral direct renin inhibitor, Pharmacol Rep, 60, 5, pp. 623-631, (2008); Jm W., Vm M., Gill R., First-line drugs for hypertension (Review), Summary of Findings for the Main Comparison, (2018); Carter B.L., Ernst M.E., Cohen J.D., Hydrochlorothiazide versus chlorthalidone: Evidence supporting their interchangeability, Hypertension, 43, 1, pp. 4-9, (2004); Zillich A.J., Garg J., Basu S., Bakris G.L., Carter B.L., Thiazide diuretics, potassium, and the development of diabetes: A quantitative review, Hypertension, 48, 2, pp. 219-224, (2006); Hoogwerf B.J., Young J.B., The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not, Cleve Clin J Med, 67, 4, pp. 287-293, (2000); Fein A., ACE inhibitors worsen inflammatory pain, Med Hypotheses, 72, 6, (2009); Ram C.V.S., Beta-blockers in hypertension, Am J Cardiol, 106, 12, pp. 1819-1825, (2010); Quinn U., Renin genotype as a predictor of response to antihypertensive therapy: A personalized approach to management of high blood pressure R, Coll Surg Irel, (2017); Rochlani Y., Khan M.H., Banach M., Aronow W.S., Are two drugs better than one? A review of combination therapies for hypertension, Expert Opin Pharmacother, 18, 4, pp. 377-386, (2017); Dhanachandra Singh K., Jajodia A., Kaur H., Kukreti R., Karthikeyan M., Gender specific association of RAS gene polymorphism with essential hypertension: A case-control study, Biomed Res Int, (2014); Strauss M.H., Hall A.S., Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradox, Circulation, 114, 8, pp. 838-854, (2006); Weir M.R., Bush C., Anderson D.R., Zhang J., Keefe D., Satlin A., Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis, J am Soc Hypertens, 1, 4, pp. 264-277, (2007); Musini V.M., Tejani A.M., Bassett K., Wright J.M., Pharmacotherapy for Hypertension in the Elderly, Cochrane Database of Systematic Reviews, (2009); Hypertension: Developing fixed-dose combination drugs for treatment guidance for industry Center for Drug Evaluation Research, CDER, (2018); Hann M.M., Leach A.R., Harper G., Molecular complexity and its impact on the probability of finding leads for drug discovery, J Chem Inf Comput Sci, 41, 3, pp. 856-864, (2001); Myers S., Baker A., Drug discovery--an operating model for a new era, Nat Biotechnol, 19, 8, pp. 727-730, (2001); Dimasi J.A., Hansen R.W., Grabowski H.G., The price of innovation: New estimates of drug development costs, J Health Econ, 22, 2, pp. 151-185, (2003); McAlister F.A., Straus S., Sackett D., Randomized clinical trials of antihypertensive drugs: All that glitters is not gold, CMAJ, 159, 5, pp. 488-490, (1998); Chakraborty B.S., Clinical trials of antihypertensives: Nature of control and design, Indian J Pharmacol, 43, 1, pp. 13-17, (2011); Karaman B., Sippl W., Computational Drug Repurposing: Current Trends, Curr Med Chem, 25, (2018); Katsila T., Spyroulias G.A., Patrinos G.P., Matsoukas M.T., Computational approaches in target identification and drug discovery, Comput Struct Biotechnol J, 14, pp. 177-184, (2016); Blundell T.L., Structure-based drug design, Nature, 384, 6604, pp. 23-26, (1996); Yousefpour A., Modarress H., Goharpey F., Amjad-Iranagh S., Interaction of PEGylated anti-hypertensive drugs, amlodipine, atenolol and lisinopril with lipid bilayer membrane: A molecular dynamics simulation study, Biochim Biophys Acta, 1848, 8, pp. 1687-1698, (2015); Wang Z., Cheng L.P., Zhang X.H., Pang W., Li L., Zhao J.L., Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors, Bioorg Med Chem Lett, 27, 24, pp. 5429-5435, (2017); Loganathan L., Muthusamy K., Investigation of Drug Interaction Potentials and Binding Modes on Direct Renin Inhibitors. A Computational Modeling Studies, Lett Drug Des Discov, 15, (2018); Garcia-Mora P., Martin-Martinez M., Angeles Bonache M., Et al., Identification, functional gastrointestinal stability and molecular docking studies of lentil peptides with dual antioxidant and angiotensin I converting enzyme inhibitory activities, Food Chem, 221, pp. 464-472, (2017); Arya H., Syed S.B., Singh S.S., Ampasala D.R., Coumar M.S., In Silico Investigations of Chemical Constituents of Clerodendrum cole-brookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, And PDE5. Interdiscip Sci, 10, 4, pp. 792-804, (2018); Kecel-Gunduz S., Budama-Kilinc Y., Cakir Koc R., Et al., Computational design of Phe-tyr dipeptide and preparation, characterization, cytotoxicity studies of Phe-tyr dipeptide loaded PLGA nanoparticles for the treatment of hypertension, J Biomol Struct Dyn, 1102, August, pp. 1-15, (2017); Deng Z., Liu Y., Wang J., Et al., Antihypertensive effects of two novel angiotensin I-converting enzyme (ACE) inhibitory peptides from Gracilariopsis lemaneiformis (Rhodophyta) in spontaneously hypertensive rats (SHRs), Mar Drugs, 16, 9, (2018); Triputra M.A., Yanuar A., Analysis of compounds isolated from gnetum gnemon L. Seeds as potential ACE inhibitors through molecular docking and molecular dynamics simulations, J Young Pharm, 10, 2s, pp. S32-S39, (2018); Walsh C.G., Johnson K.B., Observational cohort studies and the challenges of in silico experiments, JAMA Oncol, 3, 1, pp. 55-57, (2017); Singh K.D., Muthusamy K., Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imi-dazole series as dual AT(1) and ET(A) receptor antagonists, Acta Pharmacol Sin, 34, 12, pp. 1592-1606, (2013); Zheng M., Zhao J., Cui C., Et al., Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies, Med Res Rev, 38, 3, pp. 914-950, (2018); Kircher M., Witten D.M., Jain P., O'Roak B.J., Cooper G.M., Shendure J., A general framework for estimating the relative pathogenicity of human genetic variants, Nat Genet, 46, 3, pp. 310-315, (2014); Karahalil B., Overview of Systems Biology and Omics Technologies, Curr Med Chem, 23, 37, pp. 4221-4230, (2016); Lek M., Karczewski K.J., Minikel E.V., Et al., Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans, Nature, 536, 7616, pp. 285-291, (2016); Singh K., Karthikeyan M., Combined sequence and sequence-structure-based methods for analyzing RAAS gene SNPs: A computational approach, J Recept Signal Transduct Res, 34, 6, pp. 513-526, (2014); Nagamani S., Singh K., Muthusamy K., Combined sequence and sequence-structure based methods for analyzing FGF23, CYP24A1 and VDR genes, Meta Gene, 9, pp. 26-36, (2016); Wang Z., Moult J., SNPs, protein structure, and disease, Hum Mutat, 17, 4, pp. 263-270, (2001); Miller M.P., Kumar S., Understanding human disease mutations through the use of interspecific genetic variation, Hum Mol Genet, 10, 21, pp. 2319-2328, (2001); Sunil K., Giovanna A., Philipp B., SNP2TFBS-a database of regulatory SNPs affecting predicted transcription factor binding site affinity, Nucleic Acids Res, 45, D1, pp. 139-144, (2017); Xiong P., Zhang C., Zheng W., Zhang Y., BindProfX: Assessing mutation-induced binding affinity change by protein interface profiles with pseudo-counts, J Mol Biol, 429, 3, pp. 426-434, (2017); Jubb H.C., Pandurangan A.P., Turner M.A., Ochoa-Montano B., Blundell T.L., Ascher D.B., Mutations at protein-protein interfaces: Small changes over big surfaces have large impacts on human health, Prog Biophys Mol Biol, 128, pp. 3-13, (2017); Patriotis C., Maruvada P., Srivastava S., Molecular Detection and Diagnosis of Cancer, Mol. Basis Hum. Cancer, pp. 797-809, (2016); Acharya K.R., Sturrock E.D., Riordan J.F., Ehlers M.R.W., Ace revisited: A new target for structure-based drug design, Nat Rev Drug Discov, 2, 11, pp. 891-902, (2003); Patchett A.A., Harris E., Tristram E.W., Et al., A new class of angiotensin-converting enzyme inhibitors, Nature, 288, 5788, pp. 280-283, (1980); von Itzstein M., Wu W.Y., Kok G.B., Et al., Rational design of potent sialidase-based inhibitors of influenza virus replication, Nature, 363, 6428, pp. 418-423, (1993); Colman P.M., Varghese J.N., Laver W.G., Structure of the catalytic and antigenic sites in influenza virus neuraminidase, Nature, 303, 5912, pp. 41-44, (1983); Lu X., Yang H., Chen Y., Et al., The development of pharmacophore modeling: Generation and recent applications in drug discovery, Curr Pharm Des, 24, 29, pp. 3424-3439, (2018)","K. Muthusamy; Department of Bioinformatics, Alagappa University, Karaikudi, India; email: mkbioinformatics@gmail.com","","Bentham Science Publishers","","","","","","13894501","","CDTUA","31393243","English","Curr. Drug Targets","Review","Final","","Scopus","2-s2.0-85076082571"
"Padullés A.; Rama I.; Llaudó I.; Lloberas N.","Padullés, Ariadna (17346673700); Rama, Inés (6508118497); Llaudó, Inés (35774436100); Lloberas, Núria (6602858744)","17346673700; 6508118497; 35774436100; 6602858744","Developments in renal pharmacogenomics and applications in chronic kidney disease","2014","Pharmacogenomics and Personalized Medicine","7","1","","251","266","15","10","10.2147/PGPM.S52763","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940322474&doi=10.2147%2fPGPM.S52763&partnerID=40&md5=0ec5446602aebe7bf13650c7ea22f7c4","Pharmacy Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Nephrology Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain","Padullés A., Pharmacy Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Rama I., Nephrology Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Llaudó I., Nephrology Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Lloberas N., Nephrology Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain","Chronic kidney disease (CKD) has shown an increasing prevalence in the last century. CKD encompasses a poor prognosis related to a remarkable number of comorbidities, and many patients suffer from this disease progression. Once the factors linked with CKD evolution are distinguished, it will be possible to provide and enhance a more intensive treatment to high-risk patients. In this review, we focus on the emerging markers that might be predictive or related to CKD progression physiopathology as well as those related to a different pattern of response to treatment, such as inhibitors of the renin-angiotensin system (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; the vitamin D receptor agonist; salt sensitivity hypertension; and progressive kidney-disease markers with identified genetic polymorphisms). Candidate-gene association studies and genome-wide association studies have analyzed the genetic basis for common renal diseases, including CKD and related factors such as diabetes and hypertension. This review will, in brief, consider genotype-based pharmacotherapy, risk prediction, drug target recognition, and personalized treatments, and will mainly focus on findings in CKD patients. An improved understanding will smooth the progress of switching from classical clinical medicine to gene-based medicine. © 2014 Padullés et al.","Angiotensin-converting enzyme; Biomarkers; Diabetes; Gene polymorphisms; Hypertension; Renal treatment","5,10 methylenetetrahydrofolate reductase (FADH2); amlodipine; angiotensin receptor antagonist; atenolol; bardoxolone; calcitriol; candesartan; captopril; chemokine receptor CCR5; cyclosporin; cytochrome P450 1A2; cytochrome P450 2C9; cytochrome P450 3A5; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; enalapril; hydroxymethylglutaryl coenzyme A reductase inhibitor; irbesartan; lisinopril; losartan; multidrug resistance protein 1; myosin IIA; palmidrol; peroxisome proliferator activated receptor alpha; pregnane X receptor; sodium chloride; tacrolimus; valsartan; vitamin D receptor; ABCB1 gene; ACE gene; antihypertensive activity; antiinflammatory activity; chronic kidney disease; CYP1A2 gene; CYP3A5 gene; diabetes mellitus; disease course; disease marker; drug blood level; drug metabolism; drug targeting; gene; gene expression regulation; gene mutation; genetic association; genetic polymorphism; genotype; hemodialysis; homozygosity; human; hypertension; MYH9 gene; pathogenesis; pathophysiology; personalized medicine; pharmacogenomics; phase 2 clinical trial (topic); phase 3 clinical trial (topic); prediction; review; risk assessment; salt intake; single nucleotide polymorphism; sodium restriction; treatment response; unspecified side effect","","5,10 methylenetetrahydrofolate reductase (FADH2), 9028-69-7; amlodipine, 88150-42-9, 103129-82-4, 736178-83-9; atenolol, 29122-68-7, 93379-54-5; bardoxolone, 218600-44-3; calcitriol, 32222-06-3, 32511-63-0, 66772-14-3; candesartan, 139481-59-7; captopril, 62571-86-2; cyclosporin, 79217-60-0; cytochrome P450 3A5, 336874-97-6; dipeptidyl carboxypeptidase, 9015-82-1; enalapril, 75847-73-3; irbesartan, 138402-11-6; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; palmidrol, 544-31-0; peroxisome proliferator activated receptor alpha, 147258-70-6; pregnane X receptor, 259206-22-9; sodium chloride, 7647-14-5; tacrolimus, 104987-11-3; valsartan, 137862-53-4","","","","","Levey A.S., Atkins R., Coresh J., Et al., Chronic kidney disease as a global public health problem: Approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes, Kidney Int, 72, 3, pp. 247-259, (2007); Taal M.W., Chronic Kidney Disease in General Populations and Primary Care, Curr Opin Nephrol Hypertens, 22, 6, pp. 593-598, (2013); Jha V., Garcia-Garcia G., Iseki K., Et al., Chronic kidney disease: Global dimension and perspectives, Lancet, 382, 9888, pp. 260-272, (2013); Ball S., Lloyd J., Cairns T., Et al., Why is there so much end-stage renal failure of undetermined cause in UK Indo-Asians?, QJM, 94, 4, pp. 187-193, (2001); Kronenberg F., Emerging risk factors and markers of chronic kidney disease progression, Nat Rev Nephrol, 5, 12, pp. 677-689, (2009); Hallan S.I., Coresh J., Astor B.C., Et al., International comparison of the relationship of chronic kidney disease prevalence and ESRD risk, J Am Soc Nephrol, 17, 8, pp. 2275-2284, (2006); Chadban S.J., Briganti E.M., Kerr P.G., Et al., Prevalence of kidney damage in Australian adults: The AusDiab kidney study, J Am Soc Nephrol, 14, 7 SUPPL. 2, (2003); Bowling C.B., Inker L.A., Gutierrez O.M., Et al., Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications, Clin J Am Soc Nephrol, 6, 12, pp. 2822-2828, (2011); Dalrymple L.S., Mohammed S.M., Mu Y., Et al., Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis, Clin J Am Soc Nephrol, 6, 7, pp. 1708-1713, (2011); Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med, 351, 13, pp. 1296-1305, (2004); Coresh J., Selvin E., Stevens L.A., Et al., Prevalence of chronic kidney disease in the United States, JAMA, 298, 17, pp. 2038-2047, (2007); Otero A., de Francisco A., Gayoso P., Garcia F., Prevalence of chronic renal disease in Spain: Results of the EPIRCE study, Nefrologia, 30, 1, pp. 78-86, (2010); Taal M.W., Screening for chronic kidney disease: Preventing harm or harming the healthy?, PLoS Med, 9, 11, (2012); Hallan S.I., Vikse B.E., Relationship between chronic kidney disease prevalence and end-stage renal disease risk, Curr Opin Nephrol Hypertens, 17, 3, pp. 286-291, (2008); Bochud M., Burnier M., Guessous I., Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine, Curr Pharmacogenomics Person Med, 9, 4, pp. 299-322, (2011); Foley R.N., Collins A.J., End-stage renal disease in the United States: An update from the United States Renal Data System, J Am Soc Nephrol, 18, 10, pp. 2644-2648, (2007); Drawz P.E., Sedor J.R., The genetics of common kidney disease: A pathway toward clinical relevance, Nat Rev Nephrol, 7, 8, pp. 458-468, (2011); Ruggenenti P., Cravedi P., Remuzzi G., The RAAS in the pathogenesis and treatment of diabetic nephropathy, Nat Rev Nephrol, 6, 6, pp. 319-330, (2010); Rossing P., Hommel E., Smidt U.M., Parving H.H., Reduction in albuminuria predicts diminished progression in diabetic nephropathy, Kidney Int Suppl, 45, (1994); Apperloo A.J., de Zeeuw D., de Jong P.E., Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease, Kidney Int Suppl, 45, (1994); Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 20, pp. 1456-1462, (1993); Brenner B.M., Cooper M.E., de Zeeuw D., Et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 12, pp. 861-869, (2001); Sowers J.R., Whaley-Connell A., Epstein M., Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension, Ann Intern Med, 150, 11, pp. 776-783, (2009); Ruster C., Wolf G., Renin-angiotensin-aldosterone system and progression of renal disease, J Am Soc Nephrol, 17, 11, pp. 2985-2991, (2006); Taal M.W., Brenner B.M., Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists, Kidney Int, 57, 5, pp. 1803-1817, (2000); Liu S., Vaziri N.D., Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome, Nephrol Dial Transplant, 29, 3, pp. 538-543, (2014); Levin A., Bakris G.L., Molitch M., Et al., Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease, Kidney Int, 71, 1, pp. 31-38, (2007); Wolf M., Betancourt J., Chang Y., Et al., Impact of activated vitamin D and race on survival among hemodialysis patients, J Am Soc Nephrol, 19, 7, pp. 1379-1388, (2008); Tan X., Li Y., Liu Y., Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy, J Am Soc Nephrol, 17, 12, pp. 3382-3393, (2006); Makibayashi K., Tatematsu M., Hirata M., Et al., A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis, Am J Pathol, 158, 5, pp. 1733-1741, (2001); Fishbane S., Chittineni H., Packman M., Dutka P., Ali N., Durie N., Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial, Am J Kidney Dis, 54, 4, pp. 647-652, (2009); Szeto C.C., Chow K.M., Kwan B.C., Chung K.Y., Leung C.B., Li P.K., Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: An uncontrolled trial, Am J Kidney Dis, 51, 5, pp. 724-731, (2008); Bonizzi G., Karin M., The two NF-kappaB activation pathways and their role in innate and adaptive immunity, Trends Immunol, 25, 6, pp. 280-288, (2004); Resnick L.M., Muller F.B., Laragh J.H., Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism, Ann Intern Med, 105, 5, pp. 649-654, (1986); Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P., 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system, J Clin Invest, 110, 2, pp. 229-238, (2002); Guijarro C., Egido J., Transcription factor-kappa B (NF-kappa B) and renal disease, Kidney Int, 59, 2, pp. 415-424, (2001); Richart T., Li Y., Staessen J.A., Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension, Am J Hypertens, 20, 9, pp. 1007-1015, (2007); Sanada H., Jones J.E., Jose P.A., Genetics of salt-sensitive hypertension, Curr Hypertens Rep, 13, 1, pp. 55-66, (2011); Lambers H.H.J., Holtkamp F.A., Parving H.H., Et al., Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers, Kidney Int, 82, 3, pp. 330-337, (2012); Vegter S., Perna A., Postma M.J., Navis G., Remuzzi G., Ruggenenti P., Sodium intake, ACE inhibition, and progression to ESRD, J Am Soc Nephrol, 23, 1, pp. 165-173, (2012); Turner J.M., Bauer C., Abramowitz M.K., Melamed M.L., Hostetter T.H., Treatment of chronic kidney disease, Kidney Int, 81, 4, pp. 351-362, (2012); Pergola P.E., Krauth M., Huff J.W., Et al., Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD, Am J Nephrol, 33, 5, pp. 469-476, (2011); Pergola P.E., Raskin P., Toto R.D., Et al., Bardoxolone methyl and kidney function in CKD with type 2 diabetes, N Engl J Med, 365, 4, pp. 327-336, (2011); Indraccolo U., Barbieri F., Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations, Eur J Obstet Gynecol Reprod Biol, 150, 1, pp. 76-79, (2010); Truini A., Biasiotta A., Di Stefano G., Et al., Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy, CNS Neurol Disord Drug Targets, 10, 8, pp. 916-920, (2011); Yoshihara D., Kugita M., Yamaguchi T., Et al., Global Gene Expression Profiling in PPAR-γ Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease, PPAR Res, 2012, (2012); Park C.W., Zhang Y., Zhang X., Et al., PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice, Kidney Int, 69, 9, pp. 1511-1517, (2006); Merk D., Schubert-Zsilavecz M., New hope or drawbacks: Will chronic kidney disease be treatable with small molecules in the near future?, Future Med Chem, 4, 3, pp. 269-271, (2012); Wang L., McLeod H.L., Weinshilboum R.M., Genomics and drug response, N Engl J Med, 364, 12, pp. 1144-1153, (2011); Rahmioglu N., Heaton J., Clement G., Et al., Genetic epidemiology of induced CYP3A4 activity, Pharmacogenet Genomics, 21, 10, pp. 642-651, (2011); Soderland P., Lovekar S., Weiner D.E., Brooks D.R., Kaufman J.S., Chronic kidney disease associated with environmental toxins and exposures, Adv Chronic Kidney Dis, 17, 3, pp. 254-264, (2010); Rajapurkar M.M., John G.T., Kirpalani A.L., Et al., What do we know about chronic kidney disease in India: First report of the Indian CKD registry, BMC Nephrol, 13, (2012); Wang X.L., Greco M., Sim A.S., Duarte N., Wang J., Wilcken D.E., Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes, Atherosclerosis, 162, 2, pp. 391-397, (2002); Sergentanis T.N., Economopoulos K.P., Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: A meta-analysis, Breast Cancer Res Treat, 122, 2, pp. 459-469, (2010); Wright C.M., Larsen J.E., Colosimo M.L., Et al., Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer, Eur Respir J, 35, 1, pp. 152-159, (2010); Chen J., Cheng M., Yi L., Jiang C.B., Relationship between CYP1A1 genetic polymorphisms and renal cancer in China, Asian Pac J Cancer Prev, 12, 9, pp. 2163-2166, (2011); Siddarth M., Datta S.K., Ahmed R.S., Banerjee B.D., Kalra O.P., Tripathi A.K., Association of CYP1A1 gene polymorphism with chronic kidney disease: A case control study, Environ Toxicol Pharmacol, 36, 1, pp. 164-170, (2013); Sobti R.C., Sharma S., Joshi A., Jindal S.K., Janmeja A., Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a North Indian population, Mol Cell Biochem, 266, 1-2, pp. 1-9, (2004); Sreeja L., Syamala V., Hariharan S., Madhavan J., Devan S.C., Ankathil R., Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphism in lung cancer susceptibility in a south Indian population, J Hum Genet, 50, 12, pp. 618-627, (2005); Anantharaman D., Chaubal P.M., Kannan S., Bhisey R.A., Mahimkar M.B., Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: Tobacco exposure a risk modulator, Cacinogenesis, 28, 7, pp. 1455-1462, (2007); Gunes A., Dahl M.L., Variation in CYP1A2 activity and its clinical implications: Influence of environmental factors and genetic polymorphisms, Pharmacogenomics, 9, 5, pp. 625-637, (2008); Hallberg P., Karlsson J., Kurland L., Et al., The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, J Hypertens, 20, 10, pp. 2089-2093, (2002); Cornelis M.C., Monda K.L., Yu K., Et al., Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption, PLoS Genet, 7, 4, (2011); Noordzij M., Uiterwaal C.S., Arends L.R., Kok F.J., Grobbee D.E., Geleijnse J.M., Blood pressure response to chronic intake of coffee and caffeine: A meta-analysis of randomized controlled trials, J Hypertens, 23, 5, pp. 921-928, (2005); Klag M.J., Wang N.Y., Meoni L.A., Et al., Coffee intake and risk of hypertension: The Johns Hopkins precursors study, Arch Intern Med, 162, 6, pp. 657-662, (2002); Winkelmayer W.C., Stampfer M.J., Willett W.C., Curhan G.C., Habitual caffeine intake and the risk of hypertension in women, JAMA, 294, 18, pp. 2330-2335, (2005); Bochud M., Bovet P., Burnier M., Eap C.B., CYP3A5 and ABCB1 genes and hypertension, Pharmacogenomics, 10, 3, pp. 477-487, (2009); Wilkinson G.R., Drug metabolism and variability among patients in drug response, N Engl J Med, 352, 21, pp. 2211-2221, (2005); Siest G., Jeannesson E., Visvikis-Siest S., Enzymes and pharmacogenetics of cardiovascular drugs, Clin Chim Acta, 381, 1, pp. 26-31, (2007); Daly A.K., Significance of the minor cytochrome P450 3A isoforms, Clin Pharmacokinet, 45, 1, pp. 13-31, (2006); Willrich M.A., Hirata M.H., Hirata R.D., Statin regulation of CYP3A4 and CYP3A5 expression, Pharmacogenomics, 10, 6, pp. 1017-1024, (2009); Jin Y., Wang Y.H., Miao J., Et al., Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects, Clin Pharmacol Ther, 82, 5, pp. 579-585, (2007); Eap C.B., Bochud M., Elston R.C., Et al., CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt, Hypertension, 49, 5, pp. 1007-1014, (2007); Kim K.A., Park P.W., Lee O.J., Et al., Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects, Clin Pharmacol Ther, 80, 6, pp. 646-656, (2006); Kim R.B., Drugs as P-glycoprotein substrates, inhibitors, and inducers, Drug Metab Rev, 34, 1-2, pp. 47-54, (2002); Llaudo I., Colom H., Gimenez-Bonafe P., Et al., Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study, Transpl Int, 26, 2, pp. 177-186, (2013); Liu M., Li Y., Citterio L., Et al., A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese, Am J Hypertens, 26, 12, pp. 1428-1436, (2013); Burk O., Arnold K.A., Geick A., Tegude H., Eichelbaum M., A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression, Biol Chem, 386, 6, pp. 503-513, (2005); Tachibana S., Yoshinari K., Chikada T., Toriyabe T., Nagata K., Yamazoe Y., Involvement of Vitamin D receptor in the intestinal induction of human ABCB1, Drug Metab Dispos, 37, 8, pp. 1604-1610, (2009); Saeki M., Kurose K., Tohkin M., Hasegawa R., Identification of the functional vitamin D response elements in the human MDR1 gene, Biochem Pharmacol, 76, 4, pp. 531-542, (2008); Chow E.C., Durk M.R., Cummins C.L., Pang K.S., 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo, J Pharmacol Exp Ther, 337, 3, pp. 846-859, (2011); Kumar R., Schaefer J., Grande J.P., Roche P.C., Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney, Am J Physiol, 266, 3 PART 2, (1994); Schuster I., Cytochromes P450 are essential players in the vitamin D signaling system, Biochim Biophys Acta, 1814, 1, pp. 186-199, (2011); Wang T.T., Tavera-Mendoza L.E., Laperriere D., Et al., Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes, Mol Endocrinol, 19, 11, pp. 2685-2695, (2005); Makishima M., Lu T.T., Xie W., Et al., Vitamin D receptor as an intestinal bile acid sensor, Science, 296, 5571, pp. 1313-1316, (2002); Barthel T.K., Mathern D.R., Et al., 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism, J Steroid Biochem Mol Biol, 103, 3-5, pp. 381-388, (2007); Santoro D., Caccamo D., Gagliostro G., Et al., Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients, J Nephrol, 26, 4, pp. 636-644, (2013); Grzegorzewska A.E., Ostromecki G., Gene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patients, Przegl Lek, 70, 9, pp. 735-738, (2013); de Souza C.M., Braosi A.P., Luczyszyn S.M., Et al., Association between vitamin D receptor gene polymorphisms and susceptibility to chronic kidney disease and periodontitis, Blood Purif, 25, 5-6, pp. 411-419, (2007); Velayoudom-Cephise F.L., Larifla L., Donnet J.P., Et al., Vitamin D deficiency, vitamin D receptor gene polymorphisms and cardiovascular risk factors in Caribbean patients with type 2 diabetes, Diabetes Metab, 37, 6, pp. 540-545, (2011); Alborzi P., Patel N.A., Peterson C., Et al., Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial, Hypertension, 52, 2, pp. 249-255, (2008); Agarwal R., Acharya M., Tian J., Et al., Antiproteinuric effect of oral paricalcitol in chronic kidney disease, Kidney Int, 68, 6, pp. 2823-2828, (2005); de Zeeuw D., Agarwal R., Amdahl M., Et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial, Lancet, 376, 9752, pp. 1543-1551, (2010); Levi M., Nuclear receptors in renal disease, Biochim Biophys Acta, 1812, 8, pp. 1061-1067, (2011); Gard P.R., Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: A snapshot review, Int J Mol Epidemiol Genet, 1, 2, pp. 145-157, (2010); Sayed-Tabatabaei F.A., Oostra B.A., Isaacs A., van Duijn C.M., Witteman J.C., ACE polymorphisms, Circ Res, 98, 9, pp. 1123-1133, (2006); Kramers C., Danilov S.M., Deinum J., Et al., Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease, Circulation, 104, 11, pp. 1236-1240, (2001); Rieder M.J., Taylor S.L., Clark A.G., Nickerson D.A., Sequence variation in the human angiotensin converting enzyme, Nat Genet, 22, 1, pp. 59-62, (1999); Ruggenenti P., Bettinaglio P., Pinares F., Remuzzi G., Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies, Clin J Am Soc Nephrol, 3, 5, pp. 1511-1525, (2008); Santos P.C., Krieger J.E., Pereira A.C., Renin-angiotensin system, hypertension, and chronic kidney disease: Pharmacogenetic implications, J Pharmacol Sci, 120, 2, pp. 77-88, (2012); Penno G., Chaturvedi N., Talmud P.J., Et al., Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: Findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM, Diabetes, 47, 9, pp. 1507-1511, (1998); Ueda S., Meredith P.A., Morton J.J., Connell J.M., Elliott H.L., ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans, Circulation, 98, 20, pp. 2148-2153, (1998); Jacobsen P., Rossing K., Rossing P., Et al., Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy, Kidney Int, 53, 4, pp. 1002-1006, (1998); Jacobsen P., Tarnow L., Carstensen B., Hovind P., Poirier O., Parving H.H., Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy, J Am Soc Nephrol, 14, 11, pp. 2843-2850, (2003); Parving H.H., de Zeeuw D., Cooper M.E., Et al., ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy, J Am Soc Nephrol, 19, 4, pp. 771-779, (2008); So W.Y., Ma R.C., Ozaki R., Et al., Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism, Kidney Int, 69, 8, pp. 1438-1443, (2006); Filigheddu F., Argiolas G., Bulla E., Et al., Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians, Pharmacogenomics, 9, 10, pp. 1419-1427, (2008); Yu H., Zhang Y., Liu G., Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients, Hypertens Res, 26, 11, pp. 881-886, (2003); Arnett D.K., Davis B.R., Ford C.E., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, 25, pp. 3374-3383, (2005); Nonoguchi H., Nakayama Y., Shiigai T., Et al., Low-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme, Clin Nephrol, 68, 4, pp. 209-215, (2007); Adler S., Renal disease: Environment, race, or genes?, Ethn Dis, 16, 2 SUPPL. 2, pp. 35-39, (2006); Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, 9455, pp. 217-223, (2005); Ibrahim M.M., Damasceno A., Hypertension in developing countries, Lancet, 380, 9841, pp. 611-619, (2012); Shaw J.E., Sicree R.A., Zimmet P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030, Diabetes Res Clin Pract, 87, 1, pp. 4-14, (2010); Wang Y., Mi J., Shan X.Y., Wang Q.J., Ge K.Y., Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China, Int J Obes (Lond), 31, 1, pp. 177-188, (2007); Hall M.E., do Carmo J.M., da Silva A.A., Juncos L.A., Wang Z., Hall J.E., Obesity, hypertension, and chronic kidney disease, Int J Nephrol Renovasc Dis, 7, pp. 75-88, (2014); Kottgen A., Pattaro C., Boger C.A., Et al., New loci associated with kidney function and chronic kidney disease, Nat Genet, 42, 5, pp. 376-384, (2010); Summers S.A., Steinmetz O.M., Ooi J.D., Et al., Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis, Am J Pathol, 177, 5, pp. 2234-2244, (2010); Summers S.A., Hoi A., Steinmetz O.M., Et al., TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy, J Autoimmun, 35, 4, pp. 291-298, (2010); Bochud P.Y., Hersberger M., Taffe P., Et al., Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection, AIDS, 21, 4, pp. 441-446, (2007); Krayenbuehl P.A., Hersberger M., Truninger K., Et al., Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis, Eur J Gastroenterol Hepatol, 22, 7, pp. 835-841, (2010); Yang H.Y., Lu K.C., Lee H.S., Et al., Role of the functional Toll-Like receptor-9 promoter polymorphism (1237T/C) in increased risk of end-stage renal disease: A case-control study, PLoS One, 8, 3, (2013); Jimenez-Sousa M.A., Lopez E., Fernandez-Rodriguez A., Et al., Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: A preliminary study, BMC Med Genet, 13, (2012); Singh V., Jaiswal P.K., Tiwari P., Kapoor R., Mittal R.D., Association of chemokine gene variants with end stage renal disease in North Indian population, Transpl Immunol, 28, 4, pp. 189-192, (2013); Nabrdalik K., Gumprecht J., Adamczyk P., Gorczynska-Kosiorz S., Zywiec J., Grzeszczak W., Association of rs1800471 polymorphism of TGFB1 gene with chronic kidney disease occurrence and progression and hypertension appearance, Arch Med Sci, 9, 2, pp. 230-237, (2013); Buraczynska M., Baranowicz-Gaszczyk I., Borowicz E., Ksiazek A., TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes, Nephron Physiol, 106, 4, (2007); Coll E., Cormand B., Campos B., Et al., Association of TGF-beta1 polymorphisms with chronic renal disease, J Nephrol, 17, 6, pp. 794-799, (2004); Ng D.P., Warram J.H., Krolewski A.S., TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: An investigation of multiple known DNA sequence variants, Am J Kidney Dis, 41, 1, pp. 22-28, (2003); McKnight A.J., Savage D.A., Patterson C.C., Sadlier D., Maxwell A.P., Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy, BMC Med Genet, 8, (2007); Babel N., Gabdrakhmanova L., Hammer M.H., Et al., Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease, J Nephrol, 19, 6, pp. 802-807, (2006); Yu Z.Y., Chen L.S., Zhang L.C., Zhou T.B., Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy, Nephrology (Carlton), 17, 5, pp. 480-487, (2012); Zhou T.B., Yin S.S., Qin Y.H., Association of angiotensinogen M235T gene polymorphism with end-stage renal disease risk: A meta-analysis, Mol Biol Rep, 40, 2, pp. 765-772, (2013); Silva P.S., Fontana V., Luizon M.R., Et al., eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril, Eur J Clin Pharmacol, 69, 2, pp. 167-177, (2013); Behar D.M., Rosset S., Tzur S., Et al., African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans, Hum Mol Genet, 19, 9, pp. 1816-1827, (2010); Freedman B.I., Hicks P.J., Bostrom M.A., Et al., Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD, Nephrol Dial Transplant, 24, 11, pp. 3366-3371, (2009); Freedman B.I., Hicks P.J., Bostrom M.A., Et al., Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans, Kidney Int, 75, 7, pp. 736-745, (2009); Kao W.H., Klag M.J., Meoni L.A., Et al., MYH9 is associated with nondiabetic end-stage renal disease in African Americans, Nat Genet, 40, 10, pp. 1185-1192, (2008); Kopp J.B., Smith M.W., Nelson G.W., Et al., MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis, Nat Genet, 40, 10, pp. 1175-1184, (2008); Cooke J.N., Bostrom M.A., Hicks P.J., Et al., Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans, Nephrol Dial Transplant, 27, 4, pp. 1505-1511, (2012); Matsha T.E., Masconi K., Yako Y.Y., Et al., Polymorphisms in the non-muscle myosin heavy chain gene (MYH9) are associated with lower glomerular filtration rate in mixed ancestry diabetic subjects from South Africa, PLoS One, 7, 12, (2012); Tavira B., Coto E., Gomez J., Et al., Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort, Gene, 520, 1, pp. 73-76, (2013); Freedman B.I., Kopp J.B., Langefeld C.D., Et al., The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans, J Am Soc Nephrol, 21, 9, pp. 1422-1426, (2010); Genovese G., Friedman D.J., Ross M.D., Et al., Association of trypanolytic ApoL1 variants with kidney disease in African Americans, Science, 329, 5993, pp. 841-845, (2010); Genovese G., Tonna S.J., Knob A.U., Et al., A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9, Kidney Int, 78, 7, pp. 698-704, (2010); Tzur S., Rosset S., Shemer R., Et al., Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene, Hum Genet, 128, 3, pp. 345-350, (2010); O'Seaghdha C.M., Parekh R.S., Hwang S.J., Et al., The MYH9/APOL1 region and chronic kidney disease in European-Americans, Hum Mol Genet, 20, 12, pp. 2450-2456, (2011); Witasp A., Nordfors L., Carrero J.J., Et al., Genetic studies in chronic kidney disease: Interpretation and clinical applicability, J Nephrol, 25, 6, pp. 851-864, (2012); Prior T.W., Carrier screening for spinal muscular atrophy, Genet Med, 10, 11, pp. 840-842, (2008); Miller D.T., Adam M.P., Aradhya S., Et al., Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies, Am J Hum Genet, 86, 5, pp. 749-764, (2010); Robson M., Offit K., Clinical practice. Management of an inherited predisposition to breast cancer, N Engl J Med, 357, 2, pp. 154-162, (2007); Frueh F.W., Amur S., Mummaneni P., Et al., Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: Prevalence of related drug use, Pharmacotherapy, 28, 8, pp. 992-998, (2008); Wienkers L.C., Heath T.G., Predicting in vivo drug interactions from in vitro drug discovery data, Nat Rev Drug Discov, 4, 10, pp. 825-833, (2005); Molanaei H., Carrero J.J., Heimburger O., Et al., Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease, Eur J Clin Pharmacol, 66, 3, pp. 269-273, (2010); van Essen G.G., Rensma P.L., de Zeeuw D., Et al., Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy, Lancet, 347, 8994, pp. 94-95, (1996); Carrero J.J., Qureshi A.R., Parini P., Et al., Low serum testosterone increases mortality risk among male dialysis patients, J Am Soc Nephrol, 20, 3, pp. 613-620, (2009); Muntinghe F.L., Verduijn M., Zuurman M.W., Et al., CCR5 deletion protects against inflammation-associated mortality in dialysis patients, J Am Soc Nephrol, 20, 7, pp. 1641-1649, (2009); Muntinghe F.L., Vegter S., Verduijn M., Et al., Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients, Pharmacogenet Genomics, 21, 7, pp. 417-425, (2011); Board P., Coggan M., Johnston P., Ross V., Suzuki T., Webb G., Genetic heterogeneity of the human glutathione transferases: A complex of gene families, Pharmacol Ther, 48, 3, pp. 357-369, (1990); Ryberg D., Skaug V., Hewer A., Et al., Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk, Carcinogenesis, 18, 7, pp. 1285-1289, (1997); Lin Y.S., Hung S.C., Wei Y.H., Tarng D.C., GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients, J Am Soc Nephrol, 20, 2, pp. 405-415, (2009); Filiopoulos V., Vlassopoulos D., Inflammatory syndrome in chronic kidney disease: Pathogenesis and influence on outcomes, Inflamm Allergy Drug Targets, 8, 5, pp. 369-382, (2009); Nordfors L., Lindholm B., Stenvinkel P., End-stage renal disease - not an equal opportunity disease: The role of genetic polymorphisms, J Intern Med, 258, 1, pp. 1-12, (2005); Stenvinkel P., Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease, J Intern Med, 268, 5, pp. 456-467, (2010); Hunter D.J., Gene-environment interactions in human diseases, Nat Rev Genet, 6, 4, pp. 287-298, (2005); Smilde T.D., Asselbergs F.W., Hillege H.L., Et al., Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy, Am J Hypertens, 18, 3, pp. 342-347, (2005); Smilde T.D., Zuurman M.W., Hillege H.L., Et al., Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy, Am J Hypertens, 20, 10, pp. 1097-1103, (2007); Kuznetsova T., Staessen J.A., Thijs L., Et al., Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion, Circulation, 110, 17, pp. 2644-2650, (2004); Ohishi M., Rakugi H., Ogihara T., Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy, N Engl J Med, 331, 16, pp. 1097-1098, (1994); Schunkert H., Controversial association of left ventricular hypertrophy and the ACE I/D polymorphism - is the mist clearing up?, Nephrol Dial Transplant, 13, 5, pp. 1109-1112, (1998); Brewster U.C., Perazella M.A., The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease, Am J Med, 116, 4, pp. 263-272, (2004); van der Kleij F.G., Schmidt A., Navis G.J., Et al., Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status, Kidney Int Suppl, 63, (1997)","N. Lloberas; Nephrology Service, Hospital, Universitari de Bellvitge, Lab Exp Nephrology 4122, 08907 L'Hospitalet de Llobregat, Barcelona, Pab Govern, 4a planta, UB, Feixa Llarga s/n, Spain; email: nlloberas@ub.edu","","","","","","","","11787066","","","","English","PharmacoEcon. Personalized Med.","Review","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84940322474"
"Carnevale D.; Lembo G.","Carnevale, Daniela (22936816400); Lembo, Giuseppe (6506460100)","22936816400; 6506460100","PI3Kγ in hypertension: A novel therapeutic target controlling vascular myogenic tone and target organ damage","2012","Cardiovascular Research","95","4","","403","408","5","31","10.1093/cvr/cvs166","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865275725&doi=10.1093%2fcvr%2fcvs166&partnerID=40&md5=6bfc6a91231af9776dade5571eb84f56","Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli (IS), Italy; Department of Molecular Medicine, Sapienza University of Rome C/o IRCCS Neuromed, Pozzilli (IS), Italy","Carnevale D., Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli (IS), Italy, Department of Molecular Medicine, Sapienza University of Rome C/o IRCCS Neuromed, Pozzilli (IS), Italy; Lembo G., Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli (IS), Italy, Department of Molecular Medicine, Sapienza University of Rome C/o IRCCS Neuromed, Pozzilli (IS), Italy","In the past decade, several studies have characterized a number of cellular and molecular mechanisms that contribute to the regulation of the vascular myogenic response, thus affecting blood pressure regulation. Recently, phosphoinositide 3-kinase γ (PI3Kγ) has been identified as a main regulator of vascular myogenic tone and blood pressure, a result further strengthened by a highly significant genome-wide association of a single nucleotide polymorphism flanking this gene with blood pressure regulation, in a large human population. The goal of this review is to summarize the available information regarding the mechanism whereby PI3Kγ exerts blood pressure control, regulating myogenic tone at the level of L-type calcium channel in smooth muscle cells. Moreover, an overview of the pharmacological approaches available for targeting this signalling pathway shows that PI3Kγ is a suitable candidate for antihypertensive therapy, capable of lowering blood pressure. Finally, a survey of the studies dissecting the role of PI3Kγ in pathological conditions that are typically induced by hypertension in its target organs provides a more complete picture of the high potential of this novel therapeutic approach for fighting hypertension and, at the same time, its target organ damage, independently of bloodpressure-lowering effects. © 2012 The Author.","Cell signalling; Inflammation; Myogenic tone; Phosphoinositide 3-kinase γ; Signal transduction","Animals; Antihypertensive Agents; Arterial Pressure; Calcium Channels, L-Type; Genetic Predisposition to Disease; Humans; Hypertension; Muscle, Smooth, Vascular; Phenotype; Phosphatidylinositol 3-Kinase; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Signal Transduction; 5 (6 quinoxalinylmethylene) 2,4 thiazolidinedione; 5 [5 (4 fluoro 2 hydroxyphenyl)furfurylidene] 2,4 thiazolidinedione; angiotensin II; beta adrenergic receptor; calcium channel; calcium channel L type; cyclic AMP; G protein coupled receptor; ge 21; isoenzyme; phosphatidylinositol 3 kinase gamma; phosphatidylinositol 3 kinase inhibitor; protein kinase B; Ras protein; unclassified drug; adrenergic stimulation; atherosclerosis; blood pressure regulation; calcium transport; disease course; drug targeting; environmental stress; enzyme activity; enzyme structure; enzyme subunit; genetic association; heart failure; heart infarction; heart muscle cell; heart muscle contractility; heart muscle necrosis; human; hypertension; immune deficiency; intracellular signaling; lupus erythematosus nephritis; mean arterial pressure; mechanotransduction; nonhuman; priority journal; protein expression; pulse pressure; review; rheumatoid arthritis; signal transduction; single nucleotide polymorphism; smooth muscle fiber; systemic lupus erythematosus; vasoconstriction; vasodilatation","","angiotensin II, 11128-99-7; cyclic AMP, 60-92-4; protein kinase B, 148640-14-6; Antihypertensive Agents, ; Calcium Channels, L-Type, ; Phosphatidylinositol 3-Kinase, 2.7.1.137; Protein Kinase Inhibitors, ","as 252424; as 605240; ge 21","","Fondazione Roma; Italian Ministry of Health","This work was supported by Italian Ministry of Health ‘Ricerca corrente’, ‘Cinquepermille’, ‘Ricerca finalizzata 2007’, by ‘Sapienza’ University ‘Ateneo Federato 2008’, and by ‘Fondazione Roma’ to G.L.","MacMahon S., Blood pressure and the risk of cardiovascular disease, N Eng J Med, 342, pp. 50-52, (2000); Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., Et al., Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction, J Exp Med, 204, pp. 2449-2460, (2007); Tang K.M., Wang G.R., Lu P., Karas R.H., Aronovitz M., Heximer S.P., Et al., Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure, Nat Med, 9, pp. 1506-1512, (2003); Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Et al., Hypertension in mice lacking the gene for endothelial nitric oxide synthase, Nature, 377, pp. 239-242, (1995); Sonoyama K., Greenstein A., Price A., Khavandi K., Heagerty T., Vascular remodeling: Implications for small artery function and target organ damage, Ther Adv Cardiovasc Dis, 1, pp. 129-137, (2007); Hill M.A., Meininger G.A., Davis M.J., Laher I., Therapeutic potential of pharmacologically targeting arteriolar myogenic tone, Trends Pharmacol Sci, 30, pp. 363-374, (2009); Yamazaki D., Tabara Y., Kita S., Hanada H., Komazaki S., Naitou D., Et al., TRIC-A channels in vascular smooth muscle contribute to blood pressure maintenance, Cell Metab, 14, pp. 231-241, (2011); Bergaya S., Faure S., Baudrie V., Rio M., Escoubet B., Bonnin P., Et al., WNK1 regulates vasoconstriction and blood pressure response to a1-adrenergic stimulation in mice, Hypertension, 58, pp. 439-445, (2011); Osol G., Brekke J.F., McElroy-Yaggy K., Gokina N.I., Myogenic tone, reactivity, and forced dilatation: A three-phase model of in vitro arterial myogenic behavior, Am J Physiol Heart Circ Physiol, 283, (2002); Hill M.A., Davis M.J., Meininger G.A., Potocnik S.J., Murphy T.V., Arteriolar myogenic signalling mechanisms: Implications for local vascular function, Clin Hemorheol Microcirc, 34, pp. 67-79, (2006); Wain L.V., Verwoert G.C., O'Reilly P.F., Shi G., Johnson T., Johnson A.D., Et al., Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure, Nat Genet, 43, pp. 1005-1011, (2011); Carnevale D., Vecchione C., Mascio G., Esposito G., Cifelli G., Martinello K., Et al., PI3Kg inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism, Cardiovasc Res, 93, pp. 200-209, (2012); Vecchione C., Patrucco E., Marino G., Barberis L., Poulet R., Aretini A., Et al., Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kg, J Exp Med, 201, pp. 1217-1228, (2005); Cantley L.C., The phosphoinositide 3-kinase pathway, Science, 296, pp. 1655-1657, (2002); Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B., The emerging mechanisms of isoform-specific PI3K signaling, Nat Rev Mol Cell Biol, 11, pp. 329-341, (2010); Kok K., Geering B., Vanhaesebroeck B., Regulation of phosphoinositide 3-kinase expression in health and disease, Trends Biochem Sci, 34, pp. 115-127, (2009); Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., Backx P.H., The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease, J Mol Cell Cardiol, 37, pp. 449-471, (2004); Morello M., Perino A., Hirsch E., Phosphoinositide 3-kinase signalling in the vascular system, Cardiovasc Res, 82, pp. 261-271, (2009); Shiojima I., Walsh K., Role of Akt signaling in vascular homeostasis and angiogenesis, Circ Res, 90, pp. 1243-1250, (2002); Hirsch E., Ciraolo E., Ghigo A., Costa C., Taming the PI3K team to hold inflammation and cancer at bay, Pharmacol Ther, 118, pp. 192-205, (2008); Oudit G.Y., Penninger J.M., Cardiac regulation by phosphoinositide 3-kinases and PTEN, Cardiovasc Res, 82, pp. 250-260, (2009); Harris S.J., Parry R.V., Westwick J., Ward S.G., Phosphoinositide lipid phosphatases: Natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes, J Biol Chem, 283, pp. 2465-2469, (2008); Maehama T., Taylor G.S., Dixon J.E., PTEN and myotubularin: Novel phosphoinositide phosphatases, Annu Rev Biochem, 70, pp. 247-279, (2001); Rohrschneider L.R., Fuller J.F., Wolf I., Liu Y., Lucas D.M., Structure, function, and biology of SHIP proteins, Genes Dev, 14, pp. 505-520, (2000); House S.J., Potier M., Bisaillon J., Singer H.A., Trebak M., The non-excitable smooth muscle: Calcium signaling and phenotypic switching during vascular disease, Pflugers Arch, 456, pp. 769-785, (2008); Suzuki Y., Inoue T., Ra C., L-type Ca<sup>2+</sup> channels: A new player in the regulation of Ca<sup>2+</sup> signaling, cell activation and cell survival in immune cells, Mol Immunol, 47, pp. 640-648, (2010); Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., Et al., Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways, Cell, 110, pp. 737-749, (2002); Naga Prasad S.V., Esposito G., Mao L., Koch W.J., Rockman H.A., Gbg-dependent phos-phoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy, J Biol Chem, 275, pp. 4693-4698, (2000); Oudit G.Y., Crackower M.A., Eriksson U., Sarao R., Kozieradzki I., Sasaki T., Et al., Phos-phoinositide 3-kinase g-deficient mice are protected from isoproterenol-induced heart failure, Circulation, 108, pp. 2147-2152, (2003); Patrucco E., Notte A., Barberis L., Selvetella G., Maffei A., Brancaccio M., Et al., PI3Kg modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects, Cell, 118, pp. 375-387, (2004); Perino A., Ghigo A., Ferrero E., Morello F., Santulli G., Baillie G.S., Et al., Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110g, Mol Cell, 42, pp. 84-95, (2011); Damilano F., Franco I., Perrino C., Schaefer K., Azzolino O., Carnevale D., Et al., Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase g activity in pressure overload-induced cardiac failure, Circulation, 123, pp. 391-399, (2011); Viard P., Exner T., Maier U., Mironneau J., Nurnberg B., MacRez N., Gbg dimers stimulate vascular L-type Ca<sup>2+</sup> channels via phosphoinositide 3-kinase, FASEB J, 13, pp. 685-694, (1999); Quignard J.F., Mironneau J., Carricaburu V., Fournier B., Babich A., Nurnberg B., Et al., Phosphoinositide 3-kinase g mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes, J Biol Chem, 276, pp. 32545-32551, (2001); MacRez N., Mironneau C., Carricaburu V., Quignard J.F., Babich A., Czupala C., Et al., Phos-phoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca<sup>2+</sup> channels, Circ Res, 89, pp. 692-699, (2001); Le Blanc C., Mironneau C., Barbot C., Henaff M., Bondeva T., Wetzker R., Et al., Regulation of vascular L-type Ca<sup>2+</sup> channels by phosphatidylinositol 3, 4, 5-trisphosphate, Circ Res, 95, pp. 300-307, (2004); Viard P., Butcher A.J., Halet G., Davies A., Nurnberg B., Heblich F., Et al., PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane, Nat Neurosci, 7, pp. 939-946, (2004); Catalucci D., Zhang D.H., Desantiago J., Aimond F., Barbara G., Chemin J., Et al., Akt regulates L-type Ca<sup>2+</sup> channel activity by modulating Cava1 protein stability, J Cell Biol, 184, pp. 923-933, (2009); Schubert R., Lidington D., Bolz S., The emerging role of Ca<sup>2+</sup> sensitivity regulation in promoting myogenic vasoconstriction, Cardiovasc Res, 77, pp. 8-18, (2008); Patel A., Sharif-Naeini R., Folgering J.R., Bichet D., Duprat F., Honore E., Canonical TRP channels and mechanotransduction: From physiology to disease states, Pflugers Arch, 460, pp. 571-581, (2010); Camps M., Ruckle T., Ji H., Ardissone V., Rintelen F., Shaw J., Et al., Blockade of PI3Kg suppresses joint inflammation and damage in mouse models of rheumatoid arthritis, Nat Med, 11, pp. 936-943, (2005); Barber D.F., Bartolome A., Hernandez C., Flores J.M., Redondo C., Fernandez-Arias C., Et al., PI3Kg inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus, Nat Med, 11, pp. 933-935, (2005); Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Fine R., Weis S., Et al., Phosphoi-nositide 3-kinase g/d inhibition limits infarct size after myocardial ischemia/reperfu-sion injury, Proc Natl Acad Sci USA, 103, pp. 19866-19871, (2006); Siragusa M., Katare R., Meloni M., Damilano F., Hirsch E., Emanueli C., Et al., Involvement of phosphoinositide 3-kinase g in angiogenesis and healing of experimental myocar-dial infarction in mice, Circ Res, 106, pp. 757-768, (2010); Fougerat A., Gayral S., Gourdy P., Schambourg A., Ruckle T., Schwarz M.K., Et al., Genetic and pharmacological targeting of phosphoinositide 3-kinase-g reduces atherosclerosis and favors plaque stability by modulating inflammatory processes, Circulation, 117, pp. 1310-1317, (2008); Cohuet G., Struijker-Boudier H., Mechanisms of target organ damage caused by hypertension: Therapeutic potential, Pharmacol Ther, 111, pp. 81-98, (2006); Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., Et al., Nonster-oidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events, Circulation, 113, pp. 1578-1587, (2006); Brophy J.M., Cardiovascular risk associated with celecoxib, N Engl J Med, 352, pp. 2648-2650, (2005)","G. Lembo; Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli (IS), Italy; email: giuseppe.lembo@uniroma1.it","","","","","","","","17553245","","CVREA","22610309","English","Cardiovasc. Res.","Review","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84865275725"
"Menni C.; Bagnardi V.; Padmanabhan S.; Facchetti R.; Sega R.; Ferrario M.M.; Brambilla P.; Lee W.K.; Dominiczak A.F.; Mancia G.; Cesana G.","Menni, Cristina (25622426300); Bagnardi, Vincenzo (6602455042); Padmanabhan, Sandosh (7005770659); Facchetti, Rita (55245316000); Sega, Roberto (55397417500); Ferrario, Marco M. (57217784032); Brambilla, Paolo (58336857600); Lee, Wai K. (57194896002); Dominiczak, Anna F. (57203682077); Mancia, Giuseppe (36039693200); Cesana, Giancarlo (7006053466)","25622426300; 6602455042; 7005770659; 55245316000; 55397417500; 57217784032; 58336857600; 57194896002; 57203682077; 36039693200; 7006053466","Evaluation of how gene-job strain interaction affects blood pressure in the PAMELA study","2011","Psychosomatic Medicine","73","4","","304","309","5","10","10.1097/PSY.0b013e318212e0be","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955857888&doi=10.1097%2fPSY.0b013e318212e0be&partnerID=40&md5=a6da4e4f26e3d4ee4172a9cc29493a2b","Department of Statistics, University of Milano-Bicocca, Milano, 20126 Milano, Via Bicocca degli Arcimboldi 8, Italy; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milano, Italy; Study Centre on Public Health, Italy; Department of Experimental Medicine, University of Milano-Bicocca, Monza, Italy; Department of Clinical Medicine and Prevention, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy","Menni C., Department of Statistics, University of Milano-Bicocca, Milano, 20126 Milano, Via Bicocca degli Arcimboldi 8, Italy, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Bagnardi V., Department of Statistics, University of Milano-Bicocca, Milano, 20126 Milano, Via Bicocca degli Arcimboldi 8, Italy, Division of Epidemiology and Biostatistics, European Institute of Oncology, Milano, Italy; Padmanabhan S., BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Facchetti R., Study Centre on Public Health, Italy; Sega R., Study Centre on Public Health, Italy; Ferrario M.M., Study Centre on Public Health, Italy; Brambilla P., Department of Experimental Medicine, University of Milano-Bicocca, Monza, Italy; Lee W.K., BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Dominiczak A.F., BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Mancia G., Department of Clinical Medicine and Prevention, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy; Cesana G., Study Centre on Public Health, Italy","Objective: To see whether there is interaction between single nucleotide polymorphisms (SNPs) belonging to candidate genes for hypertension and job strain and its components (job demand and job control) in an accurately phenotyped Italian cohort (Pressioni Arteriose Monitorate E Loro Associazioni). Methods: From the Pressioni Arteriose Monitorate E Loro Associazioni cohort, we sampled 924 employed men and women who had completed a modified version of the Karasek questionnaire and for whom deoxyribonucleic acid information was available. We selected 1,510 common tagging and putative functional SNPs in 92 candidate autosomal genes involved in sympathetic nervous system, oxidative stress, renin-angiotensin-aldosterone system, and sodium balance. The interaction of each candidate SNP with the perceived job stress scores on ambulatory systolic and diastolic blood pressures was evaluated by adding product terms to a multiple regression linear model, adjusted for sex, age, total cholesterol, and body mass index. Results: Among all the SNPs tested, the interaction of SNP rs11210278 located on the endothelin 2 gene and job control was statistically significant after controlling for multiple testing, using false discovery rate (unadjusted p = .0004661; p adjusted for false discovery rate = .0085), indicating an inverse association with systolic blood pressure for the homozygous wild-type allele (C/C) and a positive association for the variant genotypes (C/T and T/T). Conclusions: We show that the hypertensive response to job strain is present only in carriers of the rs11210278 wild-type genotype. The phenomenon is discussed in relationship to the controversial results of field studies on job strain and hypertension. Copyright © 2011 by the American Psychosomatic Society.","blood pressure; candidate genes; Job strain; psychophysiology; stress perception","Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cohort Studies; Endothelin-2; Female; Gene-Environment Interaction; Genetic Predisposition to Disease; Genotype; Humans; Hypertension; Italy; Linear Models; Male; Middle Aged; Oxidative Stress; Phenotype; Polymorphism, Single Nucleotide; Questionnaires; Renin-Angiotensin System; Risk Factors; Stress, Psychological; Workload; cholesterol; cysteine; DNA; high density lipoprotein cholesterol; sodium; threonine; triacylglycerol; adrenergic system; adult; age distribution; aged; allele; article; autosomal inheritance; blood pressure measurement; body mass; cardiovascular risk; cholesterol blood level; diastolic blood pressure; female; gene interaction; genetic variability; genotype; homozygote; human; hypertension; Italy; job control; job demand; job stress; Karasek questionnaire; lipoprotein blood level; major clinical study; male; occupational health; oxidative stress; phenotype; priority journal; questionnaire; renin angiotensin aldosterone system; sex difference; single nucleotide polymorphism; sodium balance; systolic blood pressure; triacylglycerol blood level; wild type; work","","DNA, 9007-49-2; cholesterol, 57-88-5; cysteine, 4371-52-2, 52-89-1, 52-90-4; sodium, 7440-23-5; threonine, 36676-50-3, 72-19-5; Endothelin-2, ","","","","","Beilin L.J., Puddey I.B., Burke V., Lifestyle and hypertension, American Journal of Hypertension, 12, 9, pp. 934-945, (1999); Kivimaki M., Leino-Arjas P., Luukkonen R., Riihimaki H., Vahtera J., Kirjonen J., Work stress and risk of cardiovascular mortality: Prospective cohort study of industrial employees, BMJ, 325, (2002); Lucini D., Riva S., Pizzinelli P., Pagani M., Stress management at the worksite: Reversal of symptoms profile and cardiovascular dysregulation, Hypertension, 49, 2, pp. 291-297, (2007); Berkman L.F., Tracking social and biological experiences: The social etiology of cardiovascular disease, Circulation, 111, 23, pp. 3022-3024, (2005); McEwen B.S., Protective and damaging effects of stress mediators, N Engl J Med, 338, pp. 171-179, (1998); Rozanski A., Blumenthal J.A., Davidson K.W., Saab P.G., Kubzansky L., The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: The emerging field of behavioral cardiology, Journal of the American College of Cardiology, 45, 5, pp. 637-651, (2005); Schnall P.L., Schwartz J.E., Landsbergis P.A., Warren K., Pickering T.G., A longitudinal study of job strain and ambulatory blood pressure: Results from a three-year follow-up, Psychosomatic Medicine, 60, 6, pp. 697-706, (1998); Schnall P.L., Landsbergis P.A., Baker D., Job strain and cardiovascular disease, Annual Review of Public Health, 15, pp. 381-411, (1994); Pickering T., The effects of occupational stress on blood pressure in men and women, Acta Physiologica Scandinavica, Supplement, 161, 640, pp. 125-128, (1997); Ohlin B., Berglund G., Rosvall M., Nilsson P.M., Job strain in men, but not in women, predicts a significant rise in blood pressure after 6.5 years of follow-up, Journal of Hypertension, 25, 3, pp. 525-531, (2007); Theorell T., Karasek R.A., Current issues relating to psychosocial job strain and cardiovascular disease research, J Occup Health Psychol, 1, pp. 9-26, (1996); Landsbergis P.A., Schnall P.L., Pickering T.G., Warren K., Schwartz J.E., Life-course exposure to job strain and ambulatory blood pressure in men, American Journal of Epidemiology, 157, 11, pp. 998-1006, (2003); Kawakami N., Haratani T., Araki S., Job strain and arterial blood pressure, serum cholesterol, and smoking as risk factors for coronary heart disease in Japan, International Archives of Occupational and Environmental Health, 71, 6, pp. 429-432, (1998); Kang M.G., Koh S.B., Cha B.S., Park J.K., Baik S.K., Chang S.J., Job stress and cardiovascular risk factors in male workers, Preventive Medicine, 40, 5, pp. 583-588, (2005); Guimont C., Brisson C., Dagenais G.R., Milot A., Vezina M., Masse B., Moisan J., Laflamme N., Blanchette C., Effects of job strain on blood pressure: A prospective study of male and female white-collar workers, American Journal of Public Health, 96, 8, pp. 1436-1443, (2006); Karasek R.A., Job demands, job decision latitude and mental strain: Implication for job redesign, Administrative Science Quarterly, 24, pp. 285-307, (1979); Greiner B.A., Krause N., Ragland D., Fisher J.M., Occupational stressors and hypertension: A multi-method study using observer-based job analysis and self-reports in urban transit operators, Social Science and Medicine, 59, 5, pp. 1081-1094, (2004); Imumorin I.G., Dong Y., Zhu H., Poole J.C., Harshfield G.A., Treiber F.A., Snieder H., A gene-environment interaction model of stress-induced hypertension, Cardiovascular Toxicology, 5, 2, pp. 109-132, (2005); Ohlin B., Berglund G., Nilsson P.M., Melander O., Job strain, decision latitude and α2B-adrenergic receptor polymorphism significantly interact, and associate with higher blood pressures in men, Journal of Hypertension, 25, 8, pp. 1613-1619, (2007); Ohlin B., Berglund G., Nilsson P.M., Melander O., Job strain, job demands and adrenergic beta1-receptor-polymorphism: A possible interaction affecting blood pressure in men, J Hypertens, 26, pp. 1583-1589, (2008); Cesana G., Ferrario M., Sega R., Milesi C., De Vito G., Mancia G., Zanchetti A., Job strain and ambulatory blood pressure levels in a population-based employed sample of men from northern Italy, Scandinavian Journal of Work, Environment and Health, 22, 4, pp. 294-305, (1996); Cesana G., Sega R., Ferrario M., Chiodini P., Corrao G., Mancia G., Job strain and blood pressure in employed men and women: A pooled analysis of four Northern Italian population samples, Psychosomatic Medicine, 65, 4, pp. 558-563, (2003); Mancia G., Sega R., Bravi C., De Vito G., Valagussa F., Cesana G., Zanchetti A., Ambulatory blood pressure normality: Results from the PAMELA study, Journal of Hypertension, 13, 12, pp. 1377-1390, (1995); MONICA Project (monitoring trends and determinants in cardiovascular disease): A major international collaboration WHO MONICA Project Principal Investigators, J Clin Epidemiol, 41, pp. 105-114, (1988); Belkic K.L., Landsbergis P.A., Schnall P.L., Baker D., Is job strain a major source of cardiovascular disease risk?, Scandinavian Journal of Work, Environment and Health, 30, 2, pp. 85-128, (2004); MONICA Psychosocial Optional Study: MOPSY Suggested Measurement and Instruments, (1988); Cesana G., Poncato E., Duzioni F., Indagine pilota sulla affidabilità di un questionario per lo studio dei fattori psico-socio-occupazionali in relazione alla insorgenza di coronaropatia, Arch Sci Lav, 3, pp. 151-170, (1987); Landsbergis P.A., Schnall P.L., Warren K., Pickering T.G., Schwartz J.E., Association between ambulatory blood pressure and alternative formulations of job strain, Scandinavian Journal of Work, Environment and Health, 20, 5, pp. 349-363, (1994); Padmanabhan S., Menni C., Lee W.K., Laing S., Brambilla P., Sega R., Perego R., Grassi G., Cesana G., Delles C., Mancia G., Dominiczak A.F., The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study, J Hypertens, 28, pp. 465-477, (2010); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J R Statis Soc B, 57, pp. 289-300, (1995); Lu X., Perkins D.L., Re-sampling strategy to improve the estimation of number of null hypotheses in FDR control under strong correlation structures, BMC Bioinformatics, 8, (2007); Steptoe A., Willemsen G., The influence of low job control on ambulatory blood pressure and perceived stress over the working day in men and women from the Whitehall II cohort, Journal of Hypertension, 22, 5, pp. 915-920, (2004); Marmot M.G., Bosma H., Hemingway H., Brunner E., Stansfeld S., Contribution of job control and other risk factors to social variations in coronary heart disease incidence, Lancet, 350, 9073, pp. 235-239, (1997); (1907); Beevers G., Lip G.Y.H., O'Brien E., ABC of hypertension: The pathophysiology of hypertension, British Medical Journal, 322, 7291, pp. 912-916, (2001); Luft F.C., Twins in cardiovascular genetic research, Hypertension, 37, 2, pp. 350-356, (2001); Levine S., Infantile experience and resistance to physiological stress, Science, 126, (1957); Meaney M.J., Bhatnagar S., Diorio J., Larocque S., Francis D., O'Donnell D., Shanks N., Sharma S., Smythe J., Viau V., Molecular basis for the development of individual differences in the hypothalamic-pituitary-adrenal stress response, Cellular and Molecular Neurobiology, 13, 4, pp. 321-347, (1993); Cesana G., Menni C., Cardiovascular risk as a paradigm of the negative consequences of stress at work: A ""conflicting evidence., Psychological Factors and Cardiovascular Disorders: The Role of Stress and Psychosocial Influences, (2009); Padmanabhan S., Melander O., Hastie C., Menni C., Delles C., Connell J.M., Dominiczak A.F., Hypertension and genome-wide association studies: Combining high fidelity phenotyping and hypercontrols, J Hypertens, 26, pp. 1275-1281, (2008)","C. Menni; Department of Statistics, University of Milano-Bicocca, Milano, 20126 Milano, Via Bicocca degli Arcimboldi 8, Italy; email: cristinamenni@gmail.com","","","","","","","","15347796","","PSMEA","21364195","English","Psychosom. Med.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-79955857888"
"Udomsinprasert W.; Nontawong N.; Saengsiwaritt W.; Panthan B.; Jiaranai P.; Thongchompoo N.; Santon S.; Runcharoen C.; Sensorn I.; Jittikoon J.; Chaikledkaew U.; Chantratita W.","Udomsinprasert, Wanvisa (36997664500); Nontawong, Nuttakant (57971521900); Saengsiwaritt, Wacharapol (57408544100); Panthan, Bhakbhoom (57191292779); Jiaranai, Poramate (57220834407); Thongchompoo, Nartthawee (58516230400); Santon, Siwalee (55833074600); Runcharoen, Chakkaphan (57193098539); Sensorn, Insee (55749995400); Jittikoon, Jiraphun (21934464700); Chaikledkaew, Usa (23993682600); Chantratita, Wasun (6603680415)","36997664500; 57971521900; 57408544100; 57191292779; 57220834407; 58516230400; 55833074600; 57193098539; 55749995400; 21934464700; 23993682600; 6603680415","Host genetic polymorphisms involved in long-term symptoms of COVID-19","2023","Emerging Microbes and Infections","12","2","2239952","","","","11","10.1080/22221751.2023.2239952","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166391935&doi=10.1080%2f22221751.2023.2239952&partnerID=40&md5=abf2dff582fd04fb153a0ab7b5a78719","Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Department of Medicine, Prachatipat Hospital, Pathum Thani, Thailand; Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand","Udomsinprasert W., Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Nontawong N., Department of Medicine, Prachatipat Hospital, Pathum Thani, Thailand; Saengsiwaritt W., Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Panthan B., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Jiaranai P., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Thongchompoo N., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Santon S., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Runcharoen C., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Sensorn I., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Jittikoon J., Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; Chaikledkaew U., Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand, Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand; Chantratita W., Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand","Host genetic polymorphisms are recognized as a critical determinant of diversity in clinical symptoms of Coronavirus disease 2019 (COVID-19). Accordingly, this study aimed to determine possible associations between single nucleotide polymorphisms (SNPs) in 37 candidate genetic variants and clinical consequences of COVID-19–especially long-term symptoms, Long COVID. A total of 260 COVID-19 patients, divided into mild (n = 239) and severe (n = 21) and further categorized based on the presence of Long COVID (no, n = 211; yes, n = 49), were recruited. Genotyping of selected polymorphisms responsible for viral entry, immune response, and inflammation was performed using MassARRAY system. Out of 37 SNPs, 9 including leucine zipper transcription factor like-1 (LZTFL1) rs10490770 C allele, LZTFL1 rs11385942 dupA allele, nicotinamide adenine dinucleotide synthetase-1 (NADSYN1) rs12785878 TT genotype, plexin A-4 (PLXNA4) rs1424597 AA genotype, LZTFL1 rs17713054 A allele, interleukin-10 (IL10) rs1800896 TC genotype and C allele, angiotensin converting enzyme-2 (ACE2) rs2285666 T allele, and plasmanylethanolamine desaturase-1 (PEDS1) rs6020298 GG genotype and G allele were significantly associated with an increased risk of developing Long COVID, whereas interleukin-10 receptor subunit beta (IL10RB) rs8178562 GG genotype was significantly associated with a reduced risk of Long COVID. Kaplan-Meier curve displayed that the above gene polymorphisms were significantly associated with cumulative rate of Long COVID occurrence. Polymorphisms in LZTFL1 rs10490770, LZTFL1 rs11385942, LZTFL1 rs17713054, NADSYN1 rs12785878, PLXNA4 rs1424597, IL10 rs1800896, ACE2 rs2285666, PEDS1 rs6020298, and IL10RB rs8178562 appear to be genetic factors involved in development of Long COVID. © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd.","COVID-19; COVID-19 severity; Genetic polymorphism; Long COVID; SARS-CoV-2","Angiotensin-Converting Enzyme 2; COVID-19; Genetic Predisposition to Disease; Humans; Interleukin-10; Polymorphism, Single Nucleotide; Post-Acute COVID-19 Syndrome; 2',5' oligoadenylate synthetase; 2',5' oligoadenylate synthetase 3; alpha beta interferon receptor; angiotensin converting enzyme 2; biological marker; chemokine receptor CXCR1; chemokine receptor CXCR2; complementary RNA; dipeptidyl peptidase; dipeptidyl peptidase 9; discoidin domain receptor 1; forkhead box p4 antisense RNA 1; guanine nucleotide exchange factor; interferon alpha and beta receptor subunit 2; interferon induced helicase C domain containing protein 1; interferon induced protein 44; interferon induced transmembrane protein 3; interferon lambda3; interleukin 10; interleukin 10 receptor beta; interleukin 17; interleukin 17F; interleukin 6 antisense RNA 1; lambda interferon; leucine zipper protein; leucine zipper transcription factor like 1; membrane protein; nicotinamide adenine dinucleotide; nicotinamide adenine dinucleotide synthetase 1; plasmanylethanolamine desaturase 1; plexin; plexin a4; rap guanine nucleotide exchange factor 1; SARS-CoV-2 vaccine; toll like receptor 3; tolloid like 1; transmembrane protease serine 2; tumour necrosis factor receptor superfamily member 1b; unclassified drug; vasculotropin receptor 2; ventricular zone expressed ph domain containing 1; vitamin D binding protein; angiotensin converting enzyme 2; interleukin 10; adult; Article; Cochrane Library; comorbidity; controlled study; coronavirus disease 2019; female; gene frequency; genetic association; genetic risk; genetic susceptibility; genetic variability; genotype; heredity; human; hypertension; long COVID; male; Medline; nonhuman; SARS-CoV-2 (lineage BA.1); SARS-CoV-2 (lineage BA.2); SARS-CoV-2 (lineage BA.2.12.1); SARS-CoV-2 (lineage BA.4); SARS-CoV-2 (lineage BA.5); SARS-CoV-2 Delta; SARS-CoV-2 Omicron; Scopus; search engine; single nucleotide polymorphism; systematic review; vaccination; virus entry; coronavirus disease 2019; genetic predisposition; genetics; long COVID; single nucleotide polymorphism","","2',5' oligoadenylate synthetase, 69106-44-1; dipeptidyl peptidase, 9032-67-1; discoidin domain receptor, ; discoidin domain receptor 1, ; discoidin domain receptor 2, ; interferon induced helicase C domain containing protein 1, ; nicotinamide adenine dinucleotide, 53-84-9; protein kinase Mer, ; RNA helicase, ; Angiotensin-Converting Enzyme 2, ; Interleukin-10, ","","","Mahidol University, MU; National Research Council of Thailand, NRCT, (332/2564)","This research project was supported by the National Research Council of Thailand (NRCT) (วช.อว. (อ) (กบท2) 332/2564) and Mahidol University (Fundamental Fund: fiscal year 2023 by National Science Research and Innovation Fund (NSRF)) (FF-048/2566).","Guo G., Ye L., Pan K., Et al., New insights of emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention, Front Cell Dev Biol, 8, (2020); Yu X., Yang R., COVID-19 transmission through asymptomatic carriers is a challenge to containment, Influenza Other Respir Viruses, 14, pp. 474-475, (2020); Alshoabi S.A., Alhazmi F.H., Abdulaal O.M., Et al., Frequent clinical and radiological manifestations of the novel SARS-CoV-2: A review article, J Family Med Prim Care, 10, pp. 122-126, (2021); Atzrodt C.L., Maknojia I., McCarthy R.D.P., Et al., A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2, FEBS J, 287, pp. 3633-3650, (2020); Chen C., Haupert S.R., Zimmermann L., Et al., Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review, J Infect Dis, 226, pp. 1593-1607, (2022); Huang C., Huang L., Wang Y., Et al., 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study, Lancet, 397, pp. 220-232, (2021); Zhou F., Yu T., Du R., Et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, pp. 1054-1062, (2020); Abou-Ghaida J., Foster A., Klein S., Et al., The world-wide adaptations of diabetic management in the face of COVID-19 and socioeconomic disparities: a scoping review, Cureus, 14, (2022); Patarcic I., Gelemanovic A., Kirin M., Et al., The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis, Sci Rep, 5, (2015); Kenney A.D., Dowdle J.A., Bozzacco L., Et al., Human genetic determinants of viral diseases, Annu Rev Genet, 51, pp. 241-263, (2017); Debnath M., Banerjee M., Berk M., Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes, FASEB J, 34, pp. 8787-8795, (2020); Ramos-Lopez O., Daimiel L., Ramirez de Molina A., Et al., Exploring host genetic polymorphisms involved in SARS-CoV infection outcomes: implications for personalized medicine in COVID-19, Int J Genomics, 2020, (2020); Nakanishi T., Pigazzini S., Degenhardt F., Et al., Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality, J Clin Invest, 131, (2021); Et al., Genomewide association study of severe COVID-19 with respiratory failure, N Engl J Med., 383, pp. 1522-1534, (2020); Saengsiwaritt W., Jittikoon J., Chaikledkaew U., Et al., Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: a systematic review with meta-analysis, Rev Med Virol, 32, (2022); Grolmusz V.K., Bozsik A., Papp J., Et al., Germline genetic variants of viral entry and innate immunity may influence susceptibility to SARS-CoV-2 infection: toward a polygenic risk score for risk stratification, Front Immunol, 12, (2021); Anastassopoulou C., Gkizarioti Z., Patrinos G.P., Et al., Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity, Hum Genomics, 14, (2020); NICE COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19.; The Genome Aggregation Database (Gnomad) V2.1., (2022); Valenti L., Griffini S., Lamorte G., Et al., Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19, J Autoimmun, 117, (2021); Kotur N., Skakic A., Klaassen K., Et al., Association of vitamin D, zinc and selenium related genetic variants with COVID-19 disease severity, Front Nutr, 8, (2021); Abbood S.J.A., Anvari E., Fateh A., Association between interleukin-10 gene polymorphisms (rs1800871, rs1800872, and rs1800896) and severity of infection in different SARS-CoV-2 variants, Hum Genomics, 17, 1, (2023); Traets M.J.M., Nijhuis R.H.T., Morre S.A., Et al., Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19, PLoS One, 17, 1, (2022); Mohlendick B., Schonfelder K., Breuckmann K., Et al., ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19, Pharmacogenet Genomics, 31, 8, pp. 165-171, (2021); Jevnikar K., Lapajne L., Petrovic D., Et al., The role of ACE, ACE2, and AGTR2 polymorphisms in COVID-19 severity and the presence of COVID-19-related retinopathy, Genes (Basel), 13, 7, (2022); Khalilzadeh F., Sakhaee F., Sotoodehnejadnematalahi F., Et al., Angiotensin-converting enzyme 2 rs2285666 polymorphism and clinical parameters as the determinants of COVID-19 severity in Iranian population, Int J Immunogenet, 49, 5, pp. 325-332, (2022); He J., Cai S., Feng H., Et al., Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients, Protein Cell, 11, pp. 680-687, (2020); Borczuk A.C., Salvatore S.P., Seshan S.V., Et al., COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York city, Mod Pathol, 33, pp. 2156-2168, (2020); Downes D.J., Cross A.R., Hua P., Et al., Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus, Nat Genet, 53, pp. 1606-1615, (2021); Ravindra N.G., Alfajaro M.M., Gasque V., Et al., Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes, PLoS Biol, 19, (2021); Yang Z., Macdonald-Dunlop E., Chen J., Et al., Genetic landscape of the ACE2 coronavirus receptor, Circulation, 145, pp. 1398-1411, (2022); Grant W.B., Lahore H., McDonnell S.L., Et al., Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths, Nutrients, 12, (2020); Hossein-nezhad A., Spira A., Holick M.F., Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial, PLoS One, 8, (2013); Freitas A.T., Calhau C., Antunes G., Et al., Vitamin D-related polymorphisms and vitamin D levels as risk biomarkers of COVID-19 disease severity, Sci Rep, 11, (2021); Razzaq M., Iglesias M.J., Ibrahim-Kosta M., Et al., An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism, Sci Rep, 11, (2021); Fard D., Tamagnone L., Semaphorins in health and disease, Cytokine Growth Factor Rev, 57, pp. 55-63, (2021); Chen G., Wu D., Guo W., Et al., Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, 130, pp. 2620-2629, (2020); Karcioglu Batur L., Hekim N., Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries, J Med Virol, 93, pp. 5853-5863, (2021); Bakhshandeh B., Sorboni S.G., Javanmard A.R., Et al., Variants in ACE2; potential influences on virus infection and COVID-19 severity, Infect Genet Evol, 90, (2021); Martinez-Gomez L.E., Herrera-Lopez B., Martinez-Armenta C., Et al., ACE and ACE2 gene variants are associated with severe outcomes of COVID-19 in men, Front Immunol, 13, (2022); Wang F., Huang S., Gao R., Et al., Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility, Cell Discov, 6, (2020); Voloudakis G., Vicari J.M., Venkatesh S., Et al., A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility, NPJ Genom Med, 7, (2022); Luo S., Dong X., Guo S., Et al., Regulation of the human IL-10RB gene expression by Sp8 and Sp9, J Alzheimers Dis, 88, pp. 1469-1485, (2022); Karakas Celik S., Cakmak Genc G., Dursun A., A bioinformatic approach to investigating cytokine genes and their receptor variants in relation to COVID-19 progression, Int J Immunogenet, 48, pp. 211-218, (2021); Karakas Celik S., Cakmak Genc G., Et al., Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: a case study, J Med Virol., 93, 10, pp. 5947-5952, (2021)","W. Chantratita; Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand; email: wasun.cha@mahidol.ac.th","","Taylor and Francis Ltd.","","","","","","22221751","","","37497655","English","Emerg. Microbes Infect.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85166391935"
"GUTIÉRREZ N.M.; MUÑOZ S.B.; VALLES A.P.","GUTIÉRREZ, NACIM MOLINA (57265860800); MUÑOZ, SANDRA BECERRA (57349118900); VALLES, ALEJANDRO PACHECO (57349255500)","57265860800; 57349118900; 57349255500","Effect of angiotensin converting enzyme 2 rs1978124 gene polymorphism on the hemodynamic response to exercise; [Influencia del polimorfismo de la enzima convertidora de angiotensina 2 (rs1978124) en la respuesta hemodinámica posterior a la prueba aeróbica submáxima en jóvenes estudiantes chilenos sedentarios]","2021","Revista Medica de Chile","149","5","","733","737","4","0","10.4067/S0034-98872021000500733","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119587153&doi=10.4067%2fS0034-98872021000500733&partnerID=40&md5=37c4d375418d712aa0f624a6f71bd838","Universidad Católica del Maule, Facultad de Ciencias de la Salud, Departamento de Kinesiología, Talca, Chile; Universidad de Talca, Facultad de Ciencias de la Salud, Escuela de Kinesiología, Talca, Chile","GUTIÉRREZ N.M., Universidad Católica del Maule, Facultad de Ciencias de la Salud, Departamento de Kinesiología, Talca, Chile; MUÑOZ S.B., Universidad de Talca, Facultad de Ciencias de la Salud, Escuela de Kinesiología, Talca, Chile; VALLES A.P.","Background: Angiotensin-converting enzyme 2 (ACE2) has a protective role in the regulation of blood pressure. Aim: To evaluate the influence of ACE2 rs1978124 gene polymorphism on the hemodynamic response after a six-minute walk submaximal aerobic test. Material and Methods: A six-minute walk submaximal aerobic test was carried out in 47 men and 55 women, aged 22 ± 2 years. Blood pressure was recorded before and after the test. Pulse rate was recorded continuously. ACE2 polymorphism was determined in DNA extracted from a blood sample. Results: For women, the genotype distribution did not deviate from Hardy-Weinberg equilibrium (χ2 = 0.804, d.f. = 1, P = 0.4) and no significant differences in heart rate, systolic and diastolic blood pressure were observed between CC, CT and TT genotypes before and after the test. Among men no differences in these parameters were observed either between the three phenotypes. Conclusions: ACE2 rs1978124 gene polymorphism did not influence the hemodynamic response to submaximal exercise in these participants. © 2021 Sociedad Medica de Santiago. All rights reserved.","Exercise; Hemodynamics; Polymorphism, Single Nucleotide","Angiotensin-Converting Enzyme 2; Blood Pressure; Exercise; Female; Genotype; Hemodynamics; Humans; Hypertension; Male; Peptidyl-Dipeptidase A; Polymorphism, Genetic; angiotensin converting enzyme 2; DNA; dipeptidyl carboxypeptidase; adult; aerobic exercise; Article; blood pressure; diastolic blood pressure; exercise; female; genetic association; genetic polymorphism; genotype; Hardy Weinberg equilibrium; heart rate; hemodynamics; human; human experiment; male; mathematical model; phenotype; pulse rate; six minute walk test; systolic blood pressure; young adult; exercise; genetic polymorphism; genetics; hemodynamics; hypertension","","DNA, 9007-49-2; dipeptidyl carboxypeptidase, 9015-82-1; Angiotensin-Converting Enzyme 2, ; Peptidyl-Dipeptidase A, ","","","","","Gronek P, Holdys J., Genes and physical fitness, Trends Sport Sci, 20, 1, pp. 16-29, (2013); Fagard RH., Exercise characteristics and the blood pressure response to dynamic physical training, Medicine and Science in Sports and Exercise, (2001); Kurtz TW, Spence MA., Genetics of essential hypertension, Am J Med, 94, 1, pp. 77-84, (1993); Coates D., The angiotensin converting enzyme (ACE), Int J Biochem Cell Biol, 35, 6, pp. 769-773, (2003); Eriksson U, Danilczyk U, Penninger JM., Just the beginning: Novel functions for angiotensin-converting enzymes, Current Biology, 12, (2002); Santos RAS, Simoes e Silva AC, Maric C, Silva DMR, Machado RP, De Buhr I, Et al., Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas, Proc Natl Acad Sci U S A, 100, 14, pp. 8258-8263, (2003); Prasannarong M, Santos FR, Henriksen EJ., ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle, Biochem Biophys Res Commun, 426, 3, pp. 369-373, (2012); Ocaranza Dr MP, Michea L, Chiong M, Lagos CF, Lavandero S, Jalil JE., Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system [Internet], Clinical Science, 127, pp. 549-557, (2014); Yang M, Zhao J, Xing L, Shi L., The association between angiotensinconverting enzyme 2 polymorphisms and essential hypertension risk: A metaanalysis involving 14,122 patients, JRAAS - J Renin-Angiotensin-Aldosterone Syst, 16, 4, pp. 1240-1244, (2015); Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J Biol Chem, 275, 43, pp. 33238-33243, (2000); Yagil Y, Yagil C., Hypothesis: ACE2 modulates blood pressure in the mammalian organism, Hypertens, 41, 4, pp. 871-873, (1979); Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Et al., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, J Biol Chem, 277, 17, pp. 14838-14843, (2002); Burrell LM, Johnston CI, Tikellis C, Cooper ME., ACE2, a new regulator of the renin-angiotensin system [Internet], Trends in Endocrinology and Metabolism, 15, pp. 166-169, (2004); Benjafield AV, Wang WYS, Morris BJ., No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension, Am J Hypertens, 17, 7, pp. 624-628, (2004); Lieb W, Graf J, Gotz A, Konig IR, Mayer B, Fischer M, Et al., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men: Results of the MONICA Augsburg echocardiographic substudy, J Mol Med, 84, 1, pp. 88-96, (2006); Niu W, Qi Y, Hou S, Zhou W, Qiu C., Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese, Transl Res, 150, 6, pp. 374-380, (2007); Crapo RO, Casaburi R, Coates AL, Enright PL, MacIntyre NR, McKay RT, Et al., ATS statement: Guidelines for the six-minute walk test, American Journal of Respiratory and Critical Care Medicine. American Lung Association, 166, pp. 111-117, (2002); Salazar L, Melo C, Cavalli S, Hinuy H, Hirata M, Hirata RD., Micrométodo para extraçäo de DNA genômico útil no diagnóstico molecular da Hipercolesterolemia Familial, Rev bras anal clin, 33, 3, pp. 111-116, (2001); Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF, Burrell LM., From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension, Front Physiol, 5, pp. 1-12, (2014); LM LK, AL LP, Et al., Association between the angiotensin-converting enzyme-2 gene and blood pressure in a cohort of canadian adolescents, Circulation, 125, 10, (2012); Liu D, Chen Y, Zhang P, Zhong J, Jin L, Zhang C, Et al., Association between circulating levels of ACE2-Ang-(1- 7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients, Med (United States), 95, 24, pp. 1-6, (2016); Huang W, Yang W, Wang Y, Zhao Q, Gu D, Chen R., Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese, J Hum Hypertens, 20, 12, pp. 968-971, (2006); Goessler KF, Polito MD, Mota G de F, de Oliveira EM, Cornelissen VA., Angiotensin converting enzyme 2 polymorphisms and postexercise hypotension in hypertensive medicated individuals, Clin Physiol Funct Imaging, 38, 2, pp. 206-212, (2018); Gomes-Santos IL, Fernandes T, Couto GK, Ferreira-Filho JCA, Salemi VMC, Fernandes FB, Et al., Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats, PLoS One, 9, 5, pp. 1-11, (2014)","A.P. VALLES; Universidad Católica del Maule, Facultad de Ciencias de la Salud, Departamento de Kinesiología, Talca, Avda. San Miguel 3605, Chile; email: apacheco@ucm.cl","","Sociedad Medica de Santiago","","","","","","00349887","","","34751326","Spanish","Rev. Med. Chile","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85119587153"
"Chu P.-L.; Gigliotti J.C.; Cechova S.; Bodonyi-Kovacs G.; Wang Y.T.; Chen L.; Wassertheil-Smoller S.; Cai J.; Isakson B.E.; Franceschini N.; Le T.H.","Chu, Pei-Lun (56201658400); Gigliotti, Joseph C. (24080404800); Cechova, Sylvia (14068427600); Bodonyi-Kovacs, Gabor (23099105500); Wang, Yves T. (35243819200); Chen, Luojing (57969219100); Wassertheil-Smoller, Sylvia (57209258874); Cai, Jianwen (7403153136); Isakson, Brant E. (6507817173); Franceschini, Nora (7006270916); Le, Thu H. (7202708726)","56201658400; 24080404800; 14068427600; 23099105500; 35243819200; 57969219100; 57209258874; 7403153136; 6507817173; 7006270916; 7202708726","Collectrin (Tmem27) deficiency in proximal tubules causes hypertension in mice and a TMEM27 variant associates with blood pressure in males in a Latino cohort","2023","American Journal of Physiology - Renal Physiology","324","1","","F30","F42","12","5","10.1152/ajprenal.00176.2022","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144585233&doi=10.1152%2fajprenal.00176.2022&partnerID=40&md5=a5dbc29c90fd113ec5b558584fa41b87","Division of Nephrology, Fu Jen Catholic University Hospital, School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Department of Integrated Physiology and Pharmacology, Liberty University College of Osteopathic Medicine, Lynchburg, VA, United States; Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States; Division of Nephrology, Department of Medicine, University of Rochester Medical Center Rochester, Rochester, NY, United States; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States; Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, United States; Department of Biostatistics, University of North Carolina, Chapel Hill, NC, United States; Robert M. Berne Cardiovascular Research Center, Department of Molecular Physiology and Biophysics, University of Virginia Health System, Charlottesville, VA, United States; Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States","Chu P.-L., Division of Nephrology, Fu Jen Catholic University Hospital, School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Gigliotti J.C., Department of Integrated Physiology and Pharmacology, Liberty University College of Osteopathic Medicine, Lynchburg, VA, United States; Cechova S., Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States; Bodonyi-Kovacs G., Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States; Wang Y.T., Division of Nephrology, Department of Medicine, University of Rochester Medical Center Rochester, Rochester, NY, United States; Chen L., Division of Nephrology, Department of Medicine, University of Rochester Medical Center Rochester, Rochester, NY, United States; Wassertheil-Smoller S., Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States, Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, United States; Cai J., Department of Biostatistics, University of North Carolina, Chapel Hill, NC, United States; Isakson B.E., Robert M. Berne Cardiovascular Research Center, Department of Molecular Physiology and Biophysics, University of Virginia Health System, Charlottesville, VA, United States; Franceschini N., Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States; Le T.H., Division of Nephrology, Department of Medicine, University of Rochester Medical Center Rochester, Rochester, NY, United States","Collectrin (Tmem27), an angiotensin-converting enzyme 2 homologue, is a chaperone of amino acid transporters in the kidney and endothelium. Global collectrin knockout (KO) mice have hypertension, endothelial dysfunction, exaggerated salt sensitivity, and diminished renal blood flow. This phenotype is associated with altered nitric oxide and superoxide balance and increased proximal tubule (PT) Naþ/Hþ exchanger isoform 3 (NHE3) expression. Collectrin is located on the X chromosome where genome-wide association population studies have largely been excluded. In the present study, we generated PT-specific collectrin KO (PT KO) mice to determine the precise contribution of PT collectrin in blood pressure homeostasis. We also examined the association of human TMEM27 single-nucleotide polymorphisms with blood pressure traits in 11,926 Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Hispanic/Latino participants. PT KO mice exhibited hypertension, and this was associated with increased baseline NHE3 expression and diminished lithium excretion. However, PT KO mice did not display exaggerated salt sensitivity or a reduction in renal blood flow compared with control mice. Furthermore, PT KO mice exhibited enhanced endothelium-mediated dilation, suggesting a compensatory response to systemic hypertension induced by deficiency of collectrin in the PT. In HCHS/SOL participants, we observed sex-specific single-nucleotide polymorphism associations with diastolic blood pressure. In conclusion, loss of collectrin in the PT is sufficient to induce hypertension, at least in part, through activation of NHE3. Importantly, our model supports the notion that altered renal blood flow may be a determining factor for salt sensitivity. Further studies are needed to investigate the role of the TMEM27 locus on blood pressure and salt sensitivity in humans. © 2023 American Physiological Society. All rights reserved.","hypertension; proximal tubule; Tmem27","Animals; Blood Pressure; Female; Genome-Wide Association Study; Hispanic or Latino; Humans; Hypertension; Kidney Tubules, Proximal; Male; Mice; Mice, Knockout; Sodium Chloride, Dietary; Sodium-Hydrogen Exchanger 3; angiotensin converting enzyme 2; collectrin; lithium; sodium proton exchange protein 3; superoxide; unclassified drug; sodium proton exchange protein 3; adult; angiotensin converting enzyme 2 deficiency; animal experiment; animal model; Article; blood pressure; cohort analysis; collectrin deficiency; controlled study; diastolic blood pressure; endothelium; excretion; gene; genetic association; genetic polymorphism; genome-wide association study; Hispanic; homeostasis; human; hypertension; kidney blood flow; kidney proximal tubule; major clinical study; male; mouse; nonhuman; population research; protein expression; protein function; salt tolerance; single nucleotide polymorphism; systolic blood pressure; tmem27 gene; vasodilatation; X chromosome; animal; blood pressure; female; genetics; genome-wide association study; kidney proximal tubule; knockout mouse; metabolism; physiology; salt intake","","lithium, 7439-93-2; sodium proton exchange protein 3, 170349-61-8; superoxide, 11062-77-4; Sodium Chloride, Dietary, ; Sodium-Hydrogen Exchanger 3, ","","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK113632); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01DK113632 (to T.H.L and N.F.).","Zhang H, Wada J, Hida K, Tsuchiyama Y, Hiragushi K, Shikata K, Wang H, Lin S, Kanwar YS, Makino H., Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys, J Biol Chem, 276, pp. 17132-17139, (2001); Zhang Y, Wada J., Collectrin, a homologue of ACE2, its transcriptional control and functional perspectives, Biochem Biophys Res Commun, 363, pp. 1-5, (2007); Malakauskas SM, Quan H, Fields TA, McCall SJ, Yu MJ, Kourany WM, Frey CW, Le TH., Aminoaciduria and altered renal expression of luminal amino acid transporters in mice lacking novel gene collectrin, Am J Physiol Renal Physiol, 292, pp. F533-F544, (2007); Cechova S, Zeng Q, Billaud M, Mutchler S, Rudy CK, Straub AC, Chi L, Chan FR, Hu J, Griffiths R, Howell NL, Madsen K, Jensen BL, Palmer LA, Carey RM, Sung SS, Malakauskas SM, Isakson BE, Le TH., Loss of collectrin, an angiotensin-converting enzyme 2 homolog, uncouples endothelial nitric oxide synthase and causes hypertension and vascular dysfunction, Circulation, 128, pp. 1770-1780, (2013); Dolina JS, Cechova S, Rudy CK, Sung SJ, Tang WW, Lee J, Hahn YS, Le TH., Cross-presentation of soluble and cell-associated antigen by murine hepatocytes is enhanced by collectrin expression, J Immunol, 198, pp. 2341-2351, (2017); Akpinar P, Kuwajima S, Krutzfeldt € J, Stoffel M., Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation, Cell Metab, 2, pp. 385-397, (2005); Danilczyk U, Sarao R, Remy C, Benabbas C, Stange G, Richter A, Arya S, Pospisilik JA, Singer D, Camargo SM, Makrides V, Ramadan T, Verrey F, Wagner CA, Penninger JM., Essential role for collectrin in renal amino acid transport, Nature, 444, pp. 1088-1091, (2006); Esterhazy D, Akpinar P, Stoffel M., Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2, Biol Chem, 393, pp. 473-484, (2012); Esterhazy D, Stutzer € I, Wang H, Rechsteiner MP, Beauchamp J, Dobeli € H, Hilpert H, Matile H, Prummer M, Schmidt A, Lieske N, Boehm B, Marselli L, Bosco D, Kerr-Conte J, Aebersold R, Spinas GA, Moch H, Migliorini C, Stoffel M., Bace2 is a b cell-enriched protease that regulates pancreatic b cell function and mass, Cell Metab, 14, pp. 365-377, (2011); Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, Vassar R., Expression analysis of BACE2 in brain and peripheral tissues, J Biol Chem, 275, pp. 20647-20651, (2000); Harrap SB, Wong ZY, Stebbing M, Lamantia A, Bahlo M., Blood pressure QTLs identified by genome-wide linkage analysis and dependence on associated phenotypes, Physiol Genomics, 8, pp. 99-105, (2002); Hilbert P, Lindpaintner K, Beckmann JS, Serikawa T, Soubrier F, Dubay C, Cartwright P, Gouyon BD, Julier C, Takahasi S, Vincent M, Ganten D, Georges M, Lathrop GM., Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats, Nature, 353, pp. 521-529, (1991); Yagil C, Sapojnikov M, Kreutz R, Zurcher € H, Ganten D, Yagil Y., Role of chromosome X in the sabra rat model of salt-sensitive hypertension, Hypertension, 33, pp. 261-265, (1999); Herrera VL, Traverse S, Lopez LV, Ruiz-Opazo N., X-linked locus associated with hypertensive renal disease susceptibility in Dahl rats, J Hypertens, 21, pp. 67-71, (2003); Yasuhara A, Wada J, Malakauskas SM, Zhang Y, Eguchi J, Nakatsuka A, Murakami K, Kanzaki M, Teshigawara S, Yamagata K, Le TH, Makino H., Collectrin is involved in the development of salt-sensitive hypertension by facilitating the membrane trafficking of apical membrane proteins via interaction with soluble N-ethylmaleiamide-sensitive factor attachment protein receptor complex, Circulation, 118, pp. 2146-2155, (2008); Chu PL, Gigliotti JC, Cechova S, Bodonyi-Kovacs G, Chan F, Ralph DL, Howell N, Kalantari K, Klibanov AL, Carey RM, McDonough AA, Le TH., Renal collectrin protects against salt-sensitive hypertension and is downregulated by angiotensin II, J Am Soc Nephrol, 28, pp. 1826-1837, (2017); Kohan DE., Progress in gene targeting: using mutant mice to study renal function and disease, Kidney Int, 74, pp. 427-437, (2008); Nguyen MT, Lee DH, Delpire E, McDonough AA., Differential regulation of Na <sup>þ</sup> transporters along nephron during ANG II-dependent hypertension: distal stimulation counteracted by proximal inhibition; Am J Physiol Renal Physiol, 305, pp. F510-E519, (2013); Gigliotti JC, Tin A, Pourafshar S, Cechova S, Wang YT, Sung SJ, Bodonyi-Kovacs G, Cross JV, Yang G, Nguyen N, Chan F, Rebholz C, Yu B, Grove ML, Grams ME, Kottgen € A, Scharpf R, Ruiz P, Boerwinkle E, Coresh J, Le TH., GSTM1 deletion exaggerates kidney injury in experimental mouse models and confers the protective effect of cruciferous vegetables in mice and humans, J Am Soc Nephrol, 31, pp. 102-116, (2020); Kogan P, Johnson KA, Feingold S, Garrett N, Guracar I, Arendshorst WJ, Dayton PA., Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion, Ultrasound Med Biol, 37, pp. 900-908, (2011); Billaud M, Lohman AW, Straub AC, Parpaite T, Johnstone SR, Isakson BE., Characterization of the thoracodorsal artery: morphology and reactivity, Microcirculation, 19, pp. 360-372, (2012); Looft-Wilson RC, Billaud M, Johnstone SR, Straub AC, Isakson BE., Interaction between nitric oxide signaling and gap junctions: effects on vascular function, Biochim Biophys Acta, 1818, pp. 1895-1902, (2012); Straub AC, Lohman AW, Billaud M, Johnstone SR, Dwyer ST, Lee MY, Bortz PS, Best AK, Columbus L, Gaston B, Isakson BE., Endothelial cell expression of haemoglobin a regulates nitric oxide signalling, Nature, 491, pp. 473-477, (2012); Sorlie PD, Aviles-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML, Giachello AL, Schneiderman N, Raij L, Talavera G, Allison M, Lavange L, Chambless LE, Heiss G., Design and implementation of the Hispanic Community Health Study/Study of Latinos, Ann Epidemiol, 20, pp. 629-641, (2010); Lavange LM, Kalsbeek WD, Sorlie PD, Aviles-Santa LM, Kaplan RC, Barnhart J, Liu K, Giachello A, Lee DJ, Ryan J, Criqui MH, Elder JP., Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos, Ann Epidemiol, 20, pp. 642-649, (2010); Sorlie PD, Allison MA, Aviles-Santa ML, Cai J, Daviglus ML, Howard AG, Kaplan R, Lavange LM, Raij L, Schneiderman N, Wassertheil-Smoller S, Talavera GA., Prevalence of hypertension, awareness, treatment, and control in the Hispanic Community Health Study/Study of Latinos, Am J Hypertens, 27, pp. 793-800, (2014); Conomos MP, Laurie CA, Stilp AM, Gogarten SM, McHugh CP, Nelson SC, Et al., Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos, Am J Hum Genet, 98, pp. 165-184, (2016); Laurie CC, Doheny KF, Mirel DB, Pugh EW, Bierut LJ, Bhangale T, Boehm F, Caporaso NE, Cornelis MC, Edenberg HJ, Gabriel SB, Harris EL, Hu FB, Jacobs KB, Kraft P, Landi MT, Lumley T, Manolio TA, McHugh C, Painter I, Paschall J, Rice JP, Rice KM, Zheng X, Weir BS, Quality control and quality assurance in genotypic data for genome-wide association studies, Genet Epidemiol, 34, pp. 591-602, (2010); Lin DY, Tao R, Kalsbeek WD, Zeng D, Gonzalez F, Fernandez-Rhodes L, Graff M, Koch GG, North KE, Heiss G., Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos, Am J Hum Genet, 95, pp. 675-688, (2014); Combe R, Mudgett J, El Fertak L, Champy MF, Ayme-Dietrich E, Petit-Demouliere B, Sorg T, Herault Y, Madwed JB, Monassier L., How does circadian rhythm impact salt sensitivity of blood pressure in mice? a study in two close C57Bl/6 substrains, PLoS One, 11, (2016); Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM., Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors, Hypertension, 23, pp. 195-199, (1994); Garrett MR, Dene H, Rapp JP., Time-course genetic analysis of albuminuria in Dahl salt-sensitive rats on low-salt diet, J Am Soc Nephrol, 14, pp. 1175-1187, (2003); Jiang X, Eales JM, Scannali D, Nazgiewicz A, Prestes P, Maier M, Denniff M, Xu X, Saluja S, Cano-Gamez E, Wystrychowski W, Szulinska M, Antczak A, Byars S, Skrypnik D, Glyda M, Krol R, Zywiec J, Zukowska-Szczechowska E, Burrell LM, Woolf AS, Greenstein A, Bogdanski P, Keavney B, Morris AP, Heagerty A, Williams B, Harrap SB, Trynka G, Samani NJ, Guzik TJ, Charchar FJ, Tomaszewski M., Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney, Eur Heart J, 41, pp. 4580-4588, (2020); Banday AA, Lokhandwala MF., Oxidative stress causes renal angiotensin II type 1 receptor upregulation, Na <sup>þ</sup>/H <sup>þ</sup> exchanger 3 overstimulation, and hypertension, Hypertension, 57, pp. 452-459, (2011); Banday AA, Lokhandwala MF., Angiotensin II-mediated biphasic regulation of proximal tubular Na <sup>þ</sup>/H <sup>þ</sup> exchanger 3 is impaired during oxidative stress, Am J Physiol Renal Physiol, 301, pp. F364-F370, (2011); Kurtz TW, DiCarlo SE, Pravenec M, Morris RC, The American Heart Association Scientific Statement on salt sensitivity of blood pressure: prompting consideration of alternative conceptual frameworks for the pathogenesis of salt sensitivity?, J Hypertens, 35, pp. 2214-2225, (2017); Elijovich F, Weinberger MH, Anderson CA, Appel LJ, Bursztyn M, Cook NR, Dart RA, Newton-Cheh CH, Sacks FM, Laffer CL, Salt sensitivity of blood pressure: a scientific statement from the American Heart Association, Hypertension, 68, pp. e7-e46, (2016); Hall JE., Renal dysfunction, rather than nonrenal vascular dysfunction, mediates salt-induced hypertension, Circulation, 133, pp. 894-906, (2016); Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC., Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney, Kidney Int, 46, pp. 653-665, (1994); Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S., Location of an inducible nitric oxide synthase mRNA in the normal kidney, Kidney Int, 45, pp. 998-1005, (1994); Wilcox CS., Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors, Hypertension, 75, pp. 894-901, (2020); Richardson SI, Freedman BI, Ellison DH, Rodriguez CJ., Salt sensitivity: a review with a focus on non-Hispanic blacks and Hispanics, J Am Soc Hypertens, 7, pp. 170-179, (2013); Campese VM, Amar M, Anjali C, Medhat T, Wurgaft A., Effect of Larginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension, J Hum Hypertens, 11, pp. 527-532, (1997); Hallund J, Bugel € S, Tholstrup T, Ferrari M, Talbot D, Hall WL, Reimann M, Williams CM, Wiinberg N., Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women, Br J Nutr, 95, pp. 1120-1126, (2006); He J, Gu D, Wu X, Chen J, Duan X, Chen J, Whelton PK., Effect of soybean protein on blood pressure: a randomized, controlled trial, Ann Intern Med, 143, pp. 1-9, (2005); Elfassy T, Zeki A, Hazzouri A, Cai J, Baldoni PL, Llabre MM, Rundek T, Raij L, Lash JP, Talavera GA, Wassertheil-Smoller S, Daviglus M, Booth JN, Castaneda SF, Garcia M, Schneiderman N., Incidence of hypertension among US Hispanics/Latinos: the Hispanic Community Health Study/Study of Latinos, 2008 to 2017, J Am Heart Assoc, 9, (2020); Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D., Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study, Circulation, 103, pp. 1245-1249, (2001); Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WB, Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension, Circulation, 131, pp. e435-e470, (2015); Machiela MJ, Zhou W, Karlins E, Sampson JN, Freedman ND, Yang Q, Et al., Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome, Nat Commun, 7, (2016)","T.H. Le; Division of Nephrology, Department of Medicine, University of Rochester Medical Center Rochester, Rochester, United States; email: Thu_Le@URMC.Rochester.edu","","American Physiological Society","","","","","","1931857X","","AJPPF","36264884","English","Am. J. Physiol. Renal Physiol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85144585233"
"Machado I.B.S.; Tofanelli M.R.; da Silva A.A.S.; e Silva A.C.S.","Machado, Isabella Barreto S. (57224101158); Tofanelli, Matheus Rampinelli (57222877924); da Silva, Ariadna A. Saldanha (57200045634); e Silva, Ana Cristina Simões (57213535762)","57224101158; 57222877924; 57200045634; 57213535762","Factors associated with primary hypertension in pediatric patients: An up-to-date","2021","Current Pediatric Reviews","17","1","","15","37","22","4","10.2174/1573396317999210111200222","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104159792&doi=10.2174%2f1573396317999210111200222&partnerID=40&md5=ed9b002fd840ed67f76890476aa25906","Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil","Machado I.B.S., Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Tofanelli M.R., Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; da Silva A.A.S., Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; e Silva A.C.S., Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil","Background: Arterial hypertension in children is considered a common alteration nowadays, mainly because obesity is a growing worldwide problem closely related to increased blood pressure. Childhood hypertension can be classified as primary or secondary, depending on the etiology. Primary or essential hypertension still has its pathophysiology not fully elucidated, and there is no consensus in the literature on most underlying mechanisms. In this review, genetic and environmental factors, including sodium and potassium intake, socioeconomic status, ethnicity, family structure, obesity, sedentary lifestyle, prematurity and low birth weight, prenatal and postnatal exposures are highlighted. Objective: The present study aimed to perform an update on primary hypertension in childhood, providing clinicians and researchers an overview of the current state of the literature regarding the influence of genetic and environmental factors. Methods: This integrative review searched for articles on genetic and environmental factors related to primary hypertension in pediatric patients. The databases evaluated were PubMed and Scopus. Results: The studies have provided insights regarding many genetic and environmental factors, in addition to their association with the pathophysiology of primary hypertension in childhood. Findings corroborated the idea that primary hypertension is a multifactorial disease. Further studies in the pediatric population are needed to elucidate the underlying mechanisms. Conclusion: The study of primary hypertension in pediatrics has utmost importance for the adoption of preventive measures and the development of more efficient treatments, therefore reducing childhood morbidity and the incidence of cardiovascular diseases and other health consequences later in life. © 2021 Bentham Science Publishers.","Arterial hypertension; Blood pressure; Cardiovascular diseases; Environmental factors; Genetic factors; Pediatrics; Primary hypertension; Risk factors","Adolescent; Child; Environmental Exposure; Essential Hypertension; Family; Female; Gene-Environment Interaction; Genetic Predisposition to Disease; Humans; Pediatric Obesity; Pregnancy; Prenatal Exposure Delayed Effects; Risk Factors; Sedentary Behavior; Social Determinants of Health; Socioeconomic Factors; aldosterone synthase; angiotensin 2 receptor; angiotensinogen; corticosteroid; cotinine; endothelial nitric oxide synthase; epithelial sodium channel; fibroblast growth factor 5; glutathione; high density lipoprotein cholesterol; hydrocortisone; leptin; leptin receptor; microRNA; neuropeptide Y; nitric oxide; triacylglycerol; uric acid; acromegaly; adoption; adrenal cortex carcinoma; adrenalectomy; air pollution; anemia; angiogenesis; anxiety; apparent mineralocorticoid excess syndrome; arterial stiffness; arterial wall thickness; Article; atherosclerosis; birth weight; blood pressure; blood pressure monitoring; body mass; capillary density; cardiometabolic risk; cardiorespiratory fitness; cardiovascular disease; cardiovascular response; cardiovascular risk; cesarean section; child; child growth; childhood; childhood obesity; chronic kidney failure; congenital heart disease; depression; diastolic blood pressure; DNA methylation; DNA polymorphism; DNA sequence; echocardiography; elevated blood pressure; energy expenditure; environmental factor; essential hypertension; ethnicity; fat mass; fatigue; fibromuscular dysplasia; food intake; gastric banding; gene expression; genetic background; genetic polymorphism; genetic risk; genome-wide association study; genotype; gestational age; glomerulosclerosis; glucose blood level; haplotype; headache; health disparity; heart arrhythmia; heart left ventricle mass; heart performance; heart rate; heredity; high birth weight; histone modification; hospitalization; human; hyperglycemia; hyperleptinemia; hypertension; hypokalemia; hypospadias; hypotension; hypoxia; incidence; insulin resistance; intrauterine growth retardation; iron intake; kidney artery stenosis; kidney distal tubule; kidney fibrosis; low birth weight; maternal hypertension; mean arterial pressure; mean corpuscular volume; mental disease; mental stress; metabolic syndrome X; morbidity; multifactorial inheritance; nephrectomy; nerve cell differentiation; neurotoxicity; noise pollution; obesity; oxidative stress; parental smoking; particulate matter; passive smoking; pathophysiology; pheochromocytoma; physical activity; plasma renin activity; positive end expiratory pressure ventilation; potassium excretion; potassium intake; pregnancy diabetes mellitus; premature labor; prematurity; prenatal exposure; prevalence; primary hyperaldosteronism; protein intake; protein restriction; pulse pressure; questionnaire; randomized controlled trial (topic); renin angiotensin aldosterone system; risk factor; Scopus; sedentary lifestyle; single nucleotide polymorphism; skinfold thickness; sleep disordered breathing; sleep time; social status; socioeconomics; sodium intake; systolic blood pressure; upregulation; vascular smooth muscle cell; waist circumference; adolescent; adverse event; complication; environmental exposure; essential hypertension; family; female; genetic predisposition; genetics; genotype environment interaction; pregnancy; social determinants of health","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; cotinine, 486-56-6; endothelial nitric oxide synthase, 503473-02-7; fibroblast growth factor 5, 129653-64-1; glutathione, 70-18-8; hydrocortisone, 50-23-7; neuropeptide Y, 82785-45-3, 83589-17-7; nitric oxide, 10102-43-9; uric acid, 69-93-2","","","Brazilian National Council of Research Development; CPNq, (302153/2019-5); Coordination of High Education Level Personnel; Foundation of Research of Minas Gerais; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES, (002345/2019); Fundação de Amparo à Pesquisa do Estado de Minas Gerais, FAPEMIG, (CDS - APQ-02541-17)","This work was partially supported by Brazilian National Council of Research Development (CPNq - Grant # 302153/2019-5), Coordination of High Education Level Personnel (CAPES - Grant # 002345/2019), and Foundation of Research of Minas Gerais (FAPEMIG - CDS - APQ-02541-17).","Chen X, Wang Y., Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis, Circulation, 117, 25, pp. 3171-3180, (2008); Flynn JT, Kaelber DC, Baker-Smith CM, Et al., Clinical practice guideline for screening and management of high blood pressure in children and adolescents, Pediatrics, 140, 3, (2017); The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, Pediatrics, 1142, pp. 555-576, (2004); Jackson SL, Zhang Z, Wiltz JL, Et al., Hypertension among youths - United States, 2001-2016, MMWR Morb Mortal Wkly Rep, 67, 27, pp. 758-762, (2018); Kit BK, Kuklina E, Carroll MD, Ostchega Y, Freedman DS, Ogden CL., Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999-2012, JAMA Pedi atr, 169, 3, pp. 272-279, (2015); Luma GB, Spiotta RT., Hypertension in children and adolescents, Am Fam Physician, 73, 9, pp. 1558-1568, (2006); Baracco R, Kapur G, Mattoo T, Et al., Prediction of primary vs secondary hypertension in children, J Clin Hypertens (Greenwich), 14, 5, pp. 316-321, (2012); Flynn JT., Differentiation between primary and secondary hypertension in children using ambulatory blood pressure monitoring, Pediatrics, 110, 1, pp. 89-93, (2002); Flynn JT, Alderman MH., Characteristics of children with primary hypertension seen at a referral center, Pediatr Nephrol, 20, 7, pp. 961-966, (2005); Gupta-Malhotra M, Banker A, Shete S, Et al., Essential hypertension vs. secondary hypertension among children, Am J Hypertens, 28, 1, pp. 73-80, (2015); Charles L, Triscott J, Dobbs B., Secondary hypertension: discovering the underlying cause, Am Fam Physician, 96, 7, pp. 453-461, (2017); Ahn SY, Gupta C., Genetic programming of hypertension, Front Pediatr, 5, (2018); Textor SC, Lerman L., Renovascular hypertension and ischemic nephropathy, Am J Hypertens, 23, 11, pp. 1159-1169, (2010); Warnes CA, Williams RG, Bashore TM, Et al., ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease), Circulation, 118, 23, pp. 2395-2451, (2008); Mulatero P, Stowasser M, Loh KC, Et al., Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents, J Clin Endocrinol Metab, 89, 3, pp. 1045-1050, (2004); Magiakou MA, Smyrnaki P, Chrousos GP., Hypertension in Cushing’s syndrome, Best Pract Res Clin Endocrinol Metab, 20, 3, pp. 467-482, (2006); Haas DC, Foster GL, Nieto FJ, Et al., Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study, Circulation, 111, 5, pp. 614-621, (2005); Manger WM, Gifford RW., Pheochromocytoma, J Clin Hypertens (Greenwich), 4, 1, pp. 62-72, (2002); O'Byrne S, Caulfield M., Genetics of hypertension. Therapeutic implications, Drugs, 56, 2, pp. 203-214, (1998); Luft FC., Preparation for hypertension specialists: genomics reveals the pathogenesis of hypertension, J Am Soc Hypertens, 8, 8, pp. 607-611, (2014); Wilson RC, Krozowski ZS, Li K, Et al., A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess, J Clin Endocrinol Metab, 80, 7, pp. 2263-2266, (1995); Simonetti GD, Mohaupt MG, Bianchetti MG., Monogenic forms of hypertension, Eur J Pediatr, 171, 10, pp. 1433-1439, (2012); Rossier BC, Schild L., Epithelial sodium channel: mendelian versus essential hypertension, Hypertension, 52, 4, pp. 595-600, (2008); Burrello J, Monticone S, Buffolo F, Et al., Is There a Role for Genomics in the Management of Hypertension?, Int J Mol Sci, 18, 6, (2017); Bigazzi R, Zagato L, Lanzani C, Et al., Hypertension in high school students: genetic and environmental factors: The HYGEF Study, Hypertension, 75, 1, pp. 71-78, (2020); Ehret GB, Munroe PB, Rice KM, Et al., Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk, Nature, 478, 7367, pp. 103-109, (2011); Zafarmand MH, Spanjer M, Nicolaou M, Et al., Influence of dietary approaches to stop hypertension-type diet, known genetic variants and their interplay on blood pressure in early childhood:abcd study, Hypertension, 75, 1, pp. 59-70, (2020); Sladowska-Kozlowska J, Litwin M, Niemirska A, Wierzbicka A, Roszczynko M, Szperl M., Associations of the eNOS G894T gene polymorphism with target organ damage in children with newly diagnosed primary hypertension, Pediatr Nephrol, 30, 12, pp. 2189-2197, (2015); Ajala AR, Almeida SS, Rangel M, Et al., Association of ACE gene insertion/deletion polymorphism with birth weight, blood pressure levels, and ACE activity in healthy children, Am J Hypertens, 25, 7, pp. 827-832, (2012); Simonyte S, Kuciene R, Medzioniene J, Dulskiene V, Lesauskaite V., Renin-angiotensin system gene polymorphisms and high blood pressure in Lithuanian children and adolescents, BMC Med Genet, 18, 1, (2017); Xi B, Cheng H, Shen Y, Et al., Physical activity modifies the associations between genetic variants and hypertension in the Chinese children, Atherosclerosis, 225, 2, pp. 376-380, (2012); Yang YD, Song JY, Wang S, Et al., Interaction between lifestyle behaviors and genetic polymorphism in SCAP gene on blood pressure among Chinese children, Pediatr Res, 86, 3, pp. 389-395, (2019); Siklar Z, Berberoglu M, Savas Erdeve S, Et al., Contribution of clinical, metabolic, and genetic factors on hypertension in obese children and adolescents, J Pediatr Endocrinol Metab, 24, 1-2, pp. 21-24, (2011); Papp F, Friedman AL, Bereczki C, Et al., Renin-angiotensin gene polymorphism in children with uremia and essential hypertension, Pediatr Nephrol, 18, 2, pp. 150-154, (2003); Xi B, Zhao X, Chandak GR, Et al., Influence of obesity on association between genetic variants identified by genome-wide association studies and hypertension risk in Chinese children, Am J Hypertens, 26, 8, pp. 990-996, (2013); Souza-Costa DC, Belo VA, Silva PS, Et al., eNOS haplotype associated with hypertension in obese children and adolescents, Int J Obes, 35, 3, pp. 387-392, (2011); Xi B, Shen Y, Zhao X, Et al., Association of common variants in/n ear six genes (ATP2B1, CSK, MTHFR, CYP17A1, STK39 and FGF5) with blood pressure/hypertension risk in Chinese children, J Hum Hypertens, 28, 1, pp. 32-36, (2014); Camci L, Kilic Z, Dinleyici EC, Muslumanoglu H, Tepeli E, Ucar B., Angiotensin-converting enzyme gene insertion/deletion polymorphism frequency in normotensive children with a positive family history of essential hypertension, J Paediatr Child Health, 45, 12, pp. 742-746, (2009); Santoro N, Del Giudice EM, Grandone A, Et al., Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents, J Hypertens, 26, 8, pp. 1590-1594, (2008); Kato N, Loh M, Takeuchi F, Et al., Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation, Nat Genet, 47, 11, pp. 1282-1293, (2015); Friso S, Carvajal CA, Fardella CE, Olivieri O., Epigenetics and arterial hypertension: the challenge of emerging evidence, Transl Res, 165, 1, pp. 154-165, (2015); Wise IA, Charchar FJ., Epigenetic modifications in essential hypertension, Int J Mol Sci, 17, 4, (2016); Smolarek I, Wyszko E, Barciszewska AM, Et al., Global DNA methylation changes in blood of patients with essential hypertension, Med Sci Monit, 16, 3, pp. CR149-CR155, (2010); Fish JE, Matouk CC, Rachlis A, Et al., The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code, J Biol Chem, 280, 26, pp. 24824-24838, (2005); Marques FZ, Campain AE, Tomaszewski M, Et al., Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs, Hypertension, 58, 6, pp. 1093-1098, (2011); Iwamoto T., Vascular Na+/Ca2+ exchanger: implications for the pathogenesis and therapy of salt-dependent hypertension, Am J Physiol Regul Integr Comp Physiol, 290, 3, pp. R536-R545, (2006); Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K., Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake, Circulation, 101, 8, pp. 856-861, (2000); Adrogue HJ, Madias NE., Sodium and potassium in the pathogenesis of hypertension, N Engl J Med, 356, 19, pp. 1966-1978, (2007); Vasan RS, Evans JC, Larson MG, Et al., Serum aldosterone and the incidence of hypertension in nonhypertensive persons, N Engl J Med, 351, 1, pp. 33-41, (2004); Hayashi M, Katz AI., The kidney in potassium depletion. I. Na+-K+-ATPase activity and [3H]ouabain binding in MCT, Am J Physiol, 252, 3, pp. F437-F446, (1987); Imbert-Teboul M, Doucet A, Marsy S, Siaume-Perez S., Alterations of enzymatic activities along rat collecting tubule in potassium depletion, Am J Physiol, 253, 3, pp. F408-F417, (1987); Daniels SD, Meyer RA, Loggie JM., Determinants of cardiac involvement in children and adolescents with essential hypertension, Circulation, 82, 4, pp. 1243-1248, (1990); Yang Q, Zhang Z, Kuklina EV, Et al., Sodium intake and blood pressure among US children and adolescents, Pediatrics, 130, 4, pp. 611-619, (2012); Simons-Morton DG, Obarzanek E., Diet and blood pressure in children and adolescents, Pediatr Nephrol, 11, 2, pp. 244-249, (1997); He FJ, Marrero NM, Macgregor GA., Salt and blood pressure in children and adolescents, J Hum Hypertens, 22, 1, pp. 4-11, (2008); Overwyk KJ, Zhao L, Zhang Z, Wiltz JL, Dunford EK, Cogswell ME., Trends in blood pressure and usual dietary sodium intake among children and adolescents, national health and nutrition examination survey 2003 to 2016, Hypertension, 74, 2, pp. 260-266, (2019); He FJ, MacGregor GA., Importance of salt in determining blood pressure in children: meta-analysis of controlled trials, Hypertension, 48, 5, pp. 861-869, (2006); Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ., Effect of lower sodium intake on health: systematic review and meta-analyses, BMJ, 346, (2013); Leyvraz M, Chatelan A, da Costa BR, Et al., Sodium intake and blood pressure in children and adolescents: a systematic review and meta-analysis of experimental and observational studies, Int J Epidemiol, 47, 6, pp. 1796-1810, (2018); Rios-Leyvraz M, Bloetzer C, Chatelan A, Et al., Sodium intake and blood pressure in children with clinical conditions: A systematic review with meta-analysis, J Clin Hypertens (Greenwich), 21, 1, pp. 118-126, (2019); Pomeranz A, Dolfin T, Korzets Z, Eliakim A, Wolach B., Increased sodium concentrations in drinking water increase blood pressure in neonates, J Hypertens, 20, 2, pp. 203-207, (2002); Hofman A, Hazebroek A, Valkenburg HA., A randomized trial of sodium intake and blood pressure in newborn infants, JAMA, 250, 3, pp. 370-373, (1983); Geleijnse JM, Hofman A, Witteman JC, Hazebroek AA, Valkenburg HA, Grobbee DE., Long-term effects of neonatal sodium restriction on blood pressure, Hypertension, 29, 4, pp. 913-917, (1997); Brion MJ, Ness AR, Davey Smith G, Et al., Sodium intake in infancy and blood pressure at 7 years: findings from the Avon Longitudinal Study of Parents and Children, Eur J Clin Nutr, 62, 10, pp. 1162-1169, (2008); Buendia JR, Bradlee ML, Daniels SR, Singer MR, Moore LL., Longitudinal effects of dietary sodium and potassium on blood pressure in adolescent girls, JAMA Pediatr, 169, 6, pp. 560-568, (2015); Correia-Costa L, Cosme D, Nogueira-Silva L, Et al., Gender and obesity modify the impact of salt intake on blood pressure in children, Pediatr Nephrol, 31, 2, pp. 279-288, (2016); Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion, BMJ, 297, 6644, pp. 319-328, (1988); Geleijnse JM, Grobbee DE, Hofman A., Sodium and potassium intake and blood pressure change in childhood, BMJ, 300, 6729, pp. 899-902, (1990); Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP., Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses, BMJ, 346, (2013); Sinaiko AR, Gomez-Marin O, Prineas RJ., Effect of low sodium diet or potassium supplementation on adolescent blood pressure, Hypertension, 21, 6, pp. 989-994, (1993); Wilson DK, Sica DA, Devens M, Nicholson SC., The influence of potassium intake on dipper and nondipper blood pressure status in an African-American adolescent population, Blood Press Monit, 1, 6, pp. 447-455, (1996); Miller JZ, Weinberger MH, Christian JC., Blood pressure response to potassium supplementation in normotensive adults and children, Hypertension, 10, 4, pp. 437-442, (1987); Chmielewski J, Carmody JB., Dietary sodium, dietary potassium, and systolic blood pressure in US adolescents, J Clin Hypertens (Greenwich), 19, 9, pp. 904-909, (2017); WHO Guidelines Approved by the Guidelines Review Committee, (2012); Soylu A, Kavukcu S, Turkmen M, Cabuk N, Duman M., Effect of socioeconomic status on the blood pressure in children living in a developing country, Pediatr Int, 42, 1, pp. 37-42, (2000); Wilson DK, Kliewer W, Plybon L, Sica DA., Socioeconomic status and blood pressure reactivity in healthy black adolescents, Hypertension, 35, 1, pp. 496-500, (2000); Schreier HM, Chen E., Socioeconomic status in one’s childhood predicts offspring cardiovascular risk, Brain Behav Immun, 24, 8, pp. 1324-1331, (2010); Kaczmarek M, Stawinska-Witoszynska B, Krzyzaniak A, Krzywinska-Wiewiorowska M, Siwinska A., Who is at higher risk of hypertension? Socioeconomic status differences in blood pressure among Polish adolescents: a population-based ADOPOLNOR study, Eur J Pediatr, 174, 11, pp. 1461-1473, (2015); Lawlor DA, Smith GD., Early life determinants of adult blood pressure, Curr Opin Nephrol Hypertens, 14, 3, pp. 259-264, (2005); Blane D, Hart CL, Smith GD, Gillis CR, Hole DJ, Hawthorne VM., Association of cardiovascular disease risk factors with socioeconomic position during childhood and during adulthood, BMJ, 313, 7070, pp. 1434-1438, (1996); Wannamethee SG, Whincup PH, Shaper G, Walker M., Influence of fathers’ social class on cardiovascular disease in middle-aged men, Lancet, 348, 9037, pp. 1259-1263, (1996); Hardy R, Kuh D, Langenberg C, Wadsworth ME., Birthweight, childhood social class, and change in adult blood pressure in the 1946 British birth cohort, Lancet, 362, 9391, pp. 1178-1183, (2003); Lindgarde F, Furu M, Ljung BO., A longitudinal study on the significance of environmental and individual factors associated with the development of essential hypertension, J Epidemiol Community Health, 41, 3, pp. 220-226, (1987); Balogun JA, Obajuluwa VA, Olaogun MO, Et al., Influence of parental socioeconomic status on casual blood pressures of Nigerian school children, Int J Cardiol, 29, 1, pp. 63-69, (1990); Gupta-Malhotra M, Shete S, Barratt MS, Milewicz D, Hashmi SS., Epidemiology of childhood onset essential hypertension, J Hum Hypertens, 32, 12, pp. 808-813, (2018); Colhoun HM, Hemingway H, Poulter NR., Socio-economic status and blood pressure: an overview analysis, J Hum Hypertens, 12, 2, pp. 91-110, (1998); Jackson RW, Treiber FA, Turner JR, Davis H, Strong WB., Effects of race, sex, and socioeconomic status upon cardiovascular stress responsivity and recovery in youth, Int J Psychophysiol, 31, 2, pp. 111-119, (1999); Barnes VA, Treiber FA, Musante L, Turner JR, Davis H, Strong WB., Ethnicity and socioeconomic status: impact on cardiovascular activity at rest and during stress in youth with a family history of hypertension, Ethn Dis, 10, 1, pp. 4-16, (2000); Barrington DS, Adeyemo AA, Rotimi CN., Childhood family living arrangements and blood pressure in black men: the Howard University Family Study, Hypertension, 63, 1, pp. 48-53, (2014); Su S, Wang X, Pollock JS, Et al., Adverse childhood experiences and blood pressure trajectories from childhood to young adulthood:the Georgia stress and Heart study, Circulation, 131, 19, pp. 1674-1681, (2015); Musante L, Treiber FA, Kapuku G, Moore D, Davis H, Strong WB., The effects of life events on cardiovascular reactivity to behavioral stressors as a function of socioeconomic status, ethnicity, and sex, Psychosom Med, 62, 6, pp. 760-767, (2000); Lehman BJ, Taylor SE, Kiefe CI, Seeman TE., Relationship of early life stress and psychological functioning to blood pressure in the CARDIA study, Health Psychol, 28, 3, pp. 338-346, (2009); Alastalo H, Raikkonen K, Pesonen AK, Et al., Early life stress and blood pressure levels in late adulthood, J Hum Hypertens, 27, 2, pp. 90-94, (2013); Gupta-Malhotra M, Hashmi SS, Barratt MS, Milewicz DM, Shete S., Childhood-onset essential hypertension and the family structure, J Clin Hypertens (Greenwich), 18, 5, pp. 431-438, (2016); Ribeiro J, Guerra S, Pinto A, Oliveira J, Duarte J, Mota J., Overweight and obesity in children and adolescents: relationship with blood pressure, and physical activity, Ann Hum Biol, 30, 2, pp. 203-213, (2003); Angelopoulos PD, Milionis HJ, Moschonis G, Manios Y., Relations between obesity and hypertension: preliminary data from a cross-sectional study in primary schoolchildren: the children study, Eur J Clin Nutr, 60, 10, pp. 1226-1234, (2006); Raj M, Sundaram KR, Paul M, Deepa AS, Kumar RK., Obesity in Indian children: time trends and relationship with hypertension, Natl Med J India, 20, 6, pp. 288-293, (2007); Chiolero A, Madeleine G, Gabriel A, Burnier M, Paccaud F, Bovet P., Prevalence of elevated blood pressure and association with overweight in children of a rapidly developing country, J Hum Hypertens, 21, 2, pp. 120-127, (2007); Chiolero A, Cachat F, Burnier M, Paccaud F, Bovet P., Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight, J Hypertens, 25, 11, pp. 2209-2217, (2007); Salvadori M, Sontrop JM, Garg AX, Et al., Elevated blood pressure in relation to overweight and obesity among children in a rural Canadian community, Pediatrics, 122, 4, pp. e821-e827, (2008); Tu W, Eckert GJ, DiMeglio LA, Yu Z, Jung J, Pratt JH., Intensified effect of adiposity on blood pressure in overweight and obese children, Hypertension, 58, 5, pp. 818-824, (2011); Lo JC, Chandra M, Sinaiko A, Et al., Severe obesity in children:prevalence, persistence and relation to hypertension, Int J Pediatr Endocrinol, 2014, 1, (2014); Pozuelo-Carrascosa DP, Sanchez-Lopez M, Cavero-Redondo I, Torres-Costoso A, Bermejo-Cantarero A, Martinez-Vizcaino V., Obesity as a mediator between cardiorespiratory fitness and blood pressure in preschoolers, J Pediatr, 182, pp. 114-119, (2017); Maric GD, Dusanovic MG, Kostic AV, Pekmezovic TD, Kisic-Tepavcevic DB., Prevalence of hypertension in a sample of schoolchildren in the Belgrade district, Blood Press Monit, 21, 3, pp. 155-159, (2016); Cheung EL, Bell CS, Samuel JP, Poffenbarger T, Redwine KM, Samuels JA., Race and Obesity in Adolescent Hypertension, Pediatrics, 139, 5, (2017); Zhang YX, Wang SR., Monitoring of blood pressure in overweight and obese children in Shandong, China, Ann Hum Biol, 38, 5, pp. 603-607, (2011); Juonala M, Magnussen CG, Berenson GS, Et al., Childhood adiposity, adult adiposity, and cardiovascular risk factors, N Engl J Med, 365, 20, pp. 1876-1885, (2011); Souza MG, Rivera IR, Silva MA, Carvalho AC., Relationship of obesity with high blood pressure in children and adolescents, Arq Bras Cardiol, 94, 6, pp. 714-719, (2010); Ying-Xiu Z, Da-Yong S, Jing-Yang Z, Jin-Shan Z, Zun-Hua C., Blood pressure among children and adolescents with normal weight but large waist circumference in Shandong, China, Eur J Pediatr, 173, 3, pp. 285-289, (2014); Rerksuppaphol S, Rerksuppaphol L., Association of obesity with the prevalence of hypertension in school children from central Thailand, J Res Health Sci, 15, 1, pp. 17-21, (2015); Dong B, Wang Z, Yang Y, Wang HJ, Ma J., Intensified association between waist circumference and hypertension in abdominally overweight children, Obes Res Clin Pract, 10, 1, pp. 24-32, (2016); Dhuper S, Abdullah RA, Weichbrod L, Mahdi E, Cohen HW., Association of obesity and hypertension with left ventricular geometry and function in children and adolescents, Obesity (Silver Spring), 19, 1, pp. 128-133, (2011); Oosterhoff M, Joore M, Ferreira I., The effects of school-based lifestyle interventions on body mass index and blood pressure: a multivariate multilevel meta-analysis of randomized controlled trials, Obes Rev, 17, 11, pp. 1131-1153, (2016); Cai L, Wu Y, Wilson RF, Segal JB, Kim MT, Wang Y., Effect of childhood obesity prevention programs on blood pressure: a systematic review and meta-analysis, Circulation, 129, 18, pp. 1832-1839, (2014); Hvidt KN., Blood pressure and arterial stiffness in obese children and adolescents, Dan Med J, 62, 3, (2015); O'Brien PE, Sawyer SM, Laurie C, Et al., Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial, JAMA, 303, 6, pp. 519-526, (2010); Flynn J., The changing face of pediatric hypertension in the era of the childhood obesity epidemic, Pediatr Nephrol, 28, 7, pp. 1059-1066, (2013); Brady TM., Obesity-related hypertension in children, Front Pediatr, 5, (2017); Wuhl E., Hypertension in childhood obesity, Acta Paediatr, 108, 1, pp. 37-43, (2019); Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G., Mechanisms of obesity-induced hypertension, Hypertens Res, 33, 5, pp. 386-393, (2010); Ouchi N, Parker JL, Lugus JJ, Walsh K., Adipokines in inflammation and metabolic disease, Nat Rev Immunol, 11, 2, pp. 85-97, (2011); Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME., Obesity- induced hypertension: interaction of neurohumoral and renal mechanisms, Circ Res, 116, 6, pp. 991-1006, (2015); Wirix AJ, Kaspers PJ, Nauta J, Chinapaw MJ, Kist-van Holthe JE., Pathophysiology of hypertension in obese children: a systematic review, Obes Rev, 16, 10, pp. 831-842, (2015); Kalil GZ, Haynes WG., Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications, Hypertens Res, 35, 1, pp. 4-16, (2012); Vecchiola A, Lagos CF, Carvajal CA, Baudrand R, Fardella CE., Aldosterone Production and Signaling Dysregulation in Obesity, Curr Hypertens Rep, 18, 3, (2016); Dorresteijn JA, Visseren FL, Spiering W., Mechanisms linking obesity to hypertension, Obes Rev, 13, 1, pp. 17-26, (2012); Nishina M, Kikuchi T, Yamazaki H, Kameda K, Hiura M, Uchiyama M., Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children, Hypertens Res, 26, 4, pp. 281-288, (2003); von Schnurbein J, Manzoor J, Brandt S, Et al., Leptin is not essential for obesity-associated hypertension, Obes Facts, 12, 4, pp. 460-475, (2019); Ewart CK, Young DR, Hagberg JM., Effects of school-based aerobic exercise on blood pressure in adolescent girls at risk for hypertension, Am J Public Health, 88, 6, pp. 949-951, (1998); Gidding SS, Barton BA, Dorgan JA, Et al., Higher self-reported physical activity is associated with lower systolic blood pressure:the Dietary Intervention Study in Childhood (DISC), Pediatrics, 118, 6, pp. 2388-2393, (2006); Leary SD, Ness AR, Smith GD, Et al., Physical activity and blood pressure in childhood: findings from a population-based study, Hypertension, 51, 1, pp. 92-98, (2008); Andersen LB, Riddoch C, Kriemler S, Hills AP., Physical activity and cardiovascular risk factors in children, Br J Sports Med, 45, 11, pp. 871-876, (2011); Ekelund U, Luan J, Sherar LB, Esliger DW, Griew P, Cooper A., International Children’s Accelerometry Database (ICAD) Collaborators. Moderate to vigorous physical activity and sedentary time and cardiometabolic risk factors in children and adolescents, JAMA, 307, 7, pp. 704-712, (2012); Chaput JP, Saunders TJ, Mathieu ME, Et al., Combined associa tions between moderate to vigorous physical activity and sedentary behaviour with cardiometabolic risk factors in children, Appl Physiol Nutr Metab, 38, 5, pp. 477-483, (2013); de Moraes AC, Carvalho HB, Siani A, Et al., IDEFICS consortium. Incidence of high blood pressure in children - effects of physical activity and sedentary behaviors: the IDEFICS study: High blood pressure, lifestyle and children, Int J Cardiol, 180, pp. 165-170, (2015); Stamatakis E, Coombs N, Tiling K, Et al., Sedentary time in late childhood and cardiometabolic risk in adolescence, Pediatrics, 135, 6, pp. e1432-e1441, (2015); Carson V, Tremblay MS, Chaput JP, Chastin SF., Associations between sleep duration, sedentary time, physical activity, and health indicators among Canadian children and youth using compositional analyses, Appl Physiol Nutr Metab, 41, 6, pp. S294-S302, (2016); Karatzi K, Moschonis G, Botelli S, Et al., Physical activity and sedentary behavior thresholds for identifying childhood hypertension and its phenotypes: The Healthy Growth Study, J Am Soc Hypertens, 12, 10, pp. 714-722, (2018); Wijndaele K, White T, Andersen LB, Et al., International Children’s Accelerometry Database (ICAD) Collaborators. Substituting prolonged sedentary time and cardiovascular risk in children and youth: a meta-analysis within the International Children’s Accelerometry database (ICAD), Int J Behav Nutr Phys Act, 16, 1, (2019); Garcia-Hermoso A, Hormazabal-Aguayo I, Gonzalez-Calderon N, Et al., Exercise program and blood pressure in children: The moderating role of sedentary time, J Sci Med Sport, 23, 9, pp. 854-859, (2020); Sobngwi E, Mbanya JC, Unwin NC, Et al., Physical activity and its relationship with obesity, hypertension and diabetes in urban and rural Cameroon, Int J Obes Relat Metab Disord, 26, 7, pp. 1009-1016, (2002); Torrance B, McGuire KA, Lewanczuk R, McGavock J., Overweight, physical activity and high blood pressure in children: a review of the literature, Vasc Health Risk Manag, 3, 1, pp. 139-149, (2007); Pardee PE, Norman GJ, Lustig RH, Preud'homme D, Schwimmer JB., Television viewing and hypertension in obese children, Am J Prev Med, 33, 6, pp. 439-443, (2007); Farpour-Lambert NJ, Aggoun Y, Marchand LM, Martin XE, Herrmann FR, Beghetti M., Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children, J Am Coll Cardiol, 54, 25, pp. 2396-2406, (2009); Betz HH, Eisenmann JC, Laurson KR, Et al., Physical Activity, BMI, and Blood Pressure in US Youth: NHANES 2003-2006, Pediatr Exerc Sci, 30, 3, pp. 418-425, (2018); Sugiyama T, Xie D, Graham-Maar RC, Inoue K, Kobayashi Y, Stettler N., Dietary and lifestyle factors associated with blood pressure among U.S. adolescents, J Adolesc Health, 40, 2, pp. 166-172, (2007); Martinez-Gomez D, Tucker J, Heelan KA, Welk GJ, Eisenmann JC., Associations between sedentary behavior and blood pressure in young children, Arch Pediatr Adolesc Med, 163, 8, pp. 724-730, (2009); Knowles G, Pallan M, Thomas GN, Et al., Physical activity and blood pressure in primary school children: a longitudinal study, Hypertension, 61, 1, pp. 70-75, (2013); Gopinath B, Baur LA, Hardy LL, Et al., Relationship between a range of sedentary behaviours and blood pressure during early adolescence, J Hum Hypertens, 26, 6, pp. 350-356, (2012); de Moraes AC, Carvalho HB, Rey-Lopez JP, Et al., Independent and combined effects of physical activity and sedentary behavior on blood pressure in adolescents: gender differences in two cross-- sectional studies, PLoS One, 8, 5, (2013); Kelley GA, Kelley KS, Tran ZV., The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials, Prev Cardiol, 6, 1, pp. 8-16, (2003); Vaisto J, Eloranta AM, Viitasalo A, Et al., Physical activity and sedentary behaviour in relation to cardiometabolic risk in children:cross-sectional findings from the Physical Activity and Nutrition in Children (PANIC) Study, Int J Behav Nutr Phys Act, 11, (2014); Macdonald-Wallis C, Solomon-Moore E, Sebire SJ, Thompson JL, Lawlor DA, Jago R., A longitudinal study of the associations of children’s body mass index and physical activity with blood pressure, PLoS One, 12, 12, (2017); Solomon-Moore E, Salway R, Emm-Collison L, Et al., Associations of body mass index, physical activity and sedentary time with blood pressure in primary school children from south-west England: A prospective study, PLoS One, 15, 4, (2020); Seidman DS, Laor A, Gale R, Stevenson DK, Mashiach S, Danon YL., Birth weight, current body weight, and blood pressure in late adolescence, BMJ, 302, 6787, pp. 1235-1237, (1991); Donker GA, Labarthe DR, Harrist RB, Selwyn BJ, Wattigney W, Berenson GS., Low birth weight and blood pressure at age 7-11 years in a biracial sample, Am J Epidemiol, 145, 5, pp. 387-397, (1997); Levitt NS, Steyn K, De Wet T, Et al., An inverse relation between blood pressure and birth weight among 5 year old children from Soweto, South Africa, J Epidemiol Community Health, 53, 5, pp. 264-268, (1999); Barros FC, Victora CG., Increased blood pressure in adolescents who were small for gestational age at birth: a cohort study in Brazil, Int J Epidemiol, 28, 4, pp. 676-681, (1999); Yiu V, Buka S, Zurakowski D, McCormick M, Brenner B, Jabs K., Relationship between birthweight and blood pressure in childhood, Am J Kidney Dis, 33, 2, pp. 253-260, (1999); Primatesta P, Falaschetti E, Poulter NR., Birth weight and blood pressure in childhood: results from the Health Survey for England, Hypertension, 45, 1, pp. 75-79, (2005); Franco MC, Christofalo DM, Sawaya AL, Ajzen SA, Sesso R., Effects of low birth weight in 8- to 13-year-old children: implications in endothelial function and uric acid levels, Hypertension, 48, 1, pp. 45-50, (2006); Hemachandra AH, Howards PP, Furth SL, Klebanoff MA., Birth weight, postnatal growth, and risk for high blood pressure at 7 years of age: results from the Collaborative Perinatal Project, Pediatrics, 119, 6, pp. e1264-e1270, (2007); Pereira JA, Rondo PH, Lemos JO, Pacheco de Souza JM, Dias RS., The influence of birthweight on arterial blood pressure of children, Clin Nutr, 29, 3, pp. 337-340, (2010); Bowers K, Liu G, Wang P, Et al., Birth weight, postnatal weight change, and risk for high blood pressure among chinese children, Pediatrics, 127, 5, pp. e1272-e1279, (2011); Rossi P, Tauzin L, Marchand E, Boussuges A, Gaudart J, Frances Y., Respective roles of preterm birth and fetal growth restriction in blood pressure and arterial stiffness in adolescence, J Adolesc Health, 48, 5, pp. 520-522, (2011); de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB., Systematic review and meta-analysis of preterm birth and later systolic blood pressure, Hypertension, 59, 2, pp. 226-234, (2012); Mu M, Wang SF, Sheng J, Et al., Birth weight and subsequent blood pressure: a meta-analysis, Arch Cardiovasc Dis, 105, 2, pp. 99-113, (2012); Zarrati M, Shidfar F, Razmpoosh E, Et al., Does low birth weight predict hypertension and obesity in schoolchildren?, Ann Nutr Metab, 63, 1-2, pp. 69-76, (2013); Zhang Y, Li H, Liu SJ, Et al., The associations of high birth weight with blood pressure and hypertension in later life: a systematic review and meta-analysis, Hypertens Res, 36, 8, pp. 725-735, (2013); Sipola-Leppanen M, Vaarasmaki M, Tikanmaki M, Et al., Cardiovascular risk factors in adolescents born preterm, Pediatrics, 134, 4, pp. e1072-e1081, (2014); Juonala M, Cheung MM, Sabin MA, Et al., Effect of birth weight on life-course blood pressure levels among children born premature:the Cardiovascular Risk in Young Finns Study, J Hypertens, 33, 8, pp. 1542-1548, (2015); Pocobelli G, Dublin S, Enquobahrie DA, Mueller BA., Birth weight and birth weight for gestational age in relation to risk of hospitalization with primary hypertension in children and young adults, Matern Child Health J, 20, 7, pp. 1415-1423, (2016); Kuciene R, Dulskiene V, Medzioniene J., Associations between high birth weight, being large for gestational age, and high blood pressure among adolescents: a cross-sectional study, Eur J Nutr, 57, 1, pp. 373-381, (2018); Lindberg J, Norman M, Westrup B, Domellof M, Berglund SK., Lower systolic blood pressure at age 7 y in low-birth-weight children who received iron supplements in infancy: results from a randomized controlled trial, Am J Clin Nutr, 106, 2, pp. 475-480, (2017)","A.C.S. e Silva; Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; email: acssilva@hotmail.com","","Bentham Science Publishers","","","","","","15733963","","","33430749","English","Curr. Pediatr. Rev.","Article","Final","","Scopus","2-s2.0-85104159792"
"Agostini L.D.C.; Silva N.N.T.; Belo V.D.A.; Luizon M.R.; Lima A.A.; da Silva G.N.","Agostini, Lívia da Cunha (57219707241); Silva, Nayara Nascimento Toledo (55671544900); Belo, Vanessa de Almeida (34871391600); Luizon, Marcelo Rizzatti (14621886500); Lima, Angelica Alves (35512292500); da Silva, Glenda Nicioli (57214164534)","57219707241; 55671544900; 34871391600; 14621886500; 35512292500; 57214164534","Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases","2024","European Journal of Pharmacology","981","","176907","","","","0","10.1016/j.ejphar.2024.176907","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201257440&doi=10.1016%2fj.ejphar.2024.176907&partnerID=40&md5=d9d1127846995d5f3bf0165d55c5dc14","Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; Departamento de Análises Clínicas (DEACL), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; Departamento de Farmácia (DEFAR), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, MG, Belo Horizonte, CEP 31270-901, Brazil","Agostini L.D.C., Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; Silva N.N.T., Departamento de Análises Clínicas (DEACL), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; Belo V.D.A., Departamento de Farmácia (DEFAR), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; Luizon M.R., Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, MG, Belo Horizonte, CEP 31270-901, Brazil; Lima A.A., Departamento de Análises Clínicas (DEACL), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil; da Silva G.N., Departamento de Análises Clínicas (DEACL), Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Ouro Preto, CEP 35400-000, Brazil","Cardiovascular diseases (CVDs) have a high mortality rate, and despite the several available therapeutic targets, non-response to antihypertensives remains a common problem. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are important classes of drugs recommended as first-line therapy for several CVDs. However, response to ACEIs and ARBs varies among treated patients. Pharmacogenomics assesses how an individual's genetic characteristics affect their likely response to drug therapy. Currently, numerous studies suggest that genetic polymorphisms may contribute to variability in drug response. Moreover, further studies evaluating gene-gene interactions within signaling pathways in response to antihypertensives might help to unravel potential genetic predictors for antihypertensive response. This review summarizes the pharmacogenetic data for ACEIs and ARBs in patients with CVD, and discusses the potential pharmacogenetics of these classes of antihypertensives in clinical practice. However, replication studies in different populations are needed. In addition, studies that evaluate gene-gene interactions that share signaling pathways in the response to antihypertensive drugs might facilitate the discovery of genetic predictors for antihypertensive response. © 2024 Elsevier B.V.","Angiotensin II receptor blockers; Angiotensin-converting enzyme inhibitors; Cardiovascular diseases; Hypertension; Pharmacogenetics; Single nucleotide polymorphisms","Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Humans; Pharmacogenetics; aldosterone synthase; angiotensin 2 receptor antagonist; angiotensin II; angiotensin receptor; angiotensin receptor antagonist; angiotensinogen; antihypertensive agent; atenolol; atorvastatin; calcium channel blocking agent; candesartan; captopril; carboxylesterase; cytochrome P450 2C9; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; enalapril; felodipine; fucosyltransferase; hydrochlorothiazide; hydroxymethylglutaryl coenzyme A reductase inhibitor; irbesartan; liraglutide; lisinopril; losartan; multidrug resistance protein 1; nephrin; nitrendipine; nitric oxide; perindopril; ramipril; reactive oxygen metabolite; telmisartan; valsartan; angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; acute coronary syndrome; adverse drug reaction; article; Article; atherosclerosis; binding affinity; blood vessel reactivity; brain blood flow; cardiovascular risk; chronic cough; chronic kidney failure; clinical decision support system; clinical practice; coronary artery disease; drug response; drug therapy; first-line treatment; gene interaction; genetic trait; glucose blood level; haplotype; heart failure; heart ventricle remodeling; hemodynamics; human; hypertension; mean arterial pressure; metabolic syndrome X; mortality; mortality rate; multidrug resistance; non ST segment elevation myocardial infarction; pharmacokinetic parameters; pharmacokinetics; pharmacology; plasma concentration-time curve; prevalence; replication study; restriction fragment length polymorphism; risk factor; signal transduction; single nucleotide polymorphism; ST segment elevation myocardial infarction; systemic lupus erythematosus; systolic blood pressure; animal; cardiovascular disease; genetics; pharmacogenetics","","aldosterone synthase, 122933-89-5; angiotensin II, 11128-99-7, 68521-88-0; angiotensinogen, 11002-13-4, 64315-16-8; atenolol, 29122-68-7, 93379-54-5; atorvastatin, 134523-00-5, 134523-03-8, 110862-48-1; candesartan, 139481-59-7; captopril, 62571-86-2; carboxylesterase, 59536-71-9, 83380-83-0, 9016-18-6, 9028-01-7; dipeptidyl carboxypeptidase, 9015-82-1; enalapril, 75847-73-3; felodipine, 72509-76-3; fucosyltransferase, 56626-18-7; hydrochlorothiazide, 58-93-5; irbesartan, 138402-11-6, 329055-23-4; liraglutide, 204656-20-2; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; nephrin, 255039-20-4; nitrendipine, 39562-70-4; nitric oxide, 10102-43-9; perindopril, 82834-16-0, 99149-83-4; ramipril, 87333-19-5; telmisartan, 144701-48-4; valsartan, 137862-53-4; Angiotensin Receptor Antagonists, ; Angiotensin-Converting Enzyme Inhibitors, ","","","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES; Universidade Federal de Ouro Preto, UFOP, (23109.009436/2023–56, 23109.016819/2023-81); Universidade Federal de Ouro Preto, UFOP; Fundação de Amparo à Pesquisa do Estado de Minas Gerais, FAPEMIG, (APQ-03555-22); Fundação de Amparo à Pesquisa do Estado de Minas Gerais, FAPEMIG; Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, (314486/2023-2, 310905/2020-6); Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq","Funding text 1: This study was supported by Coordination for the Improvement of Higher Education Personnel (CAPES) [Finance Code 001], National Council for Scientific and Technological Development (CNPq) [grants n\u00BA. 310905/2020-6 and 314486/2023-2, CNPq Research Productivity Scholarship] and Federal University of Ouro Preto [grant n\u00BA. 23109.016819/2023-81 and 23109.009436/2023-56]. The funders did not assist in carrying writing the article.; Funding text 2: This study was supported by Coordination for the Improvement of Higher Education Personnel (CAPES) [Finance Code 001], National Council for Scientific and Technological Development (CNPq) [grants n\u00BA. 310905/2020-6 and 314486/2023-2, CNPq Research Productivity Scholarship], Federal University of Ouro Preto [grant n\u00BA. 23109.016819/2023-81 and 23109.009436/2023\u201356] and Funda\u00E7\u00E3o de Amparo \u00E0 Pesquisa do Estado de Minas Gerais [grant n\u00BA. APQ-03555-22]. The funders did not assist in carrying writing the article.","Ahmed H., VanderPluym C., Medical management of pediatric heart failure, Cardiovasc. Diagn. Ther., 11, 1, pp. 323-335, (2021); Ancion A., Et al., A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril, Cardiology and Therapy, 8, 2, pp. 179-191, (2019); Ayers R., Et al., Racial and ethnic differences in response to treatment for Marfan syndrome, Cardiol. Young, 31, 12, pp. 1991-1998, (2021); Benetos A., Et al., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, 6, pp. 1081-1084, (1996); Bhatnagar V., Et al., G-Protein-Coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among african Americans: sex-specificity and interactions, Am. J. Hypertens., 22, 3, pp. 332-338, (2009); Bozkurt O., Et al., Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics, Am. J. Hypertens., 22, 5, pp. 545-551, (2009); Cicoira M., Et al., Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure, Am. J. Med., 116, 10, pp. 657-661, (2004); Clemmer J.S., Pruett W.A., Lirette S.T., Racial and sex differences in the response to first-line antihypertensive therapy, Frontiers in Cardiovascular Medicine, 7, December, pp. 1-9, (2020); Collins K.S., Et al., Genotype-guided hydralazine therapy, Am. J. Nephrol., 51, 10, pp. 764-776, (2020); Cooper-DeHoff R.M., Johnson J.A., Hypertension pharmacogenomics: in search of personalized treatment approaches, Nat. Rev. Nephrol., 12, 2, pp. 110-122, (2016); da C Agostini L., Et al., Single nucleotide polymorphism (SNP) rs4291 of the angiotensin-converting enzyme (ACE) gene is associated with the response to losartan treatment in hypertensive patients, Mol. Biol. Rep., 51, 1, (2024); Das B.B., Current state of pediatric heart failure, Children, 5, 7, (2018); de Denus S., Et al., A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure, Pharmacogenomics, 19, 7, pp. 599-612, (2018); de Oliveira F., Et al., Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia, Indian J. Med. Res., 150, 3, (2019); Denus S.D., Et al., Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan, Ann. Pharmacother., 42, 7-8, pp. 925-932, (2008); Dezsi C.A., Szentes V., Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on prothrombotic processes and myocardial infarction risk, Am. J. Cardiovasc. Drugs, 16, 6, pp. 399-406, (2016); Do A.N., Et al., The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study, J. Hum. Hypertens., 30, 9, pp. 549-554, (2016); Duarte J.D., Cavallari L.H., Pharmacogenetics to guide cardiovascular drug therapy, Nat. Rev. Cardiol., (2021); Eadon M.T., Et al., Pharmacogenomics of hypertension in CKD: the CKD-PGX study, Kidney360, 3, 2, pp. 307-316, (2022); US food and drug administration: cozaar (losartan) prescribing information, (2024); Fontana V., Luizon M.R., Sandrim V.C., An update on the pharmacogenetics of treating hypertension, J. Hum. Hypertens., 29, 5, pp. 283-291, (2015); Frau F., Et al., Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the sophia study, Pharmacogenomics, 15, 13, pp. 1643-1652, (2014); Ghafil F.A., Et al., Genetic polymorphism of angiotensin II type 1 receptors and their effect on the clinical outcome of captopril treatment in arab Iraqi patients with acute coronary syndrome (mid euphrates), Indian J. Clin. Biochem., 36, 1, pp. 81-87, (2021); Gong H.-T., Et al., Association of mononucleotide polymorphisms of angiotensinogen gene at promoter region with antihypertensive response to angiotensin receptor blockers in hypertensive Chinese, J. Renin-Angiotensin-Aldosterone Syst. JRAAS, 20, 1, (2019); Gong H., Et al., Association of polymorphisms of CYP11B2 gene –344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension, J. Genet., 98, 1, (2019); Grimson S., Et al., The prevalence of unique <scp>SNP</scp> s in the renin‐angiotensin system highlights the need for pharmacogenetics in Indigenous Australians, Clin. Exp. Pharmacol. Physiol., 43, 2, pp. 157-160, (2016); Hallberg P., Et al., Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population, Pharmacogenomics, 18, 3, pp. 201-213, (2017); Harrap S.B., Et al., The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition, Hypertension, 42, 3, pp. 297-303, (2003); He H., Et al., A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril, Ann. Hum. Biol., 32, 1, pp. 30-43, (2005); He F., Et al., TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension, Ann. Transl. Med., 8, 7, (2020); Heidari F., Et al., Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors, J. Renin-Angiotensin-Aldosterone Syst. JRAAS, 16, 4, pp. 872-879, (2015); Herrera-Gonzalez S., Et al., Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population, Biomedical Reports, (2017); Hicks B.M., Et al., Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study, BMJ, (2018); Hiltunen T.P., Et al., Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs, J. Am. Heart Assoc., 4, 1, (2015); Hristova M., Stanilova S., Miteva L., Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy, Clin. Exp. Hypertens., 41, 7, pp. 662-669, (2019); Hundemer G.L., Sood M.M., Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management, Pharmacol. Res., 172, (2021); Hussain M., Bilal A., Awan F., Pharmacogenetic study of ACE, AGT, CYP11B1, CYP11B2 and eNOS gene variants in hypertensive patients from Faisalabad, Pakistan, JPMA (J. Pak. Med. Assoc.), (2020); Ikonnikova A., Et al., The influence of structural variants of the CES1 gene on the pharmacokinetics of enalapril, presumably due to linkage disequilibrium with the intronic rs2244613, Genes, 13, 12, (2022); Irvin M.R., Et al., Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study, J. Hypertens., 28, 10, pp. 2076-2083, (2010); Ito T., Et al., Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II at 1 antagonist, Stroke, 33, 9, pp. 2297-2303, (2002); Jacobsen P., Et al., Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy, Kidney Int., 53, 4, pp. 1002-1006, (1998); Jiang S., Et al., Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan, J. Hypertens., 29, 5, pp. 890-895, (2011); Johnson R., Et al., Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review, Heart Fail. Rev., 24, 3, pp. 343-357, (2019); Jung E.H., Et al., Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients, Arch Pharm. Res. (Seoul), 44, 12, pp. 1109-1119, (2021); Kitsios G., Zintzaras E., ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation, BMC Med. Genet., 10, 1, (2009); Kolovou V., Et al., Angiotensinogen (AGT) M235T, AGT T174M and angiotensin-1- converting enzyme (ACE) I/D gene polymorphisms in essential hypertension: effects on ramipril efficacy, Open Cardiovasc. Med. J., 9, 1, pp. 118-126, (2015); Kurland L., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J. Hypertens., 19, 10, pp. 1783-1787, (2001); Lee Y.-J., Tsai J.C.R., Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non[ndash ]insulin-dependent diabetes mellitu, Metabolism, 50, 11, pp. 1346-1350, (2001); Lee J.-K., Et al., Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease, Pharmacogenetics Genom., 23, 4, pp. 181-189, (2013); Lee C.J., Et al., Genetic variants associated with adverse events after angiotensin-converting enzyme inhibitor use: replication after GWAS-based discovery, Yonsei Med. J., 63, 4, (2022); Levy B.I., Mourad J.J., Renin angiotensin blockers and cardiac protection: from basics to clinical trials, Am. J. Hypertens., 35, 4, pp. 293-302, (2022); Li Y., Et al., Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in han Chinese hypertensive patients, Clin. Exp. Hypertens., 33, 3, pp. 141-146, (2011); Li Y.-F., Et al., Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis, PLoS One, 7, 6, (2012); Li D., Et al., Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China, BMC Genomic Data, 22, 1, (2021); Lin P., Et al., The effect of angiotensin-converting enzyme gene polymorphisms on the clinical efficacy of perindopril prescribed for acute myocardial infarction in Chinese han patients, Genet. Test. Mol. Biomarkers, 23, 5, pp. 316-324, (2019); Liu Y., Et al., Association of AGTR1 A1166C and CYP2C9∗3 gene polymorphisms with the antihypertensive effect of valsartan, Int. J. Hypertens., pp. 1-7, (2022); Luizon M.R., Pereira D.A., Sandrim V.C., Pharmacogenomics of hypertension and preeclampsia: focus on gene–gene interactions, Front. Pharmacol., 9, (2018); Luizon M.R., Pereira D.A., Tanus-Santos J.E., Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions, Pharmacogenomics, 19, 18, pp. 1423-1435, (2018); Luo J.-Q., Wang L.-Y., Et al., Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment, Pharmacogenomics, 15, 2, pp. 201-208, (2014); Luo J.-Q., He F.-Z., Et al., Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension, Pharmacogenetics Genom., 24, 6, pp. 306-313, (2014); Mas S., Et al., Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough, Pharmacogenetics Genom., 21, 9, pp. 531-538, (2011); Masilela C., Adeniyi O.V., Benjeddou M., Single nucleotide polymorphisms in amlodipine-associated genes and their correlation with blood pressure control among South African adults with hypertension, Genes, 13, 8, (2022); Metzger I.F., Et al., Effects of endothelial nitric oxide synthase tagSNPs haplotypes on nitrite levels in black subjects, Nitric Oxide, 28, pp. 33-38, (2013); Moholisa R.R., Et al., Association of <scp>B</scp> <sub>2</sub> receptor polymorphisms and <scp>ACE</scp> activity with <scp>ACE</scp> inhibitor–induced angioedema in black and mixed‐race South Africans, J. Clin. Hypertens., 15, 6, pp. 413-419, (2013); Montezano A.C., Et al., Angiotensin II and vascular injury, Curr. Hypertens. Rep., 16, 6, (2014); Mosley J.D., Et al., A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough, Pharmacogenomics J., 16, 3, pp. 231-237, (2016); Mu G., Et al., Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis, Pharmacogenomics, 20, 3, pp. 189-212, (2019); Mukae S., Et al., Bradykinin B 2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor–related cough, Hypertension, 36, 1, pp. 127-131, (2000); Mulerova T., Et al., Genetic forms and pathophysiology of essential arterial hypertension in minor indigenous peoples of Russia, BMC Cardiovasc. Disord., 20, 1, (2020); Muller P., Et al., ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload, Cardiovasc. Res., 83, 1, pp. 106-114, (2009); Oemrawsingh R.M., Et al., Individualized angiotensin‐converting enzyme (ACE)‐Inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: the PERindopril GENEtic (PERGENE) risk model, J. Am. Heart Assoc., 5, 3, (2016); Oliveira-Paula G.H., Et al., Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril, Eur. J. Clin. Pharmacol., 71, 8, pp. 949-957, (2015); Oliveira-Paula G.H., Et al., Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension, Nitric Oxide, 55-56, pp. 62-69, (2016); Oliveira-Paula G.H., Et al., Gene–gene interactions among PRKCA, NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril, Basic Clin. Pharmacol. Toxicol., 120, 3, pp. 284-291, (2017); Padmanabhan S., Joe B., Towards precision medicine for hypertension: a review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans, Physiol. Rev., 97, 4, pp. 1469-1528, (2017); Penno G., Et al., Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM, Diabetes, 47, 9, pp. 1507-1511, (1998); Picard N., Et al., Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs, Ther. Drug Monit., 38, 2, pp. S57-S69, (2016); Potaczek D.P., Et al., The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease, Thrombosis and haemostasis, 94, 1, pp. 224-225, (2005); Rahman F., Muthaiah N., Kumaramanickavel G., Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension, Indian J. Pharmacol., 53, 4, (2021); Rimpela J.M., Et al., Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses, Pharmacogenomics, 18, 5, pp. 445-458, (2017); Rosenman M.B., Et al., Lessons learned when introducing pharmacogenomic panel testing into clinical practice, Value Health, 20, 1, pp. 54-59, (2017); Rossios C., Et al., ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: results from the LACE trial, PLoS One, 18, 10, (2023); Roth G.A., Et al., Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study, J. Am. Coll. Cardiol., 76, 25, pp. 2982-3021, (2020); Sadee W., Et al., Missing heritability of common diseases and treatments outside the protein-coding exome, Hum. Genet., 133, 10, pp. 1199-1215, (2014); Sasaki M., Et al., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies, J. Hypertens., 14, 12, pp. 1403-1408, (1996); Schelleman H., Et al., Interaction between polymorphisms in the renin–angiotensin–system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke, Pharmacogenomics J., 8, 6, pp. 400-407, (2008); Schmieder R., Mechanisms for the clinical benefits of angiotensin II receptor blockers, Am. J. Hypertens., 18, 5, pp. 720-730, (2005); Schneider T.M., Et al., Multi-institutional implementation of clinical decision support for APOL1, NAT2, and YEATS4 genotyping in antihypertensive management, J. Personalized Med., 11, 6, (2021); Sharma B., Jaiswal V., Khan M.A., In silico approach for exploring the role of AT1R polymorphism on its function, structure and drug interactions, Curr. Comput. Aided Drug Des., 17, 7, pp. 927-935, (2021); Shin H.-B., Et al., ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan, Arch Pharm. Res. (Seoul), 43, 11, pp. 1187-1196, (2020); Silva P.S., Et al., eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril, Eur. J. Clin. Pharmacol., 69, 2, pp. 167-177, (2013); Su X., Et al., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, 6, pp. 725-732, (2007); Sychev I.V., Et al., Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension, Int. J. Risk Saf. Med., 35, 1, pp. 37-47, (2024); Te Riet L., Et al., Hypertension, Circ. Res., 116, 6, pp. 960-975, (2015); Thomas C.D., Johnson J.A., Pharmacogenetic factors affecting β-blocker metabolism and response, Expet Opin. Drug Metabol. Toxicol., 16, 10, pp. 953-964, (2020); Trevelyan J., Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function, Heart, 91, 8, pp. 1053-1057, (2005); Turner S.T., Et al., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, 6, pp. 1204-1211, (2012); Urhan Kucuk M., Et al., Role of ACE I/D gene polymorphisms on the effect of ramipril in inflammatory response and myocardial injury in patients undergoing coronary artery bypass grafts, Eur. J. Clin. Pharmacol., 70, 12, pp. 1443-1451, (2014); Van Driest S.L., Et al., Variants in ADRB1 and CYP2C9: association with response to atenolol and losartan in marfan syndrome, J. Pediatr., 222, pp. 213-220, (2020); Wang X., Et al., CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors, Pharmacogenomics J., 16, 3, pp. 220-230, (2016); Whirl-Carrillo M., Et al., Pharmacogenomics knowledge for personalized medicine, Clin. Pharmacol. Therapeut., 92, 4, pp. 414-417, (2012); Whirl-Carrillo M., Et al., An evidence‐based framework for evaluating pharmacogenomics knowledge for personalized medicine, Clin. Pharmacol. Therapeut., 110, 3, pp. 563-572, (2021); 9 Steps to Improve Data Quality in Healthcare in 2023, (2023); Williams B., Et al., 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur. Heart J., 39, 33, pp. 3021-3104, (2018); Woo S.W., Et al., Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans, J. Clin. Pharm. Therapeut., 34, 5, pp. 561-567, (2009); Wu L., Et al., Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury, Circulation, 104, 22, pp. 2716-2721, (2001); Wu Z., Et al., Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis, Br. J. Cancer, 128, 2, pp. 168-176, (2023); Yang H., Et al., Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor, Peptides, 32, 10, pp. 2108-2115, (2011); YU H., Et al., Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors, Clin. Pharmacol. Therapeut., 79, 6, pp. 581-589, (2006); Zanger U.M., Pharmacogenetics – challenges and opportunities ahead, Front. Pharmacol., (2010); Zee R., Et al., A prospective evaluation of the angiotensin‐converting enzyme D/I polymorphism and left ventricular remodeling in the “Healing and Early Afterload Reducing Therapy” Study, Clin. Genet., 61, 1, pp. 21-25, (2002); Zhang Y., Et al., E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients, Chin. Med. J., 122, 20, pp. 2461-2465, (2009); Zhou J., Et al., Polytropic influence of TRIB3 rs2295490 genetic polymorphism on response to antihypertensive agents in patients with essential hypertension, Front. Pharmacol., 10, (2019); Zhou B., Et al., Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, Lancet, 398, 10304, pp. 957-980, (2021)","G.N. da Silva; Clinical Analysis Department, Pharmacy School, UFOP, Ouro Preto, Morro do Cruzeiro, 35400-000, Brazil; email: nicioli@ufop.edu.br","","Elsevier B.V.","","","","","","00142999","","EJPHA","39154825","English","Eur. J. Pharmacol.","Article","Final","","Scopus","2-s2.0-85201257440"
"Butler D.; Mozsary C.; Meydan C.; Foox J.; Rosiene J.; Shaiber A.; Danko D.; Afshinnekoo E.; MacKay M.; Sedlazeck F.J.; Ivanov N.A.; Sierra M.; Pohle D.; Zietz M.; Gisladottir U.; Ramlall V.; Sholle E.T.; Schenck E.J.; Westover C.D.; Hassan C.; Ryon K.; Young B.; Bhattacharya C.; Ng D.L.; Granados A.C.; Santos Y.A.; Servellita V.; Federman S.; Ruggiero P.; Fungtammasan A.; Chin C.-S.; Pearson N.M.; Langhorst B.W.; Tanner N.A.; Kim Y.; Reeves J.W.; Hether T.D.; Warren S.E.; Bailey M.; Gawrys J.; Meleshko D.; Xu D.; Couto-Rodriguez M.; Nagy-Szakal D.; Barrows J.; Wells H.; O’Hara N.B.; Rosenfeld J.A.; Chen Y.; Steel P.A.D.; Shemesh A.J.; Xiang J.; Thierry-Mieg J.; Thierry-Mieg D.; Iftner A.; Bezdan D.; Sanchez E.; Campion T.R., Jr.; Sipley J.; Cong L.; Craney A.; Velu P.; Melnick A.M.; Shapira S.; Hajirasouliha I.; Borczuk A.; Iftner T.; Salvatore M.; Loda M.; Westblade L.F.; Cushing M.; Wu S.; Levy S.; Chiu C.; Schwartz R.E.; Tatonetti N.; Rennert H.; Imielinski M.; Mason C.E.","Butler, Daniel (57217094034); Mozsary, Christopher (57220604383); Meydan, Cem (25723491400); Foox, Jonathan (56690620400); Rosiene, Joel (57225149623); Shaiber, Alon (57192180957); Danko, David (56845411400); Afshinnekoo, Ebrahim (56747949200); MacKay, Matthew (57196437322); Sedlazeck, Fritz J. (55246029800); Ivanov, Nikolay A. (57222372267); Sierra, Maria (57216321432); Pohle, Diana (56627143100); Zietz, Michael (57201525789); Gisladottir, Undina (57203091321); Ramlall, Vijendra (57203660479); Sholle, Evan T. (57202978780); Schenck, Edward J. (56989074500); Westover, Craig D. (57219809794); Hassan, Ciaran (57195473100); Ryon, Krista (57208803204); Young, Benjamin (57217094616); Bhattacharya, Chandrima (57217092130); Ng, Dianna L. (56446316000); Granados, Andrea C. (57216490483); Santos, Yale A. (57219092206); Servellita, Venice (57216484905); Federman, Scot (8581246100); Ruggiero, Phyllis (57221247232); Fungtammasan, Arkarachai (55241800200); Chin, Chen-Shan (7202170798); Pearson, Nathaniel M. (7004954554); Langhorst, Bradley W. (36851146500); Tanner, Nathan A. (18438673300); Kim, Youngmi (57222371214); Reeves, Jason W. (57216649798); Hether, Tyler D. (57222504101); Warren, Sarah E. (35727418100); Bailey, Michael (57650180700); Gawrys, Justyna (57222370120); Meleshko, Dmitry (57194195798); Xu, Dong (57202035681); Couto-Rodriguez, Mara (56147234400); Nagy-Szakal, Dorottya (35368772300); Barrows, Joseph (57222371612); Wells, Heather (56448302500); O’Hara, Niamh B. (57031682900); Rosenfeld, Jeffrey A. (7202782843); Chen, Ying (55721234600); Steel, Peter A. D. (57189349595); Shemesh, Amos J. (57217420464); Xiang, Jenny (14619939100); Thierry-Mieg, Jean (6603657235); Thierry-Mieg, Danielle (6603117044); Iftner, Angelika (7801321237); Bezdan, Daniela (15845248400); Sanchez, Elizabeth (57210421986); Campion, Thomas R. (8432457900); Sipley, John (57208966012); Cong, Lin (57221251548); Craney, Arryn (16300695400); Velu, Priya (57202013468); Melnick, Ari M. (7004323589); Shapira, Sagi (7005671127); Hajirasouliha, Iman (58948369000); Borczuk, Alain (35464946100); Iftner, Thomas (57191196700); Salvatore, Mirella (56523440600); Loda, Massimo (23080476100); Westblade, Lars F. (6506389941); Cushing, Melissa (16303136400); Wu, Shixiu (15046133500); Levy, Shawn (57207787926); Chiu, Charles (57216111033); Schwartz, Robert E. (57203555733); Tatonetti, Nicholas (35604787200); Rennert, Hanna (57205845902); Imielinski, Marcin (8382413000); Mason, Christopher E. (7202125538)","57217094034; 57220604383; 25723491400; 56690620400; 57225149623; 57192180957; 56845411400; 56747949200; 57196437322; 55246029800; 57222372267; 57216321432; 56627143100; 57201525789; 57203091321; 57203660479; 57202978780; 56989074500; 57219809794; 57195473100; 57208803204; 57217094616; 57217092130; 56446316000; 57216490483; 57219092206; 57216484905; 8581246100; 57221247232; 55241800200; 7202170798; 7004954554; 36851146500; 18438673300; 57222371214; 57216649798; 57222504101; 35727418100; 57650180700; 57222370120; 57194195798; 57202035681; 56147234400; 35368772300; 57222371612; 56448302500; 57031682900; 7202782843; 55721234600; 57189349595; 57217420464; 14619939100; 6603657235; 6603117044; 7801321237; 15845248400; 57210421986; 8432457900; 57208966012; 57221251548; 16300695400; 57202013468; 7004323589; 7005671127; 58948369000; 35464946100; 57191196700; 56523440600; 23080476100; 6506389941; 16303136400; 15046133500; 57207787926; 57216111033; 57203555733; 35604787200; 57205845902; 8382413000; 7202125538","Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions","2021","Nature Communications","12","1","1660","","","","89","10.1038/s41467-021-21361-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102515730&doi=10.1038%2fs41467-021-21361-7&partnerID=40&md5=f084a037390d59be461cc6413e2c6881","Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States; WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, United States; New York Genome Center, New York, NY, United States; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Englander Institute for Precision Medicine and the Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, United States; Clinical & Translational Science Center, Weill Cornell Medicine, New York, NY, United States; Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, Tuebingen, Germany; Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, NY, United States; Department of Cellular, Molecular Physiology & Biophysics, Columbia University, Columbia, NY, United States; Information Technologies & Services Department, Weill Cornell Medicine, New York, NY, United States; Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Department of Laboratory Medicine, University of California, San Francisco, CA, United States; UCSF—Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States; DNAnexus, Inc., Mountain View, CA, United States; Root Deep Insight, Boston, MA, United States; New England Biolabs, Ipswich, MA, United States; NanoString Technologies, Seattle, WA, United States; Tri-Institutional Computational Biology & Medicine Program, Weill Cornell Medicine, New York, NY, United States; Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY, United States; Biotia, Inc., New York, NY, United States; Department of Cell Biology, SUNY Downstate Health Sciences University, New York, NY, United States; Rutgers Cancer Institute of New Jersey, New York, NJ, United States; Department of Pathology, Robert Wood Johnson Medical School, New York, NJ, United States; Department of Emergency Medicine, Weill Cornell Medicine, New York, NY, United States; National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States; Hangzhou Cancer Institute, Hangzhou Cancer Hospital, Hangzhou, China; Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, China; HudsonAlpha Discovery Institute, Huntsville, AL, United States; Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA, United States; The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States","Butler D., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Mozsary C., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Meydan C., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States, WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, United States; Foox J., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States; Rosiene J., New York Genome Center, New York, NY, United States, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Shaiber A., New York Genome Center, New York, NY, United States, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States, Englander Institute for Precision Medicine and the Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States; Danko D., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Afshinnekoo E., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States, WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, United States; MacKay M., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Sedlazeck F.J., Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, United States; Ivanov N.A., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States, Clinical & Translational Science Center, Weill Cornell Medicine, New York, NY, United States; Sierra M., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States; Pohle D., Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, Tuebingen, Germany; Zietz M., Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, NY, United States; Gisladottir U., Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, NY, United States; Ramlall V., Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, NY, United States, Department of Cellular, Molecular Physiology & Biophysics, Columbia University, Columbia, NY, United States; Sholle E.T., Information Technologies & Services Department, Weill Cornell Medicine, New York, NY, United States; Schenck E.J., Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Westover C.D., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Hassan C., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Ryon K., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Young B., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Bhattacharya C., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States; Ng D.L., Department of Laboratory Medicine, University of California, San Francisco, CA, United States; Granados A.C., Department of Laboratory Medicine, University of California, San Francisco, CA, United States, UCSF—Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States; Santos Y.A., Department of Laboratory Medicine, University of California, San Francisco, CA, United States, UCSF—Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States; Servellita V., Department of Laboratory Medicine, University of California, San Francisco, CA, United States, UCSF—Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States; Federman S., Department of Laboratory Medicine, University of California, San Francisco, CA, United States, UCSF—Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States; Ruggiero P., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Fungtammasan A., DNAnexus, Inc., Mountain View, CA, United States; Chin C.-S., DNAnexus, Inc., Mountain View, CA, United States; Pearson N.M., Root Deep Insight, Boston, MA, United States; Langhorst B.W., New England Biolabs, Ipswich, MA, United States; Tanner N.A., New England Biolabs, Ipswich, MA, United States; Kim Y., NanoString Technologies, Seattle, WA, United States; Reeves J.W., NanoString Technologies, Seattle, WA, United States; Hether T.D., NanoString Technologies, Seattle, WA, United States; Warren S.E., NanoString Technologies, Seattle, WA, United States; Bailey M., NanoString Technologies, Seattle, WA, United States; Gawrys J., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Meleshko D., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, Tri-Institutional Computational Biology & Medicine Program, Weill Cornell Medicine, New York, NY, United States; Xu D., Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY, United States; Couto-Rodriguez M., Biotia, Inc., New York, NY, United States; Nagy-Szakal D., Biotia, Inc., New York, NY, United States, Department of Cell Biology, SUNY Downstate Health Sciences University, New York, NY, United States; Barrows J., Biotia, Inc., New York, NY, United States; Wells H., Biotia, Inc., New York, NY, United States; O’Hara N.B., Biotia, Inc., New York, NY, United States, Department of Cell Biology, SUNY Downstate Health Sciences University, New York, NY, United States; Rosenfeld J.A., Rutgers Cancer Institute of New Jersey, New York, NJ, United States, Department of Pathology, Robert Wood Johnson Medical School, New York, NJ, United States; Chen Y., Rutgers Cancer Institute of New Jersey, New York, NJ, United States; Steel P.A.D., Department of Emergency Medicine, Weill Cornell Medicine, New York, NY, United States; Shemesh A.J., Department of Emergency Medicine, Weill Cornell Medicine, New York, NY, United States; Xiang J., Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY, United States; Thierry-Mieg J., National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States; Thierry-Mieg D., National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States; Iftner A., Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, Tuebingen, Germany; Bezdan D., Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, Tuebingen, Germany; Sanchez E., Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Campion T.R., Jr., Information Technologies & Services Department, Weill Cornell Medicine, New York, NY, United States, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States; Sipley J., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Cong L., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Craney A., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Velu P., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Melnick A.M., Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Shapira S., Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, NY, United States; Hajirasouliha I., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States, Englander Institute for Precision Medicine and the Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States; Borczuk A., Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Iftner T., Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, Tuebingen, Germany; Salvatore M., Department of Medicine, Weill Cornell Medicine, New York, NY, United States, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States; Loda M., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Westblade L.F., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States, Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Cushing M., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Wu S., Hangzhou Cancer Institute, Hangzhou Cancer Hospital, Hangzhou, China, Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, China; Levy S., HudsonAlpha Discovery Institute, Huntsville, AL, United States; Chiu C., Department of Laboratory Medicine, University of California, San Francisco, CA, United States, UCSF—Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, United States, Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA, United States; Schwartz R.E., Department of Medicine, Weill Cornell Medicine, New York, NY, United States; Tatonetti N., Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, NY, United States; Rennert H., Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Imielinski M., New York Genome Center, New York, NY, United States, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States, Englander Institute for Precision Medicine and the Meyer Cancer Center, Weill Cornell Medicine, New York, NY, United States; Mason C.E., Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States, The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, United States, WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, United States, The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States","In less than nine months, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) killed over a million people, including >25,000 in New York City (NYC) alone. The COVID-19 pandemic caused by SARS-CoV-2 highlights clinical needs to detect infection, track strain evolution, and identify biomarkers of disease course. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs and a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, viral, and microbial profiling. We applied these methods to clinical specimens gathered from 669 patients in New York City during the first two months of the outbreak, yielding a broad molecular portrait of the emerging COVID-19 disease. We find significant enrichment of a NYC-distinctive clade of the virus (20C), as well as host responses in interferon, ACE, hematological, and olfaction pathways. In addition, we use 50,821 patient records to find that renin–angiotensin–aldosterone system inhibitors have a protective effect for severe COVID-19 outcomes, unlike similar drugs. Finally, spatial transcriptomic data from COVID-19 patient autopsy tissues reveal distinct ACE2 expression loci, with macrophage and neutrophil infiltration in the lungs. These findings can inform public health and may help develop and drive SARS-CoV-2 diagnostic, prevention, and treatment strategies. © 2021, The Author(s).","","Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; COVID-19; COVID-19 Nucleic Acid Testing; Drug Interactions; Female; Gene Expression Profiling; Genome, Viral; HLA Antigens; Host Microbial Interactions; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; New York City; Nucleic Acid Amplification Techniques; Pandemics; RNA-Seq; SARS-CoV-2; New York [New York (STT)]; SARS coronavirus; aldosterone antagonist; alpha interferon; angiotensin antagonist; angiotensin converting enzyme 2; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; calcium channel blocking agent; CXCL11 chemokine; dipeptidyl carboxypeptidase inhibitor; gamma interferon inducible protein 10; hect containing e3 ubiquitin protein ligase family member 6; insulin; interferon alpha inducible protein 27; monocyte chemotactic protein 2; nonstructural protein 2; noradrenalin; phenylephrine; renin inhibitor; ribosome RNA; serine proteinase; thiazide diuretic agent; transcriptome; transmembrane proteinase serine 11b; ubiquitin protein ligase E3; unclassified drug; vasopressin; viral protease; virus RNA; angiotensin receptor antagonist; antivirus agent; dipeptidyl carboxypeptidase inhibitor; HLA antigen; biomarker; detection method; drug; gene expression; infectious disease; olfaction; public health; RNA; severe acute respiratory syndrome; viral disease; adult; aged; antihypertensive therapy; Article; autopsy; case control study; cohort analysis; colorimetry; common cold; controlled study; coronavirus disease 2019; deconvolution; diabetes mellitus; disease severity; down regulation; drug exposure; false negative result; female; gene expression; genetic variability; haplogroup; high throughput sequencing; hospital based case control study; housekeeping gene; human; human cell; human tissue; hypertension; insulin treatment; limit of detection; major clinical study; male; medical record review; metatranscriptomics; microbial diversity; nasopharyngeal swab; New York; nonhuman; observational study; oropharyngeal swab; phenotype; reaction time; real time polymerase chain reaction; renin angiotensin aldosterone system; retrospective study; reverse transcription loop mediated isothermal amplification; sensitivity and specificity; single nucleotide polymorphism; transcriptome shotgun sequencing; upregulation; virus detection; virus genome; virus immunity; virus load; classification; drug effect; drug interaction; drug therapy; epidemiology; gene expression profiling; genetics; middle aged; molecular diagnosis; nucleic acid amplification; pandemic; virology","","gamma interferon inducible protein 10, 97741-20-3; insulin, 9004-10-8; noradrenalin, 1407-84-7, 51-41-2; peptide hydrolase, ; phenylephrine, 532-38-7, 59-42-7, 61-76-7; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; vasopressin, 11000-17-2; viral protease, ; Angiotensin Receptor Antagonists, ; Angiotensin-Converting Enzyme Inhibitors, ; Antiviral Agents, ; HLA Antigens, ","AMPure XP beads, Beckman Coulter; BOND RX FFPE, Leica Biosystems; DSP Virus/Pathogen, Qiagen; Direct-zol; LAMP Master Mix; Lightmix MODULAR, TIB Molbiol; NEBNext Ultra II, New England Nuclear; NextSeq 550, Illumina; ProtoScript II First Strand, New England Nuclear; Rotor-Gene Q thermocycler, Qiagen; TapeStation 2200, Agilent; Universal Viral Transport Media, Becton Dickinson, United States; nCounter MAX, NanoString, United States; nCounter PanCancer IO360","Agilent; Beckman Coulter; Becton Dickinson, United States; Illumina; Leica Biosystems; NanoString, United States; New England Nuclear; New England Nuclear; Qiagen; Qiagen; TIB Molbiol","National Institute of Allergy and Infectious Diseases, NIAID, (U19AI144297); National Institute of Allergy and Infectious Diseases, NIAID","","He F., Deng Y., Li W., Coronavirus disease 2019 (COVID-19): what we know?, J. Med. Virol., 92, pp. 719-725, (2020); Fauver J.R., Et al., Coast-to-coast spread of SARS-CoV-2 during the early epidemic in the United States, Cell, 181, pp. 990-996, (2020); Gonzalez-Reiche A., Et al., Introductions and early spread of SARS-CoV-2 in the New York City area, Medaxiv, (2020); Zhao Z., Sokhansanj B.A., Rosen G., Characterizing Geographical and Temporal Dynamics of Novel Coronavirus Sars-Cov-2 Using Informative Subytype Markers, (2020); Lu J., Et al., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China, Cell, 181, pp. 997-1003, (2020); Dong E., Du H., Gardner L., An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis., 20, pp. P533-P534, (2020); Hadfield J., Et al., Nextstrain: real-time tracking of pathogen evolution, Bioinformatics, 34, pp. 4121-4123, (2018); Meyers L., Et al., Enterovirus D68 outbreak detection through a syndromic disease epidemiology network, J. Clin. Virol., 124, Mar, (2020); Li C.K., Xiaoning X., Host immune responses to SARS coronavirus in humans, Mol. Biol. SARS Coronavirus, 22, Jul, pp. 259-278, (2009); Long Q.X., Et al., Antibody responses to SARS-CoV-2 in patients with COVID-19, Nat. Med., 26, pp. 845-848, (2020); Catanzaro M., Et al., Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2, Signal Transduct. Target. Ther., 5, 1, (2020); Lucas C., Et al., Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature, 584, pp. 463-469, (2020); Lansbury L., Lim B., Baskaran V., Lim W.S., Co-infections in people with COVID-19: a systematic review and meta-analysis, J. Infect., 81, Aug, pp. 266-275, (2020); Siu K.L., Et al., Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC, FASEB J, (2019); Koyama T., Platt D., Parida L., Variant analysis of SARS-CoV-2 genomes, Bull. World Health Organ, 98, Jul, pp. 495-504, (2020); Hoffmann M., Et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, pp. 271-280, (2020); Sungnak W., Et al., SARS-CoV-2 enry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat. Med., 26, pp. 681-687, (2020); Oudshoorn D., Et al., HERC6 is the main E3 ligase for global ISG15 conjugation in mouse cells, PLoS ONE, 7, (2012); Blanco-Melo D., Et al., Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell, 181, pp. 1036-1045, (2020); Updegraff B.L., Et al., Transmembrane protease TMPRSS11B promotes lung cancer growth by enhancing lactate export and glycolytic metabolism, Cell Rep, 25, Nov, pp. 2223-2233.e6, (2018); Ajioka R.S., Phillips J.D., Kushner J.P., Biosynthesis of heme in mammals, Biochim Biophys. Acta, 1763, Jul, pp. 723-736, (2006); Agata J., Et al., Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme, Hypertens. Res., 29, pp. 865-874, (2006); Fang L., Karakiulakis G., Roth M., Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet, Respir. Med., 8, (2020); Orenbuch R., Et al., arcasHLA: high-resolution HLA typing from RNAseq, Bioinformatics, 36, pp. 33-40, (2020); MacKay M.J., Et al., The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing, Nat. Biotechnol., 38, pp. 1021-1024, (2020); Monteil V., Et al., Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2, Cell., 181, pp. 905-913, (2020); Ferrario C.M., Et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, pp. 2605-2610, (2005); Zhang P., Et al., Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ. Res., 126, pp. 1671-1681, (2020); Kuznetsova A., Brockhoff P.B., Christensen R.H.B., lmerTest package: tests in linear mixed effects models, J. Stat. Softw., 82, (2017); Liu R., Et al., Positive rate of RT-PCR detection of SARS-COV-2 infection of 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020, Clin. Chim. Acta, 505, pp. 172-175, (2020); Woelfel R., Et al., Virological assessment of hospitalized cases of coronavirus disease 2019, Medrxiv, (2020); Wylie A.L., Et al., Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs, Medrxiv, (2020); McIntyre A.B.R., Et al., Single-molecule sequencing detection of N6- methyladenine in microbial reference materials, Nat. Commun., 10, Feb, (2019); O'Leary N.A., Et al., Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation, Nucleic Acids Res, 44, pp. D733-D745, (2016); Wood D.E., Lu J., Langmead B., Improved metagenomic analysis with Kraken 2, Genome Biol, 20, (2019); Segata N., Et al., BBMap short-read aligner, and other bioinformatics tools, Bioinformatics, (2016); Li H., Seqtk: Toolkit for processing sequences in FASTA/Q formats, (2015); Li H., Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM., (2013); Grubaugh N.D., Et al., An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar, Genome Biol, 20, (2019); Li H., Et al., The sequence Alignment/Map format and SAMtools, Bioinformatics, 25, pp. 2078-2079, (2009); Elbe S., Buckland-Merrett G., Data, disease and diplomacy: GISAID’s innovative contribution to global health, Glob. Chall, 1, pp. 33-46, (2017); Shu Y., McCauley J., GISAID: Global initiative on sharing all influenza data —from vision to reality, Eurosurveillance, 22, (2017); Katoh K., Standley D.M., MAFFT multiple sequence alignment software version 7: improvements in performance and usability, Mol. Biol. Evol., 30, pp. 772-780, (2013); Sagulenko P., Puller V., Neher R.A., TreeTime: Maximum-likelihood phylodynamic analysis, Virus Evol, (2018); Brown N.P., Leroy C., Sander C., MView: A Web compatible database search or multiple alignment viewer, Bioinformatics, 14, pp. 380-381, (1998); Yu L., Et al., Rapid colorimetric detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform: ILACO, Medrxiv, (2020); Wang X., Park J., Susztak K., Zhang N.R., Li M., Bulk tissue cell type deconvolution with multi-subject single-cell expression reference, Nat. Commun., (2019); Lukassen S., Et al., SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells, EMBO J, (2020); Ewels P.A., Et al., Nf-core: Community curated bioinformatics pipelines, Nat. Biotechnol., 38, pp. 276-278, (2020); Johnson W.E., Li C., Rabinovic A., Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics, 8, pp. 118-127, (2007); Naccache S.N., Et al., A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples, Genome Res, 24, pp. 1180-1192, (2014); Pertea M., Et al., StringTie enables improved reconstruction of a transcriptome from RNA-seq reads, Nat. Biotechnol., 33, pp. 290-295, (2015); Robinson M.D., Oshlack A., A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, 11, (2010); Zamani S., Et al., Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients, Gut Pathog, 9, (2017); Andrews S., FastQC: A quality control tool for high throughput sequence data, Babraham Inst, (2010); Ewels P., Magnusson M., Lundin S., Kaller M., MultiQC: summarize analysis results for multiple tools and samples in a single report, Bioinformatics, 32, pp. 3047-3048, (2016); Okonechnikov K., Conesa A., Garcia-Alcalde F., Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data, Bioinformatics, 32, pp. 292-294, (2016); Sayols S., Scherzinger D., Klein H., dupRadar: a bioconductor package for the assessment of PCR artifacts in RNA-Seq data, BMC Bioinform., (2016); Wang L., Wang S., Li W., RSeQC: Quality control of RNA-seq experiments, Bioinformatics, 28, pp. 2184-2185, (2012); Love M.I., Et al., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, (2014); Law C.W., Chen Y., Shi W., Smyth G.K., Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts, Genome Biol., (2014); Leek J.T., Johnson W.E., Parker H.S., Jaffe A.E., Storey J.D., The SVA package for removing batch effects and other unwanted variation in highthroughput experiments, Bioinformatics, (2012); Kuleshov M.V., Et al., Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res, (2016); Liberzon A., Et al., Molecular signatures database (MSigDB) 3.0, Bioinformatics, 27, pp. 1739-1740, (2011); Sergushichev A., An Algorithm for Fast Preranked Gene Set Enrichment Analysis Using Cumulative Statistic Calculation, (2016); Smith C.L., Blake J.A., Kadin J.A., Richardson J.E., Bult C.J., Mouse genome database (MGD)-2018: knowledgebase for the laboratory mouse, Nucleic Acids Res, 46, pp. D836-D842, (2018); Subramanian A., Et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U.S.A., 102, pp. 15545-15550, (2005); Vincent J.L., Et al., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine, Intensive Care Med, 22, pp. 707-710, (1996); Rice T.W., Et al., Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS, Chest, 132, pp. 410-417, (2007); Khanna A., Et al., Angiotensin II for the treatment of vasodilatory shock, N. Engl. J. Med, 377, pp. 419-430, (2017); Le S., Josse J., Husson F., FactoMineR: An R Package for multivariate analysis, J. Stat. Softw., 25, (2008); van der Maaten L.J.P., Accelerating t-SNE using tree-based algorithms, J. Mach. Learn. Res., 15, Oct, pp. 3221-3245, (2014); Zilionis R., Et al., Single-Cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species, Immunity, 50, pp. 1317-1334, (2019); Wingett S.W., Andrews S., FastQ screen: a tool for multi-genome mapping and quality control, F1000Res, 7, (2018); Dobin A., Gingeras T.R., Mapping RNA-seq reads with STAR, Curr. Protoc. Bioinform., 51, pp. 11.14.11-11.14.19, (2015); Liao Y., Smyth G.K., Shi W., featureCounts: an efficient general purpose program for assigning sequence reads to genomic features, Bioinformatics, 30, pp. 923-930, (2014); Kramer A., Green J., Pollard J., Tugendreich S., Causal analysis approaches in Ingenuity Pathway Analysis, Bioinformatics, 30, pp. 523-530, (2014); Pedregosa F., Et al., Scikit-learn: machine learning in Python, J. Mach. Learn. Res., 12, pp. 2825-2830, (2011); Hastie T., Tibshirani R., Wainwright M., Statistical learning with sparsity: The lasso and generalizations. Monographs on statistics and applied probability (CRC Press, Taylor & Francis Group, (2015); Robin X., Et al., pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinform, 12, (2011); Amanat F., Et al., A serological assay to detect SARS-CoV-2 seroconversion in humans, Medrxiv, (2020); Chen X., Et al., Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications, Bioinformatics, 32, 15 April, pp. 1220-1222, (2016); Chiang C., Et al., SpeedSeq: ultra-fast personal genome analysis and interpretation, Nat. Methods, 12, pp. 966-968, (2015); Danko D., Et al., Global Genetic Cartography of Urban Metagenomes and Antimicrobrial Resistance, (2019); Deng X., Et al., Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance, Nat. Microbiol., 5, Mar, pp. 443-454, (2020); Farek J., Et al., xAtlas: scalable small variant calling across heterogeneous nextgeneration sequencing experiments, bioRxiv, (2018); Jeffares D.C., Et al., Transient structural variations have strong effects on quantitative traits and reproductive isolation in fission yeast, Nat. Commun., 8, Jan, (2017); Jenkins C., Orsburn B., In Silico Approach to Accelerate the Development of Mass Spectrometry-Based Proteomics Methods for Detection of Viral Proteins: Application to COVID-19., (2020); Konrad R., Et al., Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020, Eurosurveillance, 25, (2020); Kim D., Et al., The Architecture of Sars-Cov-2 Transcriptome, (2020); Langmead B., Salzberg S., Fast Gapped-Read Alignment with Bowtie 2, Nat. Methods, 9, pp. 357-359, (2012); Lauer S.A., Et al., The incubation period of coronavirus disease 2019 (COVID- 19) from publicly reported confirmed cases: estimation and application, Ann. Intern. Med., 172, pp. 577-582, (2020); Layer R.M., Chiang C., Quinlan A.R., Hall I.M., LUMPY: a probabilistic framework for structural variant discovery, Genome Biol, 15, (2014); Lee J.S., Et al., Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19, Sci. Immunol., 5, (2020); Li R., Et al., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2), Science, 368, pp. 489-493, (2020); Narayanan K., Ramirez S.I., Lokugamage K.G., Makino S., Coronavirus nonstructural protein 1: Common and distinct functions in the regulation of host and viral gene expression, Virus Res, 202, Apr, pp. 89-100, (2015); Patel A.B., Verma A., COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence?, JAMA, 323, pp. 1769-1770, (2020); Quilty B., Clifford S., Flasche S., Eggo R.M., Effectiveness of Airport Screening at Detecting Travellers Infected with 2019-Ncov, (2020); Rausch T., Et al., DELLY: structural variant discovery by integrated paired-end and split-read analysis, Bioinformatics, 28, 15 September, pp. i333-i339, (2012); Robinson J.T., Et al., Integrative genomics viewer, Nat. Biotechnol., 29, pp. 24-26, (2011); Robinson M.D., McCarthy D.J., Smyth G., K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics, 26, pp. 139-140, (2010); Rodriguez-Santana J., Burchard E.G., Seibold M.A., Type 2 and Interferon Inflammation Strongly Regulate Sars-Cov-2 Related Gene Expression in the Airway Epithelium., (2020); Santarpia J.L., Et al., (2020); Sajuthi S.P., Et al., Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium, Nat Commun, 11, (2020); Taiaroa G., Et al., Direct RNA sequencing and early evolution 2 of SARS-CoV- 2, Biorxiv, (2020); Tang X., Et al., On the origin and continuing evolution of SARS-CoV-2, Natl Sci. Rev., 7, pp. 1012-1023, (2020); Chen Y., Lanjuan L., SARS-CoV-2: virus dynamics and host response, Lancet Infect. Dis., 20, 5, pp. 515-516, (2020)","C.E. Mason; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, United States; email: chm2042@med.cornell.edu; M. Imielinski; New York Genome Center, New York, United States; email: mai9037@med.cornell.edu; H. Rennert; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States; email: har2006@med.cornell.edu; N. Tatonetti; Department of Biomedical Informatics, Department of Systems Biology, Department of Medicine, Institute for Genomic Medicine, Columbia University, Columbia, United States; email: npt2105@cumc.columbia.edu; R.E. Schwartz; Department of Medicine, Weill Cornell Medicine, New York, United States; email: res2025@med.cornell.edu","","Nature Research","","","","","","20411723","","","33712587","English","Nat. Commun.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85102515730"
"Singh S.; Wang Z.; Shahin M.H.; Langaee T.Y.; Gong Y.; Turner S.T.; Chapman A.B.; Gums J.G.; McDonough C.W.; Bailey K.R.; Beitelshees A.L.; Cooper-DeHoff R.M.; Scherer S.; Boerwinkle E.; Johnson J.A.","Singh, Sonal (57201182650); Wang, Zhiying (37012275300); Shahin, Mohamed H. (39162024400); Langaee, Taimour Y. (6506611928); Gong, Yan (8560522600); Turner, Stephen T. (7402275413); Chapman, Arlene B. (57194303466); Gums, John G. (7004125953); McDonough, Caitrin W. (16176122100); Bailey, Kent R. (7202891244); Beitelshees, Amber L. (6508117914); Cooper-DeHoff, Rhonda M. (35078393500); Scherer, Steve (56324405900); Boerwinkle, Eric (7102087489); Johnson, Julie A. (55439192600)","57201182650; 37012275300; 39162024400; 6506611928; 8560522600; 7402275413; 57194303466; 7004125953; 16176122100; 7202891244; 6508117914; 35078393500; 56324405900; 7102087489; 55439192600","Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide","2018","Pharmacogenetics and Genomics","28","11","","251","255","4","6","10.1097/FPC.0000000000000353","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055080476&doi=10.1097%2fFPC.0000000000000353&partnerID=40&md5=dcec4c52484ef73bdd006e4016549898","Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; Department of Medicine, Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States; Department of Human Genetics, Institute of Molecular Medicine, University of Texas Health Science Center, United States; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, United States; Department of Health Sciences Research, Division of Biostatistics, United States; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; College of Medicine, University of Maryland, Baltimore, MD, United States; Division of Nephrology, University of Chicago, Chicago, IL, United States","Singh S., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; Wang Z., Department of Human Genetics, Institute of Molecular Medicine, University of Texas Health Science Center, United States; Shahin M.H., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; Langaee T.Y., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; Gong Y., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; Turner S.T., Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; Chapman A.B., Division of Nephrology, University of Chicago, Chicago, IL, United States; Gums J.G., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; McDonough C.W., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States; Bailey K.R., Department of Health Sciences Research, Division of Biostatistics, United States; Beitelshees A.L., College of Medicine, University of Maryland, Baltimore, MD, United States; Cooper-DeHoff R.M., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States, Department of Medicine, Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States; Scherer S., Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, United States; Boerwinkle E., Department of Human Genetics, Institute of Molecular Medicine, University of Texas Health Science Center, United States; Johnson J.A., Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, FL, United States, Department of Medicine, Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States","Chromosome 12q15 was identified in Genetic Epidemiology of Response Assessment (GERA) and replicated in Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) for its association with blood pressure (BP) response to hydrochlorothiazide (HCTZ). However, the functional variant is unknown and we aimed to identify the likely functional variants through targeted sequencing. The chromosome 12q15 region was sequenced in 397 best and worst responders to HCTZ in PEAR (N=199) and GERA (N=198) hypertensive study participants. Logistic regression was used for the association analysis adjusting for age, sex, race, and principal components 1 and 2. For validation, the significant single nucleotide polymorphism was tested for association with the change in systolic (ΔSBP) and diastolic BP (ΔDBP) post-treatment in the entire PEAR (N=370) and GERA (N=570) cohorts. A novel missense polymorphism (GA, Pro383Leu) in BEST3, rs61747221, was significantly associated with better HCTZ response (P=0.0021, odds ratio=2.05). It was validated in the entire cohort of PEAR (ΔSBP: P=0.021, β=-1.60, ΔDBP: P=0.023, β=-1.08) and GERA (ΔSBP: P=0.028, β=-1.95, ΔDBP: P=0.032, β=-1.28). BEST3 encodes the calcium sensitive chloride channel in the vascular smooth muscle implicated in the regulation of BP, especially in response to vasoconstrictors like angiotensin II. These results suggest that BEST3 is involved in the chronic BP lowering mechanism of thiazides and highlight its importance as a genetic predictor of the BP response to thiazide diuretics. © 2018 Wolters Kluwer Health, Inc. All rights reserved.","BEST3; bestrophin-3; diuretics; genomics; high blood pressure; hydrochlorothiazide; hypertension; pharmacogenomics; targeted sequencing","Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Bestrophins; Blood Pressure; Female; Genetic Association Studies; Humans; Hypertension; Male; Middle Aged; Muscle Proteins; Polymorphism, Single Nucleotide; Sodium Chloride Symporter Inhibitors; bestrophin; bestrophin 3; hydrochlorothiazide; unclassified drug; angiotensin II; antihypertensive agent; atenolol; BEST3 protein, human; bestrophin; muscle protein; thiazide diuretic agent; Article; blood pressure regulation; chromosome 12q; chromosome 12q15; clinical trial (topic); controlled study; diastolic blood pressure; drug response; gene frequency; gene function; gene linkage disequilibrium; gene sequence; genetic association; haplotype; homozygote; human; major clinical study; pharmacogenomics; priority journal; single nucleotide polymorphism; systolic blood pressure; treatment response; adult; blood pressure; drug effect; female; genetic association study; genetics; hypertension; male; middle aged; pathology; single nucleotide polymorphism","","hydrochlorothiazide, 58-93-5; angiotensin II, 11128-99-7, 68521-88-0; atenolol, 29122-68-7, 93379-54-5; Angiotensin II, ; Antihypertensive Agents, ; Atenolol, ; BEST3 protein, human, ; Bestrophins, ; Muscle Proteins, ; Sodium Chloride Symporter Inhibitors, ","","","National Institute of General Medical Sciences, NIGMS, (U01GM074492); National Institute of General Medical Sciences, NIGMS","","Butler M.G., Genetics of hypertension. Current status, J Med Liban, 58, pp. 175-178, (2010); Cooper-DeHoff R.M., Johnson J.A., Hypertension pharmacogenomics: In search of personalized treatment approaches, Nat Rev Nephrol, 12, pp. 110-122, (2016); Turner S.T., Bailey K.R., Fridley B.L., Chapman A.B., Schwartz G.L., Chai H.S., Et al., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension, 52, pp. 359-365, (2008); Duarte J.D., Turner S.T., Tran B., Chapman A.B., Bailey K.R., Gong Y., Et al., Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression, Pharmacogenomics J, 13, pp. 257-263, (2013); Johnson J.A., Boerwinkle E., Zineh I., Chapman A.B., Bailey K., Cooper-DeHoff R.M., Et al., Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, Am Heart J, 157, pp. 442-449, (2009); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int, 61, pp. 1047-1055, (2002); Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Et al., PLINK: A tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, pp. 559-575, (2007); Chang C.C., Chow C.C., Tellier L.C., Vattikuti S., Purcell S.M., Lee J.J., Secondgeneration PLINK: Rising to the challenge of larger and richer datasets, Gigascience, 4, (2015); Huang F., Wong X., Jan L.Y., International Union of Basic and Clinical Pharmacology LXXXV: Calcium-activated chloride channels, Pharmacol Rev, 64, pp. 1-15, (2012); Tsunenari T., Sun H., Williams J., Cahill H., Smallwood P., Yau K.W., Nathans J., Structure-function analysis of the bestrophin family of anion channels, J Biol Chem, 278, pp. 41114-41125, (2003); O'Driscoll K.E., Hatton W.J., Burkin H.R., Leblanc N., Britton F.C., Expression, localization, and functional properties of Bestrophin 3 channel isolated from mouse heart, Am J Physiol Cell Physiol, 295, pp. C1610-C1624, (2008); Matchkov V.V., Larsen P., Bouzinova E.V., Rojek A., Boedtkjer D.M., Golubinskaya V., Et al., Bestrophin-3 (vitelliform macular dystrophy 2-like 3 protein) is essential for the cGMP-dependent calcium-activated chloride conductance in vascular smooth muscle cells, Circ Res, 103, pp. 864-872, (2008); Song W., Yang Z., He B., Bestrophin 3 ameliorates TNFalpha-induced inflammation by inhibiting NF-kappaB activation in endothelial cells, PLoS One, 9, (2014); Golubinskaya V., Elvin J., Ebefors K., Gustafsson H., Mallard C., Nystrom J., Nilsson H., Bestrophin-3 is differently expressed in normal and injured mouse glomerular podocytes, Acta Physiol (Oxf), 214, pp. 481-496, (2015); Dam V.S., Boedtkjer D.M., Nyvad J., Aalkjaer C., Matchkov V., TMEM16A knockdown abrogates two different Ca(2 +)-activated Cl () currents and contractility of smooth muscle in rat mesenteric small arteries. Pflugers Arch, 466, pp. 1391-1409, (2014); Broegger T., Jacobsen J.C., Secher Dam V., Boedtkjer D.M., Kold-Petersen H., Pedersen F.S., Et al., Bestrophin is important for the rhythmic but not the tonic contraction in rat mesenteric small arteries, Cardiovasc Res, 91, pp. 685-693, (2011); Davis A.J., Shi J., Pritchard H.A., Chadha P.S., Leblanc N., Vasilikostas G., Et al., Potent vasorelaxant activity of the TMEM16A inhibitor T16A(inh)-A01, Br J Pharmacol, 168, pp. 773-784, (2013); Bulley S., Neeb Z.P., Burris S.K., Bannister J.P., Thomas-Gatewood C.M., Jangsangthong W., Jaggar J.H., TMEM16A/ANO1 channels contribute to the myogenic response in cerebral arteries, Circ Res, 111, pp. 1027-1036, (2012); Archer S.L., Huang J.M., Hampl V., Nelson D.P., Shultz P.J., Weir E.K., Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase, Proc Natl Acad Sci USA, 91, pp. 7583-7587, (1994); Fukao M., Mason H.S., Britton F.C., Kenyon J.L., Horowitz B., Keef K.D., Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072, J Biol Chem, 274, pp. 10927-10935, (1999); Duarte J.D., Cooper-DeHoff R.M., Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics, Expert Rev Cardiovasc Ther, 8, pp. 793-802, (2010); The Genotype-Tissue Expression (GTEx) project, Nat Genet, 45, pp. 580-585, (2013); Loke S.-Y., Pt-H W., Ong W.-Y., Global gene expression changes in the prefrontal cortex of rabbits with hypercholesterolemia and/or hypertension, Neurochem Int, 102, pp. 33-56, (2017); Newman J.H., Holt T.N., Hedges L.K., Womack B., Memon S.S., Willers E.D., Et al., High-altitude pulmonary hypertension in cattle (brisket disease): Candidate genes and gene expression profiling of peripheral blood mononuclear cells, Pulm Circ, 1, pp. 462-469, (2011); Hiltunen T.P., Donner K.M., Sarin A.P., Saarela J., Ripatti S., Chapman A.B., Et al., Pharmacogenomics of hypertension: A genome?wide, placebo?controlled cross?over study, using four classes of antihypertensive drugs, J Am Heart Assoc, 4, (2015); Salvi E., Wang Z., Rizzi F., Gong Y., McDonough C.W., Padmanabhan S., Et al., Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide, Hypertension, 69, pp. 51-59, (2017); Turner S.T., Boerwinkle E., O'Connell J.R., Bailey K.R., Gong Y., Chapman A.B., Et al., Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide, Hypertension, 62, pp. 391-397, (2013)","J.A. Johnson; Departments of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Division of Cardiovascular Medicine, University of Florida, Gainesville, 32610-0486, United States; email: johnson@cop.ufl.edu","","Lippincott Williams and Wilkins","","","","","","17446872","","","30289819","English","Pharmacogenet. Genomics","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85055080476"
"Hayman S.R.; Leung N.; Grande J.P.; Garovic V.D.","Hayman, Suzanne R. (35394154300); Leung, Nelson (7006841128); Grande, Joseph P. (7004996226); Garovic, Vesna D. (6603419874)","35394154300; 7006841128; 7004996226; 6603419874","Vegf inhibition, hypertension, and renal toxicity","2012","Current Oncology Reports","14","4","","285","294","9","184","10.1007/s11912-012-0242-z","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865658329&doi=10.1007%2fs11912-012-0242-z&partnerID=40&md5=af229c5290ef112a7e071adf9616f3df","Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States","Hayman S.R., Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Leung N., Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States, Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Grande J.P., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Garovic V.D., Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States","The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target vascular endothelial growth factor (VEGF) and/or its receptors, and include bevacizumab, a humanized monoclonal antibody against VEGF, as well as tyrosine kinase inhibitors that target several receptor tyrosine kinases (RTK), including VEGF receptors. These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure. Knowledge of these common side effects and their underlying mechanisms may allow for more accurate and prompt diagnoses, timely clinical interventions, and the development of rational and standard treatments. These measures may minimize patient morbidity and mortality, not only by the treatment of side effects, but also by minimizing the disruption of treatment of the underlying malignancy, as well as improving patient quality of life. © Springer Science+Business Media, LLC 2012.","Bevacizumab; Hypertension; Podocyturia; Proteinuria; Renal toxicity; Thrombotic microangiopathy; Tyrosine kinase inhibitors; Vascular endothelial growth factor","Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Hypertension; Protein Kinase Inhibitors; Proteinuria; Renal Insufficiency; Vascular Endothelial Growth Factor A; alpha adrenergic receptor blocking agent; amlodipine; angiogenesis inhibitor; angiotensin receptor antagonist; axitinib; beta adrenergic receptor blocking agent; bevacizumab; bisphosphonic acid derivative; capecitabine; cediranib; dipeptidyl carboxypeptidase inhibitor; diuretic agent; felodipine; nebivolol; nephrin; nifedipine; nitric oxide; pamidronic acid; pazopanib; sorafenib; sunitinib; vasculotropin; vasculotropin inhibitor; vasculotropin receptor 1; vasculotropin receptor 2; vasculotropin receptor 3; adverse outcome; antiangiogenic therapy; article; blood pressure measurement; breast cancer; cancer combination chemotherapy; cardiovascular risk; chronic lymphatic leukemia; colorectal carcinoma; congestive heart failure; cryoglobulinemia; dose response; down regulation; drug dose comparison; drug dose escalation; drug efficacy; drug treatment failure; gastrointestinal stromal tumor; glomerulonephritis; glomerulosclerosis; glomerulus epithelium; glomerulus filtration; hemolytic anemia; human; hypertension; inhibition kinetics; interstitial nephritis; kidney carcinoma; kidney injury; kidney metastasis; leukoencephalopathy; low drug dose; lung non small cell cancer; microangiopathy; microvasculature; molecular model; nephrotoxicity; outcome assessment; overall survival; pharmacological blocking; progression free survival; protein expression; protein function; protein protein interaction; proteinuria; quality of life; reticuloendotheliosis; retina macula degeneration; risk assessment; single nucleotide polymorphism; soft tissue sarcoma; thrombocytopenia; thrombotic thrombocytopenic purpura; upregulation","","amlodipine, 103129-82-4, 736178-83-9, 88150-42-9; axitinib, 319460-85-0; bevacizumab, 216974-75-3; capecitabine, 154361-50-9; cediranib, 288383-20-0, 857036-77-2; felodipine, 72509-76-3; nebivolol, 118457-15-1, 118457-16-2, 99200-09-6; nephrin, 255039-20-4; nifedipine, 21829-25-4; nitric oxide, 10102-43-9; pamidronic acid, 40391-99-9, 57248-88-1; pazopanib, 444731-52-6, 635702-64-6; sorafenib, 284461-73-0; sunitinib, 341031-54-7, 557795-19-4; vasculotropin, 127464-60-2; Angiogenesis Inhibitors, ; Antineoplastic Agents, ; Protein Kinase Inhibitors, ; Vascular Endothelial Growth Factor A, ","bay 43 9006","","National Institute of Child Health and Human Development, NICHD, (K08HD051714)","","Folkman J., Tumor angiogenesis: Therapeutic implications, N Engl J Med, 285, pp. 1182-1186, (1971); Eremina V., Quaggin S.E., Biology of anti-angiogenic therapy-induced thrombotic microangiopathy, Semin Nephrol, 30, pp. 582-590, (2010); Eskens F.A.L.M., Verweij J., The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review, European Journal of Cancer, 42, 18, pp. 3127-3139, (2006); Ferrara N., Gerber H.-P., LeCouter J., The biology of VEGF and its receptors, Nature Medicine, 9, 6, pp. 669-676, (2003); Kappers M.H., Van Esch J.H., Sleijfer S., Danser A.H., Van Den Meiracker A.H., Cardiovascular and renal toxicity during angiogenesis inhibition: Clinical and mechanistic aspects, J Hypertens., 27, pp. 2297-2309, (2009); Ebos J.M.L., Bocci G., Man S., Thorpe P.E., Hicklin D.J., Zhou D., Jia X., Kerbel R.S., A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma, Molecular Cancer Research, 2, 6, pp. 315-326, (2004); Kitamoto Y., Tokunaga H., Miyamoto K., Tomita K., VEGF is an essential molecule for glomerular structuring, Nephrol Dial Transplant., 17, SUPPL. 9, pp. 25-27, (2002); Zhu X., Wu S., Dahut W.L., Parikh C.R., Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis, American Journal of Kidney Diseases, 49, 2, pp. 186-193, (2007); Sane D.C., Anton L., Brosnihan K.B., Angiogenic growth factors and hypertension, Angiogenesis., 7, pp. 193-201, (2004); Verheul H.M.W., Pinedo H.M., Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nature Reviews Cancer, 7, 6, pp. 475-485, (2007); Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, New England Journal of Medicine, 350, 23, pp. 2335-2342, (2004); Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., Dickler M., Overmoyer B.A., Reimann J.D., Sing A.P., Langmuir V., Rugo H.S., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, Journal of Clinical Oncology, 23, 4, pp. 792-799, (2005); Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, New England Journal of Medicine, 349, 5, pp. 427-434, (2003); Mourad J.J., Levy B.I., Mechanisms of antiangiogenic-induced arterial hypertension, Curr Hypertens Rep, 13, pp. 289-293, (2011); Chen H.X., Cleck J.N., Adverse effects of anticancer agents that target the VEGF pathway, Nat Rev Clin Oncol, 6, pp. 465-477, (2009); Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., Harder J., Blum H., Robertson J., Jurgensmeier J.M., Puchalski T.A., Young H., Saunders O., Unger C., Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors, Journal of Clinical Oncology, 25, 21, pp. 3045-3054, (2007); Sleijfer S., Ray-Coquard I., Papai Z., Et al., Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043, J Clin Oncol., 27, pp. 3126-3132, (2009); Trotti A., Byhardt R., Stetz J., Gwede C., Corn B., Fu K., Gunderson L., McCormick B., Morris M., Rich T., Shipley W., Curran W., Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy, International Journal of Radiation Oncology Biology Physics, 47, 1, pp. 13-47, (2000); Agabiti-Rosei E., Modifications structurelles et fonctionnelles de la microcirculation dans l'hypertension: Influence du traitement pharmacologique, Drugs, 63, SPEC. ISS. 1, pp. 19-29, (2003); Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., Langer C., Murphy B., Cumberlin R., Coleman C.N., Rubin P., CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment, Seminars in Radiation Oncology, 13, 3, pp. 176-181, (2003); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 6, pp. 1206-1252, (2003); Wu S., Chen J.J., Kudelka A., Lu J., Zhu X., Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis, Lancet Oncol., 9, pp. 117-123, (2008); Feldman D.R., Baum M.S., Ginsberg M.S., Et al., Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol., 27, pp. 1432-1439, (2009); Azad N.S., Posadas E.M., Kwitkowski V.E., Et al., Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity, J Clin Oncol, 26, pp. 3709-3714, (2008); Maitland M.L., Bakris G.L., Black H.R., Et al., Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors, J Natl Cancer Inst, 102, pp. 596-604, (2010); Hood J.D., Meininger C.J., Ziche M., Granger H.J., VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells, Am J Physiol., 274, (1998); Horowitz J.R., Rivard A., Van Der Zee R., Hariawala M., Sheriff D.D., Esakof D.D., Muqtada Chaudhry G., Symes J.F., Isner J.M., Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: Evidence for a maintenance role in quiescent adult endothelium, Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 11, pp. 2793-2800, (1997); Zachary I., VEGF signalling: Integration and multi-tasking in endothelial cell biology, Biochemical Society Transactions, 31, 6, pp. 1171-1177, (2003); Gelinas D.S., Bernatchez P.N., Rollin S., Bazan N.G., Sirois M.G., Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: Role of PI3K, PKC and PLC pathways, British Journal of Pharmacology, 137, 7, pp. 1021-1030, (2002); Li B., Ogasawara A.K., Yang R., Wei W., He G.-W., Zioncheck T.F., Bunting S., De Vos A.M., Jin H., KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF, Hypertension, 39, 6, pp. 1095-1100, (2002); Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., Shah P.K., Willerson J.T., Benza R.L., Berman D.S., Gibson C.M., Bajamonde A., Rundle A.C., Fine J., McCluskey E.R., The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis, Circulation, 107, 10, pp. 1359-1365, (2003); Zou A.P., Cowley Jr. A.W., Role of nitric oxide in the control of renal function and salt sensitivity, Curr Hypertens Rep, 1, pp. 178-186, (1999); Mourad J.-J., Des Guetz G., Debbabi H., Levy B.I., Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation, Annals of Oncology, 19, 5, pp. 927-934, (2008); Feihl F., Liaudet L., Waeber B., Levy B.I., Hypertension: A disease of the microcirculation?, Hypertension, 48, 6, pp. 1012-1017, (2006); Kiefer F.N., Misteli H., Kalak N., Tschudin K., Fingerle J., Van Der Kooij M., Stumm M., Sumanovski L.T., Sieber C.C., Battegay E.J., Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension, Blood Pressure, 11, 2, pp. 116-124, (2002); Steeghs N., Gelderblom H., Roodt J.O., Et al., Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor, Clin Cancer Res., 14, pp. 3470-3476, (2008); Veronese M.L., Mosenkis A., Flaherty K.T., Gallagher M., Stevenson J.P., Townsend R.R., O'Dwyer P.J., Mechanisms of hypertension associated with BAY 43-9006, Journal of Clinical Oncology, 24, 9, pp. 1363-1369, (2006); Mundel P., Kriz W., Cell culture of podocytes, Experimental Nephrology, 4, 5, pp. 263-266, (1996); Nagata M., Yamaguchi Y., Ito K., Loss of mitotic activity and the expression of vimentin in glomerular epithelial cells of developing human kidneys, Anatomy and Embryology, 187, 3, pp. 275-279, (1993); Reiser J., Kriz W., Kretzler M., Mundel P., The glomerular slit diaphragm is a modified adherens junction, Journal of the American Society of Nephrology, 11, 1, pp. 1-8, (2000); Kestila M., Lenkkeri U., Mannikko M., Lamerdin J., McCready P., Putaala H., Ruotsalainen V., Morita T., Nissinen M., Herva R., Kashtan C.E., Peltonen L., Holmberg C., Olsen A., Tryggvason K., Positionally cloned gene for a novel glomerular protein - Nephrin - Is mutated in congenital nephrotic syndrome, Molecular Cell, 1, 4, pp. 575-582, (1998); Donoviel D.B., Freed D.D., Vogel H., Potter D.G., Hawkins E., Barrish J.P., Mathur B.N., Turner C.A., Geske R., Montgomery C.A., Starbuck M., Brandt M., Gupta A., Ramirez-Solis R., Zambrowicz B.P., Powell D.R., Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN, Molecular and Cellular Biology, 21, 14, pp. 4829-4836, (2001); Schwarz K., Simons M., Reiser J., Saleem M.A., Faul C., Kriz W., Shaw A.S., Holzman L.B., Mundel P., Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin, Journal of Clinical Investigation, 108, 11, pp. 1621-1629, (2001); Shih N.-Y., Li J., Karpitskii V., Nguyen A., Dustin M.L., Kanagawa O., Miner J.H., Shaw A.S., Congenital nephrotic syndrome in mice lacking CD2-associated protein, Science, 286, 5438, pp. 312-315, (1999); Barisoni L., Kriz W., Mundel P., D'Agati V., The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV- associated nephropathy, Journal of the American Society of Nephrology, 10, 1, pp. 51-61, (1999); Garovic V.D., Wagner S.J., Petrovic L.M., Gray C.E., Hall P., Sugimoto H., Kalluri R., Grande J.P., Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia, Nephrology Dialysis Transplantation, 22, 4, pp. 1136-1143, (2007); Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C., Kopp J.B., Kabir M.G., Backx P.H., Gerber H.-P., Ferrara N., Barisoni L., Alpers C.E., Quaggin S.E., VEGF inhibition and renal thrombotic microangiopathy, New England Journal of Medicine, 358, 11, pp. 1129-1136, (2008); Patel T.V., Morgan J.A., Demetri G.D., George S., Maki R.G., Quigley M., Humphreys B.D., A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib, Journal of the National Cancer Institute, 100, 4, pp. 282-284, (2008); Eskens F.A.P., Van Doorn A., An open label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors (Abstract, J Clin Oncol., 24, (2006); Izzedine H., Massard C., Spano J.P., Et al., VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management, Eur J Cancer, 46, pp. 439-448, (2010); Nasr S.H., Snyder R.W., Bhagat G., Markowitz G.S., Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis, Kidney International, 71, 2, (2007); Khurana A., Allergic interstitial nephritis possibly related to sunitinib use, Am J Geriatr Pharmacother, 5, pp. 341-344, (2007); Izzedine H., Brocheriou I., Rixe O., Deray G., Interstitial nephritis in a patient taking sorafenib [8], Nephrology Dialysis Transplantation, 22, 8, (2007); Stokes M.B., Erazo M.C., D'Agati V.D., Glomerular disease related to anti-VEGF therapy, Kidney Int, 74, pp. 1487-1491, (2008); Stylianou K., Lioudaki E., Papadimitraki E., Et al., Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration, Nephrol Dial Transplant, 26, pp. 1742-1745, (2011); Costero O., Picazo M.L., Zamora P., Et al., Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy, Nephrol Dial Transplant, 25, pp. 1001-1003, (2010); Bollee G., Patey N., Cazajous G., Et al., Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib, Nephrol Dial Transplant, 24, pp. 682-685, (2009); Izzedine H., Brocheriou I., Deray G., Rixe O., Thrombotic microangiopathy and anti-VEGF agents, Nephrol Dial Transplant., 22, pp. 1481-1482, (2007); Pelle G., Shweke N., Duong Van Huyen J.P., Et al., Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors, Am J Kidney Dis., 57, pp. 756-759, (2011); Yu D., Petermann A., Kunter U., Rong S., Shankland S.J., Floege J., Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria, Journal of the American Society of Nephrology, 16, 6, pp. 1733-1741, (2005); Muller-Deile J., Brocker V., Grunwald V., Et al., Renal side effects of VEGF-blocking therapy, NDT Plus., 3, pp. 172-175, (2010); Takahashi D., Nagahama K., Tsuura Y., Tanaka H., Tamura T., Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction, Clin Exp Nephrol., (2011); Steeghs N., Rabelink T.J., Op't Roodt J., Et al., Reversibility of capillary density after discontinuation of bevacizumab treatment, Ann Oncol., 21, pp. 1100-1105, (2010); Ravaud A., Sire M., Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer, Ann Oncol., 20, pp. 966-967, (2009); Rixe O., Billemont B., Izzedine H., Hypertension as a predictive factor of Sunitinib activity [1], Annals of Oncology, 18, 6, (2007); Levy B.I., Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor, Ann Oncol, 20, pp. 200-203, (2009); Bono P., Elfving H., Utriainen T., Et al., Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma, Ann Oncol., 20, pp. 393-394, (2009); Mir O., Ropert S., Alexandre J., Goldwasser F., Hypertension as a surrogate marker for the activity of anti-VEGF agents, Ann Oncol, 20, pp. 967-970, (2009); Osterlund P., Soveri L.M., Isoniemi H., Et al., Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy, Br J Cancer., 104, pp. 599-604, (2011); Kim J.J., Vaziri S.A.J., Rini B.I., Et al., Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib, Cancer., 118, 7, pp. 1946-1954, (2012); Garcia-Donas J., Esteban E., Leandro-Garcia L.J., Et al., Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study, Lancet Oncol, 12, pp. 1143-1150, (2011); Langenberg M.H., Van Herpen C.M., De Bono J., Et al., Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors, J Clin Oncol, 27, pp. 6152-6159, (2009); Miura S.-I., Fujino M., Matsuo Y., Tanigawa H., Saku K., Nifedipine-induces vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial-containing receptor/fetal liver kinase-1/NO pathway, Hypertension Research, 28, 2, pp. 147-153, (2005); Molteni A., Heffelfinger S., Moulder J.E., Uhal B., Castellani W.J., Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy, Anti-Cancer Agents in Medicinal Chemistry, 6, 5, pp. 451-460, (2006); Izzedine H., Ederhy S., Goldwasser F., Et al., Management of hypertension in angiogenesis inhibitor-treated patients, Ann Oncol, 20, pp. 807-815, (2009); Kelly D.J., Aaltonen P., Cox A.J., Rumble J.R., Langham R., Panagiotopoulos S., Jerums G., Holthofer H., Gilbert R.E., Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: Differing effects of anti-proteinuric therapies, Nephrology Dialysis Transplantation, 17, 7, pp. 1327-1332, (2002); Dirix K.Y., Maes H., Sweldens C., Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors [5], Annals of Oncology, 18, 6, pp. 1121-1122, (2007); Oliver J.J., Melville V.P., Webb D.J., Effect of regular phosphodiesterase type 5 inhibition in hypertension, Hypertension, 48, 4, pp. 622-627, (2006); Porta C., Paglino C., Imarisio I., Bonomi L., Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib, Clin Exp Med, 7, pp. 127-134, (2007); Launay-Vacher V., Ayllon J., Janus N., Et al., Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma, Urol Oncol, 29, pp. 492-494, (2011); Gupta S., Parsa V., Heilbrun L.K., Et al., Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction, Anticancer Drugs., 22, pp. 794-800, (2011); Raina S., Honer M., Kramer S.D., Et al., Anti-VEGF antibody treatment accelerates polycystic kidney disease, Am J Physiol Renal Physiol., 301, (2011)","V.D. Garovic; Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; email: Garovic.vesna@mayo.edu","","","","","","","","15346269","","CORUA","22544560","English","Curr. Oncol. Rep.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84865658329"
"Tanaka K.; Matsumoto S.; Ainiding G.; Nakahara I.; Nishi H.; Hashimoto T.; Ohta T.; Sadamasa N.; Ishibashi R.; Gomi M.; Saka M.; Miyata H.; Watanabe S.; Okata T.; Sonoda K.; Koge J.; Iinuma K.M.; Furuta K.; Nagata I.; Matsuo K.; Matsushita T.; Isobe N.; Yamasaki R.; Kira J.-I.","Tanaka, Koji (57198410253); Matsumoto, Shoji (26654407500); Ainiding, Gulibahaer (55165394200); Nakahara, Ichiro (7005735970); Nishi, Hidehisa (56537849100); Hashimoto, Tetsuya (57191041253); Ohta, Tsuyoshi (55893536400); Sadamasa, Nobutake (6506433048); Ishibashi, Ryota (56538103800); Gomi, Masanori (12805589700); Saka, Makoto (56559556900); Miyata, Haruka (58586505600); Watanabe, Sadayoshi (56537456100); Okata, Takuya (55364053700); Sonoda, Kazutaka (57204285011); Koge, Junpei (57191623306); Iinuma, Kyoko M. (54401275600); Furuta, Konosuke (53881194600); Nagata, Izumi (56466148900); Matsuo, Keitaro (7401602814); Matsushita, Takuya (16402748300); Isobe, Noriko (23568196500); Yamasaki, Ryo (8679640100); Kira, Jun-Ichi (7103358419)","57198410253; 26654407500; 55165394200; 7005735970; 56537849100; 57191041253; 55893536400; 6506433048; 56538103800; 12805589700; 56559556900; 58586505600; 56537456100; 55364053700; 57204285011; 57191623306; 54401275600; 53881194600; 56466148900; 7401602814; 16402748300; 23568196500; 8679640100; 7103358419","PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study","2021","PLoS ONE","16","8 August","e0254067","","","","2","10.1371/journal.pone.0254067","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112609468&doi=10.1371%2fjournal.pone.0254067&partnerID=40&md5=a1142f06111fde5779e1d8c6c35306a1","Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Department of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan; Department of Cancer Epidemiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan; Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan","Tanaka K., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Matsumoto S., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Ainiding G., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Nakahara I., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Nishi H., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Hashimoto T., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Ohta T., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Sadamasa N., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Ishibashi R., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Gomi M., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Saka M., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Miyata H., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Watanabe S., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Okata T., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Sonoda K., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Koge J., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Iinuma K.M., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Furuta K., Department of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan; Nagata I., Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan; Matsuo K., Department of Cancer Epidemiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan, Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan; Matsushita T., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Isobe N., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Yamasaki R., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; Kira J.-I., Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan","Background and purpose The impact of the paraoxonase-1 (PON1) polymorphism, Q192R, on platelet inhibition in response to clopidogrel remains controversial. We aimed to investigate the association between carrier status of PON1 Q192R and high platelet reactivity (HPR) with clopidogrel in patients undergoing elective neurointervention. Methods Post-clopidogrel platelet reactivity was measured using a VerifyNow® P2Y12 assay in P2Y12 reaction units (PRU) for consecutive patients before the treatment. Genotype testing was performed for PON1 Q192R and CYP2C19*2 and*3 (no function alleles), and*17. PRU was corrected on the basis of hematocrit. We investigated associations between factors including carrying ≥1 PON1 192R allele and HPR defined as original and corrected PRU ≥208. Results Of 475 patients (232 men, median age, 68 years), HPR by original and corrected PRU was observed in 259 and 199 patients (54.5% and 41.9%), respectively. Carriers of ≥1 PON1 192R allele more frequently had HPR by original and corrected PRU compared with noncarriers (91.5% vs 85.2%, P = 0.031 and 92.5% vs 85.9%, P = 0.026, respectively). In multivariate analyses, carrying ≥1 PON1 192R allele was associated with HPR by original (odds ratio [OR] 1.96, 95% confidence interval [CI] 1.03-3.76) and corrected PRU (OR 2.34, 95% CI 1.21-4.74) after adjustment for age, sex, treatment with antihypertensive medications, hematocrit, platelet count, total cholesterol, and carrying ≥1 CYP2C19 no function allele. Conclusions Carrying ≥1 PON1 192R allele is associated with HPR by original and corrected PRU with clopidogrel in patients undergoing elective neurointervention, although alternative results related to other genetic polymorphisms cannot be excluded. © 2021 Tanaka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","Aged; Alleles; Amino Acid Substitution; Aryldialkylphosphatase; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Mutation, Missense; Neurosurgical Procedures; Platelet Activation; Prospective Studies; acetylsalicylic acid; angiotensin receptor antagonist; aryldialkylphosphatase 1; beta adrenergic receptor blocking agent; calcium channel blocking agent; clopidogrel; cytochrome P450 2C19; dipeptidyl carboxypeptidase inhibitor; genomic DNA; high density lipoprotein cholesterol; low density lipoprotein cholesterol; proton pump inhibitor; aryldialkylphosphatase; clopidogrel; PON1 protein, human; adult; aged; Article; cardiovascular risk factor; carotid artery obstruction; carotid artery stenting; cerebrovascular disease; cholesterol blood level; cohort analysis; coil embolization; controlled study; CYP2C19 gene; diabetes mellitus; DNA extraction; dyslipidemia; endovascular surgery; female; gene frequency; genetic association; genetic screening; genotyping technique; hematocrit; human; hypertension; ischemic heart disease; loading drug dose; low drug dose; major clinical study; male; observational study; platelet count; platelet reactivity; PON1 gene; prevalence; prospective study; protein expression; single nucleotide polymorphism; smoking; allele; amino acid substitution; clinical trial; drug effect; genetics; metabolism; middle aged; missense mutation; neurosurgery; thrombocyte; thrombocyte activation","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8, 120202-65-5, 120202-67-7, 894353-16-3; aryldialkylphosphatase, 117698-12-1; Aryldialkylphosphatase, ; Clopidogrel, ; PON1 protein, human, ","","","","","Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb Haemost, 89, pp. 783-787, (2003); Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Et al., Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, pp. 3171-3175, (2004); Ryu DS, Hong CK, Sim YS, Kim CH, Jung JY, Joo JY., Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention, J Korean Nerosurg Soc, 48, pp. 319-324, (2010); Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Et al., Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, 302, pp. 849-857, (2009); Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Et al., Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, pp. 363-375, (2009); Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Et al., Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel, Am J Cardiol, 110, pp. 502-508, (2012); Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Et al., Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement, Circulation, 121, pp. 512-518, (2010); Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, Et al., Paraoxonase-1 is a major determinant of clopidogrel efficacy, Nat Med, 17, pp. 110-116, (2011); Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A., CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients, Circ Cardiovasc Interv, 4, pp. 422-428, (2011); Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Et al., No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting, Eur Heart J, 32, pp. 1605-1613, (2011); Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Et al., Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement, Circ Cardiovasc Genet, 4, pp. 429-436, (2011); Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Et al., PON1 Q192R genetic variant and response to clopidogrel and prasugrel: Pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes, J Thromb Thrombolysis, 41, pp. 374-383, (2016); Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Et al., PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity, Thromb Res, 132, pp. 444-449, (2013); Li X, Wang Z, Wang Q, Xu Q, Lv Q., Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients, Basic Clin Pharmacol Toxicol, 124, pp. 84-93, (2019); Peng W, Shi X, Xu X, Lin Y., Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome, Cardiovasc Ther, 2019, (2019); Zhang Z, Chen M, Zhang L, Zhao Q., The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention, BMC Pharmacol Toxicol, 21, (2020); Adeeb N, Griessenauer CJ, Foreman PM, Moore JM, Shallwani H, Motiei-Langroudi R, Et al., Use of Platelet Function Testing Before Pipeline Embolization Device Placement: A Multicenter Cohort Study, Stroke, 48, pp. 1322-1330, (2017); Saiz-Rodriguez M, Belmonte C, Caniego JL, Koller D, Zubiaur P, Barcena E, Et al., Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention, Clin Ther, 41, pp. 1199-1212, (2019); Kakouros N, Kickler TS, Laws KM, Rade JJ., Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness, J Thromb Haemost, 11, pp. 1814-1822, (2013); Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Et al., Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial, JAMA, 305, pp. 1097-1105, (2011); A global reference for human genetic variation, Nature, 526, 7571, pp. 68-74, (2015); Yaseen IF, Farhan HA, Abbas HM., Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: Frequency and predictors, Eur J Hosp Pharm, 26, pp. 113-116, (2019); Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Et al., Ticagrelor versus clopidogrel in black patients with stable coronary artery disease: Prospective, randomized, open-label, multipledose, crossover pilot study, Circ Cardiovasc Interv, 8, (2015); Cui H, Lin S, Chen X, Gao W, Li X, Zhou H, Et al., Correlation between SNPs in candidate genes and VerifyNow-detected platelet responsiveness to aspirin and clopidogrel treatment, Cardiovasc Drugs Ther, 29, pp. 137-146, (2015); Voisin S, Bongard V, Tidjane MA, Lhermusier T, Carrie D, Sie P., Are P2Y12 reaction unit (PRU) and% inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels, Thromb Haemost, 106, pp. 227-229, (2011); Desta Z, Zhao X, Shin JG, Flockhart DA., Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, 41, pp. 913-958, (2002); Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Et al., Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite, Drug Metab Dispos, 38, pp. 92-99, (2010); Dansette PM, Rosi J, Bertho G, Mansuy D., Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer, Chem Res Toxicol, 25, pp. 348-356, (2012); Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Et al., Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response, Eur Heart J, 33, pp. 2856-2464a, (2012); Mackness MI, Arrol S, Abbott C, Et al., Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase, Atherosclerosis, 104, pp. 129-135, (1993); Pare G, Caku A, McQueen M, Et al., Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups, Circulation, 139, pp. 1472-1482, (2019); Miller MM, Henninger N, Slowik A., Mean platelet volume and its genetic variants relate to stroke severity and 1-year mortality, Neurology, 95, pp. e1153-e1162, (2020); Su J, Zheng N, Li Z, Huangfu N, Mei L, Xu X, Et al., Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients, J Clin Lab Anal, 34, (2020); Brophy VH, Jampsa RL, Clendenning JB, Et al., Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression, Am J Hum Genet, 68, pp. 1428-1436, (2001)","J.-I. Kira; Department of Neurology, Graduate School of Medical Sciences, Neurological Institute, Kyushu University, Fukuoka, Japan; email: kira@neuro.med.kyushu-u.ac.jp","","Public Library of Science","","","","","","19326203","","POLNC","34351918","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85112609468"
"Smiley R.","Smiley, R. (7005313680)","7005313680","Do genes matter?","2021","International Journal of Obstetric Anesthesia","45","","","1","4","3","0","10.1016/j.ijoa.2020.11.006","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097765447&doi=10.1016%2fj.ijoa.2020.11.006&partnerID=40&md5=14a85f7cc00a01a5ea044eb62957af87","Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States","Smiley R., Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States","[No abstract available]","","aldosterone synthase; angiotensin 1 receptor; angiotensin receptor; beta 2 adrenergic receptor; dipeptidyl carboxypeptidase; ephedrine; fentanyl; hypertensive factor; melanocortin 1 receptor; morphine; mu opiate receptor; phenylephrine; propofol; sufentanil; cesarean section; clinical outcome; drug efficacy; drug response; Editorial; gene; genetic association; genetic variability; genetic variation; genotype; heredity; human; human genome; hypertension; hypotension; indel mutation; obstetric analgesia; obstetric anesthesia; pharmacogenetics; postoperative analgesia; sequence analysis; single nucleotide polymorphism; spinal anesthesia; whole exome sequencing; whole genome sequencing","","aldosterone synthase, 122933-89-5; dipeptidyl carboxypeptidase, 9015-82-1; ephedrine, 299-42-3, 50-98-6; fentanyl, 437-38-7, 1443-54-5; melanocortin 1 receptor, 234764-00-2, 234764-02-4; morphine, 52-26-6, 57-27-2; phenylephrine, 532-38-7, 59-42-7, 61-76-7; propofol, 2078-54-8; sufentanil, 56030-54-7","","","","","Tan H.S., Gan Y.Y., Tan E.C., Et al.; (2020); Liem E.B., Lin C.M., Suleman M.I., Et al., Anesthetic requirement is increased in redheads, Anesthesiology, 101, pp. 279-283, (2004); Liem E.B., Joiner T.V., Tsueda K., Sessler D.I., Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads, Anesthesiology, 102, pp. 509-514, (2005); Yonekura H., Murayama N., Yamazaki H., Sobue K., A Case of delayed emergence after propofol anesthesia: genetic analysis, A case of Rep, 7, pp. 243-246, (2016); Zhang Y., Poler S.M., Li J., Et al., Dissecting genetic factors affecting phenylephrine infusion rates during anesthesia: a genome-wide association study employing EHR data, BMC Med, 17, (2019); Riazi S., Kraeva N., Hopkins P.M., Malignant hyperthermia in the post-genomics era: new perspectives on an old concept, Anesthesiology, 128, pp. 168-180, (2018); Landau R., Morales M.A., Antonarakis S.E., Blouin J.L., Smiley R.M., Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta<sub>2</sub>-agonist tocolysis for preterm labor, Clin Pharmacol Ther, 78, pp. 656-663, (2005); Ozkur M., Dogulu F., Ozkur A., Gokmen B., Inaloz S.S., Aynacioglu A.S., Association of the Gln27Glu polymorphism of the beta-<sub>2</sub>-adrenergic receptor with preterm labor, Int J Gynaecol Obstet, 77, pp. 209-215, (2002); Landau R., Xie H.G., Dishy V., Et al., beta<sub>2</sub>-adrenergic receptor genotype and preterm delivery, Am J Obstet Gynecol, 187, pp. 1294-1298, (2002); Pettini E., Micaglio M., Bitossi U., Et al., Influence of OPRM1 polymorphism on postoperative pain after intrathecal morphine administration in Italian patients undergoing elective cesarean section, Clin J Pain, 34, pp. 178-181, (2018); Sia A.T., Lim Y., Lim E.C., Et al., A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia, Anesthesiology, 109, pp. 520-526, (2008); Xie W., Zhuang W., Chen L., Xie W., Jiang C., Liu N., 4218T/C polymorphism associations with post-cesarean patient-controlled epidural fentanyl consumption and pain perception, Acta Anaesthesiol Scand, 62, pp. 376-383, (2018); Xu G.H., Gao M., Sheng Q.Y., Liu X.S., Gu E.W., Opioid receptor A118G polymorphism does not affect the consumption of sufentanil and ropivacaine by patient-controlled epidural analgesia after cesarean section, Ther Drug Monit, 37, pp. 53-57, (2015); Camorcia M., Capogna G., Stirparo S., Berritta C., Blouin J.L., Landau R., Effect of mu-opioid receptor A118G polymorphism on the ED50 of epidural sufentanil for labor analgesia, Int J Obstet Anesth, 21, pp. 40-44, (2012); Landau R., Kern C., Columb M.O., Smiley R.M., Blouin J.L., Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women, Pain, 139, pp. 5-14, (2008); Sng B.L., Du W., Lee M.X., Et al., Comparison of double intravenous vasopressor automated system using nexfin versus manual vasopressor bolus administration for maintenance of haemodynamic stability during spinal anaesthesia for caesarean delivery: a randomised double-blind controlled trial, Eur J Anaesthesiol, 35, pp. 390-397, (2018); Almustafa M.M., Al-Oweidi A.S., Al-Zaben K.R., Et al., Ephedrine requirements during spinal anesthesia for cesarean delivery in Jordanian parturients: association with b<sub>2</sub> adrenoceptor gene variants, Ann Saudi Med, 36, pp. 29-36, (2016); Odekon L., Landau R., Blouin J.L., Brodow D., Wang S., Smiley R.M., The effect of beta<sub>2</sub>-adrenoceptor genotype on phenylephrine dose administered during spinal anesthesia for cesarean delivery, Anesth Analg, 120, pp. 1309-1316, (2015); Sng B.L., Tan H.S., Sia A.T., Closed-loop double-vasopressor automated system vs manual bolus vasopressor to treat hypotension during spinal anaesthesia for caesarean section: a randomised controlled trial, Anaesthesia, 69, pp. 37-45, (2014); Sia A.T., Tan H.S., Sng B.L., Closed-loop double-vasopressor automated system to treat hypotension during spinal anaesthesia for caesarean section: a preliminary study, Anaesthesia, 67, pp. 1348-1355, (2012); Landau R., Liu S.K., Blouin J.L., Smiley R.M., Ngan Kee W.D., The effect of maternal and fetal beta2-adrenoceptor and nitric oxide synthase genotype on vasopressor requirement and fetal acid-base status during spinal anesthesia for cesarean delivery, Anesth Analg, 112, pp. 1432-1437, (2011); Smiley R.M., Blouin J.L., Negron M., Landau R., beta<sub>2</sub>-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery, Anesthesiology, 104, pp. 644-650, (2006); Sng B.L., Wang H., Assam P.N., Sia A.T., Assessment of an updated double-vasopressor automated system using Nexfin for the maintenance of haemodynamic stability to improve peri-operative outcome during spinal anaesthesia for caesarean section, Anaesthesia, 70, pp. 691-698, (2015); Kinsella S.M., Carvalho B., Dyer R.A., Et al., International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia, Anaesthesia, 73, pp. 71-92, (2018); Dyer R.A., Emmanuel A., Adams S.C., Et al., A randomised comparison of bolus phenylephrine and ephedrine for the management of spinal hypotension in patients with severe preeclampsia and fetal compromise, Int J Obstet Anesth, 33, pp. 23-31, (2018); Gratz I., Baruch M., Takla M., Et al., The application of a neural network to predict hypotension and vasopressor requirements non-invasively in obstetric patients having spinal anesthesia for elective cesarean section (C/S), BMC Anesthesiol, 20, (2020); Sakata K., Yoshimura N., Tanabe K., Kito K., Nagase K., Iida H., Prediction of hypotension during spinal anesthesia for elective cesarean section by altered heart rate variability induced by postural change, Int J Obstet Anesth, 29, pp. 34-38, (2017); Wong C.A., McCarthy R.J., Blouin J., Landau R., Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia, Int J Obstet Anesth, 19, pp. 246-253, (2010)","","","Churchill Livingstone","","","","","","0959289X","","IOANE","33317927","English","Int. J. Obstet. Anesth.","Editorial","Final","","Scopus","2-s2.0-85097765447"
"Bosso M.; Thanaraj T.A.; Abu-Farha M.; Alanbaei M.; Abubaker J.; Al-Mulla F.","Bosso, Mira (57194182069); Thanaraj, Thangavel Alphonse (6701473706); Abu-Farha, Mohamed (10045707200); Alanbaei, Muath (22833680700); Abubaker, Jehad (23491561800); Al-Mulla, Fahd (6603636413)","57194182069; 6701473706; 10045707200; 22833680700; 23491561800; 6603636413","The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19","2020","Molecular Therapy Methods and Clinical Development","18","","","321","327","6","114","10.1016/j.omtm.2020.06.017","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087295188&doi=10.1016%2fj.omtm.2020.06.017&partnerID=40&md5=2f039ee1d3802ecbef95ede9d5e50792","Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, 15462, Kuwait; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman, 15462, Kuwait; Health Sciences Center, Kuwait University, Kuwait City, 13110, Kuwait","Bosso M., Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, 15462, Kuwait; Thanaraj T.A., Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, 15462, Kuwait; Abu-Farha M., Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman, 15462, Kuwait; Alanbaei M., Health Sciences Center, Kuwait University, Kuwait City, 13110, Kuwait; Abubaker J., Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman, 15462, Kuwait; Al-Mulla F., Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, 15462, Kuwait","The mechanism for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection requires the binding of the virus to the angiotensin-converting enzyme 2 (ACE2) receptor, well-known for its role in counteracting ACE. ACE2 is involved in modulating blood pressure and establishing blood pressure homeostasis. Recently, a critical debatable question has arisen whether using antihypertensive medications will have a favorable impact on people infected with SARS-CoV-2 or a deleterious one, mainly because angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-receptor blocker (ARB) therapy can modulate the expression of ACE2 protein. The concern is that the use of ACEIs and ARBs will increase the expression of ACE2 and increase patient susceptibility to viral host cell entry and propagation. On the other hand, several genetic association studies have examined the relationship between ACE2 genetic variants and the risk of developing hypertension in different ethnic populations. In this review, we discuss the ongoing arguments in the literature about ACE2's role in mortality rate among coronavirus disease 2019 (COVID-19) patients comorbid with hypertension and critically evaluate the current debate about the usage or discontinuation of ACEI/ARB antihypertensive drugs. Moreover, we explore the two opposing roles that ACE2 genetic variants might be playing in COVID-19 by reducing ACE2 receptor effectiveness and mitigating SARS-CoV-2 infectivity. © 2020 Dasman Diabetes Institute; Bosso et al. discuss the ongoing arguments about ACE2's role in the mortality associated with COVID-19 cases and weigh on the current debate about the usage or discontinuation of ACEI/ARB anti-hypertensive medication. They also explore the two opposing roles that ACE2 genetic variants might be playing in COVID-19. © 2020 Dasman Diabetes Institute","ACE2; ACEI; angiotensin-renin system; ARBs; genetic variants; hypertension; SARS-CoV-2","angiotensin converting enzyme 2; angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; antihypertensive therapy; coronavirus disease 2019; disease predisposition; drug use; genetic variability; human; hypertension; mortality; mortality rate; priority journal; Review; Severe acute respiratory syndrome coronavirus 2; single nucleotide polymorphism; treatment response","","","","","Kuwait Foundation for the Advancement of Sciences, KFAS","The study was supported by Kuwait Foundation for the Advancement of Sciences (KFAS) COVID-19 resilience grant.","Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., Et al., Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur. Respir. J., 55, (2020); Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern. Med, (2020); Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, pp. 1054-1062, (2020); Li J., Wang X., Chen J., Zhang H., Deng A., Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China, JAMA Cardiol., (2020); Reynolds H.R., Adhikari S., Pulgarin C., Troxel A.B., Iturrate E., Johnson S.B., Hausvater A., Newman J.D., Berger J.S., Bangalore S., Et al., Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19, N. Engl. J. Med., 382, pp. 2441-2448, (2020); Gaddam R.R., Chambers S., Bhatia M., ACE and ACE2 in inflammation: a tale of two enzymes, Inflamm. Allergy Drug Targets, 13, pp. 224-234, (2014); Rice G.I., Jones A.L., Grant P.J., Carter A.M., Turner A.J., Hooper N.M., Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study, Hypertension, 48, pp. 914-920, (2006); Devaux C.A., Rolain J.M., Raoult D., ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome, J. Microbiol. Immunol. Infect., 53, pp. 425-435, (2020); Vangjeli C., Dicker P., Tregouet D.A., Shields D.C., Evans A., Stanton A.V., A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project, J. Renin Angiotensin Aldosterone Syst., 12, pp. 504-509, (2011); Zhang Q., Cong M., Wang N., Li X., Zhang H., Zhang K., Jin M., Wu N., Qiu C., Li J., Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study, Medicine (Baltimore), 97, (2018); Zhong J., Yan Z., Liu D., Ni Y., Zhao Z., Zhu S., Tepel M., Zhu Z., Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome, J. Lab. Clin. Med., 147, pp. 91-95, (2006); Niu W., Qi Y., Hou S., Zhou W., Qiu C., Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese, Transl. Res., 150, pp. 374-380, (2007); Lu N., Yang Y., Wang Y., Liu Y., Fu G., Chen D., Dai H., Fan X., Hui R., Zheng Y., ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects, Mol. Biol. Rep., 39, pp. 6581-6589, (2012); Liu D., Chen Y., Zhang P., Zhong J., Jin L., Zhang C., Lin S., Wu S., Yu H., Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients, Medicine (Baltimore), 95, (2016); Patnaik M., Pati P., Swain S.N., Mohapatra M.K., Dwibedi B., Kar S.K., Ranjit M., Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India, Ann. Hum. Biol., 41, pp. 145-152, (2014); Wang S.X., Fu C.Y., Zou Y.B., Wang H., Shi Y., Xu X.Q., Chen J.Z., Song X.D., Huan T.J., Hui R.T., Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy, Chin. Med. J. (Engl.), 121, pp. 27-31, (2008); Pan Y., Wang T., Li Y., Guan T., Lai Y., Shen Y., Zeyaweiding A., Maimaiti T., Li F., Zhao H., Liu C., Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China, Lipids Health Dis., 17, (2018); Luo Y., Liu C., Guan T., Li Y., Lai Y., Li F., Zhao H., Maimaiti T., Zeyaweiding A., Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang, Hypertens. Res., 42, pp. 681-689, (2019); Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., Stritzke J., Hengstenberg C., Holmer S.R., Doring A., Et al., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy, J. Mol. Med. (Berl.), 84, pp. 88-96, (2006); Santos R.A., Angiotensin-(1-7), Hypertension, 63, pp. 1138-1147, (2014); El-Hashim A.Z., Renno W.M., Raghupathy R., Abduo H.T., Akhtar S., Benter I.F., Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways, Br. J. Pharmacol., 166, pp. 1964-1976, (2012); Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V., Pfeffer M.A., Solomon S.D., Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19, N. Engl. J. Med., 382, pp. 1653-1659, (2020); Yagil Y., Yagil C., Hypothesis: ACE2 modulates blood pressure in the mammalian organism, Hypertension, 41, pp. 871-873, (2003); Bitker L., Burrell L.M., Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill, Crit. Care Clin., 35, pp. 213-227, (2019); Crackower M.A., Sarao R., Oliveira-dos-Santos A.J., Da Costa J., Zhang L., Et al., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, 417, pp. 822-828, (2002); Bean D., Kraljevic Z., Searle T., Bendayan R., Pickles A., Folarin A., Roguski L., Noor K., Shek A., O'Gallagher K., Et al., Treatment with ACE-inhibitors is not associated with early severe SARS-Covid-19 infection in a multi-site UK acute Hospital Trust, ResearchGate, (2020); Glowacka I., Bertram S., Herzog P., Pfefferle S., Steffen I., Muench M.O., Simmons G., Hofmann H., Kuri T., Weber F., Et al., Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63, J. Virol., 84, pp. 1198-1205, (2010); South A.M., Tomlinson L., Edmonston D., Hiremath S., Sparks M.A., Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic, Nat. Rev. Nephrol., 16, pp. 305-307, (2020); Chen L., Hao G., The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease, Cardiovasc. Res., (2020); Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S., Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med., 46, pp. 586-590, (2020); Oliveira-Paula G.H., Pereira S.C., Tanus-Santos J.E., Lacchini R., Pharmacogenomics and hypertension: Current insights, Pharm. Genomics Pers. Med., 12, pp. 341-359, (2019); Chen Y.Y., Zhang P., Zhou X.M., Liu D., Zhong J.C., Zhang C.J., Jin L.J., Yu H.M., Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites, J. Clin. Pharm. Ther., 43, pp. 189-195, (2018); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Zhen Y., Wang J., Li W., Han Y., Et al., Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women, Clin. Pharmacol. Ther., 82, pp. 187-196, (2007); Asselta R., Paraboschi E.-M., Mantovani A., Duga S., ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy, Aging (Albany NY), 12, pp. 10087-10098, (2020); Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X., Wen F., Huang X., Ning G., Wang W., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov., 6, (2020); Al-mulla F., Mohammad A., Al Madhoun A., Haddad D., Ali H., Eaaswarkhanth M., John S.E., Nizam R., Channanath A., Abu-Farha M., Et al., A comprehensive germline variant and expression analyses of ACE2, TMPRSS2 and SARS-CoV-2 activator FURIN genes from the Middle East: Combating SARS-CoV-2 with precision medicine, bioRxiv, (2020); Stawiski E.W., Diwanji D., Suryamohan K., Gupta R., Fellouse F.A., Sathirapongsasuti J.F., Liu J., Jiang Y.-P., Ratan A., Mis M., Et al., Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility, bioRxiv, (2020); Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O., Pohlmann S., TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein, J. Virol., 88, pp. 1293-1307, (2014); Benjafield A.V., Wang W.Y.S., Morris B.J., No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension, Am. J. Hypertens., 17, pp. 624-628, (2004); Palmer B.R., Jarvis M.D., Pilbrow A.P., Ellis K.L., Frampton C.M., Skelton L., Yandle T.G., Doughty R.N., Whalley G.A., Ellis C.J., Et al., Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort, Am. Heart J., 156, pp. 752-758, (2008); Wang S., Fu C., Zou Y., Wang H., Shi Y., Xu X., Chen J., Song X., Huan T., Hui R., Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy, Chin. Med. J. (Engl)., 121, pp. 27-31, (2008)","J. Abubaker; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman, 15462, Kuwait; email: jehad.abubakr@dasmaninstitute.org; F. Al-Mulla; Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, P.O. Box 1180, 15462, Kuwait; email: fahd.almulla@dasmaninstitute.org","","Cell Press","","","","","","23290501","","","","English","Mol. Ther. Methods Clin. Dev.","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85087295188"
"Jiang S.; Venners S.A.; Hsu Y.-H.; Weinstock J.; Wang B.; Xing H.; Wang X.; Xu X.","Jiang, Shanqun (8639463000); Venners, Scott Alan (7801645038); Hsu, Yi-Hsiang (8071612400); Weinstock, Justin (57104688800); Wang, Binyan (12797489300); Xing, Houxun (57202564565); Wang, Xiaobin (8585424100); Xu, Xiping (34868966600)","8639463000; 7801645038; 8071612400; 57104688800; 12797489300; 57202564565; 8585424100; 34868966600","Interactive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients","2016","American Journal of Hypertension","29","5","","553","559","6","2","10.1093/ajh/hpv144","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84965121210&doi=10.1093%2fajh%2fhpv144&partnerID=40&md5=5f5d149680fea0b6179d8397a45fd3cc","School of Life Sciences, Anhui University, Hefei, China; Institute of Biomedicine, Anhui Medical University, Hefei, China; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; Institute for Aging Research, HSL and Harvard Medical School, Boston, MA, United States; Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, United States; Department of Statistics, University of Virginia, Charlottesville, VA, United States; Center on the Early Life Origins of Disease, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States; Division of Epidemiology and Biostatistics, University of Illinois, Chicago School of Public Health, Chicago, IL, United States","Jiang S., School of Life Sciences, Anhui University, Hefei, China, Institute of Biomedicine, Anhui Medical University, Hefei, China; Venners S.A., Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; Hsu Y.-H., Institute for Aging Research, HSL and Harvard Medical School, Boston, MA, United States, Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, MA, United States; Weinstock J., Department of Statistics, University of Virginia, Charlottesville, VA, United States; Wang B., Institute of Biomedicine, Anhui Medical University, Hefei, China; Xing H., Institute of Biomedicine, Anhui Medical University, Hefei, China; Wang X., Center on the Early Life Origins of Disease, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States; Xu X., Institute of Biomedicine, Anhui Medical University, Hefei, China, Division of Epidemiology and Biostatistics, University of Illinois, Chicago School of Public Health, Chicago, IL, United States","OBJECTIVE: This study was designed to detect the association of the potassium inwardly rectifying channel, subfamily J, member 11 (KCNJ11) gene polymorphism with antihypertensive therapeutic response to irbesartan in a large-scale Chinese hypertensive population. METHODS: A total of 1,099 patients with essential hypertension were enrolled to receive a daily dose of 150mg irbesartan for 27 days. Pretreatment baseline blood pressure (BP) and posttreatment BP on the 28th day were measured. Plasma irbesartan concentrations were measured by high-performance liquid chromatography-fluorescence. The KCNJ11 I337V gene polymorphism was determined using high-throughput TaqMan technology. RESULTS: The HapMap data in the Han Chinese population showed that the I337V was used as a representative for 4 common functional polymorphisms. Our results showed that the association of antihypertensive response to irbesartan and the KCNJ11 genetic variant in the total sample was not significant. However, in nonsmokers, relative to the GG genotype, subjects with the homozygous AA genotype had a significantly higher therapeutic response to irbesartan (adjusted beta ± SE: 4.7±1.9mm Hg, P = 0.015). In smokers, the subjects with the homozygous AA genotype had a significantly lower therapeutic response to irbesartan (adjusted beta ± SE: -5.6±2.5mm Hg, P = 0.026). A multivariate linear regression model confirmed that there was a significant interactive effect between the KCNJ11 gene and smoking on irbesartan treatment (interaction P = 0.001). CONCLUSION The interactive effect of smoking status and the KCNJ11 genotype may influence the antihypertensive effects of irbesartan, which indicates a consideration for future individualized antihypertensive drug treatment. © American Journal of Hypertension, Ltd 2015. All rights reserved.","blood pressure; blood pressure response; essential hypertension hypertension; irbesartan; KCNJ11 gene polymorphism; smoking","Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian Continental Ancestry Group; Biphenyl Compounds; Blood Pressure; Chi-Square Distribution; China; Chromatography, High Pressure Liquid; Female; Gene Frequency; Gene-Environment Interaction; Genetic Association Studies; Genetic Predisposition to Disease; Heterozygote; High-Throughput Nucleotide Sequencing; Homozygote; Humans; Hypertension; Least-Squares Analysis; Linear Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Risk Assessment; Risk Factors; Smoking; Tetrazoles; Treatment Outcome; inwardly rectifying potassium channel subunit Kir6.2; irbesartan; angiotensin 1 receptor antagonist; antihypertensive agent; biphenyl derivative; inwardly rectifying potassium channel; inwardly rectifying potassium channel subunit Kir6.2; irbesartan; tetrazole derivative; adult; alcohol consumption; antihypertensive therapy; Article; blood pressure measurement; body height; body mass; body weight; diastolic blood pressure; DNA polymorphism; drinking behavior; drug efficacy; environmental factor; essential hypertension; female; genetic variability; genotype; Han Chinese; high performance liquid chromatography; homozygote; human; major clinical study; male; phenotype; priority journal; smoking; steady state; systolic blood pressure; treatment duration; treatment response; adverse effects; aged; Asian continental ancestry group; blood; blood pressure; chi square distribution; China; clinical trial; drug effects; epidemiology; ethnology; gene frequency; genetic association study; genetic predisposition; genetics; genotype environment interaction; heterozygote; high throughput sequencing; hypertension; least square analysis; middle aged; multicenter study; multivariate analysis; risk assessment; risk factor; single nucleotide polymorphism; smoking; statistical model; treatment outcome","","irbesartan, 138402-11-6; Angiotensin II Type 1 Receptor Blockers, ; Antihypertensive Agents, ; Biphenyl Compounds, ; irbesartan, ; Kir6.2 channel, ; Potassium Channels, Inwardly Rectifying, ; Tetrazoles, ","","","Academic Leader and Reserve Candidate of Anhui Province, (05010543); National Natural Science Foundation of China, NSFC, (30700454, 81141116, 81373484); National Natural Science Foundation of China, NSFC; Anhui Medical University, AHMU","This study was supported by the National Natural Science Foundation of China (Grant No. 81373484, 81141116 and 30700454) and Academic Leader and Reserve Candidate of Anhui Province (No. 05010543). We gratefully acknowledge the assistance and cooperation of the faculty and staff of the Anhui Medical University and thank all of the participants in our study.","Gao Y., Chen G., Tian H., Lin L., Lu J., Weng J., Jia W., Ji L., Xiao J., Zhou Z., Ran X., Ren Y., Chen T., Yang W., Prevalence of hypertension in china: A cross-sectional study, PLoS One, 8, (2013); Taverne K., De Groot M., De Boer A., Klungel O., Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs, Expert Opin Drug Metab Toxicol, 6, pp. 439-460, (2010); Croom K.F., Curran M.P., Goa K.L., Perry C.M., Irbesartan: A review of its use in hypertension and in the management of diabetic nephropathy, Drugs, 64, pp. 999-1028, (2004); Schelleman H., Stricker B.H., De Boer A., Kroon A.A., Verschuren M.W., Van Duijn C.M., Psaty B.M., Klungel O.H., Drug-gene interactions between genetic polymorphisms and antihypertensive therapy, Drugs, 64, pp. 1801-1816, (2004); Jiang S., Hsu Y.H., Venners S.A., Zhang Y., Xing H., Wang X., Xu X., Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan, J Hypertens, 29, pp. 890-895, (2011); Jiang S., Mao G., Zhang S., Hong X., Tang G., Li Z., Liu X., Zhang Y., Wang B., Xu X., Wang X., Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects, Clin Pharmacol Ther, 78, pp. 239-248, (2005); Gong Y., McDonough C.W., Wang Z., Hou W., Cooper-DeHoff R.M., Langaee T.Y., Beitelshees A.L., Chapman A.B., Gums J.G., Bailey K.R., Boerwinkle E., Turner S.T., Johnson J.A., Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study, Circ Cardiovasc Genet, 5, pp. 686-691, (2012); Campbell C.Y., Blumenthal R.S., Pharmacogenetics of antihypertensive response, Hypertension, 59, pp. 1094-1096, (2012); Jiang S., Hsu Y.H., Venners S.A., Zhang Y., Xing H., Wang X., Xu X., Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients, J Hum Hypertens, 25, pp. 327-333, (2011); Liu H., Zhang S., Jiang S., Mao G., Hong X., Yu Y., Zhang Y., Tang G., Xing H., Xu X., Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives, Methods Find Exp Clin Pharmacol, 30, pp. 307-312, (2008); Kurland L., Hallberg P., Melhus H., Liljedahl U., Hashemi N., Syvanen A.C., Lind L., Kahan T., The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial, Am J Hypertens, 21, pp. 836-839, (2008); Zhang S., Mao G., Zhang Y., Tang G., Wen Y., Hong X., Jiang S., Yu Y., Xu X., Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension, Clin Ther, 27, pp. 1774-1784, (2005); Zevin S., Benowitz N.L., Drug interactions with tobacco smoking. An update, Clin Pharmacokinet, 36, pp. 425-438, (1999); Miller L.G., Clinical pharmacokinetics and clinical pharmacodynamics, Clin Pharmacokinet, 17, pp. 90-108, (1989); Fuhr U., Muller-Peltzer H., Kern R., Effects of grapefruit juice and smoking on verapamil concentrations in steady state, Eur J Clin Pharmacol, 58, pp. 45-53, (2002); Carrillo J.A., Herraiz A.G., Ramos S.I., Role of the smoking induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine, J Clin Psychopharmacol, 23, pp. 119-127, (2003); Aguilar-Bryan L., Clement J.P., Gonzalez G., Kunjilwar K., Babenko A., Bryan J., Toward understanding the assembly and structure of KATP channels, Physiol Rev, 78, pp. 227-245, (1998); Gong B., Yu J., Li H., Li W., Tong X., The effect of KCNJ11 polymorphism on the risk of type 2 diabetes: A global meta-analysis based on 49 case-control studies, DNA Cell Biol, 31, pp. 801-810, (2012); Li Y.Y., The KCNJ11 E23K gene polymorphism and type 2 diabetes mellitus in the Chinese Han population: A meta-analysis of 6,109 subjects, Mol Biol Rep, 40, pp. 141-146, (2013); Koo B.K., Cho Y.M., Park B.L., Cheong H.S., Shin H.D., Jang H.C., Kim S.Y., Lee H.K., Park K.S., Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with type 2 diabetes and hypertension in the Korean population, Diabet Med, 24, pp. 178-186, (2007); Sakamoto Y., Inoue H., Keshavarz P., Miyawaki K., Yamaguchi Y., Moritani M., Kunika K., Nakamura N., Yoshikawa T., Yasui N., Shiota H., Tanahashi T., Itakura M., SNPs in the KCNJ11-ABCC8 gene locus are associated with type 2 diabetes and blood pressure levels in the Japanese population, J Hum Genet, 52, pp. 781-793, (2007); Zhuang L., Zhao Y., Zhao W., Li M., Yu M., Lu M., Zhang R., Ge X., Zheng T., Li C., Yin J., Yin J., Bao Y., Liu L., Jia W., Liu Y., The E23K and A190A variations of the KCNJ11 gene are associated with early-onset type 2 diabetes and blood pressure in the Chinese population, Mol Cell Biochem, 404, pp. 133-141, (2015); Duan R.F., Cui W.Y., Wang H., Association of the antihypertensive response of iptakalim with KCNJ11 (Kir6.2 gene) polymorphisms in Chinese Han hypertensive patients, Acta Pharmacol Sin, 32, pp. 1078-1084, (2011); Goodfriend T.L., Elliott M.E., Catt K.J., Angiotensin receptors and their antagonists, N Engl J Med, 334, pp. 1649-1654, (1996); Riedel M.J., Boora P., Steckley D., De Vries G., Light P.E., Kir6.2 polymorphisms sensitize beta-cell ATP-sensitive potassium channels to activation by acyl CoAs: A possible cellular mechanism for increased susceptibility to type 2 diabetes?, Diabetes, 52, pp. 2630-2635, (2003); Israili Z.H., Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man, Annu Rev Pharmacol Toxicol, 19, pp. 25-52, (1979); Von Bahr C., Collste P., Frisk-Holmberg M., Haglund K., Jorfelt L., Orme M., Ostman J., Sjoqvist F., Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension, Clin Pharmacol Ther, 20, pp. 130-137, (1976); Kroon L.A., Drug interactions with smoking, Am J Health Syst Pharm, 64, pp. 1917-1921, (2007); Zhang S., Liu P., Jiang S., Hong X., Xing H., Xu X., Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension, Methods Find Exp Clin Pharmacol, 27, pp. 173-178, (2005)","S. Jiang; School of Life Sciences, Anhui University, Hefei, China; email: shanqunjiang2014@163.com","","Oxford University Press","","","","","","08957061","","AJHYE","26304961","English","Am. J. Hypertens.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84965121210"
"Stanton A.M.; Heydarpour M.; Williams J.S.; Williams G.H.; Adler G.K.","Stanton, Ana Maria (57274075600); Heydarpour, Mahyar (57192004916); Williams, Jonathan S. (55499948300); Williams, Gordon H. (7406079866); Adler, Gail K. (58825046400)","57274075600; 57192004916; 55499948300; 7406079866; 58825046400","CACNA1D Gene Polymorphisms Associate with Increased Blood Pressure and Salt Sensitivity of Blood Pressure in White Individuals","2023","Hypertension","80","12","","2665","2673","8","2","10.1161/HYPERTENSIONAHA.123.21229","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85177102760&doi=10.1161%2fHYPERTENSIONAHA.123.21229&partnerID=40&md5=d3588b1a720dddc80ad59ac19e5bbb4b","Division of Endocrinology, Diabetes and Hypertension, Brigham and Womeńs Hospital, Harvard Medical School, Boston, MA, United States","Stanton A.M., Division of Endocrinology, Diabetes and Hypertension, Brigham and Womeńs Hospital, Harvard Medical School, Boston, MA, United States; Heydarpour M., Division of Endocrinology, Diabetes and Hypertension, Brigham and Womeńs Hospital, Harvard Medical School, Boston, MA, United States; Williams J.S., Division of Endocrinology, Diabetes and Hypertension, Brigham and Womeńs Hospital, Harvard Medical School, Boston, MA, United States; Williams G.H., Division of Endocrinology, Diabetes and Hypertension, Brigham and Womeńs Hospital, Harvard Medical School, Boston, MA, United States; Adler G.K., Division of Endocrinology, Diabetes and Hypertension, Brigham and Womeńs Hospital, Harvard Medical School, Boston, MA, United States","BACKGROUND: Disease-causing mutations in CACNA1D gene occur in aldosterone-producing adenomas and familial hyperaldosteronism. We determined whether single nucleotide polymorphisms in CACNA1D gene associate with higher aldosterone resulting in salt sensitivity of blood pressure (BP) and increased BP in men and women. METHODS: Data were obtained from the HyperPATH (International Hypertension Pathotypes) cohort, where participants completed a cross-over intervention of liberal and restricted sodium diets. Multi-Ethnic Genotyping Array identified 104 CACNA1D single nucleotide polymorphisms that met quality control. Single nucleotide polymorphism is rs7612148 strongly associated with systolic BP and was selected for study in 521 White participants in 3 scenarios ([1] hypertensives; [2] normotensives; [3] total population=hypertensives+normotensives) using multivariate regression analysis. RESULTS: In the total population and hypertensives, but not normotensives, risk allele carriers (CC, GC), as compared with nonrisk allele homozygotes (GG), exhibited higher salt sensitivity of BP and, on liberal sodium diet, higher systolic BP, lower baseline and angiotensin II-stimulated aldosterone, and lower plasma renin activity. On restricted sodium diet, BP was similar across genotypes, suggesting sodium restriction corrected/neutralized the genotype effect on BP. Because increased aldosterone did not seem to drive the increased salt sensitivity of BP and increased BP on liberal sodium diet, we assessed renal plasma flow. Renal plasma flow increase from restricted to liberal sodium diets was blunted in risk allele homozygotes in the total population and in hypertensives. A replication study in another cohort HyperPATH B (International Hypertension Pathotypes Cohort B) confirmed BP-genotype associations. CONCLUSIONS: CACNA1D rs7612148 risk allele associated with increased BP and salt sensitivity of BP, likely due to an impaired ability to increase renal plasma flow in response to a liberal sodium diet and not to excess aldosterone. © 2023 Lippincott Williams and Wilkins. All rights reserved.","aldosterone; allele; blood pressure; renal plasma flow","Aldosterone; Blood Pressure; Calcium Channels, L-Type; Diet, Sodium-Restricted; Female; Humans; Hypertension; Male; Polymorphism, Single Nucleotide; Renin; Sodium; Sodium Chloride; Sodium Chloride, Dietary; White People; aldosterone; angiotensin II; calcium channel L type; creatinine; L type calcium channel alpha 1D; nitrogen; sodium chloride; unclassified drug; urea; aldosterone; CACNA1D protein, human; calcium channel L type; renin; sodium; sodium chloride; adult; aged; Article; blood sampling; Caucasian; cohort analysis; comparative study; controlled study; creatinine blood level; creatinine urine level; crossover procedure; diastolic blood pressure; female; gain of function mutation; gene frequency; genetic association; genotype; genotyping; heterozygote; homozygote; human; hydrocortisone blood level; hypertension; kidney plasma flow; leukocyte; major clinical study; male; observational study; plasma renin activity; quality control; renin angiotensin aldosterone system; replication study; saluresis; single nucleotide polymorphism; sodium balance; sodium restriction; systolic blood pressure; urea nitrogen blood level; blood pressure; Caucasian; genetics; hypertension; metabolism; salt intake; single nucleotide polymorphism; sodium restriction","","aldosterone, 52-39-1, 6251-69-0; angiotensin II, 11128-99-7, 68521-88-0; creatinine, 19230-81-0, 60-27-5; nitrogen, 7727-37-9; sodium chloride, 7647-14-5, 23724-87-0, 49658-21-1; urea, 57-13-6; renin, 61506-93-2, 9015-94-5; sodium, 7440-23-5; Aldosterone, ; CACNA1D protein, human, ; Calcium Channels, L-Type, ; Renin, ; Sodium, ; Sodium Chloride, ; Sodium Chloride, Dietary, ","Coat-A-Count Radioimmunometric Assay Kit, Siemens, United States; Dinamap, Critikon, United States","Critikon, United States; Siemens, United States","National Institutes of Health, NIH, (K24 HL103845, T32HL007609-34); National Institutes of Health, NIH","This study was conducted with support from the National Institutes of Health: K24 HL103845 (G.K. Adler), T32HL007609-34 (G.K. Adler and A.M. Stanton). ","Monticone S., Burrello J., Tizzani D., Bertello C., Viola A., Buffolo F., Gabetti L., Mengozzi G., Williams T.A., Rabbia F., Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice., J Am Coll Cardiol, 69, pp. 1811-1820, (2017); Mulatero P., Monticone S., Deinum J., Amar L., Prejbisz A., Zennaro M.C., Beuschlein F., Rossi G.P., Nishikawa T., Morganti A., Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension., J Hypertens, 38, pp. 1919-1928, (2020); Vaidya A., Hundemer G.L., Nanba K., Parksook W.W., Brown J.M., Primary aldosteronism: State-of-the-art review., Am J Hypertens, 35, pp. 967-988, (2022); Zennaro M.C., Boulkroun S., Fernandes-Rosa F.L., Pathogenesis and treatment of primary aldosteronism., Nat Rev Endocrinol, 16, pp. 578-589, (2020); Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., Papadopoulos N., Vogiatzis K., Zamboulis C., Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study., Lancet, 371, pp. 1921-1926, (2008); Rossi G.P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M., A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients., J Am Coll Cardiol, 48, pp. 2293-2300, (2006); Fernandes-Rosa F.L., Williams T.A., Riester A., Steichen O., Beuschlein F., Boulkroun S., Strom T.M., Monticone S., Amar L., Meatchi T., Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma., Hypertension, 64, pp. 354-361, (2014); Scholl U.I., Goh G., Stolting G., De Oliveira R.C., Choi M., Overton J.D., Fonseca A.L., Korah R., Starker L.F., Kunstman J.W., Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism., Nat Genet, 45, pp. 1050-1054, (2013); Nanba K., Baker J.E., Blinder A.R., Bick N.R., Liu C.J., Lim J.S., Wachtel H., Cohen D.L., Williams T.A., Reincke M., Histopathology and genetic causes of primary aldosteronism in young adults., J Clin Endocrinol Metab, 107, pp. 2473-2482, (2022); Monticone S., D'Ascenzo F., Moretti C., Williams T.A., Veglio F., Gaita F., Mulatero P., Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis., Lancet Diabetes Endocrinol, 6, pp. 41-50, (2018); Fernandes-Rosa F.L., Boulkroun S., Zennaro M.C., Genetic and genomic mechanisms of primary aldosteronism., Trends Mol Med, 26, pp. 819-832, (2020); Scholl U.I., Genetics of primary aldosteronism., Hypertension, 79, pp. 887-897, (2022); Zennaro M.C., Boulkroun S., Fernandes-Rosa F., Genetic causes of functional adrenocortical adenomas., Endocr Rev, 38, pp. 516-537, (2017); Feng T., Kalyaanamoorthy S., Barakat K., Shad K.F., L-type calcium channels: Structure and functions., Ion Channels in Health and Sickness, (2018); Zamponi G.W., Striessnig J., Koschak A., Dolphin A.C., The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential., Pharmacol Rev, 67, pp. 821-870, (2015); Ortner N.J., Kaserer T., Copeland J.N., Striessnig J., De novo CACNA1D Ca(2+) channelopathies: Clinical phenotypes and molecular mechanism., Pflugers Arch, 472, pp. 755-773, (2020); Pinggera A., Mackenroth L., Rump A., Schallner J., Beleggia F., Wollnik B., Striessnig J., New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy., Hum Mol Genet, 26, pp. 2923-2932, (2017); Chamarthi B., Williams J.S., Williams G.H., A mechanism for salt-sensitive hypertension: Abnormal dietary sodium-mediated vascular response to angiotensin-II., J Hypertens, 28, pp. 1020-1026, (2010); Pojoga L.H., Underwood P.C., Goodarzi M.O., Williams J.S., Adler G.K., Jeunemaitre X., Hopkins P.N., Raby B.A., Lasky-Su J., Sun B., Variants of the caveolin-1 gene: A translational investigation linking insulin resistance and hypertension., J Clin Endocrinol Metab, 96, pp. E1288-E1292, (2011); Elijovich F., Weinberger M.H., Anderson C.A., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L., Salt sensitivity of blood pressure: A scientific statement from the American Heart Association., Hypertension, 68, pp. e7-e46, (2016); Manosroi W., Williams G.H., Genetics of human primary hypertension: Focus on hormonal mechanisms., Endocr Rev, 40, pp. 825-856, (2019); Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: An individual participant-level data meta-analysis., Lancet, 397, pp. 1625-1636, (2021); Dimmitt S.B., Stampfer H.G., Martin J.H., Ferner R.E., Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50., Br J Clin Pharmacol, 85, pp. 2218-2227, (2019); Paz M.A., De-La-Sierra A., Saez M., Barcelo M.A., Rodriguez J.J., Castro S., Lagaron C., Garrido J.M., Vera P., Coll-De-Tuero G., Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement., Medicine (Baltim), 95, (2016); Visser F.W., Boonstra A.H., Titia Lely A., Boomsma F., Navis G., Renal response to angiotensin II is blunted in sodium-sensitive normotensive men., Am J Hypertens, 21, pp. 323-328, (2008); Lu X., Wang L., Lin X., Huang J., Charles Gu C., He M., Shen H., He J., Zhu J., Li H., Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension., Hum Mol Genet, 24, pp. 865-874, (2015); Kamide K., Yang J., Matayoshi T., Takiuchi S., Horio T., Yoshii M., Miwa Y., Yasuda H., Yoshihara F., Nakamura S., Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers., Circ J, 73, pp. 732-740, (2009); Bao M., Li P., Li Q., Chen H., Zhong Y., Li S., Jin L., Wang W., Chen Z., Zhong J., Genetic screening for monogenic hypertension in hypertensive individuals in a clinical setting., J Med Genet, 57, pp. 571-580, (2020); Wang H., Zhu J.K., Cheng L., Mao G., Chen H., Wu X., Hong H., Wang C., Lin P., Chen J., Dominant role of CACNA1D exon mutations for blood pressure regulation., J Hypertens, 40, pp. 819-834, (2022)","A.M. Stanton; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, 221 Longwood Ave, 02115, United States; email: amstanton@bwh.harvard.edu","","Lippincott Williams and Wilkins","","","","","","0194911X","","HPRTD","37846579","English","Hypertension","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85177102760"
"Krishnamoorthy S.; Smith C.D.; Al-Rubaye A.A.; Erf G.F.; Wideman R.F.; Anthony N.B.; Rhoads D.D.","Krishnamoorthy, Sriram (56031274100); Smith, Candace D. (57225867505); Al-Rubaye, Adnan A. (55830598800); Erf, Gisela F. (7004401919); Wideman, Robert F. (7004655938); Anthony, Nicholas B. (7006730702); Rhoads, Douglas D. (7005270349)","56031274100; 57225867505; 55830598800; 7004401919; 7004655938; 7006730702; 7005270349","A quantitative trait locus for ascites on chromosome 9 in broiler chicken lines","2014","Poultry Science","93","2","","307","317","10","12","10.3382/ps.2013-03359","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893771999&doi=10.3382%2fps.2013-03359&partnerID=40&md5=3a9396f9a8b83b413d43db27d309134f","Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States; Department of Biological Sciences, University of Arkansas, Fayetteville 72701, United States; Department of Poultry Sciences, University of Arkansas, Fayetteville 72701, United States","Krishnamoorthy S., Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States; Smith C.D., Department of Biological Sciences, University of Arkansas, Fayetteville 72701, United States; Al-Rubaye A.A., Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States; Erf G.F., Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States, Department of Poultry Sciences, University of Arkansas, Fayetteville 72701, United States; Wideman R.F., Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States, Department of Poultry Sciences, University of Arkansas, Fayetteville 72701, United States; Anthony N.B., Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States, Department of Poultry Sciences, University of Arkansas, Fayetteville 72701, United States; Rhoads D.D., Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States, Department of Biological Sciences, University of Arkansas, Fayetteville 72701, United States","A genome-wide SNP survey was used to identify chromosomal regions that showed linkage disequilibrium with respect to ascites susceptibility and ventricular hypertrophy in an F2 cross between previously described ascites-resistant and -susceptible lines. Variable number tandem repeats were used to obtain genotype data to further characterize these regions. A region on chromosome 9 (12 to 13 Mbp in 2011 assembly) shows association with ascites in the ascites lines and in several commercial broiler breeder lines with a significant sex effect. There are 2 candidate genes, AGTR1 (an angiotensin II type 1 receptor) and UTS2D (urotensin 2 domain containing), in this region that have been associated with hypertension and hypoxic response in mammals. © 2014 Poultry Science Association Inc.","Ascites; Commercial broiler; Hypertension; Quantitative trait locus","Animals; Ascites; Avian Proteins; Cardiomegaly; Chickens; Disease Susceptibility; Genome-Wide Association Study; Linkage Disequilibrium; Peptide Hormones; Polymorphism, Single Nucleotide; Poultry Diseases; Quantitative Trait Loci; Receptor, Angiotensin, Type 1; ascites; commercial broiler; hypertension; quantitative trait locus; angiotensin 1 receptor; avian protein; peptide hormone; animal; animal disease; article; ascites; bird disease; cardiomegaly; chicken; commercial broiler; disease predisposition; gene linkage disequilibrium; genetic association; genetics; hypertension; metabolism; quantitative trait locus; single nucleotide polymorphism","","","","","National Institutes of Health, NIH; National Heart, Lung, and Blood Institute, NHLBI, (R15HL092517); Arkansas Biosciences Institute, ABI, (1R15HL092517–0); Ministry of Higher Education and Scientific Research, MHESR","Anthony and Rhoads contributed equally to the design and direction of this research. Support was provided by grants to Rhoads and Anthony from the Arkansas Biosciences Institute (Little Rock, AR) and Grant number: 1R15HL092517–0 from National Institutes of Health/National Heart Lung Blood Institute (Bethesda, MD) to Wideman. Al-Rubaye was supported by a fellowship from the Iraqi Ministry of Higher Education and Scientific Research (Baghdad, Iraq).","Abraham W.T., Raynolds M.V., Badesch D.B., Wynne K.M., Groves B.M., Roden R.L., Robertson A.D., Lowes B.D., Zisman L.S., Voelkel N.F., Bristow M.R., Perryman M.B., Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: Increased frequency and association with preserved haemodynamics, J. Renin Angiotensin Aldosterone Syst., 4, pp. 27-30, (2003); Anthony N.B., Balog J.M., Divergent selection for ascites: Development of susceptible and resistant lines, Proc, pp. 39-58, (2003); Bailes S., Devers J., Kirby J.D., Rhoads D., An inexpensive, simple protocol for DNA isolation from blood for highthroughput genotyping by polymerase chain reaction or restriction endonuclease digestion, Poult. Sci., 86, pp. 102-106, (2007); Balog J.M., Kidd B.D., Huff W.E., Huff G.R., Rath N.C., Anthony N.B., Effect of cold stress on broilers selected for resistance or susceptibility to ascites syndrome, Poult. Sci., 82, pp. 1383-1387, (2003); Carlborg O., Kerje S., Schutz K., Jacobsson L., Jensen P., Andersson L., A global search reveals epistatic interaction between QTL for early growth in the chicken, Genome Res., 13, pp. 413-421, (2003); Chung W., Deng L., Carroll J., Mallory N., Diamond B., Rosenzweig E., Barst R., Morse J., Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension, J. Heart Lung Transplant., 28, pp. 373-379, (2009); De Greef K., Kwakernaak C., Ducro B., Pit R., Gerritsen C., Evaluation of between-line variation for within-line selection against ascites in broilers, Poult. Sci., 80, pp. 13-21, (2001); Deeb N., Shlosberg A., Cahaner A., Genotype-by-environment interaction with broiler genotypes differing in growth rate. 4. Association between responses to heat stress and to coldinduced ascites, Poult. Sci., 81, pp. 1454-1462, (2002); Druyan S., Ben-David A., Cahaner A., Development of ascites-resistant and ascites-susceptible broiler lines, Poult. Sci., 86, pp. 811-822, (2007); Druyan S., Cahaner A., Segregation among test-cross progeny suggests that two complementary dominant genes explain the difference between ascites-resistant and ascites-susceptible broiler lines, Poult. Sci., 86, pp. 2295-2300, (2007); Druyan S., Hadad Y., Cahaner A., Growth rate of ascitesresistant versus ascites-susceptible broilers in commercial and experimental lines, Poult. Sci., 87, pp. 904-911, (2008); Druyan S., Shinder D., Shlosberg A., Cahaner A., Yahav S., Physiological parameters in broiler lines divergently selected for the incidence of ascites, Poult. Sci., 88, pp. 1984-1990, (2009); Druyan S., Shlosberg A., Cahaner A., Evaluation of growth rate, body weight, heart rate, and blood parameters as potential indicators for selection against susceptibility to the ascites syndrome in young broilers, Poult. Sci., 86, pp. 621-629, (2007); Elton T.S., Sansom S.E., Martin M.M., Cardiovascular disease, single nucleotide polymorphisms; And the renin angiotensin system: Is there a microRNA connection?, Int. J. Hypertens, (2010); Hamal K.R., Wideman R.F., Anthony N.B., Erf G.F., Differential expression of vasoactive mediators in microparticlechallenged lungs of chickens that differ in susceptibility to pulmonary arterial hypertension, Am. J. Physiol. Regul. Integr. Comp. Physiol., 298, (2010); Hamal K.R., Wideman R.F., Anthony N.B., Erf G.F., Differential gene expression of proinflammatory chemokines and cytokines in lungs of ascites-resistant and -susceptible broiler chickens following intravenous cellulose microparticle injection, Vet. Immunol. Immunopathol., 133, pp. 250-255, (2010); Hirose T., Takahashi K., Mori N., Nakayama T., Kikuya M., Ohkubo T., Kohzuki M., Totsune K., Imai Y., Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: Comparison with endothelin-1, Peptides, 30, pp. 1124-1129, (2009); Huchzermeyer F.W., De Ruyck A.C., Van Ark H., Broiler pulmonary hypertension syndrome. III. Commercial broiler strains differ in their susceptibility, Onderstepoort J. Vet. Res., 55, pp. 5-9, (1988); Julian R.J., Physiological, management and environmental triggers of the ascites syndrome: A review, Avian Pathol., 29, pp. 519-527, (2000); Julian R.J., Mirsalimi S.M., Blood oxygen concentration of fast-growing and slow-growing broiler chickens, and chickens with ascites from right ventricular failure, Avian Dis., 36, pp. 730-732, (1992); Ledur M.C., Melo C.M.R., Nones K., Zanella E.L., Ninov K., Bonassi C.A., Jaenisch F.R.F., Moura A.S.A.M.T., Coutinho L.L., Schmidt G.S., Genetic and phenotypic parameters for organs, body and carcass weights, and haematocrit value, in a broiler × layer cross resource population, Proceedings of the 8th World Congress on Genetics Applied to Livestock Production, pp. 7-24, (2006); Lorenzoni A.G., Anthony N.B., Wideman Jr. R.F., Transpulmonary pressure gradient verifies pulmonary hypertension is initiated by increased arterial resistance in broilers, Poult. Sci., 87, pp. 125-132, (2008); Lubritz D.L., Smith J.L., McPherson B.N., Heritability of ascites and the ratio of right to total ventricle weight in broiler breeder male lines, Poult. Sci., 74, pp. 1237-1241, (1995); Moghadam H., McMillan I., Chambers J.R., Julian R.J., Estimation of genetic parameters for ascites syndrome in broiler chickens, Poult. Sci., 80, pp. 844-848, (2001); Muir W.M., Wong G.K.-S., Zhang Y., Wang J., Groenen M.A.M., Crooijmans R.P.M.A., Megens H.-J., Zhang H., Okimoto R., Vereijken A., Jungerius A., Albers G.A.A., Lawley C.T., Delany M.E., Maceachern S., Cheng H.H., Genome-wide assessment of worldwide chicken SNP genetic diversity indicates significant absence of rare alleles in commercial breeds, Proc. Natl. Acad. Sci. USA, 105, pp. 17312-17317, (2008); Nadaf J., Pitel F., Gilbert H., Duclos M.J., Vignoles F., Beaumont C., Vignal A., Porter T.E., Cogburn L.A., Aggrey S.E., Simon J., Le Bihan-Duval E., QTL for several metabolic traits map to loci controlling growth and body composition in an F2 intercross between high- and low-growth chicken lines, Physiol. Genomics, 38, pp. 241-249, (2009); Nakayama T., Hirose T., Totsune K., Mori N., Maruyama Y., Maejima T., Minagawa K., Morimoto R., Asayama K., Kikuya M., Ohkubo T., Hashimoto J., Kohzuki M., Takahashi K., Imai Y., Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure, Peptides, 29, pp. 801-808, (2008); Navarro P., Visscher P.M., Chatziplis D., Koerhuis A.N.M., Haley C.S., Segregation analysis of blood oxygen saturation in broilers suggests a major gene influence on ascites, Br. Poult. Sci., 47, pp. 671-684, (2006); Pakdel A., Van Arendonk J., Vereijken A., Bovenhuis H., Direct and maternal genetic effects for ascites-related traits in broilers, Poult. Sci., 81, pp. 1273-1279, (2002); Pavlidis H.O., Balog J.M., Stamps L.K., Hughes Jr. J.D., Huff W.E., Anthony N.B., Divergent selection for ascites incidence in chickens, Poult. Sci., 86, pp. 2517-2529, (2007); Peacock A.J., Pickett C., Morris K., Reeves J.T., The relationship between rapid growth and pulmonary hemodynamics in fast-growing broiler chicken, Am. Rev. Respir. Dis., 139, pp. 1524-1530, (1989); Rabie T.S.K.M., Crooijmans R.P.M.A., Bovenhuis H., Vereijken A.L.J., Veenendaal T., Van Der Poel J.J., Van Arendonk J.A.M., Pakdel A., Groenen M.A.M., Genetic mapping of quantitative trait loci affecting susceptibility in chicken to develop pulmonary hypertension syndrome, Anim. Genet., 36, pp. 468-476, (2005); Shlosberg A., Bellaiche M., Berman E., Perk S., Deeb N., Neumark E., Cahaner A., Relationship between broiler chicken haematocrit-selected parents and their progeny, with regard to haematocrit, mortality from ascites and bodyweight, Res. Vet. Sci., 64, pp. 105-109, (1998); Shlosberg A., Bellaiche M., Zeitlin G., Ya'Acobi M., Cahaner A., Hematocrit values and mortality from ascites in cold-stressed broilers from parents selected by hematocrit, Poult. Sci., 75, pp. 1-5, (1996); Siwek M., Cornelissen S., Buitenhuis A., Nieuwland M., Bovenhuis H., Crooijmans R., Groenen M., Parmentier H., Van Der Poel J., Quantitative trait loci for body weight in layers differ from quantitative trait loci specific for antibody responses to sheep red blood cells, Poult. Sci., 83, pp. 853-859, (2004); Watanabe T., Kanome T., Miyazaki A., Katagiri T., Human urotensin II as a link between hypertension and coronary artery disease, Hypertens. Res., 29, pp. 375-387, (2006); Wideman R.F., Chapman M., Owens C., Devabhaktuni M., Cavitt L., Wang W., Erf G., Broiler survivors of intravenous micro-particle injections: Evaluation of growth, livability, meat quality, and arterial blood gas values during a cyclic heat challenge, Poult. Sci., 82, pp. 484-495, (2003); Wideman R.F., Erf G., Chapman M., Wang W., Anthony N., Xiaofang L., Intravenous micro-particle injections and pulmonary hypertension in broiler chickens: Acute post-injection mortality and ascites susceptibility, Poult. Sci., 81, pp. 1203-1217, (2002); Wideman R.F., French H., Broiler breeder survivors of chronic unilateral pulmonary artery occlusion produce progeny resistant to pulmonary hypertension syndrome (ascites) induced by cool temperatures, Poult. Sci., 78, pp. 404-411, (1999); Wideman R.F., French H., Ascites resistance of progeny from broiler breeders selected for two generations using chronic unilateral pulmonary artery occlusion, Poult. Sci., 79, pp. 396-401, (2000); Wideman R.F., Kirby Y., Owen R., French H., Chronic unilateral occlusion of an extrapulmonary primary bronchus induces pulmonary hypertension syndrome (ascites) in male and female broilers, Poult. Sci., 76, pp. 400-404, (1997); Wideman R.F., Wing T., Kirby Y., Forman M., Marson N., Tackett C., Ruiz-Feria C., Evaluation of minimally invasive indices for predicting ascites susceptibility in three successive hatches of broilers exposed to cool temperatures, Poult. Sci., 77, pp. 1565-1573, (1998); Wideman R.F., Chapman M.E., Hamal K.R., Bowen O.T., Lorenzoni A.G., Erf G.F., Anthony N.B., An inadequate pulmonary vascular capacity and susceptibility to pulmonary arterial hypertension in broilers, Poult. Sci., 86, pp. 984-998, (2007); Wideman R.F., Kirby Y.K., Evidence of a ventilationperfusion mismatch during acute unilateral pulmonary artery occlusion in broilers, Poult. Sci., 74, pp. 1209-1217, (1995); Wideman R.F., Rhoads D.D., Erf G.F., Anthony N.B., Pulmonary arterial hypertension (ascites syndrome) in broilers: A review, Poult. Sci., 92, pp. 64-83, (2013); Zhou H., Deeb N., Evock-Clover C.M., Ashwell C.M., Lamont S.J., Genome-wide linkage analysis to identify chromosomal regions affecting phenotypic traits in the chicken, II. Body Composition. Poult. Sci., 85, pp. 1712-1721, (2006)","D.D. Rhoads; Program in Cell and Molecular Biology, University of Arkansas, Fayetteville 72701, United States; email: drhoads@uark.edu","","Oxford University Press","","","","","","00325791","","","24570451","English","Poult. Sci.","Article","Final","All Open Access; Green Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-84893771999"
"Guilger-Casagrande M.; de Barros C.T.; Antunes V.A.N.; de Araujo D.R.; Lima R.","Guilger-Casagrande, Mariana (57217233525); de Barros, Cecilia T. (57203278518); Antunes, Vitória A. N. (57222590544); de Araujo, Daniele R. (6701820377); Lima, Renata (6504054154)","57217233525; 57203278518; 57222590544; 6701820377; 6504054154","Perspectives and Challenges in the Fight Against COVID-19: The Role of Genetic Variability","2021","Frontiers in Cellular and Infection Microbiology","11","","598875","","","","13","10.3389/fcimb.2021.598875","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103344087&doi=10.3389%2ffcimb.2021.598875&partnerID=40&md5=eacfe2b0b13c5f9824e410d55836d1cb","Institute of Science and Technology, São Paulo State University–UNESP, Sorocaba, Brazil; Laboratory for Evaluation of the Bioactivity and Toxicology of Nanomaterials, University of Sorocaba-UNISO, Sorocaba, Brazil; Human and Natural Sciences Center, Federal University of ABC, Santo André, Brazil","Guilger-Casagrande M., Institute of Science and Technology, São Paulo State University–UNESP, Sorocaba, Brazil, Laboratory for Evaluation of the Bioactivity and Toxicology of Nanomaterials, University of Sorocaba-UNISO, Sorocaba, Brazil; de Barros C.T., Laboratory for Evaluation of the Bioactivity and Toxicology of Nanomaterials, University of Sorocaba-UNISO, Sorocaba, Brazil; Antunes V.A.N., Laboratory for Evaluation of the Bioactivity and Toxicology of Nanomaterials, University of Sorocaba-UNISO, Sorocaba, Brazil; de Araujo D.R., Human and Natural Sciences Center, Federal University of ABC, Santo André, Brazil; Lima R., Laboratory for Evaluation of the Bioactivity and Toxicology of Nanomaterials, University of Sorocaba-UNISO, Sorocaba, Brazil","In the last year, the advent of the COVID-19 pandemic brought a new consideration for the multidisciplinary sciences. The unknown mechanisms of infection used by SARS-CoV-2 and the absence of effective antiviral pharmacological therapy, diagnosis methods, and vaccines evoked scientific efforts on the COVID-19 outcome. In general, COVID-19 clinical features are a result of local and systemic inflammatory processes that are enhanced by some preexistent comorbidities, such as diabetes, obesity, cardiovascular, and pulmonary diseases, and biological factors, like gender and age. However, the discrepancies in COVID-19 clinical signs observed among those patients lead to investigations about the critical factors that deeply influence disease severity and death. Herein, we present the viral infection mechanisms and its consequences after blocking the angiotensin-converting enzyme 2 (ACE2) axis in different tissues and the progression of inflammatory and immunological reactions, especially the influence of genetic features on those differential clinical responses. Furthermore, we discuss the role of genotype as an essential indicator of COVID-19 susceptibility, considering the expression profiles, polymorphisms, gene identification, and epigenetic modifications of viral entry factors and their recognition, as well as the infection effects on cell signaling molecule expression, which amplifies disease severity. © Copyright © 2021 Guilger-Casagrande, de Barros, Antunes, de Araujo and Lima.","ACE2 receptor; chemokines; coronaviruses; cytokines; immune response; polymorphism; SARS-CoV-2; X chromosome","Angiotensin-Converting Enzyme 2; Antiviral Agents; COVID-19; Cytokines; Humans; Renin-Angiotensin System; Risk Factors; SARS-CoV-2; Spike Glycoprotein, Coronavirus; angiotensin converting enzyme 2; apolipoprotein E; dipeptidyl peptidase IV; interferon regulatory factor 7; proprotein convertase 9; toll like receptor 3; toll like receptor 7; transmembrane protease serine 2; tumor necrosis factor alpha converting enzyme; ACE2 protein, human; antivirus agent; coronavirus spike glycoprotein; cytokine; spike protein, SARS-CoV-2; antibody response; coronavirus disease 2019; diabetes mellitus; disease severity; DNA polymorphism; epigenetic modification; gene expression; gene expression profiling; gene frequency; gene identification; gene mutation; genetic analysis; genetic association; genetic polymorphism; genetic screening; genetic susceptibility; genetic variability; genome-wide association study; genotype; human; hypertension; immune response; immune system; immunomodulation; immunopathology; innate immunity; molecular recognition; mortality; obesity; open reading frame; Review; Severe acute respiratory syndrome coronavirus 2; single nucleotide polymorphism; virus entry; virus infection; virus replication; X chromosome; blood; genetics; immunology; metabolism; pathology; physiology; renin angiotensin aldosterone system; risk factor","","dipeptidyl peptidase IV, 54249-88-6; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, ; tumor necrosis factor alpha converting enzyme, 151769-16-3; ACE2 protein, human, ; Angiotensin-Converting Enzyme 2, ; Antiviral Agents, ; Cytokines, ; Spike Glycoprotein, Coronavirus, ; spike protein, SARS-CoV-2, ","","","Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiço amento de Pessoal de Nı́ l Superior—Brasil; UNISO; University of Sorocaba; Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP, (2017/13328-5, 2019/20303-4, 2020/05816-2); Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP; Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, (307718/2019-0); Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq","Funding text 1: The authors are grateful to University of Sorocaba/UNISO for supporting the publication charges.; Funding text 2: The authors are supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [Grant #2020/05816-2 (MG-C), #2019/20303-4 (DRA) and #2017/13328-5 (RL)], Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq proc 307718/2019-0 (DRA)] and Coordenação de Aperfeiço amento de Pessoal de Nı́ l Superior—Brasil (CAPES)— Finance Code 001 (CTB).","Alisson E., Pesquisadores investigam fatores genéticos de resistência ou suscetibilidade à COVID-19, FAPESP, (2020); Anastassopoulou C., Gkizarioti Z., Patrinos G.P., Tsakris A., Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity, Hum. Genomics, 14, pp. 1-8, (2020); Andersson M., Low N., French N., Greenhalgh T., Jeffery K., Brent A., Et al., Rapid roll out of SARS-CoV-2 antibody testing-a concern, BMJ, 369, (2020); Arvin A.M., Fink K., Schmid M.A., Cathcart A., Spreafico R., Havenar-Daughton C., Et al., Perspective on Potential Antibody-Dependent Enhancement of SARS-CoV-2, Nature, 584, pp. 353-363, (2020); Asselta R., Paraboschi E.M., Mantovani A., Duga S., ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy, Aging, 12, pp. 10087-10098, (2020); Billi A.C., Kahlenberg J.M., Gudjonsson J.E., Sex bias in autoimmunity, Curr. Opin. Rheumatol, 31, pp. 53-61, (2019); Bournazos S., Ravetch J.V., Anti-retroviral antibody FcγR-mediated effector functions, Immunol. Rev, 275, pp. 285-295, (2017); Bournazos S., Gupta A., Ravetch J.V., The role of IgG Fc receptors in antibody-dependent enhancement, Nat. Rev. Immunol, 20, pp. 633-643, (2020); Brennan M.F., Foey A.D., Cytokine Regulation in RA Synovial Tissue: Role of T Cell/Macrophage Contact-Dependent Interactions, Arthritis Res, 4, pp. 177-182, (2002); Brest P., Refae S., Mograbi B., Hofman P., Milano G., Host Polymorphisms May Impact SARS-CoV-2 Infectivity, Trends Genet, 36, pp. 813-815, (2020); Britton T., Ball F., Trapman P., A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2, Science, 369, pp. 846-849, (2020); Bunyavanich S., Do A., Vicencio A., Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults, JAMA, 323, (2020); Bupp M.R.G., Jorgensen T.N., Androgen-induced immunosuppression, Front. Immunol, 9, (2018); Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X., Et al., Comparative genetic analysis of the novel coronavirus, (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov, 6, pp. 1-4, (2020); Carter L.J., Garner L.V., Smoot J.W., Li Y., Zhou Q., Saveson C.J., Et al., Assay Techniques and Test Development for COVID-19 Diagnosis, ACS Cent. Sci, 6, pp. 591-605, (2020); Casanova J.L., Su H.C., A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection, Cell, 181, pp. 1194-1199, (2020); Catanzaro M., Fagiani F., Racchi M., Corsini E., Govoni S., Lanni C., Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2, Signal Transduct. Target. Ther, 5, pp. 1-10, (2020); Chua R.L., Lukassen S., Trump S., Hennig B.P., Wendisch D., Pott F., Et al., COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis, Nat. Biotechnol, 38, pp. 970-979, (2020); Devaux C.A., Rolain J.M., Raoult D., ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome, J. Microbiol. Immunol. Infect, 53, pp. 425-435, (2020); Dhochak N., Singhal S., Kabra S.K., Lodha R., Pathophysiology of COVID-19: Why Children Fare Better than Adults, Indian J. Pediatr, 14, pp. 1-10, (2020); Du Y., Tu L., Zhu P., Mu M., Wang R., Yang P., Et al., Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study, Am. J. Respir. Care Med, 201, pp. 1372-1379, (2020); Elgueta R., Benson M.J., De Vries V.C., Wasiuk A., Guo Y., Noelle R.J., Molecular mechanism and function of CD40/CD40L engagement in the immune system, Immunol. Rev, 229, pp. 152-172, (2009); Fink A.L., Klein S.L., Sex and gender impact immune responses to vaccines among the elderly, Physiology, 30, pp. 408-416, (2015); Fink A.L., Engle K., Ursin R.L., Tang W.Y., Klein S.L., Biological sex affects vaccine efficacy and protection against influenza in mice, PNAS, 115, pp. 12477-12482, (2018); Gemmati D., Bramanti B., Serino M.L., Secchiero P., Zauli G., Tisato V., COVID-19 and individual genetic susceptibility/receptivity: Role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double x-chromosome in females be protective against SARS-COV-2 compared to the single x-chromosome in males, Int. J. Mol. Sci, 21, pp. 1-23, (2020); GeurtsvanKessel C.H., Okba N.M.A., Igloi Z., Bogers S., Embregts C.W.E., Laksono B.M., Et al., An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment, Nat. Commun, 11, (2020); Ghafouri-Fard S., Noroozi R., Vafaee R., Branicki W.,  Pospiech E., Pyrc K., Et al., Effects of host genetic variations on response to, susceptibility and severity of respiratory infections, Biomed. Pharmacother, 128, (2020); Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., Et al., Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2, Circ. Res, 126, pp. 1456-1474, (2020); Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Et al., Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure, Cell Host Microbe, 27, pp. 992-1000, (2020); Gkogkou E., Barnasas G., Vougas K., Trougakos I.P., Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators, Redox Biol, 36, (2020); Goker H., Aladag-Karakulak E., Demiroglu H., Ayaz C.M., Buyukasik Y., Inkaya A.C., Et al., The effects of blood group types on the risk of COVID-19 infection and its clinical outcome, Turk. J. Med. Sci, 50, pp. 679-683, (2020); Gomez J., Albaiceta G.M., Garcia-Clemente M., Lopez-Larrea C., Amado-Rodriguez L., Lopez-Alonso I., Et al., Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome, Gene, 762, (2020); Gottipati S., Rao N.L., Fung-Leung W.P., IRAK1: A critical signaling mediator of innate immunity, Cell. Signal, 20, pp. 269-276, (2008); Gou W., Fu Y., Yue L., Chen G., Cai X., Shuai M., Et al., Gut microbiota may underlie the predisposition of healthy individuals to COVID-19, medRxiv, (2020); Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell, 181, pp. 1489-1501, (2020); Guillon P., Clement M., Sebille V., Rivain J.G., Chou C.F., Ruvoen-Clouet N., Et al., Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies, Glycobiology, 18, pp. 1085-1093, (2008); Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P., Et al., ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection, Nat. Immunol, 21, pp. 1293-1301, (2020); Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., Van Goor H., Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis, J. Pathol, 203, pp. 631-637, (2004); Hargreaves C.E., Rose-Zerilli M.J., Machado L.R., Iriyama C., Hollox E.J., Cragg M.S., Et al., Fcgamma receptors: genetic variation, function, and disease, Immunol. Rev, pp. 6-24, (2015); Hirano T., Murakami M., COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome, Immunity, 52, pp. 731-733, (2020); Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, pp. 271-280, (2020); Hou Y., Zhao J., Martin W., Kallianpur A., Chung M.K., Jehi L., Et al., New insights into genetic susceptibility of COVID-19: An ACE2 and TMPRSS2 polymorphism analysis, BMC Med, 18, (2020); Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Et al., Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China, Lancet, 395, pp. 497-506, (2020); Hunter C.A., Jones S.A., IL-6 as a Keystone Cytokine in Health and Disease, Nat. Immunol, 16, pp. 448-457, (2015); Hussain M., Jabeen N., Raza F., Shabbir S., Baig A.A., Amanullah A., Et al., Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein, J. Med. Virol, 92, pp. 1580-1586, (2020); Jaillon S., Berthenet K., Garlanda C., Sexual Dimorphism in Innate Immunity, Clin. Rev. Allergy Immunol, 56, pp. 308-321, (2019); Jin J.M., Bai P., He W., Wu F., Liu X.F., Han D.M., Et al., Gender Differences in Patients With COVID-19: Focus on Severity and Mortality, Front. Public Heal, 8, (2020); Kissick H.T., Sanda M.G., Dunn L.K., Pellegrini K.L., On S.T., Noel J.K., Et al., Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation, PNAS, 111, pp. 9887-9892, (2014); Klein S.L., Flanagan K.L., Sex differences in immune responses, Nat. Rev. Immunol, 16, pp. 626-638, (2016); Klein S.L., Pekosz A., Sex-based biology and the rational design of influenza vaccination strategies, J. Infect. Dis, 209, pp. 114-119, (2014); Klein A., Slipping Racism into the Mainstream: A Theory of Information Laundering, Commun. Theory, 22, pp. 427-448, (2012); Kuo C.L., Pilling L.C., Atkins J.L., Masoli J.A.H., Delgado J., Kuchel G.A., Et al., APOE e4 genotype predicts severe COVID-19 in the UK biobank community cohort, J. Gerontol. A Biol. Sci. Med. Sci, 75, pp. 2231-2232, (2020); Lai J.J., Lai K.P., Zeng W., Chuang K.H., Altuwaijri S., Chang C., Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: Lessons from conditional AR knockout mice, Am. J. Pathol, 181, pp. 1504-1512, (2012); Lambert N.C., Nonendocrine mechanisms of sex bias in rheumatic diseases, Nat. Rev. Rheumatol, 15, pp. 673-686, (2019); Latini A., Agolini E., Novelli A., Borgiani P., Giannini R., Gravina P., Et al., COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells, Genes, 11, pp. 1-8, (2020); Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., SARS-CoV-2-Specific T Cell Immunity in Cases of COVID-19 and SARS, and Uninfected Controls, Nature, 584, pp. 457-462, (2020); Lee W.S., Wheatley A.K., Kent S.J., Dekosky B.J., Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies, Nat. Microbiol, 5, pp. 1185-1191, (2020); Li Y., Cui L.L., Li Q.Q., Ma G.D., Cai Y.J., Chen Y.Y., Et al., Association between ADAM17 promoter polymorphisms and ischemic stroke in a Chinese population, J. Atheroscler. Thromb, 21, pp. 878-893, (2014); Li M.Y., Li L., Zhang Y., Wang X.S., Expression of the SARS-CoV-2 Cell Receptor Gene ACE2 in a Wide Variety of Human Tissues, Infect. Dis. Poverty, 9, pp. 1-7, (2020); Li Y., Jerkic M., Slutsky A.S., Zhang H., Molecular mechanisms of sex bias differences in COVID-19 mortality, Crit. Care, 24, (2020); Li Y., Zhang Z., Yang L., Lian X., Xie Y., Li S., Et al., The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike, iScience, 23, pp. 1-8, (2020); Libert C., Dejager L., Pinheiro I., The X chromosome in immune functions: When a chromosome makes the difference, Nat. Rev. Immunol, 10, pp. 594-604, (2010); Lin M., Tseng H.K., Trejaut J.A., Lee H.L., Loo J.H., Chu C.C., Et al., Association of HLA class I with severe acute respiratory syndrome coronavirus infection, BMC Med. Genet, 4, pp. 1-7, (2003); Liu M.Y., Zheng B., Zhang Y., Li J.P., Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019, Chronic Dis. Transl. Med, 6, pp. 98-105, (2020); Long Q.X., Tang X.J., Shi Q.L., Li Q., Deng H.J., Yuan J., Et al., Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections, Nat. Med, 26, pp. 1200-1204, (2020); Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Et al., Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding, Lancet, 395, pp. 565-574, (2020); Lu L., Zhang H., Zhan M., Jiang J., Yin H., Dauphars D.J., Et al., Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm, Front. Cell Dev. Biol, 8, (2020); Luo Y., Liu C., Guan T., Li Y., Lai Y., Li F., Et al., Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang, Hypertens. Res, 42, pp. 681-689, (2019); Mahallawi W.H., Khabour O.F., Zhang Q., Makhdoum H.M., Suliman B.A., MERS-CoV Infection in Humans Is Associated with a pro-Inflammatory Th1 and Th17 Cytokine Profile, Cytokine, 104, pp. 8-13, (2018); Mahmoudabadi G., Phillips R., A Comprehensive and Quantitative Exploration of Thousands of Viral Genomes, ELife, 7, pp. 1-16, (2018); Mahmudpour M., Roozbeh J., Keshavarz M., Farrokhi S., Nabipour I., COVID-19 Cytokine Storm: The Anger of Inflammation, Cytokine, 133, (2020); Malard L., Kakinami L., O'Loughlin J., Roy-Gagnon M.H., Labbe A., Pilote L., Et al., The association between the angiotensin-converting enzyme-2 gene and blood pressure in a cohort study of adolescents, BMC Med. Genet, 14, (2013); Mangalmurti N., Hunter C.A., Cytokine Storms: Understanding COVID-19, Immunity, 53, pp. 19-25, (2020); Mauvais-Jarvis F., Bairey Merz N., Barnes P.J., Brinton R.D., Carrero J.J., DeMeo D.L., Et al., Sex and gender: modifiers of health, disease, and medicine, Lancet, 396, pp. 565-582, (2020); Mehta P., McAuley D., Brown M., Sanchez E., Tattersall R.S., Manson J.J., COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression, Lancet, 395, pp. 1033-1034, (2020); Meier A., Chang J.J., Chan E.S., Pollard R.B., Sidhu H.K., Kulkarni S., Et al., Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1, Nat. Med, 15, pp. 955-959, (2009); Mercer F., Unutmaz D., The biology of FoxP3: AKey player in immune suppression during infections, autoimmune diseases and cancer, Adv. Exp. Med. Biol, 665, pp. 47-59, (2009); Monkemuller K., Fry L.C., Rickes S., Covid-19, Coronavirus, SARS-CoV-2 and the small bowel, Rev. Esp. Enferm. Dig, 112, pp. 383-388, (2020); Moore J.B., June C.H., Cytokine Release Syndrome in Severe COVID-19, Science, 368, pp. 473-474, (2020); Muecksch F., Wise H., Batchelor B., Squires M., Semple E., Richardson C., Et al., Longitudinal Analysis of Clinical Serology Assay Performance and Neutralising Antibody Levels in COVID19 Convalescents, J. Infect. Dis, 223, pp. 389-398, (2020); Nguyen A., David J.K., Maden S.K., Wood M.A., Weeder B.R., Nellore A., Et al., Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2, J. Virol, 94, pp. 1-12, (2020); Olsen N.J., Kovacs W.J., Effects of androgens on T and B lymphocyte development, Immunol. Res, 23, pp. 281-288, (2001); Ortiz-Fernandez L., Sawalha A.H., Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations, Genes Immun, 21, pp. 269-272, (2020); Parham P., Moffett A., Variable NK cell receptors and their MHC class i ligands in immunity, reproduction and human evolution, Nat. Rev. Immunol, 13, pp. 133-144, (2013); Pati A., Mahto H., Padhi S., Panda A.K., ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population, Clin. Chim. Acta, 510, pp. 455-458, (2020); Patnaik M., Pati P., Swain S.N., Mohapatra M.K., Dwibedi B., Kar S.K., Et al., Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India, Ann. Hum. Biol, 41, pp. 145-152, (2014); Pessach I.M., Notarangelo L.D., X-linked primary immunodeficiencies as a bridge to better understandingX-chromosome related autoimmunity, J. Autoimmun, 33, pp. 17-24, (2009); Pinheiro D.S., Santos R.S., Veiga Jardim P.C.B., Silva E.G., Reis A.A.S., Pedrino G.R., Et al., The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients, PloS One, 14, (2019); Pollan M., Perez-Gomez B., Pastor-Barriuso R., Oteo J., Hernan M.A., Perez-Olmeda M., Et al., Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A Nationwide, Population-Based Seroepidemiological Study, Lancet, 396, (2020); Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Et al., Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China, Clin. Infect. Dis, 71, pp. 762-768, (2020); Radzikowska U., Ding M., Tan G., Zhakparov D., Peng Y., Wawrzyniak P., Et al., Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors, Allergy, 75, pp. 2829-2845, (2020); Rainville J.R., Tsyglakova M., Hodes G.E., Deciphering sex differences in the immune system and depression, Front. Neuroendocrinol, 50, pp. 67-90, (2018); Ren L.L., Wang Y.M., Wu Z.Q., Xiang Z.C., Guo L., Xu T., Et al., Identification of a Novel Coronavirus Causing Severe Pneumonia in Human: A Descriptive Study, Chin. Med. J, 133, pp. 1015-1024, (2020); Risitano A.M., Mastellos D.C., Huber-Lang M., Yancopoulou D., Garlanda C., Ciceri F., Et al., Complement as a Target in COVID-19, Nat. Rev. Immunol, 20, pp. 342-344, (2020); Rosado J., Pelleau S., Cockram C., Merkling S.H., Nekkab N., Demeret C., Et al., Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study, Lancet Microbe, 2, pp. e60-e69, (2020); Roshanravan N., Ghaffari S., Hedayati M., Angiotensin Converting Enzyme-2 as Therapeutic Target in COVID-19, Diabetes Metab. Syndr, 14, pp. 637-639, (2020); Roy S., Mazumder T., Banik S., The Association of Cardiovascular Diseases and Diabetes Mellitus with COVID-19 (SARS-CoV-2) and Their Possible Mechanisms, SN Compr. Clin. Med, 2, pp. 1077-1082, (2020); Saponaro F., Rutigliano G., Sestito S., Bandini L., Storti B., Bizzarri R., Et al., ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives, Front. Mol. Biosci, 7, (2020); Scheller J., Rose-John S., Interleukin-6 and Its Receptor: From Bench to Bedside, Med. Microbiol. Immunol, 195, pp. 173-183, (2006); Schurz H., Salie M., Tromp G., Hoal E.G., Kinnear C.J., Moller M., The X chromosome and sex-specific effects in infectious disease susceptibility, Hum. Genomics, 13, pp. 1-12, (2019); Scully E.P., Haverfield J., Ursin R.L., Tannenbaum C., Klein S.L., Considering how biological sex impacts immune responses and COVID-19 outcomes, Nat. Rev. Immunol, 20, pp. 442-447, (2020); Sen R., Garbati M.R., Bryant K., Lu Y., Epigenetic Mechanisms Influencing COVID-19, Genome, pp. 1-38, (2021); Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K.J.A., Et al., Longitudinal Evaluation and Decline of Antibody Responses in SARS-CoV-2 Infection, Nat. Microbiol, 5, pp. 1598-1607, (2020); South A.M., Tomlinson T., Edmonston D., Hiremath S., Sparks M.A., Controversies of Renin–Angiotensin System Inhibition during the COVID-19 Pandemic, Nat. Rev. Nephrol, 16, pp. 305-307, (2020); Souyris M., Cenac C., Azar P., Daviaud D., Canivet A., Grunenwald S., Et al., TLR7 escapes X chromosome inactivation in immune cells, Sci. Immunol, 3, (2018); Sperry J.L., Zolin S., Zuckerbraun B.S., Vodovotz Y., Namas R., Neal M.D., Et al., X chromosome-linked IRAK-1 polymorphism is a strong predictor of multiple organ failure and mortality postinjury, Ann. Surg, 260, pp. 698-705, (2014); Spolarics Z., Pena G., Qin Y., Donnelly R.J., Livingston D.H., Inherent X-linked genetic variability and cellular mosaicism unique to females contribute to sex-related differences in the innate immune response, Front. Immunol, 8, (2017); Stokes E.K., Zambrano L.D., Anderson K.N., Marder E.P., Raz K.M., El Burai Felix S., Et al., Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020, MMWR, 69, pp. 759-765, (2020); Sun D., Zhang D., Tian R., Li Y., Wang Y., Cao J., Et al., The Underlying Changes and Predicting Role of Peripheral Blood Inflammatory Cells in Severe COVID-19 Patients: A Sentinel, Clin. Chim. Acta, 508, pp. 122-129, (2020); Tan M., Liu Y., Zhou R., Deng X., Li F., Liang K., Et al., Immunopathological Characteristics of Coronavirus Disease 2019 Cases in Guangzhou, China, Immunology, 160, pp. 261-268, (2020); Tan W., Lu Y., Zhang J., Wang J., Dan Y., Tan Z., Et al., Viral Kinetics and Antibody Responses in Patients with COVID-19, MedRxiv, (2020); Taylor A., Foo S.S., Bruzzone R., Dinh L.V., King N.J.C., Mahalingam S., Fc Receptors in Antibody-Dependent Enhancement of Viral Infections, Immunol. Rev, 268, pp. 340-364, (2015); Genomewide Association Study of Severe Covid-19 with Respiratory Failure, N. Engl. J. Med, 383, pp. 1522-1534, (2020); Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G., Into the Eye of the Cytokine Storm, Microbiol. Mol. Biol. Rev, 76, pp. 16-32, (2012); Tolouian R., Vahed S.Z., Ghiyasvand S., Tolouian A., Ardalan M., COVID-19 Interactions with Angiotensin-Converting Enzyme 2 (ACE2) and the Kinin System; Looking at a Potential Treatment, J. Renal Inj. Prev, 9, (2020); Torcia M.G., Nencioni L., Clemente A.M., Civitelli L., Celestino I., Limongi D., Et al., Sex Differences in the Response to Viral Infections: TLR8 and TLR9 Ligand Stimulation Induce Higher IL10 Production in Males, PloS One, 7, (2012); Ulhaq Z.S., Soraya G.V., Interleukin-6 Is a Potential Biomarker of COVID-19 Progression: Evidence from a Meta-Analysis, Med. Mal. Infect, 50, pp. 381-383, (2020); Valencia I., Peiro C., Lorenzo O., Sanchez-Ferrer C.F., Eckel J., Romacho T., DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications, Front. Pharmacol, 11, (2020); van der Made C.I., Simons A., Schuurs-Hoeijmakers J., Van Den Heuvel G., Mantere T., Kersten S., Et al., Presence of Genetic Variants among Young Men with Severe COVID-19, JAMA, 324, pp. 663-673, (2020); Vargas-Alarcon G., Posadas-Sanchez R., Ramirez-Bello J., Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies, Life Sci, 260, (2020); Verdecchia P., Cavallini C., Spanevello A., Angeli F., The Pivotal Link between ACE2 Deficiency and SARS-CoV-2 Infection, Eur. J. Intern. Med, 76, pp. 14-20, (2020); Coronaviridae, (2020); Vodnar D.C., Mitrea L., Teleky B.E., Szabo K., Calinoiu L.F., Nemes S.A., Et al., Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota, Front. Cell. Infect. Microbiol, 10, (2020); vom Steeg L.G., Klein S.L., SeXX Matters in Infectious Disease Pathogenesis, PLoS Pathog, 12, (2016); Wang Q., Zhang Y., Wu L., Niu S., Song C., Zhang Z., Et al., Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2, Cell, 181, pp. 894-904, (2020); Wang X., Lam J.Y., Wong W.M., Yuen C.K., Cai J.P., Wing-Ngor Au S., Et al., Accurate diagnosis of covid-19 by a novel immunogenic secreted sars-cov-2 orf8 protein, mBio, 11, pp. e02431-e02420, (2020); Wang F., Huang S., Gao R., Zhou Y., Lai C., Li Z., Et al., Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility, Cell Discov, 6, (2020); Situation report - 1: Novel Coronavirus, (2019-nCoV), (2020); WHO Coronavirus Disease (COVID-19) Dashboard, (2021); Wong C.K., Lam C.W.K.A., Wu A.K.L., Ip W.K., Lee N.L.S., Chan I.H.S., Et al., Plasma Inflammatory Cytokines and Chemokines in Severe Acute Respiratory Syndrome, Clin. Exp. Immunol, 136, pp. 95-103, (2004); Wong S.H., Lui R.N.S., Sung J.J.Y., Covid-19 and the digestive system, J. Gastroenterol. Hepatol, 35, pp. 744-748, (2020); Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Et al., Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation, Science, 367, pp. 1260-1263, (2020); Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Et al., High Expression of ACE2 Receptor of 2019-NCoV on the Epithelial Cells of Oral Mucosa, Int. J. Oral. Sci, 12, pp. 1-5, (2020); Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q., Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2, Science, 367, pp. 1444-1448, (2020); Yi C., Sun X., Ye J., Deng L., Liu M., Yang Z., Et al., Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies, Cell Mol. Immunol, 17, pp. 621-630, (2020); Zeberg H., Paabo S., The major genetic risk factor for severe COVID-19 is inherited from Neandertals Authors, Nature, 587, pp. 610-612, (2020); Zhang B., Zhou X., Qiu Y., Song Y., Feng F., Feng J., Et al., Clinical Characteristics of 82 Death Cases with COVID-19, PLoS One, 15, (2020); Zhang H., Kang Z., Gong H., Xu D., Wang J., Li Z., Et al., Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process, Gut, 69, pp. 1010-1018, (2020); Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Et al., Inborn errors of type I IFN immunity in patients with life-threatening COVID19, Science, 370, (2020); Zhao Y., Zhao Z., Wang Y., Zhou Y., Ma Y., Zuo W., Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2, Am. J. Respir. Crit. Care Med, 202, pp. 756-759, (2020); Zheng J., SARS-CoV-2: An Emerging Coronavirus That Causes a Global Threat, Int. J. Biol. Sci, 16, pp. 1678-1685, (2020); Zhou X., Yu S., Zhao D.M., Harty J.T., Badovinac V.P., Xue H.H., Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1, Immunity, 33, pp. 229-240, (2010); Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Et al., A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin, Nature, 579, pp. 270-273, (2020); Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., Et al., SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues, Cell, 181, pp. 1016-1035, (2020); Zietz M., Zucker J., Tatonetti N., Associations between blood type and COVID-19 infection, intubation, and death, Nat Comm, 11, pp. 1-6, (2020)","","","Frontiers Media S.A.","","","","","","22352988","","","33791232","English","Front. Cell. Infect. Microbiol.","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85103344087"
"Pagliari S.; Tirella A.; Ahluwalia A.; Duim S.; Goumans M.-J.; Aoyagi T.; Forte G.","Pagliari, Stefania (25629799600); Tirella, Annalisa (36097450400); Ahluwalia, Arti (7004369208); Duim, Sjoerd (55228779100); Goumans, Marie-Josè (6701388504); Aoyagi, Takao (7202167350); Forte, Giancarlo (7004240474)","25629799600; 36097450400; 7004369208; 55228779100; 6701388504; 7202167350; 7004240474","A multistep procedure to prepare pre-vascularized cardiac tissue constructs using adult stem sells, dynamic cell cultures, and porous scaffolds","2014","Frontiers in Physiology","5 JUN","","210","","","","24","10.3389/fphys.2014.00210","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904427920&doi=10.3389%2ffphys.2014.00210&partnerID=40&md5=8dc496b77b8eb22cb35112bf88a10051","Biomaterials Unit, International Center for Materials Nanoarchitectonics, National Institute for Materials Science, Tsukuba, Japan; International Clinical Research Center, Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne's University Hospital, 65691 Brno, Pekarska 53, Czech Republic; Interdepartmental Research Center E. Piaggio, University of Pisa, Italy; Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy; Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands","Pagliari S., Biomaterials Unit, International Center for Materials Nanoarchitectonics, National Institute for Materials Science, Tsukuba, Japan, International Clinical Research Center, Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne's University Hospital, 65691 Brno, Pekarska 53, Czech Republic; Tirella A., Interdepartmental Research Center E. Piaggio, University of Pisa, Italy, Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy; Ahluwalia A., Interdepartmental Research Center E. Piaggio, University of Pisa, Italy, Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy; Duim S., Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands; Goumans M.-J., Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands; Aoyagi T., Biomaterials Unit, International Center for Materials Nanoarchitectonics, National Institute for Materials Science, Tsukuba, Japan; Forte G., Biomaterials Unit, International Center for Materials Nanoarchitectonics, National Institute for Materials Science, Tsukuba, Japan, International Clinical Research Center, Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne's University Hospital, 65691 Brno, Pekarska 53, Czech Republic","The vascularization of tissue engineered products represents a key issue in regenerative medicine which needs to be addressed before the translation of these protocols to the bedside can be foreseen. Here we propose a multistep procedure to prepare pre-vascularized three-dimensional (3D) cardiac bio-substitutes using dynamic cell cultures and highly porous biocompatible gelatin scaffolds. The strategy adopted exploits the peculiar differentiation potential of two distinct subsets of adult stem cells to obtain human vascularized 3D cardiac tissues. In the first step of the procedure, human mesenchymal stem cells (hMSCs) are seeded onto gelatin scaffolds to provide interconnected vessel-like structures, while human cardiomyocyte progenitor cells (hCMPCs) are stimulated in vitro to obtain their commitment toward the cardiac phenotype. The use of a modular bioreactor allows the perfusion of the whole scaffold, providing superior performance in terms of cardiac tissue maturation and cell survival. Both the cell culture on natural-derived polymers and the continuous medium perfusion of the scaffold led to the formation of a densely packaged proto-tissue composed of vascular-like and cardiac-like cells, which might complete maturation process and interconnect with native tissue upon in vivo implantation. In conclusion, the data obtained through the approach here proposed highlight the importance to provide stem cells with complementary signals in vitro able to resemble the complexity of cardiac microenvironment. © 2014 Pagliari, Tirella, Ahluwalia, Duim, Goumans, Aoyagi and Forte.","Adult stem cells; Cardiac tissue engineering; Dynamic culture; Patient-derived stem cells; Vascularized three-dimensional (3D) scaffolds","angiotensin converting enzyme 2; ACE2 gene; article; blood pressure regulation; disease model; enzyme activity; enzyme inhibition; enzyme polymorphism; gene deletion; gene interaction; gene overexpression; genetic association; genetic variability; human; hypertension; nonhuman; pathogenesis; phenotype; single nucleotide polymorphism; treatment response","","","","","","","Abramoff M.D., Magalhaes P.J., Ram S.J., Image processing with ImageJ, Biophoton. Int., 11, pp. 36-42, (2004); Akhyari P., Fedak P.W., Weisel R.D., Lee T.Y., Verma S., Mickle D.A., Et al., Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts, Circulation, 106, (2002); Bai K., Huang Y., Jia X., Fan Y., Wang W., Endothelium oriented differentiation of bone marrow mesenchymal stem cells under chemical and mechanical stimulations, J. Biomech., 43, pp. 1176-1181, (2010); Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., Et al., Adult cardiac stem cells are multipotent and support myocardial regeneration, Cell, 114, pp. 763-776, (2003); Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., Et al., Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial, Lancet, 378, pp. 1847-1857, (2011); Boschetti F., Raimondi M.T., Migliavacca F., Dubini G., Prediction of the micro-fluid dynamic environment imposed to three-dimensional engineered cell systems in bioreactors, J. Biomech., 39, pp. 418-425, (2006); Brannon-Peppas L., Peppas N.A., Dynamic and equilibrium swelling behaviour of pH-sensitive hydrogels containing 2-hydroxyethyl methacrylate, Biomaterials, 11, pp. 635-644, (1990); Bround M.J., Asghari P., Wambolt R.B., Bohunek L., Smits C., Philit M., Et al., Cardiac ryanodine receptors control heart rate and rhythmicity in adult mice, Cardiovasc. Res., 96, pp. 372-380, (2012); Burdick J.A., Vunjak-Novakovic G., Engineered microenvironments for controlled stem cell differentiation, Tissue Eng. Part A, 15, pp. 205-219, (2009); Caspi O., Lesman A., Basevitch Y., Gepstein A., Arbel G., Habib I.H., Et al., Tissue engineering of vascularized cardiac muscle from human embryonic stem cells, Circ. Res., 100, pp. 263-272, (2007); Chiu L.L., Radisic M., Scaffolds with covalently immobilized VEGF and angiopoietin-1 for vascularization of engineered tissues, Biomaterials, 31, pp. 226-241, (2010); Cimetta E., Flaibani M., Mella M., Serena E., Boldrin L., De Coppi P., Et al., Enhancement of viability of muscle precursor cells on 3D scaffold in a perfusion bioreactor, Int. J. Artif. Organs, 30, pp. 415-428, (2007); Cipolleschi M.G., Dello Sbarba P., Olivotto M., The role of hypoxia in the maintenance of hematopoietic stem cells, Blood, 82, pp. 2031-2037, (1993); Dreesmann L., Ahlers M., Schlosshauera B., The pro-angiogenic characteristics of a cross-linked gelatin matrix, Biomaterials, 28, pp. 5536-5543, (2007); Dubois C., Liu X., Claus P., Marsboom G., Pokreisz P., Vandenwijngaert S., Et al., Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction, J. Am. Coll. Cardiol., 55, pp. 2232-2243, (2010); Dvir T., Kedem A., Ruvinov E., Levy O., Freeman I., Landa N., Et al., Prevascularization of cardiac patch on the omentum improves its therapeutic outcome, Proc. Natl. Acad. Sci. U.S.A., 106, pp. 14990-14995, (2009); Engler A.J., Rehfeldt F., Sen S., Discher D.E., Microtissue elasticity: measurements by atomic force microscopy and its influence on cell differentiation, Methods Cell Biol., 83, pp. 521-545, (2007); Engler A.J., Sen S., Sweeney H.L., Discher D.E., Matrix elasticity directs stem cell lineage specification, Cell, 126, pp. 677-689, (2006); Forte G., Pagliari S., Pagliari F., Ebara M., Di Nardo P., Aoyagi T., Towards the generation of patient-specific patches for cardiac repair, Stem Cell Rev., 9, pp. 313-325, (2013); Forte G., Pietronave S., Nardone G., Zamperone A., Magnani E., Pagliari S., Et al., Human cardiac progenitor cell grafts as unrestricted source of super-numerary cardiac cells in healthy murine hearts, Stem Cells, 29, pp. 2051-2061, (2011); Gaetani R., Doevendans P.A., Metz C.H., Alblas J., Messina E., Giacomello A., Et al., Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells, Biomaterials, 33, pp. 1782-1790, (2012); Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., Et al., Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells, Nat. Med., 11, pp. 367-368, (2005); Gnecchi M., Zhang Z., Ni A., Dzau V.J., Paracrine mechanisms in adult stem cell signaling and therapy, Circ. Res., 103, pp. 1204-1219, (2008); Goumans M.J., de Boer T.P., Smits A.M., van Laake L.W., van Vliet P., Metz C.H., Et al., TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro, Stem Cell Res., 1, pp. 138-149, (2007); Haraguchi Y., Shimizu T., Yamato M., Kikuchi A., Okano T., Electrical coupling of cardiomyocyte sheets occurs rapidly via functional gap junction formation, Biomaterials, 27, pp. 4765-4774, (2006); Heng B.C., Haider H.K., Sim E.K., Cao T., Ng S.C., Strategies for directing the differentiation of stem cells into the cardiomyogenic lineage in vitro, Cardiovasc. Res., 62, pp. 34-42, (2004); Jazayeri M., Allameh A., Soleimani M., Jazayeri S.H., Piryaei A., Kazemnejad S., Molecular and ultrastructural characterization of endothelial cells differentiated from human bone marrow mesenchymal stem cells, Cell Biol. Int., 32, pp. 1183-1192, (2008); Kang K.T., Coggins M., Xiao C., Rosenzweig A., Bischoff J., Human vasculogenic cells form functional blood vessels and mitigate adverse remodeling after ischemia reperfusion injury in rats, Angiogenesis, 16, pp. 773-784, (2013); Lalu M.M., McIntyre L., Pugliese C., Fergusson D., Winston B.W., Marshall J.C., Et al., Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials, PLoS ONE, 7, (2012); Levenberg S., Rouwkema J., Macdonald M., Garfein E.S., Kohane D.S., Darland D.C., Et al., Engineering vascularized skeletal muscle tissue, Nat. Biotechnol., 23, pp. 879-884, (2005); Lian F., Xue S., Gu P., Zhu H.S., The long-term effect of autologous endothelial progenitor cells from peripheral blood implantation on infarcted myocardial contractile force, J. Int. Med. Res., 36, pp. 40-46, (2008); Lien S.M., Ko L.Y., Huang T.J., Effect of pore size and ECM secretion and cell growth in gelatin scaffold for articular cartilage tissue engineering, Acta Biomater., 5, pp. 670-679, (2009); Loffredo F.S., Steinhauser M.L., Gannon J., Lee R.T., Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair, Cell Stem Cell, 8, pp. 389-398, (2011); Lovett M., Lee K., Edwards A., Kaplan D.L., Vascularization strategies for tissue engineering, Tissue Eng. Part B Rev., 15, pp. 353-370, (2009); Lozito T.P., Kuo C.K., Taboas J.M., Tuan R.S., Human mesenchymal stem cells express vascular cell phenotypes upon interaction with endothelial cell matrix, J. Cell. Biochem., 107, pp. 714-722, (2009); Maidhof R., Tandon N., Lee E.J., Luo J., Duan Y., Yeager K., Et al., Biomimetic perfusion and electrical stimulation applied in concert improved the assembly of engineered cardiac tissue, J. Tissue Eng. Regen. Med., 6, (2012); Makkar R.R., Smith R.R., Cheng K., Malliaras K., Thomson L.E., Berman D., Et al., Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial, Lancet, 379, pp. 895-904, (2012); Martucci J.F., Ruseckaite R.A., Vazquez A., Creep of glutaraldehyde-crosslinked gelatin films, Mater. Sci. Eng. A, 435-436, pp. 681-686, (2006); Matsuura K., Wada M., Konishi K., Sato M., Iwamoto U., Sato Y., Et al., Fabrication of mouse embryonic stem cell-derived layered cardiac cell sheets using a bioreactor culture system, PLoS ONE, 7, (2012); Mazzei D., Guzzardi M.A., Giusti S., Ahluwalia A., A low shear stress modular bioreactor for connected cell culture under high flow rates, Biotechnol. Bioeng., 106, pp. 127-137, (2010); Mehta A., Shim W., Cardiac stem cell therapy: stemness or commitment?, Cell Transplant, 22, pp. 1-14, (2013); Menasche P., Cardiac cell therapy: lessons from clinical trials, J. Mol. Cell. Cardiol., 50, pp. 258-265, (2011); Meyer G.P., Wollert K.C., Lotz J., Pirr J., Rager U., Lippolt P., Et al., Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial, Eur. Heart J., 30, pp. 2978-2984, (2009); Mosqueira D., Pagliari S., Uto K., Ebara M., Romanazzo S., Escobedo-Lucea C., Et al., Hippo pathway effectors control cardiac progenitor cell fate by acting as dynamic sensors of substrate mechanics and nanostructure, ACS Nano, 8, pp. 2033-2047, (2014); Muraglia A., Cancedda R., Quarto R., Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model, J. Cell Sci., 113, pp. 1161-1166, (2000); Mwangi J.W., Ofner III C.M., Crosslinked gelatin matrices: release of a random coil macromolecular solute, Int. J. Pharm., 278, pp. 319-327, (2004); Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., Et al., Mesenchymal stem cells can be differentiated into endothelial cells in vitro, Stem Cells, 22, pp. 377-384, (2004); Pagliari S., Romanazzo S., Mosqueira D., Pinto-do-O P., Aoyagi T., Forte G., Adult stem cells and biocompatible scaffolds as powerful drug delivery tools for cardiac repair, Curr. Med. Chem., 20, pp. 3429-3447, (2013); Pagliari S., Vilela-Silva A.C., Forte G., Pagliari F., Mandoli C., Vozzi G., Et al., Cooperation of biological and mechanical signals in cardiac progenitor cell differentiation, Adv. Mater., 23, pp. 514-518, (2011); Pampaloni F., Reynaud E.G., Stelzer E.H., The third dimension bridges between cell culture and live tissue, Nat. Rev. Mol. Cell Biol., 8, pp. 839-845, (2007); Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Et al., Multilineage potential of adult human mesenchymal stem cells, Science, 284, pp. 143-147, (1999); Portalska K.J., Leferink A., Groen N., Fernandes H., Moroni L., van Blitterswijk C., Et al., Endothelial differentiation of mesenchymal stromal cells, PLoS ONE, 7, (2012); Sakaguchi K., Shimizu T., Haraguchi S., Sekine H., Yamato M., Umezu M., Et al., In vitro engineering of vascularized tissue surrogates, Sci. Rep, 3, (2013); Sakai T., Li R.K., Weisel R.D., Mickle D.A., Kim E.T., Jia Z.Q., Et al., The fate of a tissue-engineered cardiac graft in the right ventricular outflow tract of the rat, J. Thorac. Cardiovasc. Surg., 121, pp. 932-942, (2001); Sato K., Wu T., Laham R.J., Johnson R.B., Douglas P., Li J., Et al., Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia, J. Am. Coll. Cardiol., 37, pp. 616-623, (2001); Segers V.F.M., Lee R.T., Biomaterials to enhance stem cell function in the heart, Circ. Res., 109, pp. 910-922, (2011); Sekine H., Shimizu T., Sakaguchi K., Dobashi I., Wada M., Yamato M., Et al., In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels, Nat. Commun, 4, (2013); Simons M., Ware J.A., Therapeutic angiogenesis in cardiovascular disease, Nat. Rev. Drug Discov., 2, pp. 863-871, (2003); Simon-Yarza T., Formiga F.R., Tamayo E., Pelacho B., Prosper F., Blanco-Prieto M.J., Vascular endothelial growth factor-delivery systems for cardiac repair: an overview, Theranostics, 2, pp. 541-552, (2012); Singh S., Wu B.M., Dunn J.C., Delivery of VEGF using collagen-coated polycaprolactone scaffolds stimulates angiogenesis, J. Biomed. Mater. Res., 100, pp. 720-727, (2012); Smits A.M., van Laake L.W., den Ouden K., Schreurs C., Szuhai K., van Echteld C.J., Et al., Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium, Cardiovasc. Res., 83, pp. 527-535, (2009); Smits A.M., van Vliet P., Metz C.H., Korfage T., Sluijter J.P., Doevendans P.A., Et al., Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology, Nat. Protoc., 4, pp. 232-243, (2009); Spinelli A., Vinci B., Tirella A., Matteucci M., Gargani L., Ahluwalia A., Et al., Realization of a poro-elastic ultrasound replica of pulmonary tissue, Biomatter, 2, pp. 37-42, (2012); Terrovitis J.V., Smith R.R., Marban E., Assessment and optimization of cell engraftment after transplantation into the heart Circ, Res., 106, pp. 479-494, (2010); Thomas M., Augustin H.G., The role of the Angiopoietins in vascular morphogenesis, Angiogenesis, 12, pp. 125-137, (2009); Urbich C., Heeschen C., Aicher A., Sasaki K., Bruhl T., Farhadi M.R., Et al., Cathepsin L is required for endothelial progenitor cell-induced neovascularization, Nat. Med., 11, pp. 206-213, (2005); Varum S., Rodrigues A.S., Moura M.B., Momcilovic O., Easley C.A.4th Ramalho-Santos J., Et al., Energy metabolism in human pluripotent stem cells and their differentiated counterparts, PLoS ONE, 6, (2011); Vozzi F., Mazzei D., Vinci B., Vozzi G., Sbrana T., Ricotti L., Et al., A flexible bioreactor system for constructing in vitro tissue and organ models, Biotechnol. Bioeng., 108, pp. 2129-2140, (2011); Wang D.M., Tarbell J.M., Modeling interstitial flow in an artery wall allows estimation of wall shear stress on smooth muscle cells, J. Biomech. Eng., 117, pp. 358-366, (1995); Wohrle J., Merkle N., Mailander V., Nusser T., Schauwecker P., von Scheidt F., Et al., Results of intracoronary stem cell therapy after acute myocardial infarction, Am. J. Cardiol., 105, pp. 804-812, (2010); Wu S.C., Chang W.H., Dong C.G., Chen K.Y., Chen Y.S., Yao C.H., Cell adhesion and proliferation enhancement by gelatin nanofiber scaffolds, J. Bioact. Compat. Polym., 26, pp. 565-577, (2011); Xing Q., Yates K., Vogt C., Qian Z., Frost M.C., Zhao F., Increasing mechanical strength of gelatin hydrogels by divalent metal ion removal, Sci. Rep, 4, (2014); Zimmermann W.H., Melnychenko I., Wasmeier G., Didie M., Naito H., Nixdorff U., Et al., Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts, Nat. Med., 12, pp. 452-458, (2006)","T. Aoyagi; Smart Biomaterials Group, International Center for Materials Nanoarchitectonics, National Institute for Materials Science, Tsukuba, Ibaraki 305-0051, 1-1 Namiki, Japan; email: aoyagi.takao@nims.go.jp","","Frontiers Research Foundation","","","","","","1664042X","","","","English","Front. Physiol.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84904427920"
"Tsiambas E.; Chrysovergis A.; Papanikolaou V.; Mastronikolis N.; Ragos V.; Kavantzas N.; Lazaris A.C.; Patsouris E.; Riziotis C.; Paschopoulos M.; Kyrodimos E.","Tsiambas, Evangelos (12646924800); Chrysovergis, Aristeidis (34881399400); Papanikolaou, Vasileios (57514482100); Mastronikolis, Nicholas (35552266000); Ragos, Vasileios (54907175700); Kavantzas, Nikolaos (7006218125); Lazaris, Andreas C. (7005403441); Patsouris, Efstratios (35466511600); Riziotis, Christos (6603072535); Paschopoulos, Minas (6701502609); Kyrodimos, Efthymios (55407698000)","12646924800; 34881399400; 57514482100; 35552266000; 54907175700; 7006218125; 7005403441; 35466511600; 6603072535; 6701502609; 55407698000","Chromosome X riddle in SARS-CoV-2 (COVID-19) - related lung pathology","2020","Pathology and Oncology Research","26","4","","2839","2841","2","8","10.1007/s12253-020-00878-0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088256749&doi=10.1007%2fs12253-020-00878-0&partnerID=40&md5=e63104cc6bffde2c453723d7a42afd8b","Department of Cytology, VA Hospital (NIMTS), Athens, 401 & 417, Greece; Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of CME, Harvard Medical School, Boston, MA, United States; 1st ENT Department, Hippocration Hospital, National and Kapodistrian, University of Athens, Athens, Greece; Department of Otorhinolaryngology, Head and Neck Surgery, Medical School, University of Patras, Patras, Greece; Department of Maxillofacial Surgery, School of Health Sciences, University of Ioannina, Ioannina, Greece; Theoretical and Physical Chemistry Institute, Photonics for Nanoapplications Laboratory, National Hellenic Research Foundation, Athens, Greece; Department of Obstetrics and Gynaecology, School of Health Sciences, University of Ioannina, Ioannina, Greece","Tsiambas E., Department of Cytology, VA Hospital (NIMTS), Athens, 401 & 417, Greece, Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Department of CME, Harvard Medical School, Boston, MA, United States; Chrysovergis A., 1st ENT Department, Hippocration Hospital, National and Kapodistrian, University of Athens, Athens, Greece; Papanikolaou V., 1st ENT Department, Hippocration Hospital, National and Kapodistrian, University of Athens, Athens, Greece; Mastronikolis N., Department of Otorhinolaryngology, Head and Neck Surgery, Medical School, University of Patras, Patras, Greece; Ragos V., Department of Maxillofacial Surgery, School of Health Sciences, University of Ioannina, Ioannina, Greece; Kavantzas N., Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Lazaris A.C., Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Patsouris E., Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Riziotis C., Theoretical and Physical Chemistry Institute, Photonics for Nanoapplications Laboratory, National Hellenic Research Foundation, Athens, Greece; Paschopoulos M., Department of Obstetrics and Gynaecology, School of Health Sciences, University of Ioannina, Ioannina, Greece; Kyrodimos E., 1st ENT Department, Hippocration Hospital, National and Kapodistrian, University of Athens, Athens, Greece","[No abstract available]","","Betacoronavirus; Chromosomes, Human, X; Coronavirus Infections; Female; Humans; Lung; Male; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Polymorphism, Single Nucleotide; Sex Factors; furin; regucalcin; toll like receptor 7; toll like receptor 8; transcription factor FOXP3; angiotensin converting enzyme 2; dipeptidyl carboxypeptidase; aging; antiviral therapy; cancer prognosis; Chinese; cigarette smoking; coronavirus disease 2019; disease association; disease course; disease severity; DNA modification; gene; gene amplification; gene deletion; gene dosage; gene expression profiling; gene frequency; gene location; gene mutation; gene overexpression; genetic analysis; genetic association; genetic code; genome-wide association study; hACE2 gene; Hepatitis B virus; hospital admission; human; hypertension; intensive care unit; interstitial pneumonia; intracranial aneurysm; Letter; liver cell; lung adenocarcinoma; lung epithelium; metabolic syndrome X; mortality rate; mortality risk; oxygen therapy; pandemic; pathology; protein expression; Severe acute respiratory syndrome coronavirus 2; sex difference; sex ratio; single nucleotide polymorphism; systemic lupus erythematosus; treatment response; tumor suppressor gene; United States; virus cell interaction; virus transmission; X chromosomal inheritance; X chromosome; Betacoronavirus; Coronavirus infection; female; genetics; lung; male; pandemic; pathophysiology; physiology; sex factor; virology; virus pneumonia; X chromosome","","furin, ; dipeptidyl carboxypeptidase, 9015-82-1; angiotensin converting enzyme 2, ; Peptidyl-Dipeptidase A, ","","","","","Wu A., Peng Y., Huang B., Et al., Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China, Cell Host Microb, 27, 3, pp. 325-328, (2020); Lukassen S., Chua R.L., Trefzer T., Et al., SARS-CoV-2 Receptor ACE2 and TMPRSS2 Are Primarily Expressed in Bronchial Transient Secretory Cells, EMBO J, (2020); Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G., Decroly E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral Res, 176, pp. 104742-104747, (2020); Tsiambas E., Papanikolaou V., Chrysovergis A., Et al., Coronavirus in hematologic malignancies: Targeting molecules beyond the angiotensin-converting enzyme 2 (ACE2) wall, Pathol Oncol Res, pp. 1-3, (2020); Buja L.M., Wolf D.A., Zhao B., Et al., The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities, Cardiovasc Pathol, 48, pp. 107233-107243, (2020); Lewnard J.A., Liu V.X., Jackson M.L., Et al., Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study, BMJ, 369, pp. m1923-m1933, (2020); Yamada S., Utsunomiya M., Inoue K., Et al., Genome-wide Scan for Japanese Familial Intracranial Aneurysms: Linkage to Several Chromosomal Regions, Circulation, 110, pp. 3727-3733, (2004); Zhong J., Yan Z., Liu D., Et al., Association of Angiotensin-Converting Enzyme 2 Gene A/G Polymorphism and Elevated Blood Pressure in Chinese Patients With Metabolic Syndrome, J Lab Clin Med, 147, 2, pp. 91-95, (2006); Conti P., Younes A., Coronavirus COV-19/SARS-CoV-2 Affects Women Less Than Men: Clinical Response to Viral Infection, J Biol Regul Homeost Agents, 34, 2, (2020); Li G., He X., Zhang L., Et al., Assessing ACE2 Expression Patterns in Lung Tissues in the Pathogenesis of COVID-19, J Autoimmun, pp. 102463-102549, (2020); Sawalha A.H., Zhao M., Coit P., Lu Q., Epigenetic Dysregulation of ACE2 and Interferon-Regulated Genes Might Suggest Increased COVID-19 Susceptibility and Severity in Lupus Patients, Clin Immunol, 215, pp. 108410-108415, (2020); Yamaguchi M., Osuka S., Shoji M., Weitzmann M.N., Murata T., Survival of lung cancer patients is prolonged with higher regucalcin gene expression: suppressed proliferation of lung adenocarcinoma A549 cells in vitro, Mol Cell Biochem, 430, 1-2, pp. 37-46, (2017); Wei X., Yu H., Zhao P., Xie L., Li L., Zhang J., Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases, Braz J Med Biol Res, 52, 10, pp. e8845-e8850, (2019)","E. Tsiambas; Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; email: tsiambasecyto@yahoo.gr","","Springer","","","","","","12194956","","POREF","32691391","English","Pathol. Oncol. Res.","Letter","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85088256749"
"Rysz J.; Franczyk B.; Rysz-Górzyńska M.; Gluba-Brzózka A.","Rysz, Jacek (7004232269); Franczyk, Beata (57090546400); Rysz-Górzyńska, Magdalena (57190090012); Gluba-Brzózka, Anna (56386089100)","7004232269; 57090546400; 57190090012; 56386089100","Pharmacogenomics of hypertension treatment","2020","International Journal of Molecular Sciences","21","13","4709","1","26","25","43","10.3390/ijms21134709","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087362827&doi=10.3390%2fijms21134709&partnerID=40&md5=fb63990709586628c3861d64ba1b1075","Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, 90-549, Poland; Department of Ophthalmology and Visual Rehabilitation, Medical University of Lodz, Lodz, 90-549, Poland","Rysz J., Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, 90-549, Poland; Franczyk B., Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, 90-549, Poland; Rysz-Górzyńska M., Department of Ophthalmology and Visual Rehabilitation, Medical University of Lodz, Lodz, 90-549, Poland; Gluba-Brzózka A., Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, 90-549, Poland","Hypertension is one of the strongest modifiable cardiovascular risk factors, affecting an increasing number of people worldwide. Apart from poor medication adherence, the low efficacy of some therapies could also be related to inter-individual genetic variability. Genetic studies of families revealed that heritability accounts for 30% to 50% of inter-individual variation in blood pressure (BP). Genetic factors not only affect blood pressure (BP) elevation but also contribute to inter-individual variability in response to antihypertensive treatment. This article reviews the recent pharmacogenomics literature concerning the key classes of antihypertensive drugs currently in use (i.e., diuretics, β-blockers, ACE inhibitors, ARB, and CCB). Due to the numerous studies on this topic and the sometimes-contradictory results within them, the presented data are limited to several selected SNPs that alter drug response. Genetic polymorphisms can influence drug responses through genes engaged in the pathogenesis of hypertension that are able to modify the effects of drugs, modifications in drug–gene mechanistic interactions, polymorphisms within drug-metabolizing enzymes, genes related to drug transporters, and genes participating in complex cascades and metabolic reactions. The results of numerous studies confirm that genotype-based antihypertension therapies are the most effective and may help to avoid the occurrence of major adverse events, as well as decrease the costs of treatment. However, the genetic heritability of drug response phenotypes seems to remain hidden in multigenic and multifactorial complex traits. Therefore, further studies are required to analyze all associations and formulate final genome-based treatment recommendations. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","ACE inhibitors; Angiotensin II receptor blockers; Calcium channel blocking (CCB) agents; Diuretics; Pharmacogenetics; Polymorphisms; Response to drugs","Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Genome; Humans; Hypertension; Pharmacogenetics; Polymorphism, Genetic; amlodipine; angiotensin 2 receptor antagonist; atenolol; beta adrenergic receptor blocking agent; calcium channel blocking agent; candesartan; carvedilol; diltiazem; dipeptidyl carboxypeptidase inhibitor; diuretic agent; enalapril; hydrochlorothiazide; losartan; metoprolol; nitric oxide; thiazide diuretic agent; verapamil; angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; antihypertensive therapy; blood pressure; cardiovascular risk; drug efficacy; drug interaction; drug metabolism; drug response; enzyme activity; gene interaction; genetic variability; genetic variation; genome-wide association study; genotype; heritability; human; hypertension; mean arterial pressure; medication compliance; meta analysis (topic); monotherapy; nonhuman; pharmacodynamics; pharmacogenomics; pharmacokinetics; phenotype; renin angiotensin aldosterone system; Review; signal transduction; single nucleotide polymorphism; treatment outcome; drug effect; genetic polymorphism; genetics; genome; hypertension; metabolism; pharmacogenetics; procedures","","amlodipine, 88150-42-9; atenolol, 29122-68-7, 93379-54-5; candesartan, 139481-59-7; carvedilol, 72956-09-3; diltiazem, 33286-22-5, 42399-41-7; enalapril, 75847-73-3; hydrochlorothiazide, 58-93-5; losartan, 114798-26-4; metoprolol, 37350-58-6; nitric oxide, 10102-43-9; verapamil, 152-11-4, 52-53-9; Adrenergic beta-Antagonists, ; Angiotensin Receptor Antagonists, ; Angiotensin-Converting Enzyme Inhibitors, ; Antihypertensive Agents, ; Calcium Channel Blockers, ; Diuretics, ","","","","","Oliveira-Paula G.H., Pereira S.C., Tanus-Santos J.E., Lacchini R., Pharmacogenomics and Hypertension: Current Insights, Pharmgenomics Pers. Med, 12, pp. 341-359, (2019); Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J., Global burden of hypertension: analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Torrellas C., Carril J.C., Cacabelos R., Benefits of Pharmacogenetics in the Management of Hypertension, J Pharmacogenomics Pharmacoproteomics, 5, (2014); Yoon S.S., Burt V., Louis T., Carroll M.D., Hypertension among adults in the United States; 2009-2010, NCHS Data Brief, 107, pp. 1-7, (2012); Diao D., Wright J.M., Cundiff D.K., Gueyffier F., Pharmacotherapy for mild hypertension, Cochrane Database Syst. Rev, 8, (2012); Hiltunen T.P., Donner K.M., Sarin A.P., Saarela J., Ripatti S., Chapman A.B., Gums J.G., Gong Y., Cooper-DeHoff R.M., Frau F., Et al., Pharmacogenomics of hypertension: a genome-wide; placebo-controlled cross-over study; using four classes of antihypertensive drugs, J. Am. Heart Assoc, 4, (2015); Padmanabhan S., Newton-Cheh C., Dominiczak A., Genetic basis of blood pressure and hypertension, Trends Genet, 28, pp. 397-408, (2012); Ehret G.B., Caulfield M.J., Genes for blood pressure: an opportunity to understand hypertension, Eur. Heart J, 34, pp. 951-961, (2013); Munroe P.B., Barnes M.R., Caulfield M.J., Advances in blood pressure genomics, Circ. Res, 112, pp. 1365-1379, (2013); Johnson J.A., Advancing management of hypertension through pharmacogenomics, Ann. Med, 44, pp. S17-S22, (2012); Luizon M.R., Pereira D.A., Sandrim V.C., Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene–Gene Interactions, Front. Pharmacol, 9, (2018); Padmanabhan; S.; and Joe; B. Towards precision medicine for hypertension: a review of genomic; epigenomic; and microbiomic effects on blood pressure in experimental rat models and humans, Physiol. Rev, 97, pp. 1469-1528, (2017); Cacabelos R., The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders, Metabolomics, 2, (2012); Zanger U.M., Pharmacogenetics-challenges and opportunities ahead, Front. Pharmacol, 1, (2010); Johnson R., Dludla P., Mabhida S., Benjeddou M., Louw J., February F., Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review, Heart Fail. Rev, 24, pp. 343-357, (2019); Eisenberg M.J., Brox A., Bestawros A.N., Calcium channel blockers: an update, Am. J. Med, 116, pp. 35-43, (2004); Laurent S., Antihypertensive drugs, Pharmacol. Res, 124, pp. 116-125, (2017); Beitelshees A.L., Gong Y., Wang D., Schork N.J., Cooper-Dehoff R.M., Langaee T.Y., Shriver M.D., Sadee W., Knot H.J., Pepine C.J., Et al., KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST), Pharmacogenet. Genomics, 17, pp. 719-729, (2007); Niu Y., Gong Y., Langaee T.Y., Davis H. M., Elewa H., Beitelshees A. L., Moss J. I., Cooper-Dehoff R. M., Pepine C. J., Johnson J. A., Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetics association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES), Circ. Cardiovasc. Genet, 3, pp. 548-555, (2010); Kamide K., Yang J., Matayoshi T., Takiuchi S., Horio T., Yoshii M., Miwa Y., Yasuda H., Yoshihara F., Nakamura S., Et al., Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers, Circ. J, 73, pp. 732-740, (2009); Bremer T., Man A., Kask K., Diamond C., CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension, Pharmacogenomics, 7, pp. 271-279, (2006); He F., Luo J., Luo Z., Fan L., He Y., Zhu D., Gao J., Deng S., Wang Y., Qian Y., Et al., The KCNH2 genetic polymorphism (1956; C>T) is a novel biomarker that is associated with CCB and alpha;beta-ADR blocker response in EH patients in China, PLoS One, 8, (2013); Eadon M.T., Kanuri S.H., Chapman A.B., Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment, Expert Rev. Precis. Med. Drug Dev, 3, pp. 33-47, (2018); Beitelshees A.L., Navare H., Wang D., Gong Y., Wessel J., Moss J.I., Langaee T.Y., Cooper-DeHoff R.M., Sadee W., Pepine C.J., Et al., CACNA1C gene polymorphisms; cardiovascular disease outcomes; and treatment response, Circ. Cardiovasc. Genet, 2, pp. 362-370, (2009); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Kamide K., Asayama K., Katsuya T., Ohkubo T., Hirose T., Inoue R., Metoki H., Kikuya M., Obara T., Hanada H., Et al., Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the homed-BP study, Pharmacogenomics, 14, pp. 1709-1721, (2013); Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat. Genet, 27, pp. 383-391, (2001); Langaee T.Y., Gong Y., Yarandi H.N., Katz D.A., Cooper-DeHoff R.M., Pepine C.J., Johnson J.A., Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil, Clin. Pharmacol. Ther, 81, pp. 386-391, (2007); Fares H., DiNicolantonio J.J., O'Keefe J.H., Lavie C.J., Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes, Open Heart, 3, (2016); Zhu Y., Wang F., Li Q., Zhu M., Du A., Tang W., Chen W., Amlodipine metabolism in human liver microsomes and roles of cyp3a4/5 in the dihydropyridine dehydrogenation, Drug Metab. Dispos, 42, pp. 245-249, (2014); Bhatnagar V., Garcia E.P., O'Connor D.T., Brophy V.H., Alcaraz J., Richard E., Bakris G.L., Middleton J.P., Norris K.C., Wright J., Cyp3a4 and cyp3a5 polymorphisms and blood pressure response to amlodipine among African American men and women with early hypertensive renal disease, Am. J. Nephrol, 31, pp. 95-103, (2010); Meibohm B., Beierle I., Derendorf H., How important are gender differences in pharmacokinetics?, Clin. Pharmacokinet, 41, pp. 329-342, (2002); Kim K.A., Park P.W., Lee O.J., Choi S.H., Min B.H., Shin K.H., Chun B.G., Shin J.G., Park J.Y., Effect of Cyp3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects, Clin. Pharmacol. Ther, 80, pp. 646-656, (2006); Zuo X.C., Zhang W.L., Yuan H., Barrett J.S., Hua Y., Huang Z.J., Zhou H.H., Pei Q., Guo C.X., Wang J.L., Et al., ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis, Drug Metab. Pharmacokinet, 29, pp. 305-311, (2014); Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Et al., Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc. Natl. Acad. Sci. USA, 97, pp. 3473-3478, (2000); Sparks M.A., Crowley S.D., Gurley S.B., Mirotsou M., Coffman T.M., Classical renin–angiotensin system in kidney physiology, Compr. Physiol, 4, pp. 1201-1228, (2014); Ismail H., Mitchell R., McFarlane S.I., Makaryus A.N., Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering, Curr. Diab. Rep, 10, pp. 32-36, (2010); Fontana V., de Faria A.P., Oliveira-Paula G.H., Silva P.S., Biagi C., Tanus-Santos J.E., Moreno H., Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension, Basic Clin. Pharmacol. Toxicol, 114, pp. 472-475, (2014); Mason R.P., Jacob R.F., Kubant R., Jacoby A., Louka F., Corbalan J.J., Malinski T., Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants, Br. J. Clin. Pharmacol, 74, pp. 141-146, (2012); Oliveira-Paula G.H., Lacchini R., Luizon M.R., Fontana V., Silva P.S., Biagi C., Tanus-Santos J.E., Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension, Nitric Oxide, pp. 62-69, (2016); Frau F., Zaninello R., Salvi E., Ortu M.F., Braga D., Velayutham D., Argiolas G., Fresu G., Troffa C., Bulla E., Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study, Pharmacogenomics, 15, pp. 1643-1652, (2014); Turner S.T., Bailey K.R., Schwartz G.L., Chapman A.B., Chai H.S., Boerwinkle E., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, pp. 1204-1211, (2012); Freel E.M., Ingram M., Friel E.C., Fraser R., Brown M., Samani N.J., Caulfield M., Munroe P., Farrall M., Webster J., Et al., Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT study, Clin. Endocrinol, 67, pp. 832-838, (2007); Davies E., Holloway C.D., Ingram M.C., Inglis G.C., Friel E.C., Morrison C., Anderson N.H., Fraser R., Connell J.M., Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2, Hypertension, 33, pp. 703-707, (1999); Lacchini R., Sabha M., Coeli F.B., Favero F.F., Yugar-Toledo J., Izidoro-Toledo T.C., Sandrim V.C., Tanus-Santos J.E., de Mello M.P., Moreno H., T allele of −344 C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension, Hypertens Res, 32, pp. 159-162, (2009); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Nystrom F., Hagg A., Lind L., Aldosterone synthase (CYP11B2) −344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, Am. J. Hypertens, 15, pp. 389-393, (2002); Ji X., Qi H., Li D.B., Liu R.K., Zheng Y., Chen H.L., Guo J.C., Associations between human aldosterone synthase CYP11B2 (−344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension, Int. J. Clin. Exp. Med, 8, pp. 1173-1177, (2015); Ortlepp J.R., Hanrath P., Mevissen V., Kiel G., Borggrefe M., Hoffmann R., Variants of the CYP11B2 gene predict response to therapy with candesartan, Eur. J. Pharmacol, 445, pp. 151-152, (2002); Oliveira-Paula; G.H., Luizon; M. R.; Lacchini; R.; Fontana; V.; Silva; P. S.; Biagi; C.; et al. Gene-gene interactions among PRKCA.; NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril, Basic Clin. Pharmacol. Toxicol, 120, pp. 284-291, (2017); Turner S.T., Boerwinkle E., O'Connell J.R., Bailey K.R., Gong Y., Chapman A.B., McDonough C.W., Beitelshees A.L., Schwartz G.L., Gums J.G., Et al., Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide, Hypertension, 1979, pp. 391-397, (2013); Silva; P. S.; Fontana; V.; Luizon; M. R.; Lacchini; R.; Silva; WA Jr; Biagi; C.; et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril, Eur J. Clin Pharmacol, 69, pp. 167-177, (2013); James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., Lackland D.T., LeFevre M.L., MacKenzie T.D., Ogedegbe O., Et al., Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8), JAMA, 311, pp. 507-520, (2014); Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S., Sotelo J., August P., Pickering T.G., Laragh J.H., Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin–angiotensin-aldosterone system in normotensive and hypertensive subjects, Am. J. Hypertens, 12, pp. 451-459, (1999); Turner S.T., Chapman A.B., Schwartz G.L., Boerwinkle E., Effects of endothelial nitric oxide synthase; alpha-adducin; and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide, Am. J. Hypertens, 16, pp. 834-839, (2003); Li Y., Yang P., Wu S., Yuan J., Shen C., Wu Y., Zhao D., Ren Q., Feng F., Guan W., Gender-specific association between ACE gene I/D polymorphism and blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients, Biochem. Genet, 49, pp. 704-714, (2011); Johnson J.A., Liggett S.B., Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions, Clin. Pharmacol. Ther, 89, pp. 366-378, (2011); Zhang F., Steinberg S.F., S49G and R389G polymorphisms of the beta(1)-adrenergic receptor influence signaling via the cAMPPKA and ERK pathways, Physiol. Genomics, 45, pp. 1186-1192, (2013); Pacanowski M.A., Gong Y., Cooper-Dehoff R.M., Schork N.J., Shriver M.D., Langaee T.Y., Pepine C.J., Johnson J.A., Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension, Clin. Pharmacol. Ther, 84, pp. 715-721, (2008); Magvanjav O., McDonough C.W., Gong Y., McClure L.A., Talbert R.L., Horenstein R.B., Shuldiner A.R., Benavente O.R., Mitchell B.D., Johnson J.A., Et al., Pharmacogenetic associations of beta1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 trial (Secondary Prevention of Small Subcortical Strokes), Stroke, 48, pp. 1337-1343, (2017); Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F., Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin. Pharmacol. Ther, 74, pp. 44-52, (2003); Si D., Wang J., Xu Y., Chen X., Zhang M., Zhou H., Association of common polymorphisms in beta1-adrenergic receptor with antihypertensive response to carvedilol, J. Cardiovasc. Pharmacol, 64, pp. 306-309, (2014); Chen L., Xiao T., Chen L., Xie S., Deng M., Wu D., The association of ADRB1 and CYP2D6 polymorphisms with antihypertensive effects and analysis of their contribution to hypertension risk, Am. J. Med. Sci, 355, pp. 235-239, (2018); Suonsyrja T., Donner K., Hannila-Handelberg T., Fodstad H., Kontula K., Hiltunen T.P., Common genetic variation of beta1-and beta2-adrenergic receptor and response to four classes of antihypertensive treatment, Pharmacogenet. Genomics, 20, pp. 342-345, (2010); Filigheddu F., Argiolas G., Degortes S., Zaninello R., Frau F., Pitzoi S., Bulla E., Bulla P., Troffa C., Glorioso N., Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension, Pharmacogenomics, 11, pp. 319-325, (2010); Vandell A.G., Lobmeyer M.T., Gawronski B.E., Langaee T.Y., Gong Y., Gums J.G., Beitelshees A.L., Turner S.T., Chapman A.B., Cooper-DeHoff R.M., Et al., G protein receptor kinase 4 polymorphisms: beta-blocker pharmacogenetics and treatment-related outcomes in hypertension, Hypertension, 60, pp. 957-964, (2012); Felder R.A., Jose P.A., Mechanisms of disease: The role of grk4 in the etiology of essential hypertension and salt sensitivity, Nat. Clin. Pract. Nephrol, 2, pp. 637-650, (2006); Singh S., El Rouby N., McDonough C.W., Gong Y., Bailey K.R., Boerwinkle E., Chapman A.B., Gums J.G., Turner S.T., Cooper-DeHoff R.M., Et al., Genomic association analysis reveals variants associated with blood pressure response to beta-blockers in European Americans, Clin. Transl. Sci, 2, pp. 497-504, (2019); Larsson E., Wahlstrand B., Hedblad B., Hedner T., Kjeldsen S.E., Melander O., Lindahl P., Hypertension and genetic variation in endothelial-specific genes, PLoS ONE, 8, (2013); Cheng C., Haasdijk R., Tempel D., van de Kamp E.H., Herpers R., Bos F., Den Dekker W.K., Blonden L.A., de Jong R., Burgisser P.E., Endothelial cell-specific FGD5 involvement in vascular pruning defines neovessel fate in mice, Circulation, 125, pp. 3142-3158, (2012); Kurogane Y., Miyata M., Kubo Y., Nagamatsu Y., Kundu R.K., Uemura A., Ishida T., Quertermous T., Hirata K., Rikitake Y., FGD5 mediates proangiogenic action of vascular endothelial growth factor in human vascular endothelial cells, Arterioscler. Thromb. Vasc. Biol, 32, pp. 988-996, (2012); Kokubo Y., Tomoike H., Tanaka C., Banno M., Okuda T., Inamoto N., Kamide K., Kawano Y., Miyata T., Association of sixty-one non-synonymous polymorphisms in forty-one hypertension candidate genes with blood pressure variation and hypertension, Hypertens. Res, 29, pp. 611-619, (2006); Gong Y., Wang Z., Beitelshees A.L., McDonough C.W., Langaee T.Y., Hall K., Schmidt S.O., Curry R.W., Gums J.G., Bailey K.R., Et al., Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans, Hypertension, 67, pp. 556-563, (2016); Rimpela J.M., Kontula K.K., Fyhrquist F., Donner K.M., Tuiskula A.M., Sarin A.P., Mohney R.P., Stirdivant S.M., Hiltunen T.P., Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses, Pharmacogenomics, 18, pp. 445-458, (2017); Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., Lanke J., de Faire U., Dahlof B., Karlberg B.E., Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study, Lancet, 356, pp. 359-365, (2000); Hamrefors V., Sjogren M., Almgren P., Wahlstrand B., Kjeldsen S., Hedner T., Melander O., Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms, J. Hypertens, 30, pp. 1151-1160, (2012); Shahin M.H., Sa A.C., Webb A., Gong Y., Langaee T., McDonough C.W., Riva A., Beitleshees A.L., Chapman A.B., Gums J.G., Et al., Genome-wide prioritization and transcriptomics reveal novel signatures associated with thiazide diuretics blood pressure response, Circ. Cardiovasc. Genet, 10, (2017); Swen J.J., Nijenhuis M., de Boer A., Grandia L., Maitland-van der Zee A.H., Mulder H., Rongen G.A., van Schaik R.H., Schalekamp T., Touw D.J., Et al., Pharmacogenetics: from bench to byte–an update of guidelines, Clin. Pharmacol. Ther, 89, pp. 662-673, (2011); Hamadeh I.S., Langaee T.Y., Dwivedi R., Garcia S., Burkley B.M., Skaar T.C., Chapman A.B., Gums J.G., Turner S.T., Gong Y., Et al., Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate, Clin. Pharmacol. Ther, 96, pp. 175-181, (2014); Wu D., Li G., Deng M., Song W., Huang X., Guo X., Wu Z., Wu S., Xu J., Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to beta-blocker therapy in hypertension, J. Int. Med. Res, 43, pp. 424-434, (2015); Zineh I., Beitelshees A.L., Gaedigk A., Walker J.R., Pauly D.F., Eberst K., Leeder J.S., Phillips M.S., Gelfand C.A., Johnson J.A., Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension, Clin. Pharmacol. Ther, 76, pp. 536-544, (2004); Duarte J.D., Cooper-Dehoff R.M., Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics, Expert Rev. Cardiovasc. Ther, 8, pp. 793-802, (2010); Arnett D.K., Claas S.A., Glasser S.P., Pharmacogenetics of antihypertensive treatment, Vascul. Pharmacol, 44, pp. 107-118, (2006); Lund B.C., Ernst M.E., The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans, J. Clin. Hypertes, 14, pp. 623-629, (2012); Maitland-van der Zee A.H., Turner S.T., Schwartz G.L., Chapman A.B., Klungel O.H., Boerwinkle E., Demographic; environmental; and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects, Am. J. Hypertens, 18, pp. 1077-1083, (2005); Ellison D.H., Loffing J., Thiazide effects and adverse effects: insights from molecular genetics, Hypertension, 1979, pp. 196-202, (2009); Singh S., McDonough C.W., Gong Y., Alghamdi W.A., Arwood M.J., Bargal S.A., Dumeny L., Li W.Y., Mehanna M., Stockard B., Et al., Genome wide association study identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients, J. Am. Heart Assoc, 7, (2018); Neff K.M., Nawarskas J.J., Hydrochlorothiazide versus chlorthalidone in the management of hypertension, Cardiol Rev, 18, pp. 51-56, (2010); Choi H.D., Suh J.H., Lee J.Y., Bae S.K., Kang H.E., Lee M.G., Shin W.G., Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis, Int. J. Clin. Pharmacol. Ther, 51, pp. 718-724, (2013); Matsuoka Y., Li X., Bennett V., Adducin: structure; function and regulation, Cell Mol. Life Sci, 57, pp. 884-895, (2000); Townsend R.R., Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D., ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Suonsyrja T., Hannila-Handelberg T., Fodstad H., Donner K., Kontula K., Hiltunen T.P., Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study, Am. J. Hypertens, 22, pp. 169-175, (2009); Arnett D.K., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Miller M.B., Black H., Eckfeldt J.H., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, pp. 3374-3383, (2005); Glorioso N., Filigheddu F., Cusi D., Troffa C., Conti M., Natalizio M., Argiolas G., Barlassina C., Bianchi G, Alpha-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives, Hypertension, 39, pp. 357-362, (2002); Klenke S., Siffert W., SNPs in genes encoding G proteins in pharmacogenetics, Pharmacogenomics, 12, pp. 633-654, (2011); Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Sharma A.M., Ritz E., Wichmann H.E., Jakobs K.H., Association of a human G-protein beta3 subunit variant with hypertension, Nat. Genet, 18, pp. 45-48, (1998); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Adeyemo A., Gerry N., Chen G., Herbert A., Doumatey A., Huang H., Zhou J., Lashley K., Chen Y., Christman M., Et al., A genome-wide association study of hypertension and blood pressure in African Americans, PLoS Genet, (2009); Kato N., Takeuchi F., Tabara Y., Kelly T.N., Go M.J., Sim X., Tay W., Chen C.H., Zhang Y., Yamamoto K., Et al., Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians, Nat. Genet, 43, pp. 531-538, (2011); Magvanjav O., Gong Y., McDonough C.W., Chapman A.B., Turner S.T., Gums J.G., Bailey K.R., Boerwinkle E., Beitelshees A.L., Tanaka T., Et al., Genetic variants associated with uncontrolled blood pressure on thiazide diuretic/beta-blocker combination therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) trials, J. Am. Heart Assoc, 6, (2017); Duarte J.D., Turner S.T., Tran B., Chapman A.B., Bailey K.R., Gong Y., Gums J.G., Langaee T.Y., Beitelshees A.L., Cooper-Dehoff R.M., Et al., Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression, Pharm J, 13, pp. 257-263, (2013); Turner S.T., Bailey K.R., Fridley B.L., Chapman A.B., Schwartz G.L., Chai H.S., Sicotte H., Kocher J.P., Rodin A.S., Boerwinkle E., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension, 52, pp. 359-365, (2008); Johnson J.A., Boerwinkle E., Zineh I., Chapman A.B., Bailey K., Cooper-DeHoff R.M., Gums J., Curry R.W., Gong Y., Beitelshees A.L., Et al., Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, Am. Heart J, 157, pp. 442-449, (2009); Salvi E., Wang Z., Rizzi F., Gong Y., McDonough C.W., Padmanabhan S., Hiltunen T.P., Lanzani C., Zaninello R., Chittani M., Et al., Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide, Hypertension, 69, pp. 51-59, (2017); Speirs H.J., Katyk K., Kumar N.N., Benjafield A.V., Wang W.Y., Morris B.J., Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension, J. Hypertens, 22, pp. 931-936, (2004); Tripodi G., Citterio L., Kouznetsova T., Lanzani C., Florio M., Modica R., Messaggio E., Hamlyn J.M., Zagato L., Bianchi G., Et al., Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain, Am. J. Hypertens, 22, pp. 357-363, (2009); Shimodaira M., Nakayama T., Sato N., Aoi N., Sato M., Izumi Y., Soma M., Matsumoto K., Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension; aldosterone level; and left ventricular structure, Eur. J. Endocrinol, 163, pp. 671-680, (2010); Rosmond R., Chagnon M., Bouchard C., Bjorntorp P., Polymorphism in exon 4 of the human 3 beta-hydroxysteroid dehydrogenase type I gene (hsd3b1) and blood pressure, Biochem. Biophys. Res. Commun, 293, pp. 629-632, (2002); Svensson-Farbom P., Wahlstrand B., Almgren P., Dahlberg J., Fava C., Kjeldsen S., Hedner T., Melander O., A functional variant of the nedd4l gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients, J. Hypertens, 29, pp. 388-395, (2011); Luo F., Wang Y., Wang X., Sun K., Zhou X., Hui R., A functional variant of NEDD4L is associated with hypertension; antihypertensive response; and orthostatic hypotension, Hypertension, 54, pp. 796-801, (2009); Russo C.J., Melista E., Cui J., DeStefano A.L., Bakris G.L., Manolis A.J., Gavras H., Baldwin C.T., Association of NEDD4L ubiquitin ligase with essential hypertension, Hypertension, 46, pp. 488-491, (2005); Dahlberg J., Nilsson L.O., von Wowern F., Melander O., Polymorphism in NEDD4L is associated with increased salt sensitivity; reduced levels of P-renin and increased levels of NT-pro-ANP, PLoS One, 2, (2007); McDonough C.W., Burbage S.E., Duarte J.D., Gong Y., Langaee T.Y., Turner S.T., Gums J.G., Chapman A.B., Bailey K.R., Beitelshees A.L., Et al., Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics, J. Hypertens, 31, pp. 698-704, (2013); Gong Y., McDonough C.W., Wang Z., Hou W., Cooper-DeHoff R.M., Langaee T.Y., Beitelshees A.L., Chapman A.B., Gums J.G., Bailey K.R., Et al., Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomics evaluation of antihypertensive responses study, Circ. Cardiovasc. Genet, 5, pp. 686-691, (2012); Chittani M., Zaninello R., Lanzani C., Frau F., Ortu M.F., Salvi E., Fresu G., Citterio L., Braga D., Piras D.A., Et al., TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives, J. Hypertens, 33, pp. 1301-1309, (2015); Singh S., Wang Z., Shahin M.H., Langaee T.Y., Gong Y., Turner S.T., Chapman A.B., Gums J.G., McDonough C.W., Bailey K.R., Et al., Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide, Pharmacogenet Genomics, 28, pp. 251-255, (2018); Padmanabhan S., Paul L., Dominczak A.F., The Pharmacogenomics of Anti-Hypertensive Therapy, Pharmaceuticals, 3, pp. 1779-1791, (2010); Johnson; J.A., Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics, Circulation, 118, pp. 1383-1393, (2008)","A. Gluba-Brzózka; Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, 90-549, Poland; email: aniagluba@yahoo.pl","","MDPI AG","","","","","","16616596","","","32630286","English","Int. J. Mol. Sci.","Review","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85087362827"
"Wang J.; Zou H.; Corpe C.","Wang, Jin (57396606300); Zou, Heng (57214251892); Corpe, Christopher (6603027742)","57396606300; 57214251892; 6603027742","An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China","2022","Journal of Infection","84","1","","e21","e22","1","6","10.1016/j.jinf.2021.10.020","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122246176&doi=10.1016%2fj.jinf.2021.10.020&partnerID=40&md5=8a5b478a72b1053b93a117c47c5f0855","Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai, China; Nutritional Science Department, King's College London, 150 Stamford Street, Waterloo, SE19NH, London, United Kingdom","Wang J., Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai, China; Zou H., Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai, China; Corpe C., Nutritional Science Department, King's College London, 150 Stamford Street, Waterloo, SE19NH, London, United Kingdom","[No abstract available]","","Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Humans; SARS-CoV-2; angiotensin converting enzyme 2; dipeptidyl carboxypeptidase; virus spike protein; angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; ACE2 gene; adult respiratory distress syndrome; aging; allele; binding affinity; blood pressure; blood sampling; cardiovascular disease; cardiovascular risk factor; case fatality rate; China; coronavirus disease 2019; diabetes mellitus; disease association; disease severity; DNA polymorphism; endothelial dysfunction; European; gene frequency; gene mutation; genetic polymorphism; genetic variability; geographic distribution; human; hypertension; immune response; Indian; infection sensitivity; laboratory test; Letter; lung alveolus epithelium cell; mortality rate; pandemic; pathogenesis; prevalence; protein depletion; public health service; renin angiotensin aldosterone system; Severe acute respiratory syndrome coronavirus 2; single nucleotide polymorphism; Uygur (people); virus replication","","dipeptidyl carboxypeptidase, 9015-82-1; Angiotensin Receptor Antagonists, ; Angiotensin-Converting Enzyme 2, ; Angiotensin-Converting Enzyme Inhibitors, ","","","Youan Medical Alliance for the Liver and Infectious Diseases, (LM202020); Science and Technology Commission of Shanghai Municipality, STCSM, (20Y11900700)","This work was supported by grants from the Science and Technology Commission of Shanghai (20Y11900700) and a grant from the Special Research Fund of Youan Medical Alliance for the Liver and Infectious Diseases (LM202020) ","Ristic S., Pavlic S.D., Nadalin S., Cizmarevic N.S., ACE I/D polymorphism and epidemiological findings for COVID-19: one year after the pandemic outbreak in Europe, J Infect, 83, 3, pp. 381-412, (2021); Aung A.K., Aitken T., Teh B.M., Yu C., Ofori-Asenso R., Chin K.L., Et al., Angiotensin converting enzyme genotypes and mortality from COVID-19: an ecological study, J Infect, 81, 6, pp. 961-965, (2020); Gomez J., Albaiceta G.M., Garcia-Clemente M., Lopez-Larrea C., Amado-Rodriguez L., Lopez-Alonso I., Et al., Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome, Gene, 762, (2020); Srivastava A., Bandopadhyay A., Das D., Pandey R.K., Singh V., Khanam N., Et al., Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India, Front Genet, 11, (2020); Paniri A., Hosseini M.M., Moballegh-Eslam M., Akhavan-Niaki H., Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations, Gene Rep, 22, (2021); Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O., Potential effects of coronaviruses on the cardiovascular system: a review, JAMA Cardiol, 5, 7, pp. 831-840, (2020); Hussain M., Abbas S., Bilal A., Aslam M.N., Awan F.R., Association of ACE I/D Polymorphism with risk of diabetes in cardiovascular disease patients, Exp Clin Endocrinol Diabetes, 128, 2, pp. 82-88, (2020); Liu C., Li Y., Guan T., Lai Y., Shen Y., Zeyaweiding A., Et al., ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus, Cardiovasc Diabetol, 17, 1, (2018); Hamet P., Pausova Z., Attaoua R., Hishmih C., Haloui M., Shin J., Et al., SARS-CoV-2 receptor ACE2 gene is associated with hypertension and severity of COVID 19: interaction with sex, obesity, and smoking, Am J Hypertens, 34, 4, pp. 367-376, (2021); Lanjanian H., Moazzam-Jazi M., Hedayati M., Akbarzadeh M., Guity K., Sedaghati-Khayat B., Et al., SARS-CoV-2 infection susceptibility influenced by ACE2 genetic polymorphisms: insights from Tehran cardio-metabolic genetic study, Sci Rep, 11, 1, (2021)","J. Wang; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 2901 Caolang Road, China; email: jinwang@shphc.org.cn","","W.B. Saunders Ltd","","","","","","01634453","","JINFD","34728265","English","J. Infect.","Letter","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85122246176"
"Spinasse L.B.; Santos A.R.; Suffys P.N.; Muxfeldt E.S.; Salles G.F.","Spinasse, Lizania Borges (56017580900); Santos, Adalberto Rezende (7402213895); Suffys, Philip Noel (7003785604); Muxfeldt, Elizabeth Silaid (10045155900); Salles, Gil Fernando (7006070197)","56017580900; 7402213895; 7003785604; 10045155900; 7006070197","Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension","2014","Pharmacogenomics","15","2","","169","178","9","29","10.2217/pgs.13.202","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893068653&doi=10.2217%2fpgs.13.202&partnerID=40&md5=fe1321f6409c7c7cb0577858fcd051e4","Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute - Fiocruz, CEP: 21040-360, Manguinhos, Rio de Janeiro, Av. Brazil 4365, Brazil; Department of Internal Medicine, University Hospital Clementino Fraga Filho, Universidade Federal Do Rio de Janeiro, Brazil","Spinasse L.B., Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute - Fiocruz, CEP: 21040-360, Manguinhos, Rio de Janeiro, Av. Brazil 4365, Brazil; Santos A.R., Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute - Fiocruz, CEP: 21040-360, Manguinhos, Rio de Janeiro, Av. Brazil 4365, Brazil; Suffys P.N., Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute - Fiocruz, CEP: 21040-360, Manguinhos, Rio de Janeiro, Av. Brazil 4365, Brazil; Muxfeldt E.S., Department of Internal Medicine, University Hospital Clementino Fraga Filho, Universidade Federal Do Rio de Janeiro, Brazil; Salles G.F., Department of Internal Medicine, University Hospital Clementino Fraga Filho, Universidade Federal Do Rio de Janeiro, Brazil","Aim: Hydralazine, a vasodilator used in resistant hypertension (RH) treatment is metabolized by an acetylation reaction mediated by N-acetyltransferase 2, the activity of which depends on NAT2 polymorphisms. Our aim was to evaluate whether different acetylation phenotypes influenced the antihypertensive effect of hydralazine in patients with RH. Patients & methods: DNA samples from 169 RH patients using hydralazine were genotyped by sequencing the NAT2 coding region, and acetylation phenotypes were defined. Results: Sixty-five patients (38.5%) were intermediate, 60 (35.5%) slow and 21 (12.4%) fast acetylators. Twenty-three (13.6%) patients were indeterminate. Upon association analysis, only slow acetylators had significant blood pressure reductions after hydralazine use, with mean 24-h systolic and diastolic blood pressure reductions of 9.2 and 5.5 mmHg. Four patients presented hydralazine adverse effects resulting in drug withdrawal, three of them were slow acetylators. Conclusion: The slow acetylation phenotype, determined by polymorphisms within NAT2, influenced both the antihypertensive and adverse effects of hydralazine in RH. Original submitted 31 May 2013; Revision submitted 7 October 201. © 2014 Future Medicine Ltd.","Brazilian population; hydralazine; NAT2 polymorphism; resistant hypertension; SNP","Acetylation; Adult; Aged; Antihypertensive Agents; Arylamine N-Acetyltransferase; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged; Phenotype; Polymorphism, Genetic; alpha adrenergic receptor stimulating agent; angiotensin receptor antagonist; arylamine acetyltransferase; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; hydralazine; antihypertensive agent; arylamine acetyltransferase; hydralazine; NAT2 protein, human; adult; antihypertensive activity; article; Brazil; case control study; controlled study; diastolic blood pressure; DNA determination; drug acetylation; drug response; drug substitution; female; gene sequence; genetic variability; haplotype; human; lupus like syndrome; major clinical study; male; NAT2 gene; nucleotide sequence; phenotype; resistant hypertension; systolic blood pressure; unspecified side effect; acetylation; aged; blood pressure; drug effects; genetic polymorphism; genetics; hypertension; middle aged; pathology","GENBANK: AY331807","arylamine acetyltransferase, 9027-33-2; hydralazine, 304-20-1, 86-54-4; arylamine acetyltransferase, 9027-33-2; Antihypertensive Agents, ; Arylamine N-Acetyltransferase, ; Hydralazine, ; NAT2 protein, human, ","","","","","Glavnik N., Petrovic D., M235T polymorphism of the angiotensinogen gene and insertion/deletion polymorphism of the angiotensin-1 converting enzyme gene in essential arterial hypertension in Caucasians, Folia Biol., 53, pp. 69-70, (2007); Petrovic D., Association of the-262C/T polymorphism in the catalase gene promoter and the C242T polymorphism of the NADPH oxidase P22phox gene with essential arterial hypertension in patients with diabetes mellitus Type 2, Clin. Exp. Hypertens, (2013); Calhoun D.A., Jones D., Textor S., Et al., Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American heart association professional education committee of the council for high blood pressure research, Circulation, 117, pp. 510-526, (2008); Persell S.D., Prevalence of resistant hypertension in the United States 2003, Hypertension 57, 2008, pp. 1076-1080, (2011); Egan B.M., Zhao Y., Axon N., Brzezinski W.A., Ferdinand K.C., Uncontrolled apparent treatment resistant hypertension in the united states, 1988 to 2008, Circulation, 124, pp. 1046-1058, (2011); Muxfeldt E.S., De Souza F., Salles G.F., Resistant hypertension: A practical clinical approach, J. Hum. Hypertens., 27, 11, pp. 657-662, (2013); Salles G.F., Cardoso C.R.L., Muxfeldt E.S., Prognostic influence of office and ambulatory blood pressure in resistent hypertension, Arch. Intern. Med., 168, pp. 2340-2346, (2008); De Souza F., Muxfeldt E.S., Fiszman R., Salles G.F., Efficacy of spironolactone therapy in patients with true resistant hypertension, Hypertension, 55, pp. 147-152, (2010); Kandler M.R., Mah G.T., Tejani A.M., Stabler S.N., Salzwedel D.M., Hydralazine for essential hypertension, Cochrane Database Syst. Rev., 9, (2011); Shepherd A.M., McNay J.L., Ludden T.M., Lin M.S., Musgrave G.E., Plasma concentration and acetylator phenotype determine response to oral hydralazine, Hypertension, 3, pp. 580-585, (1981); Ladero J.M., Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs, Curr. Drug Metab., 9, pp. 532-537, (2008); Agundez J.A., Polymorphisms of human N-acetyltransferases and cancer acetylation polymorphisms, Cancer Epidemiol. Biomark. Prev., 9, pp. 29-42, (2000); Hein D.W., Doll M.A., Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes, Pharmacogenomics, 13, pp. 31-41, (2012); Sim E., Walters K., Boukouvala S., Arylamine N-acetytransferases: From structure to function, Drug Metab. Rev., 40, pp. 479-510, (2008); Teixeira R.L., Silva F.P., Silveira A.R., Et al., Sequence analysis of NAT2 gene in Brazilians: Identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure, Mutat. Res., 683, pp. 43-49, (2010); Teixeira R.L., Miranda A.B., Pacheco A.G., Et al., Genetic profile of the arylamine N-acetytransferase 2 coding gene among individuals from two different regions of Brazil, Mutat. Res., 624, pp. 31-40, (2007); Li N., Stephens M., Modeling linkage disequilibrium and identifying recombination hotspots using nucleotide polymorphism data, Genetics, 165, pp. 2213-2233, (2003); Stephens M., Donnelly P., A comparison of Bayesian methods for haplotype reconstruction, Am. J. Hum. Genet., 73, pp. 1162-1169, (2003); Walker K., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B., Genetic polymorphism in N-acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity, J. Toxicol. Environ. Health B Crit. Rev., 12, pp. 440-472, (2009); Malik M.A., Upadhyay R., Modi D.R., Zargar S.A., Mittal B., Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir valley, Arch. Med. Res., 40, pp. 416-423, (2009); Kozhekbaeva Z.H.M., Gra O.A., Fadeev V.S., Et al., Association of NAT2 polymorphisms with susceptibility to psoriasis in the Moscow population, Mol. Biol., 43, pp. 62-76, (2009); Sabbagh A., Darlu P., Crouau-Roy B., Poloni E.S., Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: A worldwide population survey, PLoS ONE, 6, 4, (2011); Pritchard J.K., Pickrell J.K., Coop G., The genetics of human adaptation: Hard sweeps, soft sweeps, and polygenic adaptation, Curr. Biol., 20, pp. 208-215, (2010); Magalon H., Patin E., Austerlitz F., Et al., Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in central Asia, Eur. J. Hum. Genet., 16, pp. 243-251, (2008); McVicker G., Gordon D., Davis C., Green P., Widespread genomic signatures of natural selection in hominid evolution, PLoS Genet, 5, (2009); Yokogawa N., Vivino F., Hydralazine-induced autoimmune disease: Comparison to idiopathic lupus and ANCA-positive vasculitis, Mod. Rheumatol., 19, pp. 338-347, (2009); Mancia G., Fagard R., Narkiewicz K., Et al., 2013 ESH/ESC guidelines for the management of arterial hypertension, J. Hypertens., 31, pp. 1281-1357, (2013)","A.R. Santos; Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute - Fiocruz, CEP: 21040-360, Manguinhos, Rio de Janeiro, Av. Brazil 4365, Brazil; email: adalbertorezende@yahoo.com.br","","","","","","","","17448042","","PARMF","24444407","English","Pharmacogenomics","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84893068653"
"Huang J.; Chen S.; Lu X.; Zhao Q.; Rao D.C.; Jaquish C.E.; Hixson J.E.; Chen J.; Wang L.; Cao J.; Li J.; Li H.; He J.; Liu D.-P.; Gu D.","Huang, Jianfeng (8562297400); Chen, Shufeng (8588271500); Lu, Xiangfeng (16203710100); Zhao, Qi (35488820200); Rao, Dabeeru C. (57217192196); Jaquish, Cashell E. (57223885139); Hixson, James E. (7006777202); Chen, Jichun (15032004100); Wang, Laiyuan (16204416900); Cao, Jie (26031321100); Li, Jianxin (57207801250); Li, Hongfan (14831220700); He, Jiang (7404983432); Liu, De-Pei (55888581300); Gu, Dongfeng (55802487000)","8562297400; 8588271500; 16203710100; 35488820200; 57217192196; 57223885139; 7006777202; 15032004100; 16204416900; 26031321100; 57207801250; 14831220700; 7404983432; 55888581300; 55802487000","Polymorphisms of ACE2 are associated with blood pressure response to cold pressor test: The gensalt study","2012","American Journal of Hypertension","25","8","","937","942","5","13","10.1038/ajh.2012.61","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864277556&doi=10.1038%2fajh.2012.61&partnerID=40&md5=8196835c4606efc7df39de023db13985","Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States; Division of Cardiovascular Disease Sciences, National Heart, Lung, Blood Institute, Bethesda, MD, United States; Human Genetics Center, University of Texas School of Public Health, Houston, TX, United States; Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States; National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China; Chinese National Human Genome Center, Beijing, China","Huang J., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Chen S., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Lu X., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Zhao Q., Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States; Rao D.C., Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States; Jaquish C.E., Division of Cardiovascular Disease Sciences, National Heart, Lung, Blood Institute, Bethesda, MD, United States; Hixson J.E., Human Genetics Center, University of Texas School of Public Health, Houston, TX, United States; Chen J., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Wang L., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Cao J., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Li J., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; Li H., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; He J., Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States; Liu D.-P., National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China; Gu D., Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China, Chinese National Human Genome Center, Beijing, China","Background Increased blood pressure (BP) reactivity to cold pressor test (CPT) is a risk factor for hypertension. Genetic factors may influence the variation of BP response to CPT among individuals. We explored the association of genetic variants in the apelin system genes (APLN, APLNR and ACE2) and BP response to CPT in a Chinese population. Methods A total of 1,998 Han Chinese participants from the Genetic Epidemiology Network of Salt Sensitivity completed a CPT. The percentage changes of BP right after the end of ice-water immersion were used as the measurement of BP responses to CPT. Twenty-two single nucleotide polymorphisms (SNPs) were selected and genotyped, including both tag and potential functional SNPs of the APLN, APLNR, and ACE2 genes. A mixed-effect linear model was used to assess the association between SNPs and BP responses to CPT. Results In women, three SNPs (rs1514283, rs4646176, and rs879922) of the ACE2 gene were significantly associated with the diastolic BP (DBP) response to CPT in the general and recessive genetic models after adjustment for multiple testing (all false discovery rate q>0.05). There were no significant associations of polymorphisms in APLN and APLNR genes with BP responses to CPT. Conclusions Our study identified genetic variants in the ACE2 gene that were significantly associated with DBP responses to cold stress in the Chinese female population. Future studies are warranted to confirm these findings. © 2012 American Journal of Hypertension, Ltd.","angiotensin converting enzyme 2; apelin; apelin receptor; blood pressure; cold pressor test; hypertension","Adolescent; Adult; Asian Continental Ancestry Group; Blood Pressure; Cold Temperature; Female; Humans; Hypertension; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Receptors, G-Protein-Coupled; angiotensin II; apelin; apelin receptor; ice; water; adult; blood pressure measurement; Chinese; cold pressor test; diastolic blood pressure; female; gene frequency; genetic association; genetic model; genetic screening; genetic variability; genotype; human; major clinical study; male; priority journal; recessive gene; review; single nucleotide polymorphism; systolic blood pressure; water immersion","","angiotensin II, 11128-99-7; water, 7732-18-5; APLN protein, human, ; APLNR protein, human, ; Intercellular Signaling Peptides and Proteins, ; Peptidyl-Dipeptidase A, 3.4.15.1; Receptors, G-Protein-Coupled, ; angiotensin converting enzyme 2, 3.4.17.-","","","National Institutes of Health, NIH; National Heart, Lung, and Blood Institute, NHLBI, (R01HL087263, R01HL090682, U01HL072507)","acknowledgment: the genetic Epidemiology Network of salt sensitivity (gensalt) is supported by research grants (U01HL072507, R01HL087263, and R01HL090682) from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.","Kasagi F., Akahoshi M., Shimaoka K., Relation between cold pressor test and development of hypertension based on 28-year follow-up, Hypertension, 25, pp. 71-76, (1995); Menkes M.S., Matthews K.A., Krantz D.S., Lundberg U., Mead A., Qaqish B., Liang K.-Y., Thomas C.B., Pearson T.A., Cardiovascular reactivity to the cold pressor test as a predictor of hypertension, Hypertension, 14, 5, pp. 524-530, (1989); Victor R.G., Leimbach Jr. W.N., Seals D.R., Effects of the cold pressor test on muscle sympathetic nerve activity in humans, Hypertension, 9, 5, pp. 429-436, (1987); Wood D.L., Sheps S.G., Elveback L.R., Schirger A., Cold pressor test as a predictor of hypertension, Hypertension, 6, 3, pp. 301-306, (1984); Busjahn A., Faulhaber H.-D., Viken R.J., Rose R.J., Luft F.C., Genetic influences on blood pressure with the cold-pressor test: A twin study, Journal of Hypertension, 14, 10, pp. 1195-1199, (1996); Choh A.C., Czerwinski S.A., Lee M., Demerath E.W., Wilson A.F., Towne B., Siervogel R.M., Quantitative genetic analysis of blood pressure response during the cold pressor test, American Journal of Hypertension, 18, 9, pp. 1211-1217, (2005); McIlhany M.L., Shaffer J.W., Hines Jr. E.A., The heritability of blood pressure: An investigation of 200 pairs of twins using the cold pressor test, Johns Hopkins Med J, 136, pp. 57-64, (1975); Mei H., Gu D., Rice T.K., Hixson J.E., Chen J., Jaquish C.E., Zhao Q., Chen C.S., Chen J.C., Gu C.C., Kelly T.N., He J., Heritability of blood pressure responses to cold pressor test in a chinese population, Am J Hypertens, 22, pp. 1096-1100, (2009); Roy-Gagnon M.-H., Weir M.R., Sorkin J.D., Ryan K.A., Sack P.A., Hines S., Bielak L.F., Peyser P.A., Post W., Mitchell B.D., Shuldiner A.R., Douglas J.A., Genetic influences on blood pressure response to the cold pressor test: Results from the Heredity and Phenotype Intervention Heart Study, Journal of Hypertension, 26, 4, pp. 729-736, (2008); Wu T., Snieder H., De Geus E., Genetic influences on cardiovascular stress reactivity, Neurosci Biobehav Rev, 35, pp. 58-68, (2010); Reaux A., De Mota N., Skultetyova I., Lenkei Z., Messari S.E., Gallatz K., Corvol P., Palkovitst M., Llorens-Cortes C., Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain, Journal of Neurochemistry, 77, 4, pp. 1085-1096, (2001); Lee D.L., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., Osmond D.H., George S.R., O'Dowd B.F., Characterization of apelin, the ligand for the APJ receptor, Journal of Neurochemistry, 74, 1, pp. 34-41, (2000); Ishida J., Hashimoto T., Hashimoto Y., Nishiwaki S., Iguchi T., Harada S., Sugaya T., Matsuzaki H., Yamamoto R., Shiota N., Okunishi H., Kihara M., Umemura S., Sugiyama F., Yagami K.-I., Kasuya Y., Mochizuki N., Fukamizu A., Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo, Journal of Biological Chemistry, 279, 25, pp. 26274-26279, (2004); Japp A.G., Cruden N.L., Amer D.A., Li V.K., Goudie E.B., Johnston N.R., Sharma S., Neilson I., Webb D.J., Megson I.L., Flapan A.D., Newby D.E., Vascular effects of apelin in vivo in man, J Am Coll Cardiol, 52, pp. 908-913, (2008); Kagiyama S., Fukuhara M., Matsumura K., Lin Y., Fujii K., Iida M., Central and peripheral cardiovascular actions of apelin in conscious rats, Regulatory Peptides, 125, 1-3, pp. 55-59, (2005); Zhang Q., Yao F., Raizada M.K., O'Rourke S.T., Sun C., Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats, Circ Res, 104, pp. 1421-1428, (2009); Burrell L.M., Johnston C.I., Tikellis C., Cooper M.E., ACE2, a new regulator of the renin-angiotensin system, Trends in Endocrinology and Metabolism, 15, 4, pp. 166-169, (2004); Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, Journal of Biological Chemistry, 277, 17, pp. 14838-14843, (2002); Israel A., Zavala L.E., Cierco M., Gutierrez A., Garrido M.D.R., Effect of AT<sub>1</sub> angiotensin II receptor antagonists on the sympathetic response to a cold pressor test in healthy volunteers, American Journal of Therapeutics, 14, 2, pp. 183-188, (2007); Zucker I.H., Brain angiotensin II: New insights into its role in sympathetic regulation, Circulation Research, 90, 5, pp. 503-505, (2002); Gensalt: Rationale, design, methods and baseline characteristics of study participants, J Hum Hypertens, 21, pp. 639-646, (2007); Chen J., Gu D., Jaquish C.E., Chen C.S., Rao D.C., Liu D., Hixson J.E., Hamm L.L., Gu C.C., Whelton P.K., He J., Association between blood pressure responses to the cold pressor test and dietary sodium intervention in a chinese population, Arch Intern Med, 168, pp. 1740-1746, (2008); Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., Maller J., Sklar P., De Bakker P.I.W., Daly M.J., Sham P.C., PLINK: A tool set for whole-genome association and population-based linkage analyses, American Journal of Human Genetics, 81, 3, pp. 559-575, (2007); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J R Statist Soc B, 57, pp. 289-300, (1995); Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin i to angiotensin 1-9, Circ Res, 87, (2000); Harmer D., Gilbert M., Borman R., Clark K.L., Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme, FEBS Letters, 532, 1-2, pp. 107-110, (2002); Zhong J., Basu R., Guo D., Chow F.L., Byrns S., Schuster M., Loibner H., Wang X.H., Penninger J.M., Kassiri Z., Oudit G.Y., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction, Circulation, 122, pp. 717-728, (2010); Zhong J., Yan Z., Liu D., Ni Y., Zhao Z., Zhu S., Tepel M., Zhu Z., Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome, Journal of Laboratory and Clinical Medicine, 147, 2, pp. 91-95, (2006); Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., Stritzke J., Hengstenberg C., Holmer S.R., Doring A., Lowel H., Schunkert H., Erdmann J., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men: Results of the MONICA Augsburg echocardiographic substudy, Journal of Molecular Medicine, 84, 1, pp. 88-96, (2006); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Zhen Y., Wang J., Li W., Han Y., Liu T., Wang X., Chen J., Wu H., Hui R., Xiangsheng C., Ruilin G., Depei L., Yuhua L., Xigui W., Daowen W., Meiling X., Deyu Z., Dingliang Z., Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women, Clinical Pharmacology and Therapeutics, 82, 2, pp. 187-196, (2007); Zhao Q., Gu D., Kelly T.N., Hixson J.E., Rao D.C., Jaquish C.E., Chen J., Huang J., Chen C.S., Gu C.C., Whelton P.K., He J., Association of genetic variants in the apelin-apj system and ace2 with blood pressure responses to potassium supplementation: The gensalt study, Am J Hypertens, 23, pp. 606-613, (2010); Zhao Q., Hixson J.E., Rao D.C., Gu D., Jaquish C.E., Rice T., Shimmin L.C., Chen J., Cao J., Kelly T.N., Hamm L.L., He J., Genetic variants in the apelin system and blood pressure responses to dietary sodium interventions: A family-based association study, J Hypertens, 28, pp. 756-763, (2010); Japp A.G., Cruden N.L., Barnes G., Van Gemeren N., Mathews J., Adamson J., Johnston N.R., Denvir M.A., Megson I.L., Flapan A.D., Newby D.E., Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure, Circulation, 121, pp. 1818-1827, (2010)","J. Huang; Department of Evidence Based Medicine, Division of Population Genetics, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China; email: jianfhuang@sina.com","","","","","","","","19417225","","AJHYE","22647782","English","Am. J. Hypertens.","Review","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84864277556"
"Hamada A.M.; Yamamoto I.; Nakada Y.; Kobayashi A.; Koike Y.; Miki J.; Yamada H.; Tanno Y.; Ohkido I.; Tsuboi N.; Yamamoto H.; Urashima M.; Yokoo T.","Hamada, Aki Mafune (57199508844); Yamamoto, Izumi (14029524600); Nakada, Yasuyuki (56508059700); Kobayashi, Akimitsu (23397277000); Koike, Yusuke (23992812900); Miki, Jun (56210187900); Yamada, Hiroki (59054651100); Tanno, Yudo (8074036900); Ohkido, Ichiro (35459324900); Tsuboi, Nobuo (7007127543); Yamamoto, Hiroyasu (56429889200); Urashima, Mitsuyoshi (7006713254); Yokoo, Takashi (7004381991)","57199508844; 14029524600; 56508059700; 23397277000; 23992812900; 56210187900; 59054651100; 8074036900; 35459324900; 7007127543; 56429889200; 7006713254; 7004381991","Association between GLCCI1 promoter polymorphism (Rs37972) and post-transplant hypertension in renal transplant recipients","2017","Kidney and Blood Pressure Research","42","6","","1155","1163","8","4","10.1159/000485862","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038079363&doi=10.1159%2f000485862&partnerID=40&md5=1d52f2af6a9e7101cf9e0d17d376975e","Division of Molecular Epidemiology, Germany; Department of Urology, Jikei University School of Medicine, Tokyo, Japan; Department of Internal Medicine, Atsugi City Hospital, Kanagawa, Japan; Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan","Hamada A.M., Division of Molecular Epidemiology, Germany, Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Yamamoto I., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Nakada Y., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Kobayashi A., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Koike Y., Department of Urology, Jikei University School of Medicine, Tokyo, Japan; Miki J., Department of Urology, Jikei University School of Medicine, Tokyo, Japan; Yamada H., Department of Urology, Jikei University School of Medicine, Tokyo, Japan; Tanno Y., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Ohkido I., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Tsuboi N., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan; Yamamoto H., Department of Internal Medicine, Atsugi City Hospital, Kanagawa, Japan; Urashima M., Division of Molecular Epidemiology, Germany; Yokoo T., Department of Internal Medicine, Jikei University, School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan","Background/Aims: Post-transplant hypertension is highly prevalent in renal transplant recipients and is a risk factor for graft loss, cardiovascular disease and death. Glucocorticoid is used to prevent rejection, but simultaneously increases the risk of post-transplant hypertension. The glucocorticoid-induced transcript 1 (GLCCI1) promoter polymorphism (rs37972) has been reported to be associated with response to glucocorticoid therapy in asthma. We therefore examined the association between GLCCI1 promoter polymorphism and post-transplant hypertension in renal transplant recipients. Methods: We conducted a retrospective cohort study of renal transplantation at a single university hospital from October 2003 to January 2014. Fifty consecutive adult recipients were analyzed, with clinical data retrieved from a prospectively collected database. Genotyping was carried out using genomic DNA derived from recipient's blood. GLCCI1 immunoreactivity in vascular endothelial cells was quantitatively analyzed by immunohistochemical staining of recipients' native kidney biopsy-specimens. The primary outcome measure was post-transplant hypertension. Results: Post-transplant hypertension was observed in 14/17 (82%) of recipients with CC, 18/20 (90%) with CT, and 2/13 (15%) with TT genotype. CC/CT genotype was significantly associated with post-transplant hypertension, even after adjustment for covariates (odds ratio, 10.6; 95% confidence intervals, 1.32 to 85.8; P = 0.026). In addition, we observed that GLCCI1 immunoreactivity in arteriolar endothelial cells was higher in kidney specimens obtained from recipients with a CC/ CT genotype than a TT genotype (P = 0.021). Conclusion: GLCCI1 promoter polymorphism rs37972 may be associated with post-transplant hypertension. © 2017 The Author(s) Published by S. Karger AG, Basel","Glcci1; Polymorphism; Post-transplant hypertension; Transplantation","Adult; Aged; Endothelial Cells; Female; Genotype; Humans; Hypertension; Kidney Transplantation; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Glucocorticoid; Retrospective Studies; Transplant Recipients; Young Adult; alpha adrenergic receptor blocking agent; angiotensin receptor antagonist; antihypertensive agent; basiliximab; beta adrenergic receptor blocking agent; calcineurin inhibitor; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; genomic DNA; methylprednisolone; mycophenolate mofetil; glucocorticoid receptor; glucocorticoid-induced transcript 1 protein, human; adult; Article; clinical article; cohort analysis; controlled study; drug dose reduction; female; gene; genetic association; genetic polymorphism; genotype; GLCCI1 gene; graft recipient; human; human cell; human tissue; hypertension; immunosuppressive treatment; kidney biopsy; kidney transplantation; male; postoperative complication; posttransplant hypertension; priority journal; promoter region; retrospective study; vascular endothelial cell; aged; endothelium cell; genetics; hypertension; immunology; kidney transplantation; middle aged; promoter region; single nucleotide polymorphism; young adult","","methylprednisolone, 6923-42-8, 83-43-2; mycophenolate mofetil, 116680-01-4, 128794-94-5; glucocorticoid-induced transcript 1 protein, human, ; Receptors, Glucocorticoid, ","","","","","Mange K.C., Feldman H.I., Joffe M.M., Fa K., Bloom R.D., Blood pressure and the survival of renal allografts from living donors, J Am Soc Nephrol, 15, pp. 187-193, (2004); Fernandez-Fresnedo G., Escallada R., Martin De Francisco A.L., Ruiz J.C., Rodrigo E., Sanz De Castro S., Gonzalez Cotorruelo J., Arias M., Association between pulse pressure and cardiovascular disease in renal transplant patients, Am J Transplant, 5, pp. 394-398, (2005); Cheigh J.S., Haschemeyer R.H., Wang J.C., Riggio R.R., Tapia L., Stenzel K.H., Rubin A.L., Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival, Am J Hypertens, 2, pp. 341-348, (1989); Opelz G., Dohler B., Collaborative Transplant Study; Improved long-term outcomes after renal transplantation associated with blood pressure control, Am J Transplant, 5, pp. 2725-2731, (2005); Ponticelli C., Montagnino G., Aroldi A., Angelini C., Braga M., Tarantino A., Hypertension after renal transplantation, Am J Kidney Dis, 21, pp. S73-S78, (1993); First M.R., Neylan J.F., Rocher L.L., Tejani A., Hypertension after renal transplantation, J Am Soc Nephrol, 4, pp. S30-S36, (1994); Kasiske B.L., Anjum S., Shah R., Skogen J., Kandaswamy C., Danielson B., O'Shaughnessy E.A., Dahl D.C., Silkensen J.R., Sahadevan M., Snyder J.J., Hypertension after kidney transplantation, Am J Kidney Dis, 43, pp. 1071-1081, (2004); Paul L.C., Benediktsson H., Post-transplant hypertension and chronic renal allograft failure, Kidney Int, 52, pp. S34-S37, (1995); Nakamoto H., Suzuki H., Kageyama Y., Ohishi A., Murakami M., Naitoh M., Saruta T., Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs, Clin Exp Hypertens A, 13, pp. 587-606, (1991); Hricik D.E., Lautman J., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A., Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients, Transplantation, 53, pp. 1232-11125, (1992); Wallerath T., Witte K., Schafer S.C., Schwarz P.M., Prellwitz W., Wohlfart P., Kleinert H., Lehr H.A., Lemmer B., Forstermann U., Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension, Proc Natl Acad Sci USA, 96, pp. 13357-13362, (1999); Whitworth J.A., Mangos G.J., Kelly J.J., Cushing, cortisol, and cardiovascular disease, Hypertension, 36, pp. 912-919, (2000); Mangray M., Vella J.P., Hypertension after kidney transplant, Am J Kidney Dis, 57, pp. 331-341, (2011); Saruta T., Mechanism of glucocorticoid-induced hypertension, Hypertens Res, 19, pp. 1-8, (1996); Quax R.A., Manenschijn L., Koper J.W., Hazes J.M., Lamberts S.W., Van Rossum E.F., Feelders R.A., Glucocorticoid sensitivity in health and disease, Nat Rev Endocrinol, 9, pp. 670-686, (2013); Tantisira K.G., Lasky-Su J., Harada M., Murphy A., Litonjua A.A., Himes B.E., Lange C., Lazarus R., Sylvia J., Klanderman B., Duan Q.L., Qiu W., Hirota T., Martinez F.D., Mauger D., Sorkness C., Szefler S., Lazarus S.C., Jr L.R.F., Peters S.P., Et al., Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma, N Engl J Med, 365, pp. 1173-1183, (2011); Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Yamagata K., Tomino Y., Yokoyama H., Hishida A., Collaborators developing the Japanese equation for estimated GFR, Am J Kidney Dis, 53, pp. 982-992, (2009); Maroni B.J., Steinman T.I., Mitch W.E., A method for estimating nitrogen intake of patients with chronic renal failure, Kidney Int, 27, pp. 58-65, (1985); Haas M., Sis B., Racusen L.C., Solez K., Glotz D., Colvin R.B., Castro M.C., David D.S., David-Neto E., Bagnasco S.M., Cendales L.C., Cornell L.D., Demetris A.J., Drachenberg C.B., Farver C.F., Farris A.B., Gibson I.W., Kraus E., Liapis H., Loupy A., Et al., Banff meeting report writing committee; Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions, Am J Transplant, 14, pp. 272-283, (2014); Taler S.J., Agarwal R., Bakris G.L., Flynn J.T., Nilsson P.M., Rahman M., Sanders P.W., Textor S.C., Weir M.R., Townsend R.R., KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD, Am J Kidney Dis, 62, pp. 201-213, (2013); Suzuki M., Yoshioka M., Hashimoto M., Murakami M., Kawasaki K., Noya M., Takahashi D., Urashima M., 25-hydroxyVitamin D, Vitamin D receptor gene polymorphisms, and severity of Parkinson's disease, Mov Disord, 27, pp. 264-271, (2012); Yaginuma T., Yamamoto I., Yamamoto H., Mitome J., Tanno Y., Yokoyama K., Hayashi T., Kobayashi T., Watanabe M., Yamaguchi Y., Hosoya T., Increased lymphatic vessels in patients with encapsulating peritoneal sclerosis, Perit Dial Int, 32, pp. 617-627, (2012); Laurent S., Boutouyrie P., The structural factor of hypertension: Large and small artery alterations, Circ Res, 116, pp. 1007-1021, (2015); Uesugi N., Pathology of renal arteriosclerosis, Nihon Jinzo Gakkai Shi, 58, pp. 97-103, (2016); Gattone V.H., Miller B.G., Evan A.P., Microvascular smooth muscle cell quantitation from scanning electron microscopic preparations, Anat Rec, 216, pp. 443-447, (1986); Miller B.G., Connors B.A., Bohlen H.G., Evan A.P., Cell and wall morphology of intestinal arterioles from 4- To 6- And 17- To 19-week-old Wistar-Kyoto and spontaneously hypertensive rats, Hypertension, 9, pp. 59-68, (1987); Zweifler A.J., Nicholls M.G., Diminished finger volume pulse in borderline hypertension: Evidence for early structural vascular abnormality, Am Heart J, 104, pp. 812-815, (1982); The Short Genetic Variations Database (dbSNP); Chu C., Wang Y., Wang M., Mu J.J., Liu F.Q., Wang L., Ren K.Y., Wang D., Yuan Z.Y., Common variants in serum/ glucocorticoid regulated kinase 1 (SGK1) and blood pressure responses to dietary sodium or potassium interventions: A family-based association study, Kidney Blood Press Res, 40, pp. 424-434, (2015); Chung C.C., Shimmin L., Natarajan S., Hanis C.L., Boerwinkle E., Hixson J.E., Glucocorticoid receptor gene variant in the 3' untranslated region is associated with multiple measures of blood pressure, J Clin Endocrinol Metab, 94, pp. 268-276, (2009); Chiba S., Nakamura Y., Mizuno T., Abe K., Horii Y., Nagashima H., Sasaki N., Kanno H., Tanita T., Yamauchi K., Impact of the genetic variants of GLCCI1 on clinical features of asthmatic patients, Clin Respir J; Cheong H.I., Kang H.G., Schlondorff J., GLCCI1 single nucleotide polymorphisms in pediatric nephrotic syndrome, Pediatr Nephrol, 27, pp. 1595-1599, (2012); Nishibori Y., Katayama K., Parikka M., Oddsson A., Nukui M., Hultenby K., Wernerson A., He B., Ebarasi L., Raschperger E., Norlin J., Uhlen M., Patrakka J., Betsholtz C., Tryggvason K., Glcci1 deficiency leads to proteinuria, J Am Soc Nephrol, 22, pp. 2037-2046, (2011)","","","S. Karger AG","","","","","","14204096","","KBPRF","29224020","English","Kidney Blood Press. Res.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85038079363"
"Klenke S.; Siffert W.","Klenke, Stefanie (37012155500); Siffert, Winfried (7005096601)","37012155500; 7005096601","SNPs in genes encoding G proteins in pharmacogenetics","2011","Pharmacogenomics","12","5","","633","654","21","21","10.2217/pgs.10.203","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957630479&doi=10.2217%2fpgs.10.203&partnerID=40&md5=f563e4eb844fe455ceab4fefd054aa4f","Institut für Pharmakogenetik, Universität Duisburg-Essen, 45122 Essen, Hufelandstr. 55, Germany","Klenke S., Institut für Pharmakogenetik, Universität Duisburg-Essen, 45122 Essen, Hufelandstr. 55, Germany; Siffert W., Institut für Pharmakogenetik, Universität Duisburg-Essen, 45122 Essen, Hufelandstr. 55, Germany","Heterotrimeric guanine-binding proteins (G proteins) transmit signals from the cell surface to intracellular signal cascades and are involved in various physiological and pathophysiological processes. Polymorphisms in the genes GNB3 (encoding the Gα3 subunit), GNAS (encoding the G;alpha±s subunit) and GNAQ (encoding the Gαq subunit) have been the primary focus of investigation. Polymorphisms in these genes could be associated with different complex phenotypes underlining that alterations in G-protein signaling can cause multiple disorders. G proteins present a point of convergence or ;lsquorsquor between various receptors and effectors, thus making them a sensible tool for pharmacogenetic studies. The pharmacogenetic studies performed to date mostly demonstrate an association between G-protein polymorphisms and response to therapy or occurrence of adverse drug effects. Therefore, polymorphisms in genes encoding G-protein subunits may help to individualize drug treatment in various diseases with regard to both efficacy and safety. © 2011 Future Medicine Ltd.","G protein; GNAQ; GNAS; GNB3; pharmacogenetics; polymorphism","Animals; GTP-Binding Proteins; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Protein Binding; Protein Subunits; Signal Transduction; alpha 2 adrenergic receptor blocking agent; alpha interferon; angiotensin II; antidepressant agent; antihypertensive agent; antiretrovirus agent; beta adrenergic receptor blocking agent; cisplatin; clonidine; cyclic AMP; darusentan; dexmedetomidine; dipeptidyl carboxypeptidase inhibitor; endothelin; fibrinogen receptor antagonist; fluorouracil; guanine nucleotide binding protein; nortriptyline; orbofiban; placebo; protein kinase C; protein subunit; ribavirin; serotonin noradrenalin reuptake inhibitor; sibutramine; sildenafil; thiazide diuretic agent; tricyclic antidepressant agent; unindexed drug; valsartan; adverse drug reaction; ascites; cardiovascular disease; cell surface; depression; drug efficacy; drug safety; erectile dysfunction; esophagus cancer; gene; GNAQ gene; GNAS gene; GNB3 gene; haplotype; heart failure; hepatitis C; human; Human immunodeficiency virus 1 infection; hypertension; insomnia; mood disorder; nonhuman; obesity; pharmacogenetics; phenotype; review; side effect; signal transduction; single nucleotide polymorphism; treatment response; weight gain","","angiotensin II, 11128-99-7; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; clonidine, 4205-90-7, 4205-91-8, 57066-25-8; cyclic AMP, 60-92-4; darusentan, 171714-84-4; dexmedetomidine, 113775-47-6; fluorouracil, 51-21-8; nortriptyline, 72-69-5, 894-71-3; orbofiban, 163250-90-6, 163250-91-7, 165800-05-5; protein kinase C, 141436-78-4; ribavirin, 36791-04-5; sibutramine, 106650-56-0; sildenafil, 139755-83-2; valsartan, 137862-53-4; GTP-Binding Proteins, 3.6.1.-; Protein Subunits, ","","","","","Bourne H.R., How receptors talk to trimeric G proteins, Current Opinion in Cell Biology, 9, 2, pp. 134-142, (1997); Downes G.B., Gautam N., The G protein subunit gene families, Genomics, 62, 3, pp. 544-552, (1999); Gautam N., Downes G.B., Yan K., Kisselev O., The G-protein bg complex, Cell Signal, 10, 7, pp. 447-455, (1998); Farfel Z., Bourne H.R., Iiri T., The expanding spectrum of G protein diseases, New England Journal of Medicine, 340, 13, pp. 1012-1020, (1999); Gudermann T., Kalkbrenner F., Schultz G., Diversity and selectivity of receptor-G protein interaction, Annual Review of Pharmacology and Toxicology, 36, pp. 429-459, (1996); Clapham D.E., Neer E.J., G protein b g subunits, Annu. Rev. Pharmacol. Toxicol, 37, pp. 167-203, (1997); Levine M.A., Modi W.S., O'Brien S.J., Chromosomal localization of the genes encoding two forms of the G protein β polypeptide, β1 and β3, in man, Genomics, 8, 2, pp. 380-386, (1990); Sondek J., Bohm A., Lambriht D.G., Hamm H.E., Sigler P.B., Crystal structure of a G(A) protein βγ dimer at 2.1 a resolution, Nature, 379, 6563, pp. 369-374, (1996); Logothetis D.E., Kurachi Y., Galper J., The βγ subunits of GTP-binding proteins activate the muscarinic K<sup>+</sup> channel in heart, Nature, 325, 6102, pp. 321-326, (1987); Schneider T., Igelmund P., Hescheler J., G protein interaction with K<sup>+</sup> and Ca<sup>2+</sup> channels, Trends in Pharmacological Sciences, 18, 1, pp. 8-11, (1997); Jan L.Y., Jan Y.N., Receptor-regulated ion channels, Current Opinion in Cell Biology, 9, 2, pp. 155-160, (1997); Jelsema C.L., Axelrod J., Stimulation of phospholipase A<sub>2</sub> activity in bovine rod outer segments by the βγ subunits of transducin and its inhibition by the α subunit, Proceedings of the National Academy of Sciences of the United States of America, 84, 11, pp. 3623-3627, (1987); Sternweis P.C., The active role of b g in signal transduction, Curr. Opin. Cell Biol, 6, 2, pp. 198-203, (1994); Camps M., Hou C., Sidiropoulos D., Stock J.B., Jakobs K.H., Gierschik P., Stimulation of phospholipase C by guanine-nucleotide-binding protein b g subunits, Eur. J. Biochem, 206, 3, pp. 821-831, (1992); Tang W.-J., Gilman A.G., Type-specific regulation of adenylyl cyclase by G protein βγ subunits, Science, 254, 5037, pp. 1500-1503, (1991); Gao B., Gilman A.G., Cloning and expression of a widely distributed (type IV) adenylyl cyclase, Proceedings of the National Academy of Sciences of the United States of America, 88, 22, pp. 10178-10182, (1991); Haga T., Haga K., Kameyama K., G protein-coupled receptor kinases, Journal of Neurochemistry, 63, 2, pp. 400-412, (1994); Pitcher J.A., Inglese J., Higgins J.B., Et al., Role of b g subunits of G proteins in targeting the b-adrenergic receptor kinase to membrane-bound receptors, Science, 257, 5074, pp. 1264-1267, (1992); Stephens L., Smrcka A., Cooke F.T., Jackson T.R., Sternweis P.C., Hawkins P.T., A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein βγ subunits, Cell, 77, 1, pp. 83-93, (1994); Inglese J., Koch W.J., Touhara K., Lefkowitz R.J., G b g interactions with PH domains and Ras-MAPK signaling pathways, Trends Biochem. Sci, 20, 4, pp. 151-156, (1995); Mattingly R.R., Macara I.G., Phosphorylatlon-dependent activation of the Ras-GRF/CDC25(Mm) exchange factor by muscarinic receptors and G-protein βγ subunits, Nature, 382, 6588, pp. 268-272, (1996); Pumiglia K.M., Levine H., Haske T., Habib T., Jove R., Decker S.J., A direct interaction between G-protein b g subunits and the Raf-1 protein kinase, J. Biol. Chem, 270, 24, pp. 14251-14254, (1995); Hamm H.E., The many faces of G protein signaling, Journal of Biological Chemistry, 273, 2, pp. 669-672, (1998); Neer E.J., Heterotrimeric G proteins: Organizers of transmembrane signals, Cell, 80, 2, pp. 249-257, (1995); Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Sharma A.M., Ritz E., Wichmann H.-E., Jakobs K.H., Horsthemke B., Association of a human G-protein β3 subunit variant with hypertension, Nature Genetics, 18, 1, pp. 45-48, (1998); Neer E.J., Schmidt C.J., Nambudripad R., Smith T.F., The ancient regulatory-protein family of WD-repeat proteins, Nature, 371, 6495, pp. 297-300, (1994); Iiri T., Bourne H.R., G proteins propel surprise, Nature Genetics, 18, 1, pp. 8-10, (1998); Virchow S., Ansorge N., Rubben H., Siffert G., Siffert W., Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein β3 subunit 825 T-allele, FEBS Letters, 436, 2, pp. 155-158, (1998); Lindemann M., Virchow S., Ramann F., Barsegian V., Kreuzfelder E., Siffert W., Muller N., Grosse-Wilde H., The G protein β3 subunit 825T allele is a genetic marker for enhanced T cell response, FEBS Letters, 495, 1-2, pp. 82-86, (2001); Ryden M., Faulds G., Hoffstedt J., Wennlund A., Arner P., Effect of the (C825T) Gβ<sub>3</sub> polymorphism on adrenoceptor-mediated lipolysis in human fat cells, Diabetes, 51, 5, pp. 1601-1608, (2002); Rosskopf D., Manthey I., Habich C., Kielbik M., Eisenhardt A., Nikula C., Urban M., Kohnen S., Graf E., Ravens U., Siffert W., Identification and characterization of Gβ3s2, a novel splice variant of the G-protein β3 subunit, Biochemical Journal, 371, 1, pp. 223-232, (2003); Rosskopf D., Busch S., Manthey I., Siffert W., G protein β3 gene: Structure, promoter, and additional polymorphisms, Hypertension, 36, 1, pp. 33-41, (2000); Rosskopf D., Manthey I., Siffert W., Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein β3 subunit, Pharmacogenetics, 12, 3, pp. 209-220, (2002); Sun A., Ge J., Siffert W., Frey U.H., Quantification of allele-specific G-protein β3 subunit mRNA transcripts in different human cells and tissues by Pyrosequencing, European Journal of Human Genetics, 13, 3, pp. 361-369, (2005); Schunkert H., Hense H.-W., Doring A., Riegger G.A.J., Siffert W., Association between a polymorphism in the G protein β3 subunit gene and lower renin and elevated diastolic blood pressure levels, Hypertension, 32, 3, pp. 510-513, (1998); Hengstenberg C., Schunkert H., Mayer B., Doring A., Lowel H., Hense H.-W., Fischer M., Riegger G.A.J., Holmer S.R., Association between a polymorphism in the G protein β3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction, Cardiovascular Research, 49, 4, pp. 820-827, (2001); Benjafield A.V., Jeyasingam C.L., Nyholt D.R., Griffiths L.R., Morris B.J., G-protein β3 subunit gene (GNB3) variant in causation of essential hypertension, Hypertension, 32, 6, pp. 1094-1097, (1998); Brand E., Wang J.-G., Herrmann S.-M., Staessen J.A., An epidemiological study of blood pressure and metabolic phenotypes in relation to the Gβ<sub>3</sub> C825T polymorphism, Journal of Hypertension, 21, 4, pp. 729-737, (2003); Brand E., Herrmann S.-M., Nicaud V., Ruidavets J.-B., Evans A., Arveiler D., Luc G., Plouin P.-F., Tiret L., Cambien F., The 825C/T polymorphism of the G-protein subunit β3 is not related to hypertension, Hypertension, 33, 5, pp. 1175-1178, (1999); Snapir A., Heinonen P., Tuomainen T.-P., Lakka T.A., Kauhanen J., Salonen J.T., Scheinin M., G-protein β<sub>3</sub> subunit C825T polymorphism: No association with risk for hypertension and obesity, Journal of Hypertension, 19, 12, pp. 2149-2155, (2001); Holmen O.L., Romundstad S., Melien O., Association between the G protein b3 subunit C825T polymorphism and the occurrence of cardiovascular disease in hypertensives: The Nord-Trondelag Health Study (HUNT), Am. J. Hypertens, 23, 10, pp. 1121-1127, (2010); Siffert W., G protein polymorphisms in hypertension, atherosclerosis and diabetes, Annual Review of Medicine, 56, pp. 17-28, (2005); Bagos P.G., Elefsinioti A.L., Nikolopoulos G.K., Hamodrakas S.J., The GNB3 C825T polymorphism and essential hypertension: A meta-analysis of 34 studies including 14 094 cases and 17 760 controls, Journal of Hypertension, 25, 3, pp. 487-500, (2007); Ishikawa K., Imai Y., Katsuya T., Ohkubo T., Tsuji I., Nagai K., Takami S., Nakata Y., Satoh H., Hisamichi S., Higaki J., Ogihara T., Human G-protein β3 subunit variant is associated with serum potassium and total cholesterol levels but not with blood pressure, American Journal of Hypertension, 13, 2, pp. 140-145, (2000); Shioji K., Kokubo Y., Mannami T., Inamoto N., Morisaki H., Mino Y., Tago N., Yasui N., Iwai N., Association between hypertension and the α-adducin, β1-adrenoreceptor, and G-protein β3 subunit genes in the Japanese population; the Suita study, Hypertension Research, 27, 1, pp. 31-37, (2004); Suwazono Y., Okubo Y., Kobayashi E., Miura K., Morikawa Y., Ishizaki M., Kido T., Nakagawa H., Nogawa K., Lack of association between human G-protein β3 subunit variant and overweight in Japanese workers, Obesity Research, 12, 1, pp. 4-8, (2004); Huang X., Ju Z., Song Y., Zhang H., Sun K., Lu H., Yang Z., Jose P.A., Zhou G., Wang M., Wang W., Feng S., Hui R., Lack of association between the G protein β<sub>3</sub> subunit gene and essential hypertension in Chinese: A case-control and a family-based study, Journal of Molecular Medicine, 81, 11, pp. 729-735, (2003); Siffert W., Forster P., Jockel K.-H., Mvere D.A., Brinkmann B., Naber C., Crookes R., Heyns A.D.P., Epplen J.T., Fridey J., Freedman B.I., Muller N., Stolke D., Sharma A.M., Moutaery K.A., Grosse-Wilde H., Buerbaum B., Ehrlich T., Ahmad H.R., Horsthemke B., Du Toit E.D., Tiilikainen A., Ge J., Wang Y., Yang D., Husing J., Rosskopf D., Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in caucasian, Chinese, and black African individuals, Journal of the American Society of Nephrology, 10, 9, pp. 1921-1930, (1999); Nielsen H., Mortensen F.V., Mulvany M.J., Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both α<sub>1</sub>- and α<sub>2</sub>-adrenoceptors, British Journal of Pharmacology, 99, 1, pp. 31-34, (1990); Richardson M., Robishaw J.D., The a2A-adrenergic receptor discriminates between Gi heterotrimers of different bg subunit composition in Sf9 insect cell membranes, J. Biol. Chem, 274, 19, pp. 13525-13533, (1999); Baumgart D., Naber C., Haude M., Oldenburg O., Erbel R., Heusch G., Siffert W., G protein β3 subunit 825T allele and enhanced coronary vasoconstriction on α<sub>2</sub>-adrenoceptor activation, Circulation Research, 85, 10, pp. 965-969, (1999); Meirhaeghe A., Bauters C., Helbecque N., Hamon M., McFadden E., Lablanche J.-M., Bertrand M., Amouyel P., The human G-protein β3 subunit C825T polymorphism is associated with coronary artery vasoconstriction, European Heart Journal, 22, 10, pp. 845-848, (2001); Naber C., Hermann B.L., Vietzke D., Et al., Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein b3 subunit 825T allele, FEBS Lett, 484, 3, pp. 199-201, (2000); Schafers R.F., Nurnberger J., Rutz A., Siffert W., Wenzel R.R., Mitchell A., Philipp T., Michel M.C., Haemodynamic characterization of young normotensive men carrying the 825t-allele of the g-protein β3 subunit, Pharmacogenetics, 11, 6, pp. 461-470, (2001); Nurnberger J., Opazo Saez A., Mitchell A., Buhrmann S., Wenzel R.R., Siffert W., Philipp T., Schafers R.F., The T-allele of the C825T polymorphism is associated with higher arterial stiffness in young healthy males, Journal of Human Hypertension, 18, 4, pp. 267-271, (2004); Wascher T.C., Paulweber B., Malaimare L., Stadlmayr A., Iglseder B., Schmoelzer I., Renner W., Associations of a human G protein β3 subunit dimorphism with insulin resistance and carotid atherosclerosis, Stroke, 34, 3, pp. 605-609, (2003); Morrison A.C., Doris P.A., Folsom A.R., Nieto F.J., Boerwinkle E., G-protein b3 subunit and a-adducin polymorphisms and risk of subclinical and clinical stroke, Stroke, 32, 4, pp. 822-829, (2001); Von Beckerath N., Kastrati A., Koch W., Bottiger C., Mehilli J., Seyfarth M., Schomig A., G protein β3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement, Atherosclerosis, 149, 1, pp. 151-155, (2000); Von Beckerath N., Schusterschitz Y., Koch W., Griesser K., Mehilli J., Gorchakova O., Schomig A., Kastrati A., G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease, Atherosclerosis, 167, 1, pp. 135-139, (2003); Naber C.K., Husing J., Wolfhard U., Erbel R., Siffert W., Interaction of the ACE D allele and the GNB3 825T allele in myocardial infarction, Hypertension, 36, 6, pp. 986-989, (2000); Renner W., Hoffmann M.M., Grunbacher G., Winkelmann B.R., Boehm B.O., Marz W., G-protein β3 subunit (GNB3) gene polymorphisms and cardiovascular disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study, Atherosclerosis, 192, 1, pp. 108-112, (2007); Yamada Y., Izawa H., Ichihara S., Takatsu F., Ishihara H., Hirayama H., Sone T., Tanaka M., Yokota M., Prediction of the risk of myocardial infarction from polymorphisms in candidate genes, New England Journal of Medicine, 347, 24, pp. 1916-1923, (2002); Wang H.Y., Malbon C.C., The Gs a/Gi a 2 axis controls adipogenesis independently of adenylylcyclase, Int. J. Obes. Relat. Metab. Disord, 20, SUPPL. 3, (1996); Moxham C.M., Hod Y., Malbon C.C., Induction of Gα(i2)-specific antisense RNA in vivo inhibits neonatal growth, Science, 260, 5110, pp. 991-995, (1993); Poch E., Giner V., Gonzalez-Nunez D., Coll E., Oriola J., De La Sierra A., Association of the G protein β3 subunit T allele with insulin resistance in essential hypertension, Clinical and Experimental Hypertension, 24, 5, pp. 345-353, (2002); Siffert W., Naber C., Walla M., Ritz E., G protein β3 subunit 825T allele and its potential association with obesity in hypertensive individuals, Journal of Hypertension, 17, 8, pp. 1095-1098, (1999); Stefan N., Stumvoll M., Machicao F., Koch M., Haring H.U., Fritsche A., C825T polymorphism of the G protein β<sub>3</sub> subunit is associated with obesity but not with insulin sensitivity, Obesity Research, 12, 4, pp. 679-683, (2004); Hegele R.A., Anderson C., Young T.K., Connelly P.W., G-protein β3 subunit gene splice variant and body fat distribution in nunavut Inuit, Genome Research, 9, 10, pp. 972-977, (1999); Benjafield A.V., Lin R.C.Y., Dalziel B., Gosby A.K., Caterson I.D., Morris B.J., G-protein β3 subunit gene splice variant in obesity and overweight, International Journal of Obesity, 25, 6, pp. 777-780, (2001); Rankinen T., Rice T., Leon A.S., Skinner J.S., Wilmore J.H., Rao D.C., Bouchard C., G protein β3 polymorphism and hemodynamic and body composition phenotypes in the HERITAGE Family Study, Physiological Genomics, 2002, 8, pp. 151-157, (2002); Hauner H., Rohrig K., Siffert W., Effects of the G-protein β<sub>3</sub> subunit 825T allele on adipogenesis and lipolysis in cultured human preadipocytes and adipocytes, Hormone and Metabolic Research, 34, 9, pp. 475-480, (2002); Michalsen A., Frey U.H., Merse S., Siffert W., Dobos G.J., Hunger and mood during extended fasting are dependent on the GNB3 C825T polymorphism, Ann. Nutr. Metab, 54, 3, pp. 184-188, (2009); Pollex R.L., Hanley A.J.G., Zinman B., Harris S.B., Khan H.M.R., Hegele R.A., Metabolic syndrome in aboriginal Canadians: Prevalence and genetic associations, Atherosclerosis, 184, 1, pp. 121-129, (2006); Yamamoto M., Abe M., Jin J.J., Wu Z., Tabara Y., Mogi M., Kohara K., Miki T., Nakura J., Association of GNB3 gene with pulse pressure and clustering of risk factors for cardiovascular disease in Japanese, Biochemical and Biophysical Research Communications, 316, 3, pp. 744-748, (2004); Pollex R.L., Hanley A.J., Zinman B., Harris S.B., Hegele R.A., Clinical and genetic associations wkh hypertriglyceridemic waist in a Canadian aboriginal population, Int. J. Obes. (Lond.), 30, 3, pp. 484-491, (2006); Sailer B., Nemesszeghy P., Mann K., Siffert W., Rosskopf D., Glucose and lipid metabolism in young lean normotensive males wkh the G protein p3 825T-allele, Eur. J. Med. Res, 8, 3, pp. 91-97, (2003); Suwazono Y., Kobayashi E., Uetani M., Miura K., Morikawa Y., Ishizaki M., Kido T., Nakagawa H., Nogawa K., G-protein β3 subunit polymorphism C1429T and low-density lipoprotein receptor-related protein 5 polymorphism A1330V are risk factors for hypercholesterolemia in Japanese males-a prospective study over 5 years, Metabolism: Clinical and Experimental, 55, 6, pp. 751-757, (2006); Nurnberger J., Dammer S., Philipp T., Wenzel R.R., Schafers R.F., Metabolic and haemodynamic effects of oral glucose loading in young healthy men carrying the 825T-allele of the G protein p3 subunk, Cardiovasc. Diabetol, 2, (2003); Nicholson A.C., Hajjar D.P., Transforming growth factor-β up-regulates low density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells, Journal of Biological Chemistry, 267, 36, pp. 25982-25987, (1992); Michalsen A., Knoblauch N.T., Lehmann N., Et al., Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina - The role of GNB3 C825T polymorphism, Am. Heart J, 151, 4, pp. 870-877, (2006); Rasenick M.M., Chaney K.A., Chen J., G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: Evidence from model systems, Journal of Clinical Psychiatry, 57, SUPPL. 13, pp. 49-55, (1996); Hudson C.J., Young L.T., Li P.P., Warsh J.J., CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia, Synapse, 13, 3, pp. 278-293, (1993); Zill P., Baghai T.C., Zwanzger P., Schule C., Minov C., Riedel M., Neumeier K., Rupprecht R., Bondy B., Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment, NeuroReport, 11, 9, pp. 1893-1897, (2000); Exton M.S., Artz M., Siffert W., Schedlowski M., G protein β3 subunit 825T allele is associated with depression in young, healthy subjects, NeuroReport, 14, 3, pp. 531-533, (2003); Lee H.J., Chajh Ham B.J., Et al., Association between a G-protein p 3 subunk gene polymorphism and the symptomatology and treatment responses of major depressive disorders, Pharmacogenomics J, 4, 1, pp. 29-33, (2004); Lopez-Leon S., Janssens A.C.J.W., Gonzalez-Zuloeta Ladd A.M., Del-Favero J., Claes S.J., Oostra B.A., Van Duijn C.M., Meta-analyses of genetic studies on major depressive disorder, Molecular Psychiatry, 13, 8, pp. 772-785, (2008); Kunugi H., Kato T., Fukuda R., Tatsumi M., Sakai T., Nanko S., Association study of C825T polymorphism of the G-protein b3 subunit gene with schizophrenia and mood disorders, Journal of Neural Transmission, 109, 2, pp. 213-218, (2002); Lin C.N., Tsai S.J., Hong C.J., Association analysis of a functional G protein p3 subunk gene polymorphism (C825T) in mood disorders, Neuropsychobiology, 44, 3, pp. 118-121, (2001); Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A., Involvement of chemokine receptors in breast cancer metastasis, Nature, 410, 6824, pp. 50-56, (2001); Eisenhardt A., Siffert W., Rosskopf D., Musch M., Mosters M., Roggenbuck U., Jockel K.-H., Rubben H., Lummen G., Association study of the G-protein β3 subunit C825T polymorphism with disease progression in patients with bladder cancer, World Journal of Urology, 23, 4, pp. 279-286, (2005); Lehnerdt G.F., Franz P., Bankfalvi A., Et al., Association study of the G-protein p3 subunk C825T polymorphism wkh disease progression an overall survival in patients wkh head and neck squamous cell carcinoma, Cancer Epidemiol. BiomarkersPrev, 17, 11, pp. 3203-3207, (2008); Fingas C.D., Katsounas A., Kahraman A., Et al., Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T BCL2-938C>AMCL1-386C>G) in extrahepatic cholangiocarcinoma, Cancer Invest, 28, 5, pp. 472-478, (2010); Nuckel H., Frey U., Aral N., Durig J., Duhrsen U., Siffert W., The CC genotype of the C825T polymorphism of the G protein β3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia, Leukemia and Lymphoma, 44, 10, pp. 1739-1743, (2003); Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., Paulweber B., Samonigg H., The 825C>T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer, Cancer Letters, 206, 1, pp. 59-62, (2004); Clar H., Langsenlehner U., Krippl P., Et al., A polymorphism in the G protein p3-subunk gene is associated wkh bone metastasis risk in breast cancer patients, Breast Cancer Res. Treat, 111, 3, pp. 449-452, (2008); Sheu S.-Y., Handke S., Brocker-Preuss M., Gorges R., Frey U.H., Ensinger C., Ofner D., Farid N.R., Siffert W., Schmid K.W., The C allele of the GNB3 C825T polymorphism of the G protein β3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours, Journal of Pathology, 211, 1, pp. 60-66, (2007); El Hindy N., Adamzik M., Lambertz N., Et al., Association of the GNB3 825T-allele with better survival in patients wkh glioblastoma multiforme, J. Cancer Res. Clin. Oncol, 136, 9, pp. 1423-1429, (2010); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein β<sub>3</sub>-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, 2, pp. 739-743, (2001); Schelleman H., Stricker B.H.Ch., Verschuren W.M.M., De Boer A., Kroon A.A., De Leeuw P.W., Kromhout D., Klungel O.H., Interactions between five candidate genes and antihypertensive drug therapy on blood pressure, Pharmacogenomics Journal, 6, 1, pp. 22-26, (2006); Bozkurt O., De Boer A., Grobbee D.E., Et al., Variation in renin-angiotensin system and salt-senskivity genes and the risk of diabetes mellhus associated with the use of thiazide diuretics, Am. J. Hypertens, 22, 5, pp. 545-551, (2009); Filigheddu F., Reid J.E., Troffa C., PinnaParpaglia P., Argiolas G., Testa A., Skolnick M., Glorioso N., Genetic polymorphisms of the β-adrenergic system: Association with essential hypertension and response to β-blockade, Pharmacogenomics Journal, 4, 3, pp. 154-160, (2004); Nurnberger J., Dammer S., Mitchell A., Siffert W., Wenzel R.R., Gossl M., Philipp T., Michel M.C., Schafers R.F., Effect of the C825T polymorphism of the G protein β<sub>3</sub> subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects, Clinical Pharmacology and Therapeutics, 74, 1, pp. 53-60, (2003); Kurnik D., Muszkat M., Sofowora G.G., Friedman E.A., Dupont W.D., Scheinin M., Wood A.J.J., Stein C.M., Ethnic and genetic determinants of cardiovascular response to the selective α2-adrenoceptor agonist dexmedetomidine, Hypertension, 51, 2, pp. 406-411, (2008); Yang Y.Y., Lin H.C., Lee W.P., Et al., Association of the G-protein and a2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: A randomised clinical trial, Gut, 59, 11, pp. 1545-1553, (2010); Wenzel R.R., Siffert W., Bruck H., Philipp T., Schafers R.F., Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation, Pharmacogenetics, 12, 6, pp. 489-495, (2002); Mitchell A., Pace M., Nurnberger J., Wenzel R.R., Siffert W., Philipp T., Schafers R.F., Insulin-mediated venodilation is impaired in young, healthy carriers of the 825T allele of the G-protein β<sub>3</sub> subunit gene (GNB3), Clinical Pharmacology and Therapeutics, 77, 6, pp. 495-502, (2005); Mitchell A., Buhrmann S., Seifert A., Nurnberger J., Wenzel R.R., Siffert W., Philipp T., Schafers R.F., Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein β3 subunit gene (GNB3), Clinical Pharmacology and Therapeutics, 74, 5, pp. 499-504, (2003); Mitchell A., Luckebergfeld B., Buhrmann S., Rushentsova U., Nurnberger J., Siffert W., Schafers R.F., Philipp T., Wenzel R.R., Effects of systemic endothelin A receptor antagonism in various vascular beds in men: In vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism, Clinical Pharmacology and Therapeutics, 76, 5, pp. 396-408, (2004); Mitchell A., Rushentsova U., Siffert W., Philipp T., Wenzel R.R., The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: Influence of the G-protein p3 subunk {GNB3) C825T polymorphism, Clin. Pharmacol. Ther, 79, 3, pp. 274-281, (2006); Sperling H., Eisenhardt A., Virchow S., Hauck E., Lenk S., Porst H., Stief C., Wetterauer U., Rubben H., Muller N., Siffert W., Sildenafil response is influenced by the G protein β3 subunit GNB3 C825T polymorphism: A pilot study, Journal of Urology, 169, 3, pp. 1048-1051, (2003); Frey U.H., Aral N., Muller N., Siffert W., Cooperative effect of GNB3 825C>T and GPIIIa PI(A) polymorphisms in enhanced platelet aggregation, Thrombosis Research, 109, 5-6, pp. 279-286, (2003); Maree A.O., Vangjeli C., Jneid H., Et al., G-protein p3 subunk polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial, J. Thromh. Haemost, 8, 5, pp. 934-941, (2010); Peters B.J., Maitland-Van Der Zee A.H., Strieker B.H., Et al., Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant, Pharmacogenet. Genomics, 18, 7, pp. 631-636, (2008); Hauner H., Meier M., Jockel K.-H., Frey U.H., Siffert W., Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism, Pharmacogenetics, 13, 8, pp. 453-459, (2003); Grudell A.B., Sweetser S., Camilleri M., Et al., A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults, Gastroenterology, 135, 4, pp. 1142-1154, (2008); Hsiao D.J., Wu L.S., Huang S.Y., Lin E., Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene, Pharmacogenet. Genomics, 19, 9, pp. 730-733, (2009); Serretti A., Lorenzi C., Cusin C., Zanardi R., Lattuada E., Rossini D., Lilli R., Pirovano A., Catalano M., Smeraldi E., SSRIs antidepressant activity is influenced by Gβ3 variants, European Neuropsychopharmacology, 13, 2, pp. 117-122, (2003); Keers R., Bonvicini C., Scassellati C., Et al., Variation in GNB3 predicts response and adverse reactions to antidepressants, J. Psychopharmacol., (2010); Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Miller A.L., Rogers G.R., Kennedy M.A., Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline, International Journal of Neuropsychopharmacology, 6, 4, pp. 339-346, (2003); Wilkie M.J.V., Smith D., Reid I.C., Day R.K., Matthews K., Roland Wolf C., Blackwood D., Smith G., A splice site polymorphism in the G-protein β subunit influences antidepressant efficacy in depression, Pharmacogenetics and Genomics, 17, 3, pp. 207-215, (2007); Kato M., Wakeno M., Okugawa G., Fukuda T., Takekita Y., Hosoi Y., Azuma J., Kinoshita T., Serretti A., Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 4, pp. 1041-1044, (2008); Kang R.H., Hahn S.W., Choi M.J., Lee M.S., Relationship between G-protein p-3 subunk C825T polymorphism and mirtazapine responses in Korean patients with major depression, Neuropsychohiology, 56, 1, pp. 1-5, (2007); Lindemann M., Barsegian V., Siffert W., Ferencik S., Roggendorf M., Grosse-Wilde H., Role of G protein β3 subunit C825T and HLA class II polymorphisms in the immune response after HBV vaccination, Virology, 297, 2, pp. 245-252, (2002); Sarrazin C., Berg T., Weich V., Mueller T., Frey U.H., Zeuzem S., Gerken G., Roggendorf M., Siffert W., GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection, Journal of Hepatology, 43, 3, pp. 388-393, (2005); Brockmeyer N.H., Potthoff A., Kasper A., Nabring C., Jockel K.-H., Siffert W., GNB3 C825T polymorphism and response to anti-retroviral combination therapy in HIV-1-infected patients - A pilot study, European Journal of Medical Research, 10, 11, pp. 489-494, (2005); Ahlenstiel G., Nischalke H.D., Bueren K., Berg T., Vogel M., Biermer M., Grunhage F., Sauerbruch T., Rockstroh J., Spengler U., Nattermann J., The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients, Journal of Hepatology, 47, 3, pp. 348-355, (2007); Weinstein L.S., Xie T., Zhang Q.-H., Chen M., Studies of the regulation and function of the G<sub>s</sub>α gene Gnas using gene targeting technology, Pharmacology and Therapeutics, 115, 2, pp. 271-291, (2007); Kozasa T., Itoh H., Tsukamoto T., Kaziro Y., Isolation and characterization of the human Gs a gene, Proc. Natl Acad. Sci. USA, 85, 7, pp. 2081-2085, (1988); Rockman H.A., Koch W.J., Lefkowitz R.J., Seven-transmembrane-spanning receptors and heart function, Nature, 415, 6868, pp. 206-212, (2002); Hillhouse E.W., Randeva H., Ladds G., Grammatopoulos D., Corticotropin-releasing hormone receptors, Biochemical Society Transactions, 30, 4, pp. 428-432, (2002); Smith R.G., Van Der Ploeg L.H.T., Howard A.D., Feighner S.D., Cheng K., Hickey G.J., Wyvratt Jr. M.J., Fisher M.H., Nargund R.P., Patchett A.A., Peptidomimetic regulation of growth hormone secretion, Endocrine Reviews, 18, 5, pp. 621-645, (1997); Millar R.P., Lu Z.L., Pawson A.J., Flanagan C.A., Morgan K., Maudsley S.R., Gonadotropln-releasing hormone receptors, Endocr. Rev, 25, 2, pp. 235-275, (2004); Gershengorn M.C., Osman R., Molecular and cellular biology of thyrotropin-releasing hormone receptors, Physiological Reviews, 76, 1, pp. 175-191, (1996); Freeman M.E., Kanyicska B., Lerant A., Nagy G., Prolactin: Structure, function, and regulation of secretion, Physiol. Rev, 80, 4, pp. 1523-1631, (2000); Marie J.C., Rosselin G., Skoglund G., Pancreatic p-cell receptors and G proteins coupled to adenylyl cyclase, Ann. NY Acad. Sci, 805, pp. 122-131, (1996); Holm C., Langin D., Manganiello V., Belfrage P., Degerman E., Regulation of hormone-sensitive lipase activity in adipose tissue, Methods in Enzymology, 286, pp. 45-67, (1997); Vassart G., Dumont J.E., The thyrotropin receptor and the regulation of thyrocyte function and growth, Endocr. Rev, 13, 3, pp. 596-611, (1992); Jia H., Hingorani A.D., Sharma P., Hopper R., Dickerson C., Trutwein D., Lloyd D.D., Brown M.J., Association of the G(s)α gene with essential hypertension and response to β-blockade, Hypertension, 34, 1, pp. 8-14, (1999); Abe M., Nakura J., Yamamoto M., Jin J.J., Wu Z., Tabara Y., Yamamoto Y., Igase M., Kohara K., Miki T., Association of GNAS1 gene variant with hypertension depending on smoking status, Hypertension, 40, 3, pp. 261-265, (2002); Chen Y., Nakura J., Jin J.-J., Wu Z., Yamamoto M., Abe M., Tabara Y., Yamamoto Y., Igase M., Bo X., Kohara K., Miki T., Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption, Hypertension Research, 26, 6, pp. 439-444, (2003); Nieminen T., Lehtimaki T., Laiho J., Rontu R., Niemela K., Koobi T., Lehtinen R., Viik J., Turjanmaa V., Kahonen M., Effects of polymorphisms in β<sub>1</sub>-adrenoceptor and α-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish Cardiovascular Study, Journal of Applied Physiology, 100, 2, pp. 507-511, (2006); Frey U.H., Eisenhardt A., Lummen G., Rubben H., Jockel K.-H., Schmid K.W., Siffert W., The T393C polymorphism of the Gαs gene (GNAS1) is a novel prognostic marker in bladder cancer, Cancer Epidemiology Biomarkers and Prevention, 14, 4, pp. 871-877, (2005); Yang W., White B., Spicer E.K., Weinstein B.L., Hildebrandt J.D., Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies, Pharmacogenetics, 14, 11, pp. 741-747, (2004); Frey U.H., Alakus H., Wohlschlaeger J., Schmitz K.J., Winde G., Van Calker H.G., Jockel K.-H., Siffert W., Schmid K.W., GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer, Clinical Cancer Research, 11, 14, pp. 5071-5077, (2005)","S. Klenke; Institut für Pharmakogenetik, Universität Duisburg-Essen, 45122 Essen, Hufelandstr. 55, Germany; email: stefanie.klenke@uk-essen.de","","","","","","","","17448042","","PARMF","21619427","English","Pharmacogenomics","Review","Final","","Scopus","2-s2.0-79957630479"
"Devaux C.A.; Camoin-Jau L.","Devaux, Christian A. (9941051300); Camoin-Jau, Laurence (6602229935)","9941051300; 6602229935","An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection","2022","Frontiers in Microbiology","13","","1042200","","","","12","10.3389/fmicb.2022.1042200","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143894730&doi=10.3389%2ffmicb.2022.1042200&partnerID=40&md5=0c4190623518dc0e6130deca199a2843","Aix-Marseille Université, IRD, APHM, MEPHI, IHU–Méditerranée Infection, Marseille, France; Center National de la Recherche Scientifique, Marseille, France; Laboratoire d’Hématologie, Hôpital de La Timone, APHM, Boulevard Jean-Moulin, Marseille, France","Devaux C.A., Aix-Marseille Université, IRD, APHM, MEPHI, IHU–Méditerranée Infection, Marseille, France, Center National de la Recherche Scientifique, Marseille, France; Camoin-Jau L., Aix-Marseille Université, IRD, APHM, MEPHI, IHU–Méditerranée Infection, Marseille, France, Laboratoire d’Hématologie, Hôpital de La Timone, APHM, Boulevard Jean-Moulin, Marseille, France","It has been known for many years that the angiotensin-converting enzyme 2 (ACE2) is a cell surface enzyme involved in the regulation of blood pressure. More recently, it was proven that the severe acute respiratory syndrome coronavirus (SARS-CoV-2) interacts with ACE2 to enter susceptible human cells. This functional duality of ACE2 tends to explain why this molecule plays such an important role in the clinical manifestations of coronavirus disease 2019 (COVID-19). At the very start of the pandemic, a publication from our Institute (entitled “ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome”), was one of the first reviews linking COVID-19 to the duplicitous nature of ACE2. However, even given that COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin system (RAS), we were still far from understanding the complexity of the mechanisms which are controlled by ACE2 in different cell types. To gain insight into the physiopathology of SARS-CoV-2 infection, it is essential to consider the polymorphism and expression levels of the ACE2 gene (including its alternative isoforms). Over the past 2 years, an impressive amount of new results have come to shed light on the role of ACE2 in the pathophysiology of COVID-19, requiring us to update our analysis. Genetic linkage studies have been reported that highlight a relationship between ACE2 genetic variants and the risk of developing hypertension. Currently, many research efforts are being undertaken to understand the links between ACE2 polymorphism and the severity of COVID-19. In this review, we update the state of knowledge on the polymorphism of ACE2 and its consequences on the susceptibility of individuals to SARS-CoV-2. We also discuss the link between the increase of angiotensin II levels among SARS-CoV-2-infected patients and the development of a cytokine storm associated microvascular injury and obstructive thrombo-inflammatory syndrome, which represent the primary causes of severe forms of COVID-19 and lethality. Finally, we summarize the therapeutic strategies aimed at preventing the severe forms of COVID-19 that target ACE2. Changing paradigms may help improve patients’ therapy. Copyright © 2022 Devaux and Camoin-Jau.","ACE2; coagulation; coronavirus—COVID-19; hypertension; renin-angiotensin system; therapy","ADAM10 endopeptidase; angiotensin converting enzyme 2; angiotensin II; angiotensin receptor antagonist; autoantibody; dipeptidyl carboxypeptidase inhibitor; hepatocyte nuclear factor 3alpha; RNA polymerase II; transcription factor Cdx2; transmembrane protease serine 2; age; blood clotting disorder; blood pressure regulation; computer model; coronavirus disease 2019; disease severity; enzyme synthesis; fluid balance; gene frequency; gene overexpression; genetic linkage; genetic polymorphism; genetic variation; homeostasis; human; hydrogen bond; hypertension; immune response; microvasculature; multiple organ failure; nonhuman; nucleotide sequence; pathophysiology; protein function; protein structure; renin angiotensin aldosterone system; Review; tissue distribution; transcription initiation site; viral tropism","","ADAM10 endopeptidase, 193099-09-1; angiotensin II, 11128-99-7, 68521-88-0","","","Méditerranée Infection, (10-IAHU-03); National Agency for Research; Aix-Marseille Université, AMU; Institut de Recherche pour le Développement, IRD; Agence Nationale de la Recherche, ANR","This work was supported by the French Government under the “Investissements d’avenir” (Investments for the Future) program managed by the Agence Nationale de la Recherche (French ANR: National Agency for Research; reference: Méditerranée Infection 10-IAHU-03 to Professor Didier Raoult), and annual funds from Aix-Marseille university and IRD to the MEPHI research unit (Director: Professor Jean-Christophe Lagier). Other funding sources were limited to the salaries of the authors (Center National de la Recherche Scientifique for CAD, Assistance Publique Hôpitaux de Marseille for LCJ), with no other role or involvement. ","Abbasi J., Choose ARBs over ACE inhibitors for first-line hypertension treatment, large new analysis suggests, JAMA, 326, pp. 1244-1245, (2021); AbdAlla S., Lother H., Quitterer U., AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration, Nature, 407, pp. 94-98, (2000); Abdeen S., Bdeir K., Abu-Fanne R., Maraga E., Higazi M., Khurram N., Et al., Alpha-defensins: risk factor for thrombosis in COVID-19 infection, Brit. J. Haematol, 194, pp. 44-52, (2021); Abu Hasan Z., Williams H., Ismail N.M., Othman H., Cozier G.E., Acharya K.R., Et al., The toxicity of angiotensin converting enzyme inhibitors to larvae of the disease vectors Aedes aegypti and Anopheles gambiae, Sci. Rep, 7, (2017); Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Et al., Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19, N. Engl. J. Med, 383, pp. 120-128, (2020); Advani A., Kelly D.J., Cox A.J., White K.E., Advani S.L., Thai K., Et al., The (pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney, Hypertension, 54, pp. 261-269, (2009); Afelt A., Frutos R., Devaux C., Bats, coronaviruses, and deforestation: toward the emergence of novel infectious diseases?, Front. Microbiol, 9, (2018); Afzali B., Noris M., Lambrecht B.N., Kemper C., The state of complement in COVID-19, Nat. Rev. Immunol, 22, pp. 77-84, (2021); Agachan B., Isbir T., Yilmaz H., Akoglu E., Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients, Exp. Mol. Med, 35, pp. 545-549, (2003); Aguilar R., Jedlicka A.E., Mintz M., Mahairaki V., Scott A.L., Dimopoulos G., Global gene expression analysis of Anopheles gambiae responses to microbial challenge, Insect Biochem. Mol. Biol, 35, pp. 709-719, (2005); Albini A., Di Guardo G., McClain Noonan D., Lombardo M., The SARS-CoV-2 receptor, ACE-2, is expressed on many diferent cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies, Intern. Emerg. Med, 15, pp. 759-766, (2020); Alderman M.H., Madhavan S., Ooi W.L., Cohen H., Sealey J.E., Laragh J.H., Association of the renin sodium profile with the risk of myocardial-infarction in patients with hypertension, New Engl. J. Med, 324, pp. 1098-1104, (1991); AlGhatrif M., Tanaka T., Moore A.Z., Bandinelli S., Lakatta E.G., Ferrucci L., Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study, GeroScience, 43, pp. 619-627, (2021); Amor S., Fernandez Blanco L., Baker D., Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage, Clin. Exp. Immunol, 202, pp. 193-209, (2020); Andersson R., Gebhard C., Miguel-Escalada I., Hoof I., Bornholdt J., Boyd M., Et al., An atlas of active enhancers across human cell types and tissues, Nature, 507, pp. 455-461, (2014); Aragao D.S., Cunha T.S., Arita D.Y., Andrade M.C.C., Fernandes A.B., Watanabe I.K.M., Et al., Purification and characterization of angiotensin converting enzyme 2 (ACE2) from murine model of mesangial cell in culture, Int. J. Biol. Macromol, 49, pp. 79-84, (2011); Arendse L.B., Danser A.H.J., Poglitsch M., Touyz R.M., Burnett J.C., Llorens-Cortes C., Et al., Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure, Pharmacol. Rev, 71, pp. 539-570, (2019); Aroor A., Zuberek M., Duta C., Meuth A., Sowers J.R., Whaley-Connell A., Et al., Angiotensin II stimulation of DPP4 activity regulates megalin in the proximal tubules, Int. J. Mol. Sci, 17, (2016); Arthur J.M., Forrest J.C., Boehme K.W., Kennedy J.L., Owens S., Herzog C., Et al., Development of ACE2 autoantibodies after SARSCoV-2 infection, PLoS One, 16, (2021); Avolio E., Carrabba M., Milligan R., Kavanagh Williamson M., Beltrami A.P., Gupta K., Et al., The SARS-CoV-2 spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease, Clin. Sci, 135, pp. 2667-2689, (2021); Bader M., Alenina N., Young D., Santos R.A.S., Touyz R.M., The meaning of Mas, Hypertension, 72, pp. 1072-1075, (2018); Baggen J., Vanstreels E., Jansen S., Daelemans D., Cellular host factors for SARS-CoV-2 infection, Nat. Microbiol, 6, pp. 1219-1232, (2021); Baratchian M., McManus J.M., Berk M.P., Nakamura F., Mukhopadhyay S., Xu W., Et al., Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes, Sci. Rep, 11, (2021); Barkauskas C.E., Cronce M.J., Rackley C.R., Bowie E.J., Keene D.R., Stripp B.R., Et al., Type 2 alveolar cells are stem cells in adult lung, J. Clin. Invest, 123, pp. 3025-3036, (2013); Barker H., Parkkila S., Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2, PLoS One, 15, (2020); Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Et al., Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science, 370, (2020); Bavishi C., Maddox T.M., Messerli F.H., Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers, JAMA Cardiol, 5, pp. 745-747, (2020); Bazzan M., Montaruli B., Sciascia S., Cosseddu D., Norbiato C., Roccatello D., Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients, Intern. Emerg. Med, 15, pp. 861-863, (2020); Beacon T.H., Delcuve G.P., Davie J.R., Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus, Genome, 64, pp. 386-399, (2021); Bean D.M., Kraljevic Z., Searle T., Bendayan R., Kevin O., Pickles A., Et al., Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust, Eur. J. Heart Fail, 22, pp. 967-974, (2020); Benetti E., Tita R., Spiga O., Ciolfi A., Birolo G., Bruselles A., Et al., ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population, Eur. J. Hum. Genet, 28, pp. 1602-1614, (2020); Berk B.C., Vekshtein V., Gordon H.M., Tsuda T., Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells, Hypertension, 13, pp. 305-314, (1989); Bernardi S., Toffoli B., Zennaro C., Tikellis C., Monticone S., Losurdo P., Et al., High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage, Nephrol. Dial. Transplant, 27, pp. 1793-1800, (2012); Berthelot J.M., Drouet L., Liote F., Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?, Emerg. Microb. Infect, 9, pp. 1514-1522, (2020); Bertin D., Brodovitch A., Beziane A., Hug S., Bouamri A., Mege J.L., Et al., Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity, Arthritis Rheum, 72, pp. 1953-1955, (2020); Blume C., Jackson C.L., Spalluto C.M., Legebeke J., Nazlamova L., Conforti F., Et al., A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection, Nat. Genet, 53, pp. 205-214, (2021); Boklund A., Hammer A.S., Quaade M.L., Rasmussen T.B., Lohse L., Strandbygaard B., Et al., SARS-CoV-2 in danish mink farms: course of the epidemic and a descriptive analysis of the outbreaks in 2020, Animals, 11, (2021); Bosso M., Thanaraj T.A., Abu-Farha M., Alanbaei M., Abubaker J., Fahd A.-M., The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19, Mol. Ther. Meth. Clin. Dev, 18, pp. 321-327, (2020); Boustany C.M., Bharadwaj K., Daugherty A., Brown D.R., Randall D.C., Cassis L.A., Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension, Am. J. Physiol. Regul. Integrat. Comparat. Physiol, 287, pp. R943-R949, (2004); Brambilla M., Gelosa P., Rossetti L., Castiglioni L., Zara C., Canzano P., Et al., Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats, J. Hypertens, 36, pp. 1360-1371, (2018); Brest P., Refae S., Mograbi B., Hofman P., Milano G., Host polymorphisms may impact SARS-CoV-2 infectivity, Trends Genet, 36, pp. 813-815, (2020); Brewster U.C., Perazella M.A., The renin-angiotensinaldosterone system and the kidney disease, Am. J. Med, 116, pp. 263-272, (2004); Brodard J., Kremer Hovinga J.A., Fontana P., Studt J.D., Gruel Y., Greinacher A., COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies, J. Thromb. Haemost, 19, pp. 1294-1298, (2021); Brooke G.N., Prischi F., Structural and functional modelling of SARS-CoV-2 entry in animal models, Sci. Rep, 10, (2020); Brown N.J., Vaughan D.E., Prothrombotic effects of angiotensin, Adv. Intern. Med, 45, pp. 419-429, (2000); Burnham S., Smith J.A., Lee A.J., Isaac R.E., Shirras A.D., The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae, BMC Genomics, 6, (2005); Cabral-Marques O., Marques A., Giil L.M., De Vito R., Rademacher J., Gunther J., Et al., GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis, Nat. Commun, 9, (2018); Cai H., Sex difference and smoking predisposition in patients with COVID-19, Lancet Respir. Med, 8, (2020); Caillet-Saguy C., Wolf N., PDZ-containing proteins targeted by the ACE2 receptor, Viruses, 13, (2021); Calabrese C., Annunziata A., Coppola A., Pafundi P.C., Guarino S., Di Spirito V., Et al., ACE gene I/D polymorphism and acute pulmonary embolism in COVID19 pneumonia: a potential predisposing role, Front. Med, 7, (2021); Calcagnile M., Forgez P., Iannelli A., Bucci C., Alifano M., Alifano P., Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 spike protein, Biochimie, 180, pp. 143-148, (2021); Camargo S.M., Singer D., Makrides V., Huggel K., Pos K.M., Wagner C.A., Et al., Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations, Gastroenterology, 136, pp. 872-882.e3, (2009); Campbell C.M., Kahwash R., Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis?, Circulation, 141, pp. 1739-1741, (2020); Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J., Kuivanen S., Et al., Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity, Science, 370, pp. 856-860, (2020); Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X., Et al., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov, 6, pp. 4-7, (2020); Cardenas A., Rifas-Shiman S.L., Sordillo J.E., DeMeo D.L., Baccarelli A.A., DNA methylation architecture of the ACE2 gene in nasal cells of children, Sci. Rep, 11, (2021); Cardot-Leccia N., Hubiche T., Dellamonica J., Burel-Vandenbos F., Pericyte alteration shed light on micro-vasculopathy in COVID-19 infection, Intensive Care Med, 46, pp. 1777-1778, (2020); Carsana L., Sanzagni A., Nasr A., Rossi R.S., Pellegrinelli A., Zerbi P., Et al., Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-Centre descriptive study, Lancet, 20, pp. 1135-1140, (2020); Carvelli J., Demaria O., Vely F., Batista L., Chouaki Benmansour N., Fares J., Et al., Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis, Nature, 588, pp. 146-150, (2020); Celik S.K., Genc G.C., Piskin N., Acikgoz B., Altinsoy B., Issiz B.K., Et al., Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: a case study, J. Med. Virol, 93, pp. 5947-5952, (2021); Cerda-Costa N., Gomis-Ruth F.X., Architecture and function of metallopeptidase catalytic domains, Protein Sci, 23, pp. 123-144, (2014); Chappell M.C., The angiotensin-(1-7) Axis: formation and metabolism pathways. Springer nature Switzerland, Angiotensin, 22, pp. 1-26, (2019); Chen J., Jiang Q., Xia X., Liu K., Yu Z., Tao W., Et al., Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation, Aging Cell, 19, (2020); Chen L., Li X., Chen M., Feng Y., Xiong C., The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2, Cardiovasc. Res, 116, pp. 1097-1100, (2020); Chen Y.Y., Liu D., Zhang P., Zhong J.C., Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors, J. Hum. Hypertens, 30, pp. 766-771, (2016); Chen F., Zhang Y., Li X., Li W., Liu X., Xue X., The impact of ACE2 polymorphisms on COVID-19 disease: susceptibility, severity, and therapy, Front. Cell. Infect. Microbiol, 11, (2021); Chlamydas S., Papavassiliou A.G., Piperi C., Epigenetic mechanisms regulating COVID-19 infection, Epigenetics, 16, pp. 263-270, (2020); Chung M.K., Karnik S., Saef J., Bergmann C., Barnard J., Lederman M.M., Et al., SARS-CoV-2 and ACE2: the biology and clinical data settling the ARB and ACEI controversy, EBioMed, 58, (2020); Ciceri F., Beretta L., Mara Scandroglio A., Colombo S., Landoni G., Ruggeri A., Et al., Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis, Crit. Care Resusc, 22, pp. 95-97, (2020); Clarke N.E., Belyaev N.D., Lambert D.W., Turner A.J., Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress, Clin. Sci, 126, pp. 507-516, (2014); Cohen-Haguenauer O., Soubrier F., Van Cong N., Serero S., Turleau C., Jegou C., Et al., Regional mapping of the human renin gene to 1q32 by in situ hybridisation, Ann. Genet, 32, pp. 16-20, (1989); Cole-Jeffrey C.T., Liu M., Katovich M.J., Raizada M.K., Shenoy V., ACE2 and microbiota: emerging targets for cardiopulmonary disease therapy, J. Cardiovasc. Pharmacol, 66, pp. 540-550, (2015); Corley M.J., Ndhlovu L.C., DNA methylation analysis of the COVID-19 host cell receptor, angiotensin I converting enzyme 2 gene (ACE2) in the respiratory system reveal age and gender differences, (2020); Correale P., Mutti L., Pentimalli F., Baglio G., Saladino R.E., Sileri P., Et al., HLAB * 44 and C * 01 prevalence correlates with Covid19 spreading across Italy, Int. J. Mol. Sci, 21, (2020); Cozzi E., Calabrese F., Schiavon M., Feltracco P., Seveso M., Carollo C., Et al., Immediate and catastrophic antibody-mediated rejection in a lung transplant recipient with anti-angiotensin ii receptor type 1 and AntiEndothelin-1 receptor type a antibodies, Am. J. Transplant, 17, pp. 557-564, (2017); Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Et al., Angiotensinconverting enzyme 2 is an essential regulator of heart function, Nature, 417, pp. 822-828, (2002); Crisan D., Carr J., Angiotensin I-converting enzyme, J. Mol. Diagn, 2, pp. 105-115, (2000); Dahlback B., Villoutreix B.O., Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition Arterioscler, Thromb. Vasc. Biol, 25, pp. 1311-1320, (2005); Dai S., Ding M., Liang N., Li Z., Guan L., Liu H., Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients, Sci. Rep, 9, (2019); Dai C.F., Xie X., Ma Y.T., Yang Y.N., Li X.M., Fu Z.Y., Et al., Relationship between CYP17A1 genetic polymorphism and essential hypertension in a Chinese population, Aging Dis, 6, pp. 486-498, (2015); Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K., Anton-Plagaro C., Et al., Neuropilin-1 is a host factor for SARS-CoV-2 infection, Science, 370, pp. 861-865, (2020); Damas J., Hughes G.M., Keough K.C., Painter C.A., Persky N.S., Corbo M., Et al., Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates, Proc. Natl. Acad. Sci. U. S. A, 117, pp. 22311-22322, (2020); Danilczyk U., Eriksson U., Crackower M.A., Penninger J.M., A story of two ACEs, J. Mol. Med, 81, pp. 227-234, (2003); Darbani B., The expression and polymorphism of entry machinery for COVID-19 in human: juxtaposing population groups, gender, and different tissues, Int. J. Environ. Res. Public Health, 17, (2020); Daviet F., Guervilly C., Baldesi O., Bernard-Guervilly F., Pilarczyk E., Genin A., Et al., Heparin-induced thromcytopenia in severe COVID-19, Circulation, 142, pp. 1875-1877, (2020); Davis J.O., Freeman R.H., Mechanisms regulating renin release, Physiol. Rev, 56, pp. 1-56, (1976); de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T., The angiotensin II receptors, Pharmacol. Rev, 52, pp. 415-472, (2000); de Kloet A.D., Krause E.G., Woods S.C., The renin angiotensin system and the metabolic syndrome, Physiol. Behav, 100, pp. 525-534, (2010); Delorey T.M., Ziegler C.G.K., Heimberg G., Normand R., Yang Y., Segerstolpe A., Et al., COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets, Nature, 595, pp. 107-113, (2021); Descamps G., Verset L., Trelcat A., Hopkins C., Lechien J.R., Journe F., Et al., ACE2 protein landscape in the head and neck region: the conundrum of SARS-CoV-2 infection, Biology, 9, (2020); Deshmukh V., Motwani R., Kumar A., Kurnari C., Raza K., Histopathological observations in COVID-19: a systematic review, J. Clin. Pathol, 74, pp. 76-83, (2020); Devaux C.A., Are ACE inhibitors and ARBs more beneficials than harmful in the treatment of severe COVID-19 disease?, Cardiovasc. Med. Cardiol, 7, pp. 101-103, (2020); Devaux C.A., Lagier J.-C., Raoult D., New insights into the physiopathology of COVID-19: SARS-CoV-2-associated gastrointestinal illness, Front. Med, 8, (2021); Devaux C.A., Pinault L., Delerce J., Raoult D., Levasseur A., Frutos R., Spread of mink SARS-CoV-2 variants in humans: a model of Sarbecovirus interspecies evolution, Front. Microbiol, 12, (2021); Devaux C.A., Pinault L., Osman I.O., Raoult D., Can ACE2 receptor polymorphism predict species susceptibility to SARS-CoV-2?, Front. Public Health, 8, (2021); Devaux C.A., Raoult D., The impact of COVID-19 on populations living at high altitude: role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication, Front. Physiol, 13, (2022); Devaux C.A., Rolain J.M., Raoult D., ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome, J. Microbiol. Immnol. Inf, 53, pp. 425-435, (2020); Diez-Freire C., Vazquez J., Correa de Adjounian M.F., Ferrari M.F.R., Yuan L., Silver X., Et al., ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR, Physiol. Genomics, 27, pp. 12-19, (2006); Dikalov S.I., Nazarewicz R.R., Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease, Antioxid. Redox Signal, 19, pp. 1085-1094, (2013); Dong B., Yu Q.T., Dai H.Y., Gao Y.Y., Zhou Z.L., Zhang L., Et al., Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy, J. Am. Coll. Cardiol, 59, pp. 739-747, (2012); Dong B., Zhang C., Feng J.B., Zhao Y.X., Li S.Y., Yang Y.P., Et al., Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis, Arteriosc. Thromb. Vascular Biol, 28, pp. 1270-1276, (2008); Donkor O.N., Henriksson A., Vasiljevic T., Shah N.P., Proteolytic activity of dairy lactic acid bacteria and probiotics as determinant of growth and in vitro angiotensin-converting enzyme inhibitory activity in fermented milk, Lait, 86, pp. 21-38, (2007); Donoghue M., Hsieh F., Baronas E., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9, Circ. Res, 87, pp. E1-E9, (2000); Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., Et al., Angiotensin II type 1-receptor activating antibodies in renal allograft rejection, N. Engl. J. Med, 352, pp. 558-569, (2005); Duru K., Farrow S., Wang J.M., Lockette W., Kurtz T., Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in african-Americans with hypertension, Am. J. Hypertens, 7, pp. 759-762, (1994); Ellinghaus D., Degenhardt F., Bujanda L., Buti M., Albillos A., Invernizzi P., Et al., Genomewide association study of severe Covid-19 with respiratory failure, N. Engl. J. Med, 383, pp. 1522-1534, (2020); Epelman S., Shrestha K., Troughton R.W., Francis G.S., Sen S., Klein A.L., Et al., Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes, J. Card. Fail, 15, pp. 565-571, (2009); Epelman S., Tang W.H., Chen S.Y., Lente F.V., Francis G.S., Sen S., Et al., Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system, J. Am. Coll. Cardiol, 52, pp. 750-754, (2008); Escher R., Breakey N., Lammle B., Severe COVID-19 infection associated with endothelial activation, Thromb. Res, 190, (2020); Faggiano P., Bonelli A., Paris S., Milesi G., Bisegna S., Bernardi N., Et al., Acute pulmonary embolism in COVID-19 disease: preliminary report on seven patients, Int. J. Cardiol, 313, pp. 129-131, (2020); Fairweather S.J., Broer A., O'Mara M.L., Broer S., Intestinal peptidases from functional complexes with neutral amino acid transporter B0AT1, Biochem. J, 446, pp. 135-148, (2012); Fan C., Lu W., Li K., Ding Y., Wang J., ACE2 expression in kidney and testis may cause kidney and testis infection in COVID-19 patients, Front. Med, 7, (2021); Fan R., Mao S.Q., Gu T.L., Zhong F.D., Gong M.L., Hao L.M., Et al., Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension, Mol. Med. Rep, 15, pp. 3905-3911, (2017); Fan Z., Wu G., Yue M., Ye J., Chen Y., Xu B., Et al., Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism, Life Sci, 225, pp. 39-45, (2019); Fan X., Yb W., Wang H., Sun K., Zhang W.-L., Song X., Et al., Polymorphisms of angiotensinconverting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients, Acta Pharmacol. Sin, 30, pp. 1237-1244, (2009); Fang Y., Gao F., Liu Z., Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2 pathways, QJM, 112, pp. 914-924, (2019); Fang L., Karakiulakis R.M., Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir. Med, 8, (2020); Fantini J., Chahinian H., Yahi N., Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19, Biochem. Biophys. Res. Commun, 538, pp. 132-136, (2021); Fantini J., Devaux C.A., Yahi N., Frutos R., The novel hamster-adapted SARS-CoV-2 Delta variant may be selectively advantaged in humans, J. Inf. Secur, 84, pp. e53-e54, (2022); Felmeden D.C., Spencer C.G.C., Chung N.A.Y., Belgore F.M., Blann A.D., Beevers D.G., Et al., Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian cardiac outcomes trial [ASCOT]), Am. J. Cardiol, 92, pp. 400-405, (2003); Ferrand A., Nabhani Z.A., Tapias N.S., Mas E., Hugoy J.P., Barreau F., NOD2 expression in intestinal epithelial cells protects toward the development of inflammation and associated carcinogenesis, Cell. Mol. Gastroenterol. Hepatol, 7, pp. 357-369, (2019); Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., Diz D.I., Counterregulatory actions of angiotensin-(1-7), Hypertension, 30, pp. 535-541, (1997); Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, pp. 2605-2610, (2005); Ferrario C.M., Varagic J., The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function, Am. J. Physiol. Ren. Physiol, 298, pp. F1297-F1305, (2010); Ferreira A.J., Shenoy V., Yamazato Y., Sriramula S., Francis J., Yuan L., Et al., Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension, Am. J. Respir. Crit. Care Med, 179, pp. 1048-1054, (2009); Fletcher-Sandersjoo A., Bellander B.M., Is COVID-19 associated thrombosis caused by overactivation of the complement cascade?, Thromb. Res, 194, pp. 36-41, (2020); Fogari R., Zoppi A., Mugellini A., Maffioli P., Lazzari P., Derosa G., Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome, Hypertens. Res, 34, pp. 1321-1326, (2011); Forrester S.J., Booz G.W., Sigmund C.D., Coffman T.M., Kawai T., Rizzo V., Et al., Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology, Physiol. Rev, 98, pp. 1627-1738, (2018); Fournier D., Luft F.C., Bader M., Ganten D., Andrade-Navarro M.A., Emergence and evolution of the renin–angiotensin–aldosterone system, J. Mol. Med, 90, pp. 495-508, (2012); Fraga-Silva Rodrigo A., Costa-Fraga Fabiana P., Murca Tatiane M., Moraes Patricia L., Martins Lima A., Lautner Roberto Q., Et al., Angiotensin-converting enzyme 2 activation improves endothelial function, Hypertension, 61, pp. 1233-1238, (2013); Frederich R.C., Kahn B.B., Peach M.J., Flier J.S., Tissue-specific nutritional regulation of angiotensinogen in adipose tissue, Hypertension, 19, pp. 339-344, (1992); Fricke-Galindo I., Falfa´ n-Valencia R genetics insight for COVID-19 susceptibility and severity: a review, Front. Immunol, 12, (2021); Frutos R., Gavotte L., Devaux C.A., Understanding the origin of COVID-19 requires to change the paradigm on zoonotic emergence from the spillover to the circulation model, Infect. Genet. Evol, 95, (2021); Frutos R., Serra-Cobo J., Pinault L., Lopez Roig M., Devaux C.A., Emergence of bat-related Betacoronaviruses: Hazard and risks, Front. Microbiol, 12, (2021); Frutos R., Yahi N., Gavotte L., Fantini J., Devaux C.A., Role of spike compensatory mutations in the interspecies transmission of SARS-CoV-2, One Health, 15, (2022); Fuglsang A., Rattray F.P., Nilsson D., Nyborg N.C.B., Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo, Antonie Van Leeuwenhoek, 83, pp. 27-34, (2003); Funakoshi Y., Ichiki T., Takeda K., Tokuno T., Lino N., Takeshita A., Critical role of cAMP-response element-binding protein for angiotensin II-induced hypertrophy of vascular smooth muscle cells, J. Biol. Chem, 277, pp. 18710-18717, (2002); Furuhashi M., Moniwa N., Mita T., Fuseya T., Ishimura S., Ohno K., Et al., Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker, Am. J. Hypertens, 28, pp. 15-21, (2015); Furuhashi M., Moniwa N., Takizawa H., Ura N., Shimamoto K., Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19, Hypertens. Res, 43, pp. 837-840, (2020); Gaborik Z., Szaszak M., Szidonya L., Balla B., Paku S., Catt K.J., Et al., Beta-arrestin-and dynamin-dependent endocytosis of the AT1 angiotensin receptor, Mol. Pharmacol, 59, pp. 239-247, (2001); Gagiannis D., Steinestel J., Hackenbroch C., Schreiner B., Hannemann M., Bloch W., Et al., Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD), Front. Immunol, 11, (2020); Gaidarov I., Adams J., Frazer J., Anthony T., Chen X., Gatlin J., Et al., Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor, Cell. Signal, 50, pp. 9-24, (2018); Gallucio M., Pantanella M., Gludice D., Brescia S., Indiveri C., Low temperature bacterial expression of the neutral amino acid transporters SLC1A5 (ASCT2), and SLC6A19 (B0AT1), Mol. Biol. Rep, 47, pp. 7283-7289, (2020); Gando S., Wada T., Thromboplasminflammation in COVID-19 coagulopathy: three viewpoints for diagnostic and therapeutic strategies, Front. Immunol, 12, (2021); Gao S., Zhang L., ACE2 partially dictates the host range and tropism of SARS-CoV-2, Comput. Struct. Biotechnol. J, 18, pp. 4040-4047, (2020); Garcia-Escobar A., Jimenez-Valero S., Galeote G., Jurado-Roman A., Garcia-Rodriguez J., Moreno R., The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19, Heart Fail. Rev, 26, pp. 961-971, (2021); Garrido A.M., Griendling K.K., NADPH oxidases and angiotensin II receptor signaling, Mol. Cell. Endocrinol, 302, pp. 148-158, (2009); Garvin M.R., Alvarez C., Miller J.I., Prates E.T., Walker A.M., Amos B.K., Et al., A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm, elife, 9, (2020); Gay L., Melenotte C., Lakbar I., Mezouar S., Devaux C., Raoult D., Et al., Sexual dimorphism and gender in infectious diseases, Front. Immunol, 12, (2021); Ge X.Y., Li J.L., Yang X.L., Chmura A.A., Zhu G., Epstein J.H., Et al., Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor, Nature, 503, pp. 535-538, (2013); Gerard L., Lecocq M., Bouzin C., Hoton D., Schmit G., Pereira J.P., Et al., Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19 related ARDS, Am. J. Respir. Crit. Care Med, 204, pp. 1024-1034, (2021); Ghatage T., Gopal Goyal S., Dhar A., Bhat A., Novel therapeutics for the treatment of hypertension and its associated complications: peptide-and nonpeptide-based strategies, Hypertens. Res, 44, pp. 740-755, (2021); Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., Et al., Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2, Circ. Res, 126, pp. 1456-1474, (2020); Giner V., Poch E., Bragulat E., Oriola J., Gonzalez D., Coca A., Et al., Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension, Hypertension, 35, pp. 512-517, (2000); Gjymishka A., Kulemina L.V., Shenoy V., Katovich M.J., Ostrov D.A., Raizada M.K., Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug, FASEB J, 24, (2010); Glasgow A., Glasgow J., Limonta D., Solomon P., Lui I., Zhang Y., Et al., Engineered ACE2 receptor traps potently neutralize SARS-CoV-2, Proc. Natl. Acad. Sci. U. S. A, 117, pp. 28046-28055, (2020); Goldblatt H., Lynch J., Hanzal R.F., Summerville W.W., Studies on experimental hypertension: I. the production of persistent elevation of systolic blood pressure by means of renal ischemia, J. Exp. Med, 59, pp. 347-379, (1934); Gomez J., Albaiceta G.M., Garcia-Clemente M., Lopez-Larrea C., Amado Rodriguez L., Lopez-Alonso I., Et al., Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome, Gene, 762, (2020); Gonzalez A.A., Lara L.S., Prieto M.C., Role of collecting duct renin in the pathogenesis of hypertension, Curr. Hypertens. Rep, 19, (2017); Goru S.K., Kadakol A., Malek V., Pandey A., Gaikwad S.N.A.B., Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT(2) receptor expression in a rat model of type1 diabetes, Br. J. Pharmacol, 174, pp. 3118-3130, (2017); Goshua G., Pine A.B., Meizlish M.L., Chang C.H., Zhang H., Bahel P., Et al., Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-Centre, cross-sectional study, Lancet Heamatol, 7, pp. e575-e582, (2020); Goujon C., Rebendenne A., Roy P., Bonaventure B., Valadao A.C., Desmarets L., Et al., (2021); Goulter A.B., Goddard M.J., Allen J.C., Clark K.L., ACE2 gene expression is up-regulated in the human failing heart, BMC Med, 2, (2004); Graham R.L., Donaldson E.F., Baric R.S., A decade after SARS: strategies to control emerging coronaviruses, Nat. Rev. Microbiol, 11, pp. 836-848, (2013); Greenberg B., An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling, J. Am. Coll. Cardiol, 52, pp. 755-757, (2008)","C.A. Devaux; Aix-Marseille Université, IRD, APHM, MEPHI, IHU–Méditerranée Infection, Marseille, France; email: christian.devaux@mediterranee-infection.com","","Frontiers Media S.A.","","","","","","1664302X","","","","English","Front. Microbiol.","Review","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85143894730"
"Chen Y.Y.; Liu D.; Zhang P.; Zhong J.C.; Zhang C.J.; Wu S.L.; Zhang Y.Q.; Liu G.Z.; He M.; Jin L.J.; Yu H.M.","Chen, Y.Y. (57189664333); Liu, D. (57189663473); Zhang, P. (57189663637); Zhong, J.C. (7201488610); Zhang, C.J. (35793937400); Wu, S.L. (7407183478); Zhang, Y.Q. (56183109800); Liu, G.Z. (7501457982); He, M. (59037243300); Jin, L.J. (7403329081); Yu, H.M. (56847883700)","57189664333; 57189663473; 57189663637; 7201488610; 35793937400; 7407183478; 56183109800; 7501457982; 59037243300; 7403329081; 56847883700","Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors","2016","Journal of Human Hypertension","30","12","","766","771","5","27","10.1038/jhh.2016.24","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973878962&doi=10.1038%2fjhh.2016.24&partnerID=40&md5=b1b6850fe361642111318e6452795ec5","Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; Shantou University Medical College, Shantou, China; State Key Laboratory of Medical Genomics and Shanghai Institute of Hypertension, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Division of Hypertension, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; Department of Clinical Laboratory, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China","Chen Y.Y., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China, Shantou University Medical College, Shantou, China; Liu D., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; Zhang P., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; Zhong J.C., State Key Laboratory of Medical Genomics and Shanghai Institute of Hypertension, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Zhang C.J., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; Wu S.L., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; Zhang Y.Q., Division of Hypertension, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; Liu G.Z., Division of Hypertension, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; He M., Department of Clinical Laboratory, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; Jin L.J., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; Yu H.M., Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China","Angiotensin-converting enzyme 2 (ACE2), a newly discovered member of renin-angiotensin-aldosterone system, counterbalances the actions of angiotensin-converting enzyme. The objective of our study was to assess the association between rs2106809 polymorphism in ACE2 gene and the blood pressure response to ACE inhibitors in untreated hypertensive patients. After a 2-week, double-blind placebo run-in period, either benazepril or imidapril was administered for 6 weeks to 497 patients with mild to moderate essential hypertension. The achieved changes in BP were analyzed for their association with genotypes at ACE2 gene loci. In female hypertensive patients, the genotype frequency of ACE2 rs2106809 was 36.7%, 45.2% and 18.1% for CC, CT and TT genotypes, respectively. After 6 weeks of treatment, the reductions in diastolic blood pressure were significantly greater in female patients carrying the CC or CT genotype compared with those carrying the TT genotype (9.62±6.83 or 10.2±7.2 versus 6.81±6.31 mm Hg, respectively; P=0.045, analysis of variance (ANOVA)). Moreover, the reductions in mean arterial pressure were significantly greater in female patients carrying the CC or CT genotype compared with those carrying the TT genotype (12.1±7.5 or 12.0±7.9 versus 8.38±6.83 mm Hg, respectively; P=0.035, ANOVA). In male hypertensive patients, the genotype frequency of ACE2 rs2106809 was 58.1% and 41.9% for C and T genotypes, respectively. However, no association could be observed in males. We conclude that ACE2 rs2106809 is an important predictive factor of the response to antihypertensive treatment with ACE inhibitors in Chinese female hypertensive patients. © 2016 Macmillan Publishers Limited, part of Springer Nature.","","Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterial Pressure; Asian Continental Ancestry Group; Benzazepines; China; Double-Blind Method; Gene Frequency; Heterozygote; Homozygote; Humans; Hypertension; Imidazolidines; Middle Aged; Peptidyl-Dipeptidase A; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Prospective Studies; Renin-Angiotensin System; Sex Factors; Time Factors; Treatment Outcome; benazepril; dipeptidyl carboxypeptidase inhibitor; imidapril; angiotensin converting enzyme 2; antihypertensive agent; benazepril; benzazepine derivative; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; imidapril; imidazolidine derivative; adult; aged; antihypertensive activity; Article; blood pressure regulation; diastolic blood pressure; double blind procedure; drug efficacy; essential hypertension; female; gene frequency; gene locus; genetic polymorphism; genotype; human; major clinical study; male; mean arterial pressure; arterial pressure; Asian continental ancestry group; China; controlled study; drug effects; enzymology; epidemiology; genetics; heterozygote; homozygote; hypertension; middle aged; pathophysiology; personalized medicine; pharmacogenetic variant; pharmacogenetics; phenotype; prospective study; randomized controlled trial; renin angiotensin aldosterone system; sex factor; single nucleotide polymorphism; time factor; treatment outcome","","benazepril, 86541-75-5; imidapril, 89371-37-9, 89396-94-1; dipeptidyl carboxypeptidase, 9015-82-1; angiotensin converting enzyme 2, ; Angiotensin-Converting Enzyme Inhibitors, ; Antihypertensive Agents, ; benazepril, ; Benzazepines, ; imidapril, ; Imidazolidines, ; Peptidyl-Dipeptidase A, ","","","Beijing Center for Disease Prevention and Control; Department of Epidemiology; National Major Research Plan Training Program, (91339108); Xiangfeng Dou; National Natural Science Foundation of China, NSFC, (81273599, 81370362); National Natural Science Foundation of China, NSFC; Natural Science Foundation of Guangdong Province, (2015A030313661); Natural Science Foundation of Guangdong Province; National Key Research and Development Program of China, NKRDPC, (2014CB542300); National Key Research and Development Program of China, NKRDPC; Science and Technology Planning Project of Guangdong Province, (2014A020212404); Science and Technology Planning Project of Guangdong Province","We thank Xiangfeng Dou (Department of Epidemiology, Beijing Center for Disease Prevention and Control, Beijing, People's Republic of China) for his help in statistical analysis. This study was supported by National Natural Science Foundation of China (Nos 81273599 and 81370362); Guangdong Natural Science Foundation (No. 2015A030313661); Science and Technology Planning Project of Guangdong Province (No. 2014A020212404); National Major Research Plan Training Program (No. 91339108); and the National Basic Research Program of China (No. 2014CB542300).","Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Bidiville J., Nussberger J., Waeber G., Porchet M., Waeber B., Brunner H.R., Individual responses to converting enzyme inhibitors and calcium antagonists, Hypertension, 11, pp. 166-173, (1988); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Et al., Ace and alpha-Adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Jiang S., Hsu Y.H., Venners S.A., Zhang Y., Xing H., Wang X., Et al., Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients, J Hum Hypertens, 25, pp. 327-333, (2011); Kim S., Iwao H., Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases, Pharmacol, 52, pp. 11-34, (2000); Mehta P.K., Griendling K.K., Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system, Am J Physiol Cell Physiol, 292, pp. C82-C97, (2007); Probstfield J.L., O'Brien K.D., Progression of cardiovascular damage: The role of renin-Angiotensin system blockade, Am J Cardiol, 105, pp. 10A-20A, (2010); Le Tran Y., Forster C., Angiotensin-(1-7) and the rat aorta: Modulation by the endothelium, J Cardiovasc Pharmacol, 30, pp. 676-682, (1997); Santos R.A., Simoese Silva A.C., Maric C., Silva D.M., Machado R.P., De Buhr I., Et al., Angiotensin-1-7) is an endogenous ligand for the g protein-coupled receptor mas, Proc Natl Acad Sci USA, 100, pp. 8258-8263, (2003); Santos R.A., Ferreira A.J., Nadu A.P., Braga A.N., De Almeida A.P., Campagnole-Santos M.J., Et al., Expression of an angiotensin-1-7)-producing fusion protein produces cardioprotective effects in rats, Physiol Genomics, 17, pp. 292-299, (2004); Grobe J.L., Mecca A.P., Lingis M., Shenoy V., Bolton T.A., Machado J.M., Et al., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-1-7, Am J Physiol Heart Circ Physiol, 292, pp. H736-H742, (2007); Mercure C., Yogi A., Callera G.E., Aranha A.B., Bader M., Ferreira A.J., Et al., Angiotensin 1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart, Circ Res, 103, pp. 1319-1326, (2008); Nadu A.P., Ferreira A.J., Reudelhuber T.L., Bader M., Santos R.A., Reduced isoproterenolinduced renin-Angiotensin changes and extracellular matrix deposition in hearts of tgr(a1-7)3292 rats, J Am Soc Hypertens, 2, pp. 341-348, (2008); Savergnini S.Q., Beiman M., Lautner R.Q., De Paula-Carvalho V., Allahdadi K., Pessoa D.C., Et al., Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the mas receptor, Hypertension, 56, pp. 112-120, (2010); Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Et al., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, 417, pp. 822-828, (2002); Rentzsch B., Todiras M., Iliescu R., Popova E., Campos L.A., Oliveira M.L., Et al., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of shrsp rats reduces blood pressure and improves endothelial function, Hypertension, 52, pp. 967-973, (2008); Gurley S.B., Allred A., Le T.H., Griffiths R., Mao L., Philip N., Et al., Altered blood pressure responses and normal cardiac phenotype in ace2-null mice, J Clin Invest, 116, pp. 2218-2225, (2006); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Et al., Polymorphisms of ace2 gene are associated with essential hypertension and antihypertensive effects of captopril in women, Clin Pharmacol Ther, 82, pp. 187-196, (2007); Patnaik M., Pati P., Swain S.N., Mohapatra M.K., Dwibedi B., Kar S.K., Et al., Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of odisha, India, Ann Hum Biol, 41, pp. 145-152, (2014); Imidapril and benazepril clinical study cooperation unit comparative study of hypotensive efficacy and the cough occurrence of imidapril versus benazepril, Chin J Cardiol, 32, pp. 304-307, (2004); Desmet F.O., Hamroun D., Lalande M., Collod-Beroud G., Claustres M., Beroud C., Human splicing finder an online bioinformatics tool to predict splicing signals, Nucleic Acids Res, 37, (2009); Rice G.I., Jones A.L., Grant P.J., Carter A.M., Turner A.J., Hooper N.M., Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study, Hypertension, 48, pp. 914-920, (2006); Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, pp. 2605-2610, (2005); Tikellis C., Bialkowski K., Pete J., Sheehy K., Su Q., Johnston C., Et al., Ace2 deficiency modifies renoprotection afforded by ace inhibition in experimental diabetes, Diabetes, 57, pp. 1018-1025, (2008); Sullivan J.C., Rodriguez-Miguelez P., Zimmerman M.A., Harris R.A., Differences in angiotensin 1-7) between men and women, Am J Physiol Heart Circ Physiol, 308, pp. H1171-H1176, (2015); Zimmerman M.A., Harris R.A., Sullivan J.C., Female spontaneously hypertensive rats are more dependent on ang 1-7) to mediate effects of low-dose at1 receptor blockade than males, Am J Physiol Renal Physiol, 306, pp. F1136-F1142, (2014); Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Age-specific relevance of usual blood pressure to vascular mortality: A meta-Analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, pp. 1903-1913, (2002); Sesso H.D., Stampfer M.J., Rosner B., Hennekens C.H., Gaziano J.M., Manson J.E., Et al., Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men, Hypertension, 36, pp. 801-807, (2000); Dyer A.R., Stamler J., Shekelle R.B., Schoenberger J.A., Stamler R., Shekelle S., Et al., Pulse pressure, III: Prognostic significance in four chicago epidemiologic studies, J Chron Dis, 35, pp. 283-294, (1982); Jiang L., Huang C., Sun Q., Guo H., Cheng T., Peng Z., Et al., The 5'-utr intron of the midgut-specific bmapn4 gene affects the level and location of expression in transgenic silkworms, Insect Biochem Mol Biol, 63, pp. 1-6, (2015); Le Hir H., Nott A., Moore M.J., How introns influence and enhance eukaryotic gene expression, Trends Biochem Sci, 28, pp. 215-220, (2003); Brinster R.L., Allen J.M., Behringer R.R., Gelinas R.E., Palmiter R.D., Introns increase transcriptional efficiency in transgenic mice, Proc Natl Acad Sci USA, 85, pp. 836-840, (1988); Oh V.M., Chua B.M., Heng C.K., Yeo S.B., Yim O.S., Yap E.P., Association of intronic single-nucleotide polymorphisms in the emilin1 gene with essential hypertension in a Chinese population, J Hum Hypertens, 26, pp. 553-561, (2012); Seo S., Takayama K., Uno K., Ohi K., Hashimoto R., Nishizawa D., Et al., Functional analysis of deep intronic snp rs13438494 in intron 24 of pclo gene, PLoS ONE, 8, (2013)","L.J. Jin; Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; email: lijun-jin@163.com","","Nature Publishing Group","","","","","","09509240","","JHHYE","27121444","English","J. Hum. Hypertens.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84973878962"
"Lupoli S.; Salvi E.; Barcella M.; Barlassina C.","Lupoli, Sara (26433631200); Salvi, Erika (57860926600); Barcella, Matteo (6603500049); Barlassina, Cristina (57192119717)","26433631200; 57860926600; 6603500049; 57192119717","Pharmacogenomics considerations in the control of hypertension","2015","Pharmacogenomics","16","17","","1951","1964","13","10","10.2217/pgs.15.131","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947945050&doi=10.2217%2fpgs.15.131&partnerID=40&md5=c99b05077a4f272b3362dac38b4c2832","Department of Health Sciences, Milan University, Via Rudinì 8, Milan, 20142, Italy; Filarete Foundation, Viale Ortles 22/4, Milan, 20139, Italy","Lupoli S., Department of Health Sciences, Milan University, Via Rudinì 8, Milan, 20142, Italy, Filarete Foundation, Viale Ortles 22/4, Milan, 20139, Italy; Salvi E., Department of Health Sciences, Milan University, Via Rudinì 8, Milan, 20142, Italy, Filarete Foundation, Viale Ortles 22/4, Milan, 20139, Italy; Barcella M., Department of Health Sciences, Milan University, Via Rudinì 8, Milan, 20142, Italy, Filarete Foundation, Viale Ortles 22/4, Milan, 20139, Italy; Barlassina C., Department of Health Sciences, Milan University, Via Rudinì 8, Milan, 20142, Italy, Filarete Foundation, Viale Ortles 22/4, Milan, 20139, Italy","The response to antihypertensive therapy is very heterogeneous and the need by the physicians to account for it has driven much interest in pharmacogenomics of antihypertensive drugs. The Human Genome Project and the initiatives in genomics that followed, generated a huge number of genetic data that furnished the tools to explore the genotype-phenotype association in candidate genes and at genome-wide level. In spite of the efforts and the great number of publications, pharmacogenomics of antihypertensive drugs is far from being used in clinical practice. In this review, we analyze the main findings available in PubMed from 2010 to 2015, in relation to the major classes of antihypertensive drugs. We also describe a new Phase II drug that targets two specific hypertension predisposing mechanisms. © 2015 Future Medicine Ltd.","antihypertensive drug; association study; drug response; personalized medicine; pharmacogenomics","Antihypertensive Agents; Human Genome Project; Humans; Hypertension; Pharmacogenetics; amlodipine; angiotensin receptor antagonist; atenolol; bisoprolol; calcium channel blocking agent; diltiazem; dipeptidyl carboxypeptidase inhibitor; diuretic agent; hydrochlorothiazide; losartan; rostafuroxin; valsartan; verapamil; antihypertensive agent; blood pressure regulation; cardiovascular disease; diastolic blood pressure; disease predisposition; drug choice; effect size; genotype phenotype correlation; human; human genome project; hypertension; kidney disease; molecular genetics; molecular pathology; monotherapy; nonhuman; personalized medicine; pharmacogenomics; phase 2 clinical trial (topic); Review; risk factor; single nucleotide polymorphism; treatment response; genetics; hypertension; pharmacogenetics; procedures; trends","","amlodipine, 88150-42-9, 103129-82-4, 736178-83-9; atenolol, 29122-68-7, 93379-54-5; bisoprolol, 66722-44-9; diltiazem, 33286-22-5, 42399-41-7; hydrochlorothiazide, 58-93-5; losartan, 114798-26-4; rostafuroxin, 156722-18-8; valsartan, 137862-53-4; verapamil, 152-11-4, 52-53-9; Antihypertensive Agents, ","","","","","Ehret G.B., Caulfield M.J., Genes for blood pressure: An opportunity to understand hypertension, Eur. Heart J., 34, 13, pp. 951-961, (2013); Mongeau J.G., Biron P., Sing C.F., The influence of genetics and household environment upon the variability of normal blood pressure: The Montreal Adoption Survey, Clin. Exp. Hypertens. A., 8, 4-5, pp. 653-660, (1986); Munroe P.B., Barnes M.R., Caulfield M.J., Advances in blood pressure genomics, Circ. Res., 112, 10, pp. 1365-1379, (2013); Hypertension: Clinical Management of Primary Hypertension in Adults, (2011); James P.A., Oparil S., Carter B.L., Et al., 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 5, pp. 507-520, (2014); Kearney P.M., Whelton M., Reynolds K., Et al., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, 9455, pp. 217-223, (2005); Lim S.S., Vos T., Flaxman A.D., Et al., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 9859, pp. 2224-2260, (2012); Lifton R.P., Molecular genetics of human blood pressure variation, Science, 272, 5262, pp. 676-680, (1996); Hamet P., Pausova Z., Adarichev V., Et al., Hypertension: Genes and environment, J. Hypertens., 16, 4, pp. 397-418, (1998); Egan B.M., Zhao Y., Axon R.N., US trends in prevalence awareness, treatment, and control of hypertension, 1988-2008, JAMA, 303, 20, pp. 2043-2050, (2010); Banegas J.R., Lopez-Garcia E., Dallongeville J., Et al., Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: The EURIKA study, Eur. Heart J., 32, 17, pp. 2143-2152, (2011); Johnson J.A., Advancing management of hypertension through pharmacogenomics, Ann. Med., 44, 51, pp. S17-S22, (2012); Chobanian A.V., Bakris G.L., Black H.R., Et al., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The jnc 7 report, JAMA, 289, 19, pp. 2560-2572, (2003); Ritchie M.D., The success of pharmacogenomics in moving genetic association studies from bench to bedside: Study design and implementation of precision medicine in the post-GWAS era, Hum. Genet., 131, 10, pp. 1615-1626, (2012); Abul-Husn N.S., Obeng O.A., Sanderson S.C., Et al., Implementation and utilization of genetic testing in personalized medicine, Pharmgenomics Pers Med, 7, pp. 227-240, (2014); Ingle J.N., Schaid D.J., Goss P.E., Et al., Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors, J. Clin. Oncol., 28, 31, pp. 4674-4682, (2010); Matsson P., Yee S.W., Markova S., Et al., Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping, Pharmacogenomics J., 12, 3, pp. 214-226, (2012); Duarte J.D., Turner S.T., Tran B., Et al., Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression, Pharmacogenomics J., 13, 3, pp. 257-263, (2012); Citterio L., Lanzani C., Manunta P., Polymorphisms, hypertension and thiazide diuretics, Pharmacogenomics, 12, 11, pp. 1587-1604, (2011); Thorn C.F., Ellison D.H., Turner S.T., Et al., PharmGKB summary: Diuretics pathway, pharmacodynamics, Pharmacogenet. Genomics, 23, 8, pp. 449-453, (2013); Gong Y., McDonough C.W., Wang Z., Et al., Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study, Circ. Cardiovasc. Genet., 5, 6, pp. 686-691, (2012); Turner S.T., Bailey K.R., Fridley B.L., Et al., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension, 52, 2, pp. 359-365, (2008); Svensson-Farbom P., Wahlstrand B., Almgren P., Et al., A functional variant of the NEDD4L gene is associated with beneficial treatment response with-blockers and diuretics in hypertensive patients, J. Hypertens., 29, 2, pp. 388-395, (2011); McDonough C.W., Burbage S.E., Duarte J.D., Et al., Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics, J. Hypertens., 31, 4, pp. 698-704, (2013); Turner S.T., Boerwinkle E., O'Connell J.R., Et al., Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide, Hypertension, 62, 2, pp. 391-397, (2013); Hiltunen T.P., Donner K.M., Sarin A.-P., Et al., Pharmacogenomics of hypertension: A genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs, J. Am. Heart Assoc., 4, 1, (2015); Chittani M., Zaninello R., Lanzani C., Et al., TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives, J Hypertens, 33, 6, pp. 1301-1309, (2015); Konoshita T., Do genetic variants of the renin-angiotensin system predict blood pressure response to reninangiotensin system-blocking drugs A systematic review of pharmacogenomics in the renin-angiotensin system, Curr. Hypertens. Rep., 13, 5, pp. 356-361, (2011); Yu H., Lin S., Zhong J., Et al., A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors, J. Renin-Angiotensin-Aldosterone Syst., 15, 4, pp. 540-546, (2014); Srivastava K., Chandra S., Bhatia J., Narang R., Saluja D., Association of angiotensinogen (M235T) gene polymorphism with blood pressure lowering response to angiotensin converting enzyme inhibitor (Enalapril), J. Pharm. Pharm. Sci., 15, 3, pp. 399-406, (2012); Ortlepp J.R., Hanrath P., Mevissen V., Et al., Variants of the CYP11B2 gene predict response to therapy with candesartan, Eur J Pharmacol, 445, 1-2, pp. 151-152, (2002); Donner K.M., Hiltunen T.P., Hannila-Handelberg T., Et al., STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men, Hypertens. Res., 35, 1, pp. 107-114, (2012); Turner S.T., Bailey K.R., Schwartz G.L., Et al., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, 6, pp. 1204-1211, (2012); Kamide K., Asayama K., Katsuya T., Et al., Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study, Pharmacogenomics, 14, 14, pp. 1709-1721, (2013); Frau F., Zaninello R., Salvi E., Et al., Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: The SOPHIA study, Pharmacogenomics, 15, 13, pp. 1643-1652, (2014); Glorioso N., Argiolas G., Filigheddu F., Et al., Conceptual basis and methodology of the SOPHIA study, Pharmacogenomics, 8, 11, pp. 1497-1509, (2007); Sanada H., Yoneda M., Yatabe J., Et al., Common variants of the G protein-coupled receptor type 4 are associated with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade, Pharmacogenomics J., (2015); Felder R.A., Sanada H., Xu J., Et al., G protein-coupled receptor kinase 4 gene variants in human essential hypertension, Proc. Natl Acad. Sci. USA, 99, 6, pp. 3872-3877, (2002); Harris R.C., Abnormalities in renal dopamine signaling and hypertension, Curr. Opin. Nephrol. Hypertens., 21, 1, pp. 61-65, (2012); Nordestgaard B.G., Kontula K., Benn M., Et al., Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study, Pharmacogenet. Genomics, 20, 2, pp. 77-85, (2010); Johnson J.A., Liggett S., Cardiovascular pharmacogenomics of adrenergic receptor signaling: Clinical implications and future directions, Clin. Pharmacol. Ther., 89, 3, pp. 366-378, (2012); Michel T., Hoffman B.B., Pharmacotherapy of myocardial ischemia and hypertension, In Goodman & gilman'S: The Pharmacological Basis of Therapeutics Twelfth Edition, 755-760, pp. 771-777, (2011); Materson B.J., Reda D.J., Cushman W.C., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo, N. Engl. J. Med., 328, 13, pp. 914-921, (1993); Liu J., Liu Z.-Q., Yu B.-N., Et al., Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension, Clin. Pharmacol. Ther., 80, 1, pp. 23-32, (2006); Johnson J.A., Zineh I., Puckett B.J., Et al., Beta1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin. Pharmacol. Ther., 74, 1, pp. 44-52, (2003); Filigheddu F., Argiolas G., Degortes S., Et al., Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension, Pharmacogenomics, 11, 3, pp. 319-325, (2010); Suonsyrja T., Donner K., Hannila-Handelberg T., Et al., Common genetic variation of beta1-and beta2-adrenergic receptor and response to four classes of antihypertensive treatment, Pharmacogenet. Genomics, 20, 5, pp. 342-345, (2010); Pacanowski M., Gong Y., Adrenergic receptor gene polymorphisms and-blocker treatment outcomes in hypertension, Clin. Pharmacol., 84, 6, pp. 715-721, (2008); Lemaitre R.N., Heckbert S.R., Sotoodehnia N., Et al., Beta1-and beta2-adrenergic receptor gene variation, betablocker use and risk of myocardial infarction and stroke, Am. J. Hypertens., 21, 3, pp. 290-296, (2008); Wikoff W.R., Frye R.F., Zhu H., Et al., Pharmacometabolomics reveals racial differences in response to atenolol treatment, PLoS ONE, 8, 3, pp. 1-8, (2013); Johnson J.A., Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics, Circulation, 118, 13, pp. 1383-1393, (2008); Gupta A.K., Poulter N.R., Dobson J., Et al., Ethnic differences in blood pressure response to first-and second-line antihypertensive therapies in patients randomized in the ASCOT trial, Am. J. Hypertens., 23, 9, pp. 1023-1030, (2010); Polimanti R., Iorio A., Piacentini S., Et al., Human pharmacogenomic variation of antihypertensive drugs: From population genetics to personalized medicine, Pharmacogenomics, 15, 2, pp. 157-167, (2014); Vandell A.G., Lobmeyer M.T., Gawronski B.E., Et al., G protein receptor kinase 4 polymorphisms: Beta-blocker pharmacogenetics and treatment-related outcomes in hypertension, Hypertension, 60, 4, pp. 957-964, (2012); Nguyen B.N., Parker R.B., Noujedehi M., Et al., Effects of COER-verapamil on circadian pattern of forearm vascular resistance and blood pressure, J. Clin. Pharmacol., 40, 12, pp. 1480-1487, (2000); Niu Y., Gong Y., Langaee T.Y., Et al., Genetic variation in the beta 2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the international verapamil SR-trandolapril study genetic substudy (INVEST-GENES), Circ. Cardiovasc. Genet., 3, 6, pp. 548-555, (2010); Hamrefors V., Sjogren M., Almgren P., Et al., Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms, J. Hypertens., 30, 6, pp. 1151-1160, (2012); McDonough C.W., Gong Y., Padmanabhan S., Et al., Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12 A1BG and the selectin region and cardiovascular outcomes, Hypertension, 62, 1, pp. 48-54, (2013); Bianchi G., Genetic variations of tubular sodium reabsorption leading to primary hypertension: From gene polymorphism to clinical symptoms, Am. J. Physiol. Regul. Integr. Comp. Physiol., 289, 6, pp. R1536-R1549, (2005); Manunta P., Messaggio E., Ballabeni C., Et al., Plasma ouabainlike factor during acute and chronic changes in sodium balance in essential hypertension, Hypertension, 38, 2, pp. 198-203, (2001); Casari G., Barlassina C., Cusi D., Et al., Association of the alpha-adducin locus with essential hypertension, Hypertension, 25, 3, pp. 320-326, (1995); Cusi D., Barlassina C., Azzani T., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, 9062, pp. 1353-1357, (1997); Ferrari P., Ferrandi M., Valentini G., Bianchi G., Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin dependent hypertension, Am. J. Physiol. Regul. Integr. Comp. Physiol., 290, 3, pp. R529-R535, (2006); Ferrandi M., Molinari I., Torielli L., Et al., Adducin-and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin. Part 1: Experimental studies, Sci. Transl. Med., 2, 59, pp. 59-86, (2010); Lanzani C., Citterio L., Glorioso N., Et al., Adducin-and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: Clinical studies, Sci. Transl. Med., 2, 59, pp. 59-87, (2010); Staessen J.A., Kuznetsova T., Acceto R., Et al., OASISHT: Design of a pharmacogenomic dose-finding study, Pharmacogenomics, 6, 7, pp. 755-775, (2005); Wenceslau C.F., Rossoni L.V., Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: The role of Na+K+-ATPase/cSRC pathway, J. Hypertens., 32, 3, pp. 542-554, (2013); Capasso G., Rizzo M., Evangelista C., Et al., Altered expression of renal apical plasma membrane Na+ transporters in the early phase of genetic hypertension, Am. J. Physiol. Renal Physiol., 288, 6, pp. F1173-F1182, (2005); Capasso G., Rizzo M., Garavaglia M.L., Et al., Upregulation of apical sodium-chloride cotransporter and basolateral chloride channels is responsible for the maintenance of saltsensitive hypertension, Am. J. Physiol. Renal Physiol., 295, 2, pp. F556-F567, (2008); Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment, Br. Med. J. Clin. Res. Ed., 293, 6553, pp. 988-992, (1986)","C. Barlassina; Department of Health Sciences, Milan University, Milan, Via Rudinì 8, 20142, Italy; email: cristina.barlassina@unimi.it","","Future Medicine Ltd.","","","","","","14622416","","PARMF","26555875","English","Pharmacogenomics","Review","Final","","Scopus","2-s2.0-84947945050"
"Imai Y.; Kamide K.; Asayama K.; Katsuya T.; Ohkubo T.; Hirose T.; Inoue R.; Metoki H.; Kikuya M.; Obara T.; Hanada H.; Thijs L.; Kuznetsova T.; Noguchi Y.; Sugimoto K.; Ohishi M.; Morimoto S.; Nakahashi T.; Takiuchi S.; Ishimitsu T.; Tsuchihashi T.; Soma M.; Higaki J.; Matsuura H.; Shinagawa T.; Sasaguri T.; Miki T.; Takeda K.; Shimamoto K.; Ueno M.; Hosomi N.; Kato J.; Komai N.; Kojima S.; Sase K.; Miyata T.; Tomoike H.; Kawano Y.; Ogihara T.; Rakugi H.; Staessen J.A.","Imai, Yutaka (57207210634); Kamide, Kei (7102978326); Asayama, Kei (7103182886); Katsuya, Tomohiro (7005266558); Ohkubo, Takayoshi (7201618716); Hirose, Takuo (57155751000); Inoue, Ryusuke (8536911300); Metoki, Hirohito (6701459599); Kikuya, Masahiro (57209785059); Obara, Taku (7103069231); Hanada, Hironori (56843429400); Thijs, Lutgarde (35378587200); Kuznetsova, Tatiana (35450164300); Noguchi, Yuichi (58600829300); Sugimoto, Ken (35400530500); Ohishi, Mitsuru (7102625754); Morimoto, Shigeto (56363325800); Nakahashi, Takeshi (7003804824); Takiuchi, Shin (7004120849); Ishimitsu, Toshihiko (11640295400); Tsuchihashi, Takuya (7005904737); Soma, Masayoshi (7101871928); Higaki, Jitsuo (57212329125); Matsuura, Hideo (59024379700); Shinagawa, Tatsuo (56021839500); Sasaguri, Toshiyuki (7005358404); Miki, Tetsuro (57209647067); Takeda, Kazuo (7404335150); Shimamoto, Kazuaki (35354538200); Ueno, Michio (35426713000); Hosomi, Naohisa (7004492816); Kato, Jyouji (35474613900); Komai, Norio (56664103100); Kojima, Shunichi (35355786300); Sase, Kazuhiro (56922531800); Miyata, Toshiyuki (56381961600); Tomoike, Hitonobu (7103005104); Kawano, Yuhei (26643119800); Ogihara, Toshio (57220595182); Rakugi, Hiromi (57202699453); Staessen, Jan A. (7202415416)","57207210634; 7102978326; 7103182886; 7005266558; 7201618716; 57155751000; 8536911300; 6701459599; 57209785059; 7103069231; 56843429400; 35378587200; 35450164300; 58600829300; 35400530500; 7102625754; 56363325800; 7003804824; 7004120849; 11640295400; 7005904737; 7101871928; 57212329125; 59024379700; 56021839500; 7005358404; 57209647067; 7404335150; 35354538200; 35426713000; 7004492816; 35474613900; 56664103100; 35355786300; 56922531800; 56381961600; 7103005104; 26643119800; 57220595182; 57202699453; 7202415416","Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study","2013","Pharmacogenomics","14","14","","1709","1721","12","34","10.2217/PGS.13.161","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893208653&doi=10.2217%2fPGS.13.161&partnerID=40&md5=863d8cb6554f00339abd848e105404b9","Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Aoba-ku, Sendai, 980-8575, 2-1 Seiryo-cho, Japan; Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan; Research Institute, National Cerebro and Cardiovascular Research Center, Osaka, Japan; Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan; Center for Interdisciplinary Research in Biology (CIRB), College de France, Paris, France; Department of Medical Informatics, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan; Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan; Department of Cardiovascular Medicine, Kagoshima University Graduate School of Medicine, Kagoshima, Japan; Department of Geriatric Medicine, Kanazawa Medical University, Ishikawa, Japan; Department of Cardiology, Higashi- Takarazuka Sato Hospital, Hyogo, Japan; Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Tochigi, Japan; Division of Hypertension, Clinical Research Center, National Kyushu Medical Center, Fukuoka, Japan; Division of General Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Department of Integrated Medicine and Informatics, Ehime University Graduate School of Medicine, Ehime, Japan; Saiseikai Kure Hospital, Hiroshima, Japan; Shinagawa Clinic, Nagasaki, Japan; Department of Clinical Pharmacology, Kyushu University Graduate School of Medicine, Fukuoka, Japan; Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan; Kyotokojohokenkai Hospital, Kyoto, Japan; Department of Second Internal Medicine, Sapporo Medical University, Sapporo, Japan; National Fukuoka-Higashi Medical Center, Fukuoka, Japan; Department of Clinical Neuroscience and Therapeutics, Hiroshima University, Hiroshima, Japan; Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan; Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan; National Hospital Organization Shizuoka Medical Center, Shizuoka, Japan; Juntendo University Clinical Pharmacology, Tokyo, Japan; Sakakibara Heart Institute, Tokyo, Japan; Division of Hypertension and Nephrology, National Cerebro and Cardiovascular Research Center, Osaka, Japan; Morinomiya University of Medical Sciences, Osaka, Japan; Department of Epidemiology, Maastricht University, Maastricht, Netherlands","Imai Y., Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Aoba-ku, Sendai, 980-8575, 2-1 Seiryo-cho, Japan; Kamide K., Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan, Research Institute, National Cerebro and Cardiovascular Research Center, Osaka, Japan, Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Asayama K., Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Aoba-ku, Sendai, 980-8575, 2-1 Seiryo-cho, Japan, Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Katsuya T., Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka, Japan; Ohkubo T., Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Aoba-ku, Sendai, 980-8575, 2-1 Seiryo-cho, Japan, Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan; Hirose T., Center for Interdisciplinary Research in Biology (CIRB), College de France, Paris, France; Inoue R., Department of Medical Informatics, Tohoku University Graduate School of Medicine, Sendai, Japan; Metoki H., Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan; Kikuya M., Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan; Obara T., Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan; Hanada H., Research Institute, National Cerebro and Cardiovascular Research Center, Osaka, Japan; Thijs L., Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Kuznetsova T., Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Noguchi Y., Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan; Sugimoto K., Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan; Ohishi M., Department of Cardiovascular Medicine, Kagoshima University Graduate School of Medicine, Kagoshima, Japan; Morimoto S., Department of Geriatric Medicine, Kanazawa Medical University, Ishikawa, Japan; Nakahashi T., Department of Geriatric Medicine, Kanazawa Medical University, Ishikawa, Japan; Takiuchi S., Department of Cardiology, Higashi- Takarazuka Sato Hospital, Hyogo, Japan; Ishimitsu T., Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Tochigi, Japan; Tsuchihashi T., Division of Hypertension, Clinical Research Center, National Kyushu Medical Center, Fukuoka, Japan; Soma M., Division of General Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Higaki J., Department of Integrated Medicine and Informatics, Ehime University Graduate School of Medicine, Ehime, Japan; Matsuura H., Saiseikai Kure Hospital, Hiroshima, Japan; Shinagawa T., Shinagawa Clinic, Nagasaki, Japan; Sasaguri T., Department of Clinical Pharmacology, Kyushu University Graduate School of Medicine, Fukuoka, Japan; Miki T., Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan; Takeda K., Kyotokojohokenkai Hospital, Kyoto, Japan; Shimamoto K., Department of Second Internal Medicine, Sapporo Medical University, Sapporo, Japan; Ueno M., National Fukuoka-Higashi Medical Center, Fukuoka, Japan; Hosomi N., Department of Clinical Neuroscience and Therapeutics, Hiroshima University, Hiroshima, Japan; Kato J., Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan; Komai N., Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan; Kojima S., National Hospital Organization Shizuoka Medical Center, Shizuoka, Japan; Sase K., Juntendo University Clinical Pharmacology, Tokyo, Japan; Miyata T., Research Institute, National Cerebro and Cardiovascular Research Center, Osaka, Japan; Tomoike H., Sakakibara Heart Institute, Tokyo, Japan; Kawano Y., Division of Hypertension and Nephrology, National Cerebro and Cardiovascular Research Center, Osaka, Japan; Ogihara T., Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan, Morinomiya University of Medical Sciences, Osaka, Japan; Rakugi H., Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan; Staessen J.A., Studies Coordinating Centre, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, Department of Epidemiology, Maastricht University, Maastricht, Netherlands","Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). Methods: We recruited 265 (93 for CCB, 71 for ACEI and 101 for ARB) patients who completed the genomic study. Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2-4 weeks of randomized drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were analyzed separately as a quantitative trait. For replication of SNPs with p < 10-4, we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine. Results: SNPs in PICALM, TANC2, NUMA1 and APCDD1 were found to be associated with CCB responses and those in ABCC9 and YIPF1 were found to be associated with ARB response with replication. Conclusion: Our approach, the first based on high-fidelity phenotyping by home blood pressure measurement, might be a step in moving towards the personalized treatment of hypertension.","Antihypertensive drugs; Blood pressure response; Genome wide association study; Home blood pressure; Personalized treatment","Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers, Pharmacological; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Female; Genome-Wide Association Study; Genotyping Techniques; Humans; Hypertension; Individualized Medicine; Male; Middle Aged; Pilot Projects; Randomized Controlled Trials as Topic; amlodipine; indapamide; valsartan; angiotensin receptor antagonist; antihypertensive agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; pharmacological biomarker; ABCC9 gene; adult; age distribution; antihypertensive therapy; APCDD1 gene; article; blood pressure measurement; clinical effectiveness; controlled study; DNA microarray; drug efficacy; drug response; essential hypertension; female; gene; genetic association; genotype; home care; human; major clinical study; male; multicenter study; NUMA1 gene; Picalm gene; pilot study; primary health care; quantitative trait; randomized controlled trial; single nucleotide polymorphism; TANC2 gene; YIPF1 gene; aged; blood pressure monitoring; genetic association; genetics; genotyping technique; hypertension; middle aged; pathology; personalized medicine; randomized controlled trial (topic)","","amlodipine, 103129-82-4, 736178-83-9, 88150-42-9; indapamide, 26807-65-8; valsartan, 137862-53-4; Angiotensin Receptor Antagonists, ; Angiotensin-Converting Enzyme Inhibitors, ; Antihypertensive Agents, ; Biomarkers, Pharmacological, ; Calcium Channel Blockers, ","","","Seventh Framework Programme, FP7, (201550); Seventh Framework Programme, FP7","","Ohkubo T., Obara T., Funahashi J., Et al., Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study, Hypertens. Res., 27, 10, pp. 755-763, (2004); Ogihara T., Kikuchi K., Matsuoka H., Et al., The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009), Hypertens. Res., 32, 1, pp. 3-107, (2009); Turner S.T., Schwartz G.L., Chapman A.B., Hall W.D., Boerwinkle E., Antihypertensive pharmacogenetics: Getting the right drug into the right patient, J. Hypertens., 19, 1, pp. 1-11, (2001); Kamide K., Kawano Y., Rakugi H., Pharmacogenomic approaches to study the effects of antihypertensive drugs, Hypertens. Res., 35, 8, pp. 796-799, (2012); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic, Hypertension, 46, 4, pp. 758-765, (2005); Turner S.T., Bailey K.R., Fridley B.L., Et al., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension, 52, 2, pp. 359-365, (2008); Turner S.T., Bailey K.R., Schwartz G.L., Chapman A.B., Chai H.S., Boerwinkle E., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, 6, pp. 1204-1211, (2012); Niiranen T.J., Hanninen M.R., Johansson J., Reunanen A., Jula A.M., Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The Finn-Home study, Hypertension, 55, 6, pp. 1346-1351, (2010); Asayama K., Ohkubo T., Kikuya M., Et al., Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the JNC-7 classification: The Ohasama study, Stroke, 35, 10, pp. 2356-2361, (2004); Asayama K., Ohkubo T., Metoki H., Et al., Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure, Hypertens. Res., 35, pp. 1102-1110, (2012); Fujiwara T., Matsubara M., Ohkubo T., Imai Y., Study design of HOMED-BP: Hypertension objective treatment based on measurement by electrical devices of blood pressure, Clin. Exp. Hypertens., 25, 3, pp. 143-144, (2003); Chonan K., Kikuya M., Araki T., Et al., Device for the self-measurement of blood pressure that can monitor blood pressure during sleep, Blood Press. Monit., 6, 4, pp. 203-205, (2001); Metoki H., Ohkubo T., Kikuya M., Et al., The velocity of antihypertensive effect of losartan/ hydrochlorothiazide and angiotensin II receptor blocker, J. Hypertens., 30, 7, pp. 1478-1486, (2012); Becker M.L., Visser L.E., Van Schaik R.H., Hofman A., Uitterlinden A.G., Stricker B.H., OCT1 polymorphism is associated with response and survival time in anti- Parkinsonian drug users, Neurogenetics, 12, 1, pp. 79-82, (2011); Nature, 447, 7145, pp. 661-678, (2007); Imai Y., Ohkubo T., Hozawa A., Et al., Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial, J. Hypertens., 19, 2, pp. 179-185, (2001); Dreyling M.H., Martinez-Climent J.A., Zheng M., Mao J., Rowley J.D., Bohlander S.K., The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family, Proc. Natl Acad. Sci. USA, 93, 10, pp. 4804-4809, (1996); Ferrari R., Moreno J.H., Minhajuddin A.T., Et al., Implication of common and disease specific variants in CLU, CR1, and PICALM, Neurobiol. Aging, 33, 8, (2012); Harold D., Abraham R., Hollingworth P., Et al., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nat. Genet., 41, 10, pp. 1088-1093, (2009); Masliah E., Mallory M., Alford M., Et al., Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease, Neurology, 56, 1, pp. 127-129, (2001); Bushlin I., Petralia R.S., Wu F., Et al., Clathrin assembly protein AP180 and CALM differentially control axogenesis and dendrite outgrowth in embryonic hippocampal neurons, J. Neurosci., 28, 41, pp. 10257-10271, (2008); Farrer L.A., Cupples L.A., Haines J.L., Et al., Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and Alzheimer disease A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA, 278, 16, pp. 1349-1356, (1997); Sweet R.A., Seltman H., Emanuel J.E., Et al., Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study, Am. J. Psychiatry, 169, 9, pp. 954-962, (2012); Forette F., Seux M.L., Staessen J.A., Et al., Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, Lancet, 352, 9137, pp. 1347-1351, (1998); Forette F., Seux M.L., Staessen J.A., Et al., The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study, Arch. Intern. Med., 162, 18, pp. 2046-2052, (2002); Chutkow W.A., Simon M.C., Le Beau M.M., Burant C.F., Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels, Diabetes, 45, 10, pp. 1439-1445, (1996); Inagaki N., Gonoi T., Clement J.P.T., Et al., Reconstitution of IKATP: An inward rectifier subunit plus the sulfonylurea receptor, Science, 270, 5239, pp. 1166-1170, (1995); Inagaki N., Gonoi T., Clement J.P., Et al., A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels, Neuron, 16, 5, pp. 1011-1017, (1996); Bienengraeber M., Olson T.M., Selivanov V.A., Et al., ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating, Nat. Genet., 36, 4, pp. 382-387, (2004); Olson T.M., Alekseev A.E., Moreau C., Et al., KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation, Nat. Clin. Pract. Cardiovasc. Med., 4, 2, pp. 110-116, (2007); Healey J.S., Baranchuk A., Crystal E., Et al., Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis, J. Am. Coll. Cardiol., 45, 11, pp. 1832-1839, (2005); Pedersen O.D., Bagger H., Kober L., Torp- Pedersen C., Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction, Circulation, 100, 4, pp. 376-380, (1999); Vermes E., Tardif J.C., Bourassa M.G., Et al., Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials, Circulation, 107, 23, pp. 2926-2931, (2003); Shimomura Y., Agalliu D., Vonica A., Et al., APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex, Nature, 464, 7291, pp. 1043-1047, (2010); Bergmann M.W., WNT signaling in adult cardiac hypertrophy and remodeling: Lessons learned from cardiac development, Circ. Res., 107, 10, pp. 1198-1208, (2010); Ter Horst P., Smits J.F., Blankesteijn W.M., The Wnt/Frizzled pathway as a therapeutic target for cardiac hypertrophy: Where do we stand?, Acta Physiol., 204, 1, pp. 110-117, (2012); Varela-Nallar L., Alfaro I.E., Serrano F.G., Parodi J., Inestrosa N.C., Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses, Proc. Natl Acad. Sci. USA, 107, 49, pp. 21164-21169, (2010); Martins-De-Souza D., Guest P.C., Mann D.M., Et al., Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration, J. Proteome Res., 11, 4, pp. 2533-2543, (2012); Sparks C.A., Bangs P.L., McNeil G.P., Lawrence J.B., Fey E.G., Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13, Genomics, 17, 1, pp. 222-224, (1993); Brown L.A., Kalloger S.E., Miller M.A., Et al., Amplification of 11q13 in ovarian carcinoma, Genes Chromosomes Cancer, 47, 6, pp. 481-489, (2008); Bruning-Richardson A., Bond J., Alsiary R., Et al., NuMA overexpression in epithelial ovarian cancer, PLoS ONE, 7, 6, (2012)","Y. Imai; Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Aoba-ku, Sendai, 980-8575, 2-1 Seiryo-cho, Japan; email: rinsyo@mail.pharm.tohoku.ac.jp","","","","","","","","17448042","","PARMF","24192120","English","Pharmacogenomics","Article","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-84893208653"
"Sienko J.; Marczak I.; Kotowski M.; Bogacz A.; Tejchman K.; Sienko M.; Kotfis K.","Sienko, Jerzy (56050275200); Marczak, Izabela (57719509900); Kotowski, Maciej (26024251000); Bogacz, Anna (24503183000); Tejchman, Karol (12751896000); Sienko, Magdalena (37021739600); Kotfis, Katarzyna (35229603400)","56050275200; 57719509900; 26024251000; 24503183000; 12751896000; 37021739600; 35229603400","Association of ACE2 Gene Variants with the Severity of COVID-19 Disease—A Prospective Observational Study","2022","International Journal of Environmental Research and Public Health","19","19","12622","","","","13","10.3390/ijerph191912622","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139812748&doi=10.3390%2fijerph191912622&partnerID=40&md5=ec92abbf3d52a6af82cf200b8486a7e2","Department of General Surgery and Transplantology, Pomeranian Medical University, Szczecin, 70-111, Poland; Department of Neurology, SUNY Downstate Medical Center, Brooklyn, 11023, NY, United States; Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Plewiska, 62-064, Poland; Department of Pediatrics, Endocrinology, Metabolic Diseases, and Cardiology, Pomeranian Medical University, Diabetology, Szczecin, 71-252, Poland; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, Szczecin, 70-111, Poland","Sienko J., Department of General Surgery and Transplantology, Pomeranian Medical University, Szczecin, 70-111, Poland; Marczak I., Department of Neurology, SUNY Downstate Medical Center, Brooklyn, 11023, NY, United States; Kotowski M., Department of General Surgery and Transplantology, Pomeranian Medical University, Szczecin, 70-111, Poland; Bogacz A., Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Plewiska, 62-064, Poland; Tejchman K., Department of General Surgery and Transplantology, Pomeranian Medical University, Szczecin, 70-111, Poland; Sienko M., Department of Pediatrics, Endocrinology, Metabolic Diseases, and Cardiology, Pomeranian Medical University, Diabetology, Szczecin, 71-252, Poland; Kotfis K., Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, Szczecin, 70-111, Poland","The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2), has triggered an enormous scientific response. Many studies have focused on understanding the entry of the SARS-CoV-2 virus into the host cell. The angiotensin-converting enzyme-2 (ACE2) is recognized as the host receptor used by SARS-CoV-2 to enter its target cells. Recent studies suggest that ACE2 gene polymorphisms might be candidates for genetic susceptibility to SARS-CoV-2 infection. The aim of this study is to evaluate the influence of ACE2 polymorphisms on COVID-19 disease risk and severity. In our study, we confirmed that there is a statistically significant increased risk of a more severe disease course of SARS-CoV-2 infection associated with the need for hospitalization in intensive care for patients with specific polymorphisms of the ACE2 gene. The most significant correlation was found for variant ACE2 rs2285666 (AA allele, OR = 2.12, p = 0.0189) and ACE2 rs2074192 (TT allele, OR = 2.05, p = 0.0016), and for ACE2 rs4646174 (GG allele, OR = 1.93, p = 0.0016), ACE2 rs4646156 (TT allele OR = 1.71, p = 0.008) and ACE2 rs2158083 (TT allele OR = 1.84, p = 0.0025). In conclusion, our findings identify that certain ACE2 polymorphisms impact the severity of COVID-19 disease independently of other well-known risk factors. © 2022 by the authors.","angiotensin receptors; coronavirus; gene polymorphism; SARS-CoV-2; single nucleotide polymorphism","Angiotensin-Converting Enzyme 2; Angiotensins; COVID-19; Genetic Predisposition to Disease; Humans; Pandemics; Peptidyl-Dipeptidase A; SARS-CoV-2; angiotensin converting enzyme 2; angiotensin receptor; genomic DNA; angiotensin derivative; dipeptidyl carboxypeptidase; COVID-19; disease severity; enzyme activity; gene; polymorphism; risk factor; adult; allele; analysis of variance; angiotensin converting enzyme 2 gene; Article; artificial ventilation; confidence interval; controlled study; coronavirus disease 2019; diagnostic test accuracy study; disease risk assessment; disease severity; female; gene; genetic polymorphism; genetic variability; genotyping; hospitalization; host cell; human; hypertension; hypothyroidism; insulin dependent diabetes mellitus; intensive care unit; ischemic heart disease; Kruskal Wallis test; leukocyte; major clinical study; male; non insulin dependent diabetes mellitus; nonhuman; obesity; observational study; odds ratio; pandemic; polymerase chain reaction; prospective study; Severe acute respiratory syndrome coronavirus 2; single nucleotide polymorphism; software; Student t test; target cell; epidemiology; genetic predisposition; genetics","","dipeptidyl carboxypeptidase, 9015-82-1; Angiotensin-Converting Enzyme 2, ; Angiotensins, ; Peptidyl-Dipeptidase A, ","Epoch, Biotek, United States; LightCycler 96, Hoffmann La Roche, Switzerland; PureLink, Thermo, United States","Biotek, United States; Hoffmann La Roche, Switzerland; Thermo, United States","Polish Medical Research Agency, (2020/ABM/COVID19/0023)","This research was funded by the Polish Medical Research Agency (ABM), grant number 2020/ABM/COVID19/0023.","Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., Et al., A new coronavirus associated with human respiratory disease in China, Nature, 579, pp. 265-269, (2020); Coden M.E., Loffredo L.F., Abdala-Valencia H., Berdnikovs S., Comparative Study of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-229E and Influenza Host Gene Expression in Asthma: Importance of Sex, Disease Severity, and Epithelial Heterogeneity, Viruses, 13, (2021); Gaunt E.R., Hardie A., Claas E.C., Simmonds P., Templeton K.E., Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method, J. Clin. Microbiol, 48, pp. 2940-2947, (2010); Hui D.S.C., Zumla A., Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features, Infect. Dis. Clin. N. Am, 33, pp. 869-889, (2019); Nassar M.S., Bakhrebah M.A., Meo S.A., Alsuabeyl M.S., Zaher W.A., Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: Epidemiology, pathogenesis and clinical characteristics, Eur. Rev. Med. Pharmacol. Sci, 22, pp. 4956-4961, (2018); Cui J., Li F., Shi Z.L., Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol, 17, pp. 181-192, (2019); Weiss S.R., Navas-Martin S., Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus, Microbiol. Mol. Biol. Rev, 69, pp. 635-664, (2005); Scialo F., Daniele A., Amato F., Pastore L., Matera M.G., Cazzola M., Castaldo G., Bianco A., ACE2: The Major Cell Entry Receptor for SARS-CoV-2, Lung, 198, pp. 867-877, (2020); Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, pp. 270-273, (2020); Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol, 203, pp. 631-637, (2004); Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen Q., High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, Int. J. Oral. Sci, 12, (2020); Zou X., Chen K., Zou J., Han P., Hao J., Han Z., Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front. Med, 14, pp. 185-192, (2020); Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J. Biol. Chem, 275, pp. 33238-33243, (2000); Voors A.A., Pinto Y.M., Buikema H., Urata H., Oosterga M., Rooks G., Grandjean J.G., Ganten D., van Gilst W.H., Dual pathway for angiotensin II formation in human internal mammary arteries, Br. J. Pharmacol, 125, pp. 1028-1032, (1998); Tikellis C., Thomas M.C., Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease, Int. J. Pept, 2012, (2012); Ferrario C.M., Trask A.J., Jessup J.A., Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function, Am. J. Physiol. Heart Circ. Physiol, 289, pp. H2281-H2290, (2005); Sanchis-Gomar F., Lavie C.J., Perez-Quilis C., Henry B.M., Lippi G., Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019, Mayo Clin. Proc, 95, pp. 1222-1230, (2020); Zores F., Rebeaud M.E., COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?, Front. Cardiovasc. Med, 7, (2020); Sienko J., Kotowski M., Bogacz A., Lechowicz K., Drozdzal S., Rosik J., Sietnicki M., Sienko M., Kotfis K., COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients, Clin. Interv. Aging, 15, pp. 1231-1240, (2020); Pan Y., Wang T., Li Y., Guan T., Lai Y., Shen Y., Zeyaweiding A., Maimaiti T., Li F., Zhao H., Et al., Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China, Lipids Health Dis, 17, (2018); Zhang Q., Cong M., Wang N., Li X., Zhang H., Zhang K., Jin M., Wu N., Qiu C., Li J., Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study, Medicine, 97, (2018); Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., Stritzke J., Hengstenberg C., Holmer S.R., Doring A., Et al., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy, J. Mol. Med, 84, pp. 88-96, (2006); Barash A., Machluf Y., Ariel I., Dekel Y., The Pursuit of COVID-19 Biomarkers: Putting the Spotlight on ACE2 and TMPRSS2 Regulatory Sequences, Front. Med, 7, (2020); Gemmati D., Tisato V., Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19, Genes, 11, (2020); Patel S.K., Velkoska E., Freeman M., Wai B., Lancefield T.F., Burrell L.M., From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension, Front. Physiol, 5, (2014); Pouladi N., Abdolahi S., Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis, Mol. Genet. Genomic. Med, 9, (2021); Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X., COVID-19 and the cardiovascular system, Nat. Rev. Cardiol, 17, pp. 259-260, (2020); Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y., Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis, Int. J. Infect. Dis, 94, pp. 91-95, (2020); Cafiero C., Rosapepe F., Palmirotta R., Re A., Ottaiano M.P., Benincasa G., Perone R., Varriale E., D'Amato G., Cacciamani A., Et al., Angiotensin System Polymorphisms’ in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study, Pharmgenomics Pers. Med, 14, pp. 621-629, (2021); Hamet P., Pausova Z., Attaoua R., Hishmih C., Haloui M., Shin J., Paus T., Abrahamowicz M., Gaudet D., Santucci L., Et al., SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking, Am. J. Hypertens, 34, pp. 367-376, (2021); Fan Z., Wu G., Yue M., Ye J., Chen Y., Xu B., Shu Z., Zhu J., Lu N., Tan X., Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism, Life Sci, 225, pp. 39-45, (2019); Mohlendick B., Schonfelder K., Breuckmann K., Elsner C., Babel N., Balfanz P., Dahl E., Dreher M., Fistera D., Herbstreit F., Et al., ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19, Pharm. Genomics, 31, pp. 165-171, (2021); Gomez J., Albaiceta G.M., Garcia-Clemente M., Lopez-Larrea C., Amado-Rodriguez L., Lopez-Alonso I., Hermida T., Enriquez A.I., Herrero P., Melon S., Et al., Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome, Gene, 762, (2020); Liu C., Li Y., Guan T., Lai Y., Shen Y., Zeyaweiding A., Zhao H., Li F., Maimaiti T., ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus, Cardiovasc. Diabetol, 17, (2018); Sze S., Pan D., Nevill C.R., Gray L.J., Martin C.A., Nazareth J., Minhas J.S., Divall P., Khunti K., Abrams K.R., Et al., Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis, eClinicalMedicine, 29, (2020)","K. Kotfis; Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, Szczecin, 70-111, Poland; email: katarzyna.kotfis@pum.edu.pl","","MDPI","","","","","","16617827","","","36231922","English","Int. J. Environ. Res. Public Health","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85139812748"
"Keller G.A.; Ferreiros-Gago M.L.; Di-Salvo H.; Di Girolamo G.","Keller, Guillermo Alberto (24177134500); Ferreiros-Gago, Maria Laura (57219729019); Di-Salvo, Hector (55270803400); Di Girolamo, Guillermo (7006790866)","24177134500; 57219729019; 55270803400; 7006790866","Precision medicine in the Renin-Angiotensin system: Therapeutic targets and biological variability","2020","Current Drug Targets","21","15","","1625","1637","12","0","10.2174/1389450121666200719010849","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094963908&doi=10.2174%2f1389450121666200719010849&partnerID=40&md5=732b87ff8d0c4c141aec6ef661ae3c8b","Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina; Universidad de Buenos Aires, Facultad de Medicina, Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentina; Hospital General de Agudos Donación Francisco J. Santojanni, Emergency Department, Buenos Aires, Argentina","Keller G.A., Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina, Universidad de Buenos Aires, Facultad de Medicina, Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentina, Hospital General de Agudos Donación Francisco J. Santojanni, Emergency Department, Buenos Aires, Argentina; Ferreiros-Gago M.L., Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina, Universidad de Buenos Aires, Facultad de Medicina, Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentina; Di-Salvo H., Hospital General de Agudos Donación Francisco J. Santojanni, Emergency Department, Buenos Aires, Argentina; Di Girolamo G., Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina, Universidad de Buenos Aires, Facultad de Medicina, Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentina","Pathologies linked to the renin-angiotensin system are frequent, and the drugs used in them are numerous and show great variability in therapeutic effects and adverse reactions. Genetic variants have been detected in the angiotensinogen gene (6), angiotensin-converting enzyme (9), angiotensin-converting enzyme 2 (1), and angiotensin receptor Type 1 (4) among others. However, the large num-ber of studies that have analyzed each of them makes it complex and almost impossible to consider all the existing information. This manuscript aims to review the effects of the different known variants on the expected response of different drugs as a basis for the future development of therapeutic guidelines that seek to implement therapeutic individualization strategies on the renin-angiotensin system. © 2020 Bentham Science Publishers.","Aldosterone; Angioten-sinogen gene; Angiotensin receptor; Population biological variations; Precision medicine; Renin-angiotensin-aldosterone system","Aminopeptidases; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Humans; Peptidyl-Dipeptidase A; Precision Medicine; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; acetylsalicylic acid; allopurinol; amfebutamone; amlodipine; angiotensin 1A receptor; angiotensin converting enzyme 2; angiotensin II; angiotensin receptor antagonist; angiotensinogen; antihypertensive agent; atenolol; atorvastatin; atrial natriuretic factor; beta adrenergic receptor blocking agent; bisoprolol; brain natriuretic peptide; bumetanide; calcium channel blocking agent; candesartan; captopril; carvedilol; chlortalidone; chymase; corticosteroid; creatinine; diclofenac; digoxin; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; doxazosin; enalapril; endothelin 1; fluindostatin; fluoxetine; furosemide; hexapeptide; hydrochlorothiazide; hydroxymethylglutaryl coenzyme A reductase inhibitor; ibuprofen; imidapril; insulin; irbesartan; ketorolac; lisinopril; losartan; losartan potassium; metadrenalin; metalloprotein; microsomal aminopeptidase; naproxen; nitrendipine; nitric oxide; nitroprusside sodium; nonapeptide; noradrenalin; perindopril; phenylephrine; pravastatin; ramipril; renin; serine proteinase inhibitor; sertraline; sildenafil; spironolactone; thiazide diuretic agent; torasemide; aminopeptidase; angiotensin 1 receptor; acute heart infarction; acute kidney failure; albuminuria; amino acid sequence; amyloidosis; antiinflammatory activity; antiproliferative activity; atrial fibrillation; biological variation; brain blood flow; cell proliferation; chronic kidney failure; chronic obstructive lung disease; coronary artery disease; depression; diastolic blood pressure; DNA polymorphism; DNA sequence; drug response; endothelial dysfunction; enzyme activity; enzyme inhibition; gastrointestinal hemorrhage; gene frequency; genetic polymorphism; genetic variability; genetic variation; genotype; glomerulus filtration rate; glycemic control; glycosylation; heart arrhythmia; heart failure; heart left ventricle ejection fraction; heart left ventricle hypertrophy; heart left ventricle mass; heart muscle fibrosis; heart muscle revascularization; hemodynamics; human; hypertension; individualization; inflammatory bowel disease; insulin resistance; kidney injury; liver cirrhosis; macroalbuminuria; major depression; medication compliance; non insulin dependent diabetes mellitus; personalized medicine; pharmacogenetics; pharmacogenomics; preeclampsia; renin angiotensin aldosterone system; Review; septic shock; single nucleotide polymorphism; systolic blood pressure; therapy effect; upper gastrointestinal bleeding; animal; drug effect; genetics; personalized medicine; procedures; renin angiotensin aldosterone system","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; allopurinol, 315-30-0; amfebutamone, 31677-93-7, 34911-55-2; amlodipine, 88150-42-9; angiotensin II, 11128-99-7, 68521-88-0; angiotensinogen, 11002-13-4, 64315-16-8; atenolol, 29122-68-7, 93379-54-5; atorvastatin, 134523-00-5, 134523-03-8; atrial natriuretic factor, 85637-73-6; bisoprolol, 66722-44-9; brain natriuretic peptide, 114471-18-0; bumetanide, 28395-03-1; candesartan, 139481-59-7; captopril, 62571-86-2; carvedilol, 72956-09-3; chlortalidone, 77-36-1, 1441368-45-1, 1441368-51-9; chymase, 75496-62-7, 97501-92-3; creatinine, 19230-81-0, 60-27-5; diclofenac, 15307-79-6, 15307-86-5; digoxin, 20830-75-5, 57285-89-9; dipeptidyl carboxypeptidase, 9015-82-1; doxazosin, 74191-85-8; enalapril, 75847-73-3; endothelin 1, 117399-94-7; fluindostatin, 93957-54-1; fluoxetine, 54910-89-3, 56296-78-7, 59333-67-4; furosemide, 54-31-9; hydrochlorothiazide, 58-93-5; ibuprofen, 15687-27-1, 79261-49-7, 31121-93-4, 527688-20-6; imidapril, 89371-37-9, 89396-94-1; insulin, 9004-10-8; irbesartan, 138402-11-6; ketorolac, 74103-06-3; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; losartan potassium, 124750-99-8; metadrenalin, 5001-33-2; microsomal aminopeptidase, 9054-63-1; naproxen, 22204-53-1, 26159-34-2; nitrendipine, 39562-70-4; nitric oxide, 10102-43-9; nitroprusside sodium, 14402-89-2, 15078-28-1; noradrenalin, 1407-84-7, 51-41-2; perindopril, 82834-16-0, 99149-83-4; phenylephrine, 532-38-7, 59-42-7, 61-76-7; pravastatin, 81093-37-0, 81131-70-6; ramipril, 87333-19-5; renin, 61506-93-2, 9015-94-5; sertraline, 79617-96-2, 79559-97-0; sildenafil, 139755-83-2; spironolactone, 52-01-7; torasemide, 56211-40-6; aminopeptidase, 9031-94-1; Aminopeptidases, ; Angiotensin-Converting Enzyme 2, ; Angiotensinogen, ; Peptidyl-Dipeptidase A, ; Receptor, Angiotensin, Type 1, ","","","","","Tigerstedt R., Bergman P., Niere and Kreislauf, Scand Arch Phy-siol (Germany), 8, pp. 223-271, (1898); Goldblatt H., Lynch J., Hanzal R.F., Summerville W.W., Studies on experimental hypertension: i. The production of persistent ele-vation of systolic blood pressure by means of renal ischemia, J. Exp. Med, 59, 3, pp. 347-379, (1934); Braun-Menendez E., Fasciolo J.C., Leloir L.F., Munoz J.M., The substance causing renal hypertension, J. Physiol, 98, 3, pp. 283-298, (1940); Braun-Menendez E., Page I.H., Suggested Revision of Nomencla-ture-Angiotensin, Science, 127, 3292, (1958); Page I.H., Helmer O.M., A crystalline pressor substance (angioto-nin) resulting from the reaction between renin and renin-activator, J. Exp. Med, 71, 1, pp. 29-42, (1940); Skeggs L.T., Kahn J.R., Lentz K., Shumway N.P., The prepa-ration, purification, and amino acid sequence of a polypeptide renin substrate, J. Exp. Med, 106, 3, pp. 439-453, (1957); Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Ben-field P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., Smith R.D., Angiotensin II receptors and angiotensin II receptor antago-nists, Pharmacol. Rev, 45, 2, pp. 205-251, (1993); Oudart N., The renin-angiotensin system: current data, Ann. Pharm. Fr, 63, 2, pp. 144-153, (2005); Garrido-Gil P., Valenzuela R., Villar-Cheda B., Lanciego J.L., Labandeira-Garcia J.L., Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human sub-stantia nigra: an intracellular renin-angiotensin system in the nigra, Brain Struct. Funct, 218, 2, pp. 373-388, (2013); Ribeiro-Oliveira A., Nogueira A.I., Pereira R.M., Boas W.W., Dos Santos R.A., Simoes e Silva A.C., The renin-angiotensin system and diabetes: an update, Vasc. Health Risk Ma-nag, 4, 4, pp. 787-803, (2008); Simoes e Silva A.C., Silveira K.D., Ferreira A.J., Teixeira M.M., ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis, Br. J. Pharmacol, 169, 3, pp. 477-492, (2013); Jankowski V., Vanholder R., van der Giet M., Tolle M., Kara-dogan S., Gobom J., Furkert J., Oksche A., Krause E., Tran T.N., Tepel M., Schuchardt M., Schluter H., Wiedon A., Beyer-mann M., Bader M., Todiras M., Zidek W., Jankowski J., Mass-spectrometric identification of a novel angiotensin peptide in human plasma, Arterioscler. Thromb. Vasc. Biol, 27, 2, pp. 297-302, (2007); Yang R., Smolders I., Vanderheyden P., Demaegdt H., Van Eeckhaut A., Vauquelin G., Lukaszuk A., Tourwe D., Chai S.Y., Albiston A.L., Nahmias C., Walther T., Dupont A.G., Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent, Hypertension, 57, 5, pp. 956-964, (2011); Villela D.C., Passos-Silva D.G., Santos R.A., Alamandine: a new member of the angiotensin family, Curr. Opin. Nephrol. Hyper-tens, 23, 2, pp. 130-134, (2014); Schleifenbaum J., Alamandine and Its Receptor MrgD Pair Up to Join the Protective Arm of the Renin-Angiotensin System, Front. Med. (Lausanne), 6, (2019); Kramkowski K., Mogielnicki A., Buczko W., The physiological significance of the alternative pathways of angiotensin II produc-tion, J. Physiol. Pharmacol, 57, 4, pp. 529-539, (2006); Lu H., Cassis L.A., Kooi C.W., Daugherty A., Structure and functions of angiotensinogen, Hypertens. Res, 39, 7, pp. 492-500, (2016); Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., Altman R.B., Klein T.E., Pharmacoge-nomics knowledge for personalized medicine, Clin. Pharmacol. Ther, 92, 4, pp. 414-417, (2012); Su X., Lee L., Li X., Lv J., Hu Y., Zhan S., Cao W., Mei L., Tang Y.M., Wang D., Krauss R.M., Taylor K.D., Rotter J.I., Yang H., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, 6, pp. 725-732, (2007); Yu H., Lin S., Zhong J., He M., Jin L., Zhang Y., Liu G., A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors, J. Renin Angiotensin Aldosterone Syst, 15, 4, pp. 540-546, (2014); Kurland L., Liljedahl U., Karlsson J., Kahan T., Malmqvist K., Melhus H., Syvanen A.C., Lind L., Angiotensinogen gene poly-morphisms: relationship to blood pressure response to antihyper-tensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, Am. J. Hypertens, 17, 1, pp. 8-13, (2004); Frazier L., Turner S.T., Schwartz G.L., Chapman A.B., Bo-erwinkle E., Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic, Pharmacogenomics J, 4, 1, pp. 17-23, (2004); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SIL-VHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J. Hypertens, 19, 10, pp. 1783-1787, (2001); Bis J.C., Smith N.L., Psaty B.M., Heckbert S.R., Edwards K.L., Lemaitre R.N., Lumley T., Rosendaal F.R., Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhi-bitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients, Am. J. Hypertens, 16, 12, pp. 1011-1017, (2003); St Germaine C.G., Bogaty P., Boyer L., Hanley J., Engert J.C., Brophy J.M., Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs, Am. J. Cardiol, 105, 12, pp. 1740-1745, (2010); Liljedahl U., Kahan T., Malmqvist K., Melhus H., Syvanen A.C., Lind L., Kurland L., Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihyperten-sive treatment, J. Hypertens, 22, 12, pp. 2321-2328, (2004); Toyofyuku M., Imazu M., Sumii K., Yamamoto H., Hayashi Y., Hiyama K., Kohno N., Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention, Atherosclero-sis, 160, 2, pp. 339-344, (2002); Shiotani A., Nishi R., Yamanaka Y., Murao T., Matsumoto H., Tarumi K., Kamada T., Sakakibara T., Haruma K., Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes’ po-lymorphism, Dig. Dis. Sci, 56, 2, pp. 465-471, (2011); Ellis K.L., Palmer B.R., Frampton C.M., Troughton R.W., Doughty R.N., Whalley G.A., Ellis C.J., Pilbrow A.P., Skelton L., Yandle T.G., Richards A.M., Cameron V.A., Genetic variation in the renin-angiotensin-aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease, J. Hum. Hypertens, 27, 4, pp. 237-244, (2013); Do A.N., Irvin M.R., Lynch A.I., Claas S.A., Boerwinkle E., Davis B.R., Ford C.E., Eckfeldt J.H., Tiwari H.K., Limdi N.A., Arnett D.K., The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study, Front. Pharmacol, 5, (2014); Eleni S., Dimitrios K., Vaya P., Areti M., Norma V., Magdalini G., Angiotensin-I converting enzyme gene and I/D polymorphism distribution in the Greek population and a comparison with other European populations, J. Genet, 87, 1, pp. 91-93, (2008); Parving H.H., Jacobsen P., Tarnow L., Rossing P., Lecerf L., Poirier O., Cambien F., Effect of deletion polymorphism of angio-tensin converting enzyme gene on progression of diabetic nephro-pathy during inhibition of angiotensin converting enzyme: observa-tional follow up study, BMJ, 313, 7057, pp. 591-594, (1996); Mizuiri S., Hemmi H., Inoue A., Takano M., Kadomatsu S., Tanimoto H., Tanegashima M., Hayashi I., Fushimi T., Hasega-wa A., Renal hemodynamic changes induced by captopril and an-giotensin-converting enzyme gene polymorphism, Nephron, 75, 3, pp. 310-314, (1997); Jacobsen P., Rossing K., Rossing P., Tarnow L., Mallet C., Poirier O., Cambien F., Parving H.H., Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephro-pathy, Kidney Int, 53, 4, pp. 1002-1006, (1998); O'Toole L., Stewart M., Padfield P., Channer K., Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhi-bitors in patients with heart failure, J. Cardiovasc. Pharmacol, 32, 6, pp. 988-994, (1998); Kanazawa H., Hirata K., Yoshikawa J., Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study, Thorax, 58, 7, pp. 629-631, (2003); Volkan-Salanci B., Dagdelen S., Alikasifoglu M., Erbas T., Hayran M., Erbas B., Impact of renin-angiotensin system poly-morphisms on renal haemodynamic responsiveness to acute angio-tensin-converting enzyme inhibition in type 2 diabetes mellitus, J. Renin Angiotensin Aldosterone Syst, 10, 1, pp. 41-50, (2009); Felehgari V., Rahimi Z., Mozafari H., Vaisi-Raygani A., ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria, Mol. Cell. Biochem, 346, 1-2, pp. 23-30, (2011); Penno G., Chaturvedi N., Talmud P.J., Cotroneo P., Manto A., Nannipieri M., Luong L.A., Fuller J.H., Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM pati-ents: findings from the EUCLID randomized controlled trial. EU-RODIAB controlled trial of lisinopril in IDDM, Diabetes, 47, 9, pp. 1507-1511, (1998); van Essen G.G., Rensma P.L., de Zeeuw D., Sluiter W.J., Schef-fer H., Apperloo A.J., de Jong P.E., Association between angio-tensin-converting-enzyme gene polymorphism and failure of re-noprotective therapy, Lancet, 347, 8994, pp. 94-95, (1996); Sasaki M., Oki T., Iuchi A., Tabata T., Yamada H., Manabe K., Fukuda K., Abe M., Ito S., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiogra-phic studies, J. Hypertens, 14, 12, pp. 1403-1408, (1996); Haas M., Yilmaz N., Schmidt A., Neyer U., Arneitz K., Stummvoll H.K., Wallner M., Auinger M., Arias I., Schneider B., Mayer G., Austrian study group of the effects of enalapril treatment in proteinuric renal disease. angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease, Kidney Blood Press. Res, 21, 1, pp. 66-69, (1998); Prasad A., Narayanan S., Husain S., Padder F., Waclawiw M., Epstein N., Quyyumi A.A., Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition, Circulation, 102, 1, pp. 35-41, (2000); Trevelyan J., Needham E.W., Morris A., Mattu R.K., Comparison of the effect of enalapril and losartan in conjunction with surgi-cal coronary revascularisation versus revascularisation alone on systemic endothelial function, Heart, 91, 8, pp. 1053-1057, (2005); Perez-Castrillon J.L., Silva J., Justo I., Sanz A., Martin-Luquero M., Igea R., Escudero P., Pueyo C., Diaz C., Hernandez G., Du-enas A., Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms, Am. J. Hyper-tens, 16, 6, pp. 453-459, (2003); Woo K.T., Chan C.M., Choong H.L., Tan H.K., Foo M., Lee E.J., Tan C.C., Lee G.S., Tan S.H., Vathsala A., Lim C.H., Chi-ang G.S., Fook-Chong S., Yi Z., Tan H.B., Wong K.S., High dose Losartan and ACE gene polymorphism in IgA nephritis, Geno-mic Med, 2, 3-4, pp. 83-91, (2008); Potaczek D.P., Undas A., Iwaniec T., Szczeklik A., The angio-tensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease, Thromb. Haemost, 94, 1, pp. 224-225, (2005); Cicoira M., Rossi A., Bonapace S., Zanolla L., Perrot A., Fran-cis D.P., Golia G., Franceschini L., Osterziel K.J., Zardini P., Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure, Am. J. Med, 116, 10, pp. 657-661, (2004); Butler R., Morris A.D., Burchell B., Struthers A.D., DD angio-tensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans, Hypertension, 33, 5, pp. 1164-1168, (1999); Li Y., Zhou Y., Yang P., Niu J.Q., Wu Y., Zhao D.D., Wu S.L., Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive pati-ents, Clin. Exp. Hypertens, 33, 3, pp. 141-146, (2011); Schwartz G.L., Turner S.T., Chapman A.B., Boerwinkle E., Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide, Kidney Int, 62, 5, pp. 1718-1723, (2002); Ha S.K., Yong Lee S., Su Park H., Ho Shin J., Jung Kim S., Hun Kim D., Rae Kim K., Yung Lee H., Suk Han D., ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus, Nephrol. Dial. Trans-plant, 15, 10, pp. 1617-1623, (2000); He H., Li L.M., Cao W.H., Sun N.L., Liu M.Z., Hu Y.H., A study of the relationships between angiotensin-converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril, Ann. Hum. Biol, 32, 1, pp. 30-43, (2005); Marian A.J., Safavi F., Ferlic L., Dunn J.K., Gotto A.M., Ball-antyne C.M., Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lip-oprotein and coronary atherosclerosis study, J. Am. Coll. Cardiol, 35, 1, pp. 89-95, (2000); Mulder H.J., van Geel P.P., Schalij M.J., van Gilst W.H., Zwin-derman A.H., Bruschke A.V., PREFACE trial. DD ACE gene po-lymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial, Heart, 89, 5, pp. 557-558, (2003); Bahramali E., Firouzabadi N., Yavarian I., Shayesteh M.R., Erfani N., Shoushtari A.A., Asadpour R., Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial, Eur. J. Clin. Pharmacol, 72, 9, pp. 1059-1064, (2016); Arnett D.K., Claas S.A., Glasser S.P., Pharmacogenetics of anti-hypertensive treatment, Vascul. Pharmacol, 44, 2, pp. 107-118, (2006); Palmirotta R., Barbanti P., Ludovici G., De Marchis M.L., Ia-longo C., Egeo G., Aurilia C., Fofi L., Abete P., Spila A., Fer-roni P., Della-Morte D., Guadagni F., Association between mig-raine and ACE gene (insertion/deletion) polymorphism: the Bio-BIM study, Pharmacogenomics, 15, 2, pp. 147-155, (2014); Vormfelde S.V., Brockmoller J., The genetics of loop diuretic effects, Pharmacogenomics J, 12, 1, pp. 45-53, (2012); Lee J.K., Wu C.K., Tsai C.T., Lin L.Y., Lin J.W., Chien K.L., Hwang J.J., Lin C.L., Tseng C.D., Chiang F.T., Genetic variati-on-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study, Pharmacogenet. Genomics, 23, 4, pp. 181-189, (2013); Wu C.K., Luo J.L., Tsai C.T., Huang Y.T., Cheng C.L., Lee J.K., Lin L.Y., Lin J.W., Hwang J.J., Chiang F.T., Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme in-hibitors on long-term prognosis of diastolic heart failure, Pharma-cogenomics J, 10, 1, pp. 46-53, (2010); Irvin M.R., Lynch A.I., Kabagambe E.K., Tiwari H.K., Barzilay J.I., Eckfeldt J.H., Boerwinkle E., Davis B.R., Ford C.E., Arnett D.K., Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study, J. Hypertens, 28, 10, pp. 2076-2083, (2010); Kim T.H., Chang H.S., Park S.M., Nam B.Y., Park J.S., Rhim T., Park H.S., Kim M.K., Choi I.S., Cho S.H., Chung I.Y., Park B.L., Park C.S., Shin H.D., Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics, Clin. Exp. Allergy, 38, 11, pp. 1727-1737, (2008); Ferreira de Oliveira F., Berretta J.M., Suchi Chen E., Cardoso Smith M., Ferreira Bertolucci P.H., Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease, Colomb. Med, 47, 2, pp. 76-80, (2016); Bozkurt O., de Boer A., Grobbee D.E., de Leeuw P.W., Kroon A.A., Schiffers P., Klungel O.H., Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics, Am. J. Hypertens, 22, 5, pp. 545-551, (2009); Thompson J.F., Man M., Johnson K.J., Wood L.S., Lira M.E., Lloyd D.B., Banerjee P., Milos P.M., Myrand S.P., Paulauskis J., Milad M.A., Sasiela W.J., An association study of 43 SNPs in 16 candidate genes with atorvastatin response, Pharmacogenomics J, 5, 6, pp. 352-358, (2005); Eisenhardt A., Sperling H., Hauck E., Porst H., Stief C., Rub-ben H., Muller N., Siffert W., ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dys-function, Urology, 62, 1, pp. 152-157, (2003); Bhatnagar V., O'Connor D.T., Schork N.J., Salem R.M., Nie-vergelt C.M., Rana B.K., Smith D.W., Bakris G.L., Middleton J.P., Norris K.C., Wright J.T., Cheek D., Hiremath L., Contreras G., Appel L.J., Lipkowitz M.S., Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial, J. Hypertens, 25, 10, pp. 2082-2092, (2007); Tiwari A.K., Zai C.C., Sajeev G., Arenovich T., Muller D.J., Kennedy J.L., Analysis of 34 candidate genes in bupropion and placebo remission, Int. J. Neuropsychopharmacol, 16, 4, pp. 771-781, (2013); Pavon-Romero G.F., Perez-Rubio G., Ramirez-Jimenez F., Ambrocio-Ortiz E., Banuelos-Ortiz E., Alvarado-Franco N., Xochipa-Ruiz K.E., Hernandez-Juarez E., Flores-Garcia B.A., Camarena A.E., Teran L.M., Falfan-Valencia R., MS4A2-rs573790 Is associated with aspirin-exacerbated respiratory disease: replicative study using a candidate gene strategy, Front. Genet, 9, (2018); Fang C., Ren X., Zhou H., Gong Z.C., Shen L., Bai J., Yin J.Y., Qu J., Li X.P., Zhou H.H., Liu Z.Q., Effects of eNOS rs1799983 and ACE rs4646994 polymorphisms on the therapeutic efficacy of salvianolate injection in Chinese patients with coronary heart disease, Clin. Exp. Pharmacol. Physiol, 41, 8, pp. 558-564, (2014); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Zhen Y., Wang J., Li W., Han Y., Liu T., Wang X., Chen J., Wu H., Hui R., Study group for pharmacogenomic based antihypertensive drugs selection, effects and side effects, in rural area chinese. Po-lymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women, Clin. Pharmacol. Ther, 82, 2, pp. 187-196, (2007); Tonna S., Dandapani S.V., Uscinski A., Appel G.B., Schlon-dorff J.S., Zhang K., Denker B.M., Pollak M.R., Functional genetic variation in aminopeptidase A (ENPEP): lack of clear association with focal and segmental glomerulosclerosis (FSGS), Gene, 410, 1, pp. 44-52, (2008); Benetos A., Cambien F., Gautier S., Ricard S., Safar M., Lau-rent S., Lacolley P., Poirier O., Topouchian J., Asmar R., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, 6, pp. 1081-1084, (1996); Musso G., Saba F., Cassader M., Paschetta E., De Michieli F., Pinach S., Framarin L., Berrutti M., Leone N., Parente R., Ay-oubi Khajekini M.T., Zarovska A., Gambino R., Angiotensin II type 1 receptor rs5186 gene variant predicts incident NAFLD and associated hypertension: Role of dietary fat-induced pro-inflammatory cell activation, Am. J. Gastroenterol, 114, 4, pp. 607-619, (2019); Miller J.A., Thai K., Scholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Int, 56, 6, pp. 2173-2180, (1999); Junusbekov Y., Bayoglu B., Cengiz M., Dirican A., Arslan C., AGT rs699 and AGTR1 rs5186 gene variants are associated with cardiovascular-related phenotypes in atherosclerotic peripheral arterial obstructive disease, Ir. J. Med. Sci, 189, pp. 885-894, (1971); Sookoian S., Castano G., Garcia S.I., Viudez P., Gonzalez C., Pirola C.J., A1166C angiotensin II type 1 receptor gene polymor-phism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension, Am. J. Gastroenterol, 100, 3, pp. 636-642, (2005); de Denus S., Zakrzewski-Jakubiak M., Dube M.P., Belanger F., Lepage S., Leblanc M.H., Gossard D., Ducharme A., Racine N., Whittom L., Lavoie J., Touyz R.M., Turgeon J., White M., Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan, Ann. Pharmacother, 42, 7, pp. 925-932, (2008); Latek D., Rutkowska E., Niewieczerzal S., Cielecka-Piontek J., Drug-induced diabetes type 2: In silico study involving class B GPCRs, PLoS One, 14, 1, (2019); Herrera-Gonzalez S., Martinez-Trevino D.A., Aguirre-Garza M., Gomez-Silva M., Barrera-Saldana H.A., Leon-Cachon R.B.R., Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvasta-tin metabolism in a Mexican population, Biomed. Rep, 7, 6, pp. 579-584, (2017); Brugts J.J., Boersma E., Simoons M.L., Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profi-ling of treatment benefit, Pharmacogenomics, 11, 8, pp. 1115-1126, (2010); Oemrawsingh R.M., Akkerhuis K.M., Van Vark L.C., Redekop W.K., Rudez G., Remme W.J., Bertrand M.E., Fox K.M., Ferra-ri R., Danser A.H., de Maat M., Simoons M.L., Brugts J.J., Bo-ersma E., Individualized angiotensin-converting enzyme (ACE)-inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: The PERindopril GENEtic (PERGENE) Risk Model, J. Am. Heart Assoc, 5, 3, (2016); Afruza R., Islam L.N., Banerjee S., Hassan M.M., Suzuki F., Nabi A.N., Renin gene polymorphisms in bangladeshi hypertensive population, J Genomics, 2, pp. 45-53, (2014); Zhu Y., Swanson K.M., Rojas R.L., Wang Z., St Sauver J.L., Visscher S.L., Prokop L.J., Bielinski S.J., Wang L., Weinshilbo-um R., Borah B.J., Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases, Genet. Med, 22, 3, pp. 475-486, (2020); Schelleman H., Klungel O.H., Witteman J.C., Breteler M.M., Hofman A., van Duijn C.M., de Boer A., Stricker B.H., Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke, Pharmacogenomics J, 8, 6, pp. 400-407, (2008); Arsenault J., Lehoux J., Lanthier L., Cabana J., Guillemette G., Lavigne P., Leduc R., Escher E., A single-nucleotide polymor-phism of alanine to threonine at position 163 of the human angio-tensin II type 1 receptor impairs Losartan affinity, Pharmacogenet. Genomics, 20, 6, pp. 377-388, (2010); RamIrez-Exposito M.J., MartInez-Martos J.M., Palomeque T., Lorite P., A PCR-RFLP method for detection of the LNPEP en-coding human insulin-regulated aminopeptidase (IRAP) rs4869317 polymorphism, Indian J. Med. Res, 144, 1, pp. 120-123, (2016)","G.A. Keller; Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Buenos Aires, Argentina; email: gkeller@fmed.uba.ar; G.A. Keller; Universidad de Buenos Aires, Facultad de Medicina, Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Buenos Aires, Argentina; email: gkeller@fmed.uba.ar; G.A. Keller; Hospital General de Agudos Donación Francisco J. Santojanni, Emergency Department, Buenos Aires, Argentina; email: gkeller@fmed.uba.ar","","Bentham Science Publishers","","","","","","13894501","","CDTUA","32693766","English","Curr. Drug Targets","Review","Final","","Scopus","2-s2.0-85094963908"
"Vanichakarn P.; Hwa J.; Stitham J.","Vanichakarn, P. (6507753847); Hwa, J. (7005878922); Stitham, J. (6506321499)","6507753847; 7005878922; 6506321499","Cardiovascular pharmacogenetics of antihypertensive and lipid-lowering therapies","2014","Current Molecular Medicine","14","7","","849","879","30","2","10.2174/1566524014666140811115517","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906908590&doi=10.2174%2f1566524014666140811115517&partnerID=40&md5=41e4f1827e039ec5ab0418c57932d098","Department of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, United States; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, CT 06511, United States","Vanichakarn P., Department of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, United States; Hwa J., Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, CT 06511, United States; Stitham J., Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, CT 06511, United States","Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing. © 2014 Bentham Science Publishers.","Coronary artery disease; Hyperlipidemia; Hypertension; Pharmacogenetics; Pharmacogenomics","Antihypertensive Agents; Cardiovascular Diseases; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Hypolipidemic Agents; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Risk Factors; adducin; angiotensin 1 receptor; angiotensin receptor antagonist; angiotensinogen; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; biquitin protein ligase NEDD4; calcium channel blocking agent; cytochrome P450 2D6; cytochrome P450 3A4; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; endothelial nitric oxide synthase; epithelial sodium channel; fibroblast growth factor receptor 2; G protein coupled receptor kinase; guanine nucleotide binding protein alpha subunit; guanine nucleotide binding protein beta subunit; hydroxymethylglutaryl coenzyme A reductase; hydroxymethylglutaryl coenzyme A reductase inhibitor; lysozyme; multidrug resistance protein 1; renin; solute carrier organic anion transporter 1B1; thiazide diuretic agent; unclassified drug; antihypertensive agent; antilipemic agent; angiotensin receptor; angiotensinogen; antihypertensive agent; antilipemic agent; atenolol; benazepril; bisoprolol; bumetanide; carvedilol; cytochrome P450 2D6; enalapril; endothelial nitric oxide synthase; epithelial sodium channel; fosinopril; G protein coupled receptor kinase; imidapril; irbesartan; lisinopril; losartan; metoprolol; perindopril; placebo; quinapril; ramipril; telmisartan; trandolopril; unindexed drug; valsartan; verapamil; allele; article; drug metabolism; essential hypertension; gene deletion; genetic analysis; genetic association; genetic epidemiology; genetic variability; genotype; genotype phenotype correlation; human; hyperlipidemia; hypertension; liver microsome; meta analysis (topic); pharmacogenetics; randomized controlled trial (topic); renin angiotensin aldosterone system; risk factor; single nucleotide polymorphism; systematic review (topic); Cardiovascular Diseases; genetic polymorphism; genetic predisposition; genetics; genome-wide association study; personalized medicine; pharmacogenetics; procedures; Article; gene mutation; heart failure; hypertension; prevalence; protein expression; treatment response","","angiotensinogen, 11002-13-4, 64315-16-8; cytochrome P450 3A4, 329736-03-0; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; G protein coupled receptor kinase, ; hydroxymethylglutaryl coenzyme A reductase, 37250-24-1; lysozyme, 9001-63-2; renin, 61506-93-2, 9015-94-5; atenolol, 29122-68-7, 93379-54-5; benazepril, 86541-75-5; bisoprolol, 66722-44-9; bumetanide, 28395-03-1; carvedilol, 72956-09-3; enalapril, 75847-73-3; fosinopril, 88889-14-9, 98048-97-6; imidapril, 89371-37-9, 89396-94-1; irbesartan, 138402-11-6; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; metoprolol, 37350-58-6; perindopril, 82834-16-0, 99149-83-4; quinapril, 82586-55-8, 85441-61-8; ramipril, 87333-19-5; telmisartan, 144701-48-4; valsartan, 137862-53-4; verapamil, 152-11-4, 52-53-9; Antihypertensive Agents, ; Hypolipidemic Agents, ","","","American Heart Association; National Institutes of Health, (R01HL074190, T32HL00795011, U54HL117798); National Heart, Lung, and Blood Institute, NHLBI, (R01HL115247)","","Gray L., Lee I.M., Sesso H.D., Batty G.D., Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study), J Am Coll Cardiol, 58, 23, pp. 2396-2403, (2011); Go A.S., Mozaffarian D., Roger V.L., Et al., Heart disease and stroke statistics--2013 update: A report from the American Heart Association, Circulation, 127, 1, (2013); Genest Jr. J.J., Martin-Munley S.S., McNamara J.R., Et al., Familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, 6, pp. 2025-2033, (1992); Roncaglioni M.C., Santoro L., D'Avanzo B., Et al., Role of family history in patients with myocardial infarction. An Italian casecontrol study. GISSI-EFRIM Investigators, Circulation, 85, 6, pp. 2065-2072, (1992); Yusuf S., Hawken S., Ounpuu S., Et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study, Lancet, 364, 9438, pp. 937-952, (2004); Hyre A.D., Muntner P., Menke A., Raggi P., He J., Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults, Ann Epidemiol, 17, 7, pp. 548-555, (2007); Gu Q., Burt V.L., Dillon C.F., Yoon S., Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: The National Health And Nutrition Examination Survey, 2001 to 2010, Circulation, 126, 17, pp. 2105-2114, (2012); Kotseva K., Wood D., De Backer G., Et al., EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: Cross-sectional survey in 12 European countries, Eur J Cardiovasc Prev Rehabil, 17, 5, pp. 530-540, (2010); Jones P.H., Nair R., Thakker K.M., Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: A retrospective analysis, J Am Heart Assoc, 1, 6, (2012); Musunuru K., Roden D.M., Boineau R., Et al., Cardiovascular pharmacogenomics: Current status and future directionsreport of a national heart, lung, and blood institute working group, J Am Heart Assoc, 1, 2, (2012); Psaty B.M., Lumley T., Furberg C.D., Et al., Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis, JAMA, 289, 19, pp. 2534-2544, (2003); Chobanian A.V., Bakris G.L., Black H.R., Et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report, JAMA, 289, 19, pp. 2560-2572, (2003); Ford E.S., Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States, Circulation, 123, 16, pp. 1737-1744, (2011); Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Agespecific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 9349, pp. 1903-1913, (2002); Materson B.J., Reda D.J., Cushman W.C., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, N Engl J Med, 328, 13, pp. 914-921, (1993); Turnbull F., Neal B., Ninomiya T., Et al., Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials, BMJ, 336, 7653, pp. 1121-1123, (2008); Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.C., Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008, Circulation, 124, 9, pp. 1046-1058, (2011); Sarafidis P.A., Epidemiology of resistant hypertension, J Clin Hypertens (Greenwich), 13, 7, pp. 523-528, (2011); Krakoff L.R., Identifiable Hypertension: A New Spectrum, J Clin Hypertens, (2013); Vehaskari V.M., Heritable forms of hypertension, Pediatr Nephrol, 24, 10, pp. 1929-1937, (2009); Staessen J.A., Wang J., Bianchi G., Birkenhager W.H., Essential hypertension, Lancet, 361, 9369, pp. 1629-1641, (2003); Kotchen T.A., Kotchen J.M., Grim C.E., Et al., Genetic determinants of hypertension: Identification of candidate phenotypes, Hypertension, 36, 1, pp. 7-13, (2000); Wang N.Y., Young J.H., Meoni L.A., Ford D.E., Erlinger T.P., Klag M.J., Blood pressure change and risk of hypertension associated with parental hypertension: The Johns Hopkins Precursors Study, Arch Intern Med, 168, 6, pp. 643-648, (2008); Adrogue H.J., Madias N.E., Sodium and potassium in the pathogenesis of hypertension, N Engl J Med, 356, 19, pp. 1966-1978, (2007); Lawlor D.A., Nordestgaard B.G., Benn M., Zuccolo L., Tybjaerg-Hansen A., Davey S.G., Exploring causal associations between alcohol and coronary heart disease risk factors: Findings from a Mendelian randomization study in the Copenhagen General Population Study, Eur Heart J, 34, 32, pp. 2519-2528, (2013); Arnett D.K., Claas S.A., Glasser S.P., Pharmacogenetics of antihypertensive treatment, Vascul Pharmacol., 44, 2, pp. 107-118, (2006); Taal H.R., Verwoert G.C., Demirkan A., Et al., Genome-wide profiling of blood pressure in adults and children, Hypertension, 59, 2, pp. 241-247, (2012); Arnett D.K., Claas S.A., Pharmacogenetics of antihypertensive treatment: Detailing disciplinary dissonance, Pharmacogenomics, 10, 8, pp. 1295-1307, (2009); James P.A., Oparil S., Carter B.L., Et al., 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 5, pp. 507-520, (2014); Reiter M.J., Cardiovascular drug class specificity: Betablockers, Prog Cardiovasc Dis, 47, 1, pp. 11-33, (2004); Lopez-Sendon J., Swedberg K., McMurray J., Et al., Expert consensus document on beta-adrenergic receptor blockers, Eur Heart J, 25, 15, pp. 1341-1362, (2004); Nuttall S.L., Toescu V., Kendall M.J., Beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction, BMJ, 320, 7234, (2000); Yancy C.W., Jessup M., Bozkurt B., Et al., 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 128, 16, pp. 1810-1852, (2013); Foody J.M., Farrell M.H., Krumholz H.M., Beta-Blocker therapy in heart failure: Scientific review, JAMA, 287, 7, pp. 883-889, (2002); Messerli F.H., Bangalore S., Julius S., Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension, Circulation, 117, 20, pp. 2706-2715, (2008); Mancia G., De Backer G., Dominiczak A., Et al., 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 28, 12, pp. 1462-1536, (2007); Wiysonge C.S., Bradley H.A., Volmink J., Mayosi B.M., Mbewu A., Opie L.H., Beta-blockers for hypertension, Cochrane Database Syst Rev, 11, (2012); Voora D., Ginsburg G.S., Clinical application of cardiovascular pharmacogenetics, J Am Coll Cardiol, 60, 1, pp. 9-20, (2012); Zanger U.M., Raimundo S., Eichelbaum M., Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry, Naunyn Schmiedebergs Arch Pharmacol, 369, 1, pp. 23-37, (2004); Xie H.G., Kim R.B., Wood A.J., Stein C.M., Molecular basis of ethnic differences in drug disposition and response, Annu Rev Pharmacol Toxicol, 41, pp. 815-850, (2001); Zhou S.F., Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I, Clin Pharmacokinet., 48, 11, pp. 689-723, (2009); Koytchev R., Alken R.G., Vlahov V., Et al., Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol, Eur J Clin Pharmacol, 54, 6, pp. 469-474, (1998); Jin S.K., Chung H.J., Chung M.W., Et al., Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers, J Clin Pharm Ther, 33, 5, pp. 567-573, (2008); Taguchi M., Nozawa T., Kameyama T., Et al., Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients, Eur J Clin Pharmacol, 59, 5-6, pp. 385-388, (2003); Swen J.J., Nijenhuis M., de Boer A., Et al., Pharmacogenetics: From bench to byte--an update of guidelines, Clin Pharmacol Ther, 89, 5, pp. 662-673, (2011); Orengo-Mercado C., Nieves B., Lopez L., Et al., Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population, J Pharmacogenomics Pharmacoproteomics, 4, 113, (2013); Brodde O.E., Kroemer H.K., Drug-drug interactions of betaadrenoceptor blockers, Arzneimittelforschung, 53, 12, pp. 814-822, (2003); Lennard M.S., Silas J.H., Freestone S., Ramsay L.E., Tucker G.T., Woods H.F., Oxidation phenotype--a major determinant of metoprolol metabolism and response, N Engl J Med, 307, 25, pp. 1558-1560, (1982); McGourty J.C., Silas J.H., Lennard M.S., Tucker G.T., Woods H.F., Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies, Br J Clin Pharmacol, 20, 6, pp. 555-566, (1985); Silas J.H., McGourty J.C., Lennard M.S., Tucker G.T., Woods H.F., Polymorphic metabolism of metoprolol: Clinical studies, Eur J Clin Pharmacol, 28, SUPPL., pp. 85-88, (1985); Rau T., Heide R., Bergmann K., Et al., Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment, Pharmacogenetics, 12, 6, pp. 465-472, (2002); Wuttke H., Rau T., Heide R., Et al., Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects, Clin Pharmacol Ther, 72, 4, pp. 429-437, (2002); Nozawa T., Taguchi M., Tahara K., Et al., Influence of CYP2D6 genotype on metoprolol plasma concentration and betaadrenergic inhibition during long-term treatment: A comparison with bisoprolol, J Cardiovasc Pharmacol, 46, 5, pp. 713-720, (2005); Bijl M.J., Visser L.E., van Schaik R.H., Et al., Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users, Clin Pharmacol Ther, 85, 1, pp. 45-50, (2009); Rau T., Wuttke H., Michels L.M., Et al., Impact of the CYP2D6 genotype on the clinical effects of metoprolol: A prospective longitudinal study, Clin Pharmacol Ther, 85, 3, pp. 269-272, (2009); Zineh I., Beitelshees A.L., Gaedigk A., Et al., Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension, Clin Pharmacol Ther, 76, 6, pp. 536-544, (2004); Fux R., Morike K., Prohmer A.M., Et al., Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study, Clin Pharmacol Ther, 78, 4, pp. 378-387, (2005); Oldham H.G., Clarke S.E., In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)-and S(-)-carvedilol, Drug Metab Dispos, 25, 8, pp. 970-977, (1997); Sehrt D., Meineke I., Tzvetkov M., Gultepe S., Brockmoller J., Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics, Pharmacogenomics, 12, 6, pp. 783-795, (2011); Baudhuin L.M., Miller W.L., Train L., Et al., Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure, Am J Cardiol, 106, 3, pp. 402-408, (2010); Sharp C.F., Gardiner S.J., Jensen B.P., Et al., CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure, Pharmacogenomics J, 9, 3, pp. 175-184, (2009); Blake C.M., Kharasch E.D., Schwab M., Nagele P., A metaanalysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics, Clin Pharmacol Ther, 94, 3, pp. 394-399, (2013); Shin J., Johnson J.A., Pharmacogenetics of beta-blockers, Pharmacotherapy, 27, 6, pp. 874-887, (2007); Swen J.J., van der Straaten T., Wessels J.A., Et al., Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19, Eur J Clin Pharmacol, 68, 4, pp. 363-370, (2012); Hicks J.K., Swen J.J., Thorn C.F., Et al., Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clin Pharmacol Ther, 93, 5, pp. 402-408, (2013); Crews K.R., Gaedigk A., Dunnenberger H.M., Et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype, Clin Pharmacol Ther, 91, 2, pp. 321-326, (2012); Rathz D.A., Brown K.M., Kramer L.A., Liggett S.B., Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking, J Cardiovasc Pharmacol, 39, 2, pp. 155-160, (2002); Levin M.C., Marullo S., Muntaner O., Andersson B., Magnusson Y., The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation, J Biol Chem, 277, 34, pp. 30429-30435, (2002); Mason D.A., Moore J.D., Green S.A., Liggett S.B., A gain-offunction polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor, J Biol Chem, 274, 18, pp. 12670-12674, (1999); Sofowora G.G., Dishy V., Muszkat M., Et al., A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade, Clin Pharmacol Ther, 73, 4, pp. 366-371, (2003); Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F., Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin Pharmacol Ther, 74, 1, pp. 44-52, (2003); Liu J., Liu Z.Q., Yu B.N., Et al., beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension, Clin Pharmacol Ther, 80, 1, pp. 23-32, (2006); Karlsson J., Lind L., Hallberg P., Et al., Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension, Clin Cardiol., 27, 6, pp. 347-350, (2004); O'Shaughnessy K.M., Fu B., Dickerson C., Thurston D., Brown M.J., The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects, Clin Sci (Lond), 99, 3, pp. 233-238, (2000); Filigheddu F., Reid J.E., Troffa C., Et al., Genetic polymorphisms of the beta-adrenergic system: Association with essential hypertension and response to beta-blockade, Pharmacogenomics J, 4, 3, pp. 154-160, (2004); Johnson A.D., Newton-Cheh C., Chasman D.I., Et al., Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals, Hypertension, 57, 5, pp. 903-910, (2011); Magnusson Y., Levin M.C., Eggertsen R., Et al., Ser49Gly of beta1-adrenergic receptor is associated with effective betablocker dose in dilated cardiomyopathy, Clin Pharmacol Ther, 78, 3, pp. 221-231, (2005); Borjesson M., Magnusson Y., Hjalmarson A., Andersson B., A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure, Eur Heart J, 21, 22, pp. 1853-1858, (2000); Liu W.N., Fu K.L., Gao H.Y., Et al., beta1 adrenergic receptor polymorphisms and heart failure: A meta-analysis on susceptibility, response to beta-blocker therapy and prognosis, PloS One, 7, 7, (2012); Nonen S., Okamoto H., Akino M., Et al., No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population, Br J Clin Pharmacol, 60, 4, pp. 414-417, (2005); Savva J., Maqbool A., White H.L., Et al., Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: A MERIT-HF substudy, J Card Fail, 15, 5, pp. 435-441, (2009); Metra M., Zani C., Covolo L., Et al., Role of beta1-and alpha2cadrenergic receptor polymorphisms and their combination in heart failure: A case-control study, Eur J Heart Fail, 8, 2, pp. 131-135, (2006); Pacanowski M.A., Gong Y., Cooper-Dehoff R.M., Et al., betaadrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension, Clin Pharmacol Ther, 84, 6, pp. 715-721, (2008); Green S.A., Turki J., Innis M., Liggett S.B., Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties, Biochemistry, 33, 32, pp. 9414-9419, (1994); Jia H., Sharma P., Hopper R., Dickerson C., Lloyd D.D., Brown M.J., beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians, J Hypertens, 18, 6, pp. 687-693, (2000); Lanfear D.E., Jones P.G., Marsh S., Cresci S., McLeod H.L., Spertus J.A., Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome, JAMA, 294, 12, pp. 1526-1533, (2005); Siffert W., Molecular genetics of G proteins and atherosclerosis risk, Basic Res Cardiol., 96, 6, pp. 606-611, (2001); Siffert W., Rosskopf D., Siffert G., Et al., Association of a human G-protein beta3 subunit variant with hypertension, Nat Genet, 18, 1, pp. 45-48, (1998); Benjafield A.V., Jeyasingam C.L., Nyholt D.R., Griffiths L.R., Morris B.J., G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension, Hypertension, 32, 6, pp. 1094-1097, (1998); Brand E., Herrmann S.M., Nicaud V., Et al., The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension, Hypertension, 33, 5, pp. 1175-1178, (1999); Jia H., Hingorani A.D., Sharma P., Et al., Association of the G(s)alpha gene with essential hypertension and response to beta-blockade, Hypertension, 34, 1, pp. 8-14, (1999); Abe M., Nakura J., Yamamoto M., Et al., Association of GNAS1 gene variant with hypertension depending on smoking status, Hypertension, 40, 3, pp. 261-265, (2002); Inglese J., Freedman N.J., Koch W.J., Lefkowitz R.J., Structure and mechanism of the G protein-coupled receptor kinases, J Biol Chem, 268, 32, pp. 23735-23738, (1993); Pitcher J.A., Freedman N.J., Lefkowitz R.J., G protein-coupled receptor kinases, Annu Rev Biochem, 67, pp. 653-692, (1998); Mushegian A., Gurevich V.V., Gurevich E.V., The origin and evolution of G protein-coupled receptor kinases, PloS One, 7, 3, (2012); Liggett S.B., Cresci S., Kelly R.J., Et al., A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure, Nat Med, 14, 5, pp. 510-517, (2008); Hunt S.A., Abraham W.T., Chin M.H., Et al., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult, Circulation, 112, 12, (2005); Dorn II G.W., Liggett S.B., Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure, Mol Pharmacol, 76, 3, pp. 466-480, (2009); Spinelli L., Trimarco V., Di Marino S., Marino M., Iaccarino G., Trimarco B., L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome, Eur J Heart Fail., 12, 1, pp. 13-16, (2010); Atlas S.A., The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition, J Manag Care Pharm, 13, 8 SUPPL. B, pp. 9-20, (2007); Weir M.R., Dzau V.J., The renin-angiotensin-aldosterone system: A specific target for hypertension management, Am J Hypertens, 12, 12 Pt 3, (1999); Reid I.A., Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure, Am J Physiol, 262, 6 Pt 1, (1992); Allen A.M., O'Callaghan E.L., Chen D., Bassi J.K., Central neural regulation of cardiovascular function by angiotensin: A focus on the rostral ventrolateral medulla, Neuroendocrinology, 89, 4, pp. 361-369, (2009); DiBona G.F., Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves in control of renal function, Ann N Y Acad Sci, 940, pp. 395-406, (2001); Allen A.M., Role of angiotensin in the rostral ventrolateral medulla in the development and maintenance of hypertension, Curr Opin Pharmacol, 11, 2, pp. 117-123, (2011); Matchar D.B., McCrory D.C., Orlando L.A., Et al., Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension, Ann Intern Med, 148, 1, pp. 16-29, (2008); Weir M.R., Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better?, Clin Ther, 29, 9, pp. 1803-1824, (2007); Jamerson K., Weber M.A., Bakris G.L., Et al., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients, N Engl J Med, 359, 23, pp. 2417-2428, (2008); Anderson J.L., Adams C.D., Antman E.M., Et al., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction, J Am Coll Cardiol, 50, 7, (2007); Kushner F.G., Hand M., Smith Jr. S.C., Et al., Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update), Circulation, 120, 22, pp. 2271-2306, (2009); Pfeffer M.A., McMurray J.J., Velazquez E.J., Et al., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 20, pp. 1893-1906, (2003); Kunz R., Friedrich C., Wolbers M., Mann J.F., Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease, Ann Intern Med, 148, 1, pp. 30-48, (2008); Brown M.J., Cruickshank J.K., Dominiczak A.F., Et al., Better blood pressure control: How to combine drugs, J Hum Hypertens, 17, 2, pp. 81-86, (2003); Blumenfeld J.D., Laragh J.H., Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension, Am J Hypertens, 11, 7, pp. 894-896, (1998); Preston R.A., Materson B.J., Reda D.J., Et al., Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, JAMA, 280, 13, pp. 1168-1172, (1998); Sever P., New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society, J Renin Angiotensin Aldosterone Syst, 7, 2, pp. 61-63, (2006); O'Toole L., Stewart M., Padfield P., Channer K., Effect of the insertion/deletion polymorphism of the angiotensinconverting enzyme gene on response to angiotensinconverting enzyme inhibitors in patients with heart failure, J Cardiovasc Pharmacol, 32, 6, pp. 988-994, (1998); Moriyama T., Kitamura H., Ochi S., Et al., Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin Iconverting enzyme inhibitors in patients with proteinuria, J Am Soc Nephrol, 6, 6, pp. 1676-1678, (1995); Ueda S., Meredith P.A., Morton J.J., Connell J.M., Elliott H.L., ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans, Circulation, 98, 20, pp. 2148-2153, (1998); Haas M., Yilmaz N., Schmidt A., Et al., Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease, Kidney Blood Press Res, 21, 1, pp. 66-69, (1998); Kurland L., Melhus H., Karlsson J., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, 10, pp. 1783-1787, (2001); Stavroulakis G.A., Makris T.K., Krespi P.G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc Drugs Ther, 14, 4, pp. 427-432, (2000); Voors A.A., van Geel P.P., Oosterga M., Buikema H., van Veldhuisen D.J., van Gilst W.H., Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism, J Renin Angiotensin Aldosterone Syst, 5, 3, pp. 130-134, (2004); Todd G.P., Chadwick I.G., Higgins K.S., Yeo W.W., Jackson P.R., Ramsay L.E., Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects, Br J Clin Pharmacol, 39, 2, pp. 131-134, (1995); Oshima T., Nakano Y., Matsumoto T., Et al., Evaluation of angiotensin I converting enzyme gene polymorphism in patients with essential hypertension and coronary artery disease, Rinsho byori The Japanese journal of clinical pathology., 45, 2, pp. 115-121, (1997); Mondorf U.F., Russ A., Wiesemann A., Herrero M., Oremek G., Lenz T., Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension, Am J Hypertens, 11, 2, pp. 174-183, (1998); Yu H., Zhang Y., Liu G., Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients, Hypertens Res, 26, 11, pp. 881-886, (2003); Schelleman H., Stricker B.H., Verschuren W.M., Et al., Interactions between five candidate genes and antihypertensive drug therapy on blood pressure, Pharmacogenomics J, 6, 1, pp. 22-26, (2006); Harrap S.B., Tzourio C., Cambien F., Et al., The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition, Hypertension, 42, 3, pp. 297-303, (2003); Conen D., Cheng S., Steiner L.L., Buring J.E., Ridker P.M., Zee R.Y., Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: The Women's Genome Health Study, J Hypertens, 27, 3, pp. 476-483, (2009); Arnett D.K., Davis B.R., Ford C.E., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, 25, pp. 3374-3383, (2005); Nordestgaard B.G., Kontula K., Benn M., Et al., Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study, Pharmacogenet Genomics, 20, 2, pp. 77-85, (2010); Konoshita T., Kato N., Fuchs S., Et al., Genetic variant of the Renin-Angiotensin system and diabetes influences blood pressure response to Angiotensin receptor blockers, Diabetes Care., 32, 8, pp. 1485-1490, (2009); Redon J., Luque-Otero M., Martell N., Chaves F.J., Reninangiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients, Pharmacogenomics J, 5, 1, pp. 14-20, (2005); Filigheddu F., Argiolas G., Bulla E., Et al., Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians, Pharmacogenomics, 9, 10, pp. 1419-1427, (2008); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of reninangiotensin system genes, J Hypertens, 14, 2, pp. 259-262, (1996); Parenica J., Goldbergova M.P., Kala P., Et al., ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI, BMC Cardiovasc Disord, 10, (2010); Yoshida H., Mitarai T., Kawamura T., Et al., Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy, J Clin Invest, 96, 5, pp. 2162-2169, (1995); Sasaki M., Oki T., Iuchi A., Et al., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies, J Hypertens, 14, 12, pp. 1403-1408, (1996); Hernandez D., Lacalzada J., Salido E., Et al., Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism, Kidney Int, 58, 2, pp. 889-897, (2000); Bleumink G.S., Schut A.F., Sturkenboom M.C., Et al., Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism, Pharmacogenet Genomics, 15, 2, pp. 75-81, (2005); Tsikouris J.P., Peeters M.J., Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease, Cardiovasc Drugs Ther, 21, 2, pp. 121-132, (2007); Fournier A., Achard J.M., Boutitie F., Et al., Is the angiotensin II Type 2 receptor cerebroprotective?, Curr Hypertens Rep, 6, 3, pp. 182-189, (2004); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, 1, pp. 169-180, (1992); Caulfield M., Lavender P., Farrall M., Et al., Linkage of the angiotensinogen gene to essential hypertension, N Engl J Med, 330, 23, pp. 1629-1633, (1994); Pan W.H., Chen J.W., Fann C., Jou Y.S., Wu S.Y., Linkage analysis with candidate genes: The Taiwan young-onset hypertension genetic study, Hum Genet, 107, 3, pp. 210-215, (2000); Rankinen T., Gagnon J., Perusse L., Et al., AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study, Am J Physiol Heart Circ Physiol, 279, 1, (2000); Johnson A.G., Nguyen T.V., Davis D., Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects, J Hypertens, 19, 6, pp. 1053-1060, (2001); Staines-Urias E., Paez M.C., Doyle P., Et al., Genetic association studies in pre-eclampsia: Systematic metaanalyses and field synopsis, Int J Epidemiol, 41, 6, pp. 1764-1775, (2012); Bis J.C., Smith N.L., Psaty B.M., Et al., Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients, Am J Hypertens, 16, 12, pp. 1011-1017, (2003); Yu H., Lin S., Liu G., Zhang Y., Deng C., Ma W., T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors, Hypertens Res, 28, 12, pp. 981-986, (2005); Katsuya T., Koike G., Yee T.W., Et al., Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease, Lancet, 345, 8965, pp. 1600-1603, (1995); Kurland L., Liljedahl U., Karlsson J., Et al., Angiotensinogen gene polymorphisms: Relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, Am J Hypertens, 17, 1, pp. 8-13, (2004); Rodriguez-Perez J.C., Rodriguez-Esparragon F., Hernandez-Perera O., Et al., Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: The PROCAGENE study. Prospective Cardiac Gene, J Am Coll Cardiol, 37, 6, pp. 1536-1542, (2001); Yugar-Toledo J.C., Martin J.F., Krieger J.E., Et al., Gene variation in resistant hypertension: Multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes, DNA Cell Biol, 30, 8, pp. 555-564, (2011); Su X., Lee L., Li X., Et al., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, 6, pp. 725-732, (2007); Inoue I., Nakajima T., Williams C.S., Et al., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, 7, pp. 1786-1797, (1997)","J. Stitham; Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, New Haven, CT 06511, 300 George Street, United States; email: jeremiah.stitham@yale.edu","","Bentham Science Publishers B.V.","","","","","","15665240","","CMMUB","25109793","English","Curr. Mol. Med.","Article","Final","","Scopus","2-s2.0-84906908590"
"Pawade T.A.; Newby D.E.; Dweck M.R.","Pawade, Tania A. (56016639100); Newby, David E. (57529298000); Dweck, Marc R. (12783691400)","56016639100; 57529298000; 12783691400","Calcification in aortic stenosis: The skeleton key","2015","Journal of the American College of Cardiology","66","5","","561","577","16","287","10.1016/j.jacc.2015.05.066","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938085871&doi=10.1016%2fj.jacc.2015.05.066&partnerID=40&md5=0af24037ba33d19bc9cb1eed5621e295","British Heart Foundation, University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom; Edinburgh Heart Centre, NHS Lothian, Edinburgh, United Kingdom; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States","Pawade T.A., British Heart Foundation, University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom, Edinburgh Heart Centre, NHS Lothian, Edinburgh, United Kingdom; Newby D.E., British Heart Foundation, University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom, Edinburgh Heart Centre, NHS Lothian, Edinburgh, United Kingdom; Dweck M.R., British Heart Foundation, University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom, Edinburgh Heart Centre, NHS Lothian, Edinburgh, United Kingdom, Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States","Aortic stenosis is a common, potentially fatal condition that is set to become an increasing public health burden. Once symptoms develop, there is an inexorable deterioration with a poor prognosis. Despite this, there are no medical therapies capable of modifying disease progression, and the only available treatment is aortic valve replacement, to which not all patients are suited. Conventional teaching suggests that aortic stenosis is a degenerative condition whereby ""wear and tear"" leads to calcium deposition within the valve. Although mechanical stress and injury are important factors, it is becoming increasingly appreciated that aortic stenosis is instead governed by a highly complex, regulated pathological process with similarities to skeletal bone formation. This review discusses the pathophysiology of aortic stenosis with an emphasis on the emerging importance of calcification, how this can be visualized and monitored using noninvasive imaging, and how our improved knowledge may ultimately translate into novel disease-modifying treatments. © 2015 American College of Cardiology Foundation.","aortic valve; calcification of; calcinosis; calcium; computed tomography; diphosphonates; positron emission tomography","Aortic Valve; Aortic Valve Stenosis; Calcinosis; Disease Management; Disease Progression; Heart Valve Prosthesis Implantation; Humans; Prognosis; angiotensin 2 receptor; autotaxin; beta catenin; bisphosphonic acid derivative; bone morphogenetic protein 2; denosumab; fetuin A; receptor activator of nuclear factor kappa B; transforming growth factor beta1; age distribution; aorta disease; aorta stenosis; atherosclerosis; calcification; cardiovascular risk; cell survival; coronary artery calcium score; disease course; disease severity; drug efficacy; drug mechanism; drug response; drug tolerability; echocardiography; endothelial dysfunction; human; hypertension; lipid storage; nonhuman; osteoblast; oxidative stress; pathogenesis; phenotype; positron emission tomography; priority journal; protein expression; protein function; Review; risk factor; single nucleotide polymorphism; smoking; unspecified side effect; upregulation; aorta valve; Aortic Valve Stenosis; calcinosis; disease management; heart valve replacement; metabolism; pathology; pathophysiology; procedures; prognosis; surgery","","denosumab, 615258-40-7","","","Wellcome Trust, WT, (WT103782AIA); Wellcome Trust, WT; Medical Research Council, MRC, (G0701127); Medical Research Council, MRC; British Heart Foundation, BHF, (CH/09/002, FS/14/78, NCT02132026, SS/CH/09/002); British Heart Foundation, BHF","Drs. Pawade and Dweck and Prof. Newby are supported by the British Heart Foundation (SS/CH/09/002, FS/14/78, and CH/09/002); and are the Principal Investigators of the randomized controlled trial Saltire 2: Bisphosphonates and RANKL Inhibition in Aortic Stenosis ( NCT02132026 ). Prof. Newby is also supported by a Wellcome Trust Senior Investigator Award (WT103782AIA). ","Nkomo V.T., Gardin J.M., Skelton T.N., Et al., Burden of valvular heart diseases: A population-based study, Lancet, 368, pp. 1005-1011, (2006); Osnabrugge R.L., Mylotte D., Head S.J., Et al., Aortic stenosis in the elderly: Disease prevalence and number of candidates for transcatheter aortic valve replacement: A meta-analysis and modeling study, J Am Coll Cardiol, 62, pp. 1002-1012, (2013); Rajamannan N.M., Evans F.J., Aikawa E., Et al., Calcific aortic valve disease: Not simply a degenerative process. A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease - 2011 update, Circulation, 124, pp. 1783-1791, (2011); New S.E., Aikawa E., Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification, Circ Res, 108, pp. 1381-1391, (2011); Thanassoulis G., Massaro J.M., Cury R., Et al., Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium, J Am Coll Cardiol, 55, pp. 2491-2498, (2010); Stewart B.F., Siscovick D., Lind B.K., Et al., Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study, J Am Coll Cardiol, 29, pp. 630-634, (1997); Stritzke J., Linsel-Nitschke P., Markus M.R., Et al., Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: Results of the longitudinal population-based KORA/MONICA survey, Eur Heart J, 30, pp. 2044-2053, (2009); Pachulski R.T., Chan K.L., Progression of aortic valve dysfunction in 51 adult patients with congenital bicuspid aortic valve: Assessment and follow up by Doppler echocardiography, Br Heart J, 69, pp. 237-240, (1993); Smith J.G., Luk K., Schulz C.A., Et al., Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis, JAMA, 312, pp. 1764-1771, (2014); Thanassoulis G., Campbell C.Y., Owens D.S., Et al., Genetic associations with valvular calcification and aortic stenosis, N Engl J Med, 368, pp. 503-512, (2013); Otto C.M., Kuusisto J., Reichenbach D.D., Et al., Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies, Circulation, 90, pp. 844-853, (1994); Proudfoot D., Skepper J.N., Hegyi L., Et al., Apoptosis regulates human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies, Circ Res, 87, pp. 1055-1062, (2000); Kim K.M., Calcification of matrix vesicles in human aortic valve and aortic media, Fed Proc, 35, pp. 156-162, (1976); Nadra I., Mason J.C., Philippidis P., Et al., Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: A vicious cycle of inflammation and arterial calcification?, Circ Res, 96, pp. 1248-1256, (2005); Moura L.M., Ramos S.F., Zamorano J.L., Et al., Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis, J Am Coll Cardiol, 49, pp. 554-561, (2007); Rajamannan N.M., Subramaniam M., Springett M., Et al., Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve, Circulation, 105, pp. 2660-2665, (2002); Weiss R.M., Ohashi M., Miller J.D., Et al., Calcific aortic valve stenosis in old hypercholesterolemic mice, Circulation, 114, pp. 2065-2069, (2006); Cowell S.J., Newby D.E., Prescott R.J., Et al., A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis, N Engl J Med, 352, pp. 2389-2397, (2005); Chan K.L., Teo K., Dumesnil J.G., Et al., Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial, Circulation, 121, pp. 306-314, (2010); Rossebo A.B., Pedersen T.R., Boman K., Et al., Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N Engl J Med, 359, pp. 1343-1356, (2008); Puri R., Nicholls S.J., Shao M., Et al., Impact of statins on serial coronary calcification during atheroma progression and regression, J Am Coll Cardiol, 65, pp. 1273-1282, (2015); Capoulade R., Clavel M.A., Dumesnil J.G., Et al., Impact of metabolic syndrome on progression of aortic stenosis: Influence of age and statin therapy, J Am Coll Cardiol, 60, pp. 216-223, (2012); Mohler E.R., Gannon F., Reynolds C., Et al., Bone formation and inflammation in cardiac valves, Circulation, 103, pp. 1522-1528, (2001); El Accaoui R.N., Gould S.T., Hajj G.P., Et al., Aortic valve sclerosis in mice deficient in endothelial nitric oxide synthase, Am J Physiol Heart Circ Physiol, 306, pp. H1302-H1313, (2014); O'Brien K.D., Shavelle D.M., Caulfield M.T., Et al., Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma, Circulation, 106, pp. 2224-2230, (2002); Peltonen T., Napankangas J., Ohtonen P., Et al., (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis, Atherosclerosis, 216, pp. 35-43, (2011); Capoulade R., Clavel M.A., Mathieu P., Et al., Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis, Eur J Clin Invest, 43, pp. 1262-1272, (2013); Ducy P., CBFA1: A molecular switch in osteoblast biology, Dev Dyn, 219, pp. 461-471, (2000); Rajamannan N.M., Subramaniam M., Rickard D., Et al., Human aortic valve calcification is associated with an osteoblast phenotype, Circulation, 107, pp. 2181-2184, (2003); Pohjolainen V., Taskinen P., Soini Y., Et al., Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation, Hum Pathol, 39, pp. 1695-1701, (2008); Ganss B., Kim R.H., Sodek J., Bone sialoprotein, Crit Rev Oral Biol Med, 10, pp. 79-98, (1999); Liu A.C., Joag V.R., Gotlieb A.I., The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology, Am J Pathol, 171, pp. 1407-1418, (2007); Aikawa E., Nahrendorf M., Figueiredo J.L., Et al., Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo, Circulation, 116, pp. 2841-2850, (2007); Aikawa E., Otto C.M., Look more closely at the valve: Imaging calcific aortic valve disease, Circulation, 125, pp. 9-11, (2012); Watson K.E., Bostrom K., Ravindranath R., Et al., TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify, J Clin Invest, 93, pp. 2106-2113, (1994); Tintut Y., Demer L., Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification, J Investig Med, 54, pp. 395-401, (2006); Garg V., Muth A.N., Ransom J.F., Et al., Mutations in NOTCH1 cause aortic valve disease, Nature, 437, pp. 270-274, (2005); Nigam V., Srivastava D., Notch1 represses osteogenic pathways in aortic valve cells, J Mol Cell Cardiol, 47, pp. 828-834, (2009); Bostrom K., Watson K.E., Stanford W.P., Et al., Atherosclerotic calcification: Relation to developmental osteogenesis, Am J Cardiol, 75, pp. 88B-91B, (1995); Yang X., Meng X., Su X., Et al., Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: Role of Smad1 and extracellular signal-regulated kinase 1/2, J Thorac Cardiovasc Surg, 138, pp. 1008-1015, (2009); Yang X., Fullerton D.A., Su X., Et al., Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2, J Am Coll Cardiol, 53, pp. 491-500, (2009); Caira F.C., Stock S.R., Gleason T.G., Et al., Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation, J Am Coll Cardiol, 47, pp. 1707-1712, (2006); Chen J.H., Chen W.L., Sider K.L., Et al., β-catenin mediates mechanically regulated, transforming growth factor-β1-induced myofibroblast differentiation of aortic valve interstitial cells, Arterioscl Thromb Vasc Biol, 31, pp. 590-597, (2011); Rajamannan N.M., Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS<sup>-/-</sup> null mice, J Cell Biochem, 113, pp. 1623-1634, (2012); Kado D.M., Browner W.S., Blackwell T., Et al., Rate of bone loss is associated with mortality in older women: A prospective study, J Bone Miner Res, 15, pp. 1974-1980, (2000); Pfister R., Michels G., Sharp S.J., Et al., Inverse association between bone mineral density and risk of aortic stenosis in men and women in EPIC-Norfolk prospective study, Int J Cardiol, 178, pp. 29-30, (2015); Aksoy Y., Yagmur C., Tekin G.O., Et al., Aortic valve calcification: Association with bone mineral density and cardiovascular risk factors, Coron Artery Dis, 16, pp. 379-383, (2005); Demer L.L., Tintut Y., Vascular calcification: Pathobiology of a multifaceted disease, Circulation, 117, pp. 2938-2948, (2008); Persy V., D'Haese P., Vascular calcification and bone disease: The calcification paradox, Trends Mol Med, 15, pp. 405-416, (2009); Hultgren H.N., Osteitis deformans (Paget's disease) and calcific disease of the heart valves, Am J Cardiol, 81, pp. 1461-1464, (1998); Kaden J.J., Bickelhaupt S., Grobholz R., Et al., Receptor activator of nuclear factor κb ligand and osteoprotegerin regulate aortic valve calcification, J Mol Cell Cardiol, 36, pp. 57-66, (2004); Bucay N., Sarosi I., Dunstan C.R., Et al., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, 12, pp. 1260-1268, (1998); Parhami F., Morrow A.D., Balucan J., Et al., Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients, Arterioscl Thromb Vasc Biol, 17, pp. 680-687, (1997); Demer L.L., Vascular calcification and osteoporosis: Inflammatory responses to oxidized lipids, Int J Epidemiol, 31, pp. 737-741, (2002); Schurgers L.J., Uitto J., Reutelingsperger C.P., Vitamin K-dependent carboxylation of matrix Gla-protein: A crucial switch to control ectopic mineralization, Trends Mol Med, 19, pp. 217-226, (2013); Tantisattamo E., Han K.H., O'Neill W.C., Increased vascular calcification in patients receiving warfarin, Arterioscl Thromb Vasc Biol, 35, pp. 237-242, (2015); Kaden J.J., Reinohl J.O., Blesch B., Et al., Systemic and local levels of fetuin-A in calcific aortic valve stenosis, Int J Mol Med, 20, pp. 193-197, (2007); Koos R., Brandenburg V., Mahnken A.H., Et al., Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients, Eur Heart J, 30, pp. 2054-2061, (2009); Mohty D., Cote N., Pibarot P., Et al., Reduced fetuin a serum level is associated with faster progression and increased valvular calcification in elderly patients with aortic stenosis, J Clin Exp Cardiol, 2, (2011); Capoulade R., Cote N., Mathieu P., Et al., Circulating levels of matrix GLA protein and progression of aortic stenosis: A substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial, Can J Cardiol, 30, pp. 1088-1095, (2014); Cote N., El Husseini D., Pepin A., Et al., ATP acts as a survival signal and prevents the mineralization of aortic valve, J Mol Cell Cardiol, 52, pp. 1191-1202, (2012); El Husseini D., Boulanger M.C., Mahmut A., Et al., P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: Implication for calcific aortic valve disease, J Mol Cell Cardiol, 72, pp. 146-156, (2014); Baumgartner H., Hung J., Bermejo J., Et al., Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice, Eur J Echocardiogr, 22, pp. 1-25, (2009); Rosenhek R., Binder T., Porenta G., Et al., Predictors of outcome in severe, asymptomatic aortic stenosis, N Engl J Med, 343, pp. 611-617, (2000); Cioffi G., Mazzone C., Faggiano P., Et al., Prognostic stratification by conventional echocardiography of patients with aortic stenosis: The ""cAIMAN-ECHO score., Echocardiography, 30, pp. 367-377, (2013); Messika-Zeitoun D., Aubry M.C., Detaint D., Et al., Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography, Circulation, 110, pp. 356-362, (2004); Jenkins W., Dweck M., Shah A., Et al., 18F-NaF is a predictor of progression and outcome in aortic valve disease (abstr), J Am Coll Cardiol, 63, (2014); Liu F., Coursey C.A., Grahame-Clarke C., Et al., Aortic valve calcification as an incidental finding at CT of the elderly: Severity and location as predictors of aortic stenosis, AJR Am J Roentgenol, 186, pp. 342-349, (2006); Koos R., Kuhl H.P., Muhlenbruch G., Et al., Prevalence and clinical importance of aortic valve calcification detected incidentally on CT scans: Comparison with echocardiography, Radiology, 241, pp. 76-82, (2006); Aggarwal S.R., Clavel M.A., Messika-Zeitoun D., Et al., Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis, Circ Cardiovasc Imaging, 6, pp. 40-47, (2013); Dweck M.R., Chin C., Newby D.E., Small valve area with low-gradient aortic stenosis: Beware the hard hearted, J Am Coll Cardiol, 62, pp. 2339-2340, (2013); Clavel M.A., Messika-Zeitoun D., Pibarot P., Et al., The complex nature of discordant severe calcified aortic valve disease grading: New insights from combined Doppler echocardiographic and computed tomographic study, J Am Coll Cardiol, 62, pp. 2329-2338, (2013); Clavel M.A., Pibarot P., Messika-Zeitoun D., Et al., Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: Results of an international registry study, J Am Coll Cardiol, 64, pp. 1202-1213, (2014); Feuchtner G.M., Muller S., Grander W., Et al., Aortic valve calcification as quantified with multislice computed tomography predicts short-term clinical outcome in patients with asymptomatic aortic stenosis, J Heart Valve Dis, 15, pp. 494-498, (2006); Koos R., Mahnken A.H., Sinha A.M., Et al., Aortic valve calcification as a marker for aortic stenosis severity: Assessment on 16-MDCT, AJR Am J Roentgenol, 183, pp. 1813-1818, (2004); Messika-Zeitoun D., Bielak L.F., Peyser P.A., Et al., Aortic valve calcification: Determinants and progression in the population, Arterioscl Thromb Vasc Biol, 27, pp. 642-648, (2007); Dweck M.R., Jenkins W.S., Vesey A.T., Et al., 18F-NaF uptake is a marker of active calcification and disease progression in patients with aortic stenosis, Circ Cardiovasc Imaging, 7, pp. 371-378, (2014); Nguyen V., Cimadevilla C., Estellat C., Et al., Haemodynamic and anatomic progression of aortic stenosis, Heart, 101, pp. 943-947, (2015); Dweck M.R., Jones C., Joshi N.V., Et al., Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis, Circulation, 125, pp. 76-86, (2012); Marincheva-Savcheva G., Subramanian S., Qadir S., Et al., Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography: Increased valvular fluorodeoxyglucose uptake in aortic stenosis, J Am Coll Cardiol, 57, pp. 2507-2515, (2011); Dweck M.R., Khaw H.J., Sng G.K., Et al., Aortic stenosis, atherosclerosis, and skeletal bone: Is there a common link with calcification and inflammation?, Eur Heart J, 34, pp. 1567-1574, (2013); Tahara N., Kai H., Nakaura H., Et al., The prevalence of inflammation in carotid atherosclerosis: Analysis with fluorodeoxyglucose-positron emission tomography, Eur Heart J, 28, pp. 2243-2248, (2007); Tawakol A., Migrino R.Q., Bashian G.G., Et al., In vivo <sup>18</sup>F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients, J Am Coll Cardiol, 48, pp. 1818-1824, (2006); Tahara N., Kai H., Ishibashi M., Et al., Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography, J Am Coll Cardiol, 48, pp. 1825-1831, (2006); Irkle A., Vesey A.T., Lewis D.Y., Et al., Identifying active vascular micro-calcification by 18F-sodium fluoride positron emission tomography, Nat Commun, 6, (2015); Otto C.M., Calcific aortic stenosis - Time to look more closely at the valve, N Engl J Med, 359, pp. 1395-1398, (2008); Price P.A., Faus S.A., Williamson M.K., Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption, Arterioscl Thromb Vasc Biol, 21, pp. 817-824, (2001); Fleisch H., Russell R.G., Francis M.D., Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo, Science, 165, pp. 1262-1264, (1969); Rosenblum I.Y., Flora L., Eisenstein R., The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis, Atherosclerosis, 22, pp. 411-424, (1975); Kramsch D.M., Chan C.T., The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits, Circ Res, 42, pp. 562-571, (1978); Sansoni P., Passeri G., Fagnoni F., Et al., Inhibition of antigen-presenting cell function by alendronate in vitro, J Bone Miner Res, 10, pp. 1719-1725, (1995); Giraudo E., Inoue M., Hanahan D., An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis, J Clin Invest, 114, pp. 623-633, (2004); Lai T.J., Hsu S.F., Li T.M., Et al., Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line, Acta Pharmacologica Sinica, 28, pp. 1231-1235, (2007); Elmariah S., Cimmino G., Fuster V., Et al., Bisphosphonates prevent oxidized low- density lipoprotein-induced expression of osteogenic markers in aortic valve myofibroblasts (abstr), J Am Coll Cardiol, 55, (2010); Elmariah S., Delaney J.A.C., O'Brien K.D., Et al., Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis), J Am Coll Cardiol, 56, pp. 1752-1759, (2010); Innasimuthu A.L., Katz W.E., Effect of bisphosphonates on the progression of degenerative aortic stenosis, Echocardiography, 28, pp. 1-7, (2011); Skolnick A.H., Osranek M., Formica P., Et al., Osteoporosis treatment and progression of aortic stenosis, Am J Cardiol, 104, pp. 122-124, (2009); Sterbakova G., Vyskocil V., Linhartova K., Bisphosphonates in calcific aortic stenosis: Association with slower progression in mild disease-a pilot retrospective study, Cardiology, 117, pp. 184-189, (2010); Rapoport H.S., Connolly J.M., Fulmer J., Et al., Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate, Biomaterials, 28, pp. 690-699, (2007); Aksoy O., Cam A., Goel S.S., Et al., Do bisphosphonates slow the progression of aortic stenosis?, J Am Coll Cardiol, 59, pp. 1452-1459, (2012); Dweck M.R., Newby D.E., Osteoporosis is a major confounder in observational studies investigating bisphosphonate therapy in aortic stenosis, J Am Coll Cardiol, 60, (2012); Cummings S.R., San Martin J., McClung M.R., Et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, pp. 756-765, (2009); Helas S., Goettsch C., Schoppet M., Et al., Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice, Am J Pathol, 175, pp. 473-478, (2009); Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis (SALTIRE II), (2014); Cote N., El Husseini D., Pepin A., Et al., Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats, Eur J Pharmacol, 689, pp. 139-146, (2012); Hung M.Y., Tsimikas S., What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?, Curr Opin Lipidol, 25, pp. 423-430, (2014); Cowell S.J., Newby D.E., Burton J., Et al., Aortic valve calcification on computed tomography predicts the severity of aortic stenosis, Clin Radiol, 58, pp. 712-716, (2003); Cueff C., Serfaty J.M., Cimadevilla C., Et al., Measurement of aortic valve calcification using multislice computed tomography: Correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction, Heart, 97, pp. 721-726, (2011); Utsunomiya H., Yamamoto H., Kitagawa T., Et al., Incremental prognostic value of cardiac computed tomography angiography in asymptomatic aortic stenosis: Significance of aortic valve calcium score, Int J Cardiol, 168, pp. 5205-5211, (2013)","M.R. Dweck; British Heart Foundation, University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, 49 Little France Crescent, EH16 4SB, United Kingdom; email: marc.dweck@ed.ac.uk","","Elsevier Inc.","","","","","","07351097","","JACCD","26227196","English","J. Am. Coll. Cardiol.","Review","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84938085871"
"Gong H.-T.; Du F.-H.; Chen B.-X.","Gong, Hong-Tao (56044607200); Du, Feng-He (56217774600); Chen, Bu-Xing (14023922400)","56044607200; 56217774600; 14023922400","Relationship between Polymorphisms of Angiotensin II Type 1 Receptor and Antihypertensive Responses of Telmisartan","2017","Chinese General Practice","20","20","","2455","2458","3","1","10.3969/j.issn.1007-9572.2017.20.006","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049796176&doi=10.3969%2fj.issn.1007-9572.2017.20.006&partnerID=40&md5=7a5df238df2c683e041c6b29f9f0d141","Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China","Gong H.-T., Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China; Du F.-H., Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China; Chen B.-X., Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China","Objective: This study aims to investigate the relationship between the polymorphism of angiotensin II type 1 receptor(AT1R) and the antihypertensive efficacy of telmisartan. Methods: From June 2005 to January 2007, one hundred and forty-eight patients with mild-to-moderate primary hypertension were selected. All the patients accepted monotherapy of telmisartan for 8 weeks, blood pressure was measured 1-2 times/week. The AT1R genes 1166A/C, -810A/T and -521C/T polymorphism of the patients were analyzed by polymerase chain reaction (PCR). Some biochemical indexes such as alanine aminotransferase(ALT), aspartate aminotransferase(AST), creatinine(Cr), blood urea nitrogen(BUN), uric acid(UA), fasting plasma glucose (FPG), total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), blood sodium, blood potassium, blood chloride, angiotensin II (Ang II ) were also measured at the same time. Results: The body mass index(BMI), heart rate(HR), ALT, AST, Cr, BUN, UA, FPG, TC, TG, LDL-C, HDL-C, blood sodium, blood potassium and blood chlorine levels were compared before and after treatment, the differences were all not statistically significant(P>0.05). The Ang II level of the patients before and after treatment were compared, the difference was statistically significant(P<0.05). The systolic blood pressure before and after treatment, systolic blood pressure drop, diastolic blood pressure before and after treatment, diastolic blood pressure drop between AT1R gene 1166 A/C AA genotype and AC genotype, -810A/T AA genotype and AT genotype and TT genotype were compared, there were no significant differences(P>0.05). The systolic blood pressure before and after treatment, systolic blood pressure drop, diastolic blood pressure before and after treatment between AT1R gene -521C/T CC genotype and CT+TT genotype were compared, there were no significant differences(P>0.05). The diastolic blood pressure drop was compared, there was a statistically significant difference(P<0.05). Multiple linear regression analysis showed that UA, -521C/T, Ang II before treatment and diastolic blood pressure before treatment were the influencing factors of diastolic blood pressure drop(P<0.05). Conclusion: The -521C/T polymorphism of AT1R gene can independently predict the individual difference in patients' response to telmisartan. Copyright © 2017 by the Chinese General Practice.","Angiotensin II type 1 receptor blockers; Hypertension; Polymorphism, single nucleotide; Receptor, angiotensin, type 1","","","","","","","","Turner S.T., Bailey K.R., Schwartz G.L., Et al., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, 6, pp. 1204-1211, (2012); Whitworth J.A., 2003 World Health Organization(WHO)/International Society of Hypertension(ISH) statement on management of hypertension, J Hypertens, 21, 11, pp. 1983-1992, (2003); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin II type 1 receptor gene polymorphism in human essential hypertension, Hypertension, 24, 1, pp. 63-69, (1994); Erdmann J., Riedel K., Rohde K., Et al., Characterization of polymorphisms in the promoter gene of the human angiotensin II subtype 1(AT1) receptor gene, Ann Hum Genet, 63, pp. 369-374, (1999); Kurland L., Melhus H., Karlsson J., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, 10, pp. 1783-1787, (2001); Hilgers K.F., Langenfeld M.R., Schlaich M., Et al., 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II, Circulation, 100, 13, pp. 1394-1399, (1999); Spiering W., Kroon A.A., Fuss-Lejeune M.M., Et al., Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensive on a high sodium diet, Hypertension, 36, 3, pp. 411-416, (2000); Gong H.T., Du F.H., Association of angiotension II type 1 receptor gene polymorphism with essential hypertension, Clinical Medicine of China, 26, 10, pp. 1047-1049, (2010)","B.-X. Chen; Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China; email: chbux@126.com","","Chinese General Practice","","","","","","10079572","","","","Chinese","Chin. Gen. Pract.","Article","Final","","Scopus","2-s2.0-85049796176"
"Liu X.; Wang W.; Chen W.; Jiang X.; Zhang Y.; Wang Z.; Yang J.; Jones J.E.; Jose P.A.; Yang Z.","Liu, Xing (55541685200); Wang, Wenjie (57215072691); Chen, Wei (57193873453); Jiang, Xiaoliang (55978705000); Zhang, Yanrong (54911520900); Wang, Zihao (56670480600); Yang, Jian (55179587800); Jones, John E. (55488148500); Jose, Pedro A. (55382768900); Yang, Zhiwei (55716622300)","55541685200; 57215072691; 57193873453; 55978705000; 54911520900; 56670480600; 55179587800; 55488148500; 55382768900; 55716622300","Regulation of blood pressure, oxidative stress and AT1R by high salt diet in mutant human dopamine D5 receptor transgenic mice","2015","Hypertension Research","38","6","","394","399","5","16","10.1038/hr.2015.17","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930508739&doi=10.1038%2fhr.2015.17&partnerID=40&md5=29ccc3d7b6744423b22c278f31a74b49","Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States; Department of Physiology, University of Maryland, School of Medicine, Baltimore, MD, United States","Liu X., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Wang W., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Chen W., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Jiang X., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Zhang Y., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Wang Z., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China; Yang J., Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States; Jones J.E., Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States; Jose P.A., Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States, Department of Physiology, University of Maryland, School of Medicine, Baltimore, MD, United States; Yang Z., Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical Collage (PUMC), 5 Pan Jia Yuan Nan Li, Chaoyang District, Beijing, 100021, China","Humans have dopamine D5 receptors (hD5R) with single-nucleotide polymorphisms and a diminished function. We generated hD5F173L cDNA that has a decreased response to D5R agonist-mediated increase in cAMP production and increased production of reactive oxygen species, relative to wild-type hD5R (hD5WT) cDNA expressed in Chinese hamster ovary cells. To investigate the role of hD5F173L in the pathogenesis of salt-sensitive hypertension, we generated transgenic mice overexpressing hD5F173L or hD5WT and fed them normal (0.8% NaCl) or high (4% NaCl) salt diet. On normal salt diet, the blood pressure, and renal NADPH oxidase activity and angiotensin type 1 receptor (AT1R) expression were higher in hD5F173L than hD5WT transgenic mice. After 2 weeks on high salt diet, the blood pressure and renal NADPH oxidase activity, but not AT1R expression, were increased in hD5F173L but not in hD5WT transgenic mice. Candesartan, an AT1R antagonist, decreased the blood pressure and NADPH oxidase activity in hD5F173L but not in hD5WT transgenic mice. We suggest that the ability of the hD5R to negatively regulate the renal NADPH oxidase activity and AT1R function may have important implications in the pathogenesis of salt-sensitive blood pressure. However, the mechanisms involved in regulating the balance of renal D5R and AT1R function in the oxidative stress-mediated salt-sensitive blood pressure remain to be determined. © 2015 The Japanese Society of Hypertension All rights reserved.","AT1R; D5R; NADPH oxidase; salt-sensitive hypertension","Animals; Blood Pressure; CHO Cells; Cricetulus; Hypertension; Kidney; Mice; Mice, Transgenic; NADP; Oxidative Stress; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptors, Dopamine D5; Sodium Chloride, Dietary; angiotensin 1 receptor; complementary DNA; cyclic AMP; dopamine 5 receptor; reactive oxygen metabolite; reduced nicotinamide adenine dinucleotide phosphate oxidase; angiotensin 1 receptor; dopamine 5 receptor; nicotinamide adenine dinucleotide phosphate; reactive oxygen metabolite; salt intake; animal experiment; animal model; Article; blood pressure measurement; blood pressure regulation; CHO cell line; controlled study; enzyme activity; genetic transfection; high salt diet; human; hypertension; mean arterial pressure; mouse; nonhuman; oxidative stress; salt intake; single nucleotide polymorphism; animal; blood pressure; Cricetulus; genetics; hypertension; kidney; metabolism; oxidative stress; physiology; salt intake; transgenic mouse","","cyclic AMP, 60-92-4; reduced nicotinamide adenine dinucleotide phosphate oxidase, 9032-22-8; nicotinamide adenine dinucleotide phosphate, 53-59-8; NADP, ; Reactive Oxygen Species, ; Receptor, Angiotensin, Type 1, ; Receptors, Dopamine D5, ; Sodium Chloride, Dietary, ","","","National Heart, Lung, and Blood Institute, NHLBI, (P01HL068686)","","Basson J., Simino J., Rao D.C., Between candidate genes and whole genomes: Time for alternative approaches in blood pressure genetics, Curr Hypertens Rep, 14, pp. 46-61, (2012); Asghar M., Tayebati S.K., Lokhandwala M.F., Hussain T., Potential dopamine-1 receptor stimulation in hypertension management, Curr Hypertens Rep, 13, pp. 294-302, (2011); Whelton P.K., Appel L.J., Sacco R.L., Anderson C.A., Antman E.M., Campbell N., Dunbar S.B., Frohlich E.D., Hall J.E., Jessup M., Labarthe D.R., MacGregor G.A., Sacks F.M., Stamler J., Vafiadis D.K., Van Horn L.V., Sodium, blood pressure, and cardiovascular disease: Further evidence supporting the American Heart Association sodium reduction recommendations, Circulation, 126, pp. 2880-2889, (2012); Okamura D.M., Himmelfarb J., Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease, Pediatr Nephrol, 24, pp. 2309-2319, (2009); Jaimes E.A., Zhou M.S., Pearse D.D., Puzis L., Raij L., Upregulation of cortical COX-2 in saltsensitive hypertension: Role of angiotensin II and reactive oxygen species, Am J Physiol Renal Physiol, 294, pp. F385-F392, (2008); Geiszt M., Kopp J.B., Varnai P., Leto T.L., Identification of renox, an NAD(P)H oxidase in kidney, Proc Natl Acad Sci USA, 97, pp. 8010-8014, (2000); Montezano A.C., Touyz R.M., Oxidative stress, Noxs, and hypertension: Experimental evidence and clinical controversies, Ann Med, 44, pp. S2-S16, (2012); Ueda A., Ozono R., Oshima T., Yano A., Kambe M., Teranishi Y., Katsuki M., Chayama K., Disruption of the type 2 dopamine receptor gene causes a sodium-dependent increase in blood pressure in mice, Am J Hypertens, 16, pp. 853-858, (2003); Johnson T.L., Tulis D.A., Keeler B.E., Virag J.A., Lust R.M., Clemens S., The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis, PLoS One, 8, (2013); Yang Z., Zheng S., Asico L.D., Yu P., Bek M., Sibley D.R., Jose P.A., Increased PLD activity and elevated blood pressure in D5 receptor knockout mice, Am J Physiol Heart Circ Physiol, 288, pp. H55-H61, (2005); Yang Z., Asico L.D., Yu P., Wang Z., Jones J.E., Escano C.S., Wang X., Quinn M.T., Sibley D.R., Romero G.G., Felder R.A., Jose P.A., D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure, Am J Physiol Regul Integr Comp Physiol, 290, pp. R96-R104, (2006); Allayee H., De Bruin T.W., Michelle Dominguez K., Cheng L.S., Ipp E., Cantor R.M., Krass K.L., Et al., Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p, Hypertension, 38, pp. 773-778, (2001); Grandy D.K., Allen L.J., Zhang Y., Magenis R.E., Civelli O., Chromosomal localization of three human D5 dopamine receptor genes, Genomics, 13, pp. 968-973, (1992); Cooper R.S., Luke A., Zhu X., Kan D., Adeyemo A., Rotimi C., Bouzekri N., Ward R., Rorimi C., Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19, Hypertension, 40, pp. 629-633, (2002); Cravchik A., Gejman P.V., Functional analysis of the human D5 dopamine receptor missense and nonsense variants: Differences in dopamine binding affinities, Pharmacogenetics, 9, pp. 199-206, (1999); Jose P.A., Soares-Da-Silva P., Eisner G.M., Felder R.A., Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation, Biochim Biophys Acta, 1802, pp. 1259-1267, (2010); Zhang M.Z., Yao B., Wang S., Fan X., Wu G., Yang H., Yin H., Yang S., Harris R.C., Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice, J Clin Invest, 121, pp. 2845-2854, (2011); Aperia A., Bertorello A., Seri I., Dopamine causes inhibition of Na-K-ATPase activity in rat proximal convoluted tubule segments, Am J Physiol Renal Fluid Electrolyte Physiol, 252, pp. F39-F45, (1987); Bacic D., Kaissling B., McLeroy P., Zou L., Baum M., Moe O.W., Dopamine acutely decreases apical membrane Na/H exchanger NHE3 protein in mouse renal proximal tubule, Kidney Int, 64, pp. 2133-2141, (2003); Grider J.S., Ott C.E., Jackson B.A., Dopamine D1 receptor-dependent inhibition of NaCl transport in the rat thick ascending limb: Mechanism of action, Eur J Pharmacol, 473, pp. 185-190, (2003); Pedrosa R., Jose P.A., Soares-Da-Silva P., Defective D1-like receptor-mediated inhibition of Cl-/HCO3-exchanger in immortalized SHR proximal tubular epithelial cells, Am J Physiol Renal Physiol, 286, pp. F1120-F1126, (2004); Zeng C., Yang Z., Wang Z., Jones J., Wang X., Altea J., Mangrum A.J., Hopfer U., Sibley D.R., Eisner G.M., Felder R.A., Jose P.A., Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells, Hypertension, 45, pp. 804-810, (2005); Li H., Armando I., Yu P., Escano C., Mueller S.C., Asico L., Pascua A., Lu Q., Wang X., Villar V.A., Jones J.E., Wang Z., Periasamy A., Lau Y.S., Soares-Da-Silva P., Creswell K., Guillemette G., Sibley D.R., Eisner G., Gildea J.J., Felder R.A., Jose P.A., Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells, J Clin Invest, 118, pp. 2180-2189, (2008); Kinoshita S., Sidhu A., Felder F.A., Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat, J Clin Invest, 84, pp. 1849-1856, (1989); Mori T., Ogawa S., Cowely A.W., Ito S., Role of renal medullary oxidative and/or carbonyl stress in salt-sensitive hypertension and diabetes, Clin Exp Pharmacol Physiol, 39, pp. 125-131, (2012); Ando K., Fujita M., Reactive oxygen species and the central nervous system in salt-sensitive hypertension: Possible relationship with obesity-induced hypertension, Clin Exp Pharmacol Physiol, 39, pp. 111-116, (2012); Manning R.D., Tian N., Meng S., Oxidative stress and antioxidant treatment in hypertension and the associated renal damage, Am J Nephrol, 25, pp. 311-317, (2005); Varela M., Herrera M., Garvin J.L., Inhibition of Na-K-ATPase in thick ascending limbs by NO depends on O2-and is diminished by a high-salt diet, Am J Physiol Renal Physiol, 287, pp. F224-F230, (2004); Wilcox C.S., Redox regulation of the afferent arteriole and tubuloglomerular feedback, Acta Physiol Scand, 179, pp. 217-223, (2003); Banday A.A., Muhammad A.B., Fazili F.R., Lokhandwala M., Mechanisms of oxidative stress-induced increase in salt sensitivity and development of hypertension in Sprague-Dawley rats, Hypertension, 49, pp. 664-671, (2007); Kourie J.I., Interaction of reactive oxygen species with ion transport mechanisms, Am J Physiol, 275, pp. C1-24, (1998); Kim Y.H., Hwang J.H., Noh J.R., Gang G.T., Tadi S., Yim Y.H., Jeoung N.H., Kwak T.H., Lee S.H., Kweon G.R., Kim J.M., Shong M., Lee I.K., Lee C.H., Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase, Free Radic Biol Med, 52, pp. 880-888, (2012); Kitiyakara C., Chabrashvili T., Chen Y., Blau J., Karber A., Aslam S., Welch W.J., Wilcox C.S., Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase, J Am Soc Nephrol, 14, pp. 2775-2782, (2003); Lu Q., Yang Y., Villar V.A., Asico L., Jones J.E., Yu P., Li H., Weinman E.J., Eisner G.M., Jose P.A., D5 dopamine receptor decreases NADPH oxidase, reactive oxygen species and blood pressure via heme oxygenase-1, Hypertens Res, 36, pp. 684-690, (2013); Yang Y., Zhang Y., Cuevas S., Villar V.A., Escano C., Asico D., Yu L., Grandy P., Felder D.K., Armando R.A., Jose I., Paraoxonase P.A., 2 decreases renal reactive oxygen species production, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of NADPH oxidase, Free Radic Biol Med, 53, pp. 437-446, (2012); Cuevas S., Villar V.A., Jose P.A., Armando I., Renal dopamine receptors, oxidative stress, and hypertension, Int J Mol Sci, 14, pp. 17553-17572, (2013); Crowley S.D., Coffman T.M., Recent advances involving the renin-angiotensin system, Exp Cell Res, 318, pp. 1049-1056, (2012); Navar L.G., Prieto M.C., Satou R., Kobori H., Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension, Curr Opin Pharmacol, 11, pp. 180-186, (2011); Zhang G.X., Lu X.M., Kimura S., Nishiyama A., Role of mitochondria in angiotensin IIinduced reactive oxygen species and mitogen-activated protein kinase activation, Cardiovasc Res, 76, pp. 204-212, (2007); Yamamoto E., Tamamaki N., Nakamura T., Kataoka K., Tokutomi Y., Dong Y.F., Fukuda M., Matsuba S., Ogawa H., Kim-Mitsuyama S., Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation, Stroke, 39, pp. 3049-3056, (2008); Gao L., Wang W., Li Y.L., Schultz H.D., Liu D., Cornish K.G., Zucker I.H., Superoxide mediates sympathoexcitation in heart failure: Roles of angiotensin II and NAD(P)H oxidase, Circ Res, 95, pp. 937-944, (2004); Zeng C., Wang Z., Hopfer U., Asico L.D., Eisner G.M., Felder R.A., Jose P.A., Rat strain effects of AT1 receptor activation on D1 dopamine receptors in immortalized renal proximal tubule cells, Hypertension, 46, pp. 799-805, (2005); Chugh G., Lokhandwala M.F., Asghar M., Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats, Hypertension, 59, pp. 1029-1036, (2012); Yang S., Yao B., Zhou Y., Yin H., Zhang M.Z., Harris R.C., Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury, Am J Physiol Renal Physiol, 302, pp. F742-F749, (2012); Li D., Scott L., Crambert S., Zelenin S., Eklof A.C., Di Ciano L., Ibarra F., Aperia A., Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation, J Am Soc Nephrol, 23, pp. 421-428, (2012)","","","Japanese Society of Hypertension","","","","","","09169636","","HRESE","25716648","English","Hypertens. Res.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-84930508739"
"Chen Q.; Yu C.-Q.; Tang X.; Chen D.-F.; Tian J.; Cao Y.; Fan W.-Y.; Cao W.-H.; Zhan S.-Y.; Lv J.; Guo X.-X.; Hu Y.-H.; Lee L.-M.","Chen, Qing (55696094900); Yu, Can-Qing (35313661600); Tang, Xun (37051473500); Chen, Da-Fang (55521510300); Tian, Jun (53882009300); Cao, Yang (57198761953); Fan, Wen-Yi (41461133200); Cao, Wei-Hua (7402082953); Zhan, Si-Yan (57205304353); Lv, Jun (57209876570); Guo, Xiao-Xia (12801592300); Hu, Yong-Hua (34770189700); Lee, Li-Ming (15029843200)","55696094900; 35313661600; 37051473500; 55521510300; 53882009300; 57198761953; 41461133200; 7402082953; 57205304353; 57209876570; 12801592300; 34770189700; 15029843200","Interactions of renin-angiotensin system gene polymorphisms and antihypertensive effect of benazepril in Chinese population","2011","Pharmacogenomics","12","5","","735","743","8","4","10.2217/pgs.11.2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957629879&doi=10.2217%2fpgs.11.2&partnerID=40&md5=3cb7b1699282fa743f2de9881667614d","Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China; Key Laboratory of Epidemiology, Ministry of Education, Beijing, China","Chen Q., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Yu C.-Q., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Tang X., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Chen D.-F., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Tian J., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Cao Y., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Fan W.-Y., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Cao W.-H., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Zhan S.-Y., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Lv J., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Guo X.-X., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Hu Y.-H., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China; Lee L.-M., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China, Key Laboratory of Epidemiology, Ministry of Education, Beijing, China","Aim: Angiotensin-converting enzyme inhibitors are widely used antihypertensive drugs with individual response variation. We studied whether interactions of AGT, AGTR1 and ACE2 gene polymorphisms affect this response. Materials & methods: Our study is based on a 3-year field trial with 1831 hypertensive patients prescribed benazepril. Generalized multifactor dimensionality reduction was used to explore interaction models and logistic regressions were used to confirm them. Results: A two-locus model involving the AGT and ACE2 genes was found in males, the sensitive genotypes showed an odds ratio (OR) of 1.9 (95% CI: 1.3-2.8) when compared with nonsensitive genotypes. Two AGT-AGTR1 models were found in females, with an OR of 3.5 (95% CI: 2.0-5.9) and 3.1 (95% CI: 1.8-5.3). Conclusion: Gender-specific gene-gene interactions of the AGT, AGTR1 and ACE2 genes were associated with individual variation of response to benazepril. Further studies are needed to confirm this finding. © 2011 Future Medicine Ltd.","angiotensin-converting enzyme inhibitors; epistasis; generalized multifactor dimensionality reduction; hypertension; pharmacogenetics; renin-angiotensin system","Adult; Aged; Angiotensinogen; Antihypertensive Agents; Asian Continental Ancestry Group; Benzazepines; Female; Gene Frequency; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; benazepril; ACE2 gene; adult; AGT gene; AGTR1 gene; article; Chinese; controlled study; DNA polymorphism; drug response; female; gene; gene interaction; gene locus; genetic variability; genotype; human; hypertension; logistic regression analysis; major clinical study; male; multifactor dimensionality reduction; renin angiotensin aldosterone system; sex difference","","benazepril, 86541-75-5; AGT protein, human, ; AGTR1 protein, human, ; Angiotensinogen, 11002-13-4; Antihypertensive Agents, ; Benzazepines, ; Peptidyl-Dipeptidase A, 3.4.15.1; Receptor, Angiotensin, Type 1, ; angiotensin converting enzyme 2, 3.4.17.-; benazepril, UDM7Q7QWP8","lotensin, Novartis, Switzerland","Novartis, Switzerland","","","Arnett D.K., Claas S.A., Glasser S.P., Pharmacogenetics of antihypertensive treatment, Vascular Pharmacology, 44, 2, pp. 107-118, (2006); Marteau J.-B., Gambier N., Jeannesson E., Siest G., Visvikis-Siest S., Pharmacogenomics and antihypertensive drugs: A path toward personalized medicine, Personalized Medicine, 4, 4, pp. 393-412, (2007); Ocaranza M.P., Godoy I., Jalil J.E., Varas M., Collantes P., Pinto M., Roman M., Ramirez C., Copaja M., Diaz-Araya G., Castro P., Lavandero S., Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat, Hypertension, 48, 4, pp. 572-578, (2006); Ferrario C.M., Jessup J., Gallagher P.E., Averill D.B., Brosnihan K.B., Tallant E.A., Smith R.D., Chappell M.C., Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors, Kidney International, 68, 5, pp. 2189-2196, (2005); Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Diz D.I., Gallagher P.E., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, 111, 20, pp. 2605-2610, (2005); Fleming I., Signaling by the angiotensin-converting enzyme, Circ. Res., 98, 7, pp. 887-896, (2006); Woodiwiss A.J., Nkeh B., Samani N.J., Badenhorst D., Maseko M., Tiago A.D., Candy G.P., Libhaber E., Sareli P., Brooksbank R., Norton G.R., Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin, Journal of Hypertension, 24, 6, pp. 1057-1064, (2006); Gluszek J., Jankowska K., Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT<sub>1</sub> and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy?, Polskie Archiwum Medycyny Wewnetrznej, 118, 4, pp. 194-200, (2008); Filigheddu F., Argiolas G., Bulla E., Et al., Clinical variables, not RAASpolymorphisms, predict blood pressure response to ACE inhibitors in Sardinians, Pharmacogenomics, 9, 10, pp. 1419-1427, (2008); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Zhen Y., Wang J., Li W., Han Y., Liu T., Wang X., Chen J., Wu H., Hui R., Xiangsheng C., Ruilin G., Depei L., Yuhua L., Xigui W., Daowen W., Meiling X., Deyu Z., Dingliang Z., Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women, Clinical Pharmacology and Therapeutics, 82, 2, pp. 187-196, (2007); Morales-Suarez-Varela M.M., Mansego M.L., Martin-Escudero J.C., Et al., How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angiotensin-aldosterone system, Eur. J. Pharm. Sa., 39, 5, pp. 380-386, (2010); Schelleman H., Stricker B.H.Ch., Verschuren W.M.M., De Boer A., Kroon A.A., De Leeuw P.W., Kromhout D., Klungel O.H., Interactions between five candidate genes and antihypertensive drug therapy on blood pressure, Pharmacogenomics Journal, 6, 1, pp. 22-26, (2006); Brugts J.J., Boersma E., Simoons M.L., Tailored therapy of ACE inhibitors in stable coronary artery disease: Pharmacogenetic profiling of treatment benefit, Pharmacogenomics, 11, 8, pp. 1115-1126, (2010); Su X.W., Lixh L.L., Et al., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, pp. 725-732, (2007); Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., Nickerson D.A., Selecting a Maximally Informative Set of Single-Nucleotide Polymorphisms for Association Analyses Using Linkage Disequilibrium, American Journal of Human Genetics, 74, 1, pp. 106-120, (2004); Pereira A.C., Mota G.F.A., Cunha R.S., Herbenhoff F.L., Mill J.G., Krieger J.E., Angiotensinogen 235T allele ""dosage"" is associated with blood pressure phenotypes, Hypertension, 41, 1, pp. 25-30, (2003); Tiago A.D., Samani N.J., Candy G.P., Et al., Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension, Circulation, 106, 12, pp. 1483-1487, (2002); Wu S.-J., Chiang F.-T., Chen W.J., Liu P.-H., Hsu K.-L., Hwang J.-J., Lai L.-P., Lin J.-L., Tseng C.-D., Tseng Y.-Z., Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: Single locus genotype vs. haplotype analysis, Physiological Genomics, 17, pp. 79-86, (2004); Liu Y., Zhuoma C., Shan G.L., Et al., A1166C polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in Han, Tibetan and Yi populations, Hypertens. Res., 25, 4, pp. 515-521, (2002); Alfakih K., Maqbool A., Sivananthan M., Walters K., Bainbridge G., Ridgway J., Balmforth A.J., Hall A.S., Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension, Hypertension, 43, 6, pp. 1189-1194, (2004); Jin J.J., Wu Zh N., Et al., Association of angiotensin II type 2 receptor gene variant with hypertension, Hypertens. Res., 26, 7, pp. 547-552, (2003); Jones A., Dhamrait S.S., Payne J.R., Hawe E., Li P., Toor I.S., Luong L., Wootton P.T.E., Miller G.J., Humphries S.E., Montgomery H.E., Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension, Hypertension, 42, 4, pp. 500-506, (2003); Yi L., Gu Y.H., Wang X.L., An L.Z., Xie X.D., Shao W., Ma L.Y., Fang J.R., An Y.D., Wang F., Zhang D.L., Association of ACE, ACE2 and UTS2 polymorphisms wih essential hypertension in Han and Dongxiang populations from North-western China, Journal of International Medical Research, 34, 3, pp. 272-283, (2006); Lou X.-Y., Chen G.-B., Yan L., Ma J.Z., Zhu J., Elston R.C., Li M.D., A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence, American Journal of Human Genetics, 80, 6, pp. 1125-1137, (2007); Jessup J.A., Gallagher P.E., Averill D.B., Et al., Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats, Am. J. Physiol. Heart Circ. Physiol., 291, 5, (2006); Gao L., Wang W., Li Y.-L., Schultz H.D., Liu D., Cornish K.G., Zucker I.H., Sympathoexcitation by central ANG II: Roles for AT<sub>1</sub> receptor upregulation and NAD(P)H oxidase in RVLM, American Journal of Physiology - Heart and Circulatory Physiology, 288, 5, (2005); Zhou Y., Dirksen W.P., Babu G.J., Periasamy M., Differential vasoconstrictions induced by angiotensin II: Role of AT1 and AT2 receptors in isolated C57BL/6J mouse blood vessels, American Journal of Physiology - Heart and Circulatory Physiology, 285, 6, (2003); De Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T., International union of pharmacology XXIII. The angiotensin II receptors, Pharmacol. Rev., 52, 3, pp. 415-472, (2000); Ras S., Silvaace F., Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis, Exp. Physiol., 93, 5, pp. 519-527, (2008); Gallagher P.E., Chappell M.C., Ferrario C.M., Tallant E.A., Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes, Am. J. Physiol. Cell Physiol., 290, 2, (2006); Koka V., Xiao R.H., Chung A.C.K., Wang W., Truong L.D., Lan H.Y., Angiotensin II up-regulates Angiotensin I-Converting Enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway, American Journal of Pathology, 172, 5, pp. 1174-1183, (2008); Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., Ogihara T., Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II, Hypertension, 47, 4, pp. 718-726, (2006); Hartwell L., Robust Interactions, Science, 303, 5659, pp. 774-775, (2004); Phillips P.C., Epistasis -the essential role of gene interactions in the structure and evolution of genetic systems, Nat. Rev. Genet., 9, 11, pp. 855-867, (2008); Brugts J.J., Isaacs A., Boersma E., Et al., Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease, Eur. Heart J., 31, 15, pp. 1854-1864, (2010); Fenty-Stewart N., Park J.Y., Roth S.M., Et al., Independent and combined influence of AGTRl variants and aerobic exercise on oxidative stress in hypertensives, Blood Press., 18, 4, pp. 204-212, (2009); Harvey P.J., Morris B.L., Miller J.A., Floras J.S., Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women, Hypertension, 45, 3, pp. 399-405, (2005); Brosnihan K.B., Hodgin J.B., Smithies O., Maeda N., Gallagher P., Tissue-specific regulation of ACE/ACE2 and AT<sub>1</sub>/AT<sub>2</sub> receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-α knock-out mice, Experimental Physiology, 93, 5, pp. 658-664, (2008); Milsted A., Dunmirej U.A., Et al., Regulation of multiple renin-angiotensin system genes by Sry, J. Hypertens., 28, 1, pp. 59-64, (2010)","L.-M. Lee; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, 100191, 38 Xueyuan Road, Haidian District, China; email: lmlee@pumc.edu.cn","","","","","","","","17448042","","PARMF","21449848","English","Pharmacogenomics","Article","Final","","Scopus","2-s2.0-79957629879"
"Liu Y.; Goldfarb D.S.; El-Achkar T.M.; Lieske J.C.; Wu X.-R.","Liu, Yan (36241835200); Goldfarb, David S. (7102329925); El-Achkar, Tarek M. (8308554900); Lieske, John C. (7003441017); Wu, Xue-Ru (7408231238)","36241835200; 7102329925; 8308554900; 7003441017; 7408231238","Tamm-horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia","2018","American Journal of Physiology - Renal Physiology","314","6","","F1062","F1076","14","31","10.1152/ajprenal.00233.2017","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047903840&doi=10.1152%2fajprenal.00233.2017&partnerID=40&md5=03fb3d485787248f5b0df3adee92eb86","Department of Urology, New York University School of Medicine, New York, NY, United States; Department of Nephrology, New York University School of Medicine, New York, NY, United States; Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York, NY, United States; Division of Nephrology, Indiana University School of Medicine and Indianapolis Veterans Affairs, Indianapolis, IN, United States; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; Department of Pathology, New York University School of Medicine, New York, NY, United States","Liu Y., Department of Urology, New York University School of Medicine, New York, NY, United States; Goldfarb D.S., Department of Nephrology, New York University School of Medicine, New York, NY, United States, Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York, NY, United States; El-Achkar T.M., Division of Nephrology, Indiana University School of Medicine and Indianapolis Veterans Affairs, Indianapolis, IN, United States; Lieske J.C., Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; Wu X.-R., Department of Urology, New York University School of Medicine, New York, NY, United States, Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York, NY, United States, Department of Pathology, New York University School of Medicine, New York, NY, United States","Expression of Tamm-Horsfall protein (THP or uromodulin) is highly restricted to the kidney thick ascending limb (TAL) of loop of Henle. Despite the unique location and recent association of THP gene mutations with hereditary uromodulin-associated kidney disease and THP single nucleotide polymorphisms with chronic kidney disease and hypertension, the physiological function(s) of THP and its pathological involvement remain incompletely understood. By studying age-dependent changes of THP knockout (KO) mice, we show here that young KO mice had significant salt and water wasting but were partially responsive to furosemide, due to decreased luminal translocation of Na-K-Cl cotransporter 2 (NKCC2) in the TAL. Aged THP KO mice were, however, markedly oliguric and unresponsive to furosemide, and their NKCC2 was localized primarily in the cytoplasm as evidenced by lipid raft floatation assay, cell fractionation, and confocal and immunoelectron microscopy. These aged KO mice responded to metolazone and acetazolamide, known to target distal and proximal tubules, respectively. They also had marked upregulation of renin in juxtaglomerular apparatus and serum, and they were hypertensive. Finally, the aged THP KO mice had significant upregulation of Na-coupled urate transporters Slc5a8 and Slc22a12 as well as sodium-hydrogen exchanger 3 (NHE3) in the proximal tubule and elevated serum uric acid and allantoin. Collectively, our results suggest that THP deficiency can cause progressive disturbances in renal functions via initially NKCC2 dysfunction and later compensatory responses, resulting in prolonged activation of the renin-angiotensin-aldosterone axis and hyperuricemia. © 2018 American Physiological Society. All rights reserved.","Hyperuricemia; Lipid rafts; NKCC2; Tamm-Horsfall protein; Thick ascending limb; Uromodulin","Age Factors; Animals; Blood Pressure; Cation Transport Proteins; Disease Models, Animal; Diuretics; Genetic Predisposition to Disease; Hypertension; Hyperuricemia; Kidney; Kidney Diseases; Male; Membrane Microdomains; Mice, 129 Strain; Mice, Knockout; Oliguria; Organic Anion Transporters; Phenotype; Renin-Angiotensin System; Sodium-Hydrogen Exchanger 3; Solute Carrier Family 12, Member 1; Urination; Uromodulin; acetazolamide; allantoin; angiotensin II; furosemide; metolazone; renin; sodium potassium chloride cotransporter 2; sodium proton exchange protein 3; Tamm Horsfall glycoprotein; urate transporter; uric acid; cation transport protein; diuretic agent; organic anion transporter; Slc12a1 protein, mouse; Slc22a12 protein, mouse; Slc5a8 protein, mouse; Slc9a3 protein, mouse; sodium potassium chloride cotransporter 2; sodium proton exchange protein 3; Tamm Horsfall glycoprotein; Umod protein, mouse; animal experiment; Article; cell fractionation; chronic kidney failure; controlled study; gene mutation; hypertension; hyperuricemia; immunoelectron microscopy; juxtaglomerular apparatus; kidney proximal tubule; lipid raft; mouse; nonhuman; priority journal; protein expression; renin angiotensin aldosterone system; single nucleotide polymorphism; upregulation; uric acid blood level; Western blotting; 129 mouse; age; animal; blood pressure; disease model; drug effect; genetic predisposition; genetics; hypertension; hyperuricemia; kidney; kidney disease; knockout mouse; male; membrane microdomain; metabolism; micturition; oliguria; pathophysiology; phenotype; ultrastructure","","acetazolamide, 1424-27-7, 59-66-5; allantoin, 97-59-6, 3844-67-5, 7303-80-2; angiotensin II, 11128-99-7, 68521-88-0; furosemide, 54-31-9; metolazone, 17560-51-9, 56436-31-8, 56436-32-9; renin, 61506-93-2, 9015-94-5; sodium proton exchange protein 3, 170349-61-8; uric acid, 69-93-2; Cation Transport Proteins, ; Diuretics, ; Organic Anion Transporters, ; Slc12a1 protein, mouse, ; Slc22a12 protein, mouse, ; Slc5a8 protein, mouse, ; Slc9a3 protein, mouse, ; Sodium-Hydrogen Exchanger 3, ; Solute Carrier Family 12, Member 1, ; Umod protein, mouse, ; Uromodulin, ","","","Biomedical Laboratory Research and Development Service, (1I01BX002049); Veterans Affairs Office of Research and Development; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK056903); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK; School of Medicine, New York University, NYUSM","This work was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK-056903; Veterans Affairs Office of Research and Development, Biomedical Laboratory Research and Development Service Grant 1I01BX002049; and a grant-in-aid from the Goldstein Fund for Urological Research of the New York University School of Medicine.","Anzai N., Jutabha P., Amonpatumrat-Takahashi S., Sakurai H., Recent advances in renal urate transport: Characterization of candidate transporters indicated by genome-wide association studies, Clin Exp Nephrol, 16, pp. 89-95, (2012); Bachmann S., Koeppen-Hagemann I., Kriz W., Ultrastructural localization of Tamm-Horsfall glycoprotein (THP) in rat kidney as revealed by protein A-gold immunocytochemistry, Histochemistry, 83, pp. 531-538, (1985); Bachmann S., Mutig K., Bates J., Welker P., Geist B., Gross V., Luft F.C., Alenina N., Bader M., Thiele B.J., Prasadan K., Raffi H.S., Kumar S., Renal effects of Tamm-Horsfall protein (Uromodulin) deficiency in mice, Am J Physiol Renal Physiol, 288, pp. F559-F567, (2005); Bates J.M., Raffi H.M., Prasadan K., Mascarenhas R., Laszik Z., Maeda N., Hultgren S.J., Kumar S., Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: Rapid communication, Kidney Int, 65, pp. 791-797, (2004); Bernascone I., Janas S., Ikehata M., Trudu M., Corbelli A., Schaeffer C., Rastaldi M.P., Devuyst O., Rampoldi L., A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating defect and renal failure, Hum Mol Genet, 19, pp. 2998-3010, (2010); Bleyer A.J., Kmoch S., Tamm Horsfall glycoprotein and uromodulin: It is all about the tubules!, Clin J am Soc Nephrol, 11, pp. 6-8, (2016); Bleyer A.J., Zivna M., Kmoch S., Uromodulin-associated kidney disease, Nephron Clin Pract, 118, pp. c31-c36, (2011); Brown D., Waneck G.L., Glycosyl-phosphatidylinositol-anchored membrane proteins, J am Soc Nephrol, 3, pp. 895-906, (1992); Brunati M., Perucca S., Han L., Cattaneo A., Consolato F., Andolfo A., Schaeffer C., Olinger E., Peng J., Santambrogio S., Perrier R., Li S., Bokhove M., Bachi A., Hummler E., Devuyst O., Wu Q., Jovine L., Rampoldi L., The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin, Elife, 4, (2015); Cameron J.S., Simmonds H.A., Hereditary hyperuricemia and renal disease, Semin Nephrol, 25, pp. 9-18, (2005); Capasso G., Jaeger P., Robertson W.G., Unwin R.J., Uric acid and the kidney: Urate transport, stone disease and progressive renal failure, Curr Pharm Des, 11, pp. 4153-4159, (2005); Castrop H., Schiessl I.M., Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2), Am J Physiol Renal Physiol, 307, pp. FF991-F1002, (2014); Cavallone D., Malagolini N., Monti A., Wu X.R., Serafini-Cessi F., Variation of high mannose chains of Tamm-Horsfall glycoprotein confers differential binding to type 1-fimbriated Escherichia coli, J Biol Chem, 279, pp. 216-222, (2004); Devuyst O., Bochud M., Uromodulin, kidney function, cardiovascular disease, and mortality, Kidney Int, 88, pp. 944-946, (2015); El-Achkar T.M., McCracken R., Liu Y., Heitmeier M.R., Bourgeois S., Ryerse J., Wu X.R., Tamm-Horsfall protein translocates to the basolateral domain of thick ascending limbs, interstitium, and circulation during recovery from acute kidney injury, Am J Physiol Renal Physiol, 304, pp. F1066-F1075, (2013); El-Achkar T.M., McCracken R., Rauchman M., Heitmeier M.R., Al-Aly Z., Dagher P.C., Wu XR. Tamm-Horsfall protein-deficient thick ascending limbs promote injury to neighboring S3 segments in an MIP-2-dependent mechanism, Am J Physiol Renal Physiol, 300, pp. FF999-F1007, (2011); El-Achkar T.M., Wu X.R., Uromodulin in kidney injury: An instigator, bystander, or protector?, Am J Kidney Dis, 59, pp. 452-461, (2012); El-Achkar T.M., Wu X.R., Rauchman M., McCracken R., Kiefer S., Dagher P.C., Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression, Am J Physiol Renal Physiol, 295, pp. F534-F544, (2008); Garimella P.S., Biggs M.L., Katz R., Ix J.H., Bennett M.R., Devarajan P., Kestenbaum B.R., Siscovick D.S., Jensen M.K., Shlipak M.G., Chaves P.H., Sarnak M.J., Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults, Kidney Int, 88, pp. 1126-1134, (2015); Gersch M., Mutig K., Bachmann S., Kumar S., Ouyang X., Johnson R., Is salt-wasting the long awaited answer to the hyperuricaemia seen in uromodulin storage diseases?, Nephrol Dial Transplant, 21, pp. 2028-2029, (2006); Gudbjartsson D.F., Holm H., Indridason O.S., Thorleifsson G., Edvard-Sson V., Sulem P., de Vegt F., D'Ancona F.C., Den Heijer M., Wetzels J.F., Franzson L., Rafnar T., Kristjansson K., Bjornsdottir U.S., Eyjolfsson G.I., Kiemeney L.A., Kong A., Palsson R., Thorsteinsdottir U., Stefansson K., Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases, Plos Genet, 6, (2010); Haas M., Forbush B., The Na-K-Cl cotransporters, J Bioenerg Biomembr, 30, pp. 161-172, (1998); Kemter E., Rathkolb B., Bankir L., Schrewe A., Hans W., Landbrecht C., Klaften M., Ivandic B., Fuchs H., Gailus-Durner V., Hrabe de Angelis M., Wolf E., Wanke R., Aigner B., Mutation of the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporter NKCC2 in mice is associated with severe polyuria and a urea-selective concentrating defect without hyperreninemia, Am J Physiol Renal Physiol, 298, pp. F1405-F1415, (2010); Khan S.R., Kok D.J., Modulators of urinary stone formation, Front Biosci, 9, pp. 1450-1482, (2004); Kottgen A., Glazer N.L., Dehghan A., Hwang S.J., Katz R., Li M., Yang Q., Gudnason V., Launer L.J., Harris T.B., Smith A.V., Arking D.E., Astor B.C., Boerwinkle E., Ehret G.B., Ruczinski I., Scharpf R.B., Chen Y.D., de Boer I.H., Haritunians T., Lumley T., Sarnak M., Siscovick D., Benjamin E.J., Levy D., Upadhyay A., Aulchenko Y.S., Hofman A., Rivadeneira F., Uitterlinden A.G., van Duijn C.M., Chasman D.I., Pare G., Ridker P.M., Kao W.H., Witteman J.C., Coresh J., Shlipak M.G., Fox C.S., Multiple loci associated with indices of renal function and chronic kidney disease, Nat Genet, 41, pp. 712-717, (2009); Kottgen A., Hwang S.J., Larson M.G., van Eyk J.E., Fu Q., Benjamin E.J., Dehghan A., Glazer N.L., Kao W.H., Harris T.B., Gudnason V., Shlipak M.G., Yang Q., Coresh J., Levy D., Fox C.S., Uromodulin levels associate with a common UMOD variant and risk for incident CKD, Jamsoc Nephrol, 21, pp. 337-344, (2010); Kumar S., Muchmore A., Tamm-Horsfall protein–uromodulin (1950– 1990), Kidney Int, 37, pp. 1395-1401, (1990); Lhotta K., Uromodulin and chronic kidney disease, Kidney Blood Press Res, 33, pp. 393-398, (2010); Liu Y., El-Achkar T.M., Wu X.R., Tamm-Horsfall protein regulates circulating and renal cytokines by affecting glomerular filtration rate and acting as a urinary cytokine trap, J Biol Chem, 287, pp. 16365-16378, (2012); Liu Y., Mo L., Goldfarb D.S., Evan A.P., Liang F., Khan S.R., Lieske J.C., Wu X.R., Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein, Am J Physiol Renal Physiol, 299, pp. F469-F478, (2010); Malagolini N., Cavallone D., Serafini-Cessi F., Intracellular transport, cell-surface exposure and release of recombinant Tamm-Horsfall glycoprotein, Kidney Int, 52, pp. 1340-1350, (1997); Mandal A.K., Mount D.B., The molecular physiology of uric acid homeostasis, Annu Rev Physiol, 77, pp. 323-345, (2015); Micanovic R., Chitteti B.R., Dagher P.C., Srour E.F., Khan S., Hato T., Lyle A., Tong Y., Wu X.R., El-Achkar T.M., Tamm-Horsfall protein regulates granulopoiesis and systemic neutrophil homeostasis, J am Soc Nephrol, 26, pp. 2172-2182, (2015); Mo L., Huang H.Y., Zhu X.H., Shapiro E., Hasty D.L., Wu X.R., Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation, Kidney Int, 66, pp. 1159-1166, (2004); Mo L., Zhu X.H., Huang H.Y., Shapiro E., Hasty D.L., Wu X.R., Ablation of the Tamm-Horsfall protein gene increases susceptibility of mice to bladder colonization by type 1-fimbriated Escherichia coli, Am J Physiol Renal Physiol, 286, pp. F795-F802, (2004); Mutig K., Kahl T., Saritas T., Godes M., Persson P., Bates J., Raffi H., Rampoldi L., Uchida S., Hille C., Dosche C., Kumar S., Castaneda-Bueno M., Gamba G., Bachmann S., Activation of the bumetanide-sensitive Na<sup>+</sup>,K<sup>+</sup>,2Cl<sup>-</sup> cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner, J Biol Chem, 286, pp. 30200-30210, (2011); Olden M., Corre T., Hayward C., Toniolo D., Ulivi S., Gasparini P., Pistis G., Hwang S.J., Bergmann S., Campbell H., Cocca M., Gandin I., Girotto G., Glaudemans B., Hastie N.D., Loffing J., Polasek O., Rampoldi L., Rudan I., Sala C., Traglia M., Vollenweider P., Vuckovic D., Youhanna S., Weber J., Wright A.F., Kutalik Z., Bochud M., Fox C.S., Devuyst O., Common variants in UMOD associate with urinary uromodulin levels: A meta-analysis, J am Soc Nephrol, 25, pp. 1869-1882, (2014); Pak J., Pu Y., Zhang Z.T., Hasty D.L., Wu X.R., Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. Coli from binding to uroplakin Ia and Ib receptors, J Biol Chem, 276, pp. 9924-9930, (2001); Paladino S., Sarnataro D., Zurzolo C., Detergent-resistant membrane microdomains and apical sorting of GPI-anchored proteins in polarized epithelial cells, Int J Med Microbiol, 291, pp. 439-445, (2002); Palmer B.F., Metabolic complications associated with use of diuretics, Semin Nephrol, 31, pp. 542-552, (2011); Peach R.J., Day W.A., Ellingsen P.J., McGiven A.R., Ultrastructural localization of Tamm-Horsfall protein in human kidney using immunogold electron microscopy, Histochem J, 20, pp. 156-164, (1988); Puschett JB. Pharmacological classification and renal actions of diuretics, Cardiology, 84, pp. 4-13, (1994); Quan A., Baum M., Regulation of proximal tubule transport by angiotensin II, Semin Nephrol, 17, pp. 423-430, (1997); Raffi H., Bates J., Kumar S., Laszik Z., Buffington C.A., Tamm-Horsfall protein knockout mice have increased stress induced micturition, Neurourol Urodyn, 28, (2009); Rampoldi L., Kottgen A., Devuyst O., The effect of common uromodulin variants on urinary protein level and gene transcription, Kidney Int, 84, pp. 410-411, (2013); Rampoldi L., Scolari F., Amoroso A., Ghiggeri G., Devuyst O., The rediscovery of uromodulin (Tamm-Horsfall protein): From tubulointerstitial nephropathy to chronic kidney disease, Kidney Int, 80, pp. 338-347, (2011); Renigunta A., Renigunta V., Saritas T., Decher N., Mutig K., Waldegger S., Tamm-Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and regulates its function, J Biol Chem, 286, pp. 2224-2235, (2011); Rindler M.J., Naik S.S., Li N., Hoops T.C., Peraldi M.N., Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein, J Biol Chem, 265, pp. 20784-20789, (1990); Saha S., Anilkumar A.A., Mayor S., GPI-anchored protein organization and dynamics at the cell surface, J Lipid Res, 57, pp. 159-175, (2016); Schmitt R., Kahl T., Mutig K., Bachmann S., Selectively reduced expression of thick ascending limb Tamm-Horsfall protein in hypothyroid kidneys, Histochem Cell Biol, 121, pp. 319-327, (2004); Scolari F., Caridi G., Rampoldi L., Tardanico R., Izzi C., Pirulli D., Amoroso A., Casari G., Ghiggeri G.M., Uromodulin storage diseases: Clinical aspects and mechanisms, Am J Kidney Dis, 44, pp. 987-999, (2004); Sedor J.R., Uromodulin and translational medicine: Will the SNPs bring zip to clinical practice?, J am Soc Nephrol, 21, pp. 204-206, (2010); Seely J.F., Dirks J.H., Site of action of diuretic drugs, Kidney Int, 11, pp. 1-8, (1977); Serafini-Cessi F., Malagolini N., Cavallone D., Tamm-Horsfall glycoprotein: Biology and clinical relevance, Am J Kidney Dis, 42, pp. 658-676, (2003); Serafini-Cessi F., Monti A., Cavallone D., N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases, Glycoconj J, 22, pp. 383-394, (2005); Steubl D., Block M., Herbst V., Nockher W.A., Schlumberger W., Sa-Tanovskij R., Angermann S., Hasenau A.L., Stecher L., Heemann U., Renders L., Scherberich J., Plasma uromodulin correlates with kidney function and identifies early stages in chronic kidney disease patients, Medicine (Baltimore), 95, (2016); Takiue Y., Hosoyamada M., Yokoo T., Kimura M., Shibasaki T., Progressive accumulation of intrinsic mouse uromodulin in the kidneys of transgenic mice harboring the mutant human uromodulin gene, Biol Pharm Bull, 31, pp. 405-411, (2008); Trudu M., Janas S., Lanzani C., Debaix H., Schaeffer C., Ikehata M., Citterio L., Demaretz S., Trevisani F., Ristagno G., Glaudemans B., Laghmani K., Dell'Antonio G., Loffing J., Rastaldi M.P., Manunta P., Devuyst O., Rampoldi L., SKIPOGH team. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression, Nat Med, 19, pp. 1655-1660, (2013); Wu X., Wakamiya M., Vaishnav S., Geske R., Montgomery C., Jones P., Bradley A., Caskey C.T., Hyperuricemia and urate nephropathy in urate oxidase-deficient mice, Proc Natl Acad Sci USA, 91, pp. 742-746, (1994)","X.-R. Wu; Urological Research, New York Univ. School of Medicine, Veterans Affairs Medical Center in Manhattan, New York, 423 E. 23rd St., 18th Floor, Rm. 18064 South, 10010, United States; email: xue-ru.wu@med.nyu.edu","","American Physiological Society","","","","","","1931857X","","AJPPF","29357410","English","Am. J. Physiol. Renal Physiol.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-85047903840"
"Abdelaziz T.A.; Mohamed R.H.; Balata G.F.; El-Azzazy O.Y.","Abdelaziz, Tarek A. (6506564468); Mohamed, Randa H. (35275704400); Balata, Gehan F. (15724558400); El-Azzazy, Omar Y. (57218378213)","6506564468; 35275704400; 15724558400; 57218378213","Effect of angiotensin converting enzyme gene polymorphism on patients with in-stent restenosis after percutaneous coronary intervention","2021","Tropical Journal of Pharmaceutical Research","20","2","","403","409","6","3","10.4314/tjpr.v20i2.26","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102876703&doi=10.4314%2ftjpr.v20i2.26&partnerID=40&md5=a5079ea4feb8c333c51a4594c1e51333","Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt; Department of Pharmacy Practice, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt","Abdelaziz T.A., Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Mohamed R.H., Department of Medical Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Balata G.F., Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt; El-Azzazy O.Y., Department of Pharmacy Practice, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt","Purpose: To evaluate the association between common single nucleotide polymorphisms (SNPs) in angiotensin converting enzyme (ACE) gene and the risk of in-stent restenosis (ISR) and/or the response to angiotensin converting enzyme inhibitor ACEI in individuals with stable coronary artery disease (CAD) after stent implantation. Methods: The total population of this study consisted of 200 Egyptian individuals divided into 2 groups - in-stent restenosis (ISR) and non ISR group). Genomic DNA was withdrawn from EDTA whole blood applying a spin column approach and ACE gene insertion/deletion (I/D) polymorphisms were determined by polymerase chain reaction (PCR). Results: Carriers of allele D of ACE gene were significantly more liable to ISR occurrence. However, carriers of allele I were significantly more liable to ISR occurrence after administration of ACEI. There is a negative interaction between DD genotype of ACE gene and ACEI administration on ISR after percutaneous coronary intervention (PCI). However, there is a positive interaction between II and ID genotype of ACE gene and ACEI administration on ISR after PCI with bare metal stents (BMS). Conclusion: It is beneficial to implement ACEI in therapeutic regimen in individuals with ID or II genotypes of ACE gene, especially with BMS implementation. © 2021 The authors.","ACE gene; Coronary artery disease; In-stent restenosis; Polymorphism","dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; adult; Article; case control study; chronic kidney failure; controlled study; diabetes mellitus; DNA polymorphism; female; gender; gene frequency; gene interaction; genotype; human; hypertension; in-stent restenosis; indel mutation; major clinical study; male; middle aged; obesity; percutaneous coronary intervention; polymerase chain reaction; single nucleotide polymorphism; synergistic effect","","dipeptidyl carboxypeptidase, 9015-82-1","","","","","Kim M, Dean L., In-stent restenosis, Cardiovasc Ther, 29, pp. 190-198, (2011); Pallero M, Talbert R, Chen Y, Anderson P, Lemons J, Brott B, Murphy-Ullrich J., Stainless steel ions stimulate increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: Implications for in-stent restenosis, J Vasc Res, 47, pp. 309-322, (2010); Gomma A, Elrayess M, Knight C, Hawe E, Fox K, Humphries S., The endothelial nitric oxide synthase (Glu298Asp and-786T> C) gene polymorphisms are associated with coronary in-stent restenosis, Eur Heart J, 23, pp. 1955-1962, (2002); Osadnik T, Strzelczyk J, Regula R, Bujak K, Fronczek M, Gonera M, Gawlita M, Wasilewski J, Lekston A, Kurek A, Et al., The relationships between polymorphisms in genes encoding the growth factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the restenosis process in patients with stable coronary artery disease treated with bare metal stent, PLoS One, 11, (2016); Brockmoller J, Tzvetkov M., Pharmacogenetics: Data, concepts and tools to improve drug discovery and drug treatment, Eur J Clin Pharmaco, 64, pp. 133-157, (2008); Association W M., Declaration of Helsinki. Ethical principles for medical research involving human subjects, Jahrb Für Wiss Und Ethik, 14, pp. 233-238, (2009); Rothman K., Synergy and antagonism in cause-effect relationships, Am J Epidemiol, 99, pp. 385-388, (1974); Attallah N., Yassine L, Fisher K, Yee J., Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention, Clin Nephrol, 64, pp. 412-418, (2005); Kornowski R, Hong M, Tio F, Bramwell O, Wu H, Leon M., In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia, J Am Coll Cardiol, 31, pp. 224-230, (1998); Ekizler F., Impact of Gender on Restenosis Following Coronary Artery Stenting, Am J Cardiol, 121, (2018); Solinas E, Nikolsky E, Lansky A, Kirtane A, Morice M, Popma J, Schofer J, Schampaert E, Pucelikova T, Aoki J, Et al., Gender-specific outcomes after sirolimus-eluting stent implantation, J Am Coll Cardiol, 50, pp. 2111-2116, (2007); Agema W, Jukema J, Zwinderman A, Wall E., A metaanalysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: Evidence for publication bias, Am Heart J, 144, pp. 760-768, (2002); Guneri S, Baris N, Aytekin D, Akdeniz B, Pekel N, Bozdemir V., The relationship between Angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis, Int Heart J, 46, pp. 889-897, (2005); Wang S, Dai Y, Chen L, Dong Z, Chen Y, Li C, Zhong X, Lin W, Zhang J., Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: Evidence from 33 cohort studies, PLoS One, 8, (2013); Meurice T, Bauters C, Hermant X, Codronb V, VanBelle E, Fadden E, Lablanche J, Bertrand M, Amouyel P., Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial, Lancet, 357, pp. 1321-1324, (2001); Danser A, Schalekamp M, Bax W, Brink A, Saxena P, Riegger G, Schunkert H., Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism, Circulation, 92, pp. 1387-1388, (1995); Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F., Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin Iconverting enzyme (ACE) gene controls plasma ACE levels, Am J Hum Genet, 51, pp. 197-205, (1992); Okamura A, Ohishi M, Rakugi H, Katsuya T, Yanagitani Y, Takiuchi S, Taniyama Y, Moriguchi K, Ito H, Higashino Y, Et al., Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty, Angiology, 50, pp. 811-822, (1990); Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, Quyyumi A., Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition, Circulation, 102, pp. 35-41, (2000); Baris N, Ozerkan F, Onder M, Akdeniz B, Guneri S., Relationship between angiotensin converting enzyme gene polymorphism and number of target organ damage in essential hypertension, Arch Turkish Soc Cardiol, 32, pp. 107-114, (2004); Lee J, Wu C, Tsai C, Lin L, Lin J, Chien K, Hwang J, Lin C, Tseng C, Chiang F, Et al., Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: A 12-year follow-up study, Pharmacogenet Genomics, 23, pp. 181-189, (2013); Mizuiri S, Hemmi H, Inoue A, Takano M, Kadomatsu S, Tanimoto H, Tanegashima M, Hayashi I, Fushimi T, Hasegawa A, Et al., Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism, Nephron, 75, pp. 310-314, (1997); Blendea C, Chitu M, Orzan M, Bajka B, Craciun A, Benedek I., The Study of Factors Associated with Severity of In-Stent Restenosis in Patients Treated with PCI for Acute Coronary Syndromes, Acta Medica Marisiensis, 62, pp. 64-67, (2016)","T.A. Abdelaziz; Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; email: oyhaz631@gmail.com","","University of Benin","","","","","","15965996","","","","English","Trop. J. Pharm. Res.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85102876703"
"Cardin S.; Scott-Boyer M.-P.; Praktiknjo S.; Jeidane S.; Picard S.; Reudelhuber T.L.; Deschepper C.F.","Cardin, Sophie (7004156337); Scott-Boyer, Marie-Pier (55551091100); Praktiknjo, Samantha (55937877000); Jeidane, Saloua (56290627700); Picard, Sylvie (7006431455); Reudelhuber, Timothy L. (7006151174); Deschepper, Christian F. (7006549222)","7004156337; 55551091100; 55937877000; 56290627700; 7006431455; 7006151174; 7006549222","Differences in cell-type-specific responses to angiotensin II explain cardiac remodeling differences in C57BL/6 mouse substrains","2014","Hypertension","64","5","","1040","1046","6","24","10.1161/HYPERTENSIONAHA.114.04067","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922393219&doi=10.1161%2fHYPERTENSIONAHA.114.04067&partnerID=40&md5=c83407f363862d43bdd06094b6421d16","Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada; Department of Medicine, Université de Montréal, Montréal, QC, Canada","Cardin S., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada; Scott-Boyer M.-P., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada; Praktiknjo S., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada; Jeidane S., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada; Picard S., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada; Reudelhuber T.L., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada; Deschepper C.F., Institut de Recherches Cliniques de Montréal (IRCM), 110 Ave des Pins Ouest, Montréal, H2W 1R7, QC, Canada, Department of Medicine, Université de Montréal, Montréal, QC, Canada","Despite indications that hearts from the C57BL/6N and C57BL/6J mouse substrains differ in terms of their contractility and their responses to stress-induced overload, no information is available about the underlying molecular and cellular mechanisms. We tested whether subacute (48 hours) and chronic (14 days) administration of angiotensin II (500 ng/kg per day) had different effects on the left ventricles of male C57BL/6J and C57BL/6N mice. Despite higher blood pressure in C57BL/6J mice, chronic angiotensin II induced fibrosis and increased the left ventricular weight/body weight ratio and cardiac expression of markers of left ventricular hypertrophy to a greater extent in C57BL/6N mice. Subacute angiotensin II affected a greater number of cardiac genes in C57BL/6N than in C57BL/6J mice. Some of the most prominent differences were observed for markers of (1) macrophage activation and M2 polarization, including 2 genes (osteopontin and galectin-3) whose inactivation was reported as sufficient to prevent angiotensin II-induced myocardial fibrosis; and (2) fibroblast activation. These differences were confirmed in macrophage- and fibroblast-enriched populations of cells isolated from the hearts of experimental mice. When testing F2 animals, the amount of connective tissue present after chronic angiotensin II administration did not cosegregate with the inactivation mutation of the nicotinamide nucleotide transhydrogenase gene from C57BL/6J mice, thus discounting its possible contribution to differences in cardiac remodeling. However, expression levels of osteopontin and galectin-3 were cosegregated in hearts from angiotensin II-treated F2 animals and may represent endophenotypes that could facilitate the identification of genetic regulators of the cardiac fibrogenic response to angiotensin II. © 2014 American Heart Association, Inc.","Angiotensin II; Endomyocardial fibrosis; Genetic; Macrophages; Polymorphisms; Ventricular remodeling","Angiotensin II; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblasts; Fibrosis; Galectin 3; Heart; Heart Ventricles; Hypertrophy, Left Ventricular; In Vitro Techniques; Macrophages; Male; Mice; Mice, Inbred C57BL; Myocardium; Osteopontin; Ventricular Remodeling; angiotensin II; arginase 1; galectin 3; nicotinamide adenine dinucleotide (phosphate) transhydrogenase; osteopontin; protein; protein col1a1; protein lgals3; protein lysine 6 oxidase; protein myh7; tenascin; tissue inhibitor of metalloproteinase 1; unclassified drug; angiotensin II; galectin 3; osteopontin; animal cell; animal experiment; animal model; Article; body weight; C57BL 6 mouse; cell activation; cell isolation; cell polarity; cells by body anatomy; connective tissue; controlled study; endophenotype; fibroblast; gene inactivation; gene locus; genetic regulation; genotype; heart left ventricle; heart left ventricle hypertrophy; heart left ventricle mass; heart left ventricle remodeling; heart muscle fibrosis; heart ventricle remodeling; heritability; hypertension; long term care; macrophage activation; male; mouse; mouse strain; mutation; nonhuman; priority journal; protein expression; animal; C57BL mouse; chemically induced; comparative study; disease model; dose response; drug effects; fibrosis; genetics; heart; heart muscle; heart ventricle; heart ventricle remodeling; in vitro study; macrophage; metabolism; pathology; physiology","","angiotensin II, 11128-99-7, 68521-88-0; galectin 3, 208128-56-7; nicotinamide adenine dinucleotide (phosphate) transhydrogenase, 9014-18-0, 9072-60-0; osteopontin, 106441-73-0; protein, 67254-75-5; protein lysine 6 oxidase, 99676-44-5; tissue inhibitor of metalloproteinase 1, 140208-24-8; angiotensin II, 11128-99-7; Angiotensin II, ; Galectin 3, ; Osteopontin, ","","","Heart and Stroke Foundation of Canada","","Zurita E., Chagoyen M., Cantero M., Alonso R., Gonzalez-Neira A., Lopez-Jimenez A., Lopez-Moreno J.A., Landel C.P., Benitez J., Pazos F., Montoliu L., Genetic polymorphisms among C57BL/6 mouse inbred strains, Transgenic Res, 20, pp. 481-489, (2011); Waterston R.H., Lindblad-Toh K., Et al., Initial sequencing and comparative analysis of the mouse genome, Nature, 420, pp. 520-562, (2002); Mekada K., Abe K., Murakami A., Nakamura S., Nakata H., Moriwaki K., Obata Y., Yoshiki A., Genetic differences among C57BL/6 substrains, Exp Anim, 58, pp. 141-149, (2009); Taft R.A., Davisson M., Wiles M.V., Know thy mouse, Trends Genet, 22, pp. 649-653, (2006); Vaillant F., Lauzier B., Poirier I., Gelinas R., Rivard M.-E., Frayne I.R., Thorin E., Rosiers C.D., Mouse strain differences in metabolic fluxes and function of ex vivo working hearts, Am J Physiol Heart Circ Physiol, 306, pp. H78-H87, (2014); Garcia-Menendez L., Karamanlidis G., Kolwicz S., Tian R., Substrain specific response to cardiac pressure overload in C57BL/6 mice, Am J Physiol Heart Circ Physiol, 305, pp. H397-H402, (2013); Larkin J.E., Frank B.C., Gaspard R.M., Duka I., Gavras H., Quackenbush J., Cardiac transcriptional response to acute and chronic angiotensin II treatments, Physiol Genomics, 18, pp. 152-166, (2004); Sopel M.J., Rosin N.L., Lee T.D., Legare J.F., Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells, Lab Invest, 91, pp. 565-578, (2011); Lovelock J.D., Baker A.H., Gao F., Dong J.F., Bergeron A.L., McPheat W., Sivasubramanian N., Mann D.L., Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts, Am J Physiol Heart Circ Physiol, 288, pp. H461-H468, (2005); Carey W.A., Taylor G.D., Dean W.B., Bristow J.D., Tenascin-C deficiency attenuates TGF-β-mediated fibrosis following murine lung injury, Am J Physiol Lung Cell Mol Physiol, 299, pp. L785-L793, (2010); Zibadi S., Vazquez R., Moore D., Larson D.F., Watson R.R., Myocardial lysyl oxidase regulation of cardiac remodeling in a murine model of diet-induced metabolic syndrome, Am J Physiol Heart Circ Physiol, 297, pp. H976-H982, (2009); Krause S.W., Rehli M., Kreutz M., Schwarzfischer L., Paulauskis J.D., Andreesen R., Differential screening identifies genetic markers of monocyte to macrophage maturation, J Leukoc Biol, 60, pp. 540-545, (1996); Munder M., Eichmann K., Modolell M., Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: Competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype, J Immunol, 160, pp. 5347-5354, (1998); Novak R., Dabelic S., Dumic J., Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages, Biochim Biophys Acta, 1820, pp. 1383-1390, (2012); Lee M.H., El-Shewy H.M., Luttrell D.K., Luttrell L.M., Role of beta-arrestinmediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription, J Biol Chem, 283, pp. 2088-2097, (2008); Simon M.M., Greenaway S., White J.K., Et al., A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains, Genome Biol, 14, (2013); Collins A.R., Schnee J., Wang W., Kim S., Fishbein M.C., Bruemmer D., Law R.E., Nicholas S., Ross R.S., Hsueh W.A., Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart, J Am Coll Cardiol, 43, pp. 1698-1705, (2004); Matsui Y., Jia N., Okamoto H., Kon S., Onozuka H., Akino M., Liu L., Morimoto J., Rittling S.R., Denhardt D., Kitabatake A., Uede T., Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy, Hypertension, 43, pp. 1195-1201, (2004); Yu L., Ruifrok W.P., Meissner M., Bos E.M., Van Goor H., Sanjabi B., Van Der Harst P., Pitt B., Goldstein I.J., Koerts J.A., Van Veldhuisen D.J., Bank R.A., Van Gilst W.H., Sillje H.H., De Boer R.A., Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis, Circ Heart Fail, 6, pp. 107-117, (2013); Sharma U.C., Pokharel S., Van Brakel T.J., Van Berlo J.H., Cleutjens J.P., Schroen B., Andre S., Crijns H.J., Gabius H.J., Maessen J., Pinto Y.M., Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, 110, pp. 3121-3128, (2004); Psarras S., Mavroidis M., Sanoudou D., Davos C.H., Xanthou G., Varela A.E., Panoutsakopoulou V., Capetanaki Y., Regulation of adverse remodelling by osteopontin in a genetic heart failure model, Eur Heart J, 33, pp. 1954-1963, (2012); Schroen B., Heymans S., Sharma U., Et al., Thrombospondin-2 is essential for myocardial matrix integrity: Increased expression identifies failureprone cardiac hypertrophy, Circ Res, 95, pp. 515-522, (2004); Cholewa B.C., Meister C.J., Mattson D.L., Importance of the renin-angiotensin system in the regulation of arterial blood pressure in conscious mice and rats, Acta Physiol Scand, 183, pp. 309-320, (2005); Polichnowski A.J., Griffin K.A., Long J., Williamson G.A., Bidani A.K., Blood pressure-renal blood flow relationships in conscious angiotensin II- and phenylephrine-infused rats, Am J Physiol Renal Physiol, 305, pp. F1074-F1084, (2013); Mosser D.M., Edwards J.P., Exploring the full spectrum of macrophage activation, Nat Rev Immunol, 8, pp. 958-969, (2008); Gordon S., Alternative activation of macrophages, Nat Rev Immunol, 3, pp. 23-35, (2003); Classen A., Lloberas J., Celada A., Macrophage activation: Classical vs. Alternative, Macrophages and Dendritic Cells, pp. 29-43, (2009); Huang X.R., Chung A.C., Yang F., Yue W., Deng C., Lau C.P., Tse H.F., Lan H.Y., Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling, Hypertension, 55, pp. 1165-1171, (2010); Lin S.L., Castano A.P., Nowlin B.T., Lupher M.L., Duffield J.S., Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations, J Immunol, 183, pp. 6733-6743, (2009); Braga T.T., Correa-Costa M., Guise Y.F., Castoldi A., De Oliveira C.D., Hyane M.I., Cenedeze M.A., Teixeira S.A., Muscara M.N., Perez K.R., Cuccovia I.M., Pacheco-Silva A., Goncalves G.M., Camara N.O., MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages, Mol Med, 18, pp. 1231-1239, (2012); Murray P.J., Wynn T.A., Protective and pathogenic functions of macrophage subsets, Nat Rev Immunol, 11, pp. 723-737, (2011); Yang M., Zheng J., Miao Y., Wang Y., Cui W., Guo J., Qiu S., Han Y., Jia L., Li H., Cheng J., Du J., Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis, Arterioscler Thromb Vasc Biol, 32, pp. 1675-1686, (2012); Li Y., Zhang C., Wu Y., Han Y., Cui W., Jia L., Cai L., Cheng J., Li H., Du J., Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensin II-Induced cardiac fibrosis, Arterioscler Thromb Vasc Biol, 32, pp. 1662-1674, (2012); Ronchi J.A., Figueira T.R., Ravagnani F.G., Oliveira H.C., Vercesi A.E., Castilho R.F., A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities, Free Radic Biol Med, 63, pp. 446-456, (2013); Tsutsui H., Kinugawa S., Matsushima S., Mitochondrial oxidative stress and dysfunction in myocardial remodelling, Cardiovasc Res, 81, pp. 449-456, (2009); Svenson K.L., Gatti D.M., Valdar W., Welsh C.E., Cheng R., Chesler E.J., Palmer A.A., McMillan L., Churchill G.A., High-resolution genetic mapping using the Mouse Diversity outbred population, Genetics, 190, pp. 437-447, (2012); Kumar V., Kim K., Joseph C., Kourrich S., Yoo S.H., Huang H.C., Vitaterna M.H., De Villena F.P., Churchill G., Bonci A., Takahashi J.S., C57BL/6N mutation in cytoplasmic FMRP interacting protein 2 regulates cocaine response, Science, 342, pp. 1508-1512, (2013); Zeisberg M., Kalluri R., Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis, Am J Physiol Cell Physiol, 304, pp. C216-C225, (2013); Wynn T.A., Ramalingam T.R., Mechanisms of fibrosis: Therapeutic translation for fibrotic disease, Nat Med, 18, pp. 1028-1040, (2012)","C.F. Deschepper; Institut de Recherches Cliniques de Montréal (IRCM), Montréal, 110 Ave des Pins Ouest, H2W 1R7, Canada; email: deschec@ircm.qc.ca","","Lippincott Williams and Wilkins","","","","","","0194911X","","HPRTD","25069667","English","Hypertension","Article","Final","","Scopus","2-s2.0-84922393219"
"Felder R.A.; Gildea J.J.; Xu P.; Yue W.; Armando I.; Carey R.M.; Jose P.A.","Felder, Robin A. (7103080074); Gildea, John J. (7003637575); Xu, Peng (56991962400); Yue, Wei (7102549270); Armando, Ines (7005258061); Carey, Robert M. (7202065232); Jose, Pedro A. (55382768900)","7103080074; 7003637575; 56991962400; 7102549270; 7005258061; 7202065232; 55382768900","Inverse Salt Sensitivity of Blood Pressure: Mechanisms and Potential Relevance for Prevention of Cardiovascular Disease","2022","Current Hypertension Reports","24","9","","361","374","13","11","10.1007/s11906-022-01201-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132149477&doi=10.1007%2fs11906-022-01201-9&partnerID=40&md5=aabe2a47426ba6ea43949562539401d0","Department of Pathology, The University of Virginia, Charlottesville, VA, United States; Department of Medicine and Department of Physiology/Pharmacology, Division of Renal Diseases & Hypertension, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States; Department of Medicine, Division of Endocrinology and Metabolism, The University of Virginia, Charlottesville, VA, United States","Felder R.A., Department of Pathology, The University of Virginia, Charlottesville, VA, United States; Gildea J.J., Department of Pathology, The University of Virginia, Charlottesville, VA, United States; Xu P., Department of Pathology, The University of Virginia, Charlottesville, VA, United States; Yue W., Department of Pathology, The University of Virginia, Charlottesville, VA, United States; Armando I., Department of Medicine and Department of Physiology/Pharmacology, Division of Renal Diseases & Hypertension, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States; Carey R.M., Department of Medicine, Division of Endocrinology and Metabolism, The University of Virginia, Charlottesville, VA, United States; Jose P.A., Department of Medicine and Department of Physiology/Pharmacology, Division of Renal Diseases & Hypertension, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States","Purpose of Review: To review the etiology of inverse salt sensitivity of blood pressure (BP). Recent Findings: Both high and low sodium (Na+) intake can be associated with increased BP and cardiovascular morbidity and mortality. However, little is known regarding the mechanisms involved in the increase in BP in response to low Na+ intake, a condition termed inverse salt sensitivity of BP, which affects approximately 15% of the adult population. The renal proximal tubule is important in regulating up to 70% of renal Na+ transport. The renin-angiotensin and renal dopaminergic systems play both synergistic and opposing roles in the regulation of Na+ transport in this nephron segment. Clinical studies have demonstrated that individuals express a “personal salt index” (PSI) that marks whether they are salt-resistant, salt-sensitive, or inverse salt-sensitive. Inverse salt sensitivity results in part from genetic polymorphisms in various Na+ regulatory genes leading to a decrease in natriuretic activity and an increase in renal tubular Na+ reabsorption leading to an increase in BP. Summary: This article reviews the potential mechanisms of a new pathophysiologic entity, inverse salt sensitivity of BP, which affects approximately 15% of the general adult population. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","Angiotensin; Angiotensin receptor; Dopamine; Dopamine receptor; Inverse salt sensitivity; Renin; Salt sensitivity","Adult; Blood Pressure; Cardiovascular Diseases; Diet, Sodium-Restricted; Humans; Hypertension; Sodium; Sodium Chloride; Sodium Chloride, Dietary; angiotensin receptor; dopamine 2 receptor; dopamine receptor; renin; sodium ion; sodium; sodium chloride; blood pressure; cardiovascular disease; cardiovascular mortality; catecholaminergic system; dopaminergic system; elevated blood pressure; epigenetics; gene control; genetic association; heterozygote; homozygote; human; hypertension; kidney proximal tubule; morbidity; nonhuman; protein expression; Review; salt tolerance; single nucleotide polymorphism; sodium absorption; sodium intake; sodium transport; adult; adverse event; blood pressure; complication; hypertension; physiology; salt intake; sodium restriction","","renin, 61506-93-2, 9015-94-5; sodium ion, 17341-25-2; sodium, 7440-23-5; sodium chloride, 7647-14-5, 23724-87-0, 49658-21-1; Sodium, ; Sodium Chloride, ; Sodium Chloride, Dietary, ","","","Department of Medicine University of Maryland School of Medicine; Division of Endocrinology, Diabetes and Hypertension; Division of Endocrinology, Diabetes and Nutrition; National Heart, Lung, and Blood Institute, NHLBI, (P01HL074940, R01 DK039308, R01 DK119652, R01 HL128189); National Heart, Lung, and Blood Institute, NHLBI; Harvard Medical School, HMS","We thank Drs. Brackston Mitchell and Huichun Xu at the Division of Endocrinology, Diabetes and Nutrition, Department of Medicine University of Maryland School of Medicine, and Dr. Gordon Williams at Brigham and Woman’s Hospital, Harvard Medical School, Division of Endocrinology, Diabetes and Hypertension, for sharing their salt sensitivity data that appear in Fig. 2. This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) P01 HL074940; the Principal Investigator is Dr. Felder. Dr. Carey is Principal Investigator of R01 HL128189 and Project Director for Program Project Grant, P01 HL074940. Dr. Jose is Principal Investigator of R01 DK039308 and R01 DK119652 and Project Director of P01 HL074940.","Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., Et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 138, pp. e484-e594, (2018); He F.J., Tan M., Ma Y., MacGregor G.A., Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review, J Am Coll Cardiol, 75, pp. 632-647, (2020); Cappuccio F.P., Beer M., Strazzullo P., Population dietary salt reduction and the risk of cardiovascular disease, Nutr Metab Cardiovasc Dis, 29, pp. 107-114, (2018); Elfassy T., Chamany S., Bartley K., Yi S.S., Angell S.Y., Lower 24-h urinary sodium excretion is associated with hypertension control: the 2010 Heart Follow-Up Study, J Hum Hypertens, 34, pp. 624-632, (2020); Carey R.M., Schoeffel C.D., Gildea J.J., Jones J.E., McGrath H.E., Gordon L.N., Park M.J., Sobota R.S., Underwood P.C., Williams J., Et al., Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter, Hypertension, 60, pp. 1359-1366, (2012); Elijovich F., Weinberger M.H., Anderson C.A., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L., Et al., Salt sensitivity of blood pressure: a scientific statement from the American Heart Association, Hypertension, 68, pp. e7-e46, (2016); Rucker A.J., Rudemiller N.P., Crowley S.D., Salt, hypertension, and immunity, Annu Rev Physiol, 80, pp. 283-307, (2018); Lastra G., Dhuper S., Johnson M.S., Sowers J.R., Salt, aldosterone, and insulin resistance: impact on the cardiovascular system, Nat Rev Cardiol, 7, pp. 577-584, (2010); Kurtz T.W., DiCarlo S.E., Pravenec M., Morris R.C., The American Heart Association Scientific Statement on salt sensitivity of blood pressure: prompting consideration of alternative conceptual frameworks for the pathogenesis of salt sensitivity?, J Hypertens, 35, pp. 2214-2225, (2017); Skrabal F., Herholz H., Neumayr M., Hamberger L., Ledochowski M., Sporer H., Hortnagl H., Schwarz S., Schonitzer D., Salt sensitivity in humans is linked to enhanced sympathetic responsiveness and to enhanced proximal tubular reabsorption, Hypertension, 6, pp. 152-158, (1984); Majid D.S., Kopkan L., Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension, Clin Exp Pharmacol Physiol, 34, pp. 946-952, (2007); Sigmund C.D., Carey R.M., Appel L.J., Arnett D.K., Bosworth H.B., Cushman W.C., Galis Z.S., Green Parker M., Hall J.E., Harrison D.G., Et al., Report of the National Heart, Lung, and Blood Institute Working Group on hypertension: barriers to translation, Hypertension, 75, pp. 902-917, (2020); Raizada M.K., Joe B., Bryan N.S., Chang E.B., Dewhirst F.E., Borisy G.G., Galis Z.S., Henderson W., Jose P.A., Ketchum C.J., Et al., Report of the National Heart, Lung, and Blood Institute Working Group on the role of microbiota in blood pressure regulation: Current status and future directions, Hypertension.; Weinberger M.H., Fineberg N.S., Fineberg S.E., Weinberger M., Salt sensitivity, pulse pressure, and death in normal and hypertensive humans, Hypertension, 37, pp. 429-432, (2001); Alderman M.H., Cohen H.W., Dietary sodium intake and cardiovascular mortality: controversy resolved?, Curr Hypertens Rep, 14, pp. 193-201, (2012); O'Donnell M., Mente A., Alderman M.H., Brady A.J.B., Diaz R., Gupta R., Lopez-Jaramillo P., Luft F.C., Luscher T.F., Mancia G., Et al., Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake, Eur Heart J, 41, pp. 3363-3373, (2020); Asayama K., Stolarz-Skrzypek K., Persu A., Staessen J.A., Systematic review of health outcomes in relation to salt intake highlights the widening divide between guidelines and the evidence, Am J Hypertens, 27, pp. 1138-1142, (2014); O'Donnell M., Mente A., Rangarajan S., McQueen M.J., Wang X., Liu L., Yan H., Lee S.F., Mony P., Devanath A., Et al., Urinary sodium and potassium excretion, mortality, and cardiovascular events, N Engl J Med, 371, pp. 612-623, (2014); Strom B.L., Anderson C.A., Ix J.H., Sodium reduction in populations: insights from the Institute of Medicine committee, JAMA, 310, pp. 31-32, (2013); Morimoto A., Uzu T., Fujii T., Nishimura M., Kuroda S., Nakamura S., Inenaga T., Kimura G., Sodium sensitivity and cardiovascular events in patients with essential hypertension, Lancet, 350, pp. 1734-1737, (1997); Gildea J.J., Lahiff D.T., Van Sciver R.E., Weiss R.S., Shah N., McGrath H.E., Schoeffel C.D., Jose P.A., Carey R.M., Felder R.A., A linear relationship between the ex-vivo sodium mediated expression of two sodium regulatory pathways as a surrogate marker of salt sensitivity of blood pressure in exfoliated human renal proximal tubule cells: the virtual renal biopsy, Clin Chim Acta, 421, pp. 236-242, (2013); Overlack A., Ruppert M., Kolloch R., Gobel B., Kraft K., Diehl J., Schmitt W., Stumpe K.O., Divergent hemodynamic and hormonal responses to varying salt intake in normotensive subjects, Hypertension, 22, pp. 331-338, (1993); Montasser M.E., Douglas J.A., Roy-Gagnon M.H., Van Hout C.V., Weir M.R., Vogel R., Parsa A., Steinle N.I., Snitker S., Brereton N.H., Chang Y.P., Shuldiner A.R., Mitchell B.D., Determinants of blood pressure response to low-salt intake in a healthy adult population, Journal of Clinical Hypertension (Greenwich), 13, pp. 795-800, (2011); Overlack A., Ruppert M., Kolloch R., Kraft K., Stumpe K.O., Age is a major determinant of the divergent blood pressure responses to varying salt intake in essential hypertension, Am J Hypertens, 8, 8, pp. 829-836, (1995); Mente A., O'Donnell M.J., Rangarajan S., McQueen M.J., Poirier P., Wielgosz A., Morrison H., Li W., Wang X., Di C., Et al., Association of urinary sodium and potassium excretion with blood pressure, N Engl J Med, 371, pp. 601-611, (2014); Miller J.Z., Weinberger M.H., Daugherty S.A., Fineberg N.S., Christian J.C., Grim C.E., Heterogeneity of blood pressure response to dietary sodium restriction in normotensive adults, J Chronic Dis, 40, pp. 245-250, (1987); Carey R.M., Muntner P., Bosworth H.B., Whelton P.K., Prevention and control of hypertension: JACC health promotion series, J Am Coll Cardiol, 72, pp. 1278-1293, (2018); Stolarz-Skrzypek K., Kuznetsova T., Thijs L., Tikhonoff V., Seidlerova J., Richart T., Jin Y., Olszanecka A., Malyutina S., Casiglia E., Et al., Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion, JAMA, 305, pp. 1777-1785, (2011); Graudal N., Jurgens G., Conflicting evidence on health effects associated with salt reduction calls for a redesign of the salt dietary guidelines, Prog Cardiovasc Dis, 61, pp. 20-26, (2018); Alderman M.H., Blumenfeld J.D., Hypertension: evolving from standardized to individualized care, J Hypertens, 38, pp. 1251-1254, (2020); Thomas M.C., Moran J., Forsblom C., Harjutsalo V., Thorn L., Ahola A., Waden J., Tolonen N., Saraheimo M., Gordin D., Et al., The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes, Diabetes Care, 34, pp. 861-866, (2011); Longworth D.L., Drayer J.I., Weber M.A., Laragh J.H., Divergent blood pressure responses during short-term sodium restriction in hypertension, Clin Pharmacol Ther, 27, pp. 544-546, (1980); Castiglioni P., Parati G., Lazzeroni D., Bini M., Faini A., Brambilla L., Brambilla V., Coruzzi P., Hemodynamic and autonomic response to different salt intakes in normotensive individuals, J Am Heart Assoc, 5, (2016); Felder R.A., White M.J., Williams S.M., Jose P.A., Diagnostic tools for hypertension and salt sensitivity testing, Curr Opin Nephrol Hypertens, 22, pp. 65-76, (2013); Willett W.C., McCullough M.L., Dietary pattern analysis for the evaluation of dietary guidelines, Asia Pac J Clin Nutr, 17, pp. 75-78, (2008); Mitchell B.D., McArdle P.F., Shen H., Rampersaud E., Pollin T.I., Bielak L.F., Jaquish C., Douglas J.A., Roy-Gagnon M.H., Sack P., Et al., The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study, Am Heart J, 155, pp. 823-828, (2008); Welling P.A., Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function, Curr Opin Nephrol Hypertens, 23, 1, pp. 1-8, (2014); Ji W., Foo J.N., O'Roak B.J., Zhao H., Larson M.G., Simon D.B., Newton-Cheh C., State M.W., Levy D., Lifton R.P., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat Genet, 40, pp. 592-599, (2008); Gildea J.J., Van Sciver R., McGrath H.E., Weiss R., Shah I., Shan N., Felder R.A., Renal proximal tubule cells isolated from human urine report the degree of salt sensitivity in test subjects, Hypertension, 56, (2010); Gildea J.J., Carlson J.M., Schoeffel C.D., Carey R.M., Felder R.A., Urinary exosome miRNome analysis and its applications to salt sensitivity of blood pressure, Clin Biochem, 46, pp. 1131-1134, (2013); Pisitkun T., Shen R.F., Knepper M.A., Identification and proteomic profiling of exosomes in human urine, Proc Natl Acad Sci U S A, 101, pp. 13368-13373, (2004); Tan P.P.S., Hall D., Chilian W.M., Chia Y.C., Mohd Zain S., Lim H.M., Kumar D.N., Ching S.M., Low T.Y., Md Noh M.F., Et al., Exosomal microRNAs in the development of essential hypertension and its potential as biomarkers, Am J Physiol Heart Circ Physiol, 320, pp. H1486-H1497, (2021); Manosroi W., Williams G.H., Genetics of human primary hypertension: focus on hormonal mechanisms, Endocr Rev, 40, pp. 825-856, (2019); Rayner B., Ramesar R., Steyn K., Levitt N., Lombard C., Charlton K., G-protein-coupled receptor kinase 4 polymorphisms predict blood pressure response to dietary modification in Black patients with mild-to-moderate hypertension, J Hum Hypertens, 26, pp. 334-339, (2012); Jeong S., Kim J.Y., Cho Y., Koh S.B., Kim N., Choi J.R., Genetically, dietary sodium intake is causally associated with salt-sensitive hypertension risk in a community-based cohort study: a Mendelian randomization approach, Curr Hypertens Rep, 22, (2020); Lee M., Kim M.K., Kim S.M., Park H., Park C.G., Park H.K., Gender-based differences on the association between salt-sensitive genes and obesity in Korean children aged between 8 and 9 years, PLoS ONE, 10, (2015); Sanada H., Yatabe J., Midorikawa S., Hashimoto S., Watanabe T., Moore J.H., Ritchie M.D., Williams S.M., Pezzullo J.C., Sasaki M., Et al., Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension, Clin Chem, 52, pp. 352-360, (2006); Bengra C., Mifflin T.E., Khripin Y., Manunta P., Williams S.M., Jose P.A., Felder R.A., Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers, Clin Chem, 48, pp. 2131-2140, (2002); Wang Z., Zeng C., Villar V.A., Chen S.Y., Konkalmatt P., Wang X., Asico L.D., Jones J.E., Yang Y., Sanada H., Felder R.A., Eisner G.M., Weir M.R., Armando I., Jose P.A., Human GRK4γ142v variant promotes angiotensin II type I receptor-mediated hypertension via renal histone deacetylase type 1 inhibition, Hypertension, 67, pp. 325-334, (2016); Sanada H., Yoneda M., Yatabe J., Williams S.M., Bartlett J., White M.J., Gordon L.N., Felder R.A., Eisner G.M., Armando I., Et al., Common variants of the G protein-coupled receptor type 4 are associated with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade, Pharmacogenomics J, 16, pp. 3-9, (2016); Diao Z., Asico L.D., Villar V.A.M., Zheng X., Cuevas S., Armando I., Jose P.A., Wang X., Increased renal oxidative stress in salt-sensitive human GRK4γ486V transgenic mice, Free Radic Biol Med, 106, pp. 80-90, (2017); Armando I., Konkalmatt P., Felder R.A., Jose P.A., The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease, Transl Res, 165, pp. 505-511, (2015); Harris R.C., Zhang M.Z., Dopamine, the kidney, and hypertension, Curr Hypertens Rep, 14, pp. 138-143, (2012); Felder R.A., Jose P.A., Xu P., Gildea J.J., The renal sodium bicarbonate cotransporter NBCe2: is it a major contributor to sodium and pH homeostasis?, Curr Hypertens Rep, 18, (2016); Padia S.H., Kemp B.A., Howell N.L., Fournie-Zaluski M.C., Roques B.P., Carey R.M., Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats, Hypertension, 51, pp. 460-465, (2008); Rohnert P., Schmidt W., Emmerlich P., Goihl A., Wrenger S., Bank U., Nordhoff K., Tager M., Ansorge S., Reinhold D., Et al., Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia, J Neuroinflammation, 9, (2012); Kotlo K., Shukla S., Tawar U., Skidgel R.A., Danziger R.S., Aminopeptidase N reduces basolateral Na+ -K+ -ATPase in proximal tubule cells, Am J Physiol Renal Physiol, 293, pp. F1047-F1053, (2007); Padia S.H., Howell N.L., Kemp B.A., Fournie-Zaluski M.C., Roques B.P., Carey R.M., Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats, Hypertension, 55, pp. 474-480, (2010); Hussain T., Abdul-Wahab R., Kotak D.K., Lokhandwala M.F., Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules, Hypertension, 32, pp. 1054-1059, (1998); Sarkar C., Ganju R.K., Pompili V.J., Chakroborty D., Enhanced peripheral dopamine impairs post-ischemic healing by suppressing angiotensin receptor type 1 expression in endothelial cells and inhibiting angiogenesis, Angiogenesis, 20, pp. 97-107, (2017); Garrido-Gil P., Dominguez-Meijide A., Moratalla R., Guerra M.J., Labandeira-Garcia J.L., Aging-related dysregulation in enteric dopamine and angiotensin system interactions: implications for gastrointestinal dysfunction in the elderly, Oncotarget, 9, pp. 10834-10846, (2018); Gao D.Q., Canessa L.M., Mouradian M.M., Jose P.A., Expression of the D2 subfamily of dopamine receptor genes in kidney, Am J Physiol, 266, pp. F646-F650, (1994); Choi M.R., Kouyoumdzian N.M., Rukavina Mikusic N.L., Kravetz M.C., Roson M.I., Rodriguez Fermepin M., Fernandez B.E., Renal dopaminergic system: pathophysiological implications and clinical perspectives, World J Nephrol, 4, pp. 196-212, (2015); Feng Y., Lu Y., Immunomodulatory effects of dopamine in inflammatory diseases, Front Immunol, 12, (2021); Yang Y., Zhang Y., Cuevas S., Villar V.A., Escano C., D Asico L., Yu P., Grandy D.K., Felder R.A., Armando I., Et al., Paraoxonase 2 decreases renal reactive oxygen species production, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of NADPH oxidase, Free Radic Biol Med, 53, pp. 437-446, (2012); Yang Y., Cuevas S., Yang S., Villar V.A., Escano C., Asico L., Yu P., Jiang X., Weinman E.J., Armando I., Et al., Sestrin2 decreases renal oxidative stress, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of reactive oxygen species production, Hypertension, 64, pp. 825-832, (2014); Jiang X., Konkalmatt P., Yang Y., Gildea J., Jones J.E., Cuevas S., Felder R.A., Jose P.A., Armando I., Single-nucleotide polymorphisms of the dopamine D2 receptor increase inflammation and fibrosis in human renal proximal tubule cells, Hypertension, 63, pp. e74-e80, (2014); Zhang Y., Cuevas S., Asico L.D., Escano C., Yang Y., Pascua A.M., Wang X., Jones J.E., Grandy D., Eisner G., Et al., Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure, PLoS ONE, 7, (2012); Konkalmatt P.R., Asico L.D., Zhang Y., Yang Y., Drachenberg C., Zheng X., Han F., Jose P.A., Armando I., Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure, JCI Insight, 1, (2016); Gildea J., Daley M., Xu P., Shiermeyer K., Yue W., Carey R., Jose P., Felder R., (2020); Cao G., Della Penna S.L., Kouyoumdzian N.M., Choi M.R., Gorzalczany S., Fernandez B.E., Toblli J.E., Roson M.I., Immunohistochemical expression of intrarenal renin angiotensin system components in response to tempol in rats fed a high salt diet, World J Nephrol, 6, pp. 29-40, (2017); Samuel P., Ali Q., Sabuhi R., Wu Y., Hussain T., High Na intake increases renal angiotensin II levels and reduces expression of the ACE2-AT(2)R-MasR axis in obese Zucker rats, Am J Physiol Renal Physiol, 303, pp. F412-F419, (2012); Gonzalez M., Lobos L., Castillo F., Galleguillos L., Lopez N.C., Michea L., High-salt diet inhibits expression of angiotensin type 2 receptor in resistance arteries, Hypertension, 45, pp. 853-859, (2005); Dopona E.P.B., Rocha V.F., Furukawa L.N.S., Oliveira I.B., Heimann J.C., Myocardial hypertrophy induced by high salt consumption is prevented by angiotensin II AT2 receptor agonist, Nutr Metab Cardiovasc Dis, 29, pp. 301-305, (2019); Gildea J.J., Wang X., Shah N., Tran H., Spinosa M., Van Sciver R., Sasaki M., Yatabe J., Carey R.M., Jose P.A., Et al., Dopamine and angiotensin type 2 receptors cooperatively inhibit sodium transport in human renal proximal tubule cells, Hypertension, 60, pp. 396-403, (2012); Yang S., Han Y., Zheng S., Kou X., Asico L.D., Huang H., Gao Z., Jose P.A., Zeng C., Enhanced natriuresis and diuresis in Wistar rats caused by the costimulation of renal dopamine D3 and angiotensin II type 2 receptors, Am J Hypertens, 28, pp. 1267-1276, (2015); Escano C.S., Armando I., Wang X., Asico L.D., Pascua A., Yang Y., Wang Z., Lau Y.S., Jose P.A., Renal dopaminergic defect in C57Bl/6J mice, Am J Physiol Regul Integr Comp Physiol, 297, pp. R1660-R1669, (2009); Jiang X., Chen W., Liu X., Wang Z., Liu Y., Felder R.A., Gildea J.J., Jose P.A., Qin C., Yang Z., The synergistic roles of cholecystokinin B and dopamine D5 receptors on the regulation of renal sodium excretion, PLoS ONE, 11, (2016); Jiang X., Zhang Y., Yang Y., Yang J., Asico L.D., Chen W., Felder R.A., Armando I., Jose P.A., Yang Z., Gastrin stimulates renal dopamine production by increasing the renal tubular uptake of l-DOPA, Am J Physiol Endocrinol Metab, 312, pp. E1-E10, (2017); Svitok P., Molcan L., Vesela A., Kruzliak P., Moravcik R., Zeman M., Increased salt intake during early ontogenesis lead to development of arterial hypertension in salt-resistant Wistar rats, Clin Exp Hypertens, 37, pp. 142-147, (2015); Walsh K.R., Kuwabara J.T., Shim J.W., Wainford R.D., Norepinephrine-evoked salt-sensitive hypertension requires impaired renal sodium chloride cotransporter activity in Sprague-Dawley rats, Am J Physiol Regul Integr Comp Physiol, 310, pp. R115-R124, (2016); Sharma A.M., Schorr U., Oelkers W., Distler A., Effects of sodium salts on plasma renin activity and norepinephrine response to orthostasis in salt-sensitive normotensive subjects, Am J Hypertens, 6, pp. 780-785, (1993); Wainford R.D., Carmichael C.Y., Pascale C.L., Kuwabara J.T., Gαi2-protein-mediated signal transduction: central nervous system molecular mechanism countering the development of sodium-dependent hypertension, Hypertension, 65, pp. 178-186, (2015); Stein C.M., Nelson R., Brown M., He H., Wood M., Wood A.J., Dietary sodium intake modulates systemic but not forearm norepinephrine release, Clin Pharmacol Ther, 58, pp. 425-433, (1995); Stupin A., Drenjancevic I., Susnjara P., Debeljak Z., Kolobaric N., Jukic I., Mihaljevic Z., Martinovic G., Selthofer-Relatic K., Is there association between altered adrenergic system activity and microvascular endothelial dysfunction induced by a 7-day high salt intake in young healthy individuals, Nutrients, 13, (2021); Friberg P., Meredith I., Jennings G., Lambert G., Fazio V., Esler M., Evidence for increased renal norepinephrine overflow during sodium restriction in humans, Hypertension, 16, pp. 121-130, (1990); Graudal N.A., Hubeck-Graudal T., Jurgens G., Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride, Cochrane Database Syst Rev, 4, (2017); Yang L., Sandberg M., Can A, Pihakashi-Maunsback K, McDonough A. Effects of dietary salt on renal Na+ transporters’ subcellular distribution, abundance, and phosphorylation status, Am J Physiol Renal Physiol, 295, pp. F1003-F1016, (2008); Natarajan A.R., Eisner G.M., Armando I., Browning S., Pezzullo J.C., Rhee L., Dajani M., Carey R.M., Jose P.A., The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans, J Am Soc Nephrol, 27, pp. 265-279, (2016); Masilamani S., Wang X., Kim G.H., Brooks H., Nielsen J., Nielsen S., Nakamura K., Stokes J.B., Knepper M.A., Time course of renal Na-K-ATPase, NHE3, NKCC2, NCC, and ENaC abundance changes with dietary NaCl restriction, Am J Physiol Renal Physiol, 283, pp. F648-F657, (2002); Frindt G., Palmer L.G., Surface expression of sodium channels and transporters in rat kidney: effects of dietary sodium, Am J Physiol Renal Physiol, 297, pp. F1249-F1255, (2009); Udwan K., Abed A., Roth I., Dizin E., Maillard M., Bettoni C., Loffing J., Wagner C.A., Edwards A., Feraille E., Dietary sodium induces a redistribution of the tubular metabolic workload, J Physiol, 595, pp. 6905-6922, (2017); Fenton R.A., Poulsen S.B., de la Mora C.S., Soleimani M., Dominguez Rieg J.A., Rieg T., Renal tubular NHE3 is required in the maintenance of water and sodium chloride homeostasis, Kidney Int, 92, pp. 397-414, (2017); Lahjouji K., Aouameur R., Bissonnette P., Coady M.J., Bichet D.G., Lapointe J.Y., Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney, Biochim Biophys Acta, 1768, pp. 1154-1159, (2007); Groenen P.M., Klootwijk R., Schijvenaars M.M., Straatman H., Mariman E.C., Franke B., Steegers-Theunissen R.P., Spina bifida and genetic factors related to myo-inositol, glucose, and zinc, Mol Genet Metab, 82, pp. 154-161, (2004); Packer M., Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure, Circulation, 136, pp. 1548-1559, (2017); Yang L.E., Leong P.K., Ye S., Campese V.M., McDonough A.A., Responses of proximal tubule sodium transporters to acute injury-induced hypertension, Am J Physiol Renal Physiol, 284, pp. F313-F322, (2003); Crajoinas R.O., Polidoro J.Z., Carneiro de Morais C.P., Castelo-Branco R.C., Girardi A.C., Angiotensin II counteracts the effects of cAMP/PKA on NHE3 activity and phosphorylation in proximal tubule cells, Am J Physiol Cell Physiol, 311, pp. C768-C776, (2016); Titze J., Rakova N., Kopp C., Dahlmann A., Jantsch J., Luft F.C., Balancing wobbles in the body sodium, Nephrol Dial Transplant, 31, 7, pp. 1078-1081, (2016); Kirabo A., A new paradigm of sodium regulation in inflammation and hypertension, Am J Physiol Regul Integr Comp Physiol, 313, 6, pp. R706-R710, (2017); Viknesh Selvarajah V., Maki-Petaja K., Pedro L., Bruggraber S., Keith Burling K., Goodhart A., Brown M., McEniery C., Wilkinson I., Novel mechanism for buffering dietary salt in humans: Efects of salt loading on skin sodium, vascular endothelial growth factor C, and blood pressure, . Hypertension, 70, 5, pp. 930-937, (2017); Wang J., Deng Y., Zou X., Luo H., Jose P.A., Fu C., Yang J., Zeng C., Long-term low salt diet increases blood pressure by activation of the renin-angiotensin and sympathetic nervous systems, Clin Exp Hypertens, 41, pp. 739-746, (2019); Webb D.J., Clark S.A., Brown W.B., Fraser R., Lever A.F., Murray G.D., Robertson J.I., Dietary sodium deprivation raises blood pressure in the rat but does not produce irreversible hyperaldosteronism, J Hypertens, 5, pp. 525-531, (1987); Ott C.E., Welch W.J., Lorenz J.N., Whitescarver S.A., Kotchen T.A., Effect of salt deprivation on blood pressure in rats, Am J Physiol, 256, pp. H1426-H1431, (1989); Drueke T.B., Muntzel M., Heterogeneity of blood pressure responses to salt restriction and salt appetite in rats, Klin Wochenschr, 69, pp. 73-78, (1991); Vari R.C., Freeman R.H., Davis J.O., Sweet W.D., Role of renal nerves in rats with low-sodium, one-kidney hypertension, Am J Physiol, 250, pp. H189-H194, (1986); Rakova N., Juttner K., Dahlmann A., Schroder A., Linz P., Kopp C., Rauh M., Goller U., Beck L., Agureev A., Et al., Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance, Cell Metab, 17, pp. 125-131, (2013); Huang L., Trieu K., Yoshimura S., Neal B., Woodward M., Campbell N.R.C., Li Q., Lackland D.T., Leung A.A., Anderson C.A.M., Et al., Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials, BMJ, 368, (2020); Galan-Rodriguez B., Martin E., Brouillet E., Deglon N., Betuing S., Caboche J., Coupling of D<sub>2</sub>R Short but not D2R long receptor isoform to the Rho/ROCK signaling pathway renders striatal neurons vulnerable to mutant huntingtin, Eur J Neurosci, 45, pp. 198-206, (2017); Glier M.B., Green T.J., Devlin A.M., Methyl nutrients, DNA methylation, and cardiovascular disease, Mol Nutr Food Res, 58, pp. 172-182, (2014); Randunu R.S., Bertolo R.F., The effects of maternal and postnatal dietary methyl nutrients on epigenetic changes that lead to non-communicable diseases in adulthood, Int J Mol Sci, 21, (2020); Wang J., Yin N., Deng Y., Wei Y., Huang Y., Pu X., Li L., Zheng Y., Guo J., Yu J., Et al., Ascorbic acid protects against hypertension through downregulation of ACE1 gene expression mediated by histone deacetylation in prenatal inflammation-induced offspring, Sci Rep, 6, (2016); Lamothe J., Khurana S., Tharmalingam S., Williamson C., Byrne C.J., Lees S.J., Khaper N., Kumar A., Tai T.C., Oxidative stress mediates the fetal programming of hypertension by glucocorticoids, Antioxidants (Basel), 10, (2021); Feng W., Dell'Italia L.J., Sanders P.W., Novel paradigms of salt and hypertension, J Am Soc Nephrol, 28, pp. 1362-1369, (2017); Shabaka A., Cases-Corona C., Fernandez-Juarez G., Therapeutic insights in chronic kidney disease progression, Front Med (Lausanne), 8, (2021); Kawarazaki W., Fujita T., Kidney and epigenetic mechanisms of salt-sensitive hypertension, Nat Rev Nephrol, 17, pp. 350-363, (2021); Cuevas S., Yang Y., Konkalmatt P., Asico L.D., Feranil J., Jones J., Villar V.A., Armando I., Jose P.A., Role of nuclear factor erythroid 2-related factor 2 in the oxidative stress-dependent hypertension associated with the depletion of DJ-1, Hypertension, 65, pp. 1251-1257, (2015); Qaddumi W.N., Jose P.A., The role of the renal dopaminergic system and oxidative stress in the pathogenesis of hypertension, Biomedicines, 9, (2021); Armando I., Asico L.D., Wang X., Jones J.E., Serrao M.P., Cuevas S., Grandy D.K., Soares-da-Silva P., Jose P.A., Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice, Hypertens Res, 41, pp. 489-498, (2018); Armando I., Wang X., Villar V.A., Jones J.E., Asico L.D., Escano C., Jose P.A., Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice, Hypertension, 49, pp. 672-678, (2007); Cuevas S., Villar V.A.M., Jose P.A., Genetic polymorphisms associated with reactive oxygen species and blood pressure regulation, Pharmacogenomics J, 19, pp. 315-336, (2019); Banday A.A., Lokhandwala M.F., Transcriptional regulation of renal dopamine D1 receptor function during oxidative stress, Hypertension, 65, pp. 1064-1072, (2015); Yang S., Yang Y., Yu P., Yang J., Jiang X., Villar V.A., Sibley D.R., Jose P.A., Zeng C., Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells, Free Radic Res, 49, pp. 397-410, (2015); Xia X.G., Schmidt N., Teismann P., Ferger B., Schulz J.B., Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation, J Neurochem, 79, pp. 63-70, (2001); Gero D., Modis K., Nagy N., Szoleczky P., Toth Z.D., Dorman G., Szabo C., Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay, Int J Mol Med, 20, pp. 749-761, (2007); Gildea J.J., Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance, Curr Opin Nephrol Hypertens, 18, pp. 28-32, (2009); Bek M.J., Wang X., Asico L.D., Jones J.E., Zheng S., Li X., Eisner G.M., Grandy D.K., Carey R.M., Soares-da-Silva P., Et al., Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice, Hypertension, 47, pp. 288-295, (2006); Li H., Armando I., Yu P., Escano C., Mueller S.C., Asico L., Pascua A., Lu Q., Wang X., Villar V.A., Et al., Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells, J Clin Invest, 118, pp. 2180-2189, (2008); Gildea J.J., Wang X., Jose P.A., Felder R.A., Differential D1 and D5 receptor regulation and degradation of the angiotensin type 1 receptor, Hypertension, 51, pp. 360-366, (2008); Khella H.W., Bakhet M., Lichner Z., Romaschin A.D., Jewett M.A., Yousef G.M., MicroRNAs in Kidney Disease: an emerging understanding, Am J Kidney Dis, 61, pp. 798-808, (2013); Gildea J., Xu P., Schiermeyer K., Yue W., Carey R., Jose P., Felder R., The etiology of inverse salt sensitivity of blood pressure: Mirna-485-5p binds to the dopamine type 2 receptor (D<sub>2</sub>R) SNP Rs6276 and decreases D2R expression, Hypertension, 76, (2020); Wu M., Liang G., Duan H., Yang X., Qin G., Sang N., Synergistic effects of sulfur dioxide and polycyclic aromatic hydrocarbons on pulmonary pro-fibrosis via mir-30c-1-3p/transforming growth factor β type II receptor axis, Chemosphere, 219, pp. 268-276, (2019); Zhang Y., Jiang X., Qin C., Cuevas S., Jose P.A., Armando I., Dopamine D2 receptors’ effects on renal inflammation are mediated by regulation of PP2A function, Am J Physiol Renal Physiol, 310, pp. F128-F134, (2016); Rukavina Mikusic N.L., Silva M.G., Mazzitelli L.R., Santos R.A.S., Gomez K.A., Grecco H.E., Gironacci M.M., Interaction between the angiotensin-(1–7) Mas receptor and the dopamine D2 receptor: implications in inflammation, Hypertension, 77, pp. 1659-1669, (2021); Han X., Li B., Ye X., Mulatibieke T., Wu J., Dai J., Wu D., Ni J., Zhang R., Xue J., Wan R., Wang X., Hu G., Dopamine D 2 receptor signalling controls inflammation in acute pancreatitis via a PP2A-dependent Akt/NF-κB signalling pathway, Br J Pharmacol, 174, pp. 4751-4770, (2017); Wang X., Li F., Jose P.A., Ecelbarger C.M., Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II, Am J Physiol Renal Physiol, 299, 5, pp. F1164-F1170, (2010)","R.A. Felder; Department of Pathology, The University of Virginia, Charlottesville, United States; email: robin@virginia.edu","","Springer","","","","","","15226417","","CHRUC","35708819","English","Curr. Hypertens. Rep.","Review","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85132149477"
"Gong H.T.; Ma X.L.; Chen B.X.; Xu X.Y.; Li Q.; Guo C.X.; Du F.H.","Gong, H.T. (56044607200); Ma, X.L. (59066306000); Chen, B.X. (14023922400); Xu, X.Y. (57196742888); Li, Q. (55772633400); Guo, C.X. (57214625769); Du, F.H. (56217774600)","56044607200; 59066306000; 14023922400; 57196742888; 55772633400; 57214625769; 56217774600","Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese","2013","Genetics and Molecular Research","12","2","","2068","2075","7","4","10.4238/2013.June.21.2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879306717&doi=10.4238%2f2013.June.21.2&partnerID=40&md5=39425d24aced4d661d418885565972ed","Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; Department of Cardiology, Beijing Jian Gong Hospital, Beijing, China","Gong H.T., Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; Ma X.L., Department of Cardiology, Beijing Jian Gong Hospital, Beijing, China; Chen B.X., Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; Xu X.Y., Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; Li Q., Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; Guo C.X., Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; Du F.H., Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China","The renin-angiotensin-aldosterone system plays a key role in regulating blood pressure by maintaining vascular tone and the water/sodium balance. Many antihypertensive drugs target the renin-angiotensin-aldosterone system, but the effect differs considerably among hypertensive patients. We investigated whether genetic variants of the angiotensin II type 1 receptor are associated with blood pressure response to angiotensin II receptor blockers in hypertensive Chinese patients. After a 2-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day telmisartan and then were followed up for 8 weeks. The 1166A/C, 573T/C, -810A/T, and -521C/T polymorphisms of the AT1R gene were determined through PCR and RFLP analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after 8 weeks of treatment. Patients with the AT1R -521CC genotype had a significant reduction in diastolic blood pressure compared to those carrying the T allele. No significant reduction in blood pressure was found in individuals with the 1166A/C, 573T/C, or -810A/T polymorphisms of the AT1R gene. We conclude that only the AT1R -521CC genotype is associated with a significant decrease in blood pressure in response to telmisartan treatment in Chinese hypertensive patients. © FUNPEC-RP.","Angiotensin II type 1 receptor; Angiotensin receptor blocker; Essential hypertension; Single nucleotide polymorphism","Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Asian Continental Ancestry Group; Benzimidazoles; Benzoates; Blood Pressure; Drug Administration Schedule; Female; Genotype; Humans; Hypertension; Male; Middle Aged; Polymorphism, Genetic; Receptor, Angiotensin, Type 1; Single-Blind Method; Young Adult; angiotensin 1 receptor; antihypertensive agent; telmisartan; adult; aged; angiotensin II type 1 receptor gene; article; blood pressure measurement; Chinese; controlled study; drug response; female; follow up; gene; gene frequency; gene function; gene identification; gene location; genetic polymorphism; genetic variability; genotype; human; hypertension; major clinical study; male; outcome assessment; patient assessment; polymerase chain reaction; prediction; promoter region; restriction fragment length polymorphism; sensitivity analysis","","telmisartan, 144701-48-4; Angiotensin II, 11128-99-7; Angiotensin Receptor Antagonists, ; Antihypertensive Agents, ; Benzimidazoles, ; Benzoates, ; Receptor, Angiotensin, Type 1, ; telmisartan, U5SYW473RQ","","","","","Benetos A., Gautier S., Ricard S., Topouchian J., Et al., Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients, Circulation, 94, pp. 698-703, (1996); Bis J.C., Smith N.L., Psaty B.M., Heckbert S.R., Et al., Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients, Am. J. Hypertens., 16, pp. 1011-1017, (2003); Bonnardeaux A., Davies E., Jeunemaitre X., Fery I., Et al., Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, pp. 63-69, (1994); Chapman C.M., Palmer L.J., McQuillan B.M., Hung J., Et al., Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population, Atherosclerosis, 159, pp. 209-217, (2001); Chaves F.J., Pascual J.M., Rovira E., Armengod M.E., Et al., Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension, Am. J. Hypertens., 14, pp. 364-370, (2001); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report, JAMA, 289, pp. 2560-2572, (2003); Doria A., Onuma T., Warram J.H., Krolewski A.S., Synergistic effect of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM, Diabetologia, 40, pp. 1293-1299, (1997); Erdmann J., Riedel K., Rohde K., Folgmann I., Et al., Characterization of polymorphisms in the promoter of the human angiotensin II subtype 1 (AT1) receptor gene, Ann. Hum. Genet., 63, pp. 369-374, (1999); Filigheddu F., Reid J.E., Troffa C., Pinna Parpaglia P., Et al., Genetic polymorphisms of the beta-adrenergic system: Association with essential hypertension and response to beta-blockade, Pharmacogenomics J., 4, pp. 154-160, (2004); Guo D.F., Furuta H., Mizukoshi M., Inagami T., The genomic organization of human angiotensin II type 1 receptor, Biochem. Biophys. Res. Commun., 200, pp. 313-319, (1994); Jin W., Liu Y., Sheng H.H., Jin L., Et al., Single nucleotide polymorphisms in promoter of angiotensin II type 1 receptor gene associated with essential hypertension and coronary heart disease in Chinese population, Acta Pharmacol. Sin, 24, pp. 1083-1088, (2003); Kikuya M., Sugimoto K., Katsuya T., Suzuki M., Et al., A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: The Ohasama Study, Hypertens. Res., 26, pp. 141-145, (2003); Kurland L., Melhus H., Karlsson J., Kahan T., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J. Hypertens., 19, pp. 1783-1787, (2001); Laragh J.H., Lamport B., Sealey J., Alderman M.H., Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Lind L., Berne C., Andersson P.E., Hanni A., Et al., Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment?, J. Hum. Hypertens., 9, pp. 759-763, (1995); Miller J.A., Thai K., Scholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Int., 56, pp. 2173-2180, (1999); Nakauchi Y., Suehiro T., Yamamoto M., Yasuoka N., Et al., Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease, Atherosclerosis, 125, pp. 161-169, (1996); Poirier O., Georges J.L., Ricard S., Arveiler D., Et al., New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: The ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde, J. Hypertens., 16, pp. 1443-1447, (1998); Preston R.A., Materson B.J., Reda D.J., Williams D.W., Et al., Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, JAMA, 280, pp. 1168-1172, (1998); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Et al., Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Redon J., Luque-Otero M., Martell N., Chaves F.J., Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients, Pharmacogenomics J., 5, pp. 14-20, (2005); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Et al., ACE and α-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Su X., Lee L., Li X., Lv J., Et al., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, pp. 725-732, (2007); Takami S., Katsuya T., Rakugi H., Sato N., Et al., Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension, Am. J. Hypertens., 11, pp. 316-321, (1998); Tilzer L., Thomas S., Moreno R.F., Use of silica gel polymer for DNA extraction with organic solvents, Anal. Biochem., 183, pp. 13-15, (1989); Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Et al., Angiotensin II receptors and angiotensin II receptor antagonists, Pharmacol. Rev., 45, pp. 205-251, (1993); Yu H.M., Lin S.G., Liu G.Z., Zhang Y.Q., Et al., Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors, Clin. Pharmacol. Ther., 79, pp. 581-589, (2006)","F. H. Du; Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, Beijing, China; email: fhduu@yahoo.com.cn","","","","","","","","16765680","","","23913386","English","Genet. Mol. Res.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84879306717"
"Karst M.; Hollenhorst J.; Achenbach J.","Karst, Matthias (7004342917); Hollenhorst, Josef (6602823150); Achenbach, Johannes (16068090700)","7004342917; 6602823150; 16068090700","Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia?","2020","Medical Hypotheses","144","","110234","","","","24","10.1016/j.mehy.2020.110234","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090340497&doi=10.1016%2fj.mehy.2020.110234&partnerID=40&md5=849379a533e2c6123f75309d8d2a2ae4","Department of Anesthesiology and Intensive Care Medicine, Pain Clinic, Hannover Medical School, Hannover, Germany; Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Medicine, Nordstadt Krankenhaus Hannover, Hannover, Germany","Karst M., Department of Anesthesiology and Intensive Care Medicine, Pain Clinic, Hannover Medical School, Hannover, Germany; Hollenhorst J., Department of Anesthesiology and Intensive Care Medicine, Pain Clinic, Hannover Medical School, Hannover, Germany; Achenbach J., Department of Anesthesiology and Intensive Care Medicine, Pain Clinic, Hannover Medical School, Hannover, Germany, Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Medicine, Nordstadt Krankenhaus Hannover, Hannover, Germany","As the current COVID-19 pandemic develops and epidemiological data reveals differences in geographical spread as well as risk factors for developing a severe course of illness, hypotheses regarding possible underlying mechanisms need to be developed and tested. In our hypothesis, we explore the rational for a role of MTHFR polymorphism C677T as a possible explanation for differences in geographical and gender distribution in disease severity. We also discuss the role of the resulting hyper-homocysteinemia, its interaction with the C677T polymorphism and its influence on immune state as well as risk factors for severe disease. Finally, we consider possible dietary ways to influence the underlying pathomechanisms prophylactically and supportively. © 2020 Elsevier Ltd","Covid-19; Hyper-homocysteinemia; MTHFR C677T; One-carbon metabolism","COVID-19; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Humans; Hyperhomocysteinemia; Male; Methylenetetrahydrofolate Reductase (NADPH2); Models, Theoretical; Nutritional Sciences; Pandemics; Polymorphism, Genetic; Reactive Oxygen Species; Risk Factors; Virus Replication; 5 methyltetrahydrofolic acid; ademetionine; androgen; angiotensin receptor; cell protein; collagen; creatinine; cyanocobalamin; cystathionine beta synthase; dipeptidyl carboxypeptidase; DNA ligase; elastin; estrogen; flavine adenine nucleotide; folic acid; glutathione; homocysteine; immunoglobulin enhancer binding protein; interleukin 6; methionine; methionine synthase; nitric oxide; protein 5,10 methylenetetrahydrofolic acid reductase; pyridoxine; reactive oxygen metabolite; tumor necrosis factor; tumor necrosis factor receptor; tumor necrosis factor receptor superfamily member 8; unclassified drug; unindexed drug; vitamin B group; methylenetetrahydrofolate reductase (NADPH2); MTHFR protein, human; reactive oxygen metabolite; acute lymphoblastic leukemia; African; aging; alcohol consumption; allele; amino acid blood level; androgen blood level; Article; Asian; atherosclerosis; blood clotting disorder; blood clotting test; breast cancer; cardiovascular disease; cell function; China; chromosome 1; chronic kidney failure; colon cancer; comorbidity; comparative study; computer assisted tomography; congestive heart failure; coronary artery disease; coronavirus disease 2019; creatinine blood level; critically ill patient; diabetes mellitus; dietary intake; disease association; disease course; disease severity; disseminated intravascular clotting; DNA methylation; DNA repair; down regulation; endothelial dysfunction; enzyme activation; enzyme activity; enzyme mechanism; enzyme polymorphism; estrogen blood level; European; Finland; folic acid blood level; France; gene cluster; genetic code; genetic screening; genome-wide association study; geographic distribution; glutathione metabolism; high risk population; hospital admission; hospital mortality; human; hyperhomocysteinemia; hypertension; hypothyroidism; immune response; infection risk; infection sensitivity; intensive care unit; Iran; Italy; life threat; lifestyle; macrophage; membrane transport; methylome; mortality rate; neurotransmission; neutrophil; nonhuman; North American; ovary cancer; oxidative stress; pancreas cancer; pandemic; pathophysiology; physical inactivity; predictive value; prevalence; protein interaction; randomized controlled trial (topic); risk factor; severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; sex difference; sex ratio; signal transduction; single nucleotide polymorphism; smoking; Southeast Asia; Spain; thorax radiography; TNFRSF8 gene; ultraviolet radiation; United States; upregulation; vascular cell line; vasodilatation; virus cell interaction; virus entry; virus replication; vitamin blood level; vitamin supplementation; vulnerable population; disease exacerbation; female; genetic polymorphism; genetic predisposition; genetics; genotype; hyperhomocysteinemia; male; nutritional science; pathophysiology; theoretical model","","5 methyltetrahydrofolic acid, 134-35-0, 31690-09-2, 151533-22-1; ademetionine, 29908-03-0, 485-80-3; collagen, 9007-34-5; creatinine, 19230-81-0, 60-27-5; cyanocobalamin, 53570-76-6, 68-19-9, 8064-09-3; cystathionine beta synthase, 9023-99-8; dipeptidyl carboxypeptidase, 9015-82-1; DNA ligase, 9015-85-4; elastin, 9007-58-3; flavine adenine nucleotide, 146-14-5; folic acid, 59-30-3, 6484-89-5; glutathione, 70-18-8; homocysteine, 454-28-4, 6027-13-0; methionine, 59-51-8, 63-68-3, 7005-18-7; methionine synthase, 37290-90-7; nitric oxide, 10102-43-9; pyridoxine, 12001-77-3, 58-56-0, 65-23-6, 8059-24-3; tumor necrosis factor receptor, 129203-93-6, 184595-01-5; vitamin B group, 12001-76-2; methylenetetrahydrofolate reductase (NADPH2), 71822-25-8; Methylenetetrahydrofolate Reductase (NADPH2), ; MTHFR protein, human, ; Reactive Oxygen Species, ","","","","","Kakodkar P., Kaka N., Baig M.N., A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19), Cureus, 12, (2020); Grasselli G., Zangrillo A., Zanella A., Et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA, (2020); Tang N., Li D., Wang X., Et al., Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, pp. 844-847, (2020); Yafei W., Lijun P., Jinfeng W., Et al., Is the prevalence of MTHFR C677T polymorphism associated with ultraviolet radiation in Eurasia, J Hum Genet, 57, pp. 780-786, (2012); Yadav U., Kumar P., Gupta S., Et al., Distribution of MTHFR C677T gene polymorphism in healthy North Indian population and an updated meta-analysis, Indian J Clin Biochem, 32, pp. 399-410, (2017); Wilcken B., Bamforth F., Li Z., Et al., Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide, J Med Genet, 40, pp. 619-625, (2003); Russo G.T., Friso S., Jacques P.F., Et al., Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study Cohort, J Nutr, 133, pp. 3416-3421, (2003); Papoutsakis C., Yiannakouris N., Manios Y., Et al., The effect of MTHFR(C677T) genotype on plasma homocysteine concentrations in healthy children is influenced by gender, Eur J Clin Nutr, 60, pp. 155-162, (2006); Rios D.L., D'Onofrio L.O., Carvalho H.G., Et al., Sex-specific effect of the thermolabile C677T mutation in the methylenetetrahydrofolate reductase gene on angiographically assessed coronary artery disease in Brazilians, Hum Biol, 79, pp. 453-461, (2007); Kim J., Kim H., Roh H., Et al., Causes of hyperhomocysteinemia and its pathological significance, Arch Pharm Res, 41, pp. 372-383, (2018); Moretti R., Homocysteine: new aspects of an ancient enigma, Cardiology, 144, pp. 36-39, (2019); Gariglio L., Riviere S., Morales A., Et al., Comparison of homocysteinemia and MTHFR 677CT polymorphism with Framingham Coronary Heart Risk Score, Arch Cardiol Mex, 84, pp. 71-78, (2014); Bowman T.S., Gaziano J.M., Stampfer M.J., Et al., Homocysteine and risk of developing hypertension in men, J Hum Hypertens, 20, pp. 631-634, (2006); White M.C., Fleeman R., Arnold A.C., Sex differences in the metabolic effects of the renin-angiotensin system, Biol Sex Differ, 10, (2019); Smits S.L., de Lang A., van den Brand J.M., Et al., Exacerbated innate host response to SARS-CoV in aged non-human primates, PLoS Pathog, 6, (2010); Yang Z., Shi J., He Z., Et al., Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients, Aging (Albany NY), 12, pp. 6037-6048, (2020); Corbin J.M., Ruiz-Echevarria M.J., One-carbon metabolism in prostate cancer: the role of androgen signaling, Int J Mol Sci, (2016); Horowitz R.I., Freeman P.R., Bruzzese J.; Nash A.J., Mandaviya P.R., Dib M.J., Et al., Interaction between plasma homocysteine and the MTHFR c.677C > T polymorphism is associated with site-specific changes in DNA methylation in humans, FASEB J, 33, pp. 833-843, (2019); Barazzoni R., Bischoff S.C., Breda J., Et al., ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection, Clin Nutr, (2020); McCully K.S., Homocysteine, vitamins, and vascular disease prevention, Am J Clin Nutr, 86, pp. 1563S-1568S, (2007); Servy E.J., Jacquesson-Fournols L., Cohen M., Et al., MTHFR isoform carriers. 5-MTHF (5-methyl tetrahydrofolate) vs folic acid: a key to pregnancy outcome: a case series, J Assist Reprod Genet, 35, pp. 1431-1435, (2018); Hustad S.S., Ueland P.M., (2013); McNulty H., Dowey L.R.C., Strain J.J., Et al., Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism, Circulation, 113, pp. 74-80, (2006); Selhub J., Homocysteine metabolism, Annu Rev Nutr, 19, pp. 217-246, (1999); Lakshmi A.V., Ramalakshmi B.A., Effect of pyridoxine or riboflavin supplementation on plasma homocysteine levels in women with oral lesions, Natl Med J India, 11, pp. 171-172, (1998); Zhang L., Liu Y., Potential interventions for novel coronavirus in China: a systematic review, J Med Virol, 92, pp. 479-490, (2020); Reshi M.L., Su Y.C., Hong J.R., RNA viruses: ROS-mediated cell death, Int J Cell Biol, 2014, (2014); Hemila H., Vitamin C and SARS coronavirus, J Antimicrob Chemother, 52, pp. 1049-1050, (2003); (2020)","J. Achenbach; Department of Anesthesiology and Intensive Care Medicine, Pain Clinic, Hannover Medical School, Hannover, Germany; email: johannes.achenbach@googlemail.com","","Churchill Livingstone","","","","","","03069877","","MEHYD","33254541","English","Med. Hypotheses","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85090340497"
"Herse F.; Lamarca B.; Hubel C.A.; Kaartokallio T.; Lokki A.I.; Ekholm E.; Laivuori H.; Gauster M.; Huppertz B.; Sugulle M.; Ryan M.J.; Novotny S.; Brewer J.; Park J.-K.; Kacik M.; Hoyer J.; Verlohren S.; Wallukat G.; Rothe M.; Luft F.C.; Muller D.N.; Schunck W.-H.; Staff A.C.; Dechend R.","Herse, Florian (23476866000); Lamarca, Babbette (8627193500); Hubel, Carl A. (7004232677); Kaartokallio, Tea (55507864700); Lokki, A. Inkeri (36918704900); Ekholm, Eeva (7003951644); Laivuori, Hannele (18836289900); Gauster, Martin (6506344554); Huppertz, Berthold (55621882500); Sugulle, Meryam (26668036600); Ryan, Michael J. (55568516468); Novotny, Sarah (55221375800); Brewer, Justin (39862749800); Park, Joon-Keun (57188967668); Kacik, Michael (14039265500); Hoyer, Joachim (56020495600); Verlohren, Stefan (6508173207); Wallukat, Gerd (35429621200); Rothe, Michael (7102678885); Luft, Friedrich C. (36041114800); Muller, Dominik N. (55552281600); Schunck, Wolf-Hagen (7003825133); Staff, Anne C. (23398378300); Dechend, Ralf (7003575856)","23476866000; 8627193500; 7004232677; 55507864700; 36918704900; 7003951644; 18836289900; 6506344554; 55621882500; 26668036600; 55568516468; 55221375800; 39862749800; 57188967668; 14039265500; 56020495600; 6508173207; 35429621200; 7102678885; 36041114800; 55552281600; 7003825133; 23398378300; 7003575856","Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia","2012","Circulation","126","25","","2990","2999","9","59","10.1161/CIRCULATIONAHA.112.127340","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871346041&doi=10.1161%2fCIRCULATIONAHA.112.127340&partnerID=40&md5=880aedf7f94e48e2fa283fd5391767fa","Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrueck Center for Molecular Medicine, 13125 Berlin, Lindenberger Weg 80, Germany; Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, United States; Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Haartman Institute, Department of Medical Genetics, University of Helsinki, Helsinki, Finland; Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland; Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Medical School of Hannover, Hannover, Germany; Department of Internal Medicine and Nephrology, Philipps-University, Marburg, Germany; Department of Obstetrics, Campus Virchow-Clinic, Charité University Medicine Berlin, Berlin, Germany; Lipidomix, Berlin, Germany; Friedrich-Alexander University, Erlangen, Germany; Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany; HELIOS-Klinikum Berlin Buch, Berlin, Germany","Herse F., Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrueck Center for Molecular Medicine, 13125 Berlin, Lindenberger Weg 80, Germany; Lamarca B., Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, United States; Hubel C.A., Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Kaartokallio T., Haartman Institute, Department of Medical Genetics, University of Helsinki, Helsinki, Finland; Lokki A.I., Haartman Institute, Department of Medical Genetics, University of Helsinki, Helsinki, Finland; Ekholm E., Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland; Laivuori H., Haartman Institute, Department of Medical Genetics, University of Helsinki, Helsinki, Finland; Gauster M., Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; Huppertz B., Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; Sugulle M., Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway; Ryan M.J., Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, United States; Novotny S., Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, United States; Brewer J., Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, United States; Park J.-K., Medical School of Hannover, Hannover, Germany; Kacik M., Department of Internal Medicine and Nephrology, Philipps-University, Marburg, Germany; Hoyer J., Department of Internal Medicine and Nephrology, Philipps-University, Marburg, Germany; Verlohren S., Department of Obstetrics, Campus Virchow-Clinic, Charité University Medicine Berlin, Berlin, Germany; Wallukat G., Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrueck Center for Molecular Medicine, 13125 Berlin, Lindenberger Weg 80, Germany; Rothe M., Lipidomix, Berlin, Germany; Luft F.C., Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrueck Center for Molecular Medicine, 13125 Berlin, Lindenberger Weg 80, Germany; Muller D.N., Friedrich-Alexander University, Erlangen, Germany; Schunck W.-H., Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany; Staff A.C., Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway; Dechend R., Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrueck Center for Molecular Medicine, 13125 Berlin, Lindenberger Weg 80, Germany, HELIOS-Klinikum Berlin Buch, Berlin, Germany","BACKGROUND-: Preeclampsia is a multisystem disorder of pregnancy, originating in the placenta. Cytochrome P450 (CYP)-dependent eicosanoids regulate vascular function, inflammation, and angiogenesis, which are mechanistically important in preeclampsia. METHODS AND RESULTS-: We performed microarray screening of placenta and decidua (maternal placenta) from 25 preeclamptic women and 23 control subjects. The CYP subfamily 2J polypeptide 2 (CYP2J2) was upregulated in preeclamptic placenta and decidua. Reverse-transcription polymerase chain reaction confirmed the upregulation, and immunohistochemistry localized CYP2J2 in trophoblastic villi and deciduas at 12 weeks and term. The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corresponding dihydroxyeicosatrienoic acids, were elevated in preeclamptic women compared with controls in the latter two thirds of pregnancy and after delivery. Stimulating a trophoblast-derived cell line with the preeclampsia-associated cytokine tumor necrosis factor-α enhanced CYP2J2 gene and protein expression. In 2 independent rat models of preeclampsia, reduced uterine-perfusion rat and the transgenic angiotensin II rat, we observed elevated EET, dihydroxyeicosatrienoic acid, and preeclamptic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2- propynyloxy)-benzenehexanamide (MsPPOH). Uterine arterial rings of these rats also dilated in response to MsPPOH. Furthermore, 5,6-EET could be metabolized to a thromboxane analog. In a bioassay, 5,6-EET increased the beating rate of neonatal cardiomyocytes. Blocking thromboxane synthesis reversed that finding and also normalized large-conductance calcium-activated potassium channel activity. CONCLUSIONS-: Our data implicate CYP2J2 in the pathogenesis of preeclampsia and as a potential candidate for the disturbed uteroplacental remodeling, leading to hypertension and endothelial dysfunction. © 2012 American Heart Association, Inc.","cytochrome P450; hypertension; preeclampsia; pregnancy","8,11,14-Eicosatrienoic Acid; Animals; Cells, Cultured; Cytochrome P-450 Enzyme System; Female; Humans; Hydrazines; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Oligonucleotide Array Sequence Analysis; Placenta; Polymorphism, Single Nucleotide; Pre-Eclampsia; Pregnancy; Rats; Rats, Sprague-Dawley; 14,15 epoxy 5,8,11 icosatrienoic acid; 5,6 epoxy 8,11,14 icosatrienoic acid; amide; angiotensin II; calcium activated potassium channel; cytochrome P450 2J2; dihydroxyicosatrienoic acid; n (methylsulfonyl) 2 (2 propynyloxy) benzenehexanamide; thromboxane; tumor necrosis factor alpha; unclassified drug; unsaturated fatty acid; animal experiment; animal model; article; controlled study; decidua; gestational age; heart muscle cell; heart rate; human; human cell; immunohistochemistry; lipogenesis; microarray analysis; nonhuman; placenta; placenta circulation; preeclampsia; priority journal; protein expression; protein localization; rat; reverse transcription polymerase chain reaction; trophoblast; upregulation","","14,15 epoxy 5,8,11 icosatrienoic acid, 81276-03-1; 5,6 epoxy 8,11,14 icosatrienoic acid, 81246-84-6; amide, 17655-31-1; angiotensin II, 11128-99-7; thromboxane, 66719-58-2; 14,15-epoxy-5,8,11-eicosatrienoic acid, 81276-03-1; 5,6-epoxy-8,11,14-eicosatrienoic acid, 81246-84-6; 8,11,14-Eicosatrienoic Acid, 7324-41-6; Cytochrome P-450 Enzyme System, 9035-51-2; Hydrazines, ; KCNMA1 protein, human, ; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits, ; SQ 29548, 98299-61-7; arachidonate epoxygenase, 1.14.14.1","","","National Institute of Child Health and Human Development, NICHD, (R01HD067541)","","Sibai B., Dekker G., Kupferminc M., Preeclampsia, Lancet., 365, pp. 785-799, (2005); Gant N.F., Daley G.L., Chand S., Whalley P.J., MacDonald P.C., A study of angiotensin II pressor response throughout primigravid pregnancy, J Clin Invest., 52, pp. 2682-2689, (1973); Llinas M.T., Alexander B.T., Capparelli M.F., Carroll M.A., Granger J.P., Cytochrome P-450 inhibition attenuates hypertension induced by reductions in uterine perfusion pressure in pregnant rats, Hypertension., 43, pp. 623-628, (2004); Vince G.S., Starkey P.M., Austgulen R., Kwiatkowski D., Redman C.W., Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women withpre-eclampsia, BrJ Obstet Gynaecol., 102, pp. 20-25, (1995); Sunderland N.S., Thomson S.E., Heffernan S.J., Lim S., Thompson J., Ogle R., McKenzie P., Kirwan P.J., Makris A., Hennessy A., Tumor necrosis factor a induces a model of preeclampsia in pregnant baboons (Papio hamadryas), Cytokine., 56, pp. 192-199, (2011); Gilbert J.S., Ryan M.J., Lamarca B.B., Sedeek M., Murphy S.R., Granger J.P., Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction, Am J Physiol Heart Circ Physiol., 294, (2008); Powe C.E., Levine R.J., Karumanchi S.A., Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease, Circulation., 123, pp. 2856-2869, (2011); Luksha L., Luksha N., Kublickas M., Nisell H., Kublickiene K., Diverse mechanisms of endothelium-derived hyperpolarizing factor-mediated dilatation in small myometrial arteries in normal human pregnancy and preeclampsia, Biol Reprod., 83, pp. 728-735, (2010); Capdevila J.H., Falck J.R., Harris R.C., Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties of the arachido-nate monooxygenase, J Lipid Res., 41, pp. 163-181, (2000); Balazy M., Metabolism of 5, 6-epoxyeicosatrienoic acid by the human platelet: Formation of novel thromboxane analogs, J Biol Chem., 266, pp. 23561-23567, (1991); Catella F., Lawson J.A., Fitzgerald D.J., Fitzgerald G.A., Endogenous biosynthesis of arachidonic acid epoxides in humans: Increased formation in pregnancy-induced hypertension, Proc Natl Acad Sci USA., 87, pp. 5893-5897, (1990); Schafer W.R., Zahradnik H.P., Arbogast E., Wetzka B., Werner K., Breckwoldt M., Arachidonate metabolism in human placenta, fetal membranes, decidua and myometrium: Lipoxygenase and cytochrome P450 metabolites as main products in HPLC profiles, Placenta., 17, pp. 231-238, (1996); Zhang J.H., Pearson T., Matharoo-Ball B., Ortori C.A., Warren A.Y., Khan R., Barrett D.A., Quantitative profiling of epoxyeicosatrienoic, hydroxyeico-satetraenoic, and dihydroxyeicosatetraenoic acids in human intrauterine tissues using liquid chromatography/electrospray ionization tandem mass spectrometry, Anal Biochem., 365, pp. 40-51, (2007); Staff A.C., Ranheim T., Khoury J., Henriksen T., Increased contents of phospholipids, cholesterol, and lipid peroxides in decidua basalis in women with preeclampsia, Am J Obstet Gynecol., 180, pp. 587-592, (1999); McCormick J., Whitley G.S., Le Bouteiller P., Cartwright J.E., Soluble HLA-G regulates motility and invasion of the trophoblast-derived cell line SGHPL-4, Hum Reprod., 24, pp. 1339-1345, (2009); Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., Konkel A., Von Schacky C., Luft F.C., Muller D.N., Rothe M., Schunck W.H., Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of to-3 fatty acids, J Biol Chem., 285, pp. 32720-32733, (2010); Wallukat G., Neichel D., Nissen E., Homuth V., Luft F.C., Agonistic auto-antibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia, Can J Physiol Pharmacol., 81, pp. 79-83, (2003); Kohler R., Degenhardt C., Kuhn M., Runkel N., Paul M., Hoyer J., Expression and function of endothelial Ca(2 +)-activated K(+) channels in human mesenteric artery: A single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ, Circ Res., 87, pp. 496-503, (2000); Llinas M.T., Alexander B.T., Seedek M., Abram S.R., Crell A., Granger J.P., Enhanced thromboxane synthesis during chronic reductions in uterine perfusion pressure in pregnant rats, Am J Hypertens., 15, pp. 793-797, (2002); Hering L., Herse F., Geusens N., Verlohren S., Wenzel K., Staff A.C., Brosnihan K.B., Huppertz B., Luft F.C., Muller D.N., Pijnenborg R., Cart-Wright J.E., Dechend R., Effects of circulating and local uteroplacental angiotensin II in rat pregnancy, Hypertension., 56, pp. 311-318, (2010); Verlohren S., Niehoff M., Hering L., Geusens N., Herse F., Tintu A.N., Plagemann A., Lenoble F., Pijnenborg R., Muller D.N., Luft F.C., Duden-Hausen J.W., Gollasch M., Dechend R., Uterine vascular function in a transgenic preeclampsia rat model, Hypertension., 51, pp. 547-553, (2008); Pijnenborg R., McLaughlin P.J., Vercruysse L., Hanssens M., Johnson P.M., Keith Jr. J.C., Van Assche F.A., Immunolocalization of tumour necrosis factor-a (TNF-a) in the placental bed of normotensive and hypertensive human pregnancies, Placenta., 19, pp. 231-239, (1998); Wu S., Moomaw C.R., Tomer K.B., Falck J.R., Zeldin D.C., Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart, J Biol Chem., 271, pp. 3460-3468, (1996); Hubel C.A., Wallukat G., Wolf M., Herse F., Rajakumar A., Roberts J.M., Markovic N., Thadhani R., Luft F.C., Dechend R., Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia, Hypertension., 49, pp. 612-617, (2007); Zhou Y., Chang H.H., Du J., Wang C.Y., Dong Z., Wang M.H., Renal epoxyeicosatrienoic acid synthesis during pregnancy, Am J Physiol Renal Physiol., 288, (2005); Lamarca B., Speed J., Fournier L., Babcock S.A., Berry H., Cockrell K., Granger J.P., Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: Effect of tumor necrosis factor-a blockade, Hypertension., 52, pp. 1161-1167, (2008); Roman R.J., P-450 metabolites of arachidonic acid in the control of cardiovascular function, Physiol Rev., 82, pp. 131-185, (2002); Spector A.A., Norris A.W., Action of epoxyeicosatrienoic acids on cellular function, Am J Physiol Cell Physiol., 292, (2007); Campbell W.B., Fleming I., Epoxyeicosatrienoic acids and endothelium-dependent responses, Pflugers Arch., 459, pp. 881-895, (2010); Konkel A., Schunck W.H., Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids, Biochim Biophys Acta., 1814, pp. 210-222, (2011); Imig J.D., Hammock B.D., Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases, Nat Rev Drug Discov., 8, pp. 794-805, (2009); Huang H., Chang H.H., Xu Y., Reddy D.S., Du J., Zhou Y., Dong Z., Falck J.R., Wang M.H., Epoxyeicosatrienoic acid inhibition alters renal hemodynam-ics during pregnancy, Exp Biol Med (Maywood)., 231, pp. 1744-1752, (2006); Nithipatikom K., Gross G.J., Review article: Epoxyeicosatrienoic acids: Novel mediators of cardioprotection, J Cardiovasc Pharmacol Ther., 15, pp. 112-119, (2010); Iliff J.J., Jia J., Nelson J., Goyagi T., Klaus J., Alkayed N.J., Epoxyeicosanoid signaling in CNS function and disease, Prostaglandins Other Lipid Mediat., 91, pp. 68-84, (2010); Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., Liao J.K., Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science., 285, pp. 1276-1279, (1999); Yang B., Graham L., Dikalov S., Mason R.P., Falck J.R., Liao J.K., Zeldin D.C., Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells, Mol Pharmacol., 60, pp. 310-320, (2001); Kanasaki K., Kalluri R., The biology of preeclampsia, Kidney Int., 76, pp. 831-837, (2009); Lee S.B., Wong A.P., Kanasaki K., Xu Y., Shenoy V.K., McElrath T.F., Whitesides G.M., Kalluri R., Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions, Am J Pathol., 176, pp. 710-720, (2010); Suzuki S., Oguro A., Osada-Oka M., Funae Y., Imaoka S., Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells, J Pharmacol Sci., 108, pp. 79-88, (2008); Spiecker M., Liao J.K., Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids, Arch Biochem Biophys., 433, pp. 413-420, (2005); Zosmer A., Elder M.G., Sullivan M.H., The regulation of arachidonic acid metabolism in human first trimester trophoblast by cyclic AMP, Prostaglandins Other Lipid Mediat., 71, pp. 43-53, (2003); Pascoal I.F., Lindheimer M.D., Nalbantian-Brandt C., Umans J.G., Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries, J Clin Invest., 101, pp. 464-470, (1998); Wenzel K., Rajakumar A., Haase H., Geusens N., Hubner N., Schulz H., Brewer J., Roberts L., Hubel C.A., Herse F., Hering L., Qadri F., Lindschau C., Wallukat G., Pijnenborg R., Heidecke H., Riemekasten G., Luft F.C., Muller D.N., Lamarca B., Dechend R., Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats, Hypertension., 58, pp. 77-84, (2011); Fernandez-Fernandez J.M., Tomas M., Vazquez E., Orio P., Latorre R., Senti M., Marrugat J., Valverde M.A., Gain-of-function mutation in the KCNMB1 potassium channel subunit is associated with low prevalence of diastolic hypertension, J Clin Invest., 113, pp. 1032-1039, (2004); Kohler R., Single-nucleotide polymorphisms in vascular Ca2 +-activated K +-channel genes and cardiovascular disease, Pflugers Arch., 460, pp. 343-351, (2010); Roberts J.M., Hubel C.A., The two stage model of preeclampsia: Variations on the theme, Placenta., 30, SUPPL. A, (2009)","F. Herse; Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrueck Center for Molecular Medicine, 13125 Berlin, Lindenberger Weg 80, Germany; email: florian.herse@charite.de","","","","","","","","15244539","","CIRCA","23155181","English","Circulation","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-84871346041"
"Mulerova T.A.; Tsygankova D.P.; Chigisova A.N.; Ogarkov M.Y.","Mulerova, T.A. (55229340900); Tsygankova, D.P. (57194717730); Chigisova, A.N. (57203370035); Ogarkov, M.Yu. (8303956200)","55229340900; 57194717730; 57203370035; 8303956200","The role of risk factors and genetic polymorphism in assessing the effectiveness of combined antihypertensive therapy in a small population of shor people","2021","Profilakticheskaya Meditsina","24","2","","52","61","9","2","10.17116/profmed20212402152","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102534739&doi=10.17116%2fprofmed20212402152&partnerID=40&md5=3f3c7f324d7348c54ab4cd69e32b5229","Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation","Mulerova T.A., Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation; Tsygankova D.P., Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation; Chigisova A.N., Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation; Ogarkov M.Y., Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation","According to the latest Russian guidelines for arterial hypertension (AH), the first choice drugs include combinations of blockers of the renin-angiotensin-aldosterone system (RAAS) with calcium antagonists (CA) or with thiazide / thiazide-like diuretics. How-ever, in some patients despite the introduction of more and more advanced drugs for the treatment of hypertension into clinical practice it is not possible to achieve the target level of blood pressure. In this regard a number of authors propose to prescribe an-tihypertensive drugs taking into account the role of gene polymorphism. In addition, there are racial differences in drug tolerance and efficacy. Objective. To assess the role of traditional risk factors and genetic markers in the effectiveness of combined antihypertensive therapy in the indigenous population of Mountain Shoria. Material and methods. In 2013—2017 the indigenous small-numbered population, the Shors, was surveyed by a continuous method in the villages of Mountain Shoria. The prospective observation included 320 patients with hypertension who had not previ-ously received antihypertensive therapy. The subjects were randomized by the method of plain envelopes into two groups of 160 patients each. In group 1 the patients were prescribed initial therapy with a combination of RAAS blockers with CA; in group 2 the patients received a combination of RAAS blockers with a thiazide-like diuretic. The study of molecular genetic parameters included: DNA isolation from venous blood by phenol-chloroform extraction, determination by PCR of single nucleotide polymorphisms: ACE (I/D, rs 4340), AGT (c.803T>C, rs699), AGTR1 (A1166C, rs5186), MTHFR (C677T, rs1801133), eNOS (VNTR 4b/4a). Results. A prospective observation in Mountain Shoria demonstrated the same antihypertensive efficacy of both drug combina-tions. However, in comorbid pathology (hypertension and concomitant obesity or impaired carbohydrate metabolism) the combination of RAAS blockers with a diuretic was more effective. In Shors a pronounced hypotensive effect using a combination of RAAS blockers with CA was established for carriers of genotypes I/D of the ACE gene, genotypes T/C of the AGT gene, genotypes C/C of the AGTR1 gene. The presence of various cardiovascular risk factors in addition to hypertension in patients did not reduce the positive result of treatment. The polymorphism of the MTHFR and eNOS genes in the Shors determined a more significant dynamics of blood pressure in case of antihypertensive therapy with RAAS blockers and diuretic, in persons with impaired carbohydrate metabolism and obesity, accordingly. Conclusion. Personalized medicine which studies the genetic basis of an individual response to drugs opens up new opportunities in the treatment of patients with hypertension and is aimed at increasing the effectiveness of therapy. © 2021, Media Sphera Publishing Group. All rights reserved.","Antihypertensive therapy; Ethnicity; Personalized medicine; The role of gene polymorphism","calcium antagonist; thiazide diuretic agent; adult; antihypertensive therapy; Article; carbohydrate metabolism; cardiovascular risk; combination drug therapy; controlled study; DNA isolation; drug efficacy; genetic marker; genetic parameters; genotype; human; hypertension; major clinical study; obesity; practice guideline; prospective study; randomized controlled trial; renin angiotensin aldosterone system; risk factor; single nucleotide polymorphism; venous blood","","","","","","","Boytsov S.A., Balanova Y.A., Shalnova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M., Duplyakov D.V., Efanov A.Y., Zhernakova Y.V., Konradi A.O., Libis R.A., Minakov A.V., Nedogoda S.V., Oshchepkova E.V., Romanchuk S.A., Rotar O.P., Trubacheva I.A., Chazova I.E., Shlyakhto E.V., Muromtseva G.A., Evstifeeva S.E., Kapustina A.V., Konstantinov V.V., Oganov R.G., Mamedov M.N., Baranova E.I., Nazarova O.A., Shutemova O.A., Furmenko G.I., Babenko N.I., Azarin O.G., Bondartsov L.V., Khvostikova A.E., Ledyaeva A.A., Chumachek E.V., Isaeva E.N., Basyrova I.R., Kondratenko V.Y., Lopina E.A., Safonova D.V., Skrip-Chenko A.E., Indukaeva E.V., Cherkass N.V., Maksimov S.A., Danilchenko Y.V., Mulerova T.A., Shalaev S.V., Medvedeva I.V., Shava V.G., Storozhok M.A., Tolp-Arov G.V., Astakhova Z.T., Toguzova Z.A., Kaveshnikov V.S., Karpov R.S., Sere-Bryakova V.N., Arterial hypertension among individuals of 25-64 years old: Prevalence, awareness, treatment and control. By the data from ECCE, Cardiovascular Therapy and Prevention, 13, 4, pp. 4-14, (2014); Smirnova E.A., Terekhovskaya Y.V., Molodtsova A.A., Yakushin S.S., Arterial hypertension in Ryazan region: Data of the third section of the EPOHA study, Russian Journal of Cardiology, 6, pp. 49-53, (2019); Konradi A.O., Nedogoda S.V., Nedoshivin A.O., Ratova L.G., Libis R.A., Arutyu-Nov G.P., Borovkova N., Galyavich A.S., Grinshtein Y., Duplyakov D.V., Kashtalap V.V., Lopatinlyaminamalchikova Y.S.V., Mikhin V.P., Nechaeva G.I., Ostroumova O.D., Ripp T.M., Chumakova G.A., Shaposhnik I.I., Yakusevich V.V., Modern antihypertensive therapy: The effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide, Russian Journal of Cardiology, 25, 3, (2020); Chazova I.E., Zhernakova Y., Clinical guidelines. Diagnosis and treatment of arterial hypertension, Systemic Hypertension, 16, 1, pp. 6-31, (2019); Kobalava Z., Kulakov V.V., Goreva L.A., Villevalde S.V., Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hyperten-sion, Russian Journal of Cardiology, 24, 6, pp. 122-130, (2019); Ponasenko A.V., Tsepokina A.V., Tkhorenko B.A., Golubenko M.V., Gubieva E.K., Trefilova L.P., Variability of mitochondrial DNA in the development of ath-erosclerosis and myocardial infarction (A review), Complex Issues of Cardiovascular Diseases, 7, 4, pp. 75-85, (2018); Drobotya N.V., Harutyunyan L.V., Pirozhenko A.A., The role of determining genetic polymorphism in the pathogenesis of arterial hypertension in order to individualize drug therapy, Consilium Medicum, 19, 5, pp. 26-30, (2017); Darenskaya M.A., Ethnic and regional aspects of the human pathology pro-cesses, Bulletin of the SSC of the RAMS, 2, 84, pp. 152-159, (2012); Mulerova T.A., Maksimov S.A., Ogarkov M.Y., Gruzdeva O.V., Ponasenko A.V., Maksimov V.N., Voevoda M.I., Filimonov E.S., Artamonova G.V., Associations of cardiovascular risk factors and genetic markers with development of arterial hypertension in the population of Mountain Shoriya, Rational Pharma-Cotherapy in Cardiology, 14, 5, pp. 678-686, (2018); Mulerova T.A., Clinical and genetic factors determining lesions of target or-gans in patients with arterial hypertension among the population of Mountain Shoria, Systemic Hypertension, 14, 3, pp. 42-50, (2017); Gaponova N.I., Abdarkhamanov V.R., Chumakova E.A., Arterial hypertension complicated by hypertensive crises: Frequency and course features in Mos-cow, Diary of the Kazan Medical School, 2, pp. 51-55, (2013); Gortbat T.V., Nechesova T.A., Liventseva M.M., Korobko I., Arterial hypertension and hypomagnesemia: Pathogenetic possibilities of effective control of blood pressure, Medical Business, 1, 41, pp. 7-10, (2015); Morozova T.E., Sychev D.A., Shikh N.V., Pharmacogenetic approach for fore-casting the efficacy and safety of pharmacotherapy of arterial hypertension, Attending Doctor, 3, pp. 77-81, (2016); Shlyakhto E.V., Conradi A.O., Zvartau N.E., Arterial hypertension, Cardiology: National Guidelines, (2015); Booth H.P., Prevost A.T., Gulliford M.C., Severity of obesity and management of hypertension, hypercholesterolaemia and smoking in primary care: Pop-ulation-based cohort study, J Hum Hypertens, 30, pp. 40-45, (2016); Vasyuk Y.A., Shupenina E.Y., Yuschuk E.N., Namazova G.A., Modern fixed combinations of antihypertensive drugs in the treatment of arterial hypertension and obesity: Can this comorbid pathology be effectively controlled?, Russian Journal of Cardiology, 9, pp. 14-21, (2019); Kremneva L.V., Abaturova O.V., Shalaev S.V., The features of antihypertensive therapy in patients with metabolic syndrome, Ration Pharmacother Cardiol, 10, 2, pp. 212-219, (2014); Boutouyrie P., Achouba A., Trunet P., Laurent S., Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: The EXPLOR study, Hypertension, 55, pp. 1314-1322, (2010); Matsui Y., Eguchi K., O'Rourke M.F., Ishikawa J., Shimada K., Kario K., Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: The J-CORE Study, Atherosclerosis, 215, 1, pp. 184-188, (2011); Nedogoda S.V., Chumachek E.V., Ledyaeva A.A., Tsoma V.V., Salasyuk A.S., Smirnova V.O., Khripaeva V., Palashkin R.V., Popova E.A., Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin, Systemic Hypertension, 15, 2, pp. 24-31, (2018)","T.A. Mulerova; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation; email: mulerova-77@mail.ru","","Media Sphera Publishing Group","","","","","","23054948","","","","Russian","Profilakticheskaya Meditsina","Article","Final","","Scopus","2-s2.0-85102534739"
"Armando I.; Villar V.A.M.; Jose P.A.","Armando, Ines (7005258061); Villar, Van Anthony M. (15849432000); Jose, Pedro A. (55382768900)","7005258061; 15849432000; 55382768900","Genomics and pharmacogenomics of salt-sensitive hypertension","2015","Current Hypertension Reviews","11","1","","49","56","7","27","10.2174/1573402111999150521102331","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84934767059&doi=10.2174%2f1573402111999150521102331&partnerID=40&md5=8c0892a61dbe39c7813b6270f9c232d9","Division of Nephrology, Department of Medicine, Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, MD, United States","Armando I., Division of Nephrology, Department of Medicine, Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, MD, United States; Villar V.A.M., Division of Nephrology, Department of Medicine, Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, MD, United States; Jose P.A., Division of Nephrology, Department of Medicine, Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, MD, United States","Salt sensitivity is estimated to be present in 51% of the hypertensive and 26% of the normotensive populations. The individual blood pressure response to salt is heterogeneous and possibly related to inherited susceptibility. Although the mechanisms underlying salt sensitivity are complex and not well understood, genetics can help to determine the blood response to salt intake. So far only a few genes have been found to be associated with salt-sensitive hypertension using candidate gene association studies. The kidney is critical to overall fluid and electrolyte balance and long-term regulation of blood pressure. Thus, the pathogenesis of salt sensitivity must involve a derangement in renal NaCl handling: an inability to decrease renal sodium transport and increase sodium excretion in the face of an increase in NaCl load that could be caused by aberrant counter-regulatory natriuretic/antinatriuretic pathways. We review here the literature regarding the gene variants associated with salt-sensitive hypertension and how the presence of these gene variants influences the response to antihypertensive therapy. © 2015 Bentham Science Publishers.","Hypertension; Kidney; Pharmacogenomics; Salt sensitivity","Blood Pressure; Gene Expression Regulation; Genetic Association Studies; Genetic Variation; Humans; Hypertension; Kidney; Polymorphism, Genetic; Reactive Oxygen Species; Renin-Angiotensin System; Sodium, Dietary; 11beta hydroxysteroid dehydrogenase 2; aldosterone synthase; alpha adducin; angiotensin 1 receptor; angiotensinogen; beta 2 adrenergic receptor; bradykinin B2 receptor; branched chain amino acid aminotransferase; chloride channel; cyclic GMP dependent protein kinase 1; cytochrome P450 3A5; dimethylargininase; dipeptidyl carboxypeptidase; endothelial nitric oxide synthase; endothelin B receptor; endothelin converting enzyme; epithelial sodium channel; fibroblast growth factor 5; G protein coupled receptor kinase 4; guanine nucleotide binding protein; natriuretic factor; protein kinase WNK1; reactive oxygen metabolite; retinoblastoma binding protein 2; serum and glucocorticoid regulated kinase 1; sodium calcium exchange protein; Tamm Horsfall glycoprotein; vasoactive intestinal polypeptide; von Willebrand factor; reactive oxygen metabolite; sodium intake; adrenergic system; Article; blood pressure; blood vessel reactivity; DNA polymorphism; dopaminergic system; electrolyte balance; gene interaction; genetic association; human; hypertension; oxidative stress; pharmacogenomics; priority journal; renin angiotensin aldosterone system; salt intake; sodium transport; vascular smooth muscle; drug effects; gene expression regulation; genetic association study; genetic polymorphism; genetic variation; genetics; hypertension; kidney; metabolism; pathophysiology; pharmacology; physiology; sodium intake","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; branched chain amino acid aminotransferase, 9054-65-3; cytochrome P450 3A5, 336874-97-6; dimethylargininase, 123644-75-7; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; endothelin converting enzyme, ; fibroblast growth factor 5, 129653-64-1; natriuretic factor, 9088-07-7; vasoactive intestinal polypeptide, 37221-79-7; von Willebrand factor, 109319-16-6; Reactive Oxygen Species, ; Sodium, Dietary, ","","","National Institutes of Health, (P01HL068686, P01HL074940, R01DK090918, R01HL092196, R37HL023081); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK039308)","","Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Franco V., Oparil S., Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival, J Am Coll Nutr, 25, pp. 2455-2470, (2006); Strazzullo P., D'Elia L., Kandala N.B., Cappuccio F.P., Salt intake, stroke, and cardiovascular disease: Metaanalysis of prospective studies, BMJ, 339, (2009); He F.J., McGregor G.A., Reducing population salt intake worldwide: From evidence to implementation, Prog Cardiovasc Dis, 52, pp. 363-382, (2010); Sanada H., Jones J.E., Jose P.A., Genetics of salt-sensitive hypertension, Curr Hypertens Rep, 13, pp. 55-66, (2011); Kanbay M., Chen Y., Solak Y., Sanders P.W., Mechanisms and consequences of salt sensitivity and dietary salt intake, Curr Opin Nephrol Hypertens, 20, pp. 37-43, (2011); Rettig R., Bandelow N., Patschan O., Kuttler B., Frey B., Uber A., The importance of the kidney in primary hypertension: Insights from cross-transplantation, J Hum Hypertens, 10, pp. 641-644, (1996); Strazzullo P., Galletti F., Genetics of salt-sensitive hypertension, Curr Hypertens Rep, 9, pp. 25-32, (2007); Hall J.E., Granger J.P., do Carmo J.M., Et al., Hypertension: Physiology and pathophysiology, Compr Physiol, 2, pp. 2393-2442, (2012); Navar L.G., Prieto M.C., Satou R., Kobori H., Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension, Curr Opin Pharmacol, 11, pp. 180-186, (2011); DiBona G.F., Sympathetic nervous system and the kidney in hypertension, Curr Opin Nephrol Hypertens, 11, pp. 197-200, (2002); Osborn J.W., Fink G.D., Kuroki M.T., Neural mechanisms of angiotensin II-salt hypertension: Implications for therapies targeting neural control of the splanchnic circulation, Curr Hypertens Rep, 13, pp. 221-228, (2011); Zhang M.Z., Harris R.C., Antihypertensive mechanisms of intra-renal dopamine, Curr Opin Nephrol Hypertens, 24, pp. 117-122, (2015); Zeng C., Jose P.A., Dopamine receptors: Important antihypertensive counterbalance against hypertensive factors, Hypertension, 57, pp. 11-17, (2011); Banday A.A., Lokhandwala M.F., Inhibition of natriuretic factors increases blood pressure in rats, Am J Physiol Renal Physiol, 297, pp. F397-F402, (2009); Kobori H., Nangaku M., Navar L.G., Nishiyama A., The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease, Pharmacol Rev, 59, pp. 251-287, (2007); Williams J.S., Chamarthi B., Goodarzi M.O., Et al., Lysine-specific demethylase 1: An epigenetic regulator of salt-sensitive hypertension, Am J Hypertens, 25, pp. 812-817, (2012); Garza A.E., Rariy C.M., Sun B., Et al., Variants in striatin gene are associated with salt-sensitive blood pressure in mice and humans, Hypertension, 65, pp. 211-217, (2015); Carey R.M., Schoeffel C.D., Gildea J.J., Et al., Salt sensitivity of blood pressure is associated with polymorphisms in the sodiumbicarbonate cotransporter, Hypertension, 60, pp. 1359-1366, (2012); Padmanabhan S., Melander O., Johnson T., Et al., Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension, PLoS Genet, 6, (2010); Trudu M., Janas S., Lanzani C., Et al., Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression, Nat Med, 19, pp. 1655-1660, (2013); Bengra C., Mifflin T.E., Khripin Y., Et al., Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers, Clin Chem, 48, pp. 2131-2140, (2002); Speirs H.J., Katyk K., Kumar N.N., Benjafield A.V., Wang W.Y., Morris B.J., Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension, J Hypertens, 22, pp. 931-936, (2004); Sanada H., Yatabe J., Midorikawa S., Et al., Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension, Clin Chem, 52, pp. 352-360, (2006); Gu D., Su S., Ge D., Et al., Association study with 33 singlenucleotide polymorphisms in 11 candidate genes for hypertension in Chinese, Hypertension, 47, pp. 1147-1154, (2006); Lohmueller K.E., Wong L.J., Mauney M.M., Et al., Patterns of genetic variation in the hypertension candidate gene GRK4: Ethnic variation and haplotype structure, Ann Hum Genet, 70, pp. 27-41, (2006); Lee M., Kim M.K., Kim S.M., Park H., Park C.G., Park H.K., Genderbased differences on the association between salt-sensitive genes and obesity in Korean children aged between 8 and 9 years, PLoS One, 10, (2015); Giacomini K.M., Yee S.W., Ratain M.J., Weinshilboum R.M., Kamatani N., Nakamura Y., Pharmacogenomics and patient care: One size does not fit all, Sci Transl Med, 4, (2012); Beeks E., Kessels A.G., Kroon A.A., Et al., Genetic predisposition to salt-sensitivity: A systematic review, J Hypertens, 22, pp. 1243-1249, (2004); Hunt S.C., Geleijnse J.M., Wu L.L., Witteman J.C., Williams R.R., Grobbee D.E., Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene, Am J Hypertens, 12, pp. 460-466, (1999); Li Y., Yang P., Wu S., Et al., Gender-specific association between ACE gene I/D polymorphism and blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients, Biochem Genet, 49, pp. 704-714, (2011); Li Y., Zhou Y., Yang P., Et al., Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients, Clin Exp Hypertens, 33, pp. 141-146, (2011); Konoshita T., Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs?: A systematic review of pharmacogenomics in the Renin-Angiotensin system, Curr Hypertens Rep, 13, pp. 356-361, (2011); Zhao Q., Gu D., Hixson J.E., Et al., Common variants in epithelial sodium channel genes contribute to salt sensitivity of blood pressure: The GenSalt study, Circ Cardiovasc Genet, 4, pp. 375-380, (2011); Luo F., Wang Y., Wang X., Sun K., Zhou X., Hui R., A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension, Hypertension, 54, pp. 796-801, (2009); Svensson-Farbom P., Wahlstrand B., Almgren P., Dahlberg J., Fava C., Kjeldsen S., A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients, J Hypertens, 29, pp. 388-395, (2011); McDonough C.W., Burbage S.E., Duarte J.D., Et al., Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics, J Hypertens, 31, pp. 698-704, (2013); Donner K.M., Hiltunen T.P., Hannila-Handelberg T., Suonsyrja T., Kontula K., STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men, Hypertens Res, 35, pp. 107-114, (2012); Duarte J.D., Lobmeyer M.T., Wang Z., Chapman A.B., Gums J.G., Langaee T.Y., Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide, Pharmacogenet Genomics, 20, pp. 516-519, (2010); San-Cristobal P., Pacheco-Alvarez D., Richardson C., Et al., Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway, Proc Natl Acad Sci U S A, 106, pp. 4384-4389, (2009); Filigheddu F., Argiolas G., Degortes S., Et al., Haplotypes of the adrenergic system predict the blood pressure response to betablockers in women with essential hypertension, Pharmacogenomics, 11, pp. 319-325, (2010); Liu K., Liu J., Huang Y., Et al., Alpha-adducin Gly460Trp polymorphism and hypertension risk: A meta-analysis of 22 studies including 14303 cases and 15961 controls, PLoS One, (2010); Lanzani C., Citterio L., Glorioso N., Et al., Adducin-and ouabainrelated gene variants predict the antihypertensive activity of rostafuroxin, part 2: Clinical studies, Sci Transl Med, 2, (2010); Staessen J.A., Thijs L., Stolarz-Skrzypek K., Et al., Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): A randomized placebo-controlled phase-2 dose-finding study of rostafuroxin, Trials, 12, (2011); Manunta P., Lavery G., Lanzani C., Et al., Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation, Hypertension, 52, pp. 366-372, (2008); Turner S.T., Bailey K.R., Schwartz G.L., Chapman A.B., Chai H.S., Boerwinkle E., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, pp. 1204-1211, (2012); Jose P.A., Soares-da-Silva P., Eisner G.M., Felder R.A., Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation, Biochim Biophys Acta, 1802, pp. 1259-1266, (2010); Liu C., Xi B., Pooled analyses of the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk, Int J Med Sci, 9, pp. 274-279, (2012); Bhatnagar V., O'Connor D.T., Brophy V.H., Et al., G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: Sex-specificity and interactions, Am J Hypertens, 22, pp. 332-338, (2009); Vandell A.G., Lobmeyer M.T., Gawronski B.E., Et al., G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension, Hypertension, 60, pp. 957-964, (2012); Rayner B., Ramesar R., Steyn K., Levitt N., Lombard C., Charlton K., G-protein-coupled receptor kinase 4 polymorphisms predict blood pressure response to dietary modification in Black patients with mild-to-moderate hypertension, J Hum Hypertens, 26, pp. 334-339, (2012); Wagner F., Malice M.P., Wiegert E., McGrath H.E., Gildea J., Mitta S., A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans, J Hypertens, 30, pp. 819-827, (2012); Sanada H., Yoneda M., Yatabe J., Et al., Common variants of the G protein-coupled receptor type 4 are associated with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade, Pharmacogenomics J, (2015); Norat T., Bowman R., Luben R., Et al., Blood pressure and interactions between the angiotensin polymorphism AGT M235T and sodium intake: A cross-sectional population study, Am J Clin Nutr, 88, pp. 392-396, (2008); Gu D., Kelly T.N., Hixson J.E., Chen J., Liu D., Chen J.C., Genetic variants in the renin-angiotensin-aldosterone system and salt sensitivity of blood pressure, J Hypertens, 28, pp. 1210-1220, (2010); Iwai N., Kajimoto K., Tomoike H., Takashima N., Polymorphism of CYP11B2 determines salt sensitivity in Japanese, Hypertension, 49, pp. 825-831, (2007); Tang W., Wu H., Zhou X., Et al., Association of the C-344T polymorphism of CYP11B2 gene with essential hypertension in Hani and Yi minorities of China, Clin Chim Acta, 364, pp. 222-225, (2006); Alikhani-Koupaei R., Fouladkou F., Fustier P., Et al., Identification of polymorphisms in the human11beta-hydroxysteroid dehydrogenase type 2 gene promoter: Functional characterization and relevance for salt sensitivity, FASEB J, 21, pp. 3618-3628, (2007); Pojoga L., Kolatkar N.S., Williams J.S., Perlstein T.S., Jeunemaitre X., Brown N.J., Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension, Hypertension, 48, pp. 892-900, (2006); Barlassina C., Dal Fiume C., Lanzani C., Et al., Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension, Hum Mol Genet, 16, pp. 1630-1638, (2007); Dahlberg J., Nilsson L.O., von Wowern F., Melander O., Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of NtproANP, PLoS One, 2, (2007); Li C., Yang X., He J., Et al., A gene-based analysis of variants in the serum/glucocorticoid regulated kinase (SGK) genes with blood pressure responses to sodium intake: The GenSalt Study, PLoS One, 9, (2014); Rao A.D., Sun B., Saxena A., Et al., Polymorphisms in the serum-and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake, J Hum Hypertens, 27, pp. 176-180, (2013); Wang Y., O'Connell J.R., McArdle P.F., Et al., Whole-genome association study identifies STK39 as a hypertension susceptibility gene, Proc Natl Acad Sci USA, 106, pp. 226-231, (2009); Adeyemo A., Gerry N., Chen G., Et al., A genome-wide association study of hypertension and blood pressure in African Americans, PLoS Genet, 5, (2009); Fava C., Danese E., Montagnana M., Et al., Serine/threonine kinase 39 is a candidate gene for primary hypertension especially in women: Results from two cohort studies in Swedes, J Hypertens, 29, pp. 484-491, (2011); Rhee M.Y., Yang S.J., Oh S.W., Et al., Novel genetic variations associated with salt sensitivity in the Korean population, Hypertens Res, 34, pp. 606-611, (2011); Eap C.B., Bochud M., Elston R.C., Et al., CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt, Hypertension, 49, pp. 1007-1014, (2007); Bagos P.G., Elefsinioti A.L., Nikolopoulos G.K., Hamodrakas S.J., The GNB3 C825T polymorphism and essential hypertension: A metaanalysis of 34 studies including 14, 094 cases and 17, 760 controls, J Hypertens, 25, pp. 487-500, (2007); Citterio L., Simonini M., Zagato L., Et al., Genes involved in vasoconstriction and vasodilation system affect salt-sensitive hypertension, PLoS One, 6, (2011); Gu D., Zhao Q., Kelly T.N., Et al., The role of the kallikrein-kinin system genes in the salt sensitivity of blood pressure: The GenSalt Study, Am J Epidemiol, 176, pp. S72-S80, (2012); Schreiber R., Bellinazzi V.R., Sposito A.C., Et al., Influence of the C242T polymorphism of the p22-phox gene (CYBA) on the interaction between urinary sodium excretion and blood pressure in an urban Brazilian population, PLoS One, 8, (2013); Castejon A.M., Bracero J., Hoffmann I.S., Alfieri A.B., Cubeddu L.X., NAD(P)H oxidase p22phox gene C242T polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics, J Hum Hypertens, 20, pp. 772-779, (2006); Wang R., Zhong B., Liu Y., Wang C., Association between alphaadducin gene polymorphism (Gly460Trp) and genetic predisposition to salt sensitivity: A meta-analysis, J Appl Genet, 51, pp. 87-94, (2010); Miyaki K., Tohyama S., Murata M., Et al., Salt intake affects the relation between hypertension and the T-786 C polymorphism in the endothelial nitric oxide synthase gene, Am J Hypertens, 18, pp. 1556-1562, (2005); Dengel D.R., Brown M.D., Ferrell R.E., Reynolds T.H., Supiano M.A., A preliminary study on T-786 C endothelial nitric oxide synthase gene and renal hemodynamic and blood pressure responses to dietary sodium, Physiol Res, 56, pp. 393-401, (2007); Defago M.D., Gu D., Hixson J.E., Et al., Common genetic variants in the endothelial system predict blood pressure response to sodium intake: The GenSalt study, Am J Hypertens, 26, pp. 643-656, (2013); Williams J.S., Hopkins P.N., Jeunemaitre X., Brown N.J., CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow, J Hypertens, 29, pp. 1913-1918, (2011); Poch E., Gonzalez D., Giner V., Bragulat E., Coca A., de La Sierra A., Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms, Hypertension, 38, pp. 1204-1209, (2001); Caprioli J., Mele C., Mossali C., Gallizioli L., Giacchetti G., Noris M., Remuzzi G., Benigni A., Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension, Can J Physiol Pharmacol, 86, pp. 505-551, (2008); Wang J.G., Liu L., Zagato L., Et al., Blood pressure in relation to three candidate genes in a Chinese population, J Hypertens, 22, pp. 937-944, (2004); Williams S.M., Ritchie M.D., Phillips J.A., Et al., Multilocus analysis of hypertension: A hierarchical approach, Hum Hered, 57, pp. 28-38, (2004)","I. Armando; Division of Nephrology, Department of Medicine, Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, United States; email: iarmando@medicine.umaryland.edu","","Bentham Science Publishers B.V.","","","","","","15734021","","","26028245","English","Curr. Hypertens. Rev.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84934767059"
"Song L.; Chen X.; Swanson T.A.; Laviolette B.; Pang J.; Cunio T.; Nagle M.W.; Asano S.; Hales K.; Shipstone A.; Sobon H.; Al-Harthy S.D.; Ahn Y.; Kreuser S.; Robertson A.; Ritenour C.; Voigt F.; Boucher M.; Sun F.; Sessa W.C.; Flach R.J.R.","Song, Loujin (58059836300); Chen, Xian (57211101298); Swanson, Terri A. (17344511100); Laviolette, Brianna (57220125483); Pang, Jincheng (53364235700); Cunio, Teresa (57220124446); Nagle, Michael W. (24344580000); Asano, Shoh (57190047699); Hales, Katherine (57200163828); Shipstone, Arun (57218484694); Sobon, Hanna (57220124292); Al-Harthy, Sabra D. (57220124713); Ahn, Youngwook (36652370600); Kreuser, Steven (22980349200); Robertson, Andrew (57194199511); Ritenour, Casey (57208390462); Voigt, Frank (57220125638); Boucher, Magalie (57189518066); Sun, Furong (57220124182); Sessa, William C. (7103173389); Flach, Rachel J Roth (36655685200)","58059836300; 57211101298; 17344511100; 57220125483; 53364235700; 57220124446; 24344580000; 57190047699; 57200163828; 57218484694; 57220124292; 57220124713; 36652370600; 22980349200; 57194199511; 57208390462; 57220125638; 57189518066; 57220124182; 7103173389; 36655685200","Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension","2020","eLife","9","","e58376","1","29","28","34","10.7554/eLife.58376","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097004218&doi=10.7554%2feLife.58376&partnerID=40&md5=d45d5500d01d2d9e4d1033afec9f57f0","Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States; Comparative Medicine, Pfizer Inc, Cambridge, United States; Drug Safety Research & Development, Pfizer Inc, Groton, United States; Early Clinical Development, Pfizer Inc, Cambridge, United States; Acceleron Pharma, Cambridge, United States; Eisai Inc, Cambridge, United States; Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, United States; Target Sciences, Emerging Science and Innovation, Pfizer Inc, Cambridge, United States; Department of Pharmacology, Yale University School of Medicine, New Haven, United States","Song L., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States; Chen X., Comparative Medicine, Pfizer Inc, Cambridge, United States, Drug Safety Research & Development, Pfizer Inc, Groton, United States; Swanson T.A., Early Clinical Development, Pfizer Inc, Cambridge, United States; Laviolette B., Comparative Medicine, Pfizer Inc, Cambridge, United States; Pang J., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States; Cunio T., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States, Acceleron Pharma, Cambridge, United States; Nagle M.W., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States, Eisai Inc, Cambridge, United States; Asano S., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States; Hales K., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States; Shipstone A., Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, United States; Sobon H., Inflammation and Immunology Research Unit, Pfizer Inc, Cambridge, United States; Al-Harthy S.D., Comparative Medicine, Pfizer Inc, Cambridge, United States, Drug Safety Research & Development, Pfizer Inc, Groton, United States; Ahn Y., Target Sciences, Emerging Science and Innovation, Pfizer Inc, Cambridge, United States; Kreuser S., Comparative Medicine, Pfizer Inc, Cambridge, United States; Robertson A., Drug Safety Research & Development, Pfizer Inc, Groton, United States; Ritenour C., Drug Safety Research & Development, Pfizer Inc, Groton, United States; Voigt F., Drug Safety Research & Development, Pfizer Inc, Groton, United States; Boucher M., Drug Safety Research & Development, Pfizer Inc, Groton, United States; Sun F., Early Clinical Development, Pfizer Inc, Cambridge, United States; Sessa W.C., Department of Pharmacology, Yale University School of Medicine, New Haven, United States; Flach R.J.R., Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States","The lymphatic vasculature is involved in the pathogenesis of acute cardiac injuries, but little is known about its role in chronic cardiac dysfunction. Here, we demonstrate that angiotensin II infusion induced cardiac inflammation and fibrosis at 1 week and caused cardiac dysfunction and impaired lymphatic transport at 6 weeks in mice, while co-administration of VEGFCc156s improved these parameters. To identify novel mechanisms underlying this protection, RNA sequencing analysis in distinct cell populations revealed that VEGFCc156s specifically modulated angiotensin II-induced inflammatory responses in cardiac and peripheral lymphatic endothelial cells. Furthermore, telemetry studies showed that while angiotensin II increased blood pressure acutely in all animals, VEGFCc156s-treated animals displayed a delayed systemic reduction in blood pressure independent of alterations in angiotensin II-mediated aortic stiffness. Overall, these results demonstrate that VEGFCc156s had a multifaceted therapeutic effect to prevent angiotensin II-induced cardiac dysfunction by improving cardiac lymphatic function, alleviating fibrosis and inflammation, and ameliorating hypertension. © Song et al.","","Angiotensin II; Animals; Biomarkers; Endothelial Cells; Gene Knock-In Techniques; Genome-Wide Association Study; Green Fluorescent Proteins; Heart Diseases; Homeodomain Proteins; Humans; Hypertension; Male; Mice; Mice, Inbred C57BL; Myocardium; Random Allocation; Sequence Analysis, RNA; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor C; adenosine; alpha 1,3 mannosyl glycoprotein 2 beta N acetylglucosaminyltransferase; angiotensin II; brain natriuretic peptide; buprenorphine; carprofen; CD68 antigen; collagen type 1; collagen type 1 alpha 1 chain; collagen type 1 alpha 2 chain; collagen type 3; collagen type 3 alpha 1; complementary DNA; fatty acid; hemoglobin; heparin; isoflurane; messenger RNA; n acetylglucosaminyltransferase; olfactory receptor family two subfamily y member 1; papaverine; podoplanin; potassium chloride; secretoglobin; secretoglobin family 3A member 1; toll like receptor 3; toll like receptor 4; unclassified drug; vasculotropin C; vasculotropin C 156s; vasculotropin receptor 2; vasculotropin receptor 3; wheat germ agglutinin; angiotensin II; biological marker; enhanced green fluorescent protein; green fluorescent protein; homeodomain protein; prospero-related homeobox 1 protein; tumor suppressor protein; vasculotropin C; albumin to creatinine ratio; animal experiment; animal model; Article; cardiac muscle cell; carditis; cell infiltration; cell population; CRISPR-CAS9 system; diastolic blood pressure; down regulation; echocardiography; endothelium cell; enzyme linked immunosorbent assay; fibrosis; gene; gene expression; gene locus; gene sequence; genome-wide association study; gravimetry; heart disease; heart failure; heart function; heart left ventricle ejection fraction; heart muscle contractility; heart rate; heart ventricle hypertrophy; heart weight; hematocrit; histology; hypertension; interstitial mononuclear cell; kidney function; lymph vessel; lymph vessel density; lymphangiogenesis; lymphangiography; LYVE1 gene; male; metabolic phenotype; mononuclear cell; mouse; mRNA expression level; nonhuman; olfactory receptor; peripheral lymphatic endothelial cell; protein degradation; protein expression; protein urine level; RNA extraction; RNA isolation; RNA sequence; RNA sequencing; signal transduction; single nucleotide polymorphism; systolic blood pressure; telemetry; animal; C57BL mouse; cardiac muscle; gene knock-in; heart disease; human; hypertension; metabolism; randomization; sequence analysis","","adenosine, 58-61-7; angiotensin II, 11128-99-7, 68521-88-0; brain natriuretic peptide, 114471-18-0; buprenorphine, 52485-79-7, 53152-21-9; carprofen, 52263-47-5, 53716-49-7; hemoglobin, 9008-02-0; heparin, 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; isoflurane, 26675-46-7; n acetylglucosaminyltransferase, 9054-49-3; papaverine, 58-74-2, 61-25-6; potassium chloride, 7447-40-7; toll like receptor 4, 203811-83-0; vasculotropin C, 171342-42-0, 185969-81-7; Angiotensin II, ; Biomarkers, ; enhanced green fluorescent protein, ; Green Fluorescent Proteins, ; Homeodomain Proteins, ; prospero-related homeobox 1 protein, ; Tumor Suppressor Proteins, ; Vascular Endothelial Growth Factor C, ","AimStrip Hb Hemoglobin system; Alzet 1002 pump, Alzet, United States; Alzet 2006 pump, Alzet, United States; DVEC00 ELISA kit, R and D Systems, United States; Vevo 3100 Imaging System, VisualSonics, Canada","Alzet, United States; Alzet, United States; R and D Systems, United States; VisualSonics, Canada","Pfizer, Inc; Pfizer","Funding text 1: We thank Dr. Kendra Bence for helpful discussions and suggestions for the project. We thank Rob Webster and John Litchfield for their help with the pharmacokinetic analysis for the studies. We thank Donald Bennett for helpful advice on biostatistics. We thank Matthew Peloquin and Dr. Federico Damilano for their helpful advice on experiments. We thank the genetically engineered murine model (GEMM) facility at Pfizer Inc for their support in transgenic animal model generation. The project is supported by funding from Pfizer, IncPfizer Rachel J Roth Flach.; Funding text 2: Federico Damilano for their helpful advice on experiments. We thank the genetically engineered murine model (GEMM) facility at Pfizer Inc for their support in transgenic animal model generation. The project is supported by funding from Pfizer, Inc","Atsma F, Veldhuizen I, de Kort W, van Kraaij M, Pasker-de Jong P, Deinum J., Hemoglobin level is positively associated with blood pressure in a large cohort of healthy individuals, Hypertension, 60, pp. 936-941, (2012); Balasubbramanian D, Gelston CAL, Lopez AH, Iskander G, Tate W, Holderness H, Rutkowski JM, Mitchell BM., Augmenting renal lymphatic density prevents angiotensin II-Induced hypertension in male and female mice, American Journal of Hypertension, 33, pp. 61-69, (2020); Beaini S, Saliba Y, Hajal J, Smayra V, Bakhos JJ, Joubran N, Chelala D, Fares N., VEGF-C attenuates renal damage in salt-sensitive hypertension, Journal of Cellular Physiology, 234, pp. 9616-9630, (2019); Benigni A, Cassis P, Remuzzi G., Angiotensin II revisited: new roles in inflammation, immunology and aging, EMBO Molecular Medicine, 2, pp. 247-257, (2010); Brakenhielm E, Gonzalez A, Diez J., Role of cardiac lymphatics in myocardial Edema and Fibrosis: JACC Review Topic of the Week, Journal of the American College of Cardiology, 76, pp. 735-744, (2020); Brakenhielm E, Alitalo K., Cardiac lymphatics in health and disease, Nature Reviews Cardiology, 16, pp. 56-68, (2019); Breslin JW, Gaudreault N, Watson KD, Reynoso R, Yuan SY, Wu MH., Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism, American Journal of Physiology-Heart and Circulatory Physiology, 293, pp. H709-H718, (2007); Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP., Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse, Neuromuscular Disorders, 14, pp. 675-682, (2004); Caillon A, Paradis P, Schiffrin EL., Role of immune cells in hypertension, British Journal of Pharmacology, 176, pp. 1818-1828, (2019); Chachaj A, Pula B, Chabowski M, Grzegrzolka J, Szahidewicz-Krupska E, Karczewski M, Janczak D, Dziegiel P, Podhorska-Okolow M, Mazur G, Gamian A, Szuba A., Role of the lymphatic system in the pathogenesis of hypertension in humans, Lymphatic Research and Biology, 16, pp. 140-146, (2018); Chindelevitch L, Ziemek D, Enayetallah A, Randhawa R, Sidders B, Brockel C, Huang ES., Causal reasoning on biological networks: interpreting transcriptional changes, Bioinformatics, 28, pp. 1114-1121, (2012); Cimini M, Cannata A, Pasquinelli G, Rota M, Goichberg P., Phenotypically heterogeneous podoplanin-expressing cell populations are associated with the lymphatic vessel growth and fibrogenic responses in the acutely and chronically infarcted myocardium, PLOS ONE, 12, (2017); Cimini M, Garikipati VNS, de Lucia C, Cheng Z, Wang C, Truongcao MM, Lucchese AM, Roy R, Benedict C, Goukassian DA, Koch WJ, Kishore R., Podoplanin neutralization improves cardiac remodeling and function after acute myocardial infarction, JCI Insight, 5, (2019); Cui Y, Urschel JD, Petrelli NJ., The effect of cardiopulmonary lymphatic obstruction on heart and lung function, The Thoracic and Cardiovascular Surgeon, 49, pp. 35-40, (2001); Dashkevich A, Bloch W, Antonyan A, Fries JU, Geissler HJ., Morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure, Lymphatic Research and Biology, 7, pp. 21-27, (2009); Dashkevich A, Bloch W, Antonyan A, Goebel H, Fries JU, Schlensak C, Beyersdorf F, Geissler HJ., Immunohistochemical study of remodeling of myocardial lymphatic and blood microvascular structures in terminal heart failure: differences between ischemic and dilated cardiomyopathy, Lymphology, 43, pp. 110-117, (2010); Dieterich LC, Ducoli L, Shin JW, Detmar M., Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation, Scientific Data, 4, (2017); Dongaonkar RM, Stewart RH, Geissler HJ, Laine GA., Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function, Cardiovascular Research, 87, pp. 331-339, (2010); Dongaonkar RM, Nguyen TL, Quick CM, Heaps CL, Hardy J, Laine GA, Wilson E, Stewart RH., Mesenteric lymphatic vessels adapt to mesenteric venous hypertension by becoming weaker pumps, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 308, pp. R391-R399, (2015); Dorans KS, Mills KT, Liu Y, He J., Trends in prevalence and control of hypertension according to the 2017 American college of cardiology/American heart association (ACC/AHA) Guideline, Journal of the American Heart Association, 7, (2018); Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K., Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, The Lancet, 387, pp. 957-967, (2016); Franssen EJF, Moolenaar F, de Zeeuw D, Meijer DKF., Drug targeting to the kidney with low-molecular-weight proteins, Advanced Drug Delivery Reviews, 14, pp. 67-88, (1994); Fung K, Ramirez J, Warren HR, Aung N, Lee AM, Tzanis E, Petersen SE, Munroe PB., Genome-wide association study identifies loci for arterial stiffness index in 127,121 UK biobank participants, Scientific Reports, 9, (2019); Gomolak JR, Didion SP., Angiotensin II-induced endothelial dysfunction is temporally linked with increases in interleukin-6 and vascular macrophage accumulation, Frontiers in Physiology, 5, (2014); Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Levy F, Henry J-P, Dumesnil A, Boukhalfa I, Banquet S, Schapman D, Thuillez C, Richard V, Mulder P, Brakenhielm E., Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction, Circulation, 133, pp. 1484-1497, (2016); Houssari M, Dumesnil A, Tardif V, Kivela R, Pizzinat N, Boukhalfa I, Godefroy D, Schapman D, Hemanthakumar KA, Bizou M, Henry JP, Renet S, Riou G, Rondeaux J, Anouar Y, Adriouch S, Fraineau S, Alitalo K, Richard V, Mulder P, Et al., Lymphatic and immune cell Cross-Talk regulates cardiac recovery after experimental myocardial infarction, Arteriosclerosis, Thrombosis, and Vascular Biology, 40, pp. 1722-1737, (2020); Huang LH, Lavine KJ, Randolph GJ., Cardiac lymphatic vessels, transport, and healing of the infarcted heart, JACC: Basic to Translational Science, 2, pp. 477-483, (2017); Johansson A, Marroni F, Hayward C, Franklin CS, Kirichenko AV, Jonasson I, Hicks AA, Vitart V, Isaacs A, Axenovich T, Campbell S, Floyd J, Hastie N, Knott S, Lauc G, Pichler I, Rotim K, Wild SH, Zorkoltseva IV, Wilson JF, Et al., Linkage and Genome-wide Association analysis of Obesity-related phenotypes: association of weight with the MGAT1 Gene, Obesity, 18, pp. 803-808, (2010); Joukov V, Kumar V, Sorsa T, Arighi E, Weich H, Saksela O, Alitalo K., A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities, Journal of Biological Chemistry, 273, pp. 6599-6602, (1998); Karaderi T, Highland HM, Young KL, Graff M, Lu Y, Turcot V, Auer PL, Fine RS, Guo X, Schurmann C, Lempradl A, Marouli E, Mahajan A, Winkler TW, Locke AE, Medina-Gomez C, Esko T, Vedantam S, Giri A, Et al., Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution, Nature Genetics, 51, pp. 452-469, (2019); Karlsen TV, Nikpey E, Han J, Reikvam T, Rakova N, Castorena-Gonzalez JA, Davis MJ, Titze JM, Tenstad O, Wiig H., High-Salt diet causes expansion of the lymphatic network and increased lymph flow in skin and muscle of rats, Arteriosclerosis, Thrombosis, and Vascular Biology, 38, pp. 2054-2064, (2018); Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, Vaarhorst A, Kangas AJ, Lyytikainen LP, Pirinen M, Pool R, Sarin AP, Soininen P, Tukiainen T, Wang Q, Tiainen M, Tynkkynen T, Amin N, Zeller T, Beekman M, Et al., Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA, Nature Communications, 7, (2016); Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, Schoech A, Pasaniuc B, Price AL., Leveraging polygenic functional enrichment to improve GWAS power, The American Journal of Human Genetics, 104, pp. 65-75, (2019); King KC, Goldstein S., Congestive Heart Failure and Pulmonary Edema, (2020); Klotz L, Norman S, Vieira JM, Masters M, Rohling M, Dube KN, Bollini S, Matsuzaki F, Carr CA, Riley PR., Cardiac lymphatics are heterogeneous in origin and respond to injury, Nature, 522, pp. 62-67, (2015); Liu X, Oliver G., New insights about the lymphatic vasculature in cardiovascular diseases, F1000Research, 8, (2019); Lopez Gelston CA, Balasubbramanian D, Abouelkheir GR, Lopez AH, Hudson KR, Johnson ER, Muthuchamy M, Mitchell BM, Rutkowski JM., Enhancing renal lymphatic expansion prevents hypertension in mice, Circulation Research, 122, pp. 1094-1101, (2018); Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, Day FR, Li C, Bowker N, Cai L, De Lucia Rolfe E, Khaw KT, Perry JRB, O'Rahilly S, Scott RA, Savage DB, Burgess S, Wareham NJ, Langenberg C., Association of genetic variants related to gluteofemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors, Jama, 320, pp. 2553-2563, (2018); Lu X, Peloso GM, Liu DJ, Wu Y, Zhang H, Zhou W, Li J, Tang CS, Dorajoo R, Li H, Long J, Guo X, Xu M, Spracklen CN, Chen Y, Liu X, Zhang Y, Khor CC, Liu J, Sun L, Et al., Exome chip meta-analysis identifies novel loci and east Asian-specific coding variants that contribute to lipid levels and coronary artery disease, Nature Genetics, 49, pp. 1722-1730, (2017); Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J., Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice, Hypertension, 35, pp. 985-991, (2000); Mehlhorn U, Davis KL, Burke EJ, Adams D, Laine GA, Allen SJ., Impact of cardiopulmonary bypass and cardioplegic arrest on myocardial lymphatic function, American Journal of Physiology-Heart and Circulatory Physiology, 268, pp. H178-H183, (1995); Mehta PK, Griendling KK., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system, American Journal of Physiology-Cell Physiology, 292, pp. C82-C97, (2007); Nasa Sinnott-Armstrong YT, Amar Mars DD, Aguirre M., Genetics of 38 blood and urine biomarkers in the UK biobank, bioRxiv, (2019); Norrmen C, Tammela T, Petrova TV, Alitalo K., Biological basis of therapeutic lymphangiogenesis, Circulation, 123, pp. 1335-1351, (2011); Oliver G, Kipnis J, Randolph GJ, Harvey NL., The lymphatic vasculature in the 21<sup>st</sup> Century: Novel Functional Roles in Homeostasis and Disease, Cell, 182, pp. 270-296, (2020); Pertl C, Eblenkamp M, Pertl A, Pfeifer S, Wintermantel E, Lochmuller H, Walter MC, Krause S, Thirion C., A new web-based method for automated analysis of muscle histology, BMC Musculoskeletal Disorders, 14, (2013); Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E., Podoplanin in inflammation and Cancer, International Journal of Molecular Sciences, 20, (2019); Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WH, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Boesgaard TW, Et al., Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge, Nature Genetics, 42, pp. 142-148, (2010); Shimizu Y, Polavarapu R, Eskla KL, Pantner Y, Nicholson CK, Ishii M, Brunnhoelzl D, Mauria R, Husain A, Naqvi N, Murohara T, Calvert JW., Impact of lymphangiogenesis on cardiac remodeling after ischemia and reperfusion injury, Journal of the American Heart Association, 7, (2018); Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J., Inflammation and angiotensin II, The International Journal of Biochemistry & Cell Biology, 35, pp. 881-900, (2003); Sweet ME, Cocciolo A, Slavov D, Jones KL, Sweet JR, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG., Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure, BMC Genomics, 19, (2018); Tackling G, Borhade MB., Hypertensive Heart Disease, (2019); Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K., Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation, Nature Medicine, 13, pp. 1458-1466, (2007); Tatin F, Renaud-Gabardos E, Godet AC, Hantelys F, Pujol F, Morfoisse F, Calise D, Viars F, Valet P, Masri B, Prats AC, Garmy-Susini B., Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction, JCI Insight, 2, (2017); Trincot CE, Xu W, Zhang H, Kulikauskas MR, Caranasos TG, Jensen BC, Sabine A, Petrova TV, Caron KM., Adrenomedullin induces cardiac lymphangiogenesis after myocardial infarction and regulates cardiac edema via connexin 43, Circulation Research, 124, pp. 101-113, (2019); van der Harst P, Verweij N., Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease, Circulation Research, 122, pp. 433-443, (2018); van Heesch S, Witte F, Schneider-Lunitz V, Schulz JF, Adami E, Faber AB, Kirchner M, Maatz H, Blachut S, Sandmann C-L, Kanda M, Worth CL, Schafer S, Calviello L, Merriott R, Patone G, Hummel O, Wyler E, Obermayer B, Mucke MB, Et al., The translational landscape of the human heart, Cell, 178, pp. 242-260, (2019); Vieira JM, Norman S, Villa Del Campo C, Cahill TJ, Barnette DN, Gunadasa-Rohling M, Johnson LA, Greaves DR, Carr CA, Jackson DG, Riley PR., The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction, Journal of Clinical Investigation, 128, pp. 3402-3412, (2018); Vivien CJ, Pichol-Thievend C, Sim CB, Smith JB, Bower NI, Hogan BM, Hudson JE, Francois M, Porrello ER., Vegfc/d-dependent regulation of the lymphatic vasculature during cardiac regeneration is influenced by injury context, npj Regenerative Medicine, 4, (2019); Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Ura S, Wada K, Iguchi M, Et al., VEGF-C and mortality in patients with suspected or known coronary artery disease, Journal of the American Heart Association, 7, (2018); Watanabe T, Barker TA, Berk BC., Angiotensin II and the endothelium: diverse signals and effects, Hypertension, 45, pp. 163-169, (2005); Wild PS, Felix JF, Schillert A, Teumer A, Chen MH, Leening MJG, Volker U, Grossmann V, Brody JA, Irvin MR, Shah SJ, Pramana S, Lieb W, Schmidt R, Stanton AV, Malzahn D, Smith AV, Sundstrom J, Minelli C, Ruggiero D, Et al., Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function, Journal of Clinical Investigation, 127, pp. 1798-1812, (2017); Xu H, Dorn GW, Shetty A, Parihar A, Dave T, Robinson SW, Gottlieb SS, Donahue MP, Tomaselli GF, Kraus WE, Mitchell BD, Liggett SB., A Genome-Wide association study of idiopathic dilated cardiomyopathy in african americans, Journal of Personalized Medicine, 8, (2018)","R.J.R. Flach; Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States; email: Rachel.RothFlach@pfizer.com","","eLife Sciences Publications Ltd","","","","","","2050084X","","","33200983","English","eLife","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85097004218"
"Patel S.K.; Velkoska E.; Freeman M.; Wai B.; Lancefield T.F.; Burrell L.M.","Patel, Sheila K. (7403903273); Velkoska, Elena (24767072500); Freeman, Melanie (57203685284); Wai, Bryan (26435652200); Lancefield, Terase F. (36610369700); Burrell, Louise M. (35467191500)","7403903273; 24767072500; 57203685284; 26435652200; 36610369700; 35467191500","From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension","2014","Frontiers in Physiology","5 JUN","","227","","","","115","10.3389/fphys.2014.00227","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904431923&doi=10.3389%2ffphys.2014.00227&partnerID=40&md5=63cdc38db9e01ece13536567f5d492cb","Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Department of Cardiology, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Department of Cardiology, The Northern Hospital, University of Melbourne, Epping, VIC, Australia","Patel S.K., Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Velkoska E., Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Freeman M., Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Wai B., Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia, Department of Cardiology, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Lancefield T.F., Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; Burrell L.M., Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia, Department of Cardiology, Austin Health, University of Melbourne, Heidelberg, VIC, Australia, Department of Cardiology, The Northern Hospital, University of Melbourne, Epping, VIC, Australia","Hypertension is a major risk factor for stroke, coronary events, heart and renal failure, and the renin-angiotensin system (RAS) plays a major role in its pathogenesis. Within the RAS, angiotensin converting enzyme (ACE) converts angiotensin (Ang) I into the vasoconstrictor Ang II. An ""alternate"" arm of the RAS now exists in which ACE2 counterbalances the effects of the classic RAS through degradation of Ang II, and generation of the vasodilator Ang 1-7. ACE2 is highly expressed in the heart, blood vessels, and kidney. The catalytically active ectodomain of ACE2 undergoes shedding, resulting in ACE2 in the circulation. The ACE2 gene maps to a quantitative trait locus on the X chromosome in three strains of genetically hypertensive rats, suggesting that ACE2 may be a candidate gene for hypertension. It is hypothesized that disruption of tissue ACE/ACE2 balance results in changes in blood pressure, with increased ACE2 expression protecting against increased blood pressure, and ACE2 deficiency contributing to hypertension. Experimental hypertension studies have measured ACE2 in either the heart or kidney and/or plasma, and have reported that deletion or inhibition of ACE2 leads to hypertension, whilst enhancing ACE2 protects against the development of hypertension, hence increasing ACE2 may be a therapeutic option for the management of high blood pressure in man. There have been relatively few studies of ACE2, either at the gene or the circulating level in patients with hypertension. Plasma ACE2 activity is low in healthy subjects, but elevated in patients with cardiovascular risk factors or cardiovascular disease. Genetic studies have investigated ACE2 gene polymorphisms with either hypertension or blood pressure, and have produced largely inconsistent findings. This review discusses the evidence regarding ACE2 in experimental hypertension models and the association between circulating ACE2 activity and ACE2 polymorphisms with blood pressure and arterial hypertension in man. © 2014 Patel, Velkoska, Freeman, Wai, Lancefield and Burrell.","Angiotensin converting enzyme; Angiotensin converting enzyme 2; Blood pressure; Hypertension; Renin angiotensin system","angiotensin converting enzyme 2; ACE2 gene; article; blood pressure regulation; clinical study; disease association; enzyme activity; enzyme inhibition; experimental model; experimental study; gene deletion; gene overexpression; genetic association; human; hypertension; nonhuman; potassium intake; single nucleotide polymorphism; sodium intake; treatment response","","","","","","","Bai S., Huang Z.G., Chen L., Wang J.T., Ding B.P., Effects of felodipine combined with puerarin on ACE2-Ang (1-7)-Mas axis in renovascular hypertensive rat, Regul. Pept., 184, pp. 54-61, (2013); Benjafield A.V., Wang W.Y., Morris B.J., No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension, Am. J. Hypertens., 17, pp. 624-628, (2004); Burchill L., Velkoska E., Dean R.G., Lew R.A., Smith A.I., Levidiotis V., Et al., Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression, Exp. Physiol., 93, pp. 622-630, (2008); Burgelova M., Vanourkova Z., Thumova M., Dvorak P., Opocensky M., Kramer H.J., Et al., Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension, J. Hypertens., 27, pp. 1988-2000, (2009); Burrell L.M., Burchill L., Dean R.G., Griggs K., Patel S.K., Velkoska E., Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition, Exp. Physiol., 97, pp. 477-485, (2012); Burrell L.M., Harrap S.B., Velkoska E., Patel S.K., The ACE2 gene: its potential as a functional candidate for cardiovascular disease, Clin. Sci. (Lond. ), 124, pp. 65-76, (2013); Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S., Et al., Myocardial infarction increases ACE2 expression in rat and humans, Eur. Heart J., 26, pp. 369-375, (2005); Chong C.P., Lim W.K., Velkoska E., Van Gaal W.J., Ryan J.E., Savige J., Et al., N-terminal pro-brain natriuretic peptide and angiotension converting enzyme 2 levels and their association with post-operative cardiac complications after emergency orthopaedic surgery, Am. J. Cardiol., 109, pp. 1365-1373, (2012); Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Et al., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, 417, pp. 822-828, (2002); Dales N.A., Gould A.E., Brown J.A., Calderwood E.F., Guan B., Minor C.A., Et al., Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors, J. Am. Chem. Soc., 124, pp. 11852-11853, (2002); Diez-Freire C., Vazquez J., Correa de Adjounian, M. F., Ferrari, M. F., Yuan, L., Silver, X., et al, Physiol. Genomics, 27, pp. 12-19, (2006); Dilauro M., Zimpelmann J., Robertson S.J., Genest D., Burns K.D., The effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease, Am. J. Physiol. Renal Physiol., 298, (2010); Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9, Circ. Res., 87, (2000); Doobay M.F., Talman L.S., Obr T.D., Tian X., Davisson R.L., Lazartigues E., Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system, Am. J. Physiol. Regul. Integr. Comp. Physiol., 292, (2007); Dzau V., The cardiovascular continuum and renin-angiotensin-aldosterone system blockade, J. Hypertens. Suppl., 23, (2005); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Et al., Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women, Clin. Pharmacol. Ther., 82, pp. 187-196, (2007); Fan X.H., Wang Y.B., Wang H., Sun K., Zhang W.L., Song X.D., Et al., Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients, Acta Pharmacol. Sin., 30, pp. 1237-1244, (2009); Ferreira A.J., Shenoy V., Qi Y., Fraga-Silva R.A., Santos R.A., Katovich M.J., Et al., Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases, Exp. Physiol., 96, pp. 287-294, (2011); Freeman M., Patel S.K., Lancefield T., Velkoska E., Griggs K., Dean R.G., Et al., Angiotensin converting enzyme 2 a novel marker of coronary artery disease, Eur. Heart J., 31, (2011); Gurley S.B., Allred A., Le T.H., Griffiths R., Mao L., Philip N., Et al., Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice, J. Clin. Invest., 116, pp. 2218-2225, (2006); Haber P.K., Ye M., Wysocki J., Maier C., Haque S.K., Batlle D., Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro, Hypertension, 63, pp. 774-782, (2014); Haschke M., Schuster M., Poglitsch M., Loibner H., Salzberg M., Bruggisser M., Et al., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects, Clin. Pharmacokinet., 52, pp. 783-792, (2013); Hernandez Prada J.A., Ferreira A.J., Katovich M.J., Shenoy V., Qi Y., Santos R.A., Et al., Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents, Hypertension, 51, pp. 1312-1317, (2008); Huang J., Chen S., Lu X., Zhao Q., Rao D.C., Jaquish C.E., Et al., Polymorphisms of ACE2 are associated with blood pressure response to cold pressor test: the GenSalt study, Am. J. Hypertens., 25, pp. 937-942, (2012); Huang W., Yang W., Wang Y., Zhao Q., Gu D., Chen R., Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese, J. Hum. Hypertens., 20, pp. 968-971, (2006); Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., Et al., Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats, Exp. Physiol., 90, pp. 783-790, (2005); Johnston C.I., Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling, Hypertension, 23, pp. 258-268, (1994); Kamilic J., Hamming I., Kreutz R., Bolbrinker J., Siems W.E., Nassar I., Et al., Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27, Hypertens. Res., 33, pp. 123-128, (2010); Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J., Global burden of hypertension: analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Keidar S., Strizevsky A., Raz A., Gamliel-Lazarovich A., ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects, Nephrol. Dial. Transplant, 22, pp. 597-601, (2007); Kulemina L.V., Ostrov D.A., Prediction of off-target effects on angiotensin-converting enzyme 2, J. Biomol. Screen., 16, pp. 878-885, (2011); Lambert D.W., Clarke N.E., Hooper N.M., Turner A.J., Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain, FEBS Lett, 582, pp. 385-390, (2008); Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., Et al., Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2), J. Biol. Chem., 280, pp. 30113-30119, (2005); Landau D., Chayat C., Zucker N., Golomb E., Yagil C., Yagil Y., Et al., Early blood pressure-independent cardiac changes in diabetic rats, J. Endocrinol., 197, pp. 75-83, (2008); Lemarie C.A., Schiffrin E.L., The angiotensin II type 2 receptor in cardiovascular disease, J. Renin Angiotensin Aldosterone Syst., 11, pp. 19-31, (2010); Lew R.A., Warner F.J., Hanchapola I., Yarski M.A., Manohar J., Burrell L.M., Et al., Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor, Exp. Physiol., 93, pp. 685-693, (2008); Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., Et al., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men Results of the MONICA Augsburg echocardiographic substudy, J. Mol. Med., 84, pp. 88-96, (2006); Lo J., Patel V.B., Wang Z., Levasseur J., Kaufman S., Penninger J.M., Et al., Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats, Exp. Physiol., 98, pp. 109-122, (2013); Lu N., Yang Y., Wang Y., Liu Y., Fu G., Chen D., Et al., ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11, 051 subjects. Mol. Biol. Rep., 39, pp. 6581-6589, (2012); Malard L., Kakinami L., O'Loughlin J., Roy-Gagnon M.H., Labbe A., Pilote L., Et al., The association between the Angiotensin-Converting Enzyme-2 gene and blood pressure in a cohort study of adolescents, BMC Med. Genet., 14, (2013); Martins Lima A., Xavier C.H., Ferreira A.J., Raizada M.K., Wallukat G., Velloso E.P., Et al., Activation of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis attenuates the cardiac reactivity to acute emotional stress, Am. J. Physiol. Heart Circ. Physiol., 305, (2013); McCarthy C.A., Widdop R.E., Denton K.M., Jones E.S., Update on the angiotensin AT(2) receptor, Curr. Hypertens. Rep., 15, (2013); Meng W., Zhao W., Zhao T., Liu C., Chen Y., Liu H., Et al., Autocrine and paracrine function of angiotensin 1-7 in tissue repair during hypertension, Am. J. Hypertens., 27, pp. 775-782, (2014); Mizuiri S., Hemmi H., Arita M., Ohashi Y., Tanaka Y., Miyagi M., Et al., Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls, Am. J. Kidney Dis., 51, pp. 613-623, (2008); Niu W., Qi Y., Hou S., Zhou W., Qiu C., Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese, Transl. Res., 150, pp. 374-380, (2007); Ocaranza M.P., Rivera P., Novoa U., Pinto M., Gonzalez L., Chiong M., Et al., Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension, J. Hypertens., 29, pp. 706-715, (2011); Ohtsuki M., Morimoto S., Izawa H., Ismail T.F., Ishibashi-Ueda H., Kato Y., Et al., Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure, Int. J. Cardiol., 145, pp. 333-334, (2010); Ortiz-Perez J.T., Riera M., Bosch X., De Caralt T.M., Perea R.J., Pascual J., Et al., Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study, PLoS ONE, 8, (2013); Oudit G.Y., Liu G.C., Zhong J., Basu R., Chow F.L., Zhou J., Et al., Human recombinant ACE2 reduces the progression of diabetic nephropathy, Diabetes, 59, pp. 529-538, (2010); Paizis G., Tikellis C., Cooper M.E., Schembri J.M., Lew R.A., Smith A.I., Et al., Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2, Gut, 54, pp. 1790-1796, (2005); Patel S.K., Velkoska E., Burrell L.M., Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin, Exp. Pharmacol. Physiol., 40, pp. 551-559, (2013); Patel S.K., Wai B., Ord M., Macisaac R.J., Grant S., Velkoska E., Et al., Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes, Am. J. Hypertens., 25, pp. 216-222, (2012); Patel V.B., Clarke N., Wang Z., Fan D., Parajuli N., Basu R., Et al., Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS, J. Mol. Cell. Cardiol., 66, pp. 167-176, (2013); Patnaik M., Pati P., Swain S.N., Mohapatra M.K., Dwibedi B., Kar S.K., Et al., Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India. Ann. Hum. Biol., 41, pp. 143-150, (2014); Pendergrass K.D., Pirro N.T., Westwood B.M., Ferrario C.M., Brosnihan K.B., Chappell M.C., Sex differences in circulating and renal angiotensins of hypertensive mRen(2) Lewis but not normotensive Lewis rats, Am. J. Physiol. Heart Circ. Physiol., 295, (2008); Prieto M.C., Gonzalez-Villalobos R.A., Botros F.T., Martin V.L., Pagan J., Sato R., Et al., Reciprocal changes in renal ACE/Ang II and ACE2/Ang 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats, Am. J. Physiol. Renal Physiol., 300, (2011); Reich H.N., Oudit G.Y., Penninger J.M., Scholey J.W., Herzenberg A.M., Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease, Kidney Int, 74, pp. 1610-1616, (2008); Rentzsch B., Todiras M., Iliescu R., Popova E., Campos L.A., Oliveira M.L., Et al., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function, Hypertension, 52, pp. 967-973, (2008); Rice G.I., Jones A.L., Grant P.J., Carter A.M., Turner A.J., Hooper N.M., Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study, Hypertension, 48, pp. 914-920, (2006); Roberts M.A., Velkoska E., Ierino F.L., Burrell L.M., Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease, Nephrol. Dial. Transplant, 28, pp. 2287-2294, (2013); Santiago N.M., Guimaraes P.S., Sirvente R.A., Oliveira L.A., Irigoyen M.C., Santos R.A., Campagnole-Santos, MJ. Lifetime overproduction of circulating angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling, Hypertension, 55, pp. 889-896, (2010); Santos R.A., Angiotensin-(1-7), Hypertension, 63, pp. 1138-1147, (2014); Santos R.A., Simoese Silva A.C., Maric C., Silva D.M., Machado R.P., De Buhr I., Et al., Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas, Proc. Natl. Acad. Sci. U.S.A., 100, pp. 8258-8263, (2003); Shiota A., Yamamoto K., Ohishi M., Tatara Y., Ohnishi M., Maekawa Y., Et al., Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice, Hypertens. Res., 33, pp. 298-307, (2010); Sluimer J.C., Gasc J.M., Hamming I., Van Goor H., Michaud A., Van Den Akker L.H., Et al., Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions, J. Pathol., 215, pp. 273-279, (2008); Song S.B., Jin H.S., Hong K.W., Lim J.E., Moon J.Y., Jeong K.H., Et al., Association between renin-angiotensin-aldosterone system-related genes and blood pressure in a Korean population, Blood Press, 20, pp. 204-210, (2011); Soro-Paavonen A., Gordin D., Forsblom C., Rosengard-Barlund M., Waden J., Thorn L., Et al., Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications, J. Hypertens., 30, pp. 375-383, (2012); Sriramula S., Cardinale J.P., Lazartigues E., Francis J., ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension, Cardiovasc. Res., 92, pp. 401-408, (2011); Takeda Y., Zhu A., Yoneda T., Usukura M., Takata H., Yamagishi M., Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats, Am. J. Hypertens., 20, pp. 1119-1124, (2007); Tallant E.A., Clark M.A., Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7), Hypertension, 42, pp. 574-579, (2003); Tan Z., Wu J., Ma H., Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1-7) in heart and kidney of spontaneously hypertensive rats, J. Renin Angiotensin Aldosterone Syst., 12, pp. 413-419, (2011); Tikellis C., Bialkowski K., Pete J., Sheehy K., Su Q., Johnston C., Et al., ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes, Diabetes, 57, pp. 1018-1025, (2008); Tikellis C., Cooper M.E., Bialkowski K., Johnston C.I., Burns W.C., Lew R.A., Et al., Developmental expression of ACE2 in the SHR kidney: a role in hypertension?, Kidney Int, 70, pp. 34-41, (2006); Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Burrell L.M., Risvanis J., Et al., Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy, Hypertension, 41, pp. 392-397, (2003); Tikellis C., Pickering R., Tsorotes D., Du X.J., Kiriazis H., Nguyen-Huu T.P., Et al., Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes, Clin. Sci. (Lond. ), 123, pp. 519-529, (2012); Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J., A human homolog of angiotensin-converting enzyme Cloning and functional expression as a captopril-insensitive carboxypeptidase, J. Biol. Chem., 275, pp. 33238-33243, (2000); Trask A.J., Groban L., Westwood B.M., Varagic J., Ganten D., Gallagher P.E., Et al., Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats, Am. J. Hypertens., 23, pp. 687-693, (2010); Uri K., Fagyas M., Manyine Siket I., Kertesz A., Csanadi Z., Sandorfi G., Et al., New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure, PLoS ONE, 9, (2014); Varagic J., Ahmad S., Brosnihan K.B., Groban L., Chappell M.C., Tallant E.A., Et al., Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction, Ther. Adv. Cardiovasc. Dis., 4, pp. 17-25, (2010); Varagic J., Ahmad S., Voncannon J.L., Moniwa N., Simington Jr S.W., Brosnihan B.K., Et al., Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats, J. Hypertens., 30, pp. 1766-1774, (2012); Velkoska E., Dean R.G., Burchill L., Levidiotis V., Burrell L.M., Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition, Clin. Sci. (Lond. ), 118, pp. 269-279, (2010); Velkoska E., Dean R.G., Griggs K., Burchill L., Burrell L.M., Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy, Clin. Sci. (Lond. ), 120, pp. 335-345, (2011); Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Et al., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, J. Biol. Chem., 277, pp. 14838-14843, (2002); World Health Organizati on Global Atlas on Cardiovascular Disease Prevention and Control, (2011); Wysocki J., Ye M., Rodriguez E., Gonzalez-Pacheco F.R., Barrios C., Evora K., Et al., Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2 prevention of angiotensin II-dependent hypertension, Hypertension, 55, pp. 90-98, (2010); Xia H., Feng Y., Obr T.D., Hickman P.J., Lazartigues E., Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice, Hypertension, 53, pp. 210-216, (2009); Xia H., Sriramula S., Chhabra K.H., Lazartigues E., Brain ACE2 shedding contributes to the development of neurogenic hypertension, Circ. Res., 113, pp. 1087-1096, (2013); Xu P., Sriramula S., Lazartigues E., ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good, Am. J. Physiol. Regul. Integr. Comp. Physiol., 300, (2011); Yagil Y., Yagil C., Hypothesis: ACE2 modulates blood pressure in the mammalian organism, Hypertension, 41, pp. 871-873, (2003); Yamazato M., Yamazato Y., Sun C., Diez-Freire C., Raizada M.K., Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats, Hypertension, 49, pp. 926-931, (2007); Yang Z., Yu X., Cheng L., Miao L.-Y., Li H.-X., Han L.-H., Et al., Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats, Arch. Cardiovasc. Dis., 106, pp. 196-201, (2013); Ye M., Wysocki J., Gonzalez-Pacheco F.R., Salem M., Evora K., Garcia-Halpin L., Et al., Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2, Hypertension, 60, pp. 730-740, (2012); Yi L., Gu Y.H., Wang X.L., An L.Z., Xie X.D., Shao W., Et al., Association of ACE ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western, China. J. Int. Med. Res., 34, pp. 272-283, (2006); Zhao Q., Gu D., Kelly T.N., Hixson J.E., Rao D.C., Jaquish C.E., Et al., Association of genetic variants in the apelin-APJ system and ACE2 with blood pressure responses to potassium supplementation: the GenSalt study, Am. J. Hypertens., 23, pp. 606-613, (2010); Zhao Q., Hixson J.E., Rao D.C., Gu D., Jaquish C.E., Rice T., Et al., Genetic variants in the apelin system and blood pressure responses to dietary sodium interventions: a family-based association study, J. Hypertens., 28, pp. 756-763, (2010); Zhong J., Basu R., Guo D., Chow F.L., Byrns S., Schuster M., Et al., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction, Circulation, 122, pp. 717-728, (2010); Zhong J., Guo D., Chen C.B., Wang W., Schuster M., Loibner H., Et al., Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2, Hypertension, 57, pp. 314-322, (2011); Zhong J., Yan Z., Liu D., Ni Y., Zhao Z., Zhu S., Et al., Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome, J. Lab. Clin. Med., 147, pp. 91-95, (2006); Zhong J.C., Huang D.Y., Yang Y.M., Li Y.F., Liu G.F., Song X.H., Et al., Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats, Hypertension, 44, pp. 907-912, (2004); Zhou J.B., Yang J.K., Meta-analysis of association of ACE2 G8790A polymorphism with Chinese Han essential hypertension, J. Renin Angiotensin Aldosterone Syst., 10, pp. 31-34, (2009); Zulli A., Burrell L.M., Buxton B.F., Hare D.L., ACE2 and AT4R are present in diseased human blood vessels, Eur. J. Histochem., 52, pp. 39-44, (2008); Zulli A., Burrell L.M., Widdop R.E., Black M.J., Buxton B.F., Hare D.L., Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques, J. Histochem. Cytochem., 54, pp. 147-150, (2006)","L.M. Burrell; Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Level 7, Lance Townsend Building, 145 Studley Road, Australia; email: l.burrell@unimelb.edu.au","","Frontiers Research Foundation","","","","","","1664042X","","","","English","Front. Physiol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-84904431923"
"Ammar Y.A.; Maharem D.A.; Mohamed A.H.; Khalil G.I.; Shams-Eldin R.S.; Dwedar F.I.","Ammar, Yaser Aly (57218550458); Maharem, Dalia Aly (55315398600); Mohamed, Amira Hussein (58279045900); Khalil, Gihane Ibrahim (7004998823); Shams-Eldin, Riham Said (57225997660); Dwedar, Fatma Ibrahim (57192919860)","57218550458; 55315398600; 58279045900; 7004998823; 57225997660; 57192919860","Fibroblast growth factor-23 rs7955866 polymorphism and risk of chronic kidney disease","2022","Egyptian Journal of Medical Human Genetics","23","1","76","","","","0","10.1186/s43042-022-00289-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128075122&doi=10.1186%2fs43042-022-00289-7&partnerID=40&md5=585e223e9ab7dd2af903f466e43e9bcf","Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt","Ammar Y.A., Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; Maharem D.A., Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; Mohamed A.H., Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; Khalil G.I., Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; Shams-Eldin R.S., Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Dwedar F.I., Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt","Background: A missense gain-of-function fibroblast growth factor-23 (FGF23) gene single nucleotide polymorphism (SNP) (rs7955866) has been associated with FGF23 hypersecretion, phosphaturia, and bone disease. Excess circulating FGF23 was linked with atherosclerosis, hypertension, initiation, and progression of chronic kidney disease (CKD). Methods: The study included 72 CKD stage 2/3 Egyptian patients (27–71 years old, 37 females) and 26 healthy controls matching in age and sex. Repeated measures of blood pressure were used to quantify hypertension on a semiquantitative scale (grades 0 to 5). Fasting serum urea, creatinine, uric acid, total proteins, albumin, calcium, phosphorus, vitamin D3, intact parathyroid hormone (iPTH), and intact FGF23 (iFGF23) were measured. DNA extracted from peripheral blood leucocytes was used for genotyping of FGF23 rs7955866 SNP using the TaqMan SNP genotyping allelic discrimination method. Results: Major causes of CKD were hypertension, diabetic kidney disease, and CKD of unknown etiology. There was no significant difference in minor allele (A) frequency between the studied groups (0.333 in GI and 0.308 in GII). Median (IQR) serum iFGF23 was significantly higher in GI [729.2 (531.9–972.3)] than in GII [126.1 (88.5–152.4)] pg/mL, P < 0.001. Within GI, the minor allele (A) frequency load, coded for codominant inheritance, had a significant positive correlation with both hypertension grade (r = 0.385, P = 0.001) and serum iFGF23 (r = 0.259, P = 0.028). Hypertension grade had a significant positive correlation with serum phosphorus and iFGF23. Conclusions: For the first time in an Egyptian cohort, we report a relatively high frequency of the rs7955866 SNP. It may remain dormant or become upregulated in response to some environmental triggers, notably dietary phosphorus excess, leading to increased circulating iFGF23 with ensuing hypertension and/or renal impairment. Subjects with this SNP, particularly in the homozygous form, are at increased risk for CKD of presumably “unknown” etiology, with a tendency for early onset hypertension and increased circulating iFGF23 out of proportion with the degree of renal impairment. Large-scale population studies are needed to confirm these findings and explore the role of blockers of the renin–angiotensin–aldosterone system and sodium chloride cotransporters in mitigating hypertension associated with FGF23 excess. © 2022, The Author(s).","Chronic kidney disease; Fibroblast growth factor-23; Gene polymorphism; Hypertension; Phosphorus","albumin; antihypertensive agent; calcium; colecalciferol; creatinine; fibroblast growth factor 23; parathyroid hormone; phosphorus; protein; urea; uric acid; adult; albumin blood level; antihypertensive therapy; Article; calcium blood level; case control study; chronic kidney failure; codominance; cohort analysis; controlled study; creatinine blood level; diabetic nephropathy; DNA extraction; Egypt; female; gene frequency; genotype; genotyping; homozygote; human; human cell; hypertension; idiopathic disease; leukocyte; major clinical study; male; parathyroid hormone blood level; phosphate blood level; protein blood level; serum; single nucleotide polymorphism; urea blood level; uric acid blood level; vitamin blood level","","calcium, 7440-70-2, 14092-94-5; colecalciferol, 1406-16-2, 67-97-0; creatinine, 19230-81-0, 60-27-5; parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6; phosphorus, 7723-14-0; protein, 67254-75-5; urea, 57-13-6; uric acid, 69-93-2","","","","","Levey A.S., Coresh J., Balk E., Kausz A.T., Levin A., Steffes M.W., Et al., National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Ann Intern Med, 139, 2, pp. 137-147, (2003); Bikbov B., Purcell C.A., Levey A.S., Smith M., Abdoli A., Abebe M., Et al., Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 395, pp. 709-733, (2020); Ameh O.I., Ekrikpo U.E., Kengne A.-P., Preventing CKD in low-and middle-income countries: a call for urgent action, Kidney Int Rep, 5, 3, pp. 255-262, (2020); Wheeler D.C., Winkelmayer W.C., KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) foreword, Kidney Int Suppl, 7, 1, pp. 1-59, (2017); Witasp A., Ekstrom T.J., Schalling M., Lindholm B., Stenvinkel P., Nordfors L., How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?, Nephrol Dial Transplant, 29, 5, pp. 972-980, (2014); Wohrle S., Bonny O., Beluch N., Gaulis S., Stamm C., Scheibler M., Et al., FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone, J Bone Miner Res, 26, 10, pp. 2486-2497, (2011); Kocelak P., Olszanecka-Glinianowicz M., Chudek J., Fibroblast growth factor 23–structure, function and role in kidney diseases, Adv Clin Exp Med, 21, 3, pp. 391-401, (2012); Liu S., Quarles L.D., How fibroblast growth factor 23 works, J Am Soc Nephrol, 18, 6, pp. 1637-1647, (2007); Goetz R., Nakada Y., Hu M.C., Kurosu H., Wang L., Nakatani T., Et al., Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation, Proc Natl Acad Sci, 107, 1, pp. 407-412, (2010); Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., Et al., Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo, Endocrinol, 143, 8, pp. 3179-3182, (2002); White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J., Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23, Kidney Int, 60, 6, pp. 2079-2086, (2001); White K.E., Evans W.E., O'Riordan J.L., Speer M.C., Econs M.J., Lorenz-Depiereux B., Et al., Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23, Nat Genet, 26, 3, pp. 345-348, (2000); Pekkinen M., Laine C.M., Makitie R., Leinonen E., Lamberg-Allardt C., Viljakainen H., Et al., FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents, Bone, 71, pp. 124-130, (2015); Rendina D., Esposito T., Mossetti G., De Filippo G., Gianfrancesco F., Perfetti A., Et al., A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis, J Clin Endocrinol, 97, 5, pp. E840-E844, (2012); den Dunnen J.T., Dalgleish R., Maglott D.R., Hart R.K., Greenblatt M.S., McGowan-Jordan J., Et al., HGVS recommendations for the description of sequence variants: 2016 update, Hum Mutat, 37, 6, pp. 564-569, (2016); De Filippo G., Rendina D., Esposito T., Gianfrancesco F., Mossetti G., Magliocca, Et al., A common variant of FGF23 gene significantly influences phosphate homeostasis, Horm Res Paediatr, 74, (2010); Econs M.J., McEnery P.T., Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder, J Clin Endocrinol Metab, 82, 2, pp. 674-681, (1997); Imel E.A., Hui S.L., Ecibs M.J., FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets, J Bone Miner Res, 22, 4, pp. 520-526, (2007); Quarles L.D., FGF-23 and α-Klotho co-dependent and independent functions, Curr Opin Nephrol Hypertens, 28, 1, (2019); Erben R.G., Pleiotropic actions of FGF23, Toxicol Pathol, 45, 7, pp. 904-910, (2017); Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., Et al., Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease, Kidney Int, 79, 12, pp. 1370-1378, (2011); Burnett S.A.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S., Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women, J Bone Miner Res, 21, 8, pp. 1187-1196, (2006); Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L.I., White K.E., Et al., Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo, Bone, 49, 4, pp. 636-643, (2011); Lu X., Hu M.C., Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease, Kidney Dis, 3, 1, pp. 15-23, (2017); van Ballegooijen A.J., Rhee E.P., Elmariah S., de Boer I.H., Kestenbaum B., Renal clearance of mineral metabolism biomarkers, J Am Soc Nephrol, 27, 2, pp. 392-397, (2016); Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., Et al., Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease, J Am Med Assoc, 305, 23, pp. 2432-2439, (2011); Lima F., El-Husseini A., Monier-Faugere M.-C., David V., Mawad H., Quarles D., Et al., FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis, Clin Nephrol, 82, 5, (2014); De Jong M.A., Eisenga M.F., van Ballegooijen A.J., Beulens J.W., Vervloet M.G., Navis G., Et al., Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study, Nephrol dial Transplant, 36, 1, pp. 121-128, (2021); Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., Et al., Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study, J Am Soc Nephrol, 18, 9, pp. 2600-2608, (2007); Lundberg S., Qureshi A.R., Olivecrona S., Gunnarsson I., Jacobson S.H., Larsson T.E., FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy, Clin J Am Soc Nephrol, 7, 5, pp. 727-734, (2012); Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., Et al., Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality, J Am Soc Nephrol, 22, 5, pp. 956-966, (2011); Sezer S., Bal Z., Uyar E.M., Ozdemir H., Guliyev O., Yildirim S., Et al., Fibroblast growth factor 23/Klotho axis is a risk factor for kidney transplant loss. Abstract A261, Transplantation, 98, pp. 473-474, (2014); David V., Francis C., Babitt J.L., Ironing out the cross talk between FGF23 and inflammation, Am J Physiol Renal Physiol, 312, 1, pp. F1-F8, (2017); Abdullah Z., Kurts C., More trouble with FGF23: a novel role in systemic immunosuppression, Kidney Int, 89, 6, pp. 1176-1177, (2016); Hanks L.J., Casazza K., Judd S.E., Jenny N.S., Gutierrez O.M., Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults, PLoS ONE, 10, 3, (2015); Yan J., Zhang M., Ni Z., Jin S., Zhu M., Pang H., Associations of serum fibroblast growth factor 23 with dyslipidemia and carotid atherosclerosis in chronic kidney disease stages 3–5D, Clin Exp Med, 10, pp. 13588-13597, (2017); Mirza M.A., Larsson A., Lind L., Larsson T.E., Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community, Atherosclerosis, 205, 2, pp. 385-390, (2009); Yilmaz M.I., Sonmez A., Saglam M., Yaman H., Kilic S., Demirkaya E., Et al., FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease, Kidney Int, 78, 7, pp. 679-685, (2010); Shah N.H., Dong C., Elkind M.S., Sacco R.L., Mendez A.J., Hudson B.I., Et al., Fibroblast growth factor 23 is associated with carotid plaque presence and area: the Northern Manhattan Study, Arterioscler Thromb Vasc Biol, 35, 9, pp. 2048-2053, (2015); Mirza M.A., Hansen T., Johansson L., Ahlstrom H., Larsson A., Lind L., Et al., Relationship between circulating FGF23 and total body atherosclerosis in the community, Nephrol Dial Transplant, 24, 10, pp. 3125-3131, (2009); Donate-Correa J., Martin-Nunez E., Hernandez-Carballo C., Ferri C., Tagua V.G., Delgado-Molinos A., Et al., Fibroblast growth factor 23 expression in human calcified vascular tissues, Aging (Albany NY), 11, 18, (2019); Fyfe-Johnson A.L., Alonso A., Selvin E., Bower J.K., Pankow J.S., Agarwal S.K., Et al., Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study, J Hypertens, 34, 7, pp. 1266-1272, (2016); Akhabue E., Montag S., Reis J.P., Pool L.R., Mehta R., Yancy C.W., Et al., FGF23 (fibroblast growth factor-23) and incident hypertension in young and middle-aged adults: the CARDIA study, Hypertension, 72, 1, pp. 70-76, (2018); Li J., Yu G., Zhuang Y., Impact of serum FGF23 levels on blood pressure of patients with chronic kidney disease, Eur Rev Med Pharmacol Sci, 22, 3, pp. 721-725, (2018); Stevens K.K., McQuarrie E.P., Sands W., Hillyard D.Z., Patel R.K., Mark P.B., Et al., Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation, Int J Nephrol, 2011, pp. 1-6, (2011); Poelzl G., Trenkler C., Kliebhan J., Wuertinger P., Seger C., Kaser S., Et al., FGF 23 is associated with disease severity and prognosis in chronic heart failure, Eur J Clin Invest, 44, 12, pp. 1150-1158, (2014); Arnlov J., Carlsson A.C., Sundstrom J., Ingelsson E., Larsson A., Lind L., Et al., Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community, Kidney Int, 83, 1, pp. 160-166, (2013); Ix J.H., Katz R., Kestenbaum B.R., de Boer I.H., Chonchol M., Mukamal K.J., Et al., Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study), J Am Coll Cardiol, 60, 3, pp. 200-207, (2012); Xue C., Yang B., Zhou C., Dai B., Liu Y., Mao Z., Et al., Fibroblast growth factor 23 predicts all-cause mortality in a dose-response fashion in pre-dialysis patients with chronic kidney disease, Am J Nephrol, 45, 2, pp. 149-159, (2017); Bouma-de Krijger A., de Roij van Zuijdewijn C.L., Nube M.J., Grooteman M.P., Vervloet M.G., Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration, Clin Kidney J, 14, 3, pp. 891-897, (2021); Komaba H., Fuller D.S., Taniguchi M., Yamamoto S., Nomura T., Zhao J., Et al., Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study, Kidney Int Rep, 5, 11, pp. 1956-1964, (2020); Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., Et al., Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis, New Engl J Med, 359, 6, pp. 584-592, (2008); Jean G., Terrat J.-C., Vanel T., Hurot J.-M., Lorriaux C., Mayor B., Et al., High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients, Nephrol Dial Transplant, 24, 9, pp. 2792-2796, (2009); Soliman A.R., Fathy A., Roshd D., The growing burden of end-stage renal disease in Egypt, Ren Fail, 34, 4, pp. 425-428, (2012); Ibrahim M.M., Rizk H., Appel L.J., Aroussy W.E., Helmy S., Sharaf Y., Et al., Hypertension prevalence, awareness, treatment, and control in Egypt: results from the Egyptian National Hypertension Project (NHP), Hypertension, 26, 6, pp. 886-890, (1995); Elbaz W.F., Eissa S.S., Mohamed R.A., Aly N.K., Reda T.M., Essential hypertension among Egyptian adults, Egypt J Hosp Med, 61, 1, pp. 643-652, (2018); Ibrahim M.M., Problem of hypertension in Egypt, Egypt Heart J, 65, 3, pp. 233-234, (2013); Ghonemy T.A., Farag S.E., Soliman S.A., El-Okely A., El-Hendy Y., Epidemiology and risk factors of chronic kidney disease in the El-Sharkia Governorate, Egypt, Saudi J Kidney Dis Transplant, 27, 1, (2016); El-Ballat M.A.-F., El-Sayed M.A., Emam H.K., Epidemiology of end stage renal disease patients on regular hemodialysis in El-Beheira governorate, Egypt Egypt J Hosp Med, 76, 3, pp. 3618-3625, (2019); Ahmed H.A., Zahran A.M., Issawi R.A., Prevalence and etiology of end-stage renal disease patients on maintenance hemodialysis, Menoufia Medical J, 33, 3, pp. 766-771, (2020); Wijerathne B.T., Meier R.J., Salgado L.S., Rathnayake G.K., Kumara S.S., Agampodi S.B., Chronic kidney disease of unknown etiology: the tip of the iceberg?, Ceylon J Med Sci, 55, 2, pp. 55-57, (2018); Levey A.S., Coresh J., Bolton K., Culleton B., Harvey K.S., Ikizler T.A., Et al., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am J Kid Dis, 39, pp. S1-S266, (2002); Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., Et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 71, 19, pp. e127-e248, (2018); Burtis C.A., Ashwood E.R., Bruns D.E., Tietz textbook of clinical chemistry and molecular diagnostics-e-book, (2012); Heijboer A.C., Levitus M., Vervloet M.G., Lips P., ter Wee P.M., Dijstelbloem H.M., Et al., Determination of fibroblast growth factor 23, Ann Clin Biochem, 46, pp. 338-340, (2009); Levey A.S., Stevens L.A., Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions, Am J Kid Dis, 55, 4, pp. 622-627, (2010); Alharbi K.K., Abudawood M., Khan I.A., Amino-acid amendment of arginine-325-tryptophan in rs13266634 genetic polymorphism studies of the SLC30A8 gene with type 2 diabetes-mellitus patients featuring a positive family history in the Saudi population, J King Saud Univ-Sci, 33, 1, (2021); Robinson-Cohen C., Bartz T.M., Lai D., Ikizler T.A., Peacock M., Imel E.A., Et al., Genetic variants associated with circulating fibroblast growth factor 23, J Am Soc Nephrol, 29, 10, pp. 2583-2592, (2018); Ishii T., Gemma A., Kida K., Senescence is involved in the pathogenesis of chronic obstructive pulmonary disease through effects on telomeres and the anti-aging molecule fibroblast growth factor 23, Geriatr Gerontol Int, 15, 7, pp. 827-833, (2015); Kim H.J., Kim K.-H., Lee J., Oh J.J., Cheong H.S., Wong E.L., Et al., Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF23, are associated with prostate cancer risk, BJU Int, 114, 2, pp. 303-310, (2013); Merlotti D., Rendina D., Gennari L., Esposito T., Magliocca S., De F.G., Et al., Interaction between FGF23 R176W mutation and C716T nonsynonymous change (T239M, rs7955866) in FGF23 on the clinical phenotype in a family with autosomal dominant hypophosphatemic rickets, Bone Abstracts, (2013); Wolf M., White K.E., Coupling FGF23 production and cleavage: iron deficiency, rickets and kidney disease, Curr Opin Nephrol Hypertens, 23, 4, pp. 411-419, (2014); Liu C., Li X., Zhao Z., Chi Y., Cui L., Zhang Q., Et al., Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets, Osteoporos Int, 32, 4, pp. 737-745, (2021); Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B., Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers, Kidney Int, 64, 6, pp. 2272-2279, (2003); David V., Martin A., Isakova T., Spaulding C., Qi L., Ramirez V., Et al., Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production, Kidney Int, 89, 1, pp. 135-146, (2016); Wheeler J.A., Clinkenbeard E.L., Regulation of fibroblast growth factor 23 by iron, EPO, and HIF, Curr Mol Biol Rep, 5, 1, pp. 8-17, (2019); Zhou B., Bentham J., Di Cesare M., Bixby H., Danaei G., Cowan M.J., Et al., Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants, Lancet, 389, pp. 37-55, (2017); Mills K.T., Bundy J.D., Kelly T.N., Reed J.E., Kearney P.M., Reynolds K., Et al., Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries, Circulation, 134, 6, pp. 441-450, (2016); Ritz E., The kidney: both culprit and victim, Hypertension, 54, 1, pp. 25-26, (2009); Ravera M., Re M., Deferrari L., Vettoretti S., Deferrari G., Importance of blood pressure control in chronic kidney disease, J Am Soc Nephrol, 17, pp. S98-S103, (2006); Sarafidis P.A., Li S., Chen S.-C., Collins A.J., Brown W.W., Klag M.J., Et al., Hypertension awareness, treatment, and control in chronic kidney disease, Am J Med, 121, 4, pp. 332-340, (2008); Bress A.P., Irvin R., Muntner P., Genetics of blood pressure: new insights into a complex trait, Am J kid Dis, 69, 6, pp. 723-725, (2017); Zajac M., Rybi-Szuminska A., Wasilewska A., Urine fibroblast growth factor 23 levels in hypertensive children and adolescents, Croat Med J, 56, 4, pp. 344-350, (2015); Bockmann I., Lischka J., Richter B., Deppe J., Rahn A., Fischer D.-C., Et al., FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis, Int J Mol Sci, 20, 18, (2019); Dai B., David V., Martin A., Huang J., Li H., Jiao Y., Et al., A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model, PLoS ONE, 7, 9, (2012); Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., Et al., Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease, J Am Soc Nephrol, 16, 7, pp. 2205-2215, (2005); de Borst M.H., Vervloet M.G., ter Wee P.M., Navis G., Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease, J Am Soc Nephrol, 22, 9, pp. 1603-1609, (2011); Li Y.C., Kong J., Wei M., Chen Z.-F., Liu S.Q., Cao L.-P., 1, 25-Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin-angiotensin system, J Clin Invest, 110, 2, pp. 229-238, (2002); Li Y.C., Vitamin D regulation of the renin–angiotensin system, J Cell Biochem, 88, 2, pp. 327-331, (2003); Erben R.G., Andrukhova O., FGF23 regulation of renal tubular solute transport, Curr Opin Nephrol Hypertens, 24, 5, pp. 450-456, (2015); Andrukhova O., Slavic S., Smorodchenko A., Zeitz U., Shalhoub V., Lanske B., Et al., FGF 23 regulates renal sodium handling and blood pressure, EMBO Mol Med, 6, 6, pp. 744-759, (2014); Weber T.J., Liu S., Indridason O.S., Quarles L.D., Serum FGF23 levels in normal and disordered phosphorus homeostasis, J Bone Miner Res, 18, 7, pp. 1227-1234, (2003); Yu X., White K.E., FGF23 and disorders of phosphate homeostasis, Cytokine Growth Factor Rev, 16, 2, pp. 221-232, (2005); Huang X., Jiang Y., Xia W., FGF23 and phosphate wasting disorders, Bone Res, 1, 1, pp. 120-132, (2013); Kobayashi K., Imanishi Y., Koshiyama H., Miyauchi A., Wakasa K., Kawata T., Et al., Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia, Life Sci, 78, 20, pp. 2295-2301, (2006); Tony E.A., Sobh M.A., Abdou M.A.A., Ali M.F., Serum changes in fibroblast growth factor-23 and in parameters of phosphorus metabolism after renal transplantation, J Egypt Soc Nephrol Transplant, 18, 2, pp. 46-56, (2018); Kawarazaki H., Shibagaki Y., Fukumoto S., Kido R., Nakajima I., Fuchinoue S., Et al., The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study, Nephrol Dial Transplant, 26, 8, pp. 2691-2695, (2011); Bhan I., Shah A., Holmes J., Isakova T., Gutierrez O., Burnett S.-A., Et al., Post-transplant hypophosphatemia: tertiary ‘hyper-phosphatoninism’?, Kidney Int, 70, 8, pp. 1486-1494, (2006); Marsell R., Grundberg E., Krajisnik T., Mallmin H., Karlsson M., Mellstrom D., Et al., Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men, Eur J Endocrinol, 158, 1, pp. 125-130, (2008); Roos M., Lutz J., Salmhofer H., Luppa P., Knauss A., Braun S., Et al., Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function, Clin Endocrinol, 68, 4, pp. 660-665, (2008); Kritmetapak K., Losbanos L., Berent T.E., Ashrafzadeh-Kian S.L., Algeciras-Schimnich A., Hines J.M., Et al., Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1, 25 (OH) 2 D and normal FGF7 concentrations characterize patients with CKD, BMC Nephrol, 22, 1, pp. 1-8, (2021); Tentori F., Blayney M.J., Albert J.M., Gillespie B.W., Kerr P.G., Bommer J., Et al., Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS), Am J kid Dis, 52, 3, pp. 519-530, (2008); Slinin Y., Foley R.N., Collins A.J., Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study, J Am Soc Nephrol, 16, 6, pp. 1788-1793, (2005); Seiler S., Heine G.H., Fliser D., Clinical relevance of FGF-23 in chronic kidney disease, Kidney Int, 76, pp. S34-S42, (2009); Rodelo-Haad C., Rodriguez-Ortiz M.E., Martin-Malo A., Pendon-Ruiz de Mier M.V., Aguera M.L., Munoz-Castaneda J.R., Et al., Phosphate control in reducing FGF23 levels in hemodialysis patients, PLoS ONE, 13, 8, (2018); McGovern A.P., de Lusignan S., van Vlymen J., Liyanage H., Tomson C.R., Gallagher H., Et al., Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study, PLoS ONE, 8, 9, (2013); Gross P., Six I., Kamel S., Massy Z.A., Vascular toxicity of phosphate in chronic kidney disease, Circulation J, 78, 10, pp. 2339-2346, (2014); Disthabanchong S., Phosphate and cardiovascular disease beyond chronic kidney disease and vascular calcification, Int J Nephrol, 2018, (2018); Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G., Relation between serum phosphate level and cardiovascular event rate in people with coronary disease, Circulation, 112, 17, pp. 2627-2633, (2005); Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Gaziano J.M., Et al., Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community, Arch Int Med, 167, 9, pp. 879-885, (2007); Zhou C., Shi Z., Ouyang N., Ruan X., Hyperphosphatemia and cardiovascular disease, Front Cell Dev Biol, 9, (2021); Huang C.X., Plantinga L.C., Fink N.E., Melamed M.L., Coresh J., Powe N.R., Phosphate levels and blood pressure in incident hemodialysis patients: a longitudinal study, Adv Chronic Kidney Dis, 15, 3, pp. 321-331, (2008); Wang Q., Cui Y., Yogendranath P., Wang N., Blood pressure and heart rate variability are linked with hyperphosphatemia in chronic kidney disease patients, Chronobiol Int, 35, 10, pp. 1329-1334, (2018); Patel R.K., Jeemon P., Stevens K.K., Mccallum L., Hastie C.E., Schneider A., Et al., Association between serum phosphate and calcium, long-term blood pressure, and mortality in treated hypertensive adults, J Hypertens, 33, 10, pp. 2046-2053, (2015); Shuto E., Taketani Y., Tanaka R., Harada N., Isshiki M., Sato M., Et al., Dietary phosphorus acutely impairs endothelial function, J Am Soc Nephrol, 20, 7, pp. 1504-1512, (2009); Stevens K.K., Denby L., Patel R.K., Mark P.B., Kettlewell S., Smith G.L., Et al., Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway, Nephrol Dial Transplant, 32, 10, pp. 1617-1627, (2017); Olmos G., Martinez-Miguel P., Alcalde-Estevez E., Medrano D., Sosa P., Rodriguez-Manas L., Et al., Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin-1 production, Aging Cell, 16, 6, pp. 1300-1312, (2017); Bozic M., Panizo S., Sevilla M.A., Riera M., Soler M.J., Pascual J., Et al., High phosphate diet increases arterial blood pressure via a parathyroid hormone mediated increase of renin, J Hypertens, 32, 9, pp. 1822-1832, (2014); Mizuno M., Mitchell J.H., Crawford S., Huang C.-L., Maalouf N., Hu M.-C., Et al., High dietary phosphate intake induces hypertension and augments exercise pressor reflex function in rats, Am J Physiol Regul Integr Comp Physiol, 311, 1, pp. R39-R48, (2016); Da J., Xie X., Wolf M., Disthabanchong S., Wang J., Zha Y., Et al., Serum phosphorus and progression of CKD and mortality: a meta-analysis of cohort studies, Am J Kid Dis, 66, 2, pp. 258-265, (2015); Giachelli C.M., The emerging role of phosphate in vascular calcification, Kidney Int, 75, 9, pp. 890-897, (2009); Cozzolino M., Gallieni M., Brancaccio D., The mechanisms of hyperphosphatemia-induced vascular calcification, Int J Artif Organs, 31, 12, pp. 1002-1003, (2008); Cozzolino M., Ciceri P., Galassi A., Mangano M., Carugo S., Capelli I., Et al., The key role of phosphate on vascular calcification, Toxins, 11, 4, (2019); Gutierrez O.M., Anderson C., Isakova T., Scialla J., Negrea L., Anderson A.H., Et al., Low socioeconomic status associates with higher serum phosphate irrespective of race, J Am Soc Nephrol, 21, 11, pp. 1953-1960, (2010); Gutierrez O.M., Isakova T., Enfield G., Wolf M., Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey, J Ren Nutr, 21, 2, pp. 140-148, (2011); Erem S., Razzaque M.S., Dietary phosphate toxicity: An emerging global health concern, Histochem Cell Biol, 150, 6, pp. 711-719, (2018); Kim H.-K., Mizuno M., Vongpatanasin W., Phosphate, the forgotten mineral in hypertension, Curr Opin Nephrol Hypertens, 28, 4, pp. 345-351, (2019); Vervloet M.G., van Zuilen A.D., Heijboer A.C., ter Wee P.M., Bots M.L., Blankestijn P.J., Et al., Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort, BMC Nephrol, 13, 1, pp. 1-8, (2012); Kim H., Park J., Nam K.H., Jhee J.H., Yun H.-R., Park J.T., Et al., The effect of interactions between proteinuria, activity of fibroblast growth factor 23 and serum phosphate on renal progression in patients with chronic kidney disease: a result from the Korean cohort study for outcome in patients with chronic kidney disease study, Nephrol Dial Transplant, 35, 3, pp. 438-446, (2020); Ozeki M., Fujita S.-I., Kizawa S., Morita H., Sohmiya K., Hoshiga M., Et al., Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients, BMC Nephrol, 15, 1, pp. 1-8, (2014); Ix J.H., Shlipak M.G., Wassel C.L., Whooley M.A., Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study, Nephrol Dial Transplant, 25, 3, pp. 993-997, (2010); Tawfik A.A., Hanna E.T., Abdel-Maksoud A.M., Anemia and iron deficiency anemia in Egypt, IOSR J Pharm, 5, 4, pp. 30-34, (2015); Velasquez M.T., Beddhu S., Nobakht E., Rahman M., Raj D.S., Ambulatory blood pressure in chronic kidney disease: ready for prime time?, Kidney Int Rep, 1, 2, pp. 94-104, (2016)","Y.A. Ammar; Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt; email: yaser_ammar88@yahoo.com","","Springer Science and Business Media Deutschland GmbH","","","","","","11108630","","","","English","Egypt. J. Med. Hum. Genet.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85128075122"
"Bruneau M.L., Jr.; Johnson B.T.; Huedo-Medina T.B.; Larson K.A.; Ash G.I.; Pescatello L.S.","Bruneau, Michael L. (56009643400); Johnson, Blair T. (57212747681); Huedo-Medina, Tania B. (6504306003); Larson, Kara A. (56693996900); Ash, Garrett I. (55311648500); Pescatello, Linda S. (7004269363)","56009643400; 57212747681; 6504306003; 56693996900; 55311648500; 7004269363","The blood pressure response to acute and chronic aerobic exercise: A meta-analysis of candidate gene association studies","2016","Journal of Science and Medicine in Sport","19","5","","424","431","7","26","10.1016/j.jsams.2015.05.009","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84932164364&doi=10.1016%2fj.jsams.2015.05.009&partnerID=40&md5=1f3b5486b9b46cdc8f2cb3c26334e5a3","Department of Exercise Science and Sports Studies, Springfield College, Springfield, MA, United States; Department of Kinesiology, University of Connecticut, Storrs, CT, United States; Department of Psychology, University of Connecticut, Storrs, CT, United States; Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States; Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States","Bruneau M.L., Jr., Department of Exercise Science and Sports Studies, Springfield College, Springfield, MA, United States, Department of Kinesiology, University of Connecticut, Storrs, CT, United States; Johnson B.T., Department of Psychology, University of Connecticut, Storrs, CT, United States; Huedo-Medina T.B., Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States; Larson K.A., Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States; Ash G.I., Department of Kinesiology, University of Connecticut, Storrs, CT, United States; Pescatello L.S., Department of Kinesiology, University of Connecticut, Storrs, CT, United States, Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States","Objectives: To meta-analyze candidate gene association studies on the change in blood pressure beyond the immediate post-exercise phase after versus before aerobic exercise. Design: Meta-analysis. Methods: A systematic search was conducted. Studies retrieved included acute (short-term or postexercise hypotension) or chronic (long-term or training) aerobic exercise interventions; and blood pressure measured before and after aerobic exercise training, or before and after exercise or control under ambulatory conditions by genotype. Effect sizes were determined for genotype and adjusted for sample features. Results: Qualifying studies (k = 17, n = 3524) on average included middle-aged, overweight men (44.2%) and women (55.8%) with prehypertension (134.9 ± 11.7/78.6 ± 9.5 mmHg). Training interventions (k = 12) were performed at 60.4 ± 12.9% of maximum oxygen consumption (VO2max) for 41.9 ± 12.5 min session-1, 3.6 ± 1.2 days week-1 for 15.7 ± 7.6 week; and post-exercise hypotension interventions (k = 5) were performed at 53.5 ± 14.4% VO2max for 38.5 ± 5.4 min session-1. Sample characteristics explained 54.2-59.0% of the variability in the blood pressure change after versus before acute exercise or control under ambulatory conditions, and 57.4-67.1% of the variability in the blood pressure change after versus before training (p < 0.001). Only angiotensinogen M235T (rs699) associated with the change in diastolic blood pressure after versus before training (R2 = 0.1%, p = 0.05), but this association did not remain statistically significant after adjustment for multiple comparisons. Conclusions: Sample characteristics explained most of the variability in the change of BP beyond the immediate post-exercise phase after versus before acute and chronic aerobic exercise. Angiotensinogen M235T (rs699) was the only genetic variant that associated with the change in diastolic blood pressure after versus before training, accounting for <1% of the variance. © 2015 Sports Medicine Australia.","Heritability; Hypertension; Physical activity; Polymorphism; Systematic review","Adult; Blood Pressure; Exercise; Female; Humans; Male; Middle Aged; Regression Analysis; aldosterone synthase; alpha adducin; angiotensinogen; cholinergic receptor; dipeptidyl carboxypeptidase; endothelial nitric oxide synthase; guanine nucleotide binding protein alpha subunit; interleukin 6 receptor; lipoprotein lipase; transforming growth factor beta1; aerobic exercise; angiotensin 2 type 1 receptor gene; arginine vasopressin V1a receptor gene; blood pressure; cytochrome b 245 alpha polypeptide gene; diastolic blood pressure; effect size; gene; genetic polymorphism; genotype; human; obesity; oxygen consumption; post exercise hypotension; prehypertension; Review; systematic review; adult; blood pressure; exercise; female; genetics; male; meta analysis; middle aged; physiology; regression analysis","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; lipoprotein lipase, 83137-80-8, 9004-02-8","","","University of Connecticut's Center for Health Intervention and Prevention; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (T32DK097718); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","This meta-analysis was supported by the University of Connecticut's Center for Health Intervention and Prevention. The authors declare no conflict of interest for this meta-analysis. The authors also thank Jill Livingston of the University of Connecticut for her assistance with the systematic literature search. ","Mozaffarian D., Benjamin E.J., Go A.S., Et al., Heart disease and stroke statistics-2015 update: a report from the American heart association, Circulation, 131, 4, pp. e29-e322, (2015); James P.A., Oparil S., Carter B.L., Et al., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, pp. 507-520, (2014); Augeri A.L., Tsongalis G.J., Van Heest J.L., Et al., The endothelial nitric oxide synthase -786 T>C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure, Atherosclerosis, 204, pp. e28-e34, (2009); Blanchard B.E., Tsongalis G.J., Guidry M.A., Et al., RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension, Eur J Appl Physiol, 97, pp. 26-33, (2006); Pescatello L.S., Blanchard B.E., Tsongalis G.J., Et al., The GNAS 393 T > C polymorphism and the blood pressure response immediately following aerobic exercise among men with elevated blood pressure, Vasc Dis Prev, 6, pp. 56-64, (2009); Pescatello L.S., Blanchard B.E., Tsongalis G.J., Et al., The alpha-adducin Gly460Trp polymorphism and the antihypertensive effects of exercise among men with high blood pressure, Clin Sci (Lond), 113, pp. 251-258, (2007); Pescatello L.S., Kulikowich J.M., The aftereffects of dynamic exercise on ambulatory blood pressure, Med Sci Sports Exerc, 33, pp. 1855-1861, (2001); Ash G.I., Eicher J.D., Pescatello L.S., The promises and challenges of the use of genomics in the prescription of exercise for hypertension: the 2013 update, Curr Hypertens Rev, 9, pp. 1-17, (2013); Pescatello L.S., Franklin B.A., Fagard R., Et al., American College of Sports Medicine position stand. Exercise and hypertension, Med Sci Sports Exerc, 36, pp. 533-553, (2004); Thompson P.D., Crouse S.F., Goodpaster B., Et al., The acute versus the chronic response to exercise, Med Sci Sports Exerc, 33, pp. S438-S445, (2001); Brook R.D., Appel L.J., Rubenfire M., Et al., Beyond medications and diet: alternative approaches to lowering blood pressure-a scientific statement from the American Heart Association, Hypertension, 61, pp. 1360-1383, (2013); Pescatello L.S., Arena R., Riebe D., Et al., American College of Sports Medicine, ACSM's Guidelines for Exercise Testing and Prescription, (2013); Bouchard C., Blair S.N., Church T.S., Et al., Adverse metabolic response to regular exercise: is it a rare or common occurrence?, PLoS ONE, 7, (2012); Bouchard C., Rankinen T., Individual differences in response to regular physical activity, Med Sci Sports Exerc, 33, pp. S446-S451, (2001); Hagberg J.M., Park J.J., Brown M.D., The role of exercise training in the treatment of hypertension: an update, Sports Med, 30, pp. 193-206, (2000); Hagberg J.M., Do genetic variations alter the effects of exercise training on cardiovascular disease and can we identify the candidate variants now or in the future?, J Appl Physiol, 111, pp. 916-928, (2011); Hagberg J., Interactive effects of genetics and acute exercise and exercise training on plasma lipoprotein-lipid and blood pressure phenotypes, Exercise Genomics, pp. 129-150, (2011); Bouchard C., Overcoming barriers to progress in exercise genomics, Exerc Sport Sci Rev, 39, pp. 212-217, (2011); Feairheller D.L., Brown M.D., Park J.Y., Et al., Exercise training, NADPH oxidase p22phox gene polymorphisms, and hypertension, Med Sci Sports Exerc, 41, pp. 1421-1428, (2009); Flavell D.M., Wootton P.T., Myerson S.G., Et al., Variation in the lipoprotein lipase gene influences exercise-induced left ventricular growth, J Mol Med, 84, pp. 126-131, (2006); Jones J.M., Park J.J., Johnson J., Et al., Renin-angiotensin system genes and exercise training-induced changes in sodium excretion in African American hypertensives, Ethn Dis, 16, pp. 666-674, (2006); Hautala A.J., Rankinen T., Kiviniemi A.M., Et al., Heart rate recovery after maximal exercise is associated with acetylcholine receptor M2 (CHRM2) gene polymorphism, Am J Physiol Heart Circ Physiol, 291, pp. H459-H466, (2006); Masuki S., Mori M., Tabara Y., Et al., Vasopressin V1a receptor polymorphism and interval walking training effects in middle-aged and older people, Hypertension, 55, pp. 747-754, (2010); Rankinen T., Gagnon J., Perusse L., Et al., AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study, Am J Physiol Heart Circ Physiol, 279, pp. H368-H374, (2000); Rankinen T., Rice T., Leon A.S., Et al., G protein beta 3 polymorphism and hemodynamic and body composition phenotypes in the HERITAGE Family Study, Physiol Genomics, 8, pp. 151-157, (2002); Rauramaa R., Kuhanen R., Lakka T.A., Et al., Physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism, Physiol Genomics, 10, pp. 71-77, (2002); Rivera M.A., Echegaray M., Rankinen T., Et al., TGF-beta(1) gene-race interactions for resting and exercise blood pressure in the HERITAGE Family Study, J Appl Physiol, 91, pp. 1808-1813, (2001); Santana H.A., Moreira S.R., Neto W.B., Et al., The higher exercise intensity and the presence of allele I of ACE gene elicit a higher post-exercise blood pressure reduction and nitric oxide release in elderly women: an experimental study, BMC Cardiovasc Disord, 11, pp. 71-2261, (2011); Takakura Y., Yoshida T., Yoshioka K., Et al., Angiotensinogen gene polymorphism (Met235Thr) influences visceral obesity and insulin resistance in obese Japanese women, Metabolism, 55, pp. 819-824, (2006); Vargas V.R., Bonatto S.L., Macagnan F.E., Et al., Influence of 48867A>C (Asp358Ala) polymorphism of the interleukin 6 receptor on response to a lifestyle modification intervention in individuals with metabolic syndrome, Genet Mol Res, 12, pp. 3983-3991, (2013); Zhang B., Sakai T., Miura S., Et al., Association of angiotensin-converting-enzyme gene polymorphism with the depressor response to mild exercise therapy in patients with mild to moderate essential hypertension, Clin Genet, 62, pp. 328-333, (2002); Borenstein M., Introduction to Meta-Analysis, (2009); Ioannidis J.P., Lau J., Pooling research results: benefits and limitations of meta-analysis, Jt Comm J Qual Improv, 25, pp. 462-469, (1999); Higgins J.P., Thompson S.G., Quantifying heterogeneity in a meta-analysis, Stat Med, 21, pp. 1539-1558, (2002); Meyer G., Simple procedures to estimate chance agreement and kappa for the interrater reliability of response segments using the Rorschach Comprehensive System, J Pers Assess, 72, 2, (1999); (2005); Downs S.H., Black N., The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions, J Epidemiol Community Health, 52, pp. 377-384, (1998); Becker B.J., Synthesizing standardized mean-change measures, Br J Math Stat Psychol, 41, pp. 257-278, (1988); Hedges L.V., Distribution theory for glass's estimator of effect size and related estimators, J Educ Behav Stat, 6, pp. 107-128, (1981); Johnson B., Huedo-Medina T., Meta-analytic statistical inferences for continuous measure outcomes as a function of effect size metric and other assumptions; Begg C.B., Mazumdar M., Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, pp. 1088-1101, (1994); Egger M., Davey Smith G., Schneider M., Et al., Bias in meta-analysis detected by a simple, graphical test, Br Med J, 315, pp. 629-634, (1997); Huedo-Medina T.B., Sanchez-Meca J., Marin-Martinez F., Et al., Assessing heterogeneity in meta-analysis: Q statistic or I2 index?, Psychol Methods, 11, pp. 193-206, (2006); Johnson B.T., Huedo-Medina T.B., Depicting estimates using the intercept in meta-regression models: the moving constant technique, Res Synth Methods, 2, pp. 204-220, (2011); Abdi H., Valentin D., DISTATIS: The analysis of multiple distance matrices, The Encyclopedia of Measurement and Statistics, pp. 1-9; Harris R.J., Bradburn M.J., Deeks J.J., Et al., Metan: fixed- and random-effects meta-analysis, STATA J, 8, pp. 3-28, (2008); Lipsey M., Wilson D.B., Practical Meta-Analysis, (2001); (2009); Wilson D.B., Meta-analysis macros for SAS, SPSS, and Stata, (2001); Bouchard C., Sarzynski M.A., Rice T.K., Et al., Genomic predictors of the maximal O(2) uptake response to standardized exercise training programs, J Appl Physiol, 110, 5, pp. 1160-1170, (2011); Rankinen T., Sung Y.J., Sarzynski M.A., Et al., Heritability of submaximal exercise heart rate response to exercise training is accounted for by nine SNPs, J Appl Physiol, 112, 5, pp. 892-897, (2012); Lumley T., Network meta-analysis for indirect treatment comparisons, Stat Med, 21, pp. 2313-2324, (2002); Campbell M.J., Cluster randomized trials in general (family) practice research, Stat Methods Med Res, 9, pp. 81-94, (2000)","M.L. Bruneau; Department of Exercise Science and Sports Studies, Springfield College, Springfield, United States; email: mbruneaujr@springfieldcollege.edu","","Elsevier Ltd","","","","","","14402440","","JSMSF","26122461","English","J. Sci. Med. Sport","Review","Final","","Scopus","2-s2.0-84932164364"
"Gildea J.J.; Xu P.; Schiermeyer K.A.; Yue W.; Carey R.M.; Jose P.A.; Felder R.A.","Gildea, John J. (7003637575); Xu, Peng (56991962400); Schiermeyer, Katie A. (55631633100); Yue, Wei (7102549270); Carey, Robert M. (7202065232); Jose, Pedro A. (55382768900); Felder, Robin A. (7103080074)","7003637575; 56991962400; 55631633100; 7102549270; 7202065232; 55382768900; 7103080074","Inverse Salt Sensitivity of Blood Pressure Is Associated with an Increased Renin-Angiotensin System Activity","2022","Biomedicines","10","11","2811","","","","2","10.3390/biomedicines10112811","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141879451&doi=10.3390%2fbiomedicines10112811&partnerID=40&md5=dbb2f05df2fc1e34f2879bd671cbc5d7","Department of Pathology, The University of Virginia, Charlottesville, 22903, VA, United States; Division of Endocrinology and Metabolism, Department of Medicine, The University of Virginia, Charlottesville, 22903, VA, United States; Division of Renal Diseases & Hypertension, Department of Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, 20052, DC, United States; Department of Physiology/Pharmacology, School of Medicine and Health Sciences, The George Washington University, Washington, 20052, DC, United States","Gildea J.J., Department of Pathology, The University of Virginia, Charlottesville, 22903, VA, United States; Xu P., Department of Pathology, The University of Virginia, Charlottesville, 22903, VA, United States; Schiermeyer K.A., Department of Pathology, The University of Virginia, Charlottesville, 22903, VA, United States; Yue W., Department of Pathology, The University of Virginia, Charlottesville, 22903, VA, United States; Carey R.M., Division of Endocrinology and Metabolism, Department of Medicine, The University of Virginia, Charlottesville, 22903, VA, United States; Jose P.A., Division of Renal Diseases & Hypertension, Department of Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, 20052, DC, United States, Department of Physiology/Pharmacology, School of Medicine and Health Sciences, The George Washington University, Washington, 20052, DC, United States; Felder R.A., Department of Pathology, The University of Virginia, Charlottesville, 22903, VA, United States","High and low sodium diets are associated with increased blood pressure and cardiovascular morbidity and mortality. The paradoxical response of elevated BP in low salt diets, aka inverse salt sensitivity (ISS), is an understudied vulnerable 11% of the adult population with yet undiscovered etiology. A linear relationship between the number of single nucleotide polymorphisms (SNPs) in the dopamine D2 receptor (DRD2, rs6276 and 6277), and the sodium myo-inositol cotransporter 2 (SLC5A11, rs11074656), as well as decreased expression of these two genes in urine-derived renal proximal tubule cells (uRPTCs) isolated from clinical study participants suggest involvement of these cells in ISS. Insight into this newly discovered paradoxical response to sodium is found by incubating cells in low sodium (LS) conditions that unveil cell physiologic differences that are then reversed by mir-485-5p miRNA blocker transfection and bypassing the genetic defect by DRD2 re-expression. The renin-angiotensin system (RAS) is an important counter-regulatory mechanism to prevent hyponatremia under LS conditions. Oversensitive RAS under LS conditions could partially explain the increased mortality in ISS. Angiotensin-II (AngII, 10 nmol/L) increased sodium transport in uRPTCs to a greater extent in individuals with ISS than SR. Downstream signaling of AngII is verified by identifying lowered expression of nuclear factor erythroid 2-related factor 2 (NRF2), CCCTC-binding factor (CTCF), and manganese-dependent mitochondrial superoxide dismutase (SOD2) only in ISS-derived uRPTCs and not SR-derived uRPTCs when incubated in LS conditions. We conclude that DRD2 and SLC5A11 variants in ISS may cause an increased low sodium sensitivity to AngII and renal sodium reabsorption which can contribute to inverse salt-sensitive hypertension. © 2022 by the authors.","angiotensin; dopamine; dopamine receptor; inverse salt sensitivity; salt resistance; saltsensitivity","","","","","","National Heart, Lung, and Blood Institute, NHLBI, (P01 HL074940, R01 DK039308, R01 DK119652, R01 HL128189); National Heart, Lung, and Blood Institute, NHLBI","This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) P01 HL074940. Carey is Principal Investigator of R01 HL128189 and Project Director for Program Project Grant (P01 HL074940). Jose is Principal Investigator of R01 DK039308 and R01 DK119652 and Project Director of P01 HL074940.","Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., Et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION task force on clinical practice guidelines, Hypertension, 71, pp. e13-e115, (2018); He F.J., Tan M., Ma Y., MacGregor G.A., Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review, J. Am. Coll. Cardiol, 75, pp. 632-647, (2020); Cappuccio F.P., Beer M., Strazzullo P., Population dietary salt reduction and the risk of cardiovascular disease. A scientific statement from the European Salt Action Network, Nutr. Metab. Cardiovasc. Dis, 29, pp. 107-114, (2018); Carey R.M., Schoeffel C.D., Gildea J.J., Jones J.E., McGrath H.E., Gordon L.N., Park M.J., Sobota R.S., Underwood P.C., Williams J., Et al., Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter, Hypertension, 60, pp. 1359-1366, (2012); Elijovich F., Weinberger M.H., Anderson C.A., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L., Hypertension AHAPaPECotCo, Biology CoFGaT, Council aS. Salt sensitivity of blood pressure: A scientific statement from the American Heart Association, Hypertension, 68, pp. e7-e46, (2016); Rucker A.J., Rudemiller N.P., Crowley S.D., Salt, hypertension, and immunity, Annu. Rev. Physiol, 80, pp. 283-307, (2018); Lastra G., Dhuper S., Johnson M.S., Sowers J.R., Salt, aldosterone, and insulin resistance: Impact on the cardiovascular system, Nat. Rev. Cardiol, 7, pp. 577-584, (2010); Kurtz T.W., DiCarlo S.E., Pravenec M., Morris R.C., The American Heart Association scientific statement on salt sensitivity of blood pressure: Prompting consideration of alternative conceptual frameworks for the pathogenesis of salt sensitivity?, J. Hypertens, 35, pp. 2214-2225, (2017); Skrabal F., Herholz H., Neumayr M., Hamberger L., Ledochowski M., Sporer H., Hortnagl H., Schwarz S., Schonitzer D., Salt sensitivity in humans is linked to enhanced sympathetic responsiveness and to enhanced proximal tubular reabsorption, Hypertension, 6, pp. 152-158, (1984); Majid D.S., Kopkan L., Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension, Clin. Exp. Pharmacol. Physiol, 34, pp. 946-952, (2007); Sigmund C.D., Carey R.M., Appel L.J., Arnett D.K., Bosworth H.B., Cushman W.C., Galis Z.S., Green Parker M., Hall J.E., Harrison D.G., Et al., Report of the National Heart, Lung, and Blood Institute working group on hypertension: Barriers to translation, Hypertension, 75, pp. 902-917, (2020); Raizada M.K., Joe B., Bryan N.S., Chang E.B., Dewhirst F.E., Borisy G.G., Galis Z.S., Henderson W., Jose P.A., Ketchum C.J., Et al., Report of the National Heart, Lung, and Blood Institute working group on the role of microbiota in blood pressure regulation: Current status and future directions, Hypertension, 70, pp. 479-485, (2017); Weinberger M.H., Fineberg N.S., Fineberg S.E., Weinberger M., Salt sensitivity, pulse pressure, and death in normal and hypertensive humans, Hypertension, 37, pp. 429-432, (2001); Alderman M.H., Cohen H.W., Dietary sodium intake and cardiovascular mortality: Controversy resolved?, Curr. Hypertens. Rep, 14, pp. 193-201, (2012); O'Donnell M., Mente A., Alderman M.H., Brady A.J.B., Diaz R., Gupta R., Lopez-Jaramillo P., Luft F.C., Luscher T.F., Mancia G., Et al., Salt and cardiovascular disease: Insufficient evidence to recommend low sodium intake, Eur. Heart. J, 41, pp. 3363-3373, (2020); Asayama K., Stolarz-Skrzypek K., Persu A., Staessen J.A., Systematic review of health outcomes in relation to salt intake highlights the widening divide between guidelines and the evidence, Am. J. Hypertens, 27, pp. 1138-1142, (2014); Stolarz-Skrzypek K., Kuznetsova T., Thijs L., Tikhonoff V., Seidlerova J., Richart T., Jin Y., Olszanecka A., Malyutina S., Casiglia E., Et al., Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion, JAMA, 305, pp. 1777-1785, (2011); O'Donnell M., Mente A., Rangarajan S., McQueen M.J., Wang X., Liu L., Yan H., Lee S.F., Mony P., Devanath A., Et al., Urinary sodium and potassium excretion, mortality, and cardiovascular events, N. Engl. J. Med, 371, pp. 612-623, (2014); Strom B.L., Anderson C.A., Ix J.H., Sodium reduction in populations: Insights from the Institute of Medicine committee, JAMA, 310, pp. 31-32, (2013); Gildea J.J., Lahiff D.T., Van Sciver R.E., Weiss R.S., Shah N., McGrath H.E., Schoeffel C.D., Jose P.A., Carey R.M., Felder R.A., A linear relationship between the ex-vivo sodium mediated expression of two sodium regulatory pathways as a surrogate marker of salt sensitivity of blood pressure in exfoliated human renal proximal tubule cells: The virtual renal biopsy, Clin. Chim. Acta, 421, pp. 236-242, (2013); Graudal N., Jurgens G., Conflicting evidence on health effects associated with salt reduction calls for a redesign of the salt dietary guidelines, Prog. Cardiovasc. Dis, 61, pp. 20-26, (2018); Alderman M.H., Blumenfeld J.D., Hypertension: Evolving from standardized to individualized care, J. Hypertens, 38, pp. 1251-1254, (2020); Montasser M.E., Douglas J.A., Roy-Gagnon M.H., Van Hout C.V., Weir M.R., Vogel R., Parsa A., Steinle N.I., Snitker S., Brereton N.H., Et al., Determinants of blood pressure response to low-salt intake in a healthy adult population, J. Clin. Hypertens, 13, pp. 795-800, (2011); Overlack A., Ruppert M., Kolloch R., Gobel B., Kraft K., Diehl J., Schmitt W., Stumpe K.O., Divergent hemodynamic and hormonal responses to varying salt intake in normotensive subjects, Hypertension, 22, pp. 331-338, (1993); Overlack A., Ruppert M., Kolloch R., Kraft K., Stumpe K.O., Age is a major determinant of the divergent blood pressure responses to varying salt intake in essential hypertension, Am. J. Hypertens, 8, pp. 829-836, (1995); Cuka E., Simonini M., Lanzani C., Zagato L., Citterio L., Messaggio E., Faienza S., Brioni E., Hamlyn J.M., Manunta P., Inverse salt sensitivity: An independent risk factor for cardiovascular damage in essential hypertension, J. Hypertens, 40, pp. 1504-1512, (2022); Bihorac A., Tezcan H., Ozener C., Oktay A., Akoglu E., Association between salt sensitivity and target organ damage in essential hypertension, Am. J. Hypertens, 13, pp. 864-872, (2000); Felder R.A., White M.J., Williams S.M., Jose P.A., Diagnostic tools for hypertension and salt sensitivity testing, Curr. Opin. Nephrol. Hypertens, 22, pp. 65-76, (2013); Iatrino R., Manunta P., Zagato L., Salt Sensitivity: Challenging and Controversial Phenotype of Primary Hypertension, Curr. Hypertens. Rep, 18, (2016); Strategies to Reduce Sodium Intake in the United States, (2010); O'Donnell M., Mente A., Rangarajan S., McQueen M.J., O'Leary N., Yin L., Liu X., Swaminathan S., Khatib R., Rosengren A., Et al., Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: Prospective cohort study, BMJ, 364, (2019); Castiglioni P., Parati G., Lazzeroni D., Bini M., Faini A., Brambilla L., Brambilla V., Coruzzi P., Hemodynamic and autonomic response to different salt intakes in normotensive individuals, J. Am. Heart. Assoc, 5, (2016); Gildea J.J., Carlson J.M., Schoeffel C.D., Carey R.M., Felder R.A., Urinary exosome miRNome analysis and its applications to salt sensitivity of blood pressure, Clin. Biochem, 46, pp. 1131-1134, (2013); Barros E.R., Carvajal C.A., Urinary Exosomes and Their Cargo: Potential Biomarkers for Mineralocorticoid Arterial Hypertension?, Front. Endocrinol, 8, (2017); Tan P.P.S., Hall D., Chilian W.M., Chia Y.C., Mohd Zain S., Lim H.M., Kumar D.N., Ching S.M., Low T.Y., Md Noh M.F., Et al., Exosomal microRNAs in the development of essential hypertension and its potential as biomarkers, Am. J. Physiol. Heart Circ. Physiol, 320, pp. H1486-H1497, (2021); Manosroi W., Williams G.H., Genetics of human primary hypertension: Focus on hormonal mechanisms, Endocr. Rev, 40, pp. 825-856, (2019); Rayner B., Ramesar R., The importance of G protein-coupled receptor kinase 4 (GRK4) in pathogenesis of salt sensitivity, salt sensitive hypertension and response to antihypertensive treatment, Int. J. Mol. Sci, 16, pp. 5741-5749, (2015); Jeong S., Kim J.Y., Cho Y., Koh S.B., Kim N., Choi J.R., Genetically, dietary sodium intake is causally associated with salt-sensitive hypertension risk in a community-based cohort study: A mendelian randomization approach, Curr. Hypertens. Rep, 22, (2020); Lee M., Kim M.K., Kim S.M., Park H., Park C.G., Park H.K., Gender-based differences on the association between salt-sensitive genes and obesity in Korean children aged between 8 and 9 years, PLoS ONE, 10, (2015); Sanada H., Yatabe J., Midorikawa S., Hashimoto S., Watanabe T., Moore J.H., Ritchie M.D., Williams S.M., Pezzullo J.C., Sasaki M., Et al., Single nucleotide polymorphisms for diagnosis of salt-sensitive hypertension, Clin. Chem, 52, pp. 352-360, (2006); Bengra C., Mifflin T.E., Khripin Y., Manunta P., Williams S.M., Jose P.A., Felder R.A., Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers, Clin. Chem, 48, pp. 2131-2140, (2002); Wang Z., Zeng C., Villar V.A., Chen S.Y., Konkalmatt P., Wang X., Asico L.D., Jones J.E., Yang Y., Sanada H., Et al., Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition, Hypertension, 67, pp. 325-334, (2016); Diao Z., Asico L.D., Villar V.A.M., Zheng X., Cuevas S., Armando I., Jose P.A., Wang X., Increased renal oxidative stress in salt-sensitive human GRK4gamma486V transgenic mice, Free Radic. Biol. Med, 106, pp. 80-90, (2017); Armando I., Konkalmatt P., Felder R.A., Jose P.A., The renal dopaminergic system: Novel diagnostic and therapeutic approaches in hypertension and kidney disease, Transl. Res, 165, pp. 505-511, (2015); Harris R.C., Zhang M.Z., Dopamine, the kidney, and hypertension, Curr. Hypertens. Rep, 14, pp. 138-143, (2012); Padia S.H., Kemp B.A., Howell N.L., Fournie-Zaluski M.C., Roques B.P., Carey R.M., Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats, Hypertension, 51, pp. 460-465, (2008); Felder R.A., Gildea J.J., Xu P., Yue W., Armando I., Carey R.M., Jose P.A., Inverse Salt Sensitivity of Blood Pressure: Mechanisms and Potential Relevance for Prevention of Cardiovascular Disease, Curr. Hypertens. Rep, 9, pp. 361-374, (2022); Li X., Campbell D., Ohishi M., Yuan S., Zhuo J., AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats, Am. J. Physiol. Renal. Physiol, 290, pp. F1024-F1033, (2006); Danziger R.S., Aminopeptidase N in arterial hypertension, Heart Fail. Rev, 13, pp. 293-298, (2008); Padia S.H., Howell N.L., Kemp B.A., Fournie-Zaluski M.C., Roques B.P., Carey R.M., Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats, Hypertension, 55, pp. 474-480, (2010); Kemp B.A., Howell N.L., Gildea J.J., Keller S.R., Carey R.M., Identification of a Primary Renal AT<sub>2</sub> Receptor Defect in Spontaneously Hypertensive Rats, Circ. Res, 126, pp. 644-659, (2020); Lew R.A., Mustafa T., Ye S., McDowall S.G., Chai S.Y., Albiston A.L., Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP), J. Neurochem, 86, pp. 344-350, (2003); Walton S.L., Mirabito Colafella K.M., Ansari A., Chai S.Y., Denton K.M., Insulin-regulated aminopeptidase deficiency impairs cardiovascular adaptations and placental development during pregnancy, Clin. Sci, 134, pp. 3213-3228, (2020); Hussain T., Abdul-Wahab R., Kotak D.K., Lokhandwala M.F., Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules, Hypertension, 32, pp. 1054-1059, (1998); Sarkar C., Ganju R.K., Pompili V.J., Chakroborty D., Enhanced peripheral dopamine impairs post-ischemic healing by suppressing angiotensin receptor type 1 expression in endothelial cells and inhibiting angiogenesis, Angiogenesis, 20, pp. 97-107, (2017); Choi M.R., Kouyoumdzian N.M., Rukavina Mikusic N.L., Kravetz M.C., Roson M.I., Rodriguez Fermepin M., Fernandez B.E., Renal dopaminergic system: Pathophysiological implications and clinical perspectives, World J. Nephrol, 4, pp. 196-212, (2015); Jiang X., Konkalmatt P., Yang Y., Gildea J.J., Jones J.E., Cuevas S., Felder R.A., Jose P.A., Armando I., Single-nucleotide polymorphisms of the dopamine D2 receptor increase inflammation and fibrosis in human renal proximal tubule cells, Hypertension, 63, pp. e74-e80, (2014); Konkalmatt P.R., Asico L.D., Zhang Y., Yang Y., Drachenberg C., Zheng X., Han F., Jose P.A., Armando I., Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure, JCI Insight, 1, (2016); Zhang Y., Cuevas S., Asico L.D., Escano C., Yang Y., Pascua A.M., Wang X., Jones J.E., Grandy D., Eisner G., Et al., Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure, PLoS ONE, 7, (2012); Zhang Y., Jiang X., Qin C., Cuevas S., Jose P.A., Armando I., Dopamine D2 receptors’ effects on renal inflammation are mediated by regulation of PP2A function, Am. J. Physiol. Renal. Physiol, 310, pp. F128-F134, (2016); Barrese V., Stott J.B., Baldwin S.N., Mondejar-Parreno G., Greenwood I.A., SMIT (Sodium-Myo-Inositol Transporter) 1 Regulates Arterial Contractility Through the Modulation of Vascular Kv7 Channels, Arterioscler. Thromb. Vasc. Biol, 40, pp. 2468-2480, (2020); Lahjouji K., Aouameur R., Bissonnette P., Coady M.J., Bichet D.G., Lapointe J.Y., Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney, Biochim. Biophys. Acta, 1768, pp. 1154-1159, (2007); Gildea J.J., McGrath H.E., Van Sciver R.E., Wang D.B., Felder R.A., Isolation, growth, and characterization of human renal epithelial cells using traditional and 3D methods, Methods Mol. Biol, 945, pp. 329-345, (2013); Gildea J.J., Xu P., Kemp B.A., Carey R.M., Jose P.A., Felder R.A., The dopamine D1 receptor and angiotensin II type-2 receptor are required for inhibition of sodium transport through a protein phosphatase 2A pathway, Hypertension, 73, pp. 1258-1265, (2019); Rosic N.K., Standaert M.L., Pollet R.J., The mechanism of insulin stimulation of (Na+,K+)-ATPase transport activity in muscle, J. Biol. Chem, 260, pp. 6206-6212, (1985); Stojanovic T., Orlova M., Sialana F.J., Hoger H., Stuchlik S., Milenkovic I., Aradska J., Lubec G., Validation of dopamine receptor Drd1 and Drd2 antibodies using receptor deficient mice, Amino Acids, 49, pp. 1101-1109, (2017); Newton C.L., Wood M.D., Strange P.G., Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D<sub>2</sub> and D<sub>3</sub> Receptors, PLoS ONE, 11, (2016); Seeman P., Van Tol H.H., Dopamine receptor pharmacology, Curr. Opin. Neurol. Neurosurg, 6, pp. 602-608, (1993); Kling-Petersen T., Ljung E., Svensson K., Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain, J. Neural. Transm. Gen. Sect, 102, pp. 209-220, (1995); Gao D.Q., Canessa L.M., Mouradian M.M., Jose P.A., Expression of the D2 subfamily of dopamine receptor genes in kidney, Am. J. Physiol, 266, pp. F646-F650, (1994); Gildea J.J., Xu P., Kemp B.A., Carlson J.M., Tran H.T., Bigler Wang D., Langouet-Astrie C.J., McGrath H.E., Carey R.M., Jose P.A., Et al., Sodium bicarbonate cotransporter NBCe2 gene variants increase sodium and bicarbonate transport in human renal proximal tubule cells, PLoS ONE, 13, (2018); Diarra A., Sheldon C., Church J., In situ calibration and [H+] sensitivity of the fluorescent Na+ indicator SBFI, Am. J. Physiol. Cell Physiol, 280, pp. C1623-C1633, (2001); Crocco P., Montesanto A., Passarino G., Rose G., Polymorphisms falling within putative miRNA target sites in the 3’UTR region of SIRT2 and DRD2 genes are correlated with human longevity, J. Gerontol. A Biol. Sci. Med. Sci, 71, pp. 586-592, (2016); Hauberg M.E., Roussos P., Grove J., Borglum A.D., Mattheisen M., Analyzing the role of microRNAs in schizophrenia in the context of common genetic risk variants, JAMA Psychiatry, 73, pp. 369-377, (2016); Maffioletti E., Tardito D., Gennarelli M., Bocchio-Chiavetto L., Micro spies from the brain to the periphery: New clues from studies on micrornas in neuropsychiatric disorders, Front. Cell. Neurosci, 8, (2014); Xu P., Gildea J.J., Zhang C., Konkalmatt P., Cuevas S., Bigler Wang D., Tran H.T., Jose P.A., Felder R.A., Stomach gastrin is regulated by sodium via PPAR-α and dopamine D1 receptor, J. Mol. Endocrinol, 64, pp. 53-65, (2020); Luo Y., Hitz B.C., Gabdank I., Hilton J.A., Kagda M.S., Lam B., Myers Z., Sud P., Jou J., Lin K., Et al., New developments on the Encyclopedia of DNA Elements (ENCODE) data portal, Nucleic Acids Res, 48, pp. D882-D889, (2020); Yang Y., Cuevas S., Yang S., Villar V.A., Escano C., Asico L., Yu P., Jiang X., Weinman E.J., Armando I., Et al., Sestrin2 decreases renal oxidative stress, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of reactive oxygen species production, Hypertension, 64, pp. 825-832, (2014); Cuevas S., Yang Y., Konkalmatt P., Asico L.D., Feranil J., Jones J., Villar V.A., Armando I., Jose P.A., Role of nuclear factor erythroid 2-related factor 2 in the oxidative stress-dependent hypertension associated with the depletion of DJ-1, Hypertension, 65, pp. 1251-1257, (2015); Ryoo I.G., Kwak M.K., Regulatory crosstalk between the oxidative stress-related transcription factor Nfe2l2/Nrf2 and mitochondria, Toxicol. Appl. Pharmacol, 359, pp. 24-33, (2018); Padia S.H., Kemp B.A., Howell N.L., Gildea J.J., Keller S.R., Carey R.M., Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats, Hypertension, 53, pp. 338-343, (2009); Guirguis-Blake J.M., Evans C.V., Webber E.M., Coppola E.L., Perdue L.A., Weyrich M.S., Screening for Hypertension in adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force, (2021); MacFadyen R.J., Lees K.R., Reid J.L., Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers, Br. J. Clin. Pharmacol, 38, pp. 329-334, (1994); Dimsdale J.E., Ziegler M., Mills P., Berry C., Prediction of salt sensitivity, Am. J. Hypertens, 3, pp. 429-435, (1990); Shin Y., Kumar U., Patel Y., Patel S.C., Sidhu A., Differential expression of D2-like dopamine receptors in the kidney of the spontaneously hypertensive rat, J. Hypertens, 21, pp. 199-207, (2003); Fang Y.J., Thomas G.N., Xu Z.L., Fang J.Q., Critchley J.A., Tomlinson B., An affected pedigree member analysis of linkage between the dopamine D2 receptor gene Taq1 polymorphism and obesity and hypertension, Int. J. Cardiol, 102, pp. 111-116, (2005); Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., Court J.A., D2 dopamine receptor gene (DRD2) Taq1 a polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele, Pharmacogenetics, 7, pp. 479-484, (1997); Qaddumi W.N., Jose P.A., The role of the renal dopaminergic system and oxidative stress in the pathogenesis of hypertension, Biomedicines, 9, (2021); Armando I., Asico L.D., Wang X., Jones J.E., Serrao M.P., Cuevas S., Grandy D.K., Soares-da-Silva P., Jose P.A., Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice, Hypertens. Res, 41, pp. 489-498, (2018); Han F., Konkalmatt P., Mokashi C., Kumar M., Zhang Y., Ko A., Farino Z.J., Asico L.D., Xu G., Gildea J., Et al., Dopamine D2 receptor modulates Wnt expression and control of cell proliferation, Sci. Rep, 9, (2019); Han F., Konkalmatt P., Chen J., Gildea J., Felder R.A., Jose P.A., Armando I., miR-217 mediates the protective effects of the dopamine D2 receptor on fibrosis in human renal proximal tubule cells, Hypertension, 65, pp. 1118-1125, (2015); Armando I., Villar V.A., Jose P.A., Dopamine and renal function and blood pressure regulation, Compr. Physiol, 1, pp. 1075-1117, (2011); Zhang M.Z., Yao B., Fang X., Wang S., Smith J.P., Harris R.C., Intrarenal dopaminergic system regulates renin expression, Hypertension, 53, pp. 564-570, (2009); Kemp B.A., Howell N.L., Keller S.R., Gildea J.J., Shao W., Navar L.G., Carey R.M., Defective renal angiotensin III and AT receptor signaling in prehypertensive spontaneously hypertensive rats, J. Am. Heart Assoc, 8, (2019); Kotlo K., Shukla S., Tawar U., Skidgel R.A., Danziger R.S., Aminopeptidase N reduces basolateral Na+ -K+ -ATPase in proximal tubule cells, Am. J. Physiol. Renal. Physiol, 293, pp. F1047-F1053, (2007); Yang R., Smolders I., Dupont A.G., Blood pressure and renal hemodynamic effects of angiotensin fragments, Hypertens. Res, 34, pp. 674-683, (2011); Handa R.K., Biphasic actions of angiotensin IV on renal blood flow in the rat, Regul. Pept, 136, pp. 23-29, (2006); Cuevas S., Villar V.A., Jose P.A., Armando I., Renal dopamine receptors, oxidative stress, and hypertension, Int. J. Mol. Sci, 14, pp. 17553-17572, (2013); Rukavina Mikusic N.L., Silva M.G., Mazzitelli L.R., Santos R.A.S., Gomez K.A., Grecco H.E., Gironacci M.M., Interaction between the angiotensin-(1–7) mas receptor and the dopamine D2 receptor: Implications in inflammation, Hypertension, 77, pp. 1659-1669, (2021); Han X., Li B., Ye X., Mulatibieke T., Wu J., Dai J., Wu D., Ni J., Zhang R., Xue J., Et al., Dopamine D<sub>2</sub> receptor signalling controls inflammation in acute pancreatitis via a PP2A-dependent Akt/NF-κB signalling pathway, Br. J. Pharmacol, 174, pp. 4751-4770, (2017); Udali S., Guarini P., Moruzzi S., Choi S.W., Friso S., Cardiovascular epigenetics: From DNA methylation to microRNAs, Mol. Asp. Med, 34, pp. 883-901, (2013); Chen L.J., Wei S.Y., Chiu J.J., Mechanical regulation of epigenetics in vascular biology and pathobiology, J. Cell Mol. Med, 17, pp. 437-448, (2013); Findeisen H.M., Kahles F.K., Bruemmer D., Epigenetic regulation of vascular smooth muscle cell function in atherosclerosis, Curr. Atheroscler. Rep, 15, (2013); Wang J., Yin N., Deng Y., Wei Y., Huang Y., Pu X., Li L., Zheng Y., Guo J., Yu J., Et al., Ascorbic acid protects against hypertension through downregulation of ACE1 gene expression mediated by histone deacetylation in prenatal inflammation-induced offspring, Sci. Rep, 6, (2016); Schwenk R.W., Vogel H., Schurmann A., Genetic and epigenetic control of metabolic health, Mol. Metab, 2, pp. 337-347, (2013); Tammen S.A., Friso S., Choi S.W., Epigenetics: The link between nature and nurture, Mol. Asp. Med, 34, pp. 753-764, (2013); Banday A.A., Fazili F.R., Lokhandwala M.F., Oxidative stress causes renal dopamine D1 receptor dysfunction and hypertension via mechanisms that involve nuclear factor-kappab and protein kinase C, J. Am. Soc. Nephrol, 18, pp. 1446-1457, (2007); Kawarazaki W., Fujita T., Kidney and epigenetic mechanisms of salt-sensitive hypertension, Nat. Rev. Nephrol, 17, pp. 350-363, (2021); Cuevas S., Villar V.A.M., Jose P.A., Genetic polymorphisms associated with reactive oxygen species and blood pressure regulation, Pharm. J, 19, pp. 315-336, (2019); Lee H., Jiang X., Perwaiz I., Yu P., Wang J., Wang Y., Huttemann M., Felder R.A., Sibley D.R., Polster B.M., Et al., Dopamine D(5) receptor-mediated decreases in mitochondrial reactive oxygen species production are cAMP and autophagy dependent, Hypertens. Res, 44, pp. 628-641, (2021); Gildea J.J., Tran H.T., Van Sciver R.E., Bigler Wang D., Carlson J.M., Felder R.A., A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells, Hypertension, 61, pp. 1021-1027, (2013); Filippova G.N., Fagerlie S., Klenova E.M., Myers C., Dehner Y., Goodwin G., Neiman P.E., Collins S.J., Lobanenkov V.V., An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes, Mol. Cell. Biol, 16, pp. 2802-2813, (1996); Wu M., Liang G., Duan H., Yang X., Qin G., Sang N., Synergistic effects of sulfur dioxide and polycyclic aromatic hydrocarbons on pulmonary pro-fibrosis via mir-30c-1–3p/ transforming growth factor β type ii receptor axis, Chemosphere, 219, pp. 268-276, (2019); Ji W., Foo J.N., O'Roak B.J., Zhao H., Larson M.G., Simon D.B., Newton-Cheh C., State M.W., Levy D., Lifton R.P., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat. Genet, 40, pp. 592-599, (2008); Xu P., Sudarikova A.V., Ilatovskaya D.V., Gildea J.J., Akhter M., Carey R.M., Yue W., Jose P.A., Felder R.A., Epithelial Sodium Channel Alpha Subunit (αENaC) Is Associated with Inverse Salt Sensitivity of Blood Pressure, Biomedicines, 10, (2022); Horniblow R.D., Pathak P., Balacco D.L., Acharjee A., Lles E., Gkoutos G., Beggs A.D., Tselepis C., Iron-mediated epigenetic activation of NRF2 targets, J. Nutr. Biochem, 101, (2022); Dhillon P., Park J., Hurtado Del Pozo C., Li L., Doke T., Huang S., Zhao J., Kang H.M., Shrestra R., Balzer M.S., Et al., The Nuclear Receptor ESRRA Protects from Kidney Disease by Coupling Metabolism and Differentiation, Cell Metab, 33, pp. 379-394.e8, (2021)","R.A. Felder; Department of Pathology, The University of Virginia, Charlottesville, 22903, United States; email: raf7k@virginia.edu","","MDPI","","","","","","22279059","","","","English","Biomedicines","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85141879451"
"Rabaan A.A.; Mutair A.A.; Aljeldah M.; Shammari B.R.A.; Sulaiman T.; Alshukairi A.N.; Alfaresi M.; Al-Jishi J.M.; Al Bati N.A.; Al-Mozaini M.A.; Bshabshe A.A.; Almatouq J.A.; Abuzaid A.A.; Alfaraj A.H.; Al-Adsani W.; Alabdullah M.; Alwarthan S.; Alsalman F.; Alwashmi A.S.S.; Alhumaid S.","Rabaan, Ali A. (56049830800); Mutair, Abbas Al (55224333100); Aljeldah, Mohammed (55936544200); Shammari, Basim R. Al (56154766200); Sulaiman, Tarek (54414929100); Alshukairi, Abeer N. (15821823600); Alfaresi, Mubarak (8521674900); Al-Jishi, Jumana M. (57376992400); Al Bati, Neda A. (58026758300); Al-Mozaini, Maha A. (15836442400); Bshabshe, Ali Al (34871328100); Almatouq, Jenan A. (57979971300); Abuzaid, Abdulmonem A. (57780548000); Alfaraj, Amal H. (57878000200); Al-Adsani, Wasl (57201434377); Alabdullah, Mohammed (58025698600); Alwarthan, Sara (57217015338); Alsalman, Fatimah (57979605900); Alwashmi, Ameen S. S. (57219393726); Alhumaid, Saad (57202821008)","56049830800; 55224333100; 55936544200; 56154766200; 54414929100; 15821823600; 8521674900; 57376992400; 58026758300; 15836442400; 34871328100; 57979971300; 57780548000; 57878000200; 57201434377; 58025698600; 57217015338; 57979605900; 57219393726; 57202821008","Genetic Variants and Protective Immunity against SARS-CoV-2","2022","Genes","13","12","2355","","","","1","10.3390/genes13122355","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144550042&doi=10.3390%2fgenes13122355&partnerID=40&md5=60aa6ec3b2593596134c663dc0e3d0e1","Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, 31311, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia; Department of Public Health and Nutrition, The University of Haripur, Haripur, 22610, Pakistan; Research Center, Almoosa Specialist Hospital, Al-Ahsa, 36342, Saudi Arabia; College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh, 11564, Saudi Arabia; School of Nursing, Wollongong University, Wollongong, 2522, NSW, Australia; Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, 33048, Saudi Arabia; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin, 39831, Saudi Arabia; Infectious Diseases Section, Medical Specialties Department, King Fahad Medical City, Riyadh, 12231, Saudi Arabia; Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, 21499, Saudi Arabia; Department of Pathology and Laboratory Medicine, Sheikh Khalifa General Hospital, Umm Al Quwain, 499, United Arab Emirates; Department of Pathology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, 505055, United Arab Emirates; Internal Medicine Department, Qatif Central Hospital, Qatif, 35342, Saudi Arabia; Medical and Clinical Affairs, Rural Health Network, Eastern Health Cluster, Dammam, 31444, Saudi Arabia; Immunocompromised Host Research Section, Department of Infection and Immunity, King Faisal, Specialist Hospital and Research Centre, Riyadh, 11564, Saudi Arabia; Adult Critical Care Department of Medicine, Division of Adult Critical Care, College of Medicine, King Khalid University, Abha, 62561, Saudi Arabia; Department of Clinical Laboratory Sciences, Mohammed Al-Mana College of Health Sciences, Dammam, 34222, Saudi Arabia; Medical Microbiology Department, Security Forces Hospital Programme, Dammam, 32314, Saudi Arabia; Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq, 33261, Saudi Arabia; Department of Medicine, Infectious Diseases Hospital, Kuwait City, 63537, Kuwait; Department of Infectious Diseases, Hampton Veterans Administration Medical Center, Hampton, 23667, VA, United States; Department of Infectious Diseases, Almoosa Specialist Hospital, Al Mubarraz, 36342, Saudi Arabia; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, 34212, Saudi Arabia; Department of Emergency Medicine, Oyun City Hospital, Al-Ahsa, 36312, Saudi Arabia; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia; Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa, 31982, Saudi Arabia","Rabaan A.A., Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, 31311, Saudi Arabia, College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia, Department of Public Health and Nutrition, The University of Haripur, Haripur, 22610, Pakistan; Mutair A.A., Research Center, Almoosa Specialist Hospital, Al-Ahsa, 36342, Saudi Arabia, College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh, 11564, Saudi Arabia, School of Nursing, Wollongong University, Wollongong, 2522, NSW, Australia, Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, 33048, Saudi Arabia; Aljeldah M., Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin, 39831, Saudi Arabia; Shammari B.R.A., Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin, 39831, Saudi Arabia; Sulaiman T., Infectious Diseases Section, Medical Specialties Department, King Fahad Medical City, Riyadh, 12231, Saudi Arabia; Alshukairi A.N., College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia, Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, 21499, Saudi Arabia; Alfaresi M., Department of Pathology and Laboratory Medicine, Sheikh Khalifa General Hospital, Umm Al Quwain, 499, United Arab Emirates, Department of Pathology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, 505055, United Arab Emirates; Al-Jishi J.M., Internal Medicine Department, Qatif Central Hospital, Qatif, 35342, Saudi Arabia; Al Bati N.A., Medical and Clinical Affairs, Rural Health Network, Eastern Health Cluster, Dammam, 31444, Saudi Arabia; Al-Mozaini M.A., Immunocompromised Host Research Section, Department of Infection and Immunity, King Faisal, Specialist Hospital and Research Centre, Riyadh, 11564, Saudi Arabia; Bshabshe A.A., Adult Critical Care Department of Medicine, Division of Adult Critical Care, College of Medicine, King Khalid University, Abha, 62561, Saudi Arabia; Almatouq J.A., Department of Clinical Laboratory Sciences, Mohammed Al-Mana College of Health Sciences, Dammam, 34222, Saudi Arabia; Abuzaid A.A., Medical Microbiology Department, Security Forces Hospital Programme, Dammam, 32314, Saudi Arabia; Alfaraj A.H., Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq, 33261, Saudi Arabia; Al-Adsani W., Department of Medicine, Infectious Diseases Hospital, Kuwait City, 63537, Kuwait, Department of Infectious Diseases, Hampton Veterans Administration Medical Center, Hampton, 23667, VA, United States; Alabdullah M., Department of Infectious Diseases, Almoosa Specialist Hospital, Al Mubarraz, 36342, Saudi Arabia; Alwarthan S., Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, 34212, Saudi Arabia; Alsalman F., Department of Emergency Medicine, Oyun City Hospital, Al-Ahsa, 36312, Saudi Arabia; Alwashmi A.S.S., Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia; Alhumaid S., Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa, 31982, Saudi Arabia","The novel coronavirus-19 (SARS-CoV-2), has infected numerous individuals worldwide, resulting in millions of fatalities. The pandemic spread with high mortality rates in multiple waves, leaving others with moderate to severe symptoms. Co-morbidity variables, including hypertension, diabetes, and immunosuppression, have exacerbated the severity of COVID-19. In addition, numerous efforts have been made to comprehend the pathogenic and host variables that contribute to COVID-19 susceptibility and pathogenesis. One of these endeavours is understanding the host genetic factors predisposing an individual to COVID-19. Genome-Wide Association Studies (GWAS) have demonstrated the host predisposition factors in different populations. These factors are involved in the appropriate immune response, their imbalance influences susceptibility or resistance to viral infection. This review investigated the host genetic components implicated at the various stages of viral pathogenesis, including viral entry, pathophysiological alterations, and immunological responses. In addition, the recent and most updated genetic variations associated with multiple host factors affecting COVID-19 pathogenesis are described in the study. © 2022 by the authors.","coronaviruses; COVID-19; Genetic resistance; protective immunity","COVID-19; Genome-Wide Association Study; Humans; SARS-CoV-2; Virus Diseases; angiotensin converting enzyme 2; chemokine; cytokine; dipeptidyl peptidase; furin; interferon; major histocompatibility antigen; toll like receptor; artificial intelligence; comorbidity; coronavirus disease 2019; diabetes mellitus; disease severity; fatality; gene sequence; genetic association; genetic resistance; genetic susceptibility; genetic variability; genetic variation; HLA system; human; humoral immunity; immune response; immunity; immunosuppressive treatment; mortality rate; mouse; nonhuman; pandemic; pathogenesis; pathophysiology; prediction; review; Review; Severe acute respiratory syndrome coronavirus 2; signal transduction; single nucleotide polymorphism; virus entry; virus infection; virus replication; virus transmission; genetics; genome-wide association study; virus infection","","dipeptidyl peptidase, 9032-67-1; furin, ; toll like receptor, 409141-78-2","","","","","Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., Et al., Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science, 370, (2020); Zhang Q., Bastard P., Bolze A., Jouanguy E., Zhang S.-Y., Cobat A., Notarangelo L.D., Su H.C., Abel L., Casanova J.-L., Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation, Med, 1, pp. 14-20, (2020); Cerami C., Popkin-Hall Z.R., Rapp T., Tompkins K., Zhang H., Muller M.S., Basham C., Whittelsey M., Chhetri S.B., Smith J., Et al., Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in the United States: Living Density, Viral Load, and Disproportionate Impact on Communities of Color, Clin. Infect. Dis, 74, pp. 1776-1785, (2022); Madewell Z.J., Yang Y., Longini I.M., Halloran M.E., Dean N.E., Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis, JAMA Netw. Open, 3, (2020); Reukers D.F.M., van Boven M., Meijer A., Rots N., Reusken C., Roof I., van Gageldonk-Lafeber A.B., van der Hoek W., van den Hof S., High Infection Secondary Attack Rates of Severe Acute Respiratory Syndrome Coronavirus 2 in Dutch Households Revealed by Dense Sampling, Clin. Infect. Dis, 74, pp. 52-58, (2022); Zhang Y., Qin L., Zhao Y., Zhang P., Xu B., Li K., Liang L., Zhang C., Dai Y., Feng Y., Et al., Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated with Disease Severity in Coronavirus Disease 2019, J. Infect. Dis, 222, pp. 34-37, (2020); Bastard P., Gervais A., Le Voyer T., Rosain J., Philippot Q., Manry J., Michailidis E., Hoffmann H.-H., Eto S., Garcia-Prat M., Et al., Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths, Sci. Immunol, 6, (2021); Asano T., Boisson B., Onodi F., Matuozzo D., Moncada-Velez M., Maglorius Renkilaraj M.R.L., Zhang P., Meertens L., Bolze A., Materna M., Et al., X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19, Sci. Immunol, 6, (2021); Galani I.-E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E., Koukaki E., Fragkou P.C., Panou V., Rapti V., Et al., Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison, Nat. Immunol, 22, pp. 32-40, (2021); Bastard P., Michailidis E., Hoffmann H.-H., Chbihi M., Le Voyer T., Rosain J., Philippot Q., Seeleuthner Y., Gervais A., Materna M., Et al., Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine, J. Exp. Med, 218, (2021); Shelton J.F., Shastri A.J., Ye C., Weldon C.H., Filshtein-Sonmez T., Coker D., Symons A., Esparza-Esparza-Gordillo J., Aslibekyan S., Et al., Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity, Nat. Genet, 53, pp. 801-808, (2021); Mapping the human genetic architecture of COVID-19, Nature, 600, pp. 472-477, (2021); Zhang Y., Garner R., Salehi S., La Rocca M., Duncan D., Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: A literature review of 23 studies, Ann. Hematol, 100, pp. 1123-1132, (2021); Freeman E.E., McMahon D.E., Lipoff J.B., Rosenbach M., Kovarik C., Takeshita J., French L.E., Thiers B.H., Hruza G.J., Fox L.P., Et al., Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries, J. Am. Acad. Derm, 83, pp. 486-492, (2020); Tan S.W., Tam Y.C., Oh C.C., Skin manifestations of COVID-19: A worldwide review, JAAD Int, 2, pp. 119-133, (2021); Crow Y.J., Manel N., Aicardi–Goutières syndrome and the type I interferonopathies, Nat. Rev. Immunol, 15, pp. 429-440, (2015); Colmenero I., Santonja C., Alonso-Riano M., Noguera-Morel L., Hernandez-Martin A., Andina D., Wiesner T., Rodriguez-Peralto J.L., Requena L., Torrelo A., SARS-CoV-2 endothelial infection causes COVID-19 chilblains: Histopathological, immunohistochemical and ultrastructural study of seven paediatric cases, Br. J. Derm, 183, pp. 729-737, (2020); Wei J., Alfajaro M.M., DeWeirdt P.C., Hanna R.E., Lu-Culligan W.J., Cai W.L., Strine M.S., Zhang S.-M., Graziano V.R., Schmitz C.O., Et al., Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection, Cell, 184, (2021); Daniloski Z., Jordan T.X., Wessels H.-H., Hoagland D.A., Kasela S., Legut M., Maniatis S., Mimitou E.P., Lu L., Geller E., Et al., Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells, Cell, 184, (2021); Wang R., Simoneau C.R., Kulsuptrakul J., Bouhaddou M., Travisano K.A., Hayashi J.M., Carlson-Stevermer J., Zengel J.R., Richards C.M., Fozouni P., Et al., Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses, Cell, 184, (2021); Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., Et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, pp. 271-280.e8, (2020); Horowitz J.E., Kosmicki J.A., Damask A., Sharma D., Roberts G.H.L., Justice A.E., Banerjee N., Coignet M.V., Yadav A., Leader J.B., Et al., Genome-Wide Analysis in 756,646 Individuals Provides First Genetic Evidence that ACE2 Expression Influences COVID-19 Risk and Yields Genetic Risk Scores Predictive of Severe Disease; Genetic and Genomic Medicine, (2020); Suryamohan K., Diwanji D., Stawiski E.W., Gupta R., Miersch S., Liu J., Chen C., Jiang Y.-P., Fellouse F.A., Sathirapongsasuti J.F., Et al., Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2, Commun. Biol, 4, (2021); Schneider W.M., Luna J.M., Hoffmann H.-H., Sanchez-Rivera F.J., Leal A.A., Ashbrook A.W., Le Pen J., Ricardo-Lax I., Michailidis E., Peace A., Et al., Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks, Cell, 184, (2021); Hoffmann H.-H., Schneider W.M., Rozen-Gagnon K., Miles L.A., Schuster F., Razooky B., Jacobson E., Wu X., Yi S., Rudin C.M., Et al., TMEM41B Is a Pan-flavivirus Host Factor, Cell, 184, (2021); Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O'Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., Et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, 583, pp. 459-468, (2020); Hoffmann H.-H., Sanchez-Rivera F.J., Schneider W.M., Luna J.M., Soto-Feliciano Y.M., Ashbrook A.W., Le Pen J., Leal A.A., Ricardo-Lax I., Michailidis E., Et al., Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors, Cell Host Microbe, 29, pp. 267-280.e5, (2021); Zhang Q., Matuozzo D., Le Pen J., Lee D., Moens L., Asano T., Bohlen J., Liu Z., Moncada-Velez M., Kendir-Demirkol Y., Et al., Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia, J. Exp. Med, 219, (2022); Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Et al., Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science, 370, (2020); Gozman L., Perry K., Nikogosov D., Klabukov I., Shevlyakov A., Baranova A., A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients, Front. Genet, 12, (2021); Smieszek S.P., Polymeropoulos V.M., Xiao C., Polymeropoulos C.M., Polymeropoulos M.H., Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility, J. Glob. Antimicrob. Resist, 26, pp. 239-240, (2021); van der Made C.I., Simons A., Schuurs-Hoeijmakers J., van den Heuvel G., Mantere T., Kersten S., van Deuren R.C., Steehouwer M., van Reijmersdal S.V., Jaeger M., Et al., Presence of Genetic Variants Among Young Men with Severe COVID-19, JAMA, 324, (2020); Bullerdiek J., Reisinger E., Rommel B., Dotzauer A., ABO Blood Groups and the Risk of SARS-CoV-2 Infection, Protoplasma, 259, pp. 1381-1395, (2022); Ellinghaus D., Degenhardt F., Bujanda L., Buti M., Albillos A., Invernizzi P., Fernandez J., Prati D., Baselli G., Asselta R., Et al., The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis, medRxiv, (2020); Ren W., Zhu Y., Lan J., Chen H., Wang Y., Shi H., Feng F., Chen D.-Y., Close B., Zhao X., Et al., Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection, J. Virol, 96, (2022); Yang Z., Macdonald-Dunlop E., Chen J., Zhai R., Li T., Richmond A., Klaric L., Pirastu N., Ning Z., Zheng C., Et al., Genetic Landscape of the ACE2 Coronavirus Receptor, Circulation, 145, pp. 1398-1411, (2022); Chen F., Zhang Y., Li X., Li W., Liu X., Xue X., The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy, Front. Cell. Infect. Microbiol, 11, (2021); MacGowan S.A., Barton M.I., Kutuzov M., Dushek O., van der Merwe P.A., Barton G.J., Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants, PLoS Comput. Biol, 18, (2022); Wang B., Zhao J., Liu S., Feng J., Luo Y., He X., Wang Y., Ge F., Wang J., Ye B., Et al., ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants, Emerg. Microbes Infect, 11, pp. 1488-1499, (2022); David A., Parkinson N., Peacock T.P., Pairo-Castineira E., Khanna T., Cobat A., Tenesa A., Sancho-Shimizu V., Casanova J.-L., Abel L., Et al., A common TMPRSS2 variant has a protective effect against severe COVID-19, Curr. Res. Transl. Med, 70, (2022); Rokni M., Heidari Nia M., Sarhadi M., Mirinejad S., Sargazi S., Moudi M., Saravani R., Rahdar S., Kargar M., Association of TMPRSS2 Gene Polymorphisms with COVID-19 Severity and Mortality: A Case-Control Study with Computational Analyses, Appl. Biochem. Biotechnol, 194, pp. 3507-3526, (2022); Duman N., Tuncel G., Bisgin A., Bozdogan S.T., Sag S.O., Gul S., Kiraz A., Balta B., Erdogan M., Uyanik B., Et al., Analysis of ACE2 and TMPRSS2 coding variants as a risk factor for SARS-CoV-2 from 946 whole-exome sequencing data in the Turkish population, J. Med. Virol, 94, pp. 5225-5243, (2022); Sun L., Zhao C., Fu Z., Fu Y., Su Z., Li Y., Zhou Y., Tan Y., Li J., Xiang Y., Et al., Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication, PLoS Pathog, 17, (2021); Trimarco J.D., Heaton B.E., Chaparian R.R., Burke K.N., Binder R.A., Gray G.C., Smith C.M., Menachery V.D., Heaton N.S., TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2, PLoS Pathog, 17, (2021); Hama Y., Morishita H., Mizushima N., Regulation of ER-derived membrane dynamics by the DedA domain-containing proteins VMP1 and TMEM41B, EMBO Rep, 23, (2022); Wang F., Huang S., Gao R., Zhou Y., Lai C., Li Z., Xian W., Qian X., Li Z., Huang Y., Et al., Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility, Cell Discov, 6, (2020); Velavan T.P., Pallerla S.R., Ruter J., Augustin Y., Kremsner P.G., Krishna S., Meyer C.G., Host genetic factors determining COVID-19 susceptibility and severity, eBioMedicine, 72, (2021); Verma A., Tsao N.L., Thomann L.O., Ho Y.-L., Iyengar S.K., Luoh S.-W., Carr R., Crawford D.C., Efird J.T., Huffman J.E., Et al., A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program, PLoS Genet, 18, (2022); Pairo-Castineira E., Clohisey S., Klaric L., Bretherick A.D., Rawlik K., Pasko D., Walker S., Parkinson N., Fourman M.H., Russell C.D., Et al., Genetic mechanisms of critical illness in COVID-19, Nature, 591, pp. 92-98, (2021); Smieszek S.P., Polymeropoulos V.M., Polymeropoulos C.M., Przychodzen B.P., Birznieks G., Polymeropoulos M.H., Elevated plasma levels of CXCL16 in severe COVID-19 patients, Cytokine, 152, (2022); Jlizi A., Edouard J., Fadhlaoui-Zid K., Frigi S., Debre P., Slim A., Theodorou I., El Gaaied A.B.A., Carpentier W., Identification of the CCR5-Δ32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations, Hum. Immunol, 68, pp. 993-1000, (2007); Khanaliha K., Bokharaei-Salim F., Donyavi T., Nahand J.S., Marjani A., Jamshidi S., Khatami A., Moghaddas M., Esghaei M., Fakhim A., Evaluation of CCR5-Δ32 mutation and HIV-1 surveillance drug-resistance mutations in peripheral blood mononuclear cells of long-term non progressors of HIV-1-infected individuals, Future Virol, 17, pp. 429-439, (2022); Fath-Elrahman M.H., Alkarsany M., Nour B.Y.M., Abakar A.D., Mhammed A.E., Elzaki S.G., Osman E., Elshafia M., Ahmed E.A., Rating of CCR5-Delta 32 Homozygous Mutation in Sudanese HIV Patients and Sex Workers, WJA, 12, pp. 55-64, (2022); Veerabathiran R., Mansoor S.A., Kalarani I.B., Mohammed V., Gene-editing of CCR5 for the Treatment of HIV: A Novel Therapeutic Approach, TJI, 10, pp. 1-11, (2022); Abel L., Fellay J., Haas D.W., Schurr E., Srikrishna G., Urbanowski M., Chaturvedi N., Srinivasan S., Johnson D.H., Bishai W.R., Genetics of human susceptibility to active and latent tuberculosis: Present knowledge and future perspectives, Lancet Infect. Dis, 18, pp. e64-e75, (2018); Boisson-Dupuis S., The monogenic basis of human tuberculosis, Hum. Genet, 139, pp. 1001-1009, (2020); Altare F., Ensser A., Breiman A., Reichenbach J., Baghdadi J.E., Fischer A., Emile J., Gaillard J., Meinl E., Casanova J., Interleukin-12 Receptor β1 Deficiency in a Patient with Abdominal Tuberculosis, J. Infect. Dis, 184, pp. 231-236, (2001); Boisson-Dupuis S., El Baghdadi J., Parvaneh N., Bousfiha A., Bustamante J., Feinberg J., Samarina A., Grant A.V., Janniere L., El Hafidi N., Et al., IL-12Rβ1 Deficiency in Two of Fifty Children with Severe Tuberculosis from Iran, Morocco, and Turkey, PLoS ONE, 6, (2011); Kreins A.Y., Ciancanelli M.J., Okada S., Kong X.-F., Ramirez-Alejo N., Kilic S.S., El Baghdadi J., Nonoyama S., Mahdaviani S.A., Ailal F., Et al., Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome, J. Exp. Med, 212, pp. 1641-1662, (2015); Boisson-Dupuis S., Ramirez-Alejo N., Li Z., Patin E., Rao G., Kerner G., Lim C.K., Krementsov D.N., Hernandez N., Ma C.S., Et al., Tuberculosis and impaired IL-23–dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant, Sci. Immunol, 3, (2018); Kerner G., Laval G., Patin E., Boisson-Dupuis S., Abel L., Casanova J.-L., Quintana-Murci L., Human ancient DNA analyses reveal the high burden of tuberculosis in Europeans over the last 2,000 years, Am. J. Hum. Genet, 108, pp. 517-524, (2021); de Prost N., Bastard P., Arrestier R., Fourati S., Mahevas M., Burrel S., Dorgham K., Gorochov G., Tandjaoui-Lambiotte Y., Azzaoui I., Et al., Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia, J. Clin. Immunol, 41, pp. 536-544, (2021); Koning R., Bastard P., Casanova J.L., Brouwer M.C., van de Beek D., COVID-19 Biobank Investigator. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients, Intensive Care Med, 47, pp. 704-706, (2021); Troya J., Bastard P., Planas-Serra L., Ryan P., Ruiz M., de Carranza M., Torres J., Martinez A., Abel L., Casanova J.-L., Et al., Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain, J. Clin. Immunol, 41, pp. 914-922, (2021); Ghafouri-Fard S., Noroozi R., Vafaee R., Branicki W., Pospiech E., Pyrc K., Labaj P.P., Omrani M.D., Taheri M., Sanak M., Effects of host genetic variations on response to, susceptibility and severity of respiratory infections, Biomed. Pharmacother, 128, (2020); Gemmati D., Bramanti B., Serino M.L., Secchiero P., Zauli G., Tisato V., COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?, IJMS, 21, (2020); Sriram K., Insel P.A., A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance, Br. J. Pharm, 177, pp. 4825-4844, (2020); Tseng Y., Yang R., Lu T., Two hits to the renin-angiotensin system may play a key role in severe COVID-19, Kaohsiung J. Med. Sci, 36, pp. 389-392, (2020); Zamai L., The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients, Cells, 9, (2020); Zheng H., Cao J.J., Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019, Am. J. Pathol, 190, pp. 2013-2017, (2020); Delanghe J.R., Speeckaert M.M., De Buyzere M.L., The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections, Clin. Chim. Acta, 505, pp. 192-193, (2020); Delanghe J.R., Speeckaert M.M., De Buyzere M.L., COVID-19 infections are also affected by human ACE1 D/I polymorphism, Clin. Chem. Lab. Med. (CCLM), 58, pp. 1125-1126, (2020); Yamamoto N., Ariumi Y., Nishida N., Yamamoto R., Bauer G., Gojobori T., Shimotohno K., Mizokami M., SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype, Gene, 758, (2020); Aung A.K., Aitken T., Teh B.M., Yu C., Ofori-Asenso R., Chin K.L., Liew D., Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study, J. Infect, 81, pp. 961-965, (2020); Pati A., Mahto H., Padhi S., Panda A.K., ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population, Clin. Chim. Acta, 510, pp. 455-458, (2020); Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Et al., A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9, Circ. Res, 87, pp. E1-E9, (2000); Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.-C., Turner A.J., Raizada M.K., Grant M.B., Oudit G.Y., Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2, Circ. Res, 126, pp. 1456-1474, (2020); Verdecchia P., Cavallini C., Spanevello A., Angeli F., The pivotal link between ACE2 deficiency and SARS-CoV-2 infection, Eur. J. Intern. Med, 76, pp. 14-20, (2020); Fam B.S.O., Vargas-Pinilla P., Amorim C.E.G., Sortica V.A., Bortolini M.C., ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2, Genet. Mol. Biol, 43, (2020); Li M.-Y., Li L., Zhang Y., Wang X.-S., Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues, Infect. Dis. Poverty, 9, (2020); Pinto B.G.G., Oliveira A.E.R., Singh Y., Jimenez L., Goncalves A.N.A., Ogava R.L.T., Creighton R., Schatzmann Peron J.P., Nakaya H.I., ACE2 Expression Is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19, J. Infect. Dis, 222, pp. 556-563, (2020); Zou X., Chen K., Zou J., Han P., Hao J., Han Z., Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front. Med, 14, pp. 185-192, (2020); Lukassen S., Chua R.L., Trefzer T., Kahn N.C., Schneider M.A., Muley T., Winter H., Meister M., Veith C., Boots A.W., Et al., SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells, EMBO J, 39, (2020); Chen L., Li X., Chen M., Feng Y., Xiong C., The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2, Cardiovasc. Res, 116, pp. 1097-1100, (2020); Bunyavanich S., Do A., Vicencio A., Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults, JAMA, 323, (2020); McCoy J., Wambier C.G., Vano-Galvan S., Shapiro J., Sinclair R., Ramos P.M., Washenik K., Andrade M., Herrera S., Goren A., Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?, J. Cosmet. Derm, 19, pp. 1542-1543, (2020); Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., Li J., Yao Y., Ge S., Xu G., Kidney impairment is associated with in-hospital death of COVID-19 patients, medRxiv, (2020); El Baba R., Herbein G., Management of epigenomic networks entailed in coronavirus infections and COVID-19, Clin. Epigenet, 12, (2020); Chen Y.Y., Zhang P., Zhou X.M., Liu D., Zhong J.C., Zhang C.J., Jin L.J., Yu H.M., Relationship between genetic variants of ACE 2 gene and circulating levels of ACE 2 and its metabolites, J. Clin. Pharm. Ther, 43, pp. 189-195, (2018); Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X., Wen F., Huang X., Ning G., Wang W., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov, 6, (2020); Darbani B., The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues, IJERPH, 17, (2020); Hou Y., Zhao J., Martin W., Kallianpur A., Chung M.K., Jehi L., Sharifi N., Erzurum S., Eng C., Cheng F., New insights into genetic susceptibility of COVID-19: An ACE2 and TMPRSS2 polymorphism analysis, BMC Med, 18, (2020); Gibson W.T., Evans D.M., An J., Jones S.J., ACE 2 Coding Variants: A Potential X-linked Risk Factor for COVID-19 Disease, BioRxiv, (2020); Mohammad A., Marafie S.K., Alshawaf E., Abu-Farha M., Abubaker J., Al-Mulla F., Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2, Life Sci, 259, (2020); Hussain M., Jabeen N., Raza F., Shabbir S., Baig A.A., Amanullah A., Aziz B., Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein, J. Med. Virol, 92, pp. 1580-1586, (2020); Benetti E., Tita R., Spiga O., Ciolfi A., Birolo G., Bruselles A., Doddato G., Giliberti A., Marconi C., Musacchia F., Et al., ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population, Eur. J. Hum. Genet, 28, pp. 1602-1614, (2020); Stawiski E.W., Diwanji D., Suryamohan K., Gupta R., Fellouse F.A., Sathirapongsasuti J.F., Liu J., Jiang Y.-P., Ratan A., Mis M., Et al., Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility, BioRxiv, (2020); Torre-Fuentes L., Matias-Guiu J., Hernandez-Lorenzo L., Montero-Escribano P., Pytel V., Porta-Etessam J., Gomez-Pinedo U., Matias-Guiu J.A., ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain, J. Med. Virol, 93, pp. 863-869, (2021); Novelli A., Biancolella M., Borgiani P., Cocciadiferro D., Colona V.L., D'Apice M.R., Rogliani P., Zaffina S., Leonardis F., Campana A., Et al., Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients, Hum. Genom, 14, (2020); Fawzy M.S., Ashour H., Shafie A.A.A., Dahman N.B.H., Fares A.M., Antar S., Elnoby A.S., Fouad F.M., The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: A literature review, Egypt J. Med. Hum. Genet, 23, (2022); Deacon C.F., Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes, Front. Endocrinol, 10, (2019); Posadas-Sanchez R., Sanchez-Munoz F., Guzman-Martin C.A., Hernandez-Diaz Couder A., Rojas-Velasco G., Fragoso J.M., Vargas-Alarcon G., Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity, Life Sci, 276, (2021); Kirino Y., Sei M., Kawazoe K., Minakuchi K., Sato Y., Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people, Endocr. J, 59, pp. 949-953, (2012); Stengel A., Goebel-Stengel M., Teuffel P., Hofmann T., Busse P., Kobelt P., Rose M., Klapp B.F., Obese patients have higher circulating protein levels of dipeptidyl peptidase IV, Peptides, 61, pp. 75-82, (2014); Ghorpade D.S., Ozcan L., Zheng Z., Nicoloro S.M., Shen Y., Chen E., Bluher M., Czech M.P., Tabas I., Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance, Nature, 555, pp. 673-677, (2018); Simonnet A., Chetboun M., Poissy J., Raverdy V., Noulette J., Duhamel A., Labreuche J., Mathieu D., Pattou F., Jourdain M., Et al., High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation, Obesity, 28, pp. 1195-1199, (2020); Latini A., Agolini E., Novelli A., Borgiani P., Giannini R., Gravina P., Smarrazzo A., Dauri M., Andreoni M., Rogliani P., Et al., COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells, Genes, 11, (2020); Peacock T.P., Goldhill D.H., Zhou J., Baillon L., Frise R., Swann O.C., Kugathasan R., Penn R., Brown J.C., Sanchez-David R.Y., Et al., The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets, Nat. Microbiol, 6, pp. 899-909, (2021); Delshad M., Sanaei M.-J., Pourbagheri-Sigaroodi A., Bashash D., Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination, Int. Immunopharmacol, 111, (2022); Caldwell R.M., Schafer J.F., Compton L.E., Patterson F.L., Tolerance to Cereal Leaf Rusts, Science, 128, pp. 714-715, (1958); Roy B.A., Kirchner J.W., Evolutionary dynamics of pathogen resistance and tolerance, Evolution, 54, pp. 51-63, (2000); Vilcinskas A., Stoecker K., Schmidtberg H., Rohrich C.R., Vogel H., Invasive Harlequin Ladybird Carries Biological Weapons Against Native Competitors, Science, 340, pp. 862-863, (2013); Karupiah G., Buller R.M., Van Rooijen N., Duarte C.J., Chen J., Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection, J. Virol, 70, pp. 8301-8309, (1996); Panchanathan V., Chaudhri G., Karupiah G., Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell Function, J. Virol, 80, pp. 6333-6338, (2006); Detre C., Keszei M., Romero X., Tsokos G.C., Terhorst C., SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions, Semin. Immunopathol, 32, pp. 157-171, (2010); Chaganti S., Ma C.S., Bell A.I., Croom-Carter D., Hislop A.D., Tangye S.G., Rickinson A.B., Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients, Blood, 112, pp. 672-679, (2008); Dupre L., Andolfi G., Tangye S.G., Clementi R., Locatelli F., Arico M., Aiuti A., Roncarolo M.-G., SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells, Blood, 105, pp. 4383-4389, (2005); Palendira U., Low C., Bell A.I., Ma C.S., Abbott R.J.M., Phan T.G., Riminton D.S., Choo S., Smart J.M., Lougaris V., Et al., Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus, J. Exp. Med, 209, pp. 913-924, (2012); Hird T.R., Grassly N.C., Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge, PLoS Pathog, 8, (2012); Moran-Gilad J., Kaliner E., Gdalevich M., Grotto I., Public health response to the silent reintroduction of wild poliovirus to Israel, 2013–2014, Clin. Microbiol. Infect, 22, pp. S140-S145, (2016); van Doremalen N., Lambe T., Spencer A., Belij-Rammerstorfer S., Purushotham J.N., Port J.R., Avanzato V.A., Bushmaker T., Flaxman A., Ulaszewska M., Et al., ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques, Nature, 586, pp. 578-582, (2020); Alharbi N.K., Qasim I., Almasoud A., Aljami H.A., Alenazi M.W., Alhafufi A., Aldibasi O.S., Hashem A.M., Kasem S., Albrahim R., Et al., Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels, Sci. Rep, 9, (2019); Acosta P.L., Byrne A.B., Hijano D.R., Talarico L.B., Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections, J. Immunol. Res, 2020, (2020); Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., Perlman S., Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice, Cell Host Microbe, 19, pp. 181-193, (2016); Channappanavar R., Perlman S., Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology, Semin. Immunopathol, 39, pp. 529-539, (2017); Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., Cao Y., Yousif A.S., Bals J., Hauser B.M., Et al., SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues, Cell, 181, (2020); Su Q., Wang S., Baltzis D., Qu L., Raven J.F., Li S., Wong A.H., Koromilas A.E., Interferons induce tyrosine phosphorylation of the eIF2α kinase PKR through activation of Jak1 and Tyk2, EMBO Rep, 8, pp. 265-270, (2007); Duncan C.J.A., Mohamad S.M.B., Young D.F., Skelton A.J., Leahy T.R., Munday D.C., Butler K.M., Morfopoulou S., Brown J.R., Hubank M., Et al., Human IFNAR2 deficiency: Lessons for antiviral immunity, Sci. Transl. Med, 7, (2015); Bogdanovic Z., Marinovic-Terzic I., Kuret S., Jeroncic A., Bradaric N., Forempoher G., Polasek O., Andelinovic S., Terzic J., The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia, PeerJ, 4, (2016); Barrett S., The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: Spontaneous viral clearance and chronic HCV infection, Gut, 49, pp. 423-430, (2001); Nattermann J., Vogel M., Berg T., Danta M., Axel B., Mayr C., Bruno R., Tural C., Klausen G., Clotet B., Et al., Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients, Hepatology, 46, pp. 1016-1025, (2007); Leisman D.E., Ronner L., Pinotti R., Taylor M.D., Sinha P., Calfee C.S., Hirayama A.V., Mastroiani F., Turtle C.J., Harhay M.O., Et al., Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes, Lancet Respir. Med, 8, pp. 1233-1244, (2020); Takeda K., Kaisho T., Akira S., Toll-Like Receptors, Annu. Rev. Immunol, 21, pp. 335-376, (2003); Lim K.-H., Staudt L.M., Toll-Like Receptor Signaling, Cold Spring Harb. Perspect. Biol, 5, (2013); Amodio G., Gregori S., HLA-G genotype/expression/disease association studies: Success, hurdles, and perspectives, Front. Immunol, 11, (2020); Dendrou C.A., Petersen J., Rossjohn J., Fugger L., HLA variation and disease, Nat. Rev. Immunol, 18, pp. 325-339, (2018); Lin M., Tseng H.-K., Trejaut J.A., Lee H.-L., Loo J.-H., Chu C.-C., Chen P.-J., Su Y.-W., Lim K.H., Tsai Z.-U., Et al., Association of HLA class I with severe acute respiratory syndrome coronavirus infection, BMC Med. Genet, 4, (2003); Nguyen A., David J.K., Maden S.K., Wood M.A., Weeder B.R., Nellore A., Thompson R.F., Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2, J. Virol, 94, (2020); Vuille-dit-Bille R.N., Camargo S.M., Emmenegger L., Sasse T., Kummer E., Jando J., Hamie Q.M., Meier C.F., Hunziker S., Forras-Kaufmann Z., Et al., Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors, Amino Acids, 47, pp. 693-705, (2015); Wein A.N., McMaster S.R., Takamura S., Dunbar P.R., Cartwright E.K., Hayward S.L., McManus D.T., Shimaoka T., Ueha S., Tsukui T., Et al., CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways, J. Exp. Med, 216, pp. 2748-2762, (2019); Tu G., Ju M., Zheng Y., Hao G., Ma G., Hou J., Zhang X., Luo Z., Lu L., CXCL16/CXCR6 is involved in LPS-induced acute lung injury via P38 signalling, J. Cell Mol. Med, 23, pp. 5380-5389, (2019)","A.A. Rabaan; Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, 31311, Saudi Arabia; email: arabaan@gmail.com","","MDPI","","","","","","20734425","","","36553622","English","Genes","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85144550042"
"Lee H.K.; Knabl L.; Walter M.; Dai Y.; Füßl M.; Caf Y.; Jeller C.; Knabl P.; Obermoser M.; Baurecht C.; Kaiser N.; Zabernigg A.; Wurdinger G.M.; Furth P.A.; Hennighausen L.","Lee, Hye Kyung (57211545265); Knabl, Ludwig (56958562100); Walter, Mary (57126736900); Dai, Yuhai (57208652785); Füßl, Magdalena (57604589500); Caf, Yasemin (57605601900); Jeller, Claudia (57604090900); Knabl, Philipp (57604589600); Obermoser, Martina (57604589700); Baurecht, Christof (57605349100); Kaiser, Norbert (57221084374); Zabernigg, August (55924367600); Wurdinger, Gernot M. (57605098600); Furth, Priscilla A. (35555525200); Hennighausen, Lothar (57225465468)","57211545265; 56958562100; 57126736900; 57208652785; 57604589500; 57605601900; 57604090900; 57604589600; 57604589700; 57605349100; 57221084374; 55924367600; 57605098600; 35555525200; 57225465468","Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients","2022","Frontiers in Immunology","13","","916686","","","","18","10.3389/fimmu.2022.916686","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133045662&doi=10.3389%2ffimmu.2022.916686&partnerID=40&md5=60f43eafcc332562cc566216ed1233e9","National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States; TyrolPath Obrist Brunhuber GmbH, Zams, Austria; Clinical Core, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States; Division of Internal Medicine, Krankenhaus St. Vinzenz, Zams, Austria; Division of Internal Medicine, Krankenhaus St. Johann, St. Johann, Austria; Division of Internal Medicine, Krankenhaus Kufstein, Kufstein, Austria; Departments of Oncology and Medicine, Georgetown University, Washington, DC, United States","Lee H.K., National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States; Knabl L., TyrolPath Obrist Brunhuber GmbH, Zams, Austria, Division of Internal Medicine, Krankenhaus St. Vinzenz, Zams, Austria; Walter M., Clinical Core, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States; Dai Y., Clinical Core, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States; Füßl M., TyrolPath Obrist Brunhuber GmbH, Zams, Austria; Caf Y., TyrolPath Obrist Brunhuber GmbH, Zams, Austria; Jeller C., TyrolPath Obrist Brunhuber GmbH, Zams, Austria; Knabl P., TyrolPath Obrist Brunhuber GmbH, Zams, Austria; Obermoser M., Division of Internal Medicine, Krankenhaus St. Johann, St. Johann, Austria; Baurecht C., Division of Internal Medicine, Krankenhaus St. Johann, St. Johann, Austria; Kaiser N., Division of Internal Medicine, Krankenhaus St. Johann, St. Johann, Austria; Zabernigg A., Division of Internal Medicine, Krankenhaus Kufstein, Kufstein, Austria; Wurdinger G.M., Division of Internal Medicine, Krankenhaus Kufstein, Kufstein, Austria; Furth P.A., Departments of Oncology and Medicine, Georgetown University, Washington, DC, United States; Hennighausen L., National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States","Antibody response following Omicron infection is reported to be less robust than that to other variants. Here we investigated how prior vaccination and/or prior infection modulates that response. Disease severity, antibody responses and immune transcriptomes were characterized in four groups of Omicron-infected outpatients (n=83): unvaccinated/no prior infection, vaccinated/no prior infection, unvaccinated/prior infection and vaccinated/prior infection. The percentage of patients with asymptomatic or mild disease was highest in the vaccinated/no prior infection group (87%) and lowest in the unvaccinated/no prior infection group (47%). Significant anti-Omicron spike antibody levels and neutralizing activity were detected in the vaccinated group immediately after infection but were not present in the unvaccinated/no prior infection group. Within two weeks, antibody levels against Omicron, increased. Omicron neutralizing activity in the vaccinated group exceeded that of the prior infection group. No increase in neutralizing activity in the unvaccinated/no prior infection group was seen. The unvaccinated/prior infection group showed an intermediate response. We then investigated the early transcriptomic response following Omicron infection in these outpatient populations and compared it to that found in unvaccinated hospitalized patients with Alpha infection. Omicron infected patients showed a gradient of transcriptional response dependent upon whether or not they were previously vaccinated or infected. Vaccinated patients showed a significantly blunted interferon response as compared to both unvaccinated Omicron infected outpatients and unvaccinated Alpha infected hospitalized patients typified by the response of specific gene classes such as OAS and IFIT that control anti-viral responses and IFI27, a predictor of disease outcome. Copyright © 2022 Lee, Knabl, Walter, Knabl, Dai, Füßl, Caf, Jeller, Knabl, Obermoser, Baurecht, Kaiser, Zabernigg, Wurdinger, Furth and Hennighausen.","anti-viral response; antibody responses; COVID-19 alpha infection; immune transcriptome; interferon response; prior COVID-19 infection; SARS-CoV-2 omicron infection","Antibodies, Viral; Humans; Immunity, Humoral; Outpatients; Vaccination; alpha interferon; angiotensin converting enzyme 2; gamma interferon; immunoglobulin G; neutralizing antibody; SARS-CoV-2 vaccine; tozinameran; transcriptome; virus antibody; adolescent; adult; aged; alcoholic cardiomyopathy; antibody response; Article; bioinformatics; blood buffy coat; blood sampling; child; chronic lung disease; coronavirus disease 2019; data analysis; dementia; diabetes mellitus; differential gene expression; disease control; disease outcome; disease severity; female; goiter; hospitalization; human; humoral immunity; hypertension; immune response; immunoassay; JAK-STAT signaling; kidney disease; major clinical study; male; multiple sclerosis; neutralization test; omicron infection; omicron infection; outcome assessment; oxygen saturation; real time polymerase chain reaction; RNA sequencing; SARS-CoV-2 Omicron; school child; single nucleotide polymorphism; vaccination; outpatient; vaccination","","gamma interferon, 82115-62-6; immunoglobulin G, 97794-27-9, 308067-58-5; tozinameran, 2417899-77-3; Antibodies, Viral, ","Agilent 2100, Agilent; NovaSeq 6000, Illumina","Agilent; Illumina","Intramural Research Program; NISC; National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (ZIADK075155); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK","Funding text 1: This work was supported by the Intramural Research Program (IRP) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). ; Funding text 2: Our gratitude goes to the participants who contributed to this study to advance our understanding of Omicron and COVID-19. This work was utilized the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). RNA-sequencing was conducted in the NIH Intramural Sequencing Center, NISC (https://www.nisc.nih.gov/contact.htm).","Flemming A., Omicron, the Great Escape Artist, Nat Rev Immunol, 22, (2022); VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Purcell L.A., Et al., An Infectious SARS-CoV-2 B.1.1.529 Omicron Virus Escapes Neutralization by Therapeutic Monoclonal Antibodies, Nat Med, 28, (2022); Chatterjee D., Tauzin A., Marchitto L., Gong S.Y., Boutin M., Bourassa C., Et al., SARS-CoV-2 Omicron Spike Recognition by Plasma From Individuals Receiving BNT162b2 mRNA Vaccination With a 16-Week Interval Between Doses, Cell Rep, 38, (2022); Edara V.V., Manning K.E., Ellis M., Lai L., Moore K.M., Foster S.L., Et al., mRNA-1273 and BNT162b2 mRNA Vaccines Have Reduced Neutralizing Activity Against the SARS-CoV-2 Omicron Variant, Cell Rep Med, 3, (2022); Walls A.C., Sprouse K.R., Bowen J.E., Joshi A., Franko N., Navarro M.J., Et al., SARS-CoV-2 Breakthrough Infections Elicit Potent, Broad, and Durable Neutralizing Antibody Responses, Cell, 185, pp. 872-80.e3, (2022); Collier A.Y., Brown C.M., McMahan K.A., Yu J., Liu J., Jacob-Dolan C., Et al., Characterization of Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection With the SARS-CoV-2 Delta Variant, Sci Transl Med, 7, 5, (2022); Lee H.K., Knabl L., Knabl L., Wieser M., Mur A., Zabernigg A., Et al., Immune Transcriptome Analysis of COVID-19 Patients Infected With SARS-CoV-2 Variants Carrying the E484K Escape Mutation Identifies a Distinct Gene Module, Sci Rep, 12, (2022); Knabl L., Lee H.K., Wieser M., Mur A., Zabernigg A., Knabl L., Et al., BNT162b2 Vaccination Enhances Interferon-JAK-STAT-Regulated Antiviral Programs in COVID-19 Patients Infected With the SARS-CoV-2 Beta Variant, Commun Med, 2, (2022); Neghaiwi B.H., Austria Reports First Suspected Case of Omicron COVID-19 Variant (Reuters, November 28, 2021); Lee H.K., Knabl L., Moliva J.I., Knabl L., Werner A.P., Boyoglu-Barnum S., Et al., mRNA Vaccination in Octogenarians 15 and 20 Months After Recovery From COVID-19 Elicits Robust Immune and Antibody Responses That Include Omicron, Cell Rep, 39, 2, (2022); Basters A., Knobeloch K.P., Fritz G., USP18 - a Multifunctional Component in the Interferon Response, Biosci Rep, 38, 6, (2018); Huffman J.E., Butler-Laporte G., Khan A., Pairo-Castineira E., Drivas T.G., Peloso G.M., Et al., Multi-Ancestry Fine Mapping Implicates OAS1 Splicing in Risk of Severe COVID-19, Nat Genet, 54, (2022); Wolter N., Jassat W., Walaza S., Welch R., Moultrie H., Groome M., Et al., Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa: A Data Linkage Study, Lancet, 399, (2022); Wratil P.R., Stern M., Priller A., Willmann A., Almanzar G., Vogel E., Et al., Three Exposures to the Spike Protein of SARS-CoV-2 by Either Infection or Vaccination Elicit Superior Neutralizing Immunity to All Variants of Concern, Nat Med, 28, pp. 496-503, (2022); Servellita V., Syed A.M., Morris M.K., Brazer N., Saldhi P., Garcia-Knight M., Et al., Neutralizing Immunity in Vaccine Breakthrough Infections From the SARS-CoV-2 Omicron and Delta Variants, Cell, 185, pp. 1539-48.e5, (2022); Nyberg T., Ferguson N.M., Nash S.G., Webster H.H., Flaxman S., Andrews N., Et al., Comparative Analysis of the Risks of Hospitalisation and Death Associated With SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England: A Cohort Study, Lancet, 399, (2022); Roltgen K., Nielsen S.C.A., Silva O., Younes S.F., Zaslavsky M., Costales C., Et al., Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS-CoV-2 Infection and Vaccination, Cell, 185, (2022); Rossler A., Knabl L., von Laer D., Kimpel J., Neutralization Profile After Recovery From SARS-CoV-2 Omicron Infection, N Engl J Med, 386, (2022); Rossler A., Riepler L., Bante D., von Laer D., Kimpel J., SARS-CoV-2 Omicron Variant Neutralization in Serum From Vaccinated and Convalescent Persons, N Engl J Med, 386, pp. 698-700, (2022); Zhang Y., Guo X., Li C., Kou Z., Lin L., Yao M., Et al., Transcriptome Analysis of Peripheral Blood Mononuclear Cells in SARS-CoV-2 Naïve and Recovered Individuals Vaccinated With Inactivated Vaccine, Front Cell Infect Microbiol, 11, (2021); Arunachalam P.S., Scott M.K.D., Hagan T., Li C., Feng Y., Wimmers F., Et al., Systems Vaccinology of the BNT162b2 mRNA Vaccine in Humans, Nature, 596, 7872, (2021); Hu Z., van der Ploeg K., Chakraborty S., Arunachalam P., Mori D., Jacobson K., Et al., Early Immune Responses Have Long-Term Associations With Clinical, Virologic, and Immunologic Outcomes in Patients With COVID-19, Res Sq, (2022); Seaman M.S., Siedner M.J., Boucau J., Lavine C.L., Ghantous F., Liew M.Y., Et al., Vaccine Breakthrough Infection With the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses, medRxiv, (2022); Khan K., Karim F., Cele S., Reedoy K., San J.E., Lustig G., Et al., Omicron Infection Enhances Delta Antibody Immunity in Vaccinated Persons, Nature, (2022); Lang-Meli J., Luxenburger H., Wild K., Karl V., Oberhardt V., Salimi Alizei E., Et al., SARS-CoV-2-Specific T-Cell Epitope Repertoire in Convalescent and mRNA-Vaccinated Individuals, Nat Microbiol, 7, (2022); Kitchin D., Richardson S.I., van der Mescht M.A., Motlou T., Mzindle N., Moyo-Gwete T., Et al., Ad26.Cov2.S Breakthrough Infections Induce High Titers of Neutralizing Antibodies Against Omicron and Other SARS-CoV-2 Variants of Concern, Cell Rep Med, 3, (2022); Montefiori D.C., Enhanced Immunity After Ad26.COV2.S Vaccine Breakthrough Infection, Cell Rep Med, 3, (2022); Cheng S.M., Mok C.K.P., Chan K.C., Ng S.S., Lam B.H., Luk L.L., Et al., SARS-CoV-2 Omicron Variant BA.2 Neutralisation in Sera of People With Comirnaty or CoronaVac Vaccination, Infection or Breakthrough Infection, Hong Kong, 2020 to 2022, Euro Surveill, 27, 18, (2022); Adachi E., Nagai E., Saito M., Isobe M., Konuma T., Koga M., Et al., Anti-Spike Protein Antibody Titer at the Time of Breakthrough Infection of SARS-CoV-2 Omicron, J Infect Chemother, 28, (2022); Woldemeskel B.A., Garliss C.C., Aytenfisu T.Y., Johnston T.S., Beck E.J., Dykema A.G., Et al., SARS-CoV-2 -Specific Immune Responses in Boosted Vaccine Recipients With Breakthrough Infections During the Omicron Variant Surge, JCI Insight, 7, 10, (2022); Sievers B.L., Chakraborty S., Xue Y., Gelbart T., Gonzalez J.C., Cassidy A.G., Et al., Antibodies Elicited by SARS-CoV-2 Infection or mRNA Vaccines Have Reduced Neutralizing Activity Against Beta and Omicron Pseudoviruses, Sci Transl Med 14, 14, 634, (2022); Wang X., Sanborn M.A., Dai Y., Rehman J., Temporal Transcriptomic Analysis Using TrendCatcher Identifies Early and Persistent Neutrophil Activation in Severe COVID-19, JCI Insight, 7, 7, (2022); Zhu L., Yang P., Zhao Y., Zhuang Z., Wang Z., Song R., Et al., Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients, Immunity, 53, pp. 685-96.e3, (2020); Wang Z., Zhang Y., Yang R., Wang Y., Guo J., Sun R., Et al., Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development, Front Immunol, 13, (2022); Arora P., Zhang L., Rocha C., Sidarovich A., Kempf A., Schulz S., Et al., Comparable Neutralisation Evasion of SARS-CoV-2 Omicron Subvariants BA.1, BA.2, and BA.3, Lancet Infect Dis, 22, 6, (2022); Lai C., Wang K., Zhao Z., Zhang L., Gu H., Yang P., Et al., C-C Motif Chemokine Ligand 2 (CCL2) Mediates Acute Lung Injury Induced by Lethal Influenza H7N9 Virus, Front Microbiol, 8, (2017); Merad M., Martin J.C., Pathological Inflammation in Patients With COVID-19: A Key Role for Monocytes and Macrophages, Nat Rev Immunol, 20, (2020); Kang J.A., Jeon Y.J., Emerging Roles of USP18: From Biology to Pathophysiology, Int J Mol Sci 21, 21, 18, (2020); Bolger A.M., Lohse M., Usadel B., Trimmomatic: A Flexible Trimmer for Illumina Sequence Data, Bioinformatics, 30, (2014); Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Et al., STAR: Ultrafast Universal RNA-Seq Aligner, Bioinformatics, 29, pp. 15-21, (2013); Anders S., Pyl P.T., Huber W., HTSeq–a Python Framework to Work With High-Throughput Sequencing Data, Bioinformatics, 31, (2015); Love M.I., Huber W., Anders S., Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2, Genome Biol, 15, (2014); Zhao Y., Li M.C., Konate M.M., Chen L., Das B., Karlovich C., Et al., TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-Seq Data From the NCI Patient-Derived Models Repository, J Transl Med, 19, (2021); Risso D., Ngai J., Speed T.P., Dudoit S., Normalization of RNA-Seq Data Using Factor Analysis of Control Genes or Samples, Nat Biotechnol, 32, pp. 896-902, (2014); Wickham H., Ggplot2 : Elegant Graphics for Data Analysis, (2009)","H.K. Lee; National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, United States; email: hyekyung.lee@nih.gov; L. Hennighausen; National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, United States; email: lotharh@nih.gov; L. Knabl; TyrolPath Obrist Brunhuber GmbH, Zams, Austria; email: Ludwig.knabl@tyrolpath.at; P.A. Furth; Departments of Oncology and Medicine, Georgetown University, Washington, United States; email: paf3@georgetown.edu","","Frontiers Media S.A.","","","","","","16643224","","","35784346","English","Front. Immunol.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85133045662"
"Yan W.; Zhang Y.; Shan Z.; Wang Q.; Huang Y.; Wang C.; Yan K.","Yan, Weili (55618295600); Zhang, Yuanming (55739911600); Shan, Zimei (8963757300); Wang, Qian (58445449100); Huang, Yongdi (54684117300); Wang, Chenchen (54685275800); Yan, Kai (57213117229)","55618295600; 55739911600; 8963757300; 58445449100; 54684117300; 54685275800; 57213117229","Tagging SNPs in REN, AGTR1 and AGTR2 genes and response of renin activity, angiotensin II and aldosterone concentrations to antihypertensive treatment in Kazakans","2011","JRAAS - Journal of the Renin-Angiotensin-Aldosterone System","12","4","","581","587","6","3","10.1177/1470320311418266","https://www.scopus.com/inward/record.uri?eid=2-s2.0-83455201564&doi=10.1177%2f1470320311418266&partnerID=40&md5=d44011eeaaae87c3aef1c5e686ebdc21","Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China; Department of Hypertension, 1st Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China; Peoples' Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China","Yan W., Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China; Zhang Y., Department of Hypertension, 1st Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China; Shan Z., Peoples' Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China; Wang Q., Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China; Huang Y., Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China; Wang C., Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China; Yan K., Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China","Hypothesis: Polymorphisms of REN, AGTR1 and AGTR2 may be associated with responses of renin-angiotensin-aldosterone system (RAAS) activity phenotypes to angiotensin-converting enzyme inhibitor (ACEI) antihypertensive treatment.Materials and methods: A total of 400 first diagnosed Kazak hypertensives were randomly allocated to two groups and received a 3-week course of either captopril and atenolol as monotherapy under double blinding. Genotype-phenotype association analyses were performed by covariance analyses between baseline level and responses of blood pressure, renin, angiotensin II and aldosterone concentrations with tagging single nucleotide polymorphisms (SNPs) in REN, AGTR1 and AGTR2 genes. A false discovery rate method was used to adjust multiple testing.Results: After adjustment for multiple testing, we found that the G allele of rs6676670 (T/G) in intron 1 of REN was significantly associated with higher baseline aldosterone concentrations (p < 0.0001, explained variance (EV) = 2.3%). Significant associations after adjustments were also found between the A allele of rs2887284, with higher baseline renin activity (p = 0.022, EV = 1.0%), higher responses of renin (p = 0.018 EV = 5.4%), and higher responses of angiotensin II (p = 0.0255, EV = 3.13%) to the treatment of ACEI. The carriers of the A allele of rs2887284 appeared to be more sensitive to the ACEI treatment.Conclusion: rs2887284 in intron 9 of REN is associated with the response of renin and angiotensin II levels to ACEI treatment. © SAGE Publications 2011.","AGTR1; antihypertensive treatment; Kazak; polymorphisms; renin-angiotensin- aldosterone system","Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Pressure; China; Ethnic Groups; Female; Genetic Association Studies; Humans; Hypertension; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; aldosterone; angiotensin II; atenolol; captopril; renin; allele; antihypertensive therapy; article; blood pressure; clinical evaluation; concentration (parameters); controlled study; enzyme activity; ethnic group; female; genetic variability; genotype phenotype correlation; human; hypertension; intron; Kazakan; laboratory test; major clinical study; male; monotherapy; single nucleotide polymorphism; treatment duration","","aldosterone, 52-39-1, 6251-69-0; angiotensin II, 11128-99-7; atenolol, 29122-68-7, 93379-54-5; captopril, 62571-86-2; renin, 61506-93-2, 9015-94-5; AGTR1 protein, human, ; Aldosterone, 52-39-1; Angiotensin II, 11128-99-7; Antihypertensive Agents, ; Receptor, Angiotensin, Type 1, ; Receptor, Angiotensin, Type 2, ; Renin, 3.4.23.15","","","","","Danser A.H.J., Schunkert H., Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases, European Journal of Pharmacology, 410, 2-3, pp. 303-316, (2000); Wang J.-G., Staessen J.A., Genetic polymorphisms in the renin-angiotensin system: Relevance for susceptibility to cardiovascular disease, European Journal of Pharmacology, 410, 2-3, pp. 289-302, (2000); Jiang X., Sheng H.-H., Lin G., Li J., Lu X.-Z., Cheng Y.-L., Huang J., Xiao H., Zhan Y.-Y., Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment, Chinese Medical Journal, 120, 9, pp. 782-786, (2007); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, Journal of Hypertension, 19, 10, pp. 1783-1787, (2001); Kurland L., Liljedahl U., Karlsson J., Kahan T., Malmqvist K., Melhus H., Syvanen A.-C., Lind L., Angiotensinogen Gene Polymorphisms: Relationship to Blood Pressure Response to Antihypertensive Treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) Trial, American Journal of Hypertension, 17, 1, pp. 8-13, (2004); Kurland L., Melhus H., Karlsson J., Aldosterone synthase (CYP11B2) -334 C/T polymorphism is related to antihypertensive response: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial, Am J Hypertens, 15, pp. 387-393, (2002); Woodiwiss A.J., Nkeh B., Samani N.J., Badenhorst D., Maseko M., Tiago A.D., Candy G.P., Libhaber E., Sareli P., Brooksbank R., Norton G.R., Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin, Journal of Hypertension, 24, 6, pp. 1057-1064, (2006); The prevalence, awareness, treatment and control of hypertension in China: The report of national sampling survey of hypertension 1991, Chin J Hypertens, 3, pp. 16-18, (1995); Yan W., Yang X., Zheng Y., Ge D., Zhang Y., Shan Z., Simu H., Sukerobai M., Wang R., The metabolic syndrome in Uygur and Kazak populations, Diabetes Care, 28, 10, pp. 2554-2555, (2005); Perloff D., Grim C., Flack J., Human blood pressure determination by sphygmomanometry, Circulation, 88, pp. 2460-2470, (1993); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J R Statist Soc, 57, pp. 289-300, (1995); Nakai K., Itoh C., Miura Y., Hansen T., Deletion polymorphism of the angiotensin I-converting enzyme-gene is associated with serum ACE concentration and increased risk for CAD in the Japanese, Circulation, 90, pp. 199-202, (1994); Lachurie M., Azizi M., Guyene T., Alhenc-Gelas F., Menard J., Angiotensin converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects, Circulation, 91, pp. 2933-2942, (1995); Paillard F., Chansel D., Brand E., Benetos A., Thomas F., Czekalski S., Ardaillou R., Soubrier F., Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population, Hypertension, 34, 3, pp. 423-429, (1999); Zhao L., Wang K., Guo Y., Epidemiology study on hypertension in Boertala Mongol Autonomous Prefecture of Xinjiang, Chin J Hypertens, 14, pp. 214-218, (2006); Li N., Zhou L., Wang X., Zhang D., Wang J., DNA variants in the -164 to +73 region of angiotensinogen gene in Kazakhs and the effect of different variants on blood pressure, J Clin Cardiol (Chinese), 23, pp. 867-870, (2007); Li T., Li N., Zhou L., Study for relationship between the angiotensin α type 1 receptor gene polymorphism and essential hypertension in Kazakans of Xinjiang, J Clin Cardiol (Chinese), 24, pp. 606-608, (2008); Trikalinos T.A., Salanti G., Khoury M.J., Ioannidis J.P.A., Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations, American Journal of Epidemiology, 163, 4, pp. 300-309, (2006)","W. Yan; Pediatric Institute, Division of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China; email: 01.weili@gmail.com","","","","","","","","17528976","","JRAAA","21810897","English","JRAAS J. Renin-Angiotensin-Aldosterone Syst.","Article","Final","","Scopus","2-s2.0-83455201564"
"Xie Z.; Liu D.; Liu S.; Calderon L.; Zhao G.; Turk J.; Guo Z.","Xie, Zhongwen (55446967300); Liu, Dexiang (7410095529); Liu, Shu (27171024700); Calderon, Lindsay (55873406900); Zhao, Guogang (7403296266); Turk, John (7201527869); Guo, Zhenheng (7404658415)","55446967300; 7410095529; 27171024700; 55873406900; 7403296266; 7201527869; 7404658415","Identification of a cAMP-response element in the Regulator of G-protein Signaling-2 (RGS2) promoter as a key cis-regulatory element for RGS2 transcriptional regulation by angiotensin II in cultured vascular smooth muscles","2011","Journal of Biological Chemistry","286","52","","44646","44658","12","46","10.1074/jbc.M111.265462","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84455173156&doi=10.1074%2fjbc.M111.265462&partnerID=40&md5=4972a838603404bdd07565281ea5699f","Department of Physiology, University of Kentucky, School of Medicine, Lexington, KY 40536, United States; Department of Internal Medicine, University of Kentucky, School of Medicine, Lexington, KY 40536, United States; Department of Medicine, Washington University, School of Medicine, St. Louis, MO 63110, United States; Institute of Medical Psychology, Shandong University, School of Medicine, Jinan, Shandong, 250012, 44 Wenhua Xi Rd., China","Xie Z., Department of Physiology, University of Kentucky, School of Medicine, Lexington, KY 40536, United States; Liu D., Department of Physiology, University of Kentucky, School of Medicine, Lexington, KY 40536, United States, Institute of Medical Psychology, Shandong University, School of Medicine, Jinan, Shandong, 250012, 44 Wenhua Xi Rd., China; Liu S., Department of Internal Medicine, University of Kentucky, School of Medicine, Lexington, KY 40536, United States; Calderon L., Department of Physiology, University of Kentucky, School of Medicine, Lexington, KY 40536, United States; Zhao G., Department of Internal Medicine, University of Kentucky, School of Medicine, Lexington, KY 40536, United States; Turk J., Department of Medicine, Washington University, School of Medicine, St. Louis, MO 63110, United States; Guo Z., Department of Physiology, University of Kentucky, School of Medicine, Lexington, KY 40536, United States, Department of Internal Medicine, University of Kentucky, School of Medicine, Lexington, KY 40536, United States","Mice deficient in regulator of G-protein signaling-2 (RGS2) have severe hypertension, and RGS2 genetic variations occur in hypertensive humans. A potentially important negative feedback loop in blood pressure homeostasis is that angiotensin II (Ang II) increases vascular smooth muscle cell (VSMC) RGS2 expression. We reported that Group VIA phospholipase A 2(iPLA 2β) is required for this response (Xie, Z., Gong, M. C., Su, W., Turk, J., and Guo, Z. (2007) J. Biol. Chem. 282, 25278-25289), but the specific molecular causes and consequences of iPLA 2β activation are not known. Here we demonstrate that both protein kinases C (PKC) and A (PKA) participate in Ang II-induced VSMC RGS2 mRNA up-regulation, and that actions of PKC and PKA precede and follow iPLA 2β activation, respectively. Moreover, we identified a conserved cAMP-response element (CRE) in the murine RGS2 promoter that is critical for cAMP-response element-binding protein (CREB) binding and RGS2 promoter activation. Forskolin-stimulated RGS2 mRNA up-regulation is inhibited by CREB sequestration or specific disruption of the CREB-RGS2 promoter interaction, and Ang II-induced CREB phosphorylation and nuclear localization are blocked by iPLA 2β pharmacologic inhibition or genetic ablation. Ang II-induced intracellular cyclic AMP accumulation precedes CREB phosphorylation and is diminished by inhibiting iPLA2, cyclooxygenase, or lipoxygenase. Moreover, three single nucleotide polymorphisms identified in hypertensive patients are located in the human RGS2 promoter CREB binding site. Point mutations corresponding to these single nucleotide polymorphisms interfere with stimulation of human RGS2 promoter activity by forskolin. Our studies thus delineate a negative feedback loop to attenuate Ang II signaling in VSMC with potential importance in blood pressure homeostasis and the pathogenesis of human essential hypertension. © 2011 by The American Society for Biochemistry and Molecular Biology, Inc.","","Active Transport, Cell Nucleus; Angiotensin II; Animals; Cell Nucleus; Cells, Cultured; CREB-Binding Protein; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Forskolin; Group VI Phospholipases A2; GTP-Binding Protein Regulators; Humans; Hypertension; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Polymorphism, Single Nucleotide; Protein Kinase C; Rabbits; Rats; Response Elements; RGS Proteins; Transcription, Genetic; Up-Regulation; Vasoconstrictor Agents; Blood; Blood pressure; Enzyme activity; Feedback; Medical problems; Muscle; Nucleotides; Phosphorylation; Physiology; angiotensin II; cyclic AMP dependent protein kinase; cyclic AMP responsive element binding protein binding protein; forskolin; lipoxygenase; messenger RNA; prostaglandin synthase; protein kinase C; RGS2 protein; Angiotensin II; cAMP-response element-binding proteins; Camp-response elements; Cis-regulatory elements; Cyclooxygenases; Essential hypertension; Forskolin; G protein; Genetic ablation; Genetic variation; Hypertensive patients; Lipoxygenases; Negative feedback loop; Nuclear localization; Phospholipase A; Point mutations; Promoter activities; Protein kinases c; Single nucleotide polymorphisms; Transcriptional regulation; Up-regulation; Vascular smooth muscle cells; Vascular smooth muscles; animal cell; animal experiment; article; binding site; blood pressure; controlled study; enzyme activation; enzyme inhibition; essential hypertension; homeostasis and regulation; human; negative feedback; nonhuman; nuclear localization signal; pathophysiology; pharmacological blocking; priority journal; promoter region; protein analysis; protein binding; protein cross linking; protein function; protein phosphorylation; protein protein interaction; rat; signal transduction; transcription regulation; upregulation; vascular smooth muscle; Proteins","","angiotensin II, 11128-99-7; cyclic AMP responsive element binding protein binding protein, 190209-80-4; forskolin, 66575-29-9; lipoxygenase, 9027-17-2, 9029-60-1; prostaglandin synthase, 39391-18-9, 59763-19-8, 9055-65-6; protein kinase C, 141436-78-4; Angiotensin II, 11128-99-7; CREB-Binding Protein, 2.3.1.48; CREBBP protein, human, ; Crebbp protein, mouse, ; Crebbp protein, rat, ; Cyclic AMP, 60-92-4; Cyclic AMP-Dependent Protein Kinases, 2.7.11.11; Forskolin, 66428-89-5; GTP-Binding Protein Regulators, ; Group VI Phospholipases A2, 3.1.1.4; Pla2g6 protein, mouse, 3.1.1.4; Protein Kinase C, 2.7.11.13; RGS Proteins, ; RGS2 protein, human, ; Rgs2 protein, mouse, ; Rgs21 protein, rat, ; Vasoconstrictor Agents, ","","","National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30DK056341)","","Wieland T., Mittmann C., Pharmacol. Ther., 97, pp. 95-115, (2003); Gu S., Cifelli C., Wang S., Heximer S.P., Clin. Sci., 116, pp. 391-399, (2009); Heximer S.P., Knutsen R.H., Sun X., Kaltenbronn K.M., Rhee M.H., Peng N., Oliveira-dos-Santos A., Penninger J.M., Muslin A.J., Steinberg T.H., Wyss J.M., Mecham R.P., Blumer K.J., J. Clin. Invest., 111, pp. 445-452, (2003); Tang K.M., Wang G.R., Lu P., Karas R.H., Aronovitz M., Heximer S.P., Kaltenbronn K.M., Blumer K.J., Siderovski D.P., Zhu Y., Mendelsohn M.E., Tang M., Wang G., Nat. Med., 9, pp. 1506-1512, (2003); Sun X., Kaltenbronn K.M., Steinberg T.H., Blumer K.J., Mol. Pharmacol., 67, pp. 631-639, (2005); Gross V., Tank J., Obst M., Plehm R., Blumer K.J., Diedrich A., Jordan J., Luft F.C., Am. J. Physiol. Regul. Integr. Comp. Physiol., 288, (2005); Hercule H.C., Tank J., Plehm R., Wellner M., Da Costa Goncalves A.C., Gollasch M., Diedrich A., Jordan J., Luft F.C., Gross V., Exp. Physiol., 92, pp. 1014-1022, (2007); Yang J., Kamide K., Kokubo Y., Takiuchi S., Tanaka C., Banno M., Miwa Y., Yoshii M., Horio T., Okayama A., Tomoike H., Kawano Y., Miyata T., J. Hypertens., 23, pp. 1497-1505, (2005); Zhao Q., Wang L., Yang W., Chen S., Huang J., Fan Z., Li H., Lu X., Gu D., Pharmacogenet. Genomics, 18, pp. 459-466, (2008); Semplicini A., Lenzini L., Sartori M., Papparella I., Calo L.A., Pagnin E., Strapazzon G., Benna C., Costa R., Avogaro A., Ceolotto G., Pessina A.C., J. Hypertens., 24, pp. 1115-1124, (2006); Riddle E.L., Rana B.K., Murthy K.K., Rao F., Eskin E., O'Connor D.T., Insel P.A., Hypertension, 47, pp. 415-420, (2006); Semplicini A., Strapazzon G., Papparella I., Sartori M., Realdi A., Macchini L., Calo L.A., Ceolotto G., J. Hypertens., 28, pp. 1104-1108, (2010); Calo L.A., Pagnin E., Davis P.A., Sartori M., Ceolotto G., Pessina A.C., Semplicini A., J. Clin. Endocrinol. Metab., 89, pp. 4153-4157, (2004); Touyz R.M., Schiffrin E.L., Pharmacol. Rev., 52, pp. 639-672, (2000); Grant S.L., Lassegue B., Griendling K.K., Ushio-Fukai M., Lyons P.R., Alexander R.W., Mol. Pharmacol., 57, pp. 460-467, (2000); Xie Z., Gong M.C., Su W., Turk J., Guo Z., J. Biol. Chem., 282, pp. 25278-25289, (2007); Cho H., Harrison K., Schwartz O., Kehrl J.H., Biochem. J., 371, pp. 973-980, (2003); Li Y., Hashim S., Anand-Srivastava M.B., Cardiovasc. Res., 66, pp. 503-511, (2005); Ma Z., Turk J., Prog. Nucleic Acids Res. Mol. Biol., 67, pp. 1-33, (2001); Maggi Jr. L.B., Moran J.M., Scarim A.L., Ford D.A., Yoon J.W., McHowat J., Buller R.M., Corbett J.A., J. Biol. Chem., 277, pp. 38449-38455, (2002); Moran J.M., Buller R.M., McHowat J., Turk J., Wohltmann M., Gross R.W., Corbett J.A., J. Biol. Chem., 280, pp. 28162-28168, (2005); Hazen S.L., Zupan L.A., Weiss R.H., Getman D.P., Gross R.W., J. Biol. Chem., 266, pp. 7227-7232, (1991); Park Y.G., Nesterova M., Agrawal S., Cho-Chung Y.S., J. Biol. Chem., 274, pp. 1573-1580, (1999); Xie Z., Su W., Guo Z., Pang H., Post S.R., Gong M.C., Cardiovasc. Res., 69, pp. 491-501, (2006); Xie Z., Gong M.C., Su W., Xie D., Turk J., Guo Z., J. Biol. Chem., 285, pp. 8628-8638, (2010); Pang H., Guo Z., Su W., Xie Z., Eto M., Gong M.C., Am. J. Physiol. Cell Physiol., 289, (2005); Pang H., Guo Z., Xie Z., Su W., Gong M.C., Am. J. Physiol. Cell Physiol., 290, (2006); Guo Z., Su W., Allen S., Pang H., Daugherty A., Smart E., Gong M.C., Cardiovasc. Res., 67, pp. 723-735, (2005); Su W., Guo Z., Randall D.C., Cassis L., Brown D.R., Gong M.C., Am. J. Physiol. Heart Circ. Physiol., 295, (2008); Dyer B.W., Ferrer F.A., Klinedinst D.K., Rodriguez R., Anal. Biochem., 282, pp. 158-161, (2000); Dronadula N., Rizvi F., Blaskova E., Li Q., Rao G.N., J. Lipid Res., 47, pp. 767-777, (2006); Chava K.R., Karpurapu M., Wang D., Bhanoori M., Kundumani-Sridharan V., Zhang Q., Ichiki T., Glasgow W.C., Rao G.N., Arterioscler. Thromb. Vasc. Biol., 29, pp. 809-815, (2009); Antonarakis S.E., Hum. Mutat., 11, pp. 1-3, (1998); Mayr B., Montminy M., Nat. Rev. Mol. Cell Biol., 2, pp. 599-609, (2001); Stevenson A.S., Cartin L., Wellman T.L., Dick M.H., Nelson M.T., Lounsbury K.M., Exp. Cell Res., 263, pp. 118-130, (2001); Kubalak S.W., Webb J.G., Am. J. Physiol. Heart Circ. Physiol., 264, (1993); Pepperl D.J., Shah-Basu S., VanLeeuwen D., Granneman J.G., MacKenzie R.G., Biochem. Biophys. Res. Commun., 243, pp. 52-55, (1998); Miles R.R., Sluka J.P., Santerre R.F., Hale L.V., Bloem L., Boguslawski G., Thirunavukkarasu K., Hock J.M., Onyia J.E., Endocrinology, 141, pp. 28-36, (2000); Cheng Y.S., Lee T.S., Hsu H.C., Kou Y.R., Wu Y.L., J. Cell. Biochem., 105, pp. 922-930, (2008); Akiba S., Mizunaga S., Kume K., Hayama M., Sato T., J. Biol. Chem., 274, pp. 19906-19912, (1999); Steer S.A., Wirsig K.C., Creer M.H., Ford D.A., McHowat J., Am. J. Physiol. Cell Physiol., 283, (2002); Thirunavukkarasu K., Halladay D.L., Miles R.R., Geringer C.D., Onyia J.E., J. Cell. Biochem., 85, pp. 837-850, (2002); Funakoshi Y., Ichiki T., Takeda K., Tokuno T., Iino N., Takeshita A., J. Biol. Chem., 277, pp. 18710-18717, (2002); Martinson B.D., Albert C.J., Corbett J.A., Wysolmerski R.B., Ford D.A., J. Lipid Res., 44, pp. 1686-1691, (2003); Williams S.D., Ford D.A., FEBS Lett., 420, pp. 33-38, (1997); Williams S.D., Ford D.A., Am. J. Physiol. Heart Circ. Physiol., 281, (2001); Dulin N.O., Niu J., Browning D.D., Ye R.D., Voyno-Yasenetskaya T., J. Biol. Chem., 276, pp. 20827-20830, (2001)","Z. Guo; 515 Wethington Bldg., Lexington, KY 40536, 900 South Limestone, United States; email: zguo2@uky.edu","","","","","","","","1083351X","","JBCHA","22057271","English","J. Biol. Chem.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84455173156"
"Stachyra-Strawa P.; Szatkowska-Sieczek L.; Cisek P.; Gołębiowski P.; Grzybowska-Szatkowska L.","Stachyra-Strawa, Paulina (57217033714); Szatkowska-Sieczek, Lidia (57551481100); Cisek, Paweł (56049602400); Gołębiowski, Paweł (55895188800); Grzybowska-Szatkowska, Ludmiła (7801516077)","57217033714; 57551481100; 56049602400; 55895188800; 7801516077","Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy","2024","Genes","15","2","177","","","","3","10.3390/genes15020177","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186267052&doi=10.3390%2fgenes15020177&partnerID=40&md5=4fa6443fc4c291ce6f078a01266dd8d7","Department of Radiotherapy, Medical University of Lublin, Chodźki 7, Lublin, 20-093, Poland; Clinical Department of Cardiology, 4th Military Hospital, Rudolfa Weigla 5, Wroclaw, 50-981, Poland","Stachyra-Strawa P., Department of Radiotherapy, Medical University of Lublin, Chodźki 7, Lublin, 20-093, Poland; Szatkowska-Sieczek L., Clinical Department of Cardiology, 4th Military Hospital, Rudolfa Weigla 5, Wroclaw, 50-981, Poland; Cisek P., Department of Radiotherapy, Medical University of Lublin, Chodźki 7, Lublin, 20-093, Poland; Gołębiowski P., Department of Radiotherapy, Medical University of Lublin, Chodźki 7, Lublin, 20-093, Poland; Grzybowska-Szatkowska L., Department of Radiotherapy, Medical University of Lublin, Chodźki 7, Lublin, 20-093, Poland","The ability to undergo neoangiogenesis is a common feature with all cancers. Signaling related to vascular endothelial growth factors (VEGF) and their receptors (VEGFR) plays a key role in the process of tumor neoangiogenesis. A close relationship has been demonstrated between excessive VEGF levels and the induction of immunosuppression in the tumor microenvironment. The use of drugs blocking the VEGF function, apart from the anticancer effect, also result in adverse effects, in particular related to the circulatory system and kidneys. Cardiac toxicity associated with the use of such therapy manifests itself mainly in the form of hypertension, thromboembolic episodes and ischemic heart disease. In the case of renal complications, the most common symptoms include renal arterial hypertension, proteinuria and microangiopathy. Although these complications are reversible in 60–80% of cases after cessation of VSP (VEGF pathway inhibitor) therapy, in some cases they can lead to irreversible changes in renal function, whereas cardiac complications may be fatal. Also, the use of PD-1/PD-L1 inhibitors may result in kidney and heart damage. In the case of cardiac complications, the most common symptoms include myocarditis, pericarditis, arrhythmia, acute coronary syndrome and vasculitis, while kidney damage most often manifests as acute kidney injury (AKI), nephrotic syndrome, pyuria or hematuria. The decision whether to resume treatment after the occurrence of cardiovascular and renal complications remains a problem. © 2024 by the authors.","anti-VEGF therapy; cardiotoxicity; ICI; neurotoxicity; TKI","Angiogenesis Inhibitors; Humans; Hypertension; Kidney; Ligands; Neoplasms; Programmed Cell Death 1 Receptor; Tumor Microenvironment; Vascular Endothelial Growth Factor A; aflibercept; angiogenesis inhibitor; atezolizumab; avelumab; axitinib; B Raf kinase; bevacizumab; cemiplimab; durvalumab; mitogen activated protein kinase 1; mitogen activated protein kinase 3; nivolumab; pazopanib; pembrolizumab; phosphatidylinositol 3 kinase; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; programmed death 1 receptor; prostacyclin; protein BAD; ramucirumab; sorafenib; sunitinib; unclassified drug; Vantedanib; vasculotropin; vasculotropin receptor 1; vasculotropin receptor 2; angiogenesis inhibitor; ligand; programmed death 1 receptor; vasculotropin A; acute coronary syndrome; Akt/mTOR signaling; anemia; angiogenesis; anorexia; atherosclerosis; atrial fibrillation; bleeding; blood vessel permeability; cancer immunotherapy; carcinogenesis; cardiotoxicity; colitis; coronary artery disease; dermatitis; diarrhea; drug induced disease; essential hypertension; fatigue; fistula; headache; heart arrhythmia; heart failure; heart infarction; heart injury; heart muscle fibrosis; heart muscle revascularization; heart ventricle arrhythmia; hematuria; hepatitis; human; hypertension; hypertrophy; hypocalcemia; hypomagnesemia; hyponatremia; hypophosphatemia; immune response; intestine obstruction; ischemic heart disease; kidney distal tubule; kidney function; kidney injury; left ventricular hypertrophy; left ventricular systolic dysfunction; loss of appetite; lymphocytopenia; malignant neoplasm; membranous glomerulonephritis; microangiopathy; myocarditis; nausea and vomiting; nephrotic syndrome; nephrotoxicity; neutropenia; pericarditis; phase 1 clinical trial (topic); Pi3K/Akt signaling; platelet reactivity; protein phosphorylation; proteinuria; rash; renin angiotensin aldosterone system; Review; signal transduction; single nucleotide polymorphism; stomach perforation; stomatitis; temporal arteritis; thromboembolism; tumor microenvironment; vasculitis; venous thromboembolism; hypertension; kidney; neoplasm","","aflibercept, 845771-78-0, 862111-32-8; atezolizumab, 1380723-44-3; avelumab, 1537032-82-8; axitinib, 319460-85-0; bevacizumab, 216974-75-3, 1438851-35-4; cemiplimab, 1801342-60-8; durvalumab, 1428935-60-7; mitogen activated protein kinase 1, 137632-08-7; mitogen activated protein kinase 3, 137632-07-6; nivolumab, 946414-94-4; pazopanib, 444731-52-6, 635702-64-6; pembrolizumab, 1374853-91-4; phosphatidylinositol 3 kinase, 115926-52-8; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase, 210488-47-4; prostacyclin, 35121-78-9, 61849-14-7; ramucirumab, 947687-13-0; sorafenib, 284461-73-0, 475207-59-1; sunitinib, 341031-54-7, 557795-19-4, 1327155-72-5; vasculotropin, 127464-60-2; vasculotropin A, 489395-96-2; Angiogenesis Inhibitors, ; Ligands, ; Programmed Cell Death 1 Receptor, ; Vascular Endothelial Growth Factor A, ","","","","","Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M., Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors, Am. J. Pathol, 160, pp. 985-1000, (2002); Baluk P., Morikawa S., Haskell A., Mancuso M., McDonald D.M., Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors, Am. J. Pathol, 163, pp. 1801-1815, (2003); Fukumura D., Kloepper J., Amoozgar Z., Duda D.G., Jain R.K., Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges, Nat. Rev. Clin. Oncol, 15, pp. 325-340, (2018); Hicklin D.J., Ellis L.M., Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J. Clin. Oncol, 23, pp. 1011-1027, (2005); Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med, 350, pp. 2335-2342, (2004); Geindreau M., Ghiringhelli F., Bruchard M., Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response, Int. J. Mol. Sci, 22, (2021); Verheul H.M.W., Pinedo H.M., Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nat. Rev. Cancer, 7, pp. 475-485, (2007); Roodhart J., Langenberg M., Witteveen E., Voest E., The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway, Curr. Clin. Pharmacol, 3, pp. 132-143, (2008); Ghosh C., Luong G., Sun Y., A snapshot of the PD-1/PD-L1 pathway, J. Cancer, 12, pp. 2735-2746, (2021); Touyz R.M., Herrmann J., Cardiotoxicity with vascular endothelial growth factor inhibitor therapy, NPJ Precis Oncol, 2, (2018); Chebotareva N., Grechukhina K., Mcdonnell V., Zhukova L., Krasnova T., Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs, Biomed. Rep, 16, (2022); Stein-Merlob A.F., Rothberg M.V., Holman P., Yang E.H., Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies, Curr. Cardiol. Rep, 23, (2021); Sise M.E., Seethapathy H., Reynolds K.L., Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review, Oncologist, 24, pp. 735-742, (2019); Reardon D.A., Turner S., Peters K.B., Desjardins A., Gururangan S., Sampson J.H., McLendon R.E., Herndon J.E., Jones L.W., Kirkpatrick J.P., Et al., A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma, J. Natl. Compr. Canc. Netw, 9, pp. 414-427, (2011); Bolcaen J., Nair S., Driver C.H.S., Boshomane T.M.G., Ebenhan T., Vandevoorde C., Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma, Pharmaceuticals, 14, (2021); Shibuya M., Structure and function of VEGF/VEGF-receptor system involved in angiogenesis, Cell Struct. Funct, 26, pp. 25-35, (2001); Jayson G.C., Kerbel R., Ellis L.M., Harris A.L., Antiangiogenic therapy in oncology: Current status and future directions, Lancet, 388, pp. 518-529, (2016); Kerbel R.S., Tumor angiogenesis, N. Engl. J. Med, 358, pp. 2039-2049, (2008); Stachyra-Strawa P., Ciesielka M., Janiszewski M., Grzybowska-Szatkowska L., The role of immunotherapy and molecular-targeted therapy in the treatment of melanoma (Review), Oncol. Rep, 46, (2021); Regad T., Targeting RTK signaling pathways in cancer, Cancers, 7, pp. 1758-1784, (2015); Figueras A., Arbos M.A., Quiles M.T., Vinals F., Germa J.R., Capella G., The impact of KRAS mutations on VEGF-A production and tumour vascular network, BMC Cancer, 13, (2013); Hoxhaj G., Manning B.D., The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism, Nat. Rev. Cancer, 20, pp. 74-88, (2020); Burke J.E., Structural basis for regulation of phosphoinositide kinases and their involvement in human disease, Mol. Cell, 71, pp. 653-673, (2018); Ohaegbulam K.C., Assal A., Lazar-Molnar E., Yao Y., Zang X., Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway, Trends. Mol. Med, 21, pp. 24-33, (2015); Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., Shin T., Tsuchiya H., Pardoll D.M., Okumura K., Expression of program-med death 1 ligands by murine T cells and APC, J. Immunol, 169, pp. 5538-5545, (2002); Dobbin S.J.H., Petrie M.C., Myles R.C., Touyz R.M., Lang N.N., Cardiotoxic effects of angiogenesis inhibitors, Clin. Sci, 135, pp. 71-100, (2021); Small H.Y., Montezano A.C., Rios F.J., Savoia C., Touyz R.M., Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome, Can. J. Cardiol, 30, pp. 534-543, (2014); Abdel-Qadir H., Ethier J.L., Lee D.S., Thavendiranathan P., Amir E., Cardio- vascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis, Cancer Treat. Rev, 53, pp. 120-127, (2017); Bernard G., Mayo Clinic Heart Book, pp. 120-125, (2000); Yamaguchi H., Ishinura T., Nishiyam, Zakaria N., Guerard N., Emanuelli A., Duge P., Watts J., Liew M., Gekkieva M., Et al., Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration, Pharmacol. Res. Perspect, 10, (2022); Wilk M., Szmit S., Cardiovascular complications of antiangiogenic therapy in ovarian cancer patients, Oncol. Clin. Pract, 13, pp. 49-56, (2017); Pewsner D., Juni P., Egger M., Battaglia M., Sundstrom J., Bachmann L.M., Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: Systematic review, BMJ, 6, (2007); Vallerio P., Orenti A., Tosi F., Maistrello M., Palazzini M., Cingarlini S., Colombo P., Bertuzzi M., Spina F., Amatu A., Et al., Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: A real-life study and proposed algorithm for proactive management, ESMO Open, 7, (2022); Billemont B., Medioni J., Taillade L., Helley D., Meric J.B., Rixe O., Oudard S., Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib, Br. J. Cancer, 99, pp. 1380-1382, (2008); Choueiri T.K., Mayer E.L., Je Y., Rosenberg J.E., Nguyen P.L., Azzi G.R., Bellmunt J., Burstein H.J., Schutz F.A., Congestive heart failure risk in patients with breast cancer treated with bevacizumab, J. Clin. Oncol, 29, pp. 632-638, (2011); Ghatalia P., Morgan C.J., Je Y., Nguyen P.L., Trinh Q.D., Choueiri T.K., Sonpavde G., Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors, Crit. Rev. Oncol. Hematol, 94, pp. 228-237, (2015); Santoni M., Guerra F., Conti A., Lucarelli A., Rinaldi S., Belvederesi L., Capucci A., Berardi R., Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies, Cancer Treat. Rev, 59, pp. 123-131, (2017); Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J., Nathan P., Staehler M., de Souza P., Merchan J.R., Pazopanib versus Sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med, 369, pp. 722-731, (2013); Chen X.L., Lei Y.H., Liu C.F., Yang Q.F., Zuo P.Y., Liu C.Y., Chen C.Z., Liu Y.W., Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis, PLoS ONE, 8, (2013); Faruque L.I., Lin M., Battistella M., Wiebe N., Reiman T., Hemmelgarn B., Thomas C., Tonelli M., Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer, PLoS ONE, 9, (2014); Maison-Blanche P., Vermorken J.B., Goksel T., Machiels J.P., Agarwala S., Rottey S., Daugaard G., Volovat C., Scheulen M., Sengelov L., A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel, J. Cardiovasc. Pharmacol, 61, pp. 495-504, (2013); Zang J., Wu S., Tang L., Xu X., Bai J., Ding C., Chang Y., Yue L., Kang E., He J., Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis, PLoS ONE, 7, (2012); Lobenwein D., Kocher F., Dobner S., Gollmann-Tepekoylu C., Holfeld J., Cardiotoxic mechanisms of cancer immunotherapy—A systematic review, Int. J. Cardiol, 323, pp. 179-187, (2021); Oren O., Yang E.H., Molina J.R., Bailey K.R., Blumenthal R.S., Kopecky S.L., Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors, Am. J. Cardiol, 125, pp. 1920-1926, (2020); Van Wynsberghe M., Flejeo J., Sakhi H., Ollero M., Sahali D., Izzedine H., Henique C., Nephrotoxicity of Anti-Angiogenic Therapies, Diagnostics, 11, (2021); Hayman S.R., Leung N., Grande J.P., Garovic V.D., VEGF Inhibition, Hypertension, and Renal Toxicity, Curr. Oncol. Rep, 14, pp. 285-294, (2012); Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. Med, 349, pp. 427-434, (2003); Zhu X., Wu S., Dahut W.L., Parikh C.R., Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis, Am. J. Kidney Dis, 49, pp. 186-193, (2007); Patel T.V., Morgan J.A., Demetri G.D., George S., Maki R.G., Quigley M., Humphreys B.D., A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib, J. Natl. Cancer Inst, 100, pp. 282-284, (2008); Garovic V.D., Wagner S.J., Petrovic L.M., Gray C.E., Hall P., Sugimoto H., Kalluri R., Grande J.P., Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia, Nephrol. Dial. Transplant, 22, pp. 1136-1143, (2007); Borowka M., Lacki-Zynzeling S., Nicze M., Kozak S., Chudek J., Adverse Renal Effects of Anticancer Immunotherapy: A Review, Cancers, 14, (2022); Cortazar F.B., Marrone K.A., Troxell M.L., Ralto K.M., Hoenig M.P., Brahmer J.R., Le D.T., Lipson E.J., Glezerman I.G., Wolchok J., Et al., Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int, 90, pp. 638-647, (2016); Gupta S., Cortazar F.B., Riella L.V., Leaf D.E., Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020, Kidney360, 1, pp. 130-140, (2020); Li Y.-L., Zhao H., Ren X.-B., Relationship of vegf/vegfr with immune and cancer cells: Staggering or forward?, Cancer Biol. Med, 13, pp. 206-214, (2016); Ziogas A.C., Gavalas N.G., Tsiatas M., Tsitsilonis O., Politi E., Terpos E., Rodolakis A., Vlahos G., Thomakos N., Haidopoulos D., Et al., Vegf directly suppresses activation of t cells from ovarian cancer patients and healthy individuals via vegf receptor type 2, Int. J. Cancer, 130, pp. 857-864, (2012); Rini B.I., Plimack E.R., Stus V., Gafanov R., Hawkins R., Nosov D., Pouliot F., Alekseev B., Soulieres D., Melichar B., Et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, 380, pp. 1116-1127, (2019); Motzer R.J., Penkov K., Haanen J., Rini B., Albiges L., Campbell M.T., Venugopal B., Kollmannsberger C., Negrier S., Uemura M., Et al., Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, 380, pp. 1103-1115, (2019); Markham A., Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma, Target Oncol, 17, pp. 193-201, (2022); Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodriguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Et al., Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N. Engl. J. Med, 378, pp. 2288-2301, (2018); Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y., Kudo M., Breder V., Merle P., Kaseb A.O., Et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, N. Engl. J. Med, 382, pp. 1894-1905, (2020); Zhou X., Yao Z., Bai H., Duan J., Wang Z., Wang X., He J., Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: A systematic review and meta-analysis, Lancet Oncol, 22, pp. 1265-1274, (2021); Tzuri N., Yegodayev K.M., Novoplansky O., Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy, Sci. Rep, 13, (2023); Xiong C., Mao Y., Wu T., Kang N., Zhao M., Di R., Li X., Ji X., Liu Y., Optimized expression and characterization of a novel fully human bispecific single-chain diabody targeting vascular endothelial growth factor165 and programmed death-1 in Pichia pastoris and evaluation of antitumor activity in vivo, Int. J. Mol. Sci, 19, (2018); Frey M.K., Dao F., Olvera N., Konner J.A., Dickler M., Levine D.A., Genetic predisposition to bevacizumab-induced hypertension, Gynecol. Oncol, 147, pp. 621-625, (2017); Quintanilha J.C.F., Wang J., Sibley A.B., Jiang C., Etheridge A.S., Shen F., Jiang G., Mulkey F., Patel J.N., Hertz D.L., Et al., Bevacizumab-induced hypertension and proteinuria: A genome-wide study of more than 1000 patients, Br. J. Cancer, 126, pp. 265-274, (2022); Lambrechts D., Moisse M., Delmar P., Miles D.W., Leighl N., Escudier B., Van Cutsem E., Bansal A.T., Carmeliet P., Scherer S.J., Et al., Genetic markers of bevacizumab-induced hypertension, Angiogenesis, 17, pp. 685-694, (2014); Eechoute K., van der Veldt A.A., Oosting S., Kappers M.H., Wessels J.A., Gelderblom H., Guchelaar H.J., Reyners A.K., van Herpen C.M., Haanen J.B., Et al., Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) predict sunitinib-induced hypertension, Clin. Pharmacol. Ther, 92, pp. 503-510, (2012); Diekstra M.H., Belaustegui A., Swen J.J., Boven E., Castellano D., Gelderblom H., Mathijssen R.H., Garcia-Donas J., Rodriguez-Antona C., Rini B.I., Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma, Pharmacogenom. J, 17, pp. 42-46, (2017); Qin C., Cao Q., Li P., Wang S., Wang J., Wang M., Chu H., Zhou L., Li X., Ye D., Et al., The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma, Sci. Rep, 6, pp. 20089-20103, (2016); (2020); Groha S., Alaiwi S.A., Xu W., Naranbhai V., Nassar A.H., Bakouny Z., El Zarif T., Saliby R.M., Wan G., Rajeh A., Et al., Germline variants associated with toxicity to immune checkpoint blockade, Nat. Med, 28, pp. 2584-2591, (2022); Udagawa C., Nakano M.H., Yoshida T., Ohe Y., Kato K., Mushiroda T., Zembutsu H., Association between genetic variants and the risk of nivolumab-induced immune-related adverse events, Pharmacogenomics, 23, pp. 887-901, (2022)","L. Grzybowska-Szatkowska; Department of Radiotherapy, Medical University of Lublin, Lublin, Chodźki 7, 20-093, Poland; email: ludmila.grzybowska-szatkowska@umlub.pl","","Multidisciplinary Digital Publishing Institute (MDPI)","","","","","","20734425","","","38397167","English","Genes","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85186267052"
"Lee K.-C.; Wu P.-S.; Lin H.-C.","Lee, Kuei-Chuan (8325824500); Wu, Pei-Shan (57202512381); Lin, Han-Chieh (7405571736)","8325824500; 57202512381; 7405571736","Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis","2023","Clinical and Molecular Hepatology","29","1","","77","98","21","59","10.3350/cmh.2022.0237","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85146162389&doi=10.3350%2fcmh.2022.0237&partnerID=40&md5=2935b6efa49ffcf79c7ccabdefefbd99","Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 11217, Taiwan; Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan; Endoscopy Center for Diagnosis and Treatment, Taipei Veterans General Hospital, Taipei, Taiwan","Lee K.-C., Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 11217, Taiwan, Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan; Wu P.-S., Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 11217, Taiwan, Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan, Endoscopy Center for Diagnosis and Treatment, Taipei Veterans General Hospital, Taipei, Taiwan; Lin H.-C., Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 11217, Taiwan, Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan","The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and insulin resistance causes lipid accumulation. Lipotoxicity, oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress would further contribute to hepatocyte injury and death, leading to inflammation and immune dysfunction in the liver. During the healing process, the accumulation of an excessive amount of fibrosis might occur while healing. During the development of NASH and liver fibrosis, the gut-liver axis, adipose-liver axis, and renin-angiotensin system (RAS) may be dysregulated and impaired. Translocation of bacteria or its end-products entering the liver could activate hepatocytes, Kupffer cells, and hepatic stellate cells, exacerbating hepatic steatosis, inflammation, and fibrosis. Bile acids regulate glucose and lipid metabolism through Farnesoid X receptors in the liver and intestine. Increased adipose tissue-derived non-esterified fatty acids would aggravate hepatic steatosis. Increased leptin also plays a role in hepatic fibrogenesis, and decreased adiponectin may contribute to hepatic insulin resistance. Moreover, dysregulation of peroxisome proliferator-activated receptors in the liver, adipose, and muscle tissues may impair lipid metabolism. In addition, the RAS may contribute to hepatic fatty acid metabolism, inflammation, and fibrosis. The treatment includes lifestyle modification, pharmacological therapy, and non-pharmacological therapy. Currently, weight reduction by lifestyle modification or surgery is the most effective therapy. However, vitamin E, pioglitazone, and obeticholic acid have also been suggested. In this review, we will introduce some new clinical trials and experimental therapies for the treatment of NASH and related fibrosis. © 2023 by Korean Association for the Study of the Liver.","Fatty liver; Liver fibrosis; Steatohepatitis","acetyl coenzyme A carboxylase; acylcarnitine; alanine aminotransferase; aldafermin; alpha tocopherol; aspartate aminotransferase; belapectin; caspase 9; cenicriviroc; cytochrome c; diacylglycerol acyltransferase 2; dipeptidyl carboxypeptidase inhibitor; efruxifermin; elafibranor; emricasan; farnesoid X receptor; Fas ligand; fatty acid; fatty acid synthase; fibroblast growth factor; fibroblast growth factor 19; fibroblast growth factor 21; fibronectin; firsocostat; glucagon like peptide 1; glucokinase; glycerophospholipid; glycogen synthase kinase 3; growth arrest and DNA damage inducible protein 153; guanosine triphosphatase; hydroxymethylglutaryl coenzyme A reductase kinase kinase; inositol; interleukin 1beta; interleukin 6; lanifibranor; leptin; microRNA; obeticholic acid; pegbelfermin; pemafibrate; peroxisome proliferator activated receptor; pioglitazone; plasminogen activator inhibitor 1; polyunsaturated fatty acid; protein kinase Yes; reactive oxygen metabolite; semaglutide; short chain fatty acid; sodium glucose cotransporter 2 inhibitor; sphingolipid; STAT3 protein; sterol regulatory element binding protein 1c; toll like receptor 2; toll like receptor 4; triacylglycerol; tumor necrosis factor; very low density lipoprotein; X box binding protein 1; adipose tissue; apoptosis; autophagy (cellular); bioavailability; body mass; body weight loss; coronary artery disease; decompensated liver cirrhosis; diabetes mellitus; DNA damage; endoplasmic reticulum stress; epigenome; esophagus varices; fatty acid oxidation; fecal microbiota transplantation; fibrogenesis; follow up; gene expression; genotype; gluconeogenesis; glucose metabolism; glycogenolysis; hepatic stellate cell; high calorie diet; human; hypertension; immune response; immunocompetent cell; innate immunity; insulin resistance; insulin sensitivity; intestine flora; Kupffer cell; laparoscopic sleeve gastrectomy; lifestyle modification; lipid diet; lipid metabolism; lipid storage; lipotoxicity; liver carcinogenesis; liver cell carcinoma; liver cell damage; liver fibrosis; mitochondrial respiration; nonalcoholic steatohepatitis; obesity; oxidative stress; pathogenesis; physical activity; physical inactivity; Pi3K/Akt signaling; portal hypertension; prevalence; renin angiotensin aldosterone system; Review; risk factor; Roux-en-Y gastric bypass; sedentary lifestyle; single nucleotide polymorphism; synergistic effect; systematic review; tumor growth; unfolded protein response","","acetyl coenzyme A carboxylase, 9023-93-2; alanine aminotransferase, 9000-86-6, 9014-30-6; aldafermin, 1616639-03-2; alpha tocopherol, 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; aspartate aminotransferase, 9000-97-9; belapectin, 1980787-47-0; caspase 9, 180189-96-2; cenicriviroc, 497223-25-3, 497223-28-6; cytochrome c, 9007-43-6, 9064-84-0; efruxifermin, 2375240-92-7; elafibranor, 923978-27-2, 824932-88-9; emricasan, 254750-02-2; fatty acid synthase, 9045-77-6; fibroblast growth factor, 62031-54-3; fibronectin, 86088-83-7; firsocostat, 1434635-54-7; glucagon like peptide 1, 89750-14-1; glucokinase, 37237-53-9, 9001-36-9; guanosine triphosphatase, 9059-32-9; hydroxymethylglutaryl coenzyme A reductase kinase kinase, ; inositol, 55608-27-0, 6917-35-7, 87-89-8; lanifibranor, 927961-18-0; obeticholic acid, 459789-99-2; pegbelfermin, 2089039-22-3; pemafibrate, 848259-27-8; pioglitazone, 105355-27-9, 111025-46-8, 1266523-09-4, 105390-47-4, 112529-15-4; plasminogen activator inhibitor 1, 140208-23-7; semaglutide, 910463-68-2; toll like receptor 2, 203811-81-8; toll like receptor 4, 203811-83-0","","","Ministry of Science and Technology, Taiwan, MOST, (110-2628-B-075-016, 111-2314-B-075-051-MY3)","This study was supported in part by the grants from the Ministry of Science and Technology (110-2628-B-075-016; 111-2314-B-075-051-MY3) Taiwan.","Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Et al., The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, pp. 328-357, (2018); Browning JD, Horton JD., Molecular mediators of hepatic ste-atosis and liver injury, J Clin Invest, 114, pp. 147-152, (2004); Lemoinne S, Friedman SL., New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases, Curr Opin Pharmacol, 49, pp. 60-70, (2019); Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, Et al., Dietary fat content modifies liver fat in overweight nondiabetic subjects, J Clin Endocrinol Metab, 90, pp. 2804-2809, (2005); van der Meer RW, Hammer S, Lamb HJ, Frolich M, Diamant M, Rijzewijk LJ, Et al., Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men, J Clin Endocrinol Metab, 93, pp. 2702-2708, (2008); Lindeboom L, Nabuurs CI, Hesselink MK, Wildberger JE, Schrauwen P, Schrauwen-Hinderling VB., Proton magnetic res-onance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein, Am J Clin Nutr, 101, pp. 65-71, (2015); Hernandez EA, Kahl S, Seelig A, Begovatz P, Irmler M, Kupri-yanova Y, Et al., Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance, J Clin Invest, 127, pp. 695-708, (2017); Kaikkonen JE, Wurtz P, Suomela E, Lehtovirta M, Kangas AJ, Jula A, Et al., Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the young finns study, Hepatology, 65, pp. 491-500, (2017); Rosqvist F, Kullberg J, Stahlman M, Cedernaes J, Heurling K, Johansson HE, Et al., Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: a randomized trial, J Clini Endocrinol Metab, 104, pp. 6207-6219, (2019); Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Et al., A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, 46, pp. 1081-1090, (2007); Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, Et al., Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study, Aliment Pharmacol Ther, 36, pp. 772-781, (2012); Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, Et al., Rela-tionship of sitting time and physical activity with non-alcohol-ic fatty liver disease, J Hepatology, 63, pp. 1229-1237, (2015); Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, Et al., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, pp. 1844-1850, (2001); Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Et al., Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms, Diabe-tologia, 48, pp. 634-642, (2005); Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, pp. 1343-1351, (2005); Utzschneider KM, Kahn SE., Review: the role of insulin resistance in nonalcoholic fatty liver disease, J Clin Endocrinol Metab, 91, pp. 4753-4761, (2006); Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL., Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells, J Clin Invest, 99, pp. 846-854, (1997); Tamura S, Shimomura I., Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease, J Clin Invest, 115, pp. 1139-1142, (2005); Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M., Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes, Nature, 432, pp. 1027-1032, (2004); Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Et al., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, pp. 1461-1465, (2008); Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Et al., Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits, PLoS Genet, 7, (2011); Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Et al., Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma, Nat Genet, 43, pp. 1131-1138, (2011); Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, Et al., The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver, Hum Mol Genet, 18, pp. 4081-4088, (2009); Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, Et al., Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 46, pp. 352-356, (2014); Mahdessian H, Taxiarchis A, Popov S, Silveira A, Franco-Cereceda A, Hamsten A, Et al., TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content, Proc Natl Acad Sci U S A, 111, pp. 8913-8918, (2014); Lin YC, Chang PF, Lin HF, Liu K, Chang MH, Ni YH., Variants in the autophagy-related gene IRGM confer susceptibility to non-alcoholic fatty liver disease by modulating lipophagy, J Hepatol, 65, pp. 1209-1216, (2016); Bellini G, Miraglia Del Giudice E, Nobili V, Rossi F., The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children, J Hepatol, 67, pp. 653-655, (2017); Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Mannisto V, Sammalkorpi H, Et al., Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of nonalcoholic fatty liver disease, J Hepatol, 76, pp. 526-535, (2022); Ma J, Nano J, Ding J, Zheng Y, Hennein R, Liu C, Et al., A periph-eral blood DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease, Diabetes, 68, pp. 1073-1083, (2019); Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Et al., Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease patho-genesis, Gut, 64, pp. 800-812, (2015); Castano C, Kalko S, Novials A, Parrizas M., Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice, Proc Natl Acad Sci U S A, 115, pp. 12158-12163, (2018); Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Et al., miR-122 regulation of lipid metabolism revealed by in vivo anti-sense targeting, Cell Metab, 3, pp. 87-98, (2006); Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira O, Girones J, Et al., Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD, Int J Obes (Lond), 41, pp. 620-630, (2017); Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Et al., Essen-tial metabolic, anti-inflammatory, and anti-tumorigenic func-tions of miR-122 in liver, J Clin Invest, 122, pp. 2871-2883, (2012); Kim YS, Nam HJ, Han CY, Joo MS, Jang K, Jun DW, Et al., Liver X receptor alpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating autophagy-related 4B cysteine peptidase and Rab-8B, reducing mitochondrial fuel oxidation, Hepatology, 73, pp. 1307-1326, (2021); Wang M, Kaufman RJ., Protein misfolding in the endoplasmic reticulum as a conduit to human disease, Nature, 529, pp. 326-335, (2016); Lebeaupin C, Vallee D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B., Endoplasmic reticulum stress signalling and the pathogen-esis of non-alcoholic fatty liver disease, J Hepatol, 69, pp. 927-947, (2018); Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Et al., Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease, Gastroenterology, 134, pp. 568-576, (2008); Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Et al., Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis, J Hepatol, 52, pp. 586-593, (2010); Volmer R, van der Ploeg K, Ron D., Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains, Proc Natl Acad Sci U S A, 110, pp. 4628-4633, (2013); Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, Et al., NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression, Gut, 71, pp. 2561-2573, (2022); Sunny NE, Parks EJ, Browning JD, Burgess SC., Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease, Cell Metab, 14, pp. 804-810, (2011); Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, Et al., Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis, Cell Metab, 21, pp. 739-746, (2015); Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Et al., Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis, Hepatol-ogy, 38, pp. 999-1007, (2003); Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, Et al., Mitochondrial metabolism mediates oxi-dative stress and inflammation in fatty liver, J Clin Invest, 125, pp. 4447-4462, (2015); Martel C, Allouche M, Esposti DD, Fanelli E, Boursier C, Henry C, Et al., Glycogen synthase kinase 3-mediated voltage-de-pendent anion channel phosphorylation controls outer mito-chondrial membrane permeability during lipid accumulation, Hepatology, 57, pp. 93-102, (2013); Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE., The lyso-somal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity, Hepatology, 47, pp. 1495-1503, (2008); Meex RCR, Blaak EE., Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD, Mol Nutr Food Res, 65, (2021); Peng KY, Watt MJ, Rensen S, Greve JW, Huynh K, Jayawardana KS, Et al., Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression, J Lipid Res, 59, pp. 1977-1986, (2018); Chocian G, Chabowski A, Zendzian-Piotrowska M, Harasim E, Lukaszuk B, Gorski J., High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei, Mol Cell Biochem, 340, pp. 125-131, (2010); Chavez JA, Summers SA., A ceramide-centric view of insulin resistance, Cell Metab, 15, pp. 585-594, (2012); Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ., Ceramide induces hepatocyte cell death through disruption of mitochon-drial function in the rat, Hepatology, 25, pp. 958-963, (1997); Tovoli F, Napoli L, Negrini G, D'Addato S, Tozzi G, D'Amico J, Et al., A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease, Int J mol Sci, 18, (2017); Baratta F, Pastori D, Del Ben M, Polimeni L, Labbadia G, Di Santo S, Et al., Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease, EBioMedicine, 2, pp. 750-754, (2015); Wang X, Zhang X, Chu ESH, Chen X, Kang W, Wu F, Et al., Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis, FASEB J, 32, pp. 37-51, (2018); Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Et al., Free fatty acids promote hepatic lipo-toxicity by stimulating TNF-alpha expression via a lysosomal pathway, Hepatology, 40, pp. 185-194, (2004); Hirsova P, Ibrabim SH, Gores GJ, Malhi H., Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis, J Lipid Res, 57, pp. 1758-1770, (2016); Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Et al., Autophagy regulates lipid metabolism, Nature, 458, pp. 1131-1135, (2009); Li S, Dou X, Ning H, Song Q, Wei W, Zhang X, Et al., Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity, Hepatology, 66, pp. 936-952, (2017); Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H., How does hepatic lipid accumulation lead to lipotoxicity in nonalcoholic fatty liver disease?, Hepatol Int, 15, pp. 21-35, (2021); Cao L, Quan XB, Zeng WJ, Yang XO, Wang MJ., Mechanism of hepatocyte apoptosis, J Cell Death, 9, pp. 19-29, (2016); Rada P, Gonzalez-Rodriguez A, Garcia-Monzon C, Valverde AM., Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?, Cell Death Dis, 11, (2020); Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Et al., Prospective study of outcomes in adults with nonalcoholic fatty liver disease, N Engl J Med, 385, pp. 1559-1569, (2021); Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S., Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, pp. 543-550, (2019); Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, pp. 643-654, (2015); Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH., Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis, J Hepatol, 51, pp. 371-379, (2009); Parthasarathy G, Revelo X, Malhi H., Pathogenesis of nonalcoholic steatohepatitis: an overview, Hepatol Commun, 4, pp. 478-492, (2020); Marra F, Svegliati-Baroni G., Lipotoxicity and the gut-liver axis in NASH pathogenesis, J Hepatol, 68, pp. 280-295, (2018); Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Wer-neburg NW, Et al., Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes, Gastro-enterology, 150, pp. 956-967, (2016); Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ., Apoptotic body engulfment by a human stellate cell line is profibrogenic, Lab Invest, 83, pp. 655-663, (2003); Kwon H, Song K, Han C, Chen W, Wang Y, Dash S, Et al., Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease, Hepatology, 63, pp. 1155-1169, (2016); Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, Et al., Hedgehog-mediated epithelial-to-mesenchymal transi-tion and fibrogenic repair in nonalcoholic fatty liver disease, Gastroenterology, 137, pp. 1478-1488, (2009); Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Et al., Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohep-atitis, Hepatology, 53, pp. 106-115, (2011); Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Et al., NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease, Gut, 61, pp. 1323-1329, (2012); Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS., TLR4 links innate immunity and fatty acid-induced insulin resis-tance, J Clin Invest, 116, pp. 3015-3025, (2006); Hetherington AM, Sawyez CG, Zilberman E, Stoianov AM, Robson DL, Borradaile NM., Differential lipotoxic effects of pal-mitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells, Cell Physiol Biochem, 39, pp. 1648-1662, (2016); Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, Et al., Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic ste-atohepatitis in mice, Hepatology, 59, pp. 154-169, (2014); Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Et al., High glucose and hyperinsulinemia stimu-late connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis, Hepatology, 34, pp. 738-744, (2001); Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Et al., Insulin and insulin-like growth factor-1 stim-ulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways, Hepatology, 29, pp. 1743-1751, (1999); Cai CX, Buddha H, Castelino-Prabhu S, Zhang Z, Britton RS, Bacon BR, Et al., Activation of insulin-PI3K/akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis, Dig Dis Sci, 62, pp. 968-978, (2017); Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, Et al., PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells, Hum Mol Genet, 23, pp. 4077-4085, (2014); Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, Et al., The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent, Gastroenterology, 150, pp. 1219-1230, (2016); Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Et al., Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues, Gastroenterology, 142, pp. 938-946, (2012); Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vve-denskaya O, Buch S, Et al., Loss of hepatic Mboat7 leads to liver fibrosis, Gut, 70, pp. 940-950, (2021); Fondevila MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, Buque X, Gonzalez-Rodriguez A, Et al., The L-α-lysophosphatidylinositol/G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis, Hepatology, 73, pp. 606-624, (2021); Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Et al., TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease, Nat Commun, 5, (2014); Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Et al., A protein-truncating HSD17B13 variant and protection from chronic liver disease, N Engl J Med, 378, pp. 1096-1106, (2018); Pirola CJ, Garaycoechea M, Flichman D, Arrese M, San Mar-tino J, Gazzi C, Et al., Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease, J Lipid Res, 60, pp. 176-185, (2019); Luukkonen PK, Tukiainen T, Juuti A, Sammalkorpi H, Haridas PAN, Niemela O, Et al., Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease, JCI Insight, 5, (2020); Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, Et al., 17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease, Hepatology, 69, pp. 1504-1519, (2019); Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, Ness T, Et al., Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease, Clin Epigenetics, 7, (2015); Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Et al., Fecal microbiome and volatile organic com-pound metabolome in obese humans with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 11, pp. 868-875, (2013); Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, Et al., Intestinal microbiota in patients with nonalcoholic fatty liver disease, Hepatology, 58, pp. 120-127, (2013); Mao JW, Tang HY, Zhao T, Tan XY, Bi J, Wang BY, Et al., Intestinal mucosal barrier dysfunction participates in the prog-ress of nonalcoholic fatty liver disease, Int J Clin Exp Pathol, 8, pp. 3648-3658, (2015); Mencin A, Kluwe J, Schwabe RF., Toll-like receptors as targets in chronic liver diseases, Gut, 58, pp. 704-720, (2009); Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Et al., Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity, Nature, 482, pp. 179-185, (2012); Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Et al., Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepati-tis, Liver Int, 28, pp. 1026-1033, (2008); Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM., Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis, Proc Natl Acad Sci U S A, 94, pp. 2557-2562, (1997); Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M., Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steato-hepatitis, J Hepatol, 47, pp. 571-579, (2007); Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Et al., Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice, Gastroenterology, 139, pp. 323-334, (2010); Hsieh YC, Lee KC, Wu PS, Huo TI, Huang YH, Hou MC, Et al., Eritoran attenuates hepatic inflammation and fibrosis in mice with chronic liver injury, Cells, 10, (2021); Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Et al., TLR4 enhances TGF-beta signaling and hepatic fibro-sis, Nat Med, 13, pp. 1324-1332, (2007); Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, Et al., Inflammation and portal hypertension-the undiscovered country, J Hepatology, 61, pp. 155-163, (2014); Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Et al., Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development, J Hepatol, 71, pp. 1216-1228, (2019); Yuan J, Baker SS, Liu W, Alkhouri R, Baker RD, Xie J, Et al., Endo-toxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis, J Gastroenterol Hepatol, 29, pp. 1292-1298, (2014); Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Et al., Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability, Cell Mol Gastroenterol Hepatol, 1, pp. 222-232, (2015); Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Et al., Metabolic profiling reveals a contribution of gut mi-crobiota to fatty liver phenotype in insulin-resistant mice, Proc Natl Acad Sci U S A, 103, pp. 12511-12516, (2006); Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Et al., Activation of the nuclear receptor FXR improves hyperglyce-mia and hyperlipidemia in diabetic mice, Proc Natl Acad Sci U S A, 103, pp. 1006-1011, (2006); Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Et al., Definition of a novel growth factor-dependent signal cas-cade for the suppression of bile acid biosynthesis, Genes Dev, 17, pp. 1581-1591, (2003); Yajima M, Karaki SI, Tsuruta T, Kimura S, Nio-Kobayashi J, Kuwahara A, Et al., Diversity of the intestinal microbiota differ-ently affects non-neuronal and atropine-sensitive ileal con-tractile responses to short-chain fatty acids in mice, Biomed Res, 37, pp. 319-328, (2016); den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, Et al., Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids, Am J Physiol Gastrointest Liver Physiol, 305, pp. G900-G910, (2013); Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manches-ter JK, Et al., Effects of the gut microbiota on host adipos-ity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41, Proc Natl Acad Sci U S A, 105, pp. 16767-16772, (2008); Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Et al., Butyrate improves insulin sensitivity and increases energy expenditure in mice, Diabetes, 58, pp. 1509-1517, (2009); Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Et al., Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease, Cell Metab, 25, pp. 1054-1062, (2017); Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Et al., Characterization of gut microbiomes in nonalcoholic steato-hepatitis (NASH) patients: a connection between endogenous alcohol and NASH, Hepatology, 57, pp. 601-609, (2013); Passos MC, Goncalves MC., Regulation of insulin sensitivity by adiponectin and its receptors in response to physical exercise, Horm Metab Res, 46, pp. 603-608, (2014); Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Et al., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med, 8, pp. 1288-1295, (2002); Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest, 112, pp. 91-100, (2003); Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J., Beyond insulin resistance in NASH: TNF-alpha or adiponectin?, Hepatology, 40, pp. 46-54, (2004); Yadav A, Kataria MA, Saini V, Yadav A., Role of leptin and adipo-nectin in insulin resistance, Clin Chim Acta, 417, pp. 80-84, (2013); Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mant-zoros CS., Irisin in patients with nonalcoholic fatty liver disease, Metabolism, 63, pp. 207-217, (2014); Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS., Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis, Diabetologia, 59, pp. 30-43, (2016); Yang YY, Tsai TH, Huang YT, Lee TY, Chan CC, Lee KC, Et al., Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats, Hepatology, 55, pp. 1540-1550, (2012); Shoelson SE, Lee J, Goldfine AB., Inflammation and insulin re-sistance, J Clin Invest, 116, pp. 1793-1801, (2006); Tilg H., The role of cytokines in non-alcoholic fatty liver disease, Dig Dis, 28, pp. 179-185, (2010); Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, Et al., Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model, Horm Metab Res, 50, pp. 80-87, (2018); Han MS, White A, Perry RJ, Camporez JP, Hidalgo J, Shulman GI, Et al., Regulation of adipose tissue inflammation by interleukin 6, Proc Natl Acad Sci U S A, 117, pp. 2751-2760, (2020); Perry RJ, Camporez JG, Kursawe R, Titchenell PM, Zhang D, Perry CJ, Et al., Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes, Cell, 160, pp. 745-758, (2015); Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Et al., Renin-angiotensin system and fibrosis in nonalcoholic fatty liver disease, Liver Int, 35, pp. 979-985, (2015); Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, Et al., Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease, Hepatology, 76, pp. 469-482, (2021); Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Et al., Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats, J Hepatol, 49, pp. 417-428, (2008); Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, Et al., Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin, Cell Metab, 6, pp. 506-512, (2007); Lee KC, Chan CC, Yang YY, Hsieh YC, Huang YH, Lin HC., Aliski-ren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet, PLoS One, 8, (2013); Lee KC, Hsieh YC, Yang YY, Chan CC, Huang YH, Lin HC., Aliski-ren reduces hepatic steatosis and epididymal fat mass and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice, Sci Rep, 6, (2016); Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD., Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin, J Clin Invest, 109, pp. 1417-1427, (2002); Oliver JA., Receptor-mediated actions of renin and prorenin, Kidney Int, 69, pp. 13-15, (2006); Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Et al., Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms, Kidney Int, 69, pp. 105-113, (2006); Hsieh YC, Lee KC, Lei HJ, Lan KH, Huo TI, Lin YT, Et al., (Pro)renin receptor knockdown attenuates liver fibrosis through inactiva-tion of ERK/TGF-β1/SMAD3 pathway, Cell Mol Gastroenterol Hepatol, 12, pp. 813-838, (2021); Ren L, Sun Y, Lu H, Ye D, Han L, Wang N, Et al., (Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis, Circ Res, 122, pp. 730-741, (2018); Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ., Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, pp. 123-133, (2018); Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M., From NASH to HCC: current concepts and future challenges, Nat Rev Gastroenterol Hepatol, 16, pp. 411-428, (2019); Schwabe RF, Greten TF., Gut microbiome in HCC-mechanisms, diagnosis and therapy, J Hepatol, 72, pp. 230-238, (2020); Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Et al., Dietary and genetic obesity promote liver inflammation and tumorigen-esis by enhancing IL-6 and TNF expression, Cell, 140, pp. 197-208, (2010); Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Et al., ER stress cooperates with hypernutrition to trig-ger TNF-dependent spontaneous HCC development, Cancer Cell, 26, pp. 331-343, (2014); Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Et al., Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular car-cinoma, J Gastroenterol, 48, pp. 1249-1258, (2013); Gomes AL, Teijeiro A, Buren S, Tummala KS, Yilmaz M, Wais-man A, Et al., Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma, Cancer Cell, 30, pp. 161-175, (2016); Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Et al., NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis, Nature, 531, pp. 253-257, (2016); Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Et al., CXCR2 inhibition enables NASH-HCC Immuno-therapy, Gut, 71, pp. 2093-2106, (2022); Ye J, Li TS, Xu G, Zhao YM, Zhang NP, Fan J, Et al., JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity, Cancer Res, 77, pp. 5287-5300, (2017); Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, Et al., mTORC2 promotes tumorigenesis via lipid synthesis, Cancer Cell, 32, pp. 807-823, (2017); Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakat-suka T, Et al., CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity, Gut, 67, pp. 1493-1504, (2018); Wu H, Ng R, Chen X, Steer CJ, Song G., MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepa-tocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway, Gut, 65, pp. 1850-1860, (2016); Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Meder-acke I, Et al., Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4, Cancer Cell, 21, pp. 504-516, (2012); Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Et al., Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, J Hepatol, 61, pp. 75-81, (2014); Haufe S, Engeli S, Kast P, Bohnke J, Utz W, Haas V, Et al., Randomized comparison of reduced fat and reduced carbohy-drate hypocaloric diets on intrahepatic fat in overweight and obese human subjects, Hepatology, 53, pp. 1504-1514, (2011); EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, pp. 1388-1402, (2016); Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Et al., The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, Hepatol Int, 14, pp. 889-919, (2020)","K.-C. Lee; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 201, Section 2, Shih-Pai Road, 11217, Taiwan; email: kclee2@vghtpe.gov.tw; H.-C. Lin; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 201, Section 2, Shih-Pai Road, 11217, Taiwan; email: hclin@vghtpe.gov.tw","","Korean Association for the Study of the Liver","","","","","","22872728","","","36226471","English","Clin. Mol. Hepatol.","Review","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85146162389"
"Fatini C.; Sticchi E.; Cesari F.; Gori A.M.; Cioni G.; De Stefano M.; Bertoni E.; Paudice N.; Salvadori M.; Zanazzi M.; Abbate R.","Fatini, Cinzia (6603765875); Sticchi, Elena (6602437057); Cesari, Francesca (57190564453); Gori, Anna Maria (7005319380); Cioni, Gabriele (7005562204); De Stefano, Margherita (36804519500); Bertoni, Elisabetta (7004681915); Paudice, Nunzia (26536360600); Salvadori, Maurizio (7102105549); Zanazzi, Maria (6701562007); Abbate, Rosanna (7006557764)","6603765875; 6602437057; 57190564453; 7005319380; 7005562204; 36804519500; 7004681915; 26536360600; 7102105549; 6701562007; 7006557764","Relationship among endothelial response to hyperemia, bone marrow-derived progenitor cells, and parathyroid hormone in renal transplantation","2012","Transplantation","93","8","","835","841","6","4","10.1097/TP.0b013e318247a75d","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859630273&doi=10.1097%2fTP.0b013e318247a75d&partnerID=40&md5=8a14eb3d67a9b40a032d84f0602ad0a2","Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Fondazione Don Carlo Gnocchi ONLUS, Centro S.Maria degli Ulivi-IRCCS, Florence, Italy; Renal Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy","Fatini C., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Sticchi E., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, Fondazione Don Carlo Gnocchi ONLUS, Centro S.Maria degli Ulivi-IRCCS, Florence, Italy; Cesari F., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Gori A.M., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Cioni G., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; De Stefano M., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Bertoni E., Renal Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Paudice N., Renal Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Salvadori M., Renal Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Zanazzi M., Renal Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Abbate R., Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy","BACKGROUND. Endothelial dysfunction may contribute to modulate cardiovascular complications in renal transplant recipients (RTRs), and a relationship between endothelial dysfunction and parathyroid hormone (PTH) levels in RTRs has been demonstrated. We evaluated the relationship between endothelial response to hyperemia and circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs) PTH, and genetic parameters in RTRs. METHODS. In 120 RTRs and in healthy subjects without (n=107, group A) and with cardiovascular risk factors (n=109, group B), we evaluated endothelial response to hyperemia through digital tonometry (peripheral arterial tonometry) detected by reactive hyperemia index (RHI) and EPCs and CPCs by flow cytometry. RESULTS. In RTRs, RHI median value was lower than in group A (P=0.05). EPC number was significantly lower in RTRs than in groups A and B (P<0.0001), whereas PTH median value was significantly higher (P<0.0001). In RTRs, RHI values were significantly lower according to the presence of three or more risk factors (P=0.04) and positively correlated with EPCs (P=0.04) but not with PTH (P=0.2). In patients who underwent dialysis for more than 5 years, lower RHI values (P=0.08), EPC number (P=0.5), and higher PTH concentrations (P=0.09) than in patients with less than 1 year dialysis time were observed. No relationship between eNOS gene -786T>C, 894G>T, and 4a/4b polymorphisms and RHI, EPC, and CPC number was found. CONCLUSIONS. This study shows an altered endothelial response, associated with reduced EPCs, and increased PTH in RTRs; the evaluation of endothelial status in RTRs may contribute to better assess the risk profile of these patients. © 2012 Lippincott Williams & Wilkins, Inc.","CPCs; EPCs; Parathyroid hormone; Peripheral arterial tonometry (PAT); Renal transplantation","Adult; Aged; Bone Marrow Cells; Endothelium, Vascular; Female; Humans; Hyperemia; Kidney Transplantation; Male; Middle Aged; Nitric Oxide Synthase Type III; Parathyroid Hormone; Polymorphism, Genetic; Stem Cells; Young Adult; angiotensin receptor antagonist; azathioprine; beta adrenergic receptor blocking agent; calcium channel blocking agent; CD133 antigen; CD34 antigen; corticosteroid; cyclosporin; dipeptidyl carboxypeptidase inhibitor; diuretic agent; endothelial nitric oxide synthase; everolimus; hydroxymethylglutaryl coenzyme A reductase inhibitor; mycophenolic acid; parathyroid hormone; rapamycin; tacrolimus; vasculotropin receptor 2; adult; aged; article; cardiovascular disease; cardiovascular risk; cell count; circulating stem cell; controlled study; correlation analysis; dyslipidemia; endothelial dysfunction; endothelial progenitor cell; eNOS gene; female; flow cytometry; gene; genetic polymorphism; hematopoietic stem cell; hemodialysis; human; hyperemia; hypertension; kidney failure; kidney graft rejection; kidney transplantation; major clinical study; male; nucleotide sequence; peritoneal dialysis; priority journal; risk assessment; risk factor; tonometry; treatment duration","GENBANK: NG_011992","azathioprine, 446-86-6; cyclosporin, 79217-60-0; endothelial nitric oxide synthase, 503473-02-7; everolimus, 159351-69-6; mycophenolic acid, 23047-11-2, 24280-93-1; parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6; rapamycin, 53123-88-9; tacrolimus, 104987-11-3; Nitric Oxide Synthase Type III, 1.14.13.39; Parathyroid Hormone, ","","","","","Foley R.N., Parfrey P.S., Samak M.J., Clinical epidemiology of cardiovascular disease in chronic renal disease, Am J Kidney Dis, 32, (1998); Bonetti P.O., Lerman L.O., Lerman A., Endothelial dysfunction. A marker of atherosclerotic risk, Arterioscler Thromb Vasc Biol, 23, (2003); Hingorani A.D., Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000, Atherosclerosis, 154, (2000); Cesari F., Nencini P., Nesi M., Et al., Bone marrow-derived progenitor cells in the early phase of ischemic stroke: Relation with stroke severity and discharge outcome, J Cereb Blood Flow Metab, 29, (2009); Orlic D., Kajstura J., Chimenti S., Et al., Bone marrow cells regenerate infarcted myocardium, Nature, 410, (2001); Steiner S., Winkelmayer W.C., Kleinert J., Et al., Endothelial progenitor cells in kidney transplant recipients, Transplantation, 81, (2006); Soler M.J., Martinez-Estrada O.M., Puig-Mari J.M., Et al., Circulating endothelial progenitor cells after kidney transplantation, Am J Transplant, 5, (2005); Ozuyaman B., Ebner P., Niesler U., Et al., Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells, Thromb Haemost, 94, (2005); Van Craenenbroeck E.M., Conraads V.M., Endothelial progenitor cells in vascular health: Focus on lifestyle, Microvasc Res, 79, (2010); Fadini G.P., Pagano C., Baesso I., Et al., Reduced endothelial progenitor cells and brachial artery flow-mediated dilation as evidence of endothelial dysfunction in ocular hypertension and primary open-angle glaucoma, Acta Ophthalmol, 88, (2010); Kuvin J.T., Patel A.R., Sliney K.A., Et al., Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude, Am Heart J, 146, (2003); Hamburg N.M., Keyes M.J., Larson M.G., Et al., Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study, Circulation, 117, (2008); Rubinshtein R., Kuvin J.T., Soffler M., Et al., Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events, Eur Heart J, 31, (2010); Coen G., Manni M., Mantella D., Et al., ArePTHserum levels predictive of coronary calcifications in haemodialysis patients?, Nephrol Dial Transplant, 22, (2007); Baykan M., Erem C., Erdooan T., Et al., Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism, Int J Cardiovasc Imaging, 23, (2007); Kosch M., Hausberg M., Vormbrock K., Et al., Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy, Cardiovasc Res, 47, (2000); Fernandez-Fresnedo G., Rodrigo E., Ruiz J.C., Et al., Bone metabolism according to chronic kidney disease stages in patients undergoing kidney transplantation: A 5-year database analysis, Transplant Proc, 41, (2009); Ganesh S.K., Stack A.G., Levin N.W., Et al., Association of elevated serum PO(4), Cax PO(4) product, and parathyroidhormonewith cardiac mortality risk in chronic hemodialysis patients, J Am Soc Nephrol, 12, (2001); Michaud S.E., Dussault S., Haddad P., Et al., Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities, Atherosclerosis, 187, (2006); Gallagher K.A., Liu Z.J., Xiao M., Et al., Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha, J Clin Invest, 117, (2007); Hill J.M., Finkel T., Quyyumi A.A., Endothelial progenitor cells and endothelial dysfunction, Vox Sang, 87, (2004); Wang R., Wu L.Y., Karpinski E., Et al., The effects of parathyroid hormone on L-type voltage-dependent calcium channel currents in vascular smooth muscle cells and ventricular myocytes are mediated by a cyclic AMP dependent mechanism, FEBS Lett, 282, (1991); Vaziri N.D., Ni Z., Wang X.Q., Et al., Downregulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH, Am J Physiol, 274, (1998); Lomonte C., Derosa C., Vernaglione L., Et al., Serum parathyroid hormone and phosphate influence the levels of circulating CD34+ cells in uremia, J Nephrol, 23, (2010); Schlieper G., Hristov M., Brandenburg V., Et al., Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients, Nephrol Dial Transplant, 23, (2008); Kasiske B.L., Vazquez M.A., Harmon W.E., Et al., Recommendations for the outpatient surveillance of renal transplant recipients American Society of Transplantation, J Am Soc Nephrol, 11, (2000); Practice guidelines for primary care physicians: 2003 ESH/ESC Hypertension guidelines, ESH/ESC Hypertension Guidelines Committee. Hypertension, 21, (2003); Report of the expert committee on the diagnosis and classification of diabetes mellitus, Diabetes Care, 26, (2003); Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report, Circulation, 106, (2002); Sofi F., Marcucci R., Fedi S., Et al., High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion, Atherosclerosis, 210, (2010); Fatini C., Sofi F., Sticchi E., Et al., Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes, Am Heart J, 147, (2004)","C. Fatini; Department of Medical and Surgical Critical Care, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; email: cinzia.fatini@unifi.it","","","","","","","","00411337","","TRPLA","22343335","English","Transplantation","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84859630273"
"Phelps P.K.; Kelley E.F.; Walla D.M.; Ross J.K.; Simmons J.J.; Bulock E.K.; Ayres A.; Akre M.K.; Sprissler R.; Olson T.P.; Snyder E.M.","Phelps, Pamela K. (23028834900); Kelley, Eli F. (57200083205); Walla, Danielle M. (57246981100); Ross, Jennifer K. (57659666900); Simmons, Jerad J. (57246981200); Bulock, Emma K. (57246493200); Ayres, Audrie (56673872000); Akre, Monica K. (55450919300); Sprissler, Ryan (49862383400); Olson, Thomas P. (14049094900); Snyder, Eric M. (8923836500)","23028834900; 57200083205; 57246981100; 57659666900; 57246981200; 57246493200; 56673872000; 55450919300; 49862383400; 14049094900; 8923836500","Relationship between a weighted multi-gene algorithm and blood pressure controlin hypertension","2019","Journal of Clinical Medicine","8","3","289","","","","6","10.3390/jcm8030289","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067274586&doi=10.3390%2fjcm8030289&partnerID=40&md5=6cb583aa114facaad23cee25ca90afb3","Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; School of Kinesiology, University of Minnesota, Minneapolis, 55455, MN, United States; Geneticure, Inc, Rochester, 55902, MN, United States; University of Arizona Genomics Core, University of Arizona, Tucson, 85705, AZ, United States; College of Medicine, Mayo Clinic, Rochester, 55905, MN, United States","Phelps P.K., Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; Kelley E.F., School of Kinesiology, University of Minnesota, Minneapolis, 55455, MN, United States; Walla D.M., Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; Ross J.K., Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; Simmons J.J., Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; Bulock E.K., Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; Ayres A., Medical Center, University of Minnesota, Fairview, Minneapolis, 55455, MN, United States; Akre M.K., Geneticure, Inc, Rochester, 55902, MN, United States; Sprissler R., Geneticure, Inc, Rochester, 55902, MN, United States, University of Arizona Genomics Core, University of Arizona, Tucson, 85705, AZ, United States; Olson T.P., Geneticure, Inc, Rochester, 55902, MN, United States, College of Medicine, Mayo Clinic, Rochester, 55905, MN, United States; Snyder E.M., Geneticure, Inc, Rochester, 55902, MN, United States","Hypertension (HTN) is a complex disease with interactions among multiple organ systems, including the heart, vasculature, and kidney with a strong heritable component. Despite the multifactorial nature of HTN, no clinical guidelines utilize a multi-gene approach to guide blood pressure (BP) therapy. Non-smokers with a family history of HTN were included in the analysis (n = 384; age = 61.0 ± 0.9, 11% non-white). A total of 17 functional genotypes were weighted according to the previous effect size in the literature and entered into an algorithm. Pharmacotherapy was ranked from 1–4 as most to least likely to respond based on the algorithmic assessment of individual patient’s genotypes. Three-years of data were assessed at six-month intervals for BP and medication history. There was no difference in BP at diagnosis between groups matching the top drug recommendation using the multi-gene weighted algorithm (n = 92) vs. those who did not match (n = 292). However, from diagnosis to nadir, patients who matched the primary recommendation had a significantly greater drop in BP when compared to patients who did not. Further, the difference between diagnosis to current 1-year average BP was lower in the group that matched the top recommendation. These data suggest an association between a weighted multi-gene algorithm on the BP response to pharmacotherapy. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.","Blood pressure; Genetics; Hypertension; Pharmacogenetics; Pharmacotherapy; Treatment","alpha adducin; angiotensin; angiotensin receptor antagonist; cytochrome P450 2D6; dipeptidyl carboxypeptidase; serine/threonine protein kinase WNK1; ADRB1 gene; ADRB2 gene; adult; algorithm; Article; blood pressure; diastolic blood pressure; DNA polymorphism; drug metabolism; female; gene frequency; genetic analysis; genetic polymorphism; genetic variability; genetic variation; genome-wide association study; genotype; heart; human; hypertension; kidney; major clinical study; male; mass spectrometry; mean arterial pressure; multigene family; multiplex polymerase chain reaction; pharmacogenetics; pharmacogenomics; prevalence; retrospective study; risk assessment; SCNN1A gene; single nucleotide polymorphism; systolic blood pressure; vascularization","","angiotensin, 1407-47-2; dipeptidyl carboxypeptidase, 9015-82-1; germinal center kinase, ; mammalian target of rapamycin complex 1, ; mammalian target of rapamycin complex 2, ; NIMA related kinase 1, ; oncogene protein v akt, ; oncogene protein v raf, ; serine threonine protein kinase ULK1, ; serine/threonine protein kinase WNK1, ","","","","","Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., Et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report, JAMA, 289, pp. 2560-2572, (2003); Forouzanfar M.H., Liu P., Roth G.A., Ng M., Biryukov S., Marczak L., Alexander L., Estep K., Abate K.H., Akinyemiju T.F., Et al., Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm hg, 1990–2015, JAMA, 317, pp. 165-182, (2017); Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Cohen J.D., Hypertension epidemiology and economic burden: Refining risk assessment to lower costs, Manag. Care, 18, pp. 51-58, (2009); Wang G., Fang J., Ayala C., Hypertension-associated hospitalizations and costs in the United States, 1979–2006, Blood Press, 23, pp. 126-133, (2014); Roger Veronique L., Go Alan S., Lloyd-Jones Donald M., Benjamin Emelia J., Berry Jarett D., Borden William B., Bravata Dawn M., Dai S., Ford Earl S., Caroline F., Et al., Executive Summary: Heart Disease and Stroke Statistics—2012 Update, Circulation, 125, pp. 188-197, (2012); Egan B.M., Zhao Y., Axon R.N., US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008, JAMA, 303, pp. 2043-2050, (2010); Carey R.M., Whelton P.K., The 2017 American college of cardiology/American heart association hypertension guidelines: A resource for practicing clinicians, Ann. Intern. Med., 168, pp. 359-360, (2018); Lackland D.T., Roccella E.J., Deutsch A.F., Fornage M., George M.G., Howard G., Kissela B.M., Kittner S.J., Lichtman J.H., Lisabeth L.D., Et al., Factors Influencing the Decline in Stroke Mortality, Stroke, 45, pp. 315-353, (2014); Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., Hamburger R.J., Fye C., Lakshman R., Gottdiener J., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, N. Engl. J. Med., 328, pp. 914-921, (1993); Gong Y., Wang Z., Beitelshees A.L., McDonough C.W., Langaee T.Y., Hall K., Schmidt S.O., Curry R.W., Gums J.G., Bailey K.R., Et al., Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to beta-Blockers in Hypertensive African Americans, Hypertension, 67, pp. 556-563, (2016); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int, 61, pp. 1047-1055, (2002); Hopkins P.N., Hunt S.C., Genetics of hypertension, Genet. Med., 5, pp. 413-429, (2003); Johnson J.A., Turner S.T., Hypertension pharmacogenomics: Current status and future directions, Curr. Opin. Mol. Ther., 7, pp. 218-225, (2005); Gong Y., McDonough C.W., Wang Z., Hou W., Cooper-Dehoff R.M., Langaee T.Y., Beitelshees A.L., Chapman A.B., Gums J.G., Bailey K.R., Et al., Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study, Circ. Cardiovasc. Genet, 5, pp. 686-691, (2012); Hiltunen T.P., Donner K.M., Sarin A.P., Saarela J., Ripatti S., Chapman A.B., Gums J.G., Gong Y., Cooper-Dehoff R.M., Frau F., Et al., Pharmacogenomics of hypertension: A genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs, J. Am. Heart Assoc., 4, (2015); Schwartz G.L., Turner S.T., Sing C.F., Twenty-four-hour blood pressure profiles in normotensive sons of hypertensive parents, Hypertension, 20, pp. 834-840, (1992); Snieder H., Hayward C.S., Perks U., Kelly R.P., Kelly P.J., Spector T.D., Heritability of central systolic pressure augmentation: A twin study, Hypertension, 35, pp. 574-579, (2000); Hottenga J.J., Boomsma D.I., Kupper N., Posthuma D., Snieder H., Willemsen G., de Geus E.J., Heritability and stability of resting blood pressure, Twin Res. Hum. Genet., 8, pp. 499-508, (2005); Kupper N., Willemsen G., Riese H., Posthuma D., Boomsma D.I., de Geus E.J., Heritability of daytime ambulatory blood pressure in an extended twin design, Hypertension, 45, pp. 80-85, (2005); Farooq U., Ray S.G., Guideline for the Management of High Blood Pressure (Eighth Joint National Committee): Take-Home Messages, Med. Clin. N. Am., 99, pp. 733-738, (2014); James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., Lackland D.T., Lefevre M.L., Mackenzie T.D., Ogedegbe O., Et al., 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, pp. 507-520, (2014); Gupta P., Patel P., Strauch B., Lai F.Y., Akbarov A., Gulsin G.S., Beech A., Maresova V., Topham P.S., Stanley A., Et al., Biochemical Screening for Nonadherence Is Associated with Blood Pressure Reduction and Improvement in Adherence, Hypertension, 70, pp. 1042-1048, (2017); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic, Hypertension, 46, pp. 758-765, (2005); Rau T., Wuttke H., Michels L., Werner U., Bergmann K., Kreft M., Fromm M., Eschenhagen T., Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study, Clin. Pharmacol. Ther., 85, pp. 269-272, (2009); Bijl M., Visser L., Schaik R., Kors J., Witteman J., Hofman A., Vulto A., Gelder T., Stricker B., Genetic Variation in the CYP2D6 Gene Is Associated with a Lower Heart Rate and Blood Pressure in β-Blocker Users, Clin. Pharmacol. Ther., 85, pp. 45-50, (2009); Reshetnikov E.A., Akulova L.Y., Dobrodomova I.S., Dvornyk V.Y., Polonikov A.V., Churnosov M.I., The insertion-deletion polymorphism of the ACE gene is associated with increased blood pressure in women at the end of pregnancy, JRAAS, 16, pp. 623-632, (2015); Julve R., Chaves F.J., Rovira E., Pascual J.M., Miralles A., Armengod M.E., Redon J., Polymorphism insertion/deletion of the ACE gene and ambulatory blood pressure circadian variability in essential hypertension, Blood Press. Monit., 6, pp. 27-32, (2001); Goracy I., Dawid G., Loniewska B., Goracy J., Ciechanowicz A., Genetics of the renin-angiotensin system with respect to cardiac and blood pressure phenotypes in healthy newborn infants, JRAAS, 14, pp. 337-347, (2013); Moore N., Dicker P., O'Brien John K., Stojanovic M., Conroy Ronan M., Treumann A., O'Brien Eoin T., Fitzgerald D., Shields D., Stanton Alice V., Renin Gene Polymorphisms and Haplotypes, Blood Pressure, and Responses to Renin-Angiotensin System Inhibition, Hypertension, 50, pp. 340-347, (2007); Brodde O.-E., Stein C.M., The Gly389Arg β1-adrenergic receptor polymorphism: A predictor of response to β-blocker treatment?, Clin. Pharmacol. Ther., 74, pp. 299-302, (2003); de Groote P., Helbecque N., Lamblin N., Hermant X., Mc Fadden E., Foucher-Hossein C., Amouyel P., Dallongeville J., Bauters C., Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure, Pharm. Genom., 15, pp. 137-142, (2005); Michel M.C., Insel P.A., Receptor gene polymorphisms: Lessons on functional relevance from the β1-adrenoceptor, Br. J. Pharmacol., 138, pp. 279-282, (2003); Liao X., Wang W., Zeng Z., Yang Z., Dai H., Lei Y., Association of alpha-ADD1 gene and hypertension risk: A meta-analysis, Med. Sci. Monit., 21, pp. 1634-1641, (2015); Yang C.-L., Zhu X., Ellison D.H., The thiazide-sensitive Na-Cl cotransporter is regulated by a WNK kinase signalling complex, J. Clin. Investig., 117, pp. 3403-3411, (2007); Richardson C., Alessi D.R., The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway, J. Cell Sci., 121, pp. 3293-3304, (2008); Magvanjav O., McDonough C.W., Gong Y., McClure L.A., Talbert R.L., Horenstein R.B., Shuldiner A.R., Benavente O.R., Mitchell B.D., Johnson J.A., Et al., Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms with Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes), Stroke, 48, pp. 1337-1343, (2017); Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., Weber S.A., Greene S.M., Hodne D., Nelson B., Morrison J., Domanski M.J., Wagoner L.E., Et al., A polymorphism within a conserved β<sub>1</sub>-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure, Proc. Natl. Acad. Sci. USA, 103, pp. 11288-11293, (2006); Zeng M.-Z., Tang J., Liu Z.-Q., Zhou H.-H., Zhang W., Progress of Pharmacogenomic Research Related to Minerals and Trace Elements. Die Pharm, 70, pp. 629-635, (2015); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P., Siscovick D.S., Bis J., Lumley T., Longstreth W.T., Et al., Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Newhouse S., Farrall M., Wallace C., Hoti M., Burke B., Howard P., Onipinla A., Lee K., Shaw-Hawkins S., Dobson R., Et al., Polymorphisms in the WNK1 gene are associated with blood pressure variation and urinary potassium excretion, Plos ONE, 4, (2009); Snyder E., Sprissler R., Johnson M., Beenken G., Curry T., Cassuto N., Kelley E., Olson T., Association of A Multi-Gene Panel with Blood Pressure Medication Success in Patients with Hypertension: A Pilot Study, 2018, (2018); Evans W.E., Johnson J.A., Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response, Annu. Rev. Genom. Hum. Genet., 2, pp. 9-39, (2001); Kimmel S.E., French B., Kasner S.E., Johnson J.A., Anderson J.L., Gage B.F., Rosenberg Y.D., Eby C.S., Madigan R.A., McBane R.B., Et al., A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing, N. Engl. J. Med., 369, pp. 2283-2293, (2013); Lefebvre J., Poirier L., Poirier P., Turgeon J., Lacourciere Y., The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension, Br. J. Clin. Pharmacol., 63, pp. 575-582, (2007); Blake C.M., Kharasch E.D., Schwab M., Nagele P., A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics, Clin. Pharmacol. Ther., 94, pp. 394-399, (2013); Hamadeh I.S., Langaee T.Y., Dwivedi R., Garcia S., Burkley B.M., Skaar T.C., Chapman A.B., Gums J.G., Turner S.T., Gong Y., Et al., Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate, Clin. Pharmacol. Ther., 96, pp. 175-181, (2014); Ranade K., Jorgenson E., Sheu W.H.H., Pei D., Hsiung C.A., Chiang F.-T., Chen Y.-D.I., Pratt R., Olshen R.A., Curb D., Et al., A Polymorphism in the β1 Adrenergic Receptor Is Associated with Resting Heart Rate, Am. J. Hum. Genet, 70, pp. 935-942, (2002); Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F., β1-Adrenergic Receptor Polymorphisms and Antihypertensive Response to Metoprolol, Clin. Pharmacol. Ther., 74, pp. 44-52, (2003); Shin J., Langaee T.Y., Kayser S.R., Pharmacogenetics: From discovery to patient care, Am. J. Health-System Pharm., 66, pp. 625-637, (2009); Humma L.M., Puckett B.J., Richardson H.E., Terra S.G., Andrisin T.E., Lejeune B.L., Wallace M.R., Lewis J.F., McNamara D.M., Picoult-Newberg L., Et al., Effects of beta<sub>1</sub>-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia, Am. J. Cardiol., 88, pp. 1034-1037, (2001); Snyder E.M., Beck K.C., Dietz N.M., Eisenach J.H., Joyner M.J., Turner S.T., Johnson B.D., Arg16Gly polymorphism of the β2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans, J. Physiol., 571, pp. 121-130, (2006); Snyder E.M., Hulsebus M.L., Turner S.T., Joyner M.J., Johnson B.D., Genotype related differences in beta2 adrenergic receptor density and cardiac function, Med. Sci. Sports Exerc., 38, pp. 882-886, (2006); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J. Hypertens., 19, pp. 1783-1787, (2001); Nakajima T., Jorde L.B., Ishigami T., Umemura S., Emi M., Lalouel J.-M., Inoue I., Nucleotide Diversity and Haplotype Structure of the Human Angiotensinogen Gene in Two Populations, Am. J. Hum. Genet., 70, pp. 108-123, (2002); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.-M., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Bonnardeaux A., Davies E., Jeunemaitre X., Fery I., Charru A., Clauser E., Tiret L., Cambien F., Corvol P., Soubrier F., Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, pp. 63-69, (1994); Konoshita T., Nakaya T., Sakai A., Yamada M., Ichikawa M., Sato S., Imagawa M., Fujii M., Yamamoto K., Makino Y., Et al., Determinants of plasma renin activity: Role of a human renin gene variant as a genetic factor, Medicine, 93, (2014); Ambrosius W.T., Bloem L.J., Zhou L., Rebhun J.F., Snyder P.M., Wagner M.A., Guo C., Pratt J.H., Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension, Hypertension, 34, pp. 631-637, (1999); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Et al., Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Sehrt D., Meineke I., Tzvetkov M., Gultepe S., Brockmoller J., Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics, Pharmacogenomics, 12, pp. 783-795, (2011); Lanfear D.E., Jones P.G., Marsh S., Cresci S., McLeod H.L., Spertus J.A., β2-Adrenergic Receptor Genotype and Survival Among Patients Receiving β-Blocker Therapy After an Acute Coronary Syndrome, JAMA, 294, pp. 1526-1533, (2005); Litonjua A.A., Gong L., Duan Q.L., Shin J., Moore M.J., Weiss S.T., Johnson J.A., Klein T.E., Altman R.B., Very important pharmacogene summary ADRB2, Pharm. Genom., 20, pp. 64-69, (2010); Filigheddu F., Reid J.E., Troffa C., Pinnaparpaglia P., Argiolas G., Testa A., Skolnick M., Glorioso N., Genetic polymorphisms of the β-adrenergic system: Association with essential hypertension and response to β-blockade, Pharm. J., 4, (2004); Bashyam M.D., Savithri G.R., Kumar M.S., Narasimhan C., Nallari P., Molecular genetics of familial hypertrophic cardiomyopathy (FHC), J. Hum. Genet., 48, pp. 55-64, (2003); Ezzidi I., Mtiraoui N., Kacem M., Chaieb M., Mahjoub T., Almawi W.Y., Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy, Diabetes Metab. Res. Rev., 25, pp. 717-724, (2009); Saidi S., Mallat S.G., Almawi W.Y., Mahjoub T., Association between renin–angiotensin–aldosterone system genotypes and haplotypes and risk of ischemic stroke of atherosclerotic etiology, Acta Neurol. Scand., 119, pp. 356-363, (2009); Rasmussen-Torvik L.J., North K.E., Gu C.C., Lewis C.E., Wilk J.B., Chakravarti A., Chang Y.-P.C., Miller M.B., Li N., Devereux R.B., Et al., A Population Association Study of Angiotensinogen Polymorphisms and Haplotypes with Left Ventricular Phenotypes, Hypertension, 46, pp. 1294-1299, (2005); Lynch A.I., Eckfeldt J.H., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Arnett D.K., Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: The GenHAT study, Pharm. Genom., 22, pp. 355-366, (2012); Al-Najai M., Muiya P., Tahir A.I., Elhawari S., Gueco D., Andres E., Mazhar N., Altassan N., Alshahid M., Dzimiri N., Association of the angiotensinogen gene polymorphism with atherosclerosis and its risk traits in the Saudi population, BMC Cardiovasc. Disord., 13, (2013); Su X., Lee L., Li X., Lv J., Hu Y., Zhan S., Cao W., Mei L., Tang Y.M., Wang D., Et al., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, pp. 725-732, (2007); Baudin B., Polymorphism in angiotensin II receptor genes and hypertension, Exp. Physiol., 90, pp. 277-282, (2005); Nalogowska-Glosnicka K., Lacka B.I., Zychma M.J., Grzeszczak W., Zukowska-Szczechowska E., Poreba R., Michalski B., Kniazewski B., Rzempoluch J., Angiotensin II type 1 receptor gene A1166C polymorphism is associated with the increased risk of pregnancy-induced hypertension, Med. Sci. Monit., 6, pp. 523-529, (2000); Wu C.-K., Tsai C.-T., Chang Y.-C., Luo J.-L., Wang Y.-C., Hwang J.-J., Lin J.-L., Tseng C.-D., Chiang F.-T., Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure, J. Hypertens., 27, pp. 502-507, (2009); Lee Y.T., Chiu H.C., Huang C.T., Su H.M., Wang C.L., Lin T.H., Voon W.C., Chen H.C., Lai W.T., Sheu S.H., The A1166C polymorphism of angiotensin II Type 1 receptor as a predictor of renal function decline over 4 years follow-up in an apparently healthy Chinese population, Clin. Nephrol., 72, pp. 457-467, (2009); Spiering W., Kroon A.A., Fuss-Lejeune M.J., de Leeuw P.W., Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade, J. Hypertens., 23, pp. 753-758, (2005); Li Y., Thijs L., Kuznetsova T., Zagato L., Struijker-Boudier H., Bianchi G., Staessen J.A., Cardiovascular Risk in Relation to alpha-adducin Gly460Trp Polymorphism and Systolic Pressure, Hypertension, 46, pp. 527-532, (2005); Atlas S.A., The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition, J. Manag. Care Pharm., 13, pp. 9-20, (2007); Carey R.M., Siragy H.M., Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation, Endocr. Rev., 24, pp. 261-271, (2003); Johnson A.D., Newton-Cheh C., Chasman D.I., Ehret G.B., Johnson T., Rose L., Rice K., Verwoert G.C., Launer L.J., Gudnason V., Et al., Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals, Hypertension, 57, pp. 903-910, (2011); McCrink K.A., Lymperopoulos A., β1-adrenoceptor Arg389Gly polymorphism and heart disease: Marching toward clinical practice integration, Pharmacogenomics, 16, pp. 1035-1038, (2015); Ahles A., Engelhardt S., Polymorphic Variants of Adrenoceptors: Pharmacology, Physiology, and Role in Disease, Pharmacol. Rev., 66, pp. 598-637, (2014); Manunta P., Hamlyn J.M., Simonini M., Messaggio E., Lanzani C., Bracale M., Argiolas G., Casamassima N., Brioni E., Glorioso N., Et al., Endogenous ouabain and the renin-angiotensin-aldosterone system: Distinct effects on Na handling and blood pressure in human hypertension, J. Hypertens., 29, pp. 349-356, (2011); Loffing J., Korbmacher C., Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC), Eur. J. Physiol., 458, pp. 111-135, (2009); Yamamura H., Ugawa S., Ueda T., Nagao M., Shimada S., Protons activate the delta-subunit of the epithelial Na<sup>+</sup> channel in humans, J. Biol. Chem., 279, pp. 12529-12534, (2004); Mao S., Fan R., Gu T., Zhong Q., Gong M., Dong C., Hao L., Zhang L., Hypermethylation of SCNN1A gene-body increases the risk of essential hypertension, Int. J. Clin. Exp. Pathol., 9, pp. 8047-8056, (2016); Jin H.S., Hong K.W., Lim J.E., Hwang S.Y., Lee S.H., Shin C., Park H.K., Oh B., Genetic Variations in the Sodium Balance-Regulating Genes ENaC, NEDD4L, NDFIP2 and USP2 Influence Blood Pressure and Hypertension, Kidney Blood Press. Res., 33, pp. 15-23, (2010); Hughes C.A., Bennett V., Adducin: A physical model with implications for function in assembly of spectrin-actin complexes, J. Biol. Chem., 270, pp. 18990-18996, (1995); Kuhlman P.A., Hughes C.A., Bennett V., Fowler V.M., A new function for adducin, calcium-calmodulin regulated capping of the barbed ends of actin filaments, J. Biol. Chem., 271, pp. 7986-7991, (1996); Matsuoka Y., Li X., Bennett V., Adducin: Structure, function and regulation, Cell. Mol. Life Sci., 57, pp. 884-895, (2000); Gamba G., Molecular physiology and pathophysiology of electroneutral cation-chloride costransporters, Physiol. Rev., 85, pp. 423-493, (2005); Mayan H., Vered I., Mouallem M., Tzadok-Witkon M., Pauzner R., Farfel Z., Psuedohypoaldosteroneism type II: Marked sensitivity to thiazide, hypercalcuria, normomagnesemia, and low bone mineral density, J. Clin. Endocrinol. Metab., 87, pp. 3248-3254, (2002); Xu B.-E., English J.M., Wilsbacher J.L., Stippec S., Goldsmith E.J., Cobb M.H., WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II, J. Biol. Chem., 275, pp. 16795-16801, (2000); Wang B., Yang L.-P., Zhang X.-Z., Huang S.-Q., Bartlam M., Zhou S.-F., New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme, Drug Metab. Rev., 41, pp. 573-643, (2009); Zhou S.-F., Liu J.-P., Lai X.-S., Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development, Curr. Med. Chem., 16, pp. 2661-2805, (2009); Kjeldsen S., Feldman R.D., Lisheng L., Mourad J.-J., Chiang C.-E., Zhang W., Wu Z., Li W., Williams B., Updated National and International Hypertension Guidelines: A Review of Current Recommendations, Drugs, 74, pp. 2033-2051, (2014)","E.M. Snyder; Geneticure, Inc, Rochester, 55902, United States; email: eric@geneticure.com","","MDPI","","","","","","20770383","","","","English","J. Clin. Med.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85067274586"
"Anderson G.; Maes M.","Anderson, George (57224780851); Maes, Michael (57218157965)","57224780851; 57218157965","Melatonin: An overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects","2012","Metabolic Brain Disease","27","2","","113","119","6","77","10.1007/s11011-012-9307-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863447564&doi=10.1007%2fs11011-012-9307-9&partnerID=40&md5=0952399a8e4a3af4c513c9be734f572b","CRC, Glasgow G11 7QT, 57 Laurel St., United Kingdom; Piyavate Hospital, Bangkok, Thailand","Anderson G., CRC, Glasgow G11 7QT, 57 Laurel St., United Kingdom; Maes M., Piyavate Hospital, Bangkok, Thailand","This paper reviews melatonin as an overlooked factor in the developmental etiology and maintenance of schizophrenia; the neuroimmune and oxidative pathophysiology of schizophrenia; specific symptoms in schizophrenia, including sleep disturbance; circadian rhythms; and side effects of antipsychotics, including tardive dyskinesia and metabolic syndrome. Electronic databases, i.e. PUBMED, Scopus and Google Scholar were used as sources for this review using keywords: schizophrenia, psychosis, tardive dyskinesia, antipsychotics, metabolic syndrome, drug side effects and melatonin. Articles were selected on the basis of relevance to the etiology, course and treatment of schizophrenia. Melatonin levels and melatonin circadian rhythm are significantly decreased in schizophrenic patients. The adjunctive use of melatonin in schizophrenia may augment the efficacy of antipsychotics through its anti-inflammatory and antioxidative effects. Further, melatoninwould be expected to improve sleep disorders in schizophrenia and side effects of anti-psychotics, such as tardive dyskinesia, metaboilic syndrome and hypertension. It is proposed that melatonin also impacts on the tryptophan catabolic pathway via its effect on stress response and cortisol secretion, thereby impacting on cortex associated cognition, amygdala associated affect and striatal motivational processing. The secretion of melatonin is decreased in schizophrenia, contributing to its etiology, pathophysiology and management. Melatonin is likely to have impacts on the metabolic side effects of anti-psychotics that contribute to subsequent decreases in life-expectancy. © Springer Science+Business Media, LLC 2012.","Anti-psychotics; Inflammation; Melatonin; Metabolic; Schizophrenia; Vitamin D","Antioxidants; Antipsychotic Agents; Humans; Melatonin; Schizophrenia; Sleep; Vitamin D; Scopus; colecalciferol; gamma interferon; glycogen synthase kinase 3beta; hydrocortisone; indoleamine 2,3 dioxygenase; interleukin 18; melatonin; melatonin 1 receptor; neuroleptic agent; peroxisome proliferator activated receptor gamma coactivator 1alpha; protein bcl 2; sirtuin 1; transcription factor Nrf2; tryptophan; amygdaloid nucleus; antiinflammatory activity; antioxidant activity; bipolar disorder; circadian rhythm; cognition; drug efficacy; frontal cortex; human; hydrocortisone release; hypertension; inhibition kinetics; life expectancy; lipid peroxidation; low drug dose; Medline; metabolic syndrome X; oxidative phosphorylation; oxidative stress; paranoid schizophrenia; pathophysiology; protein blood level; protein phosphorylation; psychopharmacotherapy; quality of life; renin angiotensin aldosterone system; review; risk factor; schizophrenia; single nucleotide polymorphism; sleep disorder; systematic review; tardive dyskinesia","","colecalciferol, 1406-16-2, 67-97-0; gamma interferon, 82115-62-6; hydrocortisone, 50-23-7; interleukin 18, 189304-55-0; melatonin, 73-31-4; protein bcl 2, 219306-68-0; tryptophan, 6912-86-3, 73-22-3; Antioxidants, ; Antipsychotic Agents, ; Melatonin, 73-31-4; Vitamin D, 1406-16-2","","","","","Afonso P., Brissos S., Figueira M.L., Paiva T., Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep, Schizophr Res, 120, 1-3, pp. 227-228, (2010); Afonso P., Brissos S., Figueira M.L., Paiva T., Schizophrenia patients with predominantly positive symptoms have more disturbed sleepwake cycles measured by actigraphy, Psychiatry Res, 189, 1, pp. 62-66, (2011); Afonso P., Figueira M.L., Paiva T., Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls, Int J Psychiatry Clin Pract, 15, 4, pp. 311-315, (2011); Alonso-Vale M.I., Peres S.B., Vernochet C., Farmer S.R., Lima F.B., Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity, J Pineal Res, 47, 3, pp. 221-227, (2009); Anderson G., Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: Role of the amygdala in developmental co-ordination, Med Hypotheses, 76, 1, pp. 54-60, (2011); Anderson G., Ojalla J., Alzheimer's and seizures: Interleukin-18, indoleamine 2, 3-Dioxygenase and quinolinic acid, Int J Tryp Res, 3, pp. 169-173, (2010); Aufdenblatten M., Baumann M., Raio L., Dick B., Frey B.M., Schneider H., Surbek D., Hocher B., Mohaupt M.G., Prematurity is related to high placental cortisol in preeclampsia, Pediatr Res, 65, 2, pp. 198-202, (2009); Aversa S., Pellegrino S., Barberi I., Reiter R.J., Gitto E., Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period, J Matern-Fetal Neonatal Med, 25, 3, pp. 207-221, (2012); Bersani G., Mameli M., Garavini A., Pancheri P., Nordio M., Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia, Neuro Endocrinol Lett, 24, 3-4, pp. 181-184, (2003); Bikle D.D., Vitamin D and immune function: Understanding common pathways, Curr Osteoporos Rep, 7, 2, pp. 58-63, (2009); Boskoviae M., Vovk T., Plesniear B.K., Grabnar I., Oxidative stress in schizophrenia, Curr Neuropharmacol, 9, 2, pp. 301-312, (2011); Brown A.S., Derkitis E.J., Prenatal infection and schizophrenia: A review of epidemiologic and translational studies, Am J Psychiatry, 167, 3, pp. 261-280, (2010); Bushe C.J., Leonard B.E., Blood glucose and schizophrenia: A systematic review of prospective randomized clinical trials, J Clin Psychiatry, 68, 11, pp. 1682-1690, (2007); Byrne M., Agerbo E., Bennedsen B., Eaton W.W., Mortensen P.B., Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study, Schizophr Res, 97, 1-3, pp. 51-59, (2007); Canto C., Auwerx J., Caloric restriction, SIRT1 and longevity, Trends Endocrinol Metab, 20, 7, pp. 325-331, (2009); Causevic M., Mohaupt M., 11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia, Mol Aspects Med, 28, 2, pp. 220-226, (2007); Chang H.M., Wu U.I., Lan C.T., Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleepdeprived rats, J Pineal Res, 47, 3, pp. 211-220, (2009); Chun R.F., Adams J.S., Hewison M., Review: Back to the future: A new look at ""old"" vitamin D3, J Endocrinol, 198, pp. 261-269, (2008); Chwastiak L.A., Tek C., The unchanging mortality gap for people with schizophrenia, Lancet, 374, 9690, pp. 590-592, (2009); Condray R., Dougherty G.G., Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., Matson W.R., McEvoy J., Kaddurah-Daouk R., Yao J.K., 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia, Int J Neuropsychopharmacol, 14, pp. 756-767, (2011); Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., Van Beverens N.J.M., Drexhage H.A., An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro-and anti-inflammatory forces, Int J Neuropsychopharmacol, 14, pp. 746-755, (2011); Esposito E., Cuzzocrea S., Antiinflammatory activity of melatonin in central nervous system, Curr Neuropharmacol, 8, 3, pp. 228-242, (2010); Evans K.N., Nguyen L., Chan J., Innes B.A., Bulmer J.N., Kilby M.D., Hewison M., Effects of 25-hydroxyvitamin D3 and 1, 25-dihydroxyvitamin D3 on cytokine production by human decidual cells, Biol Reprod, 75, 6, pp. 816-822, (2006); Flaum M., Strategies to close the ""mortality gap, Am J Psychiatry, 167, 2, pp. 120-121, (2010); Graham S.M., Howgate D., Anderson W., Howes C., Heliotis M., Mantalaris A., Tsiridis E., Tsapakis E., Risk of osteoporosis and fracture incidence in patients on antipsychotic medication, Expert Opin Drug Saf, 10, 4, pp. 575-602, (2011); Grant W.B., Low vitamin D may explain the link between preeclampsia and cardiovascular disease, Am Heart J, 159, 3, (2010); Holmes V.A., Barnes M.S., Alexander H.D., McFaul P., Wallace J.M., Vitamin D deficiency and insufficiency in pregnant women: A longitudinal study, Br J Nutr, 102, 6, pp. 876-881, (2009); Jiang H.K., Wang J.Y., Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients, J Formos Med Assoc, 97, 12, pp. 830-837, (1998); Kilzieh N., Principal Investigator; Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B., Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients, Neuropsychobiology, 59, pp. 123-129, (2009); Kristo C., Godang K., Ueland T., Lien E., Aukrust P., Froland S.S., Bollerslev J., Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome, Eur J Endocrinol, 146, 3, pp. 389-395, (2002); Kuo C.J., Yang S.Y., Liao Y.T., Chen W.J., Lee W.C., Shau W.Y., Chang Y.T., Tsai S.Y., Chen C.C., Second-generation antipsychotic medications and risk of pneumonia in schizophrenia, Schizophr Bull; Lanoix D., Beghdadi H., Lafond J., Vaillancourt C., Human placental trophoblasts synthesize melatonin and express its receptors, J Pineal Res, 45, 1, pp. 50-60, (2008); Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R., Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression, Behav Brain Res, 210, 1, pp. 84-91, (2010); Lee Y.D., Kim J.Y., Lee K.H., Kwak Y.J., Lee S.K., Kim O.S., Song D.Y., Lee J.H., Baik T.K., Kim B.J., Kim J.Y., Baik H.W., Melatonin attenuates lipopolysaccharide-induced acute lung inflammation in sleep-deprived mice, J Pineal Res, 46, 1, pp. 53-57, (2009); Leow L., Simpson T., Cursons R., Karalus N., Hancox R.J., Vitamin D, innate immunity and outcomes in community acquired pneumonia, Respirology, 16, 4, (2011); Lerner V., Miodownik C., Motor symptoms of schizophrenia: Is tardive dyskinesia a symptom or side effect? A modern treatment, Curr Psychiatry Rep, 13, 4, pp. 295-304, (2011); Luchowska E., Kloc R., Olajossy B., Wnuk S., Wielosz M., Owe-Larsson B., Urbanska E.M., Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling, Prog Neuropsychopharmacol Biol Psychiatry, 33, 3, pp. 519-529, (2009); Maes M., Meltzer H.Y., Bosmans E., Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine, Acta Psychiatr Scand, 89, pp. 346-351, (1994); Maldonado M.D., Perez-San-Gregorio M.A., Reiter R.J., The role of melatonin in the immuno-neuro-psychology of mental disorders, Recent Pat CNS Drug Discov, 4, 1, pp. 61-69, (2009); Maldonado M.D., Reiter R.J., Perez-San-Gregorio M.A., Melatonin as a potential therapeutic agent in psychiatric illness, Hum Psychopharmacol, 24, 5, pp. 391-400, (2009); Mann K., Rossbach W., Muller M.J., Muller-Siecheneder F., Pott T., Linde I., Dittmann R.W., Hiemke C., Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine, Psychoneuroendocrinology, 31, 2, pp. 256-264, (2006); Marczynski T.J., Yamaguchi N., Ling G.M., Grodzinska L., Sleep induced by the administration of melatonin (5-methoxyn- acetyltryptamine) to the hypothalamus in unrestrained cats, Experientia, 20, 8, pp. 435-437, (1964); Martin M., Macias M., Leon J., Escames G., Khaldy H., Acuna-Castroviejo D., Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria, Int J Biochem Cell Biol, 34, 4, pp. 348-357, (2002); Marzullo G., Fraser F.C., Conception season and cerebral asymmetries amongAmerican baseball players: Implications for the seasonal birth effect in schizophrenia, Psychiatry Res, 167, 3, pp. 287-293, (2009); McGrath J., Eyles D., Mowry B., Yolken R., Buka S., Low maternal vitamin D as a risk factor for schizophrenia: A pilot study using banked sera, Schizophr Res, 63, 1-2, pp. 73-78, (2003); Meyer U., Feldon J., Dammann O., Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation?, Pediatr Res, 69, 2-5 PART, (2011); Miller J., Gallo R.L., Vitamin D and innate immunity, Dermatol Ther, 23, 1, pp. 13-22, (2010); Miller C.L., Llenos I.C., Dulay J.R., Weis S., Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder, Brain Res, 1073-1074, pp. 25-37, (2006); Miller C.L., Murakami P., Ruczinski I., Ross R.G., Sinkus M., Sullivan B., Leonard S., Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder, Schizophr Res, 113, 2-3, pp. 259-267, (2009); Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B., Metaanalysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects, Biol Psychiatry, 70, pp. 663-671, (2011); Monteleone P., Maj M., Fusco M., Kemali D., Reiter R.J., Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics, Schizophr Res, 7, 1, pp. 77-84, (1992); Monteleone P., Natale M., La Rocca A., Maj M., Decreased nocturnal secretion of melatonin in drug-free schizophrenics: No change after subchronic treatment with antipsychotics, Neuropsychobiology, 36, 4, pp. 159-163, (1997); Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpe S., Steinbusch H.W., Leonard B.E., Kim Y.K., Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients, Brain Behav Immun, 25, 8, pp. 1576-1581, (2011); Olcese J.M., Cao C., Mori T., Mamcarz M.B., Maxwell A., Runfeldt M.J., Wang L., Zhang C., Lin X., Zhang G., Arendash G.W., Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease, J Pineal Res, 47, 1, pp. 82-96, (2009); Park H.J., Park J.K., Kim S.K., Cho A.R., Kim J.W., Yim S.V., Chung J.H., Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients, J Mol Neurosci, 45, 2, pp. 304-308, (2011); Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E., Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review, Biol Psychiatry, 63, pp. 801-808, (2008); Praschak-Rieder N., Willeit M., Wilson A.A., Houle S., Meyer J.H., Seasonal variation in human brain serotonin transporter binding, Arch Gen Psychiatry, 65, 9, pp. 1072-1078, (2008); Proietti S., Cucina A., D'Anselmi F., Dinicola S., Pasqualato A., Lisi E., Bizzarri M., Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells, J Pineal Res, 50, 2, pp. 150-158, (2011); Quiros I., Mayo J.C., Garcia-Suarez O., Hevia D., Martin V., Rodriguez C., Sainz R.M., Melatonin prevents the glucocorticoid receptor inhibition of cell proliferation and toxicity in hippocampal cells by reducing the glucocorticoid receptor nuclear translocation, J Steroid Biochem Mol Biol, 110, pp. 116-124, (2008); Rao M.L., Gross G., Strebel B., Halaris A., Huber G., Braunig P., Marler M., Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia, Biol Psychiatry, 35, 3, pp. 151-163, (1994); Raskind M.A., Burke B.L., Crites N.J., Tapp A.M., Rasmussen D.D., Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats, Neuropsychopharmacology, 32, 2, pp. 284-288, (2007); Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., Di Nicola M., Grilli A., Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls, BMC Neurosci, 25, pp. 12-13, (2011); Rennie K., De Butte M., Pappas B.A., Melatonin promotes neurogenesis in dentate gyrus in the pinealectomized rat, J Pineal Res, 47, 4, pp. 313-317, (2009); Reynolds R.M., Walker B.R., Phillips D.I., Dennison E.M., Fraser R., Mackenzie S.M., Davies E., Connell J.M., Programming of hypertension: Associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure, Hypertension, 53, 6, pp. 932-936, (2009); Rimmele U., Spillmann M., Bartschi C., Wolf O.T., Weber C.S., Ehlert U., Wirtz P.H., Melatonin improves memory acquisition under stress independent of stress hormone release, Psychopharmacology (Berl), 202, 4, pp. 663-672, (2009); Sandyk R., Kay S.R., The relationship of pineal calcification to cortical atrophy in schizophrenia, Int J Neurosci, 57, 3-4, pp. 179-191, (1991); Sartori C., Dessen P., Mathieu C., Monney A., Bloch J., Nicod P., Scherrer U., Duplain H., Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulinresistant mice, Endocrinology, 150, 12, pp. 5311-5317, (2009); Schneider B., Weber B., Frensch A., Stein J., Fritz J., Vitamin D in schizophrenia, major depression and alcoholism, J Neural Transm, 107, 7, pp. 839-842, (2000); Shamir E., Barak Y., Plopsky I., Zisapel N., Elizur A., Weizman A., Is melatonin treatment effective for tardive dyskinesia?, J Clin Psychiatry, 61, 8, pp. 556-558, (2000); Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., Elizur A., Weizman R., Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study, Arch Gen Psychiatry, 58, 11, pp. 1049-1052, (2001); Shieh J.M., Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK-3b pathway in hepatic cells, J Pineal Res, 47, 4, pp. 339-344, (2009); Shilo L., Dagan Y., Smorjik Y., Weinberg U., Dolev S., Komptel B., Shenkman L., Effect of melatonin on sleep quality of COPD intensive care patients: A pilot study, Chronobiol Int, 17, 1, pp. 71-76, (2000); Suresh Kumar P.N., Andrade C., Bhakta S.G., Singh N.M., Melatonin in schizophrenic outpatients with insomnia: A double-blind, placebo-controlled study, J Clin Psychiatry, 68, 2, pp. 237-241, (2007); Tajes M., Gutierrez-Cuesta J., Ortuno-Sahagun D., Camins A., Pallas M., Anti-aging properties of melatonin in an in vitro murine senescence model: Involvement of the sirtuin 1 pathway, J Pineal Res, 47, 3, pp. 228-237, (2009); Tardieu S., Micallef J., Gentile S., Blin O., Weight gain profiles of new anti-psychotics: Public health consequences, Obes Rev, 4, 3, pp. 129-138, (2003); Utsunomiya K., Shinkai T., Sakata S., Yamada K., Chen H.I., De Luca V., Hwang R., Ohmori O., Nakamura J., Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: A reevaluation in East Asian populations, Neurosci Lett, 507, 1, pp. 52-56, (2012); Vigano D., Lissoni P., Rovelli F., Roselli M.G., Malugani F., Gavazzeni C., Conti A., Maestroni G., A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia, Neuro Endocrinol Lett, 22, 2, pp. 137-141, (2001); Wang F., Fan H., Sun H., Yang F., Luo Y., Liu H., Kosten T.R., Lu L., Zhang X.Y., Association between TNF-α promoter-308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 37, 1, pp. 106-110, (2012); Wareski P., Vaarmann A., Choubey V., Safiulina D., Liiv J., Kuum M., Kaasik A., PGC-1alpha and PGC-1beta regulate mitochondrial density in neurons, J Biol Chem, 284, 32, pp. 21379-21385, (2009); Watson P.E., McDonald B.W., Seasonal variation of nutrient intake in pregnancy: Effects on infant measures and possible influence on diseases related to season of birth, Eur J Clin Nutr, 61, 11, pp. 1271-1280, (2007); Wulff K., Dijk D.J., Middleton B., Foster R.G., Joyce E.M., Sleep and circadian rhythm disruption in schizophrenia, Br J Psychiatry, 200, 4, pp. 308-316, (2012); Zhang L., Su P., Xu C., Chen C., Liang A., Du K., Peng Y., Huang D., Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression, J Pineal Res, 49, 4, pp. 364-372, (2010); Zhou R., Gray N.A., Yuan P., Li X., Chen J., Chen G., Damschroder-Williams P., Du J., Zhang L., Manji H.K., The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a longterm target for the actions of mood stabilizers, J Neurosci, 25, 18, pp. 4493-4502, (2005); Zmarowski A., Wu H.Q., Brooks J.M., Potter M.C., Pellicciari R., Schwarcz R., Bruno J.P., Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release, Eur J Neurosci, 29, 3, pp. 529-538, (2009)","G. Anderson; CRC, Glasgow G11 7QT, 57 Laurel St., United Kingdom; email: anderson.george@rocketmail.com","","","","","","","","15737365","","MBDIE","22527998","English","Metab. Brain Dis.","Review","Final","","Scopus","2-s2.0-84863447564"
"Thompson M.D.; Cole D.E.; Capra V.; Siminovitch K.A.; Enrico Rovati G.; McIntyre Burnham W.; Rana B.K.","Thompson, Miles D. (7404622100); Cole, David E.C. (35426489300); Capra, Valerie (7003313806); Siminovitch, Katherine A. (35404700300); Enrico Rovati, G. (7004453023); McIntyre Burnham, W. (35552811400); Rana, Brinda K. (7006646242)","7404622100; 35426489300; 7003313806; 35404700300; 7004453023; 35552811400; 7006646242","Pharmacogenetics of the G protein-coupled receptors","2014","Methods in Molecular Biology","1175","","","189","242","53","32","10.1007/978-1-4939-0956-8_9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924348852&doi=10.1007%2f978-1-4939-0956-8_9&partnerID=40&md5=88b1436e2dda8f6f83927d77ed2eb7c9","","","Pharmacogenetics investigates the influence of genetic variants on physiological phenotypes related to drug response and disease, while pharmacogenomics takes a genome-wide approach to advancing this knowledge. Both play an important role in identifying responders and nonresponders to medication, avoiding adverse drug reactions, and optimizing drug dose for the individual. G protein-coupled receptors (GPCRs) are the primary target of therapeutic drugs and have been the focus of these studies. With the advance of genomic technologies, there has been a substantial increase in the inventory of naturally occurring rare and common GPCR variants. These variants include single-nucleotide polymorphisms and insertion or deletions that have potential to alter GPCR expression of function. In vivo and in vitro studies have determined functional roles for many GPCR variants, but genetic association studies that define the physiological impact of the majority of these common variants are still limited. Despite the breadth of pharmacogenetic data available, GPCR variants have not been included in drug labeling and are only occasionally considered in optimizing clinical use of GPCR-targeted agents. In this chapter, pharmacogenetic and genomic studies on GPCR variants are reviewed with respect to a subset of GPCR systems, including the adrenergic, calcium sensing, cysteinyl leukotriene, cannabinoid CB1 and CB2 receptors, and the deorphanized receptors such as GPR55. The nature of the disruption to receptor function is discussed with respect to regulation of gene expression, expression on the cell surface (affected by receptor trafficking, dimerization, desensitization/downregulation), or perturbation of receptor function (altered ligand binding, G protein coupling, constitutive activity). The large body of experimental data generated on structure and function relationships and receptor-ligand interactions are being harnessed for the in silico functional prediction of naturally occurring GPCR variants. We provide information on online resources dedicated to GPCRs and present applications of publically available computational tools for pharmacogenetic studies of GPCRs. As the breadth of GPCR pharmacogenomic data becomes clearer, the opportunity for routine assessment of GPCR variants to predict disease risk, drug response, and potential adverse drug effects will become possible. © Springer Science+Business Media New York 2014.","Agonist; Antagonist; Cannabinoid; Database; Efficacy; G protein-coupled receptor; GPR55; Pharmacogenetics; Potency; Variant","Databases, Genetic; Genetic Association Studies; Humans; Individualized Medicine; Mutation; Pharmacogenetics; Polymorphism, Genetic; Receptors, G-Protein-Coupled; adrenergic receptor; angiotensin receptor; beta 2 adrenergic receptor; calcium sensing receptor; cannabinoid 1 receptor; cannabinoid 2 receptor; chemokine receptor; dopamine receptor; endothelin; G protein coupled receptor; leukotriene receptor; neurotransmitter; opiate receptor; peptidoleukotriene; prostaglandin D2; prostanoid receptor; proteinase activated receptor; serotonin receptor; thrombin; thrombocyte activating factor receptor; thromboxane A2; G protein coupled receptor; Article; asthma; cell surface; developmental disorder; down regulation; gastrointestinal carcinoma; gene control; gene expression; gene mutation; gene sequence; genetic association; genetic variability; human; hypertension; myasthenia gravis; personalized medicine; pharmacogenetics; pharmacogenomics; priority journal; single nucleotide polymorphism; virus cell interaction; agonists; antagonists and inhibitors; genetic database; genetic polymorphism; genetics; metabolism; mutation","","prostaglandin D2, 41598-07-6; thrombin, 9002-04-4, 869858-13-9; thromboxane A2, 57576-52-0; Receptors, G-Protein-Coupled, ","","","","","Rana B.K., Shiina T., Insel P.A., Genetic variations and polymorphisms of G proteincoupled receptors: Functional and therapeutic implications, Annu Rev Pharmacol Toxicol, 41, pp. 593-624, (2001); Lefkowitz R.J., Historical review: A brief history and personal retrospective of seventransmembrane receptors, Trends Pharmacol Sci, 25, pp. 413-422, (2004); Silber B.M., Pharmacogenomics, biomarkers, and the promise of personalized medicine, Pharmacogenomics, pp. 10-25, (2001); Xing Q., Qian X., Li H., Et al., The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients, Int J Neuropsychopharmacol, 10, pp. 631-637, (2007); Ikeda M., Yamanouchi Y., Kinoshita Y., Et al., Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia, Pharmacogenomics, 9, pp. 1437-1443, (2008); Milligan G., Strategies to identify ligands for orphan G-protein-coupled receptors, Biochem Soc Trans, 30, pp. 789-793, (2002); Mannstadt M., Bravenboer B., Chitturi S., Et al., Germline mutations affecting Gα11 in hypoparathyroidism, N Engl J Med, 368, pp. 2532-2534, (2013); Birnbaumer M., Mutations and diseases of G-protein coupled receptors, J Recept Signal Transduct Res, 15, pp. 131-160, (1995); Raymond J.R., Hereditary and acquired defects in signaling through the hormonereceptor-G protein complex, Am J Physiol, 266, pp. 163-174, (1994); Thompson M.D., Capra V., Takasaki J., Et al., A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Tristan da Cunha isolate, Pharmacogenet Genomics, 17, pp. 539-549, (2007); Thompson M.D., Gravesandeg K., Galczenski H., Et al., A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha, Pharmacogenetics, 13, pp. 641-649, (2003); Rana B.K., Bourne P.E., Insel P.A., Receptor databases and computational websites for ligand binding, Methods Mol Biol, 897, pp. 1-13, (2012); Kazius J., Wurdinger K., Van Iterson M., Et al., GPCR NaVa database: Natural variants in human G protein-coupled receptors, Hum Mutat, 29, pp. 39-44, (2008); Vroling B., Sanders M., Baakman C., Et al., GPCRDB: Information system for G protein-coupled receptors, Nucleic Acids Res, 39, pp. D309-D319, (2011); Cole D., Peltekova V.D., Rubin L.A., Et al., A986S polymorphism of the calciumsensing receptor and circulating calcium concentrations, Lancet, 353, pp. 112-115, (1999); Cole D., Vieth R., Trang H.M., Wong B., Hendy G.N., Rubin L.A., Association between total serum calcium and the A986S polymorphism of the calcium-sensing receptor gene, Mol Genet Metab, 72, pp. 168-174, (2001); Scillitani A., Guarnieri V., De Geronimo S., Et al., Blood ionized calcium is associated with clustered polymorphisms in the carboxylterminal tail of the calcium-sensing receptor, J Clin Endocrinol Metab, 89, pp. 5634-5638, (2004); Lorentzon M., Lorentzon R., Lerner U.H., Et al., Calcium sensing receptor gene polymorphism, circulating calcium concentrations and bone mineral density in healthy adolescent girls, Eur J Endocrinol, 144, pp. 257-261, (2001); Miedlich S., Lamesch P., Mueller A., Et al., Frequency of the calcium-sensing receptor variant A986S in patients with primary hyperparathyroidism, Eur J Endocrinol, 145, pp. 421-427, (2001); Donath J., Speer G., Poor G., Et al., Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget’s disease of bone, Rheumatology, 43, pp. 692-695, (2004); Vezzoli G., Tanini A., Ferrucci L., Et al., Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients, J am Soc Nephrol, 13, pp. 2517-2523, (2002); O'Seaghdha C.M., Yang Q., Glazer N.L., Et al., Common variants in the calciumsensing receptor gene are associated with total serum calcium levels, Hum Mol Genet, 19, pp. 4296-4303, (2010); Wang J.G., Staessen J.A., Genetic polymorphisms in the renin-angiotensin system: Relevance for susceptibility to cardiovascular disease, Eur J Pharmacol, 410, pp. 289-302, (2000); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin-II type-1 receptor gene polymorphisms in human essentialhypertension, Hypertension, 24, pp. 63-69, (1994); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Et al., Molecular-basis of human hypertension—role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Rigat B., Hubert C., Alhencgelas F., Et al., An insertion deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Azizi M., Guyene T.T., Chatellier G., Et al., Additive effects of losartan and enalapril on blood pressure and plasma active renin, Hypertension, 29, pp. 634-640, (1997); Takami S., Katsuya T., Rakugi H., Et al., Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension, Am J Hypertens, 11, pp. 316-321, (1998); Tiret L., Bonnardeaux A., Poirier O., Et al., Synergistic effects of angiotensinconverting enzyme and angiotensin-II type-1 receptor gene polymorphisms on risk of myocardial-infarction, Lancet, 344, pp. 910-913, (1994); Tomino Y., Makita Y., Shike T., Et al., Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients, Nephron, 82, pp. 139-144, (1999); Benetos A., Cambien F., Gautier S., Et al., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, pp. 1081-1084, (1996); Amant C., Hamon M., Bauters C., Et al., The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction, J am Coll Cardiol, 29, pp. 486-490, (1997); Van Geel P.P., Pinto Y.M., Voors A.A., Et al., Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries, Hypertension, 35, pp. 717-721, (2000); Danser A., Schunkert H., Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases, Eur J Pharmacol, 410, pp. 303-316, (2000); Fatini C., Gensini F., Sticchi E., Et al., ACE DD genotype: An independent predisposition factor to venous thromboembolism, Eur J Clin Invest, 33, pp. 642-647, (2003); Andrikopoulos G.K., Richter D.J., Needham E.W., The paradoxical association of common polymorphisms of the renin-angiotensin system genes with risk of myocardial infarction, Eur J Cardiovasc Prev Rehabil, 11, pp. 477-483, (2004); Thompson M.D., Comings D.E., Abu-Ghazalah R., Et al., Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette’s syndrome comorbidity, Am J Med Genet, 129, pp. 69-75, (2004); A genomewide association analysis of a broad psychosis phenotype identifies three loci for further investigation, Biol Psychiatry, (2013); Missale C., Nash S.R., Robinson S.W., Et al., Dopamine receptors: From structure to function, Physiol Rev, 78, pp. 189-225, (1998); Muller D.J., Chowdhury N.I., Zai C.C., The pharmacogenetics of antipsychoticinduced adverse events, Curr Opin Psychiatry, 26, pp. 144-150, (2013); Thompson M., Comings D.E., Feder L., Et al., Mutation screening of the dopamine D1 receptor gene in Tourette’s syndrome and alcohol dependent patients, Am J Med Genet, 81, pp. 241-244, (1998); Oak J.N., Oldenhof J., Van Tol H.H., The dopamine D(4) receptor: One decade of research, Eur J Pharmacol, 405, pp. 303-327, (2000); Vandenbergh D.J., Thompson M.D., Cook E.H., Et al., Human dopamine transporter gene: Coding region conservation among normal, Tourette’s disorder, alcohol dependence and attention-deficit hyperactivity disorder populations, Mol Psychiatry, 5, pp. 283-292, (2000); Comings D.E., Gade-Andavolu R., Gonzalez N., Et al., Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder, Clin Genet, 58, pp. 31-40, (2000); Hall F.S., Drgonova J., Jain S., Uhl G.R., Implications of genome wide association studies for addiction: Are our a priori assumptions all wrong?, Pharmacol Ther, (2013); Thompson M.D., Siminovitch K.A., Cole D.E., G Protein-coupled receptor pharmacogenetics, Methods Mol Biol, 448, pp. 139-185, (2008); Lamey M., Thompson M., Varghese G., Et al., Distinct residues in the carboxyl tail mediate agonist-induced desensitization and internalization of the human dopamine D-1 receptor, J Biol Chem, 277, pp. 9415-9421, (2002); Thompson M.D., Cole D.E., Jose P., The pharmacogenomics of G protein-coupled receptor signaling: Insight from health and disease, Methods Mol Biol, 448, pp. 77-108, (2008); Thompson M.D., Percy M.E., Burnham W.M., Et al., G Protein-coupled receptors disrupted in human genetic disease, Methods Mol Biol, 448, pp. 109-138, (2008); Monsma F.J., Mahan L.C., McVittie L.D., Et al., Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation, Proc Natl Acad Sci U S A, 87, pp. 6723-6727, (1990); Zhou Q.Y., Grandy D.K., Thambi L., Et al., Cloning and expression of human and rat D1 dopamine receptors, Nature, 347, pp. 76-80, (1990); Sunahara R.K., Niznik H.B., Weiner D.M., Et al., Human dopamine D1 receptor encoded by an intronless gene on chromosome 5, Nature, 347, pp. 80-83, (1990); Sunahara R.K., Guan H.C., O'Dowd B.F., Et al., Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D5, Nature, 350, pp. 614-619, (1991); Grandy D.K., Marchionni M.A., Makam H., Et al., Cloning of the cDNA and gene for a human D2 dopamine receptor, Proc Natl Acad Sci U S A, 86, pp. 9762-9766, (1989); Sokoloff P., Giros B., Martres M.P., Barthenet M.L., Et al., Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics, Nature, 347, pp. 146-151, (1990); Van Tol H.H., Bunzow J.R., Guan H.C., Et al., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Nature, 350, pp. 610-614, (1991); Seeman P., Seeman M.V., Schizophrenia and the supersensitive synapse, Neuropsychiatry, 1, pp. 233-242, (2011); Giros B., Sokoloff P., Martres M.P., Et al., Alternative splicing directs the expression of two D2 dopamine receptor isoforms, Nature, 342, pp. 923-926, (1989); Monsma F.J., McVittie L.D., Gerfen C.R., Et al., Multiple D2 dopamine receptors produced by alternative RNA splicing, Nature, 342, pp. 926-929, (1989); Comings D.E., Gade R., Wu S., Et al., Studies of the potential role of the dopamine D-1 receptor gene in addictive behaviors, Mol Psychiatry, 2, pp. 44-56, (1997); Ni X., Trakalo J.M., Mundo E., Lee L., Et al., Family-based association study of the serotonin-2A receptor gene (5-HT2A) and bipolar disorder, Neuromolecular Med, 2, pp. 251-259, (2002); Severino G., Congiu D., Serreli C., Et al., A48G polymorphism in the D1 receptor genes associated with bipolar I disorder, Am J Med Genet, 134, pp. 37-38, (2005); Mottagui-Tabar S., Faghihi M.A., Mizuno Y., Et al., Identification of functional SNPs in the 5-prime flanking sequences of human genes, BMC Genomics, 6, (2005); Hwang R., Shinkai T., De L., Et al., Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response, J Psychopharmacol, 16, pp. 248-259, (2006); Dmitrzak-Weglarz M., Rybakowski J.K., Slopien A., Et al., Dopamine receptor D1 gene −48A/G polymorphism is associated with bipolar illness but not with schizophrenia in a Polish population, Neuropsychobiology, 53, pp. 46-50, (2006); Seeman P., Schizophrenia and dopamine receptors, Eur Neuropsychopharmacol, (2013); Liu I., Seeman P., Sanyal S., Et al., Dopamine D4 receptor variant in Africans, D (Valine194Glycine), is insensitive to dopamine and clozapine: Report of a homozygous individual, Am J Med Genet, 61, pp. 277-282, (1996); Okuyama Y., Ishiguro H., Toru M., Et al., A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia, Biochem Biophys Res Commun, 258, pp. 292-295, (1999); Kaiser R., Konneker M., Henneken M., Et al., Dopamine D4 receptor 48-bp repeat polymorphism: No association with response to antipsychotic treatment, but association with catatonic schizophrenia, Mol Psychiatry, 5, pp. 418-424, (2000); Jonsson E.G., Norton N., Gustavsson J.F., Et al., A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers, J Psychiatr Res, 34, pp. 239-244, (2000); Seeman P., Guan H.C., Van Tol H., Schizophrenia—elevation of dopamine D-4-like sites, using [H-3] nemonapride and [I-125] epidepride, Eur J Pharmacol, 286, pp. R3-R5, (1995); Seeman P., Corbett R., Van Tol H., Atypical neuroleptics have low affinity for dopamine D-2 receptors or are selective for D-4 receptors, Neuropsychopharmacology, 16, pp. 93-110, (1997); Nakajima M., Hattori E., Yamada K., Et al., Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics, J Hum Genet, 52, pp. 86-91, (2007); Manor I., Tyano S., Eisenberg J., Et al., The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a familybased design and impair performance on a continuous performance test (TOVA), Mol Psychiatry, 7, pp. 790-794, (2002); Gornick M.C., Addington A., Shaw P., Et al., Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyperactivity disorder (ADHD): An update, Am J Med Genet, 144, pp. 379-382, (2007); Brookes K., Xu X., Chen W., Et al., The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: Association signals in DRD4, DAT1 and 16 other genes, Mol Psychiatry, 11, pp. 934-953, (2006); Li D., Sham P.C., Owen M.J., He L., Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD), Hum Mol Genet, 15, pp. 2276-2284, (2006); Ronai Z., Szekely A., Nemoda Z., Et al., Association between novelty seeking and the-521 C/T polymorphism in the promoter region of the DRD4 gene, Mol Psychiatry, 6, pp. 35-38, (2001); Strobel A., Lesch K.P., Hohenberger K., Et al., No association between dopamine D4 receptor gene exon III and −521C/T polymorphism and novelty seeking, Mol Psychiatry, 7, pp. 537-538, (2002); Laucht M., Becker K., Blomeyer D., Et al., Novelty seeking involved in mediating the association between the dopamine D4 receptor gene exon III polymorphism and heavy drinking in male adolescents: Results from a high-risk community sample, Biol Psychiatry, 61, pp. 87-92, (2007); Talkowski M.E., Mansour H., Chowdari K.V., Et al., Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples, Biol Psychiatry, 60, pp. 570-577, (2006); Sivagnanasundaram S., Morris A.G., Gaitonde E.J., Et al., A cluster of single nucleotide polymorphisms in the 5-leader of the human dopamine D3 receptor gene (DRD3) and its relationship to schizophrenia, Neurosci Lett, 279, pp. 13-16, (2000); Hawi Z., McCabe U., Straub R.E., Et al., Examination of new and reported data of the DRD3/Mscl polymorphism: No support for the proposed association with schizophrenia, Mol Psychiatry, 3, pp. 150-155, (1998); Eichhammer P., Albus M., Klein H.E., Et al., Association of dopamine-receptor gene variants with neuroleptically induced acathisia in schizophrenic patients, Psychiatr Prax, 27, (2000); Liao D.L., Yeh Y.C., Chen H.M., Et al., Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients, Neuropsychobiology, 44, pp. 95-98, (2001); Lerer B., Segman R.H., Fangerau H., Et al., Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism, Neuropsychopharmacology, 27, pp. 105-119, (2002); Comings D.E., Gade R., Macmurray J.P., Et al., Genetic variants of the human obesity (OB) gene: Association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene, Mol Psychiatry, 1, pp. 325-335, (1996); Chen C.H., Wei F.C., Koong F.J., Et al., Association of TaqI a poly-morphism of dopamine D-2 receptor gene and tardive dyskinesia in schizophrenia, Biol Psychiatry, 41, pp. 827-829, (1997); Morton L.M., Wang S.S., Bergen A.W., Et al., DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, Pharmacogenet Genomics, 16, pp. 901-910, (2006); Comings D.E., Genetic-factors in substance-abuse based on studies of Tourettesyndrome and ADHD probands and relatives. 1, Drug-Abuse. Drug Alcohol Depend, 35, pp. 1-16, (1994); Noble E.P., DRD2 gene and alcoholism, Science, 281, pp. 1287-1288, (1998); Madrid G.A., Macmurray J., Lee J.W., Et al., Stress as a mediating factor in the association between the DRD2 TaqI polymorphism and alcoholism, Alcohol, 23, pp. 117-122, (2001); Sasabe T., Furukawa A., Matsusita S., Et al., Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients, Neurosci Lett, 412, pp. 139-142, (2006); Hori H., Ohmori O., Shinkai T., Et al., Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia, Am J Med Genet, 105, pp. 774-778, (2001); Zai C.C., Hwang R.W., De L., Et al., Association study of tardive dyskinesia and 12 DRD2 polymorphisms in schizophrenia patients, Int J Neuropsychopharmacol, 10, pp. 639-651, (2007); Seeman P., Weinshenker D., Quirion R., Et al., Dopamine supersensitivity correlates with D2 high states, implying many paths to psychosis, Proc Natl Acad Sci U S A, 102, pp. 3513-3518, (2005); Arranz M.J., Munro J., Birkett J., Et al., Pharmacogenetic prediction of clozapine response, Lancet, 355, pp. 1615-1616, (2000); Du L.S., Bakish D., Lapierre Y.D., Et al., Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder, Am J Med Genet, 96, pp. 56-60, (2000); Preuss U.W., Koller G., Bahlmann M., Et al., No association between suicidal behavior and 5-HT2A-T102C polymorphism in alcohol dependents, Am J Med Genet, 96, pp. 877-878, (2000); Levitan R.D., Masellis M., Basile V.S., Et al., Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder, J Affect Disord, 71, pp. 229-233, (2002); Thompson M.D., Gonzalez N., Nguyen T., Et al., Serotonin transporter gene polymorphisms in alcohol dependence, Alcohol, 22, pp. 61-67, (2000); Arranz M.J., Collier D.A., Munro J., Et al., Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine, Neurosci Lett, 217, pp. 177-178, (1996); Arranz M.J., Munro J., Sham P., Et al., Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response, Schizophr Res, 32, pp. 93-99, (1998); Yu Y.W., Tsai S.J., Yang K.H., Et al., Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine, Neuropsychobiology, 43, pp. 79-82, (2001); Davies M.A., Setola V., Strachan R.T., Et al., Pharmacologic analysis of nonsynonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies, Pharmacogenomics J, 6, pp. 42-51, (2006); Hazelwood L.A., Sanders-Bush E., His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation, Mol Pharmacol, 66, pp. 1293-1300, (2004); Archer T., Oscar-Berman M., Blum K., Et al., Epigenetic modulation of mood disorders, J Genet Syndr Gene Ther, 4, 120, (2013); Choi M.J., Kang R.H., Ham B.J., Et al., Serotonin receptor 2A gene polymorphism (−1438A/G) and short-term treatment response to citalopram, Neuropsychobiology, 52, pp. 155-162, (2005); Chee I.S., Lee S.W., Kim J.L., Et al., 5-HT2A receptor gene promoter polymorphism-1438A/G and bipolar disorder, Psychiatr Genet, 11, pp. 111-114, (2001); Vaquero L.C., Baca-Garcia E., Az-Hernandez M., Et al., Association between the T102C polymorphism of the serotonin-2A receptor gene and schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 30, pp. 1136-1138, (2006); Abdolmaleky H.M., Faraone S.V., Glatt S.J., Et al., Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia, Schizophr Res, 67, pp. 53-62, (2004); Chen R.Y., Sham P., Chen E.Y., Et al., No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients, Psychiatry Res, 105, pp. 175-185, (2001); Joober R., Benkelfat C., Brisebois K., Et al., T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability, J Psychiatry Neurosci, 24, pp. 141-146, (1999); Czerski P.M., Leszczynska-Rodziewicz A., Dmitrzak-Weglarz M., Et al., Association analysis of serotonin 2A receptor gene T102C polymorphism and schizophrenia, World J Biol Psychiatry, 4, pp. 69-73, (2003); Khait V.D., Huang Y.Y., Zalsman G., Et al., Association of serotonin 5-HT2A receptor binding and the T102C polymorphism in depressed and healthy Caucasian subjects, Neuropsychopharmacology, 30, pp. 166-172, (2005); Ono H., Shirakawa O., Nishiguchi N., Et al., Serotonin 2A receptor gene polymorphism is not associated with completed suicide, J Psychiatr Res, 35, pp. 173-176, (2001); Holmes C., Arranz M.J., Powell J.F., Et al., 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset alzheimer’s disease, Hum Mol Genet, 7, pp. 1507-1509, (1998); Rocchi A., Micheli D., Ceravolo R., Et al., Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): Association studies with psychosis in Alzheimer disease, Genet Test, 7, pp. 309-314, (2003); Yuan X., Yamada K., Ishiyama-Shigemoto S., Et al., Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes, Diabetologia, 43, pp. 373-376, (2000); Ellingrod V.L., Miller D., Ringold J.C., Et al., Distribution of the serotonin 2C (5HT2C) receptor gene-759C/T polymorphism in patients with schizophrenia and normal controls, Psychiatr Genet, 14, pp. 93-95, (2004); Reynolds G.P., Zhang Z.J., Zhang X.B., Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism, Lancet, 359, pp. 2086-2087, (2002); Basile V.S., Masellis M., De L., Et al., 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain, Lancet, 360, pp. 1790-1791, (2002); Muller D.J., Kennedy J.L., Genetics of antipsychotic treatment emergent weight gain in schizophrenia, Pharmacogenomics, 7, pp. 863-887, (2006); Miller D.D., Ellingrod V.L., Holman T.L., Et al., Clozapine-induced weight gain associated with the 5HT2C receptor −759C/T polymorphism, Am J Med Genet, 133, pp. 97-100, (2005); Sodhi M.S., Arranz M.J., Curtis D., Et al., Association between clozapine response and allelic variation in the 5-HT2C receptor gene, Neuroreport, 7, pp. 169-172, (1995); Malhotra A.K., Goldman D., Ozaki N., Et al., Clozapine response and the 5HT2C Cys23Ser polymorphism, Neuroreport, 7, pp. 2100-2102, (1996); Tsai S.J., Chiu H.J., Wang Y.C., Et al., Association study of serotonin-6 receptor variant (C267T) with schizophrenia and aggressive behavior, Neurosci Lett, 271, pp. 135-137, (1999); Kan R., Wang B., Zhang C., Et al., Association of the HTR6 polymorphism C267T with late-onset alzheimer’s disease in Chinese, Neurosci Lett, 372, pp. 27-29, (2004); Orlacchio A., Kawarai T., Paciotti E., Et al., Association study of the 5-hydroxytryptamine (6) receptor gene in Alzheimer’s disease, Neurosci Lett, 325, pp. 13-16, (2002); Thompson M.D., Noble-Topham S., Percy M.E., Et al., Chromosome 1p36 in migraine with aura: Association study of the 5HT(1D) locus, Neuroreport, 23, pp. 45-48, (2012); Chasman D.I., Schurks M., Anttila V., Et al., Genome-wide association study reveals three susceptibility loci for common migraine in the general population, Nat Genet, 43, pp. 695-698, (2011); Kiel S., Bruss M., Bonisch H., Gothert M., Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: Changes in ligand binding, G-protein coupling and second messenger formation, Pharmacogenetics, 10, pp. 655-666, (2000); Smoller J.W., Biederman J., Arbeitman L., Et al., Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD, Biol Psychiatry, 59, pp. 460-467, (2006); Ickowicz A., Feng Y., Wigg K., Et al., The serotonin receptor HTR1B: Gene polymorphisms in attention deficit hyperactivity disorder, Am J Med, 144, pp. 121-125, (2007); Nothen M.M., Erdmann J., Shimron-Abarbanell D., Et al., Identification of genetic variation in the human serotonin 1D beta receptor gene, Biochem Biophys Res Commun, 205, pp. 1194-1200, (1994); Lappalainen J., Dean M., Charbonneau L., Et al., Mapping of the serotonin 5-HT1D beta autoreceptor gene on chromosome 6 and direct analysis for sequence variants, Am J Med Genet, 60, pp. 157-161, (1995); Mundo E., Richter M.A., Zai G., Et al., 5HT1Dbeta Receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: Further evidence from a family-based association study, Mol Psychiatry, 7, pp. 805-809, (2002); Mundo E., Richter M.A., Sam F., Et al., Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder?, Am J Psychiatry, 157, pp. 1160-1161, (2000); Lochner C., Hemmings S.M., Kinnear C.J., Et al., Gender in obsessive-compulsive disorder: Clinical and genetic findings, Eur Neuropsychopharmacol, 14, pp. 105-113, (2004); Thompson M.D., Bowen R.A., Wong B.Y., Et al., Whole genome amplification of buccal cell DNA: Genotyping concordance before and after multiple displacement amplification, Clin Chem Lab Med, 43, pp. 157-162, (2005); Befort K., Filliol D., Decaillot F.M., Et al., A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling, J Biol Chem, 276, pp. 3130-3137, (2001); Mura E., Govoni S., Racchi M., Et al., Consequences of the 118A>G polymorphism in the OPRM1 gene: Translation from bench to bedside?, J Pain Res, 6, pp. 331-353, (2013); Beyer A., Koch T., Schroder H., Et al., Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor, J Neurochem, 89, pp. 553-560, (2004); Wang D.X., Quillan J.M., Winans K., Et al., Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding, J Biol Chem, 276, pp. 34624-34630, (2001); Gelernter J., Kranzler H., Cubells J., Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: Population studies, and allele frequencies in alcohol and drug-dependent subjects, Mol Psychiatry, 4, pp. 476-483, (1999); Nishizawa D., Fukuda K., Kasai S., Et al., Genome-wide association study identifies a potent locus associated with human opioid sensitivity, Mol Psychiatry, (2012); Johnson A.D., Newton-Cheh C., Chasman D.I., Et al., Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals, Hypertension, 57, pp. 903-910, (2011); Liggett S.B., Pharmacogenetics of beta-1-and beta-2-adrenergic receptors, Pharmacology, 61, pp. 167-173, (2000); Mialet-Perez J., Liggett S.B., Pharmacogenetics of betal-adrenergic receptors in heart failure and hypertension, Arch Mal Coeur Vaiss, 99, pp. 616-620, (2006); Strosberg A.D., Structure and function of the beta(3)-adrenergic receptor, Annu Rev Pharmacol Toxicol, 37, pp. 421-450, (1997); Masson S., Masseroli M., Fiordaliso F., Et al., Effects of a DA(2)/alpha(2) agonist and a beta(1)-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion, J Cardiovasc Pharmacol, 34, pp. 321-326, (1999); Mason D.A., Moore J.D., Green S.A., Liggett S.B., A gain-of-function poly-morphism in a G-protein coupling domain of the human beta(1)-adrenergic receptor, J Biol Chem, 274, pp. 12670-12674, (1999); Small K.M., Forbes S.L., Brown K.M., Et al., An Asn to Lys poly-morphism in the third intracellular loop of the human alpha(2A)-adrenergic receptor imparts enhanced agonist-promoted G(i) coupling, J Biol Chem, 275, pp. 38518-38523, (2000); Liggett S.B., Polymorphisms of betaadrenergic receptors in heart failure, Am J Med, 117, pp. 525-527, (2004); Liggett S.B., Beta(2)-Adrenergic receptor pharmacogenetics, Am J Respir Crit Care Med, 161, pp. S197-S201, (2000); Liggett S.B., Wagoner L.E., Craft L.L., Et al., The Ile164 beta(2)-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure, J Clin Invest, 102, pp. 1534-1539, (1998); Liggett S.B., Polymorphisms of the beta(2)-adrenergic receptor and asthma, Am J Respir Crit Care Med, 156, pp. S156-S162, (1997); Xu B.Y., Huang D., Pirskanen R., Lefvert A.K., Beta2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG), Clin Exp Immunol, 119, pp. 156-160, (2000); Pietras C.O., Vendelin J., Anedda F., Et al., The asthma candidate gene NPSR1 mediates isoform specific downstream signalling, BMC Pulm Med, 11, (2011); Ellinghaus D., Folseraas T., Holm K., Et al., Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4, Hepatology, (2012); Mathias R.A., Grant A.V., Rafaels N., Et al., A genome-wide association study on Africanancestry populations for asthma, J Allergy Clin Immunol, 125, pp. 336-346, (2009); Small K.M., McGraw D.W., Liggett S.B., Pharmacology and physiology of human adrenergic receptor polymorphisms, Annu Rev Pharmacol Toxicol, 43, pp. 381-411, (2003); Drysdale C.M., McGraw D.W., Stack C.B., Et al., Complex promoter and coding region beta(2)-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness, Proc Natl Acad Sci U S A, 97, pp. 10483-10488, (2000); Reihsaus E., Innis M., Macintyre N., Et al., Mutations in the gene encoding for the beta-2-adrenergic receptor in normal and asthmatic subjects, Am J Respir Cell Mol Biol, 8, pp. 334-339, (1993); Israel E., Drazen J.M., Liggett S.B., Et al., The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma, Am J Respir Crit Care Med, 162, pp. 75-80, (2000); Park J.S., Chang H.S., Park C.S., Et al., Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics, Pharmacogenet Genomics, 15, pp. 483-492, (2005); Kanaoka Y., Maekawa A., Austen K.F., Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand, J Biol Chem, 288, pp. 10967-10972, (2013); Reiss T.F., Altman L.C., Chervinsky P., Et al., Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LDT(4)) receptor antagonist, in patients with chronic asthma, J Allergy Clin Immunol, 98, pp. 528-534, (1996); Grossman J., Faiferman I., Dubb J.W., Et al., Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist, J Asthma, 34, pp. 321-328, (1997); Suissa S., Dennis R., Ernst P., Et al., Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma— a randomized, double-blind, placebo-controlled trial, Ann Intern Med, 126, pp. 177-183, (1997); Jarvis B., Markham A., Montelukast—a review of its therapeutic potential in persistent asthma, Drugs, 59, pp. 891-928, (2000); Krawiec M.E., Wenzel S.E., Use of leukotriene antagonists in childhood asthma, Curr Opin Pediatr, 11, pp. 540-547, (1999); Drazen J.M., Silverman E.K., Lee T.H., Heterogeneity of therapeutic responses in asthma, Br Med Bull, 56, pp. 1054-1070, (2000); Yoshida S., Sakamoto H., Ishizaki Y., Et al., Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma, Clin Exp Allergy, 30, pp. 64-70, (2000)","","","Humana Press Inc.","","","","","","10643745","","","25150871","English","Methods Mol. Biol.","Article","Final","","Scopus","2-s2.0-84924348852"
"Zolotov S.; Ben Yosef D.; Rishe N.D.; Yesha Y.; Karnieli E.","Zolotov, Sagit (47461716500); Ben Yosef, Dafna (47461007400); Rishe, Naphtali D. (7003524019); Yesha, Yelena (7004127331); Karnieli, Eddy (24080241000)","47461716500; 47461007400; 7003524019; 7004127331; 24080241000","Metabolic profiling in personalized medicine: Bridging the gap between knowledge and clinical practice in type 2 diabetes","2011","Personalized Medicine","8","4","","445","456","11","6","10.2217/pme.11.36","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960948909&doi=10.2217%2fpme.11.36&partnerID=40&md5=cbd08b1d1ef11f1f00020831dd7907d2","RB Rappaport Faculty of Medicine - Technion, Institue of Endocrinology, Diabetes and Metabolism, Sami Ofer Tower, Haifa 31096, 12 Ha'alya St, Israel; Florida International University, FL, United States; University of Maryland, Baltimore County, MD, United States","Zolotov S., RB Rappaport Faculty of Medicine - Technion, Institue of Endocrinology, Diabetes and Metabolism, Sami Ofer Tower, Haifa 31096, 12 Ha'alya St, Israel; Ben Yosef D., RB Rappaport Faculty of Medicine - Technion, Institue of Endocrinology, Diabetes and Metabolism, Sami Ofer Tower, Haifa 31096, 12 Ha'alya St, Israel; Rishe N.D., Florida International University, FL, United States; Yesha Y., University of Maryland, Baltimore County, MD, United States; Karnieli E., RB Rappaport Faculty of Medicine - Technion, Institue of Endocrinology, Diabetes and Metabolism, Sami Ofer Tower, Haifa 31096, 12 Ha'alya St, Israel","Type 2 diabetes mellitus (DM2) is the most commonly diagnosed metabolic disease and its prevalence is expected to increase. Epidemiological studies clearly show excess mortality associated with DM2, as well as an increased risk of DM2-related complications. Advances in personalized medicine would greatly improve patient care in the field of diabetes and other metabolic diseases. Prediction of the disease in asymptomatic patients as well as its harsh complications in patients already diagnosed is becoming a necessity, with the considerable increase in the cost of the treatment. In the current article, we review the known clinical, molecular metabolic and genetic biomarkers that should be integrated in a future bioinformatic platform to be used at the point-of-care, and discuss the challenges we face in applying this vision of personalized medicine for diabetes into reality. © 2011 Future Medicine Ltd.","biomarkers; decision support system; diabetes; metabolic profiling; personalized medicine; prediction","2,4 thiazolidinedione derivative; adiponectin; alpha glucosidase inhibitor; amylin derivative; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; biguanide derivative; biological marker; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; dipeptidyl peptidase IV inhibitor; diuretic agent; endothelial leukocyte adhesion molecule 1; endothelial nitric oxide synthase; gliclazide; glimepiride; glucose; haptoglobin; hemoglobin A1c; hydroxymethylglutaryl coenzyme A reductase inhibitor; incretin; insulin; intercellular adhesion molecule 1; lipoprotein A; meglitinide; metformin; sex hormone binding globulin; sulfonylurea derivative; triacylglycerol; vascular cell adhesion molecule 1; bioinformatics; cardiovascular disease; clinical practice; drug elimination; drug metabolism; family history; genetic variability; genotype; glucose blood level; human; hyperlipidemia; hypertension; immobilization; lifestyle modification; mass spectrometry; medical practice; metabolic syndrome X; microalbuminuria; mortality; non insulin dependent diabetes mellitus; nuclear magnetic resonance spectroscopy; obesity; patient care; personalized medicine; priority journal; review; risk assessment; single nucleotide polymorphism; treatment response","","adiponectin, 283182-39-8; endothelial leukocyte adhesion molecule 1, 128875-25-2; endothelial nitric oxide synthase, 503473-02-7; gliclazide, 21187-98-4; glimepiride, 93479-97-1; glucose, 50-99-7, 84778-64-3; haptoglobin, 9087-69-8; hemoglobin A1c, 62572-11-6; insulin, 9004-10-8; intercellular adhesion molecule 1, 126547-89-5; meglitinide, 54870-28-9; metformin, 1115-70-4, 657-24-9","","","National Science Foundation, NSF, (0931517)","","Huang E.S., Basu A., O'Grady M., Capretta J.C., Projecting the future diabetes population size and related costs for the US, Diabetes Care, 32, pp. 2225-2229, (2009); Update of ADAs major position statement standards of medical care in diabetes introduction, Diabetes Care, 34, 1, (2011); Franco O.H., Steyerberg E.W., Hu F.B., Mackenbach J., Nusselder W., Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease, Archives of Internal Medicine, 167, 11, pp. 1145-1151, (2007); Gu K., Cowie C.C., Harris M.I., Mortality in adults with and without diabetes in a National cohort of the U.S. Population, 1971-1993, Diabetes Care, 21, 7, pp. 1138-1145, (1998); Lutgers H.L., Gerrits E.G., Sluiter W.J., Et al., Life expectancy in a large cohort of type 2 diabetes patients treated in primary care ZODIAC-10, PLoS ONE, 4, 8, (2009); Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, New England Journal of Medicine, 346, 6, pp. 393-403, (2002); Tai E.S., Goh S.Y., Lee J.J.M., Wong M.-S., Heng D., Hughes K., Chew S.K., Cutter J., Chew W., Gu K., Chia K.S., Tan C.E., Lowering the criterion for impaired fasting glucose: Impact on disease prevalence and associated risk of diabetes and ischemic heart disease, Diabetes Care, 27, 7, pp. 1728-1734, (2004); Schriger D.L., Lorber B., Lowering the cut point for impaired fasting glucose: Where is the evidence where is the logic, Diabetes Care, 27, pp. 592-601, (2004); Tirosh A., Shai I., Tekes-Manova D., Israeli E., Pereg D., Shochat T., Kochba I., Rudich A., Normal fasting plasma glucose levels and type 2 diabetes in young men, New England Journal of Medicine, 353, 14, pp. 1454-1462, (2005); Tirosh A., Shai I., Bitzur R., Et al., Changes in triglyceride levels over time and risk of type 2 diabetes in young men, Diabetes Care, 31, pp. 2032-2037, (2008); Polderman K.H., Gooren L.J.G., Asscheman H., Bakker A., Heine R.J., Induction of insulin resistance by androgens and estrogens, Journal of Clinical Endocrinology and Metabolism, 79, 1, pp. 265-271, (1994); Golden S.H., Dobs A.S., Vaidya D., Szklo M., Gapstur S., Kopp P., Liu K., Ouyang P., Endogenous sex hormones and glucose tolerance status in postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 92, 4, pp. 1289-1295, (2007); Ding E.L., Song Y., Manson J.E., Et al., Sex hormone-binding globulin and risk of type 2 diabetes in women and men, N. Engl. J. Med., 361, pp. 1152-1163, (2009); Albertini J.-P., Valensi P., Lormeau B., Aurousseau M.-H., Ferriere F., Attali J.-R., Gattegno L., Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM: Effect of intensive insulin treatment, Diabetes Care, 21, 6, pp. 1008-1013, (1998); Meigs J.B., Hu F.B., Rifai N., Manson J.E., Biomarkers of endothelial dysfunction and risk of Type 2 diabetes mellitus, Journal of the American Medical Association, 291, 16, pp. 1978-1986, (2004); Sladek R., Rocheleau G., Rung J., Et al., A genome-wide association study identifies novel risk loci for type 2 diabetes, Nature, 445, pp. 881-885, (2007); Meigs J.B., Shrader P., Sullivan L.M., Et al., Genotype score in addition to common risk factors for prediction of type 2 diabetes, N. Engl. J. Med., 359, pp. 2208-2219, (2008); Lyssenko V., Jonsson A., Almgren P., Et al., Clinical risk factors DNA variants and the development of type 2 diabetes, N. Engl. J. Med., 359, pp. 2220-2232, (2008); Lindstrom J., Tuomilehto J., The diabetes risk score: A practical tool to predict type 2 diabetes risk, Diabetes Care, 26, 3, pp. 725-731, (2003); Grant R.W., Moore A.F., Florez J.C., Genetic architecture of type 2 diabetes: Recent progress and clinical implications, Diabetes Care, 32, pp. 1107-1114, (2009); Wang J., Stancakova A., Kuusisto J., Laakso M., Identification of undiagnosed type 2 diabetic individuals by the finnish diabetes risk score and biochemical and genetic markers: A population-based study of 7232 Finnish men, J. Clin. Endocrinol. Metab., 95, pp. 3858-3862, (2010); De Miguel-Yanes J., Shrader P., Pencina M., Et al., Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms, Diabetes Care, 34, pp. 121-125, (2011); Lucio M., Fekete A., Weigert C., Et al., Insulin sensitivity is reflected by characteristic metabolic fingerprints-a fourier transform mass spectrometric non-targeted metabolomics approach, PLoS ONE, 5, (2010); Feero W.G., Guttmacher A.E., McCarthy M.I., Genomics type 2 diabetes and obesity, N. Engl. J. Med., 363, pp. 2339-2350, (2010); Gallagher E.J., Leroith D., Karnieli E., Insulin resistance in obesity as the underlying cause for the metabolic syndrome, Mt. Sinai. J. Med., 77, pp. 511-523, (2010); Cheng A.Y., Leiter L.A., Cardiovascular risk and glycemic control, CMAJ, 180, pp. 907-908, (2009); Duckworth W., Abraira C., Moritz T., Et al., Glucose control and vascular complications in veterans with type 2 diabetes, N. Engl. J. Med., 360, pp. 129-139, (2009); Ceriello A., Hanefeld M., Leiter L., Monnier L., Moses A., Owens D., Tajima N., Tuomilehto J., Postprandial glucose regulation and diabetic complications, Archives of Internal Medicine, 164, 19, pp. 2090-2095, (2004); Nathan D.M., Cleary P.A., Backlund J.-Y.C., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, New England Journal of Medicine, 353, 25, pp. 2643-2653, (2005); Friedewald W.T., Buse J.B., Bigger J.T., Byington R.P., Cushman W.C., Gerstein H.C., Ginsberg H.N., Goff Jr. D.C., Grimm Jr. R.H., Ismail-Beigi F., Probstfield J.L., Simons-Morton D.G., Effects of intensive glucose lowering in type 2 diabetes, New England Journal of Medicine, 358, 24, pp. 2545-2559, (2008); Chiasson J.-L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial, Journal of the American Medical Association, 290, 4, pp. 486-494, (2003); Hernandez C., Francisco G., Chacon P., Simo R., Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: A 10-year follow-up study, Diabetes Care, 28, 4, pp. 931-933, (2005); Kollerits B., Auinger M., Reisig V., Kastenbauer T., Lingenhel A., Irsigler K., Prager R., Kronenberg F., Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes, Diabetes Care, 29, 7, pp. 1661-1663, (2006); Danesh J., Collins R., Peto R., Lipoprotein a and coronary heart disease meta-analysis of prospective studies, Circulation, 102, pp. 1082-1085, (2000); Abu-Lebdeh H.S., Hodge D.O., Nguyen T.T., Predictors of macrovascular disease in patients with type 2 diabetes mellitus, Mayo Clin. Proc., 76, pp. 707-712, (2001); Sunayama S., Daida H., Mokuno H., Miyano H., Yokoi H., Lee Y.J., Sakurai H., Yamaguchi H., Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women ≤55 years of age, Circulation, 94, 6, pp. 1263-1268, (1996); Mogensen C.E., Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes, New England Journal of Medicine, 310, 6, pp. 356-360, (1984); De Zeeuw D., Albuminuria not only a cardiovascular renal risk marker but also a target for treatment, Kidney Int. Suppl., 92, (2004); Messent J.W., Elliott T.G., Hill R.D., Jarrett R.J., Keen H., Viberti G.C., Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study, Kidney Int., 41, pp. 836-839, (1992); Agewall S., Wikstrand J., Ljungman S., Fagerberg B., Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus, American Journal of Cardiology, 80, 2, pp. 164-169, (1997); Mollsten A., Lajer M., Jorsal A., Tarnow L., The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes, Mol. Genet. Metab., 97, pp. 80-84, (2009); Qi L., Doria A., Manson J.E., Meigs J.B., Hunter D., Mantzoros C.S., Hu F.B., Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes, Diabetes, 55, 5, pp. 1512-1516, (2006); Distefano J.K., Watanabe R.M., Pharmacogenetics of anti-diabetes drugs, Pharmaceuticals Basel., 3, pp. 2610-2646, (2010); Nathan D.M., Buse J.B., Davidson M.B., Et al., Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the american diabetes association and the european association for the study of diabetes, Diabetologia, 52, pp. 17-30, (2009); Standards of medical care in diabetes-2010, Diabetes Care, 33, 1, (2010); Pearson E.R., Pharmacogenetics in diabetes, Curr. Diab. Rep., 9, pp. 172-181, (2009); Hutson S., Researchers sound alarm on silent drug interactions, Nat. Med., 17, (2011); Zhou M., Xia L., Wang J., Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine, Drug Metabolism and Disposition, 35, 10, pp. 1956-1962, (2007); Kimura N., Masuda S., Tanihara Y., Et al., Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1, Drug. Metab. Pharmacokinet., 20, pp. 379-386, (2005); Wang D.-S., Jonker J.W., Kato Y., Kusuhara H., Schinkel A.H., Sugiyama Y., Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin, Journal of Pharmacology and Experimental Therapeutics, 302, 2, pp. 510-515, (2002); Shu Y., Sheardown S.A., Brown C., Owen R.P., Zhang S., Castro R.A., Ianculescu A.G., Yue L., Lo J.C., Burchard E.G., Brett C.M., Giacomini K.M., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action, Journal of Clinical Investigation, 117, 5, pp. 1422-1431, (2007); Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E., Role of AMP-activated protein kinase in mechanism of metformin action, Journal of Clinical Investigation, 108, 8, pp. 1167-1174, (2001); Kim Y.D., Park K.G., Lee Y.S., Et al., Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP, Diabetes, 57, pp. 306-314, (2008); Shaw R.J., Lamia K.A., Vasquez D., Koo S.-H., Bardeesy N., DePinho R.A., Montminy M., Cantley L.C., Medicine: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin, Science, 310, 5754, pp. 1642-1646, (2005); Jablonski K.A., McAteer J.B., De Bakker P.I., Et al., Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program, Diabetes, 59, pp. 2672-2681, (2010); Marchetti P., Scharp D.W., Giannarelli R., Benzi L., Cecchetti P., Ciccarone A.M., Lacy P.E., Navalesi R., Metformin potentiates glucose-stimulated insulin secretion [3], Diabetes Care, 19, 7, pp. 781-782, (1996); Marchetti P., Lupi R., Del Guerra S., Et al., Goals of treatment for type 2 diabetes: B-cell preservation for glycemic control, Diabetes Care, 32, 2, (2009); Maida A., Lamont B.J., Cao X., Drucker D.J., Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-a in mice, Diabetologia, 54, 2, pp. 339-349, (2011); Pearson E.R., Starkey B.J., Powell R.J., Gribble F.M., Clark P.M., Hattersley A.T., Genetic cause of hyperglycaemia and response to treatment in diabetes, Lancet, 362, 9392, pp. 1275-1281, (2003); Blum S., Vardi M., Brown J.B., Et al., Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype, Pharmacogenomics, 11, pp. 675-684, (2010); Feng Y., Mao G., Ren X., Et al., Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in chinese type 2 diabetic patients, Diabetes Care, 31, pp. 1939-1944, (2008); Yusuf S., Vitamin E supplementation and cardiovascular events in high-risk patients, New England Journal of Medicine, 342, 3, pp. 154-160, (2000); Bain J.R., Stevens R.D., Wenner B.R., Et al., Metabolomics applied to diabetes research: Moving from information to knowledge, Diabetes, 58, pp. 2429-2443, (2009); Modan M., Halkin H., Karasik A., Lusky A., Elevated serum uric acid - A facet of hyperinsulinaemia, Diabetologia, 30, 9, pp. 713-718, (1987); Huffman K.M., Shah S.H., Stevens R.D., Et al., Relationships between circulating metabolic intermediates and insulin action in overweight to obese inactive men and women, Diabetes Care, 32, pp. 1678-1683, (2009); Hamburg M.A., Collins F.S., The path to personalized medicine, N. Engl. J. Med., 363, pp. 301-304, (2010)","E. Karnieli; RB Rappaport Faculty of Medicine - Technion, Institue of Endocrinology, Diabetes and Metabolism, Sami Ofer Tower, Haifa 31096, 12 Ha'alya St, Israel; email: eddy@tx.technion.ac.il","","","","","","","","1744828X","","","","English","Personalized Med.","Review","Final","","Scopus","2-s2.0-79960948909"
"Lamoth F.; Lewis R.E.; Walsh T.J.; Kontoyiannis D.P.","Lamoth, Frederic (16033216900); Lewis, Russell E (7404846664); Walsh, Thomas J (57216999195); Kontoyiannis, Dimitrios P (35377023000)","16033216900; 7404846664; 57216999195; 35377023000","Navigating the Uncertainties of COVID-19-Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis","2021","Journal of Infectious Diseases","224","10","","1631","1640","9","56","10.1093/infdis/jiab163","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124018822&doi=10.1093%2finfdis%2fjiab163&partnerID=40&md5=2500f59b354887781ac50b11d735d9da","Infectious Diseases Service and Institute of Microbiology, University Hospital of Lausanne and Lausanne University, Lausanne, Switzerland; Clinic of Infectious Diseases, S'Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine of Cornell University, New York, NY, United States; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States","Lamoth F., Infectious Diseases Service and Institute of Microbiology, University Hospital of Lausanne and Lausanne University, Lausanne, Switzerland; Lewis R.E., Clinic of Infectious Diseases, S'Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Walsh T.J., Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine of Cornell University, New York, NY, United States; Kontoyiannis D.P., Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States","Invasive pulmonary aspergillosis (IPA) is increasingly recognized as a life-threatening superinfection of severe respiratory viral infections, such as influenza. The pandemic of Coronavirus Disease 2019 (COVID-19) due to emerging SARS-CoV-2 rose concern about the eventuality of IPA complicating COVID-19 in intensive care unit patients. A variable incidence of such complication has been reported, which can be partly attributed to differences in diagnostic strategy and IPA definitions, and possibly local environmental/epidemiological factors. In this article, we discuss the similarities and differences between influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA). Compared to IAPA, the majority of CAPA cases have been classified as putative rather than proven/probable IPA. Distinct physiopathology of influenza and COVID-19 may explain these discrepancies. Whether CAPA represents a distinct entity is still debatable and many questions remain unanswered, such as its actual incidence, the predisposing role of corticosteroids or immunomodulatory drugs, and the indications for antifungal therapy. © 2021 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.","acute respiratory distress syndrome; Aspergillus fumigates; corticosteroids; flu; intensive care unit; mechanical ventilation; pneumonia; SARS-CoV-2","Antifungal Agents; Aspergillosis; COVID-19; Humans; Influenza, Human; Invasive Pulmonary Aspergillosis; Pulmonary Aspergillosis; SARS-CoV-2; amphotericin B; anakinra; angiotensin converting enzyme 2; autoantibody; azithromycin; corticosteroid; dexamethasone; echinocandin; hydrocortisone; immunomodulating agent; interleukin 10; interleukin 1beta; interleukin 6; liposome; oseltamivir; posaconazole; procalcitonin; remdesivir; tocilizumab; toll like receptor 2; tumor necrosis factor; voriconazole; antifungal agent; adult respiratory distress syndrome; antifungal therapy; artificial ventilation; aspergillosis; Aspergillus fumigatus; autopsy; bronchiectasis; bronchopneumonia; bronchoscopy; complement activation; computer assisted tomography; coronavirus disease 2019; critically ill patient; extracellular trap; genetic transfection; hospitalization; host pathogen interaction; hypertension; immune response; incidence; influenza; influenza B; innate immunity; intensive care unit; invasive aspergillosis; invasive pulmonary aspergillosis; lung alveolus epithelium cell; lung aspergillosis; lung lavage; lymphocytopenia; microbial community; microvascular thrombosis; mortality; mucormycosis; nebulization; obesity; pandemic; pathophysiology; pneumonia; polymerase chain reaction; Review; risk factor; Severe acute respiratory syndrome coronavirus 2; signal transduction; single nucleotide polymorphism; Staphylococcus aureus; Streptococcus pneumoniae; superinfection; Th1 cell; tracheobronchitis; tuberculosis; uncertainty; viral respiratory tract infection; aspergillosis; complication; human; influenza; invasive aspergillosis; lung aspergillosis","","amphotericin B, 1397-89-3, 30652-87-0; anakinra, 143090-92-0; azithromycin, 83905-01-5, 117772-70-0, 121470-24-4; dexamethasone, 50-02-2; echinocandin, 80619-41-6; hydrocortisone, 50-23-7; oseltamivir, 196618-13-0, 204255-09-4, 204255-11-8; posaconazole, 171228-49-2; procalcitonin, 56645-65-9; remdesivir, 1809249-37-3; tocilizumab, 375823-41-9; toll like receptor 2, 203811-81-8; voriconazole, 137234-62-9, 188416-29-7; Antifungal Agents, ","","","Henry Schueler Foundation; Save Our Sick Kids Foundation","This work was supported by the Henry Schueler Foundation and the Save Our Sick Kids Foundation (to T. J. W.).","Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E., Invasive aspergillosis in critically ill patients without malignancy, Am J Respir Crit Care Med, 170, pp. 621-625, (2004); Garcia-Vidal C, Barba P, Arnan M, Et al., Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients, Clin Infect Dis, 53, pp. e16-e19, (2011); Schauwvlieghe AFAD, Rijnders BJA, Philips N, Et al., Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study, Lancet Respir Med, 6, pp. 782-792, (2018); Wauters J, Baar I, Meersseman P, Et al., Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study, Intensive Care Med, 38, pp. 1761-1768, (2012); Bartoletti M, Pascale R, Cricca M, Et al., Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study, Clin Infect Dis; Borman AM, Palmer MD, Fraser M, Et al., COVID-19 associated invasive aspergillosis: data from the UK National Mycology Reference Laboratory, J Clin Microbiol, 59, pp. e02136-20, (2020); Fekkar A, Lampros A, Mayaux J, Et al., Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU, Am J Respir Crit Care Med, 203, pp. 307-317, (2021); Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL., Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients, Clin Microbiol Infect, 26, pp. 1706-1708, (2020); Marr KA, Platt A, Tornheim JA, Et al., Aspergillosis complicating severe coronavirus disease, Emerg Infect Dis, 27, pp. 18-25, (2021); Mohamed A, Rogers TR, Talento AF., COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges, J Fungi (Basel), 6, (2020); Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J., Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment, Curr Opin Infect Dis, 31, pp. 471-480, (2018); Donnelly JP, Chen SC, Kauffman CA, Et al., Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium, Clin Infect Dis, 71, pp. 1367-1376, (2020); Sharma A, Mishra T, Kumar N, Soubani AO., Influenzaassociated aspergillosis: nationwide trends, predictors and outcomes from 2005 to 2014, Chest, 158, pp. 1857-1866, (2020); Blot SI, Taccone FS, Van den Abeele AM, Et al., A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients, Am J Respir Crit Care Med, 186, pp. 56-64, (2012); Verweij PE, Rijnders BJA, Bruggemann RJM, Et al., Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion, Intensive Care Med, 46, pp. 1524-1535, (2020); Permpalung N, Chiang TP, Massie AB, Et al., COVID-19 associated pulmonary aspergillosis in mechanically ventilated patients, Clin Infect Dis; Abbott JD, Fernando HV, Gurling K, Meade BW., Pulmonary aspergillosis following post-influenzal bronchopneumonia treated with antibiotics, Br Med J, 1, pp. 523-525, (1952); Schwartz IS, Friedman DZP, Zapernick L, Et al., High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta, Canada, Clin Infect Dis, 71, pp. 1760-1763, (2020); Coste A, Frerou A, Raute A, Et al., The extend of aspergillosis in critically ill patients with severe influenza pneumonia: a multicenter cohort study, Crit Care Med, 49, pp. 934-942, (2021); Huang L, He H, Ding Y, Jin J, Zhan Q., Values of radiological examinations for the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary diseases, Clin Respir J, 12, pp. 499-509, (2018); Loughlin L, Hellyer TP, White PL, Et al., Pulmonary aspergillosis in patients with suspected ventilator-associated pneumonia in UK ICUs, Am J Respir Crit Care Med, 202, pp. 1125-1132, (2020); Alanio A, Delliere S, Fodil S, Bretagne S, Megarbane B., Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19, Lancet Respir Med, 8, pp. e48-e49, (2020); Koehler P, Cornely OA, Bottiger BW, Et al., COVID-19 associated pulmonary aspergillosis, Mycoses, 63, pp. 528-534, (2020); Rutsaert L, Steinfort N, Van Hunsel T, Et al., COVID-19- associated invasive pulmonary aspergillosis, Ann Intensive Care, 10, (2020); Segrelles-Calvo G, Araujo GRS, Llopis-Pastor E, Et al., Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia, Mycoses, 64, pp. 144-151, (2021); van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG., COVID- 19-associated pulmonary aspergillosis, Am J Respir Crit Care Med, 202, pp. 132-135, (2020); White PL, Dhillon R, Cordey A, Et al., A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU, Clin Infect Dis; Lamoth F, Alexander BD., Nonmolecular methods for the diagnosis of respiratory fungal infections, Clin Lab Med, 34, pp. 315-336, (2014); Liu WD, Lin SW, Shih MC, Et al., False-positive Aspergillus galactomannan immunoassays associated with intravenous human immunoglobulin administration, Clin Microbiol Infect, 26, pp. 1555e9-e14, (2020); Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J., Pulmonary pathology of severe acute respiratory syndrome in Toronto, Mod Pathol, 18, pp. 1-10, (2005); Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W., Fatal aspergillosis in a patient with SARS who was treated with corticosteroids, N Engl J Med, 349, pp. 507-508, (2003); van de Veerdonk FL, Kolwijck E, Lestrade PP, Et al., Influenza-associated aspergillosis in critically ill patients, Am J Respir Crit Care Med, 196, pp. 524-527, (2017); Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP., Outcomes in invasive pulmonary aspergillosis infections complicated by respiratory viral infections in patients with hematologic malignancies: a case-control study, Open Forum Infect Dis, 6, (2019); Nyga R, Maizel J, Nseir S, Et al., Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza. a clinical trial, Am J Respir Crit Care Med, 202, pp. 708-716, (2020); van de Veerdonk FL, Wauters J, Verweij PE., Invasive Aspergillus tracheobronchitis emerging as a highly lethal complication of severe influenza, Am J Respir Crit Care Med, 202, pp. 646-648, (2020); Shah MM, Hsiao EI, Kirsch CM, Gohil A, Narasimhan S, Stevens DA., Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature, Diagn Microbiol Infect Dis, 91, pp. 147-152, (2018); Falces-Romero I, Ruiz-Bastian M, Diaz-Pollan B, Maseda E, Garcia-Rodriguez J, Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital, Mycoses; Cheng Z, Lu Y, Cao Q, Et al., Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID- 19) in a single-center study in Shanghai, China, AJR Am J Roentgenol, 215, pp. 121-126, (2020); Koehler P, Bassetti M, Chakrabarti A, Et al., Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance, Lancet Infect Dis; Flikweert AW, Grootenboers MJJH, Yick DCY, Et al., Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series, J Crit Care, 59, pp. 149-155, (2020); Schurink B, Roos E, Radonic T, Et al., Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study, Lancet Microbe, 1, pp. e290-e299, (2020); Kula BE, Clancy CJ, Nguyen MH, Schwartz IS., Invasive mould disease in fatal COVID-19: a systematic review of autopsies, Lancet Microbe, 2, pp. e405-e414, (2021); Stergiopoulou T, Meletiadis J, Roilides E, Et al., Hostdependent patterns of tissue injury in invasive pulmonary aspergillosis, Am J Clin Pathol, 127, pp. 349-355, (2007); Delliere S, Dudoignon E, Fodil S, Et al., Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort, Clin Microbiol Infect; Crum-Cianflone NF., Invasive aspergillosis associated with severe influenza infections, Open Forum Infect Dis, 3, (2016); Tobin JM, Nickolich KL, Ramanan K, Et al., Influenza suppresses neutrophil recruitment to the lung and exacerbates secondary invasive pulmonary aspergillosis, J Immunol, 205, pp. 480-488, (2020); Yu X, Zhang X, Zhao B, Et al., Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6, PLoS One, 6, (2011); Roilides E, Dimitriadou A, Kadiltsoglou I, Et al., IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus, J Immunol, 158, pp. 322-329, (1997); Roilides E, Sein T, Roden M, Schaufele RL, Walsh TJ., Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis, J Infect Dis, 183, pp. 518-520, (2001); Cunha C, Goncalves SM, Duarte-Oliveira C, Et al., IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity, J Allergy Clin Immunol, 140, pp. 867-870, (2017); Morens DM, Taubenberger JK, Fauci AS., Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness, J Infect Dis, 198, pp. 962-970, (2008); Zhou F, Li H, Gu L, Et al., Risk factors for nosocomial infection among hospitalised severe influenza A(H1N1)pdm09 patients, Respir Med, 134, pp. 86-91, (2018); Kalil AC, Thomas PG., Influenza virus-related critical illness: pathophysiology and epidemiology, Crit Care, 23, (2019); Arastehfar A, Carvalho A, van de Veerdonk FL, Et al., COVID-19 associated pulmonary aspergillosis (CAPA)- from immunology to treatment, J Fungi (Basel), 6, (2020); Huang G, Kovalic AJ, Graber CJ., Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity, Emerg Infect Dis, 26, pp. 1839-1841, (2020); Liang Y, Li H, Li J, Et al., Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in an in vivo hACE2 transfection mouse model, Zool Res, 41, pp. 621-631, (2020); Valdivia-Mazeyra MF, Salas C, Nieves-Alonso JM, Et al., Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature, Virchows Arch, 478, pp. 487-496, (2021); Lee JS, Park S, Jeong HW, Et al., Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19, Sci Immunol, 5, (2020); Nagai H, Guo J, Choi H, Kurup V., Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis, J Infect Dis, 172, pp. 1554-1560, (1995); Eriksson O, Hultstrom M, Persson B, Et al., Mannose-binding lectin is associated with thrombosis and coagulopathy in critically ill COVID-19 patients, Thromb Haemost, 120, pp. 1720-1724, (2020); Holter JC, Pischke SE, de Boer E, Et al., Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients, Proc Natl Acad Sci U S A, 117, pp. 25018-25025, (2020); Dumestre-Perard C, Lamy B, Aldebert D, Et al., Aspergillus conidia activate the complement by the mannan-binding lectin C2 bypass mechanism, J Immunol, 181, pp. 7100-7105, (2008); Lambourne J, Agranoff D, Herbrecht R, Et al., Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients, Clin Infect Dis, 49, pp. 1486-1491, (2009); Clancy CJ, Nguyen MH., Coronavirus disease 2019, superinfections, and antimicrobial development: What can we expect?, Clin Infect Dis, 71, pp. 2736-2743, (2020); Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Et al., Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study, Clin Microbiol Infect, 27, pp. 83-88, (2021); Lansbury L, Lim B, Baskaran V, Lim WS., Co-infections in people with COVID-19: a systematic review and metaanalysis, J Infect, 81, pp. 266-275, (2020); Baddley JW, Andes DR, Marr KA, Et al., Factors associated with mortality in transplant patients with invasive aspergillosis, Clin Infect Dis, 50, pp. 1559-1567, (2010); Lionakis MS, Kontoyiannis DP., Glucocorticoids and invasive fungal infections, Lancet, 362, pp. 1828-1838, (2003); Lamoth F, Calandra T., Let's add invasive aspergillosis to the list of influenza complications, Lancet Respir Med, 6, pp. 733-735, (2018); Zhang Y, Sun W, Svendsen ER, Et al., Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis, Crit Care, 19, (2015); Dewi IMW, Cunha C, Vanderbeke L., Oseltamivir affects host defense against invasive pulmonary aspergillosis, 28th European Congress of Clinical Microbiology and Infectious Diseases, (2018); Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP., Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice, Antimicrob Agents Chemother, 51, pp. 1078-1081, (2007); Horby P, Lim WS, Et al., Dexamethasone in hospitalized patients with Covid-19, N Engl J Med, 384, pp. 693-704, (2021); Sterne JAC, Murthy S, Diaz JV, Et al., Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA, 324, pp. 1330-1341, (2020); Pawar A, Desai RJ, Solomon DH, Et al., Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study, Ann Rheum Dis, 78, pp. 456-464, (2019); Huang E, Jordan SC., Tocilizumab for Covid-19-the ongoing search for effective therapies, N Engl J Med, 383, pp. 2387-2388, (2020); Million M, Lagier JC, Gautret P, Et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, 35, (2020); Espinosa V, Dutta O, McElrath C, Et al., Type III interferon is a critical regulator of innate antifungal immunity, Sci Immunol, 2, (2017); Bastard P, Rosen LB, Zhang Q, Et al., Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science, 370, (2020); Toda M, Beekmann SE, Polgreen PM, Chiller TM, Jackson BR, Beer KD., Knowledge of infectious disease specialists regarding aspergillosis complicating influenza, United States, Emerg Infect Dis, 26, pp. 809-811, (2020)","D.P. Kontoyiannis; Division of Internal Medicine, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, 1515 Holcombe Boulevard, 77030, United States; email: dkontoyi@mdanderson.org","","Oxford University Press","","","","","","00221899","","JIDIA","33770176","English","J. Infect. Dis.","Review","Final","All Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-85124018822"
"Cole-Jeffrey C.T.; Liu M.; Katovich M.J.; Raizada M.K.; Shenoy V.","Cole-Jeffrey, Colleen T. (54585071400); Liu, Meng (56783277600); Katovich, Michael J. (7006664221); Raizada, Mohan K. (7102201054); Shenoy, Vinayak (15846918200)","54585071400; 56783277600; 7006664221; 7102201054; 15846918200","ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy","2015","Journal of Cardiovascular Pharmacology","66","6","","540","550","10","82","10.1097/FJC.0000000000000307","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84950298185&doi=10.1097%2fFJC.0000000000000307&partnerID=40&md5=407ff64812abdcbe5921fe33af3bd5a7","Department of Physiology and Functional Genomics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, FL, United States; Department of Pharmacodynamics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, 32610, FL, United States","Cole-Jeffrey C.T., Department of Physiology and Functional Genomics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, FL, United States; Liu M., Department of Physiology and Functional Genomics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, FL, United States; Katovich M.J., Department of Pharmacodynamics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, 32610, FL, United States; Raizada M.K., Department of Physiology and Functional Genomics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, FL, United States; Shenoy V., Department of Pharmacodynamics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, 32610, FL, United States","The health of the cardiovascular and pulmonary systems is inextricably linked to the renin-angiotensin system (RAS). Physiologically speaking, a balance between the vasodeleterious (Angiotensin-converting enzyme [ACE]/Angiotensin II [Ang II]/Ang II type 1 receptor [AT 1R ]) and vasoprotective (Angiotensin-converting enzyme 2 [ACE2]/Angiotensin-(1-7) [Ang-(1-7)]/Mas receptor [MasR]) components of the RAS is critical for cardiopulmonary homeostasis. Upregulation of the ACE/Ang II/AT 1 R axis shifts the system toward vasoconstriction, proliferation, hypertrophy, inflammation, and fibrosis, all factors that contribute to the development and progression of cardiopulmonary diseases. Conversely, stimulation of the vasoprotective ACE2/Ang-(1-7)/MasR axis produces a counter-regulatory response that promotes cardiovascular health. Current research is investigating novel strategies to augment actions of the vasoprotective RAS components, particularly ACE2, in order to treat various pathologies. Although multiple approaches to increase the activity of ACE2 have displayed beneficial effects against experimental disease models, the mechanisms behind its protective actions remain incompletely understood. Recent work demonstrating a non-catalytic role for ACE2 in amino acid transport in the gut has led us to speculate that the therapeutic effects of ACE2 can be mediated, in part, by its actions on the gastrointestinal tract and/or gut microbiome. This is consistent with emerging data which suggest that dysbiosis of the gut and lung microbiomes is associated with cardiopulmonary disease. This review highlights new developments in the protective actions of ACE2 against cardiopulmonary disorders, discusses innovative approaches to targeting ACE2 for therapy, and explores an evolving role for gut and lung microbiota in cardiopulmonary health. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.","ACE2; cardiovascular disease; gut microbiota; pulmonary disease","Animals; Cardiovascular Agents; Drug Delivery Systems; Heart Diseases; Humans; Lung Diseases; Microbiota; Peptidyl-Dipeptidase A; Polymorphism, Genetic; angiotensin converting enzyme 2; angiotensin receptor antagonist; angiotensin[1-7]; beta adrenergic receptor blocking agent; diminazene aceturate; dipeptidyl carboxypeptidase inhibitor; mas receptor; mineralocorticoid antagonist; probiotic agent; reactive oxygen metabolite; recombinant angiotensin converting enzyme 2; recombinant protein; unclassified drug; angiotensin converting enzyme 2; cardiovascular agent; dipeptidyl carboxypeptidase; amino acid transport; Article; brain; cardiovascular disease; enzyme activity; gastrointestinal tract; gene expression; heart failure; heart ventricle hypertrophy; human; hypertension; intestine flora; lung disease; lung fibrosis; lung injury; medication compliance; nonhuman; patient compliance; priority journal; pulmonary hypertension; renin angiotensin aldosterone system; single nucleotide polymorphism; vasoconstriction; animal; drug delivery system; drug effects; enzymology; genetic polymorphism; genetics; Heart Diseases; Lung Diseases; metabolism; microbiology; microflora; physiology; trends","","angiotensin[1-7], 39386-80-6; diminazene aceturate, 908-54-3; dipeptidyl carboxypeptidase, 9015-82-1; angiotensin converting enzyme 2, ; Cardiovascular Agents, ; Peptidyl-Dipeptidase A, ","","","American Heart Association, (14PRE18620024, SDG-12080302); National Institutes of Health, (HL 056921, HL 102033); National Heart, Lung, and Blood Institute, NHLBI, (R01HL056921); National Heart, Lung, and Blood Institute, NHLBI","","Hall J.E., Historical perspective of the renin-angiotensin system, Mol Biotechnol., 24, pp. 27-39, (2003); Paul M., Poyan Mehr A., Kreutz R., Physiology of local renin-angiotensin systems, Physiol Rev., 86, pp. 747-803, (2006); Fliser D., Buchholz K., Haller H., Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation, Circulation., 110, pp. 1103-1107, (2004); Ferrario C.M., Strawn W.B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease, Am J Cardiol., 98, pp. 121-128, (2006); Van Vark L.C., Bertrand M., Akkerhuis K.M., Et al., Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients, Eur Heart J., 33, pp. 2088-2097, (2012); Yancy C.W., Jessup M., Et al., 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, Circulation., 128, pp. e240-e327, (2013); Gavras H., Brunner H.R., Turini G.A., Et al., Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man, N Engl J Med., 298, pp. 991-995, (1978); Konstam M.A., Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure, Eur Heart J., 16, pp. 59-64, (1995); Donoghue M., Hsieh F., Baronas E., Et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin i to angiotensin 1-9, Circ Res., 87, pp. E1-E9, (2000); Tipnis S.R., Hooper N.M., Hyde R., Et al., A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase, J Biol Chem., 275, pp. 33238-33243, (2000); Tallant E.A., Ferrario C.M., Gallagher P.E., Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor, Am J Physiol Heart Circ Physiol., 289, pp. H1560-H1566, (2005); Grobe J.L., Mecca A.P., Mao H., Et al., Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension, Am J Physiol Heart Circ Physiol., 290, pp. H2417-H2423, (2006); Qi Y., Shenoy V., Wong F., Et al., Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology, Exp Physiol., 96, pp. 863-874, (2011); Mehta P.K., Griendling K.K., Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system, Am J Physiol Cell Physiol., 292, pp. C82-C97, (2007); Der Sarkissian S., Grobe J.L., Yuan L., Et al., Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemiainduced pathophysiology, Hypertension., 51, pp. 712-718, (2008); Shenoy V., Ferreira A.J., Qi Y., Et al., The angiotensin-converting enzyme 2/angiogenesis-(1-7)/mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension, Am J Respir Crit Care Med., 182, pp. 1065-1072, (2010); Grobe J.L., Mecca A.P., Lingis M., Et al., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7), Am J Physiol Heart Circ Physiol., 292, pp. H736-H742, (2007); Hernandez Prada J.A., Ferreira A.J., Katovich M.J., Et al., Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents, Hypertension., 51, pp. 1312-1317, (2008); Loot A.E., Roks A.J., Henning R.H., Et al., Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats, Circulation., 105, pp. 1548-1550, (2002); Rodgers K.E., Roda N., Felix J.E., Et al., Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice, Exp Dermatol., 12, pp. 784-790, (2003); Oudit G.Y., Liu G.C., Zhong J., Et al., Human recombinant ACE2 reduces the progression of diabetic nephropathy, Diabetes., 59, pp. 529-538, (2010); Jarajapu Y.P., Bhatwadekar A.D., Caballero S., Et al., Activation of the ACE2/angiotensin-(1-7)/mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors, Diabetes., 62, pp. 1258-1269, (2013); Chen J., Xiao X., Chen S., Et al., Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic efficacy, Hypertension., 61, pp. 681-689, (2013); Yamazato M., Ferreira A.J., Yamazato Y., Et al., Gene transfer of angiotensin-converting enzyme 2 in the nucleus tractus solitarius improves baroreceptor heart rate reflex in spontaneously hypertensive rats, J Renin Angiotensin Aldosterone Syst., 12, pp. 456-461, (2011); Xiao L., Gao L., Lazartigues E., Et al., Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure, Hypertension., 58, pp. 1057-1065, (2011); Yamazato M., Yamazato Y., Sun C., Et al., Overexpression of angiotensinconverting enzyme 2 in the rostral ventrolateral medulla causes longterm decrease in blood pressure in the spontaneously hypertensive rats, Hypertension., 49, pp. 926-931, (2007); Lu N., Yang Y., Wang Y., Et al., ACE2 gene polymorphism and essential hypertension: An updated meta-analysis involving 11,051 subjects, Mol Biol Rep., 39, pp. 6581-6589, (2012); Patel S.K., Wai B., Ord M., Et al., Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes, Am J Hypertens., 25, pp. 216-222, (2012); Lieb W., Graf J., Gotz A., Et al., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA augsburg echocardiographic substudy, J Mol Med (Berl)., 84, pp. 88-96, (2006); Van Der Merwe L., Cloete R., Revera M., Et al., Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy, Hum Genet., 124, pp. 57-61, (2008); Burrell L.M., Harrap S.B., Velkoska E., Et al., The ACE2 gene: Its potential as a functional candidate for cardiovascular disease, Clin Sci (Lond)., 124, pp. 65-76, (2013); Mozaffarian D., Benjamin E.J., Go A.S., Et al., Heart disease and stroke statistics-2015 update: A report from the American Heart Association, Circulation., 131, pp. e29-e322, (2015); Yamamoto K., Ohishi M., Katsuya T., Et al., Deletion of angiotensinconverting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II, Hypertension., 47, pp. 718-726, (2006); Bodiga S., Zhong J.C., Wang W., Et al., Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47 (phox) NADPH oxidase subunit, Cardiovasc Res., 91, pp. 151-161, (2011); Zhong J., Basu R., Guo D., Et al., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction, Circulation., 122, pp. 717-728, (2010); Trask A.J., Groban L., Westwood B.M., Et al., Inhibition of angiotensinconverting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in ren-2 hypertensive rats, Am J Hypertens., 23, pp. 687-693, (2010); Sahara M., Ikutomi M., Morita T., Et al., Deletion of angiotensinconverting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation, Cardiovasc Res., 101, pp. 236-246, (2014); Huentelman M.J., Grobe J.L., Vazquez J., Et al., Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats, Exp Physiol., 90, pp. 783-790, (2005); Johnson J.A., West J., Maynard K.B., Et al., ACE2 improves right ventricular function in a pressure overload model, PLoS One., 6, (2011); Zhao Y.X., Yin H.Q., Yu Q.T., Et al., ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction, Hum Gene Ther., 21, pp. 1545-1554, (2010); Dong B., Yu Q.T., Dai H.Y., Et al., Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy, J Am Coll Cardiol., 59, pp. 739-747, (2012); Burrell L.M., Risvanis J., Kubota E., Et al., Myocardial infarction increases ACE2 expression in rat and humans, Eur Heart J., 26, pp. 369-375, (2005); Cohen-Segev R., Francis B., Abu-Saleh N., Et al., Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure, Acta Histochem., 116, pp. 1342-1349, (2014); Zisman L.S., Keller R.S., Weaver B., Et al., Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme homologue ACE2, Circulation., 108, pp. 1707-1712, (2003); Goulter A.B., Goddard M.J., Allen J.C., Et al., ACE2 gene expression is upregulated in the human failing heart, BMC Med., 2, (2004); Kittleson M.M., Minhas K.M., Irizarry R.A., Et al., Gene expression analysis of ischemic and nonischemic cardiomyopathy: Shared and distinct genes in the development of heart failure, Physiol Genomics., 21, pp. 299-307, (2005); Batlle M., Roig E., Perez-Villa F., Et al., Increased expression of the reninangiotensin system and mast cell density but not of angiotensinconverting enzyme II in late stages of human heart failure, J Heart Lung Transpl., 25, pp. 1117-1125, (2006); Ohtsuki M., Morimoto S., Izawa H., Et al., Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure, Int J Cardiol., 145, pp. 333-334, (2010); Epelman S., Tang W.H., Chen S.Y., Et al., Detection of soluble angiotensinconverting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system, J Am Coll Cardiol., 52, pp. 750-754, (2008); Epelman S., Shrestha K., Troughton R.W., Et al., Soluble angiotensinconverting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes, J Card Fail., 15, pp. 565-571, (2009); Wang Y., Moreira Mda C., Heringer-Walther S., Et al., Plasma ACE2 activity is an independent prognostic marker in chagas' disease and equally potent as BNP, J Card Fail., 16, pp. 157-163, (2010); Ortiz-Perez J.T., Riera M., Bosch X., Et al., Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: A prospective controlled study, PLoS One., 8, (2013); Uri K., Fagyas M., Manyine Siket I., Et al., New perspectives in the reninangiotensin-aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure, PLoS One., 9, (2014); Shao Z., Shrestha K., Borowski A.G., Et al., Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure, J Card Fail., 19, pp. 605-610, (2013); Crackower M.A., Sarao R., Oudit G.Y., Et al., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature., 417, pp. 822-828, (2002); Feng Y., Xia H., Cai Y., Et al., Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension, Circ Res., 106, pp. 373-382, (2010); Kar S., Gao L., Zucker I.H., Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure, J Appl Physiol, 108, pp. 923-932, (1985); Xia H., Lazartigues E., Angiotensin-converting enzyme 2 in the brain: Properties and future directions, J Neurochem., 107, pp. 1482-1494, (2008); Feng Y., Yue X., Xia H., Et al., Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation, Circ Res., 102, pp. 729-736, (2008); Sriramula S., Cardinale J.P., Lazartigues E., Et al., ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension, Cardiovasc Res., 92, pp. 401-408, (2011); Xia H., Suda S., Bindom S., Et al., ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function, PLoS One., 6, (2011); Jun J.Y., Zubcevic J., Qi Y., Et al., Brain-mediated dysregulation of the bone marrow activity in angiotensin II-induced hypertension, Hypertension., 60, pp. 1316-1323, (2012); Zubcevic J., Jun J.Y., Kim S., Et al., Altered inflammatory response is associated with an impaired autonomic input to the bone marrow in the spontaneously hypertensive rat, Hypertension., 63, pp. 542-550, (2014); Zhang M., Malik A.B., Rehman J., Endothelial progenitor cells and vascular repair, Curr Opin Hematol., 21, pp. 224-228, (2014); Valgimigli M., Rigolin G.M., Fucili A., Et al., CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure, Circulation., 110, pp. 1209-1212, (2004); Fritzenwanger M., Lorenz F., Jung C., Et al., Differential number of CD34 +, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure, Eur J Med Res., 14, pp. 113-117, (2009); Heeschen C., Lehmann R., Honold J., Et al., Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease, Circulation., 109, pp. 1615-1622, (2004); Junhui Z., Xingxiang W., Guosheng F., Et al., Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension, Respir Med., 102, pp. 1073-1079, (2008); Heringer-Walther S., Eckert K., Schumacher S.M., Et al., Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo, Haematologica., 94, pp. 857-860, (2009); Qi Y., Zhang J., Cole-Jeffrey C.T., Et al., Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemiainduced cardiac pathophysiology, Hypertension., 62, pp. 746-752, (2013); Shenoy V., Gjymishka A., Jarajapu Y.P., Et al., Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models, Am J Respir Crit Care Med., 187, pp. 648-657, (2013); He H., Liu L., Chen Q., Et al., Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury, Cell Transplant., 24, pp. 1699-1715, (2014); Liu F., Gao F., Li Q., Et al., The functional study of human umbilical cord mesenchymal stem cells harbouring angiotensin-converting enzyme 2 in rat acute lung ischemia-reperfusion injury model, Cell Biochem Funct., 32, pp. 580-589, (2014); Li W., Moore M.J., Vasilieva N., Et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature., 426, pp. 450-454, (2003); Imai Y., Kuba K., Penninger J.M., The discovery of angiotensinconverting enzyme 2 and its role in acute lung injury in mice, Exp Physiol., 93, pp. 543-548, (2008); Yang P., Gu H., Zhao Z., Et al., Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury, Sci Rep., 4, (2014); Zou Z., Yan Y., Shu Y., Et al., Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections, Nat Commun., 5, (2014); Liu X., Yang N., Tang J., Et al., Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus, Virus Res., 185, pp. 64-71, (2014); Li G., Liu Y., Zhu Y., Et al., ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats, Lung., 191, pp. 327-336, (2013); Yuan Y.M., Luo L., Guo Z., Et al., Activation of renin-angiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats, J Renin Angiotensin Aldosterone Syst., 16, pp. 249-253, (2015); Shenoy V., Kwon K.C., Rathinasabapathy A., Et al., Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, Hypertension., 64, pp. 1248-1259, (2014); De Man F.S., Tu L., Handoko M.L., Et al., Dysregulated renin-angiotensinaldosterone system contributes to pulmonary arterial hypertension, Am J Respir Crit Care Med., 186, pp. 780-789, (2012); Dai H.L., Guo Y., Guang X.F., Et al., The changes of serum angiotensinconverting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease, Cardiology., 124, pp. 208-212, (2013); Dai H., Gong Y., Xiao Z., Et al., Decreased levels of serum angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease, Int J Cardiol., 176, pp. 1399-1401, (2014); Takahashi Y., Haga S., Ishizaka Y., Et al., Autoantibodies to angiotensinconverting enzyme 2 in patients with connective tissue diseases, Arthritis Res Ther., 12, (2010); Yamazato Y., Ferreira A.J., Hong K.H., Et al., Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer, Hypertension., 54, pp. 365-371, (2009); Kleinsasser A., Pircher I., Treml B., Et al., Recombinant angiotensinconverting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia, Wilderness Environ Med., 23, pp. 24-30, (2012); Li X., Molina-Molina M., Abdul-Hafez A., Et al., Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis, Am J Physiol Lung Cell Mol Physiol., 295, pp. L178-L185, (2008); Rey-Parra G.J., Vadivel A., Coltan L., Et al., Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury, J Mol Med (Berl)., 90, pp. 637-647, (2012); Hashimoto T., Perlot T., Rehman A., Et al., ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation, Nature., 487, pp. 477-481, (2012); Harmer D., Gilbert M., Borman R., Et al., Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme, FEBS Lett., 532, pp. 107-110, (2002); Zhang H., Wada J., Hida K., Et al., Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys, J Biol Chem., 276, pp. 17132-17139, (2001); Danilczyk U., Sarao R., Remy C., Et al., Essential role for collectrin in renal amino acid transport, Nature., 444, pp. 1088-1091, (2006); Camargo S.M., Singer D., Makrides V., Et al., Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations, Gastroenterology., 136, pp. 872-882, (2009); Kowalczuk S., Broer A., Tietze N., Et al., A protein complex in the brushborder membrane explains a hartnup disorder allele, FASEB J., 22, pp. 2880-2887, (2008); Murr C., Grammer T.B., Kleber M.E., Et al., Low serum tryptophan predicts higher mortality in cardiovascular disease, Eur J Clin Invest., 45, pp. 247-254, (2015); Karapetyan A.V., Klyachkin Y.M., Selim S., Et al., Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction, Stem Cells Dev., 22, pp. 1645-1656, (2013); Korthuis R.J., Gute D.C., Blecha F., Et al., PR-39, a proline/arginine-rich antimicrobial peptide, prevents postischemic microvascular dysfunction, Am J Physiol., 277, pp. H1007-H1013, (1999); Ikeda Y., Young L.H., Scalia R., Et al., PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion, Cardiovasc Res., 49, pp. 69-77, (2001); Higazi A.A., Lavi E., Bdeir K., Et al., Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells, Blood., 89, pp. 4290-4298, (1997); Higazi A.A., Nassar T., Ganz T., Et al., The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: A new class of inflammatory apolipoprotein and a possible contributor to atherogenesis, Blood., 96, pp. 1393-1398, (2000); Kougias P., Chai H., Lin P.H., Et al., Defensins and cathelicidins: Neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis, J Cell Mol Med., 9, pp. 3-10, (2005); Zhao H., Yan H., Yamashita S., Et al., Acute ST-segment elevation myocardial infarction is associated with decreased human antimicrobial peptide LL-37 and increased human neutrophil peptide-1 to 3 in plasma, J Atheroscler Thromb., 19, pp. 357-368, (2012); Edfeldt K., Agerberth B., Rottenberg M.E., Et al., Involvement of the antimicrobial peptide LL-37 in human atherosclerosis, Arterioscler Thromb Vasc Biol., 26, pp. 1551-1557, (2006); Serino M., Luche E., Chabo C., Et al., Intestinal microflora and metabolic diseases, Diabetes Metab., 35, pp. 262-272, (2009); Galassi A., Reynolds K., He J., Metabolic syndrome and risk of cardiovascular disease: A meta-analysis, Am J Med., 119, pp. 812-819, (2006); Yang T., Santisteban M.M., Rodriguez V., Et al., Gut dysbiosis is linked to hypertension, Hypertension., 65, pp. 1331-1340, (2015); Agerholm-Larsen L., Raben A., Haulrik N., Et al., Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases, Eur J Clin Nutr., 54, pp. 288-297, (2000); Kawase M., Hashimoto H., Hosoda M., Et al., Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure, J Dairy Sci., 83, pp. 255-263, (2000); Naruszewicz M., Johansson M.L., Zapolska-Downar D., Et al., Effect of lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers, Am J Clin Nutr., 76, pp. 1249-1255, (2002); Seppo L., Jauhiainen T., Poussa T., Et al., A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects, Am J Clin Nutr., 77, pp. 326-330, (2003); Aihara K., Kajimoto O., Hirata H., Et al., Effect of powdered fermented milk with lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension, J Am Coll Nutr., 24, pp. 257-265, (2005); Dong J.Y., Szeto I.M., Makinen K., Et al., Effect of probiotic fermented milk on blood pressure: A meta-analysis of randomised controlled trials, Br J Nutr., 110, pp. 1188-1194, (2013); Chen Y., Liu W., Xue J., Et al., Angiotensin-converting enzyme inhibitory activity of lactobacillus helveticus strains from traditional fermented dairy foods and antihypertensive effect of fermented milk of strain H9, J Dairy Sci., 97, pp. 6680-6692, (2014); Khalesi S., Sun J., Buys N., Et al., Effect of probiotics on blood pressure: A systematic review and meta-analysis of randomized, controlled trials, Hypertension., 64, pp. 897-903, (2014); Lin M.Y., Yen C.L., Reactive oxygen species and lipid peroxidation product-scavenging ability of yogurt organisms, J Dairy Sci., 82, pp. 1629-1634, (1999); Lin M.Y., Chang F.J., Antioxidative effect of intestinal bacteria bifidobacterium longum ATCC 15708 and lactobacillus acidophilus ATCC 4356, Dig Dis Sci., 45, pp. 1617-1622, (2000); Kullisaar T., Zilmer M., Mikelsaar M., Et al., Two antioxidative lactobacilli strains as promising probiotics, Int J Food Microbiol., 72, pp. 215-224, (2002); Kullisaar T., Songisepp E., Mikelsaar M., Et al., Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects, Br J Nutr., 90, pp. 449-456, (2003); Songisepp E., Kals J., Kullisaar T., Et al., Evaluation of the functional efficacy of an antioxidative probiotic in healthy volunteers, Nutr J., 4, (2005); Wang Y.C., Yu R.C., Chou C.C., Antioxidative activities of soymilk fermented with lactic acid bacteria and bifidobacteria, Food Microbiol., 23, pp. 128-135, (2006); Jarvenpaa S., Tahvonen R.L., Ouwehand A.C., Et al., A probiotic, lactobacillus fermentum ME-3, has antioxidative capacity in soft cheese spreads with different fats, J Dairy Sci., 90, pp. 3171-3177, (2007); Mikelsaar M., Zilmer M., Lactobacillus fermentum ME-3-an antimicrobial and antioxidative probiotic, Microb Ecol Health Dis., 21, pp. 1-27, (2009); Agerholm-Larsen L., Bell M.L., Grunwald G.K., Et al., The effect of a probiotic milk product on plasma cholesterol: A meta-analysis of short-term intervention studies, Eur J Clin Nutr., 54, pp. 856-860, (2000); Xiao J.Z., Kondo S., Takahashi N., Et al., Effects of milk products fermented by bifidobacterium longum on blood lipids in rats and healthy adult male volunteers, J Dairy Sci., 86, pp. 2452-2461, (2003); Wang Y., Xu N., Xi A., Et al., Effects of lactobacillus plantarum MA2 isolated from tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet, Appl Microbiol Biotechnol., 84, pp. 341-347, (2009); Ramchandran L., Shah N.P., Proteolytic profiles and angiotensin-I converting enzyme and alpha-glucosidase inhibitory activities of selected lactic acid bacteria, J Food Sci., 73, pp. M75-M81, (2008); Ellis C.L., Bokulich N.A., Kalanetra K.M., Et al., Probiotic administration in congenital heart disease: A pilot study, J Perinatol., 33, pp. 691-697, (2013); Koren O., Spor A., Felin J., Et al., Human oral, gut, and plaque microbiota in patients with atherosclerosis, Proc Natl Acad Sci U S A., 108, pp. 4592-4598, (2011); Gan X.T., Ettinger G., Huang C.X., Et al., Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat, Circ Heart Fail., 7, pp. 491-499, (2014); Tanida M., Yamano T., Maeda K., Et al., Effects of intraduodenal injection of lactobacillus johnsonii La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats, Neurosci Lett., 389, pp. 109-114, (2005); McVey Neufeld K.A., Mao Y.K., Bienenstock J., Et al., The microbiome is essential for normal gut intrinsic primary afferent neuron excitability in the mouse, Neurogastroenterol Motil., 25, pp. e183-e188, (2013); Kiliaan A.J., Saunders P.R., Bijlsma P.B., Et al., Stress stimulates transepithelial macromolecular uptake in rat jejunum, Am J Physiol., 275, pp. G1037-G1044, (1998); Ait-Belgnaoui A., Durand H., Cartier C., Et al., Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats, Psychoneuroendocrinology., 37, pp. 1885-1895, (2012); Dickson R.P., Martinez F.J., Huffnagle G.B., The role of the microbiome in exacerbations of chronic lung diseases, Lancet., 384, pp. 691-702, (2014); Han M.K., Zhou Y., Murray S., Et al., Lung microbiome and disease progression in idiopathic pulmonary fibrosis: An analysis of the COMET study, Lancet Respir Med., 2, pp. 548-556, (2014); Wang H., Liu J.S., Peng S.H., Et al., Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases, World J Gastroenterol., 19, pp. 6794-6804, (2013); Madan J.C., Koestler D.C., Stanton B.A., Et al., Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: Interaction between intestinal and respiratory tracts and impact of nutritional exposures, MBio., 3, (2012); Popova M., Molimard P., Courau S., Et al., Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens, J Appl Microbiol., 113, pp. 1305-1318, (2012); Ferreira A.J., Santos R.A., Bradford C.N., Et al., Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases, Hypertension., 55, pp. 207-213, (2010); Haschke M., Schuster M., Poglitsch M., Et al., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects, Clin Pharmacokinet., 52, pp. 783-792, (2013); Kulemina L.V., Ostrov D.A., Prediction of off-target effects on angiotensin-converting enzyme 2, J Biomol Screen., 16, pp. 878-885, (2011); Ferreira A.J., Shenoy V., Yamazato Y., Et al., Evidence for angiotensinconverting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension, Am J Respir Crit Care Med., 179, pp. 1048-1054, (2009); Li G., Xu Y.L., Ling F., Et al., Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels, Chin Med J (Engl)., 125, pp. 1381-1388, (2012); Peregrine A.S., Mamman M., Pharmacology of diminazene: A review, Acta Trop., 54, pp. 185-203, (1993); Haber P.K., Ye M., Wysocki J., Et al., Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: Studies in vivo, ex vivo, and in vitro, Hypertension., 63, pp. 774-782, (2014); Velkoska E., Patel S.K., Griggs K., Et al., Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy, PLoS One., 10, (2015); Fraga-Silva R.A., Costa-Fraga F.P., Murca T.M., Et al., Angiotensin-converting enzyme 2 activation improves endothelial function, Hypertension., 61, pp. 1233-1238, (2013); Fraga-Silva R.A., Sorg B.S., Wankhede M., Et al., ACE2 activation promotes antithrombotic activity, Mol Med., 16, pp. 210-215, (2010); Ferreira A.J., Shenoy V., Qi Y., Et al., Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases, Exp Physiol., 96, pp. 287-294, (2011); Qiu Y., Shil P.K., Zhu P., Et al., Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice, Invest Ophthalmol Vis Sci., 55, pp. 3809-3818, (2014); Thatcher S.E., Zhang X., Howatt D.A., Et al., Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms, Arterioscler Thromb Vasc Biol., 34, pp. 2617-2623, (2014); Zhang Y., Liu J., Luo J.Y., Et al., Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes, Antioxid Redox Signal., (2015); Mecca A.P., Regenhardt R.W., O'Connor T.E., Et al., Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke, Exp Physiol., 96, pp. 1084-1096, (2011); Haga S., Tsuchiya H., Hirai T., Et al., A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-beta cascades with restored caveolin-1 expression, Exp Lung Res., 41, pp. 21-31, (2015); Kirkpatrick J.N., St John Sutton M., Assessment of ventricular remodeling in heart failure clinical trials, Curr Heart Fail Rep., 9, pp. 328-336, (2012); Bleumink G.S., Knetsch A.M., Sturkenboom M.C., Et al., Quantifying the heart failure epidemic: Prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam study, Eur Heart J., 25, pp. 1614-1619, (2004); Min F., Gao F., Li Q., Et al., Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury, Mol Med Rep., 11, pp. 2387-2396, (2015); Ruf S., Karcher D., Bock R., Determining the transgene containment level provided by chloroplast transformation, Proc Natl Acad Sci U S A., 104, pp. 6998-7002, (2007); Scotti N., Cardi T., Plastid transformation as an expression tool for plantderived biopharmaceuticals, Methods Mol Biol., 847, pp. 451-466, (2012)","V. Shenoy; Department of Pharmacodynamics, Colleges of Medicine and Pharmacy, University of Florida, Gainesville, 32610, United States; email: shenoyvi@cop.ufl.edu","","Lippincott Williams and Wilkins","","","","","","01602446","","JCPCD","26322922","English","J. Cardiovasc. Pharmacol.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84950298185"
"Hiltunen T.P.; Donner K.M.; Sarin A.-P.; Saarela J.; Ripatti S.; Chapman A.B.; Gums J.G.; Gong Y.; Cooper-DeHoff R.M.; Frau F.; Glorioso V.; Zaninello R.; Salvi E.; Glorioso N.; Boerwinkle E.; Turner S.T.; Johnson J.A.; Kontula K.K.","Hiltunen, Timo P. (6701881968); Donner, Kati M. (7005325203); Sarin, Antti-Pekka (37117860200); Saarela, Janna (7004368900); Ripatti, Samuli (6603009457); Chapman, Arlene B. (7201567844); Gums, John G. (7004125953); Gong, Yan (8560522600); Cooper-DeHoff, Rhonda M. (35078393500); Frau, Francesca (23093718400); Glorioso, Valeria (57193413574); Zaninello, Roberta (23096696900); Salvi, Erika (57860926600); Glorioso, Nicola (36840433900); Boerwinkle, Eric (7102087489); Turner, Stephen T. (7402275413); Johnson, Julie A. (55439192600); Kontula, Kimmo K. (7102424929)","6701881968; 7005325203; 37117860200; 7004368900; 6603009457; 7201567844; 7004125953; 8560522600; 35078393500; 23093718400; 57193413574; 23096696900; 57860926600; 36840433900; 7102087489; 7402275413; 55439192600; 7102424929","Pharmacogenomics of hypertension: A genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs","2015","Journal of the American Heart Association","4","1","e001521","","","","70","10.1161/JAHA.114.001521","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931841427&doi=10.1161%2fJAHA.114.001521&partnerID=40&md5=96e4ecab3e016eddf0616b833dbe1041","Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland; Public Health Genomics Unit, National Institute for Health and Welfare, University of Helsinki, Helsinki, Finland; Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; Mayo Clinic, Rochester, MN, United States; Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, GA, United States; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Gainesville, FL, United States; Departments of Community Health and Family Medicine, Gainesville, FL, United States; Departments of Medicine, Gainesville, FL, United States; University of Florida, Gainesville, FL, United States; Department of Health Sciences, Genomics and Bioinformatics Unit, University of Milan and Filarete Foundation, Milan, Italy; Hypertension and Related Disease Centre, AOU-University of Sassari, Sassari, Italy; Human Genetics and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States; Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States","Hiltunen T.P., Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland; Donner K.M., Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland; Sarin A.-P., Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland, Public Health Genomics Unit, National Institute for Health and Welfare, University of Helsinki, Helsinki, Finland; Saarela J., Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland; Ripatti S., Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland, Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom; Chapman A.B., Mayo Clinic, Rochester, MN, United States, Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, GA, United States; Gums J.G., Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Gainesville, FL, United States, Departments of Community Health and Family Medicine, Gainesville, FL, United States; Gong Y., Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Gainesville, FL, United States; Cooper-DeHoff R.M., Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Gainesville, FL, United States, Departments of Medicine, Gainesville, FL, United States; Frau F., Department of Health Sciences, Genomics and Bioinformatics Unit, University of Milan and Filarete Foundation, Milan, Italy; Glorioso V., Hypertension and Related Disease Centre, AOU-University of Sassari, Sassari, Italy; Zaninello R., Hypertension and Related Disease Centre, AOU-University of Sassari, Sassari, Italy; Salvi E., Department of Health Sciences, Genomics and Bioinformatics Unit, University of Milan and Filarete Foundation, Milan, Italy; Glorioso N., Hypertension and Related Disease Centre, AOU-University of Sassari, Sassari, Italy; Boerwinkle E., University of Florida, Gainesville, FL, United States, Human Genetics and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States; Turner S.T., Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States; Johnson J.A., Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, Gainesville, FL, United States; Kontula K.K., Department of Medicine, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland","Background: Identification of genetic markers of antihypertensive drug responses could assist in individualization of hypertension treatment. Methods and Results--We conducted a genome-wide association study to identify gene loci influencing the responsiveness of 228 male patients to 4 classes of antihypertensive drugs. The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol, hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order. Replication analyses were performed in 4 studies with patients of European ancestry (PEAR Study, N=386; GERA I and II Studies, N=196 and N=198; SOPHIA Study, N=372). We identified 3 single-nucleotide polymorphisms within the ACY3 gene that showed associations with bisoprolol response reaching genome-wide significance (P<5×10-8); however, this could not be replicated in the PEAR Study using atenolol. In addition, 39 single-nucleotide polymorphisms showed P values of 10-5 to 10-7. The 20 top-associated single-nucleotide polymorphisms were different for each antihypertensive drug. None of these top single-nucleotide polymorphisms co-localized with the panel of >40 genes identified in genome-wide association studies of hypertension. Replication analyses of GENRES results provided suggestive evidence for a missense variant (rs3814995) in the NPHS1 (nephrin) gene influencing losartan response, and for 2 variants influencing hydrochlorothiazide response, located within or close to the ALDH1A3 (rs3825926) and CLIC5 (rs321329) genes. Conclusions--These data provide some evidence for a link between biology of the glomerular protein nephrin and antihypertensive action of angiotensin receptor antagonists and encourage additional studies on aldehyde dehydrogenase-mediated reactions in antihypertensive drug action. © 2015 The Authors.","Antihypertensive drug; Association study; Drug response; Genome-wide; Hypertension","Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Bisoprolol; Blood Pressure Monitoring, Ambulatory; Chloride Channels; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Essential Hypertension; Finland; Genome-Wide Association Study; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Membrane Proteins; Meta-Analysis as Topic; Microfilament Proteins; Middle Aged; Mutation, Missense; Pharmacogenetics; Polymorphism, Single Nucleotide; Severity of Illness Index; Tetrazoles; Treatment Outcome; amlodipine; bisoprolol; hydrochlorothiazide; losartan; nephrin; placebo; actin binding protein; aldehyde dehydrogenase; aldehyde dehydrogenase (NAD(P)+); amlodipine; antihypertensive agent; benzimidazole derivative; bisoprolol; candesartan; chloride channel; CLIC5 protein, human; hydrochlorothiazide; losartan; membrane protein; nephrin; tetrazole derivative; ACY3 gene; adult; ALDH1A3 gene; Article; chromosome 11; CLIC5 gene; controlled study; crossover procedure; diastolic blood pressure; double blind procedure; gene; gene identification; gene location; genetic association; genotyping technique; human; hypertension; major clinical study; male; missense mutation; NPHS1 gene; pharmacogenomics; priority journal; randomized controlled trial; single nucleotide polymorphism; systolic blood pressure; treatment response; blood pressure monitoring; comparative study; dose response; drug administration; essential hypertension; Finland; genetics; genome-wide association study; hypertension; meta analysis (topic); middle aged; pharmacogenetics; procedures; severity of illness index; treatment outcome","","amlodipine, 88150-42-9, 103129-82-4, 736178-83-9; bisoprolol, 66722-44-9; hydrochlorothiazide, 58-93-5; losartan, 114798-26-4; nephrin, 255039-20-4; aldehyde dehydrogenase, 37353-37-0, 9028-86-8; candesartan, 139481-59-7; aldehyde dehydrogenase (NAD(P)+), ; Aldehyde Oxidoreductases, ; Amlodipine, ; Antihypertensive Agents, ; Benzimidazoles, ; Bisoprolol, ; candesartan, ; Chloride Channels, ; CLIC5 protein, human, ; Hydrochlorothiazide, ; Losartan, ; Membrane Proteins, ; Microfilament Proteins, ; nephrin, ; Tetrazoles, ","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL074735); National Heart, Lung, and Blood Institute, NHLBI","","Murray C.J., Lopez A.D., Measuring the global burden of disease, N Engl J Med., 369, pp. 448-457, (2013); Egan B.M., Zhao Y., Axon R.N., US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008, JAMA., 303, pp. 2043-2050, (2010); Banegas J.R., Lopez-Garcia E., Dallongeville J., Guallar E., Halcox J.P., Borghi C., Masso-Gonzalez E.L., Jimenez F.J., Perk J., Steg P.G., De Backer G., Rodriguez-Artalejo F., Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study, Eur Heart J., 32, pp. 2143-2152, (2011); Padmanabhan S., Newton-Cheh C., Dominiczak A., Genetic basis of blood pressure and hypertension, Trends Genet., 28, pp. 397-408, (2012); Ehret G.B., Caulfield M.J., Genes for blood pressure: an opportunity to understand hypertension, Eur Heart J., 34, pp. 951-961, (2013); Munroe P.B., Barnes M.R., Caulfield M.J., Advances in blood pressure genomics, Circ Res., 112, pp. 1365-1379, (2013); Arnett D.K., Claas S.A., Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance, Pharmacogenomics., 10, pp. 1295-1307, (2009); Donner K.M., Hiltunen T.P., Hannila-Handelberg T., Suonsyrja T., Kontula K., STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men, Hypertens Res., 35, pp. 107-114, (2012); Gong Y., McDonough C.W., Wang Z., Hou W., Cooper-DeHoff R.M., Langaee T.Y., Beitelshees A.L., Chapman A.B., Gums J.G., Bailey K.R., Boerwinkle E., Turner S.T., Johnson J.A., Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study, Circ Cardiovasc Genet., 5, pp. 686-691, (2012); Turner S.T., Bailey K.R., Schwartz G.L., Chapman A.B., Chai H.S., Boerwinkle E., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension., 59, pp. 1204-1211, (2012); Turner S.T., Boerwinkle E., O'Connell J.R., Bailey K.R., Gong Y., Chapman A.B., McDonough C.W., Beitelshees A.L., Schwartz G.L., Gums J.G., Padmanabhan S., Hiltunen T.P., Citterio L., Donner K.M., Hedner T., Lanzani C., Melander O., Saarela J., Ripatti S., Wahlstrand B., Manunta P., Kontula K., Dominiczak A.F., Cooper-DeHoff R.M., Johnson J.A., Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide, Hypertension., 62, pp. 391-397, (2013); Kamide K., Asayama K., Katsuya T., Ohkubo T., Hirose T., Inoue R., Metoki H., Kikuya M., Obara T., Hanada H., Thijs L., Kuznetsova T., Noguchi Y., Sugimoto K., Ohishi M., Morimoto S., Nakahashi T., Takiuchi S., Ishimitsu T., Tsuchihashi T., Soma M., Higaki J., Matsuura H., Shinagawa T., Sasaguri T., Miki T., Takeda K., Shimamoto K., Ueno M., Hosomi N., Kato J., Komai N., Kojima S., Sase K., Miyata T., Tomoike H., Kawano Y., Ogihara T., Rakugi H., Staessen J.A., Imai Y., Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study, Pharmacogenomics., 14, pp. 1709-1721, (2013); Hiltunen T.P., Suonsyrja T., Hannila-Handelberg T., Paavonen K.J., Miettinen H.E., Strandberg T., Tikkanen I., Tilvis R., Pentikainen P.J., Virolainen J., Kontula K., Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study), Am J Hypertens., 20, pp. 311-318, (2007); Johnson J.A., Boerwinkle E., Zineh I., Chapman A.B., Bailey K., Cooper-DeHoff R.M., Gums J., Curry R.W., Gong Y., Beitelshees A.L., Schwartz G., Turner S.T., Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, Am Heart J., 157, pp. 442-449, (2009); Turner S.T., Bailey K.R., Fridley B.L., Chapman A.B., Schwartz G.L., Chai H.S., Sicotte H., Kocher J.P., Rodin A.S., Boerwinkle E., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension., 52, pp. 359-365, (2008); Glorioso N., Argiolas G., Filigheddu F., Troffa C., Cocco F., Bulla E., Bulla P., Zaninello R., Degortes S., Pitzoi S., Frau F., Fadda S., Pinna Parpaglia P., Bernini G., Bardini M., Fallo F., Malatino L., Regolisti G., Ferri C., Cusi D., Sciacqua A., Perticone F., Degli Esposti E., Baraccani C., Parati G., Veglio F., Mulatero P., Williams T.A., Macciardi F., Stancanelli B., Conceptual basis and methodology of the SOPHIA study, Pharmacogenomics., 8, pp. 1497-1509, (2007); Suonsyrja T., Hannila-Handelberg T., Paavonen K.J., Miettinen H.E., Donner K., Strandberg T., Tikkanen I., Tilvis R., Pentikainen P.J., Kontula K., Hiltunen T.P., Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study, J Hypertens., 26, pp. 1250-1256, (2008); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int., 61, pp. 1047-1055, (2002); Canzanello V.J., Baranco-Pryor E., Rahbari-Oskoui F., Schwartz G.L., Boerwinkle E., Turner S.T., Chapman A.B., Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension, Am J Hypertens., 21, pp. 61-66, (2008); Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C., PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet., 81, pp. 559-575, (2007); Willer C.J., Li Y., Abecasis G.R., METAL: fast and efficient meta-analysis of genomewide association scans, Bioinformatics., 26, pp. 2190-2191, (2010); Tasdelen I., van Beekum O., Gorbenko O., Fleskens V., van den Broek N.J., Koppen A., Hamers N., Berger R., Coffer P.J., Brenkman A.B., Kalkhoven E., The serine/threonine phosphatase PPM1B (PP2Cß) selectively modulates PPARγ activity, Biochem J., 451, pp. 45-53, (2013); Hauser P.V., Collino F., Bussolati B., Camussi G., Nephrin and endothelial injury, Curr Opin Nephrol Hypertens., 18, pp. 3-8, (2009); George B., Holzman L.B., Signaling from the podocyte intercellular junction to the actin cytoskeleton, Semin Nephrol., 32, pp. 307-318, (2012); Ristola M., Lehtonen S., Functions of the podocyte proteins nephrin and Neph3 and the transcriptional regulation of their genes, Clin Sci (Lond)., 126, pp. 315-328, (2014); Jia J., Ding G., Zhu J., Chen C., Liang W., Franki N., Singhal P.C., Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis, Am J Nephrol., 28, pp. 500-507, (2008); Bonnet F., Cooper M.E., Kawachi H., Allen T.J., Boner G., Cao Z., Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension, Diabetologia., 44, pp. 874-877, (2001); Davis B.J., Cao Z., de Gasparo M., Kawachi H., Cooper M.E., Allen T.J., Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin, J Hypertens., 21, pp. 209-216, (2003); Pettersson-Fernholm K., Forsblom C., Perola M., Groop P.H., Polymorphisms in the nephrin gene and diabetic nephropathy in type 1 diabetic patients, Kidney Int., 63, pp. 1205-1210, (2003); Pushkin A., Carpenito G., Abuladze N., Newman D., Tsuprun V., Ryazantsev S., Motemoturu S., Sassani P., Solovieva N., Dukkipati R., Kurtz I., Structural characterization, tissue distribution, and functional expression of murine aminoacylase III, Am J Physiol Cell Physiol., 286, pp. C848-C856, (2004); Garg L.C., Actions of adrenergic and cholinergic drugs on renal tubular cells, Pharmacol Rev., 44, pp. 81-102, (1992); Hanson A.S., Linas S.L., Beta-adrenergic receptor function in rat proximal tubule epithelial cells in culture, Am J Physiol., 268, pp. F553-F560, (1995); Singh H., Linas S., Beta 2-adrenergic function in cultured rat proximal tubule epithelial cells, Am J Physiol., 271, pp. F71-F77, (1996); Muzio G., Maggiora M., Paiuzzi E., Oraldi M., Canuto R.A., Aldehyde dehydrogenases and cell proliferation, Free Radic Biol Med., 52, pp. 735-746, (2012); Padhukasahasram B., Yang J.J., Levin A.M., Yang M., Burchard E.G., Kumar R., Kwok P.Y., Seibold M.A., Lanfear D.E., Williams L.K., Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups, Pharmacogenomics J., 14, pp. 365-371, (2014); Fares-Taie L., Gerber S., Chassaing N., Clayton-Smith J., Hanein S., Silva E., Serey M., Serre V., Gerard X., Baumann C., Plessis G., Demeer B., Bretillon L., Bole C., Nitschke P., Munnich A., Lyonnet S., Calvas P., Kaplan J., Ragge N., Rozet J.M., ALDH1A3 mutations cause recessive anophthalmia and microphthalmia, Am J Hum Genet., 92, pp. 265-270, (2013); Wegner B., Al-Momany K., Kulak S.C., Kozlowski K., Obeidat M., Jahroudi N., Paes J., Berryman M., Ballermann B.J., CLIC5A, a component of the ezrin-podocalyxin complex in glomeruli, is a determinant of podocyte integrity, Am J Physiol Renal Physiol., 298, pp. F1492-F1503, (2010); Adeyemo A., Gerry N., Chen G., Herbert A., Doumatey A., Huang H., Zhou J., Lashley K., Chen Y., Christman M., Rotimi C., A genome-wide association study of hypertension and blood pressure in African Americans, PLoS Genet., 5, (2009); Kato N., Takeuchi F., Tabara Y., Kelly T.N., Go M.J., Sim X., Tay W.T., Chen C.H., Zhang Y., Yamamoto K., Katsuya T., Yokota M., Kim Y.J., Ong R.T., Nabika T., Gu D., Chang L.C., Kokubo Y., Huang W., Ohnaka K., Yamori Y., Nakashima E., Jaquish C.E., Lee J.Y., Seielstad M., Isono M., Hixson J.E., Chen Y.T., Miki T., Zhou X., Sugiyama T., Jeon J.P., Liu J.J., Takayanagi R., Kim S.S., Aung T., Sung Y.J., Zhang X., Wong T.Y., Han B.G., Kobayashi S., Ogihara T., Zhu D., Iwai N., Wu J.Y., Teo Y.Y., Tai E.S., Cho Y.S., He J., Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians, Nat Genet., 43, pp. 531-538, (2011); Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet., 360, pp. 1903-1913, (2002)","","","John Wiley and Sons Inc.","","","","","","20479980","","","25622599","English","J. Am. Heart Assoc.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-84931841427"
"Castaño-Amores C.; Antúnez-Rodríguez A.; Pozo-Agundo A.; García-Rodríguez S.; Martínez-González L.J.; Dávila-Fajardo C.L.","Castaño-Amores, Celia (57218369188); Antúnez-Rodríguez, Alba (57209654239); Pozo-Agundo, Ana (57219924592); García-Rodríguez, Sonia (8877080400); Martínez-González, Luis Javier (6506820661); Dávila-Fajardo, Cristina Lucía (31168165900)","57218369188; 57209654239; 57219924592; 8877080400; 6506820661; 31168165900","Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome","2023","Biomedicine and Pharmacotherapy","169","","115869","","","","6","10.1016/j.biopha.2023.115869","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176466358&doi=10.1016%2fj.biopha.2023.115869&partnerID=40&md5=a892d7a938d81e06cd8c97e544b11e3f","Pharmacy Department, Hospital Universitario Santa Bárbara, Puertollano, Spain; GENYO, Genomics Unit, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government (GENYO), Granada, Spain; University of Granada, Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, PTS, Granada, Spain; Pharmacy Department, Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Hospital Universitario Virgen de las Nieves, Granada, Spain","Castaño-Amores C., Pharmacy Department, Hospital Universitario Santa Bárbara, Puertollano, Spain; Antúnez-Rodríguez A., GENYO, Genomics Unit, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government (GENYO), Granada, Spain; Pozo-Agundo A., GENYO, Genomics Unit, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government (GENYO), Granada, Spain; García-Rodríguez S., GENYO, Genomics Unit, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government (GENYO), Granada, Spain; Martínez-González L.J., University of Granada, Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, PTS, Granada, Spain; Dávila-Fajardo C.L., Pharmacy Department, Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Hospital Universitario Virgen de las Nieves, Granada, Spain","Betablockers (BBs) are prescribed for ischaemia in patients with acute coronary syndrome (ACS). In Spain, bisoprolol and carvedilol are the most prescribed BBs, but patients often had to discontinue them due to adverse effects. Single nucleotide polymorphisms (SNPs) in ADRB1, ADRB2 and CYP2D6 genes have strong evidence of pharmacogenetic association with BBs in heart failure or hypertension, but the evidence in ACS is limited. Therefore, our study focuses on investigating how these genes influence the response to BBs in ACS patients. We analysed the association between SNPs in ADRB1 Gly389Arg (rs1801253) and Ser49Gly (rs1801252), ADRB2 Gly16Arg (rs1042713) and Glu27Gln (rs1042714), and CYP2D* 6 (*2– rs1080985, *4- rs3892097, *10 – rs1065852) and the occurrence of bradycardia/hypotension events during one year of follow-up. We performed an observational study and included 285 ACS-PCI-stent patients. A first analysis including patients treated with bisoprolol and a second analysis including patients treated with other BBs were performed. We found that the presence of the G allele (Glu) of the ADRB2 gene (rs1042714; Glu27Gln) conferred a protective effect against hypotension-induced by BBs; OR (CI 95%) = 0,14 (0,03−0,60), p < 0.01. The ADRB2 (rs1042713; Gly16Arg) GG genotype could also prevent hypotensive events; OR (CI 95%) = 0.49 (0.28–0.88), p = 0015. SNPs in ADRB1 and CYP2D6 * 2, CYP2D6 * 4 weren´t associated with primary events. The effect of CYP2D6 * 10 does not seem to be relevant for the response to BBs. According to our findings, SNPs in ADRB2 (rs1042713, rs1042714) could potentially affect the response and tolerance to BBs in ACS-patients. Further studies are necessary to clarify the impact of ADRB2 polymorphisms. © 2023","Acute coronary syndrome; ADRB genes; Betablockers; Bisoprolol; CYP2D6 gene; Pharmacogenetic","Acute Coronary Syndrome; Adrenergic beta-Antagonists; Bisoprolol; Cytochrome P-450 CYP2D6; Genotype; Humans; Hypotension; Percutaneous Coronary Intervention; Polymorphism, Single Nucleotide; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; acetylsalicylic acid; angiotensin receptor antagonist; anticoagulant agent; antihypertensive agent; antilipemic agent; antithrombocytic agent; atenolol; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; bisoprolol; carvedilol; cytochrome P450 2D6; hydroxymethylglutaryl coenzyme A reductase inhibitor; ivabradine; nebivolol; ADRB1 protein, human; ADRB2 protein, human; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; cytochrome P450 2D6; acute coronary syndrome; adult; allele; Article; bradycardia; Caucasian; cerebrovascular accident; computer model; controlled study; coronary stenting; diastolic blood pressure; dizziness; drug dose reduction; drug withdrawal; dyslipidemia; faintness; female; follow up; gene expression level; genetic analysis; genetic association; genetic polymorphism; genotype; genotyping; heart failure; heart tissue; hospital admission; human; hybridization; hypertension; hypotension; major clinical study; male; middle aged; observational study; percutaneous coronary intervention; respiratory tract disease; single nucleotide polymorphism; systolic blood pressure; acute coronary syndrome; genetics; hypotension; percutaneous coronary intervention; single nucleotide polymorphism","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; atenolol, 29122-68-7, 93379-54-5; bisoprolol, 66722-44-9; carvedilol, 72956-09-3; ivabradine, 148849-67-6, 148870-80-8, 155974-00-8; nebivolol, 99200-09-6, 118457-15-1, 118457-16-2; ADRB1 protein, human, ; ADRB2 protein, human, ; Adrenergic beta-Antagonists, ; Bisoprolol, ; Cytochrome P-450 CYP2D6, ; Receptors, Adrenergic, beta-1, ; Receptors, Adrenergic, beta-2, ","","","Universidad de Granada, UGR","This study includes results from the doctoral thesis “Analysis of genetic variants associated with response to bisoprolol in patients with acute coronary syndrome with percutaneous coronary intervention with stent”, being developed and not yet published within the doctoral program in Pharmacy at the University of Granada, to whom we thank for their collaboration. Graphical abstract was created with BioRender.com.","Bhatt D.L., Lopes R.D., Harrington R.A., Diagnosis and treatment of acute coronary syndromes: a review, JAMA, 327, 7, pp. 662-675, (2022); Zhai C., Cong H., Liu Y., Zhang Y., Liu X., Zhang H., Ren Z., Effect of high-dose statin pretreatment on the incidence of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: grading the evidence through a cumulative meta-analysis, Clin. Cardiol., 38, 11, pp. 668-678, (2015); Collet J.P., Thiele H., Barbato E., Barthelemy O., Bauersachs J., Bhatt D.L., Et al., 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur. Heart J., 42, 14, pp. 1289-1367, (2021); Maqsood M.H., Alam M., Atar D., Birnbaum Y., Efficacy of long-term oral beta-blocker therapy in patients who underwent percutaneous coronary intervention for st-segment elevation myocardial infarction with preserved left ventricular ejection fraction: a systematic review and meta-analysis, J. Cardiovasc Pharm., 77, 1, pp. 87-93, (2021); Fontana V., Turner R.M., Francis B., Yin P., Putz B., Hiltunen T.P., Ruotsalainen S., Kontula K.K., Muller-Myhsok B., Pirmohamed M., Chromosomal region 11p14.1 is associated with pharmacokinetics and pharmacodynamics of Bisoprolol, PharmgenomicsPers Med., 15, pp. 249-260, (2022); Shin J., Johnson J.A., Beta-blocker pharmacogenetics in heart failure, Heart Fail Rev., 15, 3, pp. 187-196, (2010); Cordero A., Bertomeu-Gonzalez V., Mazon P., Moreno-Arribas J., Facila L., Bueno H., Et al., Differential effect of β-blockers for heart rate control in coronary artery disease, Clin. Cardiol., 34, 12, pp. 748-754, (2011); Singh S., Warren H.R., Hiltunen T.P., McDonough C.W., El Rouby N., Salvi E., Et al., Genome-wide meta-analysis of blood pressure response to β1-blockers: results from ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies), J. Am. Heart Assoc., 8, 16, (2019); Piriyapongsa J., Sukritha C., Kaewprommal P., Intarat C., Triparn K., Phornsiricharoenphant K., Et al., PharmVIP: a web-based tool for pharmacogenomic variant analysis and interpretation, J. Pers. Med., 11, 11, (2021); Thomas C.D., Johnson J.A., Pharmacogenetic factors affecting β-blocker metabolism and response, Expert Opin. Drug Metab. Toxicol., 16, 10, pp. 953-964, (2020); Castano-Amores C., Diaz-Villamarin X., Perez-Gutierrez A.M., Antunez-Rodriguez A., Pozo-Agundo A., Moreno-Escobar E., Et al., Pharmacogenetic polymorphisms affecting bisoprolol response, Biomed. Pharm., 142, (2021); Batty J.A., Hall A.S., White H.L., Et al., An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy, Clin. Ther., 95, 3, pp. 321-330, (2014); Goryachkina K., Burbello A., Boldueva S., Et al., CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction, Eur. J. Clin. Pharm., 64, 12, pp. 1163-1173, (2008); Hamadeh I.S., Langaee T.Y., Dwivedi R., Et al., Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate, Clin. Pharmacol. Ther., 96, 2, pp. 175-181, (2014); van der Wouden C.H., Cambon-Thomsen A., Cecchin E., Cheung K.C., Davila-Fajardo C.L., Deneer V.H., Dolzan V., Ingelman-Sundberg M., Et al., Ubiquitous pharmacogenomics consortium. implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium, Clin. Pharm., 101, 3, pp. 341-358, (2017); Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., Et al., Pharmacogenomics knowledge for personalized medicine, Clin. Pharm., 92, 4, pp. 414-417, (2012); Batty J.A., Hall A.S., White H.L., Et al., An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy, Clin. Ther., 95, 3, pp. 321-330, (2014); Yuan H., Huang Z., Yang G., Lv H., Sang H., Yao Y., Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol, J. Int Med Res, 36, 6, pp. 1354-1362, (2008); Dean L., Carvedilol Therapy and CYP2D6 Genotype. 2018 Aug 1, Medical Genetics Summaries [Internet], (2012); Yakekuma Y., Takenaka T., Kiyokawa M., Yamazaki K., Okamoto H., Kitabatake A., Tsutsui H., Sugawara M., Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis, Biol. Pharm. Bull., 30, 3, pp. 537-542, (2007); Rau T., Dungen H.D., Edelmann F., Waagstein F., Lainscak M., Dimkovic S., Et al., Impact of the β1-adrenoceptor Gly389Arg polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients, Clin. Pharm., 92, 1, pp. 21-28, (2012); Mohammed Alkreathy H., Mohammed Eid Alsayyid K., Alaama J.Y., Al Ghalayini K., Karim S., Esmat A., Damanhouri Z.A., Bisoprolol responses (PK/PD) in hypertensive patients: a cytochrome P450 (CYP) 2D6 targeted polymorphism study, Saudi J. Biol. Sci., 27, 10, pp. 2727-2732, (2020); Fedorinov D.S., Mirzaev K.B., Mustafina V.R., Sychev D.A., Maximova N.R., Chertovskikh J.V., Et al., Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking βBBs in the Republic of Sakha (YAKUTIA), Drug Metab. Pers. Ther., 33, 4, pp. 195-200, (2018); Liu J., Liu Z.Q., Tan Z.R., Chen X.P., Wang L.S., Zhou G., Et al., Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol, Clin. Pharm., 74, 4, pp. 372-379, (2003); Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F., Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin. Pharm., 74, 1, pp. 44-52, (2003); Sofowora G.G., Dishy V., Muszkat M., Xie H.G., Kim R.B., Harris P.A., Et al., A common beta1-adrenergic receptor polymorphism (Gly389Arg) affects blood pressure response to beta-blockade, Clin. Pharm., 73, 4, pp. 366-371, (2003); Terra S.G., Pauly D.F., Lee C.R., Patterson J.H., Adams K.F., Schofield R.S., Et al., Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure, Clin. Pharm. Ther., 77, 3, pp. 127-137, (2005); de Groote P., Helbecque N., Lamblin N., Hermant X., Mc Fadden E., Foucher-Hossein C., Et al., Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure, Pharm. Genom., 15, 3, pp. 137-142, (2005); Petersen M., Andersen J.T., Jimenez-Solem E., Broedbaek K., Hjelvang B.R., Henriksen T., Et al., Effect of the Gly389Arg β₁-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment, Clin. Exp. Pharm. Physiol., 39, 9, pp. 779-785, (2012); Zaugg M., Bestmann L., Wacker J., Lucchinetti E., Boltres A., Schulz C., Et al., Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up, Anesthesiology, 107, 1, pp. 33-44, (2007); Pacanowski M.A., Gong Y., Cooper-Dehoff R.M., Schork N.J., Shriver M.D., Langaee T.Y., Et al., INVEST Investigators. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension, Clin. Pharm. Ther., 84, 6, pp. 715-721, (2008); Shahin M.H., Rouby N.E., Conrado D.J., Gonzalez D., Gong Y., Lobmeyer M.T., Et al., β2 -Adrenergic receptor gene affects the heart rate response of BBs: evidence From 3 clinical studies, J. Clin. Pharm., 59, 11, pp. 1462-1470, (2019); Kaye D.M., Smirk B., Williams C., Jennings G., Esler M., Holst D., Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure, Pharmacogenetics, 13, 7, pp. 379-382, (2003); Sehrt D., Meineke I., Tzvetkov M., Gultepe S., Brockmoller J., Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics, Pharmacogenomics, 12, 6, pp. 783-795, (2011); Lanfear D.E., Jones P.G., Marsh S., Cresci S., McLeod H.L., Spertus J.A., Beta2-adrenergic receptor genotype and survival among patients receiving BB therapy after an acute coronary syndrome, JAMA, 294, 12, pp. 1526-1533, (2005); Lee H.Y., Chung W.J., Jeon H.K., Seo H.S., Choi D.J., Jeon E.S., Et al., Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study, Korean J. Intern Med, 31, 2, pp. 277-287, (2016); Suonsyrja T., Donner K., Hannila-Handelberg T., Fodstad H., Kontula K., Hiltunen T.P., Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment, Pharm. Genom., 20, 5, pp. 342-345, (2010); Bruck H., Leineweber K., Temme T., Weber M., Heusch G., Philipp T., Et al., The Gly389Arg beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity, J. Am. Coll. Cardiol., 46, 11, pp. 2111-2115, (2005); Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., Et al., Pharmacogenomics knowledge for personalized medicine, Clin. Pharm., 92, 4, pp. 414-417, (2012); Davila-Fajardo C.L., Sanchez-Ramos J., Villamarin X.D., Martinez-Gonzalez L.J., Frias P.T., Huertas S.M., Et al., The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent, Data Brief., 10, pp. 518-524, (2016); Sanchez-Ramos J., Davila-Fajardo C.L., Toledo Frias P., Diaz Villamarin X., Martinez-Gonzalez L.J., Martinez Huertas S., Et al., Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent, Int. J. Cardiol., 225, pp. 289-295, (2016); Freeman B., Smith N., Curtis C., Huckett L., Mill J., Craig I.W., DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping, Behav. Genet, 33, 1, pp. 67-72, (2003); Gomez-Martin A., Hernandez A.F., Martinez-Gonzalez L.J., Gonzalez-Alzaga B., Rodriguez-Barranco M., Lopez-Flores I., Et al., Polymorphisms of pesticide-metabolizing genes in children living in intensive farming communities, Chemosphere, 139, pp. 534-540, (2015); McLaren W., Gil L., Hunt S.E., Riat H.S., Ritchie G.R.S., Thormann A., Et al., The ensembl variant effect predictor, Genome Biol., 17, 1, (2016); Brodde O.E., Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses, Pharm. Ther., 117, 1, pp. 1-29, (2008); Snyder E.M., Kelley E.F., Sprissler R., Olson T.P., The importance and challenges of developing a pharmacogenetics test for hypertension, Pharmacogenomics, 20, 8, pp. 563-566, (2019); Cunningham P.N., Chapman A.B., The future of pharmacogenetics in the treatment of hypertension, Pharmacogenomics, 20, 3, pp. 129-132, (2019); Huang J., Li C., Song Y., Fan X., You L., Tan L., Et al., ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure, Cell Discov., 4, (2018); Johnson J.A., Liggett S.B., Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions, Clin. Pharm. Ther., 89, 3, pp. 366-378, (2011); Green S.A., Turki J., Innis M., Liggett S.B., Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties, Biochemistry, 33, 32, pp. 9414-9419, (1994); Snyder E.M., Beck K.C., Dietz N.M., Eisenach J.H., Joyner M.J., Turner S.T., Et al., Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans, J. Physiol., 571, pp. 121-130, (2006); Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L., Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years, Circulation, 111, 25, pp. 3429-3434, (2005); Filigheddu F., Argiolas G., Degortes S., Zaninello R., Frau F., Pitzoi S., Et al., Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension, Pharmacogenomics, 11, 3, pp. 319-325, (2010); Metra M., Covolo L., Pezzali N., Zaca V., Bugatti S., Lombardi C., Et al., Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure, Cardiovasc Drugs Ther., 24, 1, pp. 49-60, (2010); White H.L., de Boer R.A., Maqbool A., Greenwood D., van Veldhuisen D.J., Cuthbert R., Et al., MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study, Eur. J. Heart Fail, 5, 4, pp. 463-468, (2003); Bijl M.J., Visser L.E., van Schaik R.H., Kors J.A., Witteman J.C., Hofman A., Et al., Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users, Clin. Pharm. Ther., 85, 1, pp. 45-50, (2009); Chan S.W., Chu T.T.W., Ho C.S., Kong A.P.S., Tomlinson B., Zeng W., Influence of CYP2D6 and CYP3A5 polymorphisms on the pharmacokinetics and pharmacodynamics of bisoprolol in hypertensive chinese patients, Front. Med., 8, (2021); Hamadeh I.S., Langaee T.Y., Dwivedi R., Et al., Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate, Clin. Pharmacol. Ther., 96, 2, pp. 175-181, (2014); Zineh I., Beitelshees A.L., Gaedigk A., Walker J.R., Pauly D.F., Eberst K., Et al., Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension, Clin. Pharm. Ther., 76, 6, pp. 536-544, (2004); Valeria C., Carmine S., Valentina M., Teresa I., Maria C., Martina T., Et al., The need of a multicomponent guiding approach to personalize clopidogrel treatment, Pharm. J., 21, 2, pp. 116-127, (2021); Ignjatovic V., Pavlovic S., Miloradovic V., Andjelkovic N., Davidovic G., Djurdjevic P., Et al., Influence of different β-blockers on platelet aggregation in patients with coronary artery disease on dual antiplatelet therapy, J. Cardiovasc. Pharm. Ther., 21, 1, pp. 44-52, (2016)","C.L. Dávila-Fajardo; Pharmacy Department, Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Hospital Universitario Virgen de las Nieves, Granada, Spain; email: cristinal.davila.sspa@juntadeandalucia.es","","Elsevier Masson s.r.l.","","","","","","07533322","","BIPHE","37952358","English","Biomed. Pharmacother.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85176466358"
"McDonough C.W.; Warren H.R.; Jack J.R.; Motsinger-Reif A.A.; Armstrong N.D.; Bis J.C.; House J.S.; Singh S.; El Rouby N.M.; Gong Y.; Mychaleckyj J.C.; Rotroff D.M.; Benavente O.R.; Caulfield M.J.; Doria A.; Pepine C.J.; Psaty B.M.; Glorioso V.; Glorioso N.; Hiltunen T.P.; Kontula K.K.; Arnett D.K.; Buse J.B.; Irvin M.R.; Johnson J.A.; Munroe P.B.; Wagner M.J.; Cooper-DeHoff R.M.","McDonough, Caitrin W. (16176122100); Warren, Helen R. (55386322500); Jack, John R. (16037079400); Motsinger-Reif, Alison A. (57204797215); Armstrong, Nicole D. (57226700765); Bis, Joshua C. (6603292486); House, John S. (56241516200); Singh, Sonal (57201182650); El Rouby, Nihal M. (55918027000); Gong, Yan (8560522600); Mychaleckyj, Joesyf C. (6603325445); Rotroff, Daniel M. (26656017700); Benavente, Oscar R. (56752584200); Caulfield, Mark J. (7102853527); Doria, Alessandrio (7102703833); Pepine, Carl J. (35353341300); Psaty, Bruce M. (35374213400); Glorioso, Valeria (57193413574); Glorioso, Nicola (36840433900); Hiltunen, Timo P. (6701881968); Kontula, Kimmo K. (7102424929); Arnett, Donna K. (7101719250); Buse, John B. (57169892000); Irvin, Marguerite R. (57212852696); Johnson, Julie A. (57220840148); Munroe, Patricia B. (7005376453); Wagner, Michael J. (7404049653); Cooper-DeHoff, Rhonda M. (57222639963)","16176122100; 55386322500; 16037079400; 57204797215; 57226700765; 6603292486; 56241516200; 57201182650; 55918027000; 8560522600; 6603325445; 26656017700; 56752584200; 7102853527; 7102703833; 35353341300; 35374213400; 57193413574; 36840433900; 6701881968; 7102424929; 7101719250; 57169892000; 57212852696; 57220840148; 7005376453; 7404049653; 57222639963","Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies","2021","Clinical Pharmacology and Therapeutics","110","3","","723","732","9","9","10.1002/cpt.2355","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112363428&doi=10.1002%2fcpt.2355&partnerID=40&md5=7185717ae702e5daf62a149115a9bcfd","Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States; Clinical Pharmacology Department, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; NIHR Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Bioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, United States; Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, NC, United States; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; Center for Public Health Genomics, University of Virginia, Charlottesville, VA, United States; Department of Neurology, University of British Columbia, Vancouver, BC, Canada; National Institute for Health Research, Barts Cardiovascular Biomedical Research Center, Queen Mary University of London, London, United Kingdom; Research Division, Joslin Diabetes Center; and Department of Medicine, Harvard Medical School, Boston, MA, United States; Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Department of Epidemiology, University of Washington, Seattle, WA, United States; Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milano, Italy; Department of Clinical, Surgical and Experimental Science, University of Sassari, Medical School, Sassari, Italy; Department of Medicine and Research Program for Clinical and Molecular Metabolism, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; College of Public Health, Dean’s Office, University of Kentucky, Lexington, KY, United States; Division of Endocrinology, Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States","McDonough C.W., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States; Warren H.R., Clinical Pharmacology Department, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, NIHR Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Jack J.R., Bioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, United States; Motsinger-Reif A.A., Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, NC, United States; Armstrong N.D., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Bis J.C., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; House J.S., Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, NC, United States; Singh S., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States; El Rouby N.M., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States; Gong Y., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States; Mychaleckyj J.C., Center for Public Health Genomics, University of Virginia, Charlottesville, VA, United States; Rotroff D.M., Bioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, United States; Benavente O.R., Department of Neurology, University of British Columbia, Vancouver, BC, Canada; Caulfield M.J., National Institute for Health Research, Barts Cardiovascular Biomedical Research Center, Queen Mary University of London, London, United Kingdom; Doria A., Research Division, Joslin Diabetes Center; and Department of Medicine, Harvard Medical School, Boston, MA, United States; Pepine C.J., Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Psaty B.M., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States; Glorioso V., Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milano, Italy; Glorioso N., Department of Clinical, Surgical and Experimental Science, University of Sassari, Medical School, Sassari, Italy; Hiltunen T.P., Department of Medicine and Research Program for Clinical and Molecular Metabolism, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Kontula K.K., Department of Medicine and Research Program for Clinical and Molecular Metabolism, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Arnett D.K., College of Public Health, Dean’s Office, University of Kentucky, Lexington, KY, United States; Buse J.B., Division of Endocrinology, Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Irvin M.R., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Johnson J.A., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States, Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Munroe P.B., Clinical Pharmacology Department, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, NIHR Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Wagner M.J., Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Cooper-DeHoff R.M., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, United States, Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States","We sought to identify genome-wide variants influencing antihypertensive drug response and adverse cardiovascular outcomes, utilizing data from four randomized controlled trials in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS). Genome-wide antihypertensive drug-single nucleotide polymorphism (SNP) interaction tests for four drug classes (β-blockers, n = 9,195; calcium channel blockers (CCBs), n = 10,511; thiazide/thiazide-like diuretics, n = 3,516; ACE-inhibitors/ARBs, n = 2,559) and cardiovascular outcomes (incident myocardial infarction, stroke, or death) were analyzed among patients with hypertension of European ancestry. Top SNPs from the meta-analyses were tested for replication of cardiovascular outcomes in an independent Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) study (n = 21,267), blood pressure (BP) response in independent ICAPS studies (n = 1,552), and ethnic validation in African Americans from the Genetics of Hypertension Associated Treatment study (GenHAT; n = 5,115). One signal reached genome-wide significance in the β-blocker-SNP interaction analysis (rs139945292, Interaction P = 1.56 × 10−8). rs139945292 was validated through BP response to β-blockers, with the T-allele associated with less BP reduction (systolic BP response P = 6 × 10−4, Beta = 3.09, diastolic BP response P = 5 × 10−3, Beta = 1.53). The T-allele was also associated with increased adverse cardiovascular risk within the β-blocker treated patients’ subgroup (P = 2.35 × 10−4, odds ratio = 1.57, 95% confidence interval = 1.23–1.99). The locus showed nominal replication in CHARGE, and consistent directional trends in β-blocker treated African Americans. rs139945292 is an expression quantitative trait locus for the 50 kb upstream gene NTM (neurotrimin). No SNPs attained genome-wide significance for any other drugs classes. Top SNPs were located near CALB1 (CCB), FLJ367777 (ACE-inhibitor), and CES5AP1 (thiazide). The NTM region is associated with increased risk for adverse cardiovascular outcomes and less BP reduction in β-blocker treated patients. Further investigation into this region is warranted. © 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics","","African Americans; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Drug-Related Side Effects and Adverse Reactions; Female; Genome-Wide Association Study; Humans; Hypertension; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; angiotensin 2 receptor antagonist; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; thiazide diuretic agent; antihypertensive agent; adult; aged; antihypertensive therapy; Article; cardiovascular risk; cerebrovascular accident; clinical outcome; controlled study; death; diastolic blood pressure; expression quantitative trait locus; female; genome-wide association study; heart infarction; human; hypertension; major clinical study; male; meta analysis; middle aged; pharmacogenomics; protein expression; randomized controlled trial; single nucleotide polymorphism; systolic blood pressure; treatment response; adverse drug reaction; African American; blood pressure; cardiovascular disease; cardiovascular system; drug effect; genetics; hypertension; pharmacogenetic testing; procedures","","Antihypertensive Agents, ","","","International Centre for Circulatory Health Charity; University of Florida Opportunity Fund; National Institutes of Health, NIH, (K01 HL141690); National Institutes of Health, NIH; Centers for Disease Control and Prevention, CDC, (R01 HL074730, U01‐GM074492, UL1 RR092890); Centers for Disease Control and Prevention, CDC; National Institute on Aging, NIA; National Heart, Lung, and Blood Institute, NHLBI; National Eye Institute, NEI; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK; National Institute of Environmental Health Sciences, NIEHS, (1‐HC‐1010, 1‐HC‐9035, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, N01‐HC‐95178, N01‐HC‐95179, ZIAES103338); National Institute of Environmental Health Sciences, NIEHS; Mayo Clinic; Mayo Foundation for Medical Education and Research, MFMER; Carolinas HealthCare System, CHS, (75N92021D00006, UL1 TR000064, UL1 TR000135, UL1 TR000454); Carolinas HealthCare System, CHS; Helsingin ja Uudenmaan Sairaanhoitopiiri, HUS, (FP7‐HEALTHF4‐2007‐201550, R01 HL063082, R01 HL123782, T32 HL007457); Helsingin ja Uudenmaan Sairaanhoitopiiri, HUS; Abbott Pharmaceuticals, (R01 HL085251, R01 HL103612, R01 HL105756, R01 NS073346, U01 GM074492‐05S109, U01 NS038529); Abbott Pharmaceuticals; Medical Research Council, MRC, (G952010, R01 HL110380, R01 HL110400); Medical Research Council, MRC; National Institute for Health and Care Research, NIHR; Sydäntutkimussäätiö; RIKEN, (U01 GM074492-05S109); RIKEN; Sigrid Juséliuksen Säätiö; NIHR Imperial Biomedical Research Centre, BRC","Funding text 1: C.W.M. is supported by National Institutes of Health (NIH) grant K01 HL141690. ASCOT was funded by the National Institutes for Health Research (NIHR) as part of the portfolio of translational research of the NIHR Barts Biomedical Research Unit and the NIHR Biomedical Research Centre at Imperial College, the International Centre for Circulatory Health Charity, and the Medical Research Council through G952010. ACCORD research was supported by NIH grants R01 HL110380 and R01 HL110400, and intramural funds from the National Institute of Environmental Health Sciences. ACCORD cohort was supported by Contract Nos. N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA #Y1-HC-9035, and IAA #Y1-HC-1010 from the National Heart, Lung, and Blood Institute (NHLBI), with additional support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Eye Institute (NEI), the National Institute on Aging (NIA), and the Centers for Disease Control and Prevention (CDC). INVEST was supported by the NIH grants R01 HL074730, U01 GM074492, and NIH CTSA grant UL1 RR092890, as well as grants from the University of Florida Opportunity Fund and Abbott Pharmaceuticals. The genome-wide genotyping for INVEST-GENES was provided by RIKEN. SPS3 was supported by NIH grants R01 NS073346, U01 GM074492-05S109, and U01 NS038529. Infrastructure for the CHARGE Consortium and the CHARGE Pharmacogenetics Working Group is supported in part by the NHLBI grants R01 HL105756, R01 HL103612, and R01 HL085251, and CHS contract number 75N92021D00006. Study descriptions and acknowledgements for the participating CHARGE cohorts are available in https://doi.org/10.1371/journal.pone.0140496. Both the PEAR and PEAR-2 studies were supported by NIH grants U01-GM074492 and UL1 TR000064 (University of Florida); UL1 TR000454 (Emory University), and UL1 TR000135 (Mayo Clinic). PEAR was also supported by funds from the Mayo Foundation. LIFE-Fin and GENRES were supported by the Sigrid Juselius Foundation, The Finnish Foundation for Cardiovascular Research, and the Helsinki University Central Hospital. BB-SS studies were supported by the HYPERGENES project (FP7-HEALTHF4-2007-201550), InterOmics (PB05 MIUR-CNR Italian Flagship Project), and the “Associazione per lo sviluppo della ricerca sull'ipertensione arteriosa e sulle malattie cardiovascolari—ONLUS.” GenHAT was supported by NIH grants R01 HL123782 and R01 HL063082, and N.A. was also supported by NIH grant T32 HL007457.; Funding text 2: C.W.M. is supported by National Institutes of Health (NIH) grant K01 HL141690. ASCOT was funded by the National Institutes for Health Research (NIHR) as part of the portfolio of translational research of the NIHR Barts Biomedical Research Unit and the NIHR Biomedical Research Centre at Imperial College, the International Centre for Circulatory Health Charity, and the Medical Research Council through G952010. ACCORD research was supported by NIH grants R01 HL110380 and R01 HL110400, and intramural funds from the National Institute of Environmental Health Sciences. ACCORD cohort was supported by Contract Nos. N01‐HC‐95178, N01‐HC‐95179, N01‐HC‐95180, N01‐HC‐95181, N01‐HC‐95182, N01‐HC‐95183, N01‐HC‐95184, IAA #Y1‐HC‐9035, and IAA #Y1‐HC‐1010 from the National Heart, Lung, and Blood Institute (NHLBI), with additional support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Eye Institute (NEI), the National Institute on Aging (NIA), and the Centers for Disease Control and Prevention (CDC). INVEST was supported by the NIH grants R01 HL074730, U01 GM074492, and NIH CTSA grant UL1 RR092890, as well as grants from the University of Florida Opportunity Fund and Abbott Pharmaceuticals. The genome‐wide genotyping for INVEST‐GENES was provided by RIKEN. SPS3 was supported by NIH grants R01 NS073346, U01 GM074492‐05S109, and U01 NS038529. Infrastructure for the CHARGE Consortium and the CHARGE Pharmacogenetics Working Group is supported in part by the NHLBI grants R01 HL105756, R01 HL103612, and R01 HL085251, and CHS contract number 75N92021D00006. Study descriptions and acknowledgements for the participating CHARGE cohorts are available in https://doi.org/10.1371/journal.pone.0140496 . Both the PEAR and PEAR‐2 studies were supported by NIH grants U01‐GM074492 and UL1 TR000064 (University of Florida); UL1 TR000454 (Emory University), and UL1 TR000135 (Mayo Clinic). PEAR was also supported by funds from the Mayo Foundation. LIFE‐Fin and GENRES were supported by the Sigrid Juselius Foundation, The Finnish Foundation for Cardiovascular Research, and the Helsinki University Central Hospital. BB‐SS studies were supported by the HYPERGENES project (FP7‐HEALTHF4‐2007‐201550), InterOmics (PB05 MIUR‐CNR Italian Flagship Project), and the “Associazione per lo sviluppo della ricerca sull'ipertensione arteriosa e sulle malattie cardiovascolari—ONLUS.” GenHAT was supported by NIH grants R01 HL123782 and R01 HL063082, and N.A. was also supported by NIH grant T32 HL007457. ","Virani S.S., Et al., Tsao CW and Subcommittee AHACoEaPSCaSS. Heart disease and stroke statistics-2020 Update: a report from the American Heart Association, Circulation, 141, pp. e139-e596, (2020); Mills K.T., Stefanescu A., He J., The global epidemiology of hypertension, Nat. Rev. Nephrol., 16, pp. 223-237, (2020); Whelton P.K., Et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Hypertension, 71, pp. 1269-1324, (2018); Chobanian A.V., Et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, pp. 2560-2572, (2003); Maddox T.M., Et al., 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee, J. Am. Coll. Cardiol., 77, pp. 772-810, (2021); Pepine C.J., Et al., A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial, JAMA, 290, pp. 2805-2816, (2003); Dahlof B., Et al., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial, Lancet, 366, pp. 895-906, (2005); Cushman W.C., Et al., Effects of intensive blood-pressure control in type 2 diabetes mellitus, N. Engl. J. Med., 362, pp. 1575-1585, (2010); Benavente O.R., Et al., Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial, Lancet, 382, pp. 507-515, (2013); Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, pp. 2981-2997, (2002); Pepine C.J., Et al., Predictors of adverse outcome among patients with hypertension and coronary artery disease, J. Am. Coll. Cardiol., 47, pp. 547-551, (2006); Beitelshees A.L., Et al., KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST), Pharmacogenet. Genomics, 17, pp. 719-729, (2007); McDonough C.W., Et al., Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes, Hypertension, 1, (2013); McDonough C.W., Et al., Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics, J. Hypertens., 31, pp. 698-704, (2013); Pacanowski M.A., Et al., beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension, Clin. Pharmacol. Ther., 84, pp. 715-721, (2008); Lynch A.I., Et al., Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study, Pharmacogenet. Genomics, 22, pp. 355-366, (2012); Lynch A.I., Et al., Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study, Pharmacogenet. Genomics, 19, pp. 415-421, (2009); Bis J.C., Et al., Drug-gene interactions of antihypertensive medications and risk of incident cardiovascular disease: a pharmacogenomics study from the CHARGE Consortium, PLoS One, 10, (2015); Sever P.S., Et al., Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial, J. Hypertens., 19, pp. 1139-1147, (2001); Williamson J.D., Et al., The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods, Am. J. Cardiol., 99, pp. 112i-122i, (2007); Pepine C.J., Et al., Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension, J. Am. Coll. Cardiol., 32, pp. 1228-1237, (1998); Benavente O.R., Et al., The Secondary Prevention of Small Subcortical Strokes (SPS3) study, Int. J. Stroke, 6, pp. 164-175, (2011); Singh S., Et al., Genome-wide meta-analysis of blood pressure response to β, J. Am. Heart Assoc., 8, (2019); Arnett D.K., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, pp. 3374-3383, (2005); Buse J.B., Et al., Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods, Am. J. Cardiol., 99, pp. 21i-33i, (2007); Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D., Principal components analysis corrects for stratification in genome-wide association studies, Nat. Genet., 38, pp. 904-909, (2006); Purcell S., Et al., PLINK: a tool set for whole-genome association and population-based linkage analyses, Am. J. Hum. Genet., 81, pp. 559-575, (2007); Aulchenko Y.S., Struchalin M.V., van Duijn C.M., ProbABEL package for genome-wide association analysis of imputed data, BMC Bioinformatics, 11, (2010); Winkler T.W., Et al., Quality control and conduct of genome-wide association meta-analyses, Nat. Protoc., 9, pp. 1192-1212, (2014); Willer C.J., Li Y., Abecasis G.R., METAL: fast and efficient meta-analysis of genomewide association scans, Bioinformatics, 26, pp. 2190-2191, (2010); Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, pp. 1903-1913, (2002); The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans, Science, 348, pp. 648-660, (2015); Li C., Et al., Genome-wide linkage and positional association analyses identify associations of novel AFF3 and NTM genes with triglycerides: the GenSalt study, J. Genet. Genomics, 42, pp. 107-117, (2015); Cao T.H., Et al., Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure, Lancet, 385, (2015); Luukkonen T.M., Et al., A balanced translocation truncates Neurotrimin in a family with intracranial and thoracic aortic aneurysm, J. Med. Genet., 49, pp. 621-629, (2012); Sanz R., Ferraro G.B., Fournier A.E., IgLON cell adhesion molecules are shed from the cell surface of cortical neurons to promote neuronal growth, J. Biol. Chem., 290, pp. 4330-4342, (2015); Singh K., Et al., The combined impact of IgLON family proteins Lsamp and Neurotrimin on developing neurons and behavioral profiles in mouse, Brain Res. Bull., 140, pp. 5-18, (2018); Kim S.J., Et al., Genetic association of short sleep duration with hypertension incidence–a 6-year follow-up in the Korean genome and epidemiology study, Circ. J., 76, pp. 907-913, (2012); Kettunen E., Et al., Asbestos-associated genome-wide DNA methylation changes in lung cancer, Int. J. Cancer, 141, pp. 2014-2029, (2017); Avery C.L., Et al., Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval, Pharmacogenomics J., 14, pp. 6-13, (2014); Akbar F., Heinonen S., Pirskanen M., Uimari P., Tuomainen T.P., Salonen J.T., Haplotypic association of DDAH1 with susceptibility to pre-eclampsia, Mol. Hum. Reprod., 11, pp. 73-77, (2005); Ioannidis J.P., To replicate or not to replicate: the case of pharmacogenetic studies: Have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?, Circ. Cardiovasc. Genet., 6, pp. 413-418, (2013); Aslibekyan S., Claas S.A., Arnett D.K., To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation, Circ. Cardiovasc. Genet., 6, pp. 409-412, (2013); Beitelshees A.L., Et al., CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response, Circ. Cardiovasc. Genet., 2, pp. 362-370, (2009); Meyer U.A., Pharmacogenetics - five decades of therapeutic lessons from genetic diversity, Nat. Rev. Genet., 5, pp. 669-676, (2004); Kraus V.B., Biomarkers as drug development tools: discovery, validation, qualification and use, Nat. Rev. Rheumatol., 14, pp. 354-362, (2018); Aronson S.J., Rehm H.L., Building the foundation for genomics in precision medicine, Nature, 526, pp. 336-342, (2015)","C.W. McDonough; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, United States; email: cmcdonough@cop.ufl.edu","","John Wiley and Sons Inc","","","","","","00099236","","CLPTA","34231218","English","Clin. Pharmacol. Ther.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85112363428"
"Molina M.S.; Rocamora E.N.; Bendicho A.I.; Vázquez E.G.; Zorio E.; Rodriguez F.D.; Ortuño C.G.; Rodríguez A.I.; Sánchez-López A.J.; Rubio R.J.; Moreno-Docón A.; Marcos P.J.; Pavía P.G.; Villa R.B.; Gimeno Blanes J.R.","Molina, Maria Sabater (15726295300); Rocamora, Elisa Nicolás (57443416500); Bendicho, Asunción Iborra (57188623249); Vázquez, Elisa García (7007039892); Zorio, Esther (6508200962); Rodriguez, Fernando Domínguez (57442838800); Ortuño, Cristina Gil (57218766973); Rodríguez, Ana Isabel (57442906700); Sánchez-López, Antonio J. (58832241600); Rubio, Rubén Jara (26641241800); Moreno-Docón, Antonio (23095162700); Marcos, Pedro J. (36573662800); Pavía, Pablo García (57197883068); Villa, Roberto Barriales (57442906800); Gimeno Blanes, Juan R. (57208485659)","15726295300; 57443416500; 57188623249; 7007039892; 6508200962; 57442838800; 57218766973; 57442906700; 58832241600; 26641241800; 23095162700; 36573662800; 57197883068; 57442906800; 57208485659","Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease","2022","PLoS ONE","17","2 February","e0263140","","","","44","10.1371/journal.pone.0263140","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124188905&doi=10.1371%2fjournal.pone.0263140&partnerID=40&md5=c8ee4588ee459c7127231232fc8dba4f","Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Cardiogenetic Laboratory, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN Guard-Heart), Madrid, Spain; Microbiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Infectious Disease, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Cardiology Department, Unidad de Cardiopatías Familiares y Muerte Súbita, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain; Biobanco Hospital Universitario Puerta de Hierro, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain; IntensiveCareUnit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Dirección Asistencial, Servicio de Neumología, Complejo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain; Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain; Cardiac Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain","Molina M.S., Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, Cardiogenetic Laboratory, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain, Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN Guard-Heart), Madrid, Spain; Rocamora E.N., Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Bendicho A.I., Microbiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Vázquez E.G., Department of Infectious Disease, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Zorio E., Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, Cardiology Department, Unidad de Cardiopatías Familiares y Muerte Súbita, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Rodriguez F.D., Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN Guard-Heart), Madrid, Spain, Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain; Ortuño C.G., Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, Cardiogenetic Laboratory, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain; Rodríguez A.I., Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Sánchez-López A.J., Biobanco Hospital Universitario Puerta de Hierro, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain; Rubio R.J., IntensiveCareUnit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Moreno-Docón A., Microbiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; Marcos P.J., Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, Dirección Asistencial, Servicio de Neumología, Complejo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain; Pavía P.G., Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN Guard-Heart), Madrid, Spain, Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain; Villa R.B., Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, Cardiac Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Gimeno Blanes J.R., Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, Cardiogenetic Laboratory, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain, Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Madrid, Spain, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN Guard-Heart), Madrid, Spain","Background Infection by the SARS-Cov-2 virus produces in humans a disease of highly variable and unpredictable severity. The presence of frequent genetic single nucleotide polymorphisms (SNPs) in the population might lead to a greater susceptibility to infection or an exaggerated inflammatory response. SARS-CoV-2 requires the presence of the ACE2 protein to enter in the cell and ACE2 is a regulator of the renin-angiotensin system. Accordingly, we studied the associations between 8 SNPs from AGTR1, ACE2 and ACE genes and the severity of the disease produced by the SARS-Cov-2 virus. Methods 318 (aged 59.6±17.3 years, males 62.6%) COVID-19 patients were grouped based on the severity of symptoms: Outpatients (n = 104, 32.7%), hospitalized on the wards (n = 73, 23.0%), Intensive Care Unit (ICU) (n = 84, 26.4%) and deceased (n = 57, 17.9%). Comorbidity data (diabetes, hypertension, obesity, lung disease and cancer) were collected for adjustment. Genotype distribution of 8 selected SNPs among the severity groups was analyzed. Results Four SNPs in ACE2 were associated with the severity of disease. While rs2074192 andrs1978124showed a protector effectassuming an overdominant model of inheritance (G/A vs. GG-AA, OR = 0.32, 95%CI = 0.12–0.82; p = 0.016 and A/G vs. AA-GG, OR = 0.37, 95%CI: 0.14–0.96; p = 0.038, respectively); the SNPs rs2106809 and rs2285666were associated with an increased risk of being hospitalized and a severity course of the disease with recessive models of inheritance (C/C vs. T/C-T/T, OR = 11.41, 95% CI: 1.12–115.91; p = 0.012) and (A/A vs. GG-G/A, OR = 12.61, 95% CI: 1.26–125.87; p = 0.0081). As expected, an older age (OR = 1.47), male gender (OR = 1.98) and comorbidities (OR = 2.52) increased the risk of being admitted to ICU or death vs more benign outpatient course. Multivariable analysis demonstrated the role of the certain genotypes (ACE2) with the severity of COVID-19 (OR: 0.31, OR 0.37 for rs2074192 and rs1978124, and OR = 2.67, OR = 2.70 for rs2106809 and rs2285666, respectively). Hardy-Weinberg equilibrium in hospitalized group for I/D SNP in ACE was not showed (p<0.05), which might be due to the association with the disease. No association between COVID-19 disease and the different AGTR1 SNPs was evidenced on multivariable, nevertheless the A/A genotype for rs5183 showed an higher hospitalization risk in patients with comorbidities. Conclusions Different genetic variants in ACE2 were associated with a severe clinical course and death groups of patients with COVID-19. ACE2 common SNPs in the population might modulate severity of COVID-19 infection independently of other known markers like gender, age and comorbidities. Copyright: © 2022 Sabater Molina et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","angiotensin converting enzyme 2; apelin receptor; dipeptidyl carboxypeptidase; ACE gene; ACE2 gene; adult; AGTR1 gene; Article; comorbidity; coronavirus disease 2019; diabetes mellitus; disease severity; female; gender; gene; genetic association; genotype; hospital admission; hospitalization; human; hypertension; inheritance; intensive care unit; lung disease; major clinical study; male; malignant neoplasm; middle aged; obesity; outpatient; risk factor; single nucleotide polymorphism; ward","","dipeptidyl carboxypeptidase, 9015-82-1","","","","","Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 11, pp. 1061-1069, (2020); Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, pp. 1054-1062, (2020); Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 6965, pp. 450-454, (2003); Guo J, Huang Z, Lin L, Lv J., Coronavirus disease 2019 (covid-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection, J Am Heart Assoc, 9, 7, (2020); Sommerstein R, Kochen MM, Messerli FH, Grani C., Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?, J Am Heart Assoc, 9, 7, (2020); Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z., Covid-19 infection and mortality: a physiologist’s perspective enlightening clinical features and plausible interventional strategies, Am J Physiol Lung Cell Mol Physiol, 318, 5, pp. L1020-L1022, (2020); Busse LW, Chow JH, McCurdy MT, Khanna AK., COVID-19 and the RAAS—a potential role for angiotensin II?, Crit Care, 24, 1, (2020); Mehrabadi ME, Hemmati R, Tashakor A, Homaei A, Yousefzadeh M, Hemati K, Et al., Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity, Biomed Pharmacother, 137, (2021); Rodrigues Prestes TR, Rocha NP, Miranda AS, Teixeira AL, Simoes-E-Silva AC., The Anti-Inflammatory Potential of ACE2/Angiotensin-(1–7)/Mas Receptor Axis: Evidence from Basic and Clinical Research, Curr Drug Targets, 18, 11, pp. 1301-1313, (2017); Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A., Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity, Hum Genomics, 14, 1, (2020); Libby P, Luscher T., COVID-19 is, in the end, an endothelial disease, Eur Heart J, 41, 32, pp. 3038-3044, (2020); Choudhary S, Sreenivasulu K, Mitra P, Misra S, Sharma P., Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19, Ann Lab Med, 41, 2, pp. 129-138, (2021); Yamamoto N, Ariumi Y, Nishida N, Yamamoto R, Bauer G, Gojobori T, Et al., SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype, Gene, 758, (2020); Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Et al., Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov, 6, (2020); Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, Et al., Angiotensin converting enzyme insertion/ deletion SNP is associated with susceptibility and outcome in acute respiratory distress syndrome, Am J Respir Crit Care Med, 166, pp. 646-650, (2002); Matsuda A, Kishi T, Jacob A, Aziz M, Wang P., Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis, BMC Med Genet, 13, (2012); Chen YY, Liu D, Zhang P, Zhong JC, Zhang CJ, Wu SL, Et al., Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors, J Hum Hypertens, 30, 12, pp. 766-771, (2016); Fan Z, Wu G, Yue M, Ye J, Chen Y, Xu B, Et al., Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism, Life Sci, 225, pp. 39-45, (2019); Srivastava A, Bandopadhyay A, Das D, Pandey RK, Singh V, Khanam N, Et al., Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India, Front Genet, 11, (2020); Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Et al., Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation, Am J Gastroenterol, 114, 4, pp. 607-619, (2019); Parchwani DN, Patel DD, Rawtani J, Yadav D., Analysis of Association of Angiotensin II Type 1 Receptor Gene A1166C Gene Polymorphism with Essential Hypertension, Indian J Clin Biochem, 33, 1, pp. 53-60, (2018); Baudin B., Polymorphism in angiotensin II receptor genes and hypertension, Exp Physiol, 90, 3, pp. 277-282, (2005); Kucukarabaci B, Birdane A, Gunes HV, Ata N, Degirmenci I, Basaran A, Et al., Association between angiotensin converting enzyme (ACE) gene I/D polymorphism frequency and plasma ACE concentration in patients with idiopathic dilated cardiomyopathy, AnadoluKardiyolDerg, 8, 1, pp. 65-66, (2008); Bellone M, Calvisi SL., ACE polymorphisms and COVID-19-related mortality in Europe, J Mol Med (Berl), 98, 11, pp. 1505-1509, (2020); Abdi E, Latifi-Navid S, Zahri S, Kholghi-Oskooei V, Mostafaiy B, Yazdanbod A, Et al., SNP-SNP interactions of oncogenic long non-coding RNAs HOTAIR and HOTTIP on gastric cancer susceptibility, Sci Rep, 10, 1, (2020); Schwarz J, Cooper D, Schuelke M., Et al., MutationTaster2: mutation prediction for the deep-sequencing age, Nat Methods, 11, pp. 361-362, (2014); Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC., Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review, JAMA, 324, 8, pp. 782-793, (2020); Kouhpayeh HR, Tabasi F, Dehvari M, Naderi M, Bahari G, Khalili T, Et al., Association between angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1) polymorphisms and COVID-19 infection in the southeast of Iran: a preliminary case-control study, Transl Med Commun, 6, 1, (2021); Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 2, pp. 281-292, (2020); Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Et al., Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2, Circ Res, 126, 10, pp. 1456-1474, (2020); Zhong J, Yan Z, Liu D, Ni Y, Zhao Z, Zhu S, Et al., Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome, J Lab Clin Med, 147, 2, pp. 91-95, (2006); Luo Y, Liu C, Guan T, Li Y, Lai Y, Li F, Et al., Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang, Hypertens Res, 42, 5, pp. 681-689, (2019); Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, pp. 270-273, (2020); Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med, 11, 8, pp. 875-879, (2005); Karakas Celik S, Cakmak Genc G, Piskin N, Acikgoz B, Altinsoy B, Kurucu Issiz B, Et al., Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study, J Med Virol, 93, 10, pp. 5947-5952, (2021); Asselta R, Paraboschi EM, Mantovani A, Duga S., ACE2 andTMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy, Aging (Albany NY), 12, 11, pp. 10087-10098, (2020); Duan LJ, Wang XD., Analysis of correlations between coronary heart disease and haplotypes of the angiotensin II receptor type 1 (AGTR1) gene, Genet Mol Res, 15, 1, (2016); Feng W, Sun L, Qu XF., Association of AGTR1 and ACE2 gene polymorphisms with structural atrial fibrillation in a Chinese Han population, Pharmazie, 72, 1, pp. 17-21, (2017); Min LJ, Mogi M, Iwai M, Horiuchi M., Signaling mechanisms of angiotensin II in regulating vascular senescence, Ageing Res Rev, 8, 2, pp. 113-121, (2009); Benigni A, Orisio S, Noris M, Iatropoulos P, Castaldi D, Kamide K, Et al., Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity, Age (Dordr), 35, 3, pp. 993-1005, (2013); Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Riera-Fortuny C, Real JT, Chaves FJ, Morales-Suarez-Varela M, Martinez-Triguero ML, Morillas-Arino C, Et al., The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease, Int J Obes (Lond), 29, 1, pp. 78-84, (2005); He Q, Fan C, Yu M, Wallar G, Zhang ZF, Wang L, Et al., Associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population, PLoS One, 8, 10, (2013); Berge KE, Berg K., Cardiovascular risk factors in people with different genotypes in the insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme (ACE), Clin Genet, 52, 6, pp. 422-426, (1997); Philipp CS, Dilley A, Saidi P, Evatt B, Austin H, Zawadsky J, Et al., Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty, Thromb Haemost, 80, 6, pp. 869-873, (1998); Delanghe JR, Speeckaert MM, De Buyzere ML., COVID-19 infections are also affected by human ACE1 D/I polymorphism, Clin Chem Lab Med, 58, 7, pp. 1125-1126, (2020); Jacobs M, Lahousse L, Van Eeckhoutte HP, Wijnant SRA, Delanghe JR, Brusselle GG, Et al., Effect of ACE1 polymorphism rs1799752 on protein levels of ACE2, the SARS-CoV-2 entry receptor, in alveolar lung epithelium, ERJ Open Res, 7, 2, pp. 00940-2020, (2021)","M.S. Molina; Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; email: mariasm79es@hotmail.com","","Public Library of Science","","","","","","19326203","","POLNC","35120165","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85124188905"
"Lumpuy-Castillo J.; Lorenzo-Almorós A.; Pello-Lázaro A.M.; Sánchez-Ferrer C.; Egido J.; Tuñón J.; Peiró C.; Lorenzo Ó.","Lumpuy-Castillo, Jairo (57210829681); Lorenzo-Almorós, Ana (55892486400); Pello-Lázaro, Ana María (12238887800); Sánchez-Ferrer, Carlos (7006646703); Egido, Jesús (35463099300); Tuñón, José (57201276466); Peiró, Concepción (7003959254); Lorenzo, Óscar (54379474900)","57210829681; 55892486400; 12238887800; 7006646703; 35463099300; 57201276466; 7003959254; 54379474900","Cardiovascular damage in COVID-19: Therapeutic approaches targeting the renin-angiotensin-aldosterone system","2020","International Journal of Molecular Sciences","21","18","6471","1","18","17","16","10.3390/ijms21186471","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090729981&doi=10.3390%2fijms21186471&partnerID=40&md5=53e2a8e89190f01e7cbb7f6b61b24e76","Laboratory of Diabetes and Vascular pathology, Instituto de Investigaciones Sanitarias-Hospital Fundación Jiménez Díaz, Universidad Autónoma, Madrid, 28040, Spain; Department of Internal Medicine, Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain; Department of Cardiology, Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain; Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, 28049, Spain; Spanish Biomedical Research Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, 28029, Spain","Lumpuy-Castillo J., Laboratory of Diabetes and Vascular pathology, Instituto de Investigaciones Sanitarias-Hospital Fundación Jiménez Díaz, Universidad Autónoma, Madrid, 28040, Spain; Lorenzo-Almorós A., Department of Internal Medicine, Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain; Pello-Lázaro A.M., Department of Cardiology, Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain; Sánchez-Ferrer C., Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, 28049, Spain; Egido J., Laboratory of Diabetes and Vascular pathology, Instituto de Investigaciones Sanitarias-Hospital Fundación Jiménez Díaz, Universidad Autónoma, Madrid, 28040, Spain, Spanish Biomedical Research Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, 28029, Spain; Tuñón J., Laboratory of Diabetes and Vascular pathology, Instituto de Investigaciones Sanitarias-Hospital Fundación Jiménez Díaz, Universidad Autónoma, Madrid, 28040, Spain, Department of Cardiology, Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain; Peiró C., Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, 28049, Spain; Lorenzo Ó., Laboratory of Diabetes and Vascular pathology, Instituto de Investigaciones Sanitarias-Hospital Fundación Jiménez Díaz, Universidad Autónoma, Madrid, 28040, Spain, Spanish Biomedical Research Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, 28029, Spain","Coronavirus disease 2019 (COVID-19) is usually more severe and associated with worst outcomes in individuals with pre-existing cardiovascular pathologies, including hypertension or atherothrombosis. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can differentially infect multiple tissues (i.e., lung, vessel, heart, liver) in different stages of disease, and in an age-and sex-dependent manner. In particular, cardiovascular (CV) cells (e.g., endothelial cells, cardiomyocytes) could be directly infected and indirectly disturbed by systemic alterations, leading to hyperinflammatory, apoptotic, thrombotic, and vasoconstrictive responses. Until now, hundreds of clinical trials are testing antivirals and immunomodulators to decrease SARS-CoV-2 infection or related systemic anomalies. However, new therapies targeting the CV system might reduce the severity and lethality of disease. In this line, activation of the non-canonical pathway of the renin-angiotensin-aldosterone system (RAAS) could improve CV homeostasis under COVID-19. In particular, treatments with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARB) may help to reduce hyperinflammation and viral propagation, while infusion of soluble ACE2 may trap plasma viral particles and increase cardioprotective Ang-(1–9) and Ang-(1–7) peptides. The association of specific ACE2 polymorphisms with increased susceptibility of infection and related CV pathologies suggests potential genetic therapies. Moreover, specific agonists of Ang-(1–7) receptor could counter-regulate the hypertensive, hyperinflammatory, and hypercoagulable responses. Interestingly, sex hormones could also regulate all these RAAS components. Therefore, while waiting for an efficient vaccine, we suggest further investigations on the non-canonical RAAS pathway to reduce cardiovascular damage and mortality in COVID-19 patients. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.","ACE2/Ang-(1–7)/MasR; Cardiovascular; COVID-19; RAAS","Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Cardiovascular Diseases; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; amyloid precursor protein; androgen receptor; angiotensin converting enzyme 2; angiotensin[1-7]; bradykinin B2 receptor; D dimer; hydroxychloroquine; interleukin 18; interleukin 6; monocyte chemotactic protein 1; triacylglycerol; tumor necrosis factor; vascular cell adhesion molecule 1; angiotensin receptor antagonist; cardiotonic agent; dipeptidyl carboxypeptidase inhibitor; adult respiratory distress syndrome; cardiovascular disease; coronavirus disease 2019; disease severity; echocardiography; electrocardiogram; enzyme linked immunosorbent assay; heart failure; heart muscle fibrosis; heart rate; heart ventricle hypertrophy; human; hyperinflammation; hypertension; lethality; mean arterial pressure; mortality; renin angiotensin aldosterone system; Review; single nucleotide polymorphism; systolic blood pressure; thrombosis; upregulation; virus particle; animal; cardiovascular disease; complication; Coronavirus infection; pandemic; virus pneumonia","","angiotensin[1-7], 39386-80-6; hydroxychloroquine, 118-42-3, 525-31-5; interleukin 18, 189304-55-0; Angiotensin Receptor Antagonists, ; Angiotensin-Converting Enzyme Inhibitors, ; Cardiotonic Agents, ","","","FIS; Federación Española de Enfermedades Raras, FEDER, (DTS-2017/00203, PI17/01495); Instituto de Salud Carlos III, ISCIII, (SAF2017-84776-R); Universidad Autónoma de Madrid, UAM","The author’s research works have been supported by FIS/FEDER: PI17/01495 and DTS-2017/00203 from Instituto de Salud Carlos III (EJ), and SAF2017-84776-R. J.L.-C. is a predoctoral fellow with a FPI contract from UAM.","Chan J.W.M., Ng C.K., Chan Y.H., Mok T.Y.W., Lee S., Chu S.Y.Y., Law W.L., Lee M.P., Li P.C.K., Short Term Outcome and Risk Factors for Adverse Clinical Outcomes in Adults With Severe Acute Respiratory Syndrome (SARS), Thorax, 58, pp. 686-689, (2003); Badawi A., Ryoo S.G., Prevalence of Comorbidities in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV): A Systematic Review and Meta-Analysis, Int. J. Infect. Dis, 49, pp. 129-133, (2016); Raoult D., Zumla A., Locatelli F., Ippolito G., Kroemer G., Coronavirus Infections: Epidemiological, Clinical and Immunological Features and Hypotheses, Cell Stress, 4, pp. 66-75, (2020); Li R., Pei S., Chen B., Song Y., Zhang T., Yang W., Shaman J., Substantial Undocumented Infection Facilitates the Rapid Dissemination of Novel Coronavirus (SARS-CoV-2), Science, 368, pp. 489-493, (2020); Letko M., Marzi A., Munster V., Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses, Nat. Microbiol, 5, pp. 562-569, (2020); Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., Et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, pp. 271-280, (2020); Senapati S., Kumar S., Singh A.K., Banerjee P., Bhagavatula S., Assessment of Risk Conferred by Coding and Regulatory Variations of TMPRSS2 and CD26 in Susceptibility to SARS-CoV-2 Infection in Human, J. Genet, 99, pp. 1-5, (2020); Kim C.-H., SARS-CoV-2 Evolutionary Adaptation Toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus–Host Interaction, Int. J. Mol. Sci, 21, (2020); Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O., Pohlmann S., TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein, J. Virol, 88, pp. 1293-1307, (2013); Li M.-Y., Li L., Zhang Y., Wang X., Expression of the SARS-CoV-2 Cell Receptor Gene ACE2 in a Wide Variety of Human Tissues, Infect. Dis. Poverty, 9, pp. 1-7, (2020); Hamming I., Timens W., Bulthuis M., Lely A.T., Navis G., Van Goor H., Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis, J. Pathol, 203, pp. 631-637, (2004); Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Et al., Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China, Clin. Infect. Dis, 71, pp. 762-768, (2020); Felsenstein S., Herbert J.A., McNamara P.S., Hedrich C.M., COVID-19: Immunology and Treatment Options, Clin. Immunol, 215, (2020); Tufan A., Guler A.A., Matucci-Cerinic M., COVID-19, Immune System Response, Hyperinflammation and Repurposing Antirheumatic Drugs, Turk. J. Med Sci, 50, pp. 620-632, (2020); Sallenave J.-M., Guillot L., Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?, Front. Immunol, 11, (2020); Ratajczak M.Z., Kucia M., SARS-CoV-2 Infection and Overactivation of Nlrp3 Inflammasome As a Trigger of Cytokine “storm” and Risk Factor for Damage of Hematopoietic Stem Cells, Leukemia, 34, pp. 1726-1729, (2020); Yap J.K.Y., Moriyama M., Iwasaki A., Inflammasomes and Pyroptosis As Therapeutic Targets for COVID-19, J. Immunol, 205, pp. 307-312, (2020); De Lucena T.M.C., Santos A.F.D.S., De Lima B.R., Borborema M.E.D.A., Silva J.D.A., Fabricio B.R.D.L., Mechanism of Inflammatory Response in Associated Comorbidities in COVID-19, Diabetes Metab. Syndr. Clin. Res. Rev, 14, pp. 597-600, (2020); Weekly C.C., The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China, China CDC Wkly, 2, pp. 113-122, (2020); Porfidia A., Pola R., Venous Thromboembolism in COVID-19 Patients, J. Thromb. Haemost, 18, pp. 1516-1517, (2020); Sriram K., Insel P.A., A Hypothesis for Pathobiology and Treatment of COVID-19: The Centrality of ACE1 / ACE2 Imbalance, J. Pharmacol, (2020); Hu Y., Sun J., Dai Z., Deng H., Li X., Huang Q., Wu Y., Sun L., Xu Y., Prevalence and Severity of Corona Virus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis, J. Clin. Virol, 127, (2020); Guzik T., Mohiddin S.A., DiMarco A., Patel V., Savvatis K., Marelli-Berg F.M., Madhur M.S., Tomaszewski M., Maffia P., D'Acquisto F., Et al., COVID-19 and the Cardiovascular System: Implications for Risk Assessment, Diagnosis, and Treatment Options, Cardiovasc. Res, 116, pp. 1666-1687, (2020); Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Et al., Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study, Lancet, 395, pp. 1054-1062, (2020); Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T., Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome, Circulation, 141, pp. 1903-1914, (2020); Chen L., Li X., Chen M., Feng Y., Xiong C., The ACE2 Expression in Human Heart Indicates New Potential Mechanism of Heart Injury Among Patients Infected With SARS-CoV-2, Cardiovasc. Res, 116, pp. 1097-1100, (2020); Endemann D.H., Schiffrin E.L., Endothelial Dysfunction, J Am Soc Nephrol, 1515, pp. 1983-1992, (2004); Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H., Endothelial Cell Infection and Endotheliitis in COVID-19, Lancet, 395, pp. 1417-1418, (2020); Pons S., Fodil S., Azoulay E., Zafrani L., The Vascular Endothelium: The Cornerstone of Organ Dysfunction in Severe SARS-CoV-2 Infection, Crit. Care, 24, pp. 1-8, (2020); Aimes R., Zijlstra A., Hooper J., Ogbourne S., Sit M.-L., Fuchs S., Gotley D., Quigley J.P., Antalis T., Endothelial Cell Serine Proteases Expressed During Vascular Morphogenesis and Angiogenesis, Thromb. Haemost, 89, pp. 561-572, (2003); Vanarsdall A.L., Pritchard S.R., Wisner T.W., Liu J., Jardetzky T.S., Johnson D.C., CD147 Promotes Entry of Pentamer-Expressing Human Cytomegalovirus into Epithelial and Endothelial Cells, mBio, 9, (2018); Monteil V., Kwon H., Prado P., Hagelkruys A., Wimmer R.A., Stahl M., Leopoldi A., Garreta E., Del Pozo C.H., Prosper F., Et al., Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2, Cell, 181, pp. 905-913, (2020); Whyte C., Morrow G.B., Mitchell J.L., Chowdary P., Mutch N.J., Fibrinolytic Abnormalities in Acute Respiratory Distress Syndrome (ARDS) and Versatility of Thrombolytic Drugs to Treat COVID-19, J. Thromb. Haemost, 18, pp. 1548-1555, (2020); Menter T., Haslbauer J., Nienhold R., Savic S., Hopfer H., Deigendesch N., Frank S., Turek D., Willi N., Pargger H., Et al., A Post-Mortem Examination of COVID19 Patients Reveals Diffuse Alveolar Damage With Severe Capillary Congestion and Variegated Findings of Lungs and Other Organs Suggesting Vascular Dysfunction, Histopathology, 77, pp. 198-209, (2020); Pouletty M., Borocco C., Ouldali N., Caseris M., Basmaci R., Lachaume N., Bensaid P., Pichard S., Kouider H., Morelle G., Et al., Paediatric Multisystem Inflammatory Syndrome Temporally Associated With SARS-CoV-2 Mimicking Kawasaki Disease (Kawa-COVID-19): A Multicentre Cohort, Ann. Rheum. Dis, 79, pp. 999-1006, (2020); Yau J.W., Teoh H., Verma S., Endothelial Cell Control of Thrombosis, BMC Cardiovasc. Disord, 15, pp. 1-11, (2015); Magro C., Mulvey J.J., Berlin D., Nuovo G., Salvatore S., Harp J., Baxter-Stoltzfus A., Laurence J., Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of Severe COVID-19 Infection: A Report of Five Cases, Transl. Res, 220, pp. 1-13, (2020); Wichmann D., Sperhake J.-P., Lutgehetmann M., Steurer S., Edler C., Heinemann A., Heinrich F., Mushumba H., Kniep I., Schroder A.S., Et al., Autopsy Findings and Venous Thromboembolism in Patients With COVID-19, Ann. Intern. Med, 173, pp. 268-277, (2020); Mackman N., Antoniak S., Wolberg A., Kasthuri R., Key N., Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses, Arterioscler. Thromb. Vasc. Biol, 40, (2020); Oxley T.J., Mocco J., Majidi S., Kellner C.P., Shoirah H., Singh I.P., De Leacy R.A., Shigematsu T., Ladner T.R., Yaeger K.A., Et al., Large-Vessel Stroke As a Presenting Feature of Covid-19 in the Young, N. Engl. J. Med, 382, (2020); Tang N., Bai H., Chen X., Gong J., Li D., Sun Z., Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy, J. Thromb. Haemost, 18, pp. 1094-1099, (2020); Paranjpe I., Fuster V., Lala A., Russak A.J., Glicksberg B.S., Levin M.A., Charney A.W., Narula J., Fayad Z.A., Bagiella E., Et al., Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19, J. Am. Coll. Cardiol, 76, pp. 122-124, (2020); Santamarina M.G., Boisier D., Contreras R., Baque M., Volpacchio M., Beddings I., COVID-19: A Hypothesis Regarding the Ventilation-Perfusion Mismatch, Crit. Care, 24, pp. 1-4, (2020); Carsana L., Sonzogni A., Nasr A., Rossi R.S., Pellegrinelli A., Zerbi P., Rech R., Colombo R., Antinori S., Corbellino M., Et al., Pulmonary Post-Mortem Findings in a Series of COVID-19 Cases from Northern Italy: A Two-Centre Descriptive Study, Lancet Infect. Dis, (2020); Sardu C., Gargiulo G., Esposito G., Paolisso G., Marfella R., Impact of Diabetes Mellitus on Clinical Outcomes in Patients Affected by Covid-19, Cardiovasc. Diabetol, 19, pp. 1-4, (2020); Ryan P.M., Caplice N.M., Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?, Obesity, 28, pp. 1191-1194, (2020); Rali A.S., Ranka S., Shah Z., Sauer A.J., Mechanisms of Myocardial Injury in Coronavirus Disease 2019, Card. Fail. Rev, 6, (2020); Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z., Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19), JAMA Cardiol, 19, (2020); Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A., Jain S.S., Burkhoff D., Kumaraiah D., Rabbani L., Et al., COVID-19 and Cardiovascular Disease, Circular, 141, pp. 1648-1655, (2020); Chou C.-H., Hung C.-S., Liao C.-W., Wei L.-H., Chen C.-W., Shun C.-T., Wen W.-F., Wan C.-H., Wu X.-M., Chang Y.-Y., Et al., IL-6 Trans-Signalling Contributes to Aldosterone-Induced Cardiac Fibrosis, Cardiovasc. Res, 114, pp. 690-702, (2018); Gao L., Jiang D., Wen X.-S., Cheng X.-C., Sun M., He B., You L.-N., Lei P., Tan X.-W., Qin S., Et al., Prognostic Value of NT-ProBNP in Patients With Severe COVID-19, Respir. Res, 21, pp. 83-87, (2020); Catanzaro M., Fagiani F., Racchi M., Corsini E., Govoni S., Lanni C., Immune Response in COVID-19: Addressing a Pharmacological Challenge by Targeting Pathways Triggered by SARS-CoV-2, Signal Transduct. Target. Ther, 5, pp. 1-10, (2020); Bangalore S., Sharma A., Slotwiner A., Yatskar L., Harari R., Shah B., Ibrahim H., Friedman G.H., Thompson C., Alviar C.L., Et al., ST-Segment Elevation in Patients With Covid-19: A Case Series, N. Engl. J. Med, 382, pp. 2478-2480, (2020); Turner A.J., Hiscox J.A., Hooper N.M., ACE2: From Vasopeptidase to SARS Virus Receptor, Trends Pharmacol. Sci, 2525, pp. 291-294, (2004); Ding Y.-Q., Wang H., Shen H., Li Z., Geng J., Han H., Cai J., Li X., Kang W., Weng D., Et al., The Clinical Pathology of Severe Acute Respiratory Syndrome (SARS): A Report from China, J. Pathol, 200, pp. 282-289, (2003); Hu H., Ma F., Wei X., Fang Y., Coronavirus Fulminant Myocarditis Treated With Glucocorticoid and Human Immunoglobulin, Eur. Hear. J, 190, (2020); Song P., Li W., Xie J., Hou Y., You C., Cytokine Storm Induced by SARS-CoV-2, Clin. Chim. Acta, 509, pp. 280-287, (2020); Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C., COVID-19 and Cardiovascular Disease: From Basic Mechanisms to Clinical Perspectives, Nat. Rev. Cardiol, pp. 1-16, (2020); Park M.D., Macrophages: A Trojan Horse in COVID-19?, Nat. Rev. Immunol, 20, (2020); Kochav S.M., Coromilas E., Nalbandian A., Ranard L.S., Gupta A., Chung M.K., Gopinathannair R., Biviano A., Garan H., Wan E.Y., Cardiac Arrhythmias in COVID-19 Infection, Circ. Arrhythmia Electrophysiol, 13, (2020); Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China, JAMA, 323, pp. 1061-1069, (2020); Bhatla A., Mayer M.M., Adusumalli S., Hyman M.C., Oh E., Tierney A., Moss J., Chahal A.A., Anesi G., Denduluri S., Et al., COVID-19 and Cardiac Arrhythmias, Hear. Rhythm, 17, pp. 1439-1444, (2020); Goyal P., Choi J.J., Pinheiro L.C., Schenck E.J., Chen R., Jabri A., Satlin M.J., Campion T.R., Nahid M., Ringel J.B., Et al., Clinical Characteristics of Covid-19 in New York City, N. Engl. J. Med, 382, pp. 2372-2374, (2020); Atri D., Siddiqi H.K., Lang J.P., Nauffal V., Morrow D.A., Bohula E.A., COVID-19 for the Cardiologist, JACC Basic Transl. Sci, 5, pp. 518-536, (2020); Libby P., Loscalzo J., Ridker P.M., Farkouh M.E., Hsue P.Y., Fuster V., Hasan A.A., Amar S., Inflammation, Immunity, and Infection in Atherothrombosis, J. Am. Coll. Cardiol, 72, pp. 2071-2081, (2018); Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D., Executive Group on Behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018), J. Am. Coll Cardiol, 7272, pp. 2231-2264, (2018); Wu C.-H., Mohammadmoradi S., Chen J.Z., Sawada H., Daugherty A., Lu H.S., Renin-Angiotensin System and Cardiovascular Functions, Arter. Thromb. Vasc. Boil, 38, pp. e108-e116, (2018); Dijkman R., Jebbink M.F., Deijs M., Milewska A., Pyrc K., Buelow E., Van Der Bijl A., Van Der Hoek L., Replication-Dependent Downregulation of Cellular Angiotensin-Converting Enzyme 2 Protein Expression by Human Coronavirus NL63, J. Gen. Virol, 93, pp. 1924-1929, (2012); Dielis A.W., Smid M., Spronk H.M., Hamulyak K.A., Kroon A., Cate H.T., De Leeuw P.W., The Prothrombotic Paradox of Hypertension, Hypertension, 46, pp. 1236-1242, (2005); Ocaranza M.P., Riquelme J.A., Garcia L., Jalil J.E., Chiong M., Santos R.A.S., Lavandero S., Counter-Regulatory renin–angiotensin System in Cardiovascular Disease, Nat. Rev. Cardiol, 17, pp. 116-129, (2019); Povlsen A.L., Grimm D., Wehland M., Infanger M., Kruger M., The Vasoactive Mas Receptor in Essential Hypertension, J. Clin. Med, 9, (2020); Romero A., San Hipolito-Luengo A., Villalobos L.A., Vallejo S., Valencia I., Michalska P., Pajuelo-Lozano N., Sanchez-Perez I., Leon R., Bartha J.L., Et al., The Angiotensin-(1-7)/Mas Receptor Axis Protects from Endothelial Cell Senescence via Klotho and Nrf2 Activation, Aging Cell, 18, (2019); Sampaio W.O., De Castro C.H., Santos R.A., Schiffrin E.L., Touyz R.M., Angiotensin-(1-7) Counterregulates Angiotensin II Signaling in Human Endothelial Cells, Hypertension, 50, pp. 1093-1098, (2007); Karnik S.S., Singh K.D., Tirupula K., Unal H., Significance of Angiotensin 1-7 Coupling With MAS1 Receptor and Other GPCRs to the Renin-Angiotensin System: IUPHAR Review 22, J. Pharmacol, 174, pp. 737-753, (2017); Santos R.A.S., Sampaio W.O., Alzamora A.C., Motta-Santos D., Alenina N., Bader M., The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7), Physiol Rev, 98, pp. 505-553, (2018); Fischer M., Baessler A., Schunkert H., Renin Angiotensin System and Gender Differences in the Cardiovascular System, Cardiovasc. Res, 53, pp. 672-677, (2002); Komukai K., Mochizuki S., Yoshimura M., Gender and the Renin-Angiotensin-Aldosterone System, Fundam. Clin. Pharmacol, 24, pp. 687-698, (2010); La Vignera S., Cannarella R., Condorelli R.A., Torre F., Aversa A., Calogero A.E., Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D, Int. J. Mol. Sci, 21, (2020); Nascimento I.J.B.D., Cacic N., Abdulazeem H.M., Von Groote T.C., Jayarajah U., Weerasekara I., Esfahani M.A., Civile V.T., Marusic A., Jeroncic A., Et al., Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis, J. Clin. Med, 9, (2020); Chanana N., Palmo T., Sharma K., Kumar R., Graham B.B., Pasha Q., Sex-Derived Attributes Contributing to SARS-CoV-2 Mortality, Am. J. Physiol. Metab, (2020); Bukowska A., Spiller L., Wolke C., Lendeckel U., Weinert S., Hoffmann J., Bornfleth P., Kutschka I., Gardemann A., Isermann B., Et al., Protective Regulation of the ACE2/ACE Gene Expression by Estrogen in Human Atrial Tissue from Elderly Men, Exp Biol Med, 242, pp. 1412-1423, (2017); Stelzig K.E., Canepa-Escaro F., Schiliro M., Berdnikovs S., Prakash Y.S., Chiarella S.E., Estrogen Regulates the Expression of SARS-CoV-2 Receptor ACE2 in Differentiated Airway Epithelial Cells, Am. J. Physiol. Cell. Mol. Physiol, 318, pp. L1280-L1281, (2020); Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., Huan Y., Yang P., Zhang Y., Deng W., Et al., A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS coronavirus–induced Lung Injury, Nat. Med, 11, pp. 875-879, (2005); Klein S.L., Flanagan K.L., Sex Differences in Immune Responses, Nat. Rev. Immunol, 16, pp. 626-638, (2016); Straub R.H., The Complex Role of Estrogens in Inflammation, Endocr. Rev, 28, pp. 521-574, (2007); Gross S., Jahn C., Cushman S., Bar C., Thum T., SARS-CoV-2 Receptor ACE2-Dependent Implications on the Cardiovascular System: From Basic Science to Clinical Implications, J. Mol. Cell. Cardiol, 144, pp. 47-53, (2020); Ferrario C.M., Mullick A.E., Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease, Pharmacol. Res, 125, pp. 57-71, (2017); Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J., A Human Homolog of Angiotensin-Converting Enzyme, J. Boil. Chem, 275, pp. 33238-33243, (2000); Basu R., Poglitsch M., Yogasundaram H., Thomas J., Rowe B.H., Oudit G.Y., Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure, J. Am. Coll. Cardiol, 69, pp. 805-819, (2017); Sukumaran V., Veeraveedu P.T., Gurusamy N., Yamaguchi K., Lakshmanan A.P., Ma M., Ma M., Suzuki K., Kodama M., Watanabe K., Cardioprotective Effects of Telmisartan Against Heart Failure in Rats Induced By Experimental Autoimmune Myocarditis through the Modulation of Angiotensin-Converting Enzyme-2/Angiotensin 1-7/Mas Receptor Axis, Int. J. Biol. Sci, 7, pp. 1077-1092, (2011); Furuhashi M., Moniwa N., Mita T., Fuseya T., Ishimura S., Ohno K., Shibata S., Tanaka M., Watanabe Y., Akasaka H., Et al., Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker, Am. J. Hypertens, 28, pp. 15-21, (2014); Fang L., Karakiulakis G., Roth M., Are Patients With Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?, Lancet Respir. Med, 8, (2020); Anker S.D., Butler J., Khan M.S., Abraham W.T., Bauersachs J., Bocchi E., Bozkurt B., Braunwald E., Chopra V.K., Cleland J.G., Et al., Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur. Hear. J, 41, pp. 2109-2117, (2020); Deshotels M.R., Xia H., Sriramula S., Lazartigues E., Filipeanu C.M., Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation through an Angiotensin II Type I Receptor-Dependent Mechanism, Hypertension, 64, pp. 1368-1375, (2014); Meng J., Xiao G., Zhang J., He X., Ou M., Bi J., Yang R., Di W., Wang Z., Li Z., Et al., Renin-Angiotensin System Inhibitors Improve the Clinical Outcomes of COVID-19 Patients With Hypertension, Emerg. Microbes Infect, 9, pp. 757-760, (2020); Klimas J., Olvedy M., Ochodnicka-Mackovicova K., Kruzliak P., Cacanyiova S., Kristek F., Krenek P., Ochodnicky P., Perinatally Administered Losartan Augments Renal ACE2 Expression But Not Cardiac or Renal Mas Receptor in Spontaneously Hypertensive Rats, J. Cell. Mol. Med, 19, pp. 1965-1974, (2015); Wysocki J., Ye M., Rodriguez E., Gonzalez-Pacheco F.R., Barrios C., Evora K., Schuster M., Loibner H., Brosnihan K.B., Ferrario C.M., Et al., Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2: Prevention of Angiotensin II-Dependent Hypertension, Hypertension, 55, pp. 90-98, (2009); Batlle D., Wysocki J., Satchell K., Soluble Angiotensin-Converting Enzyme 2: A Potential Approach for Coronavirus Infection Therapy?, Clin. Sci, 134, pp. 543-545, (2020); Haschke M., Schuster M., Poglitsch M., Loibner H., Salzberg M., Bruggisser M., Penninger J.M., Krahenbuhl S., Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects, Clin. Pharmacokinet, 52, pp. 783-792, (2013); Khan A., Benthin C., Zeno B., Albertson T.E., Boyd J., Christie J.D., Hall R., Poirier G., Ronco J.J., Tidswell M., Et al., A Pilot Clinical Trial of Recombinant Human Angiotensin-Converting Enzyme 2 in Acute Respiratory Distress Syndrome, Crit. Care, 21, (2017); Ocaranza M.P., Jalil J.E., Protective Role of the ACE2/Ang-(1–9) Axis in Cardiovascular Remodeling, Int. J. Hypertens, (2012); Sharif-Askari S.N., Sharif-Askari S.F., Alabed M., Temsah M.-H., Heialy A.S., Hamid Q., Halwani R., Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases With Smoking and COPD, Mol. Ther. Methods Clin. Dev, 18, pp. 1-6, (2020); Liu P.P., Blet A., Smyth D., Li H., The Science Underlying COVID-19: Implications for the Cardiovascular System, Circulation, 142, pp. 68-78, (2020); Ziegler C.G., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., Cao Y., Yousif A.S., Bals J., Hauser B.M., Et al., SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues, Cell, 181, pp. 1016-1035, (2020); Su S., Jiang S., A Suspicious Role of Interferon in the Pathogenesis of SARS-CoV-2 by Enhancing Expression of ACE2, Signal Transduct. Target. Ther, 5, pp. 1-2, (2020); Hussain M., Jabeen N., Raza F., Shabbir S., Baig A.A., Amanullah A., Aziz B., Structural Variations in Human ACE2 May Influence Its Binding With SARS-CoV-2 Spike Protein, J. Med. Virol, 92, pp. 1580-1586, (2020); Devaux C.A., Rolain J.-M., Raoult D., ACE2 Receptor Polymorphism: Susceptibility to SARS-CoV-2, Hypertension, Multi-Organ Failure, and COVID-19 Disease Outcome, J. Microbiol. Immunol. Infect, 53, pp. 425-435, (2020); Benetti E., Tita R., Spiga O., Ciolfi A., Birolo G., Bruselles A., Doddato G., Giliberti A., Marconi C., Et al., ACE2 Gene Variants May Underlie Interindividual Variability and Susceptibility to COVID-19 in the Italian Population, Eur. J. Hum. Genet, pp. 1-13, (2020); Darbani B., The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues, Int. J. Environ. Res. Public Health, 17, (2020); Wang J., Xu X., Zhou X., Chen P., Liang H., Li X., Zhong W., Hao P., Molecular Simulation of SARS-CoV-2 Spike Protein Binding to Pangolin ACE2 or Human ACE2 Natural Variants Reveals Altered Susceptibility to Infection, J. Gen. Virol, (2020); Stawiski E.W., Diwanji D., Suryamohan K., Gupta R.A., Fellouse F., Sathirapongsasuti F., Liu J., Jiang Y.-P., Ratan A., Mis M., Et al., Human ACE2 Receptor Polymorphisms Predict SARS-CoV-2 Susceptibility, BioRxiv, (2020); Tanaka P., Santos J., Oliveira E., Miglioli N., Assis A., Monteleone-Cassiano A., Ribeiro V., Duarte M., Machado M., Mascarenhas R., Et al., A Crispr-Cas9 System Designed to Introduce Point Mutations into the Human ACE2 Gene to Weaken the Interaction of the ACE2 Receptor With the SARS-CoV-2 S Protein, Preprints, (2020); Pan Y., Wang T., Li Y., Guan T., Lai Y., Shen Y., Zeyaweiding A., Maimaiti T., Li F., Zhao H., Et al., Association of ACE2 Polymorphisms With Susceptibility to Essential Hypertension and Dyslipidemia in Xinjiang, China, Lipids Health Dis, 17, (2018); Luo Y., Liu C., Guan T., Li Y., Lai Y., Li F., Zhao H., Maimaiti T., Zeyaweiding A., Correction: Association of ACE2 Genetic Polymorphisms With Hypertension-Related Target Organ Damages in South Xinjiang, Hypertens. Res, 42, pp. 681-689, (2019); Niu W., Qi Y., Hou S., Zhou W., Qiu C., Correlation of Angiotensin-Converting Enzyme 2 Gene Polymorphisms With Stage 2 Hypertension in Han Chinese, Transl. Res, 150, pp. 374-380, (2007); Liu C., Li Y., Guan T., Lai Y., Shen Y., Zeyaweiding A., Zhao H., Li F., Maimaiti T., ACE2 Polymorphisms Associated With Cardiovascular Risk in Uygurs With Type 2 Diabetes Mellitus, Cardiovasc. Diabetol, 17, (2018); Fan Z., Wu G., Yue M., Ye J., Chen Y., Xu B., Shu Z., Zhu J., Lu N., Tan X., Hypertension and Hypertensive Left Ventricular Hypertrophy Are Associated With ACE2 Genetic Polymorphism, Life Sci, 225, pp. 39-45, (2019); Wang S.-X., Tao T., Fu Z.-Q., Xie X.-Z., Wang H., Wang Y.-T., Polymorphisms of Angiotensin-Converting Enzyme 2 Gene Confer a Risk to Lone Atrial Fibrillation in Chinese Male Patients, Chin. Med. J, 126, pp. 4608-4611, (2013); Chen Y., Yu H., A3216 Relationship Between Genetic Variants of ACE2 Gene and Circulating Levels of ACE2 and Its Metabolites, J. Hypertens, 36, (2018); Peiro C., Moncada S., Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?, Circular, 141, pp. 1665-1666, (2020); Shete A., Urgent Need for Evaluating Agonists of Angiotensin-(1-7)/Mas Receptor Axis for Treating Patients With COVID-19, Int. J. Infect. Dis, 96, pp. 348-351, (2020); Patel V.B., Zhong J.-C., Grant M.B., Oudit G.Y., Role of the ACE2/Angiotensin 1–7 Axis of the Renin-Angiotensin System in Heart Failure, Circ. Res, 118, pp. 1313-1326, (2016); Becker L.K., Totou N.L., Moura S., Kangussu L., Millan R.D.S., Campagnole-Santos M.J., Coelho D., Motta-Santos D., Santos R.A., Eccentric Overload Muscle Damage Is Attenuated By a Novel Angiotensin-(1-7) Treatment, Int. J. Sports Med, 39, pp. 743-748, (2018); Meems L.M., Andersen I.A., Pan S., Harty G., Chen Y., Zheng Y., Harders G.E., Ichiki T., Heublein D.M., Iyer S.R., Et al., Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide, Hypertension, 73, pp. 900-909, (2019)","Ó. Lorenzo; Laboratory of Diabetes and Vascular pathology, Instituto de Investigaciones Sanitarias-Hospital Fundación Jiménez Díaz, Universidad Autónoma, Madrid, 28040, Spain; email: olorenzo@fjd.es; Ó. Lorenzo; Spanish Biomedical Research Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, 28029, Spain; email: olorenzo@fjd.es","","MDPI AG","","","","","","16616596","","","32899833","English","Int. J. Mol. Sci.","Review","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85090729981"
"Jiang Y.; Shi C.; Tian S.; Zhi F.; Shen X.; Shang D.; Tian J.","Jiang, Yanan (55538395400); Shi, Chunpeng (57671883800); Tian, Songyu (57031207000); Zhi, Fengnan (57297743200); Shen, Xiuyun (57212560587); Shang, Desi (42561820400); Tian, Jinwei (48461960600)","55538395400; 57671883800; 57031207000; 57297743200; 57212560587; 42561820400; 48461960600","Comprehensive molecular characterization of hypertension-related genes in cancer","2022","Cardio-Oncology","8","1","10","","","","0","10.1186/s40959-022-00136-z","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129622820&doi=10.1186%2fs40959-022-00136-z&partnerID=40&md5=9b27ed925a7436b20bca13df0f20db73","Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China; Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, 150081, China; Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hunan, Hengyang, 421001, China; Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China; The Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical University, Harbin, 150086, China","Jiang Y., Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China, Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, 150081, China; Shi C., Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China; Tian S., Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China; Zhi F., Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China; Shen X., Department of Pharmacology (State-Province Key Laboratories of Biomedicine- Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China; Shang D., The First Affiliated Hospital, Hengyang Medical School, University of South China, Hunan, Hengyang, 421001, China; Tian J., Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China, The Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical University, Harbin, 150086, China","Background: During cancer treatment, patients have a significantly higher risk of developing cardiovascular complications such as hypertension. In this study, we investigated the internal relationships between hypertension and different types of cancer. Methods: First, we comprehensively characterized the involvement of 10 hypertension-related genes across 33 types of cancer. The somatic copy number alteration (CNA) and single nucleotide variant (SNV) of each gene were identified for each type of cancer. Then, the expression patterns of hypertension-related genes were analyzed across 14 types of cancer. The hypertension-related genes were aberrantly expressed in different types of cancer, and some were associated with the overall survival of patients or the cancer stage. Subsequently, the interactions between hypertension-related genes and clinically actionable genes (CAGs) were identified by analyzing the co-expressions and protein–protein interactions. Results: We found that certain hypertension-related genes were correlated with CAGs. Next, the pathways associated with hypertension-related genes were identified. The positively correlated pathways included epithelial to mesenchymal transition, hormone androgen receptor, and receptor tyrosine kinase, and the negatively correlated pathways included apoptosis, cell cycle, and DNA damage response. Finally, the correlations between hypertension-related genes and drug sensitivity were evaluated for different drugs and different types of cancer. The hypertension-related genes were all positively or negatively correlated with the resistance of cancer to the majority of anti-cancer drugs. These results highlight the importance of hypertension-related genes in cancer. Conclusions: This study provides an approach to characterize the relationship between hypertension-related genes and cancers in the post-genomic era. © 2022, The Author(s).","Cardio-oncology; Hypertension-related genes; Pan-cancer","adducin 1; aldosterone synthase; androgen receptor; angiotensin 2 receptor type 1; angiotensinogen; dipeptidyl carboxypeptidase; endothelial nitric oxide synthase; insulin receptor; natriuretic peptide a; peptides and proteins; prostaglandin I2 synthase; protein tyrosine kinase; renin; unclassified drug; apoptosis; Article; cancer patient; cancer staging; cancer survival; cell cycle; cell migration; controlled study; DNA damage response; drug sensitivity; epithelial mesenchymal transition; gene expression; human; hypertension; malignant neoplasm; overall survival; protein protein interaction; single nucleotide polymorphism","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; protein tyrosine kinase, 80449-02-1; renin, 61506-93-2, 9015-94-5","","","Harbin Medical University Youth Talents Start-up Funding, (2019-QD-02); National Natural Science Foundation of China, NSFC, (81803524, 81902631, 81971715); China Postdoctoral Science Foundation, (2018M641878); Natural Science Foundation of Heilongjiang Province, (LH2021H018); Heilongjiang Provincial Postdoctoral Science Foundation, (LBH-Q21134, LBH-Z18168)","This work was supported by the National Natural Science Foundation of China (Grant No. 81971715, 81803524, and 81902631), Natural Science Foundation of Heilongjiang Province (Grant No. LH2021H018), the China Postdoctoral Science Foundation (Grant No. 2018M641878), the Heilongjiang Postdoctoral Foundation (Grant No. LBH-Z18168 and LBH-Q21134), College of Pharmacy, Harbin Medical University Youth Talents Start-up Funding (2019-QD-02). ","Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2020, CA Cancer J Clin, 70, 1, pp. 7-30, (2020); Budolfsen C., Faber J., Grimm D., Kruger M., Bauer J., Wehland M., Infanger M., Magnusson N.E., Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment, Curr Vasc Pharmacol, 17, 6, pp. 618-634, (2019); Abdel-Rahman O., Lamarca A., Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival, Expert Rev Gastroenterol Hepatol, 11, 1, pp. 75-83, (2017); Chang L., An Y., Yang S., Zhang X., Meta-analysis of therapeutic effects and the risks of hypertension and hyperglycemia in patients with renal cell carcinoma who were receiving antiangiogenic drugs, J Cancer Res Ther, 12, pp. 96-103, (2016); Zhang X., Shao Y., Wang K., Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis, Expert Rev Clin Pharmacol, 9, 8, pp. 1109-1115, (2016); Zhao T., Wang X., Xu T., Xu X., Liu Z., Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis, Oncotarget, 8, 31, pp. 51492-51506, (2017); Santoni M., Conti A., Massari F., Di Nunno V., Faloppi L., Galizia E., Morbiducci J., Piva F., Buti S., Iacovelli R., Et al., Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies, Expert Rev Cardiovasc Ther, 17, 12, pp. 917-927, (2019); Largent J.A., Bernstein L., Horn-Ross P.L., Marshall S.F., Neuhausen S., Reynolds P., Ursin G., Zell J.A., Ziogas A., Anton-Culver H., Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort, Cancer causes & control: CCC, 21, 10, pp. 1615-1624, (2010); Choi M.Y., Jee S.H., Sull J.W., Nam C.M., The effect of hypertension on the risk for kidney cancer in Korean men, Kidney Int, 67, 2, pp. 647-652, (2005); Zhang L.N., Liu P.P., Wang L., Yuan F., Xu L., Xin Y., Fei L.J., Zhong Q.L., Huang Y., Xu L., Et al., Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension, PLoS ONE, 8, 5, (2013); Shen N., Liu C., Li J., Chen X., Yang Y., Zhu Y., Gong Y., Gong J., Zhong R., Cheng L., Et al., A phosphorylation-related variant ADD1-rs4963 modifies the risk of colorectal cancer, PLoS ONE, 10, 3, (2015); Carter S.L., Cibulskis K., Helman E., McKenna A., Shen H., Zack T., Laird P.W., Onofrio R.C., Winckler W., Weir B.A., Et al., Absolute quantification of somatic DNA alterations in human cancer, Nat Biotechnol, 30, 5, pp. 413-421, (2012); Leiserson M.D., Wu H.T., Vandin F., Raphael B.J., CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer, Genome Biol, 16, (2015); Wang Y., Xu X., Maglic D., Dill M.T., Mojumdar K., Ng P.K., Jeong K.J., Tsang Y.H., Moreno D., Bhavana V.H., Et al., Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer, Cell Rep, 25, 5, pp. 1304-1317 e1305, (2018); Liu B., Zhou X., Wu D., Zhang X., Shen X., Mi K., Qu Z., Jiang Y., Shang D., Comprehensive characterization of a drug-resistance-related ceRNA network across 15 anti-cancer drug categories, Mol Ther Nucleic Acids, 24, pp. 11-24, (2021); Van Allen E.M., Wagle N., Stojanov P., Perrin D.L., Cibulskis K., Marlow S., Jane-Valbuena J., Friedrich D.C., Kryukov G., Carter S.L., Et al., Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nat Med, 20, 6, pp. 682-688, (2014); Mak M.P., Tong P., Diao L., Cardnell R.J., Gibbons D.L., William W.N., Skoulidis F., Parra E.R., Rodriguez-Canales J., Wistuba I.I., Et al., A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition, Clinical cancer research: an official journal of the American Association for Cancer Research, 22, 3, pp. 609-620, (2016); Goel R., Harsha H.C., Pandey A., Prasad T.S., Human Protein Reference Database and Human Proteinpedia as resources for phosphoproteome analysis, Mol Biosyst, 8, 2, pp. 453-463, (2012); Oughtred R., Rust J., Chang C., Breitkreutz B.J., Stark C., Willems A., Boucher L., Leung G., Kolas N., Zhang F., Et al., The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions, Protein Sci, 30, 1, pp. 187-200, (2021); Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci USA, 102, 43, pp. 15545-15550, (2005); Akbani R., Ng P.K., Werner H.M., Shahmoradgoli M., Zhang F., Ju Z., Liu W., Yang J.Y., Yoshihara K., Li J., Et al., A pan-cancer proteomic perspective on The Cancer Genome Atlas, Nat Commun, 5, (2014); Armani C., Botto N., Andreassi M.G., Susceptibility genes in hypertension, Curr Pharm Des, 17, 28, pp. 2973-2986, (2011); Mermel C.H., Schumacher S.E., Hill B., Meyerson M.L., Beroukhim R., Getz G., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome biology, 12, 4, (2011); Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., Et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 7457, pp. 214-218, (2013); Peri S., Navarro J.D., Kristiansen T.Z., Amanchy R., Surendranath V., Muthusamy B., Gandhi T.K., Chandrika K.N., Deshpande N., Suresh S., Et al., Human protein reference database as a discovery resource for proteomics, Nucleic acids research, 32, Database issue, pp. D497-D501, (2004); Chatr-Aryamontri A., Breitkreutz B.J., Oughtred R., Boucher L., Heinicke S., Chen D., Stark C., Breitkreutz A., Kolas N., O'Donnell L., Et al., (Database issue), 43, pp. D470-D478, (2015); Cathcart M.C., Gray S.G., Baird A.M., Boyle E., Gately K., Kay E., Cummins R., Pidgeon G.P., O'Byrne K.J., Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer, Cancer, 117, 22, pp. 5121-5132, (2011); Li H.Y., McSharry M., Walker D., Johnson A., Kwak J., Bullock B., Neuwelt A., Poczobutt J.M., Sippel T.R., Keith R.L., Et al., Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II, Oncoimmunology, 7, 5, (2018); Camacho M., Pineiro Z., Alcolea S., Garcia J., Balart J., Terra X., Aviles-Jurado F.X., Soler M., Quer M., Leon X., Et al., Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy, J Pathol, 235, 1, pp. 125-135, (2015); Lechuga S., Amin P.H., Wolen A.R., Ivanov A.I., Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression, Biochim Biophys Acta Mol Cell Res, 1866, 3, pp. 395-408, (2019); Goncalves D.A., Xisto R., Goncalves J.D., da Silva D.B., Moura Soares J.P., Icimoto M.Y., Sant'Anna C., Gimenez M., de Angelis K., Llesuy S., Et al., Imbalance between nitric oxide and superoxide anion induced by uncoupled nitric oxide synthase contributes to human melanoma development, Int J Biochem Cell Biol, 115, (2019); Recouvreux M.V., Moldenhauer M.R., Galenkamp K.M.O., Jung M., James B., Zhang Y., Lowy A., Bagchi A., Commisso C., Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer, J Exp Med, 217, 9, (2020); McAllister M., Constancio V., Patek S., Gan H.W.G., Bailey P., Wheadon H., Underwood M., Leung H., Edwards J., Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer, Prostate, 80, 15, pp. 1353-1364, (2020); Bell E.S., Coelho P.P., Park M., LC3C mediates selective autophagy of the MET RTK, inhibiting cancer cell invasion, Autophagy, 16, 5, pp. 959-961, (2020); Bildik G., Esmaeilian Y., Vatansever D., Bilir E., Taskiran C., Oktem O., A comparative molecular analysis of DNA damage response, cell cycle progression, viability and apoptosis of malignant granulosa cells exposed to gemcitabine and cisplatin, Mol Biol Rep, 47, 5, pp. 3789-3796, (2020); Jeong S., Kim B.G., Kim D.Y., Kim B.R., Kim J.L., Park S.H., Na Y.J., Jo M.J., Yun H.K., Jeong Y.A., Et al., Cannabidiol Overcomes Oxaliplatin Resistance by Enhancing NOS3- and SOD2-Induced Autophagy in Human Colorectal Cancer Cells, Cancers (Basel), 11, 6, (2019); Rhodes D.R., Ateeq B., Cao Q., Tomlins S.A., Mehra R., Laxman B., Kalyana-Sundaram S., Lonigro R.J., Helgeson B.E., Bhojani M.S., Et al., AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist, Proc Natl Acad Sci USA, 106, 25, pp. 10284-10289, (2009); de Ronde J.J., Lips E.H., Mulder L., Vincent A.D., Wesseling J., Nieuwland M., Kerkhoven R., Vrancken Peeters M.J., Sonke G.S., Rodenhuis S., Et al., SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer, Breast Cancer Res Treat, 137, 1, pp. 213-223, (2013)","D. Shang; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; email: sds_46@163.com; J. Tian; Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China; email: jinweitian1220@yeah.net","","BioMed Central Ltd","","","","","","20573804","","","","English","Cardio-Oncol.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-85129622820"
"Cilhoroz B.T.; Schifano E.D.; Panza G.A.; Ash G.I.; Corso L.; Chen M.-H.; Deshpande V.; Zaleski A.; Farinatti P.; Santos L.P.; Taylor B.A.; O'Neill R.J.; Thompson P.D.; Pescatello L.S.","Cilhoroz, Burak T. (57198428015); Schifano, Elizabeth D. (23028664800); Panza, Gregory A. (56331857700); Ash, Garrett I. (55311648500); Corso, Lauren (57191961850); Chen, Ming-Hui (7406352982); Deshpande, Ved (57191542047); Zaleski, Amanda (56083837600); Farinatti, Paulo (6505819325); Santos, Lucas P. (57189073387); Taylor, Beth A. (10440697800); O'Neill, Rachel J. (35453942200); Thompson, Paul D. (35392374400); Pescatello, Linda S. (7004269363)","57198428015; 23028664800; 56331857700; 55311648500; 57191961850; 7406352982; 57191542047; 56083837600; 6505819325; 57189073387; 10440697800; 35453942200; 35392374400; 7004269363","FURIN variant associations with postexercise hypotension are intensity and race dependent","2019","Physiological Reports","7","3","e13952","","","","8","10.14814/phy2.13952","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060955815&doi=10.14814%2fphy2.13952&partnerID=40&md5=233c76c4de1d9c8c33c002fc16eff37f","Department of Kinesiology, University of Connecticut, Storrs, CT, United States; Department of Statistics, University of Connecticut, Storrs, CT, United States; Department of Preventive Cardiology, Hartford Hospital, Hartford, CT, United States; School of Nursing, Yale University, New Haven, CT, United States; Department of Physical Activity Sciences, Rio de Janeiro State University, Rio de Janeiro, Brazil; Department of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States; Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT, United States","Cilhoroz B.T., Department of Kinesiology, University of Connecticut, Storrs, CT, United States; Schifano E.D., Department of Statistics, University of Connecticut, Storrs, CT, United States; Panza G.A., Department of Kinesiology, University of Connecticut, Storrs, CT, United States, Department of Preventive Cardiology, Hartford Hospital, Hartford, CT, United States; Ash G.I., School of Nursing, Yale University, New Haven, CT, United States; Corso L., Department of Kinesiology, University of Connecticut, Storrs, CT, United States; Chen M.-H., Department of Statistics, University of Connecticut, Storrs, CT, United States; Deshpande V., Department of Statistics, University of Connecticut, Storrs, CT, United States; Zaleski A., Department of Kinesiology, University of Connecticut, Storrs, CT, United States, Department of Preventive Cardiology, Hartford Hospital, Hartford, CT, United States; Farinatti P., Department of Physical Activity Sciences, Rio de Janeiro State University, Rio de Janeiro, Brazil; Santos L.P., Department of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Taylor B.A., Department of Kinesiology, University of Connecticut, Storrs, CT, United States, Department of Preventive Cardiology, Hartford Hospital, Hartford, CT, United States; O'Neill R.J., Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States, Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT, United States; Thompson P.D., Department of Preventive Cardiology, Hartford Hospital, Hartford, CT, United States; Pescatello L.S., Department of Kinesiology, University of Connecticut, Storrs, CT, United States, Institute for Systems Genomics, University of Connecticut, Storrs, CT, United States","FURIN is a proprotein convertase subtilisin/kexin enzyme important in pro-renin receptor processing, and FURIN (furin, paired basic amino acid cleaving enzyme) variants are involved in multiple aspects of blood pressure (BP) regulation. Therefore, we examined associations among FURIN variants and the immediate blood pressure (BP) response to bouts of aerobic exercise, termed postexercise hypotension (PEH). Obese (30.9 ± 3.6 kgm−2) Black- (n = 14) and White- (n = 9) adults 42.0 ± 9.8 year with hypertension (139.8 ± 10.4/84.6 ± 6.2 mmHg) performed three random experiments: bouts of vigorous (VIGOROUS) and moderate (MODERATE) intensity cycling and control. Subjects were then attached to an ambulatory BP monitor for 19 h. We performed deep-targeted exon sequencing with the Illumina TruSeq Custom Amplicon kit. FURIN genotypes were coded as the number of minor alleles (#MA) and selected for additional statistical analysis based upon Bonferonni or Benjamini–Yekutieli multiple testing corrected P-values under time-adjusted linear models for 19 hourly BP measurements. After VIGOROUS over 19 h, as FURIN #MA increased in rs12917264 (P = 2.4E-04) and rs75493298 (P = 6.4E-04), systolic BP (SBP) decreased 30.4–33.7 mmHg; and in rs12917264 (P = 1.6E-03) and rs75493298 (P = 9.7E-05), diastolic BP (DBP) decreased 17.6–20.3 mmHg among Blacks only. In addition, after MODERATE over 19 h in FURIN rs74037507 (P = 8.0E-04), as #MA increased, SBP increased 20.8 mmHg among Blacks only. Whereas, after MODERATE over the awake hours in FURIN rs1573644 (P = 6.2E-04), as #MA increased, DBP decreased 12.5 mmHg among Whites only. FURIN appears to exhibit intensity and race-dependent associations with PEH that merit further exploration among a larger, ethnically diverse sample of adults with hypertension. © 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.","Blood Pressure; exercise; hypertension; polymorphism","Adolescent; Adult; African Americans; Bicycling; Blood Pressure; Case-Control Studies; European Continental Ancestry Group; Exercise; Female; Furin; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hypertension; Hypotension; Male; Middle Aged; Obesity; Phenotype; Polymorphism, Single Nucleotide; Risk Factors; Time Factors; Young Adult; angiotensin 1 receptor; angiotensin II; C reactive protein; dipeptidyl carboxypeptidase; endothelin; glucose; high density lipoprotein; insulin; low density lipoprotein; proprotein convertase 9; protein variant; renin; triacylglycerol; furin; FURIN protein, human; adult; aerobic exercise; Article; blood pressure monitoring; body composition; body mass; cardiopulmonary exercise test; cardiovascular disease; cholesterol blood level; chromatin immunoprecipitation; clinical article; controlled study; diastolic blood pressure; DNA determination; DNA polymorphism; ethnicity; female; FURIN gene; gene; genotype; heart rate; human; hypotension; male; obesity; physical activity; plasma renin activity; post exercise hypotension; sequence analysis; systolic blood pressure; waist circumference; adolescent; African American; blood pressure; case control study; Caucasian; comparative study; cycling; ethnology; exercise; genetic association study; genetic predisposition; genetics; hypertension; middle aged; pathophysiology; phenotype; risk factor; single nucleotide polymorphism; time factor; young adult","","angiotensin II, 11128-99-7, 68521-88-0; C reactive protein, 9007-41-4; dipeptidyl carboxypeptidase, 9015-82-1; glucose, 50-99-7, 84778-64-3; insulin, 9004-10-8; proprotein convertase 9, ; renin, 61506-93-2, 9015-94-5; serine protease HTRA1, ; serine proteinase, ; furin, ; Furin, ; FURIN protein, human, ","BPTRU; Monarch 839E; Oscar2, Suntech, United States; ParvoMedicsTrueOne 2400","Suntech, United States","Brazilian Council for the Scientific and Technological Development; UConn Institute for Health; University of Connecticut, UCONN; Institute of Clinical and Translational Sciences, ICTS","The University of Connecticut (UConn) Research Foundation; UConn Institute for Health, Intervention, and Policy; Connecticut Institute for Clinical and Translational Science; Experiment.Com; and Brazilian Council for the Scientific and Technological Development.","Allhat O., Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial, JAMA, 288, pp. 2981-2997, (2002); Ash G.I., Eicher J.D., Pescatello L.S., The promises and challenges of the use of genomics in the prescription of exercise for hypertension: the 2013 update, Curr. Hypertens. Rev., 9, pp. 130-147, (2013); Ash G.I., Walker T.J., Olson K.M., Stratton J.H., Gomez A.L., Kraemer W.J., Et al., Reproducibility of ambulatory blood pressure changes from the initial values on two different days, Clinics, 68, pp. 1509-1515, (2013); Augeri A.L., Tsongalis G.J., Van Heest J.L., Maresh C.M., Thompson P.D., Pescatello L.S., The endothelial nitric oxide synthase− 786 T> C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure, Atherosclerosis, 204, pp. e28-e34, (2009); Baker E., Dong Y., Sagnella G., Rothwell M., Onipinla A., Markandu N., Et al., Association of hypertension with T594M mutation in β subunit of epithelial sodium channels in black people resident in London, The Lancet, 351, pp. 1388-1392, (1998); Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., Et al., Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association, Circulation, 135, pp. e146-e603, (2017); Benjamini Y., Yekutieli D., Quantitative trait Loci analysis using the false discovery rate, Genetics, 171, pp. 783-790, (2005); Blanchard B.E., Tsongalis G.J., Guidry M.A., LaBelle L.A., Poulin M., Taylor A.L., Et al., RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension, Eur. J. Appl. Physiol., 97, pp. 26-33, (2006); Bond V., Millis R.M., Adams R.G., Oke L.M., Enweze L., Blakely R., Et al., Attenuation of exaggerated exercise blood pressure response in African-American women by regular aerobic physical activity, Ethn. Dis., 15, 4, pp. S5-S10, (2005); Bouchard C., Leon A.S., Rao D.C., Skinner J.S., Wilmore J.H., Gagnon J., The HERITAGE family study. Aims, design, and measurement protocol, Med. Sci. Sports Exerc., 27, pp. 721-729, (1995); Brandon L.J., Elliott-Lloyd M.B., Walking, body composition, and blood pressure dose-response in African American and white women, Ethn. Dis., 16, (2006); Bruneau M.L., Johnson B.T., Huedo-Medina T.B., Larson K.A., Ash G.I., Pescatello L.S., The blood pressure response to acute and chronic aerobic exercise: A meta-analysis of candidate gene association studies, J. Sci. Med. Sport., 19, pp. 424-431, (2016); Burckle C.A., Jan Danser A.H., Muller D.N., Garrelds I.M., Gasc J.M., Popova E., Et al., Elevated blood pressure and heart rate in human renin receptor transgenic rats, Hypertension, 47, pp. 552-556, (2006); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Et al., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report, JAMA, 289, pp. 2560-2571, (2003); Collier S., Kanaley J., Carhart R., Frechette V., Tobin M., Hall A., Et al., Effect of 4 weeks of aerobic or resistance exercise training on arterial stiffness, blood flow and blood pressure in pre-and stage-1 hypertensives, J. Hum. Hypertens., 22, (2008); Cousin C., Bracquart D., Contrepas A., Corvol P., Muller L., Nguyen G., Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma, Hypertension, 53, pp. 1077-1082, (2009); Danecek P., Auton A., Abecasis G., Albers C.A., Banks E., DePristo M.A., Et al., The variant call format and VCFtools, Bioinformatics, 27, pp. 2156-2158, (2011); Diaz K.M., Booth J.N., Seals S.R., Abdalla M., Dubbert P.M., Sims M., Et al., Physical activity and incident hypertension in African Americans: the Jackson Heart Study, Hypertension, 69, pp. 421-427, (2017); Dolan E., Thijs L., Li Y., Atkins N., McCormack P., McClory S., Et al., Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study, Hypertension, 47, pp. 365-370, (2006); Ehret G.B., Munroe P.B., Rice K.M., Bochud M., Johnson A.D., Chasman D.I., Et al., Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk, Nature, 478, (2011); Enweze L., Oke L.M., Thompson T., Obisesan T.O., Blakely R., Adams R.G., Et al., Acute exercise and postexercise blood pressure in African American women, Ethn. Dis., 17, pp. 664-668, (2007); Fitzgerald W., Labile hypertension and jogging: new diagnostic tool or spurious discovery?, Br. Med. J. (Clin Res Ed), 282, pp. 542-544, (1981); Foex P., Sear J., Hypertension: pathophysiology and treatment, Continuing Educ. Anaesth. Crit. Care Pain, 4, pp. 71-75, (2004); Friedewald W.T., Levy R.I., Fredrickson D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin. Chem., 18, pp. 499-502, (1972); Ganesh S.K., Tragante V., Guo W., Guo Y., Lanktree M.B., Smith E.N., Et al., Loci influencing blood pressure identified using a cardiovascular gene-centric array, Hum. Mol. Genet., 22, pp. 1663-1678, (2013); Halliwill J.R., Mechanisms and clinical implications of post-exercise hypotension in humans, Exerc. Sport Sci. Rev., 29, pp. 65-70, (2001); Haskell W.L., J.B. Wolffe Memorial Lecture. Health consequences of physical activity: understanding and challenges regarding dose-response, Med. Sci. Sports Exerc., 26, pp. 649-660, (1994); Headley S.A., Keenan T.G., Manos T.M., Phillips K., Lachowetz T., Keenan H.A., Et al., Renin and hemodynamic responses to exercise in borderline hypertensives, Ethn. Dis., 8, pp. 312-318, (1998); Hecksteden A., Grutters T., Meyer T., Association between postexercise hypotension and long-term training-induced blood pressure reduction: a pilot study, Clin. J. Sport Med., 23, pp. 58-63, (2013); Henderson S.O., Haiman C.A., Mack W., Multiple polymorphisms in the renin-angiotensin-aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in the multiethnic cohort, Am. J. Med. Sci., 328, pp. 266-273, (2004); Hoffman M.M., Ernst J., Wilder S.P., Kundaje A., Harris R.S., Libbrecht M., Et al., Integrative annotation of chromatin elements from ENCODE data, Nucleic Acids Res., 41, pp. 827-841, (2012); Hughey R.P., Bruns J.B., Kinlough C.L., Harkleroad K.L., Tong Q., Carattino M.D., Et al., Epithelial sodium channels are activated by furin-dependent proteolysis, J. Biol. Chem., 279, pp. 18111-18114, (2004); Jones J.M., Park J.J., Johnson J., Vizcaino D., Hand B., Ferrell R., Et al., Renin-angiotensin system genes and exercise training-induced changes in sodium excretion in African American hypertensives, Ethn. Dis., 16, pp. 666-674, (2006); Jones J.M., Dowling T.C., Park J., Phares D.A., Park J., Obisesan T.O., Et al., Differential aerobic exercise-induced changes in plasma aldosterone between African Americans and Caucasians, Exp. Physiol., 92, pp. 871-879, (2007); Kircher M., Witten D.M., Jain P., O'Roak B.J., Cooper G.M., Shendure J., A general framework for estimating the relative pathogenicity of human genetic variants, Nat. Genet., 46, (2014); Lindhorst J., Alexander N., Blignaut J., Rayner B., Differences in hypertension between blacks and whites: an overview, Cardiovasc. J. Afr., 18, pp. 241-247, (2007); Liu S., Goodman J., Nolan R., Lacombe S., Thomas S.G., Blood pressure responses to acute and chronic exercise are related in prehypertension, Med. Sci. Sports Exerc., 44, pp. 1644-1652, (2012); Liu X., Zhang D., Liu Y., Sun X., Han C., Wang B., Et al., Dose-response association between physical activity and incident hypertension: a systematic review and meta-analysis of Cohort Studies, Hypertension, 69, pp. 813-820, (2017); Maddala G.S., Limited-dependent and qualitative variables in econometrics, (1983); Magee L., R2 measures based on Wald and likelihood ratio joint significance tests, Am. Stat., 44, pp. 250-253, (1990); Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., Turner R., Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, pp. 412-419, (1985); Olson K.M., Augeri A.L., Seip R.L., Tsongalis G.J., Thompson P.D., Pescatello L.S., Correlates of endothelial function and the peak systolic blood pressure response to a graded maximal exercise test, Atherosclerosis, 222, pp. 202-207, (2012); Pazoki R., Dehghan A., Evangelou E., Warren H., Gao H., Caulfield M., Et al., Genetic predisposition to high blood pressure and lifestyle factors: Associations with midlife blood pressure levels and cardiovascular events, Circulation, 137, pp. 653-661, (2018); Pescatello L.S., Kulikowich J.M., The aftereffects of dynamic exercise on ambulatory blood pressure, Med. Sci. Sports Exerc., 33, pp. 1855-1861, (2001); Pescatello L.S., Bairos L., VanHeest J.L., Maresh C., Rodriguez N., Moyna N.M., Et al., Postexercise hypotension differs between white and black women, Am. Heart J., 145, pp. 364-370, (2003); Pescatello L.S., Blanchard B.E., Tsongalis G.J., O'Connell A.A., Gordish-Dressman H., Maresh C.M., Et al., A comparison of the genetic and clinical profile of men that respond and do not respond to the immediate antihypertensive effects of aerobic exercise, Appli. Clin. Genet., 1, pp. 7-17, (2008); Pescatello L.S., Riebe D., Arena R., ACSM's guidelines for exercise testing and prescription, (2013); Pescatello L.S., Schifano E.D., Ash G.I., Panza G.A., Lamberti L., Chen M., Et al., Deep-targeted exon sequencing reveals renal polymorphisms associate with postexercise hypotension among African Americans, Physiol. Rep., 4, (2016); Pescatello L.S., Schifano E.D., Ash G.I., Panza G.A., Corso L.M., Chen M., Et al., Deep-targeted sequencing of endothelial nitric oxide synthase gene exons uncovers exercise intensity and ethnicity-dependent associations with post-exercise hypotension, Physiol. Rep., 5, (2017); Pickering T.G., Hall J.E., Appel L., Falkner B., Graves J., Hill M., Et al., Response to recommendations for blood pressure measurement in human and experimental animals; part 1: blood pressure measurement in humans and miscuffing: a problem with new guidelines: addendum, Hypertension, 48, pp. e5-e6, (2006); Ren K., Jiang T., Zheng X., Zhao G., Proprotein convertase furin/PCSK3 and atherosclerosis: new insights and potential therapeutic targets, Atherosclerosis, 262, pp. 163-170, (2017); Santa-Clara H., Szymanski L., Fernhall B., Effect of exercise training on blood pressure in postmenopausal Caucasian and African-American women, Am. J. Cardiol., 91, (2003); Schafer J.A., Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct, Am. J. Physiol. Renal Physiol., 283, pp. F221-F235, (2002); Schemper M., The relative importance of prognostic factors in studies of survival, Stat. Med., 12, pp. 2377-2382, (1993); Thompson P.D., Crouse S.F., Goodpaster B., Kelley D., Moyna N., Pescatello L., The acute versus the chronic response to exercise, Med. Sci. Sports Exerc., 33, 6, pp. S438-S445, (2001); Tibana R., de Sousa N., da Cunha Nascimento D., Pereira G., Thomas S., Balsamo S., Et al., Correlation between acute and chronic 24-hour blood pressure response to resistance training in adult women, Int. J. Sports Med., 36, pp. 82-89, (2015); Turpeinen H., Seppala I., Lyytikainen L., Raitoharju E., Hutri-Kahonen N., Levula M., Et al., A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure, Hum. Genet., 134, pp. 627-636, (2015); Wegmann M., Hecksteden A., Poppendieck W., Steffen A., Kraushaar J., Morsch A., Et al., Postexercise hypotension as a predictor for long-term training-induced blood pressure reduction: a large-scale randomized controlled trial, Clin. J. Sport Med., 28, pp. 509-515, (2017); Whelton P.K., He J., Appel L.J., Cutler J.A., Havas S., Kotchen T.A., Et al., Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program, JAMA, 288, pp. 1882-1888, (2002); Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Himmelfarb C.D., Et al., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J. Am. Coll. Cardiol., 71, pp. e127-e248, (2018); Wilcox R.G., Bennett T., Brown A.M., Macdonald I.A., Is exercise good for high blood pressure?, BMJ (Clin Res Ed), 285, pp. 767-769, (1982); A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013, (2013); Xu Q., Jensen D.D., Peng H., Feng Y., The critical role of the central nervous system (pro) renin receptor in regulating systemic blood pressure, Pharmacol. Ther., 164, pp. 126-134, (2016); Yan H., Behun M.A., Cook M.D., Ranadive S.M., Lane-Cordova A.D., Kappus R.M., Et al., Differential post-exercise blood pressure responses between blacks and Caucasians, PLoS ONE, 11, (2016); Yang T., Crosstalk between (Pro) renin receptor and COX-2 in the renal medulla during angiotensin II-induced hypertension, Curr. Opin. Pharmacol., 21, pp. 89-94, (2015)","B.T. Cilhoroz; Department of Kinesiology, University of Connecticut, Storrs, United States; email: burak.cilhoroz@uconn.edu","","American Physiological Society","","","","","","2051817X","","","30706700","English","Physiol. Rep.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85060955815"
"Goessler K.F.; Polito M.D.; Mota G.F.; de Oliveira E.M.; Cornelissen V.A.","Goessler, Karla F. (37007331100); Polito, Marcos D. (7005420580); Mota, Gloria de F. (7004725263); de Oliveira, Edilamar M. (35458516000); Cornelissen, Véronique A. (6507297372)","37007331100; 7005420580; 7004725263; 35458516000; 6507297372","Angiotensin converting enzyme 2 polymorphisms and postexercise hypotension in hypertensive medicated individuals","2018","Clinical Physiology and Functional Imaging","38","2","","206","212","6","7","10.1111/cpf.12400","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85008262669&doi=10.1111%2fcpf.12400&partnerID=40&md5=351a7576c3e91f98427ecb4807e1e819","Department of Rehabilitation Sciences, Research Group of Cardiovascular Rehabilitation, KU Leuven, Leuven, Belgium; Research Group of Cardiovascular Response and Exercise, State University of Londrina, Londrina, Brazil; School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil","Goessler K.F., Department of Rehabilitation Sciences, Research Group of Cardiovascular Rehabilitation, KU Leuven, Leuven, Belgium, Research Group of Cardiovascular Response and Exercise, State University of Londrina, Londrina, Brazil; Polito M.D., Research Group of Cardiovascular Response and Exercise, State University of Londrina, Londrina, Brazil; Mota G.F., School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil; de Oliveira E.M., School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil; Cornelissen V.A., Department of Rehabilitation Sciences, Research Group of Cardiovascular Rehabilitation, KU Leuven, Leuven, Belgium","The renin-angiotensin aldosterone system (RAAS) is associated with diverse physiological responses and adaptations to exercise. The angiotensin converting enzyme (ACE) 2 has vasodilatory effects, which might be associated with the blood pressure (BP) responses to acute exercise. The aim of this study was to investigate the role of ACE2 polymorphisms in postexercise hypotension (PEH). Thirty-four medicated hypertensive (61·3 ± 1·7 years, 76·1 ± 2·7 kg, 160 ± 1·6 cm) men (n = 12) and women (n = 22), participated in a control and a moderate intensity exercise session in a randomized order. After both experimental sessions, they left the laboratory wearing an ambulatory BP device for 24-h monitoring. ACE2 polymorphisms (Int-1 and Int-3) were assessed by polymerase chain reaction. Over the course of 5-h monitoring, we observed a significant reduction in SBP and DBP following exercise in the AA/AG of the Int-1 polymorphism (p-interaction = 0·02 and 0·001, respectively), whereas this could not be found in the individuals homozygous G (p-interaction = 0·76 and 0·51, respectively). With regard to Int-3 polymorphism, individuals AA/AG showed a significant reduction in SBP following exercise (p-interaction <0·0001) but not for DBP (p-interaction = 0·06) whereas GG individuals showed only a significant reduction in DBP following exercise (p-interaction = 0·02). Our results suggest that ACE2 polymorphism could affect PEH; however, larger trials are needed to confirm our findings. © 2016 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd","aerobic exercise; ambulatory blood pressure; hypertension; RAAS polymorphism; renin-angiotensin system; walk exercise","Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Exercise; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Phenotype; Polymorphism, Genetic; Post-Exercise Hypotension; Time Factors; angiotensin converting enzyme 2; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; calcium antagonist; dipeptidyl carboxypeptidase inhibitor; diuretic agent; angiotensin converting enzyme 2; antihypertensive agent; dipeptidyl carboxypeptidase; ACE2 gene; adult; aged; allele; Article; blood pressure measurement; blood pressure monitoring; clinical article; controlled study; exercise intensity; female; gene; genetic variability; homozygote; human; hypertension; male; middle aged; polymerase chain reaction; post exercise hypotension; priority journal; single nucleotide polymorphism; systolic blood pressure; blood pressure; drug effect; exercise; gene frequency; genetic polymorphism; genetic predisposition; genetics; heterozygote; hypertension; pathophysiology; phenotype; post exercise hypotension; time factor","","dipeptidyl carboxypeptidase, 9015-82-1; angiotensin converting enzyme 2, ; Antihypertensive Agents, ; Peptidyl-Dipeptidase A, ","ABPM04, Meditech, Hungary","Meditech, Hungary","Krediet aan Navorsers of the Research Foundation Flanders; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES; Fonds Wetenschappelijk Onderzoek, FWO; Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, (308267/2013-3)","KFG was supported by Capes PhD Fellowship (Brazil). KFG is supported as a postdoctoral research fellow by CNPq (Brazil). EMO has a CNPq Fellowship (308267/2013-3, Brazil). VAC is supported as a postdoctoral research fellow by Research Foundation Flanders (FWO, Belgium). VAC received a research grant Krediet aan Navorsers of the Research Foundation Flanders (FWO, Belgium).","Angadi S.S., Bhammar D.M., Gaesser G.A., Postexercise hypotension after continuous, aerobic interval, and sprint interval exercise, J Strength Cond Res, 29, pp. 2888-2893, (2015); Ash G.I., Eicher J.D., Pescatello L.S., The promises and challenges of the use of genomics in the prescription of exercise for hypertension: the 2013 update, Curr Hypertens Rev, 9, pp. 130-147, (2013); Benjafield A.V., Wang W.Y., Morris B.J., No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension, Am J Hypertens, 17, pp. 624-628, (2004); Bouchard C., Overcoming barriers to progress in exercise genomics, Exerc Sport Sci Rev, 39, pp. 212-217, (2011); Bouchard C., Rankinen T., Individual differences in response to regular physical activity, Med Sci Sports Exerc, 33, pp. S446-S451, (2001); Bouchard C., Blair S.N., Church T.S., Et al., Adverse metabolic response to regular exercise: is it a rare or common occurrence?, PLoS ONE, 7, (2012); Bruneau M.L., Johnson B.T., Huedo-Medina T.B., Et al., The blood pressure response to acute and chronic aerobic exercise: a meta-analysis of candidate gene association studies, J Sci Med Sport, 19, pp. 424-431, (2016); Cardoso C.G., Gomides R.S., Queiroz A.C., Et al., Acute and chronic effects of aerobic and resistance exercise on ambulatory blood pressure, Clinics, 65, pp. 317-325, (2010); Chobanian A.V., Bakris G.L., Black H.R., Et al., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, pp. 1206-1252, (2003); Crackower M.A., Sarao R., Oudit G.Y., Et al., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, 417, pp. 822-828, (2002); Danilczyk U., Eriksson U., Crackower M.A., Et al., A story of two ACEs, J Mol Med, 81, pp. 227-234, (2003); Donoghue M., Hsieh F., Baronas E., Et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9, Circ Res, 87, pp. E1-E9, (2000); Doris P.A., Hypertension genetics, single nucleotide polymorphisms, and the common disease: common variant hypothesis, Hypertension, 39, pp. 323-331, (2002); Eriksson U., Danilczyk U., Penninger J.M., Just the beginning: novel functions for angiotensin-converting enzymes, Curr Biol, 12, pp. R745-R752, (2002); Goessler K.F., Cornelissen V.A., de Oliveira E.M., Et al., ACE polymorphisms and the acute response of blood pressure to a walk in medicated hypertensive patients, J Renin Angiotensin Aldosterone Syst, 16, pp. 720-729, (2015); Guidry M.A., Blanchard B.E., Thompson P.D., Et al., The influence of short and long duration on the blood pressure response to an acute bout of dynamic exercise, Am Heart J, 151, pp. 1322.e5-12, (2006); Hagberg J.M., Do genetic variations alter the effects of exercise training on cardiovascular disease and can we identify the candidate variants now or in the future?, J Appl Physiol, 111, pp. 916-928, (2011); Halliwill J.R., Buck T.M., Lacewell A.N., Et al., Postexercise hypotension and sustained postexercise vasodilatation: what happens after we exercise?, Exp Physiol, 98, pp. 7-18, (2013); Huang W., Yang W., Wang Y., Et al., Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese, J Hum Hypertens, 20, pp. 968-971, (2006); Mancia G., Fagard R., Narkiewicz K., Et al., 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension, J Hypertens, 31, pp. 1925-1938, (2013); Jalil J.E., Cordova S., Ocaranza M., Et al., Angiotensin I-converting enzyme insertion/deletion polymorphism and adrenergic response to exercise in hypertensive patients, Med Sci Monit, 8, pp. CR566-CR571, (2002); Kar S., Gao L., Zucker I.H., Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure, J Appl Physiol, 108, pp. 923-932, (2010); Liu S., Goodman J., Nolan R., Et al., Blood pressure responses to acute and chronic exercise are related in prehypertension, Med Sci Sports Exerc, 44, pp. 1644-1652, (2012); Lu N., Yang Y., Wang Y., Et al., ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects, Mol Biol Rep, 39, pp. 6581-6589, (2012); MacDonald J.R., Potential causes, mechanisms, and implications of post exercise hypotension, J Hum Hypertens, 16, pp. 225-236, (2002); Moraes M.R., Bacurau R.F., Ramalho J.D., Et al., Increase in kinins on post-exercise hypotension in normotensive and hypertensive volunteers, Biol Chem, 388, pp. 533-540, (2007); Motta-Santos D., Dos Santos R.A., Oliveira M., Et al., Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise, Hypertens Res, 39, pp. 506-512, (2016); Mozaffarian D., Benjamin E.J., Go A.S., Et al., Heart Disease and Stroke Statistics-2016 Update: a Report From the American Heart Association, Circulation, 133, pp. e38-e360, (2016); Negrao C.E., Middlekauff H.R., Exercise training in heart failure: reduction in angiotensin II, sympathetic nerve activity, and baroreflex control, J Appl Physiol, 104, pp. 577-578, (2008); Pescatello L.S., Franklin B.A., Fagard R., Et al., American College of Sports Medicine position stand. Exercise and hypertension, Med Sci Sports Exerc, 36, pp. 533-553, (2004); Petriz Bde A., de Almeida J.A., Migliolo L., Et al., Pharmacological potential of exercise and RAS vasoactive peptides for prevention of diseases, Curr Protein Pept Sci, 14, pp. 459-471, (2013); Rankinen T., Gagnon J., Perusse L., Et al., AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study, Am J Physiol Heart Circ Physiol, 279, pp. H368-H374, (2000); Rice G.I., Jones A.L., Grant P.J., Et al., Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study, Hypertension, 48, pp. 914-920, (2006); Rigat B., Hubert C., Alhenc-Gelas F., Et al., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Investig, 86, pp. 1343-1346, (1990); Rush J.W., Aultman C.D., Vascular biology of angiotensin and the impact of physical activity, Appl Physiol Nutr Metab, 33, pp. 162-172, (2008); Santana H.A., Moreira S.R., Neto W.B., Et al., The higher exercise intensity and the presence of allele I of ACE gene elicit a higher post-exercise blood pressure reduction and nitric oxide release in elderly women: an experimental study, BMC Cardiovasc Disord, 11, (2011); Turner A.J., Tipnis S.R., Guy J.L., Et al., ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors, Can J Physiol Pharmacol, 80, pp. 346-353, (2002); Wasfy M.M., Baggish A.L., Exercise dose in clinical practice, Circulation, 133, pp. 2297-2313, (2016); Wasserman K., Hansen J.E., Sue D.Y., Et al., Normal Values Principles of Exercise Testing and Interpretation, (2012)","K.F. Goessler; Department of Rehabilitation Sciences, Research Group of Cardiovascular Rehabilitation, KU Leuven, Leuven, Belgium; email: karla.gossler@kuleuven.be","","Blackwell Publishing Ltd","","","","","","14750961","","CPFIC","27925380","English","Clin. Physiol. Funct. Imaging","Article","Final","","Scopus","2-s2.0-85008262669"
"Doaei S.; Gholamalizadeh M.","Doaei, Saeid (56016552900); Gholamalizadeh, Maryam (56017715600)","56016552900; 56017715600","The association of genetic variations with sensitivity of blood pressure to dietary salt: A narrative literature review","2014","ARYA Atherosclerosis","10","3","","169","174","5","19","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902342080&partnerID=40&md5=86678980162585ed844b934e44d2c7ee","School of Health, North Khorasan University of Medical Sciences, Bojnourd, Iran; Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran","Doaei S., School of Health, North Khorasan University of Medical Sciences, Bojnourd, Iran; Gholamalizadeh M., Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran","Salt sensitivity of blood pressure (BP) is an independent risk factor for cardiovascular morbidity. Up to 50% of patients with essential hypertension are salt-sensitive, as manifested by a rise in BP with salt intake. Several genetic variations have been identified as being associated with salt sensitivity. The present study aimed to review the evidence on the effect of gene polymorphisms on the salt sensitivity of BP. We searched in PubMed website from 1990 to 2011, with the use of following keywords: hypertension, dietary salt, polymorphisms, and blood pressure"". The effect of sodium intake on BP differed by genotype at the genes of the renin-angiotensin system, aldosterone synthase, cytochrome p450 3A, epithelial sodium channel genes, genes of sympathetic nervous system, β-3 subunit of G-protein, alpha-adducin, endothelial nitric oxide synthase, Kallikrein-Kinin system. These approaches suggest that these polymorphisms may be potentially useful genetic markers of BP response to dietary salt. There is evidence that genetic predisposition modulates the BP response to diet. Therefore, diet and nutrition can mitigate or enhance the effects of genetic predisposition. Increasing our knowledge of this relationship can lead to individualized treatment and increased understanding of hypertension.","Diet therapy; Genetics; Hypertension","aldosterone synthase; alpha adducin; angiotensin 1 receptor; beta 2 adrenergic receptor; cytochrome P450; endothelial nitric oxide synthase; guanine nucleotide binding protein; ACE gene; adrenergic system; AGT gene; BHSD2 gene; blood pressure; DNA polymorphism; drug sensitivity; ENac gene; gene; genetic variability; human; hypertension; kallikrein kinin system; nonhuman; renin angiotensin aldosterone system; review; salt sensitivity; sodium intake","","aldosterone synthase, 122933-89-5; cytochrome P450, 9035-51-2; endothelial nitric oxide synthase, 503473-02-7","","","","","Hickler R.B., Hypertensive emergency: A useful diagnostic category, Am J Public Health, 78, 6, pp. 623-624, (1988); Burt V.L., Cutler J.A., Higgins M., Horan M.J., Labarthe D., Whelton P., Et al., Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991, Hypertension, 26, 1, pp. 60-69, (1995); Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., Et al., Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 6, pp. 1403-1419, (2008); Doaee S., Gholamalizadeh M., Polymorphism of A I, A IV and E apolipoprotein genes and effect of fat intake on HDL levels, Genetics In the 3rd Millennium, 9, 1, pp. 2323-2328, (2011); Knight B.S., Sunn N., Pennell C.E., Adamson S.L., Lye S.J., Developmental regulation of cardiovascular function is dependent on both genotype and environment, Am J Physiol Heart Circ Physiol, 297, 6, (2009); Hedayati S.S., Elsayed E.F., Reilly R.F., Non-pharmacological aspects of blood pressure management: What are the data?, Kidney Int, 79, 10, pp. 1061-1070, (2011); Safavi S.M., Doaei S., Gholamalizadeh M., Unsaid of nutrition and genetics, The World of Nutrition Journal, 6, 60, pp. 22-23, (2007); Doaei S., Gholamalizadeh M., The association between dietary fat with gene polymorphisms, Proceedings of the 11th Iranian Nutrition Congress, (2010); Doaei S., Gholamalizadeh M., Akbari M., Safavi S.M., Nutritional Genomics: A Window to The Future. 1st Ed. Qom, pp. 5-9, (2011); He F.J., Macgregor G.A., How far should salt intake be reduced?, Hypertension, 42, 6, pp. 1093-1099, (2003); Cohen H.W., Alderman M.H., Sodium, blood pressure, and cardiovascular disease, Curr Opin Cardiol, 22, 4, pp. 306-310, (2007); Cowley A.W., Genetic and nongenetic determinants of salt sensitivity and blood pressure, Am J Clin Nutr, 65, 2 SUPPL., (1997); Doaei S., Gholamalizadeh M., The association of genetic variations with sensitivity of blood pressure to dietary salt,  International Congress On Prevention, Diagnosis & Management of Hypertension In Iran, (2011); Poch E., Gonzalez D., Giner V., Bragulat E., Coca A., de La S.A., Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms, Hypertension, 38, 5, pp. 1204-1209, (2001); Meneton P., Jeunemaitre X., de Wardener H.E., Macgregor G.A., Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases, Physiol Rev, 85, 2, pp. 679-715, (2005); Caprioli J., Mele C., Mossali C., Gallizioli L., Giacchetti G., Noris M., Et al., Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension, Can J Physiol Pharmacol, 86, 8, pp. 505-510, (2008); Zhang L., Miyaki K., Araki J., Song Y., Kimura T., Omae K., Et al., Interaction of angiotensin I-converting enzyme insertion-deletion polymorphism and daily salt intake influences hypertension in Japanese men, Hypertens Res, 29, 10, pp. 751-758, (2006); Strazzullo P., Galletti F., Genetics of salt-sensitive hypertension, Curr Hypertens Rep, 9, 1, pp. 25-32, (2007); Norat T., Bowman R., Luben R., Welch A., Khaw K.T., Wareham N., Et al., Blood pressure and interactions between the angiotensin polymorphism AGT M235T and sodium intake: A cross-sectional population study, Am J Clin Nutr, 88, 2, pp. 392-397, (2008); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, 1, pp. 169-180, (1992); Schorr U., Blaschke K., Beige J., Distler A., Sharma A.M., Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians, J Hypertens, 17, 4, pp. 475-479, (1999); Hunt S.C., Cook N.R., Oberman A., Cutler J.A., Hennekens C.H., Allender P.S., Et al., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention phase II, Hypertension, 32, 3, pp. 393-401, (1998); Beeks E., Kessels A.G., Kroon A.A., van der Klauw M.M., de Leeuw P.W., Genetic predisposition to salt-sensitivity: A systematic review, J Hypertens, 22, 7, pp. 1243-1249, (2004); Svetkey L.P., Harris E.L., Martin E., Vollmer W.M., Meltesen G.T., Ricchiuti V., Et al., Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system, Am J Hypertens, 24, 2, pp. 209-217, (2011); Kobori H., Nangaku M., Navar L.G., Nishiyama A., The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease, Pharmacol Rev, 59, 3, pp. 251-287, (2007); Crowley S.D., Gurley S.B., Herrera M.J., Ruiz P., Griffiths R., Kumar A.P., Et al., Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney, Proc Natl Acad Sci U S A, 103, 47, pp. 17985-17990, (2006); Gu D., Kelly T.N., Hixson J.E., Chen J., Liu D., Chen J.C., Et al., Genetic variants in the renin-angiotensin-aldosterone system and salt sensitivity of blood pressure, J Hypertens, 28, 6, pp. 1210-1220, (2010); Pinto V., Pinho M.J., Hopfer U., Jose P.A., Soares-da-Silva P., Oxidative stress and the genomic regulation of aldosterone-stimulated NHE1 activity in SHR renal proximal tubular cells, Mol Cell Biochem, 310, 1-2, pp. 191-201, (2008); White P.C., Rainey W.E., Editorial: Polymorphisms in CYP11B genes and 11-hydroxylase activity, J Clin Endocrinol Metab, 90, 2, pp. 1252-1255, (2005); Brand E., Chatelain N., Mulatero P., Fery I., Curnow K., Jeunemaitre X., Et al., Structural analysis and evaluation of the aldosterone synthase gene in hypertension, Hypertension, 32, 2, pp. 198-204, (1998); Matsubara M., Sato T., Nishimura T., Suzuki M., Kikuya M., Metoki H., Et al., CYP11B2 polymorphisms and home blood pressure in a population-based cohort in Japanese: The Ohasama study, Hypertens Res, 27, 1, pp. 1-6, (2004); Tang W., Wu H., Zhou X., Cheng B., Dong Y., He L., Et al., Association of the C-344T polymorphism of CYP11B2 gene with essential hypertension in Hani and Yi minorities of China, Clin Chim Acta, 364, 1-2, pp. 222-225, (2006); White P.C., Mune T., Agarwal A.K., 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess, Endocr Rev, 18, 1, pp. 135-156, (1997); Smolenicka Z., Bach E., Schaer A., Liechti-Gallati S., Frey B.M., Frey F.J., Et al., A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene, J Clin Endocrinol Metab, 83, 5, pp. 1814-1817, (1998); Alikhani-Koupaei R., Fouladkou F., Fustier P., Cenni B., Sharma A.M., Deter H.C., Et al., Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: Functional characterization and relevance for salt sensitivity, FASEB J, 21, 13, pp. 3618-3628, (2007); Thompson E.E., Kuttab-Boulos H., Witonsky D., Yang L., Roe B.A., Di R.A., CYP3A variation and the evolution of salt-sensitivity variants, Am J Hum Genet, 75, 6, pp. 1059-1069, (2004); Zhang L., Miyaki K., Wang W., Muramatsu M., CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men, J Hum Hypertens, 24, 5, pp. 345-350, (2010); Lifton R.P., Gharavi A.G., Geller D.S., Molecular mechanisms of human hypertension, Cell, 104, 4, pp. 545-556, (2001); Dahlberg J., Nilsson L.O., von Wowern F., Melander O., Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP, PLoS One, 2, 5, (2007); Manunta P., Lavery G., Lanzani C., Braund P.S., Simonini M., Bodycote C., Et al., Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation, Hypertension, 52, 2, pp. 366-372, (2008); Yatabe M.S., Yatabe J., Yoneda M., Watanabe T., Otsuki Felder R.A., Et al., Salt sensitivity is associated with insulin resistance, sympathetic over activity, and decreased suppression of circulating renin activity in lean patients with essential hypertension, Am J Clin Nutr, 92, 1, pp. 77-82, (2010); Weber C.S., Thayer J.F., Rudat M., Sharma A.M., Perschel F.H., Buchholz K., Et al., Salt-sensitive men show reduced heart rate variability, lower norepinephrine and enhanced cortisol during mental stress, J Hum Hypertens, 22, 6, pp. 423-431, (2008); Eisenach J.H., Schroeder D.R., Pike T.L., Johnson C.P., Schrage W.G., Snyder E.M., Et al., Dietary sodium restriction and beta2-adrenergic receptor polymorphism modulate cardiovascular function in humans, J Physiol, 574, PART 3, pp. 955-965, (2006); Pojoga L., Kolatkar N.S., Williams J.S., Perlstein T.S., Jeunemaitre X., Brown N.J., Et al., Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension, Hypertension, 48, 5, pp. 892-900, (2006); Svetkey L.P., Timmons P.Z., Emovon O., Anderson N.B., Preis L., Chen Y.T., Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype, Hypertension, 27, 6, pp. 1210-1215, (1996); Martin D.N., Andreu E.P., Ramirez L.R., Garcia-Junco P.S., Vallejo I.M., Santos R.A., Et al., G-protein beta-3 subunit gene C825 T polymorphism: Influence on plasma sodium and potassium concentrations in essential hypertensive patients, Life Sci, 77, 23, pp. 2879-2886, (2005); Bagos P.G., Elefsinioti A.L., Nikolopoulos G.K., Hamodrakas S.J., The GNB3 C825T polymorphism and essential hypertension: A meta-analysis of 34 studies including 14,094 cases and 17,760 controls, J Hypertens, 25, 3, pp. 487-500, (2007); Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Et al., Association of a human G-protein beta3 subunit variant with hypertension, Nat Genet, 18, 1, pp. 45-48, (1998); Nishi A., Eklof A.C., Bertorello A.M., Aperia A., Dopamine regulation of renal Na+, K(+)- ATPase activity is lacking in Dahl salt-sensitive rats, Hypertension, 21, 6 PART 1, pp. 767-771, (1993); Manunta P., Cusi D., Barlassina C., Righetti M., Lanzani C., D'Amico M., Et al., Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients, Kidney Int, 53, 6, pp. 1471-1478, (1998); Wang R., Zhong B., Liu Y., Wang C., Association between alpha-adducin gene polymorphism (Gly460Trp) and genetic predisposition to salt sensitivity: A meta-analysis, J Appl Genet, 51, 1, pp. 87-94, (2010); Wang J.G., Liu L., Zagato L., Xie J., Fagard R., Jin K., Et al., Blood pressure in relation to three candidate genes in a Chinese population, J Hypertens, 22, 5, pp. 937-944, (2004); Harsha D.W., Sacks F.M., Obarzanek E., Svetkey L.P., Lin P.H., Bray G.A., Et al., Effect of dietary sodium intake on blood lipids: Results from the DASH-sodium trial, Hypertension, 43, 2, pp. 393-398, (2004); Miyaki K., Tohyama S., Murata M., Kikuchi H., Takei I., Watanabe K., Et al., Salt intake affects the relation between hypertension and the T-786C polymorphism in the endothelial nitric oxide synthase gene, Am J Hypertens, 18, 12 PART 1, pp. 1556-1562, (2005); Dengel D.R., Brown M.D., Ferrell R.E., Reynolds T.H., Supiano M.A., A preliminary study on T-786C endothelial nitric oxide synthase gene and renal hemodynamic and blood pressure responses to dietary sodium, Physiol Res, 56, 4, pp. 393-401, (2007); Bellini C., Ferri C., Piccoli A., Carlomagno A., Di F.L., Bonavita M.S., Et al., The influence of salt sensitivity on the blood pressure response to exogenous kallikrein in essential hypertensive patients, Nephron, 65, 1, pp. 28-35, (1993); Chao J., Zhang J.J., Lin K.F., Chao L., Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats, Hum Gene Ther, 9, 1, pp. 21-31, (1998); Cervenka L., Harrison-Bernard L.M., Dipp S., Primrose G., Imig J.D., El-Dahr S.S., Early onset salt-sensitive hypertension in bradykininB (2) receptor null mice, Hypertension, 34, 2, pp. 176-180, (1999)","M. Gholamalizadeh; Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran; email: mgholamalizade84@yahoo.com","","Isfahan University of Medical Sciences","","","","","","17353955","","","","English","Arya Atheroscler.","Review","Final","","Scopus","2-s2.0-84902342080"
"Cunningham P.N.; Wang Z.; Grove M.L.; Cooper-DeHoff R.M.; Beitelshees A.L.; Gong Y.; Gums J.G.; Johnson J.A.; Turner S.T.; Boerwinkle E.; Chapman A.B.","Cunningham, Patrick N. (7201579721); Wang, Zhiying (37012275300); Grove, Megan L. (57214664891); Cooper-DeHoff, Rhonda M. (35078393500); Beitelshees, Amber L. (6508117914); Gong, Yan (8560522600); Gums, John G. (7004125953); Johnson, Julie A. (55439192600); Turner, Stephen T. (7402275413); Boerwinkle, Eric (7102087489); Chapman, Arlene B. (57194303466)","7201579721; 37012275300; 57214664891; 35078393500; 6508117914; 8560522600; 7004125953; 55439192600; 7402275413; 7102087489; 57194303466","Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers","2019","PLoS ONE","14","9","e0221957","","","","7","10.1371/journal.pone.0221957","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072280673&doi=10.1371%2fjournal.pone.0221957&partnerID=40&md5=971e84dac877c269d7fedc823db36cba","Section of Nephrology, University of Chicago, Chicago, IL, United States; Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, United States; Department of Pharmacotherapy and Translational Research, College of Pharmacy, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Endocrinology, Diabetes, and Nutrition Division, Department of Medicine, University of Maryland, Baltimore, MD, United States; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; Baylor College of Medicine, Human Genome Sequencing Center, Houston, TX, United States","Cunningham P.N., Section of Nephrology, University of Chicago, Chicago, IL, United States; Wang Z., Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, United States; Grove M.L., Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, United States; Cooper-DeHoff R.M., Department of Pharmacotherapy and Translational Research, College of Pharmacy, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Beitelshees A.L., Endocrinology, Diabetes, and Nutrition Division, Department of Medicine, University of Maryland, Baltimore, MD, United States; Gong Y., Department of Pharmacotherapy and Translational Research, College of Pharmacy, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Gums J.G., Department of Pharmacotherapy and Translational Research, College of Pharmacy, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Johnson J.A., Department of Pharmacotherapy and Translational Research, College of Pharmacy, Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, United States; Turner S.T., Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; Boerwinkle E., Human Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, United States, Baylor College of Medicine, Human Genome Sequencing Center, Houston, TX, United States; Chapman A.B., Section of Nephrology, University of Chicago, Chicago, IL, United States","Background Hypertension (HTN) disproportionately affects African Americans (AAs), who respond better to thiazide diuretics than other antihypertensives. Variants of the APOL1 gene found in AAs are associated with a higher rate of kidney disease and play a complex role in cardiovascular disease. Methods AA subjects from four HTN trials (n = 961) (GERA1, GERA2, PEAR1, and PEAR2) were evaluated for blood pressure (BP) response based on APOL1 genotype after 4–9 weeks of monotherapy with thiazides, beta blockers, or candesartan. APOL1 G1 and G2 variants were determined by direct sequencing or imputation. Results Baseline systolic BP (SBP) and diastolic BP (DBP) levels did not differ based on APOL1 genotype. Subjects with 1–2 APOL1 risk alleles had a greater SBP response to candesartan (-12.2 +/- 1.2 vs -7.5 +/- 1.8 mmHg, p = 0.03; GERA2), and a greater decline in albuminuria with candesartan (-8.3 +/- 3.1 vs +3.7 +/- 4.3 mg/day, p = 0.02). APOL1 genotype did not associate with BP response to thiazides or beta blockers. GWAS was performed to determine associations with BP response to candesartan depending on APOL1 genotype. While no SNPs reached genome wide significance, SNP rs10113352, intronic in CSMD1, predicted greater office SBP response to candesartan (p = 3.7 x 10−7) in those with 1–2 risk alleles, while SNP rs286856, intronic in DPP6, predicted greater office SBP response (p = 3.2 x 10−7) in those with 0 risk alleles. Conclusions Hypertensive AAs without overt kidney disease who carry 1 or more APOL1 risk variants have a greater BP and albuminuria reduction in response to candesartan therapy. BP response to thiazides or beta blockers did not differ by APOL1 genotype. Future studies confirming this initial finding in an independent cohort are required. © 2019 Cunningham et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","Adult; African Americans; Angiotensin II Type 1 Receptor Blockers; Apolipoprotein L1; Benzimidazoles; Female; Genome-Wide Association Study; Genotype; Humans; Hypertension; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tetrazoles; Treatment Outcome; atenolol; candesartan; chlortalidone; hydrochlorothiazide; metoprolol; angiotensin 1 receptor antagonist; APOL1 protein, human; apolipoprotein L1; benzimidazole derivative; candesartan; tetrazole derivative; adolescent; adult; aged; albuminuria; allele; APOL1 gene; Article; blood pressure measurement; clinical trial; CSMD1 gene; diastolic blood pressure; disease association; DPP6 gene; drug dose titration; female; gene; gene sequence; genetic association; genetic risk; genotype; heterozygote; human; hypertension; intron; low risk population; major clinical study; male; single drug dose; single nucleotide polymorphism; systolic blood pressure; African American; DNA sequence; ethnology; genetics; genome-wide association study; hypertension; middle aged; pharmacogenetic variant; treatment outcome","","atenolol, 29122-68-7, 93379-54-5; candesartan, 139481-59-7; chlortalidone, 77-36-1; hydrochlorothiazide, 58-93-5; metoprolol, 37350-58-6; Angiotensin II Type 1 Receptor Blockers, ; APOL1 protein, human, ; Apolipoprotein L1, ; Benzimidazoles, ; candesartan, ; Tetrazoles, ","","","National Institutes of Health, NIH, (HL53330, HL74735, M01 RR00082, UL1 RR029890); National Institutes of Health, NIH; National Institute of General Medical Sciences, NIGMS, (U01GM074492); National Institute of General Medical Sciences, NIGMS; Mayo Clinic; National Center for Advancing Translational Sciences, NCATS, (UL1 TR000064, UL1 TR000454); National Center for Advancing Translational Sciences, NCATS; Mayo Foundation for Medical Education and Research, MFMER; University of Florida, UF, (M01 RR00039, UL1 RR024150, UL1 RR025008); University of Florida, UF","PEAR1 and PEAR2 was supported by a grant from the National Institutes of Health (https:// www.nih.gov/), grant U01 GM074492, funded as part of the Pharmacogenetics Research Network (JAJ). PEAR1 was also supported by the following grants from the NIH National Center for Research Resources: grant M01 RR00082 and UL1 RR029890 to the University of Florida, grants UL1 RR025008 and M01 RR00039 (ABC) to Emory University, and UL1 RR024150 to Mayo Clinic. PEAR2 was also supported by the National Center for Advancing Translational Sciences under the award number UL1 TR000064 (University of Florida); UL1 TR000454 (Emory University) and UL1 TR000135 (Mayo Clinic), and the Mayo Foundation. GERA was supported by NIH grants HL74735, HL53330 (STT), and the Mayo Foundation (https://www.mayo.edu/research).","Howard G., Lackland D.T., Kleindorfer D.O., Kissela B.M., Moy C.S., Judd S.E., Et al., Racial differences in the impact of elevated systolic blood pressure on stroke risk, JAMA Intern Med, 173, 1, pp. 46-51, (2013); Freedman B.I., Kopp J.B., Langefeld C.D., Genovese G., Friedman D.J., Nelson G.W., Et al., The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans, J Am Soc Nephrol, 21, 9, pp. 1422-1426, (2010); Genovese G., Friedman D.J., Ross M.D., Lecordier L., Uzureau P., Freedman B.I., Et al., Association of trypanolytic ApoL1 variants with kidney disease in African Americans, Science, 329, 5993, pp. 841-845, (2010); Kopp J.B., Smith M.W., Nelson G.W., Johnson R.C., Freedman B.I., Bowden D.W., Et al., MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis, Nat Genet, 40, 10, pp. 1175-1184, (2008); Ito K., Bick A.G., Flannick J., Friedman D.J., Genovese G., Parfenov M.G., Et al., Increased burden of cardiovascular disease in carriers of APOL1 genetic variants, Circ Res, 114, 5, pp. 845-850, (2014); Mukamal K.J., Tremaglio J., Friedman D.J., Ix J.H., Kuller L.H., Tracy R.P., Et al., APOL1 genotype, kidney and cardiovascular disease, and death in older adults, Arterioscler Thromb Vasc Biol, 36, 2, pp. 398-403, (2016); Freedman B.I., Gadegbeku C.A., Bryan R.N., Palmer N.D., Hicks P.J., Ma L., Et al., APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume, Kidney Int, 90, 2, pp. 440-449, (2016); Freedman B.I., Langefeld C.D., Lu L., Palmer N.D., Smith S.C., Bagwell B.M., Et al., APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes, Kidney Int, 87, 1, pp. 176-181, (2015); Langefeld C.D., Divers J., Pajewski N.M., Hawfield A.T., Reboussin D.M., Bild D.E., Et al., Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial, Kidney Int, 87, 1, pp. 169-175, (2015); Ma L., Langefeld C.D., Comeau M.E., Bonomo J.A., Rocco M.V., Burkart J.M., Et al., APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease, Kidney Int, 90, 2, pp. 389-395, (2016); Chen T.K., Estrella M.M., Vittinghoff E., Lin F., Gutierrez O.M., Kramer H., Et al., APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults, Kidney Int, 92, 4, pp. 964-971, (2017); Nadkarni G.N., Coca S.G., APOL1 and blood pressure changes in young adults, Kidney Int, 92, 4, pp. 793-795, (2017); Nadkarni G.N., Galarneau G., Ellis S.B., Nadukuru R., Zhang J., Scott S.A., Et al., Apolipoprotein L1 variants and blood pressure traits in African Americans, J Am Coll Cardiol, 69, 12, pp. 1564-1574, (2017); Gong Y., McDonough C.W., Wang Z., Hou W., Cooper-DeHoff R.M., Langaee T.Y., Et al., Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study, Circ Cardiovasc Genet, 5, 6, pp. 686-691, (2012); Turner S.T., Boerwinkle E., O'Connell J.R., Bailey K.R., Gong Y., Chapman A.B., Et al., Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide, Hypertension, 62, 2, pp. 391-397, (2013); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int, 61, 3, pp. 1047-1055, (2002); Turner S.T., Schwartz G.L., Chapman A.B., Beitelshees A.L., Gums J.G., Cooper-DeHoff R.M., Et al., Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension, Am J Hypertens, 23, 9, pp. 1014-1022, (2010); Gong Y., Wang Z., Beitelshees A.L., McDonough C.W., Langaee T.Y., Hall K., Et al., Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to beta-Blockers in Hypertensive African Americans, Hypertension, 67, 3, pp. 556-563, (2016); Canzanello V.J., Baranco-Pryor E., Rahbari-Oskoui F., Schwartz G.L., Boerwinkle E., Turner S.T., Et al., Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension, Am J Hypertens, 21, 1, pp. 61-66, (2008); Hamadeh I.S., Langaee T.Y., Dwivedi R., Garcia S., Burkley B.M., Skaar T.C., Et al., Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate, Clin Pharmacol Ther, 96, 2, pp. 175-181, (2014); Johnson J.A., Boerwinkle E., Zineh I., Chapman A.B., Bailey K., Cooper-DeHoff R.M., Et al., Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, Am Heart J, 157, 3, pp. 442-449, (2009); Grove M.L., Yu B., Cochran B.J., Haritunians T., Bis J.C., Taylor K.D., Et al., Best practices and joint calling of the HumanExome BeadChip: The CHARGE consortium, PLoS One, 8, 7, (2013); Zineh I., Beitelshees A.L., Gaedigk A., Walker J.R., Pauly D.F., Eberst K., Et al., Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension, Clin Pharmacol Ther, 76, 6, pp. 536-544, (2004); Li Y., Willer C.J., Ding J., Scheet P., Abecasis G.R., Mach: Using sequence and genotype data to estimate haplotypes and unobserved genotypes, Genet Epidemiol, 34, 8, pp. 816-834, (2010); Li Y., Willer C., Sanna S., Abecasis G., Genotype imputation, Annu Rev Genomics Hum Genet, 10, pp. 387-406, (2009); Rau T., Wuttke H., Michels L.M., Werner U., Bergmann K., Kreft M., Et al., Impact of the CYP2D6 genotype on the clinical effects of metoprolol: A prospective longitudinal study, Clin Pharmacol Ther, 85, 3, pp. 269-272, (2009); Kasembeli A.N., Duarte R., Ramsay M., Mosiane P., Dickens C., Dix-Peek T., Et al., APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans, J Am Soc Nephrol, 26, 11, pp. 2882-2890, (2015); Dummer P.D., Limou S., Rosenberg A.Z., Heymann J., Nelson G., Winkler C.A., Et al., APOL1 kidney disease risk variants: An evolving landscape, Semin Nephrol, 35, 3, pp. 222-236, (2015); Ma L., Shelness G.S., Snipes J.A., Murea M., Antinozzi P.A., Cheng D., Et al., Localization of APOL1 protein and mRNA in the human kidney: Nondiseased tissue, primary cells, and immortalized cell lines, J Am Soc Nephrol, 26, 2, pp. 339-348, (2015); Chen T.K., Appel L.J., Grams M.E., Tin A., Choi M.J., Lipkowitz M.S., Et al., APOL1 risk variants and cardiovascular disease: Results from the AASK (African American Study of Kidney Disease and Hypertension), Arterioscler Thromb Vasc Biol, 37, 9, pp. 1765-1769, (2017); Hughson M.D., Hoy W.E., Mott S.A., Bertram J.F., Winkler C.A., Kopp J.B., APOL1 risk variants independently associated with early cardiovascular disease death, Kidney Int Rep, 3, 1, pp. 89-98, (2018); Franceschini N., Kopp J.B., Barac A., Martin L.W., Li Y., Qian H., Et al., Association of APOL1 with heart failure with preserved ejection fraction in postmenopausal African American women, JAMA Cardiol, 3, 8, pp. 712-720, (2018); Larsen C.P., Beggs M.L., Saeed M., Ambruzs J.M., Cossey L.N., Messias N.C., Et al., Histopathologic findings associated with APOL1 risk variants in chronic kidney disease, Mod Pathol, 28, 1, pp. 95-102, (2015); Williams S.F., Nicholas S.B., Vaziri N.D., Norris K.C., African Americans, hypertension and the renin angiotensin system, World J Cardiol, 6, 9, pp. 878-889, (2014); Weir M.R., Gray J.M., Paster R., Saunders E., Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The trandolapril multicenter study group, Hypertension, 26, 1, pp. 124-130, (1995); Fisher N.D., Price D.A., Litchfield W.R., Williams G.H., Hollenberg N.K., Renal response to captopril reflects state of local renin system in healthy humans, Kidney Int, 56, 2, pp. 635-641, (1999); Price D.A., Porter L.E., Gordon M., Fisher N.D., De'Oliveira J.M., Laffel L.M., Et al., The paradox of the low-renin state in diabetic nephropathy, J Am Soc Nephrol, 10, 11, pp. 2382-2391, (1999); Kraus D.M., Elliott G.S., Chute H., Horan T., Pfenninger K.H., Sanford S.D., Et al., CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues, J Immunol, 176, 7, pp. 4419-4430, (2006); Chittani M., Zaninello R., Lanzani C., Frau F., Ortu M.F., Salvi E., Et al., TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives, J Hypertens, 33, 6, pp. 1301-1309, (2015); He J., Kelly T.N., Zhao Q., Li H., Huang J., Wang L., Et al., Genome-wide association study identifies 8 novel loci associated with blood pressure responses to interventions in Han Chinese, Circ Cardiovasc Genet, 6, 6, pp. 598-607, (2013); Honda M., Ogura Y., Toyoda W., Taguchi M., Nozawa T., Inoue H., Et al., Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers, Biol Pharm Bull, 29, 4, pp. 772-778, (2006); Koriyama H., Nakagami H., Katsuya T., Sugimoto K., Yamashita H., Takami Y., Et al., Identification of evidence suggestive of an association with peripheral arterial disease at the OSBPL10 locus by genome-wide investigation in the Japanese population, J Atheroscler Thromb, 17, 10, pp. 1054-1062, (2010); Jerng H.H., Dougherty K., Covarrubias M., Pfaffinger P.J., A novel N-terminal motif of dipeptidyl peptidaselike proteins produces rapid inactivation of KV4.2 channels by a pore-blocking mechanism, Channels (Austin), 3, 6, pp. 448-461, (2009); Strop P., Bankovich A.J., Hansen K.C., Garcia K.C., Brunger A.T., Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family, J Mol Biol, 343, 4, pp. 1055-1065, (2004); Li X.G., Zhang J.H., Xie M.Q., Liu M.S., Li B.H., Zhao Y.H., Et al., Association between DPP6 polymorphism and the risk of sporadic amyotrophic lateral sclerosis in Chinese patients, Chin Med J (Engl), 122, 24, pp. 2989-2992, (2009); Liao C., Fu F., Li R., Yang W.Q., Liao H.Y., Yan J.R., Et al., Loss-of-function variation in the DPP6 gene is associated with autosomal dominant microcephaly and mental retardation, Eur J Med Genet, 56, 9, pp. 484-489, (2013); Prontera P., Napolioni V., Ottaviani V., Rogaia D., Fusco C., Augello B., Et al., DPP6 gene disruption in a family with Gilles de la Tourette syndrome, Neurogenetics, 15, 4, pp. 237-242, (2014); Ten Sande J.N., Postema P.G., Boekholdt S.M., Tan H.L., van der Heijden J.F., De Groot N.M., Et al., Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus, Heart Rhythm, 13, 4, pp. 905-912, (2016); Wright J.T., Bakris G., Greene T., Agodoa L.Y., Appel L.J., Charleston J., Et al., Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial, Jama, 288, 19, pp. 2421-2431, (2002); Oliveira-Paula G.H., Luizon M.R., Lacchini R., Fontana V., Silva P.S., Biagi C., Et al., Gene-gene interactions among PrkCa, NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril, Basic Clin Pharmacol Toxicol, 120, 3, pp. 284-291, (2017); Turner S.T., Bailey K.R., Schwartz G.L., Chapman A.B., Chai H.S., Boerwinkle E., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension, 59, 6, pp. 1204-1211, (2012); Schwartz G.L., Bailey K., Chapman A.B., Boerwinkle E., Turner S.T., The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension, Am J Hypertens, 26, 8, pp. 957-964, (2013); Ku E., Lipkowitz M.S., Appel L.J., Parsa A., Gassman J., Glidden D.V., Et al., Strict blood pressure control associates with decreased mortality risk by APOL1 genotype, Kidney Int, 91, 2, pp. 443-450, (2017); Fu Y., Zhu J.Y., Richman A., Zhang Y., Xie X., Das J.R., Et al., APOL1-G1 in nephrocytes induces hypertrophy and accelerates cell death, J Am Soc Nephrol, (2016); Kruzel-Davila E., Shemer R., Ofir A., Bavli-Kertselli I., Darlyuk-Saadon I., Oren-Giladi P., Et al., APOL1-mediated cell injury involves disruption of conserved trafficking processes, J Am Soc Nephrol, (2016)","P.N. Cunningham; Section of Nephrology, University of Chicago, Chicago, United States; email: pcunning@medicine.bsd.uchicago.edu","","Public Library of Science","","","","","","19326203","","POLNC","31532792","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85072280673"
"Salzer L.; Tenenbaum-Gavish K.; Hod M.","Salzer, Liat (55341993400); Tenenbaum-Gavish, Kinneret (33068346400); Hod, Moshe (7006189275)","55341993400; 33068346400; 7006189275","Metabolic disorder of pregnancy (understanding pathophysiology of diabetes and preeclampsia)","2015","Best Practice and Research: Clinical Obstetrics and Gynaecology","29","3","","328","338","10","59","10.1016/j.bpobgyn.2014.09.008","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84933516471&doi=10.1016%2fj.bpobgyn.2014.09.008&partnerID=40&md5=58319bb67a1951c9e043d03ec0cb3ba5","Helen Schneider Hospital for Women, Rabin Medical Center, Department of Obstetrics and Gynecology, Petach Tikva, 49100, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel","Salzer L., Helen Schneider Hospital for Women, Rabin Medical Center, Department of Obstetrics and Gynecology, Petach Tikva, 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Tenenbaum-Gavish K., Helen Schneider Hospital for Women, Rabin Medical Center, Department of Obstetrics and Gynecology, Petach Tikva, 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Hod M., Helen Schneider Hospital for Women, Rabin Medical Center, Department of Obstetrics and Gynecology, Petach Tikva, 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel","The role of insulin resistance in human disease is implicated in the pathogenesis of some of the chief western chronic diseases: ischemic heart disease, type 2 diabetes mellitus, and essential hypertension. The occurrence of these diseases, alongside obesity, is termed the metabolic syndrome. Pregnancy is normally attended by progressive insulin resistance that begins near mide pregnancy and progresses through the third trimester to levels that approximate the insulin resistance seen in individuals with type 2 diabetes. Insulin resistance and hyperinsulinemia may be the basic common ground for the metabolic syndrome of pregnancy e elevated blood pressure and diabetes mellitus. Moreover, the metabolic syndrome is also associated with endothelial dysfunction, oxidative stress, and attenuated inflammatory responses. In this review, we discuss the development of insulin resistance during pregnancy, hormones and newly discovered factors associated with insulin resistance and secretion, lipid metabolism, and the pathogenesis of hypertension during pregnancy. © 2014 Elsevier Ltd. All rights reserved.","Gestational diabetes; Gestational hypertension; Insulin resistance; Obesity; Pathogenesis","Diabetes, Gestational; Female; Humans; Hyperinsulinism; Hypertension; Insulin Resistance; Metabolic Syndrome X; Obesity; Pre-Eclampsia; Pregnancy; Pregnancy Complications; adipocytokine; adiponectin; advanced oxidation protein product; angiotensin 1 receptor; angiotensin II; angiotensinogen; blood clotting factor 8; endothelial nitric oxide synthase; endothelin; fatty acid; fatty acid binding protein; fatty acid binding protein 4; fetal antigen; glucose; HLA antigen; hormone sensitive lipase; human placenta lactogen; hydrocortisone; insulin; leptin; lipid hydroperoxide; malonaldehyde; myeloperoxidase; placental growth factor; plasminogen activator inhibitor 1; thrombomodulin; thromboxane; triacylglycerol; vasculotropin; vasculotropin receptor 1; Article; carbohydrate intolerance; cesarean section; elevated blood pressure; endothelial dysfunction; essential hypertension; first trimester pregnancy; genetic predisposition; glucose blood level; glucose intolerance; glucose utilization; human; hyperglycemia; hyperinsulinemia; hyperlipidemia; inflammation; insulin blood level; insulin release; insulin resistance; insulin response; insulin sensitivity; ischemic heart disease; lipid metabolism; lipolysis; major histocompatibility complex; maternal hypertension; maternal obesity; metabolic syndrome X; non insulin dependent diabetes mellitus; nonhuman; obesity; oral glucose tolerance test; oxidative stress; pathogenesis; pathophysiology; preeclampsia; pregnancy diabetes mellitus; pregnancy outcome; pregnant woman; premature fetus membrane rupture; premature labor; priority journal; reproduction; single nucleotide polymorphism; sodium retention; sympathetic tone; third trimester pregnancy; trisomy 13; urinary tract infection; weight gain; female; hyperinsulinism; hypertension; insulin resistance; metabolic syndrome X; metabolism; pathophysiology; preeclampsia; pregnancy; pregnancy complication; pregnancy diabetes mellitus","","adiponectin, 283182-39-8; angiotensin II, 11128-99-7, 68521-88-0; angiotensinogen, 11002-13-4, 64315-16-8; blood clotting factor 8, 9001-27-8; endothelial nitric oxide synthase, 503473-02-7; glucose, 50-99-7, 84778-64-3; hormone sensitive lipase, ; human placenta lactogen, 11085-36-2; hydrocortisone, 50-23-7; insulin, 9004-10-8; malonaldehyde, 542-78-9; myeloperoxidase, ; plasminogen activator inhibitor 1, 140208-23-7; thrombomodulin, 112049-68-0; thromboxane, 66719-58-2; vasculotropin, 127464-60-2","","","","","Reaven G.M., Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, 12, pp. 1595-1607, (1988); Carpenter M.W., Gestational diabetes, pregnancy hypertension, and late vascular disease, Diabetes Care, 30, pp. S246-S250, (2007); Yogev Y., Bene Haroush A., Chen R., Et al., Diurnal glycemic profile in obese and normal weight nondiabetic pregnant women, Am J Obstet Gynecol, 191, 3, pp. 949-953, (2004); Practice Committee of American Society for Reproductive Medicine, Obesity and reproduction: An educational bulletin, Fertil Steril, 90, 5, (2008); Hajer G.R., Van Haeften T.W., Visseren F.L., Adipose tissue dysfunction in obesity, diabetes, and vascular diseases, Eur Heart J, 29, pp. 2959-2971, (2008); O'Sullivan J.B., Mahan C., Criteria for oral glucose tolerance test in pregnancy, Diabetes, 13, pp. 278-285, (1964); Bergman R.N., Ider Y.Z., Bowden C.R., Et al., Quantitative estimation of insulin sensitivity, Am J Physiol, 236, pp. E667-E677, (1979); Catalano P.M., Huston L., Amini S.B., Et al., Longitudinal change in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus, Am J Obstet Gynecol, 180, pp. 903-916, (1999); Ryan E.A., Ennes L., Role of gestational hormones in the induction of insulin resistance, J Clin Endocrinol Metab, 67, pp. 341-347, (1988); Catalano P.M., Tyzbir E.D., Wolfe R.R., Et al., Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes, Am J Physiol, 264, 1, pp. E60-E67, (1993); Ward W.K., Johnston C.L., Beard J.C., Et al., Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus, Diabetes, 34, 9, pp. 861-869, (1985); Radaelli T., Farrell K.A., Hustone Presley L., Et al., Estimates of insulin sensitivity using glucose and CePeptide from the hye perglycemia and adverse pregnancy outcome glucose tolerance test, Diabetes Care, 33, 3, pp. 490-494, (2010); Hyperglycemia and Adverse Pregnancy Outcomes, N Engl J Med, 2008, 358, pp. 1991-2002, (2008); Hauguel S., Leturque A., Gilbert M., Et al., Effects of pregnancy and fasting on muscle glucose utilization in the rabbit, Am J Obstet Gynecol, 158, pp. 1215-1218, (1988); Leturque A., Ferre P., Burnol A.F., Et al., Glucose utilization rates and insulin sensitivity in vivo in tissues of virgin and pregnant rats, Diabetes, 35, pp. 172-177, (1986); Gibson M., Tulchinski D., The maternal adrenal, Maternalefetal Endocrinology, pp. 129-143, (1980); Ahmed S.A., Shalayel M.H., Role of cortisol in the deterioration of glucose tolerance in Sudanese pregnant women, East Afr Med J, 76, pp. 465-467, (1999); Rizza R.A., Mandarino L.J., Gerich J.E., Cortisol induced insulin resistance in man: Impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action, Clin Endocrinol Metab, 54, pp. 131-138, (1982); Highman T.J., Friedman J.E., Huston L.P., Et al., Longitudinal changes in maternal serum leptin concentrations body composition and resting metabolic rate in pregnancy, Am J Obstet Gynecol, 178, pp. 1010-1015, (1999); Henson M.C., Swan K.F., O'Neil J.S., Expression of placental leptin and leptin receptor transcripts in early pregnancy and at term, Obstet Gynecol, 92, pp. 1020-1028, (1998); Kautzkye Willer A., Pacini G., Tura A., Et al., Increased plasma leptin in gestational diabetes, Diabetologia, 44, pp. 164-172, (2001); Vitoratos N., Salamalekis E., Kassanos D., Et al., Maternal plasma leptin levels and their relationship to insulin and glucose in gestationaleonset diabetes, Gynecol Obstet Invest, 51, pp. 17-21, (2001); Beck P., Daughday W.H., Human placental lactogen: Studies of its acute metabolic effects and disposition in normal man, J Clin Invest, 46, pp. 103-110, (1967); Kuhl C., Aetiology of gestational diabetes, Baillieres Clin Obstet Gynaecol, 5, 2, pp. 279-292, (1991); Lind T., Billewicz W.Z., Brown G., A serial study of changes occurring in the oral glucose tolerance test during pregnancy, J Obstet Gynaecol Br Commonw, 80, 12, pp. 1033-1039, (1973); Gustafson A.B., Banasiak M.F., Kalkhoff R.K., Correlation of hyperprolactinemia with altered plasma insulin and glucose: Similarity to effects of late human pregnancy, J Clin Endocrinol Metab, 51, pp. 242-246, (1980); Sorenson R.L., Brelje T.C., Roth C., Effect of steroid and lactogenic hormones on islet of Langerhans: A new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy, Endocrinology, 133, pp. 2227-2233, (1993); Skouby S.O., Kuhl C., Hornnes P.J., Et al., Prolactin and glucose tolerance in normal and gestational diabetic pregnancy, Obstet Gynecol, 67, pp. 17-20, (1986); Brelje T.C., Scharp D.W., Lacy P.E., Et al., Effect of homologous placental lactogens, prolactins, and growth hormones on islet Becell division and insulin secretion in rat, mouse, and human islets: Implication for placental lactogen regulation of islet function during pregnancy, Endocrinology, 132, pp. 879-887, (1993); Herrera E., Ortegae Senovilla H., Disturbances in lipid metabolism in diabetic pregnancy e are these the cause of the problem?, Best Pract Res Clin Endocrinol Metab, 24, 4, (2010); Darmady J., Postle A., Lipid metabolism in pregnancy, BJOG, 89, pp. 211-215, (1982); Sivan E., Homko C., Chen X., Et al., Effect of insulin on fat metabolism during and after normal pregnancy, Diabetes, 48, pp. 834-838, (1999); Catalano P.M., Nizielski S., Shao J., Et al., Down regulation of IRSe1 and PPARgamma in obese women with gestational diabetes: Relationship to free fatty acids during pregnancy, Am J Physiol Endocrinol Metab, 282, 3, pp. E522-E533, (2002); Montelongo A., Lasuncion M., Pallardo L., Et al., Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women, Diabetes, 41, pp. 1651-1659, (1992); Koukkou E., Watts G.F., Lowy C., Serum lipid, lipoprotein and apolipoprotein changes in gestational diabetes mellitus: A crossesectional and prospective study, J Clin Pathol, 49, pp. 634-637, (1996); Coe N.R., Bernlohr D.A., Physiological properties and functions of intracellular fatty acidebinding proteins, Biochim Biophys Acta, 1391, pp. 287-306, (1998); Smith A.J., Thompson B.R., Sanders M.A., Et al., Interaction of the adipocyte fatty acidebinding protein with the hormonee sensitive lipase: Regulation by fatty acids and phosphorylation, J Biol Chem, 282, pp. 32424-32432, (2007); Ortegae Senovilla H., Schaefere Graf U., Meitzner K., Et al., Gestational diabetes mellitus causes changes in the concentrations of adipocyte fatty acidebinding protein and other adipocytokines in cord blood, Diabetes Care Sep, 34, 9, pp. 2061-2066, (2011); Retnakaran R., Hanley A.J., Raif N., Et al., Reduced adiponectin concentration in women with gestational diabetes: A potential factor in progression to type 2 diabetes, Diabetes Care, 27, 3, pp. 799-800, (2004); Schmatz M., Madan J., Marino T., Et al., Maternal obesity: The interplay between inflammation, mother and fetus, J Perinatol, 30, pp. 441-446, (2010); Fujita K., Nishizawa H., Funahashi T., Et al., Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome, Circ J, 70, pp. 1437-1442, (2006); Furukawa S., Fujita T., Shimabukuro M., Et al., Increased oxidative stress in obesity and its impact on metabolic syndrome, J Clin Invest, 114, pp. 1752-1761, (2004); Karacay O., Sepicie Dincel A., Karcaaltincaba D., Et al., A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24-36 weeks of gestation, N Diabetes Res Clin Pract, 89, 3, pp. 231-238, (2010); Vikse B.E., Irgens L.M., Leivestad T., Et al., Preeclampsia and the risk of endestage renal disease, N Engl J Med, 359, (2008); Levine R.J., Vatten L.J., Horowitz G.L., Et al., Preeeclampsia, soluble fmselike tyrosine kinase 1, and the risk of reduced thyroid function: Nested caseecontrol and population based study, BMJ, 339, (2009); Xia Y., Wen H., Bobst S., Et al., Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells, J Soc Gynecol Investig, 10, (2003); Dechend R., Homuth V., Wallukat G., Et al., AT (1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor, Circulation, 101, (2000); Zhou C.C., Ahmad S., Mi T., Et al., Autoantibody from women with preeclampsia induces soluble Fmselike tyrosine kinasee1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated Tecells signaling, Hypertension, 51, (2008); Friedman S.A., Schiff E., Emeis J.J., Et al., Biochemical corroboration of endothelial involvement in severe preeclampsia, Am J Obstet Gynecol, 172, (1995); Hsu C.D., Iriye B., Johnson T.R., Et al., Elevated circulating thrombomodulin in severe preeclampsia, Am J Obstet Gynecol, 169, (1993); Taylor R.N., Crombleholme W.R., Friedman S.A., Et al., High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone, Am J Obstet Gynecol, 165, (1991); Howard G., O'Leary D.H., Zaccaro D., Et al., Insulin sensitivity and atherosclerosis, Circulation, 93, 10, pp. 1809-1817, (1996); Caruso A., Ferrazzani S., De Carolis S., Et al., Gestational hypertension but not preeeclampsia is associated with insulin resistance syndrome characteristics, Hum Reprod, 14, 1, pp. 219-223, (1999); Solomon C.G., Graves S.W., Green M.F., Et al., Glucose intolerance as a predictor of hypertension in pregnancy, Hypertension, 23, 6, pp. 717-721, (1994); Bdolah Y., Lam C., Rajakumar A., Et al., Twin pregnancy and the risk of preeclampsia: Bigger placenta or relative ischemia?, Am J Obstet Gynecol, 198, (2008); Venkatesha S., Toporsian M., Lam C., Et al., Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med, 12, (2006); Luft F.C., Soluble endoglin (sEng) joins the soluble fmselike tyrosine kinase (sFlt) receptor as a preeeclampsia molecule, Nephrol Dial Transplant, 21, (2006); Roberts J.M., Taylor R.N., Goldfien A., Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia, Am J Hypertens, 4, (1991); Harskamp R.E., Zeeman G.G., Preeclampsia: At risk for remote cardiovascular disease, Am J Med Sci, 334, (2007); Kaaja R., Laivuori H., Laakso M., Et al., Evidence of a state of increased insulin resistance in preeclampsia, Metabolism, 48, 7, pp. 892-896, (1999); Wolf M., Sandler L., Munoz K., Et al., First trimester insulin resistance and subsequent preeclampsia: A prospective study, Clin Endocrinol Metab, 87, 4, pp. 1563-1568, (2002); Srinivas S.K., Sammel M.D., Bastek J., Et al., Evaluating the association between all components of the metabolic syndrome and preeeclampsia, J Matern Fetal Neonatal Med, 22, 6, pp. 501-509, (2009); Ray J.G., Diamond P., Singh G., Et al., Brief overview of maternal triglycerides as a risk factor for preeeclampsia, BJOG, 113, 4, pp. 379-386, (2006); Sermer M., Naylor C.D., Gare D.J., Et al., Impact of increasing carbohydrate intolerance on maternalefetal outcomes in 3637 women without gestational diabetes: The Toronto Trihospital Gestational Project, Am J Obstet Gynecol, 173, pp. 146-156, (1995); Hjartardottir S., Leifsson B.G., Geirsson R.T., Et al., Recurrence of hypertensive disorder in second pregnancy, Am J Obstet Gynecol, 194, (2006); Brown M.A., Mackenzie C., Dunsmuir W., Et al., Can we predict recurrence of preeeclampsia or gestational hypertension?, BJOG, 114, (2007); Villar J., Carroli G., Wojdyla D., Et al., World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?, Am J Obstet Gynecol, 194, (2006); Tu W., Eckert G.J., Di Meglio L.A., Et al., Intensified effect of adiposity on blood pressure in overweight and obese children, Hypertension, 58, (2011); Wilson P.W., D'Agostino R.B., Sullivan L., Et al., Overweight and obesity as determinants of cardiovascular risk: The Frae mingham experience, Arch Intern Med, 2002, (1867); Nugent C.E., Punch M.R., Barr M., Et al., Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy, Obstet Gynecol, 87, (1996); Meekins J.W., Pijnenborg R., Hanssens M., Et al., A study of placental bed spiral arteries and trophoblast invasion in normal and severe preeeclamptic pregnancies, Br J Obstet Gynaecol, 101, (1994); Brosens I., Pijnenborg R., Vercruysse L., Et al., The ""Great Obstetrical Syndromes"" are associated with disorders of deep placentation, Am J Obstet Gynecol, 204, (2011); Dekker G.A., Sibai B.M., Etiology and pathogenesis of preeclampsia: Current concepts, Am J Obstet Gynecol, 179, 5, pp. 1359-1375, (1998); Dekker G.A., Risk factors for preeclampsia, Clin Obstet Gynecol, 42, (1999); Zhou Y., Damsky C.H., Fisher S.J., Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?, J Clin Invest, 2152, (1997); Zhou Y., Gormley M.J., Hunkapiller N.M., Et al., Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia, J Clin Invest, 123, (2013); Einarsson J.I., Sangie Haghpeykar H., Gardner M.O., Sperm exposure and development of preeclampsia, Am J Obstet Gynecol, 188, (2003); Smith G.N., Walker M., Tessier J.L., Et al., Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility, Am J Obstet Gynecol, 177, (1997); Wang J.X., Knottnerus A.M., Schuit G., Et al., Surgically obtained sperm, and risk of gestational hypertension and pree eclampsia, Lancet, 359, (2002); Gleicher N., Why much of the pathophysiology of preeclampsiaeeclampsia must be of an autoimmune nature, Am J Obstet Gynecol, 196, (2007); Saftlas A.F., Beydoun H., Triche E., Immunogenetic determinants of preeclampsia and related pregnancy disorders: A systematic review, Obstet Gynecol, 106, (2005); Lachmeijer A.M., Dekker G.A., Pals G., Et al., Searching for preeclampsia genes: The current position, Eur J Obstet Gynecol Reprod Biol, 105, (2002); Germain S.J., Sacks G.P., Sooranna S.R., Et al., Systemic inflammatory priming in normal pregnancy and preeclampsia: The role of circulating syncytiotrophoblast microparticles, J Immunol, 178, (2007); Condee Agudelo A., Villar J., Lindheimer M., Maternal infection and risk of preeclampsia: Systematic review and metae analysis, Am J Obstet Gynecol, 198, 1, (2008); Levine R.J., Maynard S.E., Qian C., Et al., Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, 350, (2004); Maynard S.E., Min J.Y., Merchan J., Et al., Excess placental soluble fmselike tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, 111, (2003); McKeeman G.C., Ardill J.E., Caldwell C.M., Et al., Soluble vascular endothelial growth factor receptore1 (sFlte1) is increased throughout gestation in patients who have preeclampsia develop, Am J Obstet Gynecol, 191, (2004); Huang Z., Willett W.C., Manson J.E., Et al., Body weight, weight change, and risk for hypertension in women, Ann Intern Med, 128, (1998); Carr D.B., Epplein M., Johnson C.O., Et al., A sister's risk: Family history as a predictor of preeclampsia, Am J Obstet Gynecol, 193, (2005); Treloar S.A., Cooper D.W., Brennecke S.P., Et al., An Australian twin study of the genetic basis of preeclampsia and eclampsia, Am J Obstet Gynecol, 184, (2001); Rocchini A.P., Katch V., Kveselis D., Et al., Insulin and renal sodium retention in obese adolescents, Hypertension, 14, (1989); Kincaide Smith P., Hypothesis: Obesity and the insulin resistance syndrome play a major role in endestage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis, J Hypertens, 22, (2004); Mooree Maxwell C.A., Robboy S.J., Placental site trophoblastic tumor arising from antecedent molar pregnancy, Gynecol Oncol, 92, (2004)","M. Hod; Helen Schneider Hospital for Women, Rabin Medical Center, Department of Obstetrics and Gynecology, Petach Tikva, 49100, Israel; email: Hodroyal@inter.net.il","","Bailliere Tindall Ltd","","","","","","15216934","","BPRCF","25481558","English","Best Pract. Res. Clin. Obstet. Gynaecol.","Article","Final","","Scopus","2-s2.0-84933516471"
"Katsuya T.; Morishita R.","Katsuya, Tomohiro (7005266558); Morishita, Ryuichi (7102241494)","7005266558; 7102241494","Gene polymorphism of angiotensin II Type 1 and type 2 receptors","2013","Current Pharmaceutical Design","19","17","","2996","3001","5","13","10.2174/1381612811319170004","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878644897&doi=10.2174%2f1381612811319170004&partnerID=40&md5=d32542fbdfa15b0cc8114a1122b1f549","Katsuya Clinic, Osaka University Graduate School of Medicine, Japan; Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Japan","Katsuya T., Katsuya Clinic, Osaka University Graduate School of Medicine, Japan, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Japan; Morishita R., Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Japan","Renin-angiotensin system (RAS) plays a key role in pathogenesis of cardiovascular disease and in the responsiveness for various types of medications. A large number of genetic investigations have been carried out to examine the association between gene variants of RAS and predisposition to cardiovascular diseases, such as hypertension, coronary artery disease and stroke. Even though the major results were obtained from genetic association studies of angiotensinogen or angiotensin converting enzyme, unique findings were also elucidated from investigations concerning single nucleotide polymorphisms (SNPs) of 2 types of angioteinsin II receptor genes denoted as AGTR1 and AGTR2. Both genes have many SNPs in the coding and its flanking regions but most of the studies used A1166C polymorphism of AGTR1 and G1675A polymorphism of AGTR2. In the subjects with C1166 allele of AGTR1, several investigations reported increased risk for coronary artery disease, ischemic stroke, heart failure and end-stage renal disease but not for hypertension. Interestingly, a few papers pointed out the possibility that A1166C modulates the efficacy of RAS inhibitors. In the genetic analysis of AGTR2, G1675 allele carriers had increased risk for left ventricular hypertrophy, renal insufficiency and modulated hemodynamic response to RAS inhibitors. In this review, we summarized previous investigations concerning the genetic aspects of AGTR1 and AGTR2 to consider the clinical utility of SNPs of these receptors. © 2013 Bentham Science Publishers.","Angiotensin II receptor blocker (ARB); Cardiovascular disease; Genetics; Genome wide association study (GWAS); Hypertension; Left ventricular hypertrophy; Renin angiotensin system (RAS); Single nucleotide polymorphisms (SNPs)","2 butyl 4 chloro 1 [[2' (1h tetrazol 5 yl) 4 biphenylyl]methyl] 5 imidazolecarboxylic acid; angiotensin 1 receptor; angiotensin 2 receptor; angiotensin 2 receptor antagonist; angiotensin receptor antagonist; angiotensinogen; atenolol; dipeptidyl carboxypeptidase; irbesartan; losartan; brain ischemia; cardiovascular disease; cerebrovascular accident; coronary artery disease; disease predisposition; drug receptor binding; genetic association; genetic polymorphism; genetic risk; genetic variability; heart failure; heart left ventricle hypertrophy; heterozygote; human; hypertension; kidney failure; pathogenesis; priority journal; renin angiotensin aldosterone system; review; single nucleotide polymorphism; treatment response","","2 butyl 4 chloro 1 [[2' (1h tetrazol 5 yl) 4 biphenylyl]methyl] 5 imidazolecarboxylic acid, 124750-92-1; angiotensinogen, 11002-13-4, 64315-16-8; atenolol, 29122-68-7, 93379-54-5; dipeptidyl carboxypeptidase, 9015-82-1; irbesartan, 138402-11-6, 329055-23-4; losartan, 114798-26-4","exp 3174","","","","Kato N., Takeuchi F., Tabara Y., Et al., Meta-analysis of genomewide association studies identifies common variants associated with blood pressure variation in east Asians, Nat Genet, 43, pp. 531-538, (2011); Tabara Y., Kohara K., Kita Y., Et al., Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: The Japanese Millennium Genome Project, Hypertension, 56, pp. 973-980, (2010); Dzau V., The cardiovascular continuum and renin-angiotensinaldosterone system blockade, J Hypertens Suppl, 23, (2005); Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Bernstein K.E., Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor, Nature, 351, pp. 233-236, (1991); Guo D.F., Furuta H., Mizukoshi M., Inagami T., The genomic organization of human angiotensin II type 1 receptor, Biochem Biophys Res Commun, 200, pp. 313-319, (1994); Martin M.M., Willardson B.M., Burton G.F., Et al., Human angiotensin II type 1 receptor isoforms encoded by messenger RNA splice variants are functionally distinct, Mol Endocrinol, 15, pp. 281-293, (2001); Jagannathan R., Kaveti S., Desnoyer R.W., Et al., AT1 receptor induced alterations in histone H2A reveal novel insights into GPCR control of chromatin remodeling, PLoS One, 5, (2010); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, pp. 63-69, (1994); Takami S., Katsuya T., Rakugi H., Et al., Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension, Am J Hypertens, 11, pp. 316-321, (1998); Takami S., Imai Y., Katsuya T., Et al., Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study, Am J Hypertens, 13, pp. 121-127, (2000); Benetos A., Topouchian J., Ricard S., Et al., Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients, Hypertension, 26, pp. 44-47, (1995); Kikuya M., Sugimoto K., Katsuya T., Et al., A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: The Ohasama Study, Hypertens Res, 26, pp. 141-145, (2003); Sugimoto K., Katsuya T., Ohkubo T., Et al., Association between angiotensin II type 1 receptor gene polymorphism and essential hypertension: The Ohasama Study, Hypertens Res, 27, pp. 551-556, (2004); Hindorff L.A., Heckbert S.R., Tracy R., Et al., Angiotensin II type 1 receptor polymorphisms in the cardiovascular health study: Relation to blood pressure, ethnicity, and cardiovascular events, Am J Hypertens, 15, pp. 1050-1056, (2002); Castellano M., Glorioso N., Cusi D., Et al., Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: The GENIPER Project, J Hypertens, 21, pp. 1853-1860, (2003); Mottl A.K., Shoham D.A., North K.E., Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: A HuGE review, Genet Med, 10, pp. 560-574, (2008); Rubattu S., Di Angelantonio E., Stanzione R., Et al., Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: A role of the A1166C/AT1 gene variant, J Hypertens, 22, pp. 2129-2134, (2004); Buraczynska M., Ksiazek P., Drop A., Et al., Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease, Nephrol Dial Transplant, 21, pp. 979-983, (2006); Miller J.A., Thai K., Scholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Int, 56, pp. 2173-2180, (1999); Akasaka H., Katsuya T., Saitoh S., Et al., Effects of angiotensin II type 1 receptor gene polymorphisms on insulin resistance in a Japanese general population: The Tanno-Sobetsu study, Hypertens Res, 29, pp. 961-967, (2006); Diez J., Laviades C., Orbe J., Et al., The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives, J Hypertens, 21, pp. 2085-2092, (2003); Konoshita T., Kato N., Fuchs S., Et al., Genetic variant of the Renin-Angiotensin system and diabetes influences blood pressure response to Angiotensin receptor blockers, Diabetes Care, 32, pp. 1485-1490, (2009); Redon J., Luque-Otero M., Martell N., Chaves F.J., Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients, Pharmacogenomics J, 5, pp. 14-20, (2005); Brunner M., Cooper-DeHoff R.M., Gong Y., Et al., Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study), Am J Cardiol, 99, pp. 1549-1554, (2007); Konoshita T., Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin systemblocking drugs?: A systematic review of pharmacogenomics in the Renin-Angiotensin system, Curr Hypertens Rep, 13, pp. 356-361, (2011); Kurland L., Melhus H., Karlsson J., Et al., Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, J Hypertens, 20, pp. 657-663, (2002); Jiang S., Hsu Y.H., Venners S.A., Et al., Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan, J Hypertens, 29, pp. 890-895; Li Y., Li X., Jia N., Et al., Meta-analysis of the association between angiotensin II receptor, type 1 gene A1166C polymorphism and coronary artery disease in Chinese populations, J Renin Angiotensin Aldosterone Syst, (2012); Arsenault J., Lehoux J., Lanthier L., Et al., A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity, Pharmacogenet Genomics, 20, pp. 377-388, (2010); Morales-Suarez-Varela M.M., Riera-Fortuny C., Mansego M.L., Et al., Association between AT C573T polymorphism and cardiovascular risk factors in myocardial infarction, Cardiovasc Pathol, 20, pp. 156-161, (2011); Koike G., Horiuchi M., Yamada T., Et al., Human type 2 angiotensin II receptor gene: Cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung, Biochem Biophys Res Commun, 203, pp. 1842-1850, (1994); Katsuya T., Horiuchi M., Minami S., Et al., Genomic organization and polymorphism of human angiotensin II type 2 receptor: No evidence for its gene mutation in two families of human premature ovarian failure syndrome, Mol Cell Endocrinol, 127, pp. 221-228, (1997); Niimura F., Kon V., Ichikawa I., The renin-angiotensin system in the development of the congenital anomalies of the kidney and urinary tract, Curr Opin Pediatr, 18, pp. 161-166, (2006); Vervoort V.S., Beachem M.A., Edwards P.S., Et al., AGTR2 mutations in X-linked mental retardation, Science, 296, pp. 2401-2403, (2002); Horiuchi M., Iwanami J., Mogi M., Regulation of angiotensin II receptors beyond the classical pathway, Clin Sci (Lond), 123, pp. 193-203, (2012); Rodrigues-Ferreira S., Nahmias C., An ATIPical family of angiotensin II AT2 receptor-interacting proteins, Trends Endocrinol Metab, 21, pp. 684-690, (2010); Nishimura H., Yerkes E., Hohenfellner III K., Hogan B.M., Fogo A., Brock III J.W., Inagami T., Ichikawa I., Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men, Mol Cell, 3, pp. 1-10, (1999); Schmieder R.E., Erdmann J., Delles C., Et al., Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans, J Am Coll Cardiol, 37, pp. 175-182, (2001); Warnecke C., Mugrauer P., Surder D., Et al., Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing, Am J Physiol Regul Integr Comp Physiol, 289, (2005); Herrmann S.M., Nicaud V., Schmidt-Petersen K., Et al., Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: The GLAECO and GLAOLD studies, Eur J Heart Fail, 4, pp. 707-712, (2002); Alfakih K., Brown B., Lawrance R.A., Et al., Effect of a common Xlinked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization, Atherosclerosis, 195, (2007); Pettersson-Fernholm K., Frojdo S., Fagerudd J., Et al., The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients, Kidney Int, 69, pp. 1880-1884, (2006); Cherney D.Z., Lai V., Miller J.A., Scholey J.W., Reich H.N., The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans, Nephrol Dial Transplant, 25, pp. 4093-4096, (2010); Jin J.J., Nakura J., Wu Z., Et al., Association of angiotensin II type 2 receptor gene variant with hypertension, Hypertens Res, 26, pp. 547-552, (2003)","T. Katsuya; not available, Amagasaki, Hyogo 660-0052, 2-17-21 Nanamatsu-cho, Japan; email: tkatsuya@iris.eonet.ne.jp","","Bentham Science Publishers","","","","","","13816128","","CPDEF","23176211","English","Curr. Pharm. Des.","Review","Final","","Scopus","2-s2.0-84878644897"
"Fernández-Cadenas I.; Del Río-Espínola A.; Giralt D.; Domingues-Montanari S.; Quiroga A.; Mendióroz M.; Ruíz A.; Ribó M.; Serena J.; Obach V.; Freijo M.M.; Martí-Fábregas J.; Delgado P.; Montaner J.","Fernández-Cadenas, Israel (57211973004); Del Río-Espínola, Alberto (24464190200); Giralt, Dolors (36876253200); Domingues-Montanari, Sophie (24464240000); Quiroga, Adoracion (36025728500); Mendióroz, Maite (24464361900); Ruíz, Agustin (7203006899); Ribó, Marc (7006988462); Serena, Joaquin (7004135792); Obach, Victor (6701732295); Freijo, Mari Mar (6507912961); Martí-Fábregas, Joan (7003866469); Delgado, Pilar (56526433000); Montaner, Joan (7202587137)","57211973004; 24464190200; 36876253200; 24464240000; 36025728500; 24464361900; 7203006899; 7006988462; 7004135792; 6701732295; 6507912961; 7003866469; 56526433000; 7202587137","IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke","2012","Stroke","43","10","","2659","2665","6","29","10.1161/STROKEAHA.112.657007","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866720680&doi=10.1161%2fSTROKEAHA.112.657007&partnerID=40&md5=f81f3473b1ddbee17380ee84c162af2a","Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Experimental Cardiology Research Laboratory, Vall d'Hebrón Hospital, Barcelona, Spain; Department of Structural Genomics, Neocodex, Seville, Spain; Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; Department of Neurology, Hospital Universitari Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona, Barcelona, Spain; Department of Neurological Sciences, Hospital Clínic, University of Barcelona, Barcelona, Spain; Department of Neurology, Hospital de Basurto, Bilbao, Spain; Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","Fernández-Cadenas I., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Del Río-Espínola A., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Giralt D., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Domingues-Montanari S., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Quiroga A., Experimental Cardiology Research Laboratory, Vall d'Hebrón Hospital, Barcelona, Spain; Mendióroz M., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Ruíz A., Department of Structural Genomics, Neocodex, Seville, Spain, Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; Ribó M., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Serena J., Department of Neurology, Hospital Universitari Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona, Barcelona, Spain; Obach V., Department of Neurological Sciences, Hospital Clínic, University of Barcelona, Barcelona, Spain; Freijo M.M., Department of Neurology, Hospital de Basurto, Bilbao, Spain; Martí-Fábregas J., Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Delgado P., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; Montaner J., Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain","BACKGROUND AND PURPOSE-: There is a great interindividual variability among patients with acute ischemic stroke regarding the response to intravenous tissue-type plasminogen activator treatment. The aim of this study was to identify genetic variants associated with recanalization, and thus treatment efficacy, after tissue-type plasminogen activator administration. METHODS-: A total of 140 single nucleotide polymorphisms from 97 candidate genes were successfully genotyped by SNPlex in 2 cohorts, accounting for 497 prospectively recruited tissue-type plasminogen activator-treated patients, of whom 33% recanalized during tissue-type plasminogen activator infusion. Functional studies were then performed, including assessment of interleukin 1B mRNA levels and von Willebrand factor, FIII, FVII, FVIII, and FX protein activity. RESULTS-: After replication, the following single nucleotide polymorphisms were associated with early recanalization: rs1143627 in IL1B gene (CC: 53.1% of recanalization, A-carriers: 32.7%; P=0.022; replication cohort: P=0.046), rs16944 in IL1B gene (AA: 50% of recanalization, G-carriers: 32%; P=0.038; replication cohort: P=0.049), and rs1063856 in the vWF gene (GG: 53.8% of recanalization, A-carriers: 31.5%; P=0.006; replication cohort: P=0.046). The functional studies revealed an association between the rs1063856 single nucleotide polymorphisms in vWF and FVIII activity (AA: 115.93%, AG: 156.07%, GG: 83.42%; P=0.005). CONCLUSIONS-: Three single nucleotide polymorphisms were associated with tissue-type plasminogen activator efficacy in the Spanish population, and their mechanism of action might be associated with the activity of coagulation factors. © 2012 American Heart Association, Inc.","genetics; pharmacogenetics; recanalization; stroke; tPA","Aged; Cohort Studies; Female; Genetic Testing; Genotype; Humans; Interleukin-1beta; Logistic Models; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Spain; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; von Willebrand Factor; angiotensin receptor antagonist; antithrombocytic agent; blood clotting factor 10; blood clotting factor 7; blood clotting factor 8 plus von Willebrand factor; dipeptidyl carboxypeptidase inhibitor; diuretic agent; DNA; hydroxymethylglutaryl coenzyme A reductase inhibitor; interleukin 1beta; messenger RNA; monocyte chemotactic protein 1; oral antidiabetic agent; thromboplastin; tissue inhibitor of metalloproteinase 1; tissue plasminogen activator; von Willebrand factor; aged; article; brain ischemia; clinical assessment; continuous infusion; controlled study; diabetes mellitus; DNA isolation; drug efficacy; dyslipidemia; female; fibrinolysis; functional assessment; genetic analysis; genetic variability; genotyping technique; heart atrium fibrillation; heart disease; human; hypertension; major clinical study; male; priority journal; Rankin scale; recanalization; risk assessment; single nucleotide polymorphism; smoking","","DNA, 9007-49-2; blood clotting factor 10, 9001-29-0; blood clotting factor 7, 9001-25-6; thromboplastin, 9035-58-9; tissue inhibitor of metalloproteinase 1, 140208-24-8; tissue plasminogen activator, 105913-11-9; von Willebrand factor, 109319-16-6; IL1B protein, human, ; Interleukin-1beta, ; Tissue Plasminogen Activator, 3.4.21.68; von Willebrand Factor, ","","","Seventh Framework Programme, FP7, (201024, 202213)","","Demchuk A.M., Scott Burgin W., Christou I., Felberg R.A., Barber P.A., Hill M.D., Alexandrov A.V., Thrombolysis in Brain Ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator, Stroke, 32, 1, pp. 89-93, (2001); Wahlgren N., Ahmed N., Davalos A., Ford G.A., Grond M., Hacke W., Hennerici M.G., Kaste M., Kuelkens S., Larrue V., Lees K.R., Roine R.O., Soinne L., Toni D., Vanhooren G., Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study, Lancet, 369, 9558, pp. 275-282, (2007); Christou I., Alexandrov A.V., Burgin W.S., Wojner A.W., Felberg R.A., Malkoff M., Grotta J.C., Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke, Stroke, 31, 8, pp. 1812-1816, (2000); Fernandez-Cadenas I., Alvarez-Sabin J., Ribo M., Rubiera M., Mendioroz M., Molina C.A., Rosell A., Montaner J., Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients, Journal of Thrombosis and Haemostasis, 5, 9, pp. 1862-1868, (2007); Fernandez-Cadenas I., Mendioroz M., Munuera J., Alvarez-Sabin J., Rovira A., Quiroga A., Et al., Lower concentrations of thrombin-antithrombin complex (tat) correlate to higher recanalisation rates among ischaemic stroke patients treated with tpa, Thromb Haemost, 102, pp. 759-764, (2009); Iacoviello L., Di Castelnuovo A., Gattone M., Pezzini A., Assanelli D., Lorenzet R., Del Zotto E., Colombo M., Napoleone E., Amore C., D'Orazio A., Padovani A., De Gaetano G., Giannuzzi P., Donati M.B., Polymorphisms of the interleukin-1β gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro, Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1, pp. 222-227, (2005); Chen H., Wilkins L.M., Aziz N., Cannings C., Wyllie D.H., Bingle C., Rogus J., Beck J.D., Offenbacher S., Cork M.J., Rafie-Kolpin M., Hsieh C.-M., Kornman K.S., Duff G.W., Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context, Human Molecular Genetics, 15, 4, pp. 519-529, (2006); Schonbeck U., Mach F., Libby P., Generation of biologically active il-1 beta by matrix metalloproteinases: A novel caspase-1-independent pathway of il-1 beta processing, J Immunol, 161, pp. 3340-3346, (1998); Mazzotta G., Sarchielli P., Caso V., Paciaroni M., Floridi A., Floridi A., Gallai V., Different cytokine levels in thrombolysis patients as predictors for clinical outcome, European Journal of Neurology, 11, 6, pp. 377-381, (2004); Hall S.K., Perregaux D.G., Gabel C.A., Woodworth T., Durham L.K., Huizinga T.W.F., Breedveld F.C., Seymour A.B., Correlation of polymorphic variation in the promoter region of the interleukin-1β gene with secretion of interleukin-1β protein, Arthritis and Rheumatism, 50, 6, pp. 1976-1983, (2004); Domingues-Montanari S., Fernandez-Cadenas I., Del Rio-Espinola A., Mendioroz M., Fernandez-Morales J., Corbeto N., Et al., Kcnk17 genetic variants in ischemic stroke, Atherosclerosis, 208, pp. 203-209, (2010); Kiefer T.L., Becker R.C., Inhibitors of platelet adhesion, Circulation, 120, pp. 2488-2495, (2009); Lacquemant C., Gaucher C., Delorme C., Chatellier G., Gallois Y., Rodier M., Passa P., Balkau B., Mazurier C., Marre M., Froguel P., Bouallouche A., Galtier F., Bringer J., Bouhanick B., Sert C., Grimaldi A., Dusselier L., Crea T., Drouin P., Kahal Z.Zoubida, Simon D., Chaillous L., Charbonnel B., Muller A., Marechaud R., Halimi S., Sackmann H., Tauber J.-P., Mayaudon H., Bauduceau B., Paquot N., Scheen A., Miossec P., Attali J.-R., Cerf I., Charpentier G., Thivolet C., Tielmans D., Guillausseau P.-J., Poirer J.-Y., Allanic H., Tichet J., Association between high von Willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes, Kidney International, 57, 4, pp. 1437-1443, (2000); Smith N.L., Chen M.H., Dehghan A., Strachan D.P., Basu S., Soranzo N., Et al., Novel associations of multiple genetic loci with plasma levels of factor vii, factor viii, and von willebrand factor, Circulation, 121, pp. 1382-1392, (2010); Gissel M., Undas A., Slowik A., Mann K.G., Brummel-Ziedins K.E., Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events, Thromb Res, 126, pp. 262-269, (2010)","J. Montaner; Neurovascular Research Laboratory, Institute of Research, Vall d'Hebron Hospital, 08035 Barcelona, Pg Vall d'Hebron 119-129, Spain; email: 31862jmv@comb.cat","","","","","","","","15244628","","SJCCA","22858724","English","Stroke","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84866720680"
"Bis J.C.; Sitlani C.; Irvin R.; Avery C.L.; Smith A.V.; Sun F.; Evans D.S.; Musani S.K.; Li X.; Trompet S.; Krijthe B.P.; Harris T.B.; Quibrera P.M.; Brody J.A.; Demissie S.; Davis B.R.; Wiggins K.L.; Tranah G.J.; Lange L.A.; Sotoodehnia N.; Stott D.J.; Franco O.H.; Launer L.J.; Stürmer T.; Taylor K.D.; Cupples L.A.; Eckfeldt J.H.; Smith N.L.; Liu Y.; Wilson J.G.; Heckbert S.R.; Buckley B.M.; Ikram M.A.; Boerwinkle E.; Chen Y.-D.I.; De Craen A.J.M.; Uitterlinden A.G.; Rotter J.I.; Ford I.; Hofman A.; Sattar N.; Slagboom P.E.; Westendorp R.G.J.; Gudnason V.; Vasan R.S.; Lumley T.; Cummings S.R.; Taylor H.A., Jr.; Post W.; Jukema J.W.; Stricker B.H.; Whitsel E.A.; Psaty B.M.; Arnett D.","Bis, Joshua C. (6603292486); Sitlani, Colleen (57208079621); Irvin, Ryan (28567762900); Avery, Christy L. (7005441091); Smith, Albert Vernon (56424163100); Sun, Fangui (56402332900); Evans, Daniel S. (37060867300); Musani, Solomon K. (57210974945); Li, Xiaohui (57216515050); Trompet, Stella (22954837300); Krijthe, Bouwe P. (57191195068); Harris, Tamara B. (35375662400); Quibrera, P. Miguel (8901617800); Brody, Jennifer A. (57205961011); Demissie, Serkalem (56984149300); Davis, Barry R. (24439500800); Wiggins, Kerri L. (57204456605); Tranah, Gregory J. (6602848494); Lange, Leslie A. (7103078524); Sotoodehnia, Nona (6506288380); Stott, David J. (13309434700); Franco, Oscar H. (24553920400); Launer, Lenore J. (7006392362); Stürmer, Til (7004598109); Taylor, Kent D. (7403523428); Cupples, L. Adrienne (57203177830); Eckfeldt, John H. (7006754410); Smith, Nicholas L. (7403173535); Liu, Yongmei (58871676000); Wilson, James G. (7406645019); Heckbert, Susan R. (7005828089); Buckley, Brendan M. (57211450292); Ikram, M. Arfan (57189595440); Boerwinkle, Eric (7102087489); Chen, Yii-Der Ida (8145846200); De Craen, Anton J. M. (7004695294); Uitterlinden, Andre G. (35231615000); Rotter, Jerome I. (56284453500); Ford, Ian (7006691891); Hofman, Albert (57190078722); Sattar, Naveed (7007043802); Slagboom, P. Eline (7004450759); Westendorp, Rudi G. J. (57195460711); Gudnason, Vilmundur (7003353432); Vasan, Ramachandran S. (35369677100); Lumley, Thomas (7003921176); Cummings, Steven R. (35373488900); Taylor, Herman A. (7403057991); Post, Wendy (57221279716); Jukema, J. Wouter (7005836769); Stricker, Bruno H. (35380220500); Whitsel, Eric A. (6604048496); Psaty, Bruce M. (35374213400); Arnett, Donna (7101719250)","6603292486; 57208079621; 28567762900; 7005441091; 56424163100; 56402332900; 37060867300; 57210974945; 57216515050; 22954837300; 57191195068; 35375662400; 8901617800; 57205961011; 56984149300; 24439500800; 57204456605; 6602848494; 7103078524; 6506288380; 13309434700; 24553920400; 7006392362; 7004598109; 7403523428; 57203177830; 7006754410; 7403173535; 58871676000; 7406645019; 7005828089; 57211450292; 57189595440; 7102087489; 8145846200; 7004695294; 35231615000; 56284453500; 7006691891; 57190078722; 7007043802; 7004450759; 57195460711; 7003353432; 35369677100; 7003921176; 35373488900; 7403057991; 57221279716; 7005836769; 35380220500; 6604048496; 35374213400; 7101719250","Drug-gene interactions of antihypertensive medications and risk of incident cardiovascular disease: A pharmacogenomics study from the CHARGE consortium","2015","PLoS ONE","10","10","0140496","","","","20","10.1371/journal.pone.0140496","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84950335587&doi=10.1371%2fjournal.pone.0140496&partnerID=40&md5=23b41612b304d66d39d464dbda1969c8","Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States; Icelandic Heart Association, Kopavogur, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States; California Pacific Medical Center Research Institute, San Francisco, CA, United States; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, United States; Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States; Department of Cardiology, Leiden University Medical Center, Netherlands; Department of Gerontology and Geriatrics, Leiden University Medical Center, Netherlands; Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States; Collaborative Studies Coordinating Center, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States; Department of Biostatistics, University of Texas School of Public Health, Houston, TX, United States; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States; Department of Genetics, University of North Carolina, Chapel Hill, 27599, NC, United States; Cardiology Division, University of Washington, Seattle, WA, United States; Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; University of North Carolina, GSK Center of Excellence in Pharmacoepidemiology, Chapel Hill, NC, United States; Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, United States; Framingham Heart Study, Framingham, MA, United States; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States; Department of Epidemiology, University of Washington, Seattle, WA, United States; Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, WA, United States; Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, United States; Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, United States; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland; Institute for Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; Robertson Center for Biostatistics, University of Glasgow, Glasgow, United Kingdom; BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, United Kingdom; Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, Netherlands; Faculty of Health and Medical Sciences, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; Boston University School of Medicine, Boston, MA, United States; Boston University School of Public Health, Boston, MA, United States; Department of Statistics, University of Auckland, Auckland, New Zealand; Department of Medicine, Morehouse School of Medicine, Atlanta, GA, United States; Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States; Inspectorate for Health Care, Hague, Netherlands; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Department of Health Services, University of Washington, Seattle, WA, United States; Group Health Research Institute, Group Health, Seattle, WA, United States","Bis J.C., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; Sitlani C., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; Irvin R., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Avery C.L., Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States; Smith A.V., Icelandic Heart Association, Kopavogur, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Sun F., Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States; Evans D.S., California Pacific Medical Center Research Institute, San Francisco, CA, United States; Musani S.K., Department of Medicine, University of Mississippi Medical Center, Jackson, MS, United States; Li X., Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, United States; Trompet S., Department of Cardiology, Leiden University Medical Center, Netherlands, Department of Gerontology and Geriatrics, Leiden University Medical Center, Netherlands; Krijthe B.P., Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Harris T.B., Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States; Quibrera P.M., Collaborative Studies Coordinating Center, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States; Brody J.A., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; Demissie S., Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States; Davis B.R., Department of Biostatistics, University of Texas School of Public Health, Houston, TX, United States; Wiggins K.L., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States; Tranah G.J., California Pacific Medical Center Research Institute, San Francisco, CA, United States, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States; Lange L.A., Department of Genetics, University of North Carolina, Chapel Hill, 27599, NC, United States; Sotoodehnia N., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States, Cardiology Division, University of Washington, Seattle, WA, United States; Stott D.J., Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom; Franco O.H., Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Launer L.J., Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States; Stürmer T., Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States, University of North Carolina, GSK Center of Excellence in Pharmacoepidemiology, Chapel Hill, NC, United States; Taylor K.D., Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, United States; Cupples L.A., Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States, Framingham Heart Study, Framingham, MA, United States; Eckfeldt J.H., Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States; Smith N.L., Department of Epidemiology, University of Washington, Seattle, WA, United States, Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, WA, United States, Group Health Research Institute, Group Health, Seattle, WA, United States; Liu Y., Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, United States; Wilson J.G., Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, United States; Heckbert S.R., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States, Group Health Research Institute, Group Health, Seattle, WA, United States; Buckley B.M., Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland; Ikram M.A., Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Boerwinkle E., Institute for Molecular Medicine, University of Texas Health Science Center, Houston, TX, United States; Chen Y.-D.I., Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, United States; De Craen A.J.M., Department of Gerontology and Geriatrics, Leiden University Medical Center, Netherlands; Uitterlinden A.G., Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; Rotter J.I., Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, United States; Ford I., Robertson Center for Biostatistics, University of Glasgow, Glasgow, United Kingdom; Hofman A., Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Sattar N., BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, United Kingdom; Slagboom P.E., Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, Netherlands; Westendorp R.G.J., Faculty of Health and Medical Sciences, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; Gudnason V., Icelandic Heart Association, Kopavogur, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Vasan R.S., Framingham Heart Study, Framingham, MA, United States, Boston University School of Medicine, Boston, MA, United States, Boston University School of Public Health, Boston, MA, United States; Lumley T., Department of Statistics, University of Auckland, Auckland, New Zealand; Cummings S.R., California Pacific Medical Center Research Institute, San Francisco, CA, United States; Taylor H.A., Jr., Department of Medicine, Morehouse School of Medicine, Atlanta, GA, United States; Post W., Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States; Jukema J.W., Department of Cardiology, Leiden University Medical Center, Netherlands; Stricker B.H., Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands, Inspectorate for Health Care, Hague, Netherlands; Whitsel E.A., Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Psaty B.M., Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States, Department of Health Services, University of Washington, Seattle, WA, United States, Group Health Research Institute, Group Health, Seattle, WA, United States; Arnett D., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States","Background Hypertension is a major risk factor for a spectrum of cardiovascular diseases (CVD), including myocardial infarction, sudden death, and stroke. In the US, over 65 million people have high blood pressure and a large proportion of these individuals are prescribed antihypertensive medications. Although large long-term clinical trials conducted in the last several decades have identified a number of effective antihypertensive treatments that reduce the risk of future clinical complications, responses to therapy and protection from cardiovascular events vary among individuals. Methods Using a genome-wide association study among 21,267 participants with pharmaceutically treated hypertension, we explored the hypothesis that genetic variants might influence or modify the effectiveness of common antihypertensive therapies on the risk ofmajor cardiovascular outcomes. The classes of drug treatments included angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, and diuretics. In the setting of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, each study performed array-based genome-wide genotyping, imputed to HapMap Phase II reference panels, and used additive genetic models in proportional hazards or logistic regressionmodels to evaluate drug-gene interactions for each of four therapeutic drug classes. We used meta-analysis to combine study-specific interaction estimates for approximately 2 million single nucleotide polymorphisms (SNPs) in a discovery analysis among 15,375 European Ancestry participants (3,527 CVD cases) with targeted follow-up in a case-only study of 1,751 European Ancestry GenHAT participants as well as among 4,141 African-Americans (1,267 CVD cases). Results Although drug-SNP interactions were biologically plausible, exposures and outcomes were well measured, and power was sufficient to detect modest interactions, we did not identify any statistically significant interactions from the four antihypertensive therapy meta-analyses (Pinteraction > 5.0×10-8). Similarly, findings were null for meta-analyses restricted to 66 SNPs with significant main effects on coronary artery disease or blood pressure from large published genome-wide association studies (Pinteraction ≥ 0.01). Our results suggest that there are no major pharmacogenetic influences of common SNPs on the relationship between blood pressure medications and the risk of incident CVD.","","African Americans; Aged; Antihypertensive Agents; Cardiovascular Diseases; European Continental Ancestry Group; Female; Genome-Wide Association Study; Humans; Hypertension; Incidence; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; antihypertensive agent; adult; African American; aged; Article; blood pressure; cardiovascular disease; cardiovascular risk; cerebrovascular accident; coronary artery disease; European; female; genetic association; genetic model; genetic variability; genotype; heart infarction; human; hypertension; major clinical study; male; outcome assessment; pharmacogenomics; single nucleotide polymorphism; sudden death; Cardiovascular Diseases; Caucasian; genetics; genome-wide association study; incidence; meta analysis; middle aged; single nucleotide polymorphism; treatment outcome","","Antihypertensive Agents, ","","","National Center for Advancing Translational Sciences; National Human Genome Research Institute, (U01HG004402); National Institutes of Health, (HHSN268200625226C, UL1RR025005); National Center for Advancing Translational Sciences, NCATS, (UL1TR000124); National Center for Advancing Translational Sciences, NCATS","","Ostchega Y., Yoon S.S., Hughes J., Louis T., Hypertension awareness treatment and control-continued disparities in adults: United States 2005-2006, NCHS data brief., 3, pp. 1-8, (2008); Ehret G.B., Munroe P.B., Rice K.M., Bochud M., Johnson A.D., Chasman D.I., Et al., Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk, Nature., 478, 7367, pp. 103-109, (2011); Deloukas P., Kanoni S., Willenborg C., Farrall M., Assimes T.L., Thompson J.R., Et al., Large-scale association analysis identifies new risk loci for coronary artery disease, Nat Genet., 45, 1, pp. 25-33, (2013); Turner S.T., Bailey K.R., Schwartz G.L., Chapman A.B., Chai H.S., Boerwinkle E., Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker, Hypertension., 59, 6, pp. 1204-1211, (2012); Turner S.T., Boerwinkle E., O'Connell J.R., Bailey K.R., Gong Y., Chapman A.B., Et al., Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide, Hypertension., 62, 2, pp. 391-397, (2013); Vandell A.G., McDonough C.W., Gong Y., Langaee T.Y., Lucas A.M., Chapman A.B., Et al., Hydrochlorothiazide-induced hyperuricaemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, J Intern Med., (2014); Del-Aguila J.L., Beitelshees A.L., Cooper-Dehoff R.M., Chapman A.B., Gums J.G., Bailey K., Et al., Genomewide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans, Pharmacogenomics J., 14, 1, pp. 35-40, (2014); Kamide K., Asayama K., Katsuya T., Ohkubo T., Hirose T., Inoue R., Et al., Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study, Pharmacogenomics., 14, 14, pp. 1709-1721, (2013); Chung C.M., Wang R.Y., Chen J.W., Fann C.S., Leu H.B., Ho H.Y., Et al., A genome-wide association study identifies new loci for ACE activity: Potential implications for response to ACE inhibitor, Pharmacogenomics J., 10, 6, pp. 537-544, (2010); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P., Et al., Diuretic therapy, the alphaadducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, Jama., 287, 13, pp. 1680-1689, (2002); Svensson-Farbom P., Wahlstrand B., Almgren P., Dahlberg J., Fava C., Kjeldsen S., Et al., A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients, J Hypertens., 29, 2, pp. 388-395, (2011); Niu Y., Gong Y., Langaee T.Y., Davis H.M., Elewa H., Beitelshees A.L., Et al., Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES), Circ Cardiovasc Genet., 3, 6, pp. 548-555, (2010); McDonough C.W., Gong Y., Padmanabhan S., Burkley B., Langaee T.Y., Melander O., Et al., Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12 A1BG and the selectin region and cardiovascular outcomes, Hypertension., 62, 1, pp. 48-54, (2013); Psaty B.M., O'Donnell C.J., Gudnason V., Lunetta K.L., Folsom A.R., Rotter J.I., Et al., Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of Prospective Meta-Analyses of Genome-Wide Association Studies From 5 Cohorts, Circ Cardiovasc Genet., 2, 1, pp. 73-80, (2009); Arnett D.K., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Miller M.B., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation., 111, 25, pp. 3374-3383, (2005); Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT), JAMA., 288, 23, pp. 2998-3007, (2002); Li Y., Willer C.J., Ding J., Scheet P., Abecasis G.R., Mach: Using sequence and genotype data to estimate haplotypes and unobserved genotypes, Genet Epidemiol., 34, 8, pp. 816-834, (2010); Nothnagel M., Ellinghaus D., Schreiber S., Krawczak M., Franke A., A comprehensive evaluation of SNP genotype imputation, Hum Genet., 125, 2, pp. 163-171, (2009); Servin B., Stephens M., Imputation-based analysis of association studies: Candidate regions and quantitative traits, PLoS Genet., 3, 7, (2007); Willer C.J., Li Y., Abecasis G.R., METAL: Fast and efficient meta-analysis of genomewide association scans, Bioinformatics., 26, 17, pp. 2190-2191, (2010); Devlin B., Roeder K., Genomic control for association studies, Biometrics., 55, 4, pp. 997-1004, (1999); Khoury M.J., Flanders W.D., Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: Case-control studies with no controls, Am J Epidemiol., 144, 3, pp. 207-213, (1996); Yang Q., Khoury M.J., Flanders W.D., Sample size requirements in case-only designs to detect geneenvironment interaction, Am J Epidemiol., 146, 9, pp. 713-720, (1997); Smith N.L., Psaty B.M., Heckbert S.R., Tracy R.P., Cornell E.S., The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly, Journal of Clinical Epidemiology., 52, 2, pp. 143-146, (1999); Qato D.M., Schumm L.P., Johnson M., Mihai A., Lindau S.T., Medication data collection and coding in a home-based survey of older adults, The Journals of Gerontology Series B, Psychological Sciences and Social Sciences., 64, pp. i86-93, (2009); Psaty B.M., Koepsell T.D., Lin D., Weiss N.S., Siscovick D.S., Rosendaal F.R., Et al., Assessment and control for confounding by indication in observational studies, J Am Geriatr Soc., 47, 6, pp. 749-754, (1999); Lin D.Y., Psaty B.M., Kronmal R.A., Assessing the sensitivity of regression results to unmeasured confounders in observational studies, Biometrics., 54, 3, pp. 948-963, (1998); Johnson A.D., Newton-Cheh C., Chasman D.I., Ehret G.B., Johnson T., Rose L., Et al., Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals, Hypertension., 57, 5, pp. 903-910, (2011); Gong Y., McDonough C.W., Wang Z., Hou W., Cooper-DeHoff R.M., Langaee T.Y., Et al., Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomic evaluation of antihypertensive responses study, Circ Cardiovasc Genet., 5, 6, pp. 686-691, (2012); Psaty B.M., Weiss N.S., Furberg C.D., Koepsell T.D., Siscovick D.S., Rosendaal F.R., Et al., Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease, JAMA., 282, 8, pp. 786-790, (1999); Haga S.B., Burke W., Using pharmacogenetics to improve drug safety and efficacy, JAMA., 291, 23, pp. 2869-2871, (2004)","","","Public Library of Science","","","","","","19326203","","POLNC","26516778","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-84950335587"
"Ravindranath M.H.; El Hilali F.; Filippone E.J.","Ravindranath, Mepur H. (7006300266); El Hilali, Fatiha (57195617849); Filippone, Edward J. (6602879259)","7006300266; 57195617849; 6602879259","The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection?","2021","Frontiers in Immunology","12","","667834","","","","22","10.3389/fimmu.2021.667834","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120726504&doi=10.3389%2ffimmu.2021.667834&partnerID=40&md5=99e0eb17b9ea6bd075a46d1d005d40c1","Department of Hematology and Oncology, Children’s Hospital, Los Angeles, CA, United States; Terasaki Foundation Laboratory, Santa Monica, CA, United States; Mohamed V Hospital, Moulay Ismail University, Meknes, Morocco; Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States","Ravindranath M.H., Department of Hematology and Oncology, Children’s Hospital, Los Angeles, CA, United States, Terasaki Foundation Laboratory, Santa Monica, CA, United States; El Hilali F., Mohamed V Hospital, Moulay Ismail University, Meknes, Morocco; Filippone E.J., Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States","Transplantation (Tx) remains the optimal therapy for end-stage disease (ESD) of various solid organs. Although alloimmune events remain the leading cause of long-term allograft loss, many patients develop innate and adaptive immune responses leading to graft tolerance. The focus of this review is to provide an overview of selected aspects of the effects of inflammation on this delicate balance following solid organ transplantation. Initially, we discuss the inflammatory mediators detectable in an ESD patient. Then, the specific inflammatory mediators found post-Tx are elucidated. We examine the reciprocal relationship between donor-derived passenger leukocytes (PLs) and those of the recipient, with additional emphasis on extracellular vesicles, specifically exosomes, and we examine their role in determining the balance between tolerance and rejection. The concept of recipient antigen-presenting cell “cross-dressing” by donor exosomes is detailed. Immunological consequences of the changes undergone by cell surface antigens, including HLA molecules in donor and host immune cells activated by proinflammatory cytokines, are examined. Inflammation-mediated donor endothelial cell (EC) activation is discussed along with the effect of donor-recipient EC chimerism. Finally, as an example of a specific inflammatory mediator, a detailed analysis is provided on the dynamic role of Interleukin-6 (IL-6) and its receptor post-Tx, especially given the potential for therapeutic interdiction of this axis with monoclonal antibodies. We aim to provide a holistic as well as a reductionist perspective of the inflammation-impacted immune events that precede and follow Tx. The objective is to differentiate tolerogenic inflammation from that enhancing rejection, for potential therapeutic modifications. (Words 247). Copyright © 2021 Ravindranath, El Hilali and Filippone.","allograft; endothelial cells; exosomes; IL-6; inflammation; rejection; tolerance","Allografts; Animals; Cytokines; Endothelial Cells; Extracellular Vesicles; Graft Rejection; Graft Survival; Graft vs Host Reaction; Host vs Graft Reaction; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Infections; Inflammation; Inflammation Mediators; Isoantigens; Leukocytes; Mice; Postoperative Complications; Transplantation Immunology; Virus Activation; adalimumab; alemtuzumab; angiotensin 2 receptor; C reactive protein; CD11b antigen; CD14 antigen; CD163 antigen; CD20 antigen; CD3 antigen; CD33 antigen; CD45RA antigen; CD56 antigen; CD68 antigen; CD82 antigen; CD86 antigen; CXCL9 chemokine; endothelial leukocyte adhesion molecule 1; endothelin; etanercept; gamma interferon; gamma interferon inducible protein 10; gemtuzumab; granulocyte macrophage colony stimulating factor; HLA antigen; HLA antigen class 1; HLA antigen class 2; HLA E antigen; immunoglobulin G; infliximab; intercellular adhesion molecule 1; interleukin 10; interleukin 1alpha; interleukin 1beta; interleukin 2 receptor alpha; interleukin 5 receptor alpha; interleukin 6; interleukin 6 receptor; interleukin 8; monoclonal antibody; monocyte chemotactic protein 1; PADGEM protein; platelet derived growth factor B; rituximab; syndecan 1; tumor necrosis factor; vascular cell adhesion molecule 1; vasculotropin; von Willebrand factor; alloantigen; autacoid; cytokine; immunosuppressive agent; acute graft rejection; allotransplantation; anemia; antigen presenting cell; autoimmune disease; CD4+ T lymphocyte; CD8+ T lymphocyte; cell infiltration; cell membrane; diabetes mellitus; end stage renal disease; endothelium cell; exosome; Glasgow outcome scale; human; humoral immune deficiency; HUVEC cell line; hypertension; hypoalbuminemia; immune response; immune system; immunological tolerance; inflammation; liver transplantation; lymphocyte count; major histocompatibility complex; myeloid dendritic cell; myocardial ischemia reperfusion injury; natural killer cell; neutrophil lymphocyte ratio; plasmacytoid dendritic cell; platelet lymphocyte ratio; regulatory T lymphocyte; Review; single nucleotide polymorphism; skin graft; T lymphocyte; Th1 cell; Th17 cell; transplantation; tuberculosis; allograft; animal; graft rejection; graft survival; graft versus host reaction; histocompatibility; immunology; leukocyte; metabolism; mouse; physiology; postoperative complication; procedures; virus activation","","adalimumab, 331731-18-1, 1446410-95-2; alemtuzumab, 216503-57-0; C reactive protein, 9007-41-4; endothelial leukocyte adhesion molecule 1, 128875-25-2; etanercept, 185243-69-0, 200013-86-1, 2055118-96-0; gamma interferon, 82115-62-6; gamma interferon inducible protein 10, 97741-20-3; gemtuzumab, 220578-59-6; immunoglobulin G, 97794-27-9; infliximab, 170277-31-3; intercellular adhesion molecule 1, 126547-89-5; interleukin 8, 114308-91-7; rituximab, 174722-31-7; syndecan 1, 128559-86-4; vasculotropin, 127464-60-2; von Willebrand factor, 109319-16-6; Cytokines, ; Immunosuppressive Agents, ; Inflammation Mediators, ; Isoantigens, ","","","","","Billingham R.E., Barker C.F., Recent Developments in Transplantation Immunology, Part II PlastReconstr Surg, 44, 1, (1969); Yu S., Su C., Luo X., Impact of Infection on Transplantation Tolerance, Immunol Rev, 292, 1, (2019); Welte T., Len O., Munoz P., Romani L., Lewis R., Perrella A., Invasive Mould Infections in Solid Organ Transplant Patients: Modifiers and Indicators of Disease and Treatment Response, Infection, 47, 6, (2019); Fishman J.A., Infection in Organ Transplantation, Am J Transplant, 17, 4, (2017); Adapa S., Chenna A., Balla M., Merugu G.P., Koduri N.M., Daggubati S.R., Et al., COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation, J Clin Med Res, 12, 6, (2020); Chong A.S., Alegre M.L., Transplantation Tolerance and its Outcome During Infections and Inflammation, Immunol Rev, 258, 1, pp. 80-101, (2014); Barnes R.A., Infection in Cancer and Transplantation, Med (Abingdon), 41, 11, (2013); Coussens L.M., Werb Z., Inflammation and Cancer, Nature, 420, (2002); de Visser K.E., Jonkers J., Towards Understanding the Role of Cancer Associated Inflammation in Chemoresistance, Curr Pharm Des, 15, (2009); Simmons E.M., Langone A., Sezer M.T., Vella J.P., Recupero P., Morrow J.D., Et al., Effect of Renal Transplantation on Biomarkers of and Oxidative Stress in End-Stage Renal Disease Patients, Transplantation, 79, (2005); Aveles P.R., Criminacio C.R., Goncalves S., Bignelli A.T., Claro L.M., Siqueira S.S., Et al., Association Between Biomarkers of Carbonyl Stress With Increased Systemic Inflammatory Response in Different Stages of Chronic Kidney Disease and After Renal Transplantation, Nephron Clin Inflammation Pract, 116, (2010); Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., Et al., Strong Association Between Malnutrition, Inflammation, and Atherosclerosis in Chronic Renal Failure, Kidney Int, 55, (1999); van den Bosch T.P., Kannegieter N.M., Hesselink D.A., Baan C.C., Rowshani A.T., Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation, Front Immunol, 8, (2017); Arici M., Walls J., End-Stage Renal Disease, Atherosclerosis, and Cardiovascular Mortality: Is C-Reactive Protein the Missing Link, Kidney Int, 59, (2001); Fontan M.P., Manez R., Rodriguez-Carmona A., Peteiro J., Martinez V., Garcia-Falcon T., Et al., Serum Levels of Anti-Alphagalactosyl Antibodies Predict Survival and Peritoneal Dialysis-Related Enteric Peritonitis Rates in Patients Undergoing Renal Replacement Therapy, Am J Kidney Dis, 48, 6, (2006); Lema D.A., Burlingham W.J., Role of Exosomes in Tumour and Transplant Immune Regulation, Scand J Immunol, 8, (2019); Gonzalez-Nolasco B., Wang M., Prunevieille A., Benichou G., Emerging Role of Exosomes in Allorecognition and Allograft Rejection, Curr Opin Organ Transplant, 23, 1, (2018); Gunasekaran M., Xu Z., Nayak D.K., Sharma M., Hachem R., Walia R., Et al., Donor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection, Am J Transplant, 17, (2017); Vallabhajosyula P., Korutlam L., Habertheuer A., Yu M., Rostami S., Yuan C.X., Et al., Tissue-Specific Exosome Biomarkers for Noninvasively Monitoring Immunologic Rejection of Transplanted Tissue, J Clin Invest, 127, (2017); Miranda K.C., Bond D.T., Levin J.Z., Adiconis X., Sivachenko A., Russ C., Et al., Massively Parallel Sequencing of Human Urinary Exosome/ Microvesicle RNA Reveals a Predominance of Noncoding RNA, PLoS One, 9, (2014); Miranda K.C., Bond D.T., McKee M., Skog J., Paunescu T.G., Da Silva N., Et al., Nucleic Acids Within Urinary Exosomes/Microvesicles Are Potential Biomarkers for Renal Disease, Kidney Int, 78, (2010); Gonzales P.A., Pisitkun T., Hoffert J.D., Tchapyjnikov D., Star R.A., Kleta R., Et al., Large-Scale Proteomics and Phosphoproteomics of Urinary Exosomes, J Am Soc Nephrol, 20, (2009); Nashan B., Abbud-Filho M., Citterio F., Prediction, Prevention, and Management of Delayed Graft Function: Where Are We Now, Clin Transplant, 30, (2016); Kim J.Y., Kim J.W., Yenari M.A., Heat Shock Protein Signaling in Brain Ischemia and Injury, Neurosci Lett, 715, (2020); Nakamura A., Otani K., Shichita T., Lipid Mediators and Sterile Inflammation in Ischemic Stroke, Int Immunol, pii, (2020); Krog A.H., Sahba M., Pettersen E.M., Sandven I., Thorsby P.M., Jorgensen J.J., Et al., Comparison of the Acute-Phase Response After Laparoscopic Versus Open Aortobifemoral Bypass Surgery: A Substudy of a Randomized Controlled Trial, Vasc Health Risk Manage, 12, (2016); Schnabl E., Stockinger H., Majdic O., Gaugitsch H., Lindley I.J., Maurer D., Et al., Activated Human T Lymphocytes Express MHC Class I Heavy Chains Not Associated With Beta 2microglobulin, J Exp Med, 171, 5, (1990); Madrigal J.A., Belich M.P., Benjamin R.J., Little A.M., Hildebrand W.H., Mann D.L., Et al., Molecular Definition of a Polymorphic Antigen (LA45) of Free HLA-A and -B Heavy Chains Found on the Surfaces of Activated B and T Cells, J Exp Med, 174, 5, (1991); Raine T., Brown D., Bowness P., Hill Gaston J.S., Moffett A., Trowsdale J., Et al., Consistent Patterns of Expression of HLA Class I Free Heavy Chains in Healthy Individuals and Raised Expression in Spondyloarthropathy Patients Point to Physiological and Pathological Roles, Rheumatol (Oxford), 45, 11, (2006); Santambrogio L., Sato A.K., Fischer F.R., Dorf M.E., Stern L.J., Abundant Empty Class II MHC Molecules on the Surface of Immature Dendritic Cells, Proc Natl Acad Sci U S A, 96, 26, (1999); Santos S.G., Simon J., Powis S.J., Arosa F.A., Misfolding of Major Histo- Compatibility Complex Class I Molecules in Activated T Cells Allows Cis-Interactions With Receptors and Signaling Molecules and Is Associated With Tyrosine Phosphorylation, J Biol Chem, 279, 51, (2004); Ravindranath M.H., Jucaud V., Terasaki P.I., Immunobiology of Allograft Human Leukocyte Antigens in the New Microenvironment, SOJ Immunol, 3, 4, pp. 1-19, (2015); Iwaki Y., Terasaki P.I., Primary Nonfunction in Human Cadaver Kidney Transplantation: Evidence for Hidden Hyperacute Rejection, Clin Transplant, 1, (1987); Phelan P.J., O Kelly P., Tarazi M., Tarazi N., Salehmohamed M.R., Little D.M., Et al., Renal Allograft Loss in the First Post-Operative Month: Causes and Consequences, Clin Transplant, 26, (2012); Sanchez-Fueyo A., Strom T.B., Immunologic Basis of Graft Rejection and Tolerance Following Transplantation of Liver or Other Solid Organs, Gastroenterol, 40, 1, pp. 51-64, (2011); Starzl T.E., Zinkernagel R.M., Antigen Localization and Migration in Immunity and Tolerance, N Engl J Med, 339, 26, (1998); Starz L.T.E., Demetris A.J., Trucco M., Murase N., Ricordi C., Ildstad S., Et al., Cell Migration and Chimerism After Whole-Organ Transplantation: The Basis of Graft Acceptance, Hepatology, 17, (1993); Larsen C.P., Morris P.J., Austyn J.M., Migration of Dendritic Leukocytes From Cardiac Allografts Into Host Spleens: A Novel Pathway for Initiation of Rejection, J Exp Med, 171, (1990); Demetris A.J., Murase N., Fujisaki S., Fung J.J., Rao A.S., Starzl T.E., Hematolymphoid Cell Trafficking, Microchimerism, and GVH Reactions After Liver, Bone Marrow, Andheart Transplantation, Transplant Proc, 25, (1993); Strom T.B., Tilney N.L., Carpenter C.B., Busch G.J., Identity and Cytotoxic Capacity of Cells Infiltrating Renal Allografts, N Engl J Med, 292, 24, (1975); Strom T.B., Tilney N.L., Paradysz J.M., Bancewicz J., Carpenter C.B., Cellular Components of Allograft Rejection: Identity, Specificity, and Cytotoxic Function of Cells Infiltrating Acutely Rejecting Allografts, J Immunol, 118, 6, (1977); Strom T.B., Carpenter C.B., Tilney N.L., Suthanthira M., Catto G.R., Lundin A.P., Et al., Intragraft Immune Events Causing Vascularized Organ Graft Rejection, Transplant Proc, 10, 2, (1978); Strom T.B., Kostick R., Tilney N.L., Carpenter C.B., A Characterization of the Nature and Control of Cellular Allograft Rejection, NephronImmun, 22, 1-3, (1978); Strom T.B., Garovoy M.R., Clinical and Experimental Aspects of Renal Allograft Rejection, Am J Kidney Dis, 1, 1, pp. 5-14, (1981); Lipman M.L., Stevens A.C., Bleackley R.C., Helderman J.H., McCune T.R., Harmon W.E., Et al., The Strong Correlation of Cytotoxic T Lymphocyte-Specific Serine Protease Gene Transcripts With Renal Allograft Rejection, Transplantation, 53, 1, (1992); Sablik K.A., Jordanova E.S., Pocorni N., Clahsen-van Groningen M.C., Betjes M.G.H., Immune Cell Infiltrate in Chronic-Active Antibody-Mediated Rejection, Front Immunol, 10, (2019); Carpio V.N., Noronha I.L., Martins H.L., Jobim L.F., Gil B.C., Kulzer A.S., Et al., Expression Patterns of B Cells in Acute Kidney Transplant Rejection, Exp Clin Transplant, 12, 5, (2014); Filippone E.J., Farber J.L., The Implications of B-Lineage Cells in Kidney Allografts, Transplant (in press), 104, 10, (2020); Reitamo S., Konttinen Y.T., Ranki A., Hayry P., The Relation of Different Inflammatory Cell Types to the Various Parenchymal Components of Rejecting Kidney Allografts, Histopathology, 4, 5, (1980); Harry T.R., Coles G.A., Davies M., Bryant D., Williams G.T., Griffin P.J., The Significance of Monocytes in Glomeruli of Human Renal Transplants, Transplantation, 37, (1984); Hancock W.W., Zola H., Atkins R.C., Antigenic Heterogeneity of Human Mononuclear Phagocytes: Immunohistologic Analysis Using Monoclonal Antibodies, BloodImmun, 62, 6, (1983); Fahim T., Bohmig G.A., Exner M., Huttary N., Kerschner H., Kandutsch S., Et al., The Cellular Lesion of Humoral Rejection: Predominant Recruitment of Monocytes to Peritubular and Glomerular Capillaries, Am J Transplant, 7, (2007); Alpers C.E., Gordon D., Gown A.M., Immunophenotype of Vascular Rejection in Renal Transplants, Mod Pathol, 3, pp. 198-203, (1990); Alpers C.E., Davis C.L., Barr D., Marsh C.L., Hudkinset K.L., Identification of Platelet-Derived Growth Factor A and B Chains in Human Renal Vascular Rejection, Am J Pathol, 148, (1996); Halloran P.F., de Freitas D.G., Einecke G., Famulski K.S., Hidalgo L.G., Menge L.M., Et al., An Integrated View of Molecular Changes, Histopathology and Outcomes in Kidney Transplants, Am J Transplant, 10, 10, (2010); Hidalgo L.G., Sis B., Sellares J., Campbell P.M., Mengel M., Eineck G., Et al., NK Cell Transcripts and NK Cells in Kidney Biopsies From Patients With Donor-Specific Antibodies: Evidence for NK Cell Involvement in Antibody-Mediated Rejection, Am J Transplant, 10, 8, (2010); Mengel M., Sis B., Kim D., Chang J., Famulski K.S., Hidalgo L.G., Et al., The Molecular Phenotype of Heart Transplant Biopsies: Relationship to Histopathological and Clinical Variables, Am J Transplant, 10, 9, (2010); Mannon R.B., Matas A.J., Grande J., Leduc R., Connett J., Kasiske B., Et al., Inflammation in Areas of Tubular Atrophy in Kidney Allograft Biopsies: A Potent Predictor of Allograft Failure, Am J Transplant, 10, 9, (2010); Halloran P.F., Famulski K.S., Reeve J., Molecular Assessment of Disease States in Kidney Transplant Biopsy Samples, Nat Rev Nephrol, 12, 9, (2016); Halloran P.F., Famulski K.S., Chang J.A., Probabilistic Approach to Histologic Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Biopsies, Am J Transplant, 17, 1, (2017); Halloran P.F., Reeve J., Aliabadi A.Z., Cadeiras M., Crespo-Leir M.G., Deng M., Et al., Exploring the Cardiac Response to Injury in Heart Transplant Biopsies, JCI Insight, 3, 20, (2018); Parkes M.D., Aliabadi A.Z., Cadeiras M., Crespo-Leiro M.G., Deng M., Depasquale E.C., Et al., An Integrated Molecular Diagnostic Report for Heart Transplant Biopsies Using an Ensemble of Diagnostic Algorithms, J Heart Lung Transplant, 38, 6, (2019); Halloran K.M., Parkes M.D., Chang J., Timofte I.L., Snell G.I., Westall G.P., Et al., Molecular Assessment of Rejection and Injury in Lung Transplant Biopsies, J Heart Lung Transplant, 38, 5, (2019); Halloran P.F., Matas A., Kasiske B.L., Madill-Thomsen K.S., Mackova M., Famulski K.S., Molecular Phenotype of Kidney Transplant Indication Biopsies With Inflammation in Scarred Areas, Am J Transplant, 19, 5, (2019); Halloran K., Parkes M.D., Timofte I.L., Snell G.I., Westall G.P., Hachem R., Et al., Molecular Phenotyping of Rejection-Related Changes in Mucosal Biopsies From Lung Transplants, Am J Transplant, 20, 4, (2020); Madill-Thomsen K., Abouljoud M., Bhati C., Ciszek M., Durlik M., Feng S., Et al., The Molecular Diagnosis of Rejection in Liver Transplant Biopsies: First Results of the INTERLIVER Study, Am J Transplant, 2020, (2020); Hirohashi T., Chase C.M., Della Pelle P., Sebastian D., Alessandrini A., Madsen J.C., Et al., A Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and Alloantibody, Am J Transplant, 12, 2, (2012); Taubert R., Danger R., Londono M.C., Christakoudi S., Martinez-Picola M., Rimola A., Et al., Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated, Am J Transplant, 16, 4, (2016); Baroja-Mazo A., Revilla-Nuin B., Parrilla P., Martinez-Alarcon L., Ramirez P., Pons J.A., Tolerance in Liver Transplantation: Biomarkers and Clinical Relevance, World J Gastroenterol, 22, (2016); Pons J.A., Revilla-Nuin B., Baroja-Mazo A., Ramirez P., Martinez-Alarcon L., Sanchez-Bueno F., Et al., FoxP3 in Peripheral Blood Is Associated With Operational Tolerance in Liver Transplant Patients During Immunosuppression Withdrawal, TransplantationImmun, 86, (2008); Baroja-Mazo A., Revilla-Nuin B., de Bejar A., Martinez-Alarcon L., Herrero J.I., El-Tayeb A., Et al., Extracellular Adenosine Reversibly Inhibits the Activation of Human Regulatory T Cells and Negatively Influences the Achievement of the Operational Tolerance in Liver Transplantation, Am J Transplant, 9, pp. 48-61, (2019); Li Y., Koshiba T., Yoshizawa A., Yonekawa Y., Masuda K., Ito A., Et al., Analyses of Peripheral Blood Mononuclear Cells in Operational Tolerance After Pediatric Living Donor Liver Transplantation, Am J Transplant, 4, (2004); Jhun J., Lee S.H., Lee S.K., Kim H.Y., Jung E.S., Kim D.G., Et al., Serial Monitoring of Immune Markers Being Represented Regulatory T Cell/T Helper 17 Cell Ratio: Indicating Tolerance for Tapering Immunosuppression After Liver Transplantation, Front Immunol, 9, (2018); Tokita D., Mazariegos G.V., Zahorchak A.F., Chien N., Abe M., Raimondi G., Et al., High PD-L1/CD86 Ratio on Plasmacytoid Dendritic Cells Correlates With Elevated T-Regulatory Cells in Liver Transplant Tolerance, TransplantationImmun, 85, (2008); Dai H., Zheng Y., Thomson A.W., Rogers N.M., Transplant Tolerance Induction: Insights From the Liver, Front Immunol, 11, (2020); Snell G.D., The Homograft Reaction, Annu Rev Microbiol, 11, (1957); Starzl T.E., Demetris A.J., Murase N., Ildstad S., Ricordi C., Trucco M., Cell Migration, Chimerism, and Graft Acceptance, LancetImmun, 339, 8809, (1992); Demetris A.J., Qian S., Sun H., Fung J.J., Yagihashi A., Murase N., Et al., Early Events in Liver Allograft Rejection: Delineation of Sites of Simultaneous Intragraft and Recipient Lymphoid Tissue Sensitization, Am J Pathol, 138, (1991); Qian S., Demetris A.J., Murase N., Rao A.S., Fung J.J., Starzl T.E., Murine Liver Allograft Transplantation:tolerance and Donor Cell Chimerism, Hepatology, 19, (1994); Nemlander A., Soots A., von Willebrand E., Husberg B., Hayry P., Redistribution of Renal Allograft Responding Leukocytes During Rejection. II. Kinetics and Specificity, J Exp Med, 156, (1982); Nayak D.K., Zhou F., Xu M., Huang J., Tsuji M., Hachem R., Et al., Long-Term Persistence of Donor Alveolar MPs in Human Lung Transplant Recipients That Influences Donor-Specific Immune Responses, Am J Transplant, 16, 8, (2016); Bharat A., Bhorade S.M., Morales-Nebreda L., McQuattie-Pimentel A.C., Soberanes S., Ridge K., Et al., Flow Cytometry Reveals Similarities Between Lung MPs in Humans and Mice, Am J Respir Cell Mol Biol, 54, (2016); Brown K., Sacks S.H., Wong W., Extensive and Bidirectional Transfer of Major Histocompatibility Complex Class II Molecules Between Donor and Recipient Cells In Vivo Following Solid Organ Transplantation, FASEB J, 22, (2008); Brown K., Sacks S.H., Wong W., Coexpression of Donor Peptide/Recipient MHC Complex and Intact Donor MHC: Evidence for a Link Between the Direct and Indirect Pathways, Am J Transplant, 11, (2011); Scothorne R.J., Lymphatic Repair and the Genesis of Homograft Immunity, Ann N Y Acad Sci, 73, (1958); Barker C.F., Billingham R.E., Analysis of Local Anatomic Factors That Influence the Survival Times of Pure Epidermal and Full-Thickness Skin Homografts in Guinea Pigs, Ann Surg, 176, pp. 597-604, (1972); Laffont S., Coudert J.D., Garidou L., Delpy L., Wiedemann A., Demur C., Et al., CD8+ T-Cell-Mediated Killing of Donor Dendritic Cells Prevents Alloreactive T Helper Type-2 Responses In Vivo, Blood, 108, (2006); Laffont S., Seillet C., Ortaldo J., Coudert J.D., Guery J.C., Natural Killer Cells Recruited Into Lymph Nodes Inhibit Alloreactive T-Cell Activation Through Perforin-Mediated Killing of Donor Allogeneic Dendritic Cells, Blood, 112, (2008); Garrod K.R., Liu F.C., Forrest L.E., Parker I., Kang S.M., Cahalan M.D., Et al., NK Cell Patrolling and Elimination of Donor-Derived Dendritic Cells Favor Indirect Alloreactivity, J Immunol, 184, (2010); Coupel S., Moreau A., Hamidou M., Horejsi V., Soulillou J.P., Charreau B., Expression and Release of Soluble HLA-E Is an Immunoregulatory Feature of Endothelial Cell Activation, BloodImmun, 109, 7, (2007); Sasaki T., Ravindranath M.H., Terasaki P.I., Freitas M.C., Kawakita S., Jucaud V., Gastric Cancer Progression may Involve a Shift in HLA-E Profile From an Intact Heterodimer to β2-Microglobulin-Free Monomer, Int J Cancer, 134, 7, pp. 1558-15570, (2014); Ravindranath M.H., Filippone E.J., Devarajan A., Asgharzadeh S., Enhancing Natural Killer and CD8+ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8+ T Cells With HLA-E Monospecific Monoclonal Antibodies, Monoclon Antib Immunodiagn Immunother, 38, 2, pp. 38-59, (2019); Ravindranath M.H., El Hilali F., Monospecific and Polyreactive Antibodies Against Human Leukocyte Antigen E: Diagnositic and Therapeutic Relevance. Chapter 3, In Monoclonal Antibodies, pp. 43-80, (2021); Morelli A.E., Bracamonte-Baran W., Burlingham W.J., Donor-Derived Exosomes: The Trick Behind the Semidirect Pathway of Allorecognition, Curr Opin Organ Transplant, 22, 1, pp. 46-54, (2017); Peche H., Heslan M., Usal C., Amigorena S., Cuturi M.C., Presentation of Donor Major Histocompatibility Complex Antigens by Bone Marrow Dendritic Cell-Derived Exosomes Modulates Allograft Rejection, TransplantationImmun, 76, 10, (2003); Bedford P., Gardner K., Knight S.C., MHC Class II Molecules Transferred Between Allogeneic Dendritic Cells Stimulate Primary Mixed Lymphocyte Reactions, Int Immunol, 11, (1999); Russo V., Zhou D., Sartirana P., Rovere A., Villa S., Rossini C., Et al., Acquisition of Intact Allogeneic Human Leukocyte Antigen Molecules by Human Dendritic Cells, Blood, 95, 11, (2000); Harshyne L.A., Watkins S.C., Gambotto A., Barratt-Boyes S.M., Dendritic Cells Acquire Antigens From Live Cells for Cross-Presentation to CTLs, J Immunol, 166, (2001); Herrera O.B., Golshayan D., Tibbott R., Ochoa S.F., James M.J., Marelli-Berg F.M., Et al., A Novel Pathway of Alloantigen Presentation by Dendritic Cells, J Immunol, 173, (2004); Marino J., Babiker-Mohamed M.H., Crosby-Bertorini P., Paster J.T., LeGuern C., Germana S., Et al., Donor Exosomes Rather Than Passenger Leukocytes Initiate Alloreactive T Cell Responses After Transplantation, Sci Immunol, 1, 1, (2016); Marino J., Paster J., Benichou G., Allorecognition by T Lymphocytes and Allograft Rejection, Front Immunol, 7, (2016); Gartlan K.H., Koyama M., Lineburg K.E., Chang K., Ensbey K.S., Kuns R.D., Et al., Donor T-Cell–Derived GM-CSF Drives Alloantigen Presentation by Dendritic Cells in the Gastrointestinal Tract, Blood Adv, 3, 19, (2019); Markey K.A., Banovic T., Kuns R.D., Olver S.D., Don A.L., Raffelt N.C., Et al., Conventional Dendritic Cells Are the Critical Donor APC Presenting Alloantigen After Experimental Bone Marrow Transplantation, BloodImmun, 113, (2009); Markey K., Koyama M., Gartlan K.H., Leveque L., Kuns R.D., Lineburg K.E., Et al., Cross-Dressing by Donor Dendritic Cells After Allogeneic Bone Marrow Transplantation Contributes to Formation of the Immunological Synapse and Maximizes Responses to Indirectly Presented Antigen, J Immunol, 192, (2014); Liu Q., Rojas-Canales D.M., Divito S.J., Shufesky W.J., Stolz D.B., Donor Dendritic Cell-Derived Exosomes Promote Allograft-Targeting Immune Response, J Clin Invest, 126, 8, (2016); Kabakov Y.N., Perestoronina N.N., Petrova I.V., Factors Influencing Clasmatosis In Vivo. II. Dynamics of Cytoplasmic Cell Budding in the Lymphoid Organs of Mice on Primary Immunization, J Reticuloendothel Soc, 11, 5, (1972); Grekova N.A., Vershilova P.A., Role of Clasmatosis of the Phagocytes in Immunogenesis, Bull Eksp Biol Med, 82, 2, (1976); Ravindranath M.H., A Comparative Study of the Morphology and Behaviour of Granular Haemocytes of Arthropods, Cytologia, 42, 3-4, (1977); Pan B.T., Teng K., Wu C., Adam M., Johnstone R.M., Electron Microscopic Evidence for Externalization of the Transferrin Receptor in Vesicular Form in Sheep Reticulocytes, J Cell Biol, 101, (1985); Johnstone R.M., Adam M., Hammond J.R., Orr L., Turbide C., Vesicle Formation During Reticulocyte Maturation. Association of Plasma Membrane Activities With Released Vesicles (Exosomes), J Biol Chem, 262, (1987); Kowal J., Tkach M., Dendritic Cell Extracellular Vesicles, Int Rev Cell Mol Biol, 349, (2019); Caby M.P., Lankar D., Vincendeau-Scherrer C., Raposo G., Bonnerot C., Exosomal-Like Vesicles Are Present in Human Blood Plasma, Int Immunol, 17, (2005); Alberts M., Stout T.A., Stoorvogel W., Prostasomes: Extracellular Vesicles From the Prostate, Reproduction, 147, pp. R1-R14, (2013); Gatti J.L., Metayer S., Belghazi M., Dacheux F., Dacheux J.L., Identification, Proteomicprofiling, and Origin of Ram Epididymal Fluid Exosome-Like Vesicles, Biol Reprod, 72, (2005); Kanno K., Sasaki S., Hirata Y., Ishikawa S.E., Fushimi K., Nakanishi S., Et al., Urinary Excretion of Aquaporin-2 in Patients With Diabetes Insipidus, N Engl J Med, 332, (1995); Pizzirani C., Ferrari D., Chiozzi P., Adinolfi E., Sandona D., Savaglio E., Et al., Stimulation of P2 Receptors Causes Release of IL-1beta-Loaded Microvesicles From Human Dendritic Cells, Blood, 109, (2007); Thery C., Ostrowski M., Segura E., Membrane Vesicles as Conveyors of Immune Responses, Nat Rev Immunol, 9, (2009); Ten Broeke T., Van Niel G., Wauben M.H.M., Wubbolts R., Stoorvogel W., Endosomally Stored MHC Class II Does Not Contribute to Antigen Presentation by Dendritic Cells at Inflammatory Conditions, Traffic, 12, (2011); Zitvogel L., Regnault A., Lozier J., Wolfers C., Flament D., Tenza P., Et al., Eradication of Established Murine Tumours Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes, Nat Med, 4, 5, pp. 594-600, (1998); Segura E., Review of Mouse and Human Dendritic Cell Subsets, Methods Mol Biol, 1423, pp. 3-15, (2016); Qazi K.R., Gehrmann U., Domange Jordo E., Karlsson M.C., Gabrielsson S., Antigen-Loaded Exosomes Alone Induce Th1-Type Memory Through a B-Cell-Dependent Mechanism, Blood, 113, (2009); Viaud S., Ploix S., Lapierre V., Thery C., Commere P.H., Tramalloni D., Et al., Updated Technology to Produce Highly Immunogenic Dendritic Cell-Derived Exosomes of Clinical Grade: A Critical Role of Interferon-Gamma, J Immunother, 34, pp. 65-75, (2011); Viaud S., Terme M., Flament C., Taieb J., Andre F., Novault S., Et al., Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15R Alpha, PLoS One, 4, (2009); Buschow S.I., Nolte-'T Hoen E.N., Van Niel G., Pols M.S., Ten Broeke T., Lauwen M., Et al., MHC II in Dendritic Cells Is Targeted to Lysosomes or T Cell-Induced Exosomes via Distinct Multivesicular Body Pathways, Traffic, 10, (2009); Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., Et al., B Lymphocytes Secrete Antigen-Presenting Vesicles, J Exp Med, 183, (1996); Raposo G., Stoorvogel W., Extracellular Vesicles: Exosomes, Microvesicles, and Friends, J Cell Biol, 200, (2013); Colombo M., Raposo G., Thery C., Biogenesis, Secretion and Intercellular Interactions of Exosomes and Other Extracellular Vesicles, Annu Rev Cell Dev Biol, 30, (2014); Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O., Exosome-Mediated Transfer of mRNAs and microRNAs Is a Novel Mechanism of Genetic Exchange Between Cells, Nat Cell Biol, 9, (2007); Kowal J., Tkach M., Thery C., Biogenesis and Secretion of Exosomes, Curr Opin Cell Biol, 29, (2014); Grange C., Bellucci L., Bussolati B., Ranghino A., Potential Applications of Extracellular Vesicles in Solid Organ Transplantation, CellsImmun, 9, 2, (2020); Billingham R.E., Brent L., Medawar P.B., Actively Acquired Tolerance of Foreign Cells, Nature, 172, 4379, (1953); Billingham R.E., Brent L., Medawar P.B., Sparrow E.M., Quantitative Studies on Tissue Transplantation Immunity. I. The Survival Times of Skin Homografts Exchanged Between Members of Different Inbred Strains of Mice, Proc R Soc Lond B Biol Sci, 143, 910, pp. 43-58, (1954); Billingham R.E., Brent L., Medawar P.B., Quantitative Studies on Tissue Transplantation Immunity. II. The Origin, Strength and Duration of Actively and Adoptively Acquired Immunity, Proc R Soc Lond B Biol Sci, 143, 910, pp. 58-80, (1954); Medawar P.B., The Homograft Reaction, Proc R Soc Lond B Biol Sci, 149, 935, (1958); Burnet F.M., The Clonal Selection Theory of Acquired Immunity, (1959); Hilgert I., The Involvement of Activated Specific Suppressor T Cells in Maintenance of Transplantation Tolerance, Immunol Rev, 46, pp. 27-53, (1979); Argyris B.F., Acquired Tolerance to Skin Homografts in Mice. 3. Role of Immune Status of Host in Induction and Maintenance of Tolerance, J Immunol, 93, (1964); Reynolds H.Y., Fulmer J.D., Karnierow J.A., Roberts W.C., Frank M.M., Crystal R.G., Analysis of Cellular and Protein Content Bronchoalveolar Lavage Fluid From Patients With Idiopathic Pulmonary Fibrosis and Chronic Hypersensitivity Pneumonitis, J Clin Invest, 59, (1977); Crystai R.G., Gadek J.E., Fermm J., Fuirner I.D., Line B.R., Hunninghake G.W., Interstitial Lung Disease- Current Concepts of Pathogenesis Staging and Therapy, Am J Med, 70, (1983); Godart P., Clot J., Jonquer O., Bonsquet J., Michel F.B., Lymphocyte Subpopulations in Bronchoalveolar Lavages of Patient With Sarcoidosis and Hypersensitivity Pneumonitis, Chest, 80, (1981); Mornex J.F., Cordier G., Pages J., Vergnon J.M., Lefebvre R., Brune J., Et al., Activated Lung Lymphocytes in Hypersensitivity Pneumonitis, J Allergy Clin Immunol, 74, (1984); Arosa F.A., Esgalhado A.J., Padrao C.A., Cardoso E.M., Divide, Conquer, and Sense: CD8+CD28- T Cells in Perspective, Front Immunol, 7, (2017); Arosa F.A., Santos S.G., Powis S.J., Open Conformers: The Hidden Face of MHC-I Molecules, Trends Immunol, 28, 3, (2007); Goodridge J.P., Lee N., Burian A., Pyo C.W., Tykodi S.S., Warren E.H., Et al., HLA-F and MHC-I Open Conformers Cooperate in an MHC-I Antigen Cross-Presentation Pathway, J Immunol, 191, (2013); Corte G., Moretta L., Damiani F., Mingari M.C., Bargellesi A., Surface Antigens Specifically Expressed by Activated T Cells in Humans, Eur J Immunol, 11, (1981); Puppo F., Scudeletti M., Indiveri F., Ferrone S., Serum HLA Class I Antigens: Markers and Modulators of an Immune Response, Immunol Today, 16, 3, (1995); Pistoia V., Morandi F., Wang X., Ferrone S., Soluble HLA-G: Are They Clinically Relevant, Semin Cancer Biol, 17, 6, (2007); Morandi F., Pistoia V., Interactions Between HLA-G and HLA-E in Physiological and Pathological Conditions, Front Immunol, 5, (2014); Murdaca G., Contini P., Negrini S., Ciprandi G., Puppo F., Immunoregulatory Role of HLA-G in Allergic Diseases, J Immunol Res, 2016, (2016); Florey H., The EC Cell, Br Med J, 5512, (1966); Keaney J., Campbell M., The Dynamic Blood-Brain Barrier, FEBS J, 282, 21, (2015); Mishra J.S., Te Riele G.M., Qi Q.R., Lechuga T.J., Gopalakrishnan K., Chen D.B., Et al., Estrogen Receptor-β Mediates Estradiol-Induced Pregnancy Specific Uterine Artery Endothelial Cell Angiotensin Type-2 Receptor Expression, HypertensionImmun, 74, 4, (2019); Kokkonen T.S., Augustin M.T., Makinen J.M., Kokkonen J., Karttunen T.J., High Endothelial Venules of the Lymph Nodes Express Fas Ligand, J Histochem Cytochem, 52, 5, (2004); Vestweber D., Relevance of Endothelial Junctions in Leukocyte Extravasation and Vascular Permeability, Ann N Y Acad Sci, 1257, (2012); Weibel E.R., Fifty Years of Weibel-Palade Bodies: The Discovery and Early History of an Enigmatic Organelle of Endothelial Cells, J Thromb Haemost, 10, (2012); Utgaard J.O., Jahnsen F.L., Bakka A., Brandtzaeg P., Haraldsen G., Rapid Secretion of Prestored Interleukin 8 From Weibel-Palade Bodies of Microvascular Endothelial Cells, J Exp Med, 188, (1998); Wolff B., Burns A.R., Middleton J., Rot A., Endothelial Cell “Memory” of Inflammatory Stimulation: Human Venular Endothelial Cells Store Interleukin 8 in Weibel-Palade Bodies, J Exp Med, 188, (1998); Fiedler U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J.M., Et al., The Tie-2 Ligand Angiopoietin-2 is Stored in and Rapidly Released Upon Stimulation From Endothelial Cell Weibel-Palade Bodies, Blood, 103, (2004); Erent M., Meli A., Moisoi N., Babich V., Hannah M.J., Skehel P., Et al., Rate, Extent and Concentration Dependence of Histamine-Evoked Weibel-Palade Body Exocytosis Determined From Individual Fusion Events in Human Endothelial Cells, J Physiol, 583, pp. 195-212, (2007); Nightingale T.D., White I.J., Doyle E.L., Turmaine M., HarrisonLavoie K.J., Webb K.F., Et al., Actomyosin II Contractility Expels Von Willebrand Factor From Weibel-Palade Bodies During Exocytosis, J Cell Biol, 194, (2011); Nightingale T., Cutler D., The Secretion of Von Willebrand Factor From Endothelial Cells; an Increasingly Complicated Story, J Thromb Haemost, 11, pp. 192-201, (2013); Nightingale T.D., McCormack J.J., Grimes W., Robinson C., Lopes da Silva M., White I.J., Et al., Tuning the Endothelial Response: Differential Release of Exocytic Cargos From Weibel-Palade Bodies, J Thromb Haemost, 16, 9, (2018); Andre P., P-Selectin in Haemostasis, Br J Haematol, 126, 3, pp. 298-306, (2004); Blandinieres A., Gendron N., Bacha N., Bieche I., Chocron R., Nunes H., Et al., Interleukin-8 Release by Endothelial Colony-Forming Cells Isolated From Idiopathic Pulmonary Fibrosis Patients Might Contribute to Their Pathogenicity, AngiogenesisImmun, 22, 2, (2019); Liu Q., Imaizumi T., Aizawa T., Hirono K., Kawaguchi S., Watanabe S., Et al., Cytosolic Sensors of Viral RNA Are Involved in the Production of Interleukin-6 via Toll-Like Receptor 3 Signaling in Human Glomerular Endothelial Cells, Kidney Blood Press Res, 44, 1, pp. 62-71, (2019); Chang F., Flavahan S., Flavahan N.A., Immature Endothelial Cells Initiate Endothelin-Mediated Constriction of Newborn Arteries, J Physiol, 594, 17, (2016); Gluzman Z., Koren B., Preis M., Cohen T., Tsaba A., Cosset F.L., Et al., Endothelial Cells Are Activated by Angiopoeitin-1gene Transfer and Produce Coordinated Sprouting In Vitro and Arteriogenesis In Vivo, Biochem Biophys Res Commun, 359, 2, (2017); Yang F., Liu S., Wang S.J., Yu C., Paganini-Hill A., Fisher M.J., Relative Allocation of the Content of Tissue Plasminogen Activator Expression and Barrier Properties of Human Brain Microvascular Endothelial Cells, Cell Physiol Biochem, 28, 4, (2011); Khakpour S., Wilhelmsen K., Hellman J., Vascular Endothelial Cell Toll-Like Receptor Pathways in Sepsis, Innate Immun, 21, (2015); Opitz B., Eitel J., Meixenberger K., Suttorp N., Role of Toll-Like Receptors, NOD-Like Receptors and RIG-I-Like Receptors in Endothelial Cells and Systemic Infections, Thromb Haemost, 102, (2009); Pegu A., Qin S., Fallert Junecko B.A., Nisato R.E., Pepper M.S., Reinhart T.A., Human Lymphatic Endothelial Cells Express Multiple Functional TLRs, J Immunol, 180, (2008); Fitzner N., Clauberg S., Essmann F., Liebmann J., Kolb-Bachofen V., Human Skin Endothelial Cells can Express All 10 TLR Genes and Respond to Respective Ligands, Clin Vaccine Immunol, 15, (2008); Shin H.S., Xu F., Bagchi A., Herrup E., Prakash A., Valentine C., Et al., Bacterial Lipoprotein TLR2 Agonists Broadly Modulate Endothelial Function and Coagulation Pathways In Vitro and In Vivo, J Immunol, 186, (2011)","M.H. Ravindranath; Department of Hematology and Oncology, Children’s Hospital, Los Angeles, United States; email: thiruranganath04@gmail.com","","Frontiers Media S.A.","","","","","","16643224","","","34880853","English","Front. Immunol.","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85120726504"
"Brugts J.J.; Isaacs A.; De Maat M.P.M.; Boersma E.; Van Duijn C.M.; Akkerhuis K.M.; Uitterlinden A.G.; Witteman J.C.M.; Cambien F.; Ceconi C.; Remme W.; Bertrand M.; Ninomiya T.; Harrap S.; Chalmers J.; MacMahon S.; Fox K.; Ferrari R.; Simoons M.L.; Danser A.H.J.","Brugts, Jasper J. (57218107869); Isaacs, Aaron (15135621700); De Maat, Moniek P.M. (55665186500); Boersma, Eric (7102815542); Van Duijn, Cock M. (57215768249); Akkerhuis, K Martijn (6602755087); Uitterlinden, Andre G. (35231615000); Witteman, Jacqueline C.M. (7005473334); Cambien, Francois (7101622418); Ceconi, Claudio (57190051298); Remme, Willem (7006062246); Bertrand, Michel (55429057100); Ninomiya, Toshiharu (7202864266); Harrap, Stephen (7005401249); Chalmers, John (54912078200); MacMahon, Stephen (24312201200); Fox, Kim (7402443973); Ferrari, Roberto (36047514600); Simoons, Maarten L. (35380988200); Danser, A. H. Jan (35421492100)","57218107869; 15135621700; 55665186500; 7102815542; 57215768249; 6602755087; 35231615000; 7005473334; 7101622418; 57190051298; 7006062246; 55429057100; 7202864266; 7005401249; 54912078200; 24312201200; 7402443973; 36047514600; 35380988200; 35421492100","A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals","2011","Journal of Hypertension","29","3","","509","519","10","44","10.1097/HJH.0b013e328341d117","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951673075&doi=10.1097%2fHJH.0b013e328341d117&partnerID=40&md5=343aef74de814badc7c4bf37e02542fa","Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, Thoraxcenter 's Gravendijkwal 230, Netherlands; Department of Genetic Epidemiology, Netherlands; Department of Haematology, Netherlands; Department of Internal Medicine, Netherlands; Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands; INSERM, Paris, France; University of Ferrara, Salvatore Maugeri Foundation, IRCCS, Ferrara, Italy; STICARES Cardiovascular Research, Rhoon, Netherlands; Lille Heart Institute, Lille, France; George Institute, University of Sydney, Royal Prince Alfred Hospital, Sydney, Australia; University of Melbourne, Melbourne, Australia; Royal Brompton and National Heart Institute, London, United Kingdom","Brugts J.J., Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, Thoraxcenter 's Gravendijkwal 230, Netherlands; Isaacs A., Department of Genetic Epidemiology, Netherlands; De Maat M.P.M., Department of Haematology, Netherlands; Boersma E., Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, Thoraxcenter 's Gravendijkwal 230, Netherlands; Van Duijn C.M., Department of Genetic Epidemiology, Netherlands; Akkerhuis K.M., Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, Thoraxcenter 's Gravendijkwal 230, Netherlands; Uitterlinden A.G., Department of Internal Medicine, Netherlands, Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands; Witteman J.C.M., Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands; Cambien F., INSERM, Paris, France; Ceconi C., University of Ferrara, Salvatore Maugeri Foundation, IRCCS, Ferrara, Italy; Remme W., STICARES Cardiovascular Research, Rhoon, Netherlands; Bertrand M., Lille Heart Institute, Lille, France; Ninomiya T., George Institute, University of Sydney, Royal Prince Alfred Hospital, Sydney, Australia; Harrap S., University of Melbourne, Melbourne, Australia; Chalmers J., George Institute, University of Sydney, Royal Prince Alfred Hospital, Sydney, Australia; MacMahon S., George Institute, University of Sydney, Royal Prince Alfred Hospital, Sydney, Australia; Fox K., Royal Brompton and National Heart Institute, London, United Kingdom; Ferrari R., University of Ferrara, Salvatore Maugeri Foundation, IRCCS, Ferrara, Italy; Simoons M.L., Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, Thoraxcenter 's Gravendijkwal 230, Netherlands; Danser A.H.J., Department of Internal Medicine, Netherlands","Aims: To investigate whether genetic variation in the renin-angiotensin- aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. Methods and Results: In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP 160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. Results: Hypertension was present in 28.3% of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2-3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. Conclusion: This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.","ACE inhibitors; gene; hypertension; PERGENE; pharmacogenetics; polymorphism; PROGRESS; renin-angiotensin-aldosterone system","aldosterone; angiotensinogen; bradykinin; creatinine; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; indapamide; kallikrein; perindopril; prorenin receptor; renin; adult; aged; article; blood pressure; blood pressure regulation; body mass; cerebrovascular disease; controlled study; coronary artery disease; creatinine clearance; diastolic blood pressure; female; gene linkage disequilibrium; genetic analysis; genetic variability; haplotype; human; hypertension; major clinical study; male; priority journal; renin angiotensin aldosterone system; single nucleotide polymorphism; systolic blood pressure; treatment response; vascular disease","","aldosterone, 52-39-1, 6251-69-0; angiotensinogen, 11002-13-4, 64315-16-8; bradykinin, 58-82-2, 5979-11-3; creatinine, 19230-81-0, 60-27-5; dipeptidyl carboxypeptidase, 9015-82-1; indapamide, 26807-65-8; kallikrein, 8006-48-2, 9001-01-8; perindopril, 82834-16-0, 99149-83-4; renin, 61506-93-2, 9015-94-5","","","","","Ward R., Familial aggregation and genetic epidemiology of blood pressure, Hypertension: Pathophysiology, Diagnosis, and Management, pp. 81-100, (1990); Pickering G., High blood-pressure evident cause: Essential hypertension, BMJ, 5469, pp. 1021-1026, (1965); Inagami T., The renin-angiotensin system, Essays Biochem, 28, pp. 147-164, (1994); Brugts J.J., Den Uil C.A., Danser A.H.J., Boersma E., The renin-angiotensin-aldosterone system: Approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease, Cardiology, 112, pp. 303-312, (2008); Agerholm-Larsen B., Nordestgaard B.G., Tybjaerg-Hansen A., ACE gene polymorphism in cardiovascular disease: Meta-analyses of small and large studies in whites, Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 2, pp. 484-492, (2000); Danser A.H.J., Schalekamp M.A.D.H., Bax W.A., Van Den Brink A.M., Saxena P.R., Riegger G.A., Schunkert H., Angiotensin-converting enzyme in the human heart, Effect of the Deletion/insertion Polymorphism. Circulation, 92, pp. 1387-1388, (1995); Sethi A.A., Nordestgaard Bo.G., Tybaeeg-Hansen A., Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis, Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 7, pp. 1269-1275, (2003); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Sayed-Tabatabaei F.A., Oostra B.A., Isaacs A., Van Duijn C.M., Witteman J.C.M., ACE polymorphisms, Circulation Research, 98, 9, pp. 1123-1133, (2006); Niu W., Qi Y., Hou S., Zhai X., Zhou W., Qiu C., Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: The Fangshan study, J Hypertens, 27, pp. 1384-1391, (2009); Stanton A.V., Dicker P., O'Brien E.T., Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively, Am J Hypertens, 22, pp. 954-957, (2009); Nussberger J., Gradman A.H., Schmieder R.E., Lins R.L., Chiang Y., Prescott M.F., Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension, International Journal of Clinical Practice, 61, 9, pp. 1461-1468, (2007); Harrap S.B., Tzourio C., Cambien F., Poirier O., Raoux S., Chalmers J., Chapman N., Colman S., Leguennec S., MacMahon S., Neal B., Ohkubo T., Woodward M., The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition, Hypertension, 42, 3, pp. 297-303, (2003); The European Trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: Randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study), Lancet, 362, pp. 782-788, (2003); Brugts J.J., De Maat M.P.M., Boersma E., Witteman J.C.M., Van Duijn C., Uitterlinden A.G., Et al., The Rationale and Design of the Perindopril Genetic Association Study: A pharmacogenetic analysis of ACE-inhibitor therapy in patients with stable coronary artery disease, Cardiovasc Drugs Ther, 23, pp. 171-181, (2009); Gomma A.H., Fox K.M., The EUROPA trial: Design, baseline demography and status of the substudies, Cardiovascular Drugs and Therapy, 15, 2, pp. 169-179, (2001); Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack, Lancet, 358, pp. 1033-1041, (2001); Nederhand R.J., Droog S., Kluft C., Simoons M.L., De Maat M.P., Logistics and quality control for DNA sampling in large mult-center studies, J Thromb Haemost, 1, pp. 987-991, (2003); Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: Analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 2, pp. 263-265, (2005); De Bakker P.I.W., Yelensky R., Pe'Er I., Gabriel S.B., Daly M.J., Altshuler D., Efficiency and power in genetic association studies, Nature Genetics, 37, 11, pp. 1217-1223, (2005); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Et al., Hypertension, 42, pp. 1206-1252, (2003); Churchill G.A., Doerge R.W., Empirical threshold values for quantitative trait mapping, Genetics, 138, 3, pp. 963-971, (1994); Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A., Score tests for association between traits and haplotypes when linkage phase is ambiguous, American Journal of Human Genetics, 70, 2, pp. 425-434, (2002); Hofman A., Grobbee D.E., De Jong P.T., Van Den Ouwenland F.A., Determinants of disease and disability in the elderly: The Rotterdam Elderly Study, Eur J Epidemiol, 7, pp. 403-422, (1991); Abdollahi M.R., Huang S., Rodriguez S., Guthrie P.A.I., Smith G.D., Ebrahim S., Lawlor D.A., Day I.N.M., Gaunt T.R., Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women's Heart and Health Study (BWHHS), Disease Markers, 24, 1, pp. 11-17, (2008); Danser A.H.J., Batenburg W.W., Van Den Meiracker A.H., Danilov S.M., ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?, Pharmacology and Therapeutics, 113, 3, pp. 607-618, (2007); Danser A.H.J., Derkx F.H.M., Hense H.-W., Jeunemaitre X., Riegger G.A.J., Schunkert H., Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels, Journal of Hypertension, 16, 12 SUPPL., pp. 1879-1883, (1998); Hirose T., Hashimoto M., Totsune K., Metoki H., Asayama K., Kikuya M., Et al., Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: The Ohasama study, Am J Hypertens, 22, pp. 294-299, (2009); Batenburg W.W., Krop M., Garrelds I.M., De Vries R., De Bruin R.J.A., Burckle C.A., Muller D.N., Bader M., Nguyen G., Danser A.H.J., Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor, Journal of Hypertension, 25, 12, pp. 2441-2453, (2007); Batenburg W.W., Danser A.H.J., The (pro)renin receptor: A new addition to the renin-angiotensin system?, Eur J Pharmacol, 585, pp. 320-324, (2008); Niua W., Yue Qic M., Houe S., Et al., Haplotype-based association of the renin-angiotensinaldosterone system genes polymorphisms with essential hypertension among Han Chinese: The Fangshan study, J Hypertens, 27, pp. 1384-1391; Cruciat C.M., Ohkwara B., Acebron S.P., Karaulanov E., Reinhard C., Ingelfinger D., Et al., Requirement of prorenin receptor and vacuolar H\+-ATPase-mediated acidification for Wnt signaling, Science, 327, pp. 459-465, (2010); Batenburg W.W., De Bruin Rja, Van Gool J.M., Muller D.N., Bader M., Nguyen G., Danser A.H.J., Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells, Arterioscler Thromb Vasc Biol, 28, pp. 1151-1157, (2008); Danser A.H.J., Deinum J., Renin, prorenin and the putative (Pro)renin receptor, Hypertension, 46, 5, pp. 1069-1076, (2005); Fisher N.D., Danser A.H.J., Nussberger J., Dole W.P., Hollenberg N.K., Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans, Circulation, 117, pp. 3199-3205, (2008); Feldman D.L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R.L., Et al., Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats, Hypertension, 52, pp. 130-136, (2008); Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J., Effect of bradykinin-receptor blockade on the response to angiotensin- converting-enzyme inhibitor in normotensive and hypertensive subjects, New England Journal of Medicine, 339, 18, pp. 1285-1292, (1998); Arnett D.K., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Miller M.B., Black H., Eckfeldt J.H., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, 25, pp. 3374-3383, (2005); Brugts J.J., Ninomiya T., Boersma E., Remme W.J., Bertrand M., Ferrari R., Et al., The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: A combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials, Eur Heart J, 30, pp. 1385-1394, (2009); Brugts J.J., Isaacs A., Boersma E., Van Duijn C.M., Uitterlinden A.G., Remme W., Et al., Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease, Eur Heart J, 31, pp. 1854-1864, (2010)","J. J. Brugts; Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, Thoraxcenter 's Gravendijkwal 230, Netherlands; email: j.brugts@erasmusmc.nl","","Lippincott Williams and Wilkins","","","","","","02636352","","JOHYD","21157371","English","J. Hypertens.","Article","Final","","Scopus","2-s2.0-79951673075"
"Sukasem C.; Tunthong R.; Chamnanphon M.; Santon S.; Jantararoungtong T.; Koomdee N.; Prommas S.; Puangpetch A.; Vathesatogkit P.","Sukasem, Chonlaphat (57209265337); Tunthong, Ramaimon (55832042400); Chamnanphon, Montri (55441642400); Santon, Siwalee (55833074600); Jantararoungtong, Thawinee (34876897300); Koomdee, Napatrupron (55586103700); Prommas, Santirhat (55902151400); Puangpetch, Apichaya (55200307900); Vathesatogkit, Prin (6602997853)","57209265337; 55832042400; 55441642400; 55833074600; 34876897300; 55586103700; 55902151400; 55200307900; 6602997853","CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors","2013","Pharmacogenomics and Personalized Medicine","6","1","","85","91","6","42","10.2147/PGPM.S42332","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882748728&doi=10.2147%2fPGPM.S42332&partnerID=40&md5=8deebd1a4fbeefb89e130e3d9466c409","Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Division of Cardiology, Department of Medicine, Mahidol University, Bangkok, Thailand","Sukasem C., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Tunthong R., Division of Cardiology, Department of Medicine, Mahidol University, Bangkok, Thailand; Chamnanphon M., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Santon S., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Jantararoungtong T., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Koomdee N., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Prommas S., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Puangpetch A., Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, Thailand; Vathesatogkit P., Division of Cardiology, Department of Medicine, Mahidol University, Bangkok, Thailand","Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented gradually as the determinant conversion and variability in the antiplatelet effect of clopidogrel. The aims of this study were to determine the prevalence of clinically relevant allele variants (CYP2C19*2, CYP2C19*3, and CYP2C19*17) in a Thai study population, and finally determine whether the allele distributes and predicts metabolic phenotypes in clopidogrel treated patients. A total of 1,051 Thai patients participated in this study. Genotypes for CYP2C19 polymorphisms were detected by the microarray-based technique. Furthermore, results of genotyping and platelet aggregation in 96 cardiovascular disease patients on 75 mg clopidogrel maintenance daily dose therapy also were analyzed. Among 1,051 samples, the allele frequencies of CYP2C19 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *1/*17 were found in 428 (40.72%), 369 (35.10%), 72 (6.85%), 77 (7.32%), 59 (5.61%), and 45 (4.30%) of the patients, respectively. Homozygous CYP2C19 *3/*3 was found in one patient (0.10%). Therefore, 40.72% of the patients were predicted as extensive metabolizers, 41.95% as intermediate metabolizers, 13.03% as poor metabolizers, and 4.30% as ultra-rapid metabolizers. Among 96 patients, the frequency of poor metabolizers was significantly higher in the clopidogrel non-responder group than in the responder group (36.0% and 15.5%, respectively, P = 0.03). CYP2C19*1/*17 was observed in responders (n = 2; 2.8%). As a result, CYP2C19 variants were associated with clopidogrel non-responders. However, there is a need for further elucidation of the clinical importance and use of this finding to make firm and cost-effective recommendations for drug treatment in the future. © 2013 Sukasem et al, publisher and licensee Dove Medical Press Ltd.","Clopidogrel; CYP2C19 polymorphisms; Non-responders; Responders; Thai population","angiotensin receptor antagonist; clopidogrel; cytochrome P450 2C19; dipeptidyl carboxypeptidase inhibitor; genomic DNA; hydroxymethylglutaryl coenzyme A reductase inhibitor; adult; aged; article; cardiovascular disease; controlled study; drug response; dyslipidemia; female; gene frequency; genetic polymorphism; genetic variability; genotype; homozygote; human; hypertension; maintenance drug dose; major clinical study; male; microarray analysis; pharmacogenetics; phenotype; prevalence; retrospective study; risk factor; single nucleotide polymorphism; Thailand; thrombocyte aggregation; thrombosis","","clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8","","","","","Goldstein J.A., Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br J Clin Pharmacol, 52, 4, pp. 349-355, (2001); Desta Z., Zhao X., Shin J.G., Flockhart D.A., Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, 41, 12, pp. 913-958, (2002); Ibeanu G.C., Blaisdell J., Ferguson R.J., Et al., A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin, J Pharmacol Exp Ther, 290, 2, pp. 635-640, (1999); Miao J., Liu R., Li Z., Cytochrome P-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, 21, pp. 2250-2251, (2009); Hulot J.S., Bura A., Villard E., Et al., Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 7, pp. 2244-2247, (2006); Trenk D., Hochholzer W., Fromm M.F., Et al., Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents, J Am Coll Cardiol, 51, 20, pp. 1925-1934, (2008); Sibbing D., Stegherr J., Latz W., Et al., Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention, Eur Heart J, 30, 8, pp. 916-922, (2009); Collet J.P., Hulot J.S., Pena A., Et al., Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study, Lancet, 373, 9660, pp. 309-317, (2009); Geisler T., Schaeffeler E., Dippon J., Et al., CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation, Pharmacogenomics, 9, 9, pp. 1251-1259, (2008); Simon T., Verstuyft C., Mary-Krause M., Et al., Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 4, pp. 363-375, (2009); Pirmohamed M., Park B.K., Genetic susceptibility to adverse drug reactions, Trends Pharmacol Sci, 22, 6, pp. 298-305, (2001); Sameer A.E., Amany G.M., Abdela A.A., Fadel S.A., CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip, Can J Clin Pharmacol, 16, 1, (2009); Freedman J.E., Hylek E.M., Clopidogrel, genetics, and drug responsiveness, N Engl J Med, 360, 4, pp. 411-413, (2009); Tassaneeyakul W., Mahatthanatrakul W., Niwatananun K., Et al., CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations, Drug Metab Pharmacokinet, 21, 4, pp. 286-290, (2006); Koseler A., Ilcol Y.O., Ulus I.H., Frequency of mutated allele CYP2D6*4 in the Turkish population, Pharmacology, 79, 4, pp. 203-206, (2007); Small D.S., Farid N.A., Payne C.D., Et al., Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel, J Clin Pharmacol, 48, 4, pp. 475-484, (2008); Brandt J.T., Close S.L., Iturria S.J., Et al., Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, 12, pp. 2429-2436, (2007); Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Et al., PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation, Blood Coagul Fibrinolysis, 15, 1, pp. 89-93, (2004); Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Et al., Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel, Arterioscler Thromb Vasc Biol, 26, 8, pp. 1895-1900, (2006); Fontana P., Dupont A., Gandrille S., Et al., Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects, Circulation, 108, 8, pp. 989-995, (2003); Giusti B., Gori A.M., Marcucci R., Et al., Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients, Pharmacogenet Genomics, 17, 12, pp. 1057-1064, (2007); Taubert D., von Beckerath N., Grimberg G., Et al., Impact of P-glycoprotein on clopidogrel absorption, Clin Pharmacol Ther, 80, 5, pp. 486-501, (2006); Goldstein J.A., Ishizaki T., Chiba K., Et al., Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations, Pharmacogenetics, 7, 1, pp. 59-64, (1997); Herrlin K., Massele A.Y., Jande M., Et al., Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype, Clin Pharmacol Ther, 64, 4, pp. 391-401, (1998); Allabi A.C., Gala J.L., Desager J.P., Heusterspreute M., Horsmans Y., Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations, Br J Clin Pharmacol, 56, 6, pp. 653-657, (2003); Kubota T., Chiba K., Ishizaki T., Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population, Clin Pharmacol Ther, 60, 6, pp. 661-666, (1996); Muller I., Besta F., Schulz C., Massberg S., Schonig A., Gawaz M., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb Haemost, 89, 5, pp. 783-787, (2003); He N., Yan F.X., Huang S.L., Et al., CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population, Eur J Clin Pharmacol, 58, 1, pp. 15-18, (2002); Xiao Z.S., Goldstein J.A., Xie H.G., Et al., Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele, J Pharmacol Exp Ther, 281, 1, pp. 604-609, (1997); Pang Y.S., Wong L.P., Lee T.C., Mustafa A.M., Mohamed Z., Lang C.C., Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects, Br J Clin Pharmacol, 58, 3, pp. 332-335, (2004); Lamba J.K., Dhiman R.K., Kohli K.K., Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects, Clin Pharmacol Ther, 63, 4, pp. 422-427, (1998); Aynacioglu A.S., Sachse C., Bozkurt A., Et al., Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population, Clin Pharmacol Ther, 66, 2, pp. 185-192, (1999); Ozawa S., Soyama A., Saeki M., Et al., Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1, Drug Metab Pharmacokinet, 19, 2, pp. 83-95, (2004); Zand N., Tajik N., Moghaddam A.S., Milanian I., Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population, Clin Exp Pharmacol Physiol, 34, 1-2, pp. 102-105, (2007); de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A., The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem, 269, 22, pp. 15419-15422, (1994); Nakamura K., Goto F., Ray W.A., Et al., Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations, Clin Pharmacol Ther, 38, 4, pp. 402-408, (1985); Scott S.A., Sangkuhl K., Gardner E.E., Et al., Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapy, Clin Pharmacol Ther, 90, 2, pp. 328-332, (2011); Sim S.C., Risinger C., Dahl M.L., Et al., A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther, 79, 1, pp. 103-113, (2006)","C. Sukasem; Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Mahidol University, Bangkok, 10400, Thailand; email: chonlaphat.suk@mahidol.ac.th","","","","","","","","11787066","","","","English","Pharm. Person. Med.","Article","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-84882748728"
"Lind J.M.; Chiu C.L.","Lind, Joanne Maree (15725587700); Chiu, Christine Laiwan (7402303894)","15725587700; 7402303894","Genetic discoveries in hypertension: Steps on the road to therapeutic translation","2013","Heart","99","22","","1645","1651","6","11","10.1136/heartjnl-2012-302883","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885861263&doi=10.1136%2fheartjnl-2012-302883&partnerID=40&md5=39f5e3f45fd25a81a34a197fe6ddb41c","University of Western Sydney, School of Medicine, Penrith, NSW 2751, Locked Bag 1797, Australia","Lind J.M., University of Western Sydney, School of Medicine, Penrith, NSW 2751, Locked Bag 1797, Australia; Chiu C.L., University of Western Sydney, School of Medicine, Penrith, NSW 2751, Locked Bag 1797, Australia","Genes and environmental factors contribute to an individual's risk of hypertension. Recent advances in DNA sequencing technology have enabled the discovery of new causative genes in inherited forms of hypertension, identifying novel pathways for blood pressure control. Meta-analyses of genome-wide association studies have also identified regions of the genome that are significantly associated with blood pressure control, and these regions may be involved in an individual's response to antihypertensive medication. This article reviews the latest gene discoveries in inherited forms of hypertension, recent meta-analyses of genome-wide association studies, genetic determinants of antihypertensive therapy response, and development of genetic risk scores.","","Genome-Wide Association Study; Humans; Hypertension; Genetics; angiotensin receptor antagonist; atenolol; atrial natriuretic factor; beta adrenergic receptor; brain natriuretic peptide; calcium channel blocking agent; diltiazem; dipeptidyl carboxypeptidase inhibitor; hydrochlorothiazide; protein kinase WNK1; protein kinase WNK4; thiazide diuretic agent; ADRB1 gene; antihypertensive therapy; article; ATP2B1 gene; blood pressure regulation; CUL3 gene; DNA sequence; drug efficacy; drug response; epigenetics; essential hypertension; exome; gene; gene locus; gene mutation; genetic association; genetic risk; genetic variability; human; hypertension; KCNJ5 gene; KLHL3 gene; low drug dose; Mendelian hypertension; NPPA gene; NPPB gene; personalized medicine; primary hyperaldosteronism; priority journal; pseudohypoaldosteronism; pseudohypoaldosteronism type 2; single nucleotide polymorphism; WNK1 gene; WNK4 gene","","atenolol, 29122-68-7, 93379-54-5; atrial natriuretic factor, 85637-73-6; brain natriuretic peptide, 114471-18-0; diltiazem, 33286-22-5, 42399-41-7; hydrochlorothiazide, 58-93-5","","","","","World Health Statistics 2012, (2012); Whelton P.K., He J., Appel L.J., Cutler J.A., Havas S., Kotchen T.A., Roccella E.J., Stout R., Vallbona C., Winston M.C., Karimbakas J., Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program, Journal of the American Medical Association, 288, 15, pp. 1882-1888, (2002); Miall W.E., Oldham P.D., The hereditary factor in arterial blood-pressure, Br Med J, 1, pp. 75-80, (1963); Thibonnier M., Schork N.J., The genetics of hypertension, Curr Opin Genet Dev, 5, pp. 362-370, (1995); Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P., Human hypertension caused by mutations in WNK kinases, Science, 293, 5532, pp. 1107-1112, (2001); Tobin M.D., Tomaszewski M., Braund P.S., Et al., Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population, Hypertension, 51, pp. 1658-1664, (2008); Levy D., Ehret G.B., Rice K., Et al., Genome-wide association study of blood pressure and hypertension, Nat Genet, 41, pp. 677-687, (2009); Lupton S.J., Chiu C.L., Lind J.M., A hypertension gene: Are we there yet?, Twin Res Hum Genet, 14, pp. 295-304, (2011); Luft F.C., Mendelian forms of human hypertension and mechanisms of disease, Clin Med Res, 1, pp. 291-300, (2003); Shendure J., Ji H., Next-generation DNA sequencing, Nat Biotechnol, 26, pp. 1135-1145, (2008); Choi M., Scholl U.I., Ji W., Et al., Genetic diagnosis by whole exome capture and massively parallel DNA sequencing, Proc Natl Acad Sci USA, 106, pp. 19096-19101, (2009); Ng S.B., Turner E.H., Robertson P.D., Et al., Targeted capture and massively parallel sequencing of 12 human exomes, Nature, 461, pp. 272-276, (2009); Bamshad M.J., Ng S.B., Bigham A.W., Et al., Exome sequencing as a tool for Mendelian disease gene discovery, Nat Rev Genet, 12, pp. 745-755, (2011); Mansfield T.A., Simon D.B., Farfel Z., Bia M., Tucci J.R., Lebel M., Gutkin M., Vialettes B., Christofilis M.A., Kauppinen-Makelin R., Mayan H., Risch N., Lifton R.P., Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21, Nature Genetics, 16, 2, pp. 202-205, (1997); Boyden L.M., Choi M., Choate K.A., Et al., Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities, Nature, 482, pp. 98-102, (2012); Louis-Dit-Picard H., Barc J., Trujillano D., Et al., KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron, Nat Genet, 44, pp. 456-460, (2012); Funder J.W., The genetic basis of primary aldosteronism, Curr Hypertens Rep, 14, pp. 120-124, (2012); Monticone S., Viola A., Tizzani D., Et al., Primary aldosteronism: Who should be screened?, Horm Metab Res, 44, pp. 163-169, (2012); Choi M., Scholl U.I., Yue P., Et al., K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension, Science, 331, pp. 768-772, (2011); Geller D.S., Zhang J., Wisgerhof M.V., Et al., A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism, J Clin Endocrinol Metab, 93, pp. 3117-3123, (2008); Newton-Cheh C., Johnson T., Gateva V., Et al., Genome-wide association study identifies eight loci associated with blood pressure, Nat Genet, 41, pp. 666-676, (2009); Levy D., Larson M.G., Benjamin E.J., Et al., Framingham Heart Study 100K Project: Genome-wide associations for blood pressure and arterial stiffness, BMC Med Genet, 8, SUPPL. 1, (2007); Krushkal J., Ferrell R., Mockrin S.C., Turner S.T., Sing C.F., Boerwinkle E., Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings, Circulation, 99, 11, pp. 1407-1410, (1999); Johnson A.D., Newton-Cheh C., Chasman D.I., Et al., Association of hypertension drug target genes with blood pressure and hypertension in86 588 individuals, Hypertension, 57, pp. 903-910, (2011); Olson S., Wang M.G., Carafoli E., Et al., Localization of two genes encoding plasma membrane Ca2(+)-transporting ATPases to human chromosomes 1q25-32 and 12q21-23, Genomics, 9, pp. 629-641, (1991); Ehret G.B., Munroe P.B., Rice K.M., Et al., Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk, Nature, 478, pp. 103-109, (2011); Newton-Cheh C., Larson M.G., Vasan R.S., Et al., Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure, Nat Genet, 41, pp. 348-353, (2009); Tabara Y., Kohara K., Kita Y., Et al., Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: The Japanese Millennium Genome Project, Hypertension, 56, pp. 973-980, (2010); Lin Y., Lai X., Chen B., Et al., Genetic variations in CYP17A1, CACNB2 and PLEKHA7 are associated with blood pressure and/or hypertension in She ethnic minority of China, Atherosclerosis, 219, pp. 709-714, (2011); Hong K.W., Jin H.S., Lim J.E., Et al., Recapitulation of two genomewide association studies on blood pressure and essential hypertension in the Korean population, J Hum Genet, 55, pp. 336-341, (2010); Fox E.R., Young J.H., Li Y., Et al., Association of genetic variation with systolic and diastolic blood pressure among African Americans: The Candidate Gene Association Resource study, Hum Mol Genet, 20, pp. 2273-2284, (2011); Kato N., Takeuchi F., Tabara Y., Et al., Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians, Nat Genet, 43, pp. 531-538, (2011); Ho J.E., Levy D., Rose L., Et al., Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health Study, J Hypertens, 29, pp. 62-69, (2011); Albrechtsen A., Grarup N., Li Y., Et al., Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes, Diabetologia, 56, pp. 298-310, (2013); Smolarek I., Wyszko E., Barciszewska A.M., Et al., Global DNA methylation changes in blood of patients with essential hypertension, Med Sci Monit, 16, (2010); El Shamieh S., Visvikis-Siest S., Genetic biomarkers of hypertension and future challenges integrating epigenomics, Clin Chim Acta, 414, pp. 259-265, (2012); Wang X., Prins B.P., Sober S., Et al., Beyond genome-wide association studies: New strategies for identifying genetic determinants of hypertension, Curr Hypertens Rep, 13, pp. 442-451, (2011); Erdine S., Ari O., ESH-ESC guidelines for the management of hypertension, Herz, 31, 4, pp. 331-338, (2006); Kidney Foundation N., K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, Am J Kidney Dis, 43, (2004); Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., Pignone M.P., Plutzky J., Porte D., Redberg R., Stitzel K.F., Stone N.J., Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association, Circulation, 115, 1, pp. 114-126, (2007); Ma J., Stafford R.S., Screening, treatment, and control of hypertension in US private physician offices, 2003-2004, Hypertension, 51, 5, pp. 1275-1281, (2008); Siegel D., Barriers to and strategies for effective blood pressure control, Vasc Health Risk Manag, 1, pp. 9-14, (2005); Arnett DK, Claas SA, Lynch AI. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?, Curr Opin Cardiol, 24, pp. 333-339, (2009); Konoshita T., Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs a systematic review of pharmacogenomics in the Renin-Angiotensin system, Curr Hypertens Rep, 13, pp. 356-361, (2011); Arnett D.K., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Miller M.B., Black H., Eckfeldt J.H., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, 25, pp. 3374-3383, (2005); Lynch A.I., Boerwinkle E., Davis B.R., Ford C.E., Eckfeldt J.H., Leiendecker-Foster C., Arnett D.K., Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension, JAMA - Journal of the American Medical Association, 299, 3, pp. 296-307, (2008); Suonsyrja T., Donner K., Hannila-Handelberg T., Et al., Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment, Pharmacogenet Genomics, 20, pp. 342-345, (2010); Svensson-Farbom P., Wahlstrand B., Almgren P., Et al., A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients, J Hypertens, 29, pp. 388-395, (2011); Fava C., Sjogren M., Montagnana M., Et al., Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes, Hypertension, 61, pp. 319-326, (2013); Hamrefors V., Sjogren M., Almgren P., Et al., Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms, J Hypertens, 30, pp. 1151-1160, (2012); Gong Y., McDonough C.W., Wang Z., Et al., Hypertension susceptibility loci and blood pressure response to antihypertensives-results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, Circ Cardiovasc Genet, (2012); National Human Genome Research Institute DNA Sequencing Costs, (2012); National Center for Biotechnology Information, (2012); National Heart Foundation of Australia-National Blood Pressure and Vascular Disease Advisory Committee Guide to management of hypertension 2008, Assessing and Managing Raised Blood Pressure in Adults.","J.M. Lind; University of Western Sydney, School of Medicine, Penrith, NSW 2751, Locked Bag 1797, Australia; email: j.lind@uws.edu.au","","","","","","","","1468201X","","HEARF","23474626","English","Heart","Article","Final","","Scopus","2-s2.0-84885861263"
"Zhang X.; Cai Y.; Zhou P.; Nie W.; Sun H.; Sun Y.; Zhao Y.; Han C.; Cao C.; Liu J.; Nie X.","Zhang, Xinyi (57239223700); Cai, Yuchun (57797675800); Zhou, Pei (57224950454); Nie, Wenchang (58662344600); Sun, Haoning (59151706300); Sun, Yutong (57612197600); Zhao, Yuxuan (57224959439); Han, Congxiao (57810343800); Cao, Chengfu (56402398500); Liu, Jian (55823972300); Nie, Xiaoyan (55362538900)","57239223700; 57797675800; 57224950454; 58662344600; 59151706300; 57612197600; 57224959439; 57810343800; 56402398500; 55823972300; 55362538900","Pharmacogenomic Polygenic Model of Clopidogrel Predicts Recurrent Ischemic Events in Chinese Patients With Coronary Artery Disease","2024","Clinical Therapeutics","46","8","","644","649","5","0","10.1016/j.clinthera.2024.06.019","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199793423&doi=10.1016%2fj.clinthera.2024.06.019&partnerID=40&md5=4fc19a5a57b879eb1f2894cfb80e0428","Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China; Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Department of Cardiology, Peking University People's Hospital, Beijing, China","Zhang X., Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China; Cai Y., Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China; Zhou P., Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Nie W., Department of Cardiology, Peking University People's Hospital, Beijing, China; Sun H., Department of Cardiology, Peking University People's Hospital, Beijing, China; Sun Y., Department of Cardiology, Peking University People's Hospital, Beijing, China; Zhao Y., Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China; Han C., Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China; Cao C., Department of Cardiology, Peking University People's Hospital, Beijing, China; Liu J., Department of Cardiology, Peking University People's Hospital, Beijing, China; Nie X., Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China","Purpose: Patients with coronary artery disease (CAD) need to take antiplatelet drugs regularly in order to prevent thrombosis; however, there is existing inter-individual variability in drug response. Pharmacogenomic studies indicate that drug response may also be influenced by genetic variants, and multiple genetic variants may work together. We assumed that patients carrying more risk alleles might have a worse clopidogrel drug response and that a polygenic model integrated different single variants might have the potential to explain clopidogrel drug response variability better. We aimed to investigate whether the polygenic model could be used to predict clopidogrel drug response. Methods: A total of 935 CAD patients were enrolled in the study. We investigated the association between 19 clopidogrel-related single-nucleotide polymorphisms (SNPs) and the incidence of recurrent ischemic events. Additionally, a polygenic model was constructed to assess the risk of ischemic events. Findings: There were only 2 SNPs of CYP2C8 gene (rs1934980 and rs17110453) that were nominally associated with incidence of recurrent ischemic events. We constructed a polygenic model integrated with 6 clopidogrel-related SNPs. When compared with patients carrying 6 or fewer risk alleles, patients with 7 or more risk alleles had a higher risk of ischemic events (hazard ratio = 1.87; P = 0.04). Implications: The polygenetic model may be useful for clopidogrel drug response prediction in patients with CAD. © 2024","Clopidogrel; Coronary artery disease; Polygenic; Recurrent ischemic events","Aged; Asian People; China; Clopidogrel; Coronary Artery Disease; East Asian People; Female; Humans; Male; Middle Aged; Multifactorial Inheritance; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Recurrence; acetylsalicylic acid; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; calcium antagonist; clopidogrel; cytochrome P450 1A2; cytochrome P450 2B6; cytochrome P450 2C19; cytochrome P450 2C8; cytochrome P450 2C9; cytochrome P450 3A4; cytochrome P450 3A5; dipeptidyl carboxypeptidase inhibitor; genomic DNA; hydroxymethylglutaryl coenzyme A reductase inhibitor; multidrug resistance protein 1; purinergic P2Y12 receptor; antithrombocytic agent; clopidogrel; adult; aged; allele; Article; Chinese; chronic kidney failure; comorbidity; controlled study; coronary artery disease; DNA isolation; drug response; dual antiplatelet therapy; family history; female; follow up; genetic risk; genetic risk score; genetic variability; genome analysis; genotyping; heart infarction; human; hypercholesterolemia; hyperlipidemia; hypertension; incidence; ischemia; left coronary artery; major clinical study; male; middle aged; non insulin dependent diabetes mellitus; non ST segment elevation myocardial infarction; nonbiological model; pharmacogenomics; polygenic model; prediction; recurrent disease; risk assessment; single nucleotide polymorphism; ST segment elevation myocardial infarction; stable angina pectoris; unstable angina pectoris; Asian; China; coronary artery disease; drug therapy; East Asian; epidemiology; genetics; multifactorial inheritance; pharmacogenetics; recurrent disease; single nucleotide polymorphism","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8, 120202-65-5, 120202-67-7, 894353-16-3, 744256-69-7; cytochrome P450 2B6, 330207-11-9; cytochrome P450 3A4, 329736-03-0; cytochrome P450 3A5, 336874-97-6; Clopidogrel, ; Platelet Aggregation Inhibitors, ","","","National Natural Science Foundation of China, NSFC, (81970294, 81803497); National Natural Science Foundation of China, NSFC","This work was supported by the National Natural Science Foundation of China (grant numbers 81970294 and 81803497). All authors contributed to the study conception and design. Material preparation and data collection were performed by Xinyi Zhang, Yuchun Cai, Pei Zhou, Wenchang Nie, Haoning Sun, Yutong Sun, Yuxuan Zhao and Congxiao Han. Data analysis was conducted by Xinyi Zhang and Xiaoyan Nie. The first draft of the manuscript was written by Xinyi Zhang, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request.","Ibrahim H., Kleiman N.S., Platelet pathophysiology, pharmacology, and function in coronary artery disease, Coron Artery Dis, 28, pp. 614-623, (2017); D'Ascenzo F., Barbero U., Bisi M., Et al., The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis, Biomed Res Int, 2014, (2014); Chen J., Chen S.Y., Lian J.J., Et al., Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo-a systematic review, Clin Cardiol, 36, pp. 184-189, (2013); Park J.S., Cha K.S., Lee H.W., Et al., Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention, Heart Vessels, 32, pp. 690-699, (2017); Warlo E.M.K., Arnesen H., Seljeflot I., A brief review on resistance to P2Y<sub>12</sub> receptor antagonism in coronary artery disease, Thromb J, 17, (2019); Kazui M., Nishiya Y., Ishizuka T., Et al., Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite, Drug Metab Dispos, 38, pp. 92-99, (2010); Sangkuhl K., Klein T.E., pathway A.R.C., Pharmacogenet Genomics, 20, pp. 463-465, (2010); Loer H.L.H., Turk D., Gomez-Mantilla J.D., Et al., Physiologically based pharmacokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 drug-drug-gene interaction predictions, Pharmaceutics, 14, (2022); Shuldiner A.R., O'Connell J.R., Bliden K.P., Et al., Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, 302, pp. 849-857, (2009); Cross B., Turner R., Pirmohamed M., Polygenic risk scores: an overview from bench to bedside for personalised medicine, Front Genet, 13, (2022); Zhai S., Zhang H., Mehrotra D.V., Shen J.D., Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods, Nat Commun, 13, (2022); Lu X.F., Liu Z.Y., Cui Q.M., Et al., A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study, Eur Heart J, 43, pp. 1702-1711, (2022); Docherty A.R., Moscati A., Bigdeli T.B., Et al., Pathway-based polygene risk for severe depression implicates drug metabolism in CONVERGE, Psychol Med, 50, pp. 793-798, (2020); Varma A., Maharjan J., Garikipati A., Et al.; Lanfear D.E., Luzum J.A., She R.C., Et al., Polygenic score for β-blocker survival benefit in European ancestry patients with reduced ejection fraction heart failure, Circ Heart Fail, 13, (2020); Wang X.Q., Shen C.L., Wang B.N., Et al., Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome, Gene, 558, pp. 200-207, (2015); Taubert D., von Beckerath N., Grimberg G., Et al., Impact of P-glycoprotein on clopidogrel absorption, Clin Pharmacol Ther, 80, pp. 486-501, (2006); Pan Y.S., Chen W.Q., Wang Y.L., Et al., Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial, JAMA Neurol, 76, pp. 552-560, (2019); Mega J.L., Close S.L., Wiviott S.D., Et al., Cytochrome p-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, pp. 354-362, (2009); Simon T., Verstuyft C., Mary-Krause M., Et al., French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, pp. 363-375, (2009); Wallentin L., James S., Storey R.F., Et al., Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial, Lancet, 376, pp. 1320-1328, (2010); Cavallari L.H., Lee C.R., Beitelshees A.L., Et al., Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention, JACC Cardiovasc Interv, 11, pp. 181-191, (2018); Zhang L.N., Chen Y.M., Jin Y., Et al., Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients, Thromb Res, 132, pp. 81-87, (2013); Tang X.F., Han Y.L., Zhang J.H., Et al., CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention, Thromb Res, 147, pp. 108-114, (2016); Xi Z.W., Fang F., Wang J.Y., Et al., CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis, Platelets, 30, pp. 229-240, (2019); Zhang M., Wang J.R., Zhang Y., Et al., Impacts of CYP2C19 polymorphism and clopidogrel dosing on in-stent restenosis: a retrospective cohort study in Chinese patients, Drug Des Devel Ther, 14, pp. 669-676, (2020); Lee C.R., Luzum J.A., Sangkuhl K., Et al., Clinical pharmacogenetics implementation consortium guideline for cyp2c19 genotype and clopidogrel therapy: 2022 update, Clin Pharmacol Ther, 112, pp. 959-967, (2022); Zhao K., Yang M., Lu Y., Et al., P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel: a meta-analysis, Drug Res (Stuttg), 69, pp. 23-31, (2019); Yi X.Y., Lin J., Wang Y.F., Et al., Association of cytochrome P450 genetic variants with clopidogrel resistance and outcomes in acute ischemic stroke, J Atheroscler Thromb, 23, pp. 1188-1200, (2016); Lewis J.P., Backman J.D., Reny J.L., Et al., Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients, Eur Heart J Cardiovasc Pharmacother, 6, pp. 203-210, (2020); Pereira N.L., Farkouh M.E., So D., Et al., Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial, JAMA, 324, pp. 761-771, (2020); Claassens D.M.F., Vos G.J.A., Bergmeijer T.O., Et al., A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI, N Engl J Med, 381, pp. 1621-1631, (2019); Xi Z.W., Wang Y., Lu Q.H., Et al., Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y12 inhibitors, Thromb Res, 228, pp. 85-93, (2023); Liu J., Qin L.A., Wang Z.Q., Et al., Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS, Thromb Res, 186, pp. 71-74, (2020); Li X.G., Ma N., Wang B., Et al., The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease, Sci Rep, 6, (2016)","X. Nie; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, 38 Xueyuan Road, Haidian District, 100191, China; email: niexy@pku.edu.cn","","Elsevier Inc.","","","","","","01492918","","CLTHD","39068057","English","Clin. Ther.","Article","Final","","Scopus","2-s2.0-85199793423"
"Turner S.T.; Bailey K.R.; Schwartz G.L.; Chapman A.B.; Chai H.S.; Boerwinkle E.","Turner, Stephen T. (7402275413); Bailey, Kent R. (7202891244); Schwartz, Gary L. (7403155162); Chapman, Arlene B. (7201567844); Chai, High Seng (16038484200); Boerwinkle, Eric (7102087489)","7402275413; 7202891244; 7403155162; 7201567844; 16038484200; 7102087489","Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker","2012","Hypertension","59","6","","1204","1211","7","53","10.1161/HYP.0b013e31825b30f8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861510163&doi=10.1161%2fHYP.0b013e31825b30f8&partnerID=40&md5=b02756da518b810706eb51ecbf00e1ec","Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Divisions of Biostatistics, Mayo Clinic, College of Medicine, Rochester, MN, United States; Department of Health Sciences Research, Mayo Clinic, College of Medicine, Rochester, MN, United States; Renal Division, Department of Medicine, Emory University, Atlanta, GA, United States; Human Genetics Center, School of Public Health, University of Texas-Houston Health Science Center, Houston, TX, United States","Turner S.T., Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Bailey K.R., Divisions of Biostatistics, Mayo Clinic, College of Medicine, Rochester, MN, United States; Schwartz G.L., Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; Chapman A.B., Renal Division, Department of Medicine, Emory University, Atlanta, GA, United States; Chai H.S., Department of Health Sciences Research, Mayo Clinic, College of Medicine, Rochester, MN, United States; Boerwinkle E., Human Genetics Center, School of Public Health, University of Texas-Houston Health Science Center, Houston, TX, United States","To identify genes influencing blood pressure response to an angiotensin II receptor blocker, single nucleotide polymorphisms identified by genome-wide association analysis of the response to candesartan were validated by opposite direction associations with the response to a thiazide diuretic, hydrochlorothiazide. We sampled 198 white and 193 blacks with primary hypertension from opposite tertiles of the race-sex-specific distributions of age-adjusted diastolic blood pressure response to candesartan. There were 285 polymorphisms associated with the response to candesartan at P<10 -4 in whites. A total of 273 of the 285 polymorphisms, which were available for analysis in a separate sample of 196 whites, validated for opposite direction associations with the response to hydrochlorothiazide (Fisher χ 2 1-sided P=0.02). Among the 273 polymorphisms, those in the chromosome 11q21 region were the most significantly associated with response to candesartan in whites (eg, rs11020821 near FUT4, P=8.98×10 -7), had the strongest opposite direction associations with response to hydrochlorothiazide (eg, rs3758785 in GPR83, P=7.10×10 -3), and had the same direction associations with response to candesartan in the 193 blacks (eg, rs16924603 near FUT4, P=1.52×10 -2). Also notable among the 273 polymorphisms was rs11649420 on chromosome 16 in the amiloride-sensitive sodium channel subunit SCNN1G involved in mediating renal sodium reabsorption and maintaining blood pressure when the renin-angiotensin system is inhibited by candesartan. These results support the use of genomewide association analyses to identify novel genes predictive of opposite direction associations with blood pressure responses to inhibitors of the renin-angiotensin and renal sodium transport systems. © 2012 American Heart Association, Inc.","Blood pressure; Diuretic; Genome; Pharmacogenetics; Ypertension","Adult; African Americans; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Blood Pressure; Case-Control Studies; Chi-Square Distribution; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 16; Diuretics; Drug Administration Schedule; Epithelial Sodium Channel; European Continental Ancestry Group; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; candesartan; FTU4 protein; G protein coupled receptor; g protein coupled receptor 38 protein; hydrochlorothiazide; protein; SCNN1G protein; sodium channel; unclassified drug; adult; article; Caucasian; chromosome 11q; chromosome 16; diastolic blood pressure; female; gene locus; genetic association; genotype; human; hypertension; kidney tubule absorption; major clinical study; male; Negro; priority journal; renin angiotensin aldosterone system; single nucleotide polymorphism","","candesartan, 139481-59-7; hydrochlorothiazide, 58-93-5; protein, 67254-75-5; Angiotensin II Type 1 Receptor Blockers, ; Benzimidazoles, ; Diuretics, ; Epithelial Sodium Channel, ; GPR83 protein, human, ; Hydrochlorothiazide, 58-93-5; Receptors, G-Protein-Coupled, ; SCNN1G protein, human, ; Tetrazoles, ; candesartan, 139481-59-7","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL053330); National Heart, Lung, and Blood Institute, NHLBI","","Preston R.A., Materson B.J., Reda D.J., Williams D.W., Hamburger R.J., Cushman W.C., Anderson R.J., Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy: Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, JAMA, 280, pp. 1168-1172, (1998); Turner S.T., Schwartz G.L., Chapman A.B., Beitelshees A.L., Gums J.G., Cooper-Dehoff R.M., Boerwinkle E., Johnson J.A., Bailey K.R., Plasma renin activity predicts blood pressure responses to-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension, Am J Hypertens, 23, pp. 1014-1022, (2010); Laragh J.H., Lamport B., Sealey J., Alderman M.H., Diagnosis ex juvantibus: Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Reilly R.F., Peixoto A.J., Desir G.V., The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis, Clin J Am Soc Nephrol, 5, pp. 1893-1903, (2010); Laragh J.H., Sealey J.E., The plasma renin test reveals the contribution of body sodium-volume content (v) and renin-angiotensin (r) vasoconstriction to long-term blood pressure, Am J Hypertens, 24, pp. 1164-1180, (2011); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int, 61, pp. 1047-1055, (2002); Canzanello V.J., Baranco-Pryor E., Rahbari-Oskoui F., Schwartz G.L., Boerwinkle E., Turner S.T., Chapman A.B., Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension, Am J Hypertens, 21, pp. 61-66, (2008); Turner S.T., Bailey K.R., Fridley B.L., Chapman A.B., Schwartz G.L., Chai H.S., Sicotte H., Kocher J.P., Rodin A.S., Boerwinkle E., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension, 52, pp. 359-365, (2008); Cochran W.G., Some methods for strengthening the common 2 tests, Biometrics, 10, pp. 417-451, (1954); Armitage P., Tests for linear trends in proportions and frequencies, Biometrics, 11, pp. 375-386, (1955); Fisher R.A., Statistical Methods for Research Workers, (1925); Risch N., Merikangas K., The future of genetic studies of complex human diseases, Science, 273, pp. 1516-1517, (1996); Ioannidis J.P., Ntzani E.E., Trikalinos T.A., Racial' differences in genetic effects for complex diseases, Nat Genet, 36, pp. 1312-1318, (2004); Turner S.T., Schwartz G.L., Chapman A.B., Hall W.D., Boerwinkle E., Antihypertensive pharmacogenetics: Getting the right drug into the right patient, J Hypertens, 19, pp. 1-11, (2001); Hansson J.H., Nelson-Williams C., Suzuki H., Schild L., Shimkets R., Lu Y., Canessa C., Iwasaki T., Rossier B., Lifton R.P., Hypertension caused by a truncated epithelial sodium channel subunit: Genetic heterogeneity of liddle syndrome, Nat Genet, 11, pp. 76-82, (1995); Alderman M.H., Cohen H.W., Sealey J.E., Laragh J.H., Pressor responses to antihypertensive drug types, Am J Hypertens, 23, pp. 1031-1037, (2010); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., Wnk1 kinase polymorphism and blood pressure response to a thiazide diuretic, Hypertension, 46, pp. 758-765, (2005); Gavras H., Brunner H.R., Laragh J.H., Sealey J.E., Gavras I., Vukovich R.A., An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients, N Engl J Med, 291, pp. 817-821, (1974); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, pp. 1783-1787, (2001); Ortlepp J.R., Hanrath P., Mevissen V., Kiel G., Borggrefe M., Hoffmann R., Variants of the cyp11b2 gene predict response to therapy with candesartan, Eur J Pharmacol, 445, pp. 151-152, (2002); Sekino K., Kubota T., Okada Y., Yamada Y., Yamamoto K., Horiuchi R., Kimura K., Iga T., Effect of the single cyp2c9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects, Eur J Clin Pharmacol, 59, pp. 589-592, (2003); Liljedahl U., Karlsson J., Melhus H., Kurland L., Lindersson M., Kahan T., Nystrom F., Lind L., Syvanen A.C., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenetics, 13, pp. 7-17, (2003); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Nystrom F., Hagg A., Lind L., Aldosterone synthase (cyp11b2)344 c/t polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA) Trial, Am J Hypertens, 15, pp. 389-393, (2002); Hallberg P., Karlsson J., Kurland L., Lind L., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Melhus H., The cyp2c9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) Trial, J Hypertens, 20, pp. 2089-2093, (2002); Jiang X., Sheng H.H., Lin G., Li J., Lu X.Z., Cheng Y.L., Huang J., Xiao H.S., Zhan Y.Y., Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment, Chin Med J (Engl), 120, pp. 782-786, (2007); Li Y., Zhou Y., Yang P., Niu J.Q., Wu Y., Zhao D.D., Wu S.L., Interaction of ace and cyp11b2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients, Clin Exp Hypertens, 33, pp. 141-146, (2011); Wu S.L., Li Y., Liu K.J., Hou G.S., Wang J.J., Wu Y.T., Song S.M., Association of polymorphisms in ace and cyp11b2 genes with antihypertensive effects of hydrochlorothiazide [in Chinese], Zhonghua Xin Xue Guan Bing Za Zhi, 33, pp. 595-598, (2005); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D., ACE and-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Turner S.T., Chapman A.B., Schwartz G.L., Boerwinkle E., Effects of endothelial nitric oxide synthase,α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide, Am J Hypertens, 16, pp. 834-839, (2003); Turner S.T., Schwartz G.L., Gene markers and antihypertensive therapy, Curr Hypertens Rep, 7, pp. 21-30, (2005); Mellen P.B., Herrington D.M., Pharmacogenomics of blood pressure response to antihypertensive treatment, J Hypertens, 23, pp. 1311-1325, (2005); Ohgaki R., Van I.S.C., Matsushita M., Hoekstra D., Kanazawa H., Organellar Nä/Hexchangers: Novel players in organelle pH regulation and their emerging functions, Biochemistry (Mosc), 50, pp. 443-450, (2011); Levy D., Larson M.G., Benjamin E.J., Newton-Cheh C., Wang T.J., Hwang S.J., Vasan R.S., Mitchell G.F., Framingham Heart Study 100k project: Genome-wide associations for blood pressure and arterial stiffness, BMC Med Genet, 8, SUPPL. 1, (2007); Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., Gut I., Lathrop M., Collins R., Slco1b1 variants and statin-induced myopathy: A genomewide study, N Engl J Med, 359, pp. 789-799, (2008); Lin R., Wang X., Zhou W., Fu W., Wang Y., Huang W., Jin L., Association of polymorphisms in the solute carrier organic anion transporter family member 1b1 gene with essential hypertension in the Uyghur population, Ann Hum Genet, 75, pp. 305-311, (2011); Dose A.C., Burnside B., A class III myosin expressed in the retina is a potential candidate for Bardet-Biedl syndrome, Genomics, 79, pp. 621-624, (2002); Waters A.M., Beales P.L., Bardet-biedl syndrome, GeneReviews, pp. 1993-2012; Kleinbaum L.A., Duggan C., Ferreira E., Coffey G.P., Buttice G., Burton F.H., Human chromosomal localization, tissue/tumor expression, and regulatory function of the Ets family gene Ehf, Biochem Biophys Res Commun, 264, pp. 119-126, (1999); De Moerlooze L., Williamson J., Liners F., Perret J., Parmentier M., Cloning and chromosomal mapping of the mouse and human genes encoding the orphan glucocorticoid-induced receptor (gpr83), Cytogenet Cell Genet, 90, pp. 146-150, (2000); Gill J.S., Zezulka A.V., Beevers D.G., Davies P., Relation between initial blood pressure and its fall with treatment, Lancet, 1, pp. 567-569, (1985); McCarthy M.I., Abecasis G.R., Cardon L.R., Goldstein D.B., Little J., Ioannidis J.P., Hirschhorn J.N., Genome-wide association studies for complex traits: Consensus, uncertainty and challenges, Nat Rev Genet, 9, pp. 356-369, (2008)","S.T. Turner; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, 200 First St SW, United States; email: turner.stephen@mayo.edu","","","","","","","","15244563","","HPRTD","22566498","English","Hypertension","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-84861510163"
"Fakhroo A.D.; Al Thani A.A.; Yassine H.M.","Fakhroo, Aisha D. (57221517884); Al Thani, Asmaa A. (26640267200); Yassine, Hadi M. (23098797900)","57221517884; 26640267200; 23098797900","Markers associated with covid-19 susceptibility, resistance, and severity","2021","Viruses","13","1","45","","","","29","10.3390/v13010045","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099332051&doi=10.3390%2fv13010045&partnerID=40&md5=6cb7c98c0cd2a18d83633477541d6f19","Research and Development Department, Barzan Holdings, Doha, 7178, Qatar; Biomedical Research Center, Qatar University, Doha, 2713, Qatar","Fakhroo A.D., Research and Development Department, Barzan Holdings, Doha, 7178, Qatar; Al Thani A.A., Biomedical Research Center, Qatar University, Doha, 2713, Qatar; Yassine H.M., Biomedical Research Center, Qatar University, Doha, 2713, Qatar","In December 2019, the latest member of the coronavirus family, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, leading to the outbreak of an unusual viral pneumonia known as coronavirus disease 2019 (COVID-19). COVID-19 was then declared as a pandemic in March 2020 by the World Health Organization (WHO). The initial mortality rate of COVID-19 declared by WHO was 2%; however, this rate has increased to 3.4% as of 3 March 2020. People of all ages can be infected with SARS-CoV-2, but those aged 60 or above and those with underlying medical conditions are more prone to develop severe symptoms that may lead to death. Patients with severe infection usually experience a hyper pro-inflammatory immune reaction (i.e., cytokine storm) causing acute respiratory distress syndrome (ARDS), which has been shown to be the leading cause of death in COVID-19 patients. However, the factors associated with COVID-19 susceptibility, resistance and severity remain poorly understood. In this review, we thoroughly explore the correlation between various host, viral and environmental markers, and SARS-CoV-2 in terms of susceptibility and severity. © 2020 by the authors. Li-censee MDPI, Basel, Switzerland.","COVID-19; Pathogenesis; Resistance; SARS; Susceptibility","Angiotensin-Converting Enzyme 2; Blood Group Antigens; COVID-19; Disease Outbreaks; Disease Resistance; Disease Susceptibility; Environment; Host-Pathogen Interactions; Humans; Metabolome; Microbiota; Middle Aged; Risk Factors; SARS-CoV-2; Severity of Illness Index; Vitamins; alpha tocopherol; angiotensin converting enzyme 2; angiotensin receptor antagonist; ascorbic acid; dipeptidyl carboxypeptidase inhibitor; environmental marker; furin; transmembrane protease serine 2; vitamin D; ACE2 protein, human; blood group antigen; vitamin; adult respiratory distress syndrome; blood group ABO system; CD4+ T lymphocyte; CD8+ T lymphocyte; coronavirus disease 2019; cytokine production; cytokine storm; diabetes mellitus; disease predisposition; disease resistance; disease severity; DNA methylation; environmental factor; gene mutation; genetic variability; HLA system; hypertension; immune deficiency; immune response; major histocompatibility complex; metabolome; microbiome; Middle East respiratory syndrome coronavirus; mortality rate; nonhuman; obesity; prevalence; Review; Severe acute respiratory syndrome coronavirus 2; single nucleotide polymorphism; temperature; virus load; virus transmission; environment; epidemic; genetics; host pathogen interaction; human; immunology; metabolism; microflora; middle aged; risk factor; severity of illness index","","alpha tocopherol, 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; ascorbic acid, 134-03-2, 15421-15-5, 50-81-7; furin, ; ACE2 protein, human, ; Angiotensin-Converting Enzyme 2, ; Blood Group Antigens, ; Vitamins, ","","","Barzan holdings and Qatar University, (QUHI-BRC-20/21-1)","Funding: This project was supported by funding by Barzan holdings and Qatar University grant number QUHI-BRC-20/21-1.","Coronavirus Disease (COVID-19) Situation Reports; Cui J., Li F., Shi Z.L., Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol, 17, pp. 181-192, (2019); Shereen M.A., Khan S., Kazmi A., Bashir N., Siddique R., COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses, J. Adv. Res, (2020); Ahn D.G., Shin H.J., Kim M.H., Lee S., Kim H.S., Myoung J., Kim B.T., Kim S.J., Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19), J. Microbiol. Biotechnol, 30, pp. 313-324, (2020); Li X., Geng M., Peng Y., Meng L., Lu S., Molecular immune pathogenesis and diagnosis of COVID-19, J. Pharm. Anal, 10, pp. 102-108, (2020); Tang D., Comish P., Kang R., The hallmarks of COVID-19 disease, PLoS Pathog, 16, (2020); Tai W., He L., Zhang X., Pu J., Voronin D., Jiang S., Zhou Y., Du L., Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell. Mol. Immunol, 17, pp. 613-620, (2020); Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G., Decroly E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antivir. Res, 176, (2020); Li M.Y., Li L., Zhang Y., Wang X.S., Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues, Infect. Dis. Poverty, 9, pp. 1-7, (2020); Sungnak W., Huang N., Becavin C., Berg M., Queen R., Litvinukova M., Talavera-Lopez C., Maatz H., Reichart D., Sampaziotis F., Et al., SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat. Med, 26, pp. 681-687, (2020); Azim A.A., Shabbir J., Khurshid Z., Zafar M.S., Ghabbani H.M., Dummer P.M.H., Clinical endodontic management during the COVID-19 pandemic: A literature review and clinical recommendations, Int. Endod. J, 53, pp. 1461-1471, (2020); Xiao F., Sun J., Xu Y., Li F., Huang X., Li H., Zhao J., Huang J., Zhao J., Infectious SARS-CoV-2 in feces of patient with severe COVID-19, Emerg. Infect. Dis, 26, (2020); Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med, 8, pp. 420-422, (2020); Yang X., Yu Y., Xu J., Shu H., Liu H., Wu Y., Zhang L., Yu Z., Fang M., Yu T., Et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study, Lancet Respir. Med, 8, pp. 475-481, (2020); Henderson L.A., Canna S.W., Schulert G.S., Volpi S., Lee P.Y., Kernan K.F., Caricchio R., Mahmud S., Hazen M.M., Halyabar O., Et al., On the alert for cytokine storm: Immunopathology in COVID-19, Arthritis Rheumatol, 72, pp. 1059-1063, (2020); Ye Q., Wang B., Mao J., The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19, J. Infect, 80, pp. 607-613, (2020); Sutton T.C., The pandemic threat of emerging H5 and H7 avian influenza viruses, Viruses, 10, (2018); Day M., Covid-19: Four fifths of cases are asymptomatic, China figures indicate, BMJ, 369, (2020); Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 181, pp. 281-292, (2020); Claas E.C., Osterhaus A.D., Van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., Webster R.G., Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus, Lancet, 351, pp. 472-477, (1998); Duffy S., Why are RNA virus mutation rates so damn high?, PLoS Biol, 16, (2018); Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W., Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Et al., Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the COVID-19 virus, Cell, 182, pp. 812-827, (2020); Zhao Z., Li H., Wu X., Zhong Y., Zhang K., Zhang Y.P., Boerwinkle E., Fu Y.X., Moderate mutation rate in the SARS coronavirus genome and its implications, BMC Evol. Biol, 4, (2004); Becerra-Flores M., Cardozo T., SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate, Int. J. Clin. Pract, 74, (2020); Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L., Et al., Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target, BioRxiv, (2020); Pachetti M., Marini B., Benedetti F., Giudici F., Mauro E., Storici P., Masciovecchio C., Angeletti S., Ciccozzi M., Gallo R.C., Et al., Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant, J. Transl. Med, 18, pp. 1-9, (2020); Benvenuto D., Angeletti S., Giovanetti M., Bianchi M., Pascarella S., Cauda R., Ciccozzi M., Cassone A., Evolutionary analysis of SARS-CoV-2: How mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy, J. Infect, 81, pp. e24-e27, (2020); Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet, 395, pp. 507-513, (2020); Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet, 395, pp. 1054-1062, (2020); Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., Et al., Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis, Eur. Respir. J, 55, (2020); Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L., Holden K.A., Read J.M., Dondelinger F., Carson G., Et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study, BMJ, 369, (2020); Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., Et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature, 584, pp. 430-436, (2020); Tay M.Z., Poh C.M., Renia L., MacAry P.A., Ng L.F., The trinity of COVID-19: Immunity, inflammation and intervention, Nat. Rev. Immunol, 20, pp. 1-12, (2020); Kulcsar K.A., Coleman C.M., Beck S.E., Frieman M.B., Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, JCI Insight, 4, (2019); Yang J.K., Lin S.S., Ji X.J., Guo L.M., Binding of SARS coronavirus to its receptor damages islets and causes acute Diabetes, Acta Diabetol, 47, pp. 193-199, (2010); Capua I., Mercalli A., Pizzuto M.S., Romero-Tejeda A., Kasloff S., De Battisti C., Bonfante F., Patrono L.V., Vicenzi E., Zappulli V., Et al., Influenza A viruses grow in human pancreatic cells and cause pancreatitis and diabetes in an animal model, J. Virol, 87, pp. 597-610, (2013); Hussain A., Bhowmik B., do Vale Moreira N.C., COVID-19 and diabetes: Knowledge in progress, Diabetes Res. Clin. Pract, 162, (2020); Zhou J., Tan J., Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China, Metabolism, 107, (2020); Petrakis D., Margina D., Tsarouhas K., Tekos F., Stan M., Nikitovic D., Kouretas D., Spandidos D.A., Tsatsakis A., Obesity-a risk factor for increased COVID-19 prevalence, severity and lethality, Mol. Med. Rep, 22, pp. 9-19, (2020); Hernandez-Garduno E., Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study, Obes. Res. Clin. Pract, 14, pp. 375-379, (2020); Liu M., He P., Liu H.G., Wang X.J., Li F.J., Chen S., Lin J., Chen P., Liu J.H., Li C.H., Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia, Zhonghua Jie He He Hu Xi Za Zhi= Zhonghua Jiehe He Huxi Zazhi= Chin. J. Tuberc. Respir. Dis, 43, (2020); Ignacio R.M., Kim C.S., Kim S.K., Immunological Profiling of Obesity, J. Lifestyle Med, 4, pp. 1-7, (2014); Evans A.C., Papachristou G.I., Whitcomb D.C., Obesity and the risk of severe acute pancreatitis, Minerva Gastroenterol. Dietol, 56, pp. 169-179, (2010); Pinto B.G., Oliveira A.E., Singh Y., Jimenez L., Goncalves A.N.A., Ogava R.L., Creighton R., Peron J.P.S., Nakaya H.I., ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19, MedRxiv, (2020); South A.M., Brady T.M., Flynn J.T., ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) receptor blocker use during the pandemic: The pediatric perspective, Hypertension, 76, pp. 16-22, (2020); Debnath M., Banerjee M., Berk M., Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes, FASEB J, 34, pp. 8787-8795, (2020); Giudicessi J.R., Roden D.M., Wilde A.A., Ackerman M.J., Genetic susceptibility for COVID-19–associated sudden cardiac death in African Americans, Heart Rhythm, 17, pp. 1487-1492, (2020); Ellinghaus D., Degenhardt F., Bujanda L., Buti M., Albillos A., Invernizzi P., Fernandez J., Prati D., Baselli G., Asselta R., Et al., The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis, MedRxiv, (2020); Stawiski E.W., Diwanji D., Suryamohan K., Gupta R., Fellouse F.A., Sathirapongsasuti F., Liu J., Jiang Y.P., Ratan A., Mis M., Et al., Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility, BioRxiv, (2020); Sawalha A.H., Zhao M., Coit P., Lu Q., Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients, Clin. Immunol, 215, (2020); Tabish M., Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: A potential therapeutic approach using SSOs, Clin. Sci, 134, pp. 1143-1150, (2020); Nguyen A., David J.K., Maden S.K., Wood M.A., Weeder B.R., Nellore A., Thompson R.F., Human leukocyte antigen susceptibility map for SARS-CoV-2, J. Virol, (2020); Klaassen K., Stankovic B., Zukic B., Kotur N., Gasic V., Pavlovic S., Stojiljkovic M., Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection, BioRxiv, (2020); Goker H., Aladag Karakulak E., Demiroglu H., Ayaz Ceylan C.M., Buyukasik Y., Inkaya A., The effects of blood group types on the risk of COVID-19 infection and its clinical outcome, Turk. J. Med. Sci, 50, pp. 679-683, (2020); Wu Y., Feng Z., Li P., Yu Q., Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19, Clin. Chim. Acta, 509, pp. 220-223, (2020); Guillon P., Clement M., Sebille V., Rivain J.G., Chou C.F., Ruvoen-Clouet N., Le Pendu J., Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies, Glycobiology, 18, pp. 1085-1093, (2008); Dai X., ABO blood group predisposes to COVID-19 severity and cardiovascular diseases, Eur. J. Prev. Cardiol, (2020); Dhar D., Mohanty A., Gut microbiota and Covid-19-possible link and implications, Virus Res, 285, (2020); Xiao F., Tang M., Zheng X., Liu Y., Li X., Shan H., Evidence for gastrointestinal infection of SARS-CoV-2, Gastroenterology, 158, pp. 1831-1833, (2020); Kalantar-Zadeh K., Ward S.A., Kalantar-Zadeh K., El-Omar E.M., Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles, ACS Nano, 14, pp. 5179-5182, (2020); Dickson R.P., Singer B.H., Newstead M.W., Falkowski N.R., Erb-Downward J.R., Standiford T.J., Huffnagle G.B., Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome, Nat. Microbiol, 1, pp. 1-9, (2016); Fagundes C.T., Amaral F.A., Vieira A.T., Soares A.C., Pinho V., Nicoli J.R., Vieira L.Q., Teixeira M.M., Souza D.G., Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice, J. Immunol, 188, pp. 1411-1420, (2012); Salazar N., Valdes-Varela L., Gonzalez S., Gueimonde M., de los Reyes-Gavilan C.G., Nutrition and the gut microbiome in the elderly, Gut Microbes, 8, pp. 82-97, (2017); Dimitri-Pinheiro S., Soares R., Barata P., The Microbiome of the Nose—Friend or Foe?, Allergy Rhinol, 11, (2020); Ichinohe T., Pang I.K., Kumamoto Y., Peaper D.R., Ho J.H., Murray T.S., Iwasaki A., Microbiota regulates immune defense against respiratory tract influenza A virus infection, Proc. Natl. Acad. Sci. USA, 108, pp. 5354-5359, (2011); Lehtinen M.J., Hibberd A.A., Mannikko S., Yeung N., Kauko T., Forssten S., Lehtoranta L., Lahtinen S.J., Stahl B., Lyra A., Et al., Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge, Sci. Rep, 8, pp. 1-12, (2018); Ebrahimi K.H., SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection, FEBS Lett, 594, (2020); Shen B., Yi X., Sun Y., Bi X., Du J., Zhang C., Quan S., Zhang F., Sun R., Qian L., Et al., Proteomic and metabolomic characterization of COVID-19 patient sera, Cell, 182, pp. 59-72, (2020); Vanherwegen A.S., Gysemans C., Mathieu C., Regulation of immune function by vitamin D and its use in diseases of immunity, Endocrinol. Metab. Clin, 46, pp. 1061-1094, (2017); Zhang Y., Leung D.Y., Richers B.N., Liu Y., Remigio L.K., Riches D.W., Goleva E., Vitamin D inhibits monocyte/macrophage pro-inflammatory cytokine production by targeting MAPK phosphatase-1, J. Immunol, 188, pp. 2127-2135, (2012); Laird E., Rhodes J., Kenny R.A., Vitamin D and inflammation: Potential implications for severity of COVID-19, Ir. Med. J, 113, (2020); Michele C.A., Angel B., Valeria L., Teresa M., Giuseppe C., Giovanni M., Pasquale D.L., Michele D.P., Ernestina P., Mario B., Vitamin supplements in the Era of SARS-Cov2 pandemic, GSC Biol. Pharm. Sci, 11, pp. 007-019, (2020); White L.A., Freeman C.Y., Forrester B.D., Chappell W.A., In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses, J. Clin. Microbiol, 24, pp. 527-531, (1986); Kim H., Jang M., Kim Y., Choi J., Jeon J., Kim J., Hwang Y.-i., Kang J.S., Lee W.J., Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection, J. Pharm. Pharmacol, 68, pp. 406-420, (2016); Gorton H.C., Jarvis K., The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections, J. Manip. Physiol. Ther, 22, pp. 530-533, (1999); Allard J.P., Aghdassi E., Chau J., Tam C., Kovacs C.M., Salit I.E., Walmsley S.L., Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects, Aids, 12, pp. 1653-1659, (1998); Yaqinuddin A., Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities, Med. Hypotheses, 144, (2020); Pinto D., Park Y.J., Beltramello M., Walls A.C., Tortorici M.A., Bianchi S., Jaconi S., Culap K., Zatta F., de Marco A., Et al., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, pp. 290-295, (2020); Yuan M., Wu N.C., Zhu X., Lee C.C.D., So R.T., Lv H., Mok C.K., Wilson I.A., A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science, 368, pp. 630-633, (2020); Dijkstra J.M., Hashimoto K., Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population, F1000Research, 9, (2020); Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T., Hu J., Et al., Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat. Commun, 11, (2020); Munayco C.V., Tariq A., Rothenberg R., Soto-Cabezas G.G., Reyes M.F., Valle A., Rojas-Mezarina L., Cabezas C., Loayza M., Chowell G., Et al., Early transmission dynamics of COVID-19 in a southern hemisphere setting: Lima-Peru: February 29th–March 30th, 2020, Infect. Dis. Model, 5, pp. 338-345, (2020); Dowd J.B., Andriano L., Brazel D.M., Rotondi V., Block P., Ding X., Liu Y., Mills M.C., Demographic science aids in understanding the spread and fatality rates of COVID-19, Proc. Natl. Acad. Sci. USA, 117, pp. 9696-9698, (2020); Monto A.S., DeJonge P., Callear A.P., Bazzi L.A., Capriola S., Malosh R.E., Martin E.T., Petrie J.G., Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan, J. Infect. Dis, 222, pp. 9-16, (2020); Ujiie M., Tsuzuki S., Ohmagari N., Effect of temperature on the infectivity of COVID-19, Int. J. Infect. Dis, 95, pp. 301-303, (2020); Livadiotis G., Statistical analysis of the impact of environmental temperature on the exponential growth rate of cases infected by COVID-19, PLoS ONE, 15, (2020); Wang J., Tang K., Feng K., Lv W., High temperature and high humidity reduce the transmission of COVID-19, SSRN, (2020); Zhu Y., Xie J., Association between ambient temperature and COVID-19 infection in 122 cities from China, Sci. Total Environ, 724, (2020); Aboubakr H.A., Sharafeldin T.A., Goyal S.M., Stability of SARS-CoV-2 and other coronaviruses in the environment and on common touch surfaces and the influence of climatic conditions: A review, Transbound. Emerg. Dis, (2020); Dehbandi R., Zazouli M.A., Stability of SARS-CoV-2 in different environmental conditions, Lancet Microbe, 1, (2020); Akram M.Z., Inanimate surfaces as potential source of 2019-nCoV spread and their disinfection with biocidal agents, Virus Dis, 31, pp. 94-96, (2020); Khurshid Z., Asiri F.Y.I., Al Wadaani H., Human saliva: Non-invasive fluid for detecting novel coronavirus (2019-nCoV), Int. J. Environ. Res. Public Health, 17, (2020)","H.M. Yassine; Biomedical Research Center, Qatar University, Doha, 2713, Qatar; email: hyassine@qu.edu.qa","","MDPI AG","","","","","","19994915","","","33396584","English","Viruses","Review","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85099332051"
"Rossi G.P.; Ceolotto G.; Caroccia B.; Lenzini L.","Rossi, Gian Paolo (7402913893); Ceolotto, Giulio (6603785731); Caroccia, Brasilina (25926235800); Lenzini, Livia (8512433500)","7402913893; 6603785731; 25926235800; 8512433500","Genetic screening in arterial hypertension","2017","Nature Reviews Endocrinology","13","5","","289","298","9","31","10.1038/nrendo.2016.196","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85008319007&doi=10.1038%2fnrendo.2016.196&partnerID=40&md5=ab64f91c9abd7826f8598ce804fcf0f2","Clinica Dell'Ipertensione Arteriosa, Department of Medicine (DIMED), University of Padua, Via Giustiniani 2, Padua, 35126, Italy","Rossi G.P., Clinica Dell'Ipertensione Arteriosa, Department of Medicine (DIMED), University of Padua, Via Giustiniani 2, Padua, 35126, Italy; Ceolotto G., Clinica Dell'Ipertensione Arteriosa, Department of Medicine (DIMED), University of Padua, Via Giustiniani 2, Padua, 35126, Italy; Caroccia B., Clinica Dell'Ipertensione Arteriosa, Department of Medicine (DIMED), University of Padua, Via Giustiniani 2, Padua, 35126, Italy; Lenzini L., Clinica Dell'Ipertensione Arteriosa, Department of Medicine (DIMED), University of Padua, Via Giustiniani 2, Padua, 35126, Italy","Studies involving adoptive families and twins have demonstrated the genetic basis of hypertension and shown that genetic factors account for about 40% of the variance in blood pressure among individuals. Arterial hypertension is genetically complex: multiple genes influence the blood pressure phenotype through allelic effects from single genes and gene-gene interactions. Moreover, environmental factors also modify the blood pressure phenotype. This complexity explains why the identification of the underlying genes has not been as successful in hypertension as in other diseases (such as type 1 and type 2 diabetes mellitus). The identification of the genetic determinants of hypertension has been most successful in endocrine forms of hypertension, which have well-defined phenotypes that permit a precise patient stratification into homogeneous cohorts. A promising area for the application of genetic testing to personalized medicine is the prediction of responses and adverse reactions to antihypertensive drugs. The identification of genetic markers of drug response will enable the design of randomized controlled trials in much smaller series of patients than is currently possible, decreasing the costs and times from drug design to clinical use and ultimately providing patients and doctors with a larger number of tools to combat hypertension, the most important risk factor for cardiovascular disease. This Review focuses on the rapidly developing field of genetic testing in patients with arterial hypertension. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.","","Animals; Cardiovascular Diseases; Genetic Testing; Humans; Hypertension; angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dexamethasone; dipeptidyl carboxypeptidase inhibitor; diuretic agent; placebo; apparent mineralocorticoid excess syndrome; Bartter syndrome; blood pressure regulation; blood pressure variability; congenital adrenal hyperplasia; cost control; Cushing syndrome; drug design; drug efficacy; drug safety; Geller syndrome; gene interaction; genetic predisposition; genetic screening; genetic variability; genome-wide association study; genotype environment interaction; genotype phenotype correlation; germline mutation; Gitelman syndrome; Gordon syndrome; heart output; human; hyperparathyroidism; hypertension; Liddle syndrome; meta analysis (topic); molecular pathology; paraganglioma; personalized medicine; pharmacogenetics; phase 3 clinical trial (topic); pheochromocytoma; primary hyperaldosteronism; quantitative trait locus mapping; randomized controlled trial (topic); renin angiotensin aldosterone system; Review; single nucleotide polymorphism; somatic mutation; treatment response; vascular resistance; whole exome sequencing; animal; Cardiovascular Diseases; genetic screening; genetics; hypertension; procedures; trends","","dexamethasone, 50-02-2","","","","","Kearney P.M., Et al., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Perkovic V., Huxley R., Wu Y., Prabhakaran D., MacMahon S., The burden of blood pressure-related disease: A neglected priority for global health, Hypertension, 50, pp. 991-997, (2007); Corvol P., Jeunemaitre X., Charru A., Soubrier F., Can the genetic factors influence the treatment of systemic hypertension? the case of the renin-angiotensin-aldosterone system, Am. J. Cardiol., 70, pp. 14D-20D, (1992); Lawes C.M., Vander Hoorn S., Rodgers A., Global burden of blood-pressure-related disease, 2001, Lancet, 371, pp. 1513-1518, (2008); Padmanabhan S., Newton-Cheh C., Dominiczak A.F., Genetic basis of blood pressure and hypertension, Trends Genet., 28, pp. 397-408, (2012); Havlik R.J., Et al., Blood pressure aggregation in families, Am. J. Epidemiol., 110, pp. 304-312, (1979); Stocks P.A., A biometric investigation of twins and their brothers and sisters, Ann. Eugen., 4, (1930); Feinleib M., Et al., The NHLBI twin study of cardiovascular disease risk factors: Methodology and summary of results, Am. J. Epidemiol., 106, pp. 284-285, (1977); Annest J.L., Sing C.F., Biron P., Mongeau J.G., Familial aggregation of blood pressure and weight in adoptive families. II. Estimation of the relative contributions of genetic and common environmental factors to blood pressure correlations between family members, Am. J. Epidemiol., 110, pp. 492-503, (1979); Biron P., Normal blood pressure in offspring of persons with essential hypertension, Can. Med. Assoc. J., 119, pp. 694-696, (1978); Williams C.J., Christian J.C., Norton J.A., TWINAN90: A FORTRAN program for conducting ANOVA-based and likelihood-based analyses of twin data, Comput. Methods Programs Biomed., 38, pp. 167-176, (1992); Rossi G.P., Et al., Genetic determinants of plasma ACE and renin activity in young normotensive twins, J. Hypertens., 17, pp. 647-655, (1999); Snieder H., Harshfield G.A., Treiber F.A., Heritability of blood pressure and hemodynamics in African- and European-American youth, Hypertension, 41, pp. 1196-1201, (2003); Vinck W.J., Fagard R.H., Loos R., Vlietinck R., The impact of genetic and environmental influences on blood pressure variance across age-groups, J. Hypertens., 19, pp. 1007-1013, (2001); De Faire U., Iselius L., Lundman T., Biological and cultural determinants of blood pressure, Hypertension, 4, pp. 725-728, (1982); Munroe P.B., Barnes M.R., Caulfield M.J., Advances in blood pressure genomics, Circ. Res., 112, pp. 1365-1379, (2013); Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature, 447, pp. 661-678, (2007); Org E., Et al., Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations, Hum. Mol. Genet., 18, pp. 2288-2296, (2009); Paz M.A., Et al., Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement, Medicine (Baltimore), 95, (2016); Laragh J.H., Renin system analysis defines the special value of combination antihypertensive therapy using an antirenin agent (CEI) with a long-acting calcium channel blocker (CCB), Am. J. Hypertens., 11, pp. 170S-174S, (1998); Cusi D., Et al., Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Packer M., Et al., Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), Circulation, 106, pp. 920-926, (2002); Coats A.J., Omapatrilat - The story of Overture and Octave, Int. J. Cardiol., 86, pp. 1-4, (2002); Mukae S., Et al., Bradykinin B2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough, Hypertension, 36, pp. 127-131, (2000); Weinshilboum R., Inheritance and drug response, N. Engl. J. Med., 348, pp. 529-537, (2003); Rossi G.P., Seccia T.M., Pessina A.C., Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension, Crit. Rev. Clin. Lab. Sci., 44, pp. 1-85, (2007); Neumann H.P., Et al., New genetic causes of pheochromocytoma: Current concepts and the clinical relevance, Keio J. Med., 54, pp. 15-21, (2005); Lenders J.W., Et al., Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline, J. Clin. Endocrinol. Metab., 99, pp. 1915-1942, (2014); Fliedner S.M., Lehnert H., Pacak K., Metastatic paraganglioma, Semin. Oncol., 37, pp. 627-637, (2010); Van Der Mey A.G., Maaswinkel-Mooy P.D., Cornelisse C.J., Schmidt P.H., Van De Kamp J.J., Genomic imprinting in hereditary glomus tumours: Evidence for new genetic theory, Lancet, 2, pp. 1291-1294, (1989); O'Toole S.M., Denes J., Robledo M., Stratakis C.A., Korbonits M., The association of pituitary adenomas and phaeochromocytomas or paragangliomas, Endocr. Relat. Cancer, 22, pp. T105-T122, (2015); Hansson J.H., Et al., A de novo missense mutation of the β subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity, Proc. Natl Acad. Sci. USA, 92, pp. 11495-11499, (1995); Lifton R.P., Molecular genetics of human blood pressure variation, Science, 272, pp. 676-680, (1996); Schumacher F.R., Et al., Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia, EMBO Mol. Med., 7, pp. 1285-1306, (2015); O'Shaughnessy K.M., Gordon syndrome: A continuing story, Pediatr. Nephrol., 30, pp. 1903-1908, (2015); Wilson R.C., Et al., A genetic defect resulting in mild low-renin hypertension, Proc. Natl Acad. Sci. USA, 95, pp. 10200-10205, (1998); Dave-Sharma S., Et al., Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess, J. Clin. Endocrinol. Metab., 83, pp. 2244-2254, (1998); Geller D.S., Et al., A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism, J. Clin. Endocrinol. Metab., 93, pp. 3117-3123, (2008); Pacak K., Koch C.A., Eisenhofer G., Current approaches and new advances in endocrine hypertension, Trends Endocrinol. Metab., 13, pp. 96-97, (2002); Teo A.E., Et al., Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations, N. Engl. J. Med., 373, pp. 1429-1436, (2015); Murtha T.D., Carling T., Scholl U.I., Pregnancy, primary aldosteronism, and somatic CTNNB1 mutations, N. Engl. J. Med., 374, pp. 1492-1493, (2016); Beuschlein F., Et al., Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome, N. Engl. J. Med., 370, pp. 1019-1028, (2014); Goh G., Et al., Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors, Nat. Genet., 46, pp. 613-617, (2014); Sato Y., Et al., Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome, Science, 344, pp. 917-920, (2014); Cao Y., Et al., Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome, Science, 344, pp. 913-917, (2014); Assie G., Et al., ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome, N. Engl. J. Med., 369, pp. 2105-2114, (2013); Espiard S., Et al., ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: Clinical and functional consequences, J. Clin. Endocrinol. Metab., 100, pp. E926-E935, (2015); Gagliardi L., Et al., ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia, J. Clin. Endocrinol. Metab., 99, pp. E1784-E1792, (2014); Alencar G.A., Et al., ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia, J. Clin. Endocrinol. Metab., 99, pp. E1501-E1509, (2014); Lodish M., Stratakis C.A., A genetic and molecular update on adrenocortical causes of Cushing syndrome, Nat. Rev. Endocrinol., 12, pp. 255-262, (2016); Carney J.A., Lyssikatos C., Lodish M.B., Stratakis C.A., Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes, Hum. Pathol., 46, pp. 40-49, (2015); Faillot S., Assie G., The genomics of adrenocortical tumors, Eur. J. Endocrinol., 174, pp. R249-R265, (2016); Rossi G.P., A comprehensive review of the clinical aspects of primary aldosteronism, Nat. Rev. Endocrinol., 7, pp. 485-495, (2011); Sutherland D.J., Ruse J.L., Laidlaw J.C., Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone, Can. Med. Assoc. J., 95, pp. 1109-1119, (1966); Salti I.S., Stiefel M., Ruse J.L., Laidlaw J.C., Non-tumorous ""primary"" aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism), Can. Med. Assoc. J., 101, pp. 1-10, (1969); Lifton R.P., Et al., Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase, Nat. Genet., 2, pp. 66-74, (1992); Gioco F., Seccia T.M., Gomez-Sanchez E.P., Rossi G.P., Gomez-Sanchez C.E., Adrenal histopathology in primary aldosteronism: Is it time for a change?, Hypertension, 66, pp. 724-730, (2015); Mulatero P., Et al., Prevalence and characteristics of familial hyperaldosteronism: The PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms), Hypertension, 58, pp. 797-803, (2011); Torpy D.J., Et al., Familial hyperaldosteronism type II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene, J. Clin. Endocrinol. Metab., 83, pp. 3214-3218, (1998); Carss K.J., Stowasser M., Gordon R.D., O'Shaughnessy K.M., Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II, J. Hum. Hypertens., 25, pp. 560-564, (2011); Choi M., Et al., K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension, Science, 331, pp. 768-772, (2011); Boulkroun S., Et al., Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism, Hypertension, 59, pp. 592-598, (2012); Scholl U.I., Et al., Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5, Proc. Natl Acad. Sci. USA, 109, pp. 2533-2538, (2012); Charmandari E., Et al., A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension, J. Clin. Endocrinol. Metab., 97, pp. E1532-E1539, (2012); Monticone S., Et al., A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue, J. Clin Endocrinol. Metab., 100, pp. E114-E118, (2015); Sertedaki A., Et al., Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion, Clin. Endocrinol., 85, pp. 845-851, (2016); Rossi G.P., Gioco F., Fassina A., Gomez-Sanchez C.E., Normoaldosteronemic aldosterone-producing adenoma: Immunochemical characterization and diagnostic implications, J. Hypertens., 33, pp. 2546-2549, (2015); Azizan E.A., Et al., Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension, Nat. Genet., 45, pp. 1055-1060, (2013); Scholl U.I., Et al., Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism, Nat. Genet., 45, pp. 1050-1054, (2013); Scholl U.I., Et al., Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism, ELife, 4, (2015); Lenzini L., Rossi G.P., The molecular basis of primary aldosteronism: From chimeric gene to channelopathy, Curr. Opin. Pharmacol., 21, pp. 35-42, (2015); Zennaro M.C., Jeunemaitre X., SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism, Ann. Endocrinol. (Paris), 77, pp. 214-219, (2016); Maniero C., Et al., Primary hyperparathyroidism with concurrent primary aldosteronism, Hypertension, 58, pp. 341-346, (2011); Maniero C., Et al., Mild hyperparathyroidism: A novel surgically correctable feature of primary aldosteronism, J. Hypertens., 30, pp. 390-395, (2012); Rossi G.P., Et al., Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma, Hypertension, 60, pp. 431-436, (2012); Mazzocchi G., Aragona F., Malendowicz L.K., Nussdorfer G.G., PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells, Am. J. Physiol. Endocrinol. Metab., 280, pp. E209-E213, (2001); Widimsky J., Et al., Vascular disturbances in primary aldosteronism: Clinical evidence, Kidney Blood Press. Res., 35, pp. 529-533, (2012); Mackenzie-Feder J., Sirrs S., Anderson D., Sharif J., Khan A., Primary hyperparathyroidism: An overview, Int. J. Endocrinol., 2011, (2011); Alevizaki M., Saltiki K., Primary hyperparathyroidism in MEN2 syndromes, Recent Results Cancer Res., 204, pp. 179-186, (2015); Mayr B., Schnabel D., Dorr H.G., Schofl C., Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: Current treatment concepts, Eur. J. Endocrinol., 174, pp. R189-R208, (2016); Murphy H., Et al., Neonatal severe hyperparathyroidism caused by homozygous mutation in CASR: A rare cause of life-threatening hypercalcemia, Eur. J. Med. Genet., 59, pp. 227-231, (2016); Pichardo-Lowden A.R., Manni A., Saunders B.D., Baker M.J., Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: Implications for management and age-appropriate testing of relatives at risk, Endocr. Pract., 17, pp. 602-609, (2011); Costa-Guda J., Arnold A., Genetic and epigenetic changes in sporadic endocrine tumors: Parathyroid tumors, Mol. Cell. Endocrinol., 386, pp. 46-54, (2014); Koulouridis E., Koulouridis I., Molecular pathophysiology of Bartter's and Gitelman's syndromes, World, J. Pediatr., 11, pp. 113-125, (2015); Simon D.B., Et al., Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2, Nat. Genet., 13, pp. 183-188, (1996); Ji W., Et al., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat. Genet., 40, pp. 592-599, (2008)","G.P. Rossi; Clinica Dell'Ipertensione Arteriosa, Department of Medicine (DIMED), University of Padua, Padua, Via Giustiniani 2, 35126, Italy; email: gianpaolo.rossi@unipd.it","","Nature Publishing Group","","","","","","17595029","","","28059156","English","Nat. Rev. Endocrionol.","Review","Final","","Scopus","2-s2.0-85008319007"
"Svetkey L.P.; Harris E.L.; Martin E.; Vollmer W.M.; Meltesen G.T.; Ricchiuti V.; Williams G.; Appel L.J.; Bray G.A.; Moore T.J.; Winn M.P.; Conlin P.R.","Svetkey, Laura P. (7005517676); Harris, Emily L. (7403257068); Martin, Eden (7404092528); Vollmer, William M. (57189801181); Meltesen, Gayle T. (36624018800); Ricchiuti, Vincent (6701874793); Williams, Gordon (7406079866); Appel, Lawrence J. (7102658830); Bray, George A. (35374693900); Moore, Thomas J. (35462449500); Winn, Michelle P. (7005138679); Conlin, Paul R. (7005696632)","7005517676; 7403257068; 7404092528; 57189801181; 36624018800; 6701874793; 7406079866; 7102658830; 35374693900; 35462449500; 7005138679; 7005696632","Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system","2011","American Journal of Hypertension","24","2","","209","217","8","28","10.1038/ajh.2010.223","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78751632673&doi=10.1038%2fajh.2010.223&partnerID=40&md5=78ab1626ffa1ab1fdf2629c088351d7a","Duke University Medical Center, Durham, NC, United States; Kaiser Permanente Center for Health Research, Portland, OR, United States; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Johns Hopkins University, Baltimore, MD, United States; Pennington Biomedical Research Center, Baton Rouge, LA, United States; Boston University Medical Center, Boston, MA, United States; National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, United States; University of Miami, Miami, FL, United States","Svetkey L.P., Duke University Medical Center, Durham, NC, United States; Harris E.L., Kaiser Permanente Center for Health Research, Portland, OR, United States, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, United States; Martin E., Duke University Medical Center, Durham, NC, United States, University of Miami, Miami, FL, United States; Vollmer W.M., Kaiser Permanente Center for Health Research, Portland, OR, United States; Meltesen G.T., Kaiser Permanente Center for Health Research, Portland, OR, United States; Ricchiuti V., Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Williams G., Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Appel L.J., Johns Hopkins University, Baltimore, MD, United States; Bray G.A., Pennington Biomedical Research Center, Baton Rouge, LA, United States; Moore T.J., Boston University Medical Center, Boston, MA, United States; Winn M.P., Duke University Medical Center, Durham, NC, United States; Conlin P.R., Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States","Background Essential hypertension results from the interaction of several genetic and environmental factors. Identification of genetic factors that modulate blood pressure (BP) response to interventions can lead to improved strategies for prevention and control. The purpose of this study was to identify genes that modulate BP response to dietary interventions.MethodsWe used data and samples collected in two randomized feeding studies to determine the extent to which genetic architecture is associated with the effect on BP of sodium intake and the Dietary Approaches to Stop Hypertension (DASH) dietary pattern. Participants in both trials were adults with above-optimal BP or unmedicated stage 1 hypertension. Genomic DNA was typed for several candidate genes.ResultsThe effect of sodium intake on BP differed by genotype at the angiotensinogen, Β2-adrenergic receptor, and kallikrein loci. The effect of DASH dietary pattern on BP differed by genotype at the Β2-adrenergic receptor locus.ConclusionsThese findings have implications for understanding the mechanism(s) through which diet affects BP, the heterogeneity of these effects, and the extent to which dietary interventions can modulate genetic predisposition. © 2011 American Journal of Hypertension, Ltd.","blood pressure; DASH; diet; genetics; hypertension; sodium","Adrenergic Fibers; Adult; Angiotensinogen; Blood Pressure; Diet, Sodium-Restricted; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hypertension; Kallikreins; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Receptors, Adrenergic, beta-2; Renin-Angiotensin System; Risk Assessment; Risk Factors; Sodium, Dietary; Sympathetic Nervous System; Treatment Outcome; adducin; aldosterone synthase; angiotensinogen; beta 2 adrenergic receptor; kallikrein; renin; adrenergic system; adult; article; blood pressure regulation; dietary intake; DNA fingerprinting; female; gene identification; gene locus; genetic predisposition; genotype; human; hypertension; major clinical study; male; multicenter study (topic); priority journal; randomized controlled trial (topic); renin angiotensin aldosterone system; single nucleotide polymorphism; sodium intake","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; kallikrein, 8006-48-2, 9001-01-8; renin, 61506-93-2, 9015-94-5; ADRB2 protein, human, ; Angiotensinogen, 11002-13-4; Kallikreins, 3.4.21.-; Receptors, Adrenergic, beta-2, ; Sodium, Dietary, ","","","National Institutes of Health, NIH, (K24 DK63214, R01 HL77234, R01HL57114); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK074748)","acknowledgments:This study was supported by National Institutes of Health grants R01HL57114, R01 HL77234, and K24 DK63214.","Hunt S.C., Cook N.R., Oberman A., Cutler J.A., Hennekens C.H., Allender P.S., Walker W.G., Whelton P.K., Williams R.R., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II, Hypertension, 32, pp. 393-401, (1998); Bloem L.J., Foroud T.M., Ambrosius W.T., Hanna M.P., Tewksbury D.A., Pratt J.H., Association of the angiotensinogen gene to serum angiotensinogen in blacks and whites, Hypertension, 29, pp. 1078-1082, (1997); Rotimi C., Cooper R., Ogunbiyi O., Morrison L., Ladipo M., Tewksbury D., Ward R., Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians, Circulation, 95, pp. 2348-2350, (1997); Lifton R.P., Jeunemaitre X., Finding genes that cause human hypertension, J Hypertens, 11, pp. 231-236, (1993); Borecki I.B., Province M.A., Ludwig E.H., Ellison R.C., Folsom A.R., Heiss G., Lalouel J.M., Higgins M., Rao D.C., Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study, Ann Epidemiol, 7, pp. 13-21, (1997); Ward K., Hata A., Jeunemaitre X., Helin C., Nelson L., Namikawa C., Farrington P.F., Ogasawara M., Suzumori K., Tomoda S., A molecular variant of angiotensinogen associated with preeclampsia, Nat Genet, 4, pp. 59-61, (1993); Svetkey L.P., Timmons P.Z., Emovon O., Anderson N.B., Preis L., Chen Y.T., Association of hypertension with β2- and α2c10-adrenergic receptor genotype, Hypertension, 27, pp. 1210-1215, (1996); Schorr U., Blaschke K., Beige J., Distler A., Sharma A.M., Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians, J Hypertens, 17, pp. 475-479, (1999); Svetkey L.P., Chen Y.T., McKeown S.P., Preis L., Wilson A.F., Preliminary evidence of linkage of salt sensitivity in black Americans at the β2-adrenergic receptor locus, Hypertension, 29, pp. 918-922, (1997); Svetkey L.P., Moore T.J., Simons-Morton D.G., Appel L.J., Bray G.A., Sacks F.M., Ard J.D., Mortensen R.M., Mitchell S.R., Conlin P.R., Kesari M., DASH collaborative research group. Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study, J Hypertens, 19, pp. 1949-1956, (2001); Appel L.J., Moore T.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Sacks F.M., Bray G.A., Vogt T.M., Cutler J.A., Windhauser M.M., Lin P.H., Karanja N., A clinical trial of the effects of dietary patterns on blood pressure, N Engl J Med, 336, pp. 1117-1124, (1997); Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D., Obarzanek E., Conlin P.R., Miller III E.R., Simons-Morton D.G., Karanja N., Lin P.-H., Aickin M., Most-Windhauser M.M., Moore T.J., Proschan M.A., Cutler J.A., Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (dash) diet, New England Journal of Medicine, 344, 1, pp. 3-10, (2001); Sacks F.M., Obarzanek E., Windhauser M.M., Svetkey L.P., Vollmer W.M., McCullough M., Karanja N., Lin P.H., Steele P., Proschan M.A., Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure, Ann Epidemiol, 5, pp. 108-118, (1995); Vogt T.M., Appel L.J., Obarzanek E., Moore T.J., Vollmer W.M., Svetkey L.P., Sacks F.M., Bray G.A., Cutler J.A., Windhauser M.M., Lin P.-H., Karanja N.M., Dietary Approaches to Stop Hypertension: Rationale, design, and methods, Journal of the American Dietetic Association, 99, 8 SUPPL., (1999); Craddick S.R., Elmer P.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Swain M.C., The DASH diet and blood pressure, Curr Atheroscler Rep, 5, pp. 484-491, (2003); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., JAMA, 289, pp. 2560-2572, (2003); Carroll M.D., Abraham S., Dresser C.M., Dietary intake source data: United States, 1976-80, Vital Health Stat, 11, pp. 1-483, (1983); Svetkey L.P., Sacks F.M., Obarzanek E., Vollmer W.M., Appel L.J., Lin P.H., Karanja N.M., Harsha D.W., Bray G.A., Aickin M., Proschan M.A., Windhauser M.M., Swain J.F., McCarron P.B., Rhodes D.G., Laws R.L., The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): Rationale and design, J Am Diet Assoc, 99, (1999); Xu C.F., Lewis K., Cantone K.L., Khan P., Donnelly C., White N., Crocker N., Boyd P.R., Zaykin D.V., Purvis I.J., Effectiveness of computational methods in haplotype prediction, Hum Genet, 110, pp. 148-156, (2002); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, JR Stat Soc B, 57, pp. 289-300, (1995); Conlin P.R., Erlinger T.P., Bohannon A., Miller Iii E.R., Appel L.J., Svetkey L.P., Moore T.J., The DASH diet enhances the blood pressure response to losartan in hypertensive patients, Am J Hypertens, 16, pp. 337-342, (2003); Busjahn A., Li G.H., Faulhaber H.D., Rosenthal M., Becker A., Jeschke E., Schuster H., Timmermann B., Hoehe M.R., Luft F.C., β-2 Adrenergic receptor gene variations, blood pressure, and heart size in normal twins, Hypertension, 35, pp. 555-560, (2000); Gratze G., Fortin J., Labugger R., Binder A., Kotanko P., Timmermann B., Luft F.C., Hoehe M.R., Skrabal F., β-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians, Hypertension, 33, pp. 1425-1430, (1999); Timmermann B., Mo R., Luft F.C., Gerdts E., Busjahn A., Omvik P., Li G.H., Schuster H., Wienker T.F., Hoehe M.R., Lund-Johansen P., β-2 Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study, Kidney Int, 53, pp. 1455-1460, (1998); Pojoga L., Kolatkar N.S., Williams J.S., Perlstein T.S., Jeunemaitre X., Brown N.J., Hopkins P.N., Raby B.A., Williams G.H., β-2 Adrenergic receptor diplotype defines a subset of salt-sensitive hypertension, Hypertension, 48, pp. 892-900, (2006); Berry T.D., Hasstedt S.J., Hunt S.C., Wu L.L., Smith J.B., Ash K.O., Kuida H., Williams R.R., A gene for high urinary kallikrein may protect against hypertension in Utah kindreds, Hypertension, 13, pp. 3-8, (1989); Margolius H.S., Horwitz D., Pisano J.J., Keiser H.R., Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids, Circ Res, 35, pp. 820-825, (1974); Ura N., Shimamoto K., Nakao T., Ogasawara A., Tanaka S., Mita T., Nishimiya T., Iimura O., The excretion of human urinary kallikrein quantity and activity in normal and low renin subgroups of essential hypertension, Clin Exp Hypertens A, 5, pp. 329-337, (1983); Zinner S.H., Margolius H.S., Rosner B., Keiser H.R., Kass E.H., Familial aggregation of urinary kallikrein concentration in childhood: Relation to blood pressure, race and urinary electrolytes, Am J Epidemiol, 104, pp. 124-132, (1976); Horwitz D., Margolius H.S., Keiser H.R., Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man, J Clin Endocrinol Metab, 47, pp. 296-299, (1978); Sun B., Williams J.S., Svetkey L.P., Kolatkar N.S., Conlin P.R., β2-Adrenergic receptor genotype affects the renin-angiotensin- aldosterone system response to the DASH dietary pattern, Hypertension, 54, (2010); Florez J.C., Jablonski K.A., Bayley N., Pollin T.I., De Bakker P.I., Shuldiner A.R., Knowler W.C., Nathan D.M., Altshuler D., TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program, N Engl J Med, 355, pp. 241-250, (2006); Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., Lusis A.J., Mehrabian M., Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis, N Engl J Med, 350, pp. 29-37, (2004); Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II, Arch Intern Med, 157, pp. 657-667, (1997); Pearson T.A., Manolio T.A., How to interpret a genome-wide association study, JAMA, 299, pp. 1335-1344, (2008)","L. P. Svetkey; Duke University Medical Center, Durham, NC, United States; email: svetk001@mc.duke.edu","","","","","","","","08957061","","AJHYE","21088669","English","Am. J. Hypertens.","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-78751632673"
"Flaten H.K.; Sonn B.J.; Saben J.L.; Shelton S.K.; Schwartz J.; Ryall K.; Monte A.A.","Flaten, Hania K. (56789949300); Sonn, Brandon J. (57204392712); Saben, Jessica L. (55779004800); Shelton, Shelby K. (57204324812); Schwartz, John (57225000866); Ryall, Karen (57224998293); Monte, Andrew A. (57206266595)","56789949300; 57204392712; 55779004800; 57204324812; 57225000866; 57224998293; 57206266595","Genomic markers associated with successful treatment of hypertension with lisinopril: A pilot study","2021","International Journal of Clinical Pharmacology and Therapeutics","59","7","","506","510","4","1","10.5414/CP203910","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108893750&doi=10.5414%2fCP203910&partnerID=40&md5=2060510ab93d95f947e8c82cd57795cc","Department of Emergency Medicine, University of Colorado, School of Medicine, Denver, CO, United States; Center for Bioinformatics and Personalized Medicine, University of Colorado, School of Medicine, Denver, CO, United States; University of Colorado, Skaggs School of Pharmacy, Denver Health and Hospital Authority, Denver, CO, United States; Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, United States","Flaten H.K., Department of Emergency Medicine, University of Colorado, School of Medicine, Denver, CO, United States; Sonn B.J., Department of Emergency Medicine, University of Colorado, School of Medicine, Denver, CO, United States, Center for Bioinformatics and Personalized Medicine, University of Colorado, School of Medicine, Denver, CO, United States, University of Colorado, Skaggs School of Pharmacy, Denver Health and Hospital Authority, Denver, CO, United States; Saben J.L., Department of Emergency Medicine, University of Colorado, School of Medicine, Denver, CO, United States; Shelton S.K., Department of Emergency Medicine, University of Colorado, School of Medicine, Denver, CO, United States; Schwartz J., Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, United States; Ryall K., Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, United States; Monte A.A., Department of Emergency Medicine, University of Colorado, School of Medicine, Denver, CO, United States, Center for Bioinformatics and Personalized Medicine, University of Colorado, School of Medicine, Denver, CO, United States, University of Colorado, Skaggs School of Pharmacy, Denver Health and Hospital Authority, Denver, CO, United States, Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, United States","Objective: To identify single nucleotide variants (SNVs) associated with lisinopril effectiveness. Materials and methods: This was an observational study using a candidate gene approach to examine SNVs associated with lisinopril effectiveness. Drug effectiveness was defined as 10% decrease in systolic blood pressure at 1 week follow-up. We used the Illumina GWAS MEGA chip to examine variants in the renin/angiotensin pathway that may be associated with drug effectiveness. Results: 61 subjects were enrolled, and 33 (54.1%) were responsive to lisinopril therapy. SNVs in AGT (p = 0.0141), REN (p = 0.0192), and ACE2 (p = 0.0002) were found to be associated with successful treatment on lisinopril. Conclusion and relevance: SNVs in the renin and angiotensin pathway are associated with lisinopril effectiveness in a pilot cohort of patients with uncontrolled hypertension.  © 2021 Dustri-Verlag Dr. K. Feistle.","ACE inhibitors; Hypertension; Lisinopril; Pharmacogenomics; Precision medicine","Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Genomics; Humans; Hypertension; Lisinopril; Pilot Projects; Renin-Angiotensin System; angiotensin; angiotensin converting enzyme 2; lisinopril; renin; antihypertensive agent; dipeptidyl carboxypeptidase inhibitor; lisinopril; ACE2 gene; adult; aged; AGT gene; Article; blood pressure regulation; cohort analysis; controlled study; drug efficacy; female; follow up; gene identification; genetic analysis; genetic association; genetic marker; human; hypertension; major clinical study; male; observational study; pilot study; REN gene; signal transduction; single nucleotide polymorphism; systolic blood pressure; treatment outcome; treatment response; blood pressure; genetics; genomics; renin angiotensin aldosterone system","","angiotensin, 1407-47-2; lisinopril, 76547-98-3, 83915-83-7; renin, 61506-93-2, 9015-94-5; Angiotensin-Converting Enzyme Inhibitors, ; Antihypertensive Agents, ; Lisinopril, ","","","NIH CTSI, (UL1 TR001082); National Institutes of Health, NIH, (K23 GM110516, R35GM124939-01); American Medical Association Foundation, AMAF; National Center for Advancing Translational Sciences, NCATS, (UL1TR002535)","A.A.M. received support from the National Institutes of Health (NIH) K23 GM110516, NIH R35GM124939-01 and NIH CTSI UL1 TR001082. This project received seed grant funding from the American Medical Association Foundation.","Johnson JA., Advancing management of hypertension through pharmacogenomics, Ann Med, 44, pp. S17-S22, (2012); Cohen JS., Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference, Arch Intern Med, 161, pp. 880-885, (2001); Sole X, Guino E, Valls J, Iniesta R, Moreno V., SNPStats: A web tool for the analysis of association studies, Bioinformatics, 22, pp. 1928-1929, (2006); Durinck S, Spellman PT, Birney E, Huber W., Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt, Nat Protoc, 4, pp. 1184-1191, (2009); Shaul O., How introns enhance gene expression, Int J Biochem Cell Biol, 91, pp. 145-155, (2017); Lalouel JM, Rohrwasser A, Terreros D, Morgan T, Ward K., Angiotensinogen in essential hypertension: From genetics to nephrology, J Am Soc Nephrol, 12, pp. 606-615, (2001); Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ., Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema, Pharmacogenet Genomics, 23, pp. 470-478, (2013); Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y., Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril, Clin Pharmacol Ther, 79, pp. 427-439, (2006)","A.A. Monte; Aurora, 12401 E. 17th Avenue, 80045, United States; email: Andrew.monte@cuanschutz.edu","","Dustri-Verlag Dr. Karl Feistle","","","","","","09461965","","ICTHE","33769277","English","Int. J. Clin. Pharmacol. Ther.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-85108893750"
"Schüler R.; Osterhoff M.A.; Frahnow T.; Seltmann A.-C.; Busjahn A.; Kabisch S.; Xu L.; Mosig A.S.; Spranger J.; Möhlig M.; Hornemann S.; Kruse M.; Pfeiffer A.F.H.","Schüler, Rita (56653169900); Osterhoff, Martin A. (6603208527); Frahnow, Turid (57193011221); Seltmann, Anne-Cathrin (55211987900); Busjahn, Andreas (7004503495); Kabisch, Stefan (57163103600); Xu, Li (57199908099); Mosig, Alexander S. (56159600800); Spranger, Joachim (55101740600); Möhlig, Matthias (56785697400); Hornemann, Silke (6602199265); Kruse, Michael (57197159173); Pfeiffer, Andreas F.H. (22836540000)","56653169900; 6603208527; 57193011221; 55211987900; 7004503495; 57163103600; 57199908099; 56159600800; 55101740600; 56785697400; 6602199265; 57197159173; 22836540000","High-saturated-fat diet increases circulating angiotensin-converting enzyme, which is enhanced by the rs4343 polymorphism defining persons at risk of nutrient-dependent increases of blood pressure","2017","Journal of the American Heart Association","6","1","e004465","","","","45","10.1161/JAHA.116.004465","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010004755&doi=10.1161%2fJAHA.116.004465&partnerID=40&md5=0fe36c4427e01b6a39abc7fc7279fe97","Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; HealthTwiSt GmbH, Berlin, Germany; Institute of Biochemistry II, Jena University Hospital, Jena, Germany; Charité-Center for Cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany","Schüler R., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Osterhoff M.A., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany, Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; Frahnow T., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Seltmann A.-C., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany; Busjahn A., HealthTwiSt GmbH, Berlin, Germany; Kabisch S., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany, Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; Xu L., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; Mosig A.S., Institute of Biochemistry II, Jena University Hospital, Jena, Germany; Spranger J., Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, Charité-Center for Cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany, German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany; Möhlig M., Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; Hornemann S., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Kruse M., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; Pfeiffer A.F.H., Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany, Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany","Background--Angiotensin-converting enzyme (ACE) plays a major role in blood pressure regulation and cardiovascular homeostasis. Contrary to the assumption that ACE levels are stable, circulating ACE has been shown to be altered in obesity and weight loss. We sought to examine effects of a high-saturated-fat (HF) diet on ACE within the NUtriGenomic Analysis in Twins (NUGAT) study. Methods and Results--Forty-six healthy and nonobese twin pairs initially consumed a carbohydrate-rich, low-fat diet over a period of 6 weeks to standardize for nutritional behavior prior to the study, followed by 6 weeks of HF diet under isocaloric conditions. After 6 weeks of HF diet, circulating ACE concentrations increased by 15% (P=1.6×10-30), accompanied by an increased ACE gene expression in adipose tissue (P=3.8×10-6). Stratification by ACE rs4343, a proxy for the ACE insertion/deletion polymorphism (I/D), revealed that homozygous carriers (GG) of the variant had higher baseline ACE concentrations (P=7.5×10-8) and additionally showed a 2-fold increase in ACE concentrations in response to the HF diet as compared to non- or heterozygous carriers (AA/AG, P=2×10-6). GG carriers also responded with higher systolic blood pressure as compared to AA/AG carriers (P=0.008). The strong gene-diet interaction was confirmed in a second independent, cross-sectional cohort, the Metabolic Syndrome Berlin Potsdam (MeSyBePo) study. Conclusions--The HF-diet-induced increase of ACE serum concentrations reveals ACE to be a potential molecular link between dietary fat intake and hypertension and cardiovascular disease (CVD). The GG genotype of the ACE rs4343 polymorphism represents a robust nutrigenetic marker for an unfavorable response to high-saturated-fat diets. © 2017 The Authors.","Angiotensin-converting enzyme; Blood pressure; Diet; Gene-diet interaction; Nutrigenomics genetics","Adolescent; Adult; Blood Pressure; Diet, High-Fat; Dietary Fats; Fatty Acids; Female; Genetic Predisposition to Disease; Healthy Volunteers; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Twins; Twins, Dizygotic; Twins, Monozygotic; Young Adult; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase; fatty acid; adult; Article; blood pressure measurement; carbohydrate diet; cohort analysis; controlled study; cross-sectional study; diastolic blood pressure; enzyme blood level; female; gene diet interaction; gene expression; genetic polymorphism; genotype; heredity; heterozygote; homozygote; human; lipid diet; low fat diet; male; normal human; subcutaneous fat; systolic blood pressure; adolescent; blood; blood pressure; dizygotic twins; drug effects; fat intake; genetic predisposition; genetics; middle aged; monozygotic twins; pharmacology; single nucleotide polymorphism; twins; young adult","","dipeptidyl carboxypeptidase, 9015-82-1; Dietary Fats, ; Fatty Acids, ; Peptidyl-Dipeptidase A, ","","","","","Cambien F., Costerousse O., Tiret L., Poirier O., Lecerf L., Gonzales M.F., Evans A., Arveiler D., Cambou J.P., Luc G., Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction, Circulation, 90, pp. 669-676, (1994); Samani N.J., Thompson J.R., O'Toole L., Channer K., Woods K.L., A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction, Circulation, 94, pp. 708-712, (1996); Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.P., Arveiler D., Luc G., Bard J.M., Bara L., Ricard S., Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction, Nature, 359, pp. 641-644, (1992); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Alhenc-Gelas F., Richard J., Courbon D., Warnet J.M., Corvol P., Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters, J Lab Clin Med, 117, pp. 33-39, (1991); Wang P., Holst C., Wodzig W.K.W.H., Andersen M.R., Astrup A., van Baak M.A., Larsen T.M., Jebb S.A., Kafatos A., Pfeiffer A.F.H., Martinez J.A., Handjieva-Darlenska T., Kunesova M., Viguerie N., Langin D., Saris W.H., Mariman E.C.M., Circulating ACE is a predictor of weight loss maintenance not only in overweight and obese women, but also in men, Int J Obes, 36, pp. 1545-1551, (2012); Ljungberg L., Alehagen U., Lanne T., Bjorck H., De Basso R., Dahlstrom U., Persson K., The association between circulating angiotensin-converting enzyme and cardiovascular risk in the elderly: a cross-sectional study, J Renin Angiotensin Aldosterone Syst, 12, pp. 281-289, (2011); Cooper R., McFarlane-Anderson N., Bennett F.I., Wilks R., Puras A., Tewksbury D., Ward R., Forrester T., ACE, angiotensinogen and obesity: a potential pathway leading to hypertension, J Hum Hypertens, 11, pp. 107-111, (1997); Harp J.B., Henry S.A., DiGirolamo M., Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults, Obes Res, 10, pp. 985-990, (2002); Ruano M., Silvestre V., Castro R., Garcia-Lescun M.C., Rodriguez A., Marco A., Garcia-Blanch G., Morbid obesity, hypertensive disease and the reninangiotensin-aldosterone axis, Obes Surg, 15, pp. 670-676, (2005); Jonsson J.R., Game P.A., Head R.J., Frewin D.B., The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue, Blood Press, 3, pp. 72-75, (1994); Fain J.N., Nesbit A.S., Sudlow F.F., Cheema P., Peeples J.M., Madan A.K., Tichansky D.S., Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes, Metabolism, 56, pp. 1583-1590, (2007); Alligier M., Meugnier E., Debard C., Lambert-Porcheron S., Chanseaume E., Sothier M., Loizon E., Hssain A.A., Brozek J., Scoazec J.Y., Morio B., Vidal H., Laville M., Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans, J Clin Endocrinol Metab, 97, pp. E183-E192, (2012); Johansson L., Solvoll K., Bjorneboe G.E., Drevon C.A., Under-and overreporting of energy intake related to weight status and lifestyle in a nationwide sample, Am J Clin Nutr, 68, pp. 266-274, (1998); Mensink R.P., Zock P.L., Kester A.D., Katan M.B., Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr, 77, pp. 1146-1155, (2003); McKenzie C.A., Abecasis G.R., Keavney B., Forrester T., Ratcliffe P.J., Julier C., Connell J.M., Bennett F., McFarlane-Anderson N., Lathrop G.M., Cardon L.R., Transethnic fine mapping of a quantitative trait locus for circulating angiotensin Iconverting enzyme (ACE), Hum Mol Genet, 10, pp. 1077-1084, (2001); Keavney B., McKenzie C.A., Connell J.M., Julier C., Ratcliffe P.J., Sobel E., Lathrop M., Farrall M., Measured haplotype analysis of the angiotensin-I converting enzyme gene, Hum Mol Genet, 7, pp. 1745-1751, (1998); Abdollahi M.R., Huang S., Rodriguez S., Guthrie P.A., Smith G.D., Ebrahim S., Lawlor D.A., Day I.N., Gaunt T.R., Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women's Heart and Health Study (BWHHS), Dis Markers, 24, pp. 11-17, (2008); Appel L.J., Moore T.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Sacks F.M., Bray G.A., Vogt T.M., Cutler J.A., Windhauser M.M., Lin P.H., Karanja N., A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group, N Engl J Med, 336, pp. 1117-1124, (1997); Rice T., Rankinen T., Province M.A., Chagnon Y.C., Perusse L., Borecki I.B., Bouchard C., Rao D.C., Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study, Circulation, 102, pp. 1956-1963, (2000); O'Donnell C.J., Lindpaintner K., Larson M.G., Rao V.S., Ordovas J.M., Schaefer E.J., Myers R.H., Levy D., Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study, Circulation, 97, pp. 1766-1772, (1998); Vassilikioti S., Doumas M., Douma S., Petidis K., Karagiannis A., Balaska K., Vyzantiadis A., Zamboulis C., Angiotensin converting enzyme gene polymorphism is not related to essential hypertension in a Greek population, Am J Hypertens, 9, pp. 700-702, (1996); Mattu R.K., Needham E.W., Galton D.J., Frangos E., Clark A.J., Caulfield M., A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study, Circulation, 91, pp. 270-274, (1995); Keavney B., McKenzie C., Parish S., Palmer A., Clark S., Youngman L., Delepine M., Lathrop M., Peto R., Collins R., Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators, Lancet, 355, pp. 434-442, (2000); Schunkert H., Hense H.W., Muscholl M., Luchner A., Riegger G.A., Association of angiotensin converting enzyme activity and arterial blood pressure in a population-based sample, J Hypertens, 14, pp. 571-575, (1996); Chowdhury R., Warnakula S., Kunutsor S., Crowe F., Ward H.A., Johnson L., Franco O.H., Butterworth A.S., Forouhi N.G., Thompson S.G., Khaw K.T., Mozaffarian D., Danesh J., Di Angelantonio E., Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and metaanalysis, Ann Intern Med, 160, pp. 398-406, (2014); Zhu X., Bouzekri N., Southam L., Cooper R.S., Adeyemo A., McKenzie C.A., Luke A., Chen G., Elston R.C., Ward R., Linkage and association analysis of angiotensin Iconverting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure, Am J Hum Genet, 68, pp. 1139-1148, (2001); Busjahn A., Knoblauch H., Knoblauch M., Bohlender J., Menz M., Faulhaber H.D., Becker A., Schuster H., Luft F.C., Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study, Hypertension, 29, pp. 165-170, (1997); Soubrier F., Martin S., Alonso A., Visvikis S., Tiret L., Matsuda F., Lathrop G.M., Farrall M., High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity, Eur J Hum Genet, 10, pp. 553-561, (2002); Soubrier F., From an ACE polymorphism to genome-wide searches for eQTL, J Clin Invest, 123, pp. 111-112, (2013); Tiret L., Rigat B., Visvikis S., Breda C., Corvol P., Cambien F., Soubrier F., Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels, Am J Hum Genet, 51, pp. 197-205, (1992); de Pinho L., Andrade J.M., Paraiso A., Filho A.B., Feltenberger J.D., Guimaraes A.L., de Paula A.M., Caldeira A.P., de Carvalho Botelho A.C., Campagnole-Santos M.J., Sousa Santos S.H., Diet composition modulates expression of sirtuins and renin-angiotensin system components in adipose tissue, Obesity (Silver Spring), 21, pp. 1830-1835, (2013); Sun J., Luo J., Ruan Y., Xiu L., Fang B., Zhang H., Wang M., Chen H., Free fatty acids activate renin-angiotensin system in 3T3-L1 adipocytes through nuclear factorkappa B pathway, J Diabetes Res, 2016, (2016); Zhu X., McKenzie C.A., Forrester T., Nickerson D.A., Broeckel U., Schunkert H., Doering A., Jacob H.J., Cooper R.S., Rieder M.J., Localization of a small genomic region associated with elevated ACE, Am J Hum Genet, 67, pp. 1144-1153, (2000)","R. Schüler; Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Arthur-Scheunert-Allee 114-116, 14558, Germany; email: rita.schueler@dife.de","","John Wiley and Sons Inc.","","","","","","20479980","","","28096099","English","J. Am. Heart Assoc.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-85010004755"
"Zhou T.; Garcia J.G.N.; Zhang W.","Zhou, Tong (7402989477); Garcia, Joe G.N. (35233141600); Zhang, Wei (54963907100)","7402989477; 35233141600; 54963907100","Integrating microRNAs into a system biology approach to acute lung injury","2011","Translational Research","157","4","","180","190","10","81","10.1016/j.trsl.2011.01.010","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952781841&doi=10.1016%2fj.trsl.2011.01.010&partnerID=40&md5=dda63154e9f5427a46eb3985e130824a","Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States; Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, IL, United States; Department of Pediatrics, University of Illinois at Chicago, MC856, Chicago, IL 60612, 840 S. Wood Street, United States; Institute for Human Genetics, University of Illinois at Chicago, Chicago, IL, United States","Zhou T., Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States, Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, IL, United States, Department of Pediatrics, University of Illinois at Chicago, MC856, Chicago, IL 60612, 840 S. Wood Street, United States, Institute for Human Genetics, University of Illinois at Chicago, Chicago, IL, United States; Garcia J.G.N., Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States, Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, IL, United States, Department of Pediatrics, University of Illinois at Chicago, MC856, Chicago, IL 60612, 840 S. Wood Street, United States, Institute for Human Genetics, University of Illinois at Chicago, Chicago, IL, United States; Zhang W., Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States, Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, IL, United States, Department of Pediatrics, University of Illinois at Chicago, MC856, Chicago, IL 60612, 840 S. Wood Street, United States, Institute for Human Genetics, University of Illinois at Chicago, Chicago, IL, United States","Acute lung injury (ALI), including the ventilator-induced lung injury (VILI) and the more severe acute respiratory distress syndrome (ARDS), are common and complex inflammatory lung diseases potentially affected by various genetic and nongenetic factors. Using the candidate gene approach, genetic variants associated with immune response and inflammatory pathways have been identified and implicated in ALI. Because gene expression is an intermediate phenotype that resides between the DNA sequence variation and the higher level cellular or whole-body phenotypes, the illustration of gene expression regulatory networks potentially could enhance understanding of disease susceptibility and the development of inflammatory lung syndromes. MicroRNAs (miRNAs) have emerged as a novel class of gene regulators that play critical roles in complex diseases including ALI. Comparisons of global miRNA profiles in animal models of ALI and VILI identified several miRNAs (eg, miR-146a and miR-155) previously implicated in immune response and inflammatory pathways. Therefore, via regulation of target genes in these biological processes and pathways, miRNAs potentially contribute to the development of ALI. Although this line of inquiry exists at a nascent stage, miRNAs have the potential to be critical components of a comprehensive model for inflammatory lung disease built by a systems biology approach that integrates genetic, genomic, proteomic, epigenetic as well as environmental stimuli information. Given their particularly recognized role in regulation of immune and inflammatory responses, miRNAs also serve as novel therapeutic targets and biomarkers for ALI/ARDS or VILI, thus facilitating the realization of personalized medicine for individuals with acute inflammatory lung disease. © 2011 Mosby, Inc. All rights reserved.","ACE; acute lung injury; acute respiratory distress syndrome; ALI; angiotensin converting enzyme; ARDS; CNV; copy number variant; extracellular superoxide dismutase; high tidal ventilation; HTV; IL; interleukin; LCL; lipopolysaccharide; LPS; lymphoblastoid cell line sample; microRNA; miRNA; PAI-1; PBEF; plasminogen activator inhibitor 1; pre-B-cell colony enhancing factor; single nucleotide polymorphism; SNP; SOD3; TGF-β; THBS1; thrombospondin 1; TLR; toll-like receptor; transforming growth factor β; vascular endothelial growth factor; VEGF; ventilator-induced lung injury; VILI","captopril; collagen type 16; dipeptidyl carboxypeptidase; extracellular superoxide dismutase; gamma interferon; glycogen synthase kinase 3beta; HLA G antigen; interleukin 10; interleukin 12; interleukin 13; keratinocyte growth factor; leucine rich repeat kinase 2; microRNA; phospholipase C; prostaglandin E2; protein Noxa; Smad7 protein; thrombospondin 1; transforming growth factor; vasculotropin; adult respiratory distress syndrome; asthma; Caenorhabditis elegans; chronic obstructive lung disease; congestive heart failure; copy number variation; cystic fibrosis; disease predisposition; DNA sequence; gene expression; genetic association; genetic regulation; genetic variability; human; hypertension; immune response; lung fibrosis; nonhuman; outcome assessment; personalized medicine; priority journal; review; single nucleotide polymorphism; ventilator induced lung injury","","captopril, 62571-86-2; dipeptidyl carboxypeptidase, 9015-82-1; gamma interferon, 82115-62-6; glycogen synthase kinase 3alpha, ; glycogen synthase kinase 3beta, ; interleukin 12, 138415-13-1; interleukin 13, 148157-34-0; keratinocyte growth factor, 126469-10-1; phospholipase C, 9001-86-9; prostaglandin E2, 363-24-6; Smad7 protein, 391971-60-1; thrombospondin 1, 343987-56-4; transforming growth factor, 76057-06-2; vasculotropin, 127464-60-2","","","National Heart, Lung, and Blood Institute, NHLBI, (P01HL058064)","Supported by HL 58064 and HL 94394. ","Tomlinson L., Bellingan G.J., Trauma and acute lung injury, Trauma, 4, 3, pp. 147-157, (2002); Tsushima K., King L.S., Aggarwal N.R., Et al., Acute lung injury review, Intern Med, 48, pp. 621-630, (2009); Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M., Stern E.J., Hudson L.D., Incidence and outcomes of acute lung injury, New England Journal of Medicine, 353, 16, pp. 1685-1693, (2005); Bream-Rouwenhorst H.R., Beltz E.A., Ross M.B., Moores K.G., Recent developments in the management of acute respiratory distress syndrome in adults, Am J Health Syst Pharm, 65, pp. 29-36, (2008); Gajic O., Dara S.I., Mendez J.L., Adesanya A.O., Festic E., Caples S.M., Rana R., St. Sauver J.L., Lymp J.F., Afessa B., Hubmayr R.D., Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation, Critical Care Medicine, 32, 9, pp. 1817-1824, (2004); Dhanireddy S., Altemeier W.A., Matute-Bello G., Et al., Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia, Lab Invest, 86, (2006); Altemeier W.A., Matute-Bello G., Frevert C.W., Et al., Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin, Am J Physiol Lung Cell Mol Physiol, 287, (2004); Bregeon F., Delpierre S., Chetaille B., Kajikawa O., Martin T.R., Autillo-Touati A., Jammes Y., Pugin J., Mechanical ventilation affects lung function and cytokine production in an experimental model of endotoxemia, Anesthesiology, 102, 2, pp. 331-339, (2005); Wurfel M.M., Microarray-based analysis of ventilator-induced lung injury, Proceedings of the American Thoracic Society, 4, 1, pp. 77-84, (2007); Ware L.B., Matthay M.A., The acute respiratory distress syndrome, New England Journal of Medicine, 342, 18, pp. 1334-1349, (2000); Meyer N.J., Garcia J.G.N., Wading into the genomic pool to unravel acute lung injury genetics, Proceedings of the American Thoracic Society, 4, 1, pp. 69-76, (2007); Gong M.N., Thompson B.T., Williams P., Pothier L., Boyce P.D., Christiani D.C., Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red cell transfusion, Critical Care Medicine, 33, 6, pp. 1191-1198, (2005); Moss M., Mannino D.M., Race and gender differences in acute respiratory distress syndrome deaths in the United States: An analysis of multiple-cause mortality data (1979-1996), Critical Care Medicine, 30, 8, pp. 1679-1685, (2002); Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M., Microarray analysis shows that some microRNAs downregulate large numbers of-target mRNAs, Nature, 433, 7027, pp. 769-773, (2005); Zhang W., Dolan M.E., Emerging role of microRNAs in drug response, Curr Opin Mol Ther, 12, pp. 695-702, (2010); Ghosh B., Sharma A., Kumar M., Mabalirajan U., Agrawal A., Identification of microRNA involved in il-10 expression and its implication in asthma, Am J Respir Crit Care Med, 179, (2009); Tan Z., Randall G., Fan J., Camoretti-Mercado B., Brockman-Schneider R., Pan L., Solway J., Gern J.E., Lemanske Jr. R.F., Nicolae D., Ober C., Allele-specific targeting of microRNAs to HLA-G and risk of asthma, American Journal of Human Genetics, 81, 4, pp. 829-834, (2007); Lu T.X., Munitz A., Rothenberg M.E., MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression, J Immunol, 182, pp. 4994-5002, (2009); Chiba Y., Tanabe M., Goto K., Sakai H., Misawa M., Down-regulation of miR-133a contributes to up-regulation of Rhoa in bronchial smooth muscle cells, Am J Respir Crit Care Med, 180, pp. 713-719, (2009); Mattes J., Collison A., Plank M., Phipps S., Foster P.S., Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease, Proc Natl Acad Sci U S A, 106, pp. 18704-18709, (2009); Chiba Y., Misawa M., MicroRNAs and their therapeutic potential for human diseases: Mir-133a and bronchial smooth muscle hyperresponsiveness in asthma, J Pharmacol Sci, 114, pp. 264-268, (2010); Mohamed J.S., Lopez M.A., Boriek A.M., Mechanical stretch up-regulates microRNA-26a and induces human airway smooth muscle hypertrophy by suppressing glycogen synthase kinase-3beta, J Biol Chem, 285, pp. 29336-29347, (2010); Polikepahad S., Knight J.M., Naghavi A.O., Et al., Proinflammatory role for let-7microRNAS in experimental asthma, J Biol Chem, 285, pp. 30139-30149, (2010); Christenson S.A., Campbell J.D., Zeskind J., Et al., MicroRNA as regulators of gene expression changes that occur with the progression of emphysema, Am J Respir Crit Care Med, 181, (2010); Sato T., Liu X., Nelson A., Et al., Reduced miR-146a increases prostaglandin e in chronic obstructive pulmonary disease fibroblasts, Am J Respir Crit Care Med, 182, pp. 1020-1029, (2010); Oglesby I.K., Bray I.M., Chotirmall S.H., Et al., MiR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression, J Immunol, 184, pp. 1702-1709, (2010); Pandit K.V., Corcoran D., Yousef H., Et al., Inhibition and role of let-7d in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 182, pp. 220-229, (2010); Pottier N., Maurin T., Chevalier B., Et al., Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: Implication in epithelial-mesenchymal interactions, PLoS One, 4, (2009); Liu G., Friggeri A., Yang Y., Et al., MiR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis, J Exp Med, 207, pp. 1589-1597, (2010); Reddy A.J., Kleeberger S.R., Genetic polymorphisms associated with acute lung injury, Pharmacogenomics, 10, pp. 1527-1539, (2009); Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., Huan Y., Yang P., Zhang Y., Deng W., Bao L., Zhang B., Liu G., Wang Z., Chappell M., Liu Y., Zheng D., Leibbrandt A., Wada T., Slutsky A.S., Liu D., Qin C., Jiang C., Penninger J.M., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nature Medicine, 11, 8, pp. 875-879, (2005); Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., Crackower M.A., Fukamizu A., Hui C.-C., Hein L., Uhlig S., Slutsky A.S., Jiang C., Penninger J.M., Angiotensin-converting enzyme 2 protects from severe acute lung failure, Nature, 436, 7047, pp. 112-116, (2005); Arcaroli J.J., Hokanson J.E., Abraham E., Et al., Extracellular superoxide dismutase haplotypes are associated with acute lung injury and mortality, Am J Respir Crit Care Med, 179, pp. 105-112, (2009); Meyer N.J., Christie J.D., Extracellular superoxide dismutase haplotypes and acute lung injury: Reading into the genome to understand mortality?, Am J Respir Crit Care Med, 179, pp. 89-91, (2009); Bersten A.D., Hunt T., Nicholas T.E., Doyle I.R., Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure, American Journal of Respiratory and Critical Care Medicine, 164, 4, pp. 648-652, (2001); Mora R., Arold S., Marzan Y., Suki B., Ingenito E.P., Determinants of surfactant function in acute lung injury and early recovery, Am J Physiol Lung Cell Mol Physiol, 279, (2000); Christie J.D., Interleukin-10, age and acute lung injury genetics: The action is in the interaction, European Respiratory Journal, 27, 4, pp. 669-670, (2006); Kono H., Fujii H., Hirai Y., Tsuchiya M., Amemiya H., Asakawa M., Maki A., Matsuda M., Yamamoto M., The Kupffer cell protects against acute lung injury in a rat peritonitis model: Role of IL-10, Journal of Leukocyte Biology, 79, 4, pp. 809-817, (2006); Inoue G., Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury, Journal of Infection and Chemotherapy, 6, 1, pp. 51-60, (2000); Abadie Y., Bregeon F., Papazian L., Lange F., Chailley-Heu B., Thomas P., Duvaldestin P., Adnot S., Maitre B., Delclaux C., Decreased VEGF concentration in lung tissue and vascular injury during ARDS, European Respiratory Journal, 25, 1, pp. 139-146, (2005); Medford A.R., Ibrahim N.B., Millar A.B., Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome, J Crit Care, 24, pp. 236-242, (2009); Medford A.R.L., Millar A.B., Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): Paradox or paradigm?, Thorax, 61, 7, pp. 621-626, (2006); Tsangaris I., Tsantes A., Bonovas S., Et al., The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS, Thromb Res, 123, pp. 832-836, (2009); Liu A., Mosher D.F., Murphy-Ullrich J.E., Goldblum S.E., The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia, Microvasc Res, 77, pp. 13-20, (2009); Dhainaut J.F., Charpentier J., Chiche J.D., Transforming growth factor-beta: A mediator of cell regulation in acute respiratory distress syndrome, Crit Care Med, 31, (2003); Gao L., Flores C., Fan-Ma S., Miller E.J., Moitra J., Moreno L., Wadgaonkar R., Simon B., Brower R., Sevransky J., Tuder R.M., Maloney J.P., Moss M., Shanholtz C., Yates C.R., Meduri G.U., Ye S.Q., Barnes K.C., Garcia J.G.N., Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations, Translational Research, 150, 1, pp. 18-29, (2007); Flores C., Ma S.-F., Maresso K., Wade M.S., Villar J., Garcia J.G.N., IL6 gene-wide haplotype is associated with susceptibility to acute lung injury, Translational Research, 152, 1, pp. 11-17, (2008); Grigoryev D.N., Ma S.F., Irizarry R.A., Et al., Orthologous gene-expression profiling in multi-species models: Search for candidate genes, Genome Biol, 5, (2004); Flores C., Perez-Mendez L., MacA-Meyer N., Et al., A common haplotype of the LBP gene predisposes to severe sepsis, Crit Care Med, 37, pp. 2759-2766, (2009); Christie J.D., Ma S.F., Aplenc R., Et al., Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma, Crit Care Med, 36, pp. 2794-2800, (2008); Christie J.D., Ma S.F., Aplenc R., Et al., Variation in the MYLK gene is associated with development of acute lung injury after major trauma, Crit Care Med, (2008); Flores C., Ma S.-F., Maresso K., Ober C., Garcia J.G.N., A variant of the myosin light chain kinase gene is associated with severe asthma in African Americans, Genetic Epidemiology, 31, 4, pp. 296-305, (2007); Gao L., Grant A., Halder I., Et al., Novel polymorphisms in the myosin light chain kinase gene confer risk for acute lung injury, Am J Respir Cell Mol Biol, 34, pp. 487-495, (2006); Hong S.B., Huang Y., Moreno-Vinasco L., Et al., Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury, Am J Respir Crit Care Med, 178, pp. 605-617, (2008); Ye S.Q., Simon B.A., Maloney J.P., Zambelli-Weiner A., Gao L., Grant A., Easley R.B., McVerry B.J., Tuder R.M., Standiford T., Brower R.G., Barnes K.C., Garcia J.G.N., Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury, American Journal of Respiratory and Critical Care Medicine, 171, 4, pp. 361-370, (2005); Meyer N.J., Huang Y., Singleton P.A., Et al., GADD45a is a novel candidate gene in inflammatory lung injury via influences on Akt signaling, Faseb J, 23, pp. 1325-1337, (2009); Marshall R.P., Webb S., Bellingan G.J., Montgomery H.E., Chaudhari B., McAnulty R.J., Humphries S.E., Hill M.R., Laurent G.J., Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome, American Journal of Respiratory and Critical Care Medicine, 166, 5, pp. 646-650, (2002); Wosten-Van Asperen R.M., Lutter R., Haitsma J.J., Et al., ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin, Eur Respir J, 31, pp. 363-371, (2008); Jiang J.S., Wang L.F., Chou H.C., Chen C.M., Angiotensin-converting enzyme inhibitor captopril attenuates ventilator-induced lung injury in rats, J Appl Physiol, 102, pp. 2098-2103, (2007); Chen C.M., Chou H.C., Wang L.F., Lang Y.D., Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury, Crit Care Med, 36, pp. 1880-1885, (2008); Sapru A., Curley M.A., Brady S., Matthay M.A., Flori H., Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury, Intensive Care Med, 36, pp. 157-163, (2010); Prabhakaran P., Ware L.B., White K.E., Et al., Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury, Am J Physiol Lung Cell Mol Physiol, 285, (2003); Garzon R., Calin G.A., Croce C.M., MicroRNAs in cancer, Annu Rev Med, 60, pp. 167-179, (2009); Zhang W., Dolan M.E., Use of cell lines in the investigation of pharmacogenetic loci, Curr Pharm des, 15, pp. 3782-3795, (2009); Simon B.A., Easley R.B., Grigoryev D.N., Et al., Microarray analysis of regional cellular responses to local mechanical stress in acute lung injury, Am J Physiol Lung Cell Mol Physiol, 291, (2006); Garcia J.G., Searching for candidate genes in acute lung injury: SNPs, Chips and PBEF, Trans Am Clin Climatol Assoc, 116, pp. 205-219, (2005); Zhang W., Ratain M.J., Dolan M.E., The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics, Bioinform Biol Insights, 2, pp. 15-23, (2008); Duan S., Huang R.S., Zhang W., Et al., Genetic architecture of transcript-level variation in humans, Am J Hum Genet, 82, pp. 1101-1113, (2008); The international HapMap project, Nature, 426, pp. 789-796, (2003); A haplotype map of the human genome, Nature, 437, pp. 1299-1320, (2005); Cheung V.G., Conlin L.K., Weber T.M., Arcaro M., Jen K.-Y., Morley M., Spielman R.S., Natural variation in human gene expression assessed in lymphoblastoid cells, Nature Genetics, 33, 3, pp. 422-425, (2003); Morloy M., Molony C.M., Weber T.M., Devlin J.L., Ewens K.G., Spielman R.S., Cheung V.G., Genetic analysis of genome-wide variation in human gene expression, Nature, 430, 7001, pp. 743-747, (2004); Stranger B.E., Forrest M.S., Clark A.G., Et al., Genome-wide associations of gene expression variation in humans, PLoS Genet, 1, (2005); Zhang W., Duan S., Kistner E.O., Et al., Evaluation of genetic variation contributing to differences in gene expression between populations, Am J Hum Genet, 82, pp. 631-640, (2008); Stranger B.E., Forrest M.S., Dunning M., Et al., Relative impact of nucleotide and copy number variation on gene expression phenotypes, Science, 315, pp. 848-853, (2007); Stranger B.E., Nica A.C., Forrest M.S., Dimas A., Bird C.P., Beazley C., Ingle C.E., Dunning M., Flicek P., Koller D., Montgomery S., Tavare S., Deloukas P., Dermitzakis E.T., Population genomics of human gene expression, Nature Genetics, 39, 10, pp. 1217-1224, (2007); Spielman R.S., Bastone L.A., Burdick J.T., Morley M., Ewens W.J., Cheung V.G., Common genetic variants account for differences in gene expression among ethnic groups, Nature Genetics, 39, 2, pp. 226-231, (2007); Idaghdour Y., Storey J.D., Jadallah S.J., Gibson G., A genome-wide gene expression signature of environmental geography in leukocytes of Moroccan Amazighs, PLoS Genet, 4, (2008); Zhang X., Richards E.J., Borevitz J.O., Genetic and epigenetic dissection of cis regulatory variation, Current Opinion in Plant Biology, 10, 2, pp. 142-148, (2007); Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P., An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans, Science, 294, 5543, pp. 858-862, (2001); He L., Hannon G.J., MicroRNAs: Small RNAs with a big role in gene regulation, Nature Reviews Genetics, 5, 7, pp. 522-531, (2004); Lee C.-T., Risom T., Strauss W.M., Evolutionary conservation of microRNA regulatory circuits: An examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny, DNA and Cell Biology, 26, 4, pp. 209-218, (2007); Griffiths-Jones S., Grocock R.J., Van Dongen S., Bateman A., Enright A.J., MiRBase: MicroRNA sequences, targets and gene nomenclature, Nucleic Acids Res, 34, (2006); Griffiths-Jones S., Saini H.K., Van Dongen S., Enright A.J., MiRBase: Tools for microRNA genomics, Nucleic Acids Res, 36, (2008); Griffiths-Jones S., The microRNA registry, Nucleic Acids Res, 32, (2004); Bentwich I., Avniel A., Karov Y., Aharonov R., Gilad S., Barad O., Barzilai A., Einat P., Einav U., Meiri E., Sharon E., Spector Y., Bentwich Z., Identification of hundreds of conserved and nonconserved human microRNAs, Nature Genetics, 37, 7, pp. 766-770, (2005); Enright A.J., John B., Gaul U., Tuschl T., Sander C., Marks D.S., MicroRNA targets in Drosophila, Genome Biol, 5, (2003); He L., Hannon G.J., MicroRNAs: Small RNAs with a big role in gene regulation, Nature Reviews Genetics, 5, 7, pp. 522-531, (2004); Friedman R.C., Farh K.K., Burge C.B., Bartel D.P., Most mammalian mRNAs are conserved targets of microRNAs, Genome Res, 19, pp. 92-105, (2009); Gatt M.E., Zhao J.J., Ebert M.S., Et al., MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma, Blood, (2010); Burchard J., Zhang C., Liu A.M., Et al., MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma, Mol Syst Biol, 6, (2010); Liu C., Yu J., Yu S., Et al., MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma, J Hepatol, 53, pp. 98-107, (2010); Hennessy E., O'Driscoll L., Molecular medicine of microRNAs: Structure, function and implications for diabetes, Expert Rev Mol Med, 10, (2008); Lovis P., Roggli E., Laybutt D.R., Et al., Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction, Diabetes, 57, pp. 2728-2736, (2008); Small E.M., Frost R.J., Olson E.N., MicroRNAs add a new dimension to cardiovascular disease, Circulation, 121, pp. 1022-1032, (2010); Lu Y., Zhang Y., Shan H., Et al., MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: A new mechanism for ischaemic cardioprotection, Cardiovasc Res, 84, pp. 434-441, (2009); Voellenkle C., Van Rooij J., Cappuzzello C., Et al., MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients, Physiol Genomics, 42, pp. 420-426, (2010); Matkovich S.J., Wang W., Tu Y., Et al., MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts, Circ Res, 106, pp. 166-175, (2010); Naga Prasad S.V., Duan Z.H., Gupta M.K., Et al., Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks, J Biol Chem, 284, pp. 27487-27499, (2009); Mishra P.J., Mishra P.J., Banerjee D., Bertino J.R., MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics, Cell Cycle, 7, 7, pp. 853-858, (2008); Mishra P.J., Song B., Mishra P.J., Et al., MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism, PLoS One, 4, (2009); Mishra P.J., Humeniuk R., Mishra P.J., Longo-Sorbello G.S.A., Banerjee D., Bertino J.R., A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance, Proceedings of the National Academy of Sciences of the United States of America, 104, 33, pp. 13513-13518, (2007); Duan S., Mi S., Zhang W., Dolan M.E., Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes, RNA Biol, 6, pp. 412-425, (2009); Lindsay M.A., MicroRNAs and the immune response, Trends Immunol, 29, pp. 343-351, (2008); Wang S., Aurora A.B., Johnson B.A., Et al., The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis, Dev Cell, 15, pp. 261-271, (2008); Moschos S.A., Williams A.E., Perry M.M., Et al., Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids, BMC Genomics, 8, (2007); Pino-Yanes M., Tejera P., Corrales A., Common Variants of the interleukin-1 Receptor-associated Kinase 3 Gene Are Associated with Susceptibility to Sepsis Induced-acute Lung Injury; Taganov K.D., Boldin M.P., Chang K.-J., Baltimore D., NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses, Proceedings of the National Academy of Sciences of the United States of America, 103, 33, pp. 12481-12486, (2006); Nahid M.A., Pauley K.M., Satoh M., Chan E.K., MiR-146a is critical for endotoxin-induced tolerance: Implication in innate immunity, J Biol Chem, 284, pp. 34590-34599, (2009); Bazzoni F., Rossato M., Fabbri M., Et al., Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals, Proc Natl Acad Sci U S A, 106, pp. 5282-5287, (2009); Liu X., Zhan Z., Xu L., Et al., MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha, J Immunol, 185, pp. 7244-7251, (2010); Liu G., Friggeri A., Yang Y., Et al., MiR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses, Proc Natl Acad Sci U S A, 106, pp. 15819-15824, (2009); Tili E., Michaille J.J., Cimino A., Et al., Modulation of miR-155 and miR-125b levels following lipopolysaccharide/ TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock, J Immunol, 179, pp. 5082-5089, (2007); Wang X., Zhao Q., Matta R., Et al., Inducible nitric-oxide synthase expression is regulated by mitogen-activated protein kinase phosphatase-1, J Biol Chem, 284, pp. 27123-27134, (2009); Sheedy F.J., Palsson-Mcdermott E., Hennessy E.J., Et al., Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21, Nat Immunol, 11, pp. 141-147, (2010); Ma F., Liu X., Li D., Et al., MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation, J Immunol, 184, pp. 6053-6059, (2010); Gamazon E., Im H.-K., Duan S., Et al., ExprTarget: An integrative approach to predicting human microRNA targets, PLoS ONE, 5, (2010); Vaporidi K., Iliopoulos D., Francis R.C., Bloch K.D., Zapol W.M., MicroRNA expression profile in a murine model of ventilator-induced lung injury, Am J Respir Crit Care Med, 181, (2010); Zambon M., Vincent J.-L., Mortality rates for patients with acute lung injury/ARDS have decreased over time, Chest, 133, 5, pp. 1120-1127, (2008); Spizzo R., Rushworth D., Guerrero M., Calin G.A., RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment, Clin Lymphoma Myeloma, 9, (2009); Alevizos I., Illei G.G., MicroRNAs as biomarkers in rheumatic diseases, Nature Rev, 6, pp. 391-398, (2010); Dimmeler S., Zeiher A.M., Circulating microRNAs: Novel biomarkers for cardiovascular diseases?, Eur Heart J, 31, pp. 2705-2707, (2010); Ferracin M., Veronese A., Negrini M., Micromarkers: MiRNAs in cancer diagnosis and prognosis., Expert Rev Mol Diagn, 10, pp. 297-308; Wang J.F., Yu M.L., Yu G., Et al., Serum miR-146a and miR-223 as potential new biomarkers for sepsis, Biochem Biophys Res Commun, 394, pp. 184-188, (2010); Vasilescu C., Rossi S., Shimizu M., Et al., MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis, PLoS One, 4, (2009); Lewis B.P., Burge C.B., Bartel D.P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, Cell, 120, 1, pp. 15-20, (2005); Lewis B.P., Shih I.-H., Jones-Rhoades M.W., Bartel D.P., Burge C.B., Prediction of Mammalian MicroRNA Targets, Cell, 115, 7, pp. 787-798, (2003); Krek A., Grun D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., Da Piedade I., Gunsalus K.C., Stoffel M., Rajewsky N., Combinatorial microRNA target predictions, Nature Genetics, 37, 5, pp. 495-500, (2005); Sethupathy P., Megraw M., Hatzigeorgiou A.G., A guide through present computational approaches for the identification of mammalian microRNA targets, Nature Methods, 3, 11, pp. 881-886, (2006); Papadopoulos G.L., Reczko M., Simossis V.A., Sethupathy P., Hatzigeorgiou A.G., The database of experimentally supported targets: A functional update of TarBase, Nucleic Acids Res, 37, (2009); Storey J.D., Madeoy J., Strout J.L., Et al., Gene-expression variation within and among human populations, Am J Hum Genet, 80, pp. 502-509, (2007); Zhang W., Huang R.S., Duan S., Dolan M.E., Gene set enrichment analyses revealed differences in gene expression patterns between males and females, In Silico Biol, 9, pp. 55-63, (2009); Zhang W., Bleibel W.K., Roe C.A., Cox N.J., Eileen Dolan M., Gender-specific differences in expression in human lymphoblastoid cell lines, Pharmacogenetics and Genomics, 17, 6, pp. 447-450, (2007)","W. Zhang; Department of Pediatrics, University of Illinois at Chicago, MC856, Chicago, IL 60612, 840 S. Wood Street, United States; email: weizhan1@uic.edu","","Mosby Inc.","","","","","","19315244","","","21420028","English","Transl. Res.","Review","Final","All Open Access; Green Open Access","Scopus","2-s2.0-79952781841"
"Laffer C.L.; Gainer J.V.; Waterman M.R.; Capdevila J.H.; Laniado-Schwartzman M.; Nasjletti A.; Brown N.J.; Elijovich F.","Laffer, Cheryl L. (6701373114); Gainer, James V. (7006365872); Waterman, Michael R. (7101793212); Capdevila, Jorge H. (7101602718); Laniado-Schwartzman, Michal (7005674496); Nasjletti, Alberto (7006966438); Brown, Nancy J. (54790606300); Elijovich, Fernando (7004345799)","6701373114; 7006365872; 7101793212; 7101602718; 7005674496; 7006966438; 54790606300; 7004345799","The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension","2008","Hypertension","51","3","","767","772","5","65","10.1161/HYPERTENSIONAHA.107.102921","https://www.scopus.com/inward/record.uri?eid=2-s2.0-39749115601&doi=10.1161%2fHYPERTENSIONAHA.107.102921&partnerID=40&md5=ba645786b60e735201ecddeadcc92f94","Texas A and M Health Science Center College of Medicine, Temple, TX, United States; Vanderbilt University Medical Center, Nashville, TN, United States; New York Medical College, Valhalla, NY, United States; Texas A and M Health Science Center College of Medicine, Scott and White-Hypertension/Nephrology, Temple, TX 76508, 2401 S 31st St, United States","Laffer C.L., Texas A and M Health Science Center College of Medicine, Temple, TX, United States, Texas A and M Health Science Center College of Medicine, Scott and White-Hypertension/Nephrology, Temple, TX 76508, 2401 S 31st St, United States; Gainer J.V., Vanderbilt University Medical Center, Nashville, TN, United States; Waterman M.R., Vanderbilt University Medical Center, Nashville, TN, United States; Capdevila J.H., Vanderbilt University Medical Center, Nashville, TN, United States; Laniado-Schwartzman M., New York Medical College, Valhalla, NY, United States; Nasjletti A., New York Medical College, Valhalla, NY, United States; Brown N.J., Vanderbilt University Medical Center, Nashville, TN, United States; Elijovich F., Texas A and M Health Science Center College of Medicine, Temple, TX, United States","A role for a deficit in transport actions of 20-hydroxyeicosatetraenoic acid (20-HETE) in hypertension is supported by the following: (1) diminished renal 20-HETE in Dahl-S rats; (2) altered salt- and furosemide-induced 20-HETE responses in salt-sensitive hypertensive subjects; and (3) increased population risk for hypertension in C allele carriers of the T8590C polymorphism of CYP4A11, which encodes an enzyme with reduced catalytic activity. We determined T8590C genotypes in 32 hypertensive subjects, 25 of whom were phenotyped for salt sensitivity of blood pressure and insulin sensitivity. Urine 20-HETE was lowest in insulin-resistant, salt-sensitive subjects (F=5.56; P<0.02). Genotypes were 13 TT, 2 CC, and 17 CT. C allele frequency was 32.8% (blacks: 38.9%; whites: 25.0%). C carriers (CC+CT) and TT subjects were similarly distributed among salt- and insulin-sensitivity phenotypes. C carriers had higher diastolic blood pressures and aldosterone:renin and waist:hip ratios but lower furosemide-induced fractional excretions of Na and K than TT. The T8590C genotype did not relate to sodium balance or pressure natriuresis. However, C carriers, compared with TT, had diminished 20-HETE responses to salt loading after adjustment for serum insulin concentration and resetting of the negative relationship between serum insulin and urine 20-HETE to a 1-μg/h lower level of 20-HETE. The effect of C was insulin independent and equipotent to 18 μU/mL of insulin (Δ20-HETE= 2.84-0.054×insulin-0.98×C; r=0.53; F=11.1; P<0.001). Hence, genetic (T8590C) and environmental (insulin) factors impair 20-HETE responses to salt in human hypertension. We propose that genotype analyses with sufficient homozygous CC will establish definitive relationships among 20-HETE, salt sensitivity of blood pressure, and insulin resistance. © 2008 American Heart Association, Inc.","Arachidonic acid; Cytochrome P450; Hypertension; Insulin; Insulin resistance; Obesity","Adult; Blood Pressure; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Genotype; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Insulin; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; 20 hydroxyicosatetraenoic acid; cytochrome P450 4A11; furosemide; insulin; potassium; sodium; adult; allele; article; Caucasian; clinical article; controlled study; Dahl salt sensitive rat; diastolic blood pressure; enzyme mechanism; essential hypertension; female; gene frequency; genetic polymorphism; genotype; heterozygote; homozygosity; human; insulin blood level; insulin resistance; insulin sensitivity; kidney; male; natriuresis; Negro; phenotype; population risk; priority journal; renin angiotensin aldosterone system; salt loading; sodium balance; statistical significance; urinary excretion; waist hip ratio","","20 hydroxyicosatetraenoic acid, 79551-86-3; furosemide, 54-31-9; insulin, 9004-10-8; potassium, 7440-09-7; sodium, 7440-23-5; 20-hydroxy-5,8,11,14-eicosatetraenoic acid, 79551-86-3; CYP4A11 protein, human, EC 1.14.15.3; Cytochrome P-450 Enzyme System, 9035-51-2; Hydroxyeicosatetraenoic Acids, ; Insulin, 11061-68-0","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL065193)","","Imig J.D., Zou A.P., Stec D.E., Harder D.R., Falck J.R., Roman R.J., Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles, Am J Physiol, 270, (1996); Alonso-Galicia M., Falck J.R., Reddy K.M., Roman R.J., 20-HETE agonists and antagonists in the renal circulation, Am J Physiol, 277, (1999); Kauser K., Clark J.E., Masters B.S., Ortiz de Montellano P.R., Ma Y.H., Harder D.R., Roman R.J., Inhibitors of cytochrome P-450 attenuate the myogenic response of dog renal arcuate arteries, Circ Res, 68, pp. 1154-1163, (1991); Imig J.D., Zou A.P., Ortiz de Montellano P.R., Sui Z., Roman R.J., Cytochrome P-450 inhibitors alter afferent arteriolar responses to elevations in pressure, Am J Physiol, 266, (1994); Nowicki S., Chen S.L., Aizman O., Cheng X.J., Li D., Nowicki C., Nairn A., Greengard P., Aperia A., 20-Hydroxyeicosa-tetraenoic acid (20 HETE) activates protein kinase C: Role in regulation of rat renal Na+,K+-ATPase, J Clin Invest, 99, pp. 1224-1230, (1997); Ribeiro C.M., Dubay G.R., Falck J.R., Mandel L.J., Parathyroid hormone inhibits Na(+)-K(+)-ATPase through a cytochrome P-450 pathway, Am J Physiol, 266, (1994); Escalante B., Erlij D., Falck J.R., McGiff J.C., Cytochrome P-450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb, Am J Physiol, 266, (1994); Stec D.E., Deng A.Y., Rapp J.P., Roman R.J., Cytochrome P4504A genotype cosegregates with hypertension in Dahl S rats, Hypertension, 27, pp. 564-568, (1996); Zou A.P., Drummond H.A., Roman R.J., Role of 20-HETE in elevating loop chloride reabsorption in Dahl SS/Jr rats, Hypertension, 27, pp. 631-635, (1996); Roman R.J., Hoagland K.M., Lopez B., Kwitek A.E., Garrett M.R., Rapp J.P., Lazar J., Jacob H.J., Sarkis A., Characterization of blood pressure and renal function in chromosome 5 congenic strains of Dahl S rats, Am J Physiol, 290, (2006); Vera T., Taylor M., Bohman Q., Flasch A., Roman R.J., Stec D.E., Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice, Hypertension, 45, pp. 730-735, (2005); Gainer J.V., Bellamine A., Dawson E.P., Womble K.E., Grant S.W., Wang Y., Cupples L.A., Guo C.Y., Demissie S., O'Donnell C.J., Brown N.J., Waterman M.R., Capdevila J.H., Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension, Circulation, 111, pp. 63-69, (2005); Mayer B., Lieb W., Gotz A., Konig I.R., Aherrahrou Z., Thiemig A., Holmer S., Hengstenberg C., Doering A., Loewel H., Hense H.W., Schunkert H., Erdmann J., Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy, Hypertension, 46, pp. 766-771, (2005); Laffer C.L., Laniado-Schwartzman M., Wang M.H., Nasjletti A., Elijovich F., Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension, Circulation, 107, pp. 574-578, (2003); Laffer C.L., Laniado-Schwartzman M., Wang M.H., Nasjletti A., Elijovich F., 20-HETE and furosemide-induced natriuresis in salt-sensitive essential hypertension, Hypertension, 41, pp. 703-708, (2003); Laffer C.L., Laniado-Schwartzman M., Nasjletti A., Elijovich F., 20-HETE and circulating insulin in essential hypertension with obesity, Hypertension, 43, pp. 388-392, (2004); Reaven G.M., Twersky J., Chang H., Abnormalities of carbohydrate and lipid metabolism in Dahl rats, Hypertension, 18, pp. 630-635, (1991); Radziuk J., Insulin sensitivity and its measurement: Structural commonalities among the methods, J Clin Endocrinol Metab, 85, pp. 4426-4433, (2000); Sealey J.E., Gerten-Banes J., Laragh J.H., The renin system: Variations in man measured by radioimmunoassay or bioassay, Kidney Intl, 1, pp. 240-253, (1972); Antunes J.R., Dale S.L., Melby J.C., Simplified radioimmunoassay for aldosterone using antisera to aldosterone-gamma-lactone, Steroids, 28, pp. 621-630, (1976); Stec D.E., Mattson D.L., Roman R.J., Inhibition of renal outer medullary 20-HETE production produces hypertension in Lewis rats, Hypertension, 29, pp. 315-319, (1997); Stec D.E., Roman R.J., Flasch A., Rieder M.J., Functional polymorphism in human CYP4F2 decreases 20-HETE production, Physiol Genomics, 30, pp. 74-81, (2007); Nakagawa K., Holla V.R., Wei Y., Wang W.H., Gatica A., Wei S., Mei S., Miller C.M., Cha D.R., Price Jr E., Zent R., Pozzi A., Breyer M.D., Guan Y., Falck J.R., Waterman M.R., Capdevila J.H., Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel, J Clin Invest, 116, pp. 1696-1702, (2006); Holla V.R., Adas F., Imig J.D., Zhao X., Price Jr E., Olsen N., Kovacs W.J., Magnuson M.A., Keeney D.S., Breyer M.D., Falck J.R., Waterman M.R., Capdevila J.H., Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension, Proc Natl Acad Sci U S A, 98, pp. 5211-5216, (2001); Hoagland K.M., Alonso-Galicia M., Maier K.G., Flasch A.K., Wang X., Jacob H.J., Nobrega M., Rapp J.P., Garrett M.R., Roman R.J., Evaluation of P4504a genes for hypertension and renal disease using chromosome 5 congenic strains of Dahl S rats, Hypertension, (2000); Carroll M.A., Balazy M., Huang D.D., Rybalova S., Falck J.R., McGiff J.C., Cytochrome P450-derived renal HETEs: Storage and release, Kidney Intl, 51, pp. 1696-1702, (1997); Sankaralingam S., Desai K.M., Glaeser H., Kim R.B., Wilson T.W., Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats, Am J Hypertens, 19, pp. 1174-1180, (2006); Shimojo N., Ishizaki T., Imaoka S., Funae Y., Fuji S., Okuda K., Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes, Biochem Pharmacol, 46, pp. 621-627, (1993); Klisic J., Hu M.C., Nief V., Reyes L., Fuster D., Moe O.W., Ambuhl P.M., Insulin activates Na /H exchanger 3: Biphasic response and glucocorticoid dependence, Am J Physiol, 283, (2002); Song J., Hu X., Riazi S., Tiwari S., Wade J.B., Ecelbarger C.A., Regulation of blood pressure, the epithelial sodium channel (ENaC), and other key renal sodium transporters by chronic insulin infusion in rats, Am J Physiol, 290, (2006); Zhang Y.H., Alvarez de la Rosa D., Canessa C.M., Hayslett J.P., Insulin-induced phosphorylation of ENaC correlates with increased sodium channel function in A6 cells, Am J Physiol, 288, pp. 141-147, (2005); Raji A., Williams G.H., Jeunemaitre X., Hopkins P.N., Hunt S.C., Hollenberg N.K., Seely E.W., Insulin resistance in hypertensives: Effect of salt sensitivity, renin status and sodium intake, J Hypertens, 19, pp. 99-105, (2001); Grunfeld B., Balzareti H., Romo H., Gimenez M., Gutman R., Hyperinsulinemia in normotensive offspring of hypertensive parents, Hypertension, 23, (1994); Fuenmayor N., Moreira E., Cubeddu L.X., Salt sensitivity is associated with insulin resistance in essential hypertension, Am J Hypertens, 11, pp. 397-402, (1998)","C.L. Laffer; Texas A and M Health Science Center College of Medicine, Scott and White-Hypertension/Nephrology, Temple, TX 76508, 2401 S 31st St, United States; email: claffer@swmail.sw.org","","","","","","","","0194911X","","HPRTD","18227405","English","Hypertension","Article","Final","All Open Access; Bronze Open Access; Green Open Access","Scopus","2-s2.0-39749115601"
"Semplicini A.; Lenzini L.; Sartori M.; Papparella I.; Calò L.A.; Pagnin E.; Strapazzon G.; Benna C.; Costa R.; Avogaro A.; Ceolotto G.; Pessina A.C.","Semplicini, Andrea (7007054701); Lenzini, Livia (8512433500); Sartori, Michelangelo (56670877000); Papparella, Italia (8512434200); Calò, Lorenzo A. (7006843777); Pagnin, Elisa (6603565342); Strapazzon, Giacomo (13610638800); Benna, Clara (56203904100); Costa, Rodolfo (7203063540); Avogaro, Angelo (7004560383); Ceolotto, Giulio (6603785731); Pessina, Achille C. (36041194300)","7007054701; 8512433500; 56670877000; 8512434200; 7006843777; 6603565342; 13610638800; 56203904100; 7203063540; 7004560383; 6603785731; 36041194300","Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II","2006","Journal of Hypertension","24","6","","1115","1124","9","112","10.1097/01.hjh.0000226202.80689.8f","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646852581&doi=10.1097%2f01.hjh.0000226202.80689.8f&partnerID=40&md5=d8aa732fba5a5d1f013b1881f5e00784","Department of Clinical and Experimental Medicine, University of Padova, Italy; Department of Biology, University of Padova, Italy; Clinica Medica 4 - Policlinico Universitario, Department of Clinical and Experimental Medicine, 35128 Padova, Via Giustiniani 2, Italy","Semplicini A., Department of Clinical and Experimental Medicine, University of Padova, Italy, Clinica Medica 4 - Policlinico Universitario, Department of Clinical and Experimental Medicine, 35128 Padova, Via Giustiniani 2, Italy; Lenzini L., Department of Clinical and Experimental Medicine, University of Padova, Italy; Sartori M., Department of Clinical and Experimental Medicine, University of Padova, Italy; Papparella I., Department of Clinical and Experimental Medicine, University of Padova, Italy; Calò L.A., Department of Clinical and Experimental Medicine, University of Padova, Italy; Pagnin E., Department of Clinical and Experimental Medicine, University of Padova, Italy; Strapazzon G., Department of Clinical and Experimental Medicine, University of Padova, Italy; Benna C., Department of Biology, University of Padova, Italy; Costa R., Department of Biology, University of Padova, Italy; Avogaro A., Department of Clinical and Experimental Medicine, University of Padova, Italy; Ceolotto G., Department of Clinical and Experimental Medicine, University of Padova, Italy; Pessina A.C., Department of Clinical and Experimental Medicine, University of Padova, Italy","Context: RGS2 (regulators of G-protein signaling) is a negative regulator of Gαq protein signaling, which mediates the action of several vasoconstrictors. RGS2-deficient mouse line exhibits a hypertensive phenotype and a prolonged response to vasoconstrictors. Objective: To compare RGS2 expression in peripheral blood mononuclear cells (PBMs) and cultured fibroblasts from normotensive subjects and hypertensive patients. Methods: PBMs were isolated from 100 controls and 150 essential hypertensives. Additionally, fibroblasts were isolated from skin biopsy of 11 normotensives and 12 hypertensives and cultured up to the third passage. Quantitative mRNA and protein RGS2 expression were performed by real-time quantitative reverse transcriptase-polymerase chain reaction and by immunoblotting, respectively. Free Ca2+ measurement was performed in monolayers of 24-h serum-deprived cells, using FURA-2 AM. Phosphorylation of the extracellular signal-regulated kinases ERK1/2 was measured by immunoblotting. Polymorphism (C1114G) in the 3′ untranslated region of the RGS2 gene was investigated by direct sequencing and real-time polymerase chain reaction (PCR). Results: RGS2 mRNA expression was significantly lower in PBM and in fibroblasts from hypertensives, in comparison to normotensives. C1114G polymorphism was associated with RGS2 expression, with the lowest values in GG hypertensives. The 1114G allele frequency was increased in hypertensives compared with normotensives. Angiotensin II-stimulated intracellular Ca2+ increase and ERK1/2 phosphorylation were higher in fibroblasts from hypertensive patients compared with control subjects, and in those with the G allele, independently of the blood pressure status. The angiotensin II-stimulated Ca2+ mobilization and ERK1/2 phosphorylation were negatively correlated with RGS2 mRNA expression. Conclusion: Low expression of RGS2 contributes to increased G-protein-coupled signaling in hypertensive patients. The allele G is associated with low RGS2 expression and blood pressure increase in humans. © 2006 Lippincott Williams & Wilkins.","Angiotensin II; Arterial hypertension; Fibroblasts; Intracellular calcium; RGS2","angiotensin II; calcium ion; cytosine; fura 2 acetoxymethyl ester; guanine; messenger RNA; mitogen activated protein kinase 1; mitogen activated protein kinase 3; RGS2 protein; 3' untranslated region; adult; article; calcium cell level; calcium mobilization; cell culture; cell isolation; controlled study; correlation analysis; enzyme phosphorylation; female; fibroblast; gene; gene frequency; human; hypertension; immunoblotting; major clinical study; male; monolayer culture; nucleotide sequence; peripheral blood mononuclear cell; priority journal; protein expression; protein function; quantitative assay; real time polymerase chain reaction; reverse transcription polymerase chain reaction; Rgs2 gene; sequence analysis; serum; skin biopsy","GENBANK: M33197, NM_002923","angiotensin II, 11128-99-7, 68521-88-0; calcium ion, 14127-61-8; cytosine, 71-30-7; fura 2 acetoxymethyl ester, 105344-37-4, 108964-32-5; guanine, 69257-39-2, 73-40-5; mitogen activated protein kinase 1, 137632-08-7; mitogen activated protein kinase 3, 137632-07-6","","","","","Farfel Z., Bourne H.R., Iiri T., The expanding spectrum of G protein diseases, N Engl J Med, 340, pp. 1012-1020, (1999); Iiri T., Farfel Z., Bourne H.R., G-protein diseases furnish a model for the turn-on switch, Nature, 394, pp. 35-38, (1998); Sprang S.R., G protein mechanisms: Insights from structural analysis, Annu Rev Biochem, 66, pp. 639-678, (1997); Kehrl J.H., Sinnarajah S., RGS2: A multifunctional regulator of G-protein signaling, Int J Biochem Cell Biol, 34, pp. 432-438, (2002); Le T.H., Coffman T.M., RGS2: A 'turn-off' in hypertension, J Clin Invest, 111, pp. 441-443, (2003); Heximer S.P., Knutsen R.H., Sun X., Kaltenbronn K.M., Rhee M.H., Peng N., Et al., Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice, J Clin Invest, 111, pp. 445-452, (2003); Yang J., Kamide K., Kokubo Y., Takiuchi S., Tanaka C., Banno M., Et al., Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population, J Hypertens, 23, pp. 1497-1505, (2005); Sun X., Kaltenbronn K.M., Steinberg T.H., Blumer K.J., RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling, Mol Pharmacol, 67, pp. 631-639, (2005); Dupuis M., Soubrier F., Brocheriou I., Raoux S., Haloui M., Louedec L., Et al., Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats, Circulation, 110, pp. 867-873, (2004); Ceolotto G., Gallo A., Sartori M., Valente R., Baritono E., Semplicini A., Et al., Hyperglycemia acutely increases monocyte extracellular signal-regulated kinase activity in vivo in humans, J Clin Endocrinol Metab, 86, pp. 1301-1305, (2001); Pfaffl M.W., A new mathematical model for relative quantification in real-time RT-PCR, Nucl Acids Res, 29, (2001); Ceolotto G., Pessina A.C., Iori E., Monari A., Trevisan R., Winkleswski P., Et al., Modulatory effect of insulin on release of calcium from human fibroblasts by angiotensin II, J Hypertens, 16, pp. 487-493, (1998); Trevisan R., Yip J., Sarika L., Kuen L.L., Viberti G., Enhanced collagen synthesis in cultured skin fibroblasts from insulin-dependent diabetic patients with nephropathy, J Am Soc Nephrol, 12, pp. 1133-1139, (1997); Jin D.K., Kim Y., Mauer M., Fioretto P., Vats A., Fish A.J., Relationships of cell proliferation and expression of integrin subunits and type I collagen in skin fibroblasts with renal lesions in patients with IDDM, Am J Kidney Dis, 31, pp. 293-300, (1998); Grynkiewicz G., Poenie M., Tsien R.Y., A new generation of calcium indicators with greatly improved fluorescence properties, J Biol Chem, 260, pp. 3440-3450, (1985); Papparella I., Ceolotto G., Lenzini L., Mazzoni M., Franco L., Sartori M., Et al., Angiotensin II-induced over-activation of p47phox in fibroblasts from hypertensives: Which role in the enhanced ERK1/2 responsiveness to angiotensin II?, J Hypertens, 23, pp. 793-800, (2005); Mignone F., Gissi C., Liuni S., Pesole G., Untranslated regions of mRNAs, Genome Biol, (2002); Touyz R.M., The role of angiotensin II in regulating vascular structural and functional changes in hypertension, Curr Hypertens Rep, 5, pp. 155-164, (2003); Rogers T.B., Lokuta A.J., Angiotensin II signal transduction pathways in the cardiovascular system, Trends Cardiovasc Med, 4, pp. 110-116, (1994); Li Y., Hashim S., Anand-Srivastava M.B., Angiotensin II-evoked enhanced expression of RGS2 attenuates Gi-mediated adenylyl cyclase signaling in A10 cells, Cardiovasc Res, 66, pp. 503-511, (2005); Calo L.A., Pagnin E., Davis P.A., Sartori M., Ceolotto G., Pessina A.C., Et al., Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension, J Clin Endocrinol Metab, 89, pp. 4153-4157, (2004); Tang M., Wang G., Lu P., Karas R.H., Aronovitz M., Heximer S.P., Et al., Regulator of G-protein signalling-2 mediates vascular smooth muscle relaxation and blood pressure, Nat Med, 9, pp. 1506-1512, (2003); Grant S.L., Lassegue B., Griendling K.K., Ushio-Fukai M., Lyons P.R., Alexander R.W., Specific regulation of RGS2 messenger RNA by angiotensin II in cultured vascular smooth muscle cells, Mol Pharmacol, 57, pp. 460-467, (2000); Ros R., Atherosclerosis - An inflammatory disease, N Engl J Med, 340, pp. 115-126, (1999); Hilgers K.F., Monocytes/macrophages in hypertension, J Hypertens, 20, pp. 593-596, (2002); Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., Diez J., Biochemical assessment of myocardial fibrosis in hypertensive heart disease, Hypertension, 38, pp. 1222-1226, (2001); Nickenig G., Geisen G., Vetter H., Sachinidis A., Characterization of angiotensin receptors on human skin fibroblasts, J Mol Med, 75, pp. 217-222, (1997); Raghavan A., Dhalla M., Bakheet T., Ogilvie R.L., Vlasova I.A., Khabar K.S., Et al., Patterns of coordinate down-regulation of ARE-containing transcripts following immune cell activation, Genomics, 84, pp. 1002-1013, (2004); Hofacker I.L., Vienna RNA secondary structure server, Nucl Acids Res, 31, pp. 3429-3431, (2003); Perola M., Kainulainen K., Pajukanta P., Terwilliger J.D., Hiekkalinna T., Ellonen P., Et al., Genome-wide scan of predisposing loci for increased diastolic blood pressure in Finnish siblings, J Hypertens, 8, pp. 1579-1585, (2000); Mitchell G.F., Vita J.A., Larson M.G., Parise H., Keyes M.J., Warner E., Et al., Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: The Framingham Heart Study, Circulation, 112, pp. 3722-3728, (2005); Pausova Z., Gaudet D., Gossard F., Bernard M., Kaldunski M.L., Jomphe M., Et al., Genome-wide scan for linkage to obesity-associated hypertension in French Canadians, Hypertension, 46, pp. 1280-1285, (2005); Wilk J.B., Djousse L., Arnett D.K., Hunt S.C., Province M.A., Heiss G., Et al., Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study, Am J Hypertens, 17, pp. 839-844, (2004); Benjafield A.V., Wang W.Y., Speirs H.J., Morris B.J., Genome-wide scan for hypertension in Sydney Sibships: The GENIHUSS study, Am J Hypertens, 18, pp. 828-832, (2005)","A. Semplicini; Clinica Medica 4 - Policlinico Universitario, Department of Clinical and Experimental Medicine, 35128 Padova, Via Giustiniani 2, Italy; email: andrea.semplicini@unipd.it","","Lippincott Williams and Wilkins","","","","","","02636352","","JOHYD","16685212","English","J. Hypertens.","Article","Final","","Scopus","2-s2.0-33646852581"
"Kamide K.; Kokubo Y.; Fukuhara S.; Hanada H.; Yang J.; Kada A.; Nagura J.; Takiuchi S.; Horio T.; Kawano Y.; Okayama A.; Tomoike H.; Miyata T.","Kamide, Kei (7102978326); Kokubo, Yoshihiro (56155004000); Fukuhara, Shigetomo (7102147413); Hanada, Hironori (56843429400); Yang, Jin (57192455501); Kada, Akiko (17135077400); Nagura, Junko (9736490800); Takiuchi, Shin (7004120849); Horio, Takeshi (59048932700); Kawano, Yuhei (26643119800); Okayama, Akira (56421646700); Tomoike, Hitonobu (7103005104); Miyata, Toshiyuki (56381961600)","7102978326; 56155004000; 7102147413; 56843429400; 57192455501; 17135077400; 9736490800; 7004120849; 59048932700; 26643119800; 56421646700; 7103005104; 56381961600","Protein tyrosine kinase 2β as a candidate gene for hypertension","2007","Pharmacogenetics and Genomics","17","11","","931","939","8","8","10.1097/FPC.0b013e3282ef640e","https://www.scopus.com/inward/record.uri?eid=2-s2.0-37349079875&doi=10.1097%2fFPC.0b013e3282ef640e&partnerID=40&md5=2dac663bc83037a74395229f5d52ccff","Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka, Japan; Division of Preventive Cardiology, National Cardiovascular Center, Suita, Osaka, Japan; Research Institute, National Cardiovascular Center, Suita, Osaka, Japan; Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka 565-8565, 5-7-1 Fujishirodai, Japan","Kamide K., Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka, Japan, Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka 565-8565, 5-7-1 Fujishirodai, Japan; Kokubo Y., Division of Preventive Cardiology, National Cardiovascular Center, Suita, Osaka, Japan; Fukuhara S., Research Institute, National Cardiovascular Center, Suita, Osaka, Japan; Hanada H., Research Institute, National Cardiovascular Center, Suita, Osaka, Japan; Yang J., Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka, Japan; Kada A., Research Institute, National Cardiovascular Center, Suita, Osaka, Japan; Nagura J., Division of Preventive Cardiology, National Cardiovascular Center, Suita, Osaka, Japan; Takiuchi S., Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka, Japan; Horio T., Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka, Japan; Kawano Y., Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka, Japan; Okayama A., Division of Preventive Cardiology, National Cardiovascular Center, Suita, Osaka, Japan; Tomoike H., Division of Preventive Cardiology, National Cardiovascular Center, Suita, Osaka, Japan; Miyata T., Research Institute, National Cardiovascular Center, Suita, Osaka, Japan","Protein tyrosine kinase 2β (PTK2B) is a member of the focal adhesion kinase family and is activated by angiotensin II through Ca-dependent pathways. An evidence exists that PTK2B is involved in cell growth, vascular contraction, inflammatory responses, and salt and water retention through activation of the angiotensin II type 1 receptor. To examine the contribution of PTK2B, we sequenced the PTK2B gene using 48 patients with hypertension, identified 62 genetic polymorphisms, and genotyped six representative single nucleotide polymorphisms in population-based case-control samples from 3655 Japanese individuals (1520 patients with hypertension and 2135 controls). Multivariate logistic regression analysis after adjustments for age, body mass index, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking) showed -22A>G to have an association with hypertension in men (AA vs. AG+GG: odds ratio=1.27; 95% confidence interval: 1.02-1.57; P=0.030). Another polymorphism, 53484A>C (K838T), in linkage disequilibrium with -22A>G showed a marginal association with hypertension in men (AA vs. AC+CC: odds ratio=1.25; 95% confidence interval: 0.99-1.57; P=0.059). Diastolic blood pressure was 1.6 mmHg higher in men with the AC+CC genotype of 53484A>C than those with the AA genotype (P=0.003), after adjustments for the same factors. These polymorphisms are in linkage disequilibrium with others in a range of 113 kb in PTK2B. The intracellular distribution of the recombinant PTK2B protein and that of the mutant protein with T838 were indistinguishable even after angiotensin II stimulation, both proteins localizing at a focal point in the peripheral area in the cells. Thus, a haplotype in PTK2B may play a role in essential hypertension in Japanese. © 2007 Lippincott Williams & Wilkins, Inc.","Focal adhesion kinase 2; Genetic variation; Hypertension; Protein tyrosine kinase 2β","Aged; Amino Acid Sequence; Animals; Blood Pressure; Case-Control Studies; Cells, Cultured; Endothelium, Vascular; Female; Focal Adhesion Kinase 2; Genetic Predisposition to Disease; Humans; Hypertension; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polymorphism, Single Nucleotide; Rats; Sequence Homology, Amino Acid; Umbilical Veins; calcium ion; mutant protein; protein tyrosine kinase; protein tyrosine kinase 2beta; recombinant protein; unclassified drug; adult; aged; article; body mass; cellular distribution; confidence interval; controlled study; diabetes mellitus; diastolic blood pressure; disease association; drinking; female; gene function; gene linkage disequilibrium; gene sequence; genetic association; genetic polymorphism; genotype; haplotype; human; hyperlipidemia; hypertension; Japanese; lifestyle; major clinical study; male; multivariate logistic regression analysis; population based case control study; priority journal; protein localization; sample (statistics); single nucleotide polymorphism; smoking","","calcium ion, 14127-61-8; protein tyrosine kinase, 80449-02-1; Focal Adhesion Kinase 2, 2.7.1.112; PTK2B protein, human, 2.7.1.-; Ptk2b protein, rat, 2.7.1.112","","","","","Ardaillou R., Angiotensin II receptors, J Am Soc Nephrol, 10, SUPPL. 11, (1999); Touyz R.M., Berry C., Recent advances in angiotensin II signaling, Braz J Med Biol Res, 35, pp. 1001-1015, (2002); Allen A.M., Zhuo J., Mendelsohn F.A., Localization and function of angiotensin AT1 receptors, Am J Hypertens, 13, (2000); Schaller M.D., Borgman C.A., Cobb B.S., Vines R.R., Reynolds A.B., Parsons J.T., pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions, Proc Natl Acad Sci U S A, 89, pp. 5192-5196, (1992); Orr A.W., Murphy-Ullrich J.E., Regulation of endothelial cell function BY FAK and PYK2, Front Biosci, 9, pp. 1254-1266, (2004); Avraham H., Park S.Y., Schinkmann K., Avraharm S., RAFTK/Pyk2-mediated cellular signalling, Cell Signal, 12, pp. 123-133, (2000); Inagami T., Eguchi S., Angiotensin II-mediated vascular smooth muscle cell growth signaling, Braz J Med Biol Res, 33, pp. 619-624, (2000); Schlaepfer D.D., Hauck C.R., Sieg D.J., Signaling through focal adhesion kinase, Prog Biophys Mol Biol, 71, pp. 435-478, (1999); Mannami T., Baba S., Ogata J., Strong and significant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city: The Suita Study, Arch Intern Med, 160, pp. 2297-2303, (2000); Kokubo Y., Inamoto N., Tomoike H., Kamide K., Takiuchi S., Kawano Y., Et al., Association of genetic polymorphisms of sodium-calcium exchanger 1 gene, NCX1, with hypertension in a Japanese general population, Hypertens Res, 27, pp. 697-702, (2004); Kamide K., Takiuchi S., Tanaka C., Miwa Y., Yoshii M., Horio T., Et al., Three novel missense mutations of WNK4, a kinase mutated in inherited hypertension, in Japanese hypertensives: Implication of clinical phenotypes, Am J Hypertens, 17, pp. 446-449, (2004); Matayoshi T., Kamide K., Takiuchi S., Yoshii M., Miwa Y., Takami Y., Et al., The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics, Hypertens Res, 27, pp. 821-833, (2004); Tanaka C., Kamide K., Takiuchi S., Miwa Y., Yoshii M., Kawano Y., Et al., An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms, Hypertens Res, 26, pp. 301-306, (2003); Kokubo Y., Kamide K., Inamoto N., Tanaka C., Banno M., Takiuchi S., Et al., Identification of 108 SNPs in TSC, WNK1, and WNK4 and their association with hypertension in a Japanese general population, J Hum Genet, 49, pp. 507-515, (2004); The International HapMap Project, Nature, 426, pp. 789-796, (2003); Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: Analysis and visualization of LD and haplotype maps, Bioinformatics, 21, pp. 263-265, (2005); Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J., Et al., Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions, Mol Cell Biol, 23, pp. 8019-8029, (2003); Daou G.B., Srivastava A.K., Reactive oxygen species mediate Endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells, Free Radical Biol Med, 37, pp. 208-215, (2004); Kodama H., Fukuda K., Takahashi T., Sano M., Kato T., Tahara S., Et al., Role of EGF receptor and Pyk2 in endothelin-1-induced ERK activation in rat cardiomyocytes, J Mol Cell Cardiol, 34, pp. 139-150, (2002); Wang D., Yu X., Brecher P., Nitric oxide inhibits angiotensin II-induced activation of the calcium-sensitive tyrosine kinase proline-rich tyrosine kinase 2 without affecting epidermal growth factor receptor transactivation, J Biol Chem, 274, pp. 24342-24348, (1999); Blaschke F., Stawowy P., Kappert K., Goetze S., Kintscher U., Wollert-Wulf B., Et al., Angiotensin II-augmented migration of VSMCs towards PDGF-BB involves Pyk2 and ERK 1/2 activation, Basic Res Cardiol, 97, pp. 334-342, (2002); Rocic P., Jo H., Lucchesi P.A., A role for PYK2 in ANG II-dependent regulation of the PHAS-1-eIF4E complex by multiple signaling cascades in vascular smooth muscle, Am J Physiol Cell Physiol, 285, (2003); Owens G.K., Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells, Am J Physiol, 257, (1989); Rosendorff C., Vascular hypertrophy in hypertension: Role of the renin-angiotensin system, Mt Sinai J Med, 65, pp. 108-117, (1998); Berk B.C., Vallega G., Muslin A.J., Gordon H.M., Canessa M., Alexander R.W., Spontaneously hypertensive rat vascular smooth muscle cells in culture exhibit increased growth and Na<sup>+</sup>/H<sup>+</sup> exchange, J Clin Invest, 83, pp. 822-829, (1989); Rocic P., Griffin T.M., McRae C.N., Lucchesi P.A., Altered PYK2 phosphorylation by ANG II in hypertensive vascular smooth muscle, Am J Physiol Heart Circ Physiol, 282, (2002); Herzog H., Nicholl J., Hort Y.J., Sutherland G.R., Shine J., Molecular cloning and assignment of FAK2, a novel human focal adhesion kinase, to 8p11.2-p22 by nonisotopic in situ hybridization, Genomics, 32, pp. 484-486, (1996); Diz D.I., Approaches to establishing angiotensin II as a neurotransmitter revisited, Hypertension, 47, pp. 334-336, (2006); Reckelhoff J.F., Gender differences in the regulation of blood pressure, Hypertension, 37, pp. 1199-1208, (2001); Dantas A.P., Franco Mdo C., Silva-Antonialli M.M., Tostes R.C., Fortes Z.B., Nigro D., Et al., Gender differences in superoxide generation in microvessels of hypertensive rats: Role of NAD(P)H-oxidase, Cardiovasc Res, 61, pp. 22-29, (2004); Tatchum-Talom R., Eyster K.M., Martin D.S., Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations, Can J Physiol Pharmacol, 83, pp. 413-422, (2005); Xue B., Pamidimukkala J., Hay M., Sex differences in the development of angiotensin II-induced hypertension in conscious mice, Am J Physiol Heart Circ Physiol, 288, (2005); Sainz J., Osuna A., Wangensteen R., de Dios Luna J., Rodriguez- Gomez I., Duarte J., Et al., Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension, Exp Physiol, 89, pp. 155-162, (2004); Silva-Antonialli M.M., Tostes R.C., Fernandes L., Fior-Chadi D.R., Akamine E.H., Carvalho M.H., Et al., A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats, Cardiovasc Res, 62, pp. 587-593, (2004); Tatchum-Talom R., Martel C., Labrie C., Labrie F., Marette A., Gender differences in hemodynamic responses to endothelin-1, J Cardiovasc Pharmacol, 36, (2000); Jiang C., Sarrel P.M., Poole-Wilson P.A., Collins P., Acute effect of 17 beta-estradiol on rabbit coronary artery contractile responses to endothelin-1, Am J Physiol, 263, (1992); Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., Hirschhorn J.N., Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease, Nat Genet, 33, pp. 177-182, (2003)","K. Kamide; Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Osaka 565-8565, 5-7-1 Fujishirodai, Japan; email: kamide@hsp.ncvc.go.jp","","","","","","","","17446880","","","18075463","English","Pharmacogenet. Genomics","Article","Final","","Scopus","2-s2.0-37349079875"
"Siffert W.","Siffert, Winfried (7005096601)","7005096601","Cardiovascular pharmacogenetics: On the way toward individually tailored drug therapy","2003","Kidney International, Supplement","63","84","","S168","S171","3","14","10.1046/j.1523-1755.63.s84.38.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037408343&doi=10.1046%2fj.1523-1755.63.s84.38.x&partnerID=40&md5=e62d2c97d882768ac0c018eea483f2cc","Institut für Pharmakologie, Universitätsklinikum Essen, Essen, Germany; Institut für Pharmakologie, Universitätsklinikum Essen, D-45122 Essen, Hufelandstr.55, Germany","Siffert W., Institut für Pharmakologie, Universitätsklinikum Essen, Essen, Germany, Institut für Pharmakologie, Universitätsklinikum Essen, D-45122 Essen, Hufelandstr.55, Germany","G proteins are important mediators of hormone action in all cells of the human body. Therefore, functional polymorphisms in genes encoding G protein subunits are expected to have a marked influence upon cell activation and cardiovascular responses to hormones and drugs. The 825T allele of a common C825T polymorphism in the gene, GNB3, encoding the Gβ3 subunit, was found to be associated with increased intracellular signal transduction via G protein-coupled receptors. Originally defined as a candidate gene associated with an increased risk for essential hypertension, the 825T allele turns out to be an interesting marker in cardiovascular pharmacogenetics. Carriers of the 825T allele show an increased vasoconstriction in the skin microcirculation in response to noradrenaline, angiotensin II, and endothelin I. Coronary vasoconstriction is enhanced in 825T allele carriers in response to azepexol. On the other hand, some drugs like hydrochlorothiazide, clonidine, and endothelin receptor antagonist evoke increased effects in 825T allele carriers. It appears that the GNB3 C825T polymorphism could be an attractive marker to discriminate responders and nonresponders and might, therefore, represent an excellent candidate gene in cardiovascular pharmacogenetics.","G proteins; GNB3; Hypertension; Signal transduction","Cardiovascular Diseases; Heterotrimeric GTP-Binding Proteins; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; alpha 2 adrenergic receptor stimulating agent; angiotensin; azepexole; clonidine; cyclo(dextro tryptophyl dextro aspartylprolyl dextro valylleucyl); endothelin 1; endothelin receptor antagonist; guanine nucleotide binding protein; hydrochlorothiazide; methylergometrine maleate; n (2,6 dimethylpiperidinocarbonyl) 4 methylleucyl dextro (1 methoxycarbonyltryptophanyl) dextro norleucine; noradrenalin; propanol; protein subunit; G protein beta3 subunit; G-protein beta3 subunit; heterotrimeric guanine nucleotide binding protein; allele; cardiovascular response; cell activation; clinical trial; conference paper; coronary artery constriction; drug response; drug targeting; essential hypertension; gene; genetic code; genetic polymorphism; gnb3 gene; hormone action; human; microcirculation; pharmacogenetics; priority journal; protein function; signal transduction; skin blood flow; vasoconstriction; cardiovascular disease; genetics; review; single nucleotide polymorphism","","angiotensin, 1407-47-2; azepexole, 36067-72-8, 36067-73-9; clonidine, 4205-90-7, 4205-91-8, 57066-25-8; cyclo(dextro tryptophyl dextro aspartylprolyl dextro valylleucyl), 136553-81-6; endothelin 1, 117399-94-7; hydrochlorothiazide, 58-93-5; methylergometrine maleate, 57432-61-8; n (2,6 dimethylpiperidinocarbonyl) 4 methylleucyl dextro (1 methoxycarbonyltryptophanyl) dextro norleucine, 156161-89-6; noradrenalin, 1407-84-7, 51-41-2; propanol, 62309-51-7, 71-23-8; G-protein beta3 subunit, ; Heterotrimeric GTP-Binding Proteins, EC 3.6.1.46","bq 123; bq 788","","","","Roden D.M., George A.L. Jr., The genetic basis of variability in drug responses, Nat Rev Drug Discov, 1, pp. 37-44, (2002); Siffert W., Rosskopf D., Siffert G., Et al., Association of a human G-protein beta 3 subunit variant with hypertension, Nat Genet, 18, pp. 45-48, (1998); Farfel Z., Bourne H.R., Iiri T., The expanding spectrum of G protein diseases, N Engl J Med, 340, pp. 1012-1020, (1999); Bourne H.R., How receptors talk to trimeric G proteins, Curr Opin Cell Biol, 9, pp. 134-142, (1997); Downes G.B., Gautam N., The G protein subunit gene families, Genomics, 62, pp. 544-552, (1999); Pietruck F., Moritz A., Montemurro M., Et al., Selectively enhanced cellular signaling by G<sub>i</sub> proteins in essential hypertension. Gα<sub>i2</sub>, Gα<sub>i3</sub> G<sub>β2</sub> and G<sub>β2</sub> are not mutated, Circ Res, 79, pp. 974-983, (1996); Rosskopf D., Busch S., Manthey I., Siffert W., G protein beta 3 gene: Structure, promoter, and additional polymorphisms, Hypertens, 36, pp. 33-41, (2000); Rosskopf D., Manthey I., Siffert W., Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein beta 3 subunit, Pharmacogenetics, 12, pp. 209-220, (2002); Siffert W., Forster P., Jockel K.H., Et al., Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals, J Am Soc Nephrol, 10, pp. 1921-1930, (1999); Baumgart D., Naber C., Haude M., Et al., G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation, Circ Res, 85, pp. 965-969, (1999); Meirhaeghe A., Bauters C., Helbecque N., Et al., The human G-protein beta 3 subunit C825T polymorphism is associated with coronary artery vasoconstriction, Eur Heart J, 22, pp. 845-848, (2001); Wenzel R.R., Siffert W., Bruck H., Et al., Enhanced vasoconstriction to endothelin- 1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation, Pharmacogenetics, 12, pp. 489-495, (2002); Schafers R.F., Nurnberger J., Rutz A., Et al., Haemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein beta 3 subunit, Pharmacogenetics, 11, pp. 461-470, (2001); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertens, 37, pp. 739-743, (2001)","W. Siffert; Institut für Pharmakologie, Universitätsklinikum Essen, D-45122 Essen, Hufelandstr.55, Germany; email: winfried.Siffert@uni-essen.de","","Blackwell Publishing Inc.","","","","","","00986577","","KISUD","12694337","English","Kidney Int. Suppl.","Conference paper","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0037408343"
"Hopkins P.N.; Hunt S.C.","Hopkins, Paul N. (35351179800); Hunt, Steven C. (7402383343)","35351179800; 7402383343","Genetics of hypertension","2003","Genetics in Medicine","5","6","","413","429","16","39","10.1097/01.GIM.0000096375.88710.A6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344271798&doi=10.1097%2f01.GIM.0000096375.88710.A6&partnerID=40&md5=b9245094bccecbe590f9ef0290146392","University of Utah, Cardiovascular Genetics, Room 167, Salt Lake City, UT 84108, 410 Chipeta Way, United States","Hopkins P.N., University of Utah, Cardiovascular Genetics, Room 167, Salt Lake City, UT 84108, 410 Chipeta Way, United States; Hunt S.C., University of Utah, Cardiovascular Genetics, Room 167, Salt Lake City, UT 84108, 410 Chipeta Way, United States","[No abstract available]","","Calmodulin-Binding Proteins; Family Health; Heterotrimeric GTP-Binding Proteins; Humans; Hyperlipidemias; Hypertension; Models, Biological; Renin-Angiotensin System; adducin; alpha adducin; angiotensin 1 receptor; angiotensin 2 receptor; angiotensinogen; antihypertensive agent; apolipoprotein E; atrial natriuretic factor; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; dopamine 3 receptor; endothelin 1; fibric acid derivative; fibroblast growth factor 2; guanine nucleotide binding protein; guanine nucleotide binding protein beta3 subunit; heme oxygenase 1; hydralazine; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin receptor substrate 1; membrane metalloendopeptidase; metoprolol; nicotinic acid; nitric oxide synthase; propranolol; renin; somatomedin C; steroid; unclassified drug; unindexed drug; adrenergic system; blood pressure; clinical trial; congestive heart failure; diet therapy; disease severity; drug blood level; drug choice; drug response; dyslipidemia; family history; gene inactivation; genetic analysis; genetic epidemiology; genetic polymorphism; genotype environment interaction; heredity; human; hypertension; ion transport; knockout gene; metabolic disorder; multiple organ failure; pathogenesis; pharmacogenomics; practice guideline; renin angiotensin aldosterone system; review; symptomatology; systolic blood pressure; weight reduction","","angiotensinogen, 11002-13-4, 64315-16-8; atrial natriuretic factor, 85637-73-6; hydralazine, 304-20-1, 86-54-4; insulin receptor substrate 1, 175335-32-7; membrane metalloendopeptidase, 82707-54-8, 88201-55-2; metoprolol, 37350-58-6; nicotinic acid, 54-86-4, 59-67-6; nitric oxide synthase, 125978-95-2; propranolol, 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; renin, 61506-93-2, 9015-94-5; somatomedin C, 67763-96-6; adducin, ; Calmodulin-Binding Proteins, ; G-protein beta3 subunit, ; Heterotrimeric GTP-Binding Proteins, EC 3.6.1.46","","","","","Hajjar I., Kotchen T.A., Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000, JAMA, 290, pp. 199-206, (2003); Neaton J.D., Kuller L., Stamler J., Wentworth D.N., Impact of systolic and diastolic blood pressure on cardiovascular mortality, Hypertension: Pathophysiology, Diagnosis, and Management Second Edition. 2nd ed., pp. 127-144, (1995); Robertson W.B., Strong J.P., Atherosclerosis in persons with hypertension and diabetes mellitus, Lab Invest, 18, pp. 539-551, (1968); Solberg L.A., McGarry P.A., Cerebral atherosclerosis in persons with selected diseases, Lab Invest, 18, pp. 613-619, (1968); Hollander W., Madoff I., Paddock J., Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta, Circ Res, 38, SUPPL. II, pp. 63-72, (1976); Lopez J.A.G., Armstrong M.L., Harrison D.G., Piegors D.J., Heistad D.D., Responsiveness of iliac collateral vessels to constrictor stimuli in atherosclerotic primates, Circ Res, 63, pp. 1020-1028, (1988); Curmi P.A., Juan L., Tedgui A., Effect of transmural pressure on low density lipoprotein and albumin transport and distribution across the intact arterial wall, Circ Res, 66, pp. 1692-1702, (1990); Meyer G., Merval R., Tedgui A., Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall, Circ Res, 79, pp. 532-540, (1996); Glagov S., Ozoa A.K., Significance of the relatively low incidence of atherosclerosis in the pulmonary, renal and mesenteric arteries, Ann N Y Acad Sci, 149, pp. 940-955, (1968); Buja L.M., Kovanen P.T., Bilheimer D.W., Cellular pathology of homozygous familial hypercholesterolemia, Am J Pathol, 97, pp. 327-357, (1979); Stehbens W.E., Wierzbicki E., The relationship of hypercholesterolemia to atherosclerosis with particular emphasis on familial hypercholesterolemia, diabetes mellitus, obstructive jaudice, myxedema, and the nephrotic syndrome, Prog Cardiovasc Dis, 30, pp. 289-306, (1988); Malek A.M., Alper S.L., Izumo S., Hemodynamic shear stress and its role in atherosclerosis, JAMA, 282, pp. 2035-2042, (1999); Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts, Lancet, 346, pp. 1647-1653, (1995); Shahar E., Chambless L.E., Rosamond W.D., Boland L.L., Ballantyne C.M., McGovern P.G., Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study, Stroke, 34, pp. 623-631, (2003); Koren-Morag N., Tanne D., Graff E., Goldbourt U., Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: The bezafibrate infarction prevention registry, Arch Intern Med, 162, pp. 993-999, (2002); Amarenco P., Duyckaerts C., Tzourio C., Henin D., Bousser M.-G., Hauw J.-J., The prevalence of ulcerated plaques in the aortic arch in patients with stroke, N Engl J Med, 326, pp. 221-225, (1992); Amarenco P., Cohen A., Tzourio C., Bertrand B., Hommel M., Besson G., Atherosclerotic disease of the aortic arch and the risk of ischemic stroke, N Engl J Med, 331, pp. 1474-1479, (1994); De Leeuw F.E., De Groot J.C., Oudkerk M., Witteman J.C., Hofman A., Van Gijn J., Aortic atherosclerosis at middle age predicts cerebral white matter lesions in the elderly, Stroke, 31, pp. 425-429, (2000); Levy D., Larson M.G., Vasan S., Kannel W.B., Ho K.K.L., The progression from hypertension to congestive heart failure, JAMA, 275, pp. 1557-1562, (1996); Aronow W.S., Ahn C., Incidence of heart failure in 2,737 older persons with and without diabetes mellitus, Chest, 115, pp. 867-868, (1999); Levy D., Anderson K.M., Savage D.D., Kannel W.B., Christiansen J.C., Castelli W.P., Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart Study, Ann Intern Med, 108, pp. 7-13, (1988); Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study, N Engl J Med, 322, pp. 1561-1566, (1990); Suh I., Jee S.H., Kim H.C., Nam C.M., Kim I.S., Appel L.J., Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study, Lancet, 357, pp. 922-925, (2001); Flaxman N., The course of hypertensive heart disease, 1: Age of onset development of cardiac insufficiency, duration of life, and cause of death, Ann Intern Med, 10, pp. 748-753, (1936); Luft F.C., Hypertension as a complex genetic trait, Semin Nephrol, 22, pp. 115-126, (2002); Hunt S.C., Williams R.R., Barlow G.K., A comparison of positive family history definitions for defining risk of future disease, J Chron Dis, 39, pp. 809-821, (1986); Hunt S.C., Hasstedt S.J., Kuida H., Stults B.M., Hopkins P.N., Williams R.R., Genetic heritability and common environmental components of resting and stressed blood pressures, lipids, and body mass index in Utah pedigrees and twins, Am J Epidemiol, 129, pp. 625-638, (1989); Williams R.R., Hasstedt S.J., Hunt S.C., Wu L.L., Hopkins P.N., Berry T.D., Et al., Genetic traits related to hypertension and electrolyte metabolism, Hypertension, 17, SUPPL. I, (1991); Ward R., Familial aggregation and genetic epidemiology of blood pressure, Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed, pp. 67-88, (1995); Hasstedt S.J., Wu L.L., Ash K.O., Kuida H., Williams R.R., Hypertension and sodium-lithium countertransport in Utah pedigrees: Evidence for major-locus inheritance, Am J Hum Genet, 43, pp. 14-22, (1988); Chien K.L., Yang C.Y., Lee Y.T., Major gene effects in systolic and diastolic blood pressure in families receiving a health examination in Taiwan, J Hypertens, 21, pp. 73-79, (2003); Rubattu S., Volpe M., Kreutz R., Ganten U., Ganten D., Lindpaintner K., Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease, Nat Genet, 13, pp. 429-434, (1996); Rubattu S., Ridker P., Stampfer M.J., Volpe M., Hennekens C.H., Lindpaintner K., The gene encoding atrial natriuretic peptide and the risk of human stroke, Circulation, 100, pp. 1722-1726, (1999); Palsdottir A., Abrahamson M., Thorsteinsson L., Arnason A., Olafsson I., Grubb A., Et al., Mutation in cystatin C gene causes hereditary brain haemorrhage, Lancet, 2, pp. 603-604, (1988); Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., Et al., Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia, Nature, 383, 6602, pp. 707-710, (1996); Dong Y., Hassan A., Zhang Z., Huber D., Dalageorgou C., Markus H.S., Yield of screening for CADASIL mutations in lacunar stroke and leukoaraiosis, Stroke, 34, pp. 203-205, (2003); Wardlaw J.M., Sandercock P.A., Dennis M.S., Starr J., Kalimo H., Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?, Stroke, 34, pp. 806-812, (2003); Carmelli D., DeCarli C., Swan G.E., Jack L.M., Reed T., Wolf P.A., Et al., Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins, Stroke, 29, pp. 1177-1181, (1998); De Faire U., Friberg L., Lundman T., Concordance for mortality with special reference to ischaemic heart disease and cerebrovascular disease: A study on the Swedish Twin Registry, Prev Med, 4, pp. 509-517, (1975); Welin L., Svardsudd K., Wilhelmsen L., Larsson B., Tibblin G., Analysis of risk factors for stroke in a cohort of men born in 1913, N Engl J Med, 317, pp. 521-526, (1987); Bak S., Gaist D., Sindrup S.H., Skytthe A., Christensen K., Genetic liability in stroke: A long-term follow-up study of Danish twins, Stroke, 33, pp. 769-774, (2002); Gretarsdottir S., Sveinbjornsdottir S., Jonsson H.H., Jakobsson F., Einarsdottir E., Agnarsson U., Et al., Localization of a susceptibility gene for common forms of stroke to 5q12, Am J Hum Genet, 70, pp. 593-603, (2002); Woo D., Sauerbeck L.R., Kissela B.M., Khoury J.C., Szaflarski J.P., Gebel J., Et al., Genetic and environmental risk factors for intracerebral hemorrhage: Preliminary results of a population-based study, Stroke, 33, pp. 1190-1195, (2002); Okamoto K., Horisawa R., Kawamura T., Asai A., Ogino M., Takagi T., Et al., Family history and risk of subarachnoid hemorrhage: A case-control study in Nagoya, Japan, Stroke, 34, pp. 422-426, (2003); Garner C., Lecomte E., Visvikis S., Abergel E., Lathrop M., Soubrier F., Genetic and environmental influences on left ventricular mass. A family study, Hypertension, 36, pp. 740-746, (2000); Tang W., Arnett D.K., Devereux R.B., Province M.A., Atwood L.D., Oberman A., Et al., Sibling resemblance for left ventricular structure, contractility, and diastolic filling, Hypertension, 40, pp. 233-238, (2002); Jeanclos E., Schork N.J., Kyvik K.O., Kimura M., Skurnick J.H., Aviv A., Telomere length inversely correlates with pulse pressure and is highly familial, Hypertension, 36, pp. 195-200, (2000); Jartti L., Ronnemaa T., Kaprio J., Jarvisalo M.J., Toikka J.O., Marniemi J., Et al., Population-based twin study of the effects of migration from Finland to Sweden on endothelial function and intima-media thickness, Arterioscler Thromb Vasc Biol, 22, pp. 832-837, (2002); Lange L.A., Bowden D.W., Langefeld C.D., Wagenknecht L.E., Carr J.J., Rich S.S., Et al., Heritability of carotid artery intima-medial thickness in type 2 diabetes, Stroke, 33, pp. 1876-1881, (2002); Xiang A.H., Azen S.P., Buchanan T.A., Raffel L.J., Tan S., Cheng L.S., Et al., Heritability of subclinical atherosclerosis in Latino families ascertained through a hypertensive parent, Arterioscler Thromb Vasc Biol, 22, pp. 843-848, (2002); Fox C.S., Polak J.F., Chazaro I., Cupples A., Wolf P.A., D'Agostino R.A., Et al., Genetic and environmental contributions to atherosclerosis phenotypes in men and women: Heritability of carotid intima-media thickness in the Framingham Heart Study, Stroke, 34, pp. 397-401, (2003); Hunt K.J., Duggirala R., Goring H.H., Williams J.T., Almasy L., Blangero J., Et al., Genetic basis of variation in carotid artery plaque in the San Antonio Family Heart Study, Stroke, 33, pp. 2775-2780, (2002); Jerrard-Dunne P., Sitzer M., Risley P., Steckel D.A., Buehler A., Von Kegler S., Et al., Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: The Carotid Atherosclerosis Progression Study (CAPS), Stroke, 34, pp. 402-407, (2003); Zannad F., Benetos A., Genetics of intima-media thickness, Curr Opin Lipidol, 14, pp. 191-200, (2003); Perusse L., Moll P.P., Sing C.F., Evidence that a single gene with gender- and age-dependent effects influences systolic blood pressure determination in a population-based sample, Am J Hum Genet, 49, pp. 94-105, (1991); Cheng L.S.-C., Carmelli D., Hunt S.C., Williams R.R., Evidence for a major gene influencing 7-year increases in diastolic blood pressure with age, Am J Hum Genet, 57, pp. 1169-1177, (1995); Denton D., Weisinger R., Mundy N., Wickings E.J., Dixson A., Moisson P., Et al., The effect of increased salt intake on blood pressure of chimpanzees, Nature Med, 1, pp. 1009-1016, (1995); INTERSALT: An international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion, BMJ, 297, pp. 319-328, (1988); Garrison R.J., Kannel W.B., Stokes J., Castelli W.P., Incidence and precursors of hypertension in young adults: The Framingham Offspring Study, Prev Med, 16, pp. 235-251, (1987); Cooper R., Rotimi C., Ataman S., McGee D., Osotimehin B., Kadiri S., Et al., The prevalence of hypertension in seven population of West African origin, Am J Public Health, 87, pp. 160-168, (1997); MacGregor G.A., Sodium is more important than calcium in essential hypertension, Hypertension, 7, pp. 628-637, (1985); Hollenberg N.K., Martinez G., McCullough M., Meinking T., Passan D., Preston M., Et al., Aging, acculturation, salt intake, and hypertension in the Kuna of Panama, Hypertension, 29, pp. 171-176, (1997); Brenner B.M., Garcia D.L., Anderson S., Glomeruli and blood pressure: Less of one, more the other?, Am J Hypertens, 1, PART 1, pp. 335-347, (1988); Clark A.T., Bertram J.F., Molecular regulation of nephron endowment, Am J Physiol, 276, PART 2, (1999); Manalich R., Reyes L., Herrera M., Melendi C., Fundora I., Relationship between weight at birth and the number and size of renal glomeruli in humans: A histomorphometric study, Kidney Int, 58, pp. 770-773, (2000); Vehaskari V.M., Aviles D.H., Manning J., Prenatal programming of adult hypertension in the rat, Kidney Int, 59, pp. 238-245, (2001); Cullen-McEwen L.A., Kett M.M., Dowling J., Anderson W.P., Bertram J.F., Nephron number, renal function, and arterial pressure in aged GDNF heterozygous mice, Hypertension, 41, pp. 335-340, (2003); Keller G., Zimmer G., Mall G., Ritz E., Amann K., Nephron number in patients with primary hypertension, N Engl J Med, 348, pp. 101-108, (2003); Guyton A.C., Hall J.E., Coleman T.G., Manning R.D., Norman R.A., The dominant role of the kidney in long-term arterial pressure regulation in normal and hypertensive states, Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed, pp. 1311-1326, (1995); Guyton A.C., Coleman T.G., Quantitative analysis of the pathophysiology of hypertension, Circ Res, 24, 5 SUPPL., pp. 1-19, (1969); Guyton A., Coleman T., Cowley A., Arterial pressure regulation: Overriding dominance of the kidneys in long-term regulation and in hypertension, Am J Med, 52, pp. 584-594, (1972); Guyton A., Coleman T., Cowley A., A systems analysis approach to understanding long-range arterial blood pressure control and hypertension, Circ Res, 35, pp. 159-176, (1974); Guyton A.C., Circulatory Physiology III: Arterial Pressure and Hypertension, (1980); Barlassina C., Lanzani C., Manunta P., Bianchi G., Genetics of essential hypertension: From families to genes, J Am Soc Nephrol, 13, SUPPL. 3, (2002); Lalouel J.M., Rohrwasser A., Development of genetic hypotheses in essential hypertension, J Hum Genet, 46, pp. 299-306, (2001); Lifton R.P., Gharavi A.G., Geller D.S., Molecular mechanisms of human hypertension, Cell, 104, pp. 545-556, (2001); Williams R.R., Hunt S.C., Hopkins P.N., Stults B.M., Wu L.L., Hasstedt S.J., Et al., Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension, JAMA, 259, pp. 3579-3586, (1988); Hopkins P.N., Hunt S.C., Wu L.L., Williams G.H., Williams R.R., Hypertension, dyslipidemia, and insulin resistance: Links in a chain or spokes on a wheel?, Curr Opin Lipidol, 7, pp. 241-253, (1996); Selby J.V., Newman B., Quiroga J., Christian J.C., Austin M.A., Fabsitz R.R., Concordance for dyslipidemic hypertension in male twins, JAMA, 265, pp. 2079-2084, (1991); Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Et al., Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990); Samuelsson O., Wilhelmsen L., Andersson O.K., Pennert K., Berglund G., Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: Results from the primary prevention trial in Goteborg, Sweden, JAMA, 258, pp. 1768-1776, (1987); Hong Y., Pedersen N.L., Brismar K., De Faire U., Genetic and environmental architecture of the features of the insulin-resistance syndrome, Am J Hum Genet, 60, pp. 143-152, (1997); Kronenberg F., Rich S.S., Sholinsky P., Arnett D.K., Province M.E., Myers R.H., Et al., Insulin and hypertension in the NHLBI Family Heart Study: A sibpair approach to a controversial issue, Am J Hypertens, 13, pp. 240-250, (2000); Pausova Z., Gossard F., Gaudet D., Tremblay J., Kotchen T.A., Cowley A.W., Et al., Heritability estimates of obesity measures in siblings with and without hypertension, Hypertension, 38, pp. 41-47, (2001); Egan B.M., Greene E.L., Goodfriend T.L., Insulin resistance and cardiovascular disease, Am J Hypertens, 14, June SUPPL. PART 2, (2001); Mahamat A., Richard F., Arveiler D., Bongard V., Yarnell J., Ducimetiere P., Et al., Body mass index, hypertension and 5-year coronary heart disease incidence in middle aged men: The PRIME study, J Hypertens, 21, pp. 519-524, (2003); Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Et al., Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance, Proc Natl Acad Sci U S A, 98, pp. 7522-7527, (2001); Unger R.H., Lipotoxic diseases, Annu Rev Med, 53, pp. 319-336, (2002); Schaffer J.E., Lipotoxicity: When tissues overeat, Curr Opin Lipidol, 14, pp. 281-287, (2003); Cheng L.S., Davis R.C., Raffel L.J., Xiang A.H., Wang N., Quinones M., Et al., Coincident linkage of fasting plasma insulin and blood pressure to chromosome 7q in hypertensive hispanic families, Circulation, 104, pp. 1255-1260, (2001); Pajukanta P., Terwilliger J.D., Perola M., Hiekkalinna T., Nuotio I., Ellonen P., Et al., Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels, Am J Hum Genet, 64, pp. 1453-1463, (1999); Coon H., Myers R.H., Borecki I.B., Arnett D.K., Hunt S.C., Province M.A., Et al., Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus: The NHLBI family heart study, Arterioscler Thromb Vasc Biol, 20, pp. 2275-2280, (2000); Pei W., Baron H., Muller-Myhsok B., Knoblauch H., Al-Yahyaee S.A., Hui R., Et al., Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families, Clin Genet, 57, pp. 29-34, (2000); Elbein S.C., Hoffman M.D., Teng K., Leppert M.F., Hasstedt S.J., A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians, Diabetes, 48, pp. 1175-1182, (1999); Krushkal J., Ferrell R., Mockrin S.C., Turner S.T., Sing C.F., Boerwinkle E., Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings, Circulation, 99, pp. 1407-1410, (1999); Levy D., DeStefano A.L., Larson M.G., O'Donnell C.J., Lifton R.P., Gavras H., Et al., Evidence for a gene influencing blood pressure on chromosome 17: Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study, Hypertension, 36, pp. 477-483, (2000); Hunt S.C., Ellison R.C., Atwood L.D., Pankow J.S., Province M.A., Leppert M.F., Genome scans for blood pressure and hypertension: The National Heart, Lung, and Blood Institute Family Heart Study, Hypertension, 40, pp. 1-6, (2002); Allayee H., De Bruin T.W., Michelle Dominguez K., Cheng L.S., Ipp E., Cantor R.M., Et al., Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p, Hypertension, 38, pp. 773-778, (2001); Tiret L., Poirier O., Hallet V., McDonagh T.A., Morrison C., McMurray J.J., Et al., The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people, Hypertension, 33, pp. 1169-1174, (1999); Asai T., Ohkubo T., Katsuya T., Higaki J., Fu Y., Fukuda M., Et al., Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: The Ohasama Study, Hypertension, 38, pp. 1321-1324, (2001); Jin J.J., Nakura J., Wu Z., Yamamoto M., Abe M., Tabara Y., Et al., Association of endothelin-1 gene variant with hypertension, Hypertension, 41, pp. 163-167, (2003); Province M.A., Arnett D.K., Hunt S.C., Leiendecker-Foster C., Eckfeldt J.H., Oberman A., Et al., Association between the alpha-adducin gene and hypertension in the Hyper-GEN Study, Am J Hypertens, 13, PART 1, pp. 710-718, (2000); Iwai N., Katsuya T., Mannami T., Higaki J., Ogihara T., Kokame K., Et al., Association between SAH, an acyl-CoA synthetase gene, and hypertriglyceridemia, obesity, and hypertension, Circulation, 105, pp. 41-47, (2002); Ringel J., Kreutz R., Distler A., Sharma A.M., The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus, Am J Hypertens, 13, pp. 1027-1031, (2000); Lalouel J.M., Large-scale search for genes predisposing to essential hypertension, Am J Hypertens, 16, pp. 163-166, (2003); Samani N.J., Genome scans for hypertension and blood pressure regulation, Am J Hypertens, 16, pp. 167-171, (2003); Meneton P., Comparative roles of the renal apical sodium transport systems in blood pressure control, J Am Soc Nephrol, 11, SUPPL. 16, (2000); Doris P.A., Hypertension genetics, single nucleotide polymorphisms, and the common disease: Common variant hypothesis, Hypertension, 39, PART 2, pp. 323-331, (2002); Corvol P., Persu A., Gimenez-Roqueplo A.P., Jeunemaitre X., Seven lessons from two candidate genes in human essential hypertension: Angiotensinogen and epithelial sodium channel, Hypertension, 33, pp. 1324-1331, (1999); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Staessen J.A., Kuznetsova T., Wang J.G., Emelianov D., Vlietinck R., Fagard R., M235T angiotensinogen gene polymorphism and cardiovascular renal risk, J Hypertens, 17, pp. 9-17, (1999); Inoue I., Nakajima T., Williams C.S., Quackenbush J., Puryear R., Powers M., Et al., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, pp. 1786-1797, (1997); Province M.A., Boerwinkle E., Chakravarti A., Cooper R., Fornage M., Leppert M., Et al., Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program. National Heart, Lung and Blood Institute, J Hypertens, 18, pp. 867-876, (2000); Rankinen T., Gagnon J., Perusse L., Rice T., Leon A.S., Skinner J.S., Et al., Body fat, resting and exercise blood pressure and the angiotensinogen M235T polymorphism: The HERITAGE family study, Obes Res, 7, pp. 423-430, (1999); Iso H., Harada S., Shimamoto T., Sato S., Kitamura A., Sankai T., Et al., Angiotensinogen T174M and M235T variants, sodium intake and hypertension among non-drinking, lean Japanese men and women, J Hypertens, 18, pp. 1197-1206, (2000); Ishikawa K., Baba S., Katsuya T., Iwai N., Asai T., Fukuda M., Et al., T+31C polymorphism of angiotensinogen gene and essential hypertension, Hypertension, 37, pp. 281-285, (2001); Tiago A.D., Samani N.J., Candy G.P., Brooksbank R., Libhaber E.N., Sareli P., Et al., Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension, Circulation, 106, pp. 1483-1487, (2002); Pereira A.C., Mota G.F., Cunha R.S., Herbenhoff F.L., Mill J.G., Krieger J.E., Angiotensinogen 235T allele ""dosage"" is associated with blood pressure phenotypes, Hypertension, 41, pp. 25-30, (2003); Tsai C.T., Fallin D., Chiang F.T., Hwang J.J., Lai L.P., Hsu K.L., Et al., Angiotensinogen gene haplotype and hypertension: Interaction with ACE gene I allele, Hypertension, 41, pp. 9-15, (2003); Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, PART 2, pp. 1602-1609, (1995); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, 14, pp. 259-262, (1996); Lalouel J.M., Rohrwasser A., Terreros D., Morgan T., Ward K., Angiotensin in essential hypertension: From genetics to nephrology, J Am Soc Nephrol, 12, pp. 606-615, (2001); Forrester T., McFarlane-Anderson N., Bennet F., Wilks R., Puras A., Cooper R., Rotimi C., Et al., Angiotensinogen and blood pressure among blacks: Findings from a community survey in Jamaica, J Hypertens, 14, pp. 315-321, (1996); Cooper R., Rotimi C., Ogunbiyi O., Ward R., Angiotensinogen genotype, serum level and hypertension in blacks, Am J Hypertens, 10, (1997); Pratt J.H., Ambrosius W.T., Tewksbury D.A., Wagner M.A., Zhou L., Hanna M.P., Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people, Hypertension, 32, pp. 875-879, (1998); Walker W.G., Whelton P.K., Saito H., Russell R.P., Hermann J., Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects, Hypertension, 1, pp. 287-291, (1979); Fardella C., Zamorano P., Mosso L., Gomez L., Pinto M., Soto J., Et al., A(-6)G variant of angiotensinogen gene and aldosterone levels in hypertensives, Hypertension, 34, PART 2, pp. 779-781, (1999); Kim H.S., Krege J.H., Kluckman K.D., Hagaman J.R., Hodgin J.B., F. B.C., Jennette J.C., Et al., Genetic control of blood pressure and the angiotensinogen locus, Proc Natl Acad Sci USA, 92, pp. 2735-2739, (1995); Smithies O., Kim H.S., Takahashi N., Edgell M.H., Importance of quantitative genetic variations in the etiology of hypertension, Kidney Int, 58, pp. 2265-2280, (2000); Davisson R.L., Ding Y., Stec D.E., Catterall J.F., Sigmund C.D., Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice, Physiol Genomics, 1, pp. 3-9, (1999); Makino N., Sugano M., Ohtsuka S., Sawada S., Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats, Hypertension, 31, pp. 1166-1170, (1998); Kagiyama S., Varela A., Phillips M.I., Galli S.M., Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats, Hypertension, 37, PART 2, pp. 371-375, (2001); Morimoto S., Cassell M.D., Beltz T.G., Johnson A.K., Davisson R.L., Sigmund C.D., Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter, Circ Res, 89, pp. 365-372, (2001); Rohrwasser A., Morgan T., Dillon H.F., Zhao L., Callaway C.W., Hillas E., Et al., Elements of a paracrine tubular renin-angiotensin system along the entire nephron, Hypertension, 34, pp. 1265-1274, (1999); Kobori H., Nishiyama A., Harrison-Bernard L.M., Navar L.G., Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension, Hypertension, 41, pp. 42-49, (2003); Jeng J.R., Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension, Am J Hypertens, 12, pp. 443-450, (1999); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Et al., Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, J Hypertens, 20, pp. 657-663, (2002); Tang W., Devereux R.B., Rao D.C., Oberman A., Hopkins P.N., Kitzman D.W., Et al., Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study, Am Heart J, 143, pp. 854-860, (2002); Ortlepp J.R., Vosberg H.P., Reith S., Ohme F., Mahon N.G., Schroder D., Et al., Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: A study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene, Heart, 87, pp. 270-275, (2002); Schmidt R., Schmidt H., Fazekas F., Launer L.J., Niederkorn K., Kapeller P., Et al., Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities, Hypertension, 38, pp. 110-115, (2001); Pei Y., Scholey J., Thai K., Suzuki M., Cattran D., Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in caucasian patients, J Clin Invest, 100, pp. 814-820, (1997); Maruyama K., Yoshida M., Nishio H., Shirakawa T., Kawamura T., Tanaka R., Et al., Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy, Pediatr Nephrol, 16, pp. 350-355, (2001); Lovati E., Richard A., Frey B.M., Frey F.J., Ferrari P., Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease, Kidney Int, 60, pp. 46-54, (2001); Tomino Y., Makita Y., Shike T., Gohda T., Haneda M., Kikkawa R., Et al., Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients, Nephron, 82, pp. 139-144, (1999); Hopkins P.N., Lifton R.P., Hollenberg N.K., Jeunemaitre X., Hallouin M.C., Skuppin J., Et al., Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity, J Hypertens, 14, pp. 199-207, (1996); Hopkins P.N., Hunt S.C., Jeunemaitre X., Smith B., Solorio D., Fisher N.D., Et al., Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension, Circulation, 105, pp. 1921-1927, (2002); Johnson A.G., Nguyen T.V., Davis D., Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects, J Hypertens, 19, pp. 1053-1060, (2001); Hunt S.C., Cook N.R., Oberman A., Cutler J.A., Hennekens C.H., Allender P.S., Et al., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of Hypertension Prevention, Phase II, Hypertension, 32, pp. 393-401, (1998); Hunt S.C., Geleijnse J.M., Wu L.L., Witteman J.C., Williams R.R., Grobbee D.E., Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene, Am J Hypertens, 12, pp. 460-466, (1999); Svetkey L.P., Moore T.J., Simons-Morton D.G., Appel L.J., Bray G.A., Sacks F.M., Et al., Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study, J Hypertens, 19, pp. 1949-1956, (2001); Jeunemaitre X., Charru A., Rigat B., Houot A.M., Soubrier F., Corvol P., Sib pair linkage analysis of renin gene haplotypes in human essential hypertension, Hum Genet, 88, pp. 301-306, (1992); Berge K.E., Berg K., No effect of a BglI polymorphism at the renin (REN) locus on blood pressure level or variability, Clin Genet, 46, pp. 436-438, (1994); Jeunemaitre X., Lifton R.P., Hunt S.C., Williams R.R., Lalouel J.-M., Absence of linkage between the angiotensin converting enzyme and human essential hypertension, Nature Genetics, 1, pp. 72-75, (1992); Staessen J.A., Wang J.G., Ginocchio G., Petrov V., Saavedra A.P., Soubrier F., Et al., The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk, J Hypertens, 15, PART 2, pp. 1579-1592, (1997); Henskens L.H., Spiering W., Stoffers H.E., Soomers F.L., Vlietinck R.F., De Leeuw P.W., Et al., Effects of ACE ID and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: First results of the Hippocates study, J Hypertens, 21, pp. 81-86, (2003); O'Donnell C.J., Lindpaintner K., Larson M.G., Rao V.S., Ordovas J.M., Schaefer E.J., Et al., Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study, Circulation, 97, pp. 1766-1772, (1998); Borecki I.B., Province M.A., Ludwig E.H., Ellison R.C., Folsom A.R., Heiss G., Et al., Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study, Ann Epidemiol, 7, pp. 13-21, (1997); Williams S.M., Addy J.H., Phillips III J.A., Dai M., Kpodonu J., Afful J., Et al., Combinations of variations in multiple genes are associated with hypertension, Hypertension, 36, pp. 2-6, (2000)","","","","","","","","","10983600","","GEMEF","14614392","English","Gen. Med.","Review","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0344271798"
"Liljedahl U.; Lind L.; Kurland L.; Berglund L.; Kahan T.; Syvänen A.-C.","Liljedahl, Ulrika (6602620595); Lind, Lars (26643471200); Kurland, Lisa (57198232272); Berglund, Lars (57214875804); Kahan, Thomas (7005494859); Syvänen, Ann-Christine (7005911199)","6602620595; 26643471200; 57198232272; 57214875804; 7005494859; 7005911199","Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment","2004","BMC Cardiovascular Disorders","4","","16","","","7","21","10.1186/1471-2261-4-16","https://www.scopus.com/inward/record.uri?eid=2-s2.0-13144300874&doi=10.1186%2f1471-2261-4-16&partnerID=40&md5=aa1cc555236dbd1b68af351e7baa463a","Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 751 85 Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, 751 85 Uppsala, Sweden; Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, 182 88 Stockholm, Sweden; Astra Zeneca Research/Devmt. Molndal, 431 83 Mölndal, Sweden","Liljedahl U., Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 751 85 Uppsala, Sweden; Lind L., Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 751 85 Uppsala, Sweden, Astra Zeneca Research/Devmt. Molndal, 431 83 Mölndal, Sweden; Kurland L., Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 751 85 Uppsala, Sweden; Berglund L., Uppsala Clinical Research Center, Uppsala University, 751 85 Uppsala, Sweden; Kahan T., Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, 182 88 Stockholm, Sweden; Syvänen A.-C., Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 751 85 Uppsala, Sweden","Background: Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment. Methods: Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the β1-adrenergic receptor blocker atenolol for twelve weeks. Results: The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele. Conclusions: Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control. © 2004 Liljedahl et al; licensee BioMed Central Ltd.","Antihypertensive treatment; Genotyping; Lipids; Minisequencing; Pharmacogenetics","Analysis of Variance; Antihypertensive Agents; Apolipoproteins B; Atenolol; Biphenyl Compounds; Female; Genotype; Humans; Hypertension; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Receptors, LDL; Systole; Tetrazoles; angiotensin 2 receptor antagonist; antihypertensive agent; apolipoprotein B; atenolol; beta adrenergic receptor blocking agent; DNA; irbesartan; lipid; low density lipoprotein receptor; antihypertensive agent; apolipoprotein B; atenolol; biphenyl derivative; irbesartan; low density lipoprotein receptor; tetrazole derivative; adult; allele; article; blood pressure measurement; blood pressure regulation; clinical trial; controlled clinical trial; controlled study; disease association; DNA determination; drug protein binding; drug response; dyslipidemia; female; human; hypertension; individualization; lipid metabolism; major clinical study; male; nucleotide sequence; pharmacogenetics; practice guideline; prediction; priority journal; protein microarray; protein polymorphism; randomized controlled trial; single nucleotide polymorphism; analysis of variance; DNA microarray; drug effect; genetics; genotype; methodology; middle aged; systole","GENBANK: AC074203, AF050163, AF217403, J02758, M19810, M35429","atenolol, 29122-68-7; DNA, 9007-49-2; irbesartan, 138402-11-6; lipid, 66455-18-3; atenolol, 29122-68-7, 93379-54-5; Antihypertensive Agents, ; Apolipoproteins B, ; Atenolol, 29122-68-7; Biphenyl Compounds, ; Receptors, LDL, ; Tetrazoles, ; irbesartan, 138402-11-6","","","","","Cadman P.E., O'Connor D.T., Pharmacogenomics of hypertension, Curr. Opin. Nephrol. Hypertens., 12, pp. 61-70, (2003); Turner S.T., Schwartz G.L., Chapman A.B., Hall W.D., Boerwinkle E., Antihypertensive pharmacogenetics: Getting the right drug into the right patient, J. Hypertens., 19, pp. 1-11, (2001); Turner S.T., Boerwinkle E., Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses, Pharmacogenomics, 4, pp. 53-65, (2003); Laragh J.H., Lamport B., Sealey J., Alderman M.H., Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Lind L., Berne C., Andersson P.E., Hanni A., Lithell H., Is insulin resistance a predictor of the blood pressure response to antihypertensive treatment?, J. Hum. Hypertens., 9, pp. 759-763, (1995); Koopmans R.P., Insel P.A., Michel M.C., Pharmacogenetics of hypertension treatment: A structured review, Pharmacogenetics, 13, pp. 705-713, (2003); Pausova Z., Gossard F., Gaudet D., Tremblay J., Kotchen T.A., Cowley A.W., Hamet P., Heritability estimates of obesity measures in siblings with and without hypertension, Hypertension, 38, pp. 41-47, (2001); Fagard R.H., Loos R.J., Beunen G., Derom C., Vlietinck R., Influence of chorionicity on the heritability estimates of blood pressure: A study in twins, J. Hypertens., 21, pp. 1313-1318, (2003); Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., Sherry S., Mullikin J.C., Mortimore B.J., Willey D.L., Hunt S.E., Cole C.G., Coggill P.C., Rice C.M., Ning Z., Rogers J., Bentley D.R., Kwok P.Y., Mardis E.R., Yeh R.T., Schultz B., Cook L., Davenport R., Dante M., Fulton L., Hillier L., Waterston R.H., McPherson J.D., Gilman B., Schaffner S., Van Etten W.J., Reich D., Higgins J., Daly M.J., Blumenstiel B., Baldwin J., Stange-Thomann N., Zody M.C., Linton L., Lander E.S., Attshuler D., A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409, pp. 928-933, (2001); Cardon L.R., Idury R.M., Harris T.J., Witte J.S., Elston R.C., Testing drug response in the presence of genetic information: Sampling issues for clinical trials, Pharmacogenetics, 10, pp. 503-510, (2000); Bader J.S., The relative power of SNPs and haplotype as genetic markers for association tests, Pharmacogenomics, 2, pp. 11-24, (2001); Doris P.A., Hypertension genetics, single nucleotide polymorphisms, and the common disease:common variant hypothesis, Hypertension, 39, pp. 323-331, (2002); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J. Hypertens., 19, pp. 1783-1787, (2001); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Nystrom F., Hagg A., Lind L., Aldosterone synthase (CYP11B2) - 344 C/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, Am. J. Hypertens., 15, pp. 389-393, (2002); Kurland L., Liljedahl U., Karlsson J., Kahan T., Malmqvist K., Melhus H., Syvanen A.C., Lind L., Angiotensinogen gene polymorphisms: Relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, Am. J. Hypertens., 17, pp. 8-13, (2004); Liljedahl U., Karlsson J., Melhus H., Kurland L., Lindersson M., Kahan T., Nystrom F., Lind L., Syvanen A.C., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenetics, 13, pp. 7-17, (2003); Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., Muller-Brunotte R., Nystrom F., Ohman K.P., Osbakken M.D., Ostergern J., Regression of left ventricular hypertrophy in human hypertension with irbesartan, J. Hypertens., 19, pp. 1167-1176, (2001); Syvanen A.C., Sajantila A., Lukka M., Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing, Am. J. Hum. Genet., 52, pp. 46-59, (1993); Churchill G.A., Doerge R.W., Empirical threshold values for quantitative trait mapping, Genetics, 138, pp. 963-971, (1994); Chatterton J.E., Schlapfer P., Butler E., Gutierrez M.M., Puppione D.L., Pullinger C.R., Kane J.P., Curtiss L.K., Schumaker V.N., Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: Description of a new approach involving monoclonal antibodies and dynamic light scattering, Biochemistry, 34, pp. 9571-9580, (1995); Steer P., Hulthe J., Miligard J., Sarabi D.M., Basu S., Vessby B., Lind L., Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans, Lipids, 37, pp. 1135-1140, (2002); von zur Muhlen B., Kahan T., Hagg A., Millgard J., Lind L., Treatment with irbesartan or atenolol improves endothelial function in essential hypertension, J. Hypertens., 19, pp. 1813-1818, (2001); Stepniakowski K.T., Goodfriend T.L., Egan B.M., Fatty acids enhance vascular alpha-adrenergic sensitivity, Hypertension, 25, pp. 774-778, (1995); Haastrup A.T., Stepniakowski K.T., Goodfriend T.L., Egan B.M., Intralipid enhances alpha1-adrenergic receptor mediated pressor sensitivity, Hypertension, 32, pp. 693-698, (1998); Stojiljkovic M.P., Zhang D., Lopes H.F., Lee C.G., Goodfriend T.L., Egan B.M., Hemodynamic effects of lipids in humans, Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, (2001); Lopes H.F., Stojiljkovic M.P., Zhang D., Goodfriend T.L., Egan B.M., The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents, Am. J. Hypertens., 14, pp. 1032-1037, (2001); Stepniakowski K.T., Sallee F.R., Goodfriend T.L., Zhang Z., Egan B.M., Fatty acids enhance neurovascular reflex responses by effects on alpha 1-adrenoceptors, Am. J. Physiol., 270, (1996)","U. Liljedahl; Department of Medical Sciences, Uppsala University, Uppsala University Hospital, 751 85 Uppsala, Sweden; email: Ulrika.Liljedahl@medsci.uu.se","","","","","","","","14712261","","BCDMB","15453913","English","BMC Cardiovasc. Disord.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-13144300874"
"Tiffin N.; Meintjes A.; Ramesar R.; Bajic V.B.; Rayner B.","Tiffin, Nicki (8938267600); Meintjes, Ayton (24281817600); Ramesar, Rajkumar (35373926300); Bajic, Vladimir B. (35377862500); Rayner, Brian (55861912700)","8938267600; 24281817600; 35373926300; 35377862500; 55861912700","Computational analysis of candidate disease genes and variants for Salt-sensitive hypertension in indigenous Southern Africans","2010","PLoS ONE","5","9","e12989","","","","8","10.1371/journal.pone.0012989","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77958558370&doi=10.1371%2fjournal.pone.0012989&partnerID=40&md5=ac26cea598f8419ea841b94e3fdc0732","Division of Nephrology and Hypertension, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa; Computational Biology, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Medical Research Council (MRC) Research Unit for Human Genetics, Division of Human Genetics, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia","Tiffin N., Division of Nephrology and Hypertension, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa; Meintjes A., Computational Biology, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Ramesar R., Medical Research Council (MRC) Research Unit for Human Genetics, Division of Human Genetics, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Bajic V.B., Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia; Rayner B., Division of Nephrology and Hypertension, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa","Multiple factors underlie susceptibility to essential hypertension, including a significant genetic and ethnic component, and environmental effects. Blood pressure response of hypertensive individuals to salt is heterogeneous, but salt sensitivity appears more prevalent in people of indigenous African origin. The underlying genetics of salt-sensitive hypertension, however, are poorly understood. In this study, computational methods including text- and data-mining have been used to select and prioritize candidate aetiological genes for salt-sensitive hypertension. Additionally, we have compared allele frequencies and copy number variation for single nucleotide polymorphisms in candidate genes between indigenous Southern African and Caucasian populations, with the aim of identifying candidate genes with significant variability between the population groups: identifying genetic variability between population groups can exploit ethnic differences in disease prevalence to aid with prioritisation of good candidate genes. Our top-ranking candidate genes include parathyroid hormone precursor (PTH) and type-1angiotensin II receptor (AGTR1). We propose that the candidate genes identified in this study warrant further investigation as potential aetiological genes for salt-sensitive hypertension. © 2010 Tiffin et al.","","Africa, Southern; African Continental Ancestry Group; Computational Biology; European Continental Ancestry Group; Gene Dosage; Gene Frequency; Genetic Variation; Humans; Hypertension; Polymorphism, Single Nucleotide; Sodium Chloride; angiotensin 2 receptor; hormone precursor; parathyroid hormone; sodium chloride; allele; article; Caucasian; controlled study; copy number variation; data mining; ethnic difference; gene frequency; gene identification; genetic susceptibility; genetic variability; human; hypertension; major clinical study; Negro; population genetics; prevalence; salt sensitive hypertension; single nucleotide polymorphism; South Africa; Africa; biology; ethnology; gene dosage; genetics; hypertension; metabolism","","parathyroid hormone, 12584-96-2, 68893-82-3, 9002-64-6; sodium chloride, 7647-14-5; Sodium Chloride, 7647-14-5","","","","","Shih P.A., O'Connor D.T., Hereditary determinants of human hypertension: Strategies in the setting of genetic complexity, Hypertension, 51, pp. 1456-1464, (2008); Lifton R.P., Gharavi A.G., Geller D.S., Molecular mechanisms of human hypertension, Cell, 104, pp. 545-556, (2001); Deng A.Y., Genetic basis of polygenic hypertension, Hum Mol Genet, 16, SPEC NO. 2, (2007); Puddu P., Puddu G.M., Cravero E., Ferrari E., Muscari A., The genetic basis of essential hypertension, Acta Cardiol, 62, pp. 281-293, (2007); Strazzullo P., Galletti F., Genetics of salt-sensitive hypertension, Curr Hypertens Rep, 9, pp. 25-32, (2007); Strazzullo P., Galletti F., Barba G., Altered renal handling of sodium in human hypertension: Short review of the evidence, Hypertension, 41, pp. 1000-1005, (2003); Zhao X., Pollock D.M., Zeldin D.C., Imig J.D., Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases, Hypertension, 42, pp. 775-780, (2003); Rodriguez-Iturbe B., Vaziri N.D., Salt-sensitive hypertension-update on novel findings, Nephrol Dial Transplant, 22, pp. 992-995, (2007); Iwamoto T., Kita S., Zhang J., Blaustein M.P., Arai Y., Et al., Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle, Nat Med, 10, pp. 1193-1199, (2004); Weinberger M.H., Salt sensitivity of blood pressure in humans, Hypertension, 27, pp. 481-490, (1996); Sullivan J.M., Prewitt R.L., Ratts T.E., Sodium sensitivity in normotensive and borderline hypertensive humans, Am J Med Sci, 295, pp. 370-377, (1988); Weder A.B., Gleiberman L., Sachdeva A., Whites excrete a water load more rapidly than blacks, Hypertension, 53, pp. 715-718, (2009); Rayner B.L., Myers J.E., Opie L.H., Trinder Y.A., Davidson J.S., Screening for primary aldosteronism-normal ranges for aldosterone and renin in three South African population groups, S Afr Med J, 91, pp. 594-599, (2001); Rayner B.L., Owen E.P., King J.A., Soule S.G., Vreede H., Et al., A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension, J Hypertens, 21, pp. 921-926, (2003); Yancy C.W., Race-based therapeutics, Curr Hypertens Rep, 10, pp. 276-285, (2008); A haplotype map of the human genome, Nature, 437, pp. 1299-1320, (2005); Flicek P., Aken B.L., Beal K., Ballester B., Caccamo M., Et al., Ensembl 2008, Nucleic Acids Res, 36, (2008); Harris M.A., Clark J., Ireland A., Lomax J., Ashburner M., Et al., The Gene Ontology (GO) database and informatics resource, Nucleic Acids Res, 32, (2004); Pan H., Zuo L., Choudhary V., Zhang Z., Leow S.H., Et al., Dragon TF Association Miner: A system for exploring transcription factor associations through text-mining, Nucleic Acids Res, 32, (2004); Bajic V.B., Veronika M., Veladandi P.S., Meka A., Heng M.W., Et al., Dragon Plant Biology Explorer. A text-mining tool for integrating associations between genetic and biochemical entities with genome annotation and biochemical terms lists, Plant Physiol, 138, pp. 1914-1925, (2005); Sagar S., Kaur M., Dawe A., Seshadri S.V., Christoffels A., Et al., DDESC: Dragon database for exploration of sodium channels in human, BMC Genomics, 9, (2008); Kaur M., Radovanovic A., Essack M., Schaefer U., Maqungo M., Et al., Database for exploration of functional context of genes implicated in ovarian cancer, Nucleic Acids Res, 37, (2009); Essack M., Radovanovic A., Schaefer U., Schmeier S., Seshadri S.V., Et al., DDEC: Dragon database of genes implicated in esophageal cancer, BMC Cancer, 9, (2009); Affymetrix Power Tools v 1.8.0; Hubbard T.J., Aken B.L., Beal K., Ballester B., Caccamo M., Et al., Ensembl 2007, Nucleic Acids Res, 35, (2007); Korn J.M., Kuruvilla F.G., McCarroll S.A., Wysoker A., Nemesh J., Et al., Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs, Nat Genet, 40, pp. 1253-1260, (2008); Ihaka R., Gentleman R., R: A Language for Data Analysis and Graphics, Journal of Computational and Graphical Statistics, 5, pp. 299-314, (1996); Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Bernstein K.E., Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor, Nature, 351, pp. 233-236, (1991); Garbers D.L., Chrisman T.D., Wiegn P., Katafuchi T., Albanesi J.P., Et al., Membrane guanylyl cyclase receptors: An update, Trends Endocrinol Metab, 17, pp. 251-258, (2006); Zhang K., Weder A.B., Eskin E., O'Connor D.T., Genome-wide case/control studies in hypertension: Only the 'tip of the iceberg, J Hypertens, 28, pp. 1115-1123, (2010); MacGregor G.A., Cappuccio F.P., The kidney and essential hypertension: A link to osteoporosis?, J Hypertens, 11, pp. 781-785, (1993); McCarron D.A., Pingree P.A., Rubin R.J., Gaucher S.M., Molitch M., Et al., Enhanced parathyroid function in essential hypertension: A homeostatic response to a urinary calcium leak, Hypertension, 2, pp. 162-168, (1980); Fliser D., Franek E., Fode P., Stefanski A., Schmitt C.P., Et al., Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans, Nephrol Dial Transplant, 12, pp. 933-938, (1997); Hulter H.N., Melby J.C., Peterson J.C., Cooke C.R., Chronic continuous PTH infusion results in hypertension in normal subjects, J Clin Hypertens, 2, pp. 360-370, (1986); Erne P., Bolli P., Burgisser E., Buhler F.R., Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy, N Engl J Med, 310, pp. 1084-1088, (1984); Resnick L.M., Gupta R.K., DiFabio B., Barbagallo M., Mann S., Et al., Intracellular ionic consequences of dietary salt loading in essential hypertension. Relation to blood pressure and effects of calcium channel blockade, J Clin Invest, 94, pp. 1269-1276, (1994); van Hooft I.M., Grobbee D.E., Frolich M., Pols H.A., Hofman A., Alterations in calcium metabolism in young people at risk for primary hypertension, The Dutch Hypertension and Offspring Study, 21, pp. 267-272, (1993); Kurtz T.W., Morris Jr. R.C., Sodium-calcium interactions and salt-sensitive hypertension, Am J Hypertens, 3, (1990); Jung J., Foroud T.M., Eckert G.J., Flury-Wetherill L., Edenberg H.J., Et al., Association of the calcium-sensing receptor gene with blood pressure and urinary calcium in African-Americans, J Clin Endocrinol Metab, 94, pp. 1042-1048, (2009); Nyby M.D., Hino T., Berger M.E., Ormsby B.L., Golub M.S., Et al., Desensitization of vascular tissue to parathyroid hormone and parathyroid hormone-related protein, Endocrinology, 136, pp. 2497-2504, (1995); Aloia J.F., Feuerman M., Yeh J.K., Reference range for serum parathyroid hormone, Endocr Pract, 12, pp. 137-144, (2006); Harris S.S., Vitamin D and African Americans, J Nutr, 136, pp. 1126-1129, (2006); Taylor E.N., Curhan G.C., Forman J.P., Parathyroid hormone and the risk of incident hypertension, J Hypertens, 26, pp. 1390-1394, (2008); Rothermund L., Luckert S., Kossmehl P., Paul M., Kreutz R., Renal endothelin ET(A)/ET(B) receptor imbalance differentiates salt-sensitive from salt-resistant spontaneous hypertension, Hypertension, 37, pp. 275-280, (2001); Velloso L.A., Folli F., Perego L., Saad M.J., The multi-faceted cross-talk between the insulin and angiotensin II signaling systems, Diabetes Metab Res Rev, 22, pp. 98-107, (2006); Muscogiuri G., Chavez A.O., Gastaldelli A., Perego L., Tripathy D., Et al., The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention, Curr Vasc Pharmacol, 6, pp. 301-312, (2008); Anan F., Masaki T., Ono E., Eto T., Iwao T., Et al., Predictors for prehypertension in patients with impaired glucose tolerance, Hypertens Res, 31, pp. 1913-1920, (2008); Rocchini A.P., Katch V., Kveselis D., Moorehead C., Martin M., Et al., Insulin and renal sodium retention in obese adolescents, Hypertension, 14, pp. 367-374, (1989); Tiffin N., Adie E., Turner F., Brunner H.G., van Driel M.A., Et al., Computational disease gene identification: A concert of methods prioritizes type 2 diabetes and obesity candidate genes, Nucleic Acids Res, 34, pp. 3067-3081, (2006); Lombard Z., Tiffin N., Hofmann O., Bajic V.B., Hide W., Et al., Computational selection and prioritization of candidate genes for fetal alcohol syndrome, BMC Genomics, 8, (2007); Tiffin N., Okpechi I., Perez-Iratxeta C., Andrade-Navarro M.A., Ramesar R., Prioritization of candidate disease genes for metabolic syndrome by computational analysis of its defining phenotypes, Physiol Genomics, 35, pp. 55-64, (2008); Seedat Y.K., Perspectives on research in hypertension, Cardiovasc J Afr, 20, pp. 39-42, (2009)","N. Tiffin; Division of Nephrology and Hypertension, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa; email: nickitiffin@imaginet.co.za","","","","","","","","19326203","","","20886000","English","PLoS ONE","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-77958558370"
"Suzuki H.","Suzuki, Hiromichi (34974818100)","34974818100","Therapeutic efficacy of renin—angiotensin blockade in patients receiving dialysis","2009","Therapeutic Advances in Cardiovascular Disease","3","5","","397","405","8","10","10.1177/1753944709338339","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350031621&doi=10.1177%2f1753944709338339&partnerID=40&md5=2d6c7a781bb3e6511f4ee9e661faed2b","Department of Nephrology, Saitama Medical University, Saitama, Japan","Suzuki H., Department of Nephrology, Saitama Medical University, Saitama, Japan","Observational data in dialysis patients has indicated an increased cardiovascular mortality. One pathophysiological cause of this cardiovascular mortality in these patients is volume overload. In addition, an inappropriately activated renin—angiotensin system (RAS) has been proposed as another possible mechanism for the increased cardiovascular mortality. With these possible causes in mind, blockade of the RAS with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) have both emerged as means of preventing cardiovascular events in this population. This review focuses on clinical evidence of the beneficial effects of ACE inhibitors and ARBs in dialysis patients with regard to the improvement of cardiovascular events as well as blood pressure control and maintenance of dialysis therapy. © 2009, SAGE Publications. All rights reserved.","Angiotensin converting enzyme inhibitor; Angiotensin type 1 receptor blocker; Hemodialysis; Peritoneal dialysis; Renin—angiotensin system","Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiovascular Diseases; Humans; Hypertrophy, Left Ventricular; Kidney Diseases; Male; Renal Dialysis; Renin-Angiotensin System; Treatment Outcome; aldosterone receptor; aliskiren; amlodipine; angiotensin 1 receptor; angiotensin 1 receptor antagonist; angiotensin converting enzyme 2; candesartan; captopril; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; enalapril; eplerenone; fosinopril; imidapril; lisinopril; losartan; nitrendipine; perindopril; placebo; spironolactone; trandolapril; valsartan; anaphylaxis; antihypertensive activity; blood pressure regulation; cardiovascular disease; cardiovascular risk; clinical trial; congestive heart failure; continuous ambulatory peritoneal dialysis; disease association; dose response; drug blood level; drug dose titration; drug efficacy; drug elimination; drug half life; drug megadose; drug safety; drug tolerability; erythropoiesis; heart left ventricle hypertrophy; hemodialysis patient; human; hyperkalemia; hypertension; kidney function; low drug dose; maintenance therapy; mortality; peritoneal dialysis; potassium excretion; priority journal; renin angiotensin aldosterone system; review; risk benefit analysis; risk reduction; single nucleotide polymorphism; unspecified side effect","","aliskiren, 173334-57-1, 173334-58-2, 173399-03-6; amlodipine, 88150-42-9; candesartan, 139481-59-7; captopril, 62571-86-2; dipeptidyl carboxypeptidase, 9015-82-1; enalapril, 75847-73-3; eplerenone, 107724-20-9; fosinopril, 88889-14-9, 98048-97-6; imidapril, 89371-37-9, 89396-94-1; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; nitrendipine, 39562-70-4; perindopril, 82834-16-0, 99149-83-4; spironolactone, 52-01-7; trandolapril, 87679-37-6; valsartan, 137862-53-4; Angiotensin II Type 1 Receptor Blockers, ; Angiotensin-Converting Enzyme Inhibitors, ","","","","","Agarwal R., Lewis R., Davis J.L., Becker B., Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses, Am J Kidney Dis, 38, pp. 1245-1250, (2001); Allon M., Treatment and prevention of hyperkalemia in end-stage renal disease, Kidney Int, 43, pp. 1197-1209, (1993); Bolanos L., Castro P., Falcon T.G., Mouzo R., Varela J.M., Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients, Am J Nephrol, 22, pp. 67-72, (2002); Buter H., Navis G.Y., Woittiez A.J., de Zeeuw D., de Jong P.E., (1999) Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function, Eur J Clin Pharmacol, 54, pp. 953-958; Cannella G., Paoletti E., Delfino R., Peloso G., Molinari S., Traverso G.B., Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy, Kidney Int, 44, pp. 881-886, (1993); Cannella G., Paoletti E., Delfino R., Peloso G., Rolla D., Molinari S., Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects, Am J Kidney Dis, 30, pp. 659-664, (1997); Charron R.C., Leme C.E., Wilson D.R., Ing T.S., Wrong O.M., The effect of adrenal steroids on stool composition, as revealed by in vivo dialysis of faeces, Clin Sci, 37, pp. 151-167, (1969); Chew C.G., Weise M.D., Disney A.P., The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients, Nephrol Dial Transplant, 14, pp. 2047-2049, (1999); Collins A.J., Roberts T.L., St Peter W.L., Chen S.C., Ebben J., Constantini E., United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines, Am J Kidney Dis, 39, pp. 784-795, (2002); de Rosa M.L., Cardace P., Rossi M., Baiano A., de Cristofaro A., Comparative effects of chronic ACE inhibition and AT 1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients, J Hum Hypertens, 16, pp. 133-140, (2002); de Long M., Logan J.L., Yong K.C., Lien Y.H., Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance, Nephrol Dial Transplant, 20, pp. 585-590, (2005); Dobbie J.W., Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis, Perit Dial Int, 12, pp. 14-27, (1992); Dyadyk A.I., Bagriy A.E., Lebed I.A., Yarovaya N.F., Schukina E.V., Taradin G.G., ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure, Nephrol Dial Transplant, 12, pp. 945-951, (1997); Ecder T., Edelstein C.L., Chapman A.B., Johnson A.M., Tison L., Gill E.A., Et al., Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease, Nephrol Dial Transplant, 14, pp. 1113-1116, (1999); Efrati S., Zaidenstein R., Dishy V., Beberashvili I., Sharist M., Averbukh Z., Et al., ACE inhibitors and survival of hemodialysis patients, Am J Kidney Dis, 40, pp. 1023-1029, (2002); Fang W., Oreopoulos D.G., Bargman J.M., Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis, Nephrol Dial Transplant, 23, pp. 3704-3710, (2008); Ferrario C.M., Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation, Hypertension, 47, pp. 515-521, (2006); Ferrario C.M., Strawn W.B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease, Am J Cardiol, 98, pp. 121-128, (2006); Ferrario C.M., Trask A.J., Jessup J.A., Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function, Am J Physiol Heart Circ Physiol, 289, pp. H2281-H2290, (2005); Gaddam K.K., Oparil S., Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients, Curr Opin Nephrol Hypertens, 17, pp. 484-490, (2008); Guerin A.P., Blacher J., Pannier B., Marchais S.J., Safar M.E., London G.M., Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure, Circulation, 103, pp. 987-992, (2001); Guerin A.P., Marchais S.J., Metivier F., London G.M., Arterial structural and functional alterations in uraemia, Eur J Clin Invest, 35, 3, pp. 85-88, (2005); Han S.W., Won Y.W., Yi J.H., Kim H.J., No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients, Nephrol Dial Transplant, 22, pp. 1150-1155, (2007); Hatch M., Freel R.W., Increased colonic sodium absorption in rats with chronic renal failure is partially mediated by AT 1 receptor agonism, Am J Physiol Gastrointest Liver Physiol, 295, pp. G348-G356, (2008); Hatch M., Freel R.W., Vaziri N.D., Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure, Am J Physiol, 274, pp. F275-F282, (1998); Hatch M., Freel R.W., Vaziri N.D., Losartan antagonism of angiotensin-II-induced potassium secretion across rat colon, Pflugers Arch, 436, pp. 717-724, (1998); Herzog C.A., Ma J.Z., Collins A.J., Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC / AHA practice guidelines on valve selection be modified, Circulation, 105, pp. 1336-1341, (2002); Hirakata H., Iseki K., Onoyama K., Kumagai H., Fujimi S., Omae T., Long-term hemodynamic response to captopril (SQ 14,225) in hypertensive hemodialysis patients, Clin Nephrol, 19, pp. 87-91, (1983); Hirakata H., Onoyama K., Iseki K., Omae T., Fujimi S., Kawahara Y., Captopril (SQ 14225) clearance during hemodialysis treatment, Clin Nephrol, 16, pp. 321-323, (1981); Ichihara A., Hayashi M., Kaneshiro Y., Takemitsu T., Homma K., Kanno Y., Et al., Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients, Am J Kidney Dis, 45, pp. 866-874, (2005); Igarashi Y., Suzuki H., Imafuku T., Saito I., Saruta T., Hypertension in patients on chronic hemodialysis: the role of the renin-angiotensin system, Jpn Circ J, 51, pp. 479-484, (1987); Imai H., Nakamoto H., Ishida Y., Yamanouchi Y., Inoue T., Okada H., Et al., Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum, Adv Perit Dial, 17, pp. 20-24, (2001); Kammerl M.C., Schaefer R.M., Schweda F., Schreiber M., Riegger G.A., Kramer B.K., Extracorporal therapy with AN 69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem, Clin Nephrol, 53, pp. 486-488, (2000); Kanno Y., Takenaka T., Nakamura T., Suzuki H., Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors, Clin J Am Soc Nephrol, 1, pp. 730-737, (2006); Kessler M., Zannad F., Lehert P., Grunfeld J.P., Thuilliez C., Leizorovicz A., Et al., Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study, Nephrol Dial Transplant, 22, pp. 3573-3579, (2007); Kimura G., Takahashi N., Kawano Y., Inenaga T., Inoue T., Nakamura S., Et al., Plasma renin activity in hemodialyzed patients during long-term follow-up, Am J Kidney Dis, 25, pp. 589-592, (1995); Knoll G.A., Sahgal A., Nair R.C., Graham J., van Walraven C., Burns K.D., (2002) Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients, Am J Med, 112, pp. 110-114; Li P.K., Chow K.M., Wong T.Y., Leung C.B., Szeto C.C., Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis, A randomized, controlled study. Ann Intern Med, 139, pp. 105-112, (2003); London G.M., Vascular disease and atherosclerosis in uremia, Blood Purif, 19, pp. 139-142, (2001); London G.M., Vascular disease and atherosclerosis in uremia, Nefrologia, 25, 2, pp. 91-95, (2005); Losito A., Kalidas K., Santoni S., Ceccarelli L., Jeffery S., Polymorphism of renin-angiotensin system genes in dialysis patients-association with cerebrovascular disease, Nephrol Dial Transplant, 17, pp. 2184-2188, (2002); Luik A.J., van Kuijk W.H., Spek J., de Heer F., van Bortel L.M., Schiffers P.M., Et al., (1997) Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients, Am J Kidney Dis, 30, pp. 466-474; Macdougall I.C., The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin, Nephrol Dial Transplant, 14, pp. 1836-1841, (1999); Matsumoto N., Ishimitsu T., Okamura A., Seta H., Takahashi M., Matsuoka H., Effects of imidapril on left ventricular mass in chronic hemodialysis patients, Hypertens Res, 29, pp. 253-260, (2006); McCullough P.A., Sandberg K.R., Yee J., Hudson M.P., Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease, J Renin Angiotensin Aldosterone Syst, 3, pp. 188-191, (2002); McLaughlin N., Gehr T.W., Sica D.A., Aldosterone-receptor antagonism and end-stage renal disease, Curr Hypertens Rep, 6, pp. 327-330, (2004); Meeus F., Kourilsky O., Guerin A.P., Gaudry C., Marchais S.J., London G.M., Pathophysiology of cardiovascular disease in hemodialysis patients, Kidney Int Suppl, 76, pp. S140-S147, (2000); Musini V.M., Fortin P.M., Bassett K., Wright J.M., Blood pressure lowering efficacy of renin inhibitors for primary hypertension, Cochrane Database Syst Rev, (2008); Ottosson P., Attman P.O., Agren A.C., Samuelsson O., Candesartan cilexetil in haemodialysis patients, Clin Drug Investig, 23, pp. 545-550, (2003); Paoletti E., Cassottana P., Bellino D., Specchia C., Messa P., Cannella G., Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors, Am J Kidney Dis, 40, pp. 728-736, (2002); Pfister M., Schaedeli F., Frey F.J., Uehlinger D.E., Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis, Br J Clin Pharmacol, 47, pp. 645-651, (1999); Phakdeekitcharoen B., Leelasa-nguan P., Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients, Am J Kidney Dis, 44, pp. 738-746, (2004); Raizada V., Skipper B., Luo W., Garza L., Hines C.W., Harford A.A., Et al., Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease, Kidney Int, 68, pp. 1186-1189, (2005); Roithinger F.X., Punzengruber C., Wallner M., Ulbrich W., Pachinger O., Kramar R., Et al., The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure, Clin Nephrol, 42, pp. 309-314, (1994); Rostoker G., Griuncelli M., Benmaadi A., Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients, Ren Fail, 28, pp. 283-286, (2006); Ruiz-Ortega M., Ruperez M., Esteban V., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., Et al., Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases, Nephrol Dial Transplant, 21, pp. 16-20, (2006); Sandle G.I., Gaiger E., Tapster S., Goodship T.H., Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis, Clin Sci, 73, pp. 247-252, (1987); Saracho R., Martin-Malo A., Martinez I., Aljama P., Montenegro J., Evaluation of the Losartan in Hemodialysis (ELHE) Study, Kidney Int Suppl, 68, pp. S125-S129, (1998); Schaefer R.M., Schaefer L., Horl W.H., Anaphylactoid reactions during hemodialysis, Clin Nephrol, 42, 1, pp. S44-S47, (1994); Schiffl H., Lang S.M., Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease, Nephron, 81, pp. 106-108, (1999); Shibasaki Y., Masaki H., Nishiue T., Nishikawa M., Matsubara H., Iwasaka T., Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease, Nephron, 90, pp. 256-261, (2002); Suzuki H., Kanno Y., Kaneko K., Kaneko M., Kotaki S., Mimura T., Et al., Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy, Ther Apher Dial, 8, pp. 320-327, (2004); Suzuki H., Kanno Y., Sugahara S., Ikeda N., Shoda J., Takenaka T., Et al., Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial, Am J Kidney Dis, 52, pp. 501-506, (2008); Suzuki H., Kanno Y., Sugahara S., Okada H., Nakamoto H., Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD, Am J Kidney Dis, 43, pp. 1056-1064, (2004); Suzuki H., Nakamoto H., Okada H., Sugahara S., Kanno Y., A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness, Adv Perit Dial, 19, pp. 59-66, (2003); Takahashi A., Takase H., Toriyama T., Sugiura T., Kurita Y., Ueda R., Et al., Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study, Nephrol Dial Transplant, 21, pp. 2507-2512, (2006); Tepel M., van der Giet M., Zidek W., Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN 69 dialysis membranes, Kidney Blood Press Res, 24, pp. 71-74, (2001); Toto R., Shultz P., Raij L., Mitchell H., Shaw W., Ramjit D., Et al., Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group, Hypertension, 31, pp. 684-691, (1998); Wauters J.P., Waeber B., Brunner H.R., Guignard J.P., Turini G.A., Gavras H., Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction, Clin Nephrol, 16, pp. 86-92, (1981); Weidmann P., Maxwell M.H., Lupu A.N., Lewin A.J., Massry S.G., Plasma renin activity and blood pressure in terminal renal failure, N Engl J Med, 285, pp. 757-762, (1971); Wetmore J.B., Johansen K.L., Sen S., Hung A.M., Lovett D.H., An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease, Hum Genet, 120, pp. 201-210, (2006); Yu W.C., Lin Y.P., Lin I.F., Chuang S.Y., Chen C.H., Effect of ramipril on left ventricular mass in normotensive hemodialysis patients, Am J Kidney Dis, 47, pp. 478-484, (2006); Zannad F., Kessler M., Lehert P., Grunfeld J.P., Thuilliez C., Leizorovicz A., Et al., Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies, Kidney Int, 70, pp. 1318-1324, (2006); Zheng S., Nath V., Coyne D.W., ACE inhibitor-based, directly observed therapy for hyper- ht tension in hemodialysis patients, Am J Nephrol, 27, pp. 522-529, (2007)","","","","","","","","","17539447","","","19491138","English","Ther. Adv. Cardiovasc. Dis","Review","Final","","Scopus","2-s2.0-70350031621"
"Thomas T.H.; Advani A.","Thomas, Trevor H. (7401541548); Advani, A. (7003588280)","7401541548; 7003588280","Inflammation in cardiovascular disease and regulation of the actin cytoskeleton in inflammatory cells: The actin cytoskeleton as a target","2006","Cardiovascular and Hematological Agents in Medicinal Chemistry","4","2","","165","182","17","22","10.2174/187152506776369926","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646905165&doi=10.2174%2f187152506776369926&partnerID=40&md5=2273822b1d453c43c385d9a833a4066d","UWCM Academic Unit, Wrexham LL13 7YP, Wrexham Technology Park, United Kingdom; School of Clinical Medical Sciences, Medical School, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne NE2 4HH, United Kingdom","Thomas T.H., UWCM Academic Unit, Wrexham LL13 7YP, Wrexham Technology Park, United Kingdom; Advani A., School of Clinical Medical Sciences, Medical School, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne NE2 4HH, United Kingdom","Cardiovascular disease is prevalent in developed countries causing very large burdens to health services. The underlying pathology is atheromatous plaque in the sub-endothelial region of the vascular wall. High levels of low density lipoprotein cholesterol and high blood pressure cause endothelial damage. Atheroma develop from a response to this injury that is perpetuated to chronic inflammation. The invasion of inflammatory leukocytes into atheroma during its development and in the precipitation of acute thrombotic events is mediated by adhesion molecules on the cell surface. These are regulated by the actin filament cytoskeleton which also mediates intracellular signalling from them. The actin cytoskeleton is central to NADPH oxidase activation that produces superoxide which is an intracellular signalling molecule for the hypertensive and inflammatory actions of angiotensin II. There are polymorphisms in actin filament proteins such as adducin and caldesmon and in the promoter regions of tropomyosins that may cause individual variation in these processes. Many signalling molecules in the actin filament response to inflammatory stimuli and in signalling downstream from actin filaments are small G-proteins that require post-transcriptional modification by isoprenoids from the cholesterol synthetic pathway. Statins deplete the isoprenoids and so down regulate G-proteins that mediate the inflammatory response. Angiotensin converting enzyme inhibitors and angiotensin II receptor type 1 antagonists decrease angiotensin II stimulated superoxide production thus decreasing not only blood pressure but also inflammation. The anti-inflammatory effects of these drugs, involving altered actin filament function, are a major contributor to their benefits in the treatment of cardiovascular disease. The feasibility of modifying the behaviour of actin filament proteins as a therapeutic approach for cardiovascular disease is considered. © 2006 Bentham Science Publishers Ltd.","Actin filaments; Angiotensin; Atheroma; Cardiovascular disease; Cytoskeleton; Inflammation; Isoprenoids; Statins","Actins; Cardiovascular Diseases; Cytoskeleton; Humans; Inflammation; 3 (4,4' dimethoxybenzhydrylidene) 2 indolinone; acetylsalicylic acid; actin; adducin; angiotensin; angiotensin II; angiotensin receptor antagonist; atenolol; calcium channel blocking agent; caldesmon; cell adhesion molecule; colchicine; dipeptidyl carboxypeptidase inhibitor; guanine nucleotide binding protein; hydroxymethylglutaryl coenzyme A reductase inhibitor; isoprenoid; lisinopril; low density lipoprotein cholesterol; paclitaxel; protein farnesyltransferase inhibitor; ramipril; reduced nicotinamide adenine dinucleotide phosphate oxidase; Rho kinase inhibitor; simvastatin; superoxide; thiazide diuretic agent; tropomyosin; unclassified drug; y 27362; actin; actin filament; antiinflammatory activity; atheroma; atherosclerotic plaque; blood pressure regulation; cardiovascular disease; cell invasion; cholesterol synthesis; chronic inflammation; clinical trial; cytoskeleton; down regulation; endothelium lesion; enzyme activation; genetic variability; human; hypercholesterolemia; hypertension; inflammation; inflammatory cell; leukocyte; meta analysis; nonhuman; promoter region; protein modification; review; signal transduction; single nucleotide polymorphism; stimulus response; thrombogenesis; thrombosis; vascular endothelium; cardiovascular disease; genetics; inflammation; metabolism","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; angiotensin II, 11128-99-7; angiotensin, 1407-47-2; atenolol, 29122-68-7; colchicine, 64-86-8; lisinopril, 76547-98-3, 83915-83-7; paclitaxel, 33069-62-4; ramipril, 87333-19-5; reduced nicotinamide adenine dinucleotide phosphate oxidase, 9032-22-8; simvastatin, 79902-63-9; superoxide, 11062-77-4; tropomyosin, 72067-79-9; Actins, ","aspirin; tas 301; taxol; y 27362","","","","Bonow R.O., Smaha L.A., Smith S.C., Menash G.A., Lenfant C., Circulation, 106, (2002); Murray C.J.L., Lopez A.D., Lancet, 349, (1997); Yusuf S., Reddy S., Ounpuu S., Anand S., Circulation, 104, (2001); Making a difference, (1999); Beaglehole R., Magnus P., Int. J. Epidemiol., 31, (2002); Reducing the Health consequences of Smoking: 25 years of Progress: A report of the surgeon general, (1989); World Health Day 7 April 2002- 'Move for Health; (2002); MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J., Lancet, 35, (1990); King H., Aubert R.E., Herman W.H., Diabetes Care, 121, (1998); Goodkin G., J. Occup. Med., 17, (1975); Panzram G., Diabetologia, 30, (1987); Wingard D.L., Barrett-Connors E., Diabetes in America, (1995); Nathan D.M., Meigs J., Singer D.E., Lancet, 350, SUPPL. 1, (1997); Circulation, 100, (1999); Stamler J., Vaccaro O., Neaton J.D., Wentworth D., Diabetes Care, 16, (1993); Geiss L.S., Herman W.H., Smith P.J., Diabetes in America, (1995); Diabetologia, 28, SUPPL., (1985); Rytter L., Troelsen S., Beck-Nielsen H., Diabetes Care, 8, (1985); Aronson D., Rayfield E.J., Chesebro J.H., Ann. Intern. Med., 126, (1997); Singer D.E., Moulton A.W., Nathan D.M., Diabetes, 38, (1989); Helmrich S.P., Ragland D.R., Leung R.W., Paffenbarger Jr. R.S., N. Engl. J. Med., 325, (1991); Klag M.J., Ford D.E., Mead L.A., He J., Whelton P.K., Liang K.Y., Levine D.M., N. Eng. J. Med., 328, (1993); Marenber M.E., Risch N., Berkman L.E., Floderus B., de Faire U., N. Eng. J. Med., 330, (1994); Burke L.E., J. Cardiovasc. Nurs., 18, (2003); Magnus P., Beaglehole R., Arch. Int. Med., 161, (2001); Stamler J., Wentworth D., Neaton J.D., JAMA, 256, (1986); Benditt E.P., Benditt J.M., Proc. Natl. Acad. Sci. USA, 70, (1973); Ross J.S., Stagliano N.E., Donovan M.J., Breitbart R.E., Ginsburg G.S., Am. J. Clin. Pathol., 116, (2001); Palmer R.M., Ferrige A.G., Moncada S., Nature, 327, (1987); Kubes P., Suzuki M., Ganger D.N., Proc. Natl. Acad. Sci. USA, 88, (1991); Tsao P.S., McEvoy L.M., Drexler H., Butcher E.C., Cooke J.P., Circulation, 89, (1994); Clancy R.M., Leszczynska P., Piziak, Abramson S.B., J. Clin. Invest., 90, (1992); Peng H.B., Libby P., Liao J.K., J. Biol. Chem., 270, (1995); Searles C.D., Ide L., Davis M.E., Cai H., Weber M., Circ. Res., 95, (2004); Su Y., Edwards-Bennett S., Bubb M.R., Block E.R., Am. J. Physiol. Cell. Physiol., 284, (2003); Zharikov S.I., Sigova A.A., Chen S., Bubb M.R., Block E.R., Am. J. Physiol. Lung Cell Mol. Physiol., 280, (2001); Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D.S., Yang S.X., Simoncini T., Yamada M., Rabkin E., Allen P.G., Huang P.L., Bohm M., Schoen F.J., Moskowitz M.A., Liao J.K., J. Clin. Invest., 106, (2000); Skidgel R.A., Am. J. Physiol. Lung Cell Mol. Physiol., 282, (2002); Fuster V., Badimon L., Badimon J., Chesebro J.H., N. Engl. J. Med., 326, (1992); Davies M.J., Heart, 83, (2000); Shah P.K., Cordiol. Rev., 8, (2000); Shah P.K., Prog. Cardiovasc. Dis., 44, (2002); Naruko T., Ueda M., Haze K., van der Wal A.C., van der Loos C.M., Itoh A., Komatsu R., Ikura Y., Ogami M., Shimada Y., Ehara S., Yoshiyama M., Takeuchi K., Yoskikawa J., Becker A.E., Circulation, 106, (2002); Moons A.H.M., Levi M., Peters R.J.G., Cardiovasc. Res., 53, (2002); Zwaal R.F.A., Schroit A.J., Blood, 89, (1997); Rosing J., Van Rijn J.L.M.L., Bevers E.M., van Dieijen G., Comfurius P., Zwaal R.F.A., Blood, 65, (1985); Tanner F.C., Noll G., Boulanger C.M., Luscher T.F., Circulation, 83, (1991); Steinberg D., Circulation, 84, (1991); Cathcart M.K., Arterioscler. Thromb. Vasc. Biol., 24, (2004); De Meyer G.R.Y., Herman A.G., Prog. Cardiovasc. Dis., 39, (1997); Krieglstein C.F., Granger D.N., Am. J. Hypertens., 14, (2001); Huo Y., Ley K., Acta. Physiol. Scand., 173, (2001); Pober J.S., Cotran R.S., Transplantation, 50, (1990); Zimmerman G.A., Prescott S.M., McIntyre T.M., Immunol. Today, 13, (1992); Hannan R.L., Kourembanas S., Flanders K.C., Rogelj S.J., Roberts A.B., Faller D.V., Klagsbun M., Growth Factors, 1, (1988); Li J.M., Shah A.M., Am. J. Physiol. Regul. Integr. Comp. Physiol., 287, (2004); Jaimes E.A., DeMaster E.G., Tian R.X., Raij L., Arterioscler. Thromb. Vasc. Biol., 24, (2004); Cuschleri J., Gourlay D., Garcia I., Jelacic S., Maier R.V., Shock, 19, (2003); Sobue K., Hayashi K., Nishida W., Horm. Res., 50, SUPPL., (1998); Mach F., Curr. Atheroscler. Rep., 3, (2001); Moiseeva E.P., Cardiovasc. Res., 52, (2001); Streblow D.N., Orloff S.L., Nelson J.A., J. Nutr., 131, (2001); Gonzalez-Amaro R., Sanchez-Madrid F., Crit. Rev. Immunol., 19, (1999); Schoenwaelder S.M., Burridge K., Curr. Opin. Cell Biol., 11, (1999); Calderwood D.A., Shattil S.J., Ginsberg M.H., J. Biol. Chem., 275, (2000); Buyon J.P., Slade S.G., Reibman J., Abramson S.B., Phillips M.R., Weissman G., Winchester R., J. Immunol., 144, (1990); Bevilacqua M.P., Nelson R.M., J. Clin. Invest., 91, (1993); Kucik D.F., Immunol. Res., 26, (2002); Chan J.R., Hyduk S.J., Cybulsky M.I., J. Immunol. Methods., 273, (2003); Suzuki M., Kato M., Hanaka H., Izumi T., Morikawa A., J. Allergy. Clin. Immunol., 112, (2003); Serrander L., Larsson J., Lundqvist H., Lindmark M., Fallman M., Dahlgren, Stendahl O., Biochim. Biophys. Acta, 1452, (1999); Ruf A., Patscheke H.B., J. Haematol., 90, (1995); Walzog B., Seifert R., Zakrzewicz A., Gaehtgens P., Ley K., J. Leuk. Biol., 56, (1994); Johnson-Tidey R.R., McGregor J.L., Taylor P.R., Poston R.N., Am. J. Pathol., 144, (1994); Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniatis T., FASEB J., 9, (1995); Davies M.J., Gordon J.L., Gearing A.J., Pigott R., Woolf N., Katz D., Kyriakopoulos A., J. Pathol., 171, (1993); Huo Y.F., Ley K., Acta Physiol. Scand., 173, (2001); Borregaard N., Theilgaard-Monch K., Sorensen O.E., Cowland J.B., Curr. Opin. Hematol., 8, (2001); Sengelov H., Kjldsen L., Diamond M.S., Springer T.A., Borregaard N., J. Clin. Invest., 92, (1993); Sengelov H., Kjldsen L., Kroeze W., Berger M., Borregaard N., J. Immunol., 153, (1994); Lyubchenko T.A., Wurth G.A., Zweifach A., J. Physiol, 547, (2003); Rizoli S.B., Rotstein O.D., Parodo J., Phillips M.J., Kapus A., Am. J. Physiol. Cell Physiol., 279, (2000); VandenBerg E., Reid M.D., Edwards J.D., Davis H.W., J. Cell Biochem., 91, (2004); Lauffenburger D.A., Horwitz A.F., Cell, 84, (1996); Calderwood D.A., Zent R., Grant R., Rees D.J., Hynes R.O., Ginsberg M.H., J. Biol. Chem., 274, (1999); van Kooyk Y., van Vliet S.J., Figdor C.G., J. Biol. Chem., 274, (1999); Bennett J.S., Zigmond S., Vilaire G., Cunningham M.E., Bednar B., J. Biol. Chem., 274, (1999); Kucik D.F., Immunol. Res., 26, (2002); Sheikh S., Gratzer W.B., Pinder J.C., Nash G.B., Biochem. Biophys. Res. Commun., 238, (1997); Kotovuori A., Pessa-Morikawa T., Kotovuori P., Nortamo P., Gahmberg C.G., J. Immunol., 162, (1999); Lub M., van Kooyk Y., van Vliet S.J., Figdor C.G., Mol. Biol. Cell., 8, (1997); Anderson S.I., Hotchin N.A., Nash G.B., J. Cell Sci., 113, (2000); Leitinger B., Hogg N., Mol. Biol. Cell., 11, (2000); Bertoni A., Tadokoro S., Eto K., Pampori N., Parise L.V., White G.C., Shattil S.J., J. Biol. Chem., 277, (2002); Sampath R., Gallagher P.J., Pavalko F.M., J. Biol. Chem., 273, (1998); Yan S.R., Berton G., J. Leukoc. Biol., 64, (1998); Pavalko F.M., LaRoche S.M., J. Immunol., 151, (1993); Weber C., Kitayama J., Springer T.A., Proc. Natl. Acad. Sci. USA, 93, (1996); Imhof B.A., Weerasinghe D., Brown E.J., Lindberg F.P., Hammel P., Piali L., Dessing M., Gisler R., Eur. J. Immunol., 27, (1997); Sanchez-Mateos P., Campanero M.R., Balboa M.A., Sanchez-Madrid F., J. Immunol., 151, (1993); Rabinowich H., Lin W.C., Manciulea M., Herberman R.B., Whiteside T.L., Blood, 85, (1995); Parmo-Cabanas M., Bartolome R.A., Wright N., Hidalgo A., Drager A.M., Teixido J., Exp. Cell Res., 294, (2004); Conran N., Gambero A., Ferreira H.H., Antunes E., de Nucci G., Biochem. Pharmacol., 66, (2003); Critchley D.R., Curr. Opin. Cell Biol., 12, (2000); Nolan C.M., Beaty H.N., Bagdade J.D., Diabetes, 27, (1978); Marhoffer W., Stein M., Maeser E., Federlin K., Diabetes Care, 15, (1992); Roper N.A., Bilous R.W., Kelly W.F., Unwin N.C., Connolly V.M., Diabetes Care, 25, (2002); Repine J.E., Clawson C.C., Goetz F.C., J. Infect. Dis., 142, (1980); Alexiewicz J.M., Kumar D., Smogorzewski M., Klin M., Massry S.G., Ann. Intern. Med., 123, (1995); Bagdade J.D., Root R.K., Bulger R.J., Diabetes, 23, (1974); Tan J.S., Anderson J.L., Watanakunakorn C., Phair J.P., J. Lab. Clin. Med., 85, (1975); Senior P., Marshall S.M., Thomas T.H., J. Leuk. Biol., 65, (1999); Panes J., Kurose I., Rodriguez-Vaca M.D., Anderson D.C., Miyasaka M., Tso P., Granger D.N., Circulation, 93, (1996); Salas A., Panes J., Elizalde J.I., Casadevall M., Anderson D.C., Granger D.N., Pique J.M., Am. J. Physiol., 275, (1998); Advani A., Marshall S.M., Thomas T.H., Diabetologia, 45, (2002); Rawling L.D., Advani A., Marshall S.M., Thomas T.H., Diabetologia, 47, (2004); Tong P., Khayat Z.A., Huang C., Patel N., Ueyama A., Klip A., J. Clin. Invest., 108, (2001); Kanzaki M., Pessin J.E., J. Biol. Chem., 276, (2001); Nevins A.K., Thurmond D.C., Am. J. Physiol. Cell Physiol., 285, (2003); Huo Y., Hafezi-Moghadam A., Ley K., Circ. Res., 87, (2000); Shih P.T., Brennan M.L., Vora D.K., Territo M.C., Strahl D., Elices M.J., Lusis A.J., Berliner J.A., Circ. Res., 84, (1999); Shih P.T., Elices M.J., Fang Z.T., Ugarova T.P., Strahl D., Territo M.C., Frank J.S., Kovach N.L., Cabanas C., Berliner J.A., Vora D.K., J. Clin. Invest., 103, (1999); Uno H., Ueki Y., Murashima J., Miyake S., Tominaga Y., Eguchi K., Yano K., Atherosclerosis, 116, (1995); Kawamura A., Miura S., Murayama T., Iwata A., Zhang B., Nishikawa H., Tsuchiya Y., Matsuo K., Tsuji E., Saku K., Circ. J., 68, (2004); Patricia M.K., Kim J.A., Harper C.M., Shih P.T., Berliner J.A., Natarajan R., Nadler J.L., Hedrick C.C., Arterioscler. Thromb. Vasc. Biol., 19, (1999); May A.E., Redecke V., Gruner S., Schmidt R., Massberg S., Miethke T., Ryba B., Prazeres da Costa C., Schomig A., Neumann F.J., Arterioscler. Thromb. Vasc. Biol., 23, (2003); Torres M., Coates T.D., J. Immunol. Methods, 232, (1999); Nachmias V.T., Curr. Opin. Cell Biol., 5, (1993); Safer D., Nachmias V.T., Bioessays, 16, (1994); Carlier M.F., Curr. Opin. Cell Biol., 10, (1998); Schluter K., Jockusch B.M., Rothkegel M., Biochim. Biophys. Acta, 1359, (1997); Schmidt A., Hall M.N., Ann. Rev. Cell Dev. Biol., 14, (1998); Hartwig J.H., J. Cell Biol., 118, (1992); Bearer E.L., J. Cell Biol., 115, (1991); Welch M.D., DePace A.H., Verma S., Iwamatsu A., Mitchison T.J., J.Cell Biol., 138, (1997); Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walter P., The cytoskeleton, Molecular Biology of the Cell, (2002); Cohen I., Cohen C., J. Mol. Biol., 68, (1972); Cote G.P., Smillie L.B., J. Biol. Chem., 256, (1981); Pittenger M.F., Kazzaz J.A., Helfman D.M., Curr. Opin. Cell Biol., 6, (1994); Temm-Grove C.J., Guo W., Helfman D.M., Cell Motil. Cytoskel., 33, (1996); Perry S.V., J. Muscle Res. Cell Motil., 22, (2001); Lin J.J., Warren K.S., Wamboldt D.D., Wang T., Lin J.L., Int. Rev. Cytol., 170, (1997); Erdelyi M., Michon A.M., Guichet A., Glotzer J.B., Ephrussi A., Nature, 377, (1995); Tetzlaff M.T., Jackle H., Pankratz M.J., EMBO J., 15, (1996); Pelham Jr. R.J., Lin J.J., Wang Y.L., J. Cell Sci., 109, (1996); Burgess D.R., Broschat K.O., Hayden J.M., J. Cell Biol., 104, (1987); Ishikawa R., Yamashiro S., Matsumura F., J.Biol. Chem., 264, (1989); Bernstein B.W., Bamburg J.R., Cell Motil., 2, (1982); Koteliansky V.E., Shirinsky V.P., Glukhova M.A., Nowak E., Dabrowska R., FEBS Lett., 155, (1983); Broschat K.O., Weber A., Burgess D.R., Biochemistry, 28, (1989); Ishikawa R., Yamashiro S., Matsumura F., J. Biol. Chem., 264, (1989); Marston S.B., Redwood C.S., Biochem. J., 279, (1991); Matsumura F., Yamashiro S., Curr. Opin. Cell Biol., 5, (1993); Fowler V.M., J. Biol. Chem., 262, (1987); Fowler V.M., Sussmann M.A., Miller P.G., Flucher B.E., Daniels M.P., J. Cell Biol., 120, (1993); Fowler V.M., J. Cell Biol., 111, (1990); Collins K., Sellers J.R., Matsudaira P., J. Cell Biol., 110, (1990); Umemoto S., Sellers J.R., J. Biol. Chem., 265, (1990); Casari G., Barlassina C., Cusi D., Zagato L., Muirhead R., Righetti M., Nembri P., Amar K., Gatti M., Macciardi F., Binelli G., Bianchi G., Hypertension, 25, (1995); Province M.A., Arnett D.K., Hunt S.C., Leiendecker-Foster C., Eckfeldt J.H., Oberman A., Ellison R.C., Heiss G., Mockrin S.C., Williams R.R., Am. J. Hypertens., 13, (2000); Kato N., Sugiyama T., Nabika T., Morita H., Kurihara H., Yazaki Y., Yamori Y., Hypertension, 31, (1998); Ishikawa K., Katsuya T., Sato N., Nakata Y., Takami S., Takiuchi S., Fu Y., Higaki J., Ogihara T., Am. J. Hypertens., 11, (1998); Bray M.S., Li L., Turner S.T., Kardia S.L., Boerwinkle E., Am. J. Hypertens., 13, (2000); Melander O., Bengtsson K., Orho-Melander M., Lindblad U., Forsblom C., Rastam L., Groop L., Hulthen U.L., J. Hum. Hypertens., 14, (2000); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Rivera R., Stella P., Troffa C., Zagato L., Bianchi G., Lancet, 349, (1997); Beeks E., Janssen R.G., Kroon A.A., Keulen E.T., Geurts J.M., de Leeuw P.W., de Bruin T.W., Am. J. Hypertens., 14, (2001); Tikhonoff V., Kuznetsova T., Stolarz K., Bianchi G., Casiglia E., Kawecka-Jaszcz K., Nikitin Y., Tizzone L., Wang J.G., Staessen J.A., Am. J. Hypertens., 16, (2003); Wang J.G., Staessen J.A., Barlassina C., Fagard R., Kuznetsova T., Struijker-Boudier H.A., Zagato L., Citterio L., Messaggio E., Bianchi G., Kidney Int., 62, (2002); Rutherford P.A., Thomas T.H., Wilkinson R., Clin. Sci., 82, (1992); Watkins S.L., West I.C., Wilkinson R., Thomas T.H., J. Hypertens., 19, (2001); Watkins H., Anan R., Coviello D.A., Spirito P., Seidman J.G., Seidman C.E., Circulation, 91, (1995); Nakajima-Taniguchi C., Matsui H., Nagata S., Kishimoto T., Yamauchi-Takihara K., J. Mol. Cell Cardiol., 27, (1995); Zhang T., Hillion J., Tong J.H., Cao Q., Chen S.J., Berger R., Chen Z., Leukemia, 8, (1994); Puig-Kroger A., Sanchez-Elsner T., Ruiz N., Andreu E.J., Prosper F., Jensen U.B., Gil J., Erickson P., Drabkin H., Groner Y., Corbi A.L., Blood, 102, (2003); Lutterbach B., Hiebert S.W., Gene, 245, (2000); Sobue K., Hayashi K., Nishida W., Horm. Res., 50, SUPPL. 2, (1998); Korb T., Schluter K., Enns A., Spiegel H.U., Senninger N., Nicolson G.L., Haier J., Exp. Cell Res., 299, (2004); Bakin A.V., Safina A., Rinehart C., Daroqui C., Darbary H., Helfiman D.M., Mol. Biol. Cell, 15, (2004); Begum R., Nur-E-Kamal M.S., Zaman M.A., Exp. Mol. Med., 36, (2004); Bharadwaj S., Hitchcock-DeGregori S., Thorburn A., Prasad G.L., J. Biol. Chem., (2004); Raval G.N., Bharadwaj S., Levine E.A., Willingham M.C., Geary R.L., Kute T., Prasad G.L., Oncogene, 22, (2003); Shah V., Bharadwaj S., Kaibuchi K., Prasad G.L., Oncogene, 20, (2001); Pawlak G., McGarvey T.W., Nguyen T.B., Tomaszewski J.E., Puthiyaveettil R., Malkowicz S.B., Helfman D.M., Int. J. Cancer, 110, (2004); Pittenger M.F., Kazzaz J.A., Helfman D.M., Curr. Opin. Cell Biol., 6, (1994); Miyado K., Kimura M., Taniguchi S., Biochem. Biophys. Res. Commun., 225, (1996); Takenaga K., Nakamura Y., Sakiyama S., Mol. Cell Biol., 8, (1988); Franzen B., Linder S., Uryu K., Alaiya A.A., Hirano T., Kato H., Auer G., Br. J. Cancer, 73, (1996); Mahadev K., Raval G., Bharadwaj S., Willingham M.C., Lange E.M., Vonderhaar B., Salomon D., Prasad G.L., Exp. Cell Res., 279, (2002); Abouhamed M., Reichenberg S., Robenek H., Plenz G., Eur. J. Cell Biol., 82, (2003); Zigmond S.H., Curr. Opin. Cell Biol., 8, (1996); Abdul-Manan N., Aghazadeh B., Liu G.A., Majumdar A., Ouerfelli O., Siminovitch K.A., Rosen M.K., Nature, 399, (1999); Benard V., Bohl B.P., Bokoch G.M., J. Biol. Chem., 274, (1999); Caron E., Hall A., Science, 282, (1998); Castellano F., Montcourrier P., Guillemot J.C., Gouin E., Machesky L., Cossart P., Chavrier P., Curr. Biol., 9, (1999); Guasch R.M., Scambler P., Jones G.E., Ridley A.J., Mol. Cell Biol., 18, (1998); Nobes C.D., Hall A., J. Cell Biol., 144, (1999); Hartwig J.H., Bokoch G.M., Carpenter C.L., Jamney P.A., Taylor L.A., Toker A., Stossel T.P., Cell, 82, (1995); Janmey P.A., Ann. Rev. Physiol., 56, (1994); Yonezawa N., Nishida E., Iida K., Yahara I., Sakai H., J. Biol. Chem., 265, (1990); Janmey P.A., Iida K., Yin H.L., Stossel T.P., J. Biol. Chem., 262, (1987); Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A., Cell, 70, (1992); Kozma R., Ahmed S., Best A., Lim L., Mol. Cell Biol., 15, (1995); Ridley A.J., Hall A., Cell, 70, (1992); Knaus U.G., Morris S., Dong H.J., Chernoff J., Bokoch G.M., Science, 269, (1995); Manser E., Leung T., Salihuddin H., Zhao Z.S., Lim L., Nature, 367, (1994); Prigmore E., Ahmed S., Best A., Kozma R., Manser E., Segal A.W., Lim L.J., Biol. Chem., 270, (1995); Vojtek A.B., Cooper J.A., Cell, 82, (1995); Ridley A.J., Hall A., EMBO J., 13, (1994); Chen H.C., Appeddu P.A., Parsons J.T., Hildebrand J.D., Schaller M.D., Guan J.L., J. Biol. Chem., 270, (1995); Fujii C., Yanagi S., Sada K., Nagai K., Taniguchi T., Yamamura H., Eur. J. Biochem., 226, (1994); Ferrell Jr. J.E., Noble J.A., Martin G.S., Jacques Y.V., Bainton D.F., Oncogene, 5, (1990); Frenette P.S., N. Engl. J. Med., 345, (2001); Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamat T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U., Nat. Med., 7, (2001); Sinensky M., Biochim. Biophys. Acta, 1484, (2000); Goldstein J.L., Brown M.S., Nature, 343, (1990); Takemoto M., Liao J.K., Arteriscler. Thromb. Vasc. Biol., 21, (2001); Van Aelst L., D-Souza-Schorey C., Genes Dev., 11, (1997); Laufs U., La Fata V., Plutzky J., Liao J.K., Circulation, (1998); Laufs U., Liao J.K., J. Biol. Chem., 273, (1998); Figueroa C., Taylor J., Vojtek A.B., J. Biol. Chem., 276, (2001); Pereira-Leal J.B., Hume A.N., Seabra M.C., FEBS Lett., 498, (2001); Allal C., Favre G., Couderc B., Salicio S., Sixou S., Hamilton A.D., Sebti S.M., Lajoie-Mazenc I., Pradines A.J., Biol. Chem., 275, (2000); Kim S.I., Kim H.J., Han D.C., Lee H.B., Kidney Int., 77, SUPPL., (2000); Feron O., Dessy C., Desager J.-P., Balligand J.-L., Circulation, 103, (2001); Schieffer B., Drexler H., Am. J. Cardiol., 91 S; Bhattacharyya R., Wedegaertner P.B., J. Biol. Chem., 275, (2000); Chen C.A., Manning D.R., Oncogene, 20, (2001); Willerson J.T., Ridker P.M., Circulation, 109, 21 SUPPL. 1, (2004); Crisby M., Drugs Today (Barc), 39, (2003); Kinlay S., Ganz P., Semin. Vasc. Med., 3, (2003); Kumagai K., Nakashima H., Saku K., Cardiovasc. Res., 62, (2004); Ridker P.M., Clin. Cardiol., 26, 4 SUPPL. 3, (2003); Chan A.W., Bhatt D.L., Chew D.P., Reginelli J., Schneider J.P., Topol E.J., Ellis S.G., Circulation, 107, (2003); Yoshida M., Sawada T., Ishii H., Gerszten R.E., Rosenzweig A., Gimbrone Jr. M.A., Yasukochi Y., Numano F., Arterioscler. Thromb. Vasc. Biol., 21, (2001); Kato T., Hashikabe H., Iwata C., Akimoto K., Hattori Y., Biochim. Biophys. Acta, 1689, (2004); Meisel S.R., Shapiro H., Radnay J., Neuman Y., Khaskia A.R., Gruener N., Pauzner H., David D.J., Am. Coll. Cardiol., 31, (1998); Stocker R., Keaney Jr. J.F., Physiol. Rev., 84, (2004); Li J.M., Shah A.M., J. Biol. Chem., 277, (2002); Granfeldt D., Dahlgren C., Inflammation, 25, (2001); van Bruggen R., Anthony E., Fernandez-Borja M., Roos D.J., Biol. Chem., 279, (2004); Serrander L., Larsson J., Lundqvist H., Lindmark M., Fallman M., Dahlgren C., Stendahl O., Biochim. Biophys. Acta, 1452, (1999); Holland J.A., Goss R.A., O'Donnell R.W., Chang M.M., Johnson D.K., Ziegler L.M., Endothelium, 8, (2001); Gu Y., Xu Y.C., Wu R.F., Souza R.F., Nwariaku F.E., Terada L.S., Exp. Cell Res., 272, (2002); Wang G., Anrather J., Huang J., Speth R.C., Pickel V.M., Iadecola C.J., Neurosci., 24, (2004); Touyz R.M., Yao G., Viel E., Amiri F., Schiffrin E.L., J. Hypertens., 22, (2004); Germano G., Sanguigni V., Pignatelli P., Caccese D., Lenti L., Ragazzo M., Lauro R., Violi F., J. Hypertens., 22, (2004); Keidar S., Kaplan M., Pavlotzky E., Coleman R., Hayek T., Hamoud S., Aviram M., Circulation, 109, (2004); Jung O., Schreiber J.G., Geiger H., Pedrazzini T., Busse R., Brandes R.P., Circulation, 109, (2004); Zeiher A.M., Fisslthaler B., Schray-Utz B., Busse R., Circ. Res., 76, (1995); Rees D.D., Palmer R.M.J., Moncada S., Proc. Natl. Acad. Sci. USA, 86, (1989); Sironi L., Gelosa P., Guerrini U., Banfi C., Crippa V., Brioschi M., Gianazza E., Nobili E., Gianella A., De Gasparo M., Tremoli E., J. Pharmacol. Exp. Ther., (2004); Ni W., Kitamoto S., Ishibashi M., Usui M., Inoue S., Hiasa K., Zhao Q., Nishida K., Takeshita A., Egashira K., Arterioscler. Thromb. Vasc. Biol., 24, (2004); Ishibashi M., Hiasa K., Zhao Q., Inoue S., Ohtani K., Kitamoto S., Tsuchihashi M., Sugaya T., Charo I.F., Kura S., Tsuzuki T., Ishibashi T., Takeshita A., Egashira K., Circ. Res., 94, (2004); Ando H., Jezova M., Zhou J., Saavedra J.M., Ann. N. Y. Acad. Sci., 1018, (2004); Li J.M., Wheatcroft S., Fan L.M., Kearney M.T., Shah A.M., Circulation, 109, (2004); Kutuk O., Basaga H., Trends Mol. Med., 9, (2003); Rahman I., Marwick J., Kirkham P., Biochem. Pharmacol., 68, (2004); Haddad J.J., Biochem. Biophys. Res. Commun., 316, (2004); Brigelius-Flohe R., Banning A., Kny M., Bol G.F., Arch. Biochem. Biophys., 423, (2004); Brar S.S., Kennedy T.P., Quinn M., Hoidal J.R., Protoplasma, 221, (2003); Takada Y., Khuri F.R., Aggarwal B.B., J. Biol. Chem., 279, (2004); Agarwal R., Campbell R.C., Warnock D.G., Semin. Nephrol., 24, (2004); Minor Jr. R., Myers P.R., Guerra Jr. R., Bates J.N., Harrison D.G., J. Clin. Invest., 86, (1990); Huie R.E., Padmaja S., Free Radical Res. Comms., 18, (1993); Antiplatelet Trialists' Collaboration, Brit. Med. J., 308, (1994); Maeda N.Y., Lopes A.A., Bydlowski S.P., Clin. Appl. Thromb. Hemost., 5, (1999); Oda A., Druker B.J., Smith M., Salzman E.W., J. Biol. Chem., 267, (1992); Kannel W.B., Castelli W.P., Gordon T., McNamara P.M., Ann. Int. Med., 74, (1971); Stamler J., Wentworth D., Neaton J.D., JAMA, 256, (1986); Assman G., Schulte H., Am. J. Cardial., 70, (1992); The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, (1994); Sacks F.M., Pfeffer M.A., Moyle L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E., N. Eng. J. Med., 335, (1996); The Long-Term Intervention with Pravastatin in ischaemic disease (LIPID) Study Group, N. Eng. J. Med., 339, (1998); Shepherd J., Cobbe S.M., Ford I.I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., N. Eng. J. Med., 333, (1995); Lancet, 360, (2002); Toto R.D., Rinner S., Ram V.S., Postgrad. Med., 116, (2004); Antithrombotic Trialists' Collabortaion, BMJ, 324, (2002); Brown N.J., Agirbasli M.A., Williams G.H., Litchfield W.R., Vaughan D.E., Hypertension, 32, (1998); Burnier M., Circulation, 104, (2001); Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., N. Eng. J. Med., 342, (2000); Svensson P., de Faire U., Sleight P., Yusuf S., Ostergren J., Hypertension, 38, (2001); Taylor R., BMJ, 327, (2003); JAMA, 288, (2002); Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., Lancet, 359, (2002); Lancet, 343, (1994); Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M., N. Engl. J. Med., 349, (2003); Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., N. Eng. J. Med., 327, (1992); Chan J.N., Tognoni G., Valsartan N., Eng. J. Med., 345, (2001); Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., Pocock S., Lancet, 362, (2003); Lancet, 349, (1997); Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., N. Eng. J. Med., 345, (2001); Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., N. Eng. J. Med., 345, (2001); Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S., N. Eng. J. Med., 345, (2001); Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K., Circulation, 103, (2001); Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J., Circulation, 87, (1993); Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., Tyroler H.A., N. Eng. J. Med., 322, (1990); Massy Z.A., Keane W.F., Kasiske B.L., Lancet, 347, (1996); Packard C.J., Circulation, 97, (1998); Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H., N. Eng. J. Med., 336, (1997); Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., Ridker P.M., JAMA, 288, (2002); Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E., Circulation, 100, (1999); Ridker P.M., Circulation, 107, (2003); Laufs U., Marra D., Node K., Liao J.K., J. Biol. Chem., 274, (1999); Singh R., Wang B., Shirvaikar A., Khan S., Kamat S., Schelling J.R., Konieczkowski M., Sedor J.M., J. Clin. Invest., 103, (1999); Essi M., Vrtovsnik F., Nguyen G., Sraer J.D., Friedlander G., J. Am. Soc. Nephrol., 9, (1998); Vaughan C.J., Gotto Jr. A.M., Basson C.T., J. Am. Coll. Cardiol., 35, (2000); Linz W., Wohlfart P., Schoelkaens B.A., Malinski T., Wiemer G., Cardiovasc. Res., 43, (1999); Kranzhofer R., Schmidt J., Pfeiffer C.A.H., Hagl S., Libby P., Kubler W., Arterioscler. Thromb. Vasc. Biol., 19, (1999); Schieffer B., Schieffer E., Hilfiker-Kleiner D., Hilfiker A., Kovanen P.T., Kaartinen M., Nussberger J., Harringer W., Drexler H., Circulation, 101, (2000); Ikeda F., Terajima H., Shimahara Y., Kondo T., Yamaoka Y., J. Surg. Res., 109, (2003); Hu E., Lee D., Curr. Opin. Investig. Drugs, 4, (2003); Sasaki E., Miyoshi K., Nozawa Y., Kanda A., Nakano K., Yamasaki Y., Miyake H., Matsuura N., Pharmacology, 63, (2001); Woo D.D., Miao S.Y., Pelayo J.C., Woolf A.S., Nature, 368, (1994); Woo D.D., Tabancay Jr. A.P., Wang C.J., Kidney Int., 51, (1997); Lange U., Schumann C., Schmidt K.L., Eur. J. Med. Res., 6, (2001); Tsutsui H., Ishibashi Y., Takahashi M., Namba T., Tagawa H., Imanaka-Yoshida K., Takeshita A., J. Mol. Cell Cardiol., 31, (1999)","T.H. Thomas; UWCM Academic Unit, Wrexham LL13 7YP, Wrexham Technology Park, United Kingdom; email: trevorhthomas@yahoo.co.uk","","","","","","","","18715257","","","16611050","English","cardiovasc. Hematol. Agents Med. Chem.","Review","Final","","Scopus","2-s2.0-33646905165"
"Baliga R.R.; Narula J.","Baliga, Ragavendra R. (8669929200); Narula, Jagat (7006139754)","8669929200; 7006139754","Pharmacogenomics of congestive heart failure","2003","Medical Clinics of North America","87","2","","569","578","9","10","10.1016/S0025-7125(02)00178-5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037351603&doi=10.1016%2fS0025-7125%2802%2900178-5&partnerID=40&md5=e0c62c3a6d927152a50482706ee7775c","University of Michigan, Ann Arbor, MI, United States; Drexel University Hospital, Philadelphia, PA, United States; Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI 48103, United States","Baliga R.R., University of Michigan, Ann Arbor, MI, United States, Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI 48103, United States; Narula J., Drexel University Hospital, Philadelphia, PA, United States","The future of pharmacogenomic therapy for CHF will require the determination of key genes that are critical in mediating cardiac remodeling [28]. Cardiac remodeling includes several processes including cardiac myocyte hypertrophy and apoptosis. Determination of genes that turn on and off the processes of hypertrophy and apoptosis may allow the future clinician to determine which patients with dilated cardiomyopathy would require antiapoptotic therapy, therapy directed to reducing cardiac myocyte hypertrophy, therapy directed to influencing cell survival, or a combination of such therapies. One strategy for identifying culprit heart failure genes is to compare expression profiles and cellular responses in human and mouse models of disease (Figs. 1 and 2). A high-throughput screen using common transcripts in the mouse and human models of heart failure is the initial step. This is followed by evaluation of the function of these novel genes by using the genes in mouse culture with the gain of function assay or the loss of function assay (antisense nucleotides). Other steps in the confirmation of the culprit gene include the use of transgenic animals to verify their individual contribution to the pathogenesis of CHF [29]. One group of investigators [30] using some of these techniques, particularly large-scale automated DNA sequencing, generated over 40,000 expressed sequence tags (ESTs) from human heart cDNA libraries. In addition, they retrieved over 40,000 ESTs from public databases. They found that, from the total of 84,904 ESTs, about 55% matched known genes, or approximately one third, matched other ESTs, and approximately 12% did not match any known sequences. Many of the latter are novel genes, and further efforts have to be made to verify their contribution to the pathogenesis of heart failure. Using high-density oligonucleotide arrays, one group of investigators found that several genes were altered in the failing heart, and they grouped these into five clusters. The clusters included (1) genes that encode contractile and cytoskeletal proteins (ie, SLIM1, β-acting, and myomesin MLC2); (2) genes encoding proteins that influence the disassembly and degradation of myocardial proteins (ie, ubiquitin, gelsolin, and α1-antichymotrypsin); (3) genes encoding proteins of the mitochondria (ie, aldose reductase, ATP synthase α-subunit, and TIM17 preprotein translocase); (4) genes encoding stress proteins (ie, αβ-crystallin and μ-crystallin); and (5) genes encoding proteins that influence protein synthesis including EF-2 and transcription factor homologue-HBZ17. Although the precise role of these proteins in CHF remains to be characterized, these genes should enhance our understanding of signaling pathways in the cardiac myocyte and, consequently, promote the development of newer therapies for CHF including gene delivery depending on pharmacogenomic profile (see the article by Dr. Hajjar et al elsewhere in this issue). Fast forward to the year 2010. A typical patient with CHF will require a blood test to determine his or her gene profile for the management of the disease. A deletion/insertion of the polymorphism in the ACE gene indicating that the patient is salt-sensitive suggests that salt restriction and diuretic therapy are more important in such a patient than in one who is not salt-sensitive [31-33]. A bradykinin-receptor polymorphism suggesting that the patient may develop a cough with ACE-inhibitor therapy means the clinician will have to avoid an ACE inhibitor. If the patient has beta-receptor polymorphisms suggesting that he or she will respond to beta-blocker therapy, then the patient may have only beta-blocker and diuretic therapy rather than the whole complement of ACE-I, digoxin, and diuretics. Depending on the genetic variant of CYP2D6, the clinician can decide whether the patient requires only β-1 blockade with metoprolol XL or requires α1/β blockade with carvedilol. In a different scenario, if the patient has pulmonary hypertension and a receptor polymorphism of the endothelin receptor, then the clinician may decide on an endothelin-receptor antagonist as first-line therapy (although, at this point of time, endothelin receptor antagonists have not been shown to be beneficial when added to standard therapy). Therefore, tailored therapy will not only allow a choice of which drug is more effective, but it will also allow the physician to withhold drugs that may cause side effects and to determine optimal dosages. These examples represent our incomplete understanding of the genetic modifiers of CHF and host sensitivity to therapy; ongoing studies should substantially enhance the use of such pharmacogenomic strategies. The rapid growth of ESTs and single-nucleotide polymorphism (SNP) databases coupled with advances in genomic technology should make pharmacogenomic therapy a reality in the not-too-distant future. Although the SNP profiles will provide information concerning a patient's response to medicine, it is important to reassure patients that the profiles will not determine precisely the presence of a disease-specific genetic mutation or any other disease-specific information about the patient or family members. Information on the drug's probable efficacy and safety for an individualized patient should change both the economics and the management of CHF. The rapid profiling of patients should allow more streamlined drug development and enhance the development of ""designer"" drugs for different patients with similar disease phenotypes. Another potential advantage of pharmacogenomics is that it may resurrect promising drugs that were discarded because they did not show benefit when previously added to standard therapy. The promise of pharmacogenomics has to be tempered, however, by the sensitivity to concerns regarding potential misuse of genomic information; these include loss of confidentiality for the patient, as well as possible stigmatization of groups. Such difficult genoethical issues must be addressed in order to reap the full benefits of this rapidly evolving and exciting field.","","aldehyde reductase; aldosterone synthase; alpha 1 antichymotrypsin; apoptosis inhibitor; beta actin; beta adrenergic receptor blocking agent; bradykinin receptor; captopril; carvedilol; contractile protein; crystallin; cytochrome P450 2D6; cytoskeleton protein; designer drug; digoxin; dipeptidyl carboxypeptidase inhibitor; diuretic agent; enalapril; endothelin receptor agonist; gelsolin; hydralazine; isosorbide mononitrate; lisinopril; metoprolol; mitochondrial protein; myomesin; proton transporting adenosine triphosphate synthase; transcription factor; ubiquitin; unindexed drug; adrenergic system; apoptosis; cell survival; clinical trial; congestive heart failure; coughing; DNA library; DNA microarray; DNA sequence; drug efficacy; drug safety; expressed sequence tag; gene expression; gene function; gene identification; gene mutation; gene targeting; gene therapy; genetic association; genetic polymorphism; genetic screening; heart dilatation; heart hypertrophy; heart muscle cell; heart ventricle remodeling; human; medical ethics; nonhuman; pathogenesis; pharmacogenomics; priority journal; pulmonary hypertension; renin angiotensin aldosterone system; review; sequence homology; side effect; signal transduction; single nucleotide polymorphism; sodium restriction; transgenic animal; treatment planning","","aldehyde reductase, 58591-34-7, 9023-11-4, 9028-31-3; aldosterone synthase, 122933-89-5; captopril, 62571-86-2; carvedilol, 72956-09-3; crystallin, 11046-99-4; digoxin, 20830-75-5, 57285-89-9; enalapril, 75847-73-3; hydralazine, 304-20-1, 86-54-4; isosorbide mononitrate, 1320-91-8, 16051-77-7; lisinopril, 76547-98-3, 83915-83-7; metoprolol, 37350-58-6; proton transporting adenosine triphosphate synthase, 37205-63-3; ubiquitin, 60267-61-0","","","","","Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Et al., Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 22, pp. 1651-1658, (2001); Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 10, pp. 709-717, (1999); Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 9169, pp. 2001-2007, (1999); The Cardiac Insufficiency Bisoprolol Study II. CIBIS-II a randomised trial, Lancet, 353, 9146, pp. 9-13, (1999); A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure, N Engl J Med, 344, 22, pp. 1659-1667, (2001); Collins F.S., McKusick V.A., Implications of the Human Genome Project for medical science, JAMA, 285, 5, pp. 540-544, (2001); Carson P., Ziesche S., Johnson G., Cohn J.N., Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials, J Card Fail, 5, 3, pp. 178-187, (1999); Yancy C.W., Michael B., Fowler M.B., Colucci W.S., Gilbert E.M., Bristow M.R., Et al., Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure, N Engl J Med, 344, 18, pp. 1358-1365, (2001); Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Et al., A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, N Engl J Med, 325, 5, pp. 303-310, (1991); Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Et al., Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study, N Engl J Med, 314, 24, pp. 1547-1552, (1986); Abraham M.R., Olson L.J., Joyner M.J., Turner S.T., Beck K.C., Johnson B.D., Angiotensinconverting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure, Circulation, 106, 14, pp. 1794-1799, (2002); Yigal M., Pinto Y.M., Van Gilst W.H., Kingma J.H., Schunkert H., Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction, J Am Coll Cardiol, 25, 7, pp. 1622-1626, (1995); O'Toole L., Stewart M., Padfield P., Channer K., Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure, J Cardiovasc Pharmacol, 32, 6, pp. 988-994, (1998); Cicoira M., Zanolla L., Rossi A., Golia G., Franceschini L., Cabrini G., Et al., Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype, J Am Coll Cardiol, 37, 7, pp. 1808-1812, (2001); McNamara D.M., Holubkov R., Janosko K., Palmer A., Wang J.J., MacGowan G.A., Et al., Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, Circulation, 103, 12, pp. 1644-1648, (2001); Xie H.G., Stein C.M., Kim R.B., Xiao Z.S., He N., Zhou H.H., Et al., Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals, Pharmacogenetics, 9, 4, pp. 511-516, (1999); Xie H.G., Kim R.B., Stein C.M., Gainer J., Brown N., Wood A.J., Alpha1A-adrenergic receptor polymorphism: Association with ethnicity but not essential hypertension, Pharmacogenetics, 9, 5, pp. 651-656, (1999); Xie H.G., Dishy V., Sofowora G., Kim R.B., Landau R., Richard M., Et al., Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo, Pharmacogenetics, 11, 3, pp. 191-197, (2001); Dishy V., Sofowora G.G., Xie H., Kim R.B., Byrne D.W., Stein C.M., Et al., The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization, N Engl J Med, 345, 14, pp. 1030-1035, (2001); Liggett S.B., Wagoner L.E., Craft L.L., Hornung R.W., Hoit B.D., McIntosh T.C., Et al., The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure, J Clin Invest, 102, 8, pp. 1534-1539, (1998); Wagoner L.E., Craft L.L., Singh B., Suresh D.P., Paul W., McGuire N., Et al., Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure, Circ Res, 86, 8, pp. 834-840, (2000); Small K.M., Wagoner L.E., Levin A.M., Kardia S., Ligget S.B., Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure, N Engl J Med, 347, 15, pp. 1135-1142, (2002); Hajjar R.J., MacRae C.A., Adrenergic-receptor polymorphisms and heart failure, N Engl J Med, 347, 15, pp. 1196-1199, (2002); Zhou H.H., Wood A.J., Stereoselective disposition of carvedilol is determined by CYP2D6, Clin Pharmacol Ther, 57, 5, pp. 518-524, (1995); Wood A.J., Racial differences in the response to drugs-pointers to genetic differences, N Engl J Med, 344, 18, pp. 1394-1396, (2001); Mukae S., Aoki S., Itoh S., Iwata T., Ueda H., Katagiri T., Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough, Hypertension, 36, 1, pp. 127-131, (2000); Tiago A.D., Badenhorst D., Skudicky D., Woodiwiss A.J., Candy G.P., Brooksbank R., Et al., An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy, Cardiovasc Res, 54, 3, pp. 584-589, (2002); Hoit B.D., Kiatchoosakun S., Restivo J., Kirkpatrick D., Olszens K., Shao H., Et al., Naturally occurring variation in cardiovascular traits among inbred mouse strains, Genomics, 79, 5, pp. 679-685, (2002); Glueck S.B., Dzau V.J., Lee R., Pratt R.E., Challenges of comparative expression profiling studies of complex diseases: Mouse models of myocardial hypertrophy. Focus on ""Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy, Physiol Genomics, 6, 1, pp. 1-2, (2001); Hwang D.M., Dempsey A.A., Wang R., Rezvani M., Barrans D., Dai K., Et al., A genome-based resource for molecular cardiovascular medicine: Toward a compendium of cardiovascular genes, Circulation, 96, 12, pp. 4146-4203, (1997); Kojima S., Inenaga T., Matsuoka H., Kuramolhi M., Omae T., Nara Y., Et al., The association between salt sensitivity of blood pressure and some polymorphic factors, J Hypertens, 12, 7, pp. 797-801, (1994); Hiraga H., Oshima T., Watanabe M., Ishida M., Ishida T., Shingu T., Et al., Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension, Hypertension, 27, 3, pp. 569-572, (1996); Poch E., Gonzalez D., Giner V., Bragulat E., Coca A., De la Sierra A., Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms, Hypertension, 38, 5, pp. 1204-1209, (2001)","R.R. Baliga; Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI 48103, United States; email: rrbaliga@umich.edu","","W.B. Saunders","","","","","","00257125","","MCNAA","12693740","English","Med. Clin. North Am.","Review","Final","","Scopus","2-s2.0-0037351603"
"Zhou S.-F.; Zhou Z.-W.; Huang M.","Zhou, Shu-Feng (43761748200); Zhou, Zhi-Wei (55600997600); Huang, Min (36484772800)","43761748200; 55600997600; 36484772800","Polymorphisms of human cytochrome P450 2C9 and the functional relevance","2010","Toxicology","278","2","","165","188","23","110","10.1016/j.tox.2009.08.013","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78149470864&doi=10.1016%2fj.tox.2009.08.013&partnerID=40&md5=1e00b81c18e2fcb487caf26078176739","School of Health Sciences, RMIT University, Victoria 3083, Australia; Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China","Zhou S.-F., School of Health Sciences, RMIT University, Victoria 3083, Australia; Zhou Z.-W., School of Health Sciences, RMIT University, Victoria 3083, Australia; Huang M., Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China","Human cytochrome P450 2C9 (CYP2C9) accounts for ~20% of hepatic total CYP content and metabolizes ~15% clinical drugs such as phenytoin, S-warfarin, tolbutamide, losartan, and many nonsteroidal anti-inflammatory agents (NSAIDs). CYP2C9 is highly polymorphic, with at least 33 variants of CYP2C9 (1B through 34) being identified so far. CYP2C9 2 is frequent among Caucasians with ~1% of the population being homozygous carriers and 22% are heterozygous. The corresponding figures for the CYP2C9 3 allele are 0.4% and 15%, respectively. There are a number of clinical studies addressing the impact of CYP2C9 polymorphisms on the clearance and/or therapeutic response of therapeutic drugs. These studies have highlighted the importance of the CYP2C9 2 and 3 alleles as a determining factor for drug clearance and drug response. The CYP2C9 polymorphisms are relevant for the efficacy and adverse effects of numerous NSAIDs, sulfonylurea antidiabetic drugs and, most critically, oral anticoagulants belonging to the class of vitamin K epoxide reductase inhibitors. Warfarin has served as a practical example of how pharmacogenetics can be utilized to achieve maximum efficacy and minimum toxicity. For many of these drugs, a clear gene-dose and gene-effect relationship has been observed in patients. In this regard, CYP2C9 alleles can be considered as a useful biomarker in monitoring drug response and adverse effects. Genetic testing of CYP2C9 is expected to play a role in predicting drug clearance and conducting individualized pharmacotherapy. However, prospective clinical studies with large samples are warranted to establish gene-dose and gene-effect relationships for CYP2C9 and its substrate drugs. © 2009 Elsevier Ireland Ltd.","Adverse effect; Biomarker; Clearance; CYP2C9; Enzyme activity; Ethnic; SNP","Animals; Aryl Hydrocarbon Hydroxylases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Liver; Pharmaceutical Preparations; Polymorphism, Genetic; angiotensin 2 receptor antagonist; anticoagulant agent; anticonvulsive agent; antidiabetic agent; antivitamin K; cyclooxygenase 2 inhibitor; cytochrome P450 2C9; diclofenac; diuretic agent; flurbiprofen; glibenclamide; gliclazide; glimepiride; glipizide; ibuprofen; indometacin; ketoprofen; lornoxicam; losartan; meloxicam; naproxen; nonsteroid antiinflammatory agent; phenytoin; piroxicam; sulfonylurea derivative; suprofen; tenoxicam; tolbutamide; unindexed drug; warfarin; allele; article; Caucasian; congestive heart failure; deep vein thrombosis; diabetes mellitus; drug clearance; drug efficacy; drug half life; drug metabolism; drug monitoring; drug response; enzyme activity; enzyme specificity; epilepsy; ethnicity; gene mutation; genetic difference; genetic polymorphism; genetic screening; genetic variability; heart atrium fibrillation; heart infarction; heterozygosity; homozygosity; human; hyperlipidemia; hypertension; loading drug dose; low drug dose; missense mutation; non insulin dependent diabetes mellitus; nonhuman; osteoarthritis; pain; pharmacogenetics; prediction; pregnancy diabetes mellitus; priority journal; rheumatoid arthritis; single drug dose; single nucleotide polymorphism; stomach hemorrhage; stroke; thrombosis; treatment response; unspecified side effect","","diclofenac, 15307-79-6, 15307-86-5; flurbiprofen, 5104-49-4; glibenclamide, 10238-21-8; gliclazide, 21187-98-4; glimepiride, 93479-97-1; glipizide, 29094-61-9; ibuprofen, 15687-27-1, 79261-49-7; indometacin, 53-86-1, 74252-25-8, 7681-54-1; ketoprofen, 22071-15-4, 57495-14-4; lornoxicam, 70374-39-9; losartan, 114798-26-4; meloxicam, 71125-38-7; naproxen, 22204-53-1, 26159-34-2; phenytoin, 57-41-0, 630-93-3; piroxicam, 36322-90-4; suprofen, 40828-46-4; tenoxicam, 59804-37-4; tolbutamide, 473-41-6, 64-77-7; warfarin, 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2; Aryl Hydrocarbon Hydroxylases, 1.14.14.1; CYP2C9 protein, human, 1.14.14.1; Pharmaceutical Preparations, ","glyburide","","","","Adithan C., Gerard N., Vasu S., Balakrishnan R., Shashindran C.H., Krishnamoorthy R., Allele and genotype frequency of CYP2C9 in Tamilnadu population, Eur. J. Clin. Pharmacol., 59, pp. 707-709, (2003); Aithal G.P., Day C.P., Leathart J.B., Daly A.K., Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis, Pharmacogenetics, 10, pp. 511-518, (2000); Akutsu T., Kobayashi K., Sakurada K., Ikegaya H., Furihata T., Chiba K., Identification of human cytochrome P450 isozymes involved in diphenhydramine N-demethylation, Drug Metab. Dispos., 35, pp. 72-78, (2007); Albrecht W., Unger A., Nussler A.K., Laufer S., In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase, Drug Metab. Dispos., 36, pp. 894-903, (2008); Allabi A.C., Gala J.L., Desager J.P., Heusterspreute M., Horsmans Y., Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations, Br. J. Clin. Pharmacol., 56, pp. 653-657, (2003); Allabi A.C., Gala J.L., Horsmans Y., Babaoglu M.O., Bozkurt A., Heusterspreute M., Yasar U., Functional impact of CYP2C9 5, CYP2C9 6, CYP2C9 8, and CYP2C9 11 in vivo among black Africans, Clin. Pharmacol. Ther., 76, pp. 113-118, (2004); Allabi A.C., Gala J.L., Horsmans Y., CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population, Pharmacogenet. Genom., 15, pp. 779-786, (2005); Andersson S.H., Lindgren A., Postlind H., Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs, Drug Metab. Dispos., 26, pp. 528-535, (1998); Aynacioglu A.S., Brockmoller J., Bauer S., Sachse C., Guzelbey P., Ongen Z., Nacak M., Roots I., Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin, Br. J. Clin. Pharmacol., 48, pp. 409-415, (1999); Babaoglu M.O., Yasar U., Sandberg M., Eliasson E., Dahl M.L., Kayaalp S.O., Bozkurt A., CYP2C9 genetic variants and losartan oxidation in a Turkish population, Eur. J. Clin. Pharmacol., 60, pp. 337-342, (2004); Badian M., Korn A., Lehr K.H., Malerczyk V., Waldhausl W., Absolute bioavailability of glimepiride (Amaryl) after oral administration, Drug Metabol. Drug Interact., 11, pp. 331-339, (1994); Bae J.W., Kim H.K., Kim J.H., Yang S.I., Kim M.J., Jang C.G., Park Y.S., Lee S.Y., Allele and genotype frequencies of CYP2C9 in a Korean population, Br. J. Clin. Pharmacol., 60, pp. 418-422, (2005); Bae J.W., Kim J.H., Choi C.I., Kim M.J., Kim H.J., Byun S.A., Chang Y.S., Jang C.G., Park Y.S., Lee S.Y., Effect of CYP2C9 3 allele on the pharmacokinetics of naproxen in Korean subjects, Arch. Pharm. Res., 32, pp. 269-273, (2009); Bagshaw S.M., Delaney A., Haase M., Ghali W.A., Bellomo R., Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis, Crit. Care Resusc., 9, pp. 60-68, (2007); Bajpai M., Roskos L.K., Shen D.D., Levy R.H., Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite, Drug Metab. Dispos., 24, pp. 1401-1403, (1996); Balant L., Fabre J., Zahnd G.R., Comparison of the pharmacokinetics of glipizide and glibenclamide in man, Eur. J. Clin. Pharmacol., 8, pp. 63-69, (1975); Ball S.E., Forrester L.M., Wolf C.R., Back D.J., Differences in the cytochrome P450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17α-ethinyloestradiol. Relative activities of rat and human liver enzymes, Biochem. J., 267, pp. 221-226, (1990); Barnhart J.W., The urinary excretion of dextromethorphan and three metabolites in dogs and humans, Toxicol. Appl. Pharmacol., 55, pp. 43-48, (1980); Becquemont L., Mouajjah S., Escaffre O., Beaune P., Funck-Brentano C., Jaillon P., Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism, Drug Metab. Dispos., 27, pp. 1068-1073, (1999); Benetton S.A., Borges V.M., Chang T.K., McErlane K.M., Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone, Xenobiotica, 34, pp. 335-344, (2004); Blaisdell J., Jorge-Nebert L.F., Coulter S., Ferguson S.S., Lee S.J., Chanas B., Xi T., Mohrenweiser H., Ghanayem B., Goldstein J.A., Discovery of new potentially defective alleles of human CYP2C9, Pharmacogenetics, 14, pp. 527-537, (2004); Boberg M., Angerbauer R., Fey P., Kanhai W.K., Karl W., Kern A., Ploschke J., Radtke M., Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved, Drug Metab. Dispos., 25, pp. 321-331, (1997); Bohets H., Lavrijsen K., Hendrickx J., van Houdt J., van Genechten V., Verboven P., Meuldermans W., Heykants J., Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions, Br. J. Pharmacol., 129, pp. 1655-1667, (2000); Bondesson U., Hartvig P., Danielsson B., Quantitative determination of the urinary excretion of ketobemidone and four of its metabolites after intravenous and oral administration in man, Drug Metab. Dispos., 9, pp. 376-380, (1981); Bonnabry P., Leemann T., Dayer P., Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam, Eur. J. Clin. Pharmacol., 49, pp. 305-308, (1996); Bort R., Ponsoda X., Carrasco E., Gomez-Lechon M.J., Castell J.V., Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human, Drug Metab. Dispos., 24, pp. 969-975, (1996); Bourrie M., Meunier V., Berger Y., Fabre G., Role of cytochrome P450 2C9 in irbesartan oxidation by human liver microsomes, Drug Metab. Dispos., 27, pp. 288-296, (1999); Bovill E.G., Fung M., Cushman M., Vitamin K and oral anticoagulation: thought for food, Am. J. Med., 116, pp. 711-713, (2004); Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest C.S., Lachno D.R., Salazar D., Winters K.J., Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J. Thromb. Haemost., 5, pp. 2429-2436, (2007); Bravo-Villalta H.V., Yamamoto K., Nakamura K., Baya A., Okada Y., Horiuchi R., Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study, Eur. J. Clin. Pharmacol., 61, pp. 179-184, (2005); Brenner S.S., Herrlinger C., Dilger K., Murdter T.E., Hofmann U., Marx C., Klotz U., Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib, Clin. Pharmacokinet., 42, pp. 283-292, (2003); Burian M., Grosch S., Tegeder I., Geisslinger G., Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population, Br. J. Clin. Pharmacol., 54, pp. 518-521, (2002); Busse D., Cosme J., Beaune P., Kroemer H.K., Eichelbaum M., Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans, Naunyn Schmiedebergs Arch. Pharmacol., 353, pp. 116-121, (1995); Bussey H.I., Wittkowsky A.K., Hylek E.M., Walker M.B., Genetic testing for warfarin dosing? Not yet ready for prime time, Pharmacotherapy, 28, pp. 141-143, (2008); Caraco Y., Muszkat M., Wood A.J., Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo, Pharmacogenetics, 11, pp. 587-596, (2001); Cazaubon C., Gougat J., Bousquet F., Guiraudou P., Gayraud R., Lacour C., Roccon A., Galindo G., Barthelemy G., Gautret B., Et al., Pharmacological characterization of SR 47436, a new nonpeptide AT<sub>1</sub> subtype angiotensin II receptor antagonist, J. Pharmacol. Exp. Ther., 265, pp. 826-834, (1993); Chando T.J., Everett D.W., Kahle A.D., Starrett A.M., Vachharajani N., Shyu W.C., Kripalani K.J., Barbhaiya R.H., Biotransformation of irbesartan in man, Drug Metab. Dispos., 26, pp. 408-417, (1998); Chauret N., Yergey J.A., Brideau C., Friesen R.W., Mancini J., Riendeau D., Silva J., Styhler A., Trimble L.A., Nicoll-Griffith D.A., In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663), Bioorg. Med. Chem. Lett., 11, pp. 1059-1062, (2001); Chavez M.L., DeKorte C.J., Valdecoxib: a review, Clin. Ther., 25, pp. 817-851, (2003); Chesne C., Guyomard C., Guillouzo A., Schmid J., Ludwig E., Sauter T., Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4, Xenobiotica, 28, pp. 1-13, (1998); Chiba M., Xu X., Nishime J.A., Balani S.K., Lin J.H., Hepatic microsomal metabolism of montelukast, a potent leukotriene D<sub>4</sub> receptor antagonist, in humans, Drug Metab. Dispos., 25, pp. 1022-1031, (1997); Choi M.H., Skipper P.L., Wishnok J.S., Tannenbaum S.R., Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450, Drug Metab. Dispos., 33, pp. 714-718, (2005); Christensen M.L., Meibohm B., Capparelli E.V., Velasquez-Mieyer P., Burghen G.A., Tamborlane W.V., Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with Type 2 diabetes, J. Clin. Pharmacol., 45, pp. 1137-1144, (2005); Clarke T.A., Waskell L.A., The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin, Drug Metab. Dispos., 31, pp. 53-59, (2003); Cotreau-Bibbo M.M., von Moltke L.L., Greenblatt D.J., Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes, J. Pharm. Sci., 85, pp. 1180-1185, (1996); Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., Cowley H., Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans, Drug Metab. Dispos., 28, pp. 772-780, (2000); Crespi C.L., Miller V.P., The R144C change in the CYP2C9 2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase, Pharmacogenetics, 7, pp. 203-210, (1997); Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., Gillam E.M., Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen, Drug Metab. Dispos., 30, pp. 869-874, (2002); Cribb A.E., Spielberg S.P., Griffin G.P., N<sup>4</sup>-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes, Drug Metab. Dispos., 23, pp. 406-414, (1995); Dain J.G., Fu E., Gorski J., Nicoletti J., Scallen T.J., Biotransformation of fluvastatin sodium in humans, Drug Metab. Dispos., 21, pp. 567-572, (1993); Dalvie D.K., O'Connell T.N., Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases, Drug Metab. Dispos., 32, pp. 49-57, (2004); Dang M.T., Hambleton J., Kayser S.R., The influence of ethnicity on warfarin dosage requirement, Ann. Pharmacother., 39, pp. 1008-1012, (2005); Davi H., Tronquet C., Miscoria G., Perrier L., DuPont P., Caix J., Simiand J., Berger Y., Disposition of irbesartan, an angiotensin II AT<sub>1</sub>-receptor antagonist, in mice, rats, rabbits, and macaques, Drug Metab. Dispos., 28, pp. 79-88, (2000); Davies N.M., Clinical pharmacokinetics of flurbiprofen and its enantiomers, Clin. Pharmacokinet., 28, pp. 100-114, (1995); Davies N.M., McLachlan A.J., Day R.O., Williams K.M., Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclooxygenase-2 inhibitor, Clin. Pharmacokinet., 38, pp. 225-242, (2000); de Groot M.J., Alex A.A., Jones B.C., Development of a combined protein and pharmacophore model for cytochrome P450 2C9, J. Med. Chem., 45, pp. 1983-1993, (2002); Decker C.J., Laitinen L.M., Bridson G.W., Raybuck S.A., Tung R.D., Chaturvedi P.R., Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions, J. Pharm. Sci., 87, pp. 803-807, (1998); Dickmann L.J., Rettie A.E., Kneller M.B., Kim R.B., Wood A.J., Stein C.M., Wilkinson G.R., Schwarz U.I., Identification and functional characterization of a new CYP2C9 variant (CYP2C9 5) expressed among African Americans, Mol. Pharmacol., 60, pp. 382-387, (2001); Dingemanse J., van Giersbergen P.L., Clinical pharmacology of bosentan, a dual endothelin receptor antagonist, Clin. Pharmacokinet., 43, pp. 1089-1115, (2004); Dorado P., Berecz R., Norberto M.J., Yasar U., Dahl M.L.A.L.L., CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers, Eur. J. Clin. Pharmacol., 59, pp. 221-225, (2003); Dorado P., Cavaco I., Caceres M.C., Piedade R., Ribeiro V., Llerena A., Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers, Eur. J. Clin. Pharmacol., 64, pp. 967-970, (2008); Dunn C.J., Fitton A., Brogden R.N., Torasemide. An update of its pharmacological properties and therapeutic efficacy, Drugs, 49, pp. 121-142, (1995); Eagling V.A., Howe J.L., Barry M.J., Back D.J., The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine, Biochem. Pharmacol., 48, pp. 267-276, (1994); Ebert B., Thorkildsen C., Andersen S., Christrup L.L., Hjeds H., Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists, Biochem. Pharmacol., 56, pp. 553-559, (1998); Elliot D.J., Suharjono, Lewis B.C., Gillam E.M., Birkett D.J., Gross A.S., Miners J.O., Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination, Br. J. Clin. Pharmacol., 64, pp. 450-457, (2007); Engel G., Hofmann U., Heidemann H., Cosme J., Eichelbaum M., Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation, Clin. Pharmacol. Ther., 59, pp. 613-623, (1996); Erickson D.A., Mather G., Trager W.F., Levy R.H., Keirns J.J., Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P450, Drug Metab. Dispos., 27, pp. 1488-1495, (1999); Evans D.C., O'Connor D., Lake B.G., Evers R., Allen C., Hargreaves R., Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein, Drug Metab. Dispos., 31, pp. 861-869, (2003); Facciola G., Hidestrand M., von Bahr C., Tybring G., Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes, Eur. J. Clin. Pharmacol., 56, pp. 881-888, (2001); Firkusny L., Kroemer H.K., Eichelbaum M., In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron, Biochem. Pharmacol., 49, pp. 1777-1784, (1995); Fischer T.L., Pieper J.A., Graff D.W., Rodgers J.E., Fischer J.D., Parnell K.J., Goldstein J.A., Greenwood R., Patterson J.H., Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers, Clin. Pharmacol. Ther., 72, pp. 238-246, (2002); Fischer V., Vickers A.E., Heitz F., Mahadevan S., Baldeck J.P., Minery P., Tynes R., The polymorphic cytochrome P4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron, Drug Metab. Dispos., 22, pp. 269-274, (1994); Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.P., Robinson W.T., The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions, Drug Metab. Dispos., 27, pp. 410-416, (1999); Flockhart D.A., O'Kane D., Williams M.S., Watson M.S., Flockhart D.A., Gage B., Gandolfi R., King R., Lyon E., Nussbaum R., O'Kane D., Schulman K., Veenstra D., Williams M.S., Watson M.S., Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin, Genet. Med., 10, pp. 139-150, (2008); Flores-Runk P., Raasch R.H., Ticlopidine and antiplatelet therapy, Ann. Pharmacother., 27, pp. 1090-1098, (1993); Fogelman S.M., Schmider J., Venkatakrishnan K., von Moltke L.L., Harmatz J.S., Shader R.I., Greenblatt D.J., O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants, Neuropsychopharmacology, 20, pp. 480-490, (1999); Foster D.J., Somogyi A.A., Bochner F., Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4, Br. J. Clin. Pharmacol., 47, pp. 403-412, (1999); Furuta S., Akagawa N., Kamada E., Hiyama A., Kawabata Y., Kowata N., Inaba A., Matthews A., Hall M., Kurimoto T., Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential, Br. J. Clin. Pharmacol., 54, pp. 295-303, (2002); Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., Idle J.R., Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy, Pharmacogenetics, 5, pp. 389-392, (1995); Gaedigk A., Casley W.L., Tyndale R.F., Sellers E.M., Jurima-Romet M., Leeder J.S., Cytochrome P450 2C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations, Can. J. Physiol. Pharmacol., 79, pp. 841-847, (2001); Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., McLeod H.L., Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin, Thromb. Haemost., 91, pp. 87-94, (2004); Gage B.F., Eby C., Johnson J.A., Deych E., Rieder M.J., Ridker P.M., Milligan P.E., Grice G., Lenzini P., Rettie A.E., Aquilante C.L., Grosso L., Marsh S., Langaee T., Farnett L.E., Voora D., Veenstra D.L., Glynn R.J., Barrett A., McLeod H.L., Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin, Clin. Pharmacol. Ther., 84, pp. 326-331, (2008); Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmoller J., Frotschl R., Kopke K., Gerloff T., Chernov J.N., Roots I., Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population, Eur. J. Clin. Pharmacol., 59, pp. 303-312, (2003); Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Agundez J.A., High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population, Eur. J. Clin. Pharmacol., 57, pp. 47-49, (2001); Garcia-Martin E., Martinez C., Tabares B., Frias J., Agundez J.A., Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms, Clin. Pharmacol. Ther., 76, pp. 119-127, (2004); Gardner I., Wakazono H., Bergin P., de Waziers I., Beaune P., Kenna J.G., Caldwell J., Cytochrome P450 mediated bioactivation of methyleugenol to 1'-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes, Carcinogenesis, 18, pp. 1775-1783, (1997); Gentile D.M., Verhoeven C.H., Shimada T., Back D.J., The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel, J. Pharmacol. Exp. Ther., 287, pp. 975-982, (1998); Gerber J.G., Rhodes R.J., Gal J., Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19, Chirality, 16, pp. 36-44, (2004); Ghosal A., Ramanathan R., Yuan Y., Hapangama N., Chowdhury S.K., Kishnani N.S., Alton K.B., Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist, Drug Metab. Dispos., 35, pp. 2186-2195, (2007); Giancarlo G.M., Venkatakrishnan K., Granda B.W., von Moltke L.L., Greenblatt D.J., Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine, Eur. J. Clin. Pharmacol., 57, pp. 31-36, (2001); Gilissen R.A., Ferrari L., Barnaby R.J., Kajbaf M., Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: in vitro-in vivo correlations, Xenobiotica, 30, pp. 843-856, (2000); Goldberg R., Roth D., Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine, Transplantation, 62, pp. 1559-1564, (1996); Goldstein J.A., Blaisdell J.A., Limdi N.A., A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy, Blood Cells Mol. Dis., 42, pp. 155-158, (2009); Goodstadt L., Ponting C.P., Vitamin K epoxide reductase: homology, active site and catalytic mechanism, Trends Biochem. Sci., 29, pp. 289-292, (2004); Gotoh O., Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences, J. Biol. Chem., 267, pp. 83-90, (1992); Grace J.M., Skanchy D.J., Aguilar A.J., Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A, Xenobiotica, 29, pp. 703-717, (1999); Greene M.F., Oral hypoglycemic drugs for gestational diabetes, N. Engl. J. Med., 343, pp. 1178-1179, (2000); Griskevicius L., Yasar U., Sandberg M., Hidestrand M., Eliasson E., Tybring G., Hassan M., Dahl M.L., Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes, Eur. J. Clin. Pharmacol., 59, pp. 103-109, (2003); Gschwind H.P., Pfaar U., Waldmeier F., Zollinger M., Sayer C., Zbinden P., Hayes M., Pokorny R., Seiberling M., Ben-Am M., Peng B., Gross G., Metabolism and disposition of imatinib mesylate in healthy volunteers, Drug Metab. Dispos., 33, pp. 1503-1512, (2005); Guitton J., Buronfosse T., Desage M., Flinois J.P., Perdrix J.P., Brazier J.L., Beaune P., Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol, Br. J. Anaesth., 80, pp. 788-795, (1998); Guo Y., Wang Y., Si D., Fawcett P.J., Zhong D., Zhou H., Catalytic activities of human cytochrome P450 2C9 1, 2C9 3 and 2C9 13, Xenobiotica, 35, pp. 853-861, (2005); Guo Y., Zhang Y., Wang Y., Chen X., Si D., Zhong D., Fawcett J.P., Zhou H., Role of CYP2C9 and its variants (CYP2C9 3 and CYP2C9 13) in the metabolism of lornoxicam in humans, Drug Metab. Dispos., 33, pp. 749-753, (2005); Hadama A., Ieiri I., Morita T., Kimura M., Urae A., Irie S., Kaneda T., Mamiya K., Tashiro N., Higuchi S., Otsubo K., P-Hydroxylation of phenobarbital: relationship to S-mephenytoin hydroxylation (CYP2C19) polymorphism, Ther. Drug Monit., 23, pp. 115-118, (2001); Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E., Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms, Arch. Biochem. Biophys., 333, pp. 447-458, (1996); Hall S.D., Hamman M.A., Rettie A.E., Wienkers L.C., Trager W.F., Vandenbranden M., Wrighton S.A., Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes, Drug Metab. Dispos., 22, pp. 975-978, (1994); Hallberg P., Karlsson J., Kurland L., Lind L., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Melhus H., The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, J. Hypertens., 20, pp. 2089-2093, (2002); Halling J., Petersen M.S., Damkier P., Nielsen F., Grandjean P., Weihe P., Lundgren S., Lundblad M.S., Brosen K., Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population, Eur. J. Clin. Pharmacol., 61, pp. 491-497, (2005); Hamdy S.I., Hiratsuka M., Narahara K., El-Enany M., Moursi N., Ahmed M.S., Mizugaki M., Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population, Br. J. Clin. Pharmacol., 53, pp. 596-603, (2002); Hamman M.A., Thompson G.A., Hall S.D., Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C, Biochem. Pharmacol., 54, pp. 33-41, (1997); Hanatani T., Fukuda T., Ikeda M., Imaoka S., Hiroi T., Funae Y., Azuma J., CYP2C9 3 influences the metabolism and the drug-interaction of candesartan in vitro, Pharmacogenom. J., 1, pp. 288-292, (2001); He K., Talaat R.E., Pool W.F., Reily M.D., Reed J.E., Bridges A.J., Woolf T.F., Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved, Drug Metab. Dispos., 32, pp. 639-646, (2004); He M., Rettie A.E., Neal J., Trager W.F., Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s, Drug Metab. Dispos., 29, pp. 701-711, (2001); Helsby N.A., Ward S.A., Howells R.E., Breckenridge A.M., In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme, Br. J. Clin. Pharmacol., 30, pp. 287-291, (1990); Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V., A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9 24) in a patient on warfarin therapy, Thromb. Haemost., 95, pp. 192-194, (2006); Hermans J.J., Thijssen H.H., Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics, Br. J. Pharmacol., 110, pp. 482-490, (1993); Hesse L.M., Venkatakrishnan K., von Moltke L.L., Shader R.I., Greenblatt D.J., CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam, Drug Metab. Dispos., 29, pp. 133-140, (2001); Hewitt D.J., The use of NMDA-receptor antagonists in the treatment of chronic pain, Clin. J. Pain, 16, (2000); Hidestrand M., Oscarson M., Salonen J.S., Nyman L., Pelkonen O., Turpeinen M., Ingelman-Sundberg M., CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes, Drug Metab. Dispos., 29, pp. 1480-1484, (2001); Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., Rettie A.E., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, 287, pp. 1690-1698, (2002); Hijazi Y., Boulieu R., Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes, Drug Metab. Dispos., 30, pp. 853-858, (2002); Hirani V.N., Raucy J.L., Lasker J.M., Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19, Drug Metab. Dispos., 32, pp. 1462-1467, (2004); Holstein A., Plaschke A., Ptak M., Egberts E.H., El-Din J., Brockmoller J., Kirchheiner J., Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents, Br. J. Clin. Pharmacol., 60, pp. 103-106, (2005); Hong X., Zhang S., Mao G., Jiang S., Zhang Y., Yu Y., Tang G., Xing H., Xu X., CYP2C9 3 allelic variant is associated with metabolism of irbesartan in Chinese population, Eur. J. Clin. Pharmacol., 61, pp. 627-634, (2005); Howell S.R., Shirley M.A., Grese T.A., Neel D.A., Wells K.E., Ulm E.H., Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors, Drug Metab. Dispos., 29, pp. 990-998, (2001); Hummel M.A., Dickmann L.J., Rettie A.E., Haining R.L., Tracy T.S., Differential activation of CYP2C9 variants by dapsone, Biochem. Pharmacol., 67, pp. 1831-1841, (2004); Hummel M.A., Locuson C.W., Gannett P.M., Rock D.A., Mosher C.M., Rettie A.E., Tracy T.S., CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant, Mol. Pharmacol., 68, pp. 644-651, (2005); Hung C.C., Lin C.J., Chen C.C., Chang C.J., Liou H.H., Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms, Ther. Drug Monit., 26, pp. 534-540, (2004); Hyland R., Jones B.C., Smith D.A., Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole, Drug Metab. Dispos., 31, pp. 540-547, (2003); Ieiri I., Tainaka H., Morita T., Hadama A., Mamiya K., Hayashibara M., Ninomiya H., Ohmori S., Kitada M., Tashiro N., Higuchi S., Otsubo K., Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis, Ther. Drug Monit., 22, pp. 237-244, (2000); Iida I., Miyata A., Arai M., Hirota M., Akimoto M., Higuchi S., Kobayashi K., Chiba K., Catalytic roles of CYP2C9 and its variants (CYP2C9 2 and CYP2C9 3) in lornoxicam 5'-hydroxylation, Drug Metab. Dispos., 32, pp. 7-9, (2004); Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., Yamane M., Fukumaki Y., Ninomiya H., Tashiro N., Otsubo K., Higuchi S., Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus, Pharmacogenetics, 10, pp. 85-89, (2000); Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C., Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects, Pharmacol. Ther., 116, pp. 496-526, (2007); Jacobsen W., Kuhn B., Soldner A., Kirchner G., Sewing K.F., Kollman P.A., Benet L.Z., Christians U., Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin, Drug Metab. Dispos., 28, pp. 1369-1378, (2000); Jansing R.L., Chao E.S., Kaminsky L.S., Phase II metabolism of warfarin in primary culture of adult rat hepatocytes, Mol. Pharmacol., 41, pp. 209-215, (1992); Jetter A., Kinzig-Schippers M., Skott A., Lazar A., Tomalik-Scharte D., Kirchheiner J., Walchner-Bonjean M., Hering U., Jakob V., Rodamer M., Jabrane W., Kasel D., Brockmoller J., Fuhr U., Sorgel F., Cytochrome P450 2C9 phenotyping using low-dose tolbutamide, Eur. J. Clin. Pharmacol., 60, pp. 165-171, (2004); Jeurissen S.M., Bogaards J.J., Boersma M.G., ter Horst J.P., Awad H.M., Fiamegos Y.C., van Beek T.A., Alink G.M., Sudholter E.J., Cnubben N.H., Rietjens I.M., Human cytochrome P450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol, Chem. Res. Toxicol., 19, pp. 111-116, (2006); Jones B.C., Hawksworth G., Horne V.A., Newlands A., Morsman J., Tute M.S., Smith D.A., Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase), Drug Metab. Dispos., 24, pp. 260-266, (1996); Kalgutkar A.S., Nguyen H.T., Vaz A.D., Doan A., Dalvie D.K., McLeod D.G., Murray J.C., In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active α-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes, Drug Metab. Dispos., 31, pp. 1240-1250, (2003); Kam P.C., Nethery C.M., The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments, Anaesthesia, 58, pp. 28-35, (2003); Kamali F., Pirmohamed M., The future prospects of pharmacogenetics in oral anticoagulation therapy, Br. J. Clin. Pharmacol., 61, pp. 746-751, (2006); Kaminsky L.S., Zhang Z.Y., Human P450 metabolism of warfarin, Pharmacol. Ther., 73, pp. 67-74, (1997); Kantola T., Backman J.T., Niemi M., Kivisto K.T., Neuvonen P.J., Effect of fluconazole on plasma fluvastatin and pravastatin concentrations, Eur. J. Clin. Pharmacol., 56, pp. 225-229, (2000); Karazniewicz-Lada M., Luczak M., Glowka F., Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes, Xenobiotica, 39, pp. 476-485, (2009); Kariya S., Isozaki S., Uchino K., Suzuki T., Narimatsu S., Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes, Biol. Pharm. Bull., 19, pp. 1511-1514, (1996); Kaukonen K.M., Olkkola K.T., Neuvonen P.J., Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174, Eur. J. Clin. Pharmacol., 53, pp. 445-449, (1998)","S.-F. Zhou; Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Vic. 3083, Australia; email: shufeng.zhou@rmit.edu.au","","","","","","","","0300483X","","TXCYA","19715737","English","Toxicology","Article","Final","","Scopus","2-s2.0-78149470864"
"Chen J.","Chen, Jing (35213100000)","35213100000","Sodium sensitivity of blood pressure in Chinese populations","2010","Current Hypertension Reports","12","2","","127","134","7","42","10.1007/s11906-009-0088-4","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953543176&doi=10.1007%2fs11906-009-0088-4&partnerID=40&md5=f46d9b294de725b409573d167eac5702","Department of Medicine, Tulane University, School of Medicine, New Orleans, LA 70112, 1430 Tulane Avenue, SL45, United States","Chen J., Department of Medicine, Tulane University, School of Medicine, New Orleans, LA 70112, 1430 Tulane Avenue, SL45, United States","Clinical trials have demonstrated that a reduced intake of dietary sodium lowers blood pressure. However, blood pressure reduction in response to a decrease in dietary sodium intake varies considerably among different individuals - a phenomenon described as sodium sensitivity. The Genetic Epidemiology Network of Salt Sensitivity (GenSalt) study was a large family-based dietary-feeding study conducted in rural north China. This study indicated that approximately 39% of Chinese adults were sodiumsensitive. Sodium sensitivity was more common in women and in persons who were older and had higher usual blood pressure. Sodium sensitivity was also more common in individuals with higher responses to a cold pressor test and in individuals with the metabolic syndrome. Genetic factors may play an important role in determining sodium sensitivity in the Chinese population. A better understanding of the genetic and environmental determinants of sodium sensitivity has important public health and clinical implications. © Springer Science+Business Media, LLC 2010.","Blood pressure; Cold pressor test; Dietary intervention; Genetics; Metabolic syndrome; Sodium sensitivity","Adult; Age Factors; Blood Pressure; China; Confidence Intervals; Female; Geography; Humans; Hypertension; Life Style; Male; Metabolic Syndrome X; Middle Aged; Multivariate Analysis; Nutrition Surveys; Nutritional Status; Odds Ratio; Questionnaires; Rural Population; Sex Factors; Sodium Chloride, Dietary; ABC transporter; aldosterone synthase; alpha adducin; angiotensin 2 receptor; angiotensin II; angiotensinogen; cytochrome P450 3A5; cytochrome P450 4A11; G protein coupled receptor kinase 4; guanine nucleotide binding protein beta subunit; hydroxysteroid dehydrogenase; potassium; sodium; sodium chloride; adult; blood pressure; blood pressure measurement; body mass; Chinese; cold pressor test; dietary intake; environmental factor; ethnicity; family history; female; genetic polymorphism; genetic variability; heredity; high risk population; human; hypertension; insulin resistance; lifestyle; major clinical study; male; mean arterial pressure; metabolic syndrome X; outcome assessment; research subject; review; risk factor; sensitivity analysis; sex ratio; single nucleotide polymorphism; systematic review; waist circumference","","aldosterone synthase, 122933-89-5; angiotensin II, 11128-99-7; angiotensinogen, 11002-13-4, 64315-16-8; cytochrome P450 3A5, 336874-97-6; hydroxysteroid dehydrogenase, 9001-56-3; potassium, 7440-09-7; sodium, 7440-23-5; sodium chloride, 7647-14-5; Sodium Chloride, Dietary, ","","","National Institutes of Health, NIH, (P20-RR017659); National Heart, Lung, and Blood Institute, NHLBI, (R01HL087263, R01HL090682, U01HL072507); National Center for Research Resources, NCRR","Acknowledgement The Genetic Epidemiology Network of Salt Sensitivity is supported by research grants (U01HL072507, R01HL087263, and R01HL090682) from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Dr. Jing Chen was supported by a grant (P20-RR017659) from the National Center for Research Resources, National Institutes of Health, Bethesda, MD.","Kearney P.M., Whelton M., Reynolds K., Et al., Global burden of hypertension: Analysis of worldwide data, Lancet, 365, pp. 217-223, (2005); Lawes C.M.M., Vander Hoorn S., Rodgers A., Et al., Global burden of blood-pressure-related disease, 2001, Lancet, 371, pp. 1513-1518, (2008); He J., Gu D., Chen J., Et al., Premature deaths attributable to blood pressure in China: A prospective cohort study, Lancet, 374, pp. 1765-1772, (2009); Whelton P.K., He J., Appel L.J., Et al., Primary prevention of hypertension. Clinical and public health advisory from the national high blood pressure education program, JAMA, 288, pp. 1882-1888, (2002); Chobanian A.V., Bakris G.L., Black H.R., Et al., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report, JAMA, 289, pp. 2560-2572, (2003); Weinberger M.H., Salt sensitivity of blood pressure in humans, Hypertension, 27, pp. 481-490, (1996); Morimoto A., Uzu T., Fujii T., Et al., Sodium sensitivity and cardiovascular events in patients with essential hypertension, Lancet, 350, pp. 1734-1737, (1997); Weinberger M.H., Fineberg N.S., Fineberg S.E., Weinberger M., Salt sensitivity, pulse pressure, and death in normal and hypertensive humans, Hypertension, 37, pp. 429-432, (2001); Kawasaki T., Delea C.S., Bartter F.C., Smith H., The effect of highsodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension, Am J Med, 64, pp. 193-198, (1978); Sanders P.W., Dietary salt intake, salt sensitivity, and cardiovascular health, Hypertension, 53, pp. 442-445, (2009); Beeks E., Kessels A.G., Kroon A.A., Et al., Genetic predisposition to salt-sensitivity: A systematic review, J Hypertens, 22, pp. 1243-1249, (2004); GenSalt: Rationale, design, methods and baseline characteristics of study participants, J Hum Hypertens, 21, pp. 639-646, (2007); He J., Gu D., Chen J., Et al., Gender difference in blood pressure responses to dietary sodium intervention in the GenSalt study, J Hypertens, 27, pp. 48-54, (2009); Luft F.C., Weinberger M.H., Heterogeneous responses to changes in dietary salt intake: The salt-sensitivity paradigm, Am J Clin Nutr, 65, SUPPL., (1997); Wright Jr. J.T., Rahman M., Scarpa A., Et al., Determinants of salt sensitivity in black and white normotensive and hypertensive women, Hypertension, 42, pp. 1087-1092, (2003); Vollmer W.M., Sacks F.M., Ard J., Et al., Effects of diet and sodium intake on blood pressure: Subgroup analysis of the DASH-sodium trial, Ann Intern Med, 135, pp. 1019-1028, (2001); Wood D.L., Sheps S.G., Elveback L.R., Schirger A., Cold pressor test as a predictor of hypertension, Hypertension, 6, pp. 301-306, (1984); Menkes M.S., Matthews K.A., Krantz D.S., Et al., Cardiovascular reactivity to the cold pressor test as a predictor of hypertension, Hypertension, 14, pp. 524-530, (1989); Kasagi F., Akahoshi M., Shimaoka K., Relation between cold pressor test and development of hypertension based on 28-year follow-up, Hypertension, 25, pp. 71-76, (1995); Strazzullo P., Barbato A., Vuotto P., Galletti F., Relationships between salt sensitivity of blood pressure and sympathetic nervous system activity: A short review of evidence, Clin Exper Hypertens, 23, pp. 25-33, (2001); Chen J., Gu D., Jaquish C.E., Et al., Association between blood pressure responses to the cold pressor test and dietary sodium intervention in a Chinese population, Arch Intern Med, 168, pp. 1740-1746, (2008); Shimamoto K., Hirata A., Fukuoka M., Et al., Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients, Hypertension, 23, pp. 129-133, (1994); Galletti F., Strazzullo P., Ferrara I., Et al., Salt sensitivity of essential hypertensive patients is related to insulin resistance, J Hypertens, 15, pp. 1485-1491, (1997); Chen J., Gu D., Huang J., Et al., Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: A dietary intervention study, Lancet, 373, pp. 829-835, (2009); Saavedra J.M., Studies on genes and hypertension: A daunting task, J Hypertens, 23, pp. 929-932, (2005); Rotimi C.N., Cooper R.S., Cao G., Et al., Maximum-likelihood generalized heritability estimate for blood pressure in Nigerian families, Hypertension, 33, pp. 874-878, (1999); Mitchell G.F., DeStefano A.L., Larson M.G., Et al., Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: The Framingham heart study, Circulation, 112, pp. 194-199, (2005); Gu D., Rice T., Wang S., Et al., Heritability of blood pressure responses to dietary sodium and potassium intake in a Chinese population, Hypertension, 50, pp. 116-122, (2007); Iwai N., Kajimoto K., Tomoike H., Takashima N., Polymorphism of CYP11B2 determines salt sensitivity in Japanese, Hypertension, 49, pp. 825-831, (2007); Eap C.B., Bochud M., Elston R.C., Et al., CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt, Hypertension, 49, pp. 1007-1014, (2007); Laffer C.L., Gainer J.V., Waterman M.R., Et al., The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension, Hypertension, 51, pp. 767-772, (2008); Zeng C., Villar V.A., Eisner G.M., Et al., G protein-coupled receptor kinase 4: Role in blood pressure regulation, Hypertension, 51, pp. 1449-1455, (2008); Felder R.A., Sanada H., Xu J., Et al., G protein-coupled receptor kinase 4 gene variants in human essential hypertension, Proc Natl Acad Sci USA, 99, pp. 3872-3877, (2002); Staessen J.A., Kuznetsova T., Zhang H., Et al., Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4, Hypertension, 51, pp. 1643-1650, (2008); Kelly T.N., Rice T.K., Gu D., Et al., Novel genetic variants in the alpha-adducin and guanine nucleotide binding protein beta-polypeptide 3 genes and salt sensitivity of blood pressure, Am J Hypertens, 22, pp. 985-992, (2009)","J. Chen; Department of Medicine, Tulane University, School of Medicine, New Orleans, LA 70112, 1430 Tulane Avenue, SL45, United States; email: jchen@tulane.edu","","","","","","","","15226417","","CHRUC","20424958","English","Curr. Hypertens. Rep.","Review","Final","All Open Access; Green Open Access","Scopus","2-s2.0-77953543176"
"Joy T.; Hegele R.A.","Joy, Tisha (6603863639); Hegele, Robert A. (35399481100)","6603863639; 35399481100","Genetics of Metabolic syndrome: Is there a role for phenomics?","2008","Current Atherosclerosis Reports","10","3","","201","208","7","35","10.1007/s11883-008-0032-0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-49949102267&doi=10.1007%2fs11883-008-0032-0&partnerID=40&md5=b58f8f650978029164a676802597a5de","Robarts Research Institute, London, ON N6A 5K8, 406 - 100 Perth Drive, Canada","Joy T.; Hegele R.A., Robarts Research Institute, London, ON N6A 5K8, 406 - 100 Perth Drive, Canada","Metabolic syndrome (MetS) is a common complex trait consisting of the clustering of abdominal obesity, hypertension, dyslipidemia, and dysglycemia. MetS is found in about 25% of the population in the United States and is associated with increased risk for type 2 diabetes and cardiovascular disease. Despite research into possible genetic influences for MetS, no consistently reproducible genetic markers have been obtained, partially due to lack of agreement on the definition of the phenotype. Because phenotypic precision is essential for genomic interrogation, the evolving discipline of clinical phenomics, which uses objective and systematic acquisition of phenotypic data (ie, ""deep phenotyping""), may help evaluate the genetic influences of MetS. This article reviews evidence that MetS has a genetic component and the potential applicability of clinical phenomics for the genetic evaluation of MetS using the example of hierarchical cluster analysis of phenotypic components of lipodystrophy syndromes, which serve as monogenic models of MetS. Copyright © 2008 by Current Medicine Group LLC.","","Cluster Analysis; Computational Biology; Genetic Markers; Genetic Predisposition to Disease; Genomics; Genotype; Humans; Lamin Type A; Lipodystrophy, Familial Partial; Metabolic Syndrome X; Multifactorial Inheritance; Phenotype; Polymorphism, Single Nucleotide; PPAR gamma; acetylsalicylic acid; angiotensin receptor antagonist; antihypertensive agent; dipeptidyl carboxypeptidase inhibitor; fibric acid derivative; glitazone derivative; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; lamin A; lamin C; leptin; metformin; peroxisome proliferator activated receptor gamma; sulfonylurea derivative; transcription factor 7 like 2; lamin A; LMNA protein, human; peroxisome proliferator activated receptor gamma; abdominal obesity; cardiovascular disease; cardiovascular risk; cluster analysis; Down syndrome; drug response; dyslipidemia; familial hypercholesterolemia; familial partial lipodystrophy; gene frequency; gene mutation; genetic association; genetic marker; genetic risk; genetic variability; heritability; human; hypertension; insulin resistance; metabolic syndrome X; molecular genetics; non insulin dependent diabetes mellitus; pathogenesis; phenotype; prevalence; review; single nucleotide polymorphism; systemic lupus erythematosus; Wegener granulomatosis; biology; familial partial lipodystrophy; genetic predisposition; genetics; genomics; genotype; metabolic syndrome X; methodology; multifactorial inheritance","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; insulin, 9004-10-8; metformin, 1115-70-4, 657-24-9; Genetic Markers, ; Lamin Type A, ; LMNA protein, human, ; PPAR gamma, ","","","Genome Canada; Canadian Institutes of Health Research, CIHR, (MOP-13430, MOP-79533); Ontario Genomics Institute, OGI; Heart and Stroke Foundation of Canada, HSF, (NA6059, PRG5657, T6018)","This work was supported by operating grants from the Canadian Institutes of Health Research (MOP-13430 and MOP-79533), the Heart and Stroke Foundation of Ontario (T6018; NA6059 and PRG5657), and Genome Canada through the Ontario Genomics Institute. Dr. Hegele is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics and the Jacob J. Wolfe Distinguished Medical Research Chair.","Reaven G.M., Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, pp. 1595-1607, (1988); Lemieux I., Pascot A., Couillard C., Et al., Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?, Circulation, 102, pp. 179-184, (2000); Kaplan N.M., The deadly quartet. Upper, body obesity, glucose intolerance, hypertriglyceridemia, and hypertension, Arch Intern Med, 149, pp. 15140-21520, (1989); Ferrannini E., The insulin resistance syndrome, Curr Opin Nephrol Hypertens, 1, pp. 291-298, (1992); Vague J., The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease, Am J Clin Nutr, 4, pp. 20-34, (1956); Definition, diagnosis, and classification of diabetes mellitus and its complications, Report of a WHO Consultation; Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001); Balkau B., Charles M.A., Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR), Diabet Med, 16, pp. 442-443, (1999); Einhorn D., Reaven G.M., Cobin R.H., Et al., American College of Endocrinology position statement on the insulin resistance syndrome, Endocr Pract, 9, pp. 237-252, (2003); Grundy S.M., Cleeman J.I., Daniels S.R., Et al., Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, pp. 2735-2752, (2005); Alberti K.G., Zimmet P., Shaw J., The metabolic syndrome - a new worldwide definition, Lancet, 366, pp. 1059-1062, (2005); Kahn R., Buse J., Ferrannini E., Stern M., The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 48, pp. 1684-1699, (2005); Ford E.S., Giles W.H., Dietz W.H., Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey, JAMA, 287, pp. 356-359, (2002); Malik S., Wong N.D., Franklin S.S., Et al., Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults, Circulation, 110, pp. 1245-1250, (2004); Hunt K.J., Resendez R.G., Williams K., Et al., National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study, Circulation, 110, pp. 1251-1257, (2004); Hanley A.J., Karter A.J., Williams K., Et al., Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: The Insulin Resistance Atherosclerosis Study, Circulation, 112, pp. 3713-3721, (2005); Joy T., Lahiry P., Pollex R.L., Hegele R.A., Genetics of metabolic syndrome, Curr Diab Rep, (2007); Pollex R.L., Hegele R.A., Genetic determinants of the metabolic syndrome, Nat Clin Pract Cardiovasc Med, 3, pp. 482-489, (2006); Bodhini D., Radha V., Dhar M., Et al., The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians, Metabolism, 56, pp. 1174-1178, (2007); Horikoshi M., Hara K., Ito C., Et al., A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population, Diabetologia, 50, pp. 747-751, (2007); Chandak G.R., Janipalli C.S., Bhaskar S., Et al., Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population, Diabetologia, 50, pp. 63-67, (2007); Wang J., Joy T., Mymin D., Et al., Phenotypic heterogeneity of sitosterulemia, J Lipid Res, 45, pp. 2361-2367, (2004); McCarroll S.A., Altshuler D.M., Copy-number variation and association studies of human disease, Nat Genet, 39, (2007); Schork N.J., Genetics of complex disease: Approaches, problems, and solutions, Am J Respir Crit Care Med, 156, (1997); Edwards K.L., Newman B., Mayer E., Et al., Heritability of factors of the insulin resistance syndrome in women twins, Genet Epidemiol, 14, pp. 241-253, (1997); Lin H.F., Boden-Albala B., Juo S.H., Et al., Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study, Diabetologia, 48, pp. 2006-2012, (2005); Kissebah A.H., Sonnenberg G.E., Myklebust J., Et al., Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome, Proc Natl Acad Sci U S A, 97, pp. 14478-14483, (2000); Arya R., Blangero J., Williams K., Et al., Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans, Diabetes, 51, pp. 841-847, (2002); Langefeld C.D., Wagenknecht L.E., Rotter J.I., Et al., Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: The Insulin Resistance Atherosclerosis Study Family Study, Diabetes, 53, pp. 1170-1174, (2004); Loos R.J., Katzmarzyk P.T., Rao D.C., Et al., Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study, J Clin Endocrinol Metab, 88, pp. 5935-5943, (2003); Hsueh W.C., St Jean P.L., Mitchell B.D., Et al., Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: Evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24, Diabetes, 52, pp. 550-557, (2003); Ng M.C., So W.Y., Lain V.K., Et al., Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25, Diabetes, 53, pp. 2676-2683, (2004); Kobberling J., Williams B., Kattermann R., Creutzfeldt W., Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipotrophic diabetes, Humangenetik, 29, pp. 111-120, (1975); Dunnigan M.G., Cochrane M.A., Kelly A., Scott J.W., Familial lipoatrophic diabetes with dominant transmission. A new syndrome, Q J Med, 43, pp. 33-48, (1974); Garg A., Peshock R.M., Fleckenstein J.L., Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety), J Clin Endocrinol Metab, 84, pp. 170-174, (1999); Garg A., Vinaitheerthan M., Weatherall P.T., Bowcock A.M., Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in lamin a/c gene, J Clin Endocrinol Metab, 86, pp. 59-65, (2001); Hegele R.A., Lessons from human mutations in PPARgamma, Int J Obes (Lond), 29, SUPPL. 1, (2005); Ludtke A., Genschel J., Brabant G., Et al., Hepatic steatosis in Dunnigan-type familial partial lipodystrophy, Am J Gastroenterol, 100, pp. 2218-2224, (2005); Hegele R.A., Al-Attar S.A., Rutt B.K., Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation, CMAJ, 177, pp. 743-745, (2007); Hegele R.A., Premature atherosclerosis associated with monogenic insulin resistance, Circulation, 103, pp. 2225-2229, (2001); Garg A., Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety), J Clin Endocrinol Metab, 85, pp. 1776-1782, (2000); Cao H., Hegele R.A., Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy, Hum Mol Genet, 9, pp. 109-112, (2000); Herbst K.L., Tannock L.R., Deeb S.S., Et al., Kobberling type of familial partial lipodystrophy: An underrecognized syndrome, Diabetes Care, 26, pp. 1819-1824, (2003); Al-Attar S.A., Pollex R.L., Robinson J.F., Et al., Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging, BMC Med Imaging, 7, (2007); Hegele R.A., Monogenic forms of insulin resistance: Apertures that expose the common metabolic syndrome, Trends Endocrinol Metab, 14, pp. 371-377, (2003); Decaudain A., Vantyghem M.C., Guerci B., Et al., New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome, J Clin Endocrinol Metab, 92, pp. 4835-4844, (2007); Hegele R.A., Joy T.R., Al-Attar S.A., Rutt B.K., Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism, J Lipid Res, 48, pp. 1433-1444, (2007); Hegele R.A., Kraw M.E., Ban M.R., Et al., Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy, Arterioscler Thromb Vasc Biol, 23, pp. 111-116, (2003)","R.A. Hegele; Robarts Research Institute, London, ON N6A 5K8, 406 - 100 Perth Drive, Canada; email: hegele@robarts.ca","","","","","","","","15233804","","CARUC","18489847","English","Curr. Atheroscler. Rep.","Review","Final","","Scopus","2-s2.0-49949102267"
"Garcia E.A.; Newhouse S.; Caulfield M.J.; Munroe P.B.","Garcia, E.A. (8627128400); Newhouse, S. (8931613700); Caulfield, M.J. (7102853527); Munroe, P.B. (7005376453)","8627128400; 8931613700; 7102853527; 7005376453","Genes and hypertension","2003","Current Pharmaceutical Design","9","21","","1679","1689","10","69","10.2174/1381612033454513","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0041989748&doi=10.2174%2f1381612033454513&partnerID=40&md5=b4ddfe5be8d1d4f47162f818c6026934","Department of Clinical Pharmacology, The Barts/The London Genome Centre, William Harvey Research Institute, London EC1M 6BQ, Charterhouse Square, United Kingdom","Garcia E.A., Department of Clinical Pharmacology, The Barts/The London Genome Centre, William Harvey Research Institute, London EC1M 6BQ, Charterhouse Square, United Kingdom; Newhouse S., Department of Clinical Pharmacology, The Barts/The London Genome Centre, William Harvey Research Institute, London EC1M 6BQ, Charterhouse Square, United Kingdom; Caulfield M.J., Department of Clinical Pharmacology, The Barts/The London Genome Centre, William Harvey Research Institute, London EC1M 6BQ, Charterhouse Square, United Kingdom; Munroe P.B., Department of Clinical Pharmacology, The Barts/The London Genome Centre, William Harvey Research Institute, London EC1M 6BQ, Charterhouse Square, United Kingdom","The combination of investigation of rare Mendelian forms of hypertension, candidate gene studies, comparative mapping and genome-wide screening in both animal models and man has led to significant progress in determining new mechanisms of blood pressure control. In this review, the newly discovered blood pressure/cardiovascular genes, WNK kinases and angiotensin converting enzyme 2 and the development of a new anti-hypertensive agent PST2238 are discussed. Major genes causing essential hypertension have yet to be discovered, however, there are now over 20 published genome-wide screens for blood pressure controlling genes. Several regions demonstrate suggestive linkage to the trait and there is some overlap of regions between the different studies. It is hoped that new blood pressure genes will ultimately be discovered using this method. Pharmacogenetic studies in hypertension have only been initiated recently, some are described in this paper. Small studies upon single candidate genes, suggest that the contribution of genetics to the inter-individual variation in blood pressure response to anti-hypertensive therapy, is small, approximately 3-5%. Recently micro-arrays with multiple polymorphisms in multiple genes have been used. After accounting for the additive affects of multiple blood pressure loci, an individual's genetic profile appeared to explain up to 50% of the variation in blood pressure response to therapy. Knowledge of the genetic variants that cause hypertension and influence response to anti-hypertensive therapy will ultimately provide a greater understanding of the molecular mechanisms underlying blood pressure control.","Adducin; Blood pressure; Essential hypertension; Micro-arrays; Pharmacogenetics; Renin-angiotensin system; Single nucleotide polymorphisms; WNK kinases","Androstanols; Animals; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Carboxypeptidases; Genomics; Humans; Hypertension; Oligonucleotide Array Sequence Analysis; Peptidyl-Dipeptidase A; Pharmacogenetics; Protein-Serine-Threonine Kinases; Renin-Angiotensin System; 17beta (3 furyl) 5beta androstane 3beta,14beta,17alpha triol; adducin; alpha 1 adrenergic receptor blocking agent; angiotensin 2 receptor antagonist; antihypertensive agent; atenolol; cotransporter; digitalis; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; hydrochlorothiazide; irbesartan; mineralocorticoid antagonist; phosphotransferase; thiazide diuretic agent; antihypertensive activity; blood pressure regulation; comparative gene mapping; diuretic activity; DNA microarray; drug response; gene deletion; genetic linkage; genetic screening; genetic variability; human; hypertension; missense mutation; molecular mechanics; nonhuman; priority journal; protein function; pseudohypoaldosteronism; rat; renin angiotensin aldosterone system; review; side effect; single nucleotide polymorphism","","17beta (3 furyl) 5beta androstane 3beta,14beta,17alpha triol, 156722-18-8; atenolol, 29122-68-7; digitalis, 8031-42-3, 8053-83-6; dipeptidyl carboxypeptidase, 9015-82-1; hydrochlorothiazide, 58-93-5; irbesartan, 138402-11-6; phosphotransferase, 9031-09-8, 9031-44-1; 17-(3-furyl)-5beta-androstane-3,14,17-triol, ; adducin, ; Androstanols, ; angiotensin converting enzyme 2, EC 3.4.17.-; Antihypertensive Agents, ; Calmodulin-Binding Proteins, ; Carboxypeptidases, EC 3.4.-; Peptidyl-Dipeptidase A, EC 3.4.15.1; PRKWNK4 protein, human, EC 2.7.1.-; Protein-Serine-Threonine Kinases, EC 2.7.1.37; WNK1 protein, human, EC 2.7.1.37","pst 2238","","","","Grimm R.H. Jr., Cohen J.D., Smith W.M., Falvo-Gerard L., Neaton J.D., Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups, Arch. Int. Med., 145, 1, pp. 1191-1199, (1985); Domanski M., Mitchell G., Pfeffer M., Neaton J.D., Norman J., Svendsen K., Et al., Pulse pressure and cardiovascular disease-related mortality: Follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 287, pp. 2677-2683, (2002); The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, Arch. Int. Med., 157, pp. 2413-2446, (1997); Oparil S., Weber M.A., Hypertension : A companion to Brenner and Rector's The kidney, (2000); Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., Nelson-Williams C., Desitter I., Et al., Human hypertension caused by mutations in WNK kinases, Science, 293, pp. 1107-1112, (2001); Xu B., English J.M., Wilsbacher J.L., Stippec S., Goldsmith E.J., Cobb M.H., WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II, J. Biol. Chem., 275, pp. 16795-16801, (2000); Verissimo F., Jordan P., WNK kinases, a novel protein kinase subfamily in multi-cellular organisms, Oncogene, 20, pp. 5562-5569, (2001); Choate K.A., Kahle K.T., Wilson F.H., Nelson-Williams C., Lifton R.P., WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse C1- - Transporting epithelia, Proc. Natl. Acad. Sci. U S A, 100, pp. 663-668, (2003); Mayan H., Vered I., Mouallem M., Tzadok-Witkon M., Pauzner R., Farfel Z., Pseudohypoaldosteronism type II: Marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density, J. Clin. Endocrinol. Metab., 87, pp. 3248-3254, (2002); Wilson F.H., Kahle K.T., Sabath E., Lalioti M.D., Rapson A.K., Hoover R.S., Et al., Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4, Proc. Natl. Acad. Sci. U S A, 100, pp. 680-684, (2003); Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9, Circ. Res., 87, (2000); Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J. Biol. Chem., 275, pp. 33238-33243, (2000); Zhang H., Wada J., Hida K., Tsuchiyama Y., Hiragushi K., Shikata K., Et al., Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys, J. Biol. Chem., 276, pp. 17132-17139, (2001); Turner A.J., Hooper N.M., The angiotensin-converting enzyme gene family: Genomics and pharmacology, Trends Pharmacol. Sci., 23, pp. 177-183, (2002); Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Et al., Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, 417, pp. 822-828, (2002); Boehm M., Nabel E.G., Angiotensin-converting enzyme 2 - A new cardiac regulator, N. Engl. J. Med., 347, pp. 1795-1797, (2002); Dales N.A., Gould A.E., Brown J.A., Calderwood E.F., Guan B., Minor C.A., Et al., Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors, J. Am. Chem. Soc., 124, pp. 11852-11853, (2002); Manunta P., Barlassina C., Bianchi G., Adducin in essential hypertension, FEBS Lett., 430, pp. 41-44, (1998); Salardi S., Saccardo B., Borsani G., Modica R., Ferrandi M., Tripodi M.G., Et al., Erythrocyte adducin differential properties in the normotensive and hypertensive rats of the Milan strain. Characterization of spleen adducin m-RNA, Am. J. Hypertens., 2, pp. 229-237, (1989); Bianchi G., Baer P.G., Fox U., Duzzi L., Pagetti D., Giovannetti A.M., Changes in renin, water balance, and sodium balance during development of high blood pressure in genetically hypertensive rats, Circ. Res., 36, pp. 153-161, (1975); Bianchi G., Tripodi G., Casari G., Salardi S., Barber B.R., Garcia R., Et al., Two point mutations within the adducin genes are involved in blood pressure variation, Proc. Natl. Acad. Sci. U S A, 91, pp. 3999-4003, (1994); Casari G., Barlassina C., Cusi D., Zagato L., Muirhead R., Righetti M., Et al., Association of the alpha-adducin locus with essential hypertension, Hypertension, 25, pp. 320-326, (1995); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Castellano M., Barlassina C., Muiesan M.L., Beschi M., Cinelli A., Rossi F., Et al., Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population, J. Hypertens., 15, pp. 1707-1710, (1997); Iwai N., Tamaki S., Nakamura Y., Kinoshita M., Polymorphism of alpha-adducin and hypertension, Lancet, 350, (1997); He X., Zhu D.L., Chu S.L., Jin L., Xiong M.M., Wang G.L., Et al., Alpha-Adducin gene and essential hypertension in China, Clin. Exp. Hypertens., 23, pp. 579-589, (2001); Melander O., Bengtsson K., Orho-Melander M., Lindblad U., Forsblom C., Rastam L., Et al., Role of the Gly460Trp polymorphism of the alpha-adducin gene in primary hypertension in Scandinavians, J. Hum. Hypertens., 14, pp. 43-46, (2000); Clark C.J., Davies E., Anderson N.H., Farmer R., Friel E.C., Fraser R., Et al., Alpha-adducin and angiotensin I-converting enzyme polymorphisms in essential hypertension, Hypertension, 36, pp. 990-994, (2000); Manunta P., Burnier M., D'Amico M., Buzzi L., Maillard M., Barlassina C., Et al., Adducin polymorphism affects renal proximal tubule reabsorption in hypertension, Hypertension, 33, pp. 694-697, (1999); Ferrandi M., Manunta P., Balzan S., Hamlyn J.M., Bianchi G., Ferrari P., Ouabain-like factor quantification in mammalian tissues and plasma: Comparison of two independent assays, Hypertension, 30, pp. 886-896, (1997); Ferrari P., Ferrandi M., Tripodi G., Torielli L., Padoani G., Minotti E., Et al., PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension, J. Pharmacol. Exp. Ther., 288, pp. 1074-1083, (1999); Ferrandi M., Barassi P., Minotti E., Duzzi L., Molinari I., Bianchi G., Et al., PST 2238: A new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats, J. Cardiovasc. Pharmacol., 40, pp. 881-889, (2002); Doris P.A., Ouabain in plasma from spontaneously hypertensive rats, Am. J. Physiol., 266, (1994); Nguyen A.T., Hayward-Lester A., Sabatini S., Doris P.A., Renal Na+, K+-ATPase in SHR: Studies of activity and gene expression, Clin. Exp. Hypertens., 20, pp. 641-656, (1998); Ishikawa K., Katsuya T., Sato N., Nakata Y., Takami S., Takiuchi S., Et al., No association between alpha-adducin 460 polymorphism and essential hypertension in a Japanese population, Am. J. Hypertens., 11, pp. 502-506, (1998); Barlassina C., Norton G.R., Samani N.J., Woodwiss A.J., Candy G.C., Radevski I., Et al., Alpha-adducin polymorphism in hypertensives of South African ancestry, Am. J. Hypertens., 13, pp. 719-723, (2000); Melander O., Bengtsson K., Orho-Melander M., Lindblad U., Forsblom C., Rastam L., Et al., Role of the Gly460Trp polymorphism of the alpha-adducin gene in primary hypertension in Scandinavians, J. Hum. Hypertens., 14, pp. 43-46, (2000); Angius A., Petretto E., Maestrale G.B., Forabosco P., Casu G., Piras D., Et al., A new essential hypertension susceptibility locus on chromosome 2p24-p25, detected by genomewide search, Am. J. Hum. Genet., 71, pp. 893-905, (2002); Allayee H., de Bruin T.W., Dominguez M.K., Cheng L.S., Ipp E., Cantor R.M., Et al., Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p, Hypertension, 38, pp. 773-778, (2001); Kristjansson K., Manolescu A., Kristinsson A., Hardarson T., Knudsen H., Ingason S., Et al., Linkage of essential hypertension to chromosome 18q, Hypertension, 39, pp. 1044-1049, (2002); Levy D., DeStefano A.L., Larson M.G., O'Donnell C.J., Lifton R.P., Gavras H., Et al., Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study, Hypertension, 36, pp. 477-483, (2000); Cooper R.S., Luke A., Zhu X., Kan D., Adeyemo A., Rotimi C., Et al., Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19, Hypertension, 40, pp. 629-633, (2002); Xu X., Rogus J.J., Terwedow H.A., Yang J., Wang Z., Chen C., Et al., An extreme-sib-pair genome scan for genes regulating blood pressure, Am. J. Hum. Genet., 64, pp. 1694-1701, (1999); Rao D.C., Province M.A., Leppert M.F., Oberman Al., Heiss G., Ellison R.C., Et al., A genome-wide affected sibpair linkage analysis of hypertension: The HyperGEN network, Am. J. Hypertens., 16, pp. 148-150, (2003); Rice T., Rankinen T., Province M.A., Chagnon Y.C., Perusse L., Borecki I.B., Et al., Genome-wide linkage analysis of systolic and diastolic blood pressure: The Quebec family study, Circulation, 102, pp. 1956-1963, (2000); Rice T., Rankinen T., Chagnon Y.C., Province M.A., Perusse L., Leon A.S., Et al., Genomewide linkage scan of resting blood pressure: HERITAGE family study. Health, risk factors, exercise training, and genetics, Hypertension, 39, pp. 1037-1043, (2002); Krushkal J., Ferrell R., Mockrin S.C., Turner S.T., Sing C.F., Boerwinkle E., Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings, Circulation, 99, pp. 1407-1410, (1999); Baima J., Nicolaou M., Schwartz F., DeStefano A.L., Manolis A., Gavras I., Et al., Evidence for linkage between essential hypertension and a putative locus on human chromosome 17, Hypertension, 34, pp. 4-7, (1999); Julier C., Delepine M., Keavney B., Terwilliger J., Davis S., Weeks D.E., Et al., Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10, Hum. Mol. Genet., 6, pp. 2077-2085, (1997); Kardia S.L.R., Rozek L.S., Krushkal J., Ferrell R.E., Turner S.T., Hutchinson R., Et al., Genome-wide linkage analyses for hypertension genes in two ethnically and geographically diverse populations, Am. J. Hypertens., 16, pp. 154-157, (2003); Ranade K., Hsuing A.C., Wu K.D., Chang M.S., Chen Y.T., Hebert J., Et al., Lack of evidence for an association between alpha-adducin and blood pressure regulation in Asian populations, Am. J. Hypertens., 13, pp. 704-709, (2000); Ranade K., Hinds D., Hsiung C.A., Chuang L.-M., Chang M.-S., Chen Y.-T., Et al., A genome scan for hypertension susceptibility loci in populations of Chinese and Japanese origins, Am. J. Hypertens., 16, pp. 158-162, (2003); Thiel B.A., Chakravarti A., Cooper R.S., Luke A., Lewis S., Lynn A., Et al., A genome-wide linkage analysis investigating the determinants of blood pressure in Whites and African Americans, Am. J. Hypertens., 16, pp. 151-153, (2003); Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP), Hypertension, 39, pp. 3-9, (2002); Province M.A., Arnett D.K., Hunt S.C., Leiendecker-Foster C., Eckfeldt J.H., Oberman A., Et al., Association between the alpha-adducin gene and hypertension in the HyperGEN Study, Am. J. Hypertens., 13, pp. 710-718, (2000); Arngrimsson R., Sigurardttir S., Frigge M.L., Bjarnad ttir R.I., Jonsson T., Stefansson H., Et al., A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13, Hum. Mol. Genet., 8, pp. 1799-1805, (1999); Moses E.K., Lade J.A., Guo G., Wilton A.N., Grehan M., Freed K., Et al., A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2, Am. J. Hum. Genet., 67, pp. 1581-1585, (2000); Laivuori H., Lahermo P., Ollikainen V., Widen E., Haiva-Mallinen L., Sundstrom H., Et al., Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families, Am. J. Hum. Genet., 72, pp. 168-177, (2003); Lalouel J.M., Rohrwasser A., Development of genetic hypotheses in essential hypertension, J. Hum. Genet., 46, pp. 299-306, (2001); Samani N.J., Genome scans for hypertension and blood pressure regulation, Am. J. Hypertens., 16, pp. 167-171, (2003); Chiu A.G., Krowiak E.J., Deeb Z.E., Angioedema associated with angiotensin II receptor antagonists: Challenging our knowledge of angioedema and its etiology, Laryngoscope, 111, pp. 1729-1731, (2001); Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., Et al., The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, pp. 649-654, (1999); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Okuda T., Sumiya T., Mizutani K., Tago N., Miyata T., Tanabe T., Et al., Analyses of differential gene expression in genetic hypertensive rats by microarray, Hypertens. Res., 25, pp. 249-255, (2002); Okuda T., Sumiya T., Iwai N., Miyata T., Difference of gene expression profiles in spontaneous hypertensive rats and Wistar-Kyoto rats from two sources, Biochem. Biophys. Res. Commun., 296, pp. 537-543, (2002); Sinal C.J., Miyata M., Tohkin M., Nagata K., Bend J.R., Gonzalez F.J., Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation, J. Biol. Chem., 275, pp. 40504-40510, (2000); Liljedahl U., Karlsson J., Melhus H., Kurland L., Lindersson M., Kahan T., Et al., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenetics, 13, pp. 7-17, (2003); Perola M., Kainulainen K., Pajukanta P., Terwilliger J.D., Hiekkalinna T., Ellonen P., Et al., Genome-wide scan of predisposing loci for increased diastolic blood pressure in Finnish siblings, J. Hypertens., 18, pp. 1579-1585, (2000); Sharma P., Fatibene J., Ferraro F., Jia H., Monteith S., Brown C., Et al., A genome-wide search for susceptibility loci to human essential hypertension, Hypertension, 35, pp. 1291-1296, (2000); Pankow J.S., Rose K.M., Oberman A., Hunt S.C., Atwood L.D., Djousse L., Et al., Possible locus on chromosome 18q influencing postural systolic blood pressure changes, Hypertension, 36, pp. 471-476, (2000); Atwood L.D., Samollow P.B., Hixson J.E., Stern M.P., MacCluer J.W., Genome-wide linkage analysis of pulse pressure in Mexican Americans, Hypertension, 37, pp. 425-428, (2001); Zhu D.L., Wang H.Y., Xiong M.M., He X., Chu S.L., Jin L., Et al., Linkage of hypertension to chromosome 2q14-q23 in Chinese families, J. Hypertens., 19, pp. 55-61, (2001); Hsueh W.C., Mitchell B.D., Schneider J.L., Wagner M.J., Bell C.J., Nanthakumar E., Et al., QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish, Circulation, 101, pp. 2810-2816, (2000); Harrap S.B., Wong Z.Y., Stebbing M., Lamantia A., Bahlo M., Blood pressure QTLs identified by genome-wide linkage analysis and dependence on associated phenotypes, Physiol. Genomics, 8, pp. 99-105, (2002); Hunt S.C., Ellison R.C., Atwood L.D., Pankow J.S., Province M.A., Leppert M.F., Genome scans for blood pressure and hypertension: The national heart, lung, and blood institute family heart study, Hypertension, 40, pp. 1-6, (2002); Danielsson B.R., Skold A.C., Azarbayjani F., Class III antiarrhythmics and phenytoin: Teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage, Curr. Pharm. Des., 7, 9, pp. 787-802, (2001); Kurowska E.M., Nitric oxide therapies in vascular diseases, Curr. Pharm. Des., 8, 3, pp. 155-166, (2002); Wouters J., Ooms F., Small molecule crystallography in drug design, Curr. Pharm. Des., 7, 7, pp. 529-545, (2001)","P.B. Munroe; Department of Clinical Pharmacology, The Barts/The London Genome Centre, William Harvey Research Institute, London EC1M 6BQ, Charterhouse Square, United Kingdom; email: p.b.munroe@qmul.ac.uk","","","","","","","","13816128","","CPDEF","12871201","English","Curr. Pharm. Des.","Review","Final","","Scopus","2-s2.0-0041989748"
"Ritt M.; Ott C.; Delles C.; Schneider M.P.; Schmieder R.E.","Ritt, Martin (25622786000); Ott, Christian (23095806100); Delles, Christian (7004220876); Schneider, Markus P. (34868664600); Schmieder, Roland E. (7101834901)","25622786000; 23095806100; 7004220876; 34868664600; 7101834901","Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes","2008","Pharmacogenetics and Genomics","18","8","","699","707","8","18","10.1097/FPC.0b013e32830500b1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-55749104951&doi=10.1097%2fFPC.0b013e32830500b1&partnerID=40&md5=0dfdeb4aed3d0fbd5b67272c3f1b62c0","Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany; Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, 91054 Erlangen, Krankenhausstraße 12, Germany","Ritt M., Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany; Ott C., Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany; Delles C., Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany; Schneider M.P., Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany; Schmieder R.E., Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany, Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, 91054 Erlangen, Krankenhausstraße 12, Germany","OBJECTIVE: Endothelial dysfunction and increased oxidative stress contribute to the progression of diabetic nephropathy. To analyze the functional significance of the G894T polymorphism of NOS3, the gene encoding endothelial nitric oxide synthase (NOS), we assessed basal nitric oxide activity and the amount of oxidative stress in the renal circulation of patients with type 2 diabetes. METHODS: Renal plasma flow (RPF) was assessed by steady-state input clearance technique with sodium para-aminohippurate in 84 patients with type 2 diabetes and 84 patients without diabetes. RPF was measured at baseline and after the infusion of the NOS inhibitor N-monomethyl-L-arginine (4.25 mg/kg); the substrate of NOS L-arginine (100 mg/kg); and coinfusion of vitamin C (3 g) with L-arginine (100 mg/kg). RESULTS: The decrease of RPF to N-monomethyl-L-arginine was similar between carriers of the T allele and homozygous carriers of the G allele in patients with diabetes (-56±40 vs. -68.1±74 ml/min/1.73 m2, P=0.342) and patients without diabetes (-66.7±81 vs. -58.3±63 ml/min/1.73 m2, P=0.606). In patients with diabetes, however, carriers of the T allele revealed a more pronounced increase of RPF to coinfusion of vitamin C with L-arginine than homozygous carriers of the G allele (61.8±75 vs. 22.3±73 ml/min/1.73 m2, P=0.021), whereas in patients without diabetes the response of RPF to coinfusion of vitamin C with L-arginine was similar between both groups (46.2±80 vs. 70.7±86 ml/min/1.73 m2, P=0.217). Gene-environment interaction between disease (diabetes) and genotype (genotype GG vs. genotype GT/TT) was observed for increase of RPF to coinfusion of vitamin C with L-arginine (P=0.020). CONCLUSION: G894T polymorphism of NOS3 has no impact on the basal nitric oxide activity of renal circulation. In contrast, the T allele is associated with increased oxidative stress in the renal circulation in patients with diabetes suggesting a specific role of the G894T polymorphism in the pathogenesis of diabetic nephropathy. © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins.","Basal nitric oxide activity; Diabetes; G894T polymorphism of NOS3; Oxidative stress; Renal vasculature","Alleles; Analysis of Variance; Arginine; Ascorbic Acid; Body Mass Index; Cholesterol, HDL; Diabetes Mellitus, Type 2; Endothelium; Female; Genotype; Guanine; Hemodynamics; Homozygote; Humans; Kidney; Male; Middle Aged; Nitric Oxide Synthase Type III; omega-N-Methylarginine; Polymorphism, Single Nucleotide; Renal Plasma Flow; Thymine; Triglycerides; 4 aminohippuric acid; angiotensin receptor antagonist; antidiabetic agent; antihypertensive agent; arginine; ascorbic acid; atenolol; cebion forte; dipeptidyl carboxypeptidase inhibitor; endothelial nitric oxide synthase; glycine; hydrochlorothiazide; hydroxymethylglutaryl coenzyme A reductase inhibitor; metformin; metoprolol; n(g) methylarginine; nitric oxide; nitric oxide synthase; threonine; unclassified drug; arginine; ascorbic acid; endothelial nitric oxide synthase; guanine; high density lipoprotein cholesterol; n(g) methylarginine; NOS3 protein, human; thymine; triacylglycerol; adult; allele; article; clinical assessment; controlled study; drug infusion; endothelium; enzyme activity; female; gene frequency; gene interaction; genotype; human; hypertension; kidney; kidney circulation; kidney plasma flow; major clinical study; male; non insulin dependent diabetes mellitus; oxidative stress; priority journal; single nucleotide polymorphism; steady state; analysis of variance; blood; body mass; drug effect; enzymology; genetics; hemodynamics; homozygote; middle aged; non insulin dependent diabetes mellitus; pathophysiology; single nucleotide polymorphism","","4 aminohippuric acid, 61-78-9; arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3; ascorbic acid, 134-03-2, 15421-15-5, 50-81-7; atenolol, 29122-68-7; endothelial nitric oxide synthase, 503473-02-7; glycine, 56-40-6, 6000-43-7, 6000-44-8; hydrochlorothiazide, 58-93-5; metformin, 1115-70-4, 657-24-9; metoprolol, 37350-58-6; n(g) methylarginine, 156706-47-7, 17035-90-4; nitric oxide, 10102-43-9; nitric oxide synthase, 125978-95-2; threonine, 36676-50-3, 72-19-5; guanine, 69257-39-2, 73-40-5; thymine, 65-71-4; Arginine, 74-79-3; Ascorbic Acid, 50-81-7; Cholesterol, HDL, ; Guanine, 73-40-5; Nitric Oxide Synthase Type III, EC 1.14.13.39; NOS3 protein, human, EC 1.14.13.39; omega-N-Methylarginine, 17035-90-4; Thymine, 65-71-4; Triglycerides, ","cebion forte, Merck, Germany; l arginine hydrochloride, University Hospital Pharmacy, Germany","Merck, Germany; University Hospital Pharmacy, Germany","","","Goligorsky M.S., Chen J., Brodsky S., Workshop: Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide, Hypertension, 37, pp. 744-748, (2001); Kone B.C., Nitric oxide in renal health and disease, Am J Kidney Dis, 30, pp. 311-333, (1997); Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., Et al., Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy, J Am Soc Nephrol, 18, pp. 364-366, (2007); Forstermann U., Munzel T., Endothelial nitric oxide synthase in vascular disease: From marvel to menace, Circulation, 113, pp. 1708-1714, (2006); Michel T., Feron O., Nitric oxide synthases: Which, where, how, and why?, J Clin Invest, 100, pp. 2146-2152, (1997); Komers R., Anderson S., Paradoxes of nitric oxide in the diabetic kidney, Am J Physiol Renal Physiol, 284, (2003); Rangan G.K., Wang Y., Harris D.C., Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats, J Am Soc Nephrol, 12, pp. 1696-1705, (2001); Kang D.H., Nakagawa T., Feng L., Johnson R.J., Nitric oxide modulates vascular disease in the remnant kidney model, Am J Pathol, 161, pp. 239-248, (2002); Zhao H.J., Wang S., Cheng H., Zhang M.Z., Takahashi T., Fogo A.B., Et al., Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice, J Am Soc Nephrol, 17, pp. 2664-2669, (2006); Shin Shin Y., Baek S.H., Chang K.Y., Park C.W., Yang C.W., Jin D.C., Et al., Relations between eNOS glu298asp polymorphism and progression of diabetic nephropathy, Diabetes Res Clin Pract, 65, pp. 257-265, (2004); Noiri E., Satoh H., Taguchi J., Brodsky S.V., Nakao A., Ogawa Y., Et al., Association of eNOS glu298asp polymorphism with end-stage renal disease, Hypertension, 40, pp. 535-540, (2002); Nagase S., Suzuki H., Wang Y., Kikuchi S., Hirayama A., Ueda A., Et al., Association of ecNOS gene polymorphisms with end stage renal diseases, Mol Cell Biochem, 244, pp. 113-118, (2003); Freedman B.I., Yu H., Anderson P.J., Roh B.H., Rich S.S., Bowden D.W., Genetic analysis of nitric oxide and endothelin in end-stage renal disease, Nephrol Dial Transplant, 15, pp. 1794-1800, (2000); Mollsten A., Wessman M., Svensson M., Forsblom C., Parkkonen M., Brismar K., Et al., Glu298asp and NOS4ab polymorphisms in diabetic nephropathy, Ann Med, 38, pp. 522-528, (2006); Delles C., Schneider M.P., Oehmer S., Fleischmann I., Fleischmann E.F., Schmieder R.E., Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes, Nephrol Dial Transplant, 19, pp. 2513-2518, (2004); Schneider M.P., Klingbeil A.U., Delles C., Schmidt B.M., John S., Schmieder R.E., Vitamin C augments the renal response to L-arginine in smokers, Nephrol Dial Transplant, 18, pp. 1512-1517, (2003); Smith H.W., Finkelstein N., Aliminosa L., Crawford B., Graber M., The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man, J Clin Invest, 24, pp. 388-404, (1945); Joshi M.S., Mineo C., Shaul P.W., Bauer J.A., Biochemical consequences of the NOS3 glu298asp variation in human endothelium: Altered caveolar localization and impaired response to shear, Federation Am Soc Exp Biol J, 21, pp. 2655-2663, (2007); Antoniades C., Tousoulis D., Vasiliadou C., Pitsavos C., Chrysochoou C., Panagiotakos D., Et al., Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction, J Am Coll Cardiol, 46, pp. 1101-1109, (2005); Leeson C.P., Hingorani A.D., Mullen M.J., Jeerooburkhan N., Kattenhorn M., Cole T.J., Et al., Glu298asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function, Circ Res, 90, pp. 1153-1158, (2002); Philip I., Plantefeve G., Vuillaumier-Barrot S., Vicaut E., LeMarie C., Henrion D., Et al., G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine, Circulation, 99, pp. 3096-3098, (1999); Sandrim V.C., De Syllos R.W., Lisboa H.R., Tres G.S., Tanus-Santos J.E., Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus, Atherosclerosis, 189, pp. 241-246, (2006); Sandrim V.C., Yugar-Toledo J.C., Desta Z., Flockhart D.A., Moreno Jr H., Tanus-Santos J.E., Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy, J Hypertens, 24, pp. 2393-2397, (2006); Lembo G., De Luca N., Battagli C., Iovino G., Aretini A., Musicco M., Et al., A common variant of endothelial nitric oxide synthase (glu298asp) is an independent risk factor for carotid atherosclerosis, Stroke, 32, pp. 735-740, (2001); Spoto B., Benedetto F.A., Testa A., Tripepi G., Mallamaci F., Maas R., Et al., Atherosclerosis and the glu298asp polymorphism of the eNOS gene in white patients with end-stage renal disease, Am J Hypertens, 18, pp. 1549-1555, (2005); Hingorani A.D., Liang C.F., Fatibene J., Lyon A., Monteith S., Parsons A., Et al., A common variant of the endothelial nitric oxide synthase (glu298-asp) is a major risk factor for coronary artery disease in the UK, Circulation, 100, pp. 1515-1520, (1999); Casas J.P., Bautista L.E., Humphries S.E., Hingorani A.D., Endothelial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects, Circulation, 109, pp. 1359-1365, (2004); Zhang C., Lopez-Ridaura R., Hunter D.J., Rifai N., Hu F.B., Common variants of the endothelial nitric oxide synthase gene and the risk of coronary heart disease among U.S. diabetic men, Diabetes, 55, pp. 2140-2147, (2006); Berger K., Stogbauer F., Stoll M., Wellmann J., Huge A., Cheng S., Et al., The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies, Hum Genet, 121, pp. 169-178, (2007); Ahmadi K.R., Weale M.E., Xue Z.Y., Soranzo N., Yarnall D.P., Briley J.D., Et al., A single-nucleotide polymorphism tagging set for human drug metabolism and transport, Nat Genet, 37, pp. 84-89, (2005); Tesauro M., Thompson W.C., Rogliani P., Qi L., Chaudhary P.P., Moss J., Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. Glutamate at position 298, Proc Natl Acad Sci U S A, 97, pp. 2832-2835, (2000); Fairchild T.A., Fulton D., Fontana J.T., Gratton J.P., McCabe T.J., Sessa W.C., Acidic hydrolysis as a mechanism for the cleavage of the glu(298) → asp variant of human endothelial nitric-oxide synthase, J Biol Chem, 276, pp. 26674-26679, (2001); McDonald D.M., Alp N.J., Channon K.M., Functional comparison of the endothelial nitric oxide synthase glu298asp polymorphic variants in human endothelial cells, Pharmacogenetics, 14, pp. 831-839, (2004); Hamilton C.A., Brosnan M.J., McIntyre M., Graham D., Dominiczak A.F., Superoxide excess in hypertension and aging: A common cause of endothelial dysfunction, Hypertension, 37, pp. 529-534, (2001); Delles C., Jacobi J., Schlaich M.P., John S., Schmieder R.E., Assessment of endothelial function of the renal vasculature in human subjects, Am J Hypertens, 15, pp. 3-9, (2002); Mayer B.X., Mensik C., Krishnaswami S., Derendorf H., Eichler H.G., Schmetterer L., Et al., Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-nmma in humans, Br J Clin Pharmacol, 47, pp. 539-544, (1999); Bech J.N., Nielsen C.B., Ivarsen P., Jensen K.T., Pedersen E.B., Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans, Am J Physiol, 274, (1998); Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A., Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus, J Clin Invest, 97, pp. 22-28, (1996); Taddei S., Virdis A., Ghiadoni L., Magagna A., Salvetti A., Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension, Circulation, 97, pp. 2222-2229, (1998); Sherman D.L., Keaney Jr J.F., Biegelsen E.S., Duffy S.J., Coffman J.D., Vita J.A., Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension, Hypertension, 35, pp. 936-941, (2000); John S., Delles C., Jacobi J., Schlaich M.P., Schneider M., Schmitz G., Et al., Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks, J Am Coll Cardiol, 37, pp. 1351-1358, (2001); Schaufele T.G., Schlaich M.P., Delles C., Klingbeil A.U., Fleischmann E.H., Schmieder R.E., Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress, Kidney Int, 70, pp. 1177-1181, (2006); Schlaich M.P., Oehmer S., Schneider M.P., Delles C., Schmidt B.M., Schmieder R.E., Effects of nitric oxide synthase inhibition and L-arginine on renal haemodynamics in young patients at high cardiovascular risk, Atherosclerosis, 192, pp. 155-160, (2007)","R. E. Schmieder; Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, 91054 Erlangen, Krankenhausstraße 12, Germany; email: roland.schmieder@rzmail.uni-erlangen.de","","","","","","","","17446880","","","18622262","English","Pharmacogenet. Genomics","Article","Final","","Scopus","2-s2.0-55749104951"
"Schelleman H.; Stricker B.H.Ch.; Verschuren W.M.M.; de Boer A.; Kroon A.A.; de Leeuw P.W.; Kromhout D.; Klungel O.H.","Schelleman, H. (8786514900); Stricker, B.H.Ch. (35380220500); Verschuren, W.M.M. (7003301273); de Boer, A. (56489803600); Kroon, A.A. (35452655900); de Leeuw, P.W. (35376243500); Kromhout, D. (40261987600); Klungel, O.H. (7006204390)","8786514900; 35380220500; 7003301273; 56489803600; 35452655900; 35376243500; 40261987600; 7006204390","Interactions between five candidate genes and antihypertensive drug therapy on blood pressure","2006","Pharmacogenomics Journal","6","1","","22","26","4","44","10.1038/sj.tpj.6500339","https://www.scopus.com/inward/record.uri?eid=2-s2.0-31044434665&doi=10.1038%2fsj.tpj.6500339&partnerID=40&md5=4c145a4dd3f68286df7140518bce081d","Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands; Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, PO Box 80082, Netherlands; Centre for Prevention and Health Service Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands; Department of Internal Medicine, University Hospital of Maastricht, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands; Division of Nutrition and Consumer Safety, National Institute for Public Health and the Environment, Bilthoven, Netherlands","Schelleman H., Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands, Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, PO Box 80082, Netherlands; Stricker B.H.Ch., Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands; Verschuren W.M.M., Centre for Prevention and Health Service Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands; de Boer A., Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, PO Box 80082, Netherlands; Kroon A.A., Department of Internal Medicine, University Hospital of Maastricht, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands; de Leeuw P.W., Department of Internal Medicine, University Hospital of Maastricht, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands; Kromhout D., Division of Nutrition and Consumer Safety, National Institute for Public Health and the Environment, Bilthoven, Netherlands; Klungel O.H., Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, PO Box 80082, Netherlands","Despite the availability of effective antihypertensive drugs, there is a large variation in response to these drugs. This study investigates whether polymorphisms in the angiotensin converting enzyme (I/D), angiotensinogen (M235T), α-adducin (G460W), angiotensin II type 1 receptor (1166A/C), or G protein β3-subunit (825C/T) gene modify the mean difference in blood pressure levels among diuretics, β-blockers, or ACE-inhibitors users. Data were used from the Doetinchem Cohort Study, and blood pressure data were collected from GPs (1987-1997). A marginal generalized linear model (GEE) was used to assess the gene-drug interaction on the mean difference in systolic/diastolic blood pressure. In total, 625 hypertensive individuals were included with a total of 5262 measurements of blood pressure. Only the interaction between diuretic use and the GNB3 825C/T polymorphism was significant (C allele versus TT systolic blood pressure (SBP): 4.33 mmHg [95% CI: 0.14-8.54]). Thus, the mean SBP level among diuretic users may be modified by the GNB3 825C/T polymorphism. © 2006 Nature Publishing Group All rights reserved.","Antihypertensive drugs; Candidate genes; Pharmacogenetics; Pharmacogenomics","Angiotensinogen; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Cohort Studies; Dose-Response Relationship, Drug; Female; Genotype; Heterotrimeric GTP-Binding Proteins; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Prospective Studies; Receptor, Angiotensin, Type 1; adducin; angiotensin 2 receptor; angiotensinogen; antihypertensive agent; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; guanine nucleotide binding protein beta subunit; adult; allele; antihypertensive therapy; article; blood pressure measurement; cohort analysis; controlled study; diastolic blood pressure; drug efficacy; drug mechanism; drug protein binding; drug response; female; human; hypertension; major clinical study; male; pharmacogenetics; priority journal; protein polymorphism; statistical model; systolic blood pressure","","angiotensinogen, 11002-13-4, 64315-16-8; dipeptidyl carboxypeptidase, 9015-82-1; adducin, ; Angiotensinogen, 11002-13-4; Antihypertensive Agents, ; Calmodulin-Binding Proteins, ; G-protein beta3 subunit, ; Heterotrimeric GTP-Binding Proteins, EC 3.6.1.46; Peptidyl-Dipeptidase A, EC 3.4.15.1; Receptor, Angiotensin, Type 1, ","","","National Institute for Public Health; Netherlands Heart Foundation, (2001.064); Ministerie van Volksgezondheid, Welzijn en Sport, VWS","This study was financially supported by The Netherlands Heart Foundation, grant number: 2001.064; the Ministry of Health, Welfare and Sport of the Netherlands, and the National Institute for Public Health and the Environment, Bilthoven, The Netherlands.","Collins R., MacMahon S., Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease, Br Med Bull, 50, pp. 272-298, (1994); Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B., Et al., Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, pp. 1751-1756, (1999); Schelleman H., Klungel O.H., Kromhout D., de Boer A., Stricker B.H.Ch., Verschuren W.M.M., Prevalence and determinats of undertreatment of hypertension in the Netherlands, J Hum Hypert, 18, pp. 317-324, (2004); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Manunta P., Cusi D., Barlassina C., Righetti M., Lanzani C., D'Amico M., Et al., Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients, Kidney Int, 53, pp. 1471-1478, (1998); Virchow S., Ansorge N., Rubben H., Siffert G., Siffert W., Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein beta3 subunit 825 T-allele, FEBS Lett, 436, pp. 155-158, (1998); Schelleman H., Stricker B.H., De Boer A., Kroon A.A., Verschuren M.W., Van Duijn C.M., Et al., Drug-gene interactions between genetic polymorphisms and antihypertensive therapy, Drugs, 64, pp. 1801-1816, (2004); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Verschuren W.M.M., van Leer E.M., Blokstra A., Seidell J.C., Smit H.A., Bueno de Mesquita H.B., Et al., Cardiovascular disease risk factors in The Netherlands, Neth J Cardiol, 4, pp. 205-210, (1993); International Classification of Diseases, (1992); Guidelines for ATC Classification and DDD Assignment, (2000); Beeks E., Janssen R.G., Kroon A.A., Keulen E.T., Geurts J.M., de Leeuw P.W., Et al., Association between the alpha-adducin Gly460Trp polymorphism and systolic blood pressure in familial combined hyperlipidemia, Am J Hypertens, 14, pp. 1185-1190, (2001); Russ A.P., Maerz W., Ruzicka V., Stein U., Gross W., Rapid detection of the hypertension-associated Met235->Thr allele of the human angiotensinogen gene, Hum Mol Genet, 2, pp. 609-610, (1993); Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Et al., Association of a human G-protein beta3 subunit variant with hypertension, Nat Genet, 18, pp. 45-48, (1998); Henskens L.H., Spiering W., Stoffers H.E., Soomers F.L., Vlietinck R.F., de Leeuw P.W., Et al., Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: First results of the Hippocates study, J Hypertens, 21, pp. 81-86, (2003)","O.H. Klungel; Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, PO Box 80082, Netherlands; email: o.h.klungel@pharm.uu.nl","","","","","","","","1470269X","","PJHOA","16314886","English","Pharmacogenomics J.","Article","Final","","Scopus","2-s2.0-31044434665"
"Pankow J.S.; Dunn D.M.; Hunt S.C.; Leppert M.F.; Miller M.B.; Rao D.C.; Heiss G.; Oberman A.; Lalouel J.-M.; Weiss R.B.","Pankow, James S. (7403082031); Dunn, Diane M. (57195617125); Hunt, Steven C. (7402383343); Leppert, Mark F. (35351313000); Miller, Michael B. (57213747520); Rao, D.C. (57217192196); Heiss, Gerardo (7005930629); Oberman, Albert (7006700415); Lalouel, Jean-Marc (7102287621); Weiss, Robert B. (35378752500)","7403082031; 57195617125; 7402383343; 35351313000; 57213747520; 57217192196; 7005930629; 7006700415; 7102287621; 35378752500","Further evidence of a quantitative trait locus on chromosome 18 influencing postural change in systolic blood pressure: The hypertension genetic epidemiology network (HyperGEN) study","2005","American Journal of Hypertension","18","5","","672","678","6","32","10.1016/j.amjhyper.2004.12.004","https://www.scopus.com/inward/record.uri?eid=2-s2.0-21044444155&doi=10.1016%2fj.amjhyper.2004.12.004&partnerID=40&md5=32b76156fe7f3353526be6beb71023e3","Div. of Epidemiol. and Comm. Health, University of Minnesota, Minneapolis, MN, United States; Department of Human Genetics, University of Utah, Salt Lake City, UT, United States; Cardiovasc. Genetics Research Clinic, Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States; Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States; Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States; Division of Preventive Medicine, University of Alabama-Birmingham, Birmingham, AL, United States; Div. of Epidemiol. and Comm. Health, University of Minnesota, Minneapolis, MN 55454, 1300 South Second Street, United States","Pankow J.S., Div. of Epidemiol. and Comm. Health, University of Minnesota, Minneapolis, MN, United States, Div. of Epidemiol. and Comm. Health, University of Minnesota, Minneapolis, MN 55454, 1300 South Second Street, United States; Dunn D.M., Department of Human Genetics, University of Utah, Salt Lake City, UT, United States; Hunt S.C., Cardiovasc. Genetics Research Clinic, Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States; Leppert M.F., Department of Human Genetics, University of Utah, Salt Lake City, UT, United States; Miller M.B., Div. of Epidemiol. and Comm. Health, University of Minnesota, Minneapolis, MN, United States; Rao D.C., Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States; Heiss G., Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States; Oberman A., Division of Preventive Medicine, University of Alabama-Birmingham, Birmingham, AL, United States; Lalouel J.-M., Department of Human Genetics, University of Utah, Salt Lake City, UT, United States; Weiss R.B., Department of Human Genetics, University of Utah, Salt Lake City, UT, United States","Background: Postural change in systolic blood pressure (SBP) is prospectively associated with several disease outcomes including hypertension, stroke, and coronary heart disease. The objective of this study was to characterize further a possible quantitative trait locus on chromosome 18q21 influencing SBP response to a postural challenge. Methods: A prior genome scan of postural SBP response in 636 subjects of white ethnicity from 285 hypertensive sibships in the Hypertension Genetic Epidemiology Network (HyperGEN) indicated suggestive evidence for linkage on chromosome 18q21. This study included a de novo set of 452 African American pedigrees from the HyperGEN study and an expanded set of 372 white pedigrees. Variance components linkage analysis of postural SBP change was conducted using microsatellite markers on chromosome 18, and association studies were performed with a common single nucleotide polymorphism (variant 13) in the gene encoding NEDD4L, a key regulator of fine sodium reabsorption in the distal nephron. Results: Combined analysis of all white and African American pedigrees yielded a LOD score of 4.25 at 80 cM on chromosome 18q21, with at least nominal evidence of linkage at this position in both white (LOD: 3.43) and African American (LOD: 1.14) subjects. Postural SBP response was associated with variant 13 of the NEDD4L in a subset of white subjects taking medications effective in treating sodium volume-dependent hypertension (α1-blockers, calcium channel blockers, and/or diuretics). Conclusion: These data provide further evidence for a quantitative trait locus on chromosome 18q21 influencing postural change in SBP. © 2005 American Journal of Hypertension, Ltd.","Antihypertensive agents; Blood pressure; Genetics; Polymorphism; Sodium channels","Adult; Aged; Chromosomes, Human, Pair 18; Female; Genotype; Humans; Hypertension; Lod Score; Male; Middle Aged; Posture; Quantitative Trait Loci; Systole; Ubiquitin-Protein Ligases; alpha adrenergic receptor blocking agent; angiotensin 2 receptor antagonist; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; adult; article; chromosome 18; controlled study; ethnology; female; gene locus; genetic analysis; genetic code; genetic linkage; genetic trait; genetic variability; genome analysis; human; hypertension; major clinical study; male; microsatellite marker; nephron; pedigree analysis; priority journal; quantitative analysis; single nucleotide polymorphism; sodium absorption; systolic blood pressure","","Nedd4 ubiquitin protein ligases, EC 6.3.2.19; Ubiquitin-Protein Ligases, EC 6.3.2.19","","","National Heart, Lung, and Blood Institute, NHLBI, (HL54471, HL54473, HL54495, HL54496, HL54497, HL54509, HL54515, U01HL054472); National Heart, Lung, and Blood Institute, NHLBI","This hypertension network is funded by the following cooperative agreements (U01) with the National Heart, Lung, and Blood Institute: HL54471, HL54472, HL54473, HL54495, HL54496, HL54497, HL54509, and HL54515. ","Pankow J.S., Rose K.M., Oberman A., Hunt S.C., Atwood L.D., Djousse L., Province M.A., Rao D.C., Possible locus on chromosome 18q influencing postural systolic blood pressure changes, Hypertension, 36, pp. 471-476, (2000); Destefano A.L., Baldwin C.T., Burzstyn M., Gavras I., Handy D.E., Joost O., Martel T., Nicolaou M., Schwartz F., Streeten D.H., Farrer L.A., Gavras H., Autosomal dominant orthostatic hypotensive disorder maps to chromosome 18q, Am J Hum Genet, 63, pp. 1425-1430, (1998); Atwood L.D., Samollow P.B., Hixson J.E., Stern M.P., MacCluer J.W., Genome-wide linkage analysis of blood pressure in Mexican Americans, Genet Epidemiol, 20, pp. 373-382, (2001); Kristjansson K., Manolescu A., Kristinsson A., Hardarson T., Knudsen H., Ingason S., Thorleifsson G., Frigge M.L., Kong A., Gulcher J.R., Stefansson K., Linkage of essential hypertension to chromosome 18q, Hypertension, 39, pp. 1044-1049, (2002); Chen H., Ross C.A., Wang N., Huo Y., MacKinnon D.F., Potash J.B., Simpson S.G., McMahon F.J., DePaulo Jr. J.R., McInnis M.G., NEDD4L on human chromosome 18q21 has multiple forms of transcripts and is a homologue of the mouse Nedd4-2 gene, Eur J Hum Genet, 9, pp. 922-930, (2001); Harvey K.F., Dinudom A., Cook D.I., Kumar S., The Nedd4-like protein KIAA0439 is a potential regulator of the epithelial sodium channel, J Biol Chem, 276, pp. 8597-8601, (2001); Dunn D.M., Ishigami T., Pankow J., Von Niederhausern A., Alder J., Hunt S.C., Leppert M.F., Lalouel J.M., Weiss R.B., Common variant of human NEDD4L activates a cryptic splice site to form a frameshifted transcript, J Hum Genet, 47, pp. 665-676, (2002); Kamynina E., Tauxe C., Staub O., Distinct characteristics of two human Nedd4 proteins with respect to epithelial Na(+) channel regulation, Am J Physiol Renal Physiol, 281, (2001); Snyder P.M., Steines J.C., Olson D.R., Relative contribution of Nedd4 and Nedd4-2 to ENaC regulation in epithelia determined by RNA interference, J Biol Chem, 279, pp. 5042-5046, (2004); Williams R.R., Rao D.C., Ellison R.C., Arnett D.K., Heiss G., Oberman A., Eckfeldt J.H., Leppert M.F., Province M.A., Mockrin S.C., Hunt S.C., NHLBI family blood pressure program: Methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network, Ann Epidemiol, 10, pp. 389-400, (2000); Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP), Hypertension, 39, pp. 3-9, (2002); North K.E., Rose K.M., Borecki I.B., Oberman A., Hunt S.C., Miller M.B., Blangero J., Almasy L., Pankow J.S., Evidence for a gene on chromosome 13 influencing postural systolic blood pressure change and body mass index, Hypertension, 43, pp. 780-784, (2004); Ewing B., Hillier L., Wendl M.C., Green P., Base-calling of automated sequencer traces using phred. I. Accuracy assessment, Genome Res, 8, pp. 175-185, (1998); Nickerson D.A., Tobe V.O., Taylor S.L., PolyPhred: Automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing, Nucleic Acids Res, 25, pp. 2745-2751, (1997); Abecasis G.R., Cherny S.S., Cookson W.O., Cardon L.R., Merlin--rapid analysis of dense genetic maps using sparse gene flow trees, Nat Genet, 30, pp. 97-101, (2002); Almasy L., Blangero J., Multipoint quantitative-trait linkage analysis in general pedigrees, Am J Hum Gen, 62, pp. 1198-1211, (1998); Miller M.B., MER2SOL: Translating MERLIN or Loki IBD data to SOLAR format (abstract), Genet Epidemiol, 25, pp. 261-262, (2003); SAS/STAT Users Guide, (1999); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, pp. 1206-1252, (2003); Blumenfeld J.D., JNC-7 versus renin-based strategies for optimal antihypertensive drug treatment. Another look at the evidence, Am J Hypertens, 17, pp. 1002-1004, (2004); Stoll M., Kwitek-Black A.E., Cowley Jr. A.W., Harris E.L., Harrap S.B., Krieger J.E., Printz M.P., Provoost A.P., Sassard J., Jacob H.J., New target regions for human hypertension via comparative genomics, Genome Res, 10, pp. 473-482, (2000); Wright F.A., O'Connor D.T., Roberts E., Kutey G., Berry C.C., Yoneda L.U., Timberlake D., Schlager G., Genome scan for blood pressure loci in mice, Hypertension, 34, pp. 625-630, (1999); Tabara Y., Kohara K., Miki T., Polymorphisms of genes encoding components of the sympathetic nervous system but not the renin-angiotensin system as risk factors for orthostatic hypotension, J Hypertens, 20, pp. 651-656, (2002); Scheinman S.J., Guay-Woodford L.M., Thakker R.V., Warnock D.G., Genetic disorders of renal electrolyte transport, N Engl J Med, 340, pp. 1177-1187, (1999); Fotia A.B., Dinudom A., Shearwin K.E., Koch J.P., Korbmacher C., Cook D.I., Kumar S., The role of individual Nedd4-2 (KIAA0439) WW domains in binding and regulating epithelial sodium channels, FASEB J, 17, pp. 70-72, (2003); Itani O.A., Campbell J.R., Herrero J., Snyder P.M., Thomas C.P., Alternative promoter usage and differential splicing leads to human Nedd4-2 isoforms with a C2 domain and with variable number of WW domains, Am J Physiol Renal Physiol, 285, (2003); Laederach-Hofmann K., Weidmann P., Ferrari P., Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus, Am J Med, 106, pp. 50-58, (1999); Rose K.M., Holme I., Light K.C., Sharrett A.R., Tyroler H.A., Heiss G., Association between the blood pressure response to a change in posture and the 6-year incidence of hypertension: Prospective findings from the ARIC study, J Hum Hypertens, 16, pp. 771-777, (2002); Eigenbrodt M.L., Rose K.M., Couper D.J., Arnett D.K., Smith R., Jones D., Orthostatic hypotension as a risk factor for stroke: The Atherosclerosis Risk in Communities (ARIC) study, 1987-1996, Stroke, 31, pp. 2307-2313, (2000); Rose K.M., Tyroler H.A., Nardo C.J., Arnett D.K., Light K.C., Rosamond W., Sharrett A.R., Szklo M., Orthostatic hypotension and the incidence of coronary heart disease: The Atherosclerosis Risk in Communities study, Am J Hypertens, 13, pp. 571-578, (2000); Smith J.J., Porth C.M., Erickson M., Hemodynamic response to the upright posture, J Clin Pharmacol, 34, pp. 375-386, (1994); Harrap S.B., Cui J.S., Wong Z.Y., Hopper J.L., Familial and genomic analyses of postural changes in systolic and diastolic blood pressure, Hypertension, 43, pp. 586-591, (2004)","J.S. Pankow; Div. of Epidemiol. and Comm. Health, University of Minnesota, Minneapolis, MN 55454, 1300 South Second Street, United States; email: pankow@epi.umn.edu","","","","","","","","08957061","","AJHYE","15882550","English","Am. J. Hypertens.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-21044444155"
"Zhao Q.; Gu D.; Kelly T.N.; Hixson J.E.; Rao D.C.; Jaquish C.E.; Chen J.; Huang J.; Chen C.-S.; Gu C.C.; Whelton P.K.; He J.","Zhao, Qi (35488820200); Gu, Dongfeng (55802487000); Kelly, Tanika N. (18437013100); Hixson, James E. (7006777202); Rao, Dabeeru C. (57217192196); Jaquish, Cashell E. (57223885139); Chen, Jing (35213100000); Huang, Jianfeng (8562297400); Chen, Chung-Shiuan (26027716000); Gu, C. Charles (24775504800); Whelton, Paul K. (7103041111); He, Jiang (7404983432)","35488820200; 55802487000; 18437013100; 7006777202; 57217192196; 57223885139; 35213100000; 8562297400; 26027716000; 24775504800; 7103041111; 7404983432","Association of genetic variants in the apelin-APJ system and ace2 with blood pressure responses to potassium supplementation: The gensalt study","2010","American Journal of Hypertension","23","6","","606","613","7","41","10.1038/ajh.2010.36","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952553208&doi=10.1038%2fajh.2010.36&partnerID=40&md5=4cd0164165c7fc5fb37e8b6806b814e5","Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States; Cardiovascular Institute, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese National Center for Cardiovascular Disease Control and Research, Beijing, China; Department of Epidemiology, University of Texas School of Public Health, Houston, TX, United States; Division of Biostatistics, Washington University School of Medicine, St Louis, MO, United States; Division of Cardiovascular Sciences, National Heart, Lung, Blood Institute, Bethesda, MA, United States; Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States; Office of President, Loyola University Medical Center, Maywood, IL, United States","Zhao Q., Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States; Gu D., Cardiovascular Institute, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese National Center for Cardiovascular Disease Control and Research, Beijing, China; Kelly T.N., Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States; Hixson J.E., Department of Epidemiology, University of Texas School of Public Health, Houston, TX, United States; Rao D.C., Division of Biostatistics, Washington University School of Medicine, St Louis, MO, United States; Jaquish C.E., Division of Cardiovascular Sciences, National Heart, Lung, Blood Institute, Bethesda, MA, United States; Chen J., Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States; Huang J., Cardiovascular Institute, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese National Center for Cardiovascular Disease Control and Research, Beijing, China; Chen C.-S., Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States; Gu C.C., Division of Biostatistics, Washington University School of Medicine, St Louis, MO, United States; Whelton P.K., Office of President, Loyola University Medical Center, Maywood, IL, United States; He J., Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States","Background: Genetic factors may influence blood pressure (BP) responses to dietary potassium intake. We examined the association of genetic variants in the apelin-APJ system and angiotensin-converting enzyme 2 (ACE2) with BP responses to potassium supplementation. Methods: We conducted a 7-day potassium supplementation (60mmol/day) intervention among 1,906 Chinese adults who participated in the Genetic Epidemiology Network of Salt-Sensitivity (GenSalt) study. Tag single-nucleotide polymorphisms (SNPs) based on HapMap data and potential functional SNPs were selected in the APLN, APLNR, and ACE2 genes. Because the ACE2 and APLN genes are located on the X chromosome, men and women were analyzed separately. Results: In women, SNP rs2235306 in the APLN gene was significantly associated with diastolic BP (DBP) response to potassium supplementation (P = 0.0009). The DBP responses (95% confidence interval (CI)) among those with genotypes T/T, T/C, and C/C were-2.22 (-2.74,-1.70),-1.69 (-2.20,-1.19), and-0.81 (-1.54,-0.09) mmHg, respectively. In men, SNP rs4646174 of the ACE2 gene was significantly associated with systolic BP (SBP), DBP, and mean arterial pressure (MAP) responses to potassium supplementation (P = 0.0001, P = 0.001, and P = 3.0 × 10-6, respectively). The SBP, DBP, and MAP responses (95% CI) were-0.79 (-2.27, 0.69) vs.-3.53 (-3.94,-3.12), 1.07 (-0.34, 2.49) vs.-1.06 (-1.43,-0.69), and 0.44 (-0.60, 1.48) vs.-1.89 (-2.22,-1.55) mmHg among men with minor G allele compared to those with major C allele of rs4646174, respectively. Conclusion Our study indicates that genetic variation of APLN and ACE2 may influence BP response to potassium intake. © 2010 American Journal of Hypertension, Ltd.","ACE2; Apelin; Apelin receptor; Blood pressure; Hypertension; Polymorphism; Potassium supplement","Adult; Blood Pressure; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Molecular Epidemiology; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Potassium, Dietary; Receptors, G-Protein-Coupled; Sodium Chloride, Dietary; angiotensin converting enzyme 2; apelin; potassium; adult; article; blood pressure; diastolic blood pressure; diet supplementation; female; genetic association; genetic variability; heredity; human; major clinical study; male; mean arterial pressure; priority journal; single nucleotide polymorphism; X chromosome","","potassium, 7440-09-7; AGTRL1 protein, human, ; APLN protein, human, ; Intercellular Signaling Peptides and Proteins, ; Peptidyl-Dipeptidase A, 3.4.15.1; Potassium, Dietary, ; Receptors, G-Protein-Coupled, ; Sodium Chloride, Dietary, ; angiotensin converting enzyme 2, 3.4.17.-","","","National Institutes of Health, NIH; National Heart, Lung, and Blood Institute, NHLBI, (R01HL087263, R01HL090682)","Acknowledgments:The Genetic epidemiology network of Salt Sensitivity (GenSalt) is supported by research grants (u01HL072507, R01HL087263, and R01HL090682) from the national Heart, Lung, and Blood Institute, national Institutes of Health, Bethesda, MD. upsher-Smith Laboratories, Maple Grove, Mn has provided Klor-Con M20 potassium tablets for the GenSalt study.","He F.J., MacGregor G.A., Fortnightly review: Beneficial effects of potassium, BMJ, 323, pp. 497-501, (2001); Appel L.J., Brands M.W., Daniels S.R., Karanja N., Elmer P.J., Sacks F.M., American Heart Association. Dietary approaches to prevent and treat hypertension: A scientific statement from the American Heart Association, Hypertension, 47, pp. 296-308, (2006); Whelton P.K., He J., Cutler J.A., Brancati F.L., Appel L.J., Follmann D., Klag M.J., Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials, JAMA, 277, pp. 1624-1632, (1997); Gu D., Rice T., Wang S., Yang W., Gu C., Chen C.S., Hixson J.E., Jaquish C.E., Yao Z.J., Liu D.P., Rao D.C., He J., Heritability of blood pressure responses to dietary sodium and potassium intake in a Chinese population, Hypertension, 50, pp. 116-122, (2007); Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., Kawamata Y., Fukusumi S., Hinuma S., Kitada C., Kurokawa T., Onda H., Fujino M., Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem Biophys Res Commun, 251, pp. 471-476, (1998); Japp A.G., Newby D.E., The apelin-APJ system in heart failure: Pathophysiologic relevance and therapeutic potential, Biochem Pharmacol, 75, pp. 1882-1892, (2008); Charles C.J., Putative role for apelin in pressure/volume homeostasis and cardiovascular disease, Cardiovasc Hematol Agents Med Chem, 5, pp. 1-10, (2007); Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, J Biol Chem, 277, pp. 14838-14843, (2002); Burrell L.M., Johnston C.I., Tikellis C., Cooper M.E., ACE2, a new regulator of the renin-angiotensin system, Trends Endocrinol Metab, 15, pp. 166-169, (2004); Ishida J., Hashimoto T., Hashimoto Y., Nishiwaki S., Iguchi T., Harada S., Sugaya T., Matsuzaki H., Yamamoto R., Shiota N., Okunishi H., Kihara M., Umemura S., Sugiyama F., Yagami K., Kasuya Y., Mochizuki N., Fukamizu A., Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo, J Biol Chem, 279, pp. 26274-26279, (2004); GenSalt: Rationale, design, methods and baseline characteristics of study participants, J Hum Hypertens, 21, pp. 639-646, (2007); Perloff D., Grim C., Flack J., Frohlich E.D., Hill M., McDonald M., Morgenstern B.Z., Human blood pressure determination by sphygmomanometry, Circulation, 88, pp. 2460-2470, (1993); Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., De Bakker P.I., Daly M.J., Sham P.C., PLINK: A tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, pp. 559-575, (2007); O'Connell J.R., Weeks D.E., PedCheck: A program for identification of genotype incompatibilities in linkage analysis, Am J Hum Genet, 63, pp. 259-266, (1998); Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: Analysis and visualization of LD and haplotype maps, Bioinformatics, 21, pp. 263-265, (2005); Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., Defelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., Altshuler D., The structure of haplotype blocks in the human genome, Science, 296, pp. 2225-2229, (2002); Abecasis G.R., Cherny S.S., Cookson W.O., Cardon L.R., Merlin\rapid analysis of dense genetic maps using sparse gene flow trees, Nat Genet, 30, pp. 97-101, (2002); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J Roy Statist Soc ser B, 57, pp. 289-300, (1995); Japp A.G., Cruden N.L., Amer D.A., Li V.K., Goudie E.B., Johnston N.R., Sharma S., Neilson I., Webb D.J., Megson I.L., Flapan A.D., Newby D.E., Vascular effects of apelin in vivo in man, J Am Coll Cardiol, 52, pp. 908-913, (2008); Zhang Q., Yao F., Raizada M.K., O'Rourke S.T., Sun C., Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats, Circ Res, 104, pp. 1421-1428, (2009); De Mota N., Reaux-Le Goazigo A., El Messari S., Chartrel N., Roesch D., Dujardin C., Kordon C., Vaudry H., Moos F., Llorens-Cortes C., Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release, Proc Natl Acad Sci USA, 101, pp. 10464-10469, (2004); Dray C., Knauf C., Daviaud D., Waget A., Boucher J., Buleon M., Cani P.D., Attane C., Guigne C., Carpene C., Burcelin R., Castan-Laurell I., Valet P., Apelin stimulates glucose utilization in normal and obese insulin-resistant mice, Cell Metab, 8, pp. 437-445, (2008); Oberleithner H., Callies C., Kusche-Vihrog K., Schillers H., Shahin V., Riethmuller C., MacGregor G.A., De Wardener H.E., Potassium softens vascular endothelium and increases nitric oxide release, Proc Natl Acad Sci USA, 106, pp. 2829-2834, (2009); Adrogue H.J., Madias N.E., Sodium and potassium in the pathogenesis of hypertension, N Engl J Med, 356, pp. 1966-1978, (2007); Batlle D., Soler M.J., Wysocki J., New aspects of the renin-angiotensin system: Angiotensin-converting enzyme 2\a potential target for treatment of hypertension and diabetic nephropathy, Curr Opin Nephrol Hypertens, 17, pp. 250-257, (2008); Handa R.K., Ferrario C.M., Strandhoy J.W., Renal actions of angiotensin-(1-7): In vivo and in vitro studies, Am J Physiol, 270, (1996); Heller J., Kramer H.J., Maly J., Cervenka L., Horacek V., Effect of intrarenal infusion of angiotensin-(1-7) in the dog, Kidney Blood Press Res, 23, pp. 89-94, (2000); Marteau J.B., Zaiou M., Siest G., Visvikis-Siest S., Genetic determinants of blood pressure regulation, J Hypertens, 23, pp. 2127-2143, (2005); Clark A.G., The role of haplotypes in candidate gene studies, Genet Epidemiol, 27, pp. 321-333, (2004); Horikawa Y., Oda N., Cox N.J., Li X., Orho-Melander M., Hara M., Hinokio Y., Lindner T.H., Mashima H., Schwarz P.E., Del Bosque-Plata L., Horikawa Y., Oda Y., Yoshiuchi I., Colilla S., Polonsky K.S., Wei S., Concannon P., Iwasaki N., Schulze J., Baier L.J., Bogardus C., Groop L., Boerwinkle E., Hanis C.L., Bell G.I., Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus, Nat Genet, 26, pp. 163-175, (2000); Tokuhiro S., Yamada R., Chang X., Suzuki A., Kochi Y., Sawada T., Suzuki M., Nagasaki M., Ohtsuki M., Ono M., Furukawa H., Nagashima M., Yoshino S., Mabuchi A., Sekine A., Saito S., Takahashi A., Tsunoda T., Nakamura Y., Yamamoto K., An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis, Nat Genet, 35, pp. 341-348, (2003); Li W.W., Niu W.Q., Zhang Y., Wu S., Gao P.J., Zhu D.L., Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese, J Hypertens, 27, pp. 1194-1201, (2009); Hata J., Matsuda K., Ninomiya T., Yonemoto K., Matsushita T., Ohnishi Y., Saito S., Kitazono T., Ibayashi S., Iida M., Kiyohara Y., Nakamura Y., Kubo M., Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction, Hum Mol Genet, 16, pp. 630-639, (2007); Sarzani R., Forleo C., Pietrucci F., Capestro A., Soura E., Guida P., Sorrentino S., Iacoviello M., Romito R., Dessi-Fulgheri P., Pitzalis M., Rappelli A., The 212A variant of the APJ receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardiomyopathy, J Card Fail, 13, pp. 521-529, (2007); Yang W., Huang W., Su S., Li B., Zhao W., Chen S., Gu D., Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population, Clin Sci, 111, pp. 333-340, (2006); Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., Stritzke J., Hengstenberg C., Holmer S.R., Doring A., Lowel H., Schunkert H., Erdmann J., Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men: Results of the MONICA Augsburg echocardiographic substudy, Journal of Molecular Medicine, 84, 1, pp. 88-96, (2006); Fischer M., Baessler A., Schunkert H., Renin angiotensin system and gender differences in the cardiovascular system, Cardiovasc Res, 53, pp. 672-677, (2002); Zheng W., Shi M., You S.E., Ji H., Roesch D.M., Estrogens contribute to a sex difference in plasma potassium concentration: A mechanism for regulation of adrenal angiotensin receptors, Gend Med, 3, pp. 43-53, (2006)","Q. Zhao; Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, new Orleans, LA, United States; email: qizhao@tulane.edu","","","","","","","","08957061","","AJHYE","20224560","English","Am. J. Hypertens.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-77952553208"
"Schwartz G.L.; Turner S.T.","Schwartz, Gary L. (7403155162); Turner, Stephen T. (7402275413)","7403155162; 7402275413","Pharmacogenetics of antihypertensive drug responses","2004","American Journal of PharmacoGenomics","4","3","","151","160","9","58","10.2165/00129785-200404030-00002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-3042710748&doi=10.2165%2f00129785-200404030-00002&partnerID=40&md5=20bcbfe3fbb107a79c3312a246833756","Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States; Division of Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First Street SW, United States","Schwartz G.L., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States, Division of Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First Street SW, United States; Turner S.T., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States","The blood pressure (BP) response to any single antihypertensive drug is characterized by marked interindividual variation, and the known predictors of response are of limited value in identifying the optimum drug for an individual patient. Analysis of genetic variation has the potential to improve our understanding of determinants of antihypertensive drug response in order to individualize drug selection. Genetic variation can influence both pharmacokinetic and pharmacodynamic mechanisms underlying variation in drug response. Classic pharmacogenetic investigations have identified variations in single genes that have a large effect on antihypertensive drug metabolism and are inherited in a Mendelian fashion. These include a polymorphism in the CYP2D6 gene, encoding a cytochrome P450 family member involved in phase I drug metabolism, and polymorphisms in genes encoding enzymes involved in phase II drug metabolism, including N-acetyltransferase (NAT2), catechol-O- methyltransferase (COMT), and phenol sulfotransferase (P-PST, SULT1A1). Although these polymorphisms have major effects on the pharmacokinetic profiles of both commonly used antihypertensive drugs such as metoprolol (CYP2D6), and lesser used drugs such as hydralazine (NAT2), methyldopa (COMT), and minoxidil (SULT1A1), they have not been shown to influence variation in the antihypertensive effect of these drugs at conventional doses. Interest is now focused on identifying genetic polymorphisms that influence the pharmacodynamic determinants of antihypertensive response. Using a candidate gene approach, such polymorphisms have been identified in genes encoding α-adducin (ADD1), subunits of G-proteins (GNB3 and GNAS1), the β-adrenergic receptor (ADRB1), endothelial nitric oxide synthase (NOS3), and components of the renin-angiotensin-aldosterone system (angiotensinogen [AGT], angiotensin converting enzyme [ACE], the angiotensin type I receptor [AGTR1], and aldosterone synthase [CYP11B2]). These polymorphisms have been shown to influence the BP response to diuretics (ADD1, GNB3, NOS3, and ACE), β-blockers (GNAS1 and ADRB1), ACE inhibitors (AGT, ACE, and AGTR1), angiotensin receptor blockers (ACE and CYP11B2), and clonidine (GNB3). An emerging consensus from these studies is that single gene effects on antihypertensive drug responses are small, and even the combined effects of all presently known polymorphisms do not account for enough variation in response to be clinically useful. New genome-wide scanning techniques may lead to the identification of genes previously unsuspected of influencing drug response. Additional requirements for pharmacogenetic approaches to become clinically useful are the characterization of the effects of haplotypes and multi-locus genotypes on drug response, and consideration of gene-by-environment interactions. Such studies will require huge sample sizes and novel statistical methods, but the theoretical and technical framework is in place to make this possible.","","Animals; Antihypertensive Agents; Blood Pressure; Gene Frequency; Genome; Humans; Hypertension; Pharmacogenetics; Phenotype; Polymorphism, Genetic; adducin; adrenergic receptor; alpha 2 adrenergic receptor stimulating agent; angiotensin 2 receptor antagonist; atenolol; benazepril; beta 1 adrenergic receptor blocking agent; beta adducin; beta adrenergic receptor blocking agent; calcium channel blocking agent; candesartan; captopril; catechol methyltransferase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; enalapril; endothelial nitric oxide synthase; fosinopril; guanine nucleotide binding protein; hydralazine; hydrochlorothiazide; imidapril; irbesartan; lisinopril; metoprolol; minoxidil; nifedipine; nitrendipine; perindopril; unclassified drug; unindexed drug; antihypertensive therapy; blood pressure; drug metabolism; gene locus; genetic polymorphism; genetic variability; genome; genotype; haplotype; human; hypertension; pharmacodynamics; pharmacogenetics; priority journal; renin angiotensin aldosterone system; review","","atenolol, 29122-68-7; benazepril, 86541-75-5; candesartan, 139481-59-7; captopril, 62571-86-2; catechol methyltransferase, 9012-25-3; enalapril, 75847-73-3; endothelial nitric oxide synthase, 503473-02-7; fosinopril, 88889-14-9, 98048-97-6; hydralazine, 304-20-1, 86-54-4; hydrochlorothiazide, 58-93-5; imidapril, 89371-37-9, 89396-94-1; irbesartan, 138402-11-6; lisinopril, 76547-98-3, 83915-83-7; metoprolol, 37350-58-6; minoxidil, 38304-91-5; nifedipine, 21829-25-4; nitrendipine, 39562-70-4; perindopril, 82834-16-0; Antihypertensive Agents, ","","","US Public Health Service; National Heart, Lung, and Blood Institute, NHLBI, (R01HL053330); Mayo Foundation for Medical Education and Research, MFMER","This work was supported by grants R01-HL53330 and R01-HL7473 from the US Public Health Service and National Heart, Lung, and Blood Institute, and by funds from the Mayo Foundation. The authors have no conflicts of interest relevant to this review.","Hajjar I., Kotchen T.A., Trends in the prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000, JAMA, 290, pp. 199-206, (2003); Kannel W.B., Blood pressure as a cardiovascular risk factor: Prevention and treatment, JAMA, 275, 20, pp. 1571-1576, (1996); Whelton P.K., He J., Perneger T.V., Et al., Kidney damage in 'benign' essential hypertension, Curr Opin Nephrol Hypertens, 6, 2, pp. 177-183, (1997); Skoog I., Lernfelt B., Landahl S., Et al., 15-Year longitudinal study of blood pressure and dementia, Lancet, 347, 9009, pp. 1141-1145, (1996); Staessen J.A., Wang J.G., Thijs L., Cardiovascular protection and blood pressure reduction: A meta-analysis, Lancet, 358, 9290, pp. 1305-1315, (2001); Turner S.T., Schwartz G.L., Chapman A.B., Et al., Antihypertensive pharmacogenetics: Getting the right drug into the right patient, J Hypertens, 19, pp. 1-11, (2001); Chapman A.B., Schwartz G.L., Boerwinkle E., Et al., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide in African-American an Caucasians with essential hypertension, Kidney Int, 1, 3, pp. 1047-1055, (2002); Guyton A., Hall J., Lohmeier T., Et al., Blood pressure regulation: Basic concepts, Fed Proc, 40, pp. 2252-2256, (1981); Motulsky A., Drug reactions, enzymes and biochemical genetics, JAMA, 165, pp. 835-837, (1957); Vogel F., Moderne prblems der humangenetik, Ergeb Inn Med Kinderheilk, 12, pp. 52-125, (1959); Kaplan N., Treatment of hypertension: Drug therapy, Clinical Hypertension, pp. 181-264, (1998); Israili Z., Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man, Annu Rev Pharmacol Toxicol, 19, pp. 25-52, (1979); Von Bahr C., Collste P., Frisk-Holmberg M., Et al., Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension, Clin Pharmacol Ther, 20, pp. 130-137, (1976); Beermann B., Groschinsky-Grind M., Antihypertensive effect of various doses of hydrochlorothiazide and it relation to the plasma level of the drug, Eur J Clin Pharmacol, 13, pp. 195-201, (1978); Materson B., Reda D., Cushman W., Et al., Single-drug therapy for hypertension in men: A comparision of six antihypertensive agents with placebo, N Engl J Med, 328, pp. 914-921, (1993); Materson B., Reda C., Cushman W., Department of Veterans Affairs single drug therapy of hypertension study: Revised figures and new data, Am J Hypertens, 8, pp. 189-192, (1995); Materson B., Reda D., Preston R., Et al., Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug, Arch Intern Med, 155, pp. 1757-1762, (1995); Hall W., Reed J., Flack J., Et al., Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension, Arch Intern Med, 158, 18, pp. 2029-2034, (1998); Zusman R., Are there differences among angiotensin receptor blockers?, Am J Hypertens, 12, (1999); Burnier M., Brunner H., Comparative antihypertensive effects of angiotensin II receptor antagonists, J Am Soc Nephrol, 10, (1999); Wahl J., Turlapaty P., Bramah N., Et al., Comparison of acebutolol and propranolol in essential hypertension, Am Heart J, 109, pp. 313-321, (1985); Leonetti G., Cuspidi C., Choosing the right ACE inhibitor: A guide to selection, Drugs, 49, pp. 516-535, (1995); Fletcher A., Franks P., Bulpitt C., The effect of withdrawing antihypertensive therapy: A review, J Hypertens, 6, pp. 431-436, (1988); Ekbom T., Lindholm L., Oden A., Et al., A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people, J Intern Med, 235, pp. 581-588, (1994); Kalow W., Pharmacogenetics: Its biologic roots and the medical challenge, Clin Pharmacol Ther, 54, pp. 235-241, (1993); Murphy E., One cause? Many causes? The argument from the bimodal distribution, J Chronic Dis, 17, pp. 301-324, (1964); Shah R., Oates N., Idle J., Et al., Beta-blockers and drug oxidation status, Lancet, 1, pp. 508-509, (1982); Dayer P., Balant L., Kupfer A., Et al., Conbtribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoreceptor blocking agents, Eur J Clin Pharmacol, 24, pp. 797-799, (1983); Shepherd A., McNay J., Ludden T., Et al., Plasma concentration and acetylator phenotype determine response to oral hydralazine, Hypertension, 3, pp. 580-585, (1981); Spielsberg S.P., N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism, J Parmacokinet Biopharm, 24, pp. 509-519, (1996); Campbell N., Dunnette J., Mwaluko G., Et al., Platelet phenol sulfotransferase and erythrocyte catechol-O- methyltransferase activities: Correlation with methyldopa metabolism, Clin Pharmacol Ther, 35, pp. 55-63, (1984); Anderson R.J., Kudlacek P.E., Clemens D.L., Sulfation of minoxidil by multiple human cytosolic sulfotransferases, Chem Biol Interact, 109, pp. 53-67, (1998); Evans W.E., Johnson J.A., Pharmacogenomics: The inherited basis for interindividual differences in drug response, Annu Rev Hum Genet, 2, pp. 9-39, (2001); Hallberg P., Karlsson J., Kurland L., Et al., The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, J Hypertens, 20, pp. 2089-2093, (2002); Sakeda T., Nakamura T., Okumura K., Pharmacokinetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs, Pharmacogenomics, 4, 4, pp. 397-410, (2003); Bianchi G., Swales J., Do we need more anti-hypertensive drugs: Lessons from the new biology, Lancet, 345, pp. 1555-1557, (1995); Ferari P., Pharmacogenomics: A new approach to individual therapy of hypertension?, Curr Opin Nephrol Hypertens, 7, pp. 217-222, (1998); Cusi D., Barlassina C., Azzani T., Et al., Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Glorioso N., Manunta P., Filigheddu F., Et al., The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, 4 PART 1, pp. 649-654, (1999); Sciarrone M.T., Stella P., Barlassina C., Et al., ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, 3, pp. 398-403, (2003); Turner S.T., Chapman A.B., Schwartz G.L., Et al., Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide, Am J Hypertens, 16, pp. 834-839, (2003); Hingorani A.D., Jia H., Stevens P.A., Et al., Renin-angiotensin system gene polymorphisms influence blood pressure and response to angiotensin converting enzyme inhibition, J Hypertens, 13, 12 PART 2, pp. 1602-1609, (1995); Liljedahl U., Karlsson J., Melhus H., Et al., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenetics, 13, 1, pp. 7-17, (2003); Dudley C., Keavney B., Casadei B., Et al., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J Hypertens, 14, 2, pp. 259-262, (1996); Kurland L., Melhus H., Karlsson J., Et al., Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA) Trial, Am J Hypertens, 15, pp. 389-393, (2002); Kurland L., Liljedahl U., Karlsson J., Et al., Angiotensinogen gene polymorphisms: Relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial, Am J Hypertens, 17, 1, pp. 8-13, (2004); Frazier L., Turner S.T., Schwartz G.L., Et al., Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic, Pharmacogenet J, 4, pp. 17-23, (2004); Li X., Du Y., Huang X., Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor, J Cardiovasc Pharmacol Ther, 8, 1, pp. 25-30, (2003); Stavroulakis G.A., Makris T.K., Krespi P.G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc Drugs Ther, 14, 4, pp. 427-432, (2000); Ohmichi N., Iwai N., Uchida Y., Et al., Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype, Am J Hypertens, 10, pp. 951-955, (1997); Kurland L., Melhus H., Karlson J., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, pp. 1783-1787, (2001); Schwartz G.L., Turner S.T., Chapman A.B., Et al., Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide, Kidney Int, 62, pp. 1718-1723, (2002); Sasaki M., Oki T., Luchi A., Et al., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies, J Hypertens, 14, 12, pp. 1403-1408, (1996); Moriyama T., Kitamura H., Ochi S., Et al., Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria, J Am Soc Nephrol, 6, pp. 1674-1678, (1995); Nakano Y., Oshima T., Watanabe M., Et al., Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension, Am J Hypertens, 10, pp. 1064-1068, (1997); Benetos A., Cambien F., Gautier S., Et al., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, pp. 1081-1084, (1996); Ortlepp J.R., Hanrath P., Mevissen V., Et al., Variants of the CYP11B2 gene predict response to therapy with candesartan, Eur J Pharmacol, 445, pp. 151-152, (2002); Haiyan J., Hingorani A.D., Pankaj S., Et al., Association of the G<sub>s</sub> alpha gene with essential hypertension and response to beta-blockade, Hypertension, 34, 1, pp. 8-14, (1999); Turner S.T., Schwartz G.L., Chapman A.B., Et al., C825T polymorphism of the G protein beta (3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Nurnberger J., Dammer S., Mitchell A., Et al., Effect of the C825T polymorphism of the G protein β3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects, Clin Pharmacol Ther, 74, pp. 53-60, (2003); Johnson J.A., Zineh I., Puckett B.J., Et al., β<sub>1</sub>-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin Pharmacol Ther, 74, pp. 44-52, (2003); O'Shaughnessy K.M., Fu B., Dickerson C., Et al., The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure of heart rate response to beta-blockade in hypertensive subjects, Clin Sci (Lond), 99, 3, pp. 233-238, (2000); Jia H., Sharma P., Hooper R., Et al., β<sub>2</sub>-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians, J Hypertens, 18, 6, pp. 687-693, (2000); Manunta P., Burnier M., D'Amico M., Et al., Adducin polymorphism affects renal proximal tubule reabsorption in hypertension, Hypertension, 33, pp. 694-697, (1999); Grant F.D., Romero J.R., Jeunemaitre X., Et al., Low-renin hypertension, altered sodium homeostasis, and an α-adducin polymorphism, Hypertension, 39, pp. 191-196, (2002); Schunkert H., Hense H.W., Doring A., Et al., Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels, Hypertension, 32, pp. 510-513, (1998); Siffert W., Rosskopf D., Moritz A., Et al., Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension, J Clin Invest, 96, pp. 759-766, (1995); Virchow S., Ansorge N., Rubben H., Et al., Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein beta3 subunit 825 T-allele, FEBS Lett, 436, pp. 155-158, (1998); Mason D.A., Moore J.D., Green S.A., Et al., A gain-of-function polymorphism in a G-protein coupling domain of the human β<sub>1</sub>-adrenergic receptor, Biol Chem, 274, pp. 12670-12674, (1999); Rathz D.A., Brown K.M., Kramer L.A., Et al., Amino acid 49 polymorphisms of the human β<sub>1</sub>-adrenergic receptor affect agnoist-promoted trafficking, J Cardiovasc Pharmacol, 39, pp. 155-160, (2002); Levin M.C., Marullo S., Muntaner O., Et al., The myocardium-protective Gly-49 variant of the β<sub>1</sub>- adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation, J Biol Chem, 277, 34, pp. 30429-30435, (2002); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Rigat B., Hubert C., Alhenic-Gelas F., Et al., An insertion/deletion polymorphism in the angitoensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Macmahon S., Blood pressure and the risk of cardiovascular disease, N Engl J Med, 342, pp. 50-52, (2000); Stamler J., Stamler R., Neaton J.D., Blood pressure, systolic and diastolic, and cardiovascular risks: US population data, Arch Intern Med, 153, pp. 590-615, (1993); Brass L.W., Alberts M.J., Genetic epidemiology and family studies of stroke, Genetics of Cerebrovascular Disease, pp. 159-182, (1999); Peyser P.A., Genetic epidemiology of coronary artery disease, Epidemiol Rev, 19, pp. 80-90, (1997); Fredman B.I., Satko S.G., Genes and renal disease, Curr Opin Nephrol Hypertens, 9, pp. 273-277, (2000); Psaty B.M., Smith N.L., Heckert S.R., Et al., Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction and stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Vincent M., Samani N.J., Gauguier D., Et al., A pharmacogenetic approach to blood pressure in Lyon hypertensive rats: A chromosome 2 locus influences the response to a calcium antagonist, J Clin Invest, 100, pp. 2000-2006, (1997); Kruglyak L., The use of a genetic map of biallelic markers in linkage studies, Nat Genet, 17, pp. 21-24, (1997); Sachidanandam R., Weissman D., Schmidt S.C., Et al., A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409, pp. 928-933, (2001); Olivier M., A haplotype map of the human genome, Physiol Genomics, 13, pp. 3-9, (2003); Nelson M.R., Kardia S.L., Ferrell R.E., Et al., A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation, Genome Res, 11, pp. 458-470, (2001); Sing C.F., Stengard J.H., Kardia S.L.R., Genes, environment, and cardiovascular disease, Arterioscler Thromb Vasc Biol, 23, 7, pp. 1190-1196, (2003)","G.L. Schwartz; Division of Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First Street SW, United States; email: gschwartz@mayo.edu","","","","","","","","11752203","","AJPMC","15174896","English","Am. J. PharmacoGenomics","Review","Final","","Scopus","2-s2.0-3042710748"
"Turnes J.; Bosch J.","Turnes, Juan (6507462371); Bosch, Jaime (7402325515)","6507462371; 7402325515","Influence of genetic polymorphisms in the therapeutic response to beta blockers; [Influencia de los polimorfismos genéticos en la respuesta terapéutica a los bloqueadores beta]","2007","Gastroenterologia y Hepatologia Continuada","6","4","","180","183","3","0","10.1016/S1578-1550(07)75674-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-68149179811&doi=10.1016%2fS1578-1550%2807%2975674-7&partnerID=40&md5=e6707c5b9b0642d9646ab4623268d10f","Laboratorio de Hemodinámica Hepática, Instituto de Enfermedades Digestivas y Metabólicas, Hospital Clínic, Barcelona, Spain","Turnes J., Laboratorio de Hemodinámica Hepática, Instituto de Enfermedades Digestivas y Metabólicas, Hospital Clínic, Barcelona, Spain; Bosch J., Laboratorio de Hemodinámica Hepática, Instituto de Enfermedades Digestivas y Metabólicas, Hospital Clínic, Barcelona, Spain","[No abstract available]","","alpha 1 adrenergic receptor stimulating agent; angiotensin II; arginine; beta 2 adrenergic receptor; carvedilol; catecholamine; glutamic acid; glutamine; glycine; isoprenaline; leukotriene; nitric acid derivative; prazosin; propranolol; blood vessel tone; bronchus tone; codon; esophagus varices; gene expression regulation; genetic polymorphism; haplotype; heart function; heart index; heart rate; hemodynamics; heterozygote; human; liver cirrhosis; membrane potential; portal hypertension; pressure gradient; short survey; signal transduction; single nucleotide polymorphism; systemic vascular resistance; treatment response","","angiotensin II, 11128-99-7, 68521-88-0; arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3; carvedilol, 72956-09-3; glutamic acid, 11070-68-1, 138-15-8, 56-86-0, 6899-05-4; glutamine, 56-85-9, 6899-04-3; glycine, 56-40-6, 6000-43-7, 6000-44-8; isoprenaline, 299-95-6, 51-30-9, 6700-39-6, 7683-59-2; prazosin, 19216-56-9, 19237-84-4; propranolol, 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6","","","","","Feu F., Bordas J.M., Garcia-Pagan J.C., Bosch J., Rodes J., Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension, Hepatology, 13, pp. 917-922, (1991); Abraldes J.G., Tarantino I., Turnes J., Garcia-Pagan J.C., Rodes J., Bosch J., Hemodynamic response to pharmacological treatment of portal hypertension and longterm prognosis of cirrhosis, Hepatology, 37, pp. 902-908, (2003); Escorsell A., Bordas J.M., Castaneda B., Llach J., Garcia-Pagan J.C., Rodes J., Et al., Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension, Hepatology, 31, pp. 1061-1067, (2000); Feu F., Garcia-Pagan J.C., Bosch J., Luca A., Teres J., Escorsell A., Et al., Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis, Lancet., 346, pp. 1056-1059, (1995); Groszmann R.J., Bosch J., Grace N.D., Conn H.O., Garcia-Tsao G., Navasa M., Et al., Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage, Gastroenterology, 99, pp. 1401-1407, (1990); Merkel C., Bolognesi M., Sacerdoti D., Bombonato G., Bellini B., Bighin R., Et al., The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis, Hepatology., 32, pp. 930-934, (2000); Turnes J., Garcia-Pagan J.C., Abraldes J.G., Hernandez-Guerra M., Dell'Era A., Bosch J., Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis, Am J Gastroenterol, 101, pp. 506-512, (2006); Banares R., Moitinho E., Matilla A., Garcia-Pagan J.C., Lampreave J.L., Piera C., Et al., Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis, Hepatology., 36, pp. 1367-1373, (2002); Bureau C., Peron J.M., Alric L., Morales J., Sanchez J., Barange K., Et al., A La Carte"" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding, Hepatology, 36, pp. 1361-1366, (2002); Garcia-Pagan J.C., Navasa M., Rivera F., Bosch J., Rodes J., Lymphocyte beta 2- adrenoceptors and plasma catecholamines in patients with cirrhosis, Gastroenterology, 102, pp. 2015-2023, (1992); Garovic V.D., Joyner M.J., Dietz N.M., Boerwinkle E., Turner S.T., Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans, J Physiol., 546, pp. 583-589, (2003); Drysdale C.M., Mcgraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K., Et al., Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness, Proc Natl Acad Sci USA, 97, pp. 10483-10488, (2000); Srael E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M., Et al., The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma, Am J Respir Crit Care Med., 162, pp. 75-80, (2000); Taylor D.R., Drazen J.M., Herbison G.P., Yandava C.N., Hancox R.J., Town G.I., Asthma exacerbations during long term beta agonist use: Influence of beta(2) adrenoceptor polymorphism, Thorax., 55, pp. 762-767, (2000); Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniack R., Craig T.J., Et al., Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial, Lancet., 364, pp. 1505-1512, (2004); Turnes J., Hernandez-Guerra M., Ratti L., Dell'Era A., Oliva R., Garcia-Pagan J.C., Et al., Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis, Hepatology, 38, 56 A, (2004); Turnes J., Hernandez-Guerra M., Abraldes J.G., Bellot P., Oliva R., Garcia-Pagan J.C., Et al., Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis, Hepatology, 43, pp. 34-41, (2006); Marteau P., Ballet F., Chazouilleres O., Chretien Y., Rey C., Petit D., Poupon R., Effect of vasodilators on hepatic microcirculation in cirrhosis: A study in the isolated perfused rat liver, Hepatology, 9, 6, pp. 820-823, (1989); Oben J.A., Roskams T., Yang S., Lin H., Sinelli N., Torbenson M., Et al., Hepatic fibrogenesis requires sympathetic neurotransmitters, Gut., 53, pp. 438-445, (2004); Garcia-Pagan J.C., Feu F., Bosch J., Rodes J., Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study, Ann Intern Med., 114, pp. 869-873, (1991); Albillos A., Lledo J.L., Rossi I., Perez-Paramo M., Tabuenca M.J., Banares R., Et al., Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function, Gastroenterology, 109, pp. 1257-1265, (1995)","","","Ediciones Doyma, S.L.","","","","","","15781550","","","","Spanish","Gastroenterol. Hepatol. Continuada","Short survey","Final","","Scopus","2-s2.0-68149179811"
"Bis J.C.; Smith N.L.; Psaty B.M.; Heckbert S.R.; Edwards K.L.; Lemaitre R.N.; Lumley T.; Rosendaal F.R.","Bis, Joshua C. (6603292486); Smith, Nicholas L. (7403173535); Psaty, Bruce M. (35374213400); Heckbert, Susan R. (7005828089); Edwards, Karen L. (35413422200); Lemaitre, Rozenn N. (7007028100); Lumley, Thomas (7003921176); Rosendaal, Frits R. (7004174530)","6603292486; 7403173535; 35374213400; 7005828089; 35413422200; 7007028100; 7003921176; 7004174530","Angiotensinogen Met235Thr Polymorphism, Angiotensin-Converting Enzyme Inhibitor Therapy, and the Risk of Nonfatal Stroke or Myocardial Infarction in Hypertensive Patients","2003","American Journal of Hypertension","16","12","","1011","1017","6","54","10.1016/j.amjhyper.2003.07.018","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0345490825&doi=10.1016%2fj.amjhyper.2003.07.018&partnerID=40&md5=7e52acd3672dab046c96cc962288b789","Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States; Department of Epidemiology, University of Washington, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States; Department of Biostatistics, University Of Washington, Seattle, WA, United States; Department of Health Services, Institute for Public Health Genetics, University of Washington, Seattle, WA, United States; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands; Cardiovascular Health Research Unit, Seattle, WA 98101, 1730 Minor Avenue, United States","Bis J.C., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States, Cardiovascular Health Research Unit, Seattle, WA 98101, 1730 Minor Avenue, United States; Smith N.L., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States; Psaty B.M., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States; Heckbert S.R., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States; Edwards K.L., Department of Epidemiology, University of Washington, Seattle, WA, United States, Department of Health Services, Institute for Public Health Genetics, University of Washington, Seattle, WA, United States; Lemaitre R.N., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Medicine, University of Washington, Seattle, WA, United States; Lumley T., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Biostatistics, University Of Washington, Seattle, WA, United States; Rosendaal F.R., Cardiovascular Health Research Unit, University of Washington, Seattle, WA, United States, Department of Epidemiology, University of Washington, Seattle, WA, United States, Department of Medicine, University of Washington, Seattle, WA, United States, Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands","Background: The ThrThr genotype of the angiotensinogen (AGT) Met235Thr polymorphism has been associated with elevated AGT levels, hypertension, increased heart disease risk, and improved blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitors. We hypothesized that risk of stroke or myocardial infarction (MI) associated with ACE inhibitor use varies by AGT genotype, with a larger protective effect of ACE inhibitors in individuals with the ThrThr genotype than individuals who are carriers of the Met allele. Methods: We conducted a population-based case-control study. Participants were health maintenance organization members aged 30 to 79 years with treated hypertension. Those who survived incident stroke (n = 116) or MI (n = 208) during the study period were designated as cases. Control subjects (n = 717) were randomly sampled and frequency-matched to MI cases on age, sex, and calendar year. Health history, medication use, and AGT genotype were assessed. Results: ThrThr genotype was present in 21% of stroke cases, 26% of MI cases, and 19% of control subjects. Compared with nonuse, ACE inhibitor use was associated with lower stroke risk among Thr homozygotes (odds ratio [OR] = 0.37, 95% CI = 0.14 to 0.99) than among Met carriers (OR = 1.4, 95% CI = 0.88 to 2. 4; P for interaction = .02). Compared with nonuse, ACE inhibitor use was associated with similar MI risk among Thr homozygotes (OR = 0.90, 95% CI = 0.62 to 1.3) and among Met carriers (OR = 1.2, 95% CI = 0.60 to 2.5; P for interaction = 0.5). Conclusions: In this hypertensive population, the association of ACE inhibitor use with risk of nonfatal stroke varied by genotype. The protective association between ACE inhibitor use and nonfatal stroke risk among individuals with ThrThr genotype was not observed for nonfatal MI. © 2003 American Journal of Hypertension, Ltd.","Angiotensin-converting enzyme inhibitors; Angiotensinogen; Antihypertensive drugs; Myocardial infarction; Single nucleotide polymorphism; Stroke","angiotensin receptor antagonist; angiotensinogen; antidiabetic agent; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; loop diuretic agent; methionine; thiazide diuretic agent; threonine; vasodilator agent; adult; age; aged; anamnesis; antihypertensive therapy; article; blood pressure; cardiovascular risk; case control study; controlled study; diabetes mellitus; disease association; fatality; female; gene frequency; genotype; genotype environment interaction; health maintenance organization; heart infarction; heart protection; heterozygote; homozygote; human; human cell; hypertension; major clinical study; male; population research; priority journal; randomization; sex; single nucleotide polymorphism; stroke; survival","","angiotensinogen, 11002-13-4, 64315-16-8; methionine, 59-51-8, 63-68-3, 7005-18-7; threonine, 36676-50-3, 72-19-5","","","National Institutes of Health, NIH; National Heart, Lung, and Blood Institute, NHLBI, (T32HL007902)","This research was supported in part by the Cardiovascular Epidemiology Training Program (1 T32 HL07902) and by grants HL43201, HL68639, and HL60739 from the National Heart, Lung, and Blood Institute, National Institutes of Health. ","Hall J., Guyton A., Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin angiotensin system, Hypertension: Pathophysiology, Diagnosis and Management, pp. 1105-1129, (1990); Clauser E., Gaillard I., Wei L., Corvol P., Regulation of angiotensinogen gene, Am J Hypertens, 2, pp. 403-410, (1989); Sealey J., Laragh J., The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis, Hypertension: Pathophysiology, Diagnosis and Management, pp. 1287-1317, (1990); Lifton R.P., Molecular genetics of human blood pressure variation, Science, 272, pp. 676-680, (1996); Fukamizu A., Takahashi S., Seo M.S., Tada M., Tanimoto K., Uehara S., Murakami K., Structure and expression of the human angiotensinogen gene. Identification of a unique and highly active promoter, J Biol Chem, 265, pp. 7576-7582, (1990); Gaillard I., Clauser E., Corvol P., Structure of human angiotensinogen gene, DNA, 8, pp. 87-99, (1989); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.M., Corvol P., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Caulfield M., Lavender P., Farrall M., Munroe P., Lawson M., Turner P., Clark A.J., Linkage of the angiotensinogen gene to essential hypertension, N Engl J Med, 330, pp. 1629-1633, (1994); Staessen J.A., Kuznetsova T., Wang J.G., Emelianov D., Vlietinck R., Fagard R., M235T angiotensinogen gene polymorphism and cardiovascular renal risk, J Hypertens, 17, pp. 9-17, (1999); Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, pp. 1602-1609, (1995); Svetkey L.P., Moore T.J., Simons-Morton D.G., Appel L.J., Bray G.A., Sacks F.M., Ard J.D., Mortensen R.M., Mitchell S.R., Conlin P.R., Kesari M., Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study, J Hypertens, 19, pp. 1949-1956, (2001); Hunt S.C., Cook N.R., Oberman A., Cutler J.A., Hennekens C.H., Allender P.S., Walker W.G., Whelton P.K., Williams R.R., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II, Hypertension, 32, pp. 393-401, (1998); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P., Siscovick D.S., Bis J., Lumley T., Longstreth Jr. W.T., Rosendaal F.R., Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Ives D.G., Fitzpatrick A.L., Bild D.E., Psaty B.M., Kuller L.H., Crowley P.M., Cruise R.G., Theroux S., Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study, Ann Epidemiol, 5, pp. 278-285, (1995); Price T.R., Psaty B., O'Leary D., Burke G., Gardin J., Assessment of cerebrovascular disease in the Cardiovascular Health Study, Ann Epidemiol, 3, pp. 504-507, (1993); Miller S.A., Dykes D.D., Polesky H.F., A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res, 16, (1988); Stata Statistical Software, Release 7.0, (2001); Cleves M., Hardy-Weinberg equilibrium test & allele frequency estimation, Stata Tech Bull Repr, 8, pp. 280-284, (1999); Smith P.G., Day N.E., The design of case-control studies: The influence of confounding and interaction effects, Int J Epidemiol, 13, pp. 356-365, (1984); Khoury M.J., Flanders W.D., Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: Case-control studies with no controls!, Am J Epidemiol, 144, pp. 207-213, (1996); Winkelmann B.R., Russ A.P., Nauck M., Klein B., Bohm B.O., Maier V., Zotz R., Matheis G., Wolf A., Wieland H., Gross W., Galton D.J., Marz W., Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease, Am Heart J, 137, pp. 698-705, (1999); Rodriguez-Perez J.C., Rodriguez-Esparragon F., Hernandez-Perera O., Anabitarte A., Losada A., Medina A., Hernandez E., Fiuza D., Avalos O., Yunis C., Ferrario C.M., Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: The PROCAGENE study. Prospective Cardiac Gene, J Am Coll Cardiol, 37, pp. 1536-1542, (2001); Katsuya T., Koike G., Yee T.W., Sharpe N., Jackson R., Norton R., Horiuchi M., Pratt R.E., Dzau V.J., MacMahon S., Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease, Lancet, 345, pp. 1600-1603, (1995); Ludwig E.H., Borecki I.B., Ellison R.C., Folsom A.R., Heiss G., Higgins M., Lalouel J.M., Province M.A., Rao D.C., Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: The NHLBI Family Heart Study, Ann Epidemiol, 7, pp. 3-12, (1997); Tiret L., Ricard S., Poirier O., Arveiler D., Cambou J.P., Luc G., Evans A., Nicaud V., Cambien F., Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction: The ECTIM Study, J Hypertens, 13, pp. 311-317, (1995); Ko Y.L., Ko Y.S., Wang S.M., Chu P.H., Teng M.S., Cheng N.J., Chen W.J., Hsu T.S., Kuo C.T., Chiang C.W., Lee Y.S., Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese, Hum Genet, 100, pp. 210-214, (1997); Sethi A.A., Tybjaerg-Hansen A., Gronholdt M.L., Steffensen R., Schnohr P., Nordestgaard B.G., Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study, Ann Intern Med, 134, pp. 941-954, (2001); Jeunemaitre X., Inoue I., Williams C., Charru A., Tichet J., Powers M., Sharma A.M., Gimenez-Roqueplo A.P., Hata A., Corvol P., Lalouel J.M., Haplotypes of angiotensinogen in essential hypertension, Am J Hum Genet, 60, pp. 1448-1460, (1997)","J.C. Bis; Cardiovascular Health Research Unit, Seattle, WA 98101, 1730 Minor Avenue, United States; email: joshbis@u.washington.edu","","Elsevier Inc.","","","","","","08957061","","AJHYE","14643574","English","Am. J. Hypertens.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0345490825"
"Winkelmann B.R.; März W.; Boehm B.O.; Zotz R.; Hager J.; Hellstern P.; Senges J.","Winkelmann, Bernhard R. (7006382883); März, Winfried (57220877383); Boehm, Bernhard O. (14624780200); Zotz, Rainer (7006025550); Hager, Jörg (7101717828); Hellstern, Peter (7005442447); Senges, Jochen (7103265432)","7006382883; 57220877383; 14624780200; 7006025550; 7101717828; 7005442447; 7103265432","Rationale and design of the LURIC study - A resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease","2001","Pharmacogenomics","2","1 SUPPL. 1","","S7","S38","31","313","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034937299&partnerID=40&md5=a3fd377758e89d71782e846ef6ff0211","Ludwigshafen Heart Centre, Ludwigshafen, D-67063, Bremser Str. 79, Germany; Abteilung Klinische Chemie, Medizinische Universitätsklinik und Poliklinik, 79105, Freiburg, Hugstetter Str. 55, Germany","Winkelmann B.R., Ludwigshafen Heart Centre, Ludwigshafen, D-67063, Bremser Str. 79, Germany; März W., Abteilung Klinische Chemie, Medizinische Universitätsklinik und Poliklinik, 79105, Freiburg, Hugstetter Str. 55, Germany; Boehm B.O.; Zotz R.; Hager J.; Hellstern P.; Senges J.","Background and aim. Coronary artery disease (CAD), arterial hypertension and Type 2 diabetes mellitus are common polygenetic disorders which have a major impact on public health. Disease prevalence and progression to cardiovascular complications, such as myocardial infarction (MI), stroke or heart failure, are the product of environment and gene interaction. The LUdwigshafen RIsk and Cardiovascular Health (LURIC) study aims to provide a well-defined resource for the study of environmental and genetic risk factors, and their interactions, and the study of functional relationships between gene variation and biochemical phenotype (functional genomics) or response to medication (pharmacogenomics). Long-term follow-up on clinical events will allow us to study the prognostic importance of common genetic variants (polymorphisms) and plasma biomakers. Setting. Cardiology unit in tertiary care medical centre in south-west Germany. Study design. Prospective cohort study of individuals with and without cardiovascular disease at baseline. Patients and methods. LURIC is an ongoing prospective study of currently > 3300 individuals in whom the cardiovascular and metabolic phenotypes CAD, MI, dyslipidaemia, hypertension, metabolic syndrome and diabetes mellitus have been defined or ruled out using standardised methodologies in all study participants. Inclusion criteria for LURIC were: • German ancestry (limitation of genetic heterogneity) • clinical stability (except for acute coronary syndromes [ACSs]) • availability of a coronary angiogram (this inclusion criterium was waived for family members provided that they met all other inclusion and exclusion criteria) • any acute illness other than ACSs • any chronic disease where non-cardiac disease predominated • a history of malignancy within the past five years Exclusion criteria were pre-specified in order minimise the impact of concomitant non-cardiovascular disease on intermediate biochemical phenotypes or on clinical prognosis (limitation of clinical heterogeneity). A standardised personal and family history questionnaire and an extensive laboratory work-up (including glucose tolerance testing in non-diabetics and objective assessment of smoking exposure by determination of cotinine plasma levels) was obtained from all individuals after informed consent. A total of 115 ml of fasting venous blood was sampled for the determination of a pre-specified wide range of intermediate biochemical phenotypes in serum, plasma or whole blood, for leukocyte DNA extraction and immortalisation of B-lymphocytes. Biochemical phenotypes measured included markers of endothelial dysfunction, inflammation, oxidative status, coagulation, lipid metabolism and flow cytometric surface receptor expression of lympho-, mono- and thrombocytes. In addition, multiple aliquots of blood samples were stores for future analyses. Results. A total of 3500 LURIC baseline measurements were performed in 3316 individuals between July 1997 and January 2000. The baseline examination was repeated within a median of 35 days in 5% of study participants (n = 166, including a third examination in 18 after a median of 69 days) for pharmacogenomic assessment of lipid-lowering therapy and for quality control purposes. A five-year follow-up on major clinical events (death, any cardiovascular event including MI, stroke and revascularisation, malignancy and any hospitalisation) is ongoing. The clinical phenotypes prevalent at baseline in the cohort of 2309 men (70%) with a mean age of 62 ± 11 years and 1007 women (30%), mean age 65 ± 10 years, were angiographically-documented CAD in 2567 (79%), MI in 1368 (41%), dyslipidaemia in 2050 (62%) with hypercholesterolaemia ≥ 240 mg/dl (27%), hypertriglyceridaemia ≥ 150 mg/dl (44%) and HDL-cholesterol ≤ 35 mg/dl (38%) in individuals not treated with lipid-lowering agents, systemic hypertension in 1921 (58%), metabolic syndrome in 1591 (48%), Type 2 diabetes in 1063 (32%) and obesity defined by body mass index ≥ 30 kg/m2 in 770 (23%). Control patients in whom CAD had been ruled out angiographically were five years younger than those with CAD (59 ± 12 and 64 ± 10 years, respectively; p < 0.001), twice as often females (48% compared to 25% females in the CAD group, p < 0.001) and had significantly less cardiovascular risk factors than individuals with CAD. The prevalence of specific cardiovascular risk subsets in LURIC, such as the elderly (≥ 75 years), was 375 (11%), while 213 (6%) were young adults (≤ 45 years) and 904 (27%) were postmenopausal women (90% of all females). A low risk status (≤ 1 out of the four traditional risk factors: dyslipidaemia, smoking, hypertension and diabetes mellitus) was identified in 314 (9%) individuals of the entire cohort (5% in CAD and 26% in controls, p < 0.001) and 97 (3%) carried none of the four risk factors (1% in CAD and 9% in controls, p < 0.001). A total of 35 aliquots (serum, plasma and red blood cells) were kept for long-term storage and future analyses at -80°C. Multiple stocks of whole blood and extracted DNA are available for ongoing and future genomic studies, including aliquots of B-cells frozen in liquid nitrogen for transmission into lymphoblastoid cell lines. All phenotypic data are stored in a database currently carrying 1710 variables or each individual. Conclusions. LURIC is a study to contribute to the identification and assessment of environmental and genetic factors for atherosclerosis and related metabolic diseases. Major efforts have been undertaken to establish reliable phenotypes for the cardiovascular and metabolic diseases CAD/MI, hypertension and diabetes mellitus. Phenotypic characterisation included a standardised clinical and an extensive laboratory work-up. DNA and plasma aliquots were stored for future use. Furthermore, immortalised cell lines offer a renewable source of DNA. The LURIC database and tissue bank is a resource to elucidate functional relationships between genetic variation and biochemical phenotype (functional genomics), to study genetically modified responses to medication (pharmacogenomics) and to study the prognostic importance of biomakers of cardiovascular and metabolic disease.","Cardiogenomics; Cardiovascular risk factor; Functional genomics; Genetic risk; Pharmacogenomics","Cardiovascular Diseases; Genome, Human; Humans; Pharmacogenetics; Prognosis; Research Design; Digitalis; angiotensin 1 receptor antagonist; antilipemic agent; antithrombocytic agent; apolipoprotein; beta adrenergic receptor blocking agent; biological marker; C reactive protein; calcium channel blocking agent; cell surface receptor; cotinine; creatine kinase; digitalis; dipeptidyl carboxypeptidase inhibitor; diuretic agent; DNA; fatty acid; glucose; glycerol; glycosylated hemoglobin; hemoglobin A1c; high density lipoprotein cholesterol; insulin; low density lipoprotein cholesterol; nucleotide; oral antidiabetic agent; phospholipid; triacylglycerol; troponin T; unindexed drug; very low density lipoprotein; adult; aged; anamnesis; angiocardiography; article; atherosclerosis; B lymphocyte; body mass; cardiovascular disease; cardiovascular risk; cell immortalization; clinical research; cohort analysis; controlled study; coronary artery disease; death; dyslipidemia; endothelium cell; environmental factor; exposure; extraction; female; flow cytometry; follow up; genetic disorder; genetic risk; genetic variability; Germany; glucose tolerance test; heart failure; heart infarction; hospitalization; human; human cell; hypercholesterolemia; hypertension; hypertriglyceridemia; inflammation; informed consent; leukocyte; lipid metabolism; lymphocyte; major clinical study; male; malignant neoplastic disease; metabolic disorder; metabolism; monocyte; non insulin dependent diabetes mellitus; obesity; oxidative stress; patient selection; pharmacogenomics; phenotype; postmenopause; prevalence; prognosis; prospective study; protein expression; public health; quality control; questionnaire; smoking; stroke; thrombocyte; cardiovascular disease; classification; genetics; genome; methodology; pharmacogenetics; review","","","","","","","Vogel R.A., Berger H., Epidemiology and prevention of coronary heart disease; Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arweiler D., Rajakangas A.-M., Pajak A., Myocardial infarction and coronary deaths in the World Health Organization MONICA Project - Registration procedures, event rates and case-fatality rates in 38 populations from 21 countries in four continents, Circulation, 90, pp. 583-612, (1994); Myocardial infarction community registers. Results of a WHO international collaborative study coordinated by the regional office for Europe, (1977); Medalie J.H., Goldbourt U., Unrecognized myocardial infarction: Five-year incidence, mortality and risk factors, Ann. Intern. Med., 84, pp. 526-531, (1976); Jonsdottir L.S., Sigfusson N., Sigvaldason H., Thorgeirsson G., Incidence and prevalence of recognised and unrecognised myocardial infarction in women, Eur. Heart J., 19, pp. 1011-1018, (1998); Sheifer S.E., Gersh B.J., Yanez D., Ades P.A., Burke G.L., Manolio T.A., Prevalence, predisposing factors and prognosis of unrecognized myocardial infarction in the elderly, J. Am. Coll. Cardiol., 35, pp. 119-126, (2000); Kannel W.B., Dannenberg A.L., Abbott R.D., Unrecognized myocardial infarction and hypertension: The Framingham Study, Am. Heart J., 109, pp. 581-585, (1985); (1970); Fleiss J.L., Tytun A., Ury H.K., A simple approximation for calculating sample sizes for comparing independent proportions, Biometrics, 36, pp. 343-346, (1980); Campbell M.J., Julious S.A., Altman D.G., Estimating sample sizes for binary, ordered categorical and continuous outcomes in two group comparisons, Br. Med. J., 311, pp. 1145-1148, (1995); Woodward M., Formulae for sample size, power and minimum detectable relative risk in medical studies, The Statistician, 41, pp. 185-196, (1992); Yang Q., Khoury M.J., Flanders W.D., Sample size requirements in case-only designs to detect gene-environment interactions, Am. J. Epidemiol., 146, pp. 713-720, (1997); Tukey J.W., Some thoughts on clinical trials, especially problems of multiplicity, Science, 198, pp. 679-684, (1977); Cupples L.A., Heeren T., Schatzkin A., Colton T., Multiple testing of hypotheses in comparing two groups, Ann. Intern. Med., 100, pp. 122-129, (1984); Braunwald E., Unstable angina - A classification, Circulation, 80, pp. 410-414, (1989); Austen W.G., Edwards J.E., Frye R.L., Et al., A reporting system on patients evaluated for coronary artery disease, Circulation, 50, SUPPL. 5, pp. 7-40, (1975); Little W.C., Downes T.R., Applegate R.J., The underlying coronary lesion in myocardial infarction: Implications for coronary angiography, Clin. Cardiol., 14, pp. 868-874, (1991); Papanicolaou M.N., Califf R.M., Hlatky M.A., Et al., Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries, Am. J. Cardiol., 58, pp. 1181-1187, (1986); Campeau L., Grading of angina pectoris, Circulation, 54, pp. 522-523, (1975); Braunwald E., (1994); Hamm C.W., Braunwald E., A classification of unstable angina revisited, Circulation, 102, pp. 118-122, (2000); Eur. Heart J., 21, pp. 1502-1513, (2000); Selvester R.H., Wagner G.S., Hindman N.B., The Selvester QRS scoring system for estimating infarct size: The development and application of the system, Arch. Intern. Med., 145, pp. 1877-1881, (1985); Phibbs B., Marcus F., Marriott H.J.C., Moss A., Spodick D.H., Q-wave versus non-Q-wave myocardial infarction: A meaningless distinction, J. Am. Coll. Cardiol., 33, pp. 576-582, (1999); Bertrand M.E., Simoons M.L., Fox K.A.A., Et al., Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation, Eur. Heart J., 21, pp. 1406-1432, (2000); White H.D., Simes J., Anderson N.E., Et al., Pravastatin therapy and the risk of stroke, N. Engl. J. Med., 343, pp. 317-326, (2000); Nomenclature and Criteria for Diseases of the Heart and Great Vessels, (1964); 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart, Circulation, 90, pp. 644-645, (1994); Diab. Care., 20, pp. 1183-1197, (1997); (1985); Albert K.G.M.M., Zimmet P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation, Diabetic Med., 15, pp. 539-553, (1998); (1980); Merz C.N.B., Kelsey S.F., Pepine C.F., Et al., J. Am. Coll. Cardiol., 33, pp. 1453-1461, (1999); Hopkins P.N., Williams R.R., A survey of 246 suggested coronary risk factors, Atherosclerosis, 40, pp. 1-52, (1981); Circulation, 89, pp. 1329-1445, (1994); pp. 75-628, (1974); Wanner C., Horl W.H., Luley C., Wieland H., Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis, Kidney Int., 39, pp. 754-759, (1991); Luley C., Baumstark M.W., Wieland H., Rapid apolipoprotein E phenotyping by immunofixation in agarose, J. Lipid Res., 5, pp. 880-883, (1991); Luley C.H., Haas B., Buhrer B., Wieland H., Improvement of apolipoprotein E phenotyping by isoelectric focussing/immunofixation, Clin. Chem, 38, (1992); pp. 38-43, (2000); Tohda H., Oikawa A., Kudo T., Tachibana T., A greatly simplified method of establishing B-lymphoblastoid cell lines, Cancer Res., 38, pp. 3560-3562, (1978); Wall F.E., Henkel R.D., Stern M.P., Jenson H.B., Moyer M.P., An efficient method for routine Epstein-Barr virus immortaliztion of human B lymphocytes, In Vitro Cell Dev. Biol. Anim, 31, pp. 156-159, (1995); Reinsmoen N.L., Histocompatibility testing by immunologic methods: Cellular assays, Manual of Clinical Laboratory Immunology, pp. 1080-1086, (1997); A desktop guide to Type 2 diabetes mellitus, Diab Med., 16, pp. 716-730, (1999); Kannel W.B., Dawber T.R., Kagan A., Revotskie N., Stokes J., Factors of risk in the development of coronary heart disease - Six-year follow-up experience. The Framingham Study, Ann. Intern. Med., 55, pp. 33-50, (1961); Sytkowski P.A., D'Agostino R.B., Belanger A., Kannel W.B., Sex and time trends in cardiovascular disease incidence and mortality: The Framingham Heart Study, 1950-1989, Am. J. Epidemiol., 143, pp. 338-350, (1996); Assmann G., Schulte H., Von Eckardstein A., Huang Y., High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The Procam experience and pathophysiological implications for reverse cholesterol transport, Altherosclerosis, 124, SUPPL., (1996); Assmann G., Schulte H., Identification of individuals at high risk for myocardial infarction, Atherosclerosis, 110, SUPPL., (1994); Lusis A.J., Atherosclerosis, Nature, 407, pp. 233-239, (2000); Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular in high-risk patiens, N. Engl. J. Med., 342, pp. 145-153, (2000); Canto J.G., Shilipak M.G., Rogers W.J., Et al., One-third of MI patients present to hospital without chest pain and are at increased risk for in-hospital mortality, Jama, 283, pp. 3223-3229, (2000); Harris M.I., Klein R., Welborn T.A., Knuiman M.W., Onset of Niddm occurs at least 4-7 yr before clinical diagnosis, Diab. Care, 15, pp. 815-819, (1992); Harris M.I., Hadden W.C., Knowler W.C., Benett P.H., Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr, Diabetes, 36, pp. 523-534, (1987); Winkelmann B.R., Hager J., Genetic variation in coronary heart disease and myocardial infarction; methodological overview and clinical evidence, Pharmacogenomics, 1, pp. 73-94, (2000); Winkelmann B.R., Hager J., Kraus W.E., Et al., Genetics of coronary heart disease: Current knowledge and research principles, Am. Heart J., 140, SUPPL., pp. 11-26, (2000); Lane D.A., Grant P.J., Role of gene polymorphisms in venous and arterial thrombotic disease, Blood, 95, pp. 1517-1532, (2000); Fleiss J.L., Tytun A., Ury H.K., A simple approximation for calculating sample sizes for comparing independent groups, Biometrics, 36, pp. 343-346, (1980)","B.R. Winkelmann; Ludwigshafen Heart Centre, Ludwigshafen D-67063, Bremser Str. 79, Germany; email: winkbr@gmx.de","","","","","","","","14622416","","PARMF","11258203","English","Pharmacogenomics","Article","Final","","Scopus","2-s2.0-0034937299"
"Chauhan N.; Rani S.; Padh H.","Chauhan, Neelam (57225366651); Rani, Shubha (7005597718); Padh, H. (55664717200)","57225366651; 7005597718; 55664717200","Pharmacogenetics: Genetic basis for rational drug therapy","2007","Indian Journal of Pharmaceutical Sciences","69","2","","180","189","9","8","10.4103/0250-474x.33140","https://www.scopus.com/inward/record.uri?eid=2-s2.0-34347385861&doi=10.4103%2f0250-474x.33140&partnerID=40&md5=9dd681e62537ef91bf6b4a35c1d48f5f","B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad-380 054, Thaltej-Gandhinagar Highway, India","Chauhan N., B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad-380 054, Thaltej-Gandhinagar Highway, India; Rani S., B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad-380 054, Thaltej-Gandhinagar Highway, India; Padh H., B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad-380 054, Thaltej-Gandhinagar Highway, India","Pharmacogenetics has revolutionized the way in which drug metabolism was looked upon in the pre-genomic era. Today with the advent of genomics it is possible to genotype an individual. The genetic differences, which determine the disposition of a given drug in an individual, ultimately give differences in drug response. Genotyping and phenotyping tests to predict dose requirement are now increasingly introduced during preclinical and clinical studies of new drugs. However, the hypothesis for the genotype and the phenotype correlation has to be established. Once this correlation will be established and technology to genotype advances enough to give predictive values over 90%, pharmacogenetics will enter the clinics. Pharmacogenetics will help to tailor the drug type and its dosage according to the individual's genotype. It will help to minimize adverse drug reactions as well as cases of non-responders to the drug therapy. In addition, this will provide better understanding of pharmacogenetic variations both within as well as among major populations/groups of the world.","Cytochrome P450; Drugs; Genotype; Metabolism; Pharmacogenetics; Phenotype","angiotensin 1 receptor antagonist; astemizole; benoxaprofen; beta 2 adrenergic receptor stimulating agent; beta adrenergic receptor blocking agent; bromfenac; cisapride; dipeptidyl carboxypeptidase inhibitor; encainide; grepafloxacin; isoniazid; mephenytoin; methylphenobarbital; nonsteroid antiinflammatory agent; omeprazole; phenytoin; proton pump inhibitor; rofecoxib; serotonin uptake inhibitor; sulfonamide; sulfonylurea; temafloxacin; terfenadine; thiazide diuretic agent; tienilic acid; tolbutamide; tricyclic antidepressant agent; unindexed drug; warfarin; zomepirac; asthma; cardiovascular risk; depression; diabetes mellitus; drug disposition; drug effect; drug mechanism; drug response; duodenum ulcer; genetic difference; genetic variability; genome; genotype phenotype correlation; heart arrhythmia; heart disease; heart proarrhythmia; hemolytic uremic syndrome; human; hypertension; liver toxicity; pharmacogenetics; prediction and forecasting; review; side effect; single nucleotide polymorphism","","astemizole, 68844-77-9; benoxaprofen, 51234-28-7; bromfenac, 91714-94-2; cisapride, 81098-60-4; encainide, 66778-36-7; grepafloxacin, 119914-60-2; isoniazid, 54-85-3, 62229-51-0, 65979-32-0; mephenytoin, 50-12-4; methylphenobarbital, 115-38-8; omeprazole, 73590-58-6, 95510-70-6; phenytoin, 57-41-0, 630-93-3; rofecoxib, 162011-90-7, 186912-82-3; temafloxacin, 105784-61-0, 108319-06-8; terfenadine, 50679-08-8; tienilic acid, 40180-04-9; tolbutamide, 473-41-6, 64-77-7; warfarin, 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2; zomepirac, 33369-31-2, 64092-48-4","","","","","Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Et al., The sequence of the human genome, Science, 291, pp. 1304-1351, (2001); Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Et al., Initial sequencing and analysis of the human genome, Nature, 409, pp. 860-921, (2001); Garrod A.E., Inborn factors in disease: An assay, (1931); Haldane J.B., Disease and evolution, La Ricerca Scientifica, 19, pp. 68-75, (1949); Williams R.J., Biochemical Individuality, (1956); Motulsky A.G., Drug reactions, enzymes, and biochemical genetics, JAMA, 165, pp. 835-837, (1957); Vogel F., Moderne probleme der humangenetik, Ergebnisse der inneren medizin und kinderheilkunde, 12, pp. 65-126, (1959); Vesell E.S., Twin studies in pharmacogenetics, Hum Genet, 1, pp. 19-30, (1978); Motulsky A., Pharmacogenetics and ecogenetics to pharmacogenomics, Genetica e Biotechnologie nella; Licinio J., Wong M., Pharmacogenomics: The search for individualized therapies, (2002); Lehmann H., Ryan E., The familial incidence of low pseudocholinesterase level, Lancet, 271, (1956); Kalow W., Staron N., On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers, Can J Med Sci, 35, pp. 1305-1320, (1957); Blum M., Demierre A., Grant D.M., Heim M., Meyer U.A., Molecular mechanism of slow acetylation in man, Proc Natl Acad Sci, 88, pp. 5237-5241, (1991); Hughes H.B., Biehl J.P., Jones A.P., Schmidt L.H., Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis, Am Rev Tuberc, 70, pp. 266-273, (1954); Weinstein J.N., Pharmacogenomics - Teaching old drugs new tricks, N Engl J Med, 343, pp. 1408-1409, (2000); Linder M.W., Prough R.A., Valdes R., Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency, Clin Chem, 43, pp. 254-266, (1997); Silber B.M., Pharmacogenomics, biomarkers, and the promise of personalized medicine, Pharmacogenomics, (2000); Lazarou J., Pomeranz B.H., Corey P.N., Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA, 279, pp. 1200-1205, (1998); Rubinstein E., Camm J., Cardiotoxicity of fluoroquinolones, J Antimicrob Chemother, 49, pp. 593-596, (2002); COX-2 selective and non-selective non-steroidal anti-inflammatory drugs; Monahan B.P., Ferguson C.L., Cleave E.S., Lloyd B.K., Troy J., Cantilena L.R., Torsade de pointes occurring in association with terfenadineuse, JAMA, 264, pp. 2788-2790, (1990); Rubinstein E., History of quinolones and their side effects, Chemotherapy, 47, pp. 3-8, (2001); Griffin M.R., The COX-2 report: The good, the bad, and the unknown, JCOM, 7, pp. 62-66, (2000); Antiarrhythmics; Sachidanandam R., Weissman D., Schmidst S.C., Kakol J.M., Stein L.D., Marth G., Et al., A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409, pp. 928-933, (2001); Meyer U.A., Zanger U.M., Molecular mechanisms of genetic polymorphisms of drug metabolism, Annu Rev Pharmacol Toxicol, 37, pp. 269-296, (1997); Nebert D.W., Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exists?, Am J Hum Genet, 60, pp. 265-271, (1997); Evans W.E., Relling M.V., Pharmacogenomics: Translating functional genomics into rational therapeutics, Science, 286, pp. 487-491, (1999); Meyer U.A., Pharmacogenetics and adverse drug reactions, Lancet, 356, pp. 1667-1671, (2000); Kuhlmann J., Alternative strategies in drug development: Clinical pharmacological aspects, Int J Clin Pharmacol Ther, 37, pp. 575-583, (1999); Craig A.M., Malek M., Market structure and conduct in the pharmaceutical industry, Pharmacol Ther, 66, pp. 301-337, (1995); Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., Et al., A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409, pp. 928-933, (2001); Kruglyak L., Nickerson D.A., Variation is spice of life, Nat Genet, 27, pp. 234-236, (2001); Stoneking M., Single nucleotide polymorphisms: From the evolutionary past, Nature, 409, pp. 821-822, (2001); Roses A.D., Pharmacogenetics and the practice of medicine, Nature, 405, pp. 857-865, (2000); Single nucleotide polymorphism for biomedical research; Ingelman-Sundberg M., Pharmacokinetics: An opportunity for a safer and more efficient pharmacotherapy, J Intern Med, 250, pp. 186-200, (2001); Russell A., Wilke David M.R., Jason H.M., Combinatorial pharmacogenetics, Nat Rev Drug Discov, 4, pp. 911-918, (2005); Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zangar U.M., Nebert D.W., Et al., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature, 331, pp. 442-446, (1988); Daly A.K., Molecular basis of polymorphic drug metabolism, J Mol Med, 73, pp. 539-553, (1995); Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Et al., P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6, pp. 1-42, (1996); Daly A.K., Pharmacogenetics of the major polymorphic metabolizing enzymes, Fundam Clin Pharmacol, 17, pp. 27-41, (2003); Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians, J Pharm Exp Ther, 270, pp. 414-423, (1994); Drug Interactions; Ingelman-Sundberg M., Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J, 5, pp. 6-13, (2005); Rendic S., Di Carlo F.J., Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors, Drug Metab Rev, 29, pp. 413-580, (1997); Lee C.R., Goldstein J.A., Pieper J.A., Cytochrome P450 2C9 genetic polymorphisms: A comprehensive review of the in vitro and human data, Pharmacogenetics, 12, pp. 251-263, (2002); Aithal G.P., Day C.P., Kesteven P.J., Daly A.K., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, 353, pp. 717-719, (1999); Scordo M.G., Aklillu E., Yasar U., Dahl M.L., Spina E., Ingelman-Sundberg M., Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population, Br J Clin Pharmacol, 52, pp. 447-450, (2001); Taube J., Halsall D., Baglin T., Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment, Blood, 96, pp. 1816-1819, (2000); Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., Et al., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, 287, pp. 1690-1698, (2002); Hillman M.A., Wilke R.A., Caldwell M.D., Berg R.L., Glurich I., Burmester J.K., Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype, Pharmacogenetics, 14, pp. 539-547, (2004); Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., McLeod H.L., Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin, Thromb Haemost, 91, pp. 87-94, (2004); Daly A.K., Pharmacokinetics of the major polymorphic metabolizing enzymes, Fundam Clin Pharmacol, 17, pp. 27-41, (2003); De Wildt S.N., Kearns G.L., Leeder J.S., Van Den Anker J.N., Cytochrome P450 3A: Ontogeny and drug disposition, Clin Pharmacokinet, 37, pp. 485-505, (1999); Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Hartwell P.S., Et al., Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients, J Pharmacol Exp Ther, 271, pp. 549-556, (1994); Lindholm A., Henricsson S., Lind M., Dahlqvist R., Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing, Eur J Clin Pharmacol, 34, pp. 461-464, (1988); Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B., Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4, J Natl Cancer Inst, 90, pp. 1225-1229, (1998); Sata F., Sapone A., Elizondo G., Stocker P., Miller V.P., Zheng W., Et al., CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity, Clin Pharmacol Ther, 67, pp. 48-56, (2000); Ball S.E., Scatina J., Kao J., Ferron G.M., Fruncillo R., Mayer P., Et al., Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4, Clin Pharmacol Ther, 66, pp. 288-294, (1999); Westlind A., Lofberg L., Tindberg N., Andersson T.B., Ingelman-Sundberg M., Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region, Biochem Biophys Res Commun, 259, pp. 201-205, (1999); Van Schaik R.H., De Wildt S.N., Van Iperen N.M., Uitterlinden A.G., Van Den Anker J.N., Lindemans J., CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians, Clin Chem, 46, pp. 1834-1836, (2000); Furuta T., Ohashi K., Kamata T., Takashima M., Kosuge K., Kawasaki T., Et al., Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer, Ann Int Med, 129, pp. 1027-1030, (1998); Andersson T., Regardh C.G., Dahl-Puustinen M.L., Bertilsson L., Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators, The Drug Monit, 12, pp. 415-416, (1990); Mackenzie P.I., Owens I.S., Burchell B., Bock K.W., Bairoch A., Belanger A., Et al., The UDP glycosyltransferase gene super-family: Recommended nomenclature update based on evolutionary divergence, Pharmacogenetics, 7, pp. 255-269, (1997); Woosley R.L., Drayer D.E., Reidenberg M.M., Nies A.S., Carr K., Oates J.A., Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome, N Engl J Med, 298, pp. 1157-1159, (1978); Das K.M., Eastwood M.A., McManus J.P., Sircus W., Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype, N Engl J Med, 289, pp. 491-495, (1973); Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., Et al., Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus, J Natl Cancer Inst, 91, pp. 2001-2008, (1999); Bertilsson L., Dahl M.L., Tybring G., Pharmacogenetics of antidepressants: Clinical aspects, Acta Psychiatr Scand, 96, pp. 14-21, (1997); Fagerlund T.H., Braaten O., No pain relief from codeine...? An introduction to pharmacogenomics, Acta Anaesthesiol Scand, 45, pp. 140-149, (2001); Neil A.T., Will genetics revolutionize public health; Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Et al., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature, 331, pp. 442-446, (1988); Kirchheiner J., Brosen K., Dahl M.L., Gram L.F., Kasper S., Roots I., Et al., CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages, Acta Psychiatr Scand, 104, pp. 173-192, (2001); Ingelman-Sundberg M., Oscarson M., McLellan R.A., Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment, Trends Pharmacol Sci, 20, pp. 342-349, (1999); Rani S., Padh H., Inter-individual variation in pharmacokinetics of proton pump inhibitors in healthy Indian males, Indian J Pharm Sci, 68, pp. 754-759, (2006); Padh H., Human genome project and pharmacogenomics: Leading towards individualized medication, Indian Drugs, 38, pp. 160-163, (2001)","H. Padh; B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad-380 054, Thaltej-Gandhinagar Highway, India; email: perd@perdcentre.com","","Medknow Publications and Media Pvt. Ltd","","","","","","0250474X","","IJSID","","English","Indian J. Pharm. Sci.","Review","Final","","Scopus","2-s2.0-34347385861"
"Ishimitsu T.; Ono H.; Minami J.; Matsuoka H.","Ishimitsu, Toshihiko (11640295400); Ono, Hidehiko (7401965662); Minami, Junichi (7006408352); Matsuoka, Hiroaki (7401586885)","11640295400; 7401965662; 7006408352; 7401586885","Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders","2006","Pharmacology and Therapeutics","111","3","","909","927","18","99","10.1016/j.pharmthera.2006.02.004","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746359354&doi=10.1016%2fj.pharmthera.2006.02.004&partnerID=40&md5=42cb6e0b95d43e6cfc1972c0948accef","Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293, Japan","Ishimitsu T., Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293, Japan; Ono H., Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293, Japan; Minami J., Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293, Japan; Matsuoka H., Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293, Japan","Adrenomedullin (AM) is a vasodilator peptide that originally isolated from pheochromocytoma tissue. However, the mRNA is expressed in the normal adrenal gland, heart, kidney and blood vessels. The human AM gene is located in the short arm of chromosome 11 and is composed of 4 exons. There are 2 single nucleotide polymorphisms in introns 1 and 3, and the 3′-end of the AM gene is flanked by a microsatellite marker of cytosine-adenine repeats that is associated with an increased risk of developing hypertension and diabetic nephropathy. AM gene expression is promoted by various stimuli, including inflammation, hypoxia, oxidative stress, mechanical stress and activation of the renin-angiotensin and sympathetic nervous systems. The AM gene promoter region possessed binding site for several transcription factors, including nuclear factor for interleukin-6 expression (NF-IL6) and activator protein 2 (AP-2). Further, plasma AM levels are increased in patients with various cardiovascular diseases, including hypertension, heart failure and renal failure. These findings suggest that AM plays a role in the development of or response to cardiovascular disease. Indeed, experimental and clinical studies have demonstrated that systemic infusion of AM may have a therapeutic effect on myocardial infarction, heart failure and renal failure. Further, vasopeptidase inhibitors which augment the bioactivity of endogenous AM may benefit patients with hypertension and arteriosclerosis. Finally, the angiogenic and cytoprotective properties of AM may have utility in revascularization and infarcted myocardium and ischemic limbs. Because of the potential clinical benefits of AM, indications for use and optimal dosing strategies should be established. © 2006 Elsevier Inc. All rights reserved.","Adrenomedullin; Cardiovascular disease; Cell transplantation; Gene polymorphism; Gene therapy","Adrenomedullin; Amino Acid Sequence; Animals; Carcinogens; Cardiovascular Diseases; Cell Transplantation; Gene Therapy; Heart Failure; Heart Failure, Congestive; Humans; Hypertension; Hypertension, Pulmonary; Kidney Failure; Molecular Sequence Data; Myocardial Infarction; Polymorphism, Single Nucleotide; Promoter Regions (Genetics); Promoter Regions, Genetic; Renal Insufficiency; Renin-Angiotensin System; Signal Transduction; adenovirus vector; adrenomedullin; adrenomedullin receptor; carcinogen; cyclic AMP dependent protein kinase; cytokine; microsatellite DNA; nitric oxide; omapatrilat; plasmid vector; adrenergic system; apoptosis; binding site; blood pressure; cardiovascular disease; cell transplantation; central nervous system; chemical structure; clinical trial; diuresis; DNA polymorphism; endocrine system; gene expression; gene structure; gene targeting; genetic polymorphism; genetic variability; heart; heart failure; heart infarction; human; hypertension; hypoxia; ischemia; kidney; kidney blood flow; kidney failure; lung; lung artery pressure; mechanical stimulation; mitogenesis; natriuresis; nonhuman; nucleotide sequence; oncogene; oxidative stress; pathophysiology; priority journal; promoter region; pulmonary hypertension; renin angiotensin aldosterone system; review; signal transduction; single nucleotide polymorphism; vasodilatation","","adrenomedullin, 148498-78-6; nitric oxide, 10102-43-9; omapatrilat, 167305-00-2; Adrenomedullin, 148498-78-6; Carcinogens, ","","","","","Abe M., Sata M., Nishimatsu H., Nagata D., Suzuki E., Terauchi Y., Et al., Adrenomedullin augments collateral development in response to acute ischemia, Biochem Biophys Res Commun, 306, pp. 10-15, (2003); Agata J., Zhang J.J., Chao J., Chao L., Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty, Regul Pept, 112, pp. 115-120, (2003); Akira S., Isshiki H., Sugita T., Tanabe O., Kinoshita S., Nishio Y., Et al., A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family, EMBO J, 9, pp. 1897-1906, (1990); Albertin G., Carraro G., Parnigotto P.P., Conconi M.T., Ziolkowska A., Malendowicz L.K., Et al., Human skin keratinocytes and fibroblasts express adrenomedullin and its receptors, and adrenomedullin enhances their growth in vitro by stimulating proliferation and inhibiting apoptosis, Int J Mol Med, 11, pp. 635-639, (2003); Ando K., Ito Y., Kumada M., Fujita T., Oxidative stress increases adrenomedullin mRNA levels in cultured rat vascular smooth muscle cells, Hypertens Res, 21, pp. 187-191, (1998); Andreis P.G., Mazzocchi G., Rebuffat P., Nussdorfer G.G., Effects of adrenomedullin and proadrenomedullin N-terminal 20 peptide on rat zona glomerulosa cells, Life Sci, 60, pp. 1693-1697, (1997); Andreis P.G., Neri G., Prayer-Galetti T., Rossi G.P., Gottardo G., Malendowicz L.K., Et al., Effects of adrenomedullin on the human adrenal glands: an in vitro study, J Clin Endocrinol Metab, 82, pp. 1167-1170, (1997); Arnold A., Kim H.G., Gaz R.D., Eddy R.L., Fukushima Y., Byers M.G., Et al., Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma, J Clin Invest, 83, pp. 2034-2040, (1989); Autelitano D.J., Ridings R., Tang F., Adrenomedullin is a regulated modulator of neonatal cardiomyocyte hypertrophy in vitro, Cardiovasc Res, 51, pp. 255-264, (2001); Barker S., Wood E., Clark A.J., Corder R., Cloning of bovine preproadrenomedullin and inhibition of its basal expression in vascular endothelial cells by staurosporine, Life Sci, 62, pp. 1407-1415, (1998); Belloni A.S., Guidolin D., Ceretta S., Bova S., Nussdorfer G.G., Acute effect of ischemia on adrenomedullin immunoreactivity in the rat heart: an immunocytochemical study, Int J Mol Med, 14, pp. 71-73, (2004); Bomberger J.M., Parameswaran N., Hall C.S., Aiyar N., Spielman W.S., Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking, J Biol Chem, 280, pp. 9297-9307, (2005); Bomberger J.M., Spielman W.S., Hall C.S., Parameswaran N., RAMP isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1, J Biol Chem, 280, pp. 23926-23935, (2005); Burnett Jr. J.C., Vasopeptidase inhibition: a new concept in blood pressure management, J Hypertens Suppl, 17, (1999); Burrell L.M., Droogh J., Man in't Veld O., Rockell M.D., Farina N.K., Johnston C.I., Antihypertensive and antihypertrophic effects of omapatrilat in SHR, Am J Hypertens, 13, pp. 1110-1116, (2000); Cameron V.A., Autelitano D.J., Evans J.J., Ellmers L.J., Espiner E.A., Nicholls M.G., Et al., Adrenomedullin expression in rat uterus is correlated with plasma estradiol, Am J Physiol, 282, (2002); Chao J., Kato K., Zhang J.J., Dobrzynski E., Wang C., Agata J., Et al., Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury, Peptides, 22, pp. 1731-1737, (2001); Charles C.J., Lainchbury J.G., Nicholls M.G., Rademaker M.T., Richards A.M., Troughton R.W., Adrenomedullin and the renin-angiotensin-aldosterone system, Regul Pept, 112, pp. 41-49, (2003); Chini E.N., Choi E., Grande J.P., Burnett J.C., Dousa T.P., Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway, Biochem Biophys Res Commun, 215, pp. 868-873, (1995); Chini E.N., Chini C.C., Bolliger C., Jougasaki M., Grande J.P., Burnett Jr. J.C., Et al., Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway, Kidney Int, 52, pp. 917-925, (1997); Chun T.H., Itoh H., Ogawa Y., Tamura N., Takaya K., Igaki T., Et al., Shear stress augments expression of C-type natriuretic peptide and adrenomedullin, Hypertension, 29, pp. 1296-1302, (1997); Chun T.H., Itoh H., Saito T., Yamahara K., Doi K., Mori Y., Et al., Oxidative stress augments secretion of endothelium-derived relaxing peptides, C-type natriuretic peptide and adrenomedullin, J Hypertens, 18, pp. 575-580, (2000); Cormier-Regard S., Nguyen S.V., Claycomb W.C., Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes, J Biol Chem, 273, pp. 17787-17792, (1998); Daley G.Q., Cargill M., The heart SNPs a beat: polymorphisms in candidate genes for cardiovascular disease, Trends Cardiovasc Med, 11, pp. 60-66, (2001); da Veiga Pereira L., Desnick R.J., Adler D.A., Disteche C.M., Schuchman E.H., Regional assignment of the human acid sphingomyelinase gene (SMPD1) by PCR analysis of somatic cell hybrids and in situ hybridization to 11p15.1-p15.4, Genomics, 9, pp. 229-234, (1991); De Angeli S., Del Pup L., Febas E., Conconi M.T., Tommasini M., Di Liddo R., Et al., Adrenomedullin and endothelin-1 stimulate in vitro expansion of cord blood hematopoietic stem cells, Int J Mol Med, 14, pp. 1083-1086, (2004); Dobrzynski E., Montanari D., Agata J., Zhu J., Chao J., Chao L., Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats, Am J Physiol, 283, (2002); Dotsch J., Harmjanz A., Christiansen H., Hanze J., Lampert F., Rascher W., Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR, Int J Cancer, 88, pp. 172-175, (2000); Ebara T., Miura K., Okumura M., Matsuura T., Kim S., Yukimura T., Et al., Effect of adrenomedullin on renal hemodynamics and functions in dogs, Eur J Pharmacol, 263, pp. 69-73, (1994); Fujioka H., Okamura T., Toda N., Inhibition by adrenomedullin of amine release from adrenergic nerves in dog mesenteric arteries, Eur J Pharmacol, 385, pp. 155-161, (1999); Feng C.J., Kang B., Kaye A.D., Kadowitz P.J., Nossaman B.D., l-NAME modulates responses to adrenomedullin in the hindquarters vascular bed of the rat, Life Sci, 55, (1994); Giacalone P.L., Vuaroqueaux V., Daures J.P., Houafic L., Martin P.M., Laffargue F., Et al., Expression of adrenomedullin in human ovaries, ovarian cysts and cancers. Correlation with estrogens receptor status, Eur J Obstet Gyn R B, 110, pp. 224-229, (2003); Hagner S., Stahl U., Knoblauch B., McGregor G.P., Lang R.E., Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues, Cell Tissue Res, 310, pp. 41-50, (2002); Hagner S., Knauer J., Haberberger R., Goke B., Voigt K., McGregor G.P., Calcitonin receptor-like receptor is expressed on gastrointestinal immune cells, Digestion, 66, pp. 197-203, (2002); Hanabusa K., Nagaya N., Iwase T., Itoh T., Murakami S., Shimizu Y., Et al., Adrenomedullin enhances therapeutic potency of mesenchymal stem cells after experimental stroke in rats, Stroke, 36, pp. 853-858, (2005); Hata K., Takebayashi Y., Akiba S., Fujiwaki R., Iida K., Nakayama K., Et al., Expression of the adrenomedullin gene in epithelial ovarian cancer, Mol Hum Reprod, 6, pp. 867-872, (2000); Hay D.L., Smith D.M., Adrenomedullin receptors: molecular identity and function, Peptides, 22, pp. 1753-1763, (2001); Hayakawa H., Hirata Y., Kakoki M., Suzuki Y., Nishimatsu H., Nagata D., Et al., Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat, Hypertension, 33, pp. 689-693, (1999); Heesom A.E., Hibberd M.L., Millward A., Demaine A.G., Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes, Diabetes, 46, pp. 287-291, (1997); Hinson J.P., Kapas S., Smith D.M., Adrenomedullin, a multifunctional regulatory peptide, Endocr Rev, 21, pp. 138-167, (2000); Hirano S., Imamura T., Onitsuka H., Matsuo T., Kitamura K., Koiwaya Y., Et al., Rapid increase in cardiac adrenomedullin gene expression caused by acute pressure overload: effect of the renin-angiotensin system on gene expression, Circ J, 66, pp. 397-402, (2002); Hirata Y., Hayakawa H., Suzuki Y., Suzuki E., Ikenouchi H., Kohmoto O., Et al., Mechanisms of adrenomedullin-induced vasodilation in the rat kidney, Hypertension, 25, pp. 790-795, (1995); Hirata Y., Mitaka C., Sato K., Nagura T., Tsunoda Y., Amaha K., Et al., Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis, J Clin Endocrinol Metab, 81, pp. 1449-1453, (1996); Hofbauer K.H., Schoof E., Kurtz A., Sandner P., Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathways, Hypertension, 39, pp. 161-167, (2002); Horio T., Kohno M., Kano H., Ikeda M., Yasunari K., Yokokawa K., Et al., Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells, Circ Res, 77, pp. 660-664, (1995); Huang H., Ma C., Yang M., Tang C., Wang H., Adrenomedullin impairs the profibrotic effects of transforming growth factor-beta1 through recruiting Smad6 protein in human renal tubular cells, Cell Physiol Biochem, 15, pp. 117-124, (2005); Ihara T., Ikeda U., Tate Y., Ishibashi S., Shimada K., Positive inotropic effects of adrenomedullin on rat papillary muscle, Eur J Pharmacol, 390, pp. 167-172, (2000); Ikeda K., Arao Y., Otsuka H., Kikuchi A., Kayama F., Estrogen and phytoestrogen regulate the mRNA expression of adrenomedullin and adrenomedullin receptor components in the rat uterus, Mol Cell Endocrinol, 223, pp. 27-34, (2004); Ikenouchi H., Kangawa K., Matsuo H., Hirata Y., Negative inotropic effect of adrenomedullin in isolated adult rabbit cardiac ventricular myocytes, Circulation, 95, pp. 2318-2324, (1997); Ishimitsu T., Nishikimi T., Saito Y., Kitamura K., Eto T., Kangawa K., Et al., Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure, J Clin Invest, 94, pp. 2158-2161, (1994); Ishimitsu T., Kojima M., Kangawa K., Hino J., Matsuoka H., Kitamura K., Et al., Genomic structure of human adrenomedullin gene, Biochem Biophys Res Commun, 203, pp. 631-639, (1994); Ishimitsu T., Miyata A., Matsuoka H., Kangawa K., Transcriptional regulation of human adrenomedullin gene in vascular endothelial cells, Biochem Biophys Res Commun, 243, pp. 463-470, (1998); Ishimitsu T., Minami J., Nishikimi T., Yoshida K., Tsukada H., Kangawa K., Et al., Changes in plasma adrenomedullin in physiological and pathological conditions in human subjects, J Cardiovasc Pharmacol, 34, SUPPL. 4, (1999); Ishimitsu T., Hosoya K., Tsukada K., Minami J., Ono H., Ohrui M., Et al., Chromosomal sublocalization and microsatellite DNA polymorphism of human adrenomedullin gene, Peptides, 22, pp. 1739-1744, (2001); Ishimitsu T., Hosoya K., Tsukada K., Minami J., Futoh Y., Ono H., Et al., Microsatellite DNA polymorphism of human adrenomedullin gene in normotensive subjects and patients with essential hypertension, Hypertension, 38, pp. 9-12, (2001); Ishimitsu T., Tsukada K., Minami J., Ono H., Ohrui M., Hino J., Et al., Microsatellite DNA polymorphism of human adrenomedullin gene in type 2 diabetic patients with renal failure, Kidney Int, 63, pp. 2230-2235, (2003); Ishimitsu T., Tsukada K., Minami J., Ono H., Matsuoka H., Adrenomedullin gene, Adrenomedullin in Cardiovascular Disease, pp. 41-60, (2005); Isumi Y., Shoji H., Sugo S., Tochimoto T., Yoshioka M., Kangawa K., Et al., Regulation of adrenomedullin production in rat endothelial cells, Endocrinology, 139, pp. 838-846, (1998); Iwamoto M., Osajima A., Tamura M., Suda T., Ota T., Kanegae K., Et al., Adrenomedullin inhibits pressure-induced mesangial MCP-1 expression through activation of protein kinase, Am J Nephrol, 16, pp. 673-681, (2003); Iwasaki H., Eguchi S., Shichiri M., Marumo F., Hirata Y., Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation, Endocrinology, 139, pp. 3432-3441, (1998); Iwase T., Nagaya N., Fujii T., Itoh T., Ishibashi-Ueda H., Yamagishi M., Et al., Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia, Circulation, 111, pp. 356-362, (2005); Jensen B.L., Kramer B.K., Kurtz A., Adrenomedullin stimulates renin release and renin mRNA in mouse juxtaglomerular granular cells, Hypertension, 29, pp. 1148-1155, (1997); Jiang W., Jiang H.F., Pan C.S., Cai D.Y., Qi Y.F., Pang Y.Z., Et al., Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats, Hypertens Res, 27, pp. 109-117, (2004); Jimenez N., Abasolo I., Jongsma J., Calvo A., Garayoa M., van der Kwast T.H., Et al., Androgen-independent expression of adrenomedullin and peptidylglycine alpha-amidating monooxygenase in human prostatic carcinoma, Mol Carcinogen, 38, pp. 14-24, (2003); Jougasaki M., Wei C.M., Aarhus L.L., Heublein D.M., Sandberg S.M., Burnett Jr. J.C., Renal localization and actions of adrenomedullin: a natriuretic peptide, Am J Physiol, 268, (1995); Jougasaki M., Aarhus L.L., Heublein D.M., Sandberg S.M., Burnett Jr. J.C., Role of prostaglandins and renal nerves in the renal actions of adrenomedullin, Am J Physiol, 272, (1997); Jougasaki M., Grantham J.A., Redfield M.M., Burnett Jr. J.C., Regulation of cardiac adrenomedullin in heart failure, Peptides, 22, pp. 1841-1850, (2001); Juaneda C., Dumont Y., Chabot J.G., Fournier A., Quirion R., Adrenomedullin receptor binding sites in rat brain and peripheral tissues, Eur J Pharmacol, 474, pp. 165-174, (2003); Kakishita M., Nishikimi T., Okano Y., Satoh T., Kyotani S., Nagaya N., Et al., Increased plasma levels of adrenomedullin in patients with pulmonary hypertension, Clin Sci, 96, pp. 33-39, (1999); Kanazawa H., Kurihara N., Hirata K., Kudoh S., Kawaguchi T., Takeda T., Adrenomedullin, a newly discovered hypotensive peptide, is a potent bronchodilator, Biochem Biophys Res Commun, 205, pp. 251-254, (1994); Kano H., Kohno M., Yasunari K., Yokokawa K., Horio T., Ikeda M., Et al., Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells, J Hypertens, 14, pp. 209-213, (1996); Kapas S., Brown D.W., Farthing P.M., Hagi-Pavli E., Adrenomedullin has mitogenic effects on human oral keratinocytes: involvement of cyclic AMP, FEBS Lett, 418, pp. 287-290, (1997); Kapas S., Tenchini M.L., Farthing P.M., Regulation of adrenomedullin secretion in cultured human skin and oral keratinocytes, J Invest Dermatol, 117, pp. 353-359, (2001); Kato H., Shichiri M., Marumo F., Hirata Y., Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells, Endocrinology, 138, pp. 2615-2620, (1997); Kato J., Kitamura K., Matsui E., Tanaka M., Ishizaka Y., Kita T., Et al., Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension, Hypertens Res, 22, pp. 61-65, (1999); Kato K., Yin H., Agata J., Yoshida H., Chao L., Chao J., Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion, Am J Physiol, 285, (2003); Katoh F., Kitamura K., Niina H., Yamamoto R., Washimine H., Kangawa K., Et al., Proadrenomedullin N-terminal 20 peptide (PAMP), an endogenous anticholinergic peptide: its exocytotic secretion and inhibition of catecholamine secretion in adrenal medulla, J Neurochem, 64, pp. 459-461, (1995); Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Urakawa H., Morioka K., Et al., Acute hyperinsulinemia is associated with increased circulating levels of adrenomedullin in patients with type 2 diabetes mellitus, Eur J Endocrinol, 147, pp. 71-75, (2002); Katsuki A., Sumida Y., Urakawa H., Gabazza E.C., Maruyama N., Morioka K., Et al., Increased oxidative stress is associated with elevated plasma levels of adrenomedullin in hypertensive patients with type 2 diabetes, Diabetes Care, 26, pp. 1642-1643, (2003); Khan A.I., Kato J., Kitamura K., Kangawa K., Eto T., Hypotensive effect of chronically infused adrenomedullin in conscious Wistar-Kyoto and spontaneously hypertensive rats, Clin Exp Pharmacol Physiol, 24, pp. 139-142, (1997); Khan A.I., Kato J., Ishiyama Y., Kitamura K., Kangawa K., Eto T., Effect of chronically infused adrenomedullin in two-kidney, one-clip hypertensive rats, Eur J Pharmacol, 333, pp. 187-190, (1997); Kim W., Moon S.O., Sung M.J., Kim S.H., Lee S., So J.N., Et al., Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells, FASEB J, 17, pp. 1937-1939, (2003); Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., Et al., Adrenomedullin: a novel hypotensive peptide isolated from human paeochromocytoma, Biochem Biophys Res Commun, 192, pp. 553-560, (1993); Kitamura K., Sakata J., Kangawa K., Kojima M., Matsuo H., Eto T., Cloning and characterization of cDNA encoding a precursor for human adrenomedullin, Biochem Biophys Res Commun, 194, pp. 720-725, (1993); Kitamura K., Ichiki Y., Tanaka M., Kawamoto M., Emura J., Sakakibara S., Et al., Immunoreactive adrenomedullin in human plasma, FEBS Lett, 341, pp. 288-290, (1994); Kitamura K., Kangawa K., Kojima M., Ichiki Y., Matsuo H., Eto T., Complete amino acid sequence of porcine adrenomedullin and cloning of cDNA encoding its precursor, FEBS Lett, 338, pp. 306-310, (1994); Kitamura K., Kangawa K., Ishiyama Y., Washimine H., Ichiki Y., Kawamoto M., Et al., Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP), FEBS Lett, 351, pp. 35-37, (1994); Kitamura K., Matsui E., Kato J., Katoh F., Kita T., Tsuji T., Et al., Adrenomedullin (11-26): a novel endogenous hypertensive peptide isolated from bovine adrenal medulla, Peptides, 22, pp. 1713-1718, (2001); Kobayashi H., Yamamoto R., Kitamura K., Niina H., Masumoto K., Minami S.I., Et al., Cyclic AMP-dependent synthesis and release of adrenomedullin and proadrenomedullin N-terminal 20 peptide in cultured bovine adrenal chromaffin cells, Eur J Biochem, 263, pp. 702-708, (1999); Kohno M., Kano H., Horio T., Yokokawa K., Yasunari K., Takeda T., Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells, Hypertension, 25, pp. 1185-1890, (1995); Kohno M., Hanehira T., Kano H., Horio T., Yokokawa K., Ikeda M., Et al., Plasma adrenomedullin concentrations in essential hypertension, Hypertension, 27, pp. 102-107, (1996); Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., Levy E., Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial, Am J Hypertens, 17, pp. 103-111, (2004); Ladoux A., Frelin C., Coordinated Up-regulation by hypoxia of adrenomedullin and one of its putative receptors (RDC-1) in cells of the rat blood-brain barrier, J Biol Chem, 275, pp. 39914-39919, (2000); Lainchbury J.G., Cooper G.J., Coy D.H., Jiang N.Y., Lewis L.K., Yandle T.G., Et al., Adrenomedullin: a hypotensive hormone in man, Clin Sci, 92, pp. 467-472, (1997); Lainchbury J.G., Troughton R.W., Lewis L.K., Yandle T.G., Richards A.M., Nicholls M.G., Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers, J Clin Endocrinol Metab, 85, pp. 1016-1020, (2000); Lang M.G., Paterno R., Faraci F.M., Heistad D.D., Mechanisms of adrenomedullin-induced dilatation of cerebral arterioles, Stroke, 28, pp. 181-185, (1997); Leclerc M., Brunette M.G., The paradoxical effect of adrenomedullin on Na<sup>+</sup> transport by the renal distal tubule luminal membrane, Mol Cell Endocrinol, 164, pp. 159-167, (2000); Letizia C., Tamburrano G., Alo P., Paoloni A., Caliumi C., Marinoni E., di Iorio R., d'Erasmo E., Adrenomedullin, a new peptide, in patients with insulinoma, Eur J Endocrinol, 144, pp. 517-520, (2001); Letizia C., Subioli S., Cerci S., Caliumi C., Verrelli C., Delfini E., Et al., High plasma adrenomedullin concentrations in patients with high-renin essential hypertension, J Renin Angiotensin Aldosterone Syst, 3, pp. 126-129, (2002); Letizia C., Caliumi C., Delfini E., Celi M., Subioli S., Diacinti D., Et al., Adrenomedullin concentrations are elevated in plasma of patients with primary hyperparathyroidism, Metabolism, 52, pp. 159-162, (2003); Letizia C., Ricci F., De Toma G., Cianci R., Alo P., Celi M., Et al., Adrenomedullin immunoreactivity tissue distribution in parathyroids of the patients with primary hyperparathyroidism, Horm Metab Res, 36, pp. 480-484, (2004); Li S.S., Luedemann M., Sharief F.S., Takano T., Deaven L.L., Mapping of human lactate dehydrogenase-A, -B, and -C genes and their related sequences: the gene for LDHC is located with that for LDHA on chromosome 11, Cytogenet Cell Genet, 48, pp. 16-18, (1988); Lippton H., Chang J.K., Hao Q., Summer W., Hyman A.L., Adrenomedullin dilates the pulmonary vascular bed in vivo, J Appl Physiol, 76, pp. 2154-2156, (1994); Lisy O., Jougasaki M., Schirger J.A., Chen H.H., Barclay P.T., Burnett Jr. J.C., Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin, Am J Physiol, 275, (1998); Luodonpaa M., Rysa J., Pikkarainen S., Tenhunen O., Tokola H., Puhakka J., Et al., Mechanisms regulating adrenomedullin gene expression in the left ventricle: role of mechanical load, Regul Pept, 112, pp. 153-159, (2003); Majid D.S., Kadowitz P.J., Coy D.H., Navar L.G., Renal responses to intra-arterial administration of adrenomedullin in dogs, Am J Physiol, 270, (1996); Martinez A., Weaver C., Lopez J., Bhathena S.J., Elsasser T.H., Miller M.J., Et al., Regulation of insulin secretion and blood glucose metabolism by adrenomedullin, Endocrinology, 137, pp. 2626-2632, (1996); Masada K., Nagayama T., Hosokawa A., Yoshida M., Suzuki-Kusaba M., Hisa H., Et al., Effects of adrenomedullin and PAMP on adrenal catecholamine release in dogs, Am J Physiol, 276, (1999); Mazzocchi G., Albertin G., Andreis P.G., Neri G., Malendowicz L.K., Champion H.C., Et al., Distribution, functional role, and signaling mechanism of adrenomedullin receptors in the rat adrenal gland, Peptides, 20, pp. 1479-1487, (1999); McGregor D.O., Troughton R.W., Frampton C., Lynn K.L., Yandle T., Richards A.M., Et al., Hypotensive and natriuretic actions of adrenomedullin in subjects with chronic renal impairment, Hypertension, 37, pp. 1279-1284, (2001); McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., Et al., RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor, Nature, 393, pp. 333-339, (1998); Meeran K., O'Shea D., Upton P.D., Small C.J., Ghatei M.A., Byfield P.H., Et al., Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study, J Clin Endocrinol Metab, 82, pp. 95-100, (1997); Miller M.J., Martinez A., Unsworth E.J., Thiele C.J., Moody T.W., Elsasser T., Et al., Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor, J Biol Chem, 271, pp. 23345-23351, (1996); Minamino N., Shoji H., Sugo S., Kangawa K., Matsuo H., Adrenocortical steroids, thyroid hormones and retinoic acid augment the production of adrenomedullin in vascular smooth muscle cells, Biochem Biophys Res Commun, 211, pp. 686-693, (1995); Minden A., Karin M., Regulation and function of the JNK subgroup of MAP kinases, Biochim Biophys Acta, 1333, (1997); Miyashita K., Itoh H., Sawada N., Fukunaga Y., Sone M., Yamahara K., Et al., Adrenomedullin promotes proliferation and migration of cultured endothelial cells, Hypertens Res, 26, (2003); Miyashita K., Itoh H., Sawada N., Fukunaga Y., Sone M., Yamahara K., Et al., Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo, FEBS Lett, 544, pp. 86-92, (2003); Mulder H., Ahren B., Karlsson S., Sundler F., Adrenomedullin: localization in the gastrointestinal tract and effects on insulin secretion, Regul Pept, 62, pp. 107-112, (1996); Murphy T.C., Samson W.K., The novel vasoactive hormone, adrenomedullin, inhibits water drinking in the rat, Endocrinology, 136, pp. 2459-2463, (1995); Nagaya N., Nishikimi T., Horio T., Yoshihara F., Kanazawa A., Matsuo H., Et al., Cardiovascular and renal effects of adrenomedullin in rats with heart failure, Am J Physiol, 276, (1999); Nagaya N., Satoh T., Nishikimi T., Uematsu M., Furuichi S., Sakamaki F., Et al., Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure, Circulation, 101, pp. 498-503, (2000); Nagaya N., Nishikimi T., Uematsu M., Satoh T., Oya H., Kyotani S., Et al., Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension, Heart, 84, pp. 653-658, (2000); Nagaya N., Okumura H., Uematsu M., Shimizu W., Ono F., Shirai M., Et al., Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats, Am J Physiol, 285, (2003); Nagaya N., Kangawa K., Kanda M., Uematsu M., Horio T., Fukuyama N., Et al., Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells, Circulation, 108, pp. 889-895, (2003); Nagaya N., Kyotani S., Uematsu M., Ueno K., Oya H., Nakanishi N., Et al., Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension, Circulation, 109, pp. 351-356, (2004); Nakamura R., Kato J., Kitamura K., Onitsuka H., Imamura T., Marutsuka K., Et al., Beneficial effects of adrenomedullin on left ventricular remodeling after myocardial infarction in rats, Cardiovasc Res, 56, pp. 373-380, (2002); Nakamura R., Kato J., Kitamura K., Onitsuka H., Imamura T., Cao Y., Et al., Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats, Circulation, 110, pp. 426-431, (2005); Nakayama M., Takahashi K., Kitamuro T., Murakami O., Shirato K., Transcriptional control of adrenomedullin induction by phorbol ester in human monocytic leukemia cells, Eur J Biochem, 267, pp. 3559-3566, (2000); Nakayama T., Soma M., Rehemudula D., Takahashi Y., Tobe H., Satoh M., Et al., Association of 5′ upstream promoter region of prostacyclin synthase gene variant with cerebral infarction, Am J Hypertens, 13, pp. 1263-1267, (2000); Nishikimi T., Kitamura K., Saito Y., Shimada K., Ishimitsu T., Takamiya M., Et al., Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects, Hypertension, 24, pp. 600-604, (1994); Nishikimi T., Saito Y., Kitamura K., Ishimitsu T., Eto T., Kangawa K., Et al., Increased plasma levels of adrenomedullin in patients with heart failure, J Am Coll Cardiol, 26, pp. 1424-1431, (1995); Nishikimi T., Mori Y., Kobayashi N., Tadokoro K., Wang X., Akimoto K., Et al., Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats, Hypertension, 39, pp. 1077-1082, (2002); Nishikimi T., Yoshihara F., Horinaka S., Kobayashi N., Mori Y., Tadokoro K., Et al., Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats, Hypertension, 42, pp. 1034-1041, (2003); Nishimatsu H., Suzuki E., Nagata D., Moriyama N., Satonaka H., Walsh K., Et al., Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta, Circ Res, 89, pp. 63-70, (2001); Nishimatsu H., Hirata Y., Shindo T., Kurihara H., Kakoki M., Nagata D., Et al., Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene, Circ Res, 90, pp. 657-663, (2002); Nishio K., Akai Y., Murao Y., Doi N., Ueda S., Tabuse H., Et al., Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock, Crit Care Med, 25, pp. 953-957, (1997); Oehler M.K., Norbury C., Hague S., Rees M.C., Bicknell R., Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth, Oncogene, 20, pp. 2937-2945, (2001); Ogita T., Hashimoto E., Yamasaki M., Nakaoka T., Matsuoka R., Kira Y., Et al., Hypoxic induction of adrenomedullin in cultured human umbilical vein endothelial cells, J Hypertens, 19, pp. 603-608, (2001); Okazaki T., Ogawa Y., Tamura N., Mori K., Isse N., Aoki T., Et al., Genomic organization, expression, and chromosomal mapping of the mouse adrenomedullin gene, Genomics, 37, pp. 395-399, (1996); Okumura H., Nagaya N., Kangawa K., Adrenomedullin infusion during ischemia/reperfusion attenuates left ventricular remodeling and myocardial fibrosis in rats, Hypertens Res, 26, (2003); Okumura H., Nagaya N., Itoh T., Okano I., Hino J., Mori K., Et al., Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway, Circulation, 109, pp. 242-248, (2004); Ono Y., Kojima M., Okada K., Kangawa K., cDNA cloning of canine adrenomedullin and its gene expression in the heart and blood vessels in endotoxin shock, Shock, 10, pp. 243-247, (1998); Osajima A., Kato H., Uezono Y., Suda T., Okazaki M., Oishi Y., Et al., Adrenomedullin inhibits transmural pressure induced mesangial cell proliferation through activation of protein kinase A, Nephron, 83, pp. 352-357, (1999); Owada A., Nonoguchi H., Terada Y., Marumo F., Tomita K., Microlocalization and effects of adrenomedullin in nephron segments and in mesangial cells of the rat, Am J Physiol, 272, (1997); Owji A.A., Smith D.M., Coppock H.A., Morgan D.G., Bhogal R., Ghatei M.A., Bloom S.R., An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat, Endocrinology, 136, pp. 2127-2134, (1995); Ozawa N., Shichiri M., Fukai N., Yoshimoto T., Hirata Y., Regulation of adrenomedullin gene transcription and degradation by the c-myc gene, Endocrinology, 145, pp. 4244-4250, (2004); Packer M., Califf R.M., Konstam M.A., Krum H., McMurray J.J., Rouleau J.L., Et al., Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), Circulation, 106, pp. 920-926, (2002); Parameswaran N., Nambi P., Brooks D.P., Spielman W.S., Regulation of glomerular mesangial cell proliferation in culture by adrenomedullin, Eur J Pharmacol, 372, pp. 85-95, (1999); Parkes D.G., Cardiovascular actions of adrenomedullin in conscious sheep, Am J Physiol, 268, (1995); Parkes D.G., May C.N., ACTH-suppressive and vasodilator actions of adrenomedullin in conscious sheep, J Neuroendocrinol, 7, pp. 923-929, (1995); Petrie M.C., McDonald J.E., Hillier C., Morton J.J., McMurray J.J., Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans, Br J Clin Pharmacol, 52, pp. 165-168, (2001); Poyner D.R., Sexton P.M., Marshall I., Smith D.M., Quirion R., Born W., Et al., International Union of Pharmacology, XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors, Pharmacol Rev, 54, pp. 233-246, (2002); Rademaker M.T., Charles C.J., Lewis L.K., Yandle T.G., Cooper G.J., Coy D.H., Et al., Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure, Circulation, 96, pp. 1983-1990, (1997); Rademaker M.T., Charles C.J., Cooper G.J., Coy D.H., Espiner E.A., Lewis L.K., Et al., Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure, Hypertension, 39, pp. 93-98, (2002); Rehemudula D., Nakayama T., Soma M., Takahashi Y., Uwabo J., Sato M., Et al., Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension, Circ Res, 84, pp. 605-610, (1999); Rocchi P., Boudouresque F., Zamora A.J., Muracciole X., Lechevallier E., Martin P.M., Et al., Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines, Cancer Res, 61, pp. 1196-1206, (2001)","T. Ishimitsu; Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, 321-0293, Japan; email: isimitu@dokkyomed.ac.jp","","","","","","","","01637258","","PHTHD","16616959","English","Pharmacol. Ther.","Review","Final","","Scopus","2-s2.0-33746359354"
"Chen Q.; Tang X.; Yu C.Q.; Chen D.F.; Tian J.; Cao Y.; Fan W.Y.; Cao W.H.; Zhan S.Y.; Lv J.; Guo X.X.; Li L.M.; Hu Y.H.","Chen, Qing (56000561000); Tang, Xun (37051473500); Yu, Can-qing (35313661600); Chen, Da-fang (55521510300); Tian, Jun (53882009300); Cao, Yang (57198761953); Fan, Wen-yi (41461133200); Cao, Wei-hua (7402082953); Zhan, Si-yan (57205304353); Lv, Jun (57209876570); Guo, Xiao-xia (12801592300); Li, Li-ming (57202346020); Hu, Yong-hua (34770189700)","56000561000; 37051473500; 35313661600; 55521510300; 53882009300; 57198761953; 41461133200; 7402082953; 57205304353; 57209876570; 12801592300; 57202346020; 34770189700","[Correlation of angiotensin-converting enzyme 2 gene polymorphism with antihypertensive effects of benazepril].","2010","Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences","42","3","","293","298","5","8","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959528485&partnerID=40&md5=4ecb5e6df25286c1bb05780fc6e1a054","Department of Epidemiology &amp; Biostatistics, Peking University School of Public Health, Beijing, 100191, China","Chen Q., Department of Epidemiology &amp; Biostatistics, Peking University School of Public Health, Beijing, 100191, China; Tang X.; Yu C.Q.; Chen D.F.; Tian J.; Cao Y.; Fan W.Y.; Cao W.H.; Zhan S.Y.; Lv J.; Guo X.X.; Li L.M.; Hu Y.H.","To explore the correlation of rs2106809 from angiotensin-converting enzyme 2 gene with antihypertensive effects of benazepril, as well as its interactions with polymorphisms of angiotensinogen(AGT) and angiotensin II type 1 receptor(AGTR1) gene. Correlation between rs2106809 and blood pressure reduction was estimated based on a field trail with 1 831 hypertensive patients using benazepril for 2 weeks. Generalized multifactor dimensionality reduction (GMDR) was used to explore the interactions of rs2106809 and 8 single nucleotide polymorphisms (SNPs) of AGTR1 gene and 3 SNPs of AGT gene. rs2106809 was found to be associated with reduction in systolic blood pressure and pulse pressure in women, as well as pulse pressure reduction in men. T allele carriers presented more blood pressure reduction (1.4, 1.3 and 0.9 mmHg/T allele respectively). Gene-gene interactions involving rs2106809 were found in systolic blood pressure reduction of men, and the response to benazepril of non-sensitive genotypes carriers was 8.2 (95% confidence interval: 6.6-9.7) mmHg, lower than that of sensitive genotypes carriers. rs2106809 might act as an independent influencing factor or component of gene-gene interaction in blood pressure reducing effects of benazepril.","","Adult; Aged; Antihypertensive Agents; Benzazepines; Female; Genotype; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; angiotensin 1 receptor; angiotensin converting enzyme 2; antihypertensive agent; benazepril; benzazepine derivative; dipeptidyl carboxypeptidase; adult; aged; article; female; genetics; genotype; human; hypertension; male; middle aged; single nucleotide polymorphism","","benazepril, 86541-75-5; dipeptidyl carboxypeptidase, 9015-82-1; angiotensin converting enzyme 2, EC 3.4.17.-; Antihypertensive Agents, ; benazepril, 86541-75-5; Benzazepines, ; Peptidyl-Dipeptidase A, EC 3.4.15.1; Receptor, Angiotensin, Type 1, ","","","","","","","","","","","","","","1671167X","","","20559404","Chinese","Beijing Da Xue Xue Bao","Article","Final","","Scopus","2-s2.0-79959528485"
"Eckel R.H.","Eckel, Robert H. (26643003100)","26643003100","Approach to the patient who is intolerant of statin therapy","2010","Journal of Clinical Endocrinology and Metabolism","95","5","","2015","2022","7","72","10.1210/jc.2009-2689","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952760040&doi=10.1210%2fjc.2009-2689&partnerID=40&md5=76aa281a2e0f91c077f7629f243b98f3","University of Colorado, Denver Anschutz Medical Campus, Mail Stop 8106, Aurora, CO 80045, 12801 East 17th Avenue, United States","Eckel R.H., University of Colorado, Denver Anschutz Medical Campus, Mail Stop 8106, Aurora, CO 80045, 12801 East 17th Avenue, United States","Myopathy occurs in approximately 10% of statin-treated patients and is most commonly manifested by myalgias with or without plasma creatine kinase (CK) elevations. Predisposition exists in patients treated with high doses of potent statins and those who are older, female, have a genetic predisposition, and when statins are coadministered with drugs that compete with or inhibit drug metabolism. In symptomatic patients, CK levels may assist in guiding management. If less than five times the upper limit of normal, the existing statin should be titrated to achieve cholesterol goals and the CK repeated when symptoms appear or worsen. In patients with moderate to severe symptoms and any patient with CK elevated to more than 5-fold the upper limit of normal, the statin should be stopped. Once asymptomatic and CK is reduced (if elevated previously), cholesterol goals can be approached by: 1) a different statin (e.g. fluvastatin or pravastatin), starting with a low dose and titrating up; 2) an alternate daily or weekly more potent statin (e.g. rosuvastatin or atorvastatin); or 3) the combination of the lowest tolerated statin with a cholesterol absorption inhibitor (ezetimibe) and/or bile acid sequestrant. Over-the-counter preparations, e.g. red yeast rice, containing natural statin-like agents, or plant sterols can also lower cholesterol. These, however, have limited efficacy to achieve targeted cholesterol levels for most patients. In patients without CK elevations and symptoms, progress can be followed clinically, but in patients who show CK elevations, CK should be monitored. At present, the superiority of one approach has not been demonstrated, and the need for clinical trials in well-characterized patients with statin intolerance cannot be dismissed. Copyright © 2010 by The Endocrine Society.","","Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Diltiazem; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Pyrroles; Simvastatin; antifungal agent; atorvastatin; bile acid sequestrant; cerivastatin; cholesterol; cholestin; cimetidine; clarithromycin; colesevelam; colestyramine; creatine kinase; cyclosporin; diltiazem; erythromycin; ezetimibe; fenofibric acid; fibric acid derivative; fluindostatin; gemfibrozil; Human immunodeficiency virus proteinase inhibitor; hydroxymethylglutaryl coenzyme A reductase inhibitor; mevinolin; phytosterol; pitavastatin; placebo; pravastatin; rosuvastatin; simvastatin; ubidecarenone; unindexed drug; acetylsalicylic acid; atorvastatin; beta adrenergic receptor blocking agent; diltiazem; dipeptidyl carboxypeptidase inhibitor; heptanoic acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; pyrrole derivative; simvastatin; add on therapy; alanine aminotransferase blood level; article; aspartate aminotransferase blood level; cardiac patient; cholesterol blood level; clinical trial; creatine kinase blood level; disease predisposition; disease severity; drug bioavailability; drug dose escalation; drug dose titration; drug efficacy; drug excretion; drug hypersensitivity; drug megadose; drug metabolism; drug protein binding; drug withdrawal; genetic predisposition; genetic risk; grapefruit juice; histopathology; human; hypercholesterolemia; hyperlipidemia; low drug dose; maximum plasma concentration; molecular mechanics; muscle biopsy; muscle weakness; myalgia; myopathy; myositis; patient monitoring; priority journal; rhabdomyolysis; side effect; single nucleotide polymorphism; time to maximum plasma concentration; treatment response; case report; coronary artery disease; female; hypertension; middle aged","","atorvastatin, 134523-00-5, 134523-03-8; cerivastatin, 143201-11-0; cholesterol, 57-88-5; cimetidine, 51481-61-9, 70059-30-2; clarithromycin, 81103-11-9; colesevelam, 182815-43-6, 182815-44-7; colestyramine, 11041-12-6, 58391-37-0; creatine kinase, 9001-15-4; cyclosporin, 79217-60-0; diltiazem, 33286-22-5, 42399-41-7; erythromycin, 114-07-8, 70536-18-4; ezetimibe, 163222-33-1; fenofibric acid, 26129-32-8, 42017-89-0; fluindostatin, 93957-54-1; gemfibrozil, 25812-30-0; mevinolin, 75330-75-5; pitavastatin, 147526-32-7; pravastatin, 81093-37-0, 81131-70-6; rosuvastatin, 147098-18-8, 147098-20-2; simvastatin, 79902-63-9; ubidecarenone, 303-98-0; acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; Adrenergic beta-Antagonists, ; Angiotensin-Converting Enzyme Inhibitors, ; Aspirin, 50-78-2; Diltiazem, 42399-41-7; Heptanoic Acids, ; Hydroxymethylglutaryl-CoA Reductase Inhibitors, ; Pyrroles, ; Simvastatin, 79902-63-9; atorvastatin, 110862-48-1","","","","","McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R., Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force, Am J Cardiol, 97, (2006); Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C., ACC/AHA/NHLBI clinical advisory on the use and safety of statins, Journal of the American College of Cardiology, 40, 3, pp. 567-572, (2002); Sinzinger H., Wolfram R., Peskar B.A., Muscular side effects of statins, J Cardiovasc Pharmacol, 40, pp. 163-171, (2002); Franc S., Dejager S., Bruckert E., Chauvenet M., Giral P., Turpin G., A comprehensive description of muscle symptoms associated with lipid-lowering drugs, Cardiovasc Drugs Ther, 17, pp. 459-465, (2003); Harper C.R., Jacobson T.A., The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis, Curr Opin Lipidol, 18, pp. 401-408, (2007); Law M., Rudnicka A.R., Statin safety: A systematic review, Am J Cardiol, 97, (2006); Staffa J.A., Chang J., Green L., Cerivastatin and reports of fatal rhabdomyolysis, N Engl J Med, 346, pp. 539-540, (2002); Armitage J., The safety of statins in clinical practice, Lancet, 370, pp. 1781-1790, (2007); Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., Gurwitz J.H., Chan K.A., Goodman M.J., Platt R., Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA, 292, pp. 2585-2590, (2004); Kashani A., Phillips C.O., Foody J.M., Wang Y., Mangalmurti S., Ko D.T., Krumholz H.M., Risks associated with statin therapy: A systematic overview of randomized clinical trials, Circulation, 114, pp. 2788-2797, (2006); Thompson P.D., Clarkson P., Karas R.H., Statin-associated myopathy, JAMA, 289, pp. 1681-1690, (2003); Bruckert E., Hayem G., Dejager S., Yau C., Begaud B., Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - The PRIMO study, Cardiovascular Drugs and Therapy, 19, 6, pp. 403-414, (2005); Nichols G.A., Koro C.E., Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients, Clin Ther, 29, pp. 1761-1770, (2007); Davidson M.H., Clark J.A., Glass L.M., Kanumalla A., Statin safety: An appraisal from the adverse event reporting system, Am J Cardiol, 97, (2006); Joy T.R., Hegele R.A., Narrative review: Statin-related myopathy, Ann Intern Med, 150, pp. 858-868, (2009); Frishman W.H., Horn J., Statin-drug interactions: Not a class effect, Cardiol Rev, 16, pp. 205-212, (2008); Xie H.G., Kim R.B., Wood A.J., Stein C.M., Molecular basis of ethnic differences in drug disposition and response, Annu Rev Pharmacol Toxicol, 41, pp. 815-850, (2001); Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson P.G., Baillie T.A., Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization, Drug Metab Dispos, 30, pp. 505-512, (2002); Prueksaritanont T., Richards K.M., Qiu Y., Strong-Basalyga K., Miller A., Li C., Eisenhandler R., Carlini E.J., Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes, Pharm Res, 22, pp. 71-78, (2005); Jacobson T.A., Myopathy with statin-fibrate combination therapy: Clinical considerations, Nat Rev Endocrinol, 5, pp. 507-518, (2009); Tsivgoulis G., Spengos K., Karandreas N., Panas M., Kladi A., Manta P., Presymptomatic neuromuscular disorders disclosed following statin treatment, Arch Intern Med, 166, pp. 1519-1524, (2006); Vladutiu G.D., Genetic predisposition to statin myopathy, Curr Opin Rheumatol, 20, pp. 648-655, (2008); Klopstock T., Drug-induced myopathies, Curr Opin Neurol, 21, pp. 590-595, (2008); Oh J., Ban M.R., Miskie B.A., Pollex R.L., Hegele R.A., Genetic determinants of statin intolerance, Lipids Health Dis, 6, (2007); Mulder A.B., Van Lijf H.J., Bon M.A., Van Den Bergh F.A., Touw D.J., Neef C., Vermes I., Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin, Clin Pharmacol Ther, 70, pp. 546-551, (2001); Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., Gut I., Lathrop M., Collins R., SLCO1B1 variants and statin-induced myopathy - A genomewide study, N Engl J Med, 359, pp. 789-799, (2008); Hermann M., Bogsrud M.P., Molden E., Asberg A., Mohebi B.U., Ose L., Retterstol K., Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy, Clin Pharmacol Ther, 79, pp. 532-539, (2006); Voora D., Shah S.H., Spasojevic I., Ali S., Reed C.R., Salisbury B.A., Ginsburg G.S., The SLCO1B1*5 genetic variant is associated with statin-induced side effects, J Am Coll Cardiol, 54, pp. 1609-1616, (2009); McKelvie P.A., Dennett X., Myopathy associated with HMG-CoA reductase inhibitors (statins): A series of 10 patients and review of the literature, J Clin Neuromuscul Dis, 3, pp. 143-148, (2002); Siddiqi S.A., Thompson P.D., How do you treat patients with myalgia who take statins?, Curr Atheroscler Rep, 11, pp. 9-14, (2009); Yokoyama M., Seo T., Park T., Yagyu H., Hu Y., Son N.H., Augustus A.S., Vikramadithyan R.K., Ramakrishnan R., Pulawa L.K., Eckel R.H., Goldberg I.J., Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle, J Lipid Res, 48, pp. 646-655, (2007); Galli F., Iuliano L., Do statins cause myopathy by lowering vitamin E levels?, Med Hypotheses, (2009); Lamperti C., Naini A.B., Lucchini V., Prelle A., Bresolin N., Moggio M., Sciacco M., Kaufmann P., DiMauro S., Muscle coenzyme Q10 level in statin-related myopathy, Arch Neurol, 62, pp. 1709-1712, (2005); Mohaupt M.G., Karas R.H., Babiychuk E.B., Sanchez-Freire V., Monastyrskaya K., Iyer L., Hoppeler H., Breil F., Draeger A., Association between statin-associated myopathy and skeletal muscle damage, CMAJ, 181, (2009); Schalke B.B., Schmidt B., Toyka K., Hartung H.P., Pravastatin-associated inflammatory myopathy, N Engl J Med, 327, pp. 649-650, (1992); Phillips P.S., Ciaraldi T.P., Kim D.L., Verity M.A., Wolfson T., Henry R.R., Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids, Endocrine, 35, pp. 38-46, (2009); Paolisso G., Barbagallo M., Petrella G., Ragno E., Barbieri M., Giordano M., Varricchio M., Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients, Atherosclerosis, 150, pp. 121-127, (2000); Phillips P.S., Phillips C.T., Sullivan M.J., Naviaux R.K., Haas R.H., Statin myotoxicity is associated with changes in the cardiopulmonary function, Atherosclerosis, 177, 1, pp. 183-188, (2004); Mallinson J.E., Constantin-Teodosiu D., Sidaway J., Westwood F.R., Greenhaff P.L., Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy, J Physiol, 587, pp. 219-230, (2009); Guis S., Figarella-Branger D., Mattei J.P., Nicoli F., Le Fur Y., Kozak-Ribbens G., Pellissier J.F., Cozzone P.J., Amabile N., Bendahan D., In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects, Arthritis Rheum, 55, pp. 551-557, (2006); Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., England J.D., Statin-associated myopathy with normal creatine kinase levels, Ann Intern Med, 137, pp. 581-585, (2002); Hansen K.E., Hildebrand J.P., Ferguson E.E., Stein J.H., Outcomes in 45 patients with statin-associated myopathy, Arch Intern Med, 165, pp. 2671-2676, (2005); Ahmed W., Khan N., Glueck C.J., Pandey S., Wang P., Goldenberg N., Uppal M., Khanal S., Low serum 25 (OH) vitaminDlevels (<32 ng/ml) are associated with reversible myositis-myalgia in statin-treated patients, Transl Res, 153, pp. 11-16, (2009); Smith C.C., Bernstein L.I., Davis R.B., Rind D.M., Shmerling R.H., Screening for statin-related toxicity: The yield of transaminase and creatine kinase measurements in a primary care setting, Arch Intern Med, 163, pp. 688-692, (2003); Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001); Schaars C.F., Stalenhoef A.F., Effects of ubiquinone (coenzyme Q10) on myopathy in statin users, Curr Opin Lipidol, 19, pp. 553-557, (2008); Hou R., Goldberg A.C., Lowering low-density lipoprotein cholesterol: Statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety, Endocrinol Metab Clin North Am, 38, pp. 79-97, (2009); Stein E.A., Ballantyne C.M., Windler E., Sirnes P.A., Sussekov A., Yigit Z., Seper C., Gimpelewicz C.R., Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins, Am J Cardiol, 101, pp. 490-496, (2008); Glueck C.J., Aregawi D., Agloria M., Khalil Q., Winiarska M., Munjal J., Gogineni S., Wang P., Rosuvastatin 5 and 10 mg/d: A pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies, Clin Ther, 28, pp. 933-942, (2006); Backes J.M., Venero C.V., Gibson C.A., Ruisinger J.F., Howard P.A., Thompson P.D., Moriarty P.M., Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance, Ann Pharmacother, 42, pp. 341-346, (2008); Backes J.M., Moriarty P.M., Ruisinger J.F., Gibson C.A., Effects of once weekly rosuvastatin among patients with a prior statin intolerance, Am J Cardiol, 100, pp. 554-555, (2007); Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R.M., Go V.L.W., Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement, American Journal of Clinical Nutrition, 69, 2, pp. 231-236, (1999); Huang C.F., Li T.C., Lin C.C., Liu C.S., Shih H.C., Lai M.M., Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients, Eur J Cardiovasc Prev Rehabil, 14, pp. 438-440, (2007); Becker D.J., Gordon R.Y., Halbert S.C., French B., Morris P.B., Rader D.J., Red yeast rice for dyslipidemia in statin-intolerant patients: A randomized trial, Ann Intern Med, 150, pp. 830-839, (2009); Phillips P.S., Balancing randomized trials with anecdote, Ann Intern Med, 150, pp. 885-886, (2009); Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F., Newinsights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol Ther, 84, pp. 413-428, (1999); White C.M., A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin, Journal of Clinical Pharmacology, 42, 9, pp. 963-970, (2002); Schachter M., Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update, Fundam Clin Pharmacol, 19, pp. 117-125, (2005); Hui C.K., Cheung B.M., Lau G.K., Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis, Br J Clin Pharmacol, 59, pp. 291-297, (2005); Lv H., Sun J.G., Wang G.J., Zhu X.Y., Zhang Y., Gu S.H., Liang Y., Sun J., Determination of pitavastatin inhumanplasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers, Clin Chim Acta, 386, pp. 25-30, (2007); Shitara Y., Sugiyama Y., Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3- methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions, Pharmacol Ther, 112, pp. 71-105, (2006)","R. H. Eckel; University of Colorado, Denver Anschutz Medical Campus, Mail Stop 8106, Aurora, CO 80045, 12801 East 17th Avenue, United States; email: robert.eckel@ucdenver.edu","","Endocrine Society","","","","","","0021972X","","JCEMA","20444930","English","J. Clin. Endocrinol. Metab.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-77952760040"
"Pojoga L.; Kolatkar N.S.; Williams J.S.; Perlstein T.S.; Jeunemaitre X.; Brown N.J.; Hopkins P.N.; Raby B.A.; Williams G.H.","Pojoga, Luminita (6602423224); Kolatkar, Nikheel S. (15042597600); Williams, Jonathan S. (55499948300); Perlstein, Todd S. (6602389858); Jeunemaitre, Xavier (7005820228); Brown, Nancy J. (54790606300); Hopkins, Paul N. (35351179800); Raby, Benjamin A. (6603864707); Williams, Gordon H. (7406079866)","6602423224; 15042597600; 55499948300; 6602389858; 7005820228; 54790606300; 35351179800; 6603864707; 7406079866","β-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension","2006","Hypertension","48","5","","892","900","8","50","10.1161/01.HYP.0000244688.45472.95","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750272676&doi=10.1161%2f01.HYP.0000244688.45472.95&partnerID=40&md5=9f853b4bbfd34d6300010c7c2ee9046a","Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Centre d'Investigation Clinique, Departement de Genetique, Hôpital Européen Georges Pompidou, Paris, France; Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States; Department of Medicine, University of Utah, School of Medicine, Salt Lake City, UT, United States; Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension, Boston, MA 02115, 221 Longwood Ave, United States","Pojoga L., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Kolatkar N.S., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Williams J.S., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Perlstein T.S., Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Jeunemaitre X., Centre d'Investigation Clinique, Departement de Genetique, Hôpital Européen Georges Pompidou, Paris, France; Brown N.J., Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States; Hopkins P.N., Department of Medicine, University of Utah, School of Medicine, Salt Lake City, UT, United States; Raby B.A., Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Williams G.H., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States, Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension, Boston, MA 02115, 221 Longwood Ave, United States","Two genetic variants of the β-2 adrenergic receptor, 46G>A and 79C>G, affect agonist-mediated receptor downregulation and vascular reactivity. We determined whether these variants were associated with hypertension, per se, blood pressure response to dietary sodium, 2 forms of salt-sensitive hypertension (low renin and nonmodulation), and the activity of the renin-angiotensin-aldosterone system. Included are 280 hypertensive and 65 normotensive white subjects who had the 2 β-2 adrenergic receptor genotypes available. Of all subjects, 171 hypertensive and 48 normotensive subjects had complete data for intermediate phenotyping and blood pressure evaluation on high- and low-sodium balance. The β-2 adrenergic receptor variants were not associated with hypertension per se. However, among hypertensive subjects, the change (from low to high sodium balance) in mean arterial pressure differed significantly by genotype and by diplotype. Compared with all of the other diplotypes combined, 46AA/79CC was associated with a greater change in blood pressure. Furthermore, this diplotype was associated with low-renin (LR) hypertension (identifying 32% of the LR hypertensives), higher plasma aldosterone, and lower plasma renin and serum potassium levels. In conclusion, the 46AA/79CC diplotype is associated with greater blood pressure response to dietary sodium and higher odds of LR hypertension. We propose that the mechanism for the observed association is inadequate suppression of aldosterone with salt intake, implicating the β-2 adrenergic receptor in the regulation of aldosterone secretion. This hypothesis was confirmed in isolated glomerulosa cells, where β-2 adrenergic receptor stimulation increased aldosterone secretion, whereas blockade reduced the stimulated aldosterone response. Importantly, this association could only be detected with an intermediate and not a distant phenotype. © 2006 American Heart Association, Inc.","β-2 adrenergic receptor; Diplotypes; Haplotypes; Hypertension; Low-renin hypertension; Salt-sensitive hypertension; Single nucleotide polymorphisms","Adolescent; Adult; Aged; Animals; Female; Humans; Hypertension; Middle Aged; Phenotype; Polymorphism, Genetic; Rats; Rats, Wistar; Receptors, Adrenergic, beta-2; Sodium Chloride, Dietary; Variation (Genetics); aldosterone; beta adrenergic receptor; potassium; renin; adult; aldosterone blood level; aldosterone release; article; blood pressure; blood vessel reactivity; controlled study; down regulation; female; genetic analysis; genetic variability; genotype; glomerulosa cell; human; hypertension; major clinical study; male; mean arterial pressure; phenotype; plasma renin activity; potassium blood level; priority journal; renin angiotensin aldosterone system; sodium balance; sodium intake","","aldosterone, 52-39-1, 6251-69-0; potassium, 7440-09-7; renin, 61506-93-2, 9015-94-5; Receptors, Adrenergic, beta-2, ; Sodium Chloride, Dietary, ","","","National Heart, Lung, and Blood Institute, NHLBI, (T32HL007609)","","Liggett S.B., Beta-adrenergic receptors in the failing heart: The good, the bad, and the unknown, J Clin Invest, 107, pp. 947-948, (2001); Rankinen T., An P., Rice T., Sun G., Chagnon Y.C., Gagnon J., Leon A.S., Skinner J.S., Wilmore J.H., Rao D.C., Bouchard C., Genomic scan for exercise blood pressure in the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study, Hypertension, 38, pp. 30-37, (2001); Krushkal J., Ferrell R., Mockrin S.C., Turner S.T., Sing C.F., Boerwinkle E., Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings, Circulation, 99, pp. 1407-1410, (1999); Caulfield M., Munroe P., Pembroke J., Samani N., Dominiczak A., Brown M., Benjamin N., Webster J., Ratcliffe P., O'Shea S., Papp J., Taylor E., Dobson R., Knight J., Newhouse S., Hooper J., Lee W., Brain N., Clayton D., Lathrop G.M., Farrall M., Connell J., Genome-wide mapping of human loci for essential hypertension, Lancet, 361, pp. 2118-2123, (2003); Cooper R.S., Luke A., Zhu X., Kan D., Adeyemo A., Rotimi C., Bouzekri N., Ward R., Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19, Hypertension, 40, pp. 629-633, (2002); Green S.A., Turki J., Innis M., Liggett S.B., Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties, Biochemistry, 33, pp. 9414-9419, (1994); Green S.A., Turki J., Bejarano P., Hall I.P., Liggett S.B., Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells, Am J Respir Cell Mol Biol, 13, pp. 25-33, (1995); Dishy V., Sofowora G.G., Xie H.G., Kim R.B., Byrne D.W., Stein C.M., Wood A.J., The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization, N Engl J Med, 345, pp. 1030-1035, (2001); Cockcroft J.R., Gazis A.G., Cross D.J., Wheatley A., Dewar J., Hall I.P., Noon J.P., Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans, Hypertension, 36, pp. 371-375, (2000); Gratze G., Fortin J., Labugger R., Binder A., Kotanko P., Timmermann B., Luft F.C., Hoehe M.R., Skrabal F., Beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians, Hypertension, 33, pp. 1425-1430, (1999); Hoit B.D., Suresh D.P., Craft L., Walsh R.A., Liggett S.B., Beta2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals, Am Heart J, 139, pp. 537-542, (2000); Krushkal J., Xiong M., Ferrell R., Sing C.F., Turner S.T., Boerwinkle E., Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation, Hum Mol Genet, 7, pp. 1379-1383, (1998); Svetkey L.P., Timmons P.Z., Emovon O., Anderson N.B., Preis L., Chen Y.T., Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype, Hypertension, 27, pp. 1210-1215, (1996); Kotanko P., Binder A., Tasker J., DeFreitas P., Kamdar S., Clark A.J., Skrabal F., Caulfield M., Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor, Hypertension, 30, pp. 773-776, (1997); Bray M.S., Krushkal J., Li L., Ferrell R., Kardia S., Sing C.F., Turner S.T., Boerwinkle E., Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension, Circulation, 101, pp. 2877-2882, (2000); Lin R.C.Y., Ericsson J.O., Benjafield A.V., Morris B.J., Association of beta2-adrenoceptor Gln27Glu variant with body weight but not hypertension, Am J Hypertens, 14, pp. 1201-1204, (2001); Tomaszewski M., Brain N.J., Charchar F.J., Wang W.Y., Lacka B., Padmanabahn S., Clark J.S., Anderson N.H., Edwards H.V., Zukowska-Szczechowska E., Grzeszczak W., Dominiczak A.F., Essential hypertension and beta2-adrenergic receptor gene: Linkage and association analysis, Hypertension, 40, pp. 286-291, (2002); Galletti F., Iacone R., Ragone E., Russo O., Della Valle E., Siani A., Barba G., Farinaro E., Strazzullo V., Strazzullo P., Lack of association between polymorphism in the beta2-adrenergic receptor gene, hypertension, and obesity in the Olivetti heart study, Am J Hypertens, 17, pp. 718-720, (2004); Candy G., Samani N., Norton G., Woodiwiss A., Radevski I., Wheatley A., Cockcroft J., Hall I.P., Association analysis of beta2 adrenoceptor polymorphisms with hypertension in a Black African population, J Hypertens, 18, pp. 167-172, (2000); Timmermann B., Mo R., Luft F.C., Gerdts E., Busjahn A., Omvik P., Li G.H., Schuster H., Wienker T.F., Hoehe M.R., Lund-Johansen P., Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study, Kidney Int, 53, pp. 1455-1460, (1998); Jia H., Sharma P., Hopper R., Dickerson C., Lloyd D.D., Brown M.J., Beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians, J Hypertens, 18, pp. 687-693, (2000); Ranade K., Shue W.H., Hung Y.J., Hsuing C.A., Chiang F.T., Pesich R., Hebert J., Olivier M., Chen Y.D., Pratt R., Olshen R., Curb D., Botstein D., Risch N., Cox D.R., The glycine allele of a glycine/arginine polymorphism in the beta2-adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin, Am J Hypertens, 14, pp. 1196-1200, (2001); Pereira A.C., Floriano M.S., Mota G.F., Cunha R.S., Herkenhoff F.L., Mill J.G., Krieger J.E., Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population, Hypertension, 42, pp. 685-692, (2003); Hindorff L.A., Heckbert S.R., Psaty B.M., Lumley T., Siscovick D.S., Herrington D.M., Edwards K.L., Tracy R.P., Beta(2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: The Cardiovascular Health Study, Am J Hypertens, 18, pp. 392-397, (2005); Agarwal A., Williams G.H., Fisher N.D., Genetics of human hypertension, Trends Endocrinol Metab, 16, pp. 127-133, (2005); Williams G.H., Genetic approaches to understanding the pathophysiology of complex human traits, Kidney Int, 46, pp. 1550-1553, (1994); Williams G.H., Genetic factors associated with volume-sensitive hypertension, Mol Cell Endocrinol, 217, pp. 41-44, (2004); Grant F.D., Romero J.R., Jeunemaitre X., Hunt S.C., Hopkins P.N., Hollenberg N.H., Williams G.H., Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism, Hypertension, 39, pp. 191-196, (2002); Kosachunhanun N., Hunt S.C., Hopkins P.N., Williams R.R., Jeunemaitre X., Corvol P., Ferri C., Mortensen R.M., Hollenberg N.K., Williams G.H., Genetic determinants of nonmodulating hypertension, Hypertension, 42, pp. 901-908, (2003); Svetkey L.P., Chen Y.T., McKeown S.P., Preis L., Wilson A.F., Preliminary evidence of linkage of salt sensitivity in black Americans at the beta 2-adrenergic receptor locus, Hypertension, 29, pp. 918-922, (1997); Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K., Arnold K., Ruano G., Liggett S.B., Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness, Proc Natl Acad Sci U S A, 97, pp. 10483-10488, (2000); Hopkins P.N., Lifton R.P., Hollenberg N.K., Jeunemaitre X., Hallouin M.C., Skuppin J., Williams C.S., Dluhy R.G., Lalouel J.M., Williams R.R., Williams G.H., Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity, J Hypertens, 14, pp. 199-207, (1996); Raji A., Williams G.H., Jeunemaitre X., Hopkins P.N., Hunt S.C., Hollenberg N.K., Seely E.W., Insulin resistance in hypertensives: Effect of salt sensitivity, renin status and sodium intake, J Hypertens, 19, pp. 99-105, (2001); Dluhy R.G., Hopkins P., Hollenberg N.K., Williams G.H., Williams R.R., Heritable abnormalities of the renin-angiotensin-aldosterone system in essential hypertension, J Cardiovasc Pharmacol, 12, SUPPL. 3, (1988); Jurinke C., Van Den Boom D., Cantor C.R., Koster H., Automated genotyping using the DNA MassArray technology, Methods Mol Biol, 187, pp. 179-192, (2002); Braley L.M., Menachery A.I., Yao T., Mortensen R.M., Williams G.H., Effect of progesterone on aldosterone secretion in rats, Endocrinology, 137, pp. 4773-4778, (1996); Raby B.A., Weiss S.T., Beta2-adrenergic receptor genetics, Curr Opin Mol Ther, 3, pp. 554-566, (2001); Belfer I., Buzas B., Evans C., Hipp H., Phillips G., Taubman J., Lorincz I., Lipsky R.H., Enoch M.A., Max M.B., Goldman D., Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans, Eur J Hum Genet, 13, pp. 341-351, (2005); Freel E.M., Connell J.M., Mechanisms of hypertension: The expanding role of aldosterone, J Am Soc Nephrol, 15, pp. 1993-2001, (2004); Lowenstein J., Renin assay in hypertensive disease, Annu Rev Med, 23, pp. 333-342, (1972); Cowley Jr. A.W., Genetic and nongenetic determinants of salt sensitivity and blood pressure, Am J Clin Nutr, 65, (1997); Warnock D.G., Low-renin and nonmodulating essential hypertension, Hypertension, 34, pp. 395-397, (1999); Kotanko P., Hoglinger O., Skrabal F., Beta 2-adrenoceptor density in fibroblast culture correlates with human NaCl sensitivity, Am J Physiol, 263, (1992); Feldman R.D., Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet, J Clin Invest, 85, pp. 647-652, (1990); Fisher N.D., Hurwitz S., Ferri C., Jeunemaitre X., Hollenberg N.K., Williams G.H., Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension, Hypertension, 34, pp. 388-394, (1999); Lifton R.P., Hopkins P.N., Williams R.R., Hollenberg N.K., Williams G.H., Dluhy R.G., Evidence for heritability of non-modulating essential hypertension, Hypertension, 13, pp. 884-889, (1989); Tuck M.L., Williams G.H., Cain J.P., Sullivan J.M., Dluhy R.G., Relation of age, diastolic pressure and known duration of hypertension to presence of low renin essential hypertension, Am J Cardiol, 32, pp. 637-642, (1973); Manunta P., Burnier M., D'Amico M., Buzzi L., Maillard M., Barlassina C., Lanella G., Cusi D., Bianchi G., Adducin polymorphism affects renal proximal tubule reabsorption in hypertension, Hypertension, 33, pp. 694-697, (1999); Taddei S., Virdis A., Abdel-Haq B., Giovannetti R., Duranti P., Arena A.M., Favilla S., Salvetti A., Indirect evidence for vascular uptake of circulating renin in hypertensive patients, Hypertension, 21, pp. 852-860, (1993); Muller R., Steffen H.M., Juretzko P., Bonner G., Krone W., Plasma catecholamines, thrombocyte alpha 2- and lymphocyte beta 2-adrenoceptor densities in hypertensive patients with low or normal plasma renin concentrations, Angiology, 46, pp. 221-228, (1995); Hopkins P.N., Hunt S.C., Jeunemaitre X., Smith B., Solorio D., Fisher N.D., Hollenberg N.K., Williams G.H., Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension, Circulation, 105, pp. 1921-1927, (2002); Griffing G.T., Wilson T.E., Melby J.C., Alterations in aldosterone secretion and metabolism in low renin hypertension, J Clin Endocrinol Metab, 71, pp. 1454-1460, (1990); De Lean A., Racz K., McNicoll N., Desrosiers M.L., Direct beta-adrenergic stimulation of aldosterone secretion in cultured bovine adrenal subcapsular cells, Endocrinology, 115, pp. 485-492, (1984); Ehrhart-Bornstein M., Bornstein S.R., Gonzalez-Hernandez J., Holst J.J., Waterman M.R., Scherbaum W.A., Sympathoadrenal regulation of adrenocortical steroidogenesis, Endocr Res, 21, pp. 13-24, (1995); Kosti O., King P.J., Hinson J.P., Tumour-derived human adrenocortical cells express beta-adrenergic receptors: Steroidogenic effects of beta-adrenergic input, Endocr Res, 28, pp. 363-367, (2002); Pratt J.H., McAteer J.A., Beta-adrenergic enhancement of angiotensin II-stimulated aldosterone secretion, Life Sci, 44, pp. 2089-2095, (1989); Hung C.H., Chu D.M., Wang C.L., Yang K.D., Hypokalemia and salbutamol therapy in asthma, Pediatr Pulmonol, 27, pp. 27-31, (1999); Thomas D.J., Dove A.F., Alberti K.G., Metabolic effects of salbutamol infusion during premature labour, Br J Obstet Gynaecol, 84, pp. 497-499, (1977); Tranfa C.M., Pelaia G., Grembiale R.D., Naty S., Durante S., Borrello G., Short-term cardiovascular effects of salmeterol, Chest, 113, pp. 1272-1276, (1998); Du Plooy W.J., Hay L., Kahler C.P., Schutte P.J., Brandt H.D., The dose-related hyper-and-hypokalaemic effects of salbutamol and its arrhythmogenic potential, Br J Pharmacol, 111, pp. 73-76, (1994)","G.H. Williams; Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension, Boston, MA 02115, 221 Longwood Ave, United States; email: gwilliams@partners.org","","","","","","","","0194911X","","HPRTD","17015767","English","Hypertension","Article","Final","","Scopus","2-s2.0-33750272676"
"Fan X.-H.; Wang Y.-B.; Wang H.; Sun K.; Zhang W.-L.; Song X.-D.; Cheng J.-Z.; Wu H.-Y.; Zhou X.-L.; Hui R.-T.","Fan, Xiao-Han (25921421700); Wang, Yi-Bo (57390365800); Wang, Hu (23670628500); Sun, Kai (55487085300); Zhang, Wei-Li (55706383400); Song, Xiao-Dong (57198900595); Cheng, Jing-Zhou (55492693500); Wu, Hai-Ying (12806722400); Zhou, Xiang-Liang (57210941474); Hui, Ru-Tai (35290722700)","25921421700; 57390365800; 23670628500; 55487085300; 55706383400; 57198900595; 55492693500; 12806722400; 57210941474; 35290722700","Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients","2009","Acta Pharmacologica Sinica","30","9","","1237","1244","7","28","10.1038/aps.2009.110","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70249090728&doi=10.1038%2faps.2009.110&partnerID=40&md5=77a66863bcb0b6ae7dcb84e51ea02b75","Department of Cardiology, Hypertension Division, Ministry of Education, Beijing 100037, China; Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China","Fan X.-H., Department of Cardiology, Hypertension Division, Ministry of Education, Beijing 100037, China; Wang Y.-B., Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China; Wang H., Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China; Sun K., Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China; Zhang W.-L., Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China; Song X.-D., Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China; Cheng J.-Z., Sino-German Laboratory for Molecular Medicine, FuWai Hospital, Ministry of Education, Beijing 100037, China; Wu H.-Y., Department of Cardiology, Hypertension Division, Ministry of Education, Beijing 100037, China; Zhou X.-L., Department of Cardiology, Hypertension Division, Ministry of Education, Beijing 100037, China; Hui R.-T., Department of Cardiology, Hypertension Division, Ministry of Education, Beijing 100037, China","Aim:The genetic background of orthostatic blood pressure dysregulation remains poorly understood. Since the renin-angiotensin system plays an important role in blood pressure regulation and response to position change, we hypothesized that angiotensin-converting enzyme (ACE) and ACE2 genetic polymorphisms might contribute, at least partially, to orthostatic blood pressure dysregulation in hypertensive patients.Methods:Two tag single nucleotide polymorphisms (SNPs) of ACE2 and ACE I/D were genotyped in 3630 untreated hypertensive patients and 826 normotensive subjects. Orthostatic hypertension was defined as an increase in systolic blood pressure of 20 mmHg or more and orthostatic hypotension as a drop in blood pressure of 20/10 mmHg or more within three minutes of assumption of upright posture.Results:Female and male patients had similar rates of orthostatic hypertension (16.5% vs 15.3%) and hypotension (22.5% vs 23.8%). No significant differences were detected in the minor allele frequency of ACE2 rs2106809, rs2285666, or ACE I/D in either female or male patients with orthostatic hypertension (15.1%, 22.7%, 19.6%, respectively), hypotension (13.8%, 25%, 16.5%), or normal orthostatic blood pressure response (14.4%, 21.9%, 15.8%) in additive, dominant or recessive models after adjustment for confounders (all P0.05). The orthostatic changes in systolic and diastolic blood pressure were also comparable among patients carrying different genotypes. Similar results were observed in normotensive subjects.Conclusion:These data provide no support for the involvement of ACE or ACE2 in the genetic predisposition to orthostatic hypotension or hypertension. © 2009 CPS and SIMM.","Angiotensin-converting enzyme; Hypertension; Orthostatic hypotension; Polymorphism","Analysis of Variance; Asian Continental Ancestry Group; Chi-Square Distribution; Cross-Sectional Studies; Female; Gene Frequency; Genotype; Humans; Hypertension; Hypotension, Orthostatic; Male; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Regression Analysis; Sex Factors; angiotensin converting enzyme 2; dipeptidyl carboxypeptidase; adult; article; controlled study; diastolic blood pressure; female; gene frequency; genotype; human; major clinical study; male; orthostatic blood pressure; orthostatic hypertension; orthostatic hypotension; prevalence; single nucleotide polymorphism; systolic blood pressure","","dipeptidyl carboxypeptidase, 9015-82-1; Peptidyl-Dipeptidase A, 3.4.15.1; angiotensin converting enzyme 2, 3.4.17.-","","","","","Masaki K.H., Schatz I.J., Burchfiel C.M., Sharp D.S., Chiu D., Foley D., Et al., Orthostatic hypotension predicts mortality in elderly men: The Honolulu Heart Program, Circulation, 98, pp. 2290-2295, (1998); Eigenbrodt M.L., Rose K.M., Couper D.J., Arnett D.K., Smith R., Jones D., Orthostatic hypotension as a risk factor for stroke: The Atherosclerosis Risk in Communities (ARIC) study 1987-1996, Stroke, 31, pp. 2307-2313, (2000); Rose K.M., Tyroler H.A., Nardo C.J., Arnett D.K., Light K.C., Rosamond W., Sharrett A.R., Szklo M., Orthostatic hypotension and the incidence of coronary heart disease: The Atherosclerosis Risk in Communities study, American Journal of Hypertension, 13, 6, pp. 571-578, (2000); Luukinen H., Koski K., Laippala P., Airaksinen K.E., Orthostatic hypotension and the risk of myocardial infarction in the home-dwelling elderly, J Intern Med, 255, pp. 486-493, (2004); Rose K.M., Eigenbrodt M.L., Biga R.L., Couper D.J., Light K.C., Sharrett A.R., Et al., Orthostatic hypotension predicts mortality in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) study, Circulation, 114, pp. 630-636, (2006); Nardo C.J., Chambless L.E., Light K.C., Rosamond W.D., Sharrett A.R., Tell G.S., Et al., Descriptive epidemiology of blood pressure response to change in body position: The ARIC study, Hypertension, 33, pp. 1123-1129, (1999); Kario K., Eguchi K., Hoshide S., Hoshide Y., Umeda Y., Mitsuhashi T., Et al., U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: Orthostatic hypertension as a new cardiovascular risk factor, J Am Coll Cardiol, 40, pp. 133-141, (2002); Matsubayashi K., Okumiya K., Wada T., Osaki Y., Fujisawa M., Doi Y., Et al., Postural dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral function tests and leukoaraiosis in the older elderly living in a community, Stroke, 28, pp. 2169-2173, (1997); Shin C., Abbott R.D., Lee H., Kim J., Kimm K., Prevalence and correlates of orthostatic hypotension in middle-aged men and women in Korea: The Korean Health and Genome Study, J Hum Hypertens, 18, pp. 717-723, (2004); Ray C.A., Monahan K.D., Aging attenuates the vestibulosympathetic reflex in humans, Circulation, 105, pp. 956-961, (2002); Kario K., Eguchi K., Nakagawa Y., Motai K., Shimada K., Relationship between extreme dippers and orthostatic hypertension in elderly hypertensive patients, Hypertension, 31, 1, pp. 77-82, (1998); Grubb B.P., Neurocardiogenic syncope and related disorders of orthostatic intolerance, Circulation, 111, pp. 2997-3006, (2005); Harrap S.B., Cui J.S., Wong Z.Y., Hopper J.L., Familial and genomic analyses of postural changes in systolic and diastolic blood pressure, Hypertension, 43, pp. 586-591, (2004); Shannon J.R., Flattem N.L., Jordan J., Jacob G., Black B.K., Biaggioni I., Et al., Orthostatic intolerance and tachycardia associated with norepinephrinetransporter deficiency, N Engl J Med, 342, pp. 541-549, (2000); Schwartz F., Baldwin C.T., Baima J., Gavras H., Mitochondrial DNA mutations in patients with orthostatic hypotension, Am J Med Genet, 86, pp. 145-150, (1999); Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J Biol Chem, 275, pp. 33238-33243, (2000); Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin i to angiotensin 1-9, Circ Res, 87, (2000); Yagil Y., Yagil C., Hypothesis: ACE2 modulates blood pressure in the mammalian organism, Hypertension, 41, pp. 871-873, (2003); Tabara Y., Kohara K., Miki T., Polymorphisms of genes encoding components of the sympathetic nervous system but not the reninangiotensin system as risk factors for orthostatic hypotension, J Hypertens, 20, pp. 651-656, (2002); Perloff D., Grim C., Flack J., Frohlich E.D., Hill M., McDonald M., Human blood pressure determination by sphygmomanometry, Circulation, 88, pp. 2460-2470, (1993); Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy, Neurology, 46, (1996); Fessel J., Robertson D., Orthostatic hypertension: When pressor reflexes overcompensate, Nat Clin Pract Nephrol, 2, pp. 424-431, (2006); Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., Et al., Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women, Clin Pharmacol Ther, 82, pp. 187-196, (2007); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Hamon M., Fradin S., Denizet A., Filippi-Codaccioni E., Grollier G., Morello R., Prospective evaluation of the effect of an angiotensin i converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention, Heart, 89, pp. 321-325, (2003); Gotshall R.W., Tsai P.F., Bassett Frey M.A., Gender-based differences to the cardiovascular response to standing, Aviat Space Environ Med, 62, pp. 855-859, (1991); Schondorf R., Low P.A., Gender related differences in the cardiovascular responses to upright tilt in normal subjects, Clin Auton Res, 2, pp. 183-187, (1992); Borst C., Van Brederode J.F.M., Wieling W., Van Montfrans G.A., Dunning A.J., Mechanisms of initial blood pressure response to postural change, Clin Sci, 67, pp. 321-327, (1984); Lye M., Vargas E., Faragher E.B., Davies I., Goddard C., Haemodynamic and neurohumoral responses in elderly patients with postural hypotension, Eur J Clin Invest, 20, pp. 90-96, (1990); Harrington F., Murray A., Ford G.A., Relationship of baroreflex sensitivity and blood pressure in an older population, J Hypertens, 18, pp. 1629-1633, (2000); Matsukawa T., Mano T., Gotoh E., Ishii M., Elevated sympathetic nerve activity in patients with accelerated essential hypertension, J Clin Invest, 92, pp. 25-28, (1993); Grassi G., Seravalle G., Bertinieri G., Turri C., Dell'Oro R., Stella M.L., Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly, J Hypertens, 18, pp. 587-593, (2000); Pankow J.S., Rose K.M., Oberman A., Hunt S.C., Atwood L.D., Djousse L., Et al., Possible locus on chromosome 18q influencing postural systolic blood pressure changes, Hypertension, 36, pp. 471-476, (2000); North K.E., Rose K.M., Borecki I.B., Oberman A., Hunt S.C., Miller M.B., Et al., Evidence for a gene on chromosome 13 influencing postural systolic blood pressure change and body mass index, Hypertension, 43, pp. 780-784, (2004); Winker R., Barth A., Valic E., Maier R., Osterode W., Pilger A., Et al., Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance, Int Arch Occup Environ Health, 78, pp. 171-177, (2005); Balding D.J., A tutorial on statistical methods for population association studies, Nat Rev Genet, 7, pp. 781-791, (2006)","","","","","","","","","17457254","","CYLPD","19684612","English","Acta Pharmacol. Sin.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-70249090728"
"Irvin M.R.; Lynch A.I.; Kabagambe E.K.; Tiwari H.K.; Barzilay J.I.; Eckfeldt J.H.; Boerwinkle E.; Davis B.R.; Ford C.E.; Arnett D.K.","Irvin, Marguerite R. (28567762900); Lynch, Amy I. (7102636910); Kabagambe, Edmond K. (6602704484); Tiwari, Hemant K. (7003376624); Barzilay, Joshua I. (7006291495); Eckfeldt, John H. (7006754410); Boerwinkle, Eric (7102087489); Davis, Barry R. (24439500800); Ford, Charles E. (7202669617); Arnett, Donna K. (7101719250)","28567762900; 7102636910; 6602704484; 7003376624; 7006291495; 7006754410; 7102087489; 24439500800; 7202669617; 7101719250","Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study","2010","Journal of Hypertension","28","10","","2076","2083","7","32","10.1097/HJH.0b013e32833c7a4d","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957281447&doi=10.1097%2fHJH.0b013e32833c7a4d&partnerID=40&md5=92b94b1a283f061aee50e147e62d74ae","Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States; Kaiser Permanente of Georgia3, Atlanta, GA, United States; Division of Endocrinology, Emory University, Atlanta, GA, United States; School of Public Health, University of Texas, Health Science Center at Houston, Houston, TX, United States","Irvin M.R., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Lynch A.I., Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States; Kabagambe E.K., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Tiwari H.K., Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States; Barzilay J.I., Kaiser Permanente of Georgia3, Atlanta, GA, United States, Division of Endocrinology, Emory University, Atlanta, GA, United States; Eckfeldt J.H., Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States; Boerwinkle E., School of Public Health, University of Texas, Health Science Center at Houston, Houston, TX, United States; Davis B.R., School of Public Health, University of Texas, Health Science Center at Houston, Houston, TX, United States; Ford C.E., School of Public Health, University of Texas, Health Science Center at Houston, Houston, TX, United States; Arnett D.K., Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States","Background: Several clinical studies report increased risk of diabetes mellitus with pharmacologic treatment for hypertension (HTN). HTN genes may modify glycemic response to antihypertensive treatment. Method: The current study examined the association of 24 single nucleotide polymorphisms (SNPs) in 11 HTN candidate genes with fasting glucose measured at 2, 4, and 6 years after treatment initiation. The study sample included participants free of diabetes at baseline in the Genetics of Hypertension Associated Treatment (GenHAT) study (N = 9309). GenHAT participants were randomized to receive treatment with a diuretic (chlorthalidone), calcium channel blocker (amlodipine), or angiotensin-converting enzyme (ACE) inhibitor (lisinopril). Mixed models for repeated measures were employed to test for gene and pharmacogenetic associations with fasting glucose during follow-up. Results: Fasting glucose at year 2 increased on average 6.8, 4.8 and 3.0 mg/dl from baseline in the chlorthalidone, amlodipine and lisinopril groups, respectively. Carrying the I allele (rs1799752) of the ACE I/D polymorphism was associated with lower fasting glucose levels (P = 0.02). Additionally, an ACE promoter polymorphism (-262, rs4291) was associated with lower fasting glucose for the model AA/AT vs. TT, which remained significant after correction for multiple testing (P = 0.001). Finally, a SNP in the α-subunit of the amiloride-sensitive epithelial sodium channel (SCNN1A, rs2228576) modified the association of amlodipine vs. chlorthalidone treatment with fasting glucose (P < 0.001). Conclusion: Further examination of these genes and their relationships with cardiometabolic disease could foster development of pharmacogenetic guidelines aimed to prevent increases in fasting glucose during antihypertensive treatment. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.; TypeofStudy:An open, randomized study evaluating the association of single nucleotide polymorphisms (SNPs) in hypertension (HTN) candidate genes with fasting glucose after treatment initiation with a diuretic agent (Hygroton) vs. a calcium channel blocker (amlodipine), or an angiotensin converting enzyme (ACE) inhibitor (lisinopril). The Genetics of Hypertension Associated Treatment (GenHAT) study.; Patients:9309 outpatients, mean age 66.4 years. Hygroton group: n=4318; 1785 females and 2533 males; mean age 66.3 years; 2301 non-Hispanic white, 1048 non-Hispanic black, 600 Hispanic white, 140 Hispanic black and 229 other. Amlodipine group: n=2554; 1117 females and 1437 males; mean age 66.5 years; 1385 non-Hispanic white, 628 non-Hispanic black, 333 Hispanic white, 86 Hispanic black and 122 other. Lisinopril group: n=2437; 1005 females and 1432 males; mean age 66.4 years; 1311 non-Hispanic white, 585 non-Hispanic black, 323 Hispanic white, 73 Hispanic black and 145 other. Follow-up: 2, 4 and 6 years.; DosageDuration:12.5 mg once daily for the first and second titration and 25 mg for the third. Duration: 2-6 years.; ComparativeDrug:Lisinopril 10, 20, or 40 mg once daily; and amlodipine 2.5, 5, or 10 mg once daily. Duration: 2-6 years.; AuthorsConclusions:There is ample evidence of overlap in pathways and proteins affecting both HTN and glucose metabolism. We studied 24 SNPs in 11 cardiovascular candidate genes and we hypothesized that they could have an effect on glucose metabolism during hypertension treatment in a biologically plausible way. The majority of these SNPs did not have an effect on fasting glucose. However, we report that the ACE gene has a small effect on fasting glucose during hypertension treatment. Future studies might examine whether the association of ACE with diabetes or related traits during hypertension treatment is modified by other genes or environmental factors. The magnitude of effect of the pharmacogenetic association reported for the SCNN1A polymorphism could have clinical implications. Despite the noted limitations of this result, it would be interesting to replicate this interaction in another study, as inhibition of sodium transport is theorized to be important in diuretic-associated glucose disturbance. More recent studies have identified new loci associated with blood pressure that could be important to our hypothesis and interesting to study in the future. For instance phospholipase C, delta 3 (PLCD3) was highlighted by a recent genome-wide association study and belongs to a family of enzymes important to the insulin-signaling pathway and lipid metabolism ""as reported"". Understanding risk factors for developing glucose dysregulation during antihypertensive treatment continues to be an important research question to pursue to help prevent excess CVD [cardiovascular disease] risk in a vulnerable hypertensive population.; FreeText:Mixed models for repeated measures were employed to test for gene and pharmacogenetic associations with fasting glucose during follow-up. If blood pressure control was not achieved on the maximum study medication dose, a 2nd-step, open-label agent (reserpine, clonidine, or atenolol) and/or a 3rd-step open-label agent (hydralazine) was added. Concomitant drugs: reserpine, clonidine, atenolol and hydralazine in an unspecified number of patients.; Indications:4318 patients with hypertension (systolic blood pressure of 144.6 mmHg and diastolic blood pressure of 83.9 mmHg).; Results:At year 2, mean fasting glucose increased on average 6.8, 4.8 and 3.0 mg/dl from baseline in the Hygroton, amlodipine, and lisinopril groups, respectively. Two single nucleotide polymorphisms (SNPs) in the ACE gene were associated with fasting glucose. Carriers of the insertion allele for the ACE insertion/deletion polymorphism had close to 1 mg/dl lower fasting glucose on average during antihypertensive treatment compared with DD homozygotes. Carrying an A for the ACE -262 A/T (rs4291) polymorphism was associated with a 1.72 mg/dl lower fasting glucose level on average, which met significance criteria after adjustment for multiple testing. There was a gene by treatment interaction for a SNP in alpha subunit of the amiloride-sensitive epithelial sodium channel (SCNN1A) (T663A, rs2228576). The GG genotype was associated with lower fasting glucose levels for amlodipine vs. Hygroton (100 vs. 106 mg/dl, respectively), while carrying the A allele for that SNP was not associated with as large a difference in fasting glucose levels between the 2 treatments (103 vs. 106 mg/dl, respectively).; AdverseEffects:Unspecified number of patients had increased fasting glucose.","amlodipine; angiotensin-converting enzyme; chlorthalidone; hypertension treatment; lisinopril; reninangiotensinaldosterone system; SCNN1A; thiazide diuretics","amlodipine; atenolol; chlortalidone; clonidine; epithelial sodium channel; glucose; hydralazine; lisinopril; reserpine; adult; aged; allele; article; clinical trial; controlled clinical trial; controlled study; diabetes mellitus; DNA polymorphism; double blind procedure; female; follow up; genetic association; genotype; glucose blood level; human; hypertension; major clinical study; male; multicenter study; pharmacogenetics; priority journal; promoter region; randomized controlled trial; risk assessment; single nucleotide polymorphism; statistical significance","","amlodipine, 88150-42-9; atenolol, 29122-68-7, 93379-54-5; chlortalidone, 77-36-1; clonidine, 4205-90-7, 4205-91-8, 57066-25-8; glucose, 50-99-7, 84778-64-3; hydralazine, 304-20-1, 86-54-4; lisinopril, 76547-98-3, 83915-83-7; reserpine, 50-55-5, 8001-95-4","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL063082); National Heart, Lung, and Blood Institute, NHLBI","","Jackson J.H., Sobolski J., Krienke R., Wong K.S., Frech-Tamas F., Nightengale B., Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines, J Am Board Fam Med, 21, (2008); Wright Jr. J.T., Probstfield J.L., Cushman W.C., Pressel S.L., Cutler J.A., Davis B.R., Et al., ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses, Arch Intern Med, 169, pp. 832-842, (2009); Barzilay J.I., Davis B.R., Cutler J.A., Pressel S.L., Whelton P.K., Basile J., Et al., Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern Med, 166, pp. 2191-2201, (2006); Messerli F.H., Grossman E., Goldbourt U., Antihypertensive therapy in diabetic hypertensive patients, Am J Hypertens, 14, (2001); Whaley-Connell A., Sowers J.R., Hypertension management in type 2 diabetes mellitus: Recommendations of the Joint National Committee VII, Endocrinol Metab Clin North Am, 34, pp. 63-75, (2005); Ukpds Group., Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study Group, BMJ, 317, pp. 703-713, (1998); Elliott W.J., Meyer P.M., Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis, Lancet, 369, pp. 201-207, (2007); Muscogiuri G., Chavez A.O., Gastaldelli A., Perego L., Tripathy D., Saad M.J., Et al., The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention, Curr Vasc Pharmacol, 6, pp. 301-312, (2008); Kurtz T.W., Pravenec M., Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system, J Hypertens, 22, pp. 2253-2261, (2004); Gorden P., Glucose intolerance with hypokalemia. Failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia, Diabetes, 22, pp. 544-551, (1973); Rowe J.W., Tobin J.D., Rosa R.M., Andres R., Effect of experimental potassium deficiency on glucose and insulin metabolism, Metabolism, 29, (1980); Bozkurt O., De Boer A., Grobbee D.E., De Leeuw P.W., Kroon A.A., Schiffers P., Et al., Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics, Am J Hypertens, 22, pp. 545-551, (2009); Liamis G., Milionis H., Elisaf M., Blood pressure drug therapy and electrolyte disturbances, Int J Clin Pract, 62, pp. 1572-1580, (2008); Shafi T., Appel L.J., Miller III E.R., Klag M.J., Parekh R.S., Changes in serum potassium mediate thiazide-induced diabetes, Hypertension, 52, pp. 1022-1029, (2008); Arnett D.K., Boerwinkle E., Davis B.R., Eckfeldt J., Ford C.E., Black H., Pharmacogenetic approaches to hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study, Pharmacogenomics J, 2, pp. 309-317, (2002); Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group, JAMA, 283, pp. 1967-1975, (2000); Davis B.R., Cutler J.A., Gordon D.J., Furberg C.D., Wright Jr. J.T., Cushman W.C., Et al., Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group, Am J Hypertens, 9, pp. 342-360, (1996); Grimm Jr. R.H., Margolis K.L., Papademetriou V., Cushman W.C., Ford C.E., Bettencourt J., Alderman M.H., Basile J.N., Black H.R., DeQuattro V., Eckfeldt J., Hawkins C.M., Perry Jr. H.M., Proschan M., Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Hypertension, 37, 1, pp. 19-27, (2001); Diuretic versus alpha-blocker as first-step antihypertensive therapy: Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group, Hypertension, 42, pp. 239-246, (2003); Report of the Special Emphasis Panel on Opportunities and Obstacles to Genetic Research in NHLBI Clinical Studies, (2009); Cheng S., Grow M.A., Pallaud C., Klitz W., Erlich H.A., Visvikis S., Et al., A multilocus genotyping assay for candidate markers of cardiovascular disease risk, Genome Res, 9, pp. 936-949, (1999); Kim D.S., Choi S.I., Lee H.S., Park J.K., Yi H.K., Determination of human angiotensin converting enzyme (ACE) gene polymorphisms in erectile dysfunction: Frequency differences of ACE gene polymorphisms according to the method of analysis, Clin Chem Lab Med, 39, pp. 11-14, (2001); Baroudi T., Bouhaha R., Moran-Moguel C., Sanchez-Corona J., Ben Maiz H., Kammoun A.H., Et al., Association of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene with type 2 diabetes in two ethnic groups of Jerba Island in Tunisia, J Renin Angiotensin Aldosterone Syst, 10, pp. 35-40, (2009); Daimon M., Oizumi T., Saitoh T., Kameda W., Hirata A., Yamaguchi H., Et al., The D allele of the angiotensin-converting enzyme insertion/deletion (I/D) polymorphism is a risk factor for type 2 diabetes in a population-based Japanese sample, Endocr J, 50, pp. 393-398, (2003); Feng Y., Niu T., Xu X., Chen C., Li Q., Qian R., Et al., Insertion/deletion polymorphism of the ACE gene is associated with type 2 diabetes, Diabetes, 51, pp. 1986-1988, (2002); Yang M., Qiu C.C., Xu Q., Xiang H.D., Association of angiotensin converting enzyme gene I/D polymorphism with type 2 diabetes mellitus, Biomed Environ Sci, 19, pp. 323-327, (2006); Cheverud J.M., A simple correction for multiple comparisons in interval mapping genome scans, Heredity, 87, pp. 52-58, (2001); Ramachandran V., Ismail P., Stanslas J., Shamsudin N., Moin S., Mohd J.R., Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects, J Renin Angiotensin Aldosterone Syst, 9, (2008); Ryan A.S., Nicklas B.J., Berman D.M., Ferrell R.E., The insertion/deletion polymorphism of the ACE gene is related to insulin sensitivity in overweight women, Diabetes Care, 24, pp. 1646-1652, (2001); Thomas G.N., Tomlinson B., Chan J.C., Sanderson J.E., Cockram C.S., Critchley J.A., Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: A significant association of tne ACE insertion/deletion polymorphism with type 2 diabetes, Diabetes Care, 24, pp. 356-361, (2001); Van Valkengoed I.G., Stronks K., Hahntow I.N., Hoekstra J.B., Holleman F., The angiotensin converting enzyme insertion/deletion polymorphism and differences in fasting plasma glucose in Hindustani Surinamese, African Surinamese and ethnic Dutch: The population-based SUNSET-study, Diabetes Res Clin Pract, 81, (2008); Bonnet F., Patel S., Laville M., Balkau B., Favuzzi A., Monti L.D., Et al., Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects, Diabetes Care, 31, pp. 789-794, (2008); Ohishi M., Rakugi H., Katsuyat M., Okamuraa Kamide K., Et al., Deletion polymorphism of angiotensin-converting enzyme gene is associated with postprandial hyperglycaemia in individuals undergoing general check-up, Clin Exp Pharmacol Physiol, 27, pp. 483-487, (2000); Perticone F., Ceravolo R., Iacopino S., Cloro C., Ventura G., Maio R., Et al., Relationship between angiotensin-converting enzyme gene polymorphism and insulin resistance in never-treated hypertensive patients, J Clin Endocrinol Metab, 86, pp. 172-178, (2001); Akin F., Turgut S., Dursunoglu D., Turgut G., Karasu U., Gur S., ACE gene polymorphism and cardiac structure in patients with insulin resistance, Mol Biol Rep, 36, pp. 623-629, (2009); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Danser A.H., Schalekamp M.A., Bax W.A., Van Den Brink A.M., Saxena P.R., Riegger G.A., Et al., Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism, Circulation, 92, pp. 1387-1388, (1995); Zhu X., Bouzekri N., Southam L., Cooper R.S., Adeyemo A., McKenzie C.A., Et al., Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure, Am J Hum Genet, 68, pp. 1139-1148, (2001); Villard E., Tiret L., Visvikis S., Rakotovao R., Cambien F., Soubrier F., Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis, Am J Hum Genet, 58, (1996); Keavney B., McKenzie C.A., Connell J.M., Julier C., Ratcliffe P.J., Sobel E., Et al., Measured haplotype analysis of the angiotensin-I converting enzyme gene, Hum Mol Genet, 7, pp. 1745-1751, (1998); Kimth Chang H.S., Parksm Nam B.Y., Parkjs Rhim T., Et al., Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics, Clin Exp Allergy, 38, pp. 1727-1737, (2008); Canessa C.M., Schild L., Buell G., Thorens B., Gautschi I., Horisberger J.D., Et al., Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits, Nature, 367, pp. 463-467, (1994); Conde L., Vaquerizas J.M., Dopazo H., Arbiza L., Reumers J., Rousseau F., Et al., PupaSuite: Finding functional single nucleotide polymorphisms for large-scale genotyping purposes, Nucleic Acids Res, 34, (2006); Iafrate A.J., Feuk L., Rivera M.N., Listewnik M.L., Donahoe P.K., Qi Y., Et al., Detection of large-scale variation in the human genome, Nat Genet, 36, pp. 949-951, (2004); Acr Group., Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group, JAMA, 288, pp. 2981-2997, (2002); Tobin M.D., Sheehan N.A., Scurrah K.J., Burton P.R., Adjusting for treatment effects in studies of quantitative traits: Antihypertensive therapy and systolic blood pressure, Stat Med, 24, pp. 2911-2935, (2005); Newton-Cheh C., Johnson T., Gateva V., Tobin M.D., Bochud M., Et Al. C.L., Genome-wide association study identifies eight loci associated with blood pressure, Nat Genet Epub Ahead of Print, (2009); Dolley G., Lamarche B., Despres J.P., Bouchard C., Perusse L., Vohl M.C., Phosphoinositide cycle gene polymorphisms affect the plasma lipid profile in the Quebec Family Study, Mol Genet Metab, 97, pp. 149-154, (2009); Gilon P., Henquin J.C., Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function, Endocr Rev, 22, pp. 565-604, (2001)","","","Lippincott Williams and Wilkins","","","","","","02636352","","JOHYD","20577119","English","J. Hypertens.","Article","Final","All Open Access; Green Open Access","Scopus","2-s2.0-77957281447"
"Matayoshi T.; Kamide K.; Takiuchi S.; Yoshii M.; Miwa Y.; Takami Y.; Tanaka C.; Banno M.; Horio T.; Nakamura S.; Nakahama H.; Yoshihara F.; Inenaga T.; Miyata T.; Kawano Y.","Matayoshi, Tetsutaro (8515901900); Kamide, Kei (7102978326); Takiuchi, Shin (7004120849); Yoshii, Masayoshi (7102367717); Miwa, Yoshikazu (7101723973); Takami, Yoichi (8635744100); Tanaka, Chihiro (35742025700); Banno, Mariko (6603014358); Horio, Takeshi (59048932700); Nakamura, Satoko (16936305500); Nakahama, Hajime (7005844461); Yoshihara, Fumiki (56227938800); Inenaga, Takashi (7004459467); Miyata, Toshiyuki (56381961600); Kawano, Yuhei (26643119800)","8515901900; 7102978326; 7004120849; 7102367717; 7101723973; 8635744100; 35742025700; 6603014358; 59048932700; 16936305500; 7005844461; 56227938800; 7004459467; 56381961600; 26643119800","The thiazide-sensitive Na+-CI- cotransporter gene, C1784T, and adrenergic receptor-β3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics","2004","Hypertension Research","27","11","","821","833","12","47","10.1291/hypres.27.821","https://www.scopus.com/inward/record.uri?eid=2-s2.0-20044393289&doi=10.1291%2fhypres.27.821&partnerID=40&md5=3a5a5543e715017d5dc3c6389474df42","Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Research Institute, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan","Matayoshi T., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Kamide K., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Takiuchi S., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Yoshii M., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Miwa Y., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Takami Y., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Tanaka C., Research Institute, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Banno M., Research Institute, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Horio T., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Nakamura S., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Nakahama H., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Yoshihara F., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Inenaga T., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Miyata T., Research Institute, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; Kawano Y., Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan","The response of blood pressure to thiazide diuretics (TZDs) differs among individuals. The prediction of the antihypertensive effect of TZDs is important for realizing individualized therapy in the management of hypertension. The aim of this study was to identify the single nucleotide polymorphisms (SNPs) susceptible to the antihypertensive effect of TZDs, particularly focusing on genes related to water-electrolyte absorption in the kidney. Seventy-six outpatients (mean age, 65.4±9.0 years) with essential hypertension (EHT) taking TZDs were retrospectively assessed. We defined as responders (R) those whose mean blood pressure was lowered by more than 5 mmHg after the use of TZDs. Forty-eight SNPs in 17 genes (ADD1, GNB3, TSC [SLC12A3], MLR [NR3C2], NCX1 [SLC8A1], WNK1, WNK4, AGT, ACE, AT1 [AGTR1], CYP11B2, ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1B, ADRA2A) were genotyped in the 76 patients. The SNPs in TSC, MLR, NCX1, WNK1, and WNK4 were identified by direct sequencing and those with minor frequencies of greater than 5% were genotyped in this study. The comparison of polymorphism prevalence between R and non-responders (NR) showed significant differences in TSC C1784T (C allele vs. T allele, odds ratio (OR)=3.81, p= 0.016, confidence interval (CI): 1.25-11.63) and ADRB3 T727C (Trp64Arg) (T allele vs. C allele, OR=4.59, p= 0.005, CI: 1.54-13.68). The blood pressure (BP) in patients homozygous for the major alleles of both TSC C1784T and ADRB3 T727C were significantly reduced by TZD treatment; however, the BP in those homozygous for the minor allele and heterozygous (TSC C1784T. TT+CT; ADRB3 T727C: CC+CT) for both SNPs were not significantly changed after TZD treatment. Both newly detected TSC C1784T and ADRB3 T727C are gene polymorphisms susceptible to the antihypertensive effect of TZDs in patients with EHT. Thus, the prediction of BP reduction by TZDs may be possible by evaluating these two SNPs.","Essential hypertension; Gene polymorphism; Thiazide diuretics","Benzothiadiazines; Calmodulin-Binding Proteins; Diuretics; Drug Resistance; Female; Haplotypes; Heterotrimeric GTP-Binding Proteins; Humans; Hypertension, Renal; Male; Polymorphism, Single Nucleotide; Protein-Serine-Threonine Kinases; Receptors, Adrenergic, beta-3; Receptors, Drug; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retrospective Studies; Sodium Chloride Symporter Inhibitors; Sodium Chloride Symporters; Sodium-Calcium Exchanger; Sympathetic Nervous System; Symporters; Variation (Genetics); adrenergic receptor; aldosterone synthase; alpha 1A adrenergic receptor; alpha 1B adrenergic receptor; alpha 2A adrenergic receptor; angiotensin 1 receptor; angiotensinogen; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta 3 adrenergic receptor; cotransporter; hydrochlorothiazide; indapamide; mefruside; thiazide diuretic agent; trichlormethiazide; adult; aged; allele; antihypertensive activity; article; blood sampling; chi square test; confidence interval; controlled study; DNA polymorphism; drug sensitivity; electrolyte balance; essential hypertension; female; gene frequency; gene sequence; genetic identification; genetic variability; genotype; haplotype; heterozygosity; homozygosity; human; kidney tubule absorption; major clinical study; male; monotherapy; outpatient; prediction; prevalence; retrospective study; single nucleotide polymorphism","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; hydrochlorothiazide, 58-93-5; indapamide, 26807-65-8; mefruside, 7195-27-9; trichlormethiazide, 133-67-5; adducin, ; Benzothiadiazines, ; Calmodulin-Binding Proteins, ; Diuretics, ; G-protein beta3 subunit, ; Heterotrimeric GTP-Binding Proteins, EC 3.6.1.46; PRKWNK4 protein, human, EC 2.7.1.-; Protein-Serine-Threonine Kinases, EC 2.7.1.37; Receptors, Adrenergic, beta-3, ; Receptors, Drug, ; Receptors, Mineralocorticoid, ; SLC12A3 protein, human, ; Sodium Chloride Symporter Inhibitors, ; Sodium Chloride Symporters, ; sodium-calcium exchanger 1, ; Sodium-Calcium Exchanger, ; Symporters, ; thiazide receptor, ; WNK1 protein, human, EC 2.7.1.37","","","","","Chobanian A.V., Bakris G.L., Black H.R., Et al., The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report, JAMA, 289, pp. 2560-2572, (2003); 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension, J. Hypertens., 17, pp. 151-183, (1999); Major outcomes in highrisk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic, JAMA, 288, pp. 2981-2997, (2002); Kaplan N.M., Clinical Hypertension. Treatment of Hypertension: Drug Therapy, (2002); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Glorioso N., Manunta P., Filigheddu F., Et al., The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, pp. 649-654, (1999); Sugimoto K., Hozawa A., Katsuya T., Et al., Alpha-adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the ohasama study, J. Hypertens., 20, pp. 1779-1784, (2002); Gitelman H.J., Graham J.B., Welt L.G., A new familial disorder characterized by hypokalemia and hypomagenesemia, Trans. Assoc. Am. Physicians, 79, pp. 221-235, (1966); Simon D.B., Nelson W.C., Bia M.J., Et al., Gitleman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotrasporter, Nat. Genet., 12, pp. 24-30, (1996); Wilson F.H., Disse-Nicodeme S., Choate K.A., Et al., Human hypertension caused by mutations in WNK kinases, Science, 293, pp. 1107-1112, (2001); Geller D.S., Rodriguez-Soriano J., Vallo Boado A., Et al., Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I, Nat. Genet., 19, pp. 279-281, (1998); Hwang E.F., Williams I., Kovacs G., Et al., Impaired ability of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger from the Dahl/Rapp salt sensitive rat to regulate cytosolic calcium, Am. J. Physiol. Renal. Physiol., 284, (2003); Okuda T., Fujioka Y., Kamide K., Et al., Verification of 525 coding SNPs in 179 hypertension candidate genes in the Japanese population: Identification of 159 SNPs in 93 genes, J. Hum. Genet., 47, pp. 387-394, (2002); Siffert W., Rosskopf D., Siffert G., Et al., Association of a human G-protein beta3 subunit variant with hypertension, Nat. Genet., 18, pp. 45-48, (1998); Nakajima T., Jorde L.B., Ishigami T., Et al., Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations, Am. J. Hum. Genet., 70, pp. 108-123, (2002); Hilger K.F., Delles C., Veelken R., Schmieder R.E., Angiotensionogen gene core promoter variants and non-modulating hypertension, Hypertension, 38, pp. 1250-1254, (2001); Tanaka C., Kamide K., Takiuchi S., Et al., An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms, Hypertens. Res., 26, pp. 301-306, (2003); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, pp. 63-69, (1994); Lajemi M., Labat C., Gautier S., Et al., Angiotensin II type 1 receptor - 153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects, J. Hypertens., 19, pp. 407-413, (2001); Kupari M., Hautanen A., Lankinen L., Et al., Association between human aldosterone synthase (CYP11B2) gene polymorphisms and left venyricular size, mass, and function, Circulation, 97, pp. 569-575, (1998); Bengtsson K., Melander O., Orho-Melander M., Et al., Polymorphism in β1-adrenergic receptor gene and hypertension, Circulation, 104, pp. 187-190, (2001); Bengtsson K., Orho-Melander M., Melander O., Et al., Adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes, Hypertension, 37, pp. 1303-1308, (2001); Ranade K., Jorgenson E., Sheu W.H.-H., Et al., A polymorphism in β1 adrenergic receptor is associated with resting heart rate, Am. J. Hum. Genet., 70, pp. 935-942, (2002); Tonolo G., Melis M.G., Secchi G., Et al., Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population, J. Hypertens., 17, pp. 33-38, (1999); Shibata K., Hirasawa A., Moriyama N., Kawabe K., Ogawa S., Tsujimoto G., α1a-Adrenoceptor polymorphism: Pharmacological characterization and association with benign prostatic hypertrophy, Br. J. Pharmacol., 118, pp. 1403-1408, (1996); Buscher R., Herrmann V., Ring K.M., Et al., Variability in phenylephrine response and essential hypertension: A search for human α1B-adrenergic receptor polymorphisms, J. Pharmacol. Exp. Ther., 291, pp. 793-798, (1999); Michel M.C., Plogmann C., Philipp T., Brodde O.-E., Functional correlates of α2a-adrenocetor gene polymorphism in the HANE study, Nephrol. Dial. Transplant., 14, pp. 2657-2663, (1999); Ardlie K.G., Kruglyak L., Seielstad M., Patterns of linkage disequilibrium in the human genome, Nat. Rev., 3, pp. 299-309, (2002); Cruz D.N., Simon D.B., Nelson-Williams C., Et al., Mutations in the Na-Cl contransporter reduce blood pressure in humans, Hypertension, 37, pp. 1458-1464, (2001); Melander O., Orho-Melander M., Bengtsson K., Et al., Genetic variants of thiazide-sensitive NaCl-cotransporter in Gitelman's syndrome and primary hypertension, Hypertension, 36, pp. 389-394, (2000); Wilson F.H., Kahle K.T., Sabath E., Et al., Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4, Proc. Natl. Acad. Sci. U S A, 100, pp. 680-684, (2003); Yang C.L., Angell J., Mitchell R., Ellison D.H., WNK kinases regulate thiazide-sensitive Na-Cl cotransport, J. Clin. Invest., 111, pp. 1039-1045, (2003); Garbers D.L., Dubosis S.K., The molecular basis of hypertension, Annu. Rev. Biochem., 68, pp. 127-155, (1999); Sciarrone M.T., Stella P., Barlassina C., Et al., ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Intersalt: An international study of electrolyte excretion and blood pressure: Results for 24 hour urinary sodium and potassium excretion, Br. Med. J., 297, pp. 319-328, (1988); Clement K., Vaisse C., Manning B.S.J., Et al., Genetic variation in the beta-3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity, New Engl. J. Med., 333, pp. 352-354, (1995); Urhammer S.A., Hansen T., Borch-Johnsen K., Pedersen O., Studies of the synergistic effect of the trp/arg64 polymorphism of the beta-3-adrenergic receptor gene and the - 3826 A-G variant of the uncoupling protein-1 gene on features of obesity and insulin resistance in a population-based sample of 379 young Danish subjects, J. Clin. Endocrinol. Metab., 85, pp. 3151-3154, (2000); Elbein S.C., Hoffman M., Barrett K., Et al., Role of the beta-3-adrenergic receptor locus in obesity and noninsulin-dependent diabetes among members of Caucasian families with a diabetic sibling pair, J. Clin. Endocrinol. Metab., 81, pp. 4422-4427, (1996); Fujisawa T., Ikegami H., Yamato E., Et al., Trp64Arg mutation of 3-adrenergic receptor in essential hypertension; insulin resistance and the adrenergic system, Am. J. Hypertens., 10, pp. 101-105, (1997); Rissanen J., Kuopusjari J., Pihlajamaki J., Et al., The Trp64Arg polymorphism of the beta 3-adrenergic receptor gene: Lack of association with NIDDM and features of insulin resistance syndrome, Diabetes Care, 20, pp. 1319-1323, (1997); Shihara N., Yasuda K., Moritani T., Et al., The association between Trp64Arg polymorphism of the beta 3-adrenergic receptor and autonomic nervous system activity, J. Clin. Endocrinol. Metab., 84, pp. 1623-1627, (1999)","K. Kamide; Division of Hypertension/Nephrology, National Cardiovascular Center, Suita 565-8565, 5-7-1 Fujishirodai, Japan; email: kamide@hsp.ncvc.go.jp","","","","","","","","09169636","","HRESE","15824464","English","Hypertens. Res.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-20044393289"
"Oishi Y.; Manabe I.; Imai Y.; Hara K.; Horikoshi M.; Fujiu K.; Tanaka T.; Aizawa T.; Kadowaki T.; Nagai R.","Oishi, Yumiko (57194240847); Manabe, Ichiro (6603718842); Imai, Yasushi (55505663900); Hara, Kazuo (57214065152); Horikoshi, Momoko (14021627700); Fujiu, Katsuhito (6602492977); Tanaka, Toshihiro (57201606458); Aizawa, Tadanori (56234755700); Kadowaki, Takashi (55460247700); Nagai, Ryozo (7202269191)","57194240847; 6603718842; 55505663900; 57214065152; 14021627700; 6602492977; 57201606458; 56234755700; 55460247700; 7202269191","Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension","2010","FASEB Journal","24","6","","1780","1788","8","31","10.1096/fj.09-146589","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953528432&doi=10.1096%2ffj.09-146589&partnerID=40&md5=099e1ed2866de13bea12a85f4fcb1705","Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan; Translational Systems Biology and Medicine Initiative, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Global Center of Education and Research for Chemical Biology of Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; PRESTO, Japan Science and Technology Agency, Saitama, Japan; Laboratory for Cardiovascular Diseases, Center for Genomic Medicine, RIKEN, Yokohama, Japan; Department of Cardiology, Cardiovascular Institute, Tokyo, Japan; Translational Research Center, University of Tokyo Hospital, Tokyo, Japan","Oishi Y., Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan, Translational Systems Biology and Medicine Initiative, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Manabe I., Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan, Global Center of Education and Research for Chemical Biology of Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, PRESTO, Japan Science and Technology Agency, Saitama, Japan; Imai Y., Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan; Hara K., Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Horikoshi M., Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Fujiu K., Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan, Translational Systems Biology and Medicine Initiative, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Tanaka T., Laboratory for Cardiovascular Diseases, Center for Genomic Medicine, RIKEN, Yokohama, Japan; Aizawa T., Department of Cardiology, Cardiovascular Institute, Tokyo, Japan; Kadowaki T., Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Nagai R., Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan, Translational Systems Biology and Medicine Initiative, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, Global Center of Education and Research for Chemical Biology of Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, Translational Research Center, University of Tokyo Hospital, Tokyo, Japan","Krüppel-like factor 5 (KLF5) is a zinc-finger-type transcription factor that mediates the tissue remodeling in cardiovascular diseases, such as atherosclerosis, restenosis, and cardiac hypertrophy. Our previous studies have shown that KLF5 is induced by angiotensin II (AII), although the precise molecular mechanism is not yet known. Here we analyzed regulatory single nucleotide polymorphisms (SNPs) within the KLF5 locus to identify clinically relevant signaling pathways linking AII and KLF5. One SNP was located at -1282 bp and was associated with an increased risk of hypertension: subjects with the A/A and A/G genotypes at -1282 were at significantly higher risk for hypertension than those with the G/G genotype. Interestingly, a reporter construct corresponding to the -1282G genotype showed much weaker responses to AII than a construct corresponding to -1282A. Electrophoretic mobility shift, chromatin immunoprecipitation, and reporter assays collectively showed that the -1282 SNP is located within a functional myocyte enhancer factor 2 (MEF2) binding site, and that the -1282G genotype disrupts the site and reduces the AII responsiveness of the promoter. Moreover, MEF2 activation via reactive oxygen species and p38 mitogen-activated protein kinase induced KLF5 expression in response to AII, and KLF5 and MEF2 were coexpressed in coronary atherosclerotic plaques. These results suggest that a novel signaling and transcription network involving MEF2A and KLF5 plays an important role in the pathogenesis of cardiovascular diseases such as hypertension. © FASEB.","p38 MAP kinase; Reactive oxygen species","Adult; Aged; Aged, 80 and over; Angiotensin II; Animals; Aorta; Atherosclerosis; Case-Control Studies; Cells, Cultured; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypertension; Immunoblotting; Immunoenzyme Techniques; Immunoprecipitation; Kruppel-Like Transcription Factors; MADS Domain Proteins; Male; Middle Aged; Myogenic Regulatory Factors; p38 Mitogen-Activated Protein Kinases; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Rats; Reactive Oxygen Species; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; 2 morpholino 8 phenylchromone; 4 (4 fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl)imidazole; angiotensin II; kruppel like factor 5; luciferase; mitogen activated protein kinase p38; myocyte enhancer factor 2; reactive oxygen metabolite; small interfering RNA; adult; aged; animal cell; aorta media; article; binding affinity; chromatin immunoprecipitation; controlled study; coronary artery atherosclerosis; enzyme activity; female; gel mobility shift assay; gene frequency; gene locus; genetic association; genetic risk; genotype; human; human cell; hypertension; major clinical study; male; nonhuman; nucleotide sequence; priority journal; promoter region; protein binding; protein expression; protein protein interaction; rat; signal transduction; single nucleotide polymorphism; smooth muscle fiber","GENBANK: NC_000013","2 morpholino 8 phenylchromone, 154447-36-6; 4 (4 fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl)imidazole, 152121-47-6; angiotensin II, 11128-99-7; myocyte enhancer factor 2, 148349-68-2; Angiotensin II, 11128-99-7; KLF5 protein, human, ; Kruppel-Like Transcription Factors, ; MADS Domain Proteins, ; MEF2A protein, human, ; Myogenic Regulatory Factors, ; RNA, Messenger, ; RNA, Small Interfering, ; Reactive Oxygen Species, ; p38 Mitogen-Activated Protein Kinases, 2.7.11.24","","","Japan Society for the Promotion of Science, JSPS, (20229008); Japan Society for the Promotion of Science, JSPS","","Shindo T., Manabe I., Fukushima Y., Tobe K., Aizawa K., Miyamoto S., Kawai-Kowase K., Moriyama N., Imai Y., Kawakami H., Nishimatsu H., Ishikawa T., Suzuki T., Morita H., Maemura K., Sata M., Hirata Y., Komukai M., Kagechika H., Kadowaki T., Kurabayashi M., Nagai R., Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling, Nat. Med., 8, pp. 856-863, (2002); Manabe I., Nagai R., Regulation of smooth muscle phenotype, Curr. Atheroscler. Rep., 5, pp. 214-222, (2003); Owens G.K., Kumar M.S., Wamhoff B.R., Molecular regulation of vascular smooth muscle cell differentiation in development and disease, Physiol. Rev., 84, pp. 767-801, (2004); Fujiu K., Manabe I., Ishihara A., Oishi Y., Iwata H., Nishimura G., Shindo T., Maemura K., Kagechika H., Shudo K., Nagai R., Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5, Circ. Res., 97, pp. 1132-1141, (2005); Hoshino Y., Kurabayashi M., Kanda T., Hasegawa A., Sakamoto H., Okamoto E., Kowase K., Watanabe N., Manabe I., Suzuki T., Nakano A., Takase S., Wilcox J.N., Nagai R., Regulated expression of the BTEB2 transcription factor in vascular smooth muscle cells: Analysis of developmental and pathological expression profiles shows implications as a predictive factor for restenosis, Circulation, 102, pp. 2528-2534, (2000); Kawai-Kowase K., Kurabayashi M., Hoshino Y., Ohyama Y., Nagai R., Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells, Circulation Research, 85, 9, pp. 787-795, (1999); Potthoff M.J., Olson E.N., MEF2: A central regulator of diverse developmental programs, Development, 134, pp. 4131-4140, (2007); Lin Q., Lu J., Yanagisawa H., Webb R., Lyons G.E., Richardson J.A., Olson E.N., Requirement of the MADS-box transcription factor MEF2C for vascular development, Development, 125, 22, pp. 4565-4574, (1998); Suzuki E., Nishimatsu H., Satonaka H., Walsh K., Goto A., Omata M., Fujita T., Nagai R., Hirata Y., Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes, Circ. Res., 90, pp. 1004-1011, (2002); Suzuki E., Satonaka H., Nishimatsu H., Oba S., Takeda R., Omata M., Fujita T., Nagai R., Hirata Y., Myocyte enhancer factor 2 mediates vascular inflammation via the p38-dependent pathway, Circ. Res., 95, pp. 42-49, (2004); Katoh Y., Molkentin J.D., Dave V., Olson E.N., Periasamy M., MEF2B is a component of a smooth musclespecific complex that binds an a/T-rich element important for smooth muscle myosin heavy chain gene expression, J. Biol. Chem., 273, pp. 1511-1518, (1998); Deaton R.A., Su C., Valencia T.G., Grant S.R., Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK, J. Biol. Chem., 280, pp. 31172-31181, (2005); Gregoire S., Tremblay A.M., Xiao L., Yang Q., Ma K., Nie J., Mao Z., Wu Z., Giguere V., Yang X.J., Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation, J. Biol. Chem., 281, pp. 4423-4433, (2006); Black B.L., Olson E.N., Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins, Annu. Rev. Cell Dev. Biol., 14, pp. 167-196, (1998); Firulli A.B., Miano J.M., Bi W., Johnson A.D., Casscells W., Olson E.N., Schwarz J.J., Myocyte enhancer binding factor-2 expression and activity in vascular smooth muscle cells: Association with the activated phenotype, Circulation Research, 78, 2, pp. 196-204, (1996); Wang L., Fan C., Topol S.E., Topol E.J., Wang Q., Mutation of MEF2A in an inherited disorder with features of coronary artery disease, Science, 302, pp. 1578-1581, (2003); Lieb W., Mayer B., Konig I.R., Borwitzky I., Gotz A., Kain S., Hengstenberg C., Linsel-Nitschke P., Fischer M., Doring A., Wichmann H.E., Meitinger T., Kreutz R., Ziegler A., Schunkert H., Erdmann J., Lack of association between the MEF2A gene and myocardial infarction, Circulation, 117, pp. 185-191, (2008); Prokunina L., Alarcon-Riquelme M.E., Regulatory SNPs in complex diseases: Their identification and functional validation, Expert Rev. Mol. Med., 6, pp. 1-15, (2004); World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee, J. Hypertens., 17, pp. 151-183, (1999); Oishi Y., Manabe I., Tobe K., Tsushima K., Shindo T., Fujiu K., Nishimura G., Maemura K., Yamauchi T., Kubota N., Suzuki R., Kitamura T., Akira S., Kadowaki T., Nagai R., Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation, Cell. Metab., 1, pp. 27-39, (2005); Manabe I., Owens G.K., Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system, Circulation Research, 88, 11, pp. 1127-1134, (2001); Manabe I., Owens G.K., CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo, Journal of Clinical Investigation, 107, 7, pp. 823-834, (2001); Pollock R., Treisman R., Human SRF-related proteins: DNA-binding properties and potential regulatory targets, Genes and Development, 5, 12, pp. 2327-2341, (1991); Mehta P.K., Griendling K.K., Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system, Am. J. Physiol. Cell Physiol., 292, (2007); Kearney M., Pieczek A., Haley L., Losordo D.W., Andres V., Schainfeld R., Rosenfield K., Isner J.M., Histopathology of in-stent restenosis in patients with peripheral artery disease, Circulation, 95, 8, pp. 1998-2002, (1997); Clempus R.E., Griendling K.K., Reactive oxygen species signaling in vascular smooth muscle cells, Cardiovasc. Res., 71, pp. 216-225, (2006); Ushio-Fukai M., Alexander R.W., Akers M., Griendling K.K., P38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy, J. Biol. Chem., 273, pp. 15022-15029, (1998); Han J., Molkentin J.D., Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology, Trends Cardiovasc. Med., 10, pp. 19-22, (2000); Atkins G.B., Jain M.K., Role of Krüppel-like transcription factors in endothelial biology, Circ. Res., 100, pp. 1686-1695, (2007); Parmar K.M., Larman H.B., Dai G., Zhang Y., Wang E.T., Moorthy S.N., Kratz J.R., Lin Z., Jain M.K., Gimbrone Jr. M.A., Garcia-Cardena G., Integration of flow-dependent endothelial phenotypes by Krüppel-like factor 2, J. Clin. Invest., 116, pp. 49-58, (2006); Kumar A., Hoffman T.A., Dericco J., Naqvi A., Jain M.K., Irani K., Transcriptional repression of Krüppel-like factor-2 by the adaptor protein p66shc, FASEB J., 23, pp. 4344-4352, (2009); Kumar A., Lin Z., Senbanerjee S., Jain M.K., Tumor Necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-{kappa}B and histone deacetylases, Mol. Cell. Biol., 25, pp. 5893-5903, (2005); Agarwal A., Williams G.H., Fisher N.D., Genetics of human hypertension, Trends Endocrinol. Metab., 16, pp. 127-133, (2005); Oparil S., Zaman M.A., Calhoun D.A., Pathogenesis of hypertension, Ann. Intern. Med., 139, pp. 761-776, (2003); Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature, 447, pp. 661-678, (2007)","I. Manabe; Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo 113-8655, 7-3-1 Hongo, Japan; email: manabe-tky@umin.ac.jp","","","","","","","","15306860","","FAJOE","20086047","English","FASEB J.","Article","Final","","Scopus","2-s2.0-77953528432"
"Dickson M.E.; Zimmerman M.B.; Rahmouni K.; Sigmund C.D.","Dickson, Matthew E. (36459779600); Zimmerman, M. Bridget (35518910700); Rahmouni, Kamal (7003780122); Sigmund, Curt D. (14319198500)","36459779600; 35518910700; 7003780122; 14319198500","The -20 and -217 promoter variants dominate differential angiotensinogen haplotype regulation in angiotensinogen-expressing cells","2007","Hypertension","49","3 PART 2 SUPPL.","","631","639","8","32","10.1161/01.HYP.0000254350.62876.b1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847041494&doi=10.1161%2f01.HYP.0000254350.62876.b1&partnerID=40&md5=59fcf6af226a7227af469736bf654963","Interdisciplinary Genetics Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Medical Scientist Training Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Department of Biostatistics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Departments of Internal Medicine and Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, United States","Dickson M.E., Interdisciplinary Genetics Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States, Medical Scientist Training Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Zimmerman M.B., Department of Biostatistics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Rahmouni K., Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States; Sigmund C.D., Interdisciplinary Genetics Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States, Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States, Departments of Internal Medicine and Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, United States","A number of naturally occurring polymorphisms exist in the human angiotensinogen locus, some of which have been associated with essential hypertension, preeclampsia, and other medical disorders. However, to date there has been no comprehensive determination of the significance of specific haplotypes in relation to the regulation of angiotensinogen expression. We cloned the promoters extending from -1219 to +125 bp from 11 ethnically diverse individuals to acquire a representative cross-section of known haplotype diversity. Eight nonredundant haplotypes were identified, fused to luciferase, and studied for their effect on transcriptional regulation in human astrocyte, proximal tubule, and hepatocyte cell lines endogenously expressing angiotensinogen and in a mouse adipocyte cell line. The studies were carried out under baseline conditions, in the presence of the angiotensinogen enhancer, and in response to hormonal stimulation by dexamethasone, β-estradiol, or testosterone. A statistical model was then constructed to assess the significance of individual polymorphisms. The polymorphisms with the greatest effect on transcription in these cell lines were located at -20 and -217. There were modest haplotype-specific effects of the angiotensinogen enhancer and no haplotype-specific effects of β-estradiol, dexamethasone, or testosterone treatment. We conclude the following: (1) the -20 and -217 polymorphisms have the largest influence on angiotensinogen transcription, (2) other polymorphisms have a much smaller impact on angiotensinogen transcription, and (3) the transcriptional influence of the promoter polymorphisms may act cell specifically. Therefore, our data support a hypothesis that polymorphisms in the angiotensinogen promoter may act cell specifically to differentially regulate the level of angiotensinogen transcription in angiotensin-producing tissues. © 2007 American Heart Association, Inc.","Genetics; Hypertension; Renin-angiotensin system; Transcription; Transfection","Adipose Tissue; Angiotensinogen; Animals; Cell Line; Central Nervous System; Haplotypes; Humans; Kidney Tubules, Proximal; Liver; Mice; Neuroglia; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Promoter Regions (Genetics); Transcription, Genetic; angiotensinogen; dexamethasone; estradiol; luciferase; testosterone; adipocyte; astrocyte; cell line; cloning; conference paper; controlled study; ethnicity; genetic polymorphism; genetic variability; haplotype; human; human cell; kidney proximal tubule; liver cell; priority journal; promoter region; protein expression; statistical analysis; transcription regulation","","angiotensinogen, 11002-13-4, 64315-16-8; dexamethasone, 50-02-2; estradiol, 50-28-2; testosterone, 58-22-0; Angiotensinogen, 11002-13-4","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL048058)","","Hottenga J.J., Boomsma D.I., Kupper N., Posthuma D., Snieder H., Willemsen G., de Geus E.J., Heritability and stability of resting blood pressure, Twin Res Hum Genet, 8, pp. 499-508, (2005); Gould A.B., Green B., Kinetics of the human renin and human renin substrate reaction, Cardiovasular Res, 5, pp. 86-89, (1971); Merrill D.C., Thompson M.W., Carney C., Schlager G., Robillard J.E., Sigmund C.D., Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes, J Clin Invest, 97, pp. 1047-1055, (1996); Ganten D., Wagner J., Zeh K., Koeller M., Bader M., Michel J.B., Paul M., Zimmermann F., Ruf P., Hilgenfeld U., Ganten U., Kaling M., Bachmann S., Mullins J.J., Murakami K., Species-specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes, Proc Natl Acad Sci U S A, 89, pp. 7806-7810, (1992); Kim H.S., Krege J.H., Kluckman K.D., Hagaman J.R., Hodgin J.B., Best C.F., Jennette J.C., Coffman T.M., Maeda N., Smithies O., Genetic control of blood pressure and the angiotensinogen locus, Proc Natl Acad Sci U S A, 92, pp. 2735-2739, (1995); Inoue I., Nakajima T., Williams C.S., Quackenbush J., Puryear R., Powers M., Cheng T., Ludwig E.H., Sharma A.M., Hata A., Jeunemaitre X., Lalouel J.M., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, pp. 1786-1797, (1997); Sethi A.A., Nordestgaard B.G., Tybjaerg-Hansen A., Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis, Arterioscler Thromb Vasc Biol, 23, pp. 1269-1275, (2003); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.-M., Corvol P., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Dickson M.E., Sigmund C.D., Genetic basis of hypertension: Revisiting angiotensinogen, Hypertension, 48, pp. 14-20, (2006); Nibu Y., Takahashi S., Tanimoto K., Murakami K., Fukamizu A., Identification of cell type-dependent enhancer core element located in the 3′-downstream region of the human angiotensinogen gene, J Biol Chem, 269, pp. 28598-28605, (1994); Yang G., Sigmund C.D., Regulatory elements required for human angiotensinogen expression in HepG2 cells are dispensible in transgenic mice, Hypertens, 31, pp. 734-740, (1998); Nakajima T., Inoue I., Cheng T., Lalouel J.M., Molecular cloning and functional analysis of a factor that binds to the proximal promoter of human angiotensinogen, J Hum Genet, 47, pp. 7-13, (2002); Jain S., Tang X., Narayanan C.S., Agarwal Y., Peterson S.M., Brown C.D., Ott J., Kumar A., Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans, J Biol Chem, 277, pp. 36889-36896, (2002); Jain S., Li Y., Patil S., Kumar A., A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hypertension and affects glucocorticoid induced promoter activity, J Mol Med, 83, pp. 121-131, (2005); Narayanan C.S., Cui Y., Zhao Y.Y., Zhou J., Kumar A., Orphan receptor Arp-1 binds to the nucleotide sequence located between TATA box and transcriptional initiation site of the human angiotensinogen gene and reduces estrogen induced promoter activity, Mol Cell Endocrinol, 148, pp. 79-86, (1999); Zhao Y.Y., Zhou J., Narayanan C.S., Cui Y., Kumar A., Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene, Hypertension, 33, pp. 108-115, (1999); Nakajima T., Jorde L.B., Ishigami T., Umemura S., Emi M., Lalouel J.M., Inoue I., Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations, Am J Hum Genet, 70, pp. 108-123, (2002); Fejerman L., Bouzekri N., Wu X., Adeyemo A., Luke A., Zhu X., Ward R., Cooper R.S., Association between evolutionary history of angiotensinogen haplotypes and plasma levels, Hum Genet, 115, pp. 310-318, (2004); Morimoto S., Cassell M.D., Sigmund C.D., Glial- and neuronal-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference, J Biol Chem, 277, pp. 33235-33241, (2002); Davisson R.L., Ding Y., Stec D.E., Catterall J.F., Sigmund C.D., Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice, Physiol Genomics, 1, pp. 3-9, (1999); Schinke M., Baltatu O., Bohm M., Peters J., Rascher W., Bricca G., Lippoldt A., Ganten D., Bader M., Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen, Proc Natl Acad Sci U S A, 96, pp. 3975-3980, (1999); Massiera F., Bloch-Faure M., Ceiler D., Murakami K., Fukamizu A., Gasc J.M., Quignard-Boulange A., Negrel R., Ailhaud G., Seydoux J., Meneton P., Teboul M., Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation, FASEB J, 15, pp. 2727-2729, (2001); Huang H., Lane M.D., Tang Q.Q., Effect of serum on the down-regulation of CHOP-10 during differentiation of 3T3-L1 preadipocytes, Biochem Biophys Res Commun, 338, pp. 1185-1188, (2005); Sherrod M., Liu X., Zhang X., Sigmund C.D., Nuclear Localization of Angiotensinogen in Astrocytes, Am J Physiol Regul Integr Comp Physiol, 288, (2005); Schmidt H., Aulchenko Y.S., Schweighofer N., Schmidt R., Frank S., Kostner G.M., Ott E., van Duijn C., Angiotensinogen promoter B-haplotype associated with cerebral small vessel disease enhances basal transcriptional activity, Stroke, 35, pp. 2592-2597, (2004); Ding Y., Sigmund C.D., Androgen-dependent regulation of human angiotensinogen expression in KAP-hAGT transgenic mice, Am J Physiol Renal Physiol, 280, (2001); Mosselman S., Polman J., Dijkema R., ER beta: Identification and characterization of a novel human estrogen receptor, FEBS Lett, 392, pp. 49-53, (1996); Yi P., Driscoll M.D., Huang J., Bhagat S., Hilf R., Bambara R.A., Muyan M., The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ER alpha and ER beta, Mol Endocrinol, 16, pp. 674-693, (2002); Nakajima T., Wooding S., Sakagami T., Emi M., Tokunaga K., Tamiya G., Ishigami T., Umemura S., Munkhbat B., Jin F., Guan-Jun J., Hayasaka I., Ishida T., Saitou N., Pavelka K., Lalouel J.M., Jorde L.B., Inoue I., Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world, Am J Hum Genet, 74, pp. 898-916, (2004); Morgan L., Crawshaw S., Baker P.N., Pipkin F.B., Kalsheker N., Polymorphism in oestrogen response element associated with variation in plasma angiotensinogen concentrations in healthy pregnant women, J Hypertens, 18, pp. 553-557, (2000); Zhu Y., Casado M., Vaulont S., Sharma K., Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1, Diabetes, 54, pp. 1976-1984, (2005); Casado M., Vallet V.S., Kahn A., Vaulont S., Essential role in vivo of upstream stimulatory factors for a normal dietary response of the fatty acid synthase gene in the liver, J Biol Chem, 274, pp. 2009-2013, (1999); Vallet V.S., Casado M., Henrion A.A., Bucchini D., Raymondjean M., Kahn A., Vaulont S., Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose, J Biol Chem, 273, pp. 20175-20179, (1998); Vallet V.S., Henrion A.A., Bucchini D., Casado M., Raymondjean M., Kahn A., Vaulont S., Glucose-dependent liver gene expression in upstream stimulatory factor 2 -/- mice, J Biol Chem, 272, pp. 21944-21949, (1997); Hopkins P.N., Heiss G., Ellison R.C., Province M.A., Pankow J.S., Eckfeldt J.H., Hunt S.C., Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study, Circulation, 108, pp. 519-523, (2003); Naukkarinen J., Gentile M., Soro-Paavonen A., Saarela J., Koistinen H.A., Pajukanta P., Taskinen M.R., Peltonen L., USF1 and dyslipidemias: Converging evidence for a functional intronic variant, Hum Mol Genet, 14, pp. 2595-2605, (2005); Darlington G.J., Ross S.E., MacDougald O.A., The role of C/EBP genes in adipocyte differentiation, J Biol Chem, 273, pp. 30057-30060, (1998); Wang N.D., Finegold M.J., Bradley A., Ou C.N., Abdelsayed S.V., Wilde M.D., Taylor L.R., Wilson D.R., Darlington G.J., Impaired energy homeostasis in C/EBP alpha knockout mice, Science, 269, pp. 1108-1112, (1995); Yang J., Croniger C.M., Lekstrom-Himes J., Zhang P., Fenyus M., Tenen D.G., Darlington G.J., Hanson R.W., Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha, J Biol Chem, 280, pp. 38689-38699, (2005); Timchenko N., Wilson D.R., Taylor L.R., Abdelsayed S., Wilde M., Sawadogo M., Darlington G.J., Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding, Mol Cell Biol, 15, pp. 1192-1202, (1995); Brand E., Chatelain N., Paillard F., Tiret L., Visvikis S., Lathrop M., Soubrier F., Demenais F., Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis, Eur J Hum Genet, 10, pp. 715-723, (2002)","C.D. Sigmund; Departments of Internal Medicine and Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, United States; email: curt-sigmund@uiowa.edu","","","","","","","","0194911X","","HPRTD","17200439","English","Hypertension","Conference paper","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-33847041494"
"Anderson J.L.; Carlquist J.F.; Horne B.D.; Muhlestein J.B.","Anderson, Jeffrey L. (57191817794); Carlquist, John F. (7005854322); Horne, Benjamin D. (34769653600); Muhlestein, Joseph B. (7005280963)","57191817794; 7005854322; 34769653600; 7005280963","Cardiovascular pharmacogenomics: Current status, future prospects","2003","Journal of Cardiovascular Pharmacology and Therapeutics","8","1","","71","83","12","34","10.1177/107424840300800i110","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037346529&doi=10.1177%2f107424840300800i110&partnerID=40&md5=07959499beb75655aace411bd63d7b2b","Intermt. Heart Collab. Res. Grp., LDS Hosp. Cardiovascular Department, Univ. of Utah School of Medicine, Salt Lake City, UT, United States; Division of Cardiology, LDS Hospital, Salt Lake City, UT 84143, 8th Avenue and C Street, United States","Anderson J.L., Intermt. Heart Collab. Res. Grp., LDS Hosp. Cardiovascular Department, Univ. of Utah School of Medicine, Salt Lake City, UT, United States, Division of Cardiology, LDS Hospital, Salt Lake City, UT 84143, 8th Avenue and C Street, United States; Carlquist J.F., Intermt. Heart Collab. Res. Grp., LDS Hosp. Cardiovascular Department, Univ. of Utah School of Medicine, Salt Lake City, UT, United States; Horne B.D., Intermt. Heart Collab. Res. Grp., LDS Hosp. Cardiovascular Department, Univ. of Utah School of Medicine, Salt Lake City, UT, United States; Muhlestein J.B., Intermt. Heart Collab. Res. Grp., LDS Hosp. Cardiovascular Department, Univ. of Utah School of Medicine, Salt Lake City, UT, United States","Pharmacogenomics is a field dedicated to exploring the contribution of genetics to interindividual variability in drug response. A goal of cardiovascular pharmacogenomics is to guide cardiovascular drug development and selection so as to optimize therapeutic benefit and minimize the potential for toxicity. Genetic-based differences in drug metabolism have long been recognized but just now are on the verge of wider clinical application. Differences in efficacy of cardiovascular drugs (independent of drug concentration) based on common genetic variations (polymorphisms) only recently have begun to be explored, but the potential for clinical application appears promising. Examples are presented of important pharmacodynamic effects of genetic variants on several drugs, including those in antiarrhythmic, reninangiotensin, β-blocker, lipid-lowering, and antithrombotic classes. Principles of pharmacogenomics applied to drug metabolism are discussed that are relevant to drug development and clinical use, and examples are given for CYP450 phase I enzymes, phase II enzymes, and drug transporters. Challenges in establishing true pharmacogenetic associations are discussed, and current and future clinical potential is summarized. Rapid research progress and initial clinical applications with pharmacogenomics are foreseen in the near future.","Pharmacogenetics; Pharmacogenomics","abciximab; acetylsalicylic acid; adducin; alpha 2 adrenergic receptor; angiotensin 1 receptor; angiotensinogen; antiarrhythmic agent; anticoagulant agent; antilipemic agent; apolipoprotein E; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; bradykinin; cardiovascular agent; carrier protein; cytochrome P450; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; fibrinogen; guanine nucleotide binding protein; heparin; lipoprotein lipase; liver triacylglycerol lipase; low density lipoprotein receptor; oral contraceptive agent; prothrombin; stromelysin; unindexed drug; cardiovascular disease; drug efficacy; drug metabolism; drug research; drug response; drug transport; gene mutation; gene replication; genetic polymorphism; genetic variability; haplotype; heart failure; heart muscle fibrosis; heart ventricle hypertrophy; human; hypertension; long QT syndrome; pharmacodynamics; pharmacogenomics; phenotype; potassium current; priority journal; renin angiotensin aldosterone system; review; single nucleotide polymorphism; thrombosis","","abciximab, 143653-53-6; acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; angiotensinogen, 11002-13-4, 64315-16-8; bradykinin, 58-82-2, 5979-11-3; carrier protein, 80700-39-6; cytochrome P450, 9035-51-2; dipeptidyl carboxypeptidase, 9015-82-1; fibrinogen, 9001-32-5; heparin, 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5; lipoprotein lipase, 83137-80-8, 9004-02-8; prothrombin, 9001-26-7; stromelysin, 79955-99-0","","","","","Johnson J.A., Drug Target Pharmacogenomics: An overview, Am J Pharmacogenomics, 1, pp. 271-281, (2001); Kalow W., Pharmacogenetics: Heredity and Responses To Drugs, (1962); Evans W.E., Relling M.V., Pharmacogenomics: Translating functional genomics into rational therapeutics, Science, 286, pp. 487-491, (1999); Roses A.D., Pharmacogenetics and the practice of medicine, Nature, 405, pp. 857-865, (2000); Johnson J.A., Humma L.M., Pharmacogenetics of cardiovascular drugs, Briefings in Fundamental Genomics and Proteomics, 1, pp. 1-14, (2002); Venter J.C., Adams M.D., Myers E.W., Et al., The sequence of the human genome, Science, 291, pp. 1304-1351, (2001); A physical map of the human genome, Nature, 409, pp. 934-941, (2001); Subramanian G., Adams M.D., Venter J.C., Broder S., Implications of the human genome for understanding human biology and medicine, JAMA, 286, pp. 2296-2307, (2001); Psaty B.M., Smith N.L., Heckbert S.R., Et al., Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Vincent G.M., Timothy K., Fox J., Zhang L., The inherited long QT syndromes: From ion channel to bedside, Cardiol Rev, 7, pp. 44-55, (1999); Roden D.M., Pharmacogenetics and drug-induced arrhythmias, Cardiovasc Res, 50, pp. 224-231, (2001); Abbott G.W., Sesti F., Splawski I., Et al., MiRP 1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia, Cell, 97, pp. 175-187, (1999); Sesti F., Abbott G.W., Wei J., Et al., A common polymorphism associated with antibiotic-induced cardiac arrhythmia, Proc Natl Acad Sci USA, 97, pp. 10613-10618, (2000); Napolitano C., Schwartz P.J., Brown A.M., Et al., Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias, J Cardiovasc Electrophysiol, 11, pp. 691-696, (2000); Splawski I., Timothy K.W., Tateyama M., Et al., Variant of SCN 5A sodium channel implicated in risk of cardiac arrhythmia, Science, 297, pp. 1333-1336, (2002); Makita N., Horie M., Nakamura T., Et al., Drug-induced long-QT syndrome associated with a subclinical SCN 5A mutation, Circulation, 106, pp. 1269-1274, (2002); Tiret L., Rigat B., Visvikis S., Et al., Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels, Am J Hum Genet, 51, pp. 197-205, (1992); Keavney B., McKenzie C., Parish S., Et al., Large-scale test of hypothesised association between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls, Lancet, 355, pp. 434-442, (2000); Dieguez-Lucena J.L., Aranda-Lara P., Ruiz-Galdon M., Et al., Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy, Hypertension, 28, pp. 98-103, (1996); Exner D.V., Dries D.L., Donmanski M.J., Cohn J.N., Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction, New Engl J Med, 344, pp. 1351-1357, (2001); Schunkert H., Hense H.W., Gimenez-Roqueplo A.P., Et al., The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort, Hypertension, 29, pp. 628-633, (1997); Hingorani A.D., Jia H., Stevens P.A., Et al., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, pp. 1602-1609, (1995); Miller J.A., Thai K., Sholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Int, 56, pp. 2173-2180, (1999); Benetos A., Cambien F., Gautier S., Et al., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, pp. 1081-1084, (1996); Mukae S., Aoki S., Itoh S., Et al., Bradykinin B2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough, Hypertension, 36, pp. 127-131, (2000); Takahashi T., Yamaguchi E., Furuya K., Kawakami Y., The ACE gene polymorphism and cough threshold for capaicin after cilazapril usage, Respir Med, 95, pp. 130-135, (2001); McNamara D.M., Holubkov R., Janosko K., Et al., Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, Circulation, 103, pp. 1644-1648, (2001); Roden D.M., Brown N.J., Preprescription genotyping: Not yet ready for prime time, but getting there, Circulation, 103, pp. 1608-1610, (2001); Liggett S.B., Beta-adrenergic receptors in the failing heart: The good, the bad, and the unknown, J Clin Invest, 107, pp. 947-948, (2001); Liggett S.B., Pharmacogenetic applications of the Human Genome Project, Nature Medicine, 2001, pp. 281-283, (2001); Mason D.A., Moore J.D., Green S.A., Liggett S.B., A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor, J Biol Chem, 274, pp. 12670-12674, (1999); Small K.M., Forbes S.L., Rahman F.F., Bridges K.M., Liggett S.B., A four amino acid deletion polymorphism in the third intracellular loop of the human alpha2C-adrenergic receptor confers impaired coupling to multiple effectors, J Biol Chem, 275, pp. 23059-23064, (2000); Small K.M., Wagoner L.E., Levin A.M., Kardia S.L.R., Liggett S.B., Synergistic polymorphisms of beta1- and alpha 2c-adrenergic receptors and the risk of congestive heart failure, N Engl J Med, 347, pp. 1135-1142, (2002); Humma L.M., Puckett B.J., Richardson H.E., Et al., Effect of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia, Am J Cardiol, 88, pp. 1034-1037, (2001); S'Shaughnessy K.M., Fu B., Dickerson C., Thurston D., Brown M.J., The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects, Clin Sci, 99, pp. 233-238, (2000); Kuivenhoven J.A., Jukerna J.W., Zwinderman A.H., Et al., The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis, N Engl J Med, 338, pp. 86-93, (1998); Carlquist J.F., Muhlestein J.B., Home B.D., Hart N.I., Bair T.L., Molhuizen H.O.F., Anderson J.L., The cholesterol ester transfer protein Taq 1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease, Am Heart J, (2003); Gerdes L.U., Gerdes C., Dervinen K., Et al., The apolipoprotein epsilon 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction, Circulation, 101, pp. 1366-1371, (2000); Zambon A., Deeb S.S., Brown B.G., Hokanson J.E., Brunzell J.D., Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment, Circulation, 103, pp. 792-798, (2001); Jukema J.W., Van Boven A.J., Groenemeijer B., Et al., The Asp 9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis, Circulation, 94, pp. 1913-1918, (1996); Marian A.J., Safavi F., Ferlic L., Et al., Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study, J Am Coll Cardiol, 35, pp. 89-95, (2000); Humphries S.E., Luong L.A., Talmud P.J., Et al., The 5A/6A polymorphism in the promoter of the stromelysin-1 gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study, Atherosclerosis, 139, pp. 49-56, (1998); De Maat M.P., Jukema J.W., Ye S., Et al., Effect of the stromelysin- 1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis, Am J Cardiol, 83, pp. 852-856, (1999); De Maat M.P., Kastelein J.J., Jukema J.W., Et al., 455G/A polymorphism of the betafibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men, Arterioscler Thromb Vasc Biol, 18, pp. 265-271, (1998); Dugi K.A., Brandauer K., Schmidt N., Et al., Low hepatic lipase activity is a novel risk factor for coronary artery disease, Circulation, 104, pp. 3057-3062, (2001); Glorioso N., Manunta P., Filigheddu F., Et al., The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 37, pp. 739-743, (1999); Cusi D., Barlassina C., Azzani T., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Turner S.T., Schwartz G.L., Chapman A.B., Boerwindle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Martinelli I., Sacchi E., Landi G., Et al., High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives, N Engl J Med, 338, pp. 1840-1841, (1998); Martinelli I., Taioli E., Bucciarelli P., Akhavan S., Mannucci P.M., Interaction between the G 20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis, Arterioscler Thromb Vasc Biol, 19, pp. 700-703, (1999); Michelson A.D., Furman M.I., Goldschmidt-Clermont P., Et al., Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists, Circulation, 101, pp. 1013-1018, (2000); Carlsson L.E., Santoso S., Baurichter G., Et al., Heparin-induced thrombocytopenia: New insights into the impact of the FcgammaRIIa-R-H 131 polymorphism, Blood, 92, pp. 1526-1531, (1998); Risch N.J., Searching for genetic determinants in the new millennium, Nature, 405, pp. 847-856, (2000); Hegele R.A., SNP judgments and freedom of association, Arterioscler Thromb Vasc Biol, 22, pp. 1058-1061, (2002); Ioannidis J.P.A., Ntzani E.E., Trikalinos T.A., Contopoulos-Ioannidis D.G., Replication validity of genetic association studies, Nature Genetics, 29, pp. 306-309, (2001); Ardlie K.G., Lunmetta K.L., Seielstad M., Testing for population subdivision and association in four case-control studies, Am J Hum Genet, 71, pp. 304-311, (2002); Gabriel S.B., Schaffner S.F., Nguyen H., Et al., The structure of haplotype blocks in the human genome, Science, 296, pp. 2225-2229, (2002); Dawson E., Abecasis G.R., Bumpstead S., Et al., A first-generation linkage disequilibrium map of human chromosome 22, Nature, 418, pp. 544-548, (2002); Patil N., Berno A.J., Hinds D.A., Et al., Blocks of limited haplotype diversity revealed by high resolution scanning of human chromosome 21, Science, 294, pp. 1719-1723, (2001); Phillips K.A., Veenstra D.L., Oren E., Lee J.K., Sadee W., Potential role of pharmacogenomics in reducing adverse drug reactions, JAMA, 286, pp. 2270-2279, (2001); Lazarou J., Pomeranz B., Corey P., Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA, 279, pp. 1200-1205, (1998); Takanshi K., Tainaka H., Kobayashi K., Et al., CYP 2C9 Ile359 and Leu359 variants, Pharmacogenetics, 10, pp. 95-104, (2000); Aithal G.P., Day C.P., Kesteven P.J., Et al., Association of polymorphisms in the cytochrome P 450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, 353, pp. 717-719, (1999); Higashi M.K., Veenstra D.L., Kondo L.M., Et al., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, 287, pp. 1690-1698, (2002); Hoffmeyer S., Burk L., Von Richter O., Et al., Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci USA, 97, pp. 3473-3478, (2000); Wilson P.W., Schaefer E.J., Larson M.G., Ordovas J.M., Apolipoprotein E alleles and risk of coronary disease. A meta-analysis, Arterioscler Thromb Vasc Biol, 16, pp. 1250-1255, (1996); Anderson J.L., Muhlestein J.B., Home B.D., Et al., Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease, Circulation, 102, pp. 1227-1232, (2000); Horne B.D., Anderson J.L., Muhlestein J.B., Et al., Polymorphisms of the CETP, ABC, MTHFR, LPL, and PAI-1 genes predict intermediate endpoints but not angiographic coronary artery disease, J Am Coll Cardiol, 41, (2003)","","","Westminster Publications Inc.","","","","","","10742484","","JCPTF","12652332","English","J. Cardiovasc. Pharmacol. Ther.","Review","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0037346529"
"Dervieux T.; Bala M.V.","Dervieux, Thierry (57203540247); Bala, Mohan V. (7006891817)","57203540247; 7006891817","Overview of the pharmacoeconomics of pharmacogenetics","2006","Pharmacogenomics","7","8","","1175","1184","9","35","10.2217/14622416.7.8.1175","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845898754&doi=10.2217%2f14622416.7.8.1175&partnerID=40&md5=81ecb00fe470f346a616cad5ee8bdb1f","Proprius Pharmaceuticals, San Diego, CA 92130-3062, 12264 El Camino Real, United States; Centocor Research and Development Inc., Outcomes Research, Malvern, PA, United States","Dervieux T., Proprius Pharmaceuticals, San Diego, CA 92130-3062, 12264 El Camino Real, United States; Bala M.V., Centocor Research and Development Inc., Outcomes Research, Malvern, PA, United States","Pharmacoeconomics and pharmacogenetics are two fields converging together as it is increasingly recognized that genetic markers predicting efficacy and toxicity to drugs can cost-effectively improve patient care. While pharmacogenetics aims at identifying genetic markers underlying the response to drugs, pharmacoeconomics aims at delivering healthcare cost-effectively. Several studies have investigated the potential cost-effectiveness of pharmacogenetic-based approaches. Recent evidences include screening for thiopurine methyltransferase gene polymorphisms to prevent azathioprine-induced myelosuppression, or screening for human leukocyte antigen (HLA)B5701 to prevent hypersensitivity reactions to abacavir therapy. Furthermore, examples suggesting a cost-effectiveness of markers predicting drug efficacy include screening the angiotensin-converting enzyme gene polymorphisms for statins therapy, the α-adducin gene variant for diuretic therapy and the assessment of human epidermal growth factor receptor (HER2) expression for trastuzumab therapy. However, thus far, all these pharmacoeconomic analyses are exploratory and validations in prospective randomized clinical trials are warranted. © 2006 Future Medicine Ltd.","Abacavir; Azathioprine; Cost-effectiveness; Diuretics; Drug response; Drug toxicity; Pharmacoeconomics; Pharmacogenetics; Pharmacogenomics; Single nucleotide polymorphism; Statin; Trastuzumab","Cost-Benefit Analysis; Drug Therapy; Economics, Pharmaceutical; Genetic Screening; Humans; Pharmacogenetics; 6 mercaptopurine derivative; abacavir; adducin; antihypertensive agent; antilipemic agent; antimalarial agent; antineoplastic agent; azathioprine; dipeptidyl carboxypeptidase; diuretic agent; epidermal growth factor receptor 2; HLA B antigen; hydroxymethylglutaryl coenzyme A reductase inhibitor; mercaptopurine; suxamethonium; thiopurine methyltransferase; trastuzumab; acute respiratory tract disease; blood toxicity; bone marrow suppression; breast cancer; chronic leukemia; cost effectiveness analysis; Crohn disease; drug cost; drug efficacy; drug eruption; drug fatality; drug fever; drug hypersensitivity; drug response; drug withdrawal; gastrointestinal symptom; genetic marker; genetic polymorphism; genetic screening; genetic variability; health care cost; hemolysis; human; hypercholesterolemia; hypertension; leukopenia; malignant neoplastic disease; pancytopenia; patient care; pharmacogenetics; prediction; protein expression; review; rheumatoid arthritis; ulcerative colitis; validation process","","abacavir, 136470-78-5, 188062-50-2; azathioprine, 446-86-6; dipeptidyl carboxypeptidase, 9015-82-1; epidermal growth factor receptor 2, 137632-09-8; mercaptopurine, 31441-78-8, 50-44-2, 6112-76-1; suxamethonium, 306-40-1, 71-27-2; thiopurine methyltransferase, 67339-09-7; trastuzumab, 180288-69-1","herceptin","","","","Heffler S., Smith S., Keehan S., Clemens M.K., Won G., Zezza M., Health spending projections for 2002-2012, Health Aff. (Millwood), (2003); Harrington P., Quality as a system property: Section 646 of the Medicare Modernization Act, Health Aff. (Millwood), (2004); Evans W.E., McLeod H.L., Pharmacogenomics - Drug disposition, drug targets, and side effects, N. Engl. J. Med., 348, 6, pp. 538-549, (2003); Dervieux T., Meshkin B., Neri B., Pharmacogenetic testing: Proofs of principle and pharmacoeconomic implications, Mutat. Res., 573, 1-2, pp. 180-194, (2005); Alving A.S., Carson P.E., Flanagan C.L., Ickes C.E., Enzymatic deficiency in primaquine-sensitive erythrocytes, Science, 124, 3220, pp. 484-485, (1956); Kalow W., Familial incidence of low pseudocholinesterase level, Lancet, 211, (1956); Lesko L.J., Woodcock J., Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective, Nat. Rev. Drug Discov., 3, 9, pp. 763-769, (2004); Flowers C.R., Veenstra D., The role of cost-effectiveness analysis in the era of pharmacogenomics, Pharmacoeconomics, 22, 8, pp. 481-493, (2004); Phillips K.A., Van Bebber S.L., Measuring the value of pharmacogenomics, Nat. Rev. Drug Discov, 4, 6, pp. 500-509, (2005); Phillips K.A., Van Bebber S.L., A systematic review of cost-effectiveness analyses of pharmacogenomic interventions, Pharmacogenomics, 5, 8, pp. 1139-1149, (2004); Bungay K.M., Sanchez L.A., Pharmacoeconomic and Outcomes, 2, (2003); Lazarou J., Pomeranz B.H., Corey P.N., Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA, 279, 15, pp. 1200-1205, (1998); Bates D.W., Spell N., Cullen D.J., Et al., The costs of adverse drug events in hospitalized patients, JAMA, 277, 4, pp. 307-311, (1997); Phillips K.A., Veenstra D.L., Oren E., Lee J.K., Sadee W., Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review, JAMA, 286, 18, pp. 2270-2279, (2001); Briggs A., Sculpher M., An introduction to Markov modelling for economic evaluation, Pharmacoeconomia, 13, 4, pp. 397-409, (1998); Ubel P.A., Hirth R.A., Chernew M.E., Fendrick A.M., What is the price of life and why doesn't it increase at the rate of inflation?, Arch. Intern. Med., 163, 14, pp. 1637-1641, (2003); Tietz Texbook of Clinical Chemistry, 12, (2001); Weinshilboum R.M., Sladek S.L., Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am. J. Hum. Cenet., 32, pp. 651-662, (1980); Schaeffeler E., Fischer C., Brockmeier D., Et al., Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants, Pharmacogenetics, 14, 7, pp. 407-417, (2004); McLeod H.L., Siva C., The thiopurine S-methyltransferase gene locus - Implications for clinical pharmacogenomics, Pbarmacogenomics, 3, 1, pp. 89-98, (2002); Tai H.-L., Fessing M., Bonten F.J., Et al., Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: Mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C, Pharmacogenetics, 9, pp. 641-650, (1999); Lennard L., Gibson B.E., Nicole T., Lilleyman J.S., Congenital thiopurine methyltransferase deficiency and 6- mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia, Arch. Dis. Child, 69, pp. 577-579, (1993); Relling M.V., Hancock M.L., Rivera G.K., Et al., Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus, J. Natl Cancer Inst., 91, pp. 2001-2008, (1999); Dervieux T., Medard Y., Verpillat P., Et al., Possible implication of thiopurine S-methyltransferase in the occurrence of infectious episodes during maintenance therapy of acute leukemia with mercaptopurine, Leukemia, 15, 11, pp. 1706-1712, (2001); Marra C.A., Esdaile J.M., Anis A.H., Practical pharmacogenetics: The cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine, J. Rheumatol., 29, 12, pp. 2507-2512, (2002); Winter J., Walker A., Shapiro D., Gaffney D., Spooner R.J., Mills P.R., Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease, Aliment Pharmacol. Ther., 20, 6, pp. 593-599, (2004); Clunie G.P., Lennard L., Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine, Rheumatology (Oxford), 43, 1, pp. 13-18, (2004); Dubinsky M.C., Reyes E., Ofman J., Chiou C.F., Wade S., Sandborn W.J., A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, Am. J Gastroenterol., 100, 10, pp. 2239-2247, (2005); Oh K.T., Anis A.H., Bae S.C., Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea, Rheumatology (Oxford), 43, 2, pp. 156-163, (2004); Tavadia S.M., Mydlarski P.R., Reis M.D., Et al., Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case, J. Am. Acad. Dermatol, 42, 4, pp. 628-632, (2000); van den Akker-van Marle M.E., Gurwitz D., Detmar S.B., Et al., Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe, Pharmacogenomics, 7, 5, pp. 783-792, (2006); Marinaki A.M., Ansari A., Duley J.A., Et al., Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase), Pharmacogenetics, 14, 3, pp. 181-187, (2004); von Ahsen N., Armstrong V.W., Behrens C., Et al., Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study, Clin. Chem., 51, 12, pp. 2282-2288, (2005); van Dieren J.M., van Vuuren A.J., Kusters J.G., Nieuwenhuis E.E.S., Kuipers E.J., van der Woude C.J., ITPA genotyping is not predictive for the development of side effects in AZA-treated inflammatory bowel disease patients, Gut, 54, 11, (2005); Mallal S., Nolan D., Witt C., Et al., Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet, 359, 9308, pp. 727-732, (2002); Hetherington S., Hughes A.R., Mosteller M., Et al., Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet, 359, 9312, pp. 1121-1122, (2002); Hughes D.A., Vilar F.J., Ward C.C., Alfirevic A., Park B.K., Pirmohamed M., Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity, Pharmacogenetics, 14, 6, pp. 335-342, (2004); Maitland-van der Zee A.H., Stricker B.H., Klungel O.H., Et al., Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion-deletion polymorphism, Atherosclerosis, 175, 2, pp. 377-379, (2004); Maitland-van der Zee A.H., Klungel O.H., Stricker B.H., Et al., Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor therapy in men, Pharmacogenetics, 14, 1, pp. 53-60, (2004); Meckley L.M., Veenstra D.L., Screening for the α-adducin G1y460Trp variant in hypertensive patients: A cost-effectiveness analysis, Pharmacogenet. Genomics, 16, 2, pp. 139-147, (2006); Psaty B.M., Smith N.L., Heckbert S.R., Et al., Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, 13, pp. 1680-1689, (2002); Gerhard T., Beltelshees A.L., Johnson J.A., Meckley L.M., Veenstra D.L., Screening for the alpha-adducin G1y460Trp variant in hypertensive patients: A cost-effectiveness analysis, Pharmacogenet. Genom., 16, pp. 139-147, (2006); Schelleman H., Klungel O.H., Witteman J.C., Et al., The influence of the α-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure, Eur. J. Hum. Genet., 14, 7, pp. 860-866, (2006); Schelleman H., Stricker B.H., Verschuren W.M., Et al., Interactions between five candidate genes and antihypertensive drug therapy on blood pressure, Pharmacogenomics J., 6, 1, pp. 22-26, (2006); Slamon D.J., Leyland-Jones B., Shak S., Et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 11, pp. 783-792, (2001); Bast Jr. R.C., Ravdin P., Hayes D.F., Et al., 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J. Clin. Oncol., 19, 6, pp. 1865-1878, (2001); Press M.F., Sauter G., Bernstein L., Et al., Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials, Clin. Cancer Res., 11, 18, pp. 6598-6607, (2005); Elkin E.B., Weinstein M.C., Winer E.P., Kuntz K.M., Schnitt S.J., Weeks J.C., HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis, J. Clin. Oncol., 22, 5, pp. 854-863, (2004); Lynch T.J., Bell D.W., Sordella R., Et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 21, pp. 2129-2139, (2004); Rieder M.J., Reiner A.P., Gage B.F., Et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N. Engl. J. Med., 352, 22, pp. 2285-2293, (2005)","T. Dervieux; Proprius Pharmaceuticals, San Diego, CA 92130-3062, 12264 El Camino Real, United States; email: tdervieux@propriuspharma.com","","","","","","","","17448042","","PARMF","17184205","English","Pharmacogenomics","Review","Final","","Scopus","2-s2.0-33845898754"
"Jinnai T.; Horiuchi H.; Makiyama T.; Tazaki J.; Tada T.; Akao M.; Ono K.; Hoshino K.; Naruse Y.; Takahashi K.; Watanabe H.; Kita T.; Kimura T.","Jinnai, Toshikazu (23492656300); Horiuchi, Hisanori (7202700235); Makiyama, Takeru (6701449050); Tazaki, Junichi (55763322100); Tada, Tomohisa (26026466200); Akao, Masaharu (7005056367); Ono, Koh (7403889585); Hoshino, Kozo (41161371600); Naruse, Yumiko (35311425200); Takahashi, Kanako (35312704100); Watanabe, Haruyo (25636614100); Kita, Toru (35371938700); Kimura, Takeshi (26643375000)","23492656300; 7202700235; 6701449050; 55763322100; 26026466200; 7005056367; 7403889585; 41161371600; 35311425200; 35312704100; 25636614100; 35371938700; 26643375000","Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan","2009","Circulation Journal","73","8","","1498","1503","5","77","10.1253/circj.CJ-09-0019","https://www.scopus.com/inward/record.uri?eid=2-s2.0-69049091101&doi=10.1253%2fcircj.CJ-09-0019&partnerID=40&md5=73f66e3aba326d8f6660a8c2617ef271","Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Division of Cardiology, Nagai Hospital, Tsu, Japan; Division of Cardiology, Kobe City Medical Center General Hospital, Kobe, Japan","Jinnai T., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Horiuchi H., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Makiyama T., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Tazaki J., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Tada T., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Akao M., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Ono K., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Hoshino K., Division of Cardiology, Nagai Hospital, Tsu, Japan; Naruse Y., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Takahashi K., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Watanabe H., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; Kita T., Division of Cardiology, Kobe City Medical Center General Hospital, Kobe, Japan; Kimura T., Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan","Background: The P2Y12 adenosine diphosphate (ADP) receptor blocker, clopidogrel, an essential drug for the prevention of stent thrombosis after percutaneous coronary intervention (PCI), is a prodrug that requires CYP2C19-and CYP3A4-mediating activation. CYP2C19*2 and *3 polymorphisms are known to lack enzymatic activity. CYP2C19 polymorphisms have been reported to exhibit weaker antiplatelet response to clopidogrel in healthy subjects. The effect of polymorphisms of CYP2C19, CYP3A4 and P2Y12 on the antiplatelet effect of clopidogrel in clinical patients was examined in the present study. Methods and Results: Single nucleotide polymorphisms of CYP2C19*2, *3, CYP3A4 (IVS10+12G>A) and P2Y12 (T744C) were determined in 25 PCI-scheduled patients who had been systematically analyzed for the antiplatelet effect of clopidogrel in a previous study. On the basis of CYP2C19 genotype, 11 patients (44%) were classified as extensive metabolizers (EMs), 8 (32%) as intermediate metabolizers (IMs) and 6 (24%) as poor metabolizers (PMs). The rates of inhibition of 5 μmol/L ADP-induced platelet aggregation by clopidogrel intake at 48 h were 31.6±14.3% in EMs, 18.4±10.0% in IMs (P=0.04 vs EMs) and 16.0±13.0% in PMs (P=0.02 vs EMs). Conclusions: CYP2C19 polymorphisms are frequent in Japanese, and the antiplatelet effect of clopidogrel is strongly affected by them in the real-world clinical setting.","Antiplatelet therapy; Clopidogrel; Polymorphisms; Stent; Thrombosis","Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Female; Humans; Japan; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Ticlopidine; acetylsalicylic acid; adenosine diphosphate; angiotensin receptor antagonist; antithrombocytic agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; clopidogrel; cytochrome P450 2C19; cytochrome P450 3A4; dipeptidyl carboxypeptidase inhibitor; hydroxymethylglutaryl coenzyme A reductase inhibitor; nitrate; proton pump inhibitor; adult; article; clinical article; coronary artery disease; coronary stent; drug effect; enzyme activity; female; genetic polymorphism; genotype; human; hyperlipidemia; hypertension; Japan; Japanese; low drug dose; male; percutaneous coronary intervention; single nucleotide polymorphism; stent thrombosis; thrombocyte aggregation inhibition; thrombosis; thrombosis prevention","","acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; adenosine diphosphate, 20398-34-9, 58-64-0; clopidogrel, 113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8; cytochrome P450 3A4, 329736-03-0; nitrate, 14797-55-8; Adenosine Diphosphate, 58-64-0; Aryl Hydrocarbon Hydroxylases, 1.14.14.1; CYP2C19 protein, human, 1.14.14.1; CYP3A4 protein, human, 1.14.13.67; Cytochrome P-450 CYP3A, 1.14.14.1; Platelet Aggregation Inhibitors, ; Receptors, Purinergic P2, ; Ticlopidine, 55142-85-3; clopidogrel, 90055-48-4","","","","","Hollopeter G., Jantzen H.-M., Vincent D., Li G., England L., Ramakrishnan V., Yang R.-B., Nurden P., Nurden A., Julius D., Conley P.B., Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature, 409, 6817, pp. 202-207, (2001); Goto S., Tamura N., Eto K., Ikeda Y., Handa S., Functional significance of adenosine 5′-diphosphate receptor (P2Y<sub>12</sub>) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate, Circulation, 105, 21, pp. 2531-2536, (2002); Goto S., Tamura N., Ishida H., Ruggeri Z.M., Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5′-diphosphate receptor stimulation and cyclic calcium signaling, Journal of the American College of Cardiology, 47, 1, pp. 155-162, (2006); Kamae T., Shiraga M., Kashiwagi H., Kato H., Tadokoro S., Kurata Y., Et al., Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: Association with Rap1B activation, J Thromb Haemost, 4, pp. 1379-1387, (2006); Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., Et al., A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators, N Engl J Med, 339, pp. 1665-1671, (1998); Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H.-J., Zhao F., Chrolavicius S., Copland I., Fox K.A.A., Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study, Lancet, 358, 9281, pp. 527-533, (2001); Savi P., Herbert J.-M., Clopidogrel and ticlopidine: P2Y<sub>12</sub> adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis, Seminars in Thrombosis and Hemostasis, 31, 2, pp. 174-183, (2005); Horiuchi H., Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems, Annals of Medicine, 38, 3, pp. 162-172, (2006); Fukushima K., Kobayashi Y., Okuno T., Nakamura Y., Sakakibara M., Nakayama T., Et al., Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation, Circ J, 71, pp. 617-619, (2007); A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 348, pp. 1329-1339, (1996); Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, New England Journal of Medicine, 345, 7, pp. 494-502, (2001); Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M.A., Bass T.A., Macaya C., Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention, American Journal of Cardiology, 97, 1, pp. 38-43, (2006); Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D., Platelet Function Monitoring in Patients with Coronary Artery Disease, Journal of the American College of Cardiology, 50, 19, pp. 1822-1834, (2007); Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M., Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, pp. 2908-2913, (2003); Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., Topol E.J., Variability in platelet responsiveness to clopidogrel among 544 individuals, Journal of the American College of Cardiology, 45, 2, pp. 246-251, (2005); Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., Stellos K., May A.E., Gawaz M., Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation, European Heart Journal, 27, 20, pp. 2420-2425, (2006); Savi P., Herbert J.M., Pflieger A.M., Dol F., Delebassee D., Combalbert J., Et al., Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel, Biochem Pharmacol, 44, pp. 527-532, (1992); Savi P., Combalbert J., Gaich C., Rouchon M.-C., Maffrand J.-P., Berger Y., Herbert J.-M., The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A, Thrombosis and Haemostasis, 72, 2, pp. 313-317, (1994); De Morais S.M.F., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A., The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, Journal of Biological Chemistry, 269, 22, pp. 15419-15422, (1994); De Morais S.M.F., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A., Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese, Molecular Pharmacology, 46, 4, pp. 594-598, (1994); Desta Z., Zhao X., Shin J.-G., Flockhart D.A., Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clinical Pharmacokinetics, 41, 12, pp. 913-958, (2002); Hulot J.-S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P., Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 7, pp. 2244-2247, (2006); Umemura K., Furuta T., Kondo K., The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects, Journal of Thrombosis and Haemostasis, 6, 8, pp. 1439-1441, (2008); Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Cavallari U., Trabetti E., Sabate M., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M.A., Bass T.A., Pignatti P.F., Macaya C., Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel, Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 8, pp. 1895-1900, (2006); Malek L.A., Kisiel B., Spiewak M., Grabowski M., Filipiak K.J., Kostrzewa G., Huczek Z., Ploski R., Opolski G., Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel, Circulation Journal, 72, 7, pp. 1165-1169, (2008); Hoshino K., Horiuchi H., Tada T., Tazaki J., Nishi E., Kawato M., Et al., Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention, Circ J, 73, pp. 336-342, (2009); Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Banuelos C., Hernandez-Antolin R., Escaned J., Moreno R., Alfonso F., Macaya C., High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability, European Heart Journal, 25, 21, pp. 1903-1910, (2004); Fukushima K., Kobayashi Y., Kitahara H., Iwata Y., Nakayama T., Kuroda N., Et al., Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement, Circ J, 72, pp. 1282-1284, (2008); Ohkubo Y., Ueta A., Ando N., Ito T., Yamaguchi S., Mizuno K., Sumi S., Maeda T., Yamazaki D., Kurono Y., Fujimoto S., Togari H., Novel mutations in the cytochrome P450 2C19 gene: A pitfall of the PCR-RFLP method for identifying a common mutation, Journal of Human Genetics, 51, 2, pp. 118-123, (2006); Kim K.A., Park P.W., Hong S.J., Park J.Y., The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance, Clin Pharmacol Ther, 84, pp. 236-242, (2008); Guard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., Et al., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, pp. 256-260, (2008); Small D.S., Farid N.A., Payne C.D., Weerakkody G.J., Li Y.G., Brandt J.T., Et al., Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel, J Clin Pharmacol, 48, pp. 475-484, (2008); Wilkinson G.R., Drug metabolism and variability among patients in drug response, N Engl J Med, 352, pp. 2211-2221, (2005); Andersson T., Flockhart D.A., Goldstein D.B., Huang S.-M., Kroetz D.L., Milos P.M., Ratain M.J., Thummel K., Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests, Clinical Pharmacology and Therapeutics, 78, 6, pp. 559-581, (2005); Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest II C.S., Et al., Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, pp. 2429-2436, (2007); Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., Et al., Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study, Lancet, 373, pp. 309-317, (2009); Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Et al., Cytochrome p-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, pp. 354-362, (2009); Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Meneveau N., Et al., Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, pp. 363-375, (2009)","H. Horiuchi; Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, 54 Shogoin Kawahara-cho, Japan; email: horiuchi@kuhp.kyoto-u.ac.jp","","","","","","","","13474820","","CJIOB","19531897","English","Circ. J.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-69049091101"
"Schjoedt K.J.; Lajer M.; Andersen S.; Tarnow L.; Rossing P.; Parving H.-H.","Schjoedt, K.J. (35197004600); Lajer, M. (55983251100); Andersen, S. (7201430835); Tarnow, L. (7006204047); Rossing, P. (7005170096); Parving, H.-H. (35355625800)","35197004600; 55983251100; 7201430835; 7006204047; 7005170096; 35355625800","Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy","2006","Scandinavian Journal of Clinical and Laboratory Investigation","66","3","","173","180","7","5","10.1080/00365510600548702","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745728433&doi=10.1080%2f00365510600548702&partnerID=40&md5=5ca3d98ad76dfa53941474ce4adb065f","Steno Diabetes Center, Gentofte, Denmark; Faculty of Health Science, University of Aarhus, Aarhus, Denmark; Steno Diabetes Center, DK-2820 Gentofte, Niels Steensens Vej 2, Denmark","Schjoedt K.J., Steno Diabetes Center, Gentofte, Denmark, Steno Diabetes Center, DK-2820 Gentofte, Niels Steensens Vej 2, Denmark; Lajer M., Steno Diabetes Center, Gentofte, Denmark; Andersen S., Steno Diabetes Center, Gentofte, Denmark; Tarnow L., Steno Diabetes Center, Gentofte, Denmark; Rossing P., Steno Diabetes Center, Gentofte, Denmark; Parving H.-H., Steno Diabetes Center, Gentofte, Denmark, Faculty of Health Science, University of Aarhus, Aarhus, Denmark","Objective. It has been suggested that an aldosterone synthase gene polymorphism (CYP11B2 -344T/C) is predictive of the blood pressure lowering effect of angiotensin II receptor blockers in essential hypertension. We investigated whether this polymorphism is predictive of reductions in blood pressure and albuminuria and preservation of glomerular filtration rate (GFR) during short-term and long-term treatment with losartan in 57 hypertensive type-1 diabetic patients with diabetic nephropathy. Material and methods. After a 4-week washout period, patients received losartan (100 mg o.d.) and were followed for a mean follow-up of 36 months. At baseline, after 2 and 4 months, and every 6 months thereafter, GFR (51Cr-EDTA-clearance), albuminuria and 24-h blood pressure were determined. The CYP11B2 -344T/C polymorphism was determined by standard polymerase chain reaction (PCR). Results. The TT, CT and CC genotypes were found in 28 %, 58 % and 14 % of patients, respectively. At baseline albuminuria and blood pressure did not differ between genotype groups. Plasma aldosterone levels (geometric mean (95 % CI)) were similar at baseline: 87 (60-125), 77 (53-112), and 89 (49-161) pg mL-1 and during follow-up (not significant). After initiation of losartan treatment, comparable mean (SE) reductions in blood pressure and albuminuria were seen in patients with TT, CT and CC genotypes (p >0.6 between groups). After long-term follow-up, there was a tendency towards a difference in systolic blood pressure reduction ( p = 0.07, one-way ANOVA), suggesting a poorer response in patients with the CC genotype. No significant difference in rate of decline in GFR (median (range)) was seen between groups (TT, CT, CC): 4.2 (-1.0 to 16.0), 3.2 (-1.6 to 13.8) and 2.6 (-0.1 to 11.0) mL min-1 year-1, respectively ( p = 0.5). Conclusions. Compared to a previous smaller study of angiotensin II receptor blockade in essential hypertension, we could not confirm that CYP11B2 -344T/C genotypes contribute towards explaining the observed variability in response to treatment with angiotensin II receptor blockers, which could be due to lack of power. © 2006 Taylor & Francis.","24-h blood pressure; Angiotensin II receptor blockade; GFR; Renin-angiotensin-aldosterone system","Adult; Albuminuria; Aldosterone Synthase; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypertension; Losartan; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Renin-Angiotensin System; Time Factors; aldosterone synthase; angiotensin 2 receptor antagonist; losartan; adult; article; blood pressure monitoring; blood pressure regulation; clinical article; diabetic nephropathy; dose response; drug response; female; genetic polymorphism; genotype; glomerulus filtration rate; human; insulin dependent diabetes mellitus; kidney function; male; polymerase chain reaction; priority journal; promoter region; renal protection; renin angiotensin aldosterone system; systolic blood pressure","","aldosterone synthase, 122933-89-5; losartan, 114798-26-4; Aldosterone Synthase, EC 1.14.15.4; Angiotensin II Type 1 Receptor Blockers, ; Losartan, 114798-26-4","","","","","Hommel E., Parving H.-H., Mathiesen E.R., Edsberg B., Nielsen M.D., Giese J., Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy, Br Med J, 293, pp. 466-470, (1986); Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, pp. 1456-1462, (1993); Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, pp. 851-860, (2001); Brenner B.M., Cooper M.E., De Zeeuw D., Keane W.F., Mitch W.E., Parving H.-H., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, pp. 861-869, (2001); Parving H.-H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, pp. 870-878, (2001); Epstein M., Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: A paradigm shift, J Hypertens, 19, pp. 829-842, (2001); Epstein M., Buckalew V., Martinez F., Altamirano J., Roniker B., Kleiman J., Et al., Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria, Am J Hypertens, 15, (2002); Rachmani R., Slavachevsky I., Amit M., Levi Z., Kedar Y., Berla M., Et al., The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study, Diabet Med, 21, pp. 471-475, (2004); Sato A., Hayashi K., Naruse M., Saruta T., Effectiveness of aldosterone blockade in patients with diabetic nephropathy, Hypertension, 41, pp. 64-68, (2003); Davies E., Holloway C.D., Ingram M.C., Inglis G.C., Friel E.C., Morrison C., Et al., Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2, Hypertension, 33, pp. 703-707, (1999); Brand E., Chatelain N., Mulatero P., Fery I., Curnow K., Jeunemaitre X., Corvol P., Et al., Structural analysis and evaluation of the aldosterone synthase gene in hypertension, Hypertension, 32, pp. 198-204, (1998); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Et al., Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus the Atenolol (SILVHIA) Trial, Am J Hypertens, 15, pp. 389-393, (2002); Andersen S., Tarnow L., Cambien F., Rossing P., Juhl T.R., Deinum J., Et al., Long-term renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?, Diabetes Care, 26, pp. 1501-1506, (2003); Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H., Et al., Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function, Circulation, 97, pp. 569-575, (1998); Pojoga L., Gautier S., Blanc H., Guyene T.T., Poirier O., Cambien F., Et al., Genetic determination of plasma aldosterone levels in essential hypertension, Am J Hypertens, 11, pp. 856-860, (1998); Epstein M., Aldosterone receptor blockade and the role of eplerenone: Evolving perspectives, Nephrol Dial Transplant, 18, pp. 1984-1992, (2003)","K.J. Schjoedt; Steno Diabetes Center, DK-2820 Gentofte, Niels Steensens Vej 2, Denmark; email: kjos@steno.dk","","","","","","","","15027686","","SJCLA","16714246","English","Scand. J. Clin. Lab. Invest.","Article","Final","","Scopus","2-s2.0-33745728433"
"Sultana S.R.; Roblin D.; O'Connell D.","Sultana, Stefan R. (23499757700); Roblin, David (57197060929); O'Connell, Damian (56691055600)","23499757700; 57197060929; 56691055600","Translational research in the pharmaceutical industry: from theory to reality","2007","Drug Discovery Today","12","9-10","","419","425","6","20","10.1016/j.drudis.2007.03.009","https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247387591&doi=10.1016%2fj.drudis.2007.03.009&partnerID=40&md5=b804083fe0385d1f8789c148b3376a73","Pfizer Global Research and Development, Sandwich Laboratories (IPC 340), Sandwich, Kent CT13 9NJ, Ramsgate Road, United Kingdom","Sultana S.R., Pfizer Global Research and Development, Sandwich Laboratories (IPC 340), Sandwich, Kent CT13 9NJ, Ramsgate Road, United Kingdom; Roblin D., Pfizer Global Research and Development, Sandwich Laboratories (IPC 340), Sandwich, Kent CT13 9NJ, Ramsgate Road, United Kingdom; O'Connell D., Pfizer Global Research and Development, Sandwich Laboratories (IPC 340), Sandwich, Kent CT13 9NJ, Ramsgate Road, United Kingdom","Translational research is the collaboration between scientists and clinicians to identify novel targets and develop biomarkers that increase confidence in rationale and therefore help select the mechanisms that are most likely to lead to breakthrough therapies. Here, we describe examples of the utility of linked preclinical and clinical biomarkers to measure pharmacological effects, to estimate clinical dose range, to determine efficacy, and to determine differentiation compared with existing therapies. The use of pharmacogenomics to identify novel drug targets and define enriched patient subpopulations is also discussed. We illustrate how biomarkers and a deep understanding of disease biology are used to discover additional indications for licensed drugs. © 2007 Elsevier Ltd. All rights reserved.","","Animals; Drug Design; Drug Industry; Drug Therapy; Efficiency, Organizational; Humans; Technology Transfer; aldosterone; alpha 1 adrenergic receptor blocking agent; alpha 1a adrenergic receptor blocking agent; alpha adrenergic receptor blocking agent; angiotensin II; arachidonate 5 lipoxygenase activating protein; atrial natriuretic factor; bradykinin; brain natriuretic peptide; candoxatril; candoxatrilat; chemokine receptor CCR5 antagonist; cisapride; cyclic GMP; endothelin 1; enkephalin derivative; epidermal growth factor receptor 2; maraviroc; phosphodiesterase V inhibitor; serotonin; serotonin 4 agonist; serotonin 4 receptor; sildenafil; trastuzumab; uk 338003; unclassified drug; vardenafil; adenohypophysis; blood oxygenation; breast cancer; central nervous system; congestive heart failure; corpus cavernosum; dose response; drug industry; drug research; drug targeting; electroencephalogram; erectile dysfunction; functional magnetic resonance imaging; gastroesophageal reflux; genetic linkage; genetic polymorphism; genome analysis; high sodium intake; human; Human immunodeficiency virus infection; hypertension; maximum tolerated dose; medical research; nonhuman; pharmacogenomics; positron emission tomography; prostate hypertrophy; pulmonary hypertension; review; RNA translation; single nucleotide polymorphism; theoretical study","","aldosterone, 52-39-1, 6251-69-0; angiotensin II, 11128-99-7; arachidonate 5 lipoxygenase activating protein, 137546-36-2; atrial natriuretic factor, 85637-73-6; bradykinin, 58-82-2, 5979-11-3; brain natriuretic peptide, 114471-18-0; candoxatril, 118785-03-8; candoxatrilat, 123898-42-0; cisapride, 81098-60-4; cyclic GMP, 7665-99-8; epidermal growth factor receptor 2, 137632-09-8; maraviroc, 376348-65-1; serotonin, 50-67-9; sildenafil, 139755-83-2; trastuzumab, 180288-69-1; vardenafil, 224785-90-4, 224785-91-5, 224789-15-5","herceptin; uk 338003","","","","O'Connell D., Roblin D., Translational research in the pharmaceutical industry: from bench to bedside, Drug Discov. Today, 11, pp. 833-838, (2006); Hirata Y., Et al., Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats, J. Cardiovasc. Pharmacol., 23, pp. 283-290, (1994); Northridge D.B., Et al., Effect of UK-69578: a novel atriopeptidase inhibitor, Lancet, 2, pp. 591-593, (1989); O'Connell J.E., Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man, Clin. Sci., 85, pp. 19-26, (1993); Kimmelstiel C.D., Et al., Effects of renal neutral endopeptidase on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure, Cardiology, 87, pp. 46-53, (1996); Sagnella G.A., Et al., Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake, Eur. J. Clin. Invest., 25, pp. 165-170, (1995); Lefebvre H., Et al., The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man, J. Clin. Endocrinol. Metab., 80, pp. 504-507, (1995); Lefebvre H., Et al., Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers, Endocr. Res., 24, pp. 749-752, (1998); Gale J.D., Et al., The effect of repeat dosing of mosapride on plasma aldosterone in healthy Japanese volunteers, Br. J. Clin. Pharmacol., 59, (2005); Samuels E.R., Et al., Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers, Psychopharmacology, 187, pp. 498-510, (2006); Rihet P., Et al., Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects, Psychopharmacology, 163, pp. 62-67, (2002); Preece M., Et al., Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetised rat, Brain Res., 916, pp. 107-114, (2001); Takahashi H., Et al., Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study, Neuroimage, 27, pp. 991-1001, (2005); NIH Consensus Development Panel on Impotence, JAMA, 270, pp. 83-90, (1993); Boolell M., Et al., Sildenafil, a novel effective oral therapy for male erectile dysfunction, Br. J. Urol., 78, pp. 257-261, (1996); Diamond L.E., Et al., Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction, Int. J. Impot. Res., 16, pp. 51-59, (2004); Hedlund P., PT-141 Palatin, Curr. Opin. Investig. Drugs, 5, pp. 456-462, (2004); Pryor J., Vardenafil: update on clinical experience, Int. J. Impot. Res., 14, (2002); Carter A.J., Et al., Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog, J. Urol., 160, pp. 242-246, (1998); Hosogai N., Et al., FR226807: a potent and selective phosphodiesterase type 5 inhibitor, Eur. J. Pharmacol., 428, pp. 295-302, (2001); Qiu Y., Et al., Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859, Eur. J. Pharmacol., 472, pp. 73-80, (2003); Kenny B.A., Et al., Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog, Urology, 44, pp. 52-57, (1994); Sultana S.R., Et al., Alpha-adrenoceptor antagonist selectivity determined by simultaneous blood pressure and long-term urethral pressure monitoring in men, Br. J. Clin. Pharmacol., 45, (1998); Sultana S.R., Et al., Experiences with dose finding in patients in early drug development: the use of biomarkers in early decision making, Appropriate Dose Selection: How to Optimise Clinical Drug Development; Ernst Schering Res. Found. Workshop (59), pp. 65-79, (2007); Cocchi F., Et al., Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells, Science, 270, pp. 1811-1815, (1995); Paxton W.A., Et al., Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure, Nat. Med., 2, pp. 412-417, (1996); Connor R.I., Et al., Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1, J. Virol., 70, pp. 8758-8764, (1996); Liu R., Et al., Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection, Cell, 86, pp. 367-377, (1996); Samson M., Et al., Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene, Nature, 382, pp. 722-725, (1996); Dean M., Et al., Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene, Science, 273, pp. 1856-1862, (1996); Eugen-Olsen J., Et al., Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals, AIDS, 11, pp. 305-310, (1997); Dorr P., Et al., Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity, Antimicrob. Agents Chemother., 49, pp. 4721-4732, (2005); Fatkenheuer G., Et al., Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist in HIV-1-infected patients, Nat. Med., 2005, pp. 1170-1172, (2005); Mank-Seymour A.R., Et al., Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels, Biochim. Biophys. Acta, 1636, pp. 40-46, (2004); Ishida T., Et al., Endothelial lipase is a major determinant of HDL level, J. Clin. Invest., 11, pp. 347-355, (2003); deLemos A.S., Et al., Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol, Circulation, 106, pp. 1321-1326, (2002); Ma K., Et al., Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism, Proc. Natl. Acad. Sci. U. S. A., 100, pp. 2748-2753, (2003); Gretarsdottir S., Et al., The gene encoding phosphodiesterase 4D confers risk of ischemic stroke, Nat. Genet., 35, pp. 131-138, (2005); Stefansson H., Et al., Neuregulin 1 and susceptibility to schizophrenia, Am. J. Hum. Genet., 71, pp. 877-892, (2002); Ogura Y., Et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature, 411, pp. 603-606, (2001); Helgadottir A., Et al., The gene encoding 5-lipoxygenase-activating protein confers risk of myocardial infarction and stroke, Nat. Genet., 36, pp. 233-239, (2004); Helgadottir A., Et al., A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction, Nat. Genet., 38, pp. 68-74, (2006); Slamon D.J., Et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, pp. 177-182, (1987); Shepard H.M., Et al., Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic, J. Clin. Immunol., 11, pp. 117-127, (1991); Cobleigh M.A., Et al., Multinational study of the efficacy and safety of humanized Anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, pp. 2639-2648, (1991); Ghofrani H.A., Et al., Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond, Nat. Rev. Drug Discov., 2006, pp. 689-702, (2006); Jackson G., Et al., Past, present, and future: a 7-year update of Viagra (sildenafil citrate), Int. J. Clin. Pract., 59, pp. 680-691, (2005); Gillies H.C., Et al., Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease, Int. J. Cardiol., 86, pp. 131-141, (2002); Ladha F., Et al., Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury, Am. J. Respir. Crit. Care Med., 172, pp. 750-756, (2005); Wilkens H., Et al., Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension, Circulation, 104, pp. 1218-1222, (2001); Lee A.J., Et al., Sildenafil for pulmonary hypertension, Ann. Pharmacother., 39, pp. 869-884, (2005); Rosen R.C., Et al., The international index of erectile dysfunction (IIEF): a multidimensional scale for assessment of erectile dysfunction, Urology, 49, pp. 822-830, (1997)","S.R. Sultana; Pfizer Global Research and Development, Sandwich Laboratories (IPC 340), Sandwich, Kent CT13 9NJ, Ramsgate Road, United Kingdom; email: stefan.sultana@pfizer.com","","","","","","","","13596446","","DDTOF","17467579","English","Drug Discov. Today","Review","Final","","Scopus","2-s2.0-34247387591"
"Lambert D.G.","Lambert, D.G. (57203047773)","57203047773","Urotensin II: From osmoregulation in fish to cardiovascular regulation in man","2007","British Journal of Anaesthesia","98","5","","557","559","2","4","10.1093/bja/aem088","https://www.scopus.com/inward/record.uri?eid=2-s2.0-34250315322&doi=10.1093%2fbja%2faem088&partnerID=40&md5=083a042be56f4bf050f60fcf9232e2a0","Department of Cardiovascular Science, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 5WW, United Kingdom","Lambert D.G., Department of Cardiovascular Science, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 5WW, United Kingdom","[No abstract available]","","Animals; Cardiovascular Diseases; Cardiovascular Physiology; Fishes; Humans; Urotensins; Water-Electrolyte Balance; angiotensin 2 receptor antagonist; dipeptidyl carboxypeptidase inhibitor; opiate derivative; palosuran; placebo; protein inhibitor; unclassified drug; urotensin II; urotensin II antagonist; urotensin; urotensin II; cardiovascular autoregulation; cardiovascular disease; clinical trial; diabetes mellitus; disease marker; drug absorption; drug blood level; drug mechanism; drug response; drug safety; drug tolerability; editorial; genetic code; human; hypertension; maximum plasma concentration; monotherapy; nonhuman; osmoregulation; phenotype; priority journal; protein blood level; protein deficiency; protein degradation; protein determination; protein expression; protein function; protein localization; protein protein interaction; protein synthesis; protein targeting; single nucleotide polymorphism; vasoconstriction; vasodilatation; animal; cardiovascular disease; cardiovascular function; electrolyte balance; fish; pathophysiology; physiology","","urotensin II, 95918-56-2; urotensin, 12651-34-2; urotensin II, 9047-55-6; Urotensins, ","","","British Journal of Anaesthesia/Royal College of Anaesthetists; British Heart Foundation, BHF","Work on U-II in my laboratory has been funded by the British Journal of Anaesthesia/Royal College of Anaesthetists and British Heart Foundation.","Bern H.A., Lederis K., A reference preparation for the study of bioactive substances in the caudal neurosecretory system of teleosts, J Endocrinol, 45, SUPPL., (1969); Coulouarn Y., Lihrmann I., Jegou S., Et al., Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord, Proc Natl Acad Sci USA, 95, pp. 15803-15808, (1998); Ames R.S., Sarau H.M., Chambers J.K., Et al., Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14, Nature, 401, pp. 282-286, (1999); Davenport A.P., Maguire J.J., Urotensin II: Fish neuropeptide catches orphan receptor, Trends Pharmacol Sci, 21, pp. 80-82, (2000); Douglas S.A., Ohlstein E.H., Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease, Trends Cardiovasc Med, 10, pp. 229-237, (2000); Douglas S.A., Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?, Curr Opin Pharmacol, 3, pp. 159-167, (2003); Onan D., Hannan R.D., Thomas W.G., Urotensin II: The old kid in town, Trends Endocrinol Metab, 15, pp. 175-182, (2004); Douglas S.A., Dhanak D., Johns D.G., From 'gills to pills': Urotensin-II as a regulator of mammalian cardiorenal function, Trends Pharmacol Sci, 25, pp. 76-85, (2004); Watson A.M., May C.N., Urotensin II, a novel peptide in central and peripheral cardiovascular control, Peptides, 25, pp. 1759-1766, (2004); Nothacker H.P., Clark S., From heart to mind. The urotensin II system and its evolving neurophysiological role, FEBS J, 272, pp. 5694-5702, (2005); Ong K.L., Lam K.S., Cheung B.M., Urotensin II: Its function in health and its role in disease, Cardiovasc Drugs Ther, 19, pp. 65-75, (2005); Zhu Y.C., Zhu Y.Z., Moore P.K., The role of urotensin II in cardiovascular and renal physiology and diseases, Br J Pharmacol, 148, pp. 884-901, (2006); Douglas S.A., Naselsky D., Ao Z., Et al., Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines, Br J Pharmacol, 142, pp. 921-932, (2004); Song W., McDonald J., Camarda V., Et al., Cell and tissue responses of a range of urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity, Naunyn Schmiedebergs Arch Pharmacol, 373, pp. 148-157, (2006); Oh Y.J., Lee J.H., Nam S.B., Shim J.K., Song J.H., Kwak Y.L., Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass, Br J Anaesth, 97, pp. 792-798, (2006); Zollner C., Stein C., Opioids, Hand Exp Pharmacol, 177, pp. 31-63, (2007); Aiyar N., Guida B., Ao Z., Et al., Differential levels of 'urotensin-II-like' activity determined by radio-receptor and radioimmuno-assays, Peptides, 25, pp. 1339-1347, (2004); Cowley E., Thompson J.P., Sharpe P., Waugh J., Ali N., Lambert D.G., Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: A pilot study, Br J Anaesth, 95, pp. 495-499, (2005); Balat O., Aksoy F., Kutlar I., Et al., Increased plasma levels of urotensin-II in preeclampsia - eclampsia: A new mediator in pathogenesis?, Eur J Obstet Gynecol Reprod Biol, 120, pp. 33-38, (2005); Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., Giaid A., Congestive heart failure and expression of myocardial urotensin II, Lancet, 359, pp. 1990-1997, (2002); Wilkinson I.B., Affolter J.T., de Haas S.L., Et al., High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man, Cardiovasc Res, 53, pp. 341-347, (2002); Affolter J.T., Newby D.E., Wilkinson I.B., Winter M.J., Balment R.J., Webb D.J., No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans, Br J Clin Pharmacol, 54, pp. 617-621, (2002); Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., Krum H., Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure, Circulation, 109, pp. 1212-1214, (2004); Sondermeijer B., Kompa A., Komesaroff P., Krum H., Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension, Am J Hypertens, 18, pp. 1195-1199, (2005); Sidharta P.N., Wagner F.D., Bohnemeier H., Et al., Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients, Clin Pharmacol Ther, 80, pp. 246-256, (2006); Sidharta P.N., van Giersbergen P.L.M., Schaarschmidt D., Dingemanse J., Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects, J Clin Pharmacol, 44, (2004); Sidharta P.N., van Giersbergen P.L.M., Schaarschmidt D., Dingemanse J., Multiple-dose tolerability, safety, pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects, Br J Clin Pharmacol, 60, pp. 677-678, (2005)","","","Oxford University Press","","","","","","00070912","","BJANA","17456487","English","Br. J. Anaesth.","Editorial","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-34250315322"
"Chapman A.; Millhouse-Jones F.; Lea J.; Rahbari F.; Baranco-Pryor E.","Chapman, Arlene (7201567844); Millhouse-Jones, Frieda (9734161600); Lea, Janice (26643498400); Rahbari, Frederic (9736125700); Baranco-Pryor, Evelyn (9736878700)","7201567844; 9734161600; 26643498400; 9736125700; 9736878700","Hypertensive pharmacogenomics in African Americans","2005","Current Pharmacogenomics","3","4","","271","279","8","0","10.2174/157016005774913176","https://www.scopus.com/inward/record.uri?eid=2-s2.0-28444493070&doi=10.2174%2f157016005774913176&partnerID=40&md5=a302d01fd0a448974a214ffd4b3979fa","Department of Medicine, Emory University School of Medicine, Morehouse School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States","Chapman A., Department of Medicine, Emory University School of Medicine, Morehouse School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States; Millhouse-Jones F., Department of Medicine, Emory University School of Medicine, Morehouse School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States; Lea J., Department of Medicine, Emory University School of Medicine, Morehouse School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States; Rahbari F., Department of Medicine, Emory University School of Medicine, Morehouse School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States; Baranco-Pryor E., Department of Medicine, Emory University School of Medicine, Morehouse School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States","Hypertension affects 60 million Americans and is the most common disorder for which medications are prescribed in the USA. Hypertension associates with serious complications including stroke, heart failure, ischemic heart disease, and renal failure. Racial background associates with the prevalence and complications of hypertension with African Americans more frequently and severely affected. Hypertensive African Americans demonstrate different responses to antihypertensive medications compared to other ethnic groups and specific candidate gene polymorphisms associate with the responses found. Differences between African Americans and other racial groups are present with regard to endothelial dysfunction and activation of the renin-angiotensin-aldosterone system. In addition the frequency of polymorphisms of genes involved in the regulation of endothelial function and the renin-angiotensin-aldosterone system differ between African Americans and other ethnic groups. This review highlights the current information available with regard to the genetics of hypertension in African Americans with particular attention to pharmocogenomic studies of antihypertensive therapy. ©2005 Bentham Science Publishers Ltd.","","aldosterone; aldosterone synthase; angiotensin 2 receptor; angiotensin receptor antagonist; angiotensinogen; antihypertensive agent; beta adrenergic receptor blocking agent; bicarbonate sodium cotransporter; calcium channel blocking agent; candesartan; captopril; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; endothelial nitric oxide synthase; furosemide; G protein coupled receptor; glycine; guanine nucleotide binding protein beta subunit; hydrochlorothiazide; lisinopril; mineralocorticoid receptor; nitric oxide; oxygen; perindopril; placebo; potassium; renin; sodium; thiazide diuretic agent; unindexed drug; African American; angioneurotic edema; antihypertensive activity; cardiovascular risk; Caucasian; cerebrovascular accident; clinical feature; clinical trial; coughing; diastolic blood pressure; diet therapy; disease association; disease classification; disease severity; DNA polymorphism; dose response; drug efficacy; essential hypertension; gene frequency; gene interaction; genetic analysis; genetic association; genetic polymorphism; genetic risk; genotype; heart failure; heart muscle ischemia; heritability; high risk population; Hispanic; human; hyperkalemia; kidney failure; monotherapy; pathophysiology; pharmacogenomics; physical activity; plasma renin activity; potassium intake; race difference; renin angiotensin aldosterone system; review; risk assessment; risk factor; sodium intake; systolic blood pressure; vascular endothelium","","aldosterone synthase, 122933-89-5; aldosterone, 52-39-1, 6251-69-0; angiotensinogen, 11002-13-4, 64315-16-8; candesartan, 139481-59-7; captopril, 62571-86-2; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; furosemide, 54-31-9; glycine, 56-40-6, 6000-43-7, 6000-44-8; hydrochlorothiazide, 58-93-5; lisinopril, 76547-98-3, 83915-83-7; nitric oxide, 10102-43-9; oxygen, 7782-44-7; perindopril, 82834-16-0; potassium, 7440-09-7; renin, 61506-93-2, 9015-94-5; sodium, 7440-23-5","","","","","Agodoa L.Y., Appel L., Bakris G.L., Beck G., Bourgoignie J., Briggs J.P., Charleston J., Cheek D., Cleveland W., Douglas J.G., Douglas M., Dowie D., Faulkner M., Gabriel A., Gassman J., Greene T., Hall Y., Hebert L., Hiremath L., Jamerson K., Johnson C.J., Kopple J., Kusek J., Lash J., Lea J., Lewis J.B., Lipkowitz M., Massry S., Middleton J., Miller III E.R., Norris K., O'Connor D., Ojo A., Phillips R.A., Pogue V., Rahman M., Randall O.S., Rostand S., Schulman G., Smith W., Thornley-Brown D., Tisher C.C., Toto R.D., Wright Jr. J.T., Xu S., Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial, JAMA, 285, 21, pp. 2719-2728, (2001); Comparison of Propranolol and Hydrochlorothiazide for the Initial Treatment of Hypertension. II. Results of Long-term Therapy, JAMA, 248, 16, pp. 2004-2011, (1982); Arora R., Clark L., Taylor M., Treatment of High-risk African American Patients: Left Ventricular Dysfunction, Heart Failure, Renal Disease, and Postmyocardial Infarction, J. Clin. Hypertens., 5, SUPPL. 1, pp. 26-31, (2003); Barkley R.A., Chakravarti A., Cooper R.S., Ellison R.C., Hunt S.C., Province M.A., Turner S.T., Weder A.B., Boerwinkle E., Family Blood Pressure Program Positional Identification of Hypertension Susceptibility Genes on Chromosome 2, Hypertension, 43, 2, pp. 477-482, (2004); Biron P., Mongeau J.G., Bertrand D., Familial Aggregation of Blood Pressure in 558 Adopted Children, Can. Med. Assoc. J., 115, 8, pp. 773-774, (1976); Bonds D.E., Palla S., Bertoni A.G., Mellen P., Goff D.C., Hypertension Treatment in the Ambulatory Setting: Comparison by Race and Gender in a National Survey, J. Clin. Hypertens., 6, 5, pp. 223-228, (2004); Calhoun D.A., Mutinga M.L., Wyss J.M., Oparil S., Muscle Sympathetic Nervous System Activity in Black and Caucasian Hypertensive Subjects, J. Hypertens., 12, 11, pp. 1291-1296, (1994); Calhoun D.A., Oparil S., Racial Differences in the Pathogenesis of Hypertension, Am. J. Med. Sci., 310, SUPPL. 1, (1995); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of Antihypertensive Response to a Standard Dose of Hydrochlorothiazide for Essential Hypertension, Kidney Int., 61, 3, pp. 1047-1055, (2002); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 Report, JAMA, 289, 19, pp. 2560-2572, (2003); Cohn J.N., Julius S., Neutel J., Weber M., Turlapaty P., Shen Y., Dong V., Batchelor A., Guo W., Lagast H., Clinical Experience with Perindopril in African-American Hypertensive Patients: A Large United States Community Trial, Am. J. Hypertens., 17, 12, pp. 134-138, (2004); Deary A.J., Schumann A.L., Murfet H., Haydock S.F., Foo R.S., Brown M.J., Double-blind, Placebo-controlled Crossover Comparison of Five Classes of Antihypertensive Drugs, J. Hypertens., 20, 4, pp. 771-777, (2002); Dickerson J.E., Hingorani A.D., Ashby M.J., Palmer C.R., Brown M.J., Optimisation of Antihypertensive Treatment by Crossover Rotation of Four Major Classes, Lancet, 353, 9169, pp. 2008-2013, (1999); Din-Dzietham R., Couper D., Evans G., Arnett D.K., Jones D.W., Arterial Stiffness is Greater in African Americans than in Whites: Evidence from the Forsyth County, North Carolina, ARIC Cohort, Am. J. Hypertens., 17, 4, pp. 304-313, (2004); Ding J., Visser M., Kritchevsky S.B., Nevitt M., Newman A., Sutton-Tyrrell K., Harris T.B., The Association of Regional Fat Depots with Hypertension in Older Persons of White and African American Ethnicity, Am. J. Hypertens., 17, 10, pp. 971-976, (2004); Ferdinand K.C., Recommendations for the Management of Special Populations: Racial and Ethnic Populations, Am. J. Hypertens., 16, 11 PART 2, (2003); Fox E., Taylor H., Andrew M., Han H., Mohamed E., Garrison R., Skelton T., Body Mass Index and Blood Pressure Influences on Left Ventricular Mass and Geometry in African Americans: The Atherosclerotic Risk In Communities (ARIC) Study, Hypertension, 44, 1, pp. 55-60, (2004); Frazier L., Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., Multilocus Effects of the Renin-Angiotensin-Aldosterone System Genes on Blood Pressure Response to a Thiazide Diuretic, Pharmacogenomics J., 4, 1, pp. 17-23, (2004); Frisancho A.R., Leonard W.R., Bollettino L.A., Blood Pressure in Blacks and Whites and its Relationship to Dietary Sodium and Potassium Intake, J. Chronic. Dis., 37, 7, pp. 515-519, (1984); Greenlund K.J., Croft J.B., Mensah G.A., Prevalence of Heart Disease and Stroke Risk Factors in Persons with Prehypertension in the United States, 1999-2000, Arch. Intern. Med., 164, 19, pp. 2113-2118, (2004); Grim C.E., Luft F.C., Miller J.Z., Meneely G.R., Battarbee H.D., Hames C.G., Dahl L.K., Racial Differences in Blood Pressure in Evans County, Georgia: Relationship to Sodium and Potassium Intake and Plasma Renin Activity, J. Chronic. Dis., 33, 2, pp. 87-94, (1980); Henderson S.O., Haiman C.A., Mack W., Multiple Polymorphisms in the Renin-Angiotensin-Aldosterone System (ACE, CYP11B2, AGTR1) and their Contribution to Hypertension in African Americans and Latinos in the Multiethnic Cohort, Am. J. Med. Sci., 328, 5, pp. 266-273, (2004); Hinderliter A.L., Sager A.R., Sherwood A., Light K.C., Girdler S.S., Willis P.W.T., Ethnic Differences in Forearm Vasodilator Capacity, Am. J. Cardiol., 78, 2, pp. 208-211, (1996); Hostetter T.H., Research Opportunities for Reducing Racial Disparities in Kidney Disease, Adv. Ren. Replace. Ther., 11, 1, pp. 59-65, (2004); Jha A.K., Varosy P.D., Kanaya A.M., Hunninghake D.B., Hlatky M.A., Waters D.D., Furberg C.D., Shlipak M.G., Differences in Medical Care and Disease Outcomes Among Black and White Women with Heart Disease, Circulation, 108, 9, pp. 1089-1094, (2003); Kalinowski L., Dobrucki I.T., Malinski T., Race-specific Differences in Endothelial Function: Predisposition of African Americans to Vascular Diseases, Circulation, 109, 21, pp. 2511-2517, (2004); Kizer J.R., Arnett D.K., Bella J.N., Paranicas M., Rao D.C., Province M.A., Oberman A., Kitzman D.W., Hopkins P.N., Liu J.E., Devereux R.B., Differences in Left Ventricular Structure Between Black and White Hypertensive Adults: The Hypertension Genetic Epidemiology Network Study, Hypertension, 43, 6, pp. 1182-1188, (2004); Kotchen T.A., Broeckel U., Grim C.E., Hamet P., Jacob H., Kaldunski M.L., Kotchen J.M., Schork N.J., Tonellato P.J., Cowley Jr. A.W., Identification of Hypertension-related QTLs in African American Sib Pairs, Hypertension, 40, 5, pp. 634-639, (2002); Kramer H., Han C., Post W., Goff D., Diez-Roux A., Cooper R., Jinagouda S., Shea S., Racial/ethnic Differences in Hypertension and Hypertension Treatment and Control in the Multi-ethnic Study of Atherosclerosis (MESA), Am. J. Hypertens., 17, 10, pp. 963-970, (2004); Kullo I.J., Bailey K.R., Kardia S.L., Mosley Jr. T.H., Boerwinkle E., Turner S.T., Ethnic Differences in Peripheral Arterial Disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study, Vasc. Med., 8, 4, pp. 237-242, (2003); Larson N., Hutchinson R., Boerwinkle E., Lack of Association of 3 Functional Gene Variants with Hypertension in African Americans, Hypertension, 35, 6, pp. 1297-1300, (2000); Li R., Lyn D., Lapu-Bula R., Oduwole A., Igho-Pemu P., Lankford B., Morgan J., Nkemdechi S., Liu G., Pack C., Silvestrov N., von Deutsch D.A., Song Q., Abukhalaf K., Ofili E., Relation of Endothelial Nitric Oxide Synthase Gene to Plasma Nitric Oxide Level, Endothelial Function, and Blood Pressure in African Americans, Am. J. Hypertens., 17, 7, pp. 560-567, (2004); Libhaber E.N., Libbaber C.D., Candy G.P., Sliwa K., Kachope J., Hlatshwayo N.M., Puane M.O., Woodiwiss A.J., Norton G.R., Essop M.R., Sareli P., Effect of Slow-release Indapamide and Perindopril Compared with Amlodipine on 24-hour Blood Pressure and Left Ventricular Mass in Hypertensive Patients of African Ancestry, Am. J. Hypertens., 17, 5 PART 1, pp. 428-432, (2004); Mainous III A.G., King D.E., Garr D.R., Pearson W.S., Race, Rural Residence, and Control of Diabetes and Hypertension, Ann. Fam. Med., 2, 6, pp. 563-568, (2004); Marroni A.S., Metzger I.F., Souza-Costa D.C., Nagassaki S., Sandrim V.C., Correa R.X., Rios-Santos F., Tanus-Santos J.E., Consistent Interethnic Differences in the Distribution of Clinically Relevant Endothelial Nitric Oxide Synthase Genetic Polymorphisms, Nitric Oxide, 12, 3, pp. 177-182, (2005); Martins D., Norris K., Hypertension Treatment in African Americans: Physiology is Less Important than Sociology, Cleve. Clin. J. Med., 71, 9, pp. 735-743, (2004); Materson B.J., Variability in Response to Antihypertensive Drug Treatment, Hypertension, 43, 6, pp. 1166-1167, (2004); Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., Hamburger R.J., Fye C., Lakshman R., Gottdiener J., Ramirez E.A., Henderson W.G., Single-drug Therapy for Hypertension in Men. A Comparison of Six Antihypertensive Agents with Placebo, N. Engl. J. Med., 328, 13, pp. 914-921, (1993); Morgan T.O., Anderson A.I., MacInnis R.J., ACE Inhibitors, Beta-blockers, Calcium Blockers, and Diuretics for the Control of Systolic Hypertension, Am. J. Hypertens., 14, 3, pp. 241-247, (2001); Morimoto T., Gandhi T.K., Fiskio J.M., Seger A.C., So J.W., Cook E.F., Fukui T., Bates D.W., An Evaluation of Risk Factors for Adverse Drug Events Associated with Angiotensin-converting Enzyme Inhibitors, J. Eval. Clin. Pract., 10, 4, pp. 499-509, (2004); Morrison A.C., Cooper R., Hunt S., Lewis C.E., Luke A., Mosley T.H., Boerwinkle E., Genome Scan for Hypertension in Nonobese African Americans: The National Heart, Lung, and Blood Institute Family Blood Pressure Program, Am. J. Hypertens., 17, 9, pp. 834-838, (2004); Nagi D.K., Foy C.A., Mohamed-Ali V., Yudkin J.S., Grant P.J., Knowler W.C., Angiotensin-1-converting Enzyme (ACE) Gene Polymorphism, Plasma ACE Levels, and their Association with the Metabolic Syndrome and Electrocardiographic Coronary Artery Disease in Pima Indians, Metabolism, 47, 5, pp. 622-626, (1998); Okosun I.S., Boltri J.M., Anochie L.K., Chandra K.M., Racial/ethnic Differences in Prehypertension in American Adults: Population and Relative Attributable Risks of Abdominal Obesity, J. Hum. Hypertens., 18, 12, pp. 849-855, (2004); Papademetriou V., Narayan P., Kokkinos P., Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in African-American Patients with Hypertension, J. Clin. Hypertens., 6, 6, pp. 310-314, (2004); Preston R.A., Materson B.J., Reda D.J., Williams D.W., Hamburger R.J., Cushman W.C., Anderson R.J., Age-race Subgroup Compared with Renin Profile as Predictors of Blood Pressure Response to Antihypertensive Therapy, JAMA, 280, 13, pp. 1168-1172, (1998); Randall O.S., Retta T.M., Kwagyan J., Gordeuk V.R., Xu S., Maqbool A.R., Ketete M., Obisesan T.O., Obese African Americans: The Prevalence of Dyslipidemia, Hypertension, and Diabetes Mellitus, Ethn. Dis., 14, 3, pp. 384-388, (2004); Rotimi C., Morrison L., Cooper R., Oyejide C., Effiong E., Ladipo M., Osotemihen B., Ward R., Angiotensinogen Gene in Human Hypertension. Lack of an Association of the 235T Allele among African Americans, Hypertension, 24, 5, pp. 591-594, (1994); Schork N.J., Chakravarti A., Thiel B., Fornage M., Jacob H.J., Cai R., Rotimi C.N., Cooper R.S., Weder A.B., Lack of Association Between a Biallelic Polymorphism in the Adducin Gene and Blood Pressure in Whites and African Americans, Am. J. Hypertens., 13, 6 PART 1, pp. 693-698, (2000); Schroeder K., Fahey T., Ebrahim S., How Can We Improve Adherence to Blood Pressure-lowering Medication in Ambulatory Care? Systematic Review of Randomized Controlled Trials, Arch. Intern. Med., 164, 7, pp. 722-732, (2004); Schwartz G.L., Turner S.T., Chapman A.B., Boerwinkle E., Interacting Effects of Gender and Genotype on Blood Pressure Response to Hydrochlorothiazide, Kidney Int., 62, 5, pp. 1718-1723, (2002); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D., ACE and Alpha-adducin Polymorphism as Markers of Individual Response to Diuretic Therapy, Hypertension, 41, 3, pp. 398-403, (2003); Stepniakowski K., Wang Z., Schwartz G., Turner S., Boerwinkle E., Chapman A.B., Racial Differences (African-American (AA) vs. Caucasian (C) in the Aldosterone Synthase Gene CYP11B2 Polymorphism Frequency and Differential Activation of the Renin Angiotensin System (RAAS) in Essential Hypertension, J. Am. Soc. Neph., 12, (2001); Sung J.F., Harris-Hooker S., Alema-Mensah E., Mayberry R., Is There a Difference in Hypertensive Claim Rates Among Medicaid Recipients?, Ethn. Dis., 7, 1, pp. 19-26, (1997); Tanus-Santos J.E., Desai M., Flockhart D.A., Effects of Ethnicity on the Distribution of Clinically Relevant Endothelial Nitric Oxide Variants, Pharmacogenetics, 11, 18, pp. 719-725, (2001); Tarver-Carr M.E., Powe N.R., Eberhardt M.S., LaVeist T.A., Kington R.S., Coresh J., Brancati F.L., Excess Risk of Chronic Kidney Disease Among African-American versus White Subjects in the United States: A Population-based Study of Potential Explanatory Factors, J. Am. Soc. Neph., 13, 9, pp. 2363-2370, (2002); Turner S.T., Chapman A.B., Schwartz G.L., Boerwinkle E., Effects of Endothelial Nitric Oxide Synthase, Alpha-adducin, and Other Candidate Gene Polymorphisms on Blood Pressure Response to Hydrochlorothiazide, Am. J. Hypertens., 16, 10, pp. 834-839, (2003); Turner S.T., Schwartz G.L., Gene Markers and Antihypertensive Therapy, Curr. Hypertens. Rep., 7, 1, pp. 21-30, (2005); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T Polymorphism of the G Protein beta(3)-subunit and Antihypertensive Response to a Thiazide Diuretic, Hypertension, 37, 2 PART 2, pp. 739-743, (2001); Wang Y., Wang Q.J., The Prevalence of Prehypertension and Hypertension among US Adults According to the New Joint National Committee Guidelines: New Challenges of the Old Problem, Arch. Intern. Med., 164, 19, pp. 2126-2134, (2004); Weir M.R., Population Characteristics and the Modulation of the Renin-Angiotensin System in the Treatment of Hypertension, J. Hum. Hypertens., 11, 1, pp. 17-21, (1997); Whittley C.Y., Gorelick P.B., Raman R., Harris J., Richardson D., Are there Differences in Risk Factor Profiles and Frequency of CT/MRI-based Infarcts among African American Stroke Patients with and without Hypertension? A Report from the African American Antiplatelet Stroke Prevention Study (AAASPS), J. Natl. Med. Assoc., 95, 6, pp. 423-432, (2003); Wilk J.B., Djousse L., Arnett D.K., Hunt S.C., Province M.A., Heiss G., Myers R.H., Genome-wide Linkage Analyses for Age at Diagnosis of Hypertension and Early-onset Hypertension in the HyperGEN study, Am. J. Hypertens., 17, 9, pp. 839-844, (2004); Yancy C.W., Victor R., Summary: Cardiovascular Disease in African Americans, Congest. Heart Fail., 10, 1, (2004)","A. Chapman; Emory University School of Medicine, Atlanta, GA 30322, 1639 Pierce Drive, United States; email: arlene_chapman@emory.org","","","","","","","","15701603","","CPUHA","","English","Curr. Pharmacogenomics","Review","Final","","Scopus","2-s2.0-28444493070"
"Hollenberg N.K.; Williams G.H.","Hollenberg, Norman K. (35396956700); Williams, Gordon H. (7406079866)","35396956700; 7406079866","Nonmodulation and essential hypertension","2006","Current Hypertension Reports","8","2","","127","131","4","9","10.1007/s11906-006-0008-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744471650&doi=10.1007%2fs11906-006-0008-9&partnerID=40&md5=e1aae06443571845f30bf98bf3dd30ee","Brigham and Women's Hospital, Boston, MA 02115, 75 Francis Street, United States","Hollenberg N.K., Brigham and Women's Hospital, Boston, MA 02115, 75 Francis Street, United States; Williams G.H.","Nonmodulation is a process in which there is a disorder in angiotensin-dependent control of the renal circulation and adrenal aldosterone release. The abnormalities are associated with an inability to handle a sodium load and salt-sensitive hypertension. All of the features are corrected by angiotensin-converting enzyme inhibition. A striking family history of hypertension and concordance of responses to angiotensin II in sibling pairs have suggested a familial factor. Genes governing renin substrate (angiotensinogen) production showed gene polymorphisms in nonmodulators. As nonmodulation occurs in approximately 40% of patients with essential hypertension, clearly other genes must contribute. Copyright © 2006 by Current Science Inc.","","Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Humans; Hypertension; Kidney; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Renal Circulation; Renin; Renin-Angiotensin System; Sodium; 4 aminohippuric acid; adducin; aldosterone; aldosterone synthase; angiotensin 2 receptor; angiotensin II; angiotensinogen; atrial natriuretic factor; bradykinin; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; inulin; nitric oxide; prostaglandin; renin; aldosterone release; article; DNA polymorphism; essential hypertension; genetic analysis; genetic epistasis; genotype phenotype correlation; human; kallikrein kinin system; kidney blood flow; kidney circulation; kidney perfusion; microalbuminuria; nonhuman; pathophysiology; renin angiotensin aldosterone system; renin release; salt intake; salt loading; sensitivity analysis; single nucleotide polymorphism; sodium absorption; sodium restriction; twin concordance","","4 aminohippuric acid, 61-78-9; aldosterone synthase, 122933-89-5; aldosterone, 52-39-1, 6251-69-0; angiotensin II, 11128-99-7; angiotensinogen, 11002-13-4, 64315-16-8; atrial natriuretic factor, 85637-73-6; bradykinin, 58-82-2, 5979-11-3; dipeptidyl carboxypeptidase, 9015-82-1; inulin, 9005-80-5; nitric oxide, 10102-43-9; renin, 61506-93-2, 9015-94-5; Angiotensin-Converting Enzyme Inhibitors, ; Angiotensinogen, 11002-13-4; Peptidyl-Dipeptidase A, EC 3.4.15.1; Renin, EC 3.4.23.15; Sodium, 7440-23-5","","","","","Hollenberg N.K., Williams G.H., Abnormal renal function, sodium-volume homeostasis and renin system behavior in normal-renin essential hypertension: The evolution of the nonmodulator concept, Hypertension: Pathophysiology, Diagnosis, and Management, pp. 1837-1856, (1995); Hollenberg N.K., Merrill J.P., Intrarenal perfusion in the young ""essential"" hypertensive: A subpopulation resistant to sodium restriction, Trans Assoc Am Physicians, 83, pp. 93-101, (1970); Williams G.H., Rose L.I., Dluhy R.G., Et al., Abnormal responsiveness of the renin-aldosterone system to acute stimulation in patients with essential hypertension, Ann Intern Med, 72, pp. 317-326, (1970); Hollenberg N.K., Chenitz W.R., Adams D.F., Williams G.H., Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man, J Clin Invest, 54, pp. 34-42, (1974); Williams G.H., Hollenberg N.K., Accentuated vascular and endocrine responses to SQ 20881 in hypertension, N Engl J Med, 297, pp. 184-188, (1977); Hollenberg N.K., Meggs L.G., Williams G.H., Et al., Sodium intake and renal responses to captopril in normal man and in essential hypertension, Kidney, 20, pp. 240-245, (1981); Redgrave J.E., Rabinowe S.L., Hollenberg N.K., Williams G.H., Correction of abnormal renal blood flow response to angiotensin II by converting-enzyme inhibition in essential hypertensives, J Clin Invest, 75, pp. 1285-1290, (1985); Fujita T., Henry W.L., Bartter F.C., Et al., Factors influencing blood pressure in salt-sensitive patients with hypertension, Am J Med, 69, pp. 334-344, (1980); Rystedt L.L., Williams G.H., Hollenberg N.K., The renal and endocrine response to saline infusion in essential hypertension, Hypertension, 8, pp. 217-222, (1986); Hollenberg N.K., Moore T., Shoback D., Et al., Abnormal renal sodium handling in essential hypertension: Relation to failure of renal and adrenal modulation of responses to Ang II, Am J Med, 81, pp. 412-418, (1986); Hurwitz S., Fisher N.D.L., Ferri C., Et al., Controlled analysis of blood pressure sensitivity to sodium intake: Interactions with hypertension type, J Hypertension, 21, pp. 951-958, (2003); Williams G.H., Hollenberg N.K., Moore T.J., Et al., Failure of renin suppression by angiotensin II in hypertension, Circ Res, 4, pp. 46-52, (1978); LeBoff M.S., Dluhy R.G., Hollenberg N.K., Et al., Abnormal renin short feedback loop in essential hypertension is reversible with converting enzyme inhibition, J Clin Invest, 70, pp. 335-341, (1982); Seely E.W., Moore T.J., Rogacz S., Et al., Angiotensin-mediated renin suppression is altered in non-modulating hypertension, Hypertension, 13, pp. 31-37, (1989); Williams G.H., Tuck M.L., Sullivan J.M., Et al., Parallel adrenal and renal abnormalities in the young patient with essential hypertension, Am J Med, 72, pp. 907-914, (1982); Beretta-Piccoli C., Pusterla C., Stadler P., Weidmann P., Blunted aldosterone responsiveness to Ang II in normotensive subjects with familial predisposition to essential hypertension, J Hypertension, 61, pp. 57-61, (1988); Van Hooft I.M.S., Grobbee D.E., Derkx F.H.M., Et al., Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents, N Engl J Med, 324, pp. 1305-1311, (1991); Uneda S., Fukishima S., Fujika Y., Et al., Renal hemodynamics and renin-angiotensin system in adolescents genetically predisposed to essential hypertension, J Hypertension, 263, pp. 437-439, (1984); Guidi E., Cozzi E.M.M.G., Biella E., Sodium physiopathology and nonmodulating hypertension, Cardiorenal Disease. Contrib Nephrol, 106, pp. 153-156, (1994); Luparini R.L., Ferri C., Santucci A., Balsano F., Atrial natriuretic peptide in non-modulating essential hypertension, Hypertension, 21, pp. 803-809, (1993); Ferri C., Bellini C., Coassin S., Et al., Abnormal atrial natriuretic peptide and renal responses to saline infusion in nonmodulating essential hypertensive patients, Circulation, 90, pp. 2859-2869, (1994); Bigazzi R., Bianchi S., Baldari D., Et al., Microalbuminuria in salt-sensitive patients: A marker for renal and cardiovascular risk factors, Hypertension, 23, pp. 195-199, (1994); Sanchez R.A., Amos F., Giannone C., Et al., Parallel renal and extremity blood supply abnormalities in nonmodulation. Responses to ACE inhibition, Hypertension, 41, pp. 919-924, (2003); Sanchez R.A., Ramos F., Giannone C., Et al., Increased microalbuminuria and forearm vascular abnormalities in non-modulating hypertensives and offspring of hypertensives. Similar kidney and peripheral response to ACEI, J Hum Hypertens Suppl, 16, pp. 128-132, (2002); Sanchez R., Gimenez M.I., Ramos F., Et al., Non-modulating hypertension: Evidence for the involvement of kallikrein/ kinin activity associated with overactivity of the renin-angiotensin system. Successful blood pressure control during long-term Na+ restriction, J Hypertension, 14, pp. 1287-1291, (1996); Razin M., Borosh M., Weinstock M., Rabbits with a genetic impairment in baroreceptor reflex sensitivity show abnormal renal haemodynamics and proximal tubular sodium reabsorption in response to a saline infusion, J Hypertens, 11, pp. 799-804, (1993); Widgren B.R., Herlitz H., Aurell M., Et al., Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension, Am J Hypertens, 5, pp. 167-174, (1992); Palmgren E., Widgren B., Aurell M., Herlitz H., Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased respose to prostaglandins, J Hypertens, 21, pp. 969-976, (2003); Schachinger H., Dieterle T., Martina B., Et al., Increased renovascular response to angiotensin II in persons genetically predisposed to arterial hypertension disappears after chronic angiotensin-converting enzyme inhibition, J Hypertens, 22, pp. 175-180, (2004); Lifton R.P., Hopkins P.N., Williams R.R., Et al., Evidence for heritability of non-modulating essential hypertension, Hypertension, 13, pp. 884-889, (1989); Williams G.H., Dluhy R.G., Lifton R.P., Et al., Non-modulation as an intermediate phenotype in essential hypertension, Hypertension, 20, pp. 788-796, (1992); Hopkins P.N., Lifton R.P., Hollenberg N.K., Et al., Blunted renal vascular response to angiotensin I is associated with a common variant of the angiotensinogen gene and obesity, J Hypertens, 14, pp. 199-207, (1996); Hopkins P.N., Hunt S.C., Jeunemaitre X., Et al., Angiotensin genotype effect on renal and adrenal responses to angiotensin II in essential hypertension, Circulation, 105, pp. 1921-1927, (2002); Kosachunhanun N., Hunt S.C., Hopkins P.N., Et al., Genetic determinants of nonmodulating hypertension, Hypertension, 42, pp. 901-908, (2003); Klingbeil A.U., Jacobi J., Langenfeld M.R.W., Et al., Enhanced antinatriuresis in response to angiotensin II in essential hypertension, Am J Hypertension, 13, pp. 986-993, (2000)","N.K. Hollenberg; Brigham and Women's Hosptial, Boston, MA 02115, 75 Francis Street, United States; email: djpagecapo@rics.bwh.harvard.edu","","","","","","","","15226417","","CHRUC","16672145","English","Curr. Hypertens. Rep.","Article","Final","","Scopus","2-s2.0-33744471650"
"Filigheddu F.; Troffa C.; Glorioso N.","Filigheddu, F. (6602470698); Troffa, C. (7003626242); Glorioso, N. (7006044073)","6602470698; 7003626242; 7006044073","Pharmacogenomics of essential hypertension: Are we going the right way?","2006","Cardiovascular and Hematological Agents in Medicinal Chemistry","4","1","","7","15","8","12","10.2174/187152506775268749","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646355716&doi=10.2174%2f187152506775268749&partnerID=40&md5=fc8be051a975b0302dc6495ced676b09","Hypertension and Cardiovascular Prevention Center, ASL n. 1-University of Sassari, 07100 Sassari, Viale S. Pietro, 8, Italy","Filigheddu F., Hypertension and Cardiovascular Prevention Center, ASL n. 1-University of Sassari, 07100 Sassari, Viale S. Pietro, 8, Italy; Troffa C., Hypertension and Cardiovascular Prevention Center, ASL n. 1-University of Sassari, 07100 Sassari, Viale S. Pietro, 8, Italy; Glorioso N., Hypertension and Cardiovascular Prevention Center, ASL n. 1-University of Sassari, 07100 Sassari, Viale S. Pietro, 8, Italy","Identifying the genetic predictors of the therapeutic response to drugs is the role of pharmacogenomics. Although polymorphisms in several genes have been associated with the blood pressure response to diuretics, β-blockers and ACE-inhibitors, the pharmacogenomics of essential hypertension is still attempting to find satisfactory scientific evidence to be translated into clinical practice. The main reasons for this apparent failure are: the small sample sizes of the cohorts of patients analyzed, the methodological variability, the complexity of the biological organization, the context-dependency and the genetic heterogeneity. This review will summarize the available data on antihypertensive drugs and the criteria used for study design and conduction, focusing on their strong points and limitations. © 2006 Bentham Science Publishers Ltd.","Antihypertensive agents; Drugs; Genetics; High blood pressure; Pharmacogenetics; Polymorphism","Antihypertensive Agents; Cohort Studies; Drug Design; Humans; Hypertension; Pharmacogenetics; 11beta hydroxysteroid dehydrogenase; 5,10 methylenetetrahydrofolate reductase (FADH2); adducin; aldosterone; aldosterone synthase; angiotensin; angiotensin 1 receptor; angiotensin 1 receptor antagonist; antihypertensive agent; atenolol; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; calcium antagonist; cholesterol ester transfer protein; cytochrome P450 2C9; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; drug metabolizing enzyme; endothelial nitric oxide synthase; endothelin 1; guanine nucleotide binding protein; guanine nucleotide binding protein alpha subunit; hydrochlorothiazide; irbesartan; lipoprotein lipase; methionine synthase; renin; unindexed drug; antihypertensive agent; blood pressure regulation; clinical practice; clinical trial; cohort analysis; data analysis; essential hypertension; ethnic difference; evidence based medicine; gene deletion; gene insertion; gene linkage disequilibrium; genetic heterogeneity; genetic polymorphism; genetic variability; human; information processing; methodology; patient selection; pharmacogenetics; pharmacogenomics; prediction; review; sample size; single nucleotide polymorphism; treatment outcome; drug design; genetics; hypertension; pharmacogenetics","","11beta hydroxysteroid dehydrogenase, 9041-46-7; 5,10 methylenetetrahydrofolate reductase (FADH2), 9028-69-7; aldosterone synthase, 122933-89-5; aldosterone, 52-39-1, 6251-69-0; angiotensin, 1407-47-2; atenolol, 29122-68-7; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; hydrochlorothiazide, 58-93-5; irbesartan, 138402-11-6; lipoprotein lipase, 83137-80-8, 9004-02-8; methionine synthase, 37290-90-7; renin, 61506-93-2, 9015-94-5; Antihypertensive Agents, ","","","","","Vogel F., Ergebn. Inn. Med. Kinderheilkd., 12, (1959); Evans W.E., Relling M.V., Nature, 429, (2004); Lander E.S., Schork N.J., Science, 265, 5181, (1994); Evans W.E., Relling M.V., Science, 286, (1999); Kalow W., Tang B.K., Endrenyi L., Pharmacogenetics, 8, (1998); Lazarou J., Pomeranz B.H., Corey P.N., JAMA, 279, (1998); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., JAMA, 289, 19, (2003); Meissner I., Whisnant J.P., Sheps S.G., Schwartz G.L., O'Fallon W.M., Covalt J.L., Sicks J.D., Bailey K.R., Wiebers D.O., Hypertension, 34, (1999); Ferrandi M., Salardi S., Tripodi G., Barassi P., Rivera R., Manunta P., Goldshleger R., Ferrari P., Bianchi G., Karlish S.J., Am. J. Physiol., 277, (1999); Tripodi G., Valtorta F., Torielli L., Chieregatti E., Salardi S., Trusolino L., Menegon A., Ferrari P., Marchisio P.C., Bianchi G., J. Clin. Invest., 97, (1996); Manunta P., Burnier M., D'Amico M., Buzzi L., Maillard M., Barlassina C., Lanella G., Cusi D., Bianchi G., Hypertension, 33, (1999); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Rivera R., Stella P., Troffa C., Zagato L., Bianchi G., Lancet, 349, (1997); Province M.A., Arnett D.K., Hunt S.C., Leiendecker-Foster C., Eckfeldt J.H., Oberman A., Ellison R.C., Heiss G., Mockrin S.C., Williams R.R., Am. J. Hypertens., 13, 6 PART 1, (2000); Larson N., Hutchinson R., Boerwinkle E., Hypertension, 35, 6, (2000); Clark C.J., Davies E., Anderson N.H., Farmer R., Friel E.C., Fraser R., Connell J.M., Hypertension, 36, 6, (2000); Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., Lombardi C., Soro A., Dettori F., Parpaglia P.P., Alibrandi M.T., Cusi D., Bianchi G., Hypertension, 34, 4 PART 1, (1999); Glorioso N., Filigheddu F., Cusi D., Troffa C., Conti M., Natalizio M., Argiolas G., Barlassina C., Bianchi G., Hypertension, 39, 2 PART 2, (2002); Filigheddu F., Troffa C., Argiolas G., Pinna Parpaglia P., Glorioso N., High Blood Press. Cardiovasc. Prev., 11, 4, (2004); He F.J., Markandu N.D., Mac Gregor G.A., Hypertension, 38, (2001); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D., Hypertension, 41, 3, (2003); Frazier L., Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., Pharmacogenomics J., 4, 1, (2004); Schwartz G.L., Turner S.T., Chapman A.B., Boerwinkle E., Kidney Int., 62, 5, (2002); Vaughan E.D., Laragh J.H., Gavras I., Buhler F.R., Gavras H., Brunner H.R., Baer L., Am. J. Cardiol., 32, (1973); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., Hypertension, 37, 2 PART 2, (2001); Turner S.T., Chapman A.B., Schwartz G.L., Boerwinkle E., Am. J. Hypertens., 16, 10, (2003); Agarwal A.K., Giacchetti G., Lavery G., Nikkila H., Palermo M., Ricketts M., McTernan C., Bianchi G., Manunta P., Strazzullo P., Mantero F., White P.C., Stewart P.M., Hypertension, 36, 2, (2000); Williams T.A., Mulatero P., Filigheddu F., Troffa C., Milan A., Argiolas G., Pinna Parpaglia P., Veglio F., Glorioso N., Kidney. Int., 67, 2, (2005); Mason D.A., Moore J.D., Green S.A., Liggett S.B., J. Biol. Chem., 274, (1999); O'Shaughnessy K.M., Fu B., Dickerson C., Thurston D., Brown M.J., Clin. Sci. (Lond.), 99, 3, (2000); Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F., Clin. Pharmacol. Ther., 74, 1, (2003); Karlsson J., Lind L., Hallberg P., Michaelsson K., Kurland L., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Melhus H., Clin. Cardiol., 27, 6, (2004); Filigheddu F., Reid J.E., Troffa C., PinnaParpaglia P., Argiolas G., Testa A., Skolnick M., Glorioso N., Pharmacogenomics J., 4, 3, (2004); Jia H., Hingorani A.D., Sharma P., Hopper R., Dickerson C., Trutwein D., Lloyd D.D., Brown M.J., Hypertension, 34, 1, (1999); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Nystrom F., Hagg A., Lind L., Am. J. Hypertens., 15, 5, (2002); Kurland L., Liljedahl U., Karlsson J., Kahan T., Malmqvist K., Melhus H., Syvanen A.C., Lind L., Am. J. Hypertens., 17, 1, (2004); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., J. Hypertens., 19, 10, (2001); Hallberg P., Karlsson J., Lind L., Michaelsson K., Kurland L., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Liljedahl U., Syvanen A.C., Melhus H., Clin. Cardiol., 27, 5, (2004); Li X., Du Y., Du Y., Huang X., J. Cardiovasc. Pharmacol. Ther., 8, 1, (2003); Stavroulakis G.A., Makris T.K., Krespi P.G., Hatzizacharias A.N., Gialeraki A.E., Anastasiadis G., Triposkiadis P., Kyriakidis M., Cardiovasc. Drugs Ther., 14, 4, (2000); Ohmichi N., Iwai N., Uchida Y., Shichiri G., Nakamura Y., Kinoshita M., Am. J. Hypertens., 10, 8, (1997); Yu H., Zhang Y., Liu G., Hypertens. Res., 26, 11, (2003); Harrap S.B., Tzourio C., Cambien F., Poider O., Raoux S., Chalmers J., Chapman N., Colman S., Leguennec S., MacMahon S., Neal B., Ohkubo T., Woodward M., Hypertension, 42, 3, (2003); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., J. Hypertens., 14, 2, (1996); Zhang Y., Zhang M., Niu T., Xu X., Zhu G., Hun Y., Chen C., Wang X., Xing H., Peng S., Huang A., Hong X., Xu X., J. Hum. Genet., 49, 6, (2004); Jiang S., Hsu Y.H., Xu X., Xing H., Chen C., Niu T., Zhang Y., Peng S., Xu X., Thromb. Res., 113, 6, (2004); Lim U., Cassano P.A., Am. J. Epidemiol., 156, (2002); Clarke R., Int. J. Epidemiol., 31, 1, (2002); Nagy L., Tarjan J., Samoczi M., Kovacs I., Takacs J., Am. J. Ther., 5, 4, (1998); Wacholder S., Silverman D.T., McLaughlin J.K., Mandel J.S., Am. J. Epidemiol., 135, 9, (1992); Gambaro G., Anglani F., D'Angelo A., Lancet, 355, (2000); Shifman S., Darvasi A., Nature Genetics, 28, (2001); Br. Med. J., 293, (1986); Camussi A., Bianchi G., Hypertension, 12, 6, (1988); Altman D.G., Gore S.M., Gardner M.J., Pocock S.J., Br. Med. J., 286, 6376, (1983); Altman D.G., Statist. Med., 19, (2000); Greenland S., Am. J. Public Health, 79, (1989); Ioannidis J.P., Ntzani E.E., Trikalinos T.A., Contopoulos-Ioannidis D.G., Nat. Genet., 29, 3, (2001); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., J. Clin. Invest., 86, (1990); Siffert W., Rosskopf D., Moritz A., Wieland T., Kaldenberg-Stasch S., Kettler N., Hartung K., Beckmann S., Jakobs K.H., J. Clin. Invest., 96, (1995); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P., Siscovick D.S., Bis J., Lumley T., Longstreth Jr. W.T., Rosendaal F.R., JAMA, 287, 13, (2002); Duboule D., Wilkins A.S., Trends Genet., 14, (1998); Bianchi G., Staessen J.A., Ferrari P., Pharmacogenomics, 4, 3, (2003); Kardia S.L., Curr. Hypertens. Rep., 2, 1, (2000); Risch N., Merikangas K., Science, 273, (1996); Judson R., Stephens J.C., Windemuth A., Pharmacogenomics, 1, 1, (2000); Nebert D.W., Jorge-Nebert L., Vesell E.S., Am. J. Pharmacogenomics, 3, 6, (2003)","N. Glorioso; Hypertension and Cardiovascular Prevention Center, 07100 Sassari, Viale S. Pietro, 8, Italy; email: glorioso@uniss.it","","","","","","","","18715257","","","16529546","English","cardiovasc. Hematol. Agents Med. Chem.","Review","Final","","Scopus","2-s2.0-33646355716"
"Gu C.C.; Chang Y.-P.C.; Hunt S.C.; Schwander K.; Arnett D.; Djousse L.; Heiss G.; Oberman A.; Lalouel J.-M.; Province M.; Chakravarti A.; Rao D.C.","Gu, C. Charles (24775504800); Chang, Yen-Pei C. (8158751700); Hunt, Steven C. (7402383343); Schwander, Karen (6508105955); Arnett, Donna (7101719250); Djousse, Luc (56139671900); Heiss, Gerardo (7005930629); Oberman, Al (7006700415); Lalouel, Jean-Marc (7102287621); Province, Mike (35373332400); Chakravarti, Aravinda (35355137200); Rao, D.C. (57217192196)","24775504800; 8158751700; 7402383343; 6508105955; 7101719250; 56139671900; 7005930629; 7006700415; 7102287621; 35373332400; 35355137200; 57217192196","Haplotype association analysis of AGT variants with hypertension-related traits: The HyperGEN study","2005","Human Heredity","60","3","","164","176","12","21","10.1159/000090118","https://www.scopus.com/inward/record.uri?eid=2-s2.0-31144441123&doi=10.1159%2f000090118&partnerID=40&md5=757e573eb28c46e54df11013d226af5b","Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States; Department of Genetics, Washington University, School of Medicine, St. Louis, MO, United States; Department of Psychiatry, Washington University, School of Medicine, St. Louis, MO, United States; University of Utah, School of Medicine, Salt Lake City, UT, United States; Institute of Genetic Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, United States; University of Minnesota, Department of Epidemiology, Minneapolis, MN, United States; Evans Department of Medicine, Section of Preventive Medicine and Epidemiology, Boston University, Boston, MA, United States; University of North Carolina, Department of Epidemiology, UNC-CH School of Public Health, Chapel Hill, NC, United States; UAB, Division of Preventive Medicine, Birmingham, AL, United States; Division of Biostatistics, Washington University School of Medicine, Campus Box 8067, St. Louis, MO 63110, 660 S. Euclid Avenue, United States","Gu C.C., Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States, Division of Biostatistics, Washington University School of Medicine, Campus Box 8067, St. Louis, MO 63110, 660 S. Euclid Avenue, United States; Chang Y.-P.C., Institute of Genetic Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, United States; Hunt S.C., University of Utah, School of Medicine, Salt Lake City, UT, United States; Schwander K., Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States; Arnett D., University of Minnesota, Department of Epidemiology, Minneapolis, MN, United States; Djousse L., Evans Department of Medicine, Section of Preventive Medicine and Epidemiology, Boston University, Boston, MA, United States; Heiss G., University of North Carolina, Department of Epidemiology, UNC-CH School of Public Health, Chapel Hill, NC, United States; Oberman A., UAB, Division of Preventive Medicine, Birmingham, AL, United States; Lalouel J.-M., University of Utah, School of Medicine, Salt Lake City, UT, United States; Province M., Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States, Department of Genetics, Washington University, School of Medicine, St. Louis, MO, United States; Chakravarti A., Institute of Genetic Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, United States; Rao D.C., Division of Biostatistics, Washington University, School of Medicine, St. Louis, MO, United States, Department of Genetics, Washington University, School of Medicine, St. Louis, MO, United States, Department of Psychiatry, Washington University, School of Medicine, St. Louis, MO, United States","Objective: Function of the renin-angiotensin system is important to human hypertension, but its genetic etiology remains elusive. We set out to examine a hypothesis that multiple genetic variants in the system act together in blood pressure regulation, via intermediate phenotypes such as blood pressure reactivity. Methods: A sample of 531 hypertensive cases and 417 controls was selected from the HyperGEN study. Hypertension-related traits including blood pressure responses to challenges to math test, handgrip and postural change (mathBP, gripBP, and postBP), and body mass index (BMI) were analyzed for association with 10 single nucleotide polymorphisms (SNPs) in the angiotensinogen (AGT) gene. Single-marker and haplotype analyses were performed to examine the effects of both individual and multiple variants. Multiple-trait profiling was used to assess interaction of latent intermediate factors with susceptible haplotypes. Results: In Blacks, two SNPs in exon 5 and 3′ UTR showed significant association with gripBP, and two promoter SNPs were strongly associated with postBP. In Whites, only borderline association was found for 2 promoter SNPs with mathBP. Haplotype analyses in Blacks confirmed association with gripBP, and detected significant association of a haplotype to BMI (p = 0.029). With the interactions modeled, haplotype associations found in Blacks remain significant, while significant associations to BMI (p = 0.009) and gripSBP emerged in Whites. Conclusion: Genetic variants in regulatory regions of AGT showed strong association with blood pressure reactivity. Interaction of promoter and genic SNPs in AGT revealed collective action of multiple variants on blood pressure reactivity and BMI both in Blacks and in Whites, possibly following different pathways. Copyright © 2005 S. Karger AG.","AGT; Blood pressure reactivity; BMI; Genetic interaction; Haplotype analysis; Hypertension; Intermediate phenotype","African Americans; Analysis of Variance; Angiotensinogen; Blood Pressure; Body Mass Index; Cluster Analysis; European Continental Ancestry Group; Female; Haplotypes; Humans; Hypertension; Male; Middle Aged; Polymorphism, Single Nucleotide; Regulatory Sequences, Nucleic Acid; Variation (Genetics); adult; article; blood pressure; blood pressure regulation; body mass; body posture; female; genetic trait; genetic variability; hand grip; haplotype; human; human experiment; hypertension; male; mathematical computing; phenotype; renin angiotensin aldosterone system","","Angiotensinogen, 11002-13-4","","","National Heart, Lung, and Blood Institute, NHLBI, (U01HL054471); National Heart, Lung, and Blood Institute, NHLBI","","Abecasis G.R., Cookson W.O., GOLD - Graphical overview of linkage disequilibrium, Bioinformatics, 16, pp. 182-183, (2000); Akey J., Jin L., Xiong M., Haplotypes vs single marker linkage disequilibrium tests: What do we gain?, Eur J Hum Genet, 9, pp. 291-300, (2001); Atwood L.D., Kammerer C.M., Samollow P.B., Hixson J.E., Shade R.E., MacCluer J.W., Linkage of essential hypertension to the angiotensinogen locus in Mexican Americans, Hypertension, 30, pp. 326-330, (1997); Bacanu S.A., Devlin B., Roeder K., The power of genomic control, Am J Hum Genet, 66, pp. 1933-1944, (2000); Bloem L.J., Manatunga A.K., Tewksbury D.A., Pratt J.H., The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children, J Clin Invest, 95, pp. 948-953, (1995); Borecki I.B., Province M.A., Ludwig E.H., Ellison R.C., Folsom A.R., Heiss G., Lalouel J.M., Higgins M., Rao D.C., Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study, Ann Epidemiol, 7, pp. 13-21, (1997); Caulfield M., Lavender P., Farrall M., Munroe P., Lawson M., Turner P., Clark A.J., Linkage of the angiotensinogen gene to essential hypertension, N Engl J Med, 330, pp. 1629-1633, (1994); Chapman J.M., Cooper J.D., Todd J.A., Clayton D.G., Detecting disease associations due to linkage disequilibrium using haplotype tags: A class of tests and the determinants of statistical power, Hum Hered, 56, pp. 18-31, (2003); Chen X., Levine L., Kwok P.Y., Fluorescence polarization in homogeneous nucleic acid analysis, Genome Res, 9, pp. 492-498, (1999); Devlin B., Roeder K., Bacanu S.A., Unbiased methods for population-based association studies, Genet Epidemiol, 21, pp. 273-284, (2001); Dewan A.T., Arnett D.K., Atwood L.D., Province M.A., Lewis C.E., Hunt S.C., Eckfeldt J., A genome scan for renal function among hypertensives: The HyperGEN study, Am J Hum Genet, 68, pp. 136-144, (2001); Adult/Pediatric, and Neonatal Vital Signs Monitor: Models 1846 SX and 1846 SX/P Operations Manual, (1988); Dyer A.R., Elliott P., The INTERSALT study: Relations of body mass index to blood pressure, J Hum Hypertens, 3, pp. 299-308, (1989); Fornage M., Turner S.T., Sing C.F., Boerwinkle E., Variation at the M235T locus of the angiotensinogen gene and essential hypertension: A population-based case-control study from Rochester, Minnesota, Hum Genet, 96, pp. 295-300, (1995); Frossard P.M., Hill S.H., Elshahat Y.I., Obineche E.N., Bokhari A.M., Lestringant G.G., John A., Abdulle A.M., Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population, Clin Genet, 54, pp. 285-293, (1998); Gaillard I., Clauser E., Corvol P., Structure of human angiotensinogen gene, DNA, 8, pp. 87-99, (1989); Hata A., Namikawa C., Sasaki M., Sato K., Nakamura T., Tamura K., Lalouel J.M., Angiotensinogen as a risk factor for essential hypertension in Japan, J Clin Invest, 93, pp. 1285-1287, (1994); Hegele R.A., Brunt J.H., Connelly P.W., Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate, Hypertension, 27, pp. 308-312, (1996); Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P., Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study, Circulation, 67, pp. 968-977, (1983); Inoue I., Nakajima T., Williams C.S., Quackenbush J., Puryear R., Powers M., Cheng T., Ludwig E.H., Sharma A.M., Hata A., Jeunemaitre X., Lalouel J.M., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, pp. 1786-1797, (1997); Ishigami T., Umemura S., Tamura K., Hibi K., Nyui N., Kihara M., Yabana M., Watanabe Y., Sumida Y., Nagahara T., Ochiai H., Ishii M., Essential hypertension and 5′ upstream core promoter region of human angiotensinogen gene, Hypertension, 30, pp. 1325-1330, (1997); Iso H., Harada S., Shimamoto T., Sato S., Kitamura A., Sankai T., Tanigawa T., Iida M., Komachi Y., Angiotensinogen T174M and M235T variants, sodium intake and hypertension among non-drinking, lean Japanese men and women, J Hypertens, 18, pp. 1197-1206, (2000); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.M., Et al., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Kiskimoto T., Suyama A., Igarashi A., Osaki Y., Okamoto M., Yamamoto T., Nanba E., Kurosawa Y., Fukumoto S., Angiotensinogen gene variation and hypertension in a cohort study in Japanese, J Epidemiol, 11, pp. 115-119, (2001); Kohonen T., Self-Organizing Maps, (1995); Lander E.S., Schork N.J., Genetic dissection of complex traits, Science, 265, pp. 2037-2048, (1994); Lewontin R.C., Kojima K., The evolutionary dynamics of complex polymorphisms, Evolution, 14, pp. 450-472, (1960); MacMahon S., Cutler J., Brittain E., Higgins M., Obesity and hypertension: Epidemiological and clinical issues, Eur Heart J, 8, SUPPL. B, pp. 57-70, (1987); Martinez E., Puras A., Escribano J., Sanchis C., Carrion L., Artigao M., Divison J.A., Masso J., Fernandez J.A., Threonines at position 174 and 235 of the angiotensinogen polypeptide chain are related to familial history of hypertension in a Spanish-Mediterranean population, Br J Biomed Sci, 59, pp. 95-100, (2002); Matthews K.A., Woodall K.L., Allen M.T., Cardiovascular reactivity to stress predicts future blood pressure status, Hypertension, 22, pp. 479-485, (1993); Nakajima T., Jorde L.B., Ishigami T., Umemura S., Emi M., Lalouel J.M., Inoue I., Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations, Am J Hum Genet, 70, pp. 108-123, (2002); Niu T., Chen C., Yang J., Wang B., Wang Z., Schork N., Fang Z., Xu X., Blood pressure and the T174M and M235T polymorphisms of the angiotensinogen gene, Ann Epidemiol, 9, pp. 245-253, (1999); Patterson N., Hattangadi N., Lane B., Lohmueller K.E., Hafler D.A., Oksenberg J.R., Hauser S.L., Smith M.W., O'Brien S.J., Altshuler D., Daly M.J., Reich D., Methods for high-density admixture mapping of disease genes, Am J Hum Genet, 74, pp. 979-1000, (2004); Phillips M.S., Lawrence R., Sachidanandam R., Morris A.P., Balding D.J., Donaldson M.A., Studebaker J.F., Ankener W.M., Alfisi S.V., Kuo F.S., Camisa A.L., Pazorov V., Scott K.E., Carey B.J., Faith J., Katari G., Bhatti H.A., Cyr J.M., Derohannessian V., Elosua C., Forman A.M., Grecco N.M., Hock C.R., Kuebler J.M., Lathrop J.A., Mockler M.A., Nachtman E.P., Restine S.L., Varde S.A., Hozza M.J., Gelfand C.A., Broxholme J., Abecasis G.R., Boyce-Jacino M.T., Cardon L.R., Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots, Nat Genet, 33, pp. 382-387, (2003); Posada D., Maxwell T.J., Templeton A.R., Tree-Scan: A bioinformatic application to search for genotype/phenotype associations using haplotype trees, Bioinformatics, 21, pp. 2130-2132, (2005); Pritchard J.K., Stephens M., Donnelly P., Inference of population structure using multilocus genotype data, Genetics, 155, pp. 945-959, (2000); Province M.A., Boerwinkle E., Chakravarti A., Cooper R., Fornage M., Leppert M., Risch N., Ranade K., Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program, J Hypertens, 18, pp. 867-876, (2000); Rankinen T., Gagnon J., Perusse L., Chagnon Y.C., Rice T., Leon A.S., Skinner J.S., Wilmore J.H., Rao D.C., Bouchard C., AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study, Am J Physiol Heart Circ Physiol, 279, (2000); Rice T., Rankinen T., Province M.A., Chagnon Y.C., Perusse L., Borecki I.B., Bouchard C., Rao D.C., Genome-wide linkage analysis of systolic and diastolic blood pressure: The Quebec Family Study, Circulation, 102, pp. 1956-1963, (2000); Rotimi C., Morrison L., Cooper R., Oyejide C., Effiong E., Ladipo M., Osotemihen B., Ward R., Angiotensinogen gene in human hypertension. Lack of an association of the 235T allele among African Americans, Hypertension, 24, pp. 591-594, (1994); Sethi A.A., Nordestgaard B.G., Agerholm-Larsen B., Frandsen E., Jensen G., Tybjaerg-Hansen A., Angiotensinogen polymorphisms and elevated blood pressure in the general population: The Copenhagen City Heart Study, Hypertension, 37, pp. 875-881, (2001); Sethi A.A., Nordestgaard B.G., Gronholdt M.L., Steffensen R., Jensen G., Tybjaerg-Hansen A., Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease, Hypertension, 41, pp. 1202-1211, (2003); Sethi A.A., Nordestgaard B.G., Tybjaerg-Hansen A., Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis, Arterioscler Thromb Vasc Biol, 23, pp. 1269-1275, (2003); Slatkin M., Excoffier L., Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm, Heredity, 76, 4 PART, pp. 377-383, (1996); Stamler R., Stamler J., Riedlinger W.F., Algera G., Roberts R.H., Weight and blood pressure. Findings in hypertension screening of 1 million Americans, JAMA, 240, pp. 1607-1610, (1978); Stephens M., Donnelly P., A comparison of bayesian methods for haplotype reconstruction from population genotype data, Am J Hum Genet, 73, pp. 1162-1169, (2003); Stephens M., Smith N.J., Donnelly P., A new statistical method for haplotype reconstruction from population data, Am J Hum Genet, 68, pp. 978-989, (2001); Tamayo P., Slonim D., Mesirov J., Zhu Q., Kitareewan S., Dmitrovsky E., Lander E.S., Golub T.R., Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation, Proc Natl Acad Sci, 96, pp. 2907-2912, (1999); Tang H., Quertermous T., Rodriguez B., Kardia S.L., Zhu X., Brown A., Pankow J.S., Province M.A., Hunt S.C., Boerwinkle E., Schork N.J., Risch N.J., Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies, Am J Hum Genet, 76, pp. 268-275, (2005); Templeton A.R., Maxwell T., Posada D., Stengard J.H., Boerwinkle E., Sing C.F., Tree scanning: A method for using haplotype trees in phenotype/genotype association studies, Genetics, 169, pp. 441-453, (2005); Thomas D.C., Witte J.S., Point: Population stratification: a problem for case-control studies of candidate-gene associations?, Cancer Epidemiol Biomarkers Prev, 11, pp. 505-512, (2002); Wacholder S., Rothman N., Caporaso N., Counterpoint: Bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer, Cancer Epidemiol Biomarkers Prev, 11, pp. 513-520, (2002); Wang W.Y., Glenn C.L., Zhang W., Benjafield A.V., Nyholt D.R., Morris B.J., Exclusion of angiotensinogen gene in molecular basis of human hypertension: Sibpair linkage and association analyses in Australian anglo-caucasians, Am J Med Genet, 87, pp. 53-60, (1999); Williams R.R., Rao D.C., Ellison R.C., Arnett D.K., Heiss G., Oberman A., Eckfeldt J.H., Leppert M.F., Province M.A., Mockrin S.C., Hunt S.C., NHLBI family blood pressure program: Methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network, Ann Epidemiol, 10, pp. 389-400, (2000); Zhang K., Jin L., HaploBlockFinder: Haplotype block analyses, Bioinformatics, 19, pp. 1300-1301, (2003); Zhu X., Yan D., Cooper R.S., Luke A., Ikeda M.A., Chang Y.-P.C., Weder A., Chakravarti A., Linkage Disequilibrium and Haplotype Diversity in the Genes of the Renin-Angiotensin System: Findings from the Family Blood Pressure Program, Genome Res, 13, pp. 173-181, (2003)","C.C. Gu; Division of Biostatistics, Washington University School of Medicine, Campus Box 8067, St. Louis, MO 63110, 660 S. Euclid Avenue, United States; email: gc@wubios.wustl.edu","","","","","","","","00015652","","HUHEA","16352906","English","Hum. Hered.","Article","Final","","Scopus","2-s2.0-31144441123"
"Yuan M.; Ohishi M.; Ito N.; Sugimoto K.; Takagi T.; Terai M.; Katsuya T.; Rakugi H.; Wu Z.; Ogihara T.","Yuan, Ming (7201374205); Ohishi, Mitsuru (7102625754); Ito, Norihisa (8547989400); Sugimoto, Ken (35400530500); Takagi, Takashi (57203513366); Terai, Minako (8547989700); Katsuya, Tomohiro (7005266558); Rakugi, Hiromi (57202699453); Wu, Zonggui (55567376100); Ogihara, Toshio (57220595182)","7201374205; 7102625754; 8547989400; 35400530500; 57203513366; 8547989700; 7005266558; 57202699453; 55567376100; 57220595182","Genetic influences of β-adrenoceptor polymorphisms on arterial functional changes and cardiac remodeling in hypertensive patients","2006","Hypertension Research","29","11","","875","881","6","15","10.1291/hypres.29.875","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846117517&doi=10.1291%2fhypres.29.875&partnerID=40&md5=fad84c8be4b94d181631ace64071df90","Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Department of Cardiology, Changzheng Hospital, Shanghai, China","Yuan M., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan, Department of Cardiology, Changzheng Hospital, Shanghai, China; Ohishi M., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Ito N., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Sugimoto K., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Takagi T., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Terai M., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Katsuya T., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Rakugi H., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; Wu Z., Department of Cardiology, Changzheng Hospital, Shanghai, China; Ogihara T., Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan","Three subtypes of β-adrenoceptor, β1, β2 and β3, are involved in the sympathetic nervous system, which plays an important role in the development of hypertension and hypertensive complications. These complications can include left ventricular hypertrophy and arterial stiffness, which are reported risk factors for cardiovascular diseases. We designed clinical trials to clarify the association between hypertensive complications and β-adrenoceptor single nucleotide polymorphisms in essential hypertension. Using Taqman PCR methods, we detected five polymorphisms of three β-adrenoceptors: Ser49Gly and Arg389Gly for the β1-adrenoceptor; Gly16Arg and Glu27Gln for the β2-adrenoceptor; and Trp64Arg for the β3-adrenoceptor. We included 300 subjects and measured pulse wave velocity, vasodilator response to hyperemia, left ventricular hypertrophy (by electrocardiogram and echocardiography), and cardiac enlargement (by chest X-ray). We found that pulse wave velocity and nitroglycerin-induced hyperemia were both closely associated with the Ser49Gly polymorphism (p<0.05), and Glu27Gln was found by both electrocardiogram and echocardiography to be significantly associated with left ventricular hypertrophy (p<0.05). These data suggested that two polymorphisms of different β-adrenoreceptor subtypes are the genetic inff nces on the development of arterial stiffness and left ventricular hypertrophy in essential hypertension.","β-adrenoreceptor; Arterial stiffness; Hypertensive complications; Polymorphisms","Aged; Amino Acid Substitution; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Adrenergic, beta; Risk Factors; Vasodilation; alpha adrenergic receptor blocking agent; angiotensin receptor antagonist; antihypertensive agent; arginine; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta 3 adrenergic receptor; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; genomic DNA; glutamic acid; glutamine; glyceryl trinitrate; glycine; serine; tryptophan; adult; aged; amino acid substitution; artery disease; article; cardiomegaly; cardiovascular risk; echocardiography; electrocardiography; essential hypertension; female; genetic association; heart left ventricle hypertrophy; heart ventricle remodeling; human; hyperemia; major clinical study; male; observational study; pathogenesis; polymerase chain reaction; pulse wave; risk factor; single nucleotide polymorphism; thorax radiography","","arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3; glutamic acid, 11070-68-1, 138-15-8, 56-86-0, 6899-05-4; glutamine, 56-85-9, 6899-04-3; glyceryl trinitrate, 55-63-0; glycine, 56-40-6, 6000-43-7, 6000-44-8; serine, 56-45-1, 6898-95-9; tryptophan, 6912-86-3, 73-22-3; Receptors, Adrenergic, beta, ","","","","","Walston J., Lowe A., Silver K., Et al., The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64, Gene, 188, pp. 207-213, (1997); Naga Prasad S.V., Nienaber J., Rockman H.A., Beta-adrenergic axis and heart disease, Trends Genet, 17, (2001); Johnson M., The beta-adrenoceptor, Am J Respir Crit Care Med, 158, (1998); Krum H., Sympathetic activation and the role of beta-blockers in chronic heart failure, Aust N Z J Med, 29, pp. 418-427, (1999); Bohm M., Flesch M., Schnabel P., Beta-adrenergic signal transduction in the failing and hypertrophied myocardium, J Mol Med, 75, pp. 842-848, (1997); Scarpace P.J., Tumer N., Mader S.L., Beta-adrenergic function in aging. Basic mechanisms and clinical implications, Drugs Aging, 1, pp. 116-129, (1991); Feldman R.D., Adrenergic receptor polymorphisms and cardiac function (and dysfunction): A failure to communicate?, Circulation, 103, pp. 1042-1043, (2001); Dzimiri N., Regulation of beta-adrenoceptor signaling in cardiac function and disease, Pharmacol Rev, 51, pp. 465-501, (1999); Diamond J., Phillips R., Hypertensive heart disease, Hypertens Res, 28, pp. 191-202, (2005); Imanishi R., Seto S., Toda G., Et al., High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men, Hypertens Res, 27, pp. 71-78, (2004); Nitta K., Akiba T., Uchida K., Et al., Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients, Hypertens Res, 27, pp. 47-52, (2004); Erickson R.P., Graves P.E., Genetic variation in beta-adrenergic receptors and their relationship to susceptibility for asthma and therapeutic response, Drug Metab Dispos, 29, pp. 557-561, (2001); Johnson J.A., Terra S.G., Beta-adrenergic receptor polymorphisms: Cardiovascular disease associations and pharmacogenetics, Pharm Res, 19, pp. 1779-1787, (2002); Iwai C., Akita H., Kanazawa K., Et al., Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction, Am Heart J, 146, pp. 106-109, (2003); Shioji K., Kokubo Y., Mannami T., Et al., Association between hypertension and the α-adducin, β1-adrenoreceptor, and G-protein β3 subunit genes in the Japanese population; the Suita study, Hypertens Res, 27, pp. 31-37, (2004); Svetkey L.P., Timmons P.Z., Emovon O., Anderson N.B., Preis L., Chen Y.T., Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype, Hypertension, 27, pp. 1210-1215, (1996); Fujisawa T., Ikegami H., Yamato E., Et al., Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain, Diabetologia, 39, pp. 349-352, (1996); Fujisawa T., Ikegami H., Yamato E., Et al., Trp64Arg mutation of beta3-adrenergic receptor in essential hypertension: Insulin resistance and the adrenergic system, Am J Hypertens, 10, pp. 101-105, (1997); Katsuya T., Baba S., Ishikawa K., Et al., Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: The Suita Study, J Hypertens, 20, pp. 2017-2021, (2002); Ranade K., Jorgenson E., Shen W.H., Et al., A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate, Am J Hum Genet, 70, pp. 935-942, (2002); Komai N., Ohishi M., Morishita R., Et al., Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients, Am J Hypertens, 15, pp. 499-506, (2002); Komai N., Ohishi M., Moriguchi A., Et al., Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation, Hypertens Res, 25, pp. 5-10, (2002); Asmar R., Rudnichi A., Blacher J., London G.M., Safar M.E., Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations, Am J Hypertens, 14, pp. 91-97, (2001); Ouchi N., Ohishi M., Kihara S., Et al., Association of hypoadiponectinemia with impaired vasoreactivity, Hypertension, 43, pp. 231-234, (2003); Sokolow M., Lyon T., The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads, Am Heart J, 37, pp. 161-186, (1949); Devereux R., Alonso D., Lutas E., Et al., Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings, Am J Cardiol, 57, pp. 450-458, (1986); Bengtsson K., Melander O., Orho-Melander M., Et al., Polymorphism in the β1-adrenergic receptor gene and hypertension, Circulation, 104, pp. 187-190, (2001); Yoshida N., Nishimaki Y., Sugiyama M., Et al., SNP genotyping in the β2-adrenergic receptor by electronic microchip assay, DHPLC, and direct sequencing, J Hum Genet, 47, pp. 500-503, (2002); Chang T.J., Tsai M.H., Jiang Y.D., Et al., The Arg16Gly polymorphism of human beta2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people, Clin Endocrinol (Oxf), 57, pp. 685-690, (2002); Okumura K., Matsui H., Ogawa Y., Et al., The polymorphism of the beta3-adrenergic receptor gene is associated with reduced low-density lipoprotein particle size, Metabolism, 52, pp. 356-361, (2003); Karlsson J., Lind L., Hallberg P., Et al., Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension, Clin Cardiol, 27, pp. 347-350, (2004); Mason D.A., Moore J.D., Green S.A., Liggett S.B., A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor, J Biol Chem, 274, pp. 12670-12674, (1999); Masuo K., Katsuya T., Kawaguchi H., Et al., Rebound weight gain as associated with high plasma norepinephrine levels that are mediated through polymorphisms in the beta2-adrenoceptor, Am J Hypertens, 18, pp. 1508-1516, (2005); Eisenach J., Schroeder D., Pike T., Et al., Dietary sodium restriction and β2-adrenergic receptor polymorphism modulate cardiovascular function in humans, J Physiol, 574, pp. 955-965, (2006); Hojlund K., Christiansen C., Bjornsbo K., Et al., Energy expenditure, body composition and insulin response to glucose in male twins discordant for the Trp64Arg polymorphism of the beta3-adrenergic receptor gene, Diabetes Obes Metab, 8, pp. 322-330, (2006); Kuusela T., Jartti T., Tahvanainen K., Kaila T., Effects of terbutaline on peripheral vascular resistance and arterial compliance, J Cardiovasc Pharmacol, 44, pp. 74-81, (2004)","H. Raguki; Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, 2-2 Yamadaoka, Japan; email: rakugi@geriat.med.osaka-u.ac.jp","","","","","","","","13484214","","HRESE","17345787","English","Hypertens. Res.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-33846117517"
"Trotta R.; Donati M.B.; Iacoviello L.","Trotta, Roberto (7004544301); Donati, Maria Benedetta (7102675032); Iacoviello, Licia (57205867300)","7004544301; 7102675032; 57205867300","Trends in pharmacogenomics of drugs acting on hypertension","2004","Pharmacological Research","49","4","","351","356","5","18","10.1016/j.phrs.2003.07.018","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0842328714&doi=10.1016%2fj.phrs.2003.07.018&partnerID=40&md5=0b71768b950ae04a27d158ce5f7f57f5","Angela Valenti Lab. Genetic E., 66030 Santa Maria Imbaro, Consorzio Mario Negri Sud, Italy; Ctr. High Technol. Res. Educ. B., Catholic University, Campobasso, Italy; Istituto di Cardiologia, Università di Napoli, Napoli, Italy","Trotta R., Angela Valenti Lab. Genetic E., 66030 Santa Maria Imbaro, Consorzio Mario Negri Sud, Italy, Istituto di Cardiologia, Università di Napoli, Napoli, Italy; Donati M.B., Ctr. High Technol. Res. Educ. B., Catholic University, Campobasso, Italy; Iacoviello L., Angela Valenti Lab. Genetic E., 66030 Santa Maria Imbaro, Consorzio Mario Negri Sud, Italy, Ctr. High Technol. Res. Educ. B., Catholic University, Campobasso, Italy","With the recent rapid increase in scientific understanding of the human genome it is becoming possible to identify the extent to which genetic variations influence drug response. The emergence of pharmacogenetics heralds a new era in which drug therapies will be selected on the basis of differences in individuals' genotypes, enhancing drug safety and efficacy. The major focus of this review is pharmacogenetics of antihypertensive drugs. Genetics can influence the pharmacokinetics and pharmacodynamics of such drugs at different levels. The presently available applications of genetic concepts to some drugs commonly used in the treatment of hypertension (ACE-inhibitors, diuretics, beta-blockers ...) will be summarized. Also sensitivity to salt intake will be considered as an example of pharmacogenetics. The identification of genetic markers of drug response will help to achieve a better control of blood pressure in the population, by allowing a better tailor of antihypertensive therapy to individual patients. © 2003 Elsevier Ltd. All rights reserved.","Antihypertensive drugs; Hypertension; Pharmacogenetics; Polymorphisms","11beta hydroxysteroid dehydrogenase; adducin; alpha adducin; angiotensin 1 receptor; angiotensin 2 receptor antagonist; angiotensin receptor antagonist; angiotensinogen; antihypertensive agent; arylamine acetyltransferase; atenolol; beta adrenergic receptor blocking agent; calcium channel blocking agent; catechol methyltransferase; cytochrome P450 2D6; debrisoquine; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; fosinopril; hydralazine; irbesartan; methyldopa; stimulatory guanine nucleotide binding protein; unclassified drug; adrenergic system; cardiovascular risk; clinical trial; diastolic blood pressure; DNA polymorphism; drug absorption; drug activity; drug distribution; drug efficacy; drug excretion; drug metabolism; drug response; drug targeting; gene deletion; gene insertion; gene locus; genetic risk; genetic variability; genotype; heart left ventricle hypertrophy; human; hypertension; nonhuman; pharmacogenomics; phenotype; point mutation; priority journal; protein function; renin angiotensin aldosterone system; review; salt intake; signal transduction; sodium restriction; sodium urine level; systolic blood pressure","","11beta hydroxysteroid dehydrogenase, 9041-46-7; angiotensinogen, 11002-13-4, 64315-16-8; arylamine acetyltransferase, 9027-33-2; atenolol, 29122-68-7, 93379-54-5; catechol methyltransferase, 9012-25-3; debrisoquine, 1131-64-2, 581-88-4; dipeptidyl carboxypeptidase, 9015-82-1; fosinopril, 88889-14-9, 98048-97-6; hydralazine, 304-20-1, 86-54-4; irbesartan, 138402-11-6; methyldopa, 555-29-3, 555-30-6","","","","","Motulsky A., Drug reactions, enzymes and biochemical genetics, J. Am. Med. Assoc., 165, pp. 835-837, (1957); Vogel F., Moderne probleme der humangenetik, Ergebn. Inn Med Kinderheilk, 12, pp. 52-125, (1959); Meyer U., Drugs in special patient groups: Clinical importance of genetics in drug effects, Clinical Pharmacology: Basic Principles in Therapeutics, pp. 875-894, (1992); Burt V.L., Whelton P., Roccella E.J., Brown C., Cutler J.A., Higgins M., Et al., Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991, Hypertension, 25, pp. 305-313, (1995); Sharma P., Fatibene J., Ferraro F., Jia H., Monteith S., Brown C., Et al., A genome-wide search for susceptibility loci to human essential hypertension, Hypertension, 35, pp. 1291-1296, (2000); Lifton R.P., Molecular genetics of human blood pressure variation, Science, 272, pp. 676-680, (1996); Horan M.J., Mockrin S.C., Heterogeneity of hypertension, Am. J. Hypertens., 5, (1992); Hamet P., Pausava Z., Adarichev V., Adaricheva K., Tremblay J., Hypertension: Genes and environment, J. Hypertens., 16, pp. 397-418, (1998); Sever P., The heterogeneity of hypertension: Why doesn't every patient respond to every antihypertensive drug?, J. Hum. Hypertens., 9, SUPPL. 2, (1995); Niutta E., Cusi D., Colombo R., Pellizzoni M., Cesana B., Barlassina C., Et al., Predicting interindividual variation in anti-hypertensive therapy: The role of sodium transport systems and renin, J. Hypertens., 6, SUPPL. 4, (1990); Laragh J.H., Lamport B., Sealey J., Alderman M.H., Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Menard J., Bellet M., Serrurier D., From the parallel group study to the crossover design, and from the group approach to the individual approach, Am. J. Hypertens., 3, pp. 815-819, (1990); Trotta R., De Luca N., Iovino G., Izzo R., Rozza F., Di Castelnuovo A., Et al., Italian Heart J, 3, 7 SUPPL., (2002); Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Et al., The sequence of human genome, Science, 291, pp. 1304-1351, (2001); Zito F., Di Castelnuovo A., Amore C., D'Orazio A., Donati M.B., Iacoviello L., Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients, Arterioscler. Thromb. Vasc. Biol., 17, pp. 3489-3494, (1997); Iacoviello L., Di Castelnuovo A., De Knijff P., D'Orazio A., Amore C., Arboretti R., Et al., Polimorphisms in the coagulation factor VII gene and the risk of myocardial infarction, N. Engl. J. Med., 338, pp. 79-85, (1998); Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo, N. Engl. J. Med., 328, pp. 914-921, (1993); Weder A., Julius S., Pathophysiology of hypertension and treatment, Cardiovascular Pharmacology and Therapeutics, pp. 861-883, (1994); Hall W., Pharmacologic therapy of hypertension in blacks, J. Clin. Hypertens., 3, (1987); Jamerson K., De Quattro V., The impact of ethnicity on response to antihypertensive therapy, Am. J. Med., 101, (1996); Seedat Y., Varying responses to hypotensive agents in different racial groups: Black versus white differences, J. Hypertens., 7, pp. 515-518, (1989); Gonzales F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Et al., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature, 331, pp. 442-446, (1988); Mahgoub A., Idle J.R., Dring L.G., Lancaster R., Smith R.L., Polymorphic hydroxylation of debrisoquine in man, Lancet, 2, pp. 584-586, (1977); Daly A., Brockmoller J., Broly F., Eichelbaum M., Evans W., Gonzales F., Et al., Nomenclature for human CYP2D6 alleles, Pharmacogenetics, 6, pp. 193-201, (1996); Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U.A., Debrisoquine/sparteine hydroxylase genotype and phenotype, DNA Cell Biol., 10, pp. 545-558, (1991); Alvan G., Von Bahr C., Seidman P., Sjoqvist F., High plasma concentrations of β-receptors blocking drugs and deficient debrisoquine hydroxylation, Lancet, 1, (1982); Dahl M.L., Johansson I., Palmertz M.P., Ingelman-Sundberg M., Sjoqvist F., Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population, Clin. Pharmacol. Ther., 51, pp. 12-17, (1992); Kalow W., Otton S., Kadar D., Endrenyi L., Inaba T., Ethnic difference in drug metabolism: Debrisoquine 4-hydroxylation in Caucasians and Orientals, Can. J. Physiol. Pharmacol., 58, pp. 1142-1144, (1980); Johansson I., Lundqvist E., Bertilsson I., Dahl M., Sjoqvist F., Et al., Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc. Natl. Acad. Sci. U.S.A., 90, pp. 11825-11829, (1993); Lennard M., Silas J., Freestone S., Ramsay L., Tucker G., Woods H., Oxidation phenotype - A major determinant of metoprolol metabolism and response, N. Engl. J. Med., 307, pp. 1558-1560, (1982); Lennard M., Silas J., Freestone S., Trevethick J., Defective metabolism of metoprolol in poor hydroxylators of debrisoquine, Br. J. Clin. Pharmacol., 14, pp. 301-303, (1982); Shah R., Oates N., Idle J., Smith R., Beta-blockers and drug oxidation status, Lancet, 1, pp. 508-509, (1982); Dayer P., Balant L., Kupfer A., Courvoisier F., Fabre J., Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents, Eur. J. Clin. Pharmacol., 24, pp. 797-799, (1983); Silas J., Freeston S., Lennard M., Ramsay L., Chronic dosing comparison of three formulations of metoprolol and atenolol in hypertensive patients, Br. J. Clin. Pharmacol., 18, (1984); Buchert E., Woosley R., Clinical implications of variable anti-arrhythmic drug metabolism, Pharmacogenetics, 2, pp. 2-11, (1992); Broly F., Marez D., Sabbagh N., Legrand M., Millecamps S., Lo Giudice J., Et al., An efficient strategy for detection of know and new mutations of the CYP2D6 gene using single strand conformation polymorphisms analysis, Pharmacogenetics, 5, pp. 373-384, (1995); Franke S., Klawitz I., Schnakemberg E., Rommel B., Van Der Wen W., Bullerdick J., Et al., Isolation and mapping of a cosmid clone containing the human NAT2 gene, Biochem. Biophys. Res. Commun., 199, pp. 52-55, (1994); Hickman D., Risch A., Buckie V., Spurr N., Jeremiah S., McCarthy A., Et al., Chromosomal localization of human genes for arylamine N-acetyltransferase, Biochem. J., 297, pp. 441-445, (1994); Dufour A., Knight R., Harris H., Genetics of isoniazid metabolism in Caucasian, Negro, and Japanese populations, Science, 145, (1964); Karim A., Elfellah M., Evans D., Human acetylator polymorphisms: Estimates of allele frequency in Lybia and details of global distribution, J. Med. Genet., 18, pp. 325-333, (1981); Sunahara S., Motoyuki U., Ogawa M., Genetical and geographic studies on isoniazid inactivation, Science, 134, (1961); Zacest R., Koch-Weser J., Relation of hydralazine plasma concentration to dosage and hypotensive action, Clin. Pharmacol. Ther., 13, pp. 420-425, (1972); Jounela A., Pasanen M., Mattila M., Acetylator phenotype and the antihypertensive response to hydralazine, Acta Med. Scand., 197, pp. 303-306, (1975); Shepherd A., McNay J., Ludden T., Lin M., Musgrave G., Plasma concentration and acetylator phenotype determine response to oral hydralazine, Hypertension, 3, pp. 580-585, (1981); Perry H., Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis, Am. J. Med., 54, pp. 58-72, (1973); Uetrecht J., Woosley R., Acetylator phenotype and lupus erythematosus, Clin. Pharmacokinet., 6, pp. 118-134, (1981); Batchelor J., Welsh K., Tinoco R., Dollery C., Hughes G., Bernstein R., Et al., Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility, Lancet, 1, pp. 1107-1109, (1980); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliff P., Prediction of patient response to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J. Hypertens., 14, pp. 259-262, (1996); Mayer G., ACE genotype and ACE inhibitor response in kidney disease: A perspective, Am. J. Kidney Dis., 40, pp. 227-235, (2002); Baudin B., Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations, Pharmacogenomics, 3, pp. 65-73, (2002); Hingorani A.D., Jia H., Stevens P., Hopper R., Dickerson J.E., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J. Hypertens., 13, pp. 1602-1609, (1995); Stavroulakis G.A., Makris T.K., Krespi P.G., Hatzizacharias A.N., Gialeraki A.E., Anastasiadis G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc. Drugs Ther., 14, pp. 427-432, (2000); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J. Hpertens., 19, pp. 1783-1787, (2001); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., Et al., Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA), J. Hypertens., 20, pp. 657-663, (2002); Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P., Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study, N. Engl. J. Med., 322, pp. 1561-1566, (1990); Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., Et al., Prognostic significance of serial changes in left ventricular mass in essential hypertension, Circulation, 97, pp. 48-54, (1998); Hughes C.A., Bennet V., Adducin: A physical model with implications for function in assembly of spectrin-actin complexes, J. Biol. Chem., 270, pp. 18990-18996, (1995); Matsuoka Y., Hughes C.A., Bennat V., Definition of the calmodulin-binding domain and sites of phosphorylation by protein kinase a and C, J. Biol. Chem., 271, pp. 25157-25166, (1996); Bianchi G., Tripodi G., Casari G., Salardi S., Barber B., Garcia R., Et al., Two point mutations within the adducin gene are involved in blood pressure variation, Proc. Natl. Acad. Sci. U.S.A., 91, pp. 3999-4003, (1994); Tripodi G., Valtorta F., Torielli L., Chieregatti E., Salardi S., Trusolino S., Et al., Hypertension-association point mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport, J. Clin. Invest., 97, pp. 2815-2822, (1996); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Et al., Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., Et al., The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, pp. 649-654, (1999); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D., ACE and α-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P., Et al., Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Hunt S.C., Cook N.R., Oberman A., Culter J.A., Hennekens C.H., Allender P.S., Et al., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Trials of hypertension prevention, phase II, Hypertension, 32, pp. 393-401, (1998); Poch E., Gonzales D., Giner V., Bragulat E., Coca A., De La Sierra A., Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphism, Hypertension, 38, pp. 1204-1209, (2001); Lifton R.P., Molecular genetics of human blood pressure variation, Science, 272, pp. 676-680, (1996); Ishikawa Y., Homcy C.J., The adenyl cyclases as integrators of transmembrane signal transduction, Circ. Res., 80, pp. 297-304, (1997); Yatani A., Brown A.M., Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway, Science, 245, pp. 71-74, (1989); Yoshikawa H., Fukuda K., Wanaka Y., Kasamatsu K., Baba A., Nishio I., Et al., Deficient activity of stimulatory nucleotide-binding regulatory protein in lymphocytes from patients with essential hypertension, Am. J. Hypertens., 7, pp. 713-716, (1994); Feldman R.D., Tan C.M., Chorazyczewski J., G protein alterations in hypertension and aging, Hypertension, 26, pp. 725-732, (1995); Feldman R.D., Lawton W.J., McArdle W.L., Low sodium diet corrects the defects in lymphocyte beta-adrenergic responsiveness in hypertensive subjects, J. Clin. Invest., 79, pp. 290-294, (1987); Jia H., Hingorani A.D., Shama P., Hopper R., Dickerson C., Trutwein D., Et al., Association of the Gsα gene with essential hypertension and response to β-blockade, Hypertension, 34, pp. 8-14, (1999); Moskowitz D.W., From pharmacogenomics to improved patient outcomes: Angiotensin I-converting enzyme as an example, Diabetes Technol. Ther., 4, pp. 519-532, (2002); Hamet P., Genes and hypertension: Where we are and where we should go, Clin. Exp. Hypertens, 21, pp. 947-960, (1999)","L. Iacoviello; Angela Valenti Lab. Genetic E., 66030 Santa Maria Imbaro, Consorzio Mario Negri Sud, Italy; email: iaco@negrisud.it","","Academic Press","","","","","","10436618","","PHMRE","15202514","English","Pharmacol. Res.","Article","Final","","Scopus","2-s2.0-0842328714"
"Masuo K.","Masuo, Kazuko (7004623416)","7004623416","Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome","2010","International Journal of Hypertension","2010","","832821","","","","29","10.4061/2010/832821","https://www.scopus.com/inward/record.uri?eid=2-s2.0-82255174532&doi=10.4061%2f2010%2f832821&partnerID=40&md5=5bf21b887deb364d48cdcbeef2c6f69a","Nucleus Network Ltd. and Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC 3004, 89 Commercial Road, Australia","Masuo K., Nucleus Network Ltd. and Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC 3004, 89 Commercial Road, Australia","Hypertension, diabetes mellitus (especially type 2 diabetes mellitus), metabolic syndrome and obesity are rapidly growing public health problems. Sympathetic nerve activation is observed in obesity, hypertension and diabetes mellitus, which have strong genetic as well as environmental determinants. Reduced energy expenditure and resting metabolic rate are predictive of weight gain, and the sympathetic nervous system participates in regulating energy balance through thermogenesis. The thermogenic effects of catecholamines in obesity have been mainly mediated via the β 2- and β 3-adrenergic receptors in humans. Further, β 2-adrenoceptors importantly influence vascular reactivity and may regulate blood pressure. Genetic polymorphistns of the β -adrenoceptor gene have been shown to alter the function of several adrenoceptor subtypes and thus to modify the response to catecholamine. β 2-adrenoceptor polymorphisms (Arg16Gly, Gln27Glu, and Thr164Ile) have been studied in relation to hypertension. Genetic variations in the β 3-adrenoceptor (i.e. Try64Arg variant) are also associated with both obesity and hypertension. However, the precise relationships of the polymorphisms of β 2- and β 3-adrenoceptor genes with sympathetic nervous system activity, hypertension, and metabolic syndrome have not been fully clarified. This paper will discuss the current topics involving the influence of the sympathetic nervous system and β 2- and β 3- adrenoceptor polymorphisms in hypertension and metabolic syndrome. © 2010 Kazuko Masuo.","","alpha 1 adrenergic receptor; alpha 2 adrenergic receptor; arginine; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta 3 adrenergic receptor; cyclic AMP; glycine; isoleucine; threonine; adrenergic system; controlled study; disease association; DNA polymorphism; genetic variability; homozygosity; human; hypertension; insulin resistance; metabolic syndrome X; non insulin dependent diabetes mellitus; nonhuman; obesity; pressoreceptor reflex; priority journal; protein expression; protein function; renin angiotensin aldosterone system; review; single nucleotide polymorphism; sleep disordered breathing","","arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3; cyclic AMP, 60-92-4; glycine, 56-40-6, 6000-43-7, 6000-44-8; isoleucine, 7004-09-3, 73-32-5; threonine, 36676-50-3, 72-19-5","","","","","Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., Koplan J.P., The continuing epidemics of obesity and diabetes in the United States, Journal of the American Medical Association, 286, 10, pp. 1195-1200, (2001); Heidemann C., Boeing H., Pischon T., Nothlings U., Joost H.-G., Schulze M.B., Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: A prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort, European Journal of Epidemiology, 24, 6, pp. 281-288, (2009); Flegal K.M., Graubard B.I., Williamson D.F., Gail M.H., Cause-specific excess deaths associated with underweight, overweight, and obesity, Journal of the American Medical Association, 298, 17, pp. 2028-2037, (2007); Ramsey F., Ussery-Hall A., Garcia D., Centers for disease control and prevention (CDC), MMWR Surveillance Summaries, 57, pp. 1-20, (2008); Ogden C.L., Fryar C.D., Carroll M.D., Flegal K.M., Advance data from vital and health statics, CDC, 347, pp. 1-20, (2004); Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., Koplan J.P., The spread of the obesity epidemic in the United States, 1991-1998, Journal of the American Medical Association, 282, 16, pp. 1519-1522, (1999); Preis S.R., Hwang S.-J., Coady S., Pencina M.J., D'Agostino R.B., Savage P.J., Levy D., Fox C.S., Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham heart study, 1950 to 2005, Circulation, 119, 13, pp. 1728-1735, (2009); Spraul M., Ravussin E., Fontvieille A.M., Rising R., Larson D.E., Anderson E.A., Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain, Journal of Clinical Investigation, 92, 4, pp. 1730-1735, (1993); Iwashita S., Tanida M., Terui N., Ootsuka Y., Shu M., Kang D., Suzuki M., Direct measurement of renal sympathetic nervous activity in high-fat diet-related hypertensive rats, Life Sciences, 71, 5, pp. 537-546, (2002); Monroe M.B., Seals D.R., Shapiro L.F., Bell C., Johnson D., Jones P.P., Direct evidence for tonic sympathetic support of resting metabolic rate in healthy adult humans, American Journal of Physiology, 280, 5, (2001); Blaak E.E., Van Baak M.A., Kempen K.P.G., Saris W.H.M., Role of α- and β-adrenoceptors in sympathetically mediated thermogenesis, American Journal of Physiology - Endocrinology and Metabolism, 264, (1993); Hagstrom-Toft E., Enoksson S., Moberg E., Bolinder J., Arner P., β -adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo, American Journal of Physiology, 275, 6, (1998); Enoksson S., Talbot M., Rife F., Tamborlane W.V., Sherwin R.S., Caprio S., Impaired in vivo stimulation of lipolysis in adipose tissue by selective β 2-adrenergic agonist in obese adolescent girls, Diabetes, 49, 12, pp. 2149-2153, (2000); Masuo K., Mikami H., Ogihara T., Tuck M.L., Familial hypertension, insulin, sympathetic activity, and blood pressure elevation, Hypertension, 32, 1, pp. 96-100, (1998); Masuo K., Mikami H., Ogihara T., Tuck M.L., Familial obesity, sympathetic activation and blood pressure level, Blood Pressure, 10, 4, pp. 199-204, (2001); Cui J., Hopper J.L., Harrap S.B., Genes and family environment explain correlations between blood pressure and body mass index, Hypertension, 40, 1, pp. 7-12, (2002); Cui J., Hopper J.L., Harrap S.B., Genes and family environment explain correlations between blood pressure and body mass index, Hypertension, 40, 1, pp. 7-12, (2002); Scurrah K.J., Zaloumis S.G., Hopper J.L., Harrap S.B., Contribution of genes and environment to variation in postural changes in mean arterial and pulse pressure, Journal of Hypertension, 26, 12, pp. 2319-2325, (2008); Masuo K., Mikami H., Ogihara T., Tuck M.L., Differences in insulin and sympathetic responses to glucose ingestion due to family history of hypertension, American Journal of Hypertension, 9, pp. 739-745, (1996); Pereira A.C., Floriano M.S., Mota G.F.A., Cunha R.S., Herkenhoff F.L., Mill J.G., Krieger J.E., β2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population, Hypertension, 42, pp. 685-692, (2003); Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L., β <sub>2</sub>- and β <sub>3</sub>-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years, Circulation, 111, 25, pp. 3429-3434, (2005); Masuo K., Katsuya T., Kawaguchi H., Fu Y., Rakugi H., Ogihara T., Tuck M.L., Rebound weight gain as associated with high plasma norepinephrine levels that are mediated through polymorphisms in the β2-adrenoceptor, American Journal of Hypertension, 18, 11, pp. 1508-1516, (2005); Leineweber K., Beta-adrenergic receptor polymorphism in human cardiovascular disease, Annals of Medicine, 36, SUPPL. 1, pp. 64-69, (2004); Jablonskis L.T., Howe P.R.C., Lack of influence of circulating adrenaline on blood pressure in normotensive and hypertensive rats, Blood Pressure, 3, 1-2, pp. 112-119, (1994); Doda M., Role of different subtypes of adrenoceptors in pressor responses to catecholamines released from sympathetic nerve endings, Brain Research Bulletin, 42, 1, pp. 51-57, (1996); Ferrannini E., Buzzigoli G., Bonadonna R., Insulin resistance in essential hypertension, New England Journal of Medicine, 317, 6, pp. 350-357, (1987); Masuo K., Mikami H., Ogihara T., Tuck M.L., Prevalence of hyperinsulinemia in young, nonobese Japanese men, Journal of Hypertension, 15, 2, pp. 157-165, (1997); Landsberg L., Insulin-mediated sympathetic stimulation: Role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why), Journal of Hypertension, 19, SUPPL., pp. 523-528, (2001); Ward K.D., Sparrow D., Landsberg L., Young J.B., Vokonas P.S., Weiss S.T., Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: The Normative Aging Study, Journal of Hypertension, 14, 3, pp. 301-308, (1996); Masuo K., Kawaguchi H., Mikami H., Ogihara T., Tuck M.L., Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation, Hypertension, 42, pp. 474-480, (2003); Masuo K., Obesity-related hypertension: Role of the sympathetic nervous system, insulin, and leptin, Current Hypertension Reports, 4, 2, pp. 112-118, (2002); Straznicky N.E., Lambert E.A., Lambert G.W., Masuo K., Esler M.D., Nestel P.J., Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome, Journal of Clinical Endocrinology and Metabolism, 90, 11, pp. 5998-6005, (2005); Landsberg L., Diet, obesity and hypertension: An hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis, Quarterly Journal of Medicine, 61, 236, pp. 1081-1090, (1986); Landsberg L., Young J.B., Fasting, feeding and regulation of the sympathetic nervous system, New England Journal of Medicine, 298, 23, pp. 1295-1301, (1978); O'Dea K., Esler M., Leonard P., Noradrenaline turnover during under- and over-eating in normal weight subjects, Metabolism: Clinical and Experimental, 31, 9, pp. 896-899, (1982); Julius S., Valentini M., Palatini P., Overweight and hypertension: A 2-way street?, Hypertension, 35, 3, pp. 807-813, (2000); Masuo K., Mikami H., Itoh M., Ogihara T., Tuck M.L., Sympathetic activity and body mass index contribute to blood pressure levels, Hypertension Research, 23, 4, pp. 303-310, (2000); Rocchini A.P., Mao H.Z., Babu K., Marker P., Rocchini A.J., Clonidine prevents insulin resistance and hypertension in obese dogs, Hypertension, 33, pp. 548-553, (1999); Valentini M., Julius S., Palatini P., Brook R.D., Bard R.L., Bisognano J.D., Kaciroti N., Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension, Journal of Hypertension, 22, 10, pp. 1999-2006, (2004); Large V., Hellstrom L., Reynisdottir S., Lonnqvist F., Eriksson P., Lannfelt L., Arner P., Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function, Journal of Clinical Investigation, 100, 12, pp. 3005-3013, (1997); Stob N.R., Bell C., Van Baak M.A., Seals D.R., Thermic effect of food and β-adrenergic thermogenic responsiveness in habitually exercising and sedentary healthy adult humans, Journal of Applied Physiology, 103, 2, pp. 616-622, (2007); Hayakawa T., Nagai Y., Kahara T., Yamashita H., Takamura T., Abe T., Nomura G., Kobayashi K.-I., Gln27Glu and Arg16Gly polymorphisms of the β 2-adrenergic receptor gene are not associated with obesity in Japanese men, Metabolism, 49, 9, pp. 1215-1218, (2000); Jia H., Sharma P., Hopper R., Dickerson C., Lloyd D.D., Brown M.J., β <sub>2</sub>-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians, Journal of Hypertension, 18, 6, pp. 687-693, (2000); Xie H.-G., Stein C.M., Kim R.B., Gainer J.V., Sofowora G., Dishy V., Brown N.J., Goree R.E., Haines J.L., Wood A.J.J., Human β <sub>2</sub>-adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans, Clinical Pharmacology and Therapeutics, 67, 6, pp. 670-675, (2000); Candy G., Samani N., Norton G., Woodiwiss A., Radevski I., Wheatley A., Cockcroft J., Hall I.P., Association analysis of β <sub>2</sub> adrenoceptor polymorphisms with hypertension in a Black African population, Journal of Hypertension, 18, 2, pp. 167-172, (2000); Cockcroft J.R., Gazis A.G., Cross D.J., Wheatley A., Dewar J., Hall I.P., Noon J.P., β 2-adrenoceptor polymorphism determines vascular reactivity in humans, Hypertension, 36, 3, pp. 371-375, (2000); Meirhaeghe A., Helbecque N., Cottel D., Amouyel P., Impact of polymorphisms of the human β <sub>2</sub>-adrenoceptor gene on obesity in a French population, International Journal of Obesity, 24, 3, pp. 382-387, (2000); Kato N., Sugiyama T., Morita H., Kurihara H., Sato T., Yamori Y., Yazaki Y., Association analysis of β <sub>2</sub>-adrenergic receptor polymorphisms with hypertension in Japanese, Hypertension, 37, pp. 286-292, (2001); Bengtsson K., Orho-Melander M., Melander O., Lindblad U., Ranstam J., Rastam L., Groop L., β <sub>2</sub>-Adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes, Hypertension, 37, 5, pp. 1303-1308, (2001); Ellsworth D.L., Coady S.A., Chen W., Srinivasan S.R., Elkasabany A., Gustat J., Boerwinkle E., Berenson G.S., Influence of the β2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: The Bogalusa heart study, International Journal of Obesity, 26, 7, pp. 928-937, (2002); Kim S.-H., Kim D.-J., Seo I.A., Min Y.-K., Lee M.-S., Kim K.-W., Lee M.-K., Significance of β <sub>2</sub>-adrenergic receptor gene polymorphism in obesity and type 2 diabetes mellitus in Korean subjects, Metabolism: Clinical and Experimental, 51, 7, pp. 833-837, (2002); Chang T.-J., Tsai M.-H., Jiang Y.-D., Lee B., Lee K.-C., Lin J.-Y., Chiu K.C., Tai T.-Y., Chuang L.-M., The Arg16Gly polymorphism of human β2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people, Clinical Endocrinology, 57, 5, pp. 685-690, (2002); Van Rossum C.T.M., Hoebee B., Seidell J.C., Bouchard C., Van Baak M.A., De Groot C.P.G.M., Chagnon M., De Graaf C., Saris W.H.M., Genetic factors as predictors of weight gain in young adult Dutch men and women, International Journal of Obesity, 26, 4, pp. 517-528, (2002); Garenc C., Perusse L., Chagnon Y.C., Rankinen T., Gagnon J., Borecki I.B., Leon A.S., Skinner J.S., Wilmore J.H., Rao D.C., Bouchard C., Effects of β2-adrenergic receptor gene variants on adiposity: The HERITAGE Family Study, Obesity Research, 11, 5, pp. 612-618, (2003); Galletti F., Iacone R., Ragone E., Russo O., Della Valle E., Siani A., Barba G., Farinaro E., Strazzullo V., Strazzullo P., Lack of association between polymorphism in the β <sub>2</sub>- adrenergic receptor gene, hypertension, and obesity in the Olivetti Heart Study, American Journal of Hypertension, 17, 8, pp. 718-720, (2004); Ikarashi T., Hanyu O., Maruyama S., Souda S., Kobayashi C., Abe E., Ukisu J., Naganuma K., Suzuki A., Toya M., Kaneko S., Suzuki K., Nakagawa O., Aizawa Y., Genotype Gly/Gly of the Arg16Gly polymorphism of the β <sub>2</sub>-adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients, Diabetes Research and Clinical Practice, 63, 1, pp. 11-18, (2004); Tafel J., Branscheid I., Skwarna B., Schlimme M., Morcos M., Algenstaedt P., Hinney A., Hebebrand J., Nawroth P., Hamann A., Variants in the human β <sub>1</sub>-, β <sub>2</sub>- and β <sub>3</sub>-adrenergic receptor genes are not associated with morbid obesity in children and adolescents, Diabetes, Obesity and Metabolism, 6, 6, pp. 452-455, (2004); Ellsworth D.L., Coady S.A., Chen W., Srinivasan S.R., Boerwinkle E., Berenson G.S., Interactive effects between polymorphisms in the β -adrenergic receptors and longitudinal changes in obesity, Obesity Research, 13, 3, pp. 519-526, (2005); Trombetta I.C., Batalha L.T., Rondon M.U.P.B., Laterza M.C., Frazzatto E., Alves M.J.N.N., Santos A.C., Brum P.C., Barretto A.C.P., Halpern A., Villares S.M.F., Negrao C.E., Gly <sup>16</sup> + Glu <sup>27</sup> β <sub>2</sub>-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans, Journal of Applied Physiology, 98, 3, pp. 787-794, (2005); Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L., β <sub>2</sub>-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals, American Journal of Hypertension, 18, 7, pp. 1009-1014, (2005); Masuo K., Katsuya T., Kawaguchi H., Fu Y., Rakugi H., Ogihara T., Tuck M.L., β <sub>2</sub>-Adrenoceptor Polymorphisms Relate to Obesity Through Blunted Leptin-Mediated Sympathetic Activation, American Journal of Hypertension, 19, 10, pp. 1084-1091, (2006); Kawaguchi H., Masuo K., Katsuya T., Sugimoto K., Rakugi H., Ogihara T., Tuck M.L., β2- and β3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals, Hypertension Research, 29, 12, pp. 951-959, (2006); Kurabayashi T., Yahata T., Quan J., Tanaka K., Association of polymorphisms in the β2 and β3 adrenoceptor gene with polycystic ovary syndrome, Journal of Reproductive Medicine for the Obstetrician and Gynecologist, 51, 5, pp. 389-393, (2006); Gjesing A.P., Andersen G., Burgdorf K.S., Borch-Johnsen K., Jorgensen T., Hansen T., Pedersen O., Studies of the associations between functional β <sub>2</sub>- adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects, Diabetologia, 50, 3, pp. 563-568, (2007); Masuo K., Katsuya T., Sugimoto K., Kawaguchi H., Rakugi H., Ogihara T., Tuck M.L., High plasma norepinephrine levels associated with β2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals, Hypertension Research, 30, 6, pp. 503-511, (2007); Echwald S.M., Sorensen T.I.A., Tybjaerg-Hansen A., Andersen T., Pedersen O., Gln27Glu variant of the human β <sub>2</sub>-adrenoreceptor gene is not associated with early-onset obesity in Danish men, Diabetes, 47, 10, pp. 1657-1658, (1998); Hellstrom L., Large V., Reynisdottir S., Wahrenberg H., Arner P., The different effects of a Gln27Glu β <sub>2</sub>-adrenoceptor gene polymorphism on obesity in males and in females, Journal of Internal Medicine, 245, 3, pp. 253-259, (1999); Kortner B., Wolf A., Wendt D., Beisiegel U., Evans D., Lack of association between a human β-2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity, International Journal of Obesity, 23, 10, pp. 1099-1100, (1999); Kawamura T., Egusa G., Fujikawa R., Okubo M., Gln27Glu variant of the β <sub>2</sub>-adrenergic receptor gene is not associated with obesity and diabetes in Japanese-Americans, Metabolism: Clinical and Experimental, 50, 4, pp. 443-446, (2001); Ukkola O., Tremblay A., Bouchard C., Beta-2 adrenergic receptor variants are associated with subcutaneous fat accumulation in response to long-term overfeeding, International Journal of Obesity, 25, 11, pp. 1604-1608, (2001); Gonzalez Sanchez J.L., Proenza A.M., Martinez Larrad M.T., Ramis J.M., Fernandez Perez C., Palou A., Serrano Rios M., The glutamine 27 glutamic acid polymorphism of the β <sub>2</sub>-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: A population-based study in Spain, Clinical Endocrinology, 59, 4, pp. 476-481, (2003); Rasmussen M., Belza A., Almdal T., Toubro So., Bratholm P., Astrup A., Christensen N.J., Change in β <sub>1</sub>-adrenergic receptor protein concentration in adipose tissue correlates with diet-induced weight loss, Clinical Science, 108, 4, pp. 323-329, (2005); Linne Y., Dahlman I., Hoffstedt J., β1-adrenoceptor gene polymorphism predicts long-term changes in body weight, International Journal of Obesity, 29, 5, pp. 458-462, (2005); Ryden M., Hoffstedt J., Eriksson P., Bringman S., Arner P., The Arg 389 gly β <sub>1</sub>-adrenergic receptor gene polymorphism and human fat cell lipolysis, International Journal of Obesity, 25, 11, pp. 1599-1603, (2001); Gjesing A.P., Andersen G., Albrechtsen A., Glumer C., Borch-Johnsen K., Jorgensen T., Hansen T., Pedersen O., Studies of associations between the Arg389Gly polymorphism of the β <sub>1</sub>-adrenergic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects, Diabetic Medicine, 24, 4, pp. 392-397, (2007); Clement K., Vaisse C., Manning B.S.J., Basdevant A., Guy-Grand B., Ruiz J., Silver K.D., Shuldiner A.R., Froguel P., Strosberg A.D., Genetic variation in the β 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity, The New England Journal of Medicine, 333, 6, pp. 352-354, (1995); Widen E., Lehto M., Kanninen T., Walston J., Shuldiner A.R., Groop L.C., Association of a polymorphism in the β 3-adrenergic-receptor gene with features of the insulin resistance syndrome in finns, The New England Journal of Medicine, 333, 6, pp. 348-351, (1995); Walston J., Silver K., Bogardus C., Knowler W.C., Celi F.S., Austin S., Manning B., Strosberg A.D., Stern M.P., Raben N., Sorkin J.D., Roth J., Shuldiner A.R., Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β 3-adrenergic-receptor gene, The New England Journal of Medicine, 333, 6, pp. 343-347, (1995); Fujisawa T., Ikegami H., Yamato E., Takekawa K., Nakagawa Y., Hamada Y., Oga T., Ueda H., Shintani M., Fukuda M., Ogihara T., Association of Trp64Arg mutation of the β3-adrenergic-receptor with NIDDM and body weight gain, Diabetologia, 39, 3, pp. 349-352, (1996); Silver K., Walston J., Wang Y., Dowse G., Zimmet P., Shuldiner A.R., Molecular scanning for mutations in the β <sub>3</sub>-adrenergic receptor gene in nauruans with obesity and noninsulin-dependent diabetes mellitus, Journal of Clinical Endocrinology and Metabolism, 81, 11, pp. 4155-4158, (1996); Fujisawa T., Ikegami H., Yamato E., Hamada Y., Kamide K., Rakugi H., Higaki J., Murakami H., Shimamoto K., Ogihara T., Trp64Arg mutation of β3-adrenergic receptor in essential hypertension. Insulin resistance and the adrenergic system, American Journal of Hypertension, 10, 1, pp. 101-105, (1997); Sakane N., Yoshida T., Umekawa T., Kondo M., Sakai Y., Takahashi T., β <sub>3</sub>-adrenergic-receptor polymorphism: A genetic marker for visceral fat obesity and the insulin resistance syndrome, Diabetologia, 40, 2, pp. 200-204, (1997); Rissanen J., Kuopusjarvi M., Pihlajamaki J., Sipilainen R., Heikkinen S., Vanhala M., Kekalainen P., Kuusisto J., Laakso M., The Trp64Arg polymorphism of the β <sub>3</sub>-adrenergic receptor gene: Lack of association with NIDDM and features of insulin resistance syndrome, Diabetes Care, 20, 8, pp. 1319-1323, (1997); McFarlane-Anderson N., Bennett F., Wilks R., Howell S., Newsome C., Cruickshank K., Forrester T., The Trp64Arg mutation of the β <sub>3</sub>-adrenergic receptor is associated with hyperglycemia and current body mass index in Jamaican women, Metabolism: Clinical and Experimental, 47, 5, pp. 617-621, (1998); Garcia-Rubi E., Starling R.D., Tchernof A., Matthews D.E., Walston J.D., Shuldiner A.R., Silver K., Poehlman E.T., Calles-Escandon J., Trp <sup>64</sup>Arg variant of the β <sub>3</sub>-adrenoceptor and insulin resistance in obese postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 83, 11, pp. 4002-4005, (1998); Janssen J.A.M.J.L., Koper J.W., Stolk R.P., Englaro P., Uitterlinden A.G., Huang Q., Van Leeuwen J.P.T.M., Blum W.F., Attanasio A.M.F., Pols H.A.P., Grobbee D.E., De Jong F.H., Lamberts S.W.J., Lack of associations between serum leptin, a polymorphism in the gene for the β <sub>3</sub>-adrenergic receptor and glucose tolerance in the Dutch population, Clinical Endocrinology, 49, 2, pp. 229-234, (1998); Shiwaku K., Gao T.Q., Isobe A., Fukushima T., Yamane Y., A Trp 64 Arg mutation in the β <sub>3</sub>-adrenergic receptor gene is not associated with moderate overweight in Japanese workers, Metabolism: Clinical and Experimental, 47, 12, pp. 1528-1530, (1998); Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S., Piaseu N., Chailurkit L., Komindr S., Bunnag P., Puavilai G., Relation of β <sub>3</sub>-adrenergic receptor gene mutation to total body fat but not percent body fat and insulin levels in Thais, Metabolism: Clinical and Experimental, 48, 5, pp. 564-567, (1999); Pulkkinen A., Kareinen A., Saarinen L., Heikkinen S., Lehto S., Laakso M., The codon 64 polymorphism of the β <sub>3</sub>-adrenergic receptor gene is not associated with coronary heart disease or insulin resistance in nondiabetic subjects and non-insulin-dependent diabetic patients, Metabolism: Clinical and Experimental, 48, 7, pp. 853-856, (1999); Christiansen C., Poulsen P., Beck-Nielsen H., The Trp64Arg mutation of the adrenergic β-3 receptor gene impairs insulin secretion: A twin study, Diabetic Medicine, 16, 10, pp. 835-840, (1999); Stangl K., Cascorbi I., Laule M., Stangl V., Meisel C., Wernecke K.-D., Ziemer S., Baumann G., Roots I., Hauner H., The β <sub>3</sub>-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease, Metabolism: Clinical and Experimental, 50, 2, pp. 184-188, (2001); Strazzullo P., Iacone R., Siani A., Cappuccio F.P., Russo O., Barba G., Barbato A., D'Elia L., Trevisan M., Farinaro E., Relationship of the Trp64Arg polymorphism of the beta3-adrenoceptor gene to central adiposity and high blood pressure: Interaction with age. Cross-sectional and longitudinal findings of the Olivetti prospective heart study, Journal of Hypertension, 19, 3, pp. 399-406, (2001); Ishii T., Hirose H., Kawai T., Hayashi K., Maruyama H., Saito I., Saruta T., Effects of intestinal fatty acid-binding protein gene Ala54Thr polymorphism and β <sub>3</sub>-adrenergic receptor gene Trp64Arg polymorphism on insulin resistance and fasting plasma glucose in young to older Japanese men, Metabolism: Clinical and Experimental, 50, 11, pp. 1301-1307, (2001); Kurokawa N., Nakai K., Kameo S., Liu Z.-M., Satoh H., Association of BMI with the β3-Adrenergic receptor gene polymorphism in Japanese: Meta-analysis, Obesity Research, 9, 12, pp. 741-745, (2001); Ochoa M.C., Marti A., Azcona C., Chueca M., Oyarzabal M., Pelach R., Patino A., Moreno-Aliaga M.J., Martinez-Gonzalez M.A., Martinez J.A., Gene-gene interaction between PPARγ2 and ADRβ3 increases obesity risk in children and adolescents, International Journal of Obesity, 28, SUPPL. 3, (2004); Porto P.I., Garcia S.I., Dieuzeide G., Gonzalez C., Landa M.S., Pirola C.J., Clinical Features of the Metabolic Syndrome in Adolescents: Minor Role of the Trp64Arg β <sub>3</sub>-Adrenergic Receptor Gene Variant, Pediatric Research, 55, 5, pp. 836-841, (2004); Tsai P.-J., Ho S.-C., Tsai L.-P., Lee Y.-H., Hsu S.-P., Yang S.-P., Chu C.-H., Yu C.-H., Lack of relationship between β <sub>3</sub>-adrenergic receptor gene polymorphism and gestational diabetes mellitus in a Taiwanese population, Metabolism: Clinical and Experimental, 53, 9, pp. 1136-1139, (2004); Hojlund K., Christiansen C., Bjornsbo K.S., Poulsen P., Bathum L., Henriksen J.E., Lammert O., Beck-Nielsen H., Energy body composition and insulin response to glucose in male twins discordant for the Trp64Arg polymorphism of the β 3 -adrenergic receptor gene, Diabetes, Obesity and Metabolism, 8, 3, pp. 322-330, (2006); Tamaki S., Nakamura Y., Tabara Y., Okamura T., Kita Y., Kadowaki T., Tsujita Y., Horie M., Miki T., Ueshima H., Relationship between metabolic syndrome and Trp64Arg polymorphism of the β3-adrenergic receptor gene in a general sample: The Shigaraki study, Hypertension Research, 29, 11, pp. 891-896, (2006); Morcillo S., Cardona F., Rojo-Martinez G., Almaraz M.C., Esteva I., Ruiz-De-Adana M.S., Olveira G., Garcia-Fuentes E., Gomez-Zumaquero J.M., Soriguer F., Effect of the combination of the variants -75G/A APOA1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2), Clinical Endocrinology, 68, 1, pp. 102-107, (2008); Gjesing A.P., Andersen G., Borch-Johnsen K., Jorgensen T., Hansen T., Pedersen O., Association of the β 3-adrenergic receptor Trp64Arg polymorphism with common metabolic traits: Studies of 7605 middle-aged white people, Molecular Genetics and Metabolism, 94, 1, pp. 90-97, (2008); Dunajska K., Lwow F., Milewicz A., Jedrzejuk D., Laczmanski L., Belowska-Bien K., Urban J., Szuba A., β3-Adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women, Gynecological Endocrinology, 24, 3, pp. 133-138, (2008); Maxwell T.J., Ameyaw M.M., Pritchard S., Thornton N., Folayan G., Githang'A J., Indalo A., Tariq M., Mobarek A., Evans D.A., Ofori-Adjei D., Templeton A.R., McLeod H.L., Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups, International Journal of Molecular Medicine, 16, 4, pp. 573-580, (2005); Schelleman H., Stricker B.H.Ch., De Boer A., Kroon A.A., Verschuren M.W.M., Van Duijn C.M., Psaty B.M., Klungel O.H., Drug-gene interactions between genetic polymorphisms and antihypertensive therapy, Drugs, 64, 16, pp. 1801-1816, (2004); Hoffstedt J., Poirier O., Thorne A., Lonnqvist F., Herrmann S.M., Cambien F., Arner P., Polymorphism of the human β <sub>3</sub>-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function, Diabetes, 48, 1, pp. 203-205, (1999); Sandilands A., Yeo G., Brown M.J., O'Shaughnessy K.M., Functional responses of human β1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms, Pharmacogenetics, 14, 6, pp. 343-349, (2004); Tomaszewski M., Brain N.J.R., Charchar F.J., Wang W.Y.S., Lacka B., Padmanabahn S., Clark J.S., Anderson N.H., Edwards H.V., Zukowska-Szczechowska E., Grzeszczak W., Dominiczak A.F., Essential hypertension and β <sub>2</sub>-adrenergic receptor gene: Linkage and association analysis, Hypertension, 40, 3, pp. 286-291, (2002); Green S.A., Turki J., Innis M., Liggett S.B., Amino-terminal polymorphisms of the human β <sub>2</sub>-adrenergic receptor impart distinct agonist-promoted regulatory properties, Biochemistry, 33, 32, pp. 9414-9419, (1994); Dishy V., Sofowora G.G., Xie H.-G., Kim R.B., Byrne D.W., Michael Stein C., Wood A.J.J., The effect of common polymorphisms of the β 2-adrenergic receptor on agonist-mediated vascular desensitization, The New England Journal of Medicine, 345, 14, pp. 1030-1035, (2001); Gratze G., Fortin J., Labugger R., Binder A., Kotanko P., Timmermann B., Luft F.C., Hoehe M.R., Skrabal F., β-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians, Hypertension, 33, 6, pp. 1425-1430, (1999); Hoit B.D., Suresh D.P., Craft L., Walsh R.A., Liggett S.B., β <sub>2</sub>-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals, American Heart Journal, 139, 3, pp. 537-542, (2000); Bell C., Stob N.R., Seals D.R., Thermogenic responsiveness to nonspecific β -adrenergic stimulation is not related to genetic variation in codon 16 of the β 2-adrenergic receptor, American Journal of Physiology, 290, 4, (2006); Gjesing A.P., Andersen G., Burgdorf K.S., Borch-Johnsen K., Jorgensen T., Hansen T., Pedersen O., Studies of the associations between functional β <sub>2</sub>- adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects, Diabetologia, 50, 3, pp. 563-568, (2007); Arner P., The β 3-adrenergic receptora cause and cure of obesity?, The New England Journal of Medicine, 333, 6, pp. 382-383, (1995); Enocksson S., Shimizu M., Lonnqvist F., Nordenstrom J., Arner P., Demonstration of an in vivo functional β 3-adrenoceptor in man, Journal of Clinical Investigation, 95, 5, pp. 2239-2245, (1995); Yang Y.T., McElligott M.A., Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue, Biochemical Journal, 261, 1, pp. 1-10, (1989); Oizumi T., Daimon M., Saitoh T., Kameda W., Yamaguchi H., Ohnuma H., Igarashi M., Eguchi H., Manaka H., Tominaga M., Kato T., Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the β <sub>3</sub>-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample, Diabetes Care, 24, 9, pp. 1579-1583, (2001)","K. Masuo; Nucleus Network Ltd. and Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC 3004, 89 Commercial Road, Australia; email: kazuko.masuo@bakeridi.edu.au","","","","","","","","20900392","","","","English","Intern. J. Hypertens.","Review","Final","All Open Access; Gold Open Access; Green Open Access","Scopus","2-s2.0-82255174532"
"Flordellis C.S.; Goumenos D.; Kourounis G.; Tsementzis S.A.; Paris H.; Vlachojiannis J.","Flordellis, Christodoulos S. (55979271900); Goumenos, Dimitrios (6603709366); Kourounis, George (8613867400); Tsementzis, Sotirios A. (8736073000); Paris, Hervé (7005533124); Vlachojiannis, Jaannis (6505497907)","55979271900; 6603709366; 8613867400; 8736073000; 7005533124; 6505497907","The shift in the ""paradigim"" of the pharmacology of hypertension","2004","Current Topics in Medicinal Chemistry","4","4","","487","498","11","6","10.2174/1568026043451348","https://www.scopus.com/inward/record.uri?eid=2-s2.0-3042762609&doi=10.2174%2f1568026043451348&partnerID=40&md5=ddac786a8e8203c225b22e98fe7eee66","Department of Pharmacology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; Department of Nephrology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; Dept. of Obstetrics and Gynecology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; INSERM U388, Institut Louis Bugnard, CHU Rangueil, Toulouse, France","Flordellis C.S., Department of Pharmacology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; Goumenos D., Department of Nephrology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; Kourounis G., Dept. of Obstetrics and Gynecology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; Tsementzis S.A.; Paris H., INSERM U388, Institut Louis Bugnard, CHU Rangueil, Toulouse, France; Vlachojiannis J., Department of Nephrology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece","Until recently elevated blood pressure was considered as a hemodynamic entity representing an increase in workload for the heart and the arterial tree. Control of hypertension meant hemodynamic unloading, through inhibition of vasoconstrictor pathways, principally renin-angiotensin system and sympathetic system. In recent years however a new pharmacological approach has evolved as a result of (i) the dissociation of endothelial dysfunction and vascular pathology from increased blood pressure; (ii) the recognition that endothelial dysfunction regards not only the vascular reactivity, but also promotes atherosclerosis and thrombosis; and (iii) an improved understanding of the complexity of local-tissue renin angiotensin system and of the vasodilatory and cytoprotective role of natriuretic peptides. This has led to a reconsideration of existing medicines in terms of specification on endothelial function, more rationalized application of drugs and search for new compounds targeting both vasodilatory and anti-proliferative pathways. Examples include β1-adrenergic antagonists, such as Nebivolol and Carvedilol, and vasopeptidase inhibitors, such as Omapatrilat, that inhibit simultaneously the angiotensin converting enzyme and neutral endopeptidase. Furthermore the identification of genetic polymorphisms in the effectors involved in the pathophysiology of hypertension or in the response to anti-hypertensive drugs, such as the p22phox subunit of NADPH oxidase, α -adducin or adrenergic receptors, has promoted the prospective of both better understanding of hypertension and individualized strategies for its treatment. © 2004 Bentham Science Publishers Ltd.","","Adrenergic beta-Antagonists; Angiotensins; Antihypertensive Agents; Cardiovascular System; Endothelium; GTP-Binding Proteins; Humans; Hypertension; Pharmacogenetics; Renin-Angiotensin System; Vasculitis; 1,4 dihydropyridine derivative; adducin; adrenergic receptor; alpha 1 adrenergic receptor blocking agent; angiotensin; angiotensin 1 receptor antagonist; antihypertensive agent; antioxidant; beta 1 adrenergic receptor blocking agent; beta 2 adrenergic receptor blocking agent; butoxamine; calcium antagonist; calcium channel blocking agent; carvedilol; dipeptidyl carboxypeptidase inhibitor; doxazosin; hydroxymethylglutaryl coenzyme A reductase inhibitor; labetalol; losartan; natriuretic factor; nebivolol; omapatrilat; phenylalkylamine; protein p22; reduced nicotinamide adenine dinucleotide phosphate oxidase; renin; unindexed drug; vasoconstrictor agent; vasodilator agent; vasopeptidase inhibitor; angiotensin derivative; antihypertensive agent; beta adrenergic receptor blocking agent; guanine nucleotide binding protein; angioneurotic edema; atherosclerosis; blood pressure regulation; blood vessel reactivity; cell protection; clinical trial; coughing; dizziness; DNA polymorphism; drug mechanism; drug response; dyspnea; edema; endothelium injury; enzyme inhibition; fatigue; flushing; headache; heart palpitation; heart work; hemodynamics; human; hyperglycemia; hypertension; hypertriglyceridemia; libido disorder; metabolic disorder; mitosis inhibition; paresthesia; pathophysiology; protein function; renin angiotensin aldosterone system; review; sympathetic tone; thrombosis; vasodilatation; cardiovascular system; drug effect; endothelium; genetics; hypertension; metabolism; pharmacogenetics; vasculitis","","angiotensin, 1407-47-2; butoxamine, 1937-89-9; carvedilol, 72956-09-3; doxazosin, 74191-85-8; labetalol, 32780-64-6, 36894-69-6; losartan, 114798-26-4; natriuretic factor, 9088-07-7; nebivolol, 99200-09-6; omapatrilat, 167305-00-2; reduced nicotinamide adenine dinucleotide phosphate oxidase, 9032-22-8; renin, 61506-93-2, 9015-94-5; Adrenergic beta-Antagonists, ; Angiotensins, ; Antihypertensive Agents, ; GTP-Binding Proteins, EC 3.6.1.-","","","","","Schiffrin E.L., Deng L.Y., Larochelle P., Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension, Hypertension, 23, pp. 83-91, (1994); Schiffrin E.L., Deng L.Y., Larochelle P., Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients, J. Cardiovasc. Pharmacol., 24, SUPPL. 3, (1994); Aalkjaer C., Eiskjaer H., Mulvany M.J., Jespersen B., Kjaer T., Sorensen S.S., Pedersen E.B., Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment, J. Hypertens., 7, pp. 305-310, (1989); Novo S., Abrignani M.G., Sapienza N.D., Barbagallo M., Pinto A., Di Maria G.U., Mistretta A., Strano A., Partial regression of vascular structural alterations in hypertensive patients treated with α/β-blocker, labetalol, Int. Angiol., 11, pp. 137-141, (1992); Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A., Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus, Circulation, 88, pp. 2510-2516, (1993); Taddei S., Virdis A., Ghiadoni L., Mattei P., Sudano I., Bernini G., Pinto S., Salvetti A., Menopause is associated with endothelial dysfunction in women, Hypertension, 28, pp. 576-582, (1996); Celermajer D.S., Adams M.R., Clarkson P., Robinson J., McCredie R., Donald A., Deanfield J.E., Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults, N. Engl. J. Med., 334, pp. 150-154, (1996); Dubey R.K., Jackson E.K., Luscher T.F., Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors, J. Clin. Invest., 96, pp. 141-149, (1995); Kubes P., Suzuki M., Granger D.N., Nitric oxide: An endogenous modulator of leukocyte adhesion, Proc. Natl. Acad. Sci. USA, 88, pp. 4651-4655, (1991); Panza J.A., Casino P.R., Kilcoyne C.M., Quyyumi A.A., Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension, Circulation, 87, pp. 1469-1474, (1993); Taddei S., Virdis A., Ghiadoni L., Magagna A., Salvetti A., Cyclooxygenase inhibition restrores nitric oxide activity in essential hypertension, Hypertension, 29, pp. 274-279, (1997); Luscher T.F., Endothelin, endothelin receptors, and endothelin antagonists, Curr. Opin. Nephrol. Hypertens., 3, pp. 92-98, (1994); Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S., Cloning and expression of a cDNA encoding an endothelin receptor, Nature, 348, pp. 730-732, (1990); Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T., Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor, Nature, 348, pp. 732-735, (1990); Haynes W.G., Webb D.J., Endothelin as a regulator of cardiovascular function in health and disease, J. Hypertens., 16, pp. 1081-1098, (1998); Liu J.L., Pliquett R.U., Brewer E., Cornish K.G., Shen Y.T., Zucker I.H., Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure, Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, (2001); Mosqueda-Garcia R., Appalsamy M., Fernandez-Violante R., Hamakubo T., Modulatory effects of endothelin on baroreflex activation in the nucleus of the solitary tract, Eur. J. Pharmacol., 351, pp. 203-207, (1998); Abassi Z.A., Golomb E., Bridenbaugh R., Keiser H.R., Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11, Br. J. Pharmacol., 109, pp. 1024-1028, (1993); Taddei S., Virdis A., Ghiadoni L., Sudano I., Salvetti A., Endothelial dysfunction in hypertension, J. Cardiovasc. Pharmacol., 38, SUPPL. 2, (2001); Rajagopalan S., Harrison D.G., Reversing endothelial dysfunction with ACE inhibitors. A new trend, Circulation, 94, pp. 240-243, (1996); Maeso R., Navarro-Cid J., Munoz-Garcia R., Rodrigo E., Ruilope L.M., Lahera V., Cachofeiro V., Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors, Hypertension, 28, pp. 967-972, (1996); Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A., Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors, Pharmacol. Rev., 47, pp. 25-49, (1995); Wiemer G., Scholkens B.A., Becker R.H., Busse R., Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin, Hypertension, 18, pp. 558-563, (1991); Hecker M., Porsti I., Bara A.T., Busse R., Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: Interaction at the receptor level, Br. J. Pharmacol., 111, pp. 238-244, (1994); Benzing T., Fleming I., Blaukat A., Muller-Esterl W., Busse R., Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells, Circulation, 99, pp. 2034-2040, (1999); Gillis C.N., Chen X., Merker M.M., Lisinopril and ramiprilat protection of the vascular endothelium against free radical-induced functional injury, J. Pharmacol. Exp. Ther., 262, pp. 212-216, (1992); Skidgel R.A., Erdos E.G., The broad substrate specificity of human angiotensin I converting enzyme, Clin. Exp. Hypertens. A, 9, pp. 243-259, (1987); Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W., Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions, J. Am. Coll. Cardiol., 33, pp. 234-241, (1999); Bracht C., Yan X.W., Brunner-LaRocca H.P., Sutsch G., Amann F.W., Kiowski W., Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia, J. Hypertens., 19, pp. 899-905, (2001); Cai H., Harrison D.G., Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress, Circ. Res., 87, pp. 840-844, (2000); Mohazzab K.M., Kaminski P.M., Wolin M.S., NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium, Am. J. Physiol., 266, (1994); Griendling K.K., Sorescu D., Ushio-Fukai M., NAD(P)H oxidase: Role in cardiovascular biology and disease, Circ. Res., 86, pp. 494-501, (2000); Van Heerebeek L., Meischl C., Stooker W., Meijer C.J., Niessen H.W., Roos D., NADPH oxidase(s): New source(s) of reactive oxygen species in the vascular system?, J. Clin. Pathol., 55, pp. 561-568, (2002); Ballinger S.W., Patterson C., Yan C.N., Doan R., Burow D.L., Young C.G., Yakes F.M., Van Houten B., Ballinger C.A., Freeman B.A., Runge M.S., Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells, Circ. Res., 86, pp. 960-966, (2000); Zalba G., Beaumont F.J., San Jose G., Fortuno A., Fortuno M.A., Etayo J.C., Diez J., Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats, Hypertension, 35, pp. 1055-1061, (2000); Broeders M.A., Doevendans P.A., Bekkers B.C., Bronsaer R., van Gorsel E., Heemskerk J.W., Egbrink M.G., van Breda E., Reneman R.S., van Der Zee R., Nebivolol: A third-generation β-blocker that augments vascular nitric oxide release: Endothelial β2-adrenergic receptor-mediated nitric oxide production, Circulation, 102, pp. 677-684, (2000); Shafiei M., Mahmoudian M., Atypical β-adrenoceptors of rat thoracic aorta, Gen. Pharmacol., 32, pp. 557-562, (1999); Granneman J.G., The putative β4-adrenergic receptor is a novel state of the β1-adrenergic receptor, Am. J. Physiol. Endocrinol. Metab., 280, (2001); The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, Arch. Intern. Med., 157, pp. 2413-2446, (1997); 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee, J. Hypertens., 17, pp. 151-183, (1999); Pessina A.C., Metabolic effects and safety profile of nebivolol, J. Cardiovasc. Pharmacol., 38, SUPPL. 3, (2001); Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N. Engl. J. Med., 334, pp. 1349-1355, (1996); Ruffolo Jr. R.R., Feuerstein G.Z., Pharmacology of carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure, Cardiovasc. Drugs Ther., 11, SUPPL. 1, pp. 247-256, (1997); Bevan E.G., Connell J.M., Doyle J., Carmichael H.A., Davies D.L., Lorimer A.R., McInnes G.T., Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension, J. Hypertens., 10, pp. 607-613, (1992); Richards A.M., Crozier I.G., Kosoglou T., Rallings M., Espiner E.A., Nicholls M.G., Yandle T.G., Ikram H., Frampton C., Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension, Hypertension, 22, pp. 119-126, (1993); Hall W.D., A rational approach to the treatment of hypertension in special populations, Am. Fam. Physician, 60, pp. 156-162, (1999); Burnett Jr. J.C., Vasopeptidase inhibition: A new concept in blood pressure management, J. Hypertens., 17, SUPPL., (1999); Cho Y., Somer B.G., Amatya A., Natriuretic peptides and their therapeutic potential, Heart Dis., 1, pp. 305-328, (1999); Neuser D., Stasch J.P., Knorr A., Kazda S., Inhibition by atrial natriuretic peptide of endothelin-1-stimulated proliferation of vascular smooth-muscle cells, J. Cardiovasc. Pharmacol., 22, SUPPL. 8, (1993); Ikeda M., Kohno M., Yasunari K., Yokokawa K., Horio T., Ueda M., Morisaki N., Yoshikawa J., Natriuretic peptide family as a novel antimigration factor of vascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol., 17, pp. 731-736, (1997); Lopez M.J., Wong S.K., Kishimoto I., Dubois S., Mach V., Friesen J., Garbers D.L., Beuve A., Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atria natriuretic peptide, Nature, 378, pp. 65-68, (1995); Norton G.R., Woodiwiss A.J., Hartford C., Trifunovic B., Middlemost S., Lee A., Allen M.J., Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects, Am. J. Hypertens., 12, pp. 563-571, (1999); Nawarskas J.J., Anderson J.R., Omapatrilat: A unique new agent for the treatment of cardiovascular disease, Heart Dis., 2, pp. 266-274, (2000); Campese V.M., Lasseter K.C., Ferrario C.M., Smith W.B., Ruddy M.C., Grim C.E., Smith R.D., Vargas R., Habashy M.F., Vesterqvist O., Delaney C.L., Liao W.C., Omapatrilat versus lisinopril: Efficacy and neurohormonal profile in salt-sensitive hypertensive patients, Hypertension, 38, pp. 1342-1348, (2001); Quaschning T., Corti R., Ruschitzka F.T., Noll G., Luscher T.F., Vasopeptidase inhibitors. Clinical implications of a new class of drugs, Dtsch Med. Wochenschr, 125, pp. 499-503, (2000); Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Suzuki Y., Mezzano S., Plaza J.J., Egido J., Role of the renin-angiotensin system in vascular diseases: Expanding the field, Hypertension, 38, pp. 1382-1387, (2001); Piqueras L., Kubes P., Alvarez A., O'Connor E., Issekutz A.C., Esplugues J.V., Sanz M.J., Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT<sub>1</sub> and AT<sub>2</sub> receptor-mediated P-selectin upregulation, Circulation, 102, pp. 2118-2123, (2000); Chen X.L., Tummala P.E., Olbrych M.T., Alexander R.W., Medford R.M., Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells, Circ. Res., 83, pp. 952-959, (1998); Bush E., Maeda N., Kuziel W.A., Dawson T.C., Wilcox J.N., DeLeon H., Taylor W.R., CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension, Hypertension, 36, pp. 360-363, (2000); Ruiz-Ortega M., Lorenzo O., Ruperez M., Konig S., Wittig B., Egido J., Angiotensin II activates nuclear transcription factor kappaB through AT<sub>1</sub> and AT<sub>2</sub> in vascular smooth muscle cells: Molecular mechanisms, Circ. Res., 86, pp. 1266-1272, (2000); Ruiz-Ortega M., Lorenzo O., Ruperez M., Suzuki Y., Egido J., Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT<sub>1</sub> knockout mice, Nephrol. Dial. Transplant., 16, SUPPL. 1, pp. 27-33, (2001); Border W.A., Noble N.A., Interactions of transforming growth factor-β and angiotensin II in renal fibrosis, Hypertension, 31, pp. 181-188, (1998); Khachigian L.M., Takuwa Y., Collins T., Mechanisms of angiotensin II-induced platetet-derived growth factor gene expression, Mol. Cell. Biochem., 212, pp. 183-186, (2000); Scott-Burden T., Hahn A.W., Resink T.J., Buhler F.R., Modulation of extracellular matrix by angiotensin II: Stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells, J. Cardiovasc. Pharmacol., 16, SUPPL. 4, (1990); Feener E.P., Northrup J.M., Aiello L.P., King G.L., Angiotensin II induces plasminogen activator inhibitor- and -2 expression in vascular endothelial and smooth muscle cells, J. Clin. Invest., 95, pp. 1353-1362, (1995); Caughey G.E., Cleland L.G., Penglis P.S., Gamble J.R., James M.J., Roles of cyclooxygenase COX-1 and COX-2 in prostanoid production by human endothelial cells: Selective upregulation of prostacyclin synthesis by COX-2, J. Immunol., 167, pp. 2831-2838, (2001); Lorell B.H., Role of angiotensin AT<sub>1</sub>, and AT<sub>2</sub> receptors in cardiac hypertrophy and disease, Am. J. Cardiol., 83, (1999); Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg, JAMA, 213, pp. 1143-1152, (1970); Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O., Hennekens C.H., Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990); Brush Jr. J.E., Cannon III R.O., Schenke W.H., Bonow R.O., Leon M.B., Maron B.J., Epstein S.E., Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy, N. Engl. J. Med, 319, pp. 1302-1307, (1988); Fuster V., Badimon L., Badimon J.J., Chesebro J.H., The pathogenesis of coronary artery disease and the acute coronary syndromes (1), N. Engl. J. Med., 326, pp. 242-250, (1992); Fuster V., Badimon L., Badimon J.J., Chesebro J.H., The pathogenesis of coronary artery disease and the acute coronary syndromes (2), N. Engl. J. Med., 326, pp. 310-318, (1992); Hasdai D., Gibbons R.J., Holmes Jr. D.R., Higano S.T., Lerman A., Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects, Circulation, 96, pp. 3390-3395, (1997); Schiffrin E.L., Park J.B., Intengan H.D., Touyz R.M., Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan, Circulation, 101, pp. 1653-1659, (2000); Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A., Angiotensin II-forming pathways in normal and failing human hearts, Circ. Res., 66, pp. 883-890, (1990); Balcells E., Meng Q.C., Johnson Jr. W.H., Oparil S., Dell'Italia L.J., Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations, Am. J. Physiol., 273, (1997); Campia U., Choucair W.K., Bryant M.B., Quyyumi A.A., Cardillo C., Panza J.A., Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans, Am. J. Cardiol., 89, pp. 286-290, (2002); Komers R., Anderson S., Epstein M., Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors, Am. J. Kidney Dis., 38, pp. 1145-1157, (2001); Frishman W.H., Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema, Am. J. Cardiol., 89, (2002); Young W., Mahboubi K., Haider A., Li I., Ferreri N.R., Cyclooxygenase-2 is required for tumor necrosis factor α and angiotensin II-mediated proliferation of vascular smooth muscle cells, Circ. Res., 86, pp. 906-914, (2000); Mukherjee D., Nissen S.E., Topol E.J., Risk of cardiovascular events associated with selective COX-2 inhibitors, JAMA, 286, pp. 954-959, (2001); Turner A.J., Hooper N.M., The angiotensin-converting enzyme gene family: Genomics and pharmacology, Trends Pharmacol. Sci., 23, pp. 177-183, (2002); Ramirez M., Prieto I., Martinez J.M., Vargas F., Alba F., Renal aminopeptidase activities in aninial models of hypertension, Regul. Pept., 72, pp. 155-159, (1997); Nakashima Y., Ohno Y., Itakura A., Takeuchi M., Murata Y., Kuno N., Mizutani S., Possible involvement of aminopeptidase A in hypertension in spontaneously hypertensive rats (SHRs) and change of refractoriness in response to angiotensin II in pregnant SHRs, J. Hypertens., 20, pp. 2233-2238, (2002); Reaux A., Fournie-Zaluski M.C., Llorens-Cortes C., Angiotensin III: A central regulator of vasopressin release and blood pressure, Trends Endocrinol. Metab., 12, pp. 157-162, (2001); Lorenzo O., Ruiz-Ortega M., Suzuki Y., Ruperez M., Esteban V., Sugaya T., Egido J., Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT<sub>2</sub> receptors: Studies with AT<sub>1</sub> receptor-knockout mice, J. Am. Soc. Nephrol., 13, pp. 1162-1171, (2002); Albiston A.L., McDowall S.G., Matsacos D., Sim P., Clune E., Mustafa T., Lee J., Mendelsohn F.A., Simpson R.J., Connolly L.M., Chai S.Y., Evidence that the angiotensin IV (AT<sub>4</sub>) receptor is the enzyme insulin-regulated aminopeptidase, J. Biol. Chem., 276, pp. 48623-48626, (2001); Jaiswal N., Tallant E.A., Jaiswal R.K., Diz D.I., Ferrario C.M., Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: Subtypes of angiotensin receptors involved, J. Pharmacol. Exp. Ther., 265, pp. 664-673, (1993); Psaty B.M., Smith N.L., Heckbert S.R., Vos H.L., Lemaitre R.N., Reiner A.P., Siscovick D.S., Bis J., Lumley T., Longstreth Jr. W.T., Rosendaal F.R., Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); van Essen G.G., Rensma P.L., de Zeeuw D., Sluiter W.J., Scheffer H., Apperloo A.J., de Jong P.E., Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy, Lancet, 347, pp. 94-95, (1996); McNamara D.M., Holubkov R., Janosko K., Palmer A., Wang J.J., MacGowan G.A., Murali S., Rosenblum W.D., London B., Feldman A.M., Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, Circulation, 103, pp. 1644-1648, (2001); Gros R., Benovic J.L., Tan C.M., Feldman R.D., G-protein-coupled receptor kinase activity is increased in hypertension, J. Clin. Invest., 99, pp. 2087-2093, (1997); Gros R., Chorazyczewski J., Meek M.D., Benovic J.L., Ferguson S.S., Feldman R.D., G-Protein-coupled receptor kinase activity in hypertension: Increased vascular and lymphocyte G-protein receptor kinase-2 protein expression, Hypertension, 35, pp. 38-42, (2000); Koch W.J., Rockman H.A., Samama P., Hamilton R.A., Bond R.A., Milano C.A., Lefkowitz R.J., Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a β ARK inhibitor, Science, 268, pp. 1350-1353, (1995); Chen E.P., Bittner H.B., Akhter S.A., Koch W.J., Davis R.D., Myocardial recovery after ischemia and reperfusion injury is significantly impaired in hearts with transgenic overexpression of β-adrenergic receptor kinase, Circulation, 98, (1998); Eckhart A.D., Ozaki T., Tevaearai H., Rockman H.A., Koch W.J., Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates β-adrenergic receptor signaling and increases resting blood pressure, Mol. Pharmacol., 61, pp. 749-758, (2002); Pitcher J.A., Inglese J., Higgins J.B., Arriza J.L., Casey P.J., Kim C., Benovic J.L., Kwatra M.M., Caron M.G., Lefkowitz R.J., Role of βγ subunits of G proteins in targeting the β-adrenergic receptor kinase to membrane-bound receptors, Science, 257, pp. 1264-1267, (1992); Rockman H.A., Chien K.R., Choi D.J., Iaccarino G., Hunter J.J., Ross Jr. J., Lefkowitz R.J., Koch W.J., Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice, Proc. Natl. Acad. Sci. U. S. A., 95, pp. 7000-7005, (1998); Iaccarino G., Smithwick L.A., Lefkowitz R.J., Koch W.J., Targeting Gβ gamma signaling in arterial vascular smooth muscle proliferation: A novel strategy to limit restenosis, Proc. Natl. Acad. Sci. U. S. A., 96, pp. 3945-3950, (1999); Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., Koch W.J., Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy, Science, 280, pp. 574-577, (1998); Wettschureck N., Offermanns S., Rho/Rho-kinase mediated signaling in physiology and pathophysiology, J. Mol. Med., 80, pp. 629-638, (2002); Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension, Nature, 389, pp. 990-994, (1997); Mukai Y., Shimokawa H., Matoba T., Kandabashi T., Satoh S., Hiroki J., Kaibuchi K., Takeshita A., Involvement of Rho-kinase in hypertensive vascular disease: A novel therapeutic target in hypertension, FASEB J., 15, pp. 1062-1064, (2001); Shibuya M., Suzuki Y., Sugita K., Saito I., Sasaki T., Takakura K., Nagata I., Kikuchi H., Takemae T., Hidaka H., Et al., Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial, J. Neurosurg., 76, pp. 571-577, (1992); Turner S.T., Boerwinkle E., Genetics of hypertension, target-organ complications, and response to therapy, Circulation, 102, (2000); Hall W.D., Reed J.W., Flack J.M., Yunis C., Preisser J., Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension ISHIB Investigators Group. International Society on Hypertension in Blacks, Arch. Intern. Med., 158, pp. 2029-2034, (1998); Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., Hamburger R.J., Fye C., Lakshman R., Gottdiener J., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, N. Engl. J. Med., 328, pp. 914-921, (1993); Manunta P., Barlassina C., Bianchi G., Adducin in essential hypertension, FEBS Lett., 430, pp. 41-44, (1998); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Rivera R., Stella P., Troffa C., Zagato L., Bianchi G., Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., Lombardi C., Soro A., Dettori F., Parpaglia P.P., Alibrandi M.T., Cusi D., Bianchi G., The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, pp. 649-654, (1999); Li A., Prasad A., Mincemoyer R., Satorius C., Epstein N., Finkel T., Quyyumi A.A., Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function, Am. J. Med. Genet., 86, pp. 57-61, (1999); Schachinger V., Britten M.B., Dimmeler S., Zeiher A.M., NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function, Eur. Heart J., 22, pp. 96-101, (2001); Siffert W., Rosskopf D., Moritz A., Wieland T., Kaldenberg-Stasch S., Kettler N., Hartung K., Beckmann S., Jakobs K.H., Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension, J. Clin. Invest., 96, pp. 759-766, (1995); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein β3-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Lomasney J.W., Lorenz W., Allen L.F., King K., Regan J.W., Yang-Feng T.L., Caron M.G., Lefkowitz R.J., Expansion of the α2-adrenergic receptor family: Cloning and characterization of a human α2-adrenergic receptor subtype, the gene for which is located on chromosome 2, Proc. Natl. Acad. Sci. U. S. A., 87, pp. 5094-5098, (1990); Flordellis C.S., Handy D.E., Bresnahan M.R., Zannis V.I., Gavras H., Cloning and expression of a rat brain α2B-adrenergic receptor, Proc. Natl. Acad. Sci. U. S. A., 88, pp. 1019-1023, (1991); Flordellis C.S., Berguerand M., Gouache P., Barbu V., Gavras H., Handy D.E., Bereziat G., Masliah J., Alpha2-adrenergic receptor subtypes expressed in Chinese hamster ovary cells activate differentially mitogen-activated protein kinase by a p21ras independent pathway, J. Biol. Chem., 270, pp. 3491-3494, (1995); Cussac D., Schaak S., Denis C., Paris H., Alpha2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation, J. Biol. Chem., 277, pp. 19882-19888, (2002); Eason M.G., Liggett S.B., Subtype-selective desensitization of α2-adrenergic receptors. Different mechanisms control short and long term agonist-promoted desensitization of α2C10, α2C4, and α 2C2, J. Biol. Chem., 267, pp. 25473-25479, (1992); Cayla C., Schaak S., Roquelaine C., Gales C., Quinchon F., Paris H., Homologous regulation of the α2C-adrenoceptor subtype in human hepatocarcinoma, HepG2, Br. J. Pharmacol., 126, pp. 69-78, (1999); Small K.M., Liggett S.B., Identification and functional characterization of α2-adrenoceptor polymorphisms, Trends Pharmacol. Sci., 22, pp. 471-477, (2001); Small K.M., Forbes S.L., Brown K.M., Liggett S.B., An asn to lys polymorphism in the third intracellular loop of the human α2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling, J. Biol. Chem., 275, pp. 38518-38523, (2000); Ohara K., Nagai M., Tani K., Tsukamoto T., Suzuki Y., Polymorphism in the promoter region of the α2A adrenergic receptor gene and mood disorders, Neuroreport, 9, pp. 1291-1294, (1998); Ohara K., Suzuki Y., Ochiai M., Terada H., Polymorphism in the promoter region of the α2A-adrenergic receptor gene and panic disorders, Psychiatry Res., 93, pp. 79-82, (2000); Bolonna A.A., Arranz M.J., Munro J., Osborne S., Petouni M., Martinez M., Kerwin R.W., No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response, Neurosci. Lett., 280, pp. 65-68, (2000); Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., Liggett S.B., Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure, N. Engl. J. Med., 347, pp. 1135-1142, (2002)","C.S. Flordellis; Department of Pharmacology, School of Medicine, University of Patras, 261 10 Rio Patras, Greece; email: flordell@med.upatras.gr","","","","","","","","15680266","","CTMCC","14965315","English","Curr. Top. Med. Chem.","Review","Final","","Scopus","2-s2.0-3042762609"
"Hallberg P.; Karlsson J.; Kurland L.; Lind L.; Kahan T.; Malmqvist K.; Peter Öhman K.; Nyström F.; Melhus H.","Hallberg, Pär (57213639525); Karlsson, Julia (7202167968); Kurland, Lisa (57198232272); Lind, Lars (26643471200); Kahan, Thomas (7005494859); Malmqvist, Karin (7006320147); Peter Öhman, K. (57224376653); Nyström, Fredrik (7003806204); Melhus, Håkan (7006676242)","57213639525; 7202167968; 57198232272; 26643471200; 7005494859; 7006320147; 57224376653; 7003806204; 7006676242","The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial","2002","Journal of Hypertension","20","10","","2089","2093","4","90","10.1097/00004872-200210000-00030","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036808254&doi=10.1097%2f00004872-200210000-00030&partnerID=40&md5=4f1ba17afad005f020926271b329f489","Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden","Hallberg P., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Karlsson J., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Kurland L., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Lind L., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Kahan T., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Malmqvist K., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Peter Öhman K., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Nyström F., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; Melhus H., Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden","Background: The cytochrome P450 CYP2C9 enzyme (CYP2C9) metabolizes many clinically important drugs, for example, phenytoin, warfarin and the angiotensin II type 1 (AT1) receptor antagonists, losartan and irbesartan. Single nucleotide polymorphisms in the CYP2C9 gene result in the expression of three important variants, CYP2C9*1 (wild-type), CYP2C9*2 and CYP2C9*3, the last two exhibiting reduced catalytic activity compared with the wild-type. The CYP2C9 genotype is known to determine sensitivity to and dose requirements for both warfarin and phenytoin, and also the rate of metabolism of losartan. However, its influence on clinical response to treatment with the AT1 receptor antagonist, irbesartan, has not been investigated. Objective: To determine whether the CYP2C9 genotype influences the blood pressure-decreasing response to antihypertensive treatment with irbesartan. Design and methods: One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the β1-adrenergic receptor blocker, atenolol (n = 53). Blood pressure was measured before and after 12 weeks of treatment. CYP2C9 genotyping was performed using solid-phase minisequencing. Results: The diastolic blood pressure (DBP) response differed in relation to the CYP2C9 genotype in patients given irbesartan: the reduction in patients with genotype CYP2C9*1/CYP2C9*1 (n = 33) was 7.5% and that with CYP2C9*1/CYP2C9*2 (n = 12) was 14.4% (P = 0.036). A similar trend was seen for systolic blood pressure. In contrast, no relation was seen between the CYP2C9 genotype and blood pressure response to atenolol, a drug not metabolized via CYP2C9. Conclusions: The CYP2C9 genotype seems to predict the DBP response to irbesartan, but not to atenolol, in patients with essential hypertension. © 2002 Lippincott Williams & Wilkins.","Angiotensin; Atenolol; Blood pressure; CYP2C9; Gene; Human; Hypertension; Irbesartan; Minisequencing; Pharmacogenetics","Adult; Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atenolol; Biphenyl Compounds; Blood Pressure; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Genotype; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Predictive Value of Tests; Randomized Controlled Trials; Sweden; Systole; Tetrazoles; Treatment Outcome; angiotensin 1 receptor antagonist; antihypertensive agent; atenolol; beta 1 adrenergic receptor blocking agent; cytochrome P450 2C9; irbesartan; losartan; phenytoin; warfarin; antihypertensive agent; atenolol; biphenyl derivative; CYP2C9 protein, human; irbesartan; tetrazole derivative; unspecific monooxygenase; adult; article; blood pressure; clinical trial; controlled clinical trial; controlled study; diastolic blood pressure; double blind procedure; drug metabolism; drug response; essential hypertension; female; gene expression; gene sequence; genotype; heart left ventricle hypertrophy; human; major clinical study; male; priority journal; randomized controlled trial; single nucleotide polymorphism; Sweden; systolic blood pressure; treatment outcome; wild type; aged; blood pressure; comparative study; diastole; dose response; drug effect; drug screening; genetics; heart left ventricle hypertrophy; hypertension; middle aged; pathophysiology; prediction and forecasting; systole","","atenolol, 29122-68-7, 93379-54-5; irbesartan, 138402-11-6; losartan, 114798-26-4; phenytoin, 57-41-0, 630-93-3; warfarin, 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2; Antihypertensive Agents, ; Aryl Hydrocarbon Hydroxylases, EC 1.14.14.1; Atenolol, 29122-68-7; Biphenyl Compounds, ; CYP2C9 protein, human, EC 1.14.14.1; irbesartan, 138402-11-6; Tetrazoles, ","","","","","Steward D.J., Haining R.L., Henne K.R., Davis G., Rushmore T.H., Trager W.F., Et al., Genetic association between sensitivity to warfarin and expression of CYP2C9*3, Pharmacogenetics, 7, pp. 361-367, (1997); Aithal G.P., Day C.P., Kesteven P.J., Daly A.K., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, 353, pp. 717-719, (1999); Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E., Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms, Arch Biochem Biophys, 333, pp. 447-458, (1996); Crespi C.L., Miller V.P., The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase, Pharmacogenetics, 7, pp. 203-210, (1997); Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R., Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9, Pharmacogenetics, 4, pp. 39-42, (1994); Yasar U., Eliasson E., Dahl M.L., Johansson I., Ingelman-Sundberg M., Sjoqvist F., Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population, Biochem Biophys Res Commun, 254, pp. 628-631, (1999); Taube J., Halsall D., Baglin T., Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment, Blood, 96, pp. 1816-1819, (2000); Goldstein J.A., Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br J Clin Pharmacol, 52, pp. 349-355, (2001); Brandolese R., Scordo M.G., Spina E., Gusella M., Padrini R., Severe phenytoin intoxication in a subject homozygous for CYP2C9*3, Clin Pharmacol Ther, 70, pp. 391-394, (2001); Van der Weide J., Steijns L.S., Van Weelden M.J., De Haan K., The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement, Pharmacogenetics, 11, pp. 287-291, (2001); Taavitsainen P., Kiukaanniemi K., Pelkonen O., In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists, Eur J Clin Pharmacol, 56, pp. 135-140, (2000); Bourrie M., Meunier V., Berger Y., Fabre G., Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes, Drug Metab Dispos, 27, pp. 288-296, (1999); Yasar U., Tybring G., Hidestrand M., Oscarson M., Ingelman-Sundberg M., Dahl M.L., Et al., Role of CYP2C9 polymorphism in losartan oxidation, Drug Metab Dispos, 29, pp. 1051-1056, (2001); Syvanen A.C., From gels to chips: 'Minisequencing' primer extension for analysis of point mutations and single nucleotide polymorphisms, Hum Mutat, 13, pp. 1-10, (1999); Suomalainen A., Syvanen A.C., Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing, Mol Biotechnol, 15, pp. 123-131, (2000); Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., Et al., Regression of left ventricular hypertrophy in human hypertension with irbesartan, J Hypertens, 19, pp. 1167-1176, (2001); Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R., Genetic analysis of the human cytochrome P450 CYP2C9 locus, Pharmacogenetics, 6, pp. 429-439, (1996)","P. Hallberg; Clinical Research Department 2, Uppsala University Hospital, 751 85 Uppsala, Sweden; email: par.hallberg@medsci.uu.se","","Lippincott Williams and Wilkins","","","","","","02636352","","JOHYD","12359989","English","J. Hypertens.","Article","Final","","Scopus","2-s2.0-0036808254"
"Su X.; Lee L.; Li X.; Lv J.; Hu Y.; Zhan S.; Cao W.; Mei L.; Tang Y.-M.; Wang D.; Krauss R.M.; Taylor K.D.; Rotter J.I.; Yang H.","Su, Xiaowen (15832811100); Lee, Liming (15029843200); Li, Xiaohui (57216515050); Lv, Jun (57209876570); Hu, Yonghua (34770189700); Zhan, Siyan (57205304353); Cao, Weihua (7402082953); Mei, Ling (7103211521); Tang, Yong-Ming (58596881700); Wang, Dai (58732868400); Krauss, Ronald M. (7103124166); Taylor, Kent D. (7403523428); Rotter, Jerome I. (56284453500); Yang, Huiying (7406555330)","15832811100; 15029843200; 57216515050; 57209876570; 34770189700; 57205304353; 7402082953; 7103211521; 58596881700; 58732868400; 7103124166; 7403523428; 56284453500; 7406555330","Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor","2007","Circulation","115","6","","725","732","7","72","10.1161/CIRCULATIONAHA.106.642058","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847153057&doi=10.1161%2fCIRCULATIONAHA.106.642058&partnerID=40&md5=3af7e2b20109e6125828099e2e5d3481","Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China; Children's Hospital Oakland Research Institute, Oakland, CA, United States; Medical Genetics Institute, 665 West Tower, Cedars-Sinai Medical Center, Los Angeles, CA 90048, 8700 Beverly Blvd, United States; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100730, Dongdan 3 tiao 9 hao, China","Su X., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Lee L., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China, Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100730, Dongdan 3 tiao 9 hao, China; Li X., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Lv J., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China; Hu Y., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China; Zhan S., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China; Cao W., Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China; Mei L., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Tang Y.-M., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Wang D., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Krauss R.M., Children's Hospital Oakland Research Institute, Oakland, CA, United States; Taylor K.D., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Rotter J.I., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Yang H., Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States, Medical Genetics Institute, 665 West Tower, Cedars-Sinai Medical Center, Los Angeles, CA 90048, 8700 Beverly Blvd, United States","BACKGROUND - To identify the genetic contribution to the variation in blood pressure (BP) response to angiotensin-converting enzyme inhibitors (ACEIs), single-nucleotide polymorphisms (SNPs) in the angiotensinogen (AGT), angiotensin receptor 1 (AGTR1), and angiotensin receptor 2 (AGTR2) genes were evaluated for their association with BP response to ACEI in Chinese patients with hypertension in a 2-stage design. METHODS AND RESULTS - We selected 1447 hypertensive patients from a 3-year benazepril postmarket surveillance trial and genotyped them for 14 SNPs in the AGT, AGTR1, and AGTR2 genes. The AGT rs7079 (C/T) SNP (3′-untranslated region) was significantly associated with the response of diastolic BP to benazepril (diastolic BP response: -7.4 mm Hg for subjects with the CC genotype, -8.9 mm Hg for CA, and -10.1 mm Hg for AA; P=0.001). Although there was no association of individual SNPs in the AGTR1 gene, there was a graded response between common haplotypes and systolic BP reduction in the order of haplotype 2 (H2)/lack of haplotype 3 (non-H3) (-13.6 mm Hg) > non-H2/non-H3 (-10.9 mm Hg) > H3/non-H2 (-6.6 mm Hg) (P=0.004). The total variations in response to ACEI therapy that were explained by the AGT SNP and AGTR1 haplotype groups were 13% for systolic and 9% to 9.6% for diastolic BP, respectively. CONCLUSION - AGT SNP rs7079 and AGTR1 haplotypes were associated with BP reduction in response to ACEI therapy in hypertensive Chinese patients. This will be useful in future studies, providing genetic markers to predict the hypertensive response to ACEI therapy. © 2007 American Heart Association, Inc.","Angiotensin-converting enzyme inhibitors; Angiotensinogen; Hypertension; Polymorphism, single nucleotide; Receptors, angiotensin","Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Benzazepines; Blood Pressure; Female; Haplotypes; Humans; Hypertension; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; angiotensin 1 receptor; angiotensin 2 receptor; angiotensin receptor; angiotensinogen; antihypertensive agent; benazepril; dipeptidyl carboxypeptidase inhibitor; hydrochlorothiazide; 3' untranslated region; adult; article; blood pressure; blood pressure variability; Chinese; controlled study; diastolic blood pressure; drug dose increase; female; genetic association; genetic marker; genetic variability; genotype; haplotype; heredity; human; hypertension; major clinical study; male; postmarketing surveillance; priority journal; promoter region; single nucleotide polymorphism; systolic blood pressure; treatment response","","angiotensinogen, 11002-13-4, 64315-16-8; benazepril, 86541-75-5; hydrochlorothiazide, 58-93-5; Angiotensin-Converting Enzyme Inhibitors, ; Angiotensinogen, 11002-13-4; Benzazepines, ; Receptor, Angiotensin, Type 1, ; Receptor, Angiotensin, Type 2, ; benazepril, 86541-75-5","lotensin, Novartis, Switzerland","Novartis, Switzerland","National Heart, Lung, and Blood Institute, NHLBI, (U19HL069757)","","Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O., Hennekens C.H., Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990); Koopmans R.P., Insel P.A., Michel M.C., Pharmacogenetics of hypertension treatment: A structured review, Pharmacogenetics, 13, pp. 705-713, (2003); Frampton J.E., Peters D.H., Ramipril: An updated review of its therapeutic use in essential hypertension and heart failure, Drugs, 49, pp. 440-466, (1995); Williams G.H., Converting-enzyme inhibitors in the treatment of hypertension, N Engl J Med, 319, pp. 1517-1525, (1988); Kaplan N.M., Sproul L.E., Mulcahy W.S., Large prospective study of ramipril in patients with hypertension. CARE Investigators, Clin Ther, 15, pp. 810-818, (1993); Weir M.R., Gray J.M., Paster R., Saunders E., Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group, Hypertension, 26, pp. 124-130, (1995); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.M., Corvol P., Molecular basis of human hypertension: Role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Iso H., Harada S., Shimamoto T., Sato S., Kitamura A., Sankai T., Tanigawa T., Iida M., Komachi Y., Angiotensinogen T174M and M235T variants, sodium intake and hypertension among non-drinking, lean Japanese men and women, J Hypertens, 18, pp. 1197-1206, (2000); Jeunemaitre X., Gimenez-Roqueplo A.P., Celerier J., Corvol P., Angiotensinogen variants and human hypertension, Curr Hypertens Rep, 1, pp. 31-41, (1999); Pereira A.C., Mota G.F., Cunha R.S., Herbenhoff F.L., Mill J.G., Krieger J.E., Angiotensinogen 235T allele ""dosage"" is associated with blood pressure phenotypes, Hypertension, 41, pp. 25-30, (2003); Staessen J.A., Kuznetsova T., Wang J.G., Emelianov D., Vlietinck R., Fagard R., M235T angiotensinogen gene polymorphism and cardiovascular renal risk, J Hypertens, 17, pp. 9-17, (1999); Tiago A.D., Samani N.J., Candy G.P., Brooksbank R., Libhaber E.N., Sareli P., Woodiwiss A.J., Norton G.R., Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension, Circulation, 106, pp. 1483-1487, (2002); Wu S.J., Chiang F.T., Chen W.J., Liu P.H., Hsu K.L., Hwang J.J., Lai L.P., Lin J.L., Tseng C.D., Tseng Y.Z., Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: Single locus genotype vs. haplotype analysis, Physiol Genomics, 17, pp. 79-86, (2004); Jeng J.R., Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension, Am J Hypertens, 12, pp. 443-450, (1999); Schmidt R., Schmidt H., Fazekas F., Launer L.J., Niederkorn K., Kapeller P., Lechner A., Kostner G.M., Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities, Hypertension, 38, pp. 110-115, (2001); Mellen P.B., Herrington D.M., Pharmacogenomics of blood pressure response to antihypertensive treatment, J Hypertens, 23, pp. 1311-1325, (2005); Helin K., Stoll M., Meffert S., Stroth U., Unger T., The role of angiotensin receptors in cardiovascular diseases, Ann Med, 29, pp. 23-29, (1997); Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Smith R.D., New perspectives in angiotensin system control, J Hum Hypertens, 7, SUPPL. 2, (1993); Roulston C.L., Lawrence A.J., Jarrott B., Widdop R.E., Localization of AT(2) receptors in the nucleus of the solitary tract of spontaneously hypertensive and Wistar Kyoto rats using [125I] CGP42112: Upregulation of a non-angiotensin II binding site following unilateral nodose ganglionectomy, Brain Res, 968, pp. 139-155, (2003); Henrion D., Kubis N., Levy B.I., Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: From large arteries to the microcirculation, Hypertension, 38, pp. 1150-1157, (2001); Bonnardeaux A., Davies E., Jeunemaitre X., Fery I., Charru A., Clauser E., Tiret L., Cambien F., Corvol P., Soubrier F., Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, pp. 63-69, (1994); Jiang Z., Zhao W., Yu F., Xu G., Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension, Chin Med J (Engl), 114, pp. 1249-1251, (2001); Zhu X., Chang Y.P., Yan D., Weder A., Cooper R., Luke A., Kan D., Chakravarti A., Associations between hypertension and genes in the renin-angiotensin system, Hypertension, 41, pp. 1027-1034, (2003); Alfakih K., Maqbool A., Sivananthan M., Walters K., Bainbridge G., Ridgway J., Balmforth A.J., Hall A.S., Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension, Hypertension, 43, pp. 1189-1194, (2004); Jones A., Dhamrait S.S., Payne J.R., Hawe E., Li P., Toor I.S., Luong L., Wootton P.T., Miller G.J., Humphries S.E., Montgomery H.E., Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension, Hypertension, 42, pp. 500-506, (2003); Frazier L., Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic, Pharmacogenomics J, 4, pp. 17-23, (2004); Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, pp. 1602-1609, (1995); Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Hagg A., Lind L., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, pp. 1783-1787, (2001); Miller J.A., Thai K., Scholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Int, 56, pp. 2173-2180, (1999); Hu Y., Li L., Cao W., Zhan S., Li P., Li X., Wu T., Hu R., Zhou X., Ge R., Zhu G., Dai L., Wang Y., Wang S., Guo Y., Community-based comprehensive prevention and control of hypertension in China (CCPACH Study)-prevalence and epidemiological characteristics in urban and rural area [in Chinese], Zhonghua Liu Xing Bing Xue Za Zhi, 21, pp. 177-180, (2000); Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., Nickerson D.A., Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium, Am J Hum Genet, 74, pp. 106-120, (2004); Deinum J., van Gool J.M., Kofflard M.J., ten Cate F.J., Danser A.H., Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy, Hypertension, 38, pp. 1278-1281, (2001); Jin J.J., Nakura J., Wu Z., Yamamoto M., Abe M., Chen Y., Tabara Y., Yamamoto Y., Igase M., Bo X., Kohara K., Miki T., Association of angiotensin II type 2 receptor gene variant with hypertension, Hypertens Res, 26, pp. 547-552, (2003); Kainulainen K., Perola M., Terwilliger J., Kaprio J., Koskenvuo M., Syvanen A.C., Vartiainen E., Peltonen L., Kontula K., Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension, Hypertension, 33, pp. 844-849, (1999); Liu Y., Zhuoma C., Shan G., Cui C., Hou S., Qin W., Cai D., Gesang L., Xiao Z., Pingcuo Z., Zheng H., Wu Z., Zhou W., Qiu C., A1166C polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in Han, Tibetan and Yi populations, Hypertens Res, 25, pp. 515-521, (2002); Goodarzi M.O., Guo X., Taylor K.D., Quinones M.J., Samayoa C., Yang H., Saad M.F., Palotie A., Krauss R.M., Hsueh W.A., Rotter J.I., Determination and use of haplotypes: Ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans, Genet Med, 5, pp. 322-327, (2003); Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: Analysis and visualization of LD and haplotype maps, Bioinformatics, 21, pp. 263-265, (2005); Martin M.M., Elton T.S., The sequence and genomic organization of the human type 2 angiotensin II receptor, Biochem Biophys Res Commun, 209, pp. 554-562, (1995); Jeunemaitre X., Inoue I., Williams C., Charru A., Tichet J., Powers M., Sharma A.M., Gimenez-Roqueplo A.P., Hata A., Corvol P., Lalouel J.M., Haplotypes of angiotensinogen in essential hypertension, Am J Hum Genet, 60, pp. 1448-1460, (1997); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J Hypertens, 14, pp. 259-262, (1996); Mondorf U.F., Russ A., Wiesemann A., Herrero M., Oremek G., Lenz T., Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension, Am J Hypertens, 11, pp. 174-183, (1998); Poirier O., Georges J.L., Ricard S., Arveiler D., Ruidavets J.B., Luc G., Evans A., Cambien F., Tiret L., New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: The ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde, J Hypertens, 16, pp. 1443-1447, (1998); Tsai C.T., Fallin D., Chiang F.T., Hwang J.J., Lai L.P., Hsu K.L., Tseng C.D., Liau C.S., Tseng Y.Z., Angiotensinogen gene haplotype and hypertension: Interaction with ACE gene I allele, Hypertension, 41, pp. 9-15, (2003); Staessen J.A., Ginocchio G., Wang J.G., Saavedra A.P., Soubrier F., Vlietinck R., Fagard R., Genetic variability in the renin-angiotensin system: Prevalence of alleles and genotypes, J Cardiovasc Risk, 4, pp. 401-422, (1997)","L. Lee; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100730, Dongdan 3 tiao 9 hao, China; email: lmlee@pumc.edu.cn","","","","","","","","00097322","","CIRCA","17261659","English","Circulation","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-33847153057"
"Taverne K.; De Groot M.; De Boer A.; Klungel O.","Taverne, Kim (35761811600); De Groot, Mark (7102642748); De Boer, Anthonius (56489803600); Klungel, Olaf (7006204390)","35761811600; 7102642748; 56489803600; 7006204390","Genetic polymorphisms related to the reninangiotensinaldosterone system and response to antihypertensive drugs","2010","Expert Opinion on Drug Metabolism and Toxicology","6","4","","439","460","21","16","10.1517/17425250903571670","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77949881726&doi=10.1517%2f17425250903571670&partnerID=40&md5=deeda1dba91e88434942096ebf0cefc1","Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteit Utrecht, Utrecht, Netherlands; University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands","Taverne K., Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteit Utrecht, Utrecht, Netherlands; De Groot M., Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteit Utrecht, Utrecht, Netherlands, University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands; De Boer A., Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteit Utrecht, Utrecht, Netherlands; Klungel O., Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteit Utrecht, Utrecht, Netherlands, University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands","Importance of the field: Only 23 41% of hypertensive patients receiving antihypertensive drugs achieve adequate blood pressure control. Multiple physiological systems regulate blood pressure and variation in genes involved in these systems may account for enhanced or diminished blood pressure lowering response to antihypertensive therapy. Areas covered in this review: We explored explanations for variation in blood pressure response to antihypertensive drugs by linking genetic polymorphisms in reninangiotensinaldosterone system (RAAS) genes to antihypertensive drug response on intermediate parameters (e.g., potassium excretion, aldosterone levels). A MEDLINE search (1966 - 2008) was performed to identify publications reporting effects of genetic polymorphisms in the RAAS on antihypertensive drug response with regard to intermediate parameters. What the reader will gain: With regard to the ACE insertion/deletion and the angiotensinogen -217G/A polymorphism variation in blood pressure response could be explained by effects on intermediate parameters. However, most studies that were identified with our search varied in study design, population and outcome, which complicate adequate comparisons. Take home message: Little evidence is available that explains these pharmacogenetic interactions. In the future, a better understanding of these mechanisms should provide a more solid evidence base for the individualized hypertension treatment based on genetic variation. © 2010 Informa UK Ltd.","ACE; Antihypertensive drug; Intermediate outcome parameters; Pharmacogenetics; RAAS; Reninangiotensinaldosterone system","Antihypertensive Agents; Humans; Polymorphism, Genetic; Renin-Angiotensin System; alpha adducin; angiotensin 1 receptor; antihypertensive agent; atenolol; benazepril; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta 3 adrenergic receptor; bisoprolol; candesartan; captopril; chloride; creatinine; dipeptidyl carboxypeptidase; dobutamine; enalapril; fosinopril; hydrochlorothiazide; imidapril; irbesartan; lisinopril; losartan; metoprolol; perindopril; phosphorus; potassium; protein kinase WNK1; ramipril; telmisartan; albuminuria; aldosterone blood level; amino acid substitution; antihypertensive activity; blood pressure regulation; chloride urine level; clinical trial; creatinine blood level; DNA polymorphism; drug dose increase; drug dose titration; drug effect; drug response; essential hypertension; gene frequency; genotype; genotype phenotype correlation; human; hypertension; indel mutation; insulin dependent diabetes mellitus; non insulin dependent diabetes mellitus; plasma renin activity; potassium blood level; potassium urine level; proteinuria; receptor gene; renin angiotensin aldosterone system; review; single nucleotide polymorphism; sodium blood level; sodium urine level; urea nitrogen blood level","","atenolol, 29122-68-7; benazepril, 86541-75-5; bisoprolol, 66722-44-9; candesartan, 139481-59-7; captopril, 62571-86-2; chloride, 16887-00-6; creatinine, 19230-81-0, 60-27-5; dipeptidyl carboxypeptidase, 9015-82-1; dobutamine, 34368-04-2, 52663-81-7; enalapril, 75847-73-3; fosinopril, 88889-14-9, 98048-97-6; hydrochlorothiazide, 58-93-5; imidapril, 89371-37-9, 89396-94-1; irbesartan, 138402-11-6; lisinopril, 76547-98-3, 83915-83-7; losartan, 114798-26-4; metoprolol, 37350-58-6; perindopril, 82834-16-0; phosphorus, 7723-14-0; potassium, 7440-09-7; ramipril, 87333-19-5; telmisartan, 144701-48-4; Antihypertensive Agents, ","","","Dutch Medicines Evaluation Board; GlaxoSmithKline, GSK; Ministerie van Volksgezondheid, Welzijn en Sport, VWS; Novo Nordisk; Top Institute Pharma, (T6-101)","The division of Pharmacoepidemiology and Pharmacotherapy employing authors OH Klungel, M de Groot and A de Boer has received unrestricted funding for pharmacoepidemio-logical research from GlaxoSmithKline, Novo Nordisk, the private–public funded Top Institute Pharma, the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. This work was funded by TI Pharma grant T6-101: The Mondriaan project.","Rosamond W., Flegal K., Furie K., Et al., Heart disease and stroke statistics -2008 update: A report from the American heart association statistics committee and stroke statistics subcommittee, Circulation, 117, 4, (2008); Brugts J.J., Den Uil C.A., Danser A.H., Boersma E., The renin-angiotensin-aldosterone system: Approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease, Cardiology, 112, 4, pp. 303-312, (2009); Mellen P.B., Herrington D.M., Pharmacogenomics of blood pressure response to antihypertensive treatment, J Hypertens, 23, 7, pp. 1311-1325, (2005); Arnett D.K., Claas S.A., Glasser S.P., Pharmacogenetics of antihypertensive treatment, Vascul Pharmacol, 44, 2, pp. 107-118, (2006); Jeunemaitre X., Genetics of the human renin angiotensin system, J Mol Med, 86, 6, pp. 637-641, (2008); Koopmans R.P., Insel P.A., Michel M.C., Pharmacogenetics of hypertension treatment: A structured review, Pharmacogenetics, 13, 12, pp. 705-713, (2003); Chobanian A.V., Bakris G.L., Black H.R., Et al., Seventh report of the joint National committee on prevention, detection, evaluation, and treatment of high blood pressure, Hypertension, 42, 6, pp. 1206-1252, (2003); Sciarrone M.T., Stella P., Barlassina C., Et al., ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, 3, pp. 398-403, (2003); Zhou Y., Wu S.L., Liu J.Q., Et al., Possible association of ACE gene I/D polymorphism with blood pressure - Lowering response to hydrochlorothiazide, Biomed Environ Sci, 20, 5, pp. 351-356, (2007); Vormfelde S.V., Sehrt D., Bolte D., Et al., Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers, Eur J Clin Pharmacol, 62, 3, pp. 195-201, (2006); Mondorf U.F., Russ A., Wiesemann A., Et al., Contribution of angiotensin i converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension, Am J Hypertens, 11, 2, pp. 174-183, (1998); Todd G.P., Chadwick I.G., Higgins K.S., Et al., Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects, Br J Clin Pharmacol, 39, 2, pp. 131-134, (1995); Kohno M., Yokokawa K., Minami M., Et al., Association between angiotensinconverting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors, Am J Med, 106, 5, pp. 544-549, (1999); Ohmichi N., Iwai N., Uchida Y., Et al., Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype, Am J Hypertens, 10, 8, pp. 951-955, (1997); Sasaki M., Oki T., Iuchi A., Et al., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies, J Hypertens, 14, 12, pp. 1403-1408, (1996); Ueda S., Meredith P.A., Morton J.J., Et al., ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans, Circulation, 98, 20, pp. 2148-2153, (1998); Weekers L., Bouhanick B., Hadjadj S., Et al., Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients, Diabetes, 54, 10, pp. 2961-2967, (2005); Manunta P., Barlassina C., Bianchi G., Adducin in essential hypertension, FEBS Lett, 430, 1-2, pp. 41-44, (1998); Cusi D., Barlassina C., Azzani T., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, 9062, pp. 1353-1357, (1997); Shin M.H., Chung E.K., Kim H.N., Et al., Alpha-adducin Gly460Trp polymorphism and essential hypertension in Korea, J Korean Med Sci, 19, 6, pp. 812-814, (2004); Glorioso N., Manunta P., Filigheddu F., Et al., The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, 4 PART 1, pp. 649-654, (1999); Sugimoto K., Hozawa A., Katsuya T., Et al., Alpha-adducin Gly460Trp polymorphism is associated with low renin hypertension in younger subjects in the Ohasama study, J Hypertens, 20, 9, pp. 1779-1784, (2002); Rejnmark L., Vestergaard P., Pedersen A.R., Et al., Dose-effect relations of loop-and thiazide-diuretics on calcium homeostasis: A randomized, double-blinded Latinsquare multiple cross-over study in postmenopausal osteopenic women, Eur J Clin Invest, 33, 1, pp. 41-50, (2003); Glorioso N., Filigheddu F., Cusi D., Et al., Alpha-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives, Hypertension, 39, 2 PART 2, pp. 357-362, (2002); Velazquez H., Thiazide diuretics, Ren Physiol, 10, 3-4, pp. 184-197, (1987); Subramanya A.R., Yang C.L., McCormick J.A., Ellison D.H., WNK kinases regulate sodium chloride and potassium transport by the aldosteronesensitive distal nephron, Kidney Int, 70, 4, pp. 630-634, (2006); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic, Hypertension, 46, 4, pp. 758-765, (2005); Jastrzebskal M., Widecka K., Naruszewicz M., Et al., Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms, Nutr Metab Cardiovasc Dis, 14, 5, pp. 259-269, (2004); Yu H., Zhang Y., Liu G., Relationship between polymorphism of the angiotensinconverting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients, Hypertens Res, 26, 11, pp. 881-886, (2003); Ha S.K., Yong Lee S., Su Park H., Et al., ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulindependent diabetes mellitus, Nephrol Dial Transplant, 15, 10, pp. 1617-1623, (2000); Haas M., Yilmaz N., Schmidt A., Et al., Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease, Kidney Blood Press Res, 21, 1, pp. 66-69, (1998); Stavroulakis G.A., Makris T.K., Krespi P.G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc Drugs Ther, 14, 4, pp. 427-432, (2000); Perna A., Ruggenenti P., Testa A., Et al., ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1, Kidney Int, 57, 1, pp. 274-281, (2000); Yoshida H., Mitarai T., Kawamura T., Et al., Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy, J Clin Invest, 96, 5, pp. 2162-2169, (1995); Van Essen G.G., Rensma P.L., De Zeeuw D., Et al., Association between angiotensinconverting-enzyme gene polymorphism and failure of renoprotective therapy, Lancet, 347, 8994, pp. 94-95, (1996); Van Der Kleij F.G., Navis G.J., Gansevoort R.T., Et al., ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients, Nephrol Dial Transplant, 12, SUPPL. 2, pp. 42-46, (1997); Jacobsen P., Rossing K., Rossing P., Et al., Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy, Kidney Int, 53, 4, pp. 1002-1006, (1998); Penno G., Chaturvedi N., Talmud P.J., Et al., Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: Findings from the EUCLID randomized controlled trial, Diabetes, 47, 9, pp. 1507-1511, (1998); Dudley C., Keavney B., Casadei B., Et al., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J Hypertens, 14, 2, pp. 259-262, (1996); Hingorani A.D., Jia H., Stevens P.A., Et al., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, 12 PART 2, pp. 1602-1609, (1995); Yu H., Lin S., Liu G., Et al., T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors, Hypertens Res, 28, 12, pp. 981-986, (2005); Woodiwiss A.J., Nkeh B., Samani N.J., Et al., Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin, J Hypertens, 24, 6, pp. 1057-1064, (2006); Jain S., Tang X., Narayanan C.S., Et al., Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans, J Biol Chem, 277, 39, pp. 36889-36896, (2002); Kramkowski K., Mogielnicki A., Buczko W., The physiological significance of the alternative pathways of angiotensin II production, J Physiol Pharmacol, 57, 4, pp. 529-539, (2006); Gluszek J., Jankowska K., Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy?, Pol Arch Med Wewn, 118, 4, pp. 194-200, (2008); Parving H.H., De Zeeuw D., Cooper M.E., Et al., ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy, J Am Soc Nephrol, 19, 4, pp. 771-779, (2008); Park H.C., Choi H.Y., Kim B.S., Et al., Antiproteinuric effect of losartan in nondiabetic renal disease is not dependent on ACE insertion/deletion polymorphism, Kidney Blood Press Res, 29, 4, pp. 216-224, (2006); Andersen S., Tarnow L., Cambien F., Et al., Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?, Kidney Int, 62, 1, pp. 192-198, (2002); Nakamura Y., Tamaki S., Uchida Y., Et al., Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension, Hypertens Res, 27, 3, pp. 137-140, (2004); Redon J., Luque-Otero M., Martell N., Chaves F.J., Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients, Pharmacogenomics J, 5, 1, pp. 14-20, (2005); Haneda M., Kikkawa R., Sakai H., Kawamori R., Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy, Diabetes Res Clin Pract, 66, 1, pp. 87-95, (2004); Inoue I., Nakajima T., Williams C.S., Et al., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, 7, pp. 1786-1797, (1997); Kurland L., Melhus H., Karlsson J., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, 10, pp. 1783-1787, (2001); Miller J.A., Thai K., Scholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Int, 56, 6, pp. 2173-2180, (1999); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, 1, pp. 63-69, (1994); Leenen F.H., Redmond D.P., McDonald Jr. R.H., Alpha and beta adrenergic-induced renin release in man, Clin Pharmacol Ther, 18, 1, pp. 31-38, (1975); Johnson J.A., Zineh I., Puckett B.J., Et al., Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin Pharmacol Ther, 74, 1, pp. 44-52, (2003); Liu J., Liu Z.Q., Yu B.N., Et al., Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension, Clin Pharmacol Ther, 80, 1, pp. 23-32, (2006); Bruck H., Leineweber K., Temme T., Et al., The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity, J Am Coll Cardiol, 46, 11, pp. 2111-2115, (2005); Schwartz G.L., Turner S.T., Chapman A.B., Boerwinkle E., Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide, Kidney Int, 62, 5, pp. 1718-1723, (2002); Lynch A.I., Arnett D.K., Davis B.R., Et al., Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: The GenHAT study, Ann Hum Genet, 71, PART 6, pp. 735-745, (2007); Jalil J.E., Ocaranza M.P., Oliveri C., Et al., Neutral endopeptidase and angiotensin i converting enzyme insertion/deletion gene polymorphism in humans, J Hum Hypertens, 18, 2, pp. 119-125, (2004); Lee Y.J., Tsai J.C., Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitorrelated cough in Chinese female patients with non-insulin-dependent diabetes mellitus, Metabolism, 50, 11, pp. 1346-1350, (2001)","O. Klungel; Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteit Utrecht, Utrecht, Netherlands; email: o.h.klungel@uu.nl","","","","","","","","17425255","","","20102285","English","Expert Opin. Drug Metab. Toxicol.","Review","Final","","Scopus","2-s2.0-77949881726"
"Wu S.L.; Li Y.; Liu K.J.; Hou G.S.; Wang J.J.; Wu Y.T.; Song S.M.","Wu, Shou-ling (57744442000); Li, Yun (58861850400); Liu, Ke-jian (55729545900); Hou, Guo-sheng (32167542500); Wang, Jian-jun (55742596600); Wu, Yun-Tao (57221580119); Song, Shao-min (57198630100)","57744442000; 58861850400; 55729545900; 32167542500; 55742596600; 57221580119; 57198630100","Association of polymorphisms in ACE and CYP11B2 genes with antihypertensive effects of hydrochlorothiazide","2005","Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases]","33","7","","595","598","3","3","","https://www.scopus.com/inward/record.uri?eid=2-s2.0-73349098449&partnerID=40&md5=dd3af8664e83b8c688836f67d5199ee9","The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China","Wu S.L., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China; Li Y., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China; Liu K.J., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China; Hou G.S., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China; Wang J.J., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China; Wu Y.T., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China; Song S.M., The Affiliated Kailuan Hospital, North China Coal Medical College, Tangshan, 063000, China","OBJECTIVE: To determine whether the blood pressure (BP) response to hydrochlorothiazide (HCTZ) was associated with the angiotensin converting-enzyme (ACE) I/D and aldosterone synthase (CYP11B2)-344T/C polymorphisms. METHODS: The BP response to HCTZ 12.5 mg once daily for 6 weeks was assessed in 829 subjects with mild or moderate essential hypertension, and compared across the ACE and CYP11B2 genotypes. RESULTS: Of the 829 enrolled subjects, 785 completed the study. The systolic BP response differed according to the ACE (DD 9.4 +/- 15.7 mm Hg, ID 4.8 +/- 16.3 mm Hg, and II 5.1 +/- 14.8 mm Hg, P < 0.01), but not the CYP11B2 genotype (P > 0.05). Subjects with the combination of ACE DD and CYP11B2 CC genotypes tended to have a more pronounced systolic BP reduction than the other genotypic combinations of these 2 genes. Multiple linear regression analyses showed that the ACE DD genotype and serum aldosterone concentration at baseline were associated with the systolic BP reduction after treatment. None of the genetic associations with changes in diastolic BP or mean arterial pressure reached statistical significance (P > 0.05). CONCLUSIONS: The present study suggested that the ACE DD genotype was associated with the systolic BP response to HCTZ, and that the subjects with the combination of ACE DD and CYP11B2 CC genotypes might have a better BP response to HCTZ than the other genotypic combinations of these 2 genes.","","Adult; Aged; Aged, 80 and over; Aldosterone Synthase; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Sodium Chloride Symporter Inhibitors; aldosterone synthase; dipeptidyl carboxypeptidase; hydrochlorothiazide; thiazide diuretic agent; adult; aged; article; female; genetics; human; hypertension; male; middle aged; single nucleotide polymorphism","","aldosterone synthase, 122933-89-5; dipeptidyl carboxypeptidase, 9015-82-1; hydrochlorothiazide, 58-93-5; Aldosterone Synthase, EC 1.14.15.4; Hydrochlorothiazide, 58-93-5; Peptidyl-Dipeptidase A, EC 3.4.15.1; Sodium Chloride Symporter Inhibitors, ","","","","","","S.L. Wu; email: drliyun@163.com","","","","","","","","02533758","","","16080804","Chinese","Zhonghua Xin Xue Guan Bing Za Zhi","Article","Final","","Scopus","2-s2.0-73349098449"
"Chung C.-M.; Wang R.-Y.; Chen J.-W.; Fann C.S.J.; Leu H.-B.; Ho H.-Y.; Ting C.-T.; Lin T.-H.; Sheu S.-H.; Tsai W.-C.; Chen J.-H.; Jong Y.-S.; Lin S.-J.; Chen Y.-T.; Pan W.-H.","Chung, C.-M. (22950004900); Wang, R.-Y. (15737758600); Chen, J.-W. (35267970100); Fann, C.S.J. (7003548346); Leu, H.-B. (13408577100); Ho, H.-Y. (26649875400); Ting, C.-T. (7202187141); Lin, T.-H. (34868210000); Sheu, S.-H. (7202895031); Tsai, W.-C. (56506212500); Chen, J.-H. (56062627000); Jong, Y.-S. (25940909100); Lin, S.-J. (7407605154); Chen, Y.-T. (56496251400); Pan, W.-H. (7402219783)","22950004900; 15737758600; 35267970100; 7003548346; 13408577100; 26649875400; 7202187141; 34868210000; 7202895031; 56506212500; 56062627000; 25940909100; 7407605154; 56496251400; 7402219783","A genome-wide association study identifies new loci for ACE activity: Potential implications for response to ACE inhibitor","2010","Pharmacogenomics Journal","10","6","","537","544","7","103","10.1038/tpj.2009.70","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649328373&doi=10.1038%2ftpj.2009.70&partnerID=40&md5=beecc6c279a6483df3de6d3998cca513","Division of Molecular Medicine, Institute of Public Health, National Yang-Ming University, Taipei, Taiwan; Department of Public Health, China Medical University, Taichung, Taiwan; Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Taichung Veterans General Hospital, Taichung, Taiwan; Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Cardiology, Tao Yuan General Hospital, TaoYuan City, Taiwan","Chung C.-M., Division of Molecular Medicine, Institute of Public Health, National Yang-Ming University, Taipei, Taiwan; Wang R.-Y., Department of Public Health, China Medical University, Taichung, Taiwan; Chen J.-W., Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan; Fann C.S.J., Division of Molecular Medicine, Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Leu H.-B., Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan; Ho H.-Y., Taichung Veterans General Hospital, Taichung, Taiwan; Ting C.-T., Taichung Veterans General Hospital, Taichung, Taiwan; Lin T.-H., Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Department of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Sheu S.-H., Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Department of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Tsai W.-C., College of Medicine, National Cheng Kung University, Tainan, Taiwan; Chen J.-H., College of Medicine, National Cheng Kung University, Tainan, Taiwan; Jong Y.-S., Department of Cardiology, Tao Yuan General Hospital, TaoYuan City, Taiwan; Lin S.-J., Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan; Chen Y.-T., Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Pan W.-H., Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan","Because angiotensin-converting enzyme (ACE) activity is implicated widely in biological systems, we aimed to identify its novel quantitative trait loci for the purposes of understanding ACE activity regulation and pharmacogenetics relating to ACE inhibitor (ACEI). We performed a two-stage genome-wide association study: (1) from 400 young-onset hypertension (YOH) subjects and (2) a confirmation study with an additional 623 YOH subjects. In the first stage, eight single nucleotide polymorphisms (SNPs) of the ACE structural gene and one SNP of ABO genes were significantly associated with ACE activity. SNP rs4343 in exon17 near the well-known insertion/deletion polymorphism had the strongest association. We confirmed in the second stage that three SNPs: rs4343 in ACE gene (P=3.0 × 10-25), rs495828 (P=3.5 × 10-8) and rs8176746 (P=9.3 × 10-5) in ABO gene were significantly associated with ACE activity. We further replicated the association between ABO genotype/blood types and ACE activity in an independent YOH family study (428 hypertension pedigrees), and showed a potential differential blood pressure response to ACEI in subjects with varied numbers of ACE-activity-raising alleles. These findings may broaden our understanding of the mechanisms controlling ACE activity and advance our pharmacogenetic knowledge on ACEI. © 2010 Macmillan Publishers Limited. All rights reserved.","ABO; ACE; GWAS; hypertension; pharmacogenetics","ABO Blood-Group System; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Female; Genome-Wide Association Study; Humans; Hypertension; Male; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Quantitative Trait Loci; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; ABO gene; ACE structural gene; adult; article; blood group ABO system; controlled study; enzyme activity; female; gene; gene mapping; genetic association; genotype; human; hypertension; major clinical study; male; pharmacogenetics; priority journal; quantitative trait locus; single nucleotide polymorphism","","dipeptidyl carboxypeptidase, 9015-82-1; ABO Blood-Group System, ; Angiotensin-Converting Enzyme Inhibitors, ; Peptidyl-Dipeptidase A, 3.4.15.1","","","Department of Health and Social Care, DH, (DOH90-TD-1037); National Science Council, NSC, (NSC91-3112-P-001-025-YGPCP91-25); Academia Sinica","We thank John Yin for editing the paper and Academia Sinica National Genotyping Center (Taipei, Taiwan) for performing genotyping of the second-stage subjects. This research was supported by the Department of Health (DOH90-TD-1037), the National Science Council (NSC91-3112-P-001-025-YGPCP91-25), Academia Sinica (AS91IBMS2PP-A) and Academia Sinica Genomics and Proteinomics Program (2003–2006) in Taiwan.","Genome-wide association study of 14000 cases of seven common diseases and 3000 shared controls, Nature, 447, pp. 661-678, (2007); Wang T.H., Wang H.S., A genome-wide association study primer for clinicians, Taiwan J Obstet Gynecol, 48, pp. 89-95, (2009); Samani N.J., Erdmann J., Hall A.S., Hengstenberg C., Mangino M., Mayer B., Dixon R.J., Meitinger T., Braund P., Wichmann H.-E., Barrett J.H., Konig I.R., Stevens S.E., Szymczak S., Tregouet D.-A., Iles M.M., Pahlke F., Pollard H., Lieb W., Cambien F., Fischer M., Ouwehand W., Blankenberg S., Balmforth A.J., Baessler A., Ball S.G., Strom T.M., Braenne I., Gieger C., Deloukas P., Tobin M.D., Ziegler A., Thompson J.R., Schunkert H., Genomewide association analysis of coronary artery disease, New England Journal of Medicine, 357, 5, pp. 443-453, (2007); Ikram M.A., Seshadri S., Bis J.C., Fornage M., Destefano A.L., Aulchenko Y.S., Et al., Genomewide association studies of stroke, N Engl J Med, 360, pp. 1718-1728, (2009); Gottesman I.I., Gould T.D., The endophenotype concept in psychiatry: Etymology and strategic intentions, Am J Psychiatry, 160, pp. 636-645, (2003); Pan W.H., Lynn K.S., Chen C.H., Wu Y.L., Lin C.Y., Chang H.Y., Using endophenotypes for pathway clusters to map complex disease genes, Genet Epidemiol, 30, pp. 143-154, (2006); Castellon R., Hamdi H.K., Demystifying the ACE polymorphism: From genetics to biology, Curr Pharm des, 13, pp. 1191-1198, (2007); Turner A.J., Hooper N.M., The angiotensin-converting enzyme gene family: Genomics and pharmacology, Trends Pharmacol Sci, 23, pp. 177-183, (2002); Ehlers M.R., Riordan J.F., Angiotensin-converting enzyme: New concepts concerning its biological role, Biochemistry, 28, pp. 5311-5318, (1989); Sayed-Tabatabaei F.A., Oostra B.A., Isaacs A., Van Duijn C.M., Witteman J.C., ACE polymorphisms, Circ Res, 98, pp. 1123-1133, (2006); Rudnicki M., Mayer G., Significance of genetic polymorphisms of the renin-angiotensin- aldosterone system in cardiovascular and renal disease, Pharmacogenomics, 10, pp. 463-476, (2009); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); Zhu X., Bouzekri N., Southam L., Cooper R.S., Adeyemo A., McKenzie C.A., Et al., Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure, Am J Hum Genet, 68, pp. 1139-1148, (2001); Alhenc-Gelas F., Richard J., Courbon D., Warnet J.M., Corvol P., Distribution of plasma angiotensin I-converting enzyme levels in healthy men: Relationship to environmental and hormonal parameters, J Lab Clin Med, 117, pp. 33-39, (1991); Pan W.H., Hung Y.T., Shaw N.S., Lin W., Lee S.D., Chiu C.F., Et al., Elderly Nutrition and Health Survey in Taiwan ( 1999- 2000): Research design, methodology and content, Asia Pac J Clin Nutr, 14, pp. 203-210, (2005); Kasahara Y., Ashihara Y., Colorimetry of angiotensin-I converting enzyme activity in serum, Clin Chem, 27, pp. 1922-1925, (1981); Wang R.Y., Chung C.M., Fann C.S., Yang H.C., Chen J.W., Jong Y.S., Et al., Genome-wide scan for quantitative ACE activity in Taiwan Young-Onset Hypertension study, Hum Hered, 65, pp. 85-90, (2008); Blumenfeld O.O., Patnaik S.K., Allelic genes of blood group antigens: A source of human mutations and cSNPs documented in the Blood Group Antigen Gene Mutation Database, Hum Mutat, 23, pp. 8-16, (2004); Zeger S.L., Liang K.Y., Longitudinal data analysis for discrete and continuous outcomes, Biometrics, 42, pp. 121-130, (1986); Cidl K., Strelcova L., Znojil V., Vachi J., Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity, Exp Hematol, 24, pp. 790-794, (1996); Takasaki S., Yamashita K., Kobata A., The sugar chain structures of ABO blood group active glycoproteins obtained from human erythrocyte membrane, J Biol Chem, 253, pp. 6086-6091, (1978); Borecki I.B., Elston R.C., Rosenbaum P.A., Srinivasan S.R., Berenson G.S., ABO associations with blood pressure, serum lipids and lipoproteins, and anthropometric measures, Hum Hered, 35, pp. 161-170, (1985); Bezemer I.D., Rosendaal F.R., Predictive genetic variants for venous thrombosis: What's new?, Semin Hematol, 44, pp. 85-92, (2007); Wu O., Bayoumi N., Vickers M.A., Clark P., ABO(H) blood groups and vascular disease: A systematic review and meta-analysis, J Thromb Haemost, 6, pp. 62-69, (2008); Jenkins P.V., O'Donnell J.S., ABO blood group determines plasma von Willebrand factor levels: A biologic function after all?, Transfusion, 46, pp. 1836-1844, (2006); Naim H.Y., Human small intestinal angiotensin-converting enzyme: Intracellular transport, secretion and glycosylation, Biochem J, 296, PART 3, pp. 607-615, (1993); Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy, JAMA, 248, pp. 2004-2011, (1982); Arnett D.K., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Miller M.B., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, pp. 3374-3383, (2005); Belz G.G., Breithaupt K., Erb K., Review of studies on the clinical pharmacodynamics of cilazapril, J Cardiovasc Pharmacol, 24, SUPPL. 2, (1994); Lang R.M., Dibianco R., Broderick G.T., Gottlieb S.S., Kostis J., Lyle P.A., Et al., First-dose effects of enalapril 2.5mg and captopril 6.25mg in patients with heart failure: A double-blind, randomized, multicenter study, Am Heart J, 128, pp. 551-556, (1994); Ehret G.B., Morrison A.C., O'Connor A.A., Grove M.L., Baird L., Schwander K., Et al., Replication of the Wellcome Trust genome-wide association study of essential hypertension: The Family Blood Pressure Program, Eur J Hum Genet, 16, pp. 1507-1511, (2008)","W.-H. Pan; Institute of Biomedical Sciences, Academia Sinica, Section 2, Taipei 11529, 128, Academia Road, Taiwan; email: pan@ibms.sinica.edu.tw","","","","","","","","14731150","","PJHOA","20066004","English","Pharmacogenomics J.","Article","Final","","Scopus","2-s2.0-78649328373"
"Masuo K.; Rakugi H.; Ogihara T.","Masuo, Kazuko (7004623416); Rakugi, Hiromi (57202699453); Ogihara, Toshio (57220595182)","7004623416; 57202699453; 57220595182","Relationships of Beta2-and Beta3--Adrenoceptor polymorphisms with obesity, hypertension and metabolic syndrome","2010","Current Hypertension Reviews","6","2","","118","129","11","2","10.2174/157340210791171065","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952495856&doi=10.2174%2f157340210791171065&partnerID=40&md5=74a11f608b1f1bace788c80b86954775","Nucleus Network, Ltd, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC, Australia; Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC, Australia; Department of Geriatric Medicine, Osaka University Postgraduate School of Medicine, Suita, Osaka, Japan","Masuo K., Nucleus Network, Ltd, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC, Australia, Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC, Australia; Rakugi H., Department of Geriatric Medicine, Osaka University Postgraduate School of Medicine, Suita, Osaka, Japan; Ogihara T., Department of Geriatric Medicine, Osaka University Postgraduate School of Medicine, Suita, Osaka, Japan","Obesity, hypertension, diabetes mellitus (especially type 2 diabetes mellitus) and metabolic syndrome are rapidly growing public health problems. Heightened sympathetic nerve activity is a well-established observation in obesity, hypertension and diabetes mellitus. Human obesity, hypertension and diabetes have strong genetic as well as environmental determinants. Reduced energy expenditure and resting metabolic rate are predictive of weight gain, and the sympathetic nervous system participates in regulating energy balance through thermogenesis. The thermogenic effects of catecholamines in obesity have been mainly mediated via the β2 and β3-adrenergic receptors in humans. Further, β2-adrenoceptors importantly influence vascular reactivity and may regulate blood pressure. Genetic polymorphisms of the β-adrenoceptor gene have been shown to alter the function of several adrenoceptor subtype and thus to modify the response to catecholamine. Among β2-adrenoceptor polymorphisms, Arg16Gly, Gln27Glu, and Thr164Ile are considered the most functionally important. β2-adrenoceptor genes have been studied in relation to obesity. Genetic variations in the β3-adrenoceptor, such as the Try64Arg variant, are also associated with both obesity and hypertension. However, the precise relationships of the polymorphisms of β2-and β3-adrenoceptor genes with sympathetic nervous system activity, obesity, hypertension and metabolic syndrome have not been fully clarified. A few studies regarding the relationships between sympathetic nervous activity and adrenoceptor polymorphisms in the same studies have been reported. Masuo et al. have observed in a series of studies in a Japanese male cohort that: 1) β2-adrenoceptor polymorphisms are associated with heightened sympathetic nerve activity, and predict the future onset of obesity and hypertension in nonobese individuals, 2) β2-adrenoceptor polymorphisms accompanied by heightened sympathetic nerve activity and abdominal obesity, predict weight loss resistance during a weight loss program, and also predict rebound weight gain, 3) β2-adrenoceptor polymorphisms are linked to blunted leptin-mediated sympathetic nerve activation, leptin-resistance and resultant obesity, 4) β2-adrenoceptor polymorphisms are related to insulin-resistance, in both nonobese and obese normotensive individuals, and 5) β3-adrenoceptor polymorphism is directly linked to obesity and hypertension, but only in obese individuals. These suggest that β2-and β3-adrenoceptor polymorphisms accompanying heightened sympathetic nerve activity play a major role in the onset and the maintenance of obesity, hypertension and insulin resistance. This article provides the current topics involving the influence of the sympathetic nervous system and β2-and β3-adrenoceptor polymorphisms in obesity, hypertension and metabolic syndrome (type 2 diabetes). © 2010 Bentham Science Publishers Ltd.","Beta2-adrenoceptor polymorphisms; Beta3-adrenoceptor polymorphisms; Hypertension; Metabolic syndrome; Obesity; Sympathetic nervous system activity; Type 2 diabetes mellitus","alpha 1 adrenergic receptor; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta 3 adrenergic receptor; leptin; adrenergic system; article; cardiovascular disease; diabetogenesis; ethnic difference; genetic association; haplotype; human; hyperinsulinemia; hypertension; insulin resistance; kidney disease; metabolic syndrome X; non insulin dependent diabetes mellitus; nonhuman; obesity; pathogenesis; phenotype; priority journal; protein expression; protein function; renin angiotensin aldosterone system; sex difference; single nucleotide polymorphism; vasoconstriction","","","","","","","Mokdad A.H., Bowman B.A., Ford E.S., Venicor F., Marks J.S., Koplan J.P., The continuing epidemics of obesity and diabetes in the United States, JAMA, 286, pp. 1195-1200, (2001); Heidmann C., Boeing H., Pischon T., Nothlings U., Joost H.G., Schulze M.B., Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: A prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort, Eur J Epidemiol, 24, pp. 281-288, (2009); Flegal K.M., Graubard B.L., Williamson D.F., Gail M.H., Cause-specific excess deaths associated with underweight, overweight, and obesity, JAMA, 298, pp. 2028-2037, (2007); Ramsey F., Ussery-Hall A., Garcia D., Et al., Centers for Disease Control and Prevention (CDC), MMWR Surveill Summ, 57, pp. 1-20, (2008); Masuo K., Ogihara T., Mechanisms in obesity-related hypertension in humans, Hypertension, 36, SUPPL. 2, (2000); Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., Koplam J.P., The spread of the obesity epidemic in the United States, 1991-1998, JAMA, 282, pp. 1519-1522, (1999); Preis S.R., Hwang S.J., Coady S., Et al., Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 23005, Circulation, 119, pp. 1728-1735, (2009); Spraul M., Ruvussin E., Fontvielle A.M., Rising R., Larson D.E., Anderson E.A., Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain, J Clin Invest, 92, pp. 1730-1735, (1993); Iwashita S., Tanida M., Terui N., Et al., Direct measurement of renal sympathetic nervous activity in high-fat rat diet related hypertensive rats, Life Sci, 71, pp. 537-546, (2002); Monroe M.B., Seals D.R., Shapiro L.F., Bell C., Johnson D., Parker-Jones P., Direct evidence for tonic sympathetic support for resting metabolic rate in healthy adult humans, Am J Physiol, 280, (2001); Blaak E.E., van Blaak M.A., Kempen K.P., Saris W.H., Role of alpha-and beta-adrenoceptors in the sympathetically mediated thermogenesis, Am J Physiol, 264, (1993); Hagstrom-Toft E., Enoksson S., Moberg E., Bolinder J., Arner P., β-adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo, Am J Physiol, (1998); Enoksson S., Talbot M., Rife F., Tamborlane W.V., Sherwin R.S., Caprio S., Impaired in vivo stimulation of lipolysis in adipose tissue by selective 2-adrenergic agonist in obese adolescent girls, Diabetes, 49, pp. 2149-2153, (2000); Masuo K., Mikami H., Ogihara T., Tuck M.L., Familial hypertension, insulin, sympathetic activity, and blood pressure elevation, Hypertension, 32, pp. 96-100, (1998); Masuo K., Mikami H., Ogihara T., Tuck M.L., Familial obesity, sympathetic activation and blood pressure level, Blood Press, 10, pp. 199-204, (2001); Cui J.M., Hopper J.L., Harrap S.B., Genes and family environment explain corrections between blood pressure and body mass index, Hypertension, 40, pp. 7-12, (2002); Masuo K., Mikami H., Ogihara T., Tuck M.L., Differences in insulin and sympathetic responses to glucose ingestion due to family history of hypertension, Am J Hypertens, 9, pp. 739-745, (1996); Pereira A.C., Floriano M.S., Mota C.F., Et al., β2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population, Hypertension, 42, pp. 685-692, (2003); Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L., β2-and β3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years, Circulation, 111, pp. 3429-3434, (2005); Masuo K., Katsuya T., Kawaguchi H., Et al., Rebound weight gain as associated with high plasma norepinephrine levels that are mediated through polymorphisms in the beta2-adrenoceptor, Am J Hypertens, 18, pp. 1508-1516, (2005); Jablonskis L.T., Howe P.R., Lack of influence of circulating adrenaline on blood pressure in normotensive and hypertensive rats, Blood Press, 3, pp. 112-119, (1994); Doda M., Role of different subtypes of adrenoceptors in pressure responses to catecholamine released from sympathetic nerve ending, Brain Res Bull, 42, pp. 51-57, (1997); Rasmussen M., Belza A., Almdal T., Et al., Change in beta1-adrenergic receptor protein concentration in adipose tissue correlates with diet-induced weight loss, Clin Sci, 108, pp. 323-329, (2005); Linne Y., Dahlman I., Hoffstat J., Beta-1 adrenoceptor gene polymorphism predict long-term changes in body weight, Int J Obes (Lond), 29, pp. 458-462, (2005); Ryden M., Hoffstedt J., Eriksson P., Bringman S., Arner P., The Arg389Gly beta1-adrenergic receptor gene polymorphism and human fat lipolysis, Int J Obes Relat Metab Disord, 25, pp. 1599-1603, (2001); Bengtsson K., Melander O., Orho Melander M., Et al., Polymorphism in the beta (1)-adrenergic receptor gene and hypertension, Circulation, 104, pp. 187-190, (2001); Humma L.M., Puckett B.J., Richardson H.E., Et al., Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia, Am J Cardiol, 88, pp. 1034-1037, (2001); Gjesing A.P., Andersen G., Albrechtsen A., Et al., Studies of associations between the Arg389Gly polymorphism of the beta1-adrenerhic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects, Diabet Med, 24, pp. 392-397, (2007); Green S.A., Turki J., Innis M., Liggett S.B., Amino-terminal polymorphisms of human 2-adrenergic receptor impart distinct agonist-promoted regulatory properties, Biochemistry, 33, pp. 9414-9419, (1994); Dishy V., Sofowora G.G., Xie H.C., The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization, N Engl J Med, 345, pp. 1030-1035, (2001); Large V., Hellstrom L., Reynisdottir S., Et al., Human beta2-adrenoceptor gene polymorphisms are highly frequent in obesity and altered adipocytes beta2-adrenoceptor function, J Clin Invest, 100, pp. 3005-3013, (1997); Granze G., Fortin J., Labugger R., Et al., β2-adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians, Hypertension, 33, pp. 1425-1430, (1999); Hoit B.D., Suresh D.P., Craft L., Walsh R.A., Liggett S.B., Beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals, Am Heart J, 139, pp. 539-542, (2000); Leineweber K., Beta-adrenergic receptor polymorphism in human cardiovascular disease, Ann Med, 36, SUPPL. 1, pp. 64-69, (2004); Bell C., Stob N.R., Seals D.R., Thermogenic responsiveness to non-specific beta-adrenergic stimulation is not related to genetic variation in codon 16 of the beta2-adrenergic receptor, Am J Physiol Endocrinol Metab, 290, (2006); Stob N.R., Bell C., van Baak M.A., Seals D.R., Thermic effect of food and beta-adrenergic thermogenic responsiveness in habitually exercise and sedentary healthy adult humans, J Appl Physiol, 26, (2007); Hayakawa T., Nagai Y., Kahara T., Et al., Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene are not associated with obesity in Japanese men, Metabolism, 49, pp. 1215-1218, (2000); Jia H., Sharma P., Hopper R., Dickerson C., Lloyd D.D., Brown M.J., Beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians, J Hypertens, 18, pp. 687-693, (2000); Xie H.G., Stein C.M., Kim R.B., Et al., Human beta2-adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans, Clin Pharmacol Ther, 67, pp. 670-675, (2000); Candy G., Samani N., Norton G., Et al., Association analysis of beta2-adrenoceptor polymorphisms with hypertension in a Black African Population, J Hypertens, 18, pp. 167-172, (2000); Cockcroft J.R., Gazis A.G., Cross D.J., Et al., β2-adrenoceptor polymorphisms determines vascular reactivity in humans, Hypertension, 36, pp. 371-375, (2000); Meirhaeghe A., Helbecque N., Cottel D., Amouyel P., Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population, Int J Obes Relat Metab Disord, 24, pp. 382-387, (2000); Kato N., Sugiyama T., Morita H., Et al., Association analysis of β2-adrenergic receptor polymorphisms with essential hypertension in Japanese, Hypertension, 37, pp. 286-292, (2001); Bengtsson K., Orho-Melander M., Melander O., Et al., β2-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes, Hypertension, 37, pp. 1303-1308, (2001); Ellsworth D.L., Coady S.A., Chen W., Et al., Influence of the beta2-adrenergic receptor Arg16Gly polymorphism on longitudinal change in obesity from childhood through young adulthood in a biracial cohort: The Bogalusa Heart Study, Int J Obes Relat Metab Disord, 26, pp. 928-937, (2002); Kim S.H., Kim D.J., Seo I.A., Et al., Significance of beta2-adrenergic receptor gene polymorphism in obesity and type 2 diabetes mellitus in Korean subjects, Metabolism, 51, pp. 833-837, (2002); Chang T.J., Tsai M.H., Jiang Y.D., Et al., The Arg16Gly polymorphism of human beta2-adrenoceptor is associated with type 2 diabetes in Taiwanese people, Clin Endoctinol (Oxf), 57, pp. 685-690, (2002); van Rossum C.T., Hoebee B., Seidell J.C., Et al., Genetic factors as predictor of weight gain in young adult Dutch men and women, Int J Obes Relat Metab Disord, 26, pp. 517-528, (2002); Garenc C., Perusse L., Chagnon Y.C., Et al., HERITAGE Family Study. Effect of beta 2-adrenergic receptor gene variants on adiposity: The HERITAGE Family Study, Obes Res, 11, pp. 612-618, (2003); Galletti F., Iacone R., Ragone E., Et al., Lack of association between polymorphism in the beta2-adrenergic receptor gene, hypertension, and obesity in the Olivetti heart study, Am J Hypertens, 17, pp. 718-720, (2004); Ikarashi T., Hanyu O., Maruyama S., Et al., Genotype Gly/Gly of Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients, Diabetes Res Clin Pract, 63, pp. 11-18, (2004); Tafel J., Branscheid I., Skwarna B., Et al., Variants in the human beta1-, beta2-, and beta3-adrenergic receptor genes are not associated with morbid obesity in children and adolescents, Diabetes Obes Metab, 6, pp. 452-456, (2004); Ellsworth D.L., Coady S.A., Chen W., Srinivasan S.R., Boerwinkle E., Berenson G.S., Interactive effects between polymorphisms in the bata-adrenergic receptors and longitudinal changes in obesity, Obes Res, 13, pp. 519-526, (2005); Trombetta I.C., Batalha L.T., Rondon M.U., Et al., Gly16+Glu27 beta2-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans, J Appl Physiol, 98, pp. 787-794, (2005); Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L., Beta2-adrenoceptor polymprphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals, Am J Hypertens, 18, pp. 1009-1014, (2005); Masuo K., Katsuya T., Kawaguchi H., Et al., β2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation, Am J Hypertens, 19, pp. 1084-1091, (2006); Kawaguchi H., Masuo K., Katsuya T., Et al., β2-and β3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals, Hypertens Res, 29, pp. 951-959, (2006); Kurabayashi T., Yahata T., Quan J., Tanaka K., Association of polymorphisms in the beta2 and beta3 adrenoceptor gene with polycystic ovary syndrome, J Reprod Med, 51, pp. 389-393, (2006); Giacobino J.P., Beta3-adrenoceptor: An update, Eur J Endocrinol, 132, pp. 377-385, (1995); Masuo K., Katsuya T., Sugimoto K., Et al., High plasma norepinephrine levels associated with beta2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals, Hypertens Res, 30, pp. 503-511, (2007); Echwald S.M., Sorensen T.I.A., Tyjerg-Hansen A., Anderson T., Pedersen O., Gln27Glu variant of the human 2-adrenoreceptor gene is not associated with early onset obesity in Danish men, Diabetes, 47, pp. 1657-1658, (1998); Hellstrom L., Large V., Reynisdotter H., Wahrenberg H., Arner P., The different effects of a Gln27Glu b2-adrenoceptor gene polymorphism on obesity in males and in females, J Intern Med, 245, pp. 253-259, (1999); Kortner B., Wolf A., Wendt D., Beisiegel U., Evans D., Lack of association between a human beta2-adrenoceptor gene polymorphism (Gln27Glu) and morbid obesity, Int J Obes Relat Metab Disord, 23, pp. 1099-1100, (1999); Kawamura T., Egusa G., Fujikawa R., Okubo M., Gln27Glu variant of the beta2-adrenergic receptor gene is not associated with obesity and diabetes in Japanese-Americans, Metabolism, 50, pp. 443-446, (2001); Ukkola O., Tremblay A., Bouchard C., Beta2-adrenergic receptor variants are associated with subcutaneous fat accumulation in response to long-term overfeeding, Int J Obes Relat Metab Disord, 25, pp. 1604-1608, (2001); Gonzalez Sanchez J.L., Proenza A.M., Martinez Larrad M.T., Et al., The glutamine 27 glutamic acid polymorphism of the 2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: A population-based study in Spain, Clin Endocrinol, 59, pp. 476-481, (2003); Gjesing A.P., Andersen G., Burgdorf K.S., Et al., Studies of the associations between functional beta (2) -adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7808 white subjects, Diabetologia, 50, pp. 563-568, (2007); Kurokawa N., Nakai K., Kameo S., Liu Z.M., Satoh H., Association of BMI with the β3-adrenergic receptor gene polymorphism in Japanese. Meta-analysis, Obes Res, 9, pp. 741-745, (2001); Aner P., the β3-adrenerhic receptor-A cause and cure of obesity?, N Engl J Med, 333, pp. 382-383, (1995); Enocksson S., Shimizu M., Lonnqvist F.J., Nordenstrom J., Arner P., Demonstration of in vivo functional β3-adrenoceptor in man, J Clin Invest, 95, pp. 2239-2245, (1995); Yang Y.T., McElligott M.A., Multiple actions of beta-adrenergic agonist on skeletal muscle and adipose tissue, Biochem J, 269, pp. 1-10, (1989); Oizumi T., Damian M., Saitoh T., Et al., Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the 3-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample, Diabetes Care, 24, pp. 1579-1583, (2001); Walston J., Silver K., Bogardus C., Time of onset of insulindependent diabetes mellitus and genetic variation in the 3-adrenergic-receptor gene, N Engl J Med, 333, pp. 343-347, (1995); Clement K., Vasse C., Manning B.S., Genetic variation in the β3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity, N Engl J Med, 333, pp. 352-354, (1995); Widen E., Lehto M., Kanninen T., Walston J., Shuldiner A.R., Groop L.C., Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns, N Engl J Med, 333, pp. 348-351, (1995); Fujisawa T., Ikegami H., Yamato E., Et al., Association of Trp64Arg mutation of the 3-adrenergic receptor with NIDDM and body weight gain, Diabetologia, 39, pp. 349-352, (1996); Silver K., Walston J., Wang Y., Dowse G., Zimmet P., Shuldiner A.R., Molecular scanning for mutations in the beta3-adrenergic receptor gene in Nauruans with obesity and noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 81, pp. 4155-4158, (1996); Fujisawa T., Ikegami H., Yamato E., Et al., Trp64Arg mutation of beta3-adrenergic receptor in essential hypertension: Insulin resistance and the adrenergic system, Am J Hypertens, 10, pp. 101-105, (1997); Sakane N., Yoshida T., Umekawa T., Kondo M., Sakai Y., Takahashi T., Beta3-adrenergic receptor polymorphisms: A genetic marker for visceral fat obesity and the insulin resistant syndrome, Diabetologia, 40, pp. 200-204, (1997); Rissanen J., Koupusjarvi J., Pihlamaki J., Et al., The Trp64Arg polymorphism of the beta3-adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome, Diabetes Care, 20, pp. 1319-1323, (1997); MacFarlane-Anderson N., Bennett F., Wilks R., Et al., The trp64Arg mutation of the beta3-adrenergic receptor is associated with hyperglycemia and current body mass index in Jamaican women, Metabolism, 47, pp. 617-621, (1998); Garcia-Rubi E., Starling R.D., Tchernof A., Et al., Trp64Arg variant of the beta3-adrenoceptor polymorphism and insulin resistance in obese postmenopausal women, J Clin Endocrinol Metab, 83, pp. 4002-4005, (1998); Janssen J.A., Koper J.W., Stolk R.P., Et al., Lack of associations between serum leptin, a polymorphism in the gene for the beta3-adrenergic receptor and glucose tolerance in the Dutch population, Clin Endocrinol, 49, pp. 229-234, (1998); Shiwaku K., Gao T.Q., Isobe A., Fukushima T., Yamane Y., A Trp64Arg mutation in the 3-adrenergic receptor gene is not associated with moderate overweight in Japanese workers, Metabolism, 47, pp. 1528-1530, (1998); Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S., Et al., Relationship of beta3-adrenergic receptor gene mutation to total body fat but not percent body fat and insulin levels in Thais, Metabolism, 48, pp. 564-567, (1999); Pulkkinen A., Kareinen A., Saarinen L., Heikkinen S., Lehto S., Laakso M., The codon 64 polymorphism of the beta 3-adrenergic receptor gene is not associated with coronary heart disease or insulin resistance in nondiabetic subjects and non-insulin-dependent diabetic patients, Metabolism, 48, pp. 853-856, (1999); Christiansen C., Poulsen P., Beck-Nielsen H., The Trp64Arg mutation of the adrenergic beta-3 receptor gene impairs insulin secretion: A twin study, Diabet Med, 16, pp. 835-840, (1999); Stangl K., Cascorbi I., Laule M., Et al., The beta3-adrenergic receptor Trp64Arg is not associated with coronary artery disease, Metabolism, 50, pp. 184-188, (2001); Strazzulo P., Iacone R., Siani A., Et al., Relationship of the Trp64Arg polymorphism of the beta 3-adrenoceptor gene to central adiposity and high blood pressure: Interaction with age. Cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study, J Hypertens, 19, pp. 399-406, (2001); Ishii T., Hirose H., Kawai T., Et al., Effects of intestinal fatty acid-binding protein gene Ala54Thr polymorphism and beta3-adrenergic receptor gene Trp64Arg polymorphism on insulin resistance and fasting plasma glucose in young to older Japanese men, Metabolism, 50, pp. 1301-1307, (2001); Ochoa M.C., Marti A., Azcona C., Groupo de Estudio Navarro de Obesidad Infantil (GENOI). Gene-gene interaction between PPRA gamma 2 and ADR beta 3 increases obesity risk in children and adolescents, Int J Obes Relat Metab Disord, 28, SUPPL. 3, (2004); Porto P.I., Garcia S.I., Dieuzeide G., Gonzalez C., Landa M.S., Pirola C.J., Clinical features of the metabolic syndrome in adolescents: Minor role of the Trp64Arg beta3-adrenergic receptor gene variant, Pediatr Res, 55, pp. 836-841, (2004); Tsai P.J., Ho S.C., Tsai L.P., Et al., Lack of relationship between beta3-adrenergic receptor gene polymorphism and gestational diabetes mellitus in Taiwanese population, Metabolism, 53, pp. 1136-1139, (2004); Hojlund K., Christiansen C., Bjorrnsbo K.S., Et al., Energy expenditure, body composition and insulin response to glucose in male twins discordant for the Trp64Arg polymorphism of the beta 3-adrenergic receptor gene, Diabetes Obes Metab, 8, pp. 322-330, (2006); Tamai S., Nakamura Y., Tabara Y., Relationship between metabolic syndrome and Trp64Arg polymorphism of beta-adrenergic receptor gene in a general sample: The Shigaraki study, Hypertens Res, 29, pp. 891-896, (2006); Morcillo S., Cardona F., Rojo-Martinez G., Effect of the combination of the variant-75G/A APOA 1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2), Clin Endocrionol, 68, pp. 102-107, (2008); Gjesing A.P., Andersen G., Borch-Johnsen K., Jorgensen T., Hansen T., Pedersen O., Association of the beta3-adrenergic receptor Trp64Arg polymorphism with common metabolic traits: Studies of 7065 middle-aged white people, Mol Genet Metab, 94, pp. 90-97, (2008); Dunajska K., Lwow F., Milewicz A., Et al., Beta 3-adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women, Gynecol Endocrinol, 24, pp. 133-138, (2008); Kawaguchi H., Masuo K., Katsuya T., Beta2-and beta3-adrenoceptor polymorphisms relates to subsequent weight gain and blood pressure elevation in obese normotensive individuals, Hypertens Res, 29, pp. 951-959, (2006); Maxwell T.J., Ameyaw M.M., Pritchard S., Beta2-adrenergic receptor genotypes and haplotypes in different ethnic groups, Int J Mol Med, 16, pp. 573-580, (2005); Hoffstedt J., Poirier O., Throne A., Polymorphism of the human 3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function, Diabetes, 48, pp. 203-205, (1999); Sandilands A., Yeo G., Brown M.J., O'Shaughnessy K.M., Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms, Pharmaco-genetics, 14, pp. 343-349, (2004); Tomazewski M., Brain N.J.R., Charchar F.J., Essential hypertension and 2-adrenergic receptor gene. Linkage and association analysis, Hypertension, 40, pp. 286-291, (2002); Esler M., Straznicky N., Eikelis N., Masuo K., Lambert G., Lambert E., Mechanisms of sympathetic activation in obesity-related hypertension, Hypertension, 48, pp. 787-796, (2006); Masuo K., Mikami H., Ogihara T., Tuck M.L., Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population, Am J Hypertens, 10, pp. 77-83, (1997); Arnlov J., Evans J.C., Meigs J.B., Et al., Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals. The Framingham Heart Study, Circulation, 112, pp. 969-975, (2005); Zoccali C., Mallamaci F., Parlongo S., Et al., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease, Circulation, 105, pp. 1354-1359, (2002); Masuo K., Katsuya T., Sugimoto K., Et al., High plasma norepinephrine levels associated with 2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals, Hypertens Res, 30, 6, pp. 503-511, (2007); Masuo K., Katsuya T., Sugimoto K., Rakugi H., Ogihara T., Tuck M.L., Beta1 (Arg389Gly, Ser49Gly)-and beta2 (Arg16Gly)-adrenoceptor polymorphisms are related to left ventricular hypertrophy in middle-aged, nonobese, normotensive men, but through different mechanisms, Circulation, 118, SUPPL. 2, (2008); Yuan M., Ohishi M., Ito N., Et al., Genetic influences of beta-adrenoceptor polymorphisms on arterial functional changes and cardiac remodeling in hypertensive patients, Hypertens Res, 29, pp. 875-881, (2006); Lohse M.J., Beta-adrenoceptor polymorphisms and heart failure, Trends Mol Med, 10, pp. 55-58, (2004); Sehnert A.J., Daniels S.E., Elashoff M., Et al., Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol, J Am Coll Cardiol, 52, pp. 644-651, (2008); Schelleman H., Stricker B.H., de Boer A., Et al., Drug-gene interactions between polymorphisms and antihypertensive therapy, Drugs, 64, pp. 1801-1816, (2004)","K. Masuo; Nucleus Network Ltd., Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Research Institute, Melbourne, VIC 3004, 89 Commercial Road, Australia; email: kmasuo@bakeridi.edu.au","","","","","","","","15734021","","","","English","Curr. Hypertens. Rev.","Article","Final","","Scopus","2-s2.0-77952495856"
"Turner S.T.; Schwartz G.L.; Chapman A.B.; Hall W.D.; Boerwinkle E.","Turner, Stephen T. (7402275413); Schwartz, Gary L. (7403155162); Chapman, Arlene B. (7201567844); Hall, W. Dallas (56463147700); Boerwinkle, Eric (7102087489)","7402275413; 7403155162; 7201567844; 56463147700; 7102087489","Antihypertensive pharmacogenetics: Getting the right drug into the right patient","2001","Journal of Hypertension","19","1","","1","11","10","66","10.1097/00004872-200101000-00001","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035142270&doi=10.1097%2f00004872-200101000-00001&partnerID=40&md5=3880fa95f2ea8000363bbafac1fe2f64","Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States; Renal Division, Emory University, Atlanta, GA, United States; Human Genetics Center, Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, TX, United States; Division of Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First Street SW, United States","Turner S.T., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States, Renal Division, Emory University, Atlanta, GA, United States, Human Genetics Center, Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, TX, United States, Division of Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First Street SW, United States; Schwartz G.L., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States, Renal Division, Emory University, Atlanta, GA, United States, Human Genetics Center, Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, TX, United States; Chapman A.B., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States, Renal Division, Emory University, Atlanta, GA, United States, Human Genetics Center, Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, TX, United States; Hall W.D., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States, Renal Division, Emory University, Atlanta, GA, United States, Human Genetics Center, Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, TX, United States; Boerwinkle E., Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, United States, Renal Division, Emory University, Atlanta, GA, United States, Human Genetics Center, Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, TX, United States","Pharmacogenetic investigation seeks to identify genetic factors that contribute to interpatient and interdrug variation in responses to antihypertensive drug therapy. Classical studies have characterized single gene polymorphisms of drug metabolizing enzymes that are responsible for large interindividual differences in pharmacokinetic responses to several antihypertensive drugs. Progress is being made using candidate gene and genome scanning approaches to identify and characterize many additional genes influencing pharmacodynamic mechanisms that contribute to interindividual differences in responses to antihypertensive drug therapy. Knowledge of polymorphic variation in these genes will help to predict individual patients' blood pressure responses to antihypertensive drug therapy and may also provide new insights into molecular mechanisms responsible for elevation of blood pressure. © 2001 Lippincott Williams & Wilkins.","Blood pressure; Genetics; Hypertension; Pharmacology","acyltransferase; adducin; alprenolol; angiotensin 2 receptor; angiotensinogen; antiarrhythmic agent; antidepressant agent; antihypertensive agent; beta adrenergic receptor blocking agent; bufuralol; calcium channel blocking agent; catechol methyltransferase; cytochrome P450; cytochrome P450 2D6; dihydropyridine; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; drug metabolizing enzyme; encainide; flecainide; guanine nucleotide binding protein; hydralazine; methyldopa; metoprolol; mexiletine; phenylephrine; propranolol; thiazide diuretic agent; timolol; unindexed drug; antihypertensive therapy; blood pressure; DNA polymorphism; drug metabolism; drug response; genetic variability; genome; human; hypertension; pharmacodynamics; pharmacogenetics; priority journal; review","","acyltransferase, 9012-30-0, 9054-54-0; alprenolol, 13655-52-2, 13707-88-5, 39405-98-6, 58615-82-0; angiotensinogen, 11002-13-4, 64315-16-8; bufuralol, 54340-62-4; catechol methyltransferase, 9012-25-3; cytochrome P450, 9035-51-2; dihydropyridine, 27790-75-6; dipeptidyl carboxypeptidase, 9015-82-1; encainide, 66778-36-7; flecainide, 54143-55-4; hydralazine, 304-20-1, 86-54-4; methyldopa, 555-29-3, 555-30-6; metoprolol, 37350-58-6; mexiletine, 31828-71-4, 5370-01-4; phenylephrine, 532-38-7, 59-42-7, 61-76-7; propranolol, 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; timolol, 26839-75-8","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL053330)","","Motulsky A., Drug reactions, enzymes and biochemical genetics, J Am Med Assoc, 165, pp. 835-837, (1957); Vogel F., Moderne probleme der humangenetik, Ergebn Inn Med Kinderheilk, 12, pp. 52-125, (1959); Meyer U., Drugs in special patient groups: Clinical importance of genetics in drug effects, pp. 875-894, (1992); Collins F., Shattuck lecture - Medical and societal consequences of the human genome project, N Engl J Med, 341, pp. 28-37, (1999); Jeunemaitre X., Lifton R., Hunt S., Williams R., Lalouel J., Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension, Nature Genet, 1, pp. 72-75, (1992); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Et al., Polymorphisms of a-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Siftert W., Rosskopf D., Siftert G., Busch S., Moritz A., Erbel R., Et al., Association of a human G-protein B3 subunit variant with hypertension, Nature Genet, 18, pp. 45-48, (1998); Krushkal J., Xiong M., Ferrell R., Sing C.F., Turner S.T., Boerwinkle E., Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation, Hum Mol Genet, 7, pp. 1379-1383, (1998); Murphy E., One cause? Many causes? The argument from the bimodal distribution, J Chron Dis, 17, pp. 301-324, (1964); Guyton A., Hall J., Lohmeier T., Jackson T., Kastner P., Blood pressure regulation: Basic concepts, Fed Proc, 40, pp. 2252-2256, (1981); Gifford R., Evaluation of the hypertensive patient with emphasis on detecting curable causes, Milbank Memorial Fund Q, 47, pp. 170-186, (1969); Rudnick K., Sackett D., Hirst S., Holmes C., Hypertension in a family practice, Can Med Assoc J, 117, pp. 492-497, (1977); Sinclair A., Isles C., Brown I., Secondary hypertension in a blood pressure clinic, Arch Intern Med, 147, pp. 1289-1293, (1987); Materson B., Reda D., Cushman W., Massie B., Freis E., Kochar M., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo, New Engl J Med, 328, pp. 914-921, (1993); Materson B., Reda D., Cushman W., Department of veterans affairs single drug therapy of hypertension study. Revised figures and new data, Am J Hypertens, 8, pp. 189-192, (1995); Attwood S., Bird R., Burch K., Casadei B., Coats A., Conway J., Et al., Within-patient correlation between the antihypertensive effects of atenolol, lisinopril, and nifedipine, J Hypertens, 12, pp. 1053-1060, (1994); Bidiville J., Nussberger J., Waeber G., Porchet M., Waeber B., Brunner H., Individual responses to converting enzyme inhibitors and calcium antagonists, Hypertension, 11, pp. 166-173, (1988); The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies, Arch Intern Med, 151, pp. 1413-1423, (1991); Niutta E., Cusi D., Colombo R., Pellizzoni M., Cesana B., Barlassina C., Et al., Predicting interindividual variations in antihypertensive therapy: The role of sodium transport systems and renin, J Hypertens, 8, (1990); Edmonds D., Huss R., Jeck T., Mengden T., Schubert M., Vetter W., Individualizing antihypertensive therapy with enalapril versus atenolol: The Zurich experience, J Hypertens, 8, (1990); Waeber G., Beck G., Waeber B., Bidiville J., Nussberger J., Brunner H., Comparison of betaxolol with verapamil in hypertensive patients: Discrepancy between office and ambulatory blood pressures, J Hypertens, 6, pp. 239-245, (1988); Double blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents; preliminary results, Arch Intern Med, 110, pp. 230-236, (1962); Materson B., Reda D., Preston R., Cushman W., Massie B., Freis E., Et al., Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug, Arch Intern Med, 155, pp. 1757-1762, (1995); Dickerson J., Hingorani A., Ashby M., Palmer C., Brown M., Optimization of antihypertensive treatment by crossover rotation of four major classes, Lancet, 353, pp. 2008-2013, (1999); Weder A., Julius S., Pathophysiology of hypertension and treatment, pp. 861-883, (1994); Gill J., Beevers D., Zezulka A., Davies P., Relation between initial blood pressure and its fall with treatment, Lancet, 1, pp. 567-569, (1985); Sumner D., Meredith P., Howie C., Elliott H., Initial blood pressure as a predictor of the response to antihypertensive therapy, Br J Clin Pharmacol, 26, (1988); Hall W., Pharmacologic therapy of hypertension in blacks, J Clin Hypertens, 3, (1987); Jamerson K., DeQuattro V., The impact of ethnicity on response to antihypertensive therapy, Am J Med, 101, (1996); Seedat Y., Varying responses to hypotensive agents in different racial groups: Black versus white differences, J Hypertens, 7, pp. 515-518, (1989); Kaplan N., Critical comments on recent literature. Age and the response to antihypertensive drugs, Am J Hypertens, 2, pp. 213-215, (1989); Robertson J., Comparative studies in hypertension: Some fallacious claims of age-related drug efficacy, J Hypertens, 8, (1990); Vez L., La Vecchia L., Vincenzi M., Hypertension, obesity and response to antihypertensive treatment: Results of a community survey, J Hum Hypertens, 6, pp. 215-220, (1992); Hayes S., Taler S., Hypertension in women: Current understanding of gender differences, Mayo Clin Proc, 73, pp. 157-165, (1998); Laragh J., Lamport B., Sealey J., Alderman M., Diagnosis Ex Juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Blumenfeld J., Laragh J., Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension, Am J Hypertens, 11, pp. 894-896, (1998); Buhler F., Bolli P., Kiowski W., Erne P., Hulthen U., Block L., Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients, Am J Med, 77, pp. 36-42, (1984); Preston R., Materson B., Reda D., Williams D., Hamburger R., Cushman W., Et al., Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy, JAMA, 280, pp. 1168-1172, (1998); Freis E., Materson B., Flamenbaum W., Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system, Am J Med, 74, pp. 1029-1041, (1983); The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, Arch Intern Med, 157, pp. 2413-2446, (1997); Weber W., Pharmacogenetics, (1997); Gonzalez F., Skoda R., Kimura S., Umeno M., Zanger U., Nebert D., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature, 331, pp. 442-446, (1988); Mahgoub A., Idle J., Dring L., Lancaster R., Smith R., Polymorphic hydroxylation of debrisoquine in man, Lancet, 2, pp. 584-586, (1977); Eichelbaum M., Spannbrucker N., Steincke B., Dengler H., Defective N-oxidation of sparteine in man: A new pharmacogenetic defect, Eur J Clin Pharmacol, 16, pp. 183-187, (1979); Daly A., Brockmoller J., Broly F., Eichelbaum M., Evans W., Gonzalez F., Et al., Nomenclature for human CYP2D6 alleles, Pharmacogenetics, 6, pp. 193-201, (1996); Broly F., Gaedigk A., Helm M., Eichelbaum M., Mariko K., Meyer U., Debrisoquine hydroxylase genotype and phenotype, DNA Cell Biol, 10, pp. 545-558, (1991); Dahl M., Johansson I., Palmertz M.P., Ingelman-Sundberg M., Sjoqvist F., Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population, Clin Pharmacol Ther, 52, pp. 12-17, (1992); Kalow W., Otton S., Kadar D., Endrenyi L., Inaba T., Ethnic difference in drug metabolism: Debrisoquine 4-hydroxylation in caucasians and orientals, Can J Physiol Pharmacol, 58, pp. 1142-1144, (1980); Johansson I., Lundqvist E., Bertilsson I., Dahl M., Sjoqvist F., Ingelman-Sundberg M., Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc Natl Acad Sci, 90, pp. 11825-11829, (1993); Alvan G., Von Bahr C., Seidman P., Sjoqvist F., High plasma concentrations of B-receptor blocking drugs and deficient debrisoquine hydroxylation, Lancet, 1, (1982); Lennard M., Silas J., Freestone S., Ramsay L., Tucker G., Woods H., Oxidation phenotype - A major determinant of metoprolol metabolism and response, N Engl J Med, 307, pp. 1558-1560, (1982); Lennard M., Silas J., Freestone S., Trevethick J., Defective metabolism of metoprolol in poor hydroxylators of debrisoquine, Br J Clin Pharmacol, 14, pp. 301-303, (1982); Shah R., Oates N., Idle J., Smith R., Beta-blockers and drug oxidation status, Lancet, 1, pp. 508-509, (1982); Dayer P., Balant L., Kupfer A., Courvoisier F., Fabre J., Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents, Eur J Clin Pharmacol, 24, pp. 797-799, (1983); Silas J., Freestone S., Lennard M., Ramsay L., Chronic dosing comparison of three formulations of metoprolol and atenolol in hypertensive patients, Br J Clin Pharmacol, 18, (1984); Buchert E., Woosley R., Clinical implications of variable anti-arrhythmic drug metabolism, Pharmacogenetics, 2, pp. 2-11, (1992); Broly F., Marez D., Sabbagh N., Legrand M., Millecamps S., Lo Guidice J., Et al., An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis, Pharmacogenetics, 5, pp. 373-384, (1995); Linder M., Prough R., Valdes R., Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency, Clin Chem, 43, pp. 254-266, (1997); Franke S., Klawitz I., Schnakenberg E., Rommel B., Van der Wen W., Bullerdick J., Et al., Isolation and mapping of a cosmid clone containing the human NAT2 gene, Biochem Biophys Res Commun, 199, pp. 52-55, (1994); Hickman D., Risch A., Buckie V., Spurr N., Jeremiah S., McCarthy A., Et al., Chromosomal localization of human genes for arylamine N-acetyltransferase, Biochem J, 297, pp. 441-445, (1994); Knight R., Selin M., Harris H., Genetic factors influencing isoniazid blood levels in humans, Trans Conf Chemother Tubercul, 8, pp. 52-56, (1959); Dufour A., Knight R., Harris H., Genetics of isoniazid metabolism in Caucasians, Negro, and Japanese populations, Science, 145, (1964); Karim A., Elfellah M., Evans D., Human acetylator polymorphism: Estimates of allele frequency in Libya and details of global distribution, J Med Genet, 18, pp. 325-333, (1981); Sunahara S., Motoyuki U., Ogawa M., Genetical and geographic studies on isoniazid inactivation, Science, 134, (1961); Sunahara S., Utano M., Lin H., Cheg T., Jarumalinda A., Further observations on trimodality of frequency distribution curve of biologically active isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation, Acta Tuberc Scand, 43, pp. 143-206, (1963); Zacest R., Koch-Weser J., Relation of hydralazine plasma concentration to dosage and hypotensive action, Clin Pharmacol Ther, 13, pp. 420-425, (1972); Jounela A., Pasanen M., Mattila M., Acetylator phenotype and the antihypertensive response to hydralazine, Acta Med Scand, 197, pp. 303-306, (1975); Shepherd A., McNay J., Ludden T., Lin M., Musgrave G., Plasma concentration and acetylator phenotype determine response to oral hydralazine, Hypertension, 3, pp. 580-585, (1981); Perry H., Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis, Am J Med, 54, pp. 58-72, (1973); Uetrecht J., Woosley R., Acetylator phenotype and lupus erythematosus, Clin Pharmacokinet, 6, pp. 118-134, (1981); Batchelor J., Welsh K., Tinoco R., Dollery C., Hughes G., Bernstein R., Et al., Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility, Lancet, 1, pp. 1107-1109, (1980); Weinshilboum R., Raymond F., Inheritance of low erythrocyte catechol-o-methyltransferase activity in man, Am J Hum Genet, 29, pp. 125-135, (1977); Weinshilboum R., Methyltransferase pharmacogenetics, Pharmacol Ther, 43, pp. 77-90, (1989); Weinshilboum R., Otterness D., Szumlanski C., Methylation pharmacogenetics: Catechol-o-methyltransferase, thiopurine methyltransferase, and histamine n-methyltransferase, Ann Rev Pharmacol Toxicol, 39, pp. 19-52, (1999); Campbell N., Dunnette J., Mwaluko G., Van Loon J., Weinshilboum R., Platelet phenol sulfotransferase and erythrocyte catechol-o-methyltransferase activities: Correlation with methyldopa metabolism, Clin Pharmacol Ther, 35, pp. 55-63, (1984); Campbell N., Sundaram, Werness P., Van Loon J., Weinshilboum R., Sulfate and methyldopa metabolism: Metabolite patterns and platelet phenol sulfotransferase activity, Clin Pharmacol Ther, 37, pp. 308-315, (1985); Grossman M., Littrell J., Weinstein R., Szumlanski C., Weinshilboum R., Identification of the possible molecular basis for inherited differences in human catechol-O-methyltransferase, Neurosci Soc, 18, (1992); Lachman H., Papolos D., Saito T., Yu Y., Szumlanski C., Human catechol O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders, Pharmacogenetics, 6, pp. 243-250, (1996); Spielman R., Weinshilboum R., Genetics of red cell COMT activity: Analysis of thermal stability and family data, Am J Med Genet, 10, pp. 279-290, (1981); SoRelle R., Withdrawal of posicor from market, Circulation, 98, pp. 831-832, (1998); Guengerich F., In vitro techniques for studying drug metabolism, J Pharmacokinet Biopharm, 24, pp. 521-533, (1996); Kalow W., Pharmacogenetics: Its biologic roots and the medical challenge, Clin Pharmacol Ther, 54, pp. 235-241, (1993); Kaplan N., Treatment of hypertension: Drug therapy, pp. 181-264, (1998); Israili Z., Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man, Ann Rev Pharmacol Toxicol, 19, pp. 25-52, (1979); Von Bahr C., Collste P., Frisk-Holmberg M., Haglund K., Jorfelt L., Orme M., Et al., Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension, Clin Pharmacol Ther, 20, pp. 130-137, (1976); Beermann B., Groschinsky-Grind M., Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug, Europ J Clin Pharmacol, 13, pp. 195-201, (1978); Hall W., Reed J., Flack J., Yunis C., Preisser J., Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension, Arch Intern Med, 158, pp. 2029-2034, (1998); Zusman R., Are there differences among angiotensin receptor blockers?, Am J Hypertens, 12, (1999); Burnier M., Brunner H., Comparative antihypertensive effects of angiotensin II receptor antagonists, J Am Soc Nephrol, 10, (1999); Wahl J., Turlapaty P., Bramah N., Phil D., Comparison of acebutolol and propranolol in essential hypertension, Am Heart J, 109, (1985); Leonetti G., Cuspidi C., Choosing the right ACE inhibitor. A guide to selection, Drugs, 49, pp. 516-535, (1995); Fletcher A., Franks P., Bulpitt C., The effect of withdrawing antihypertensive therapy: A review, J Hypertens, 6, pp. 431-436, (1988); Ekbom T., Lindholm L., Oden A., Dahlof B., Hansson L., Wester P., Et al., A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people, J Intern Med, 235, pp. 581-588, (1994); Bianchi G., Swales J., Do we need more anti-hypertensive drugs: Lessons from the new biology, Lancet, 345, pp. 1555-1557, (1995); Ferrari P., Pharmacogenomics: A new approach to individual therapy of hypertension?, Curr Opin Nephrol Hypertens, 7, pp. 217-222, (1998); Bianchi G., Tripodi G., Casari G., Salardi S., Barber B., Garcia R., Et al., Two point mutations within the adducin gene are involved in blood pressure variation, Proc Natl Acad Sci, 91, pp. 3999-4003, (1994); Tripodi G., Valtorta F., Torielli L., Chieregatti E., Salardi S., Trusolino S., Et al., Hypertension-association point mutations in the adducin a and B subunits affect actin cytoskeleton and ion transport, J Clin Invest, 97, pp. 2815-2822, (1996); Manunta P., Barlassin C., Bianchi G., Adducin in essential hypertension, FEBS Lett, 430, pp. 41-44, (1998); Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., Et al., The role of a-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, pp. 649-654, (1999); Pecker M., Pathophysiologic effects and strategies for long-term diuretic treatment of hypertension, pp. 2143-2167, (1990); Muntzel M., Drueke T., A comprehensive review of the salt and blood pressure relationship, Am J Hypertens, 5, (1992); Cody R., Laragh J., Case D., Atlas S., Renin system activity as a determinant of response to treatment in hypertension and heart failure, Hypertension, 5, SUPPL. III, pp. 36-42, (1983); Gavras H., Brunner H., Laragh J., Sealey J., Gavras I., Vukovich R., An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients, N Engl J Med, 291, (1974); Bloem L., Manatunga A., Tewksbury D., Pratt J., The serum angiotensin concentration and variants of the angiotensinogen gene in white and black children, J Clin Invest, 95, pp. 948-953, (1995); Inoue I., Nakajima T., Williams C., Quackenbush J., Puryear R., Powers M., Et al., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, pp. 1786-1797, (1997); Zhao Y., Zhou J., Narayanan C., Cui Y., Kumar A., Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene Hypertension, 33, pp. 108-115, (1999); Rigat B., Hubert C., Alhenc-Gelas F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, pp. 1343-1346, (1990); White P., Inherited forms of mineralocorticoid hypertension, Hypertension, 28, pp. 927-936, (1996); Hunt S., Cook N., Oberman A., Cutler J., Hennekens C., Allender P., Et al., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Trials of hypertension prevention, phase II, Hypertension, 32, pp. 393-401, (1998); Hunt S., Geleijnse J., Wu L., Witteman J., Williams R., Grobbee D., Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene, Am J Hypertens, 12, pp. 460-466, (1999); Hiraga H., Oshima T., Watanabe M., Ishida M., Ishida T., Shingu T., Et al., Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension, Hypertension, 27, pp. 569-572, (1996); Schorr U., Blaschke K., Beige J., Distler A., Sharma A., Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians, J Hypertens, 17, pp. 475-479, (1999); Kojima S., Inenaga T., Matsuoka H., Kuramochi M., Omae T., Nara Y., Et al., The association between salt sensitivity of blood pressure and some polymorphic factors, J Hypertens, 12, pp. 797-801, (1994); Hingorani A., Jia H., Stevens P., Hopper R., Claire Dickerson J., Brown M., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, pp. 1602-1609, (1995); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J Hypertens, 14, pp. 259-262, (1996); Sasaki M., Oki T., Iuchi A., Tabata T., Yamada H., Manabe K., Et al., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies, J Hypertens, 14, pp. 1403-1408, (1996); Moriyama T., Kitamura H., Ochi S., Izumi M., Yokoyama K., Yamauchi A., Et al., Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria, J Am Soc Nephrol, 6, pp. 1674-1678, (1995); Jia H., Hingorani A., Sharma P., Hopper R., Dickerson C., Trutwein D., Et al., Association of the G<sub>s</sub> gene with essential hypertension and response to B-blockade, Hypertension, 34, pp. 8-14, (1999); Furuya K., Yamaguchi E., Hirabayashi T., Itoh A., Hizawa N., Ohnuma N., Et al., Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough, Lancet, (1994); Zee R., Rao V., Paster R., Sweet C., Lindpaintner K., Three candidate genes and angiotensin-converting enzyme inhibitor-related cough, Hypertension, 31, pp. 925-928, (1998); Todd G., Chadwick I., Higgins K., Yeo W., Jackson P., Ramsay L., Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects, Br J Clin Pharmacol, 39, pp. 131-134, (1995); Nakano Y., Oshima T., Watanabe M., Matsuura H., Kajiyama G., Kambe M., Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension, Am J Hypertens, 10, pp. 1064-1068, (1997); Dieguez-Lucena J., Aranda-Lara P., Ruiz-Galdon M., Garcia-Villanova J., Morrel-Ocana M., Reyes-Engel A., Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy, Hypertension, 28, pp. 98-103, (1996); Mizuiri S., Hemmi H., Inoue A., Takano M., Kadomatsu S., Tanimoto H., Et al., Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism, Nephron, 75, pp. 310-314, (1997); Yoshida H., Mitarai T., Kawamura T., Kitajima T., Miyazaki Y., Nagasawa R., Et al., Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy, J Clin Invest, 96, pp. 2162-2169, (1995); Haas M., Yilmaz N., Schmidt A., Neyer U., Arneitz K., Stummvoll H., Et al., Angiotensin-converting enzyme gene polymorphism determines the anti-proteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease, Kidney Blood Press Res, 21, pp. 66-69, (1998); Van der Kleij F., Navis G., Gansevoort R., Heeg J., Scheffer H., De Zeeuw D., Et al., ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients, Nephrol Dial Transplant, 12, pp. 42-46, (1997); Van der Kleij F., Schmidt A., Navis G., Haas M., Yilmaz N., De Jong P., Et al., Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status, Kidney Int, 53, (1998); Cannella G., Paoletti E., Barocci S., Massarino F., Delfino R., Ravera G., Et al., Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy, Kidney Int, 54, pp. 618-626, (1998); Van Essen G., Rensma P., De Zeeuw D., Sluiter W., Scheffer H., Apperloo A., Et al., Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy, Lancet, 347, pp. 94-95, (1996); Henrion D., Amant C., Benessiano J., Philip I., Plantefeve G., Chatel D., Et al., Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro, J Vasc Res, 35, pp. 356-362, (1998); Benetos A., Cambien F., Gautier S., Ricard S., Safar M., Laurent S., Et al., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, pp. 1081-1084, (1996); Collins F., Positional cloning: Let's not call it reverse anymore, Nature Genet, 1, pp. 3-6, (1992); Collins F., Positional cloning moves from perditional to traditional, Nature Genet, 9, pp. 347-350, (1995); Hearne C., Ghosh S., Todd J., Microsatellites for linkage analysis of genetic traits, Trends Genet, 8, pp. 288-294, (1992); Vincent M., Samani N., Gauguier D., Thompson J., Lathrop G., Sassard J., A pharmacogenetic approach to blood pressure in Lyon hypertensive rats, J Clin Invest, 100, pp. 2000-2006, (1997); Resnick L., Ionic disturbances of calcium and magnesium metabolism in essential hypertension, pp. 1169-1193, (1995); Fields C., Adams M., White O., Venter J., How many genes in the human genome?, Nature Genet, 7, pp. 345-346, (1994); Collins F., Guyer M., Chakravarti A., Variations on a theme: Cataloging human DNA sequence variation, Science, 278, pp. 1580-1581, (1997); Wang D., Fan J., Siao C., Berno A., Young P., Sapolsky R., Et al., Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome, Science, 280, pp. 1077-1082, (1998); Kruglyak L., The use of a genetic map of biallelic markers in linkage studies, Nature Genet, 17, pp. 21-24, (1997); Risch N., Merikangas K., The future of genetic studies of complex human diseases, Science, 273, pp. 1516-1517, (1996); Persidis A., Biochips: An evolving clinical technology, Hosp Pract, 34, pp. 67-85, (1999); Graves D., Powerful tools for genetic analysis come of age, Trends Biotechnol, 17, pp. 127-134, (1999); Wilgenbus K., Lichter P., DNA chip technology ante portas, J Mol Med, 77, pp. 761-768, (1999); Lyall A., Bioinformatics in the pharmaceutical industry, Trends Biotechnol, 14, pp. 308-312, (1996); Schork N., Weder A., The use of genetic information in large-scale clinical trials: Applications of alzheimer research, Alzheimer Dis Assoc Disord, 10, pp. 22-26, (1996); Ruano G., Stephens J., Genetics and the drug response, Genet Eng, (1999); Dutton G., Computational genomics: Medicine of the future?, Ann Inter Med, 131, pp. 801-804, (1999); Persidis A., Biotechnologies to watch. Which technologies promise to make significant contributions to biotechnology's drug pipeline?, Nat Biotechnol, 15, (1997); Persidis A., The business of pharmacogenomics. Considered the heir apparent to functional genomics, pharmacogenomics promises to redefine basic notions of what constitutes a disease, Nature Biotechnol, 16, pp. 209-210, (1998); Dorey E., Millenium exploits retained right with new venture, Nature Biotechnol, 15, (1997); Marshall A., Phase II results in rheumatoid arthritis encouraging for Immunex, Nature Biotechnol, 15, pp. 829-830, (1997); Peyser P., Genetic epidemiology of coronary artery disease, Epidemiol Rev, 19, pp. 80-90, (1997); Boerwinkle E., Doris P., Fornage M., Field of needs. The genetics of stroke, Circulation, 99, pp. 331-333, (1999); Broeckel U., Shiozawa M., Kissebah A., Provoost A., Jacob H., Susceptibility genes for end-organ damage. New strategies to understand diabetic and hypertensive nephropathy, Nephrol Dial Transplant, 13, pp. 840-842, (1998); Grahame-Smith D., How will knowledge of the human genome affect drug therapy?, Br J Clin Pharmacol, 47, pp. 7-10, (1999); Wiley S., Genomics in the real world, Curr Pharm Design, 4, pp. 417-422, (1998); Stephenson J., Human genome studies expected to revolutionize cancer classification, JAMA, 282, pp. 927-928, (1999); Lichter J., Kurth J., The impact of pharmacogenetics on the future of healthcare, Curr Opin Biotechnol, 8, pp. 692-695, (1997); Evans W., Relling M., Pharmacogenomics: Translating functional genomics into rational therapeutics, Science, 286, pp. 487-491, (1999)","S.T. Turner; Division of Hypertension, Mayo Clinic, Rochester, MN 55905, 200 First Street SW, United States; email: turner.stephen@mayo.edu","","Lippincott Williams and Wilkins","","","","","","02636352","","JOHYD","11204288","English","J. Hypertens.","Review","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-0035142270"
"Wang Y.-X.J.; Ulu A.; Zhang L.-N.; Hammock B.","Wang, Yi-Xin Jim (34973563700); Ulu, Arzu (12545859000); Zhang, Le-Ning (8368755300); Hammock, Bruce (7101843599)","34973563700; 12545859000; 8368755300; 7101843599","Soluble epoxide hydrolase in atherosclerosis","2010","Current Atherosclerosis Reports","12","3","","174","183","9","62","10.1007/s11883-010-0108-5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953538299&doi=10.1007%2fs11883-010-0108-5&partnerID=40&md5=571201a08ca188a671e336baf4f3ede1","Arete Therapeutics Inc., South San Francisco, CA 94080, 7000 Shoreline Court, United States; Department of Entomology and Cancer Center, University of California, Davis, CA 95616, 1 Shields Avenue, United States; MuriGenics Inc., Vallejo, CA 94592, United States","Wang Y.-X.J., Arete Therapeutics Inc., South San Francisco, CA 94080, 7000 Shoreline Court, United States; Ulu A., Department of Entomology and Cancer Center, University of California, Davis, CA 95616, 1 Shields Avenue, United States; Zhang L.-N., MuriGenics Inc., Vallejo, CA 94592, United States; Hammock B., Department of Entomology and Cancer Center, University of California, Davis, CA 95616, 1 Shields Avenue, United States","Like many eicosanoids, epoxyeicosatrienoic acids (EETs) have multiple biological functions, including reduction of blood pressure, inflammation, and atherosclerosis in multiple species. Hydration of EETs by the soluble epoxide hydrolase (sEH) is the major route of their degradation to the less bioactive diols. Inhibition of the sEH stabilizes EETs, thus, enhancing the beneficial effects of EETs. Human data show an association of sEH (Ephx2) gene polymorphisms with increased risk of atherosclerosis and cardiovascular diseases. These data suggest a potential therapeutic effect of sEH inhibitors (sEHI) in the treatment of atherosclerosis. Indeed, two laboratories reported independently that using different sEHIs in apolipoprotein E-deficient mice significantly attenuated atherosclerosis development and aneurysm formation. The antiatherosclerotic effects of sEHI are correlatedwith elevation in EET levels and associated with reduction of low-density lipoprotein and elevation of highdensity lipoprotein cholesterols, as well as attenuation of expression of proinflammatory genes and proteins. In addition, the antihypertensive effects and improvement of endothelial function also contribute to the mechanism of the antiatherosclerotic effects of sEHI. The broad spectrum of biological action of EETs and sEHIs with multiple biological beneficial actions provides a promising new class of therapeutics for atherosclerosis and other cardiovascular diseases. © The Author(s) 2010.","Abdominal aortic aneurysm; Angiotensin II; Apolipoprotein E deficient mice; Atherosclerosis; Cytochrome P450; DHET; Dihydroxyeicosatrienoic acid; EET; Eicosanoids; Ephx2 gene polymorphisms; Epoxyeicosatrienoic acid; SEH; Soluble epoxide hydrolase","Animals; Atherosclerosis; Epoxide Hydrolases; Gene Therapy; Humans; Polymorphism, Genetic; Prognosis; 1 (1 methanesulfonylpiperidin 4 yl) 3 (4 trifluoromethoxyphenyl)urea; 1 (1 nicotinoylpiperidin 4 yl) 3 [4 (trifluoromethoxy)phenyl]urea; 1 adamantan 3 [5 [2 (2 ethylethoxy)ethoxy]pentyl]urea; apolipoprotein E; ar 9276; endothelin; enzyme inhibitor; epoxide hydrolase; epoxyicosatrienoic acid; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; nicotinic acid; prostaglandin synthase; soluble epoxide hydrolase; soluble epoxide hydrolase inhibitor; sorafenib; unclassified drug; epoxide hydrolase; abdominal aorta aneurysm; antihypertensive activity; atherosclerosis; blood pressure; cardiovascular risk; cell migration; cell proliferation; concentration response; disease course; drug activity; drug structure; enzyme activity; enzyme metabolism; enzyme stability; fatty acid blood level; gene expression; gene frequency; gene sequence; genetic association; heart infarction size; heart protection; heart ventricle hypertrophy; human; hydration; hypertension; in vitro study; in vivo study; ischemic heart disease; monotherapy; nonhuman; nucleotide sequence; pathogenesis; promoter region; protein expression; restenosis; review; single nucleotide polymorphism; animal; atherosclerosis; blood; enzymology; gene therapy; genetic polymorphism; genetics; procedures; prognosis","GENBANK: NM_022936","epoxide hydrolase, 51004-26-3, 9048-63-9; epoxyicosatrienoic acid, 97717-69-6; nicotinic acid, 54-86-4, 59-67-6; prostaglandin synthase, 39391-18-9, 59763-19-8, 9055-65-6; sorafenib, 284461-73-0; epoxide hydrolase, 51004-26-3, 9048-63-9; Epoxide Hydrolases, 3.3.2.-; Epoxide Hydrolases, ","ar 9276","","National Institutes of Health, NIH; National Heart, Lung, and Blood Institute, NHLBI, (R01HL059699); National Institute of Environmental Health Sciences, NIEHS","Acknowledgment Partial support for this work came from grants R01 ES002710 and P42 ES004699 from NIEHS and R01 HL059699 from NIH/NHLBI. The authors would like to thank Dr. Euan MacIntyle for critically reviewing this manuscript.","Nissen S.E., Nicholls S.J., Sipahi I., Et al., Effect of very highintensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial, JAMA, 295, pp. 1556-1565, (2006); Wang M., Song W.L., Cheng Y., Fitzgerald G.A., Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease, J Intern Med, 263, pp. 500-505, (2008); Zhang L.N., Vincelette J., Cheng Y., Et al., Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia, Arterioscler Thromb Vasc Biol, 29, pp. 1265-1270, (2009); Ulu A., Davis B.B., Tsai H.J., Et al., Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model, J Cardiovasc Pharmacol, 52, pp. 314-323, (2008); Li P.L., Campbell W.B., Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein, Circ Res, 80, pp. 877-884, (1997); Fleming I., Cytochrome P450 epoxygenases as EDHF synthase (s), Pharmacol Res, 49, pp. 525-533, (2004); Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension, Hypertension, 46, pp. 975-981, (2005); Fleming I., Cytochrome p450 and vascular homeostasis, Circ Res, 89, pp. 753-762, (2001); Morisseau C., Goodrow M.H., Dowdy D., Et al., Potent urea and carbamate inhibitors of soluble epoxide hydrolases, Proc Natl Acad Sci U S A, 96, pp. 8849-8854, (1999); Node K., Huo Y., Ruan X., Et al., Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 285, pp. 1276-1279, (1999); Morisseau C., Hammock B.D., Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles, Annu Rev Pharmacol Toxicol, 45, pp. 311-333, (2005); Schmelzer K.R., Kubala L., Newman J.W., Et al., Soluble epoxide hydrolase is a therapeutic target for acute inflammation, Proc Natl Acad Sci U S A, 102, pp. 9772-9777, (2005); Chiamvimonvat N., Ho C.M., Tsai H.J., Hammock B.D., The soluble epoxide hydrolase as a pharmaceutical target for hypertension, J Cardiovasc Pharmacol, 50, pp. 225-237, (2007); Yu Z., Xu F., Huse L.M., Et al., Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids, Circ Res, 87, pp. 992-998, (2000); Jung O., Brandes R.P., Kim I.H., Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension, Hypertension, 45, pp. 759-765, (2005); Ai D., Pang W., Li N., Et al., Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy, Proc Natl Acad Sci U S A, 106, pp. 564-569, (2009); Inceoglu B., Jinks S.L., Schmelzer K.R., Et al., Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain, Life Sci, 79, pp. 2311-2319, (2006); Zhang W., Koerner I.P., Noppens R., Et al., Soluble epoxide hydrolase: A novel therapeutic target in stroke, J Cereb Blood Flow Metab, 27, pp. 1931-1940, (2007); Ohtoshi K., Kaneto H., Node K., Et al., Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients, Biochem Biophys Res Commun, 331, pp. 347-350, (2005); Inceoglu B., Jinks S.L., Ulu A., Et al., Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways, Proc Natl Acad Sci U S A, 105, pp. 18901-18906, (2008); Ai D., Fu Y., Guo D., Et al., Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo, Proc Natl Acad Sci U S A, 104, pp. 9018-9023, (2007); Xu D., Li N., He Y., Et al., Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors, Proc Natl Acad Sci U S A, 103, pp. 18733-18738, (2006); Li N., Liu J.Y., Timofeyev V., Et al., Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches, J Mol Cell Cardiol, 47, pp. 835-845, (2009); Olearczyk J.J., Quigley J.E., Mitchell B.C., Et al., Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats, Clin Sci (Lond), 116, pp. 61-70, (2009); Dorrance A.M., Rupp N., Pollock D.M., Et al., An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in strokeprone spontaneously hypertensive rats, J Cardiovasc Pharmacol, 46, pp. 842-848, (2005); Fornage M., Hinojos C.A., Nurowska B.W., Et al., Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats, Hypertension, 40, pp. 485-490, (2002); Spiecker M., Darius H., Hankeln T., Et al., Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2, Circulation, 110, pp. 2132-2136, (2004); Wei Q., Doris P.A., Pollizotto M.V., Et al., Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: Interaction with cigarette smoking, Atherosclerosis, 190, pp. 26-34, (2007); Maresh J.G., Xu H., Jiang N., Et al., Tobacco smoke dysregulates endothelial vasoregulatory transcripts in vivo, Physiol Genomics, 21, pp. 308-313, (2005); Lee C.R., North K.E., Bray M.S., Et al., Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study, Hum Mol Genet, 15, pp. 1640-1649, (2006); Sato K., Emi M., Ezura Y., Et al., Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: Intrafamilial association study in an eight-generation hyperlipidemic kindred, J Hum Genet, 49, pp. 29-34, (2004); Corenblum M.J., Wise V.E., Georgi K., Et al., Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat, Hypertension, 51, pp. 567-573, (2008); Dreisbach A.W., Japa S., Sigel A., Et al., The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension, Am J Hypertens, 18, pp. 1276-1281, (2005); Fornage M., Boerwinkle E., Doris P.A., Et al., Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The coronary artery risk development in young adults (CARDIA) study, Circulation, 109, pp. 335-339, (2004); Fornage M., Lee C.R., Doris P.A., Et al., The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke, Hum Mol Genet, 14, pp. 2829-2837, (2005); Przybyla-Zawislak B.D., Srivastava P.K., Vazquez-Matias J., Et al., Polymorphisms in human soluble epoxide hydrolase, Mol Pharmacol, 64, pp. 482-490, (2003); Wang Y.X., Cassis L.A., Angiotensin II-induced aortic aneurysms, A Handbook of Mouse Models for Cardiovascular Diseases, pp. 125-136, (2006); Zhang L.N., Da Cunha V., Martin-McNulty B., Et al., Monocyte chemoattractant protein-1 or macrophage inflammatory protein-1alpha deficiency does not affect angiotensin IIinduced intimal hyperplasia in carotid artery ligation model, Cardiovasc Pathol, 16, pp. 231-236, (2007); Zhang L.N., Parkinson J.F., Haskell C., Wang Y.X., Mechanisms of intimal hyperplasia learned from a murine carotid artery ligation model, Curr Vasc Pharmacol, 6, pp. 37-43, (2008); Zhang L.N., Velichko S., Vincelette J., Et al., Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice, Atherosclerosis, 197, pp. 204-211, (2008); Zhang L.N., Wilson D.W., Da Cunha V., Et al., Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor- 1alpha in a mouse model of carotid artery ligation, Arterioscler Thromb Vasc Biol, 26, pp. 765-772, (2006); Teramoto T., Sasaki J., Ueshima H., Et al., Goals of dyslipidemia management, J Atheroscler Thromb, 14, pp. 209-212, (2007); Vaughan C.J., Gotto Jr. A.M., Basson C.T., The evolving role of statins in the management of atherosclerosis, J Am Coll Cardiol, 35, pp. 1-10, (2000); EnayetAllah A.E., Luria A., Luo B., Et al., Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase, J Biol Chem, 283, pp. 36592-36598, (2008); Golledge J., Muller J., Daugherty A., Norman P., Abdominal aortic aneurysm: Pathogenesis and implications for management, Arterioscler Thromb Vasc Biol, 26, pp. 2605-2613, (2006); Libby P., Ridker P.M., Maseri A., Inflammation and atherosclerosis, Circulation, 105, pp. 1135-1143, (2002); Ross R., Atherosclerosis is an inflammatory disease, Am Heart J, 138, 5 PART 2, (1999); Daugherty A., Cassis L.A., Mechanisms of abdominal aortic aneurysm formation, Curr Atheroscler Rep, 4, pp. 222-227, (2002); Martin-McNulty B., Tham D.M., Da Cunha V., Et al., 17 Betaestradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice, Arterioscler Thromb Vasc Biol, 23, pp. 1627-1632, (2003); Tham D.M., Martin-McNulty B., Wang Y.X., Et al., Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs, Physiol Genomics, 11, pp. 21-30, (2002); Wang Y.X., Martin-McNulty B., Freay A.D., Et al., Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice, Am J Pathol, 159, pp. 1455-1464, (2001); Nobuhiko A., Suganuma E., Babaev V.R., Et al., Angiotensin II amplifies macrophage-driven atherosclerosis, Arterioscler Thromb Vasc Biol, 24, pp. 2143-2148, (2004); Tedgui A., Mallat Z., Cytokines in atherosclerosis: Pathogenic and regulatory pathways, Physiol Rev, 86, pp. 515-581, (2006); Fang X., Kaduce T.L., Weintraub N.L., Et al., Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition, J Biol Chem, 276, pp. 14867-14874, (2001); Fang X., Weintraub N.L., Oltman C.L., Et al., Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide, Am J Physiol Heart Circ Physiol, 283, (2002); Galkina E., Ley K., Vascular adhesion molecules in atherosclerosis, Arterioscler Thromb Vasc Biol, 27, pp. 2292-2301, (2007); Sun J., Sui X., Bradbury J.A., Et al., Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenasederived eicosanoids, Circ Res, 90, pp. 1020-1027, (2002); Davis B.B., Thompson D.A., Howard L.L., Et al., Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation, Proc Natl Acad Sci U S A, 99, pp. 2222-2227, (2002); Davis B.B., Morisseau C., Newman J.W., Et al., Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3- dodecyl urea is independent of soluble epoxide hydrolase inhibition, J Pharmacol Exp Ther, 316, pp. 815-821, (2006); Simpkins A.N., Rudic R.D., Schreihofer D.A., Et al., Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection, Am J Pathol, 174, pp. 2086-2095, (2009); Kullmann S., Binner P., Rackebrandt K., Et al., Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention, BMC Cardiovasc Disord, 9, (2009); Imig J.D., Hammock B.D., Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases, Nat Rev Drug Discov, 8, pp. 794-805, (2009); Birnbaum Y., Ye Y., Lin Y., Et al., Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat, Circulation, 114, pp. 929-935, (2006); Levy B.D., Myocardial 15-epi-lipoxin A4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones, Circulation, 114, pp. 873-875, (2006); Planaguma A., Pfeffer M.A., Rubin G., Et al., Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A(4), Mucosal Immunol, (2010); Liu J.Y., Yang J., Inceoglu B., Et al., Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model, Biochem Pharmacol, 2010, 79, pp. 880-887; De Taeye B.M., Morisseau C., Coyle J., Et al., Expression and regulation of soluble epoxide hydrolase in adipose tissue, Obesity (Silver Spring), 2010, 18, pp. 489-498; Cheranov S.Y., Karpurapu M., Wang D., Et al., An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis, Blood, 111, pp. 5581-5591, (2008); Strumberg D., Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment, Drugs Today (Barc), 41, pp. 773-784, (2005); Shen H.C., Ding F.-X., Wang S., Et al., Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement, J Med Chem, 52, pp. 5009-5012, (2009)","Y.-X. J. Wang; Arete Therapeutics Inc., South San Francisco, CA 94080, 7000 Shoreline Court, United States; email: yxwang2000@gmail.com","","","","","","","","15233804","","CARUC","20425256","English","Curr. Atheroscler. Rep.","Review","Final","All Open Access; Green Open Access; Hybrid Gold Open Access","Scopus","2-s2.0-77953538299"
"Ormezzano O.; Poirier O.; Mallion J.-M.; Nicaud V.; Amar J.; Chamontin B.; Mounier-Véhier C.; François P.; Cambien F.; Baguet J.P.","Ormezzano, Olivier (6603161866); Poirier, Odette (7007129288); Mallion, Jean-Michel (35353985100); Nicaud, Viviane (7006504543); Amar, Jacques (7006794364); Chamontin, Bernard (7004644111); Mounier-Véhier, Claire (7005554245); François, Patrice (57206371493); Cambien, François (7101622418); Baguet, Jean Philippe (7006415764)","6603161866; 7007129288; 35353985100; 7006504543; 7006794364; 7004644111; 7005554245; 57206371493; 7101622418; 7006415764","A polymorphism in the endothelin-A receptor gene is linked to baroreflex sensitivity","2005","Journal of Hypertension","23","11","","2019","2026","7","25","10.1097/01.hjh.0000184748.49189.36","https://www.scopus.com/inward/record.uri?eid=2-s2.0-29244446240&doi=10.1097%2f01.hjh.0000184748.49189.36&partnerID=40&md5=b90dad0fe7a933d9fd0a4be71365b1de","Service de Cardiologie et Hypertension Artérielle, Grenoble, France; Département de Veille Sanitaire, CHU Michallon, Grenoble, France; INSERM U525, Faculté de Médecine Pitié-Salpêtrière, Paris, France; Service de Médecine Interne et Hypertension Artérielle, CHU Purpan, Toulouse, France; Service de Cardiologie, CHU de Lille, Lille, France; Service de Cardiologie et Hypertension Artérielle, CHU, 38043 Grenoble Cedex 09, BP 217, France","Ormezzano O., Service de Cardiologie et Hypertension Artérielle, Grenoble, France, Service de Cardiologie et Hypertension Artérielle, CHU, 38043 Grenoble Cedex 09, BP 217, France; Poirier O., INSERM U525, Faculté de Médecine Pitié-Salpêtrière, Paris, France; Mallion J.-M., Service de Cardiologie et Hypertension Artérielle, Grenoble, France; Nicaud V., INSERM U525, Faculté de Médecine Pitié-Salpêtrière, Paris, France; Amar J., Service de Médecine Interne et Hypertension Artérielle, CHU Purpan, Toulouse, France; Chamontin B., Service de Médecine Interne et Hypertension Artérielle, CHU Purpan, Toulouse, France; Mounier-Véhier C., Service de Cardiologie, CHU de Lille, Lille, France; François P., Département de Veille Sanitaire, CHU Michallon, Grenoble, France; Cambien F., INSERM U525, Faculté de Médecine Pitié-Salpêtrière, Paris, France; Baguet J.P., Service de Cardiologie et Hypertension Artérielle, Grenoble, France","Background: The baroreflex plays an essential role in regulating the cardiovascular system. However, very few studies have focused on the links between genetic polymorphisms and baroreflex sensitivity (BRS). Methods: A total of 146 hypertensive individuals who had never been treated, and 105 healthy individuals (controls) were included in the study. The genotypes of 17 polymorphisms of 11 genes involved in the regulation of the cardiovascular system were studied. BRS was measured using a sequence method: BRS was evaluated as the slope of spontaneous increases [systolic blood pressure (SBP)+/reflex response (RR)+] or decreases (SBP-/RR-) in SBP and pulse interval by recording blood pressure (BP) continuously for 20 min. Results: Following univariate analysis, the genetic polymorphism of endothelin receptor A EDNRA/C+1222T was found to be significantly correlated with the BRS (SBP-/RR-) level in both populations. In normotensive subjects, mean BRS values (SBP-/RR-) were 11.93 ± 3.69 ms/mmHg in EDNRA CC homozygotes, 9.94 ± 2.97 ms/mmHg in CT heterozygotes and 9.51 ± 3.16 ms/mmHg in TT homozygotes (P = 0.01). In hypertensive subjects, mean BRS values (SBP-/RR-) were 9.26 ± 3.59 ms/mmHg in EDNRA CC homozygotes, 9.03 ± 4.14 ms/mmHg in CT heterozygotes and 6.60 ± 2.42 ms/mmHg in TT homozygotes (P = 0.01). After adjustment for age, sex, SBP and diastolic blood pressure and body mass index, the EDNRA/C+1222T polymorphism remained significantly correlated with BRS in both normotensive (P = 0.01) and hypertensive (P = 0.01) subjects. Conclusions: These results suggest that the endothelin system may be involved in the regulation of BRS in humans. In particular, the T allele of the EDNRA/C+1222T polymorphism is associated with a reduction in BRS in both healthy and hypertensive subjects. © 2005 Lippincott Williams & Wilkins.","Baroreflex; Endothelin; Genetic; Human; Hypertension","aldosterone synthase; angiotensin 1 receptor; angiotensinogen; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta 3 adrenergic receptor; dipeptidyl carboxypeptidase; endothelial nitric oxide synthase; endothelin 1; endothelin A receptor; guanine nucleotide binding protein; adult; article; blood pressure measurement; body mass; clinical feature; controlled study; diastolic blood pressure; DNA polymorphism; essential hypertension; female; genetic analysis; genotype; heterozygote; homozygote; human; major clinical study; male; pressoreceptor reflex; priority journal; receptor gene; systolic blood pressure","","aldosterone synthase, 122933-89-5; angiotensinogen, 11002-13-4, 64315-16-8; dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; endothelin 1, 117399-94-7","","","","","Mancia G., Parati G., Pomidossi G., Casadei R., Ri Rienzo M., Zanchetti A., Arterial baroreflexes and blood pressure and heart rate variabilities in humans, Hypertension, 8, pp. 147-153, (1986); Sasaki S., Yoneda Y., Fujita H., Uchida A., Takenaka K., Takesako T., Et al., Association of blood pressure variability with induction of atherosclerosis in cholesterol-fed rats, Am J Hypertens, 7, pp. 453-459, (1994); Palatini P., Julius S., Heart rate and the cardiovascular risk, J Hypertens, 15, pp. 3-17, (1997); Kardos A., Watterich G., Menezes R.D., Csanady M., Casadei B., Rudas L., Determinants of spontaneous baroreflex sensitivity in a healthy working population, Hypertension, 37, pp. 911-916, (2001); Iellamo F., Legramante J.M., Pigozzi F., Spataro A., Norbiato G., Lucini D., Pagani M., Conversion from vagal to sympathetic predominance with strenuous training in high-performance world class athletes, Circulation, 105, pp. 2719-2724, (2002); Weinstock M., Weksler-Zangen S., Schorer-Apelbaum D., Genetic factors involved in the determination of baroreceptor heart-rate sensitivity, J Hypertens, 4, (1986); Tank J., Jordan J., Diedrich A., Stoffels M., Franke G., Faulhaber H.D., Et al., Genetic influences on baroreflex function in normal twins, Hypertension, 37, pp. 907-910, (2001); Pinna G.D., La Rovere M.T., Maestri R., Mortara A., Bigger J.T., Schwartz P.J., Comparison between invasive and non-invasive measurements of baroreflex sensitivity; implications for studies on risk stratification after a myocardial infarction, Eur Heart J, 21, pp. 1522-1529, (2000); La Rovere M.T., Pinna G.D., Hohnloser S.H., Marcus F.I., Mortara A., Nohara R., Et al., Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials, Circulation, 103, pp. 2072-2077, (2001); Mortara A., La Rovere M.T., Pinna G.D., Parziale P., Maestri R., Capomolla S., Et al., Depressed arterial baroreflex sensitivity and not reduced heart rate variability identifies patients with chronic heart failure and nonsustained ventricular tachycardia: The effect of high ventricular filling pressure, Am Heart J, 134, pp. 879-888, (1997); La Rovere M.T., Bigger Jr. J.T., Marcus F.I., Mortara A., Schwartz P.J., Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators, Lancet, 351, pp. 478-484, (1998); Osterziel K.J., Hanlein D., Willenbrock R., Eichhorn C., Luft F., Dietz R., Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure, Br Heart J, 73, pp. 517-522, (1995); Ylitalo A., Airaksinen K.E., Hautanen A., Kupari M., Carson M., Virolainen J., Et al., Baroreflex sensitivity and variants of the renin angiotensin system genes, J Am Coll Cardiol, 35, pp. 194-200, (2000); Gollasch M., Tank J., Luft F.C., Jordan J., Maass P., Krasko C., Et al., The BK channel beta1 subunit gene is associated with human baroreflex and blood pressure regulation, J Hypertens, 20, pp. 927-933, (2002); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Et al., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, pp. 1206-1252, (2003); Benetos A., Gautier S., Ricard S., Topouchian J., Asmar R., Poirier O., Et al., Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients, Circulation, 94, pp. 698-703, (1996); Imholz B.P.M., Wieling W., Langewouters G.J., Van Montfrans G.A., Continuous finger arterial pressure: Utility in the cardiovascular laboratory, Clin Auton Res, 1, pp. 43-53, (1991); Herpin D., Ragot S., Mid- and long-term reproducibility of noninvasive measurements of spontaneous arterial baroreflex sensitivity in healthy volunteers, Am J Hypertens, 10, pp. 790-797, (1997); Parati G., Di Rienzo M., Bertinieri G., Pomidossi G., Casadei R., Groppelli A., Et al., Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans, Hypertension, 12, pp. 214-222, (1988); Di Rienzo M., Parati G., Castiglioni P., Tordi R., Mancia G., Pedotti A., Baroreflex effectiveness index: An additional measure of baroreflex control of heart rate in daily life, Am J Physiol Regul Integr Comp Physiol, 280, (2001); Pitzalis M., Parati G., Massari F., Guida P., Di Rienzo M., Rizzon B., Et al., Enhanced reflex response to baroreceptor deactivation in subjects with tilt-induced syncope, J Am Coll Cardiol, 41, pp. 1167-1173, (2003); Tsuchiyama Y., Kasamatsu K., Hano T., Nishio I., Related articles, links acute effect of endothelin AB antagonist on sympathetic outflow in conscious rats with heart failure, Circ J, 66, pp. 841-845, (2002); Itoh S., Van Den Buuse M., Sensitization of baroreceptor reflex by central endothelin in conscious rats, Am J Physiol, 260, (1991); Van Den Buuse M., Itoh S., Central effects of endothelin on baroreflex of spontaneously hypertensive rats, J Hypertens, 11, pp. 379-387, (1993); Dai S.M., Shan Z.Z., Miao C.Y., Yin M., Su D.F., Hemodynamic responses to endothelin-1 and endothelin antagonists microinjected into the nucleus tractus solitarius in rats, J Cardiovasc Pharmacol, 30, pp. 475-480, (1997); Mosqueda-Garcia R., Appalsamy M., Fernandez-Violante R., Hamakubo T., Modulatory effects of endothelin on baroreflex activation in the nucleus of the solitary tract, Eur J Pharmacol, 351, pp. 203-207, (1998); Schiffrin E.L., Thibault G., Plasma endothelin in human essential hypertension, Am J Hypertens, 4, pp. 303-308, (1991); Lemne C.E., Lundeberg T., Theodorsson E., De Faire U., Increased basal concentrations of plasma endothelin in borderline hypertension, J Hypertens, 12, pp. 1069-1074, (1994); Schiffrin E.L., Deng L.Y., Sventek P., Day R., Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension, J Hypertens, 15, pp. 57-63, (1997); Hasegawa K., Fujiwara H., Doyama K., Inada T., Ohtani S., Fujiwara T., Et al., Endothelin-1-selective receptor in the arterial intima of patients with hypertension, Hypertension, 23, pp. 288-293, (1994); Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V., The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators, N Engl J Med, 338, pp. 784-790, (1998); Nicaud V., Poirier O., Behague I., Herrmann S.M., Mallet C., Troesch A., Et al., Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: The Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study, Am J Hypertens, 12, pp. 304-310, (1999); Lajemi M., Gautier S., Poirier O., Baguet J.P., Mimran A., Gosse P., Et al., Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives, Am J Hypertens, 14, pp. 755-760, (2001); Ketch T., Biaggioni I., Robertson R., Robertson D., Four faces of baroreflex failure: Hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia, Circulation, 105, pp. 2518-2523, (2002); Kardos A., Rudas L., Simon J., Gingl Z., Csanady M., Effect of postural changes on arterial baroreflex sensitivity assessed by the spontaneous sequence method and Valsalva manoeuvre in healthy subjects, Clin Auton Res, 7, pp. 143-148, (1997); Zollei E., Paprika D., Rudas L., Measures of cardiovascular autonomic regulation derived from spontaneous methods and the Valsalva maneuver, Auton Neurosci, 31, pp. 100-105, (2003); Kunst A.E., Groenhof F., Mackenbach J.P., Health E.W., Occupational class and cause specific mortality in middle aged men in 11 European countries: Comparison of population based studies. EU Working Group on Socioeconomic Inequalities in Health, BMJ, 316, pp. 1636-1642, (1998); Bertinieri G., Di Rienzo M., Cavallazzi A., Ferrari A.U., Pedotti A., Mancia G., Evaluation of baroreceptor reflex by blood pressure monitoring in unanesthetized cats, Am J Physiol, 254, (1988); Laude D., Elghozi J.L., Girard A., Bellard E., Bouhaddi M., Castiglioni P., Et al., Comparison of various techniques used to estimate spontaneous baroreflex sensitivity (the EuroBaVar study), Am J Physiol Regul Integr Comp Physiol, 286, (2004); Lipman R.D., Salisbury J.K., Taylor J.A., Spontaneous indices are inconsistent with arterial baroreflex gain, Hypertension, 42, pp. 481-487, (2003); Parati G., Di Rienzo M., Castiglioni P., Bouhaddi M., Cerutti C., Cividjian A., Et al., Assessing the sensitivity of spontaneous baroreflex control of the heart: Deeper insight into complex physiology, Hypertension, 43, (2004); Legramante J.M., Raimondi G., Massaro M., Cassarino S., Peruzzi G., Iellamo F., Investigating feed-forward neural regulation of circulation from analysis of spontaneous arterial pressure and heart rate fluctuations, Circulation, 99, pp. 1760-1766, (1999); Malberg H., Wessel N., Hasart A., Osterziel K.J., Voss A., Advanced analysis of spontaneous baroreflex sensitivity, blood pressure and heart rate variability in patients with dilated cardiomyopathy, Clin Sci, 102, pp. 465-473, (2002); Pilowsky P.M., Goodchild A.K., Baroreceptor reflex pathways and neurotransmitters: 10 years on, J Hypertens, 20, pp. 1675-1688, (2002); Pickering T.G., Gribbin B., Sleight P., Comparison of the reflex heart rate response to rising and falling arterial pressure in man, Cardiovasc Res, 6, pp. 277-283, (1972); Iellamo F., Legramante J.M., Raimondi G., Castrucci F., Massaro M., Peruzzi G., Evaluation of reproducibility of spontaneous baroreflex sensitivity at rest and during laboratory tests, J Hypertens, 14, pp. 1099-1104, (1996); Casadei B., Paterson D.J., Should we still use nitrovasodilators to test baroreflex sensitivity?, J Hypertens, 18, pp. 3-6, (2000); Tank J., Baevski R.M., Fender A., Baevski A.R., Graves K.F., Ploewka K., Weck M., Reference values of indices of spontaneous baroreceptor reflex sensitivity, Am J Hypertens, 13, pp. 268-275, (2000)","O. Ormezzano; Service de Cardiologie et Hypertension Artérielle, CHU, 38043 Grenoble Cedex 09, BP 217, France; email: oormezzano@chu-grenoble.fr","","Lippincott Williams and Wilkins","","","","","","02636352","","JOHYD","16208144","English","J. Hypertens.","Article","Final","","Scopus","2-s2.0-29244446240"
"Delmonico M.J.; Ferrell R.E.; Meerasahib A.; Martel G.F.; Roth S.M.; Kostek M.C.; Hurley B.F.","Delmonico, Matthew J. (9243520300); Ferrell, Robert E. (35380363800); Meerasahib, Anish (9243520500); Martel, Greg F. (7003300045); Roth, Stephen M. (7402433170); Kostek, Matthew C. (9243520800); Hurley, Ben F. (7006364123)","9243520300; 35380363800; 9243520500; 7003300045; 7402433170; 9243520800; 7006364123","Blood pressure response to strength training may be influenced by angiotensinogen A-20C and angiotensin II type I receptor A1166C genotypes in older men and women","2005","Journal of the American Geriatrics Society","53","2","","204","210","6","28","10.1111/j.1532-5415.2005.53104.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-15044361148&doi=10.1111%2fj.1532-5415.2005.53104.x&partnerID=40&md5=1084a6cb36aeba9a5338e41f60c6b3f3","Department of Kinesiology, College of Health and Human Performance, University of Maryland, College Park, MD, United States; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States; Department of Kinesiology, University of Maryland, College Park, MD 20742, United States","Delmonico M.J., Department of Kinesiology, College of Health and Human Performance, University of Maryland, College Park, MD, United States; Ferrell R.E., Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States; Meerasahib A., Department of Kinesiology, College of Health and Human Performance, University of Maryland, College Park, MD, United States; Martel G.F., Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States; Roth S.M., Department of Kinesiology, College of Health and Human Performance, University of Maryland, College Park, MD, United States; Kostek M.C., Department of Kinesiology, College of Health and Human Performance, University of Maryland, College Park, MD, United States; Hurley B.F., Department of Kinesiology, College of Health and Human Performance, University of Maryland, College Park, MD, United States, Department of Kinesiology, University of Maryland, College Park, MD 20742, United States","OBJECTIVES: To determine the influence of angiotensinogen (AGT) A-20C, M235 T, and angiotensin II type 1 receptor (AGTR1) A1166C genotypes on resting blood pressure (BP) response to strength training (ST) in older men and women. DESIGN: Prospective intervention study with retrospective genotyping. SETTING: University of Maryland Exercise Physiology Laboratory. PARTICIPANTS: Seventy sedentary, healthy older men (n = 34) and women (n = 36). INTERVENTION: Approximately 23 weeks of ST performed 3 days per week. MEASUREMENTS: Resting BP was measured on six separate occasions before and after ST for each subject. AGT and AGTR1 genotyping was performed retrospectively from each subject's genomic deoxyribonucleic acid. RESULTS: Systolic BP decreased in C-allele carriers at the AGT A-20C locus with ST (122 ± 1 to 116 ± 2mmHg, P<.05), which was significantly greater than the decrease in the A homozygotes (126 ± 1 to 123 ± 1 mmHg, P<.05). At the AGTR1 A1166C locus, diastolic BP decreased to a greater extent in the C-allele carriers (76 ± to 70 ± 2 mmHg, P<.05) than in the A homozygotes (75 ± 1 to 72 ± 1 mmHg, P<.05). CONCLUSION: The AGT A-20C and AGTR1 A1166C genotypes may influence resting BP response to ST, such that C-allele carriers at each of these loci reduce their resting BP in response to ST to a greater extent than A homozygotes. © 2005 by the American Geriatrics Society.","Aging; Exercise; Hypertension; Single nucleotide polymorphism","Aged; Aged, 80 and over; Angiotensinogen; Blood Pressure; Body Composition; Exercise; Female; Genotype; Humans; Male; Middle Aged; Muscle, Skeletal; Physical Endurance; Polymorphism, Genetic; Receptor, Angiotensin, Type 1; angiotensin 1 receptor; angiotensinogen; DNA; adult; aged; allele; article; controlled study; diastolic blood pressure; female; genotype; homozygote; human; human experiment; male; muscle strength; normal human; prospective study; systolic blood pressure; training; blood pressure; body composition; endurance; exercise; genetic polymorphism; genetics; middle aged; physiology; skeletal muscle","","angiotensinogen, 11002-13-4, 64315-16-8; DNA, 9007-49-2; Angiotensinogen, 11002-13-4; Receptor, Angiotensin, Type 1, ","","","National Institute on Aging, NIA, (R21AG016205)","","Carretero O.A., Oparil S., Essential hypertension part I. Definition and etiology, Circulation, 101, pp. 329-335, (2000); Black H.R., Cohen J.D., Kaplan N.M., Et al., The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Arch Intern Med, 157, pp. 2413-2446, (1997); Chobanian A.V., Bakris G.L., Black H.R., Et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-The JNC 7 Report, JAMA, 289, pp. 2560-2572, (2003); Hurley B.F., Roth S.M., Strength training in the elderly, effects on risk factors for age-related diseases, Sports Med, 30, pp. 249-268, (2000); Roth S.M., Ferrell R.E., Hurley B.F., Strength training for the prevention and treatment of sarcopenia, J Nutr Health Aging, 4, pp. 143-155, (2000); Hagberg J.M., Blair S., Ehsani A.A., Position stand. Physical activity, physical fitness, and hypertension, Med Sci Sports Exercise, 25, (1993); Martel G.F., Hurlbut D.E., Lott M.E., Et al., Strength training normalizes resting blood pressure in 65- to 73-year-old men and women with high normal blood pressure, J Am Geriatr Soc, 47, pp. 1215-1221, (1999); Guyton A., Hall J., Textbook of Medical Physiology, 9th Ed., (1996); Caulfield M., Lavender P., Newel I., Et al., Angiotensinogen in human essential hypertension, Hypertension, 28, pp. 1123-1125, (1996); Caulfield M., Lavender P., Farrall M., Et al., Linkage of the angiotensinogen gene to essential-hypertension, N Engl J Med, 330, pp. 1629-1633, (1994); Inoue I., Nakajima T., Williams C.S., Et al., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro, J Clin Invest, 99, pp. 1786-1797, (1997); Jeunemaitre X., Inoue I., Williams C., Et al., Haplotypes of angiotensinogen in essential hypertension, Am J Human Genet, 60, pp. 1448-1460, (1997); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Et al., Molecular-basis of human hypertension-role of angiotensinogen, Cell, 71, pp. 169-180, (1992); Kunz R., Kreutz R., Beige J., Et al., Association between the angiotensinogen 235T-variant and essential hypertension in whites-a systematic review and methodological appraisal, Hypertension, 30, pp. 1331-1337, (1997); Schunkert H., Hense H.W., Gimenez Roqueplo A.P., Et al., The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort, Hypertension, 29, pp. 628-633, (1997); Rankinen T., Gagnon J., Perusse L., Et al., AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study, Am J Physiol Heart Circ Physiol, 279, (2000); Rauramaa R., Kuhanen R., Lakka T.A., Et al., Physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism, Physiol Genomics, 10, pp. 71-77, (2002); Sonna L.A., Glueck S.B., Jeunemaitre X., Exercise, genetics, and blood pressure: Focus on 'physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism' and on 'angiotensinogen M235T polymorphism associates with exercise hemodynamics in postmenopausal women., Physiol Genomics, 10, pp. 45-47, (2002); Sato N., Katsuya T., Rakugi H., Et al., Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese, Hypertension, 30, pp. 321-325, (1997); Nakauchi Y., Suehiro T., Yamamoto M., Et al., Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease, Atherosclerosis, 125, pp. 161-169, (1996); Kainulainen K., Perola M., Terwilliger J., Et al., Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension, Hypertension, 33, pp. 844-849, (1999); Szombathy T., Szalai C., Katalin B., Et al., Association of angiotensin II Type 1 receptor polymorphism with resistant essential hypertension, Clinica Chimica Acta, 269, pp. 91-100, (1998); Berge K.E., Berg K., Polymorphisms at the angiotensinogen (AGT) and angiotensin II type 1 receptor (AT1R) loci and normal blood pressure, Clin Genet, 53, pp. 214-219, (1998); Wang W.Y.S., Zee R.Y.L., Morris B.J., Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension, Clin Genet, 51, pp. 31-34, (1997); Castellano M., Muiesan M.L., Beschi M., Et al., Angiotensin II type 1 receptor A/C-1166 polymorphism-relationships with blood pressure and cardiovascular structure, Hypertension, 28, pp. 1076-1080, (1996); Henskens L.H., Spiering W., Stoffers H.E., Et al., Effects of ACE I/D and at (1) R-A (1166) C Polymorphisms on bood pressure in a healthy normotensive primary care population: First results of the Hippocates Study, J Hypertension, 21, pp. 81-86, (2003); Krizanova O., Koska J., Vigas M., Et al., Correlation of M235T DNA polymorphism with cardiovascular and endocrine responses during physical exercise in healthy subjects, Physiol Res, 47, pp. 81-87, (1998); Zhao Y.Y., Zhou J., Chittampalli S., Et al., Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene, Hypertension, 33, pp. 198-1115, (1999); Terwilliger J., Ott J., Handbook for Human Genetic Linkage, (1994); Devlin B., Risch N.A., Comparison of linkage disequilibrium measures for fine-scale mapping, Genomics, 29, pp. 311-322, (1995); Tiago A.D., Samani N.J., Candy G.P., Et al., Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension, Circulation, 106, pp. 1483-1487, (2002); Tiret L., Blanc H., Ruidavets J.B., Et al., Projet d'Etude des Gènes de l'Hypertension Artérielle Sévère à Modérèe Essentielle, J Hypertens, 16, pp. 37-44, (1998); Reich H., Duncan J.A., Weinstein J., Et al., Interactions between gender and the angiotensin type 1 receptor gene polymorphism, Kidney Int, 63, pp. 1443-1449, (2003); Smutok M.A., Reece C., Kokkinos P.F., Et al., Aerobic versus strength training for risk factor intervention in middle-aged men at high-risk for coronary heart-disease, Metabolism, 42, pp. 177-184, (1993); Banz W.J., Maher M.A., Thompson W.G., Et al., Effects of resistance versus aerobic training on coronary artery disease risk factors, Exp Biol Med (Maywood), 228, pp. 434-440, (2003); Carter J.R., Ray C.A., Downs E.M., Et al., Strength training reduces arterial blood pressure but not sympathetic neural activity in young normotensrve subjects, J Appl Physiol, 94, pp. 2212-2216, (2003); Blumenthal J.A., Siegel W.C., Appelbaum M., Failure of exercise to reduce blood pressure in patients with mild hypertension - Results of a randomized controlled trial, JAMA, 266, pp. 2098-2104, (1991); Kannel W.B., Blood pressure as a cardiovascular risk factor - Prevention and treatment, JAMA, 275, pp. 1571-1576, (1996); Vasan R.S., Larson M.G., Leip E.P., Et al., Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study, Lancet, 358, pp. 1682-1686, (2001); Vasan R.S., Larson M.G., Leip E.P., Et al., Impact of high-normal blood pressure on the risk of cardiovascular disease, N Engl J Med, 345, pp. 1291-1297, (2001); Vasan R.S., Beiser A., Seshadri S., Et al., Residual lifetime risk for developing hypertension in middle-aged women and men - The Framingham Heart Study, JAMA, 287, pp. 1003-1010, (2002)","B.F. Hurley; Department of Kinesiology, University of Maryland, College Park, MD 20742, United States; email: benhur@umd.edu","","","","","","","","15325415","","JAGSA","15673342","English","J. Am. Geriatr. Soc.","Article","Final","","Scopus","2-s2.0-15044361148"
"Arnett D.K.; Claas S.A.","Arnett, Donna K. (7101719250); Claas, Steven A. (58439323700)","7101719250; 58439323700","Pharmacogenetics of antihypertensive treatment: Detailing disciplinary dissonance","2009","Pharmacogenomics","10","8","","1295","1307","12","26","10.2217/pgs.09.61","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70649094353&doi=10.2217%2fpgs.09.61&partnerID=40&md5=d8ad542753d7d21700fe57d1c979b089","University of Alabama at Birmingham, RPHB 220E, Birmingham, AL 55294-0022, 1530 3rd Avenue South, United States","Arnett D.K., University of Alabama at Birmingham, RPHB 220E, Birmingham, AL 55294-0022, 1530 3rd Avenue South, United States; Claas S.A., University of Alabama at Birmingham, RPHB 220E, Birmingham, AL 55294-0022, 1530 3rd Avenue South, United States","Hypertension is a common condition associated with increased cardiovascular morbidity and mortality. In the USA only approximately a third of those who are aware of their hypertensive status successfully control their blood pressure. One reason for this is the unpredictable response individuals have to treatment. Clinicians must often rely on empirical methods to match patients with effective drug treatment. Hypertension pharmacogenetics seeks to find genetic predictors of response to drugs that lower blood pressure and to translate this knowledge into clinical practice. To date, around 60 studies have investigated associations between genetic polymorphisms and response to antihypertensive drugs. Here we review 18 studies that have been published since 2005. While consonant findings that are insufficient for clinical translation remain the norm, some consistent findings are emerging with several gene-treatment combinations. Nonetheless, differences in study designs, variable methods for assessing pharmacologic exposures, heterogeneous phenotypes (that is, response variables and outcomes ranging from blood pressure to clinical outcomes) and small sample sizes coupled with a short duration of follow-up in many studies account for a large portion of these inconsistencies. Progress in the future will depend upon our ability to launch large studies using high-fidelity phenotyping with multiple drugs and multiple ethnic groups. © 2009 Future Medicine Ltd.","Antihypertensive; Blood pressure; Gene; Pharmacogenetics; Pharmacogenomics","Antihypertensive Agents; Humans; Hypertension; Metabolic Detoxication, Drug; Pharmacogenetics; Polymorphism, Genetic; alpha adducin; alpha adrenergic receptor blocking agent; angiotensin II; atenolol; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; calcium channel blocking agent; calcium channel L type; calcium channel voltage dependent L type alpha 1C subunit; chlortalidone; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; doxazosin; endothelial nitric oxide synthase; fosinopril; fungal protein; irbesartan; natriuretic factor; natriuretic peptide precursor; perindopril; protein kinase WNK1; sodium channel; sodium channel nonvoltage gated 1 gamma subunit; sterol regulatory element binding protein 1c; ubiquitin protein ligase NEDD4; unclassified drug; unindexed drug; verapamil; yeats domain containg protein 4; antihypertensive therapy; drug efficacy; gene expression; gene frequency; genetic association; genetic polymorphism; genetic variability; genotype; haplotype; heart infarction; human; hypertension; pharmacogenetics; phenotype; review; single nucleotide polymorphism; stroke","","angiotensin II, 11128-99-7; atenolol, 29122-68-7; chlortalidone, 77-36-1; dipeptidyl carboxypeptidase, 9015-82-1; doxazosin, 74191-85-8; endothelial nitric oxide synthase, 503473-02-7; fosinopril, 88889-14-9, 98048-97-6; irbesartan, 138402-11-6; natriuretic factor, 9088-07-7; perindopril, 82834-16-0; verapamil, 152-11-4, 52-53-9; Antihypertensive Agents, ","","","National Heart, Lung, and Blood Institute, NHLBI, (R01HL063082)","","Rosamond W., Flegal K., Furie K., Et al., Heart Disease and Stroke Statistics 2008 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 117, 4, (2008); Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy, JAMA, 248, pp. 2004-2011, (1982); Materson B.J., Variability in response to antihypertensive drugs, Am. J. Med., 120, (2007); Turner S.T., Bailey K.R., Fridley B.L., Et al., Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic, Hypertension, 52, pp. 359-365, (2008); Haas M., Yilmaz N., Schmidt A., Et al., Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease, Kidney Blood Press. Res., 21, pp. 66-69, (1998); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein β(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Liu J., Liu Z.-Q., Yu B.-N., Xu F.-H., Mo W., Zhou G., Liu Y.-Z., Li Q., Zhou H.-H., β<sub>1</sub>-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension, Clinical Pharmacology and Therapeutics, 80, 1, pp. 23-32, (2006); Siest G., Jeannesson E., Visvikis-Siest S., Enzymes and pharmacogenetics of cardiovascular drugs, Clin. Chim. Acta, 381, pp. 26-31, (2007); Flaa A., Kjeldsen S.E., Are all the hypertensives made equal?, Herz, 31, 4, pp. 323-330, (2006); Israili Z.H., Hernandez-Hernandez R., Valasco M., The future of antihypertensive treatment, Am. J. Ther., 14, pp. 121-134, (2007); Filigheddu F., Troffa C., Glorioso N., Pharmacogenomics of essential hypertension: Are we going the right way?, Cardiovascular and Hematological Agents in Medicinal Chemistry, 4, 1, pp. 7-15, (2006); Mellen P.B., Herrington D.M., Pharmacogenomics of blood pressure response to antihypertensive treatment, J. Hypertens., 23, pp. 1311-1325, (2005); Saavedra J.M., Studies on genes and hypertension: A daunting task, J. Hypertens., 23, pp. 929-932, (2005); Manunta P., Bianchi G., Pharmacogenomics and pharmacogenetics of hypertension: Update and perspectives - The adducin paradigm, J. Am. Soc. Nephrol., 17, (2006); Kurland L., Lind L., Melhus H., Using genotyping to predict responses to anti-hypertensive treatment, Trends in Pharmacological Sciences, 26, 9, pp. 443-447, (2005); Arnett D.K., Claas S.A., Glasser S.P., Pharmacogenetics of antihypertensive treatment, Vascul. Pharmacol., 44, pp. 107-118, (2006); Johnson J.A., Turner S.T., Hypertension pharmacogenomics: Current status and future directions, Curr. Opin. Mol. Ther., 7, pp. 218-225, (2005); Schwartz G.L., Turner S.T., Pharmacogenetics of antihypertensive drug responses, Am. J. Pharmacogenomics, 4, pp. 151-160, (2004); Kurland L., Hallberg P., Melhus H., Liljedahl U., Hashemi N., Syvanen A.-C., Lind L., Kahan T., The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) trial, American Journal of Hypertension, 21, 7, pp. 836-839, (2008); Lynch A.I., Boerwinkle E., Davis B.R., Ford C.E., Eckfeldt J.H., Leiendecker-Foster C., Arnett D.K., Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension, JAMA - Journal of the American Medical Association, 299, 3, pp. 296-307, (2008); Langaee T.Y., Gong Y., Yarandi H.N., Katz D.A., Cooper-DeHoff R.M., Pepine C.J., Johnson J.A., Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil, Clinical Pharmacology and Therapeutics, 81, 3, pp. 386-391, (2007); Pacanowski M.A., Gong Y., Cooper-Dehoff R.M., Et al., β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension, Clin. Pharmacol. Ther., 84, pp. 715-721, (2008); Lemaitre R.N., Heckbert S.R., Sotoodehnia N., Bis J.C., Smith N.L., Marciante K.D., Hindorff L.A., Lange L.A., Lumley T.S., Rice K.M., Wiggins K.L., Psaty B.M., β1- And β2-adrenergic receptor gene variation, β-blocker use and risk of myocardial infarction and stroke, American Journal of Hypertension, 21, 3, pp. 290-296, (2008); Lanfear D.E., Jones P.G., Marsh S., Cresci S., McLeod H.L., Spertus J.A., β<sub>2</sub>-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome, Journal of the American Medical Association, 294, 12, pp. 1526-1533, (2005); Maitland-van Der Zee A.H., Turner S.T., Schwartz G.L., Chapman A.B., Klungel O.H., Boerwinkle E., A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide, Pharmacogenet. Genomics, 15, pp. 287-293, (2005); Beitelshees A.L., Gong Y., Wang D., Schork N.J., Cooper-DeHoff R.M., Langaee T.Y., Shriver M.D., Sadee W., Knot H.J., Pepine C.J., Johnson J.A., KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST), Pharmacogenetics and Genomics, 17, 9, pp. 719-729, (2007); Kelley-Hedgepeth A., Peter I., Kip K.E., Montefusco M.C., Kogan S., Cox D., Ordovas J.M., Levy D., Reis S.E., Mendelsohn M.E., Housman D., Huggins G.S., The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with β-blockade, Journal of Human Hypertension, 22, 7, pp. 512-515, (2008); Bremer T., Man A., Kask K., Diamond C., CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension, Pharmacogenomics, 7, pp. 271-279, (2006); Milionis H.J., Kostapanos M.S., Vakalis K., Theodorou I., Bouba I., Kalaitzidis R., Georgiou I., Elisaf M.S., Siamopoulos K.C., Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome, JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 8, 4, pp. 181-189, (2007); Chobanian A.V., Bakris G.L., Black H.R., Et al., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, pp. 1206-1252, (2003); Cutler J.A., Davis B.R., Thiazide-type diuretics and β-adrenergic blockers as first-line drug treatments for hypertension, Circulation, 117, pp. 2691-2704, (2008); Messerli F.H., Bangalore S., Julius S., Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension, Circulation, 117, pp. 2706-2715, (2008); Turner S.T., Chapman A.B., Schwartz G.L., Boerwinkle E., Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide, Am. J. Hypertens., 16, pp. 834-839, (2003); Rodwell G.E.J., Sonu R., Zahn J.M., Lund J., Wilhelmy J., Wang L., Xiao W., Mindrinos M., Crane E., Segal E., Myers B.D., Brooks J.D., Davis R.W., Higgins J., Owen A.B., Kim S.K., A transcriptional profile of aging in the human kidney, PLoS Biology, 2, 12, (2004); Manunta P., Lavery G., Lanzani C., Et al., Physiological interaction between α-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation, Hypertension, 52, pp. 366-372, (2008); Bangalore S., Parkar S., Grossman E., Messerli F.H., A Meta-Analysis of 94,492 Patients with Hypertension Treated with Beta Blockers to Determine the Risk of New-Onset Diabetes Mellitus, American Journal of Cardiology, 100, 8, pp. 1254-1262, (2007); Schelleman H., Klungel O.H., Witteman J.C.M., Breteler M.M.B., Yazdanpanah M., Danser A.H.J., Hofman A., Van Duijn C.M., De Boer A., Stricker B.H.C., Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or β-blockers, European Journal of Human Genetics, 15, 4, pp. 478-484, (2007); Schelleman H., Klungel O.H., Witteman J.C., Et al., Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke, Pharmacogenomics J., 8, pp. 400-407, (2008); Jauch K.-W., Hartl W., Guenther B., Wicklmayr M., Rett K., Dietze G., Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus, European Journal of Clinical Investigation, 17, 5, pp. 448-454, (1987); Gluszek J., Jankowska K., Is there relationship between the A1166C polymorphism of the angiotensin II receptor at<sub>1</sub> and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy?, Polskie Archiwum Medycyny Wewnetrznej, 118, 4, pp. 194-200, (2008); Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E.C., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, Journal of Hypertension, 13, 12 II, pp. 1602-1609, (1995); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, Journal of Hypertension, 14, 2, pp. 259-262, (1996); Bis J.C., Smith N.L., Psaty B.M., Et al., Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients, Am. J. Hypertens., 16, pp. 1011-1017, (2003); Arnett D.K., Davis B.R., Ford C.E., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, pp. 3374-3383, (2005); Filigheddu F., Argiolas G., Bulla E., Et al., Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians, Pharmacogenomics, 9, pp. 1419-1427, (2008); Johnson A.D., Gong Y., Wang D., Et al., Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension, Clin. Pharmacol. Ther., 85, pp. 36-44, (2009); Coy V., Genetics of essential hypertension, J. Am. Acad. Nurse Pract., 17, pp. 219-224, (2005); Shin J., Johnson J.A., Pharmacogenetics of β-blockers, Pharmacotherapy, 27, pp. 874-887, (2007); Filigheddu F., Reid J.E., Troffa C., Pinnaparpaglia P., Argiolas G., Testa A., Skolnick M., Glorioso N., Genetic polymorphisms of the β-adrenergic system: Association with essential hypertension and response to β-blockade, Pharmacogenomics Journal, 4, 3, pp. 154-160, (2004); Farahani P., Dolovich L., Levine M., Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension, J. Clin. Epidemiol., 60, pp. 1-7, (2007); Frazier L., Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic, Pharmacogenomics Journal, 4, 1, pp. 17-23, (2004); Ziegler A., Konig I.R., Thompson J.R., Biostatistical aspects of genome-wide association studies, Biom. J., 50, pp. 8-28, (2008); Brain Jr. N., Dominiczak A.F., Pharmacogenomics in hypertension: Present practicalities and future potential, J. Hypertens., 23, pp. 1327-1329, (2005); Taylor M.R., Pharmacogenetics of the human β-adrenergic receptors, Pharmacogenomics J., 7, pp. 29-37, (2007); Fornage M., Unraveling hypertension: Epigenomics comes of age, Pharmacogenomics, 8, pp. 125-128, (2007); Magnusson Y., Levin M.C., Eggertsen R., Nystrom E., Mobini R., Schaufelberger M., Andersson B., Ser49Gly of β<sub>1</sub>-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy, Clinical Pharmacology and Therapeutics, 78, 3, pp. 221-231, (2005); Julius S., Nesbitt S.D., Egan B.M., Et al., Feasibility of treating prehypertension with an angiotensin-receptor blocker, N. Engl. J. Med., 354, pp. 1685-1697, (2006); Lumley T., Rice K.M., Psaty B.M., Carryover effects after cessation of drug treatment: Trophies or dreams?, Am. J. Hypertens., 21, pp. 14-16, (2008); Arnett D.K., Tang W., Province M.A., Oberman A., Ellison R.C., Morgan D., Eckfeldt J.H., Hunt S.C., Interarm differences in seated systolic and diastolic blood pressure: The Hypertension Genetic Epidemiology Network study, Journal of Hypertension, 23, 6, pp. 1141-1147, (2005); Stergiou G.S., Baibas N.M., Gantzarou A.P., Et al., Reproducibility of home, ambulatory, and clinic blood pressure: Implications for the design of trials for the assessment of antihypertensive drug efficacy, Am. J. Hypertens., 15, pp. 101-104, (2002); Charchar F.J., Zimmerli L.U., Tomaszewski M., The pressure of finding human hypertension genes: New tools, old dilemmas, J. Hum. Hypertens., 22, pp. 821-828, (2008); Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., Lombardi C., Soro A., Dettori F., Parpaglia P.P., Alibrandi M.T.S., Cusi D., Bianchi G., The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, 4 I, pp. 649-654, (1999); Sciarrone M.T., Stella P., Barlassina C., Manunta P., Lanzani C., Bianchi G., Cusi D., ACE and α-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, 3 I, pp. 398-403, (2003); Kaye D.M., Smirk B., Williams C., Jennings G., Esler M., Holst D., β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure, Pharmacogenetics, 13, 7, pp. 379-382, (2003); Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F., β<sub>1</sub>-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clinical Pharmacology and Therapeutics, 74, 1, pp. 44-52, (2003); Liu J., Liu Z.-Q., Tan Z.-R., Chen X.-P., Wang L.-S., Zhou G., Zhou H.-H., Gly389Arg polymorphism of β<sub>1</sub>-adrenergic receptor is associated with the cardiovascular response to metoprolol, Clinical Pharmacology and Therapeutics, 74, 4, pp. 372-379, (2003); Sofowora G.G., Dishy V., Muszkat M., Xie H.G., Kim R.B., Harris P.A., Prasad H.C., Byrne D.W., Nair U.B., Wood A.J.J., Stein C.M., A common β<sub>1</sub>-adrencrgic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade, Clinical Pharmacology and Therapeutics, 73, 4, pp. 366-371, (2003); Hindorff L.A., Heckbert S.R., Psaty B.M., Et al., β(2)-adrenergic receptor polymorphisms and determinants of cardiovascular risk: The Cardiovascular Health Study, Am. J. Hypertens., 18, pp. 392-397, (2005); Stavroulakis G.A., Makris T.K., Krespi P.G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc. Drugs Ther., 14, pp. 427-432, (2000); Miller J.A., Thai K., Scholey J.W., Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney International, 56, 6, pp. 2173-2180, (1999); Karlsson J., Lind L., Hallberg P., Michaelsson K., Kurland L., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Melhus H., Beta<sub>1</sub>-adrenergic receptor gene polymorphisms and response to beta<sub>1</sub>-adrenergic receptor blockade in patients with essential hypertension, Clinical Cardiology, 27, 6 SUPPL. 3, pp. 347-350, (2004); Dishy V., Sofowora G.G., Xie H.-G., Kim R.B., Byrne D.W., Michael Stein C., Wood A.J.J., The effect of common polymorphisms of the β<sub>2</sub>-adrenergic receptor on agonist-mediated vascular desensitization, New England Journal of Medicine, 345, 14, pp. 1030-1035, (2001)","D. K. Arnett; University of Alabama at Birmingham, RPHB 220E, Birmingham, AL 55294-0022, 1530 3rd Avenue South, United States; email: arnett@ms.soph.uab.edu","","","","","","","","17448042","","PARMF","19663674","English","Pharmacogenomics","Review","Final","All Open Access; Green Open Access","Scopus","2-s2.0-70649094353"
"Kardia S.L.R.; Sun Y.V.; Hamon S.C.; Barkley R.A.; Boerwinkle E.; Turner S.T.","Kardia, Sharon L.R. (7003691206); Sun, Yan V. (15045968900); Hamon, Sara C. (7003869784); Barkley, Ruth Ann (26659477100); Boerwinkle, Eric (7102087489); Turner, Stephen T. (7402275413)","7003691206; 15045968900; 7003869784; 26659477100; 7102087489; 7402275413","Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension","2007","BMC Medical Genetics","8","","61","","","","6","10.1186/1471-2350-8-61","https://www.scopus.com/inward/record.uri?eid=2-s2.0-35848964570&doi=10.1186%2f1471-2350-8-61&partnerID=40&md5=5a81f782de6ebbc5d3aa3df635f0a3f0","Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States; Department of Human Genetics, University of Michigan, Ann Arbor, MI, United States; Human Genetics Center, University of Texas Health Sciences Center, Houston, TX, United States; Department of Internal Medicine, Division of Hypertension, Mayo Clinic, Rochester, MN, United States","Kardia S.L.R., Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States; Sun Y.V., Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States; Hamon S.C., Department of Human Genetics, University of Michigan, Ann Arbor, MI, United States; Barkley R.A., Human Genetics Center, University of Texas Health Sciences Center, Houston, TX, United States; Boerwinkle E., Human Genetics Center, University of Texas Health Sciences Center, Houston, TX, United States; Turner S.T., Department of Internal Medicine, Division of Hypertension, Mayo Clinic, Rochester, MN, United States","Background: As part of the NHLBI Family Blood Pressure Program, the Genetic Epidemiology Network of Arteriopathy (GENOA) recruited 575 sibships (n = 1583 individuals) from Rochester, MN who had at least two hypertensive siblings diagnosed before age 60. Linkage analysis identified a region on chromosome 2 that was investigated using 70 single nucleotide polymorphisms (SNPs) typed in 7 positional candidate genes, including adducin 2 (ADD2). Method: To investigate whether blood pressure (BP) levels in these hypertensives (n = 1133) were influenced by gene-by-drug interactions, we used cross-validation statistical methods (i.e., estimating a model for predicting BP levels in one subgroup and testing it in a different subgroup). These methods greatly reduced the chance of false positive findings. Results: Eight SNPs in ADD2 were significantly associated with systolic BP in untreated hypertensives (p-value < 0.05). Moreover, we also identified SNPs associated with gene-by-drug interactions on systolic BP in drug-treated hypertensives. The TT genotype at SNP rs1541582 was associated with an average systolic BP of 133 mmHg in the beta-blocker subgroup and 148 mmHg in the diuretic subgroup after adjusting for overall mean differences among drug classes. Conclusion: Our findings suggest that hypertension candidate gene variation may influence BP responses to specific antihypertensive drug therapies and measurement of genetic variation may assist in identifying subgroups of hypertensive patients who will benefit most from particular antihypertensive drug therapies. © 2007 Kardia et al; licensee BioMed Central Ltd.","","Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cytoskeletal Proteins; Genetic Markers; Genotype; Humans; Hypertension; Linkage Disequilibrium; Middle Aged; Models, Genetic; Polymorphism, Single Nucleotide; Predictive Value of Tests; Regression Analysis; Variation (Genetics); adducin; adducin 2; angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; diuretic agent; renin inhibitor; unclassified drug; ADD2 protein, human; cytoskeleton protein; adult; article; blood pressure measurement; chromosome 2; controlled study; false positive result; gene interaction; genetic association; genetic variability; genotype; health program; human; hypertension; linkage analysis; major clinical study; patient selection; pharmacogenetics; prediction; sibling; single nucleotide polymorphism; statistical analysis; systolic blood pressure; treatment outcome; United States; analysis of variance; biological model; blood pressure; drug effect; gene linkage disequilibrium; genetic marker; genetic variability; genetics; middle aged; pathophysiology; prediction and forecasting; regression analysis; validation study","","ADD2 protein, human, ; Antihypertensive Agents, ; Cytoskeletal Proteins, ; Genetic Markers, ","","","National Heart, Lung, and Blood Institute, NHLBI, (U10HL054457); National Heart, Lung, and Blood Institute, NHLBI","","Hajjar I., Kotchen T.A., Trends in prevalence, awareness, treatment, and control of hypertension in the united states, 1988-2000, JAMA, 290, pp. 199-206, (2003); Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report, JAMA, 289, pp. 2560-2572, (2003); Barkley R.A., Chakravarti A., Cooper R.S., Ellison R.C., Hunt S.C., Province M.A., Turner S.T., Weder A.B., Boerwinkle E., Positional identification of hypertension susceptibility genes on chromosome 2, Hypertension, 43, pp. 477-482, (2004); Gilligan D.M., Lozovatsky L., Silberfein A., Organization of the human beta-adducin gene (ADD2), Genomics, 43, pp. 141-148, (1997); Matsuoka Y., Hughes C.A., Bennett V., Adducin regulation definition of the calmodulin-binding domain and sites of phosphorylation by protein kinases A and C, J Biol Chem, 271, pp. 25157-25166, (1996); Bianchi G., Tripodi G., Casari G., Salardi S., Barber B.R., Garcia R., Leoni P., Torielli L., Cusi D., Ferrandi M., Two point mutations within the adducin genes are involved in blood pressure variation, Proc Natl Acad Sci USA, 91, pp. 3999-4003, (1994); Hughes C.A., Bennett V., Adducin: A physical model with implications for function in assembly of spectrin-actin complexes, J Biol Chem, 270, pp. 18990-18996, (1995); Hunter D.J., Gene-environment interactions in human diseases, Nat Rev Genet, 6, pp. 287-298, (2005); Kardia S.L., Bielak L.F., Lange L.A., Cheverud J.M., Boerwinkle E., Turner S.T., Sheedy II P.F., Peyser P.A., Epistatic effects between two genes in the renin-angiotensin system and systolic blood pressure and coronary artery calcification, Med Sci Monit, 12, (2006); Ge D., Zhu H., Huang Y., Treiber F.A., Harshfield G.A., Snieder H., Dong Y., Multilocus analyses of renin-angiotensin-aldosterone system gene variants on blood pressure at rest and during behavioral stress in young normotensive subjects, Hypertension, 49, pp. 107-112, (2007); Sing C.F., Stengard J.H., Kardia S.L., Dynamic relationships between the genome and exposures to environments as causes of common human diseases, World Rev Nutr Diet, 93, pp. 77-91, (2004); Mosier C.I., Problems and designs of cross-validation, Educational and Psychological Measurement, 11, (1951); Browne M.W., Cross-validation methods, J Math Psychol, 44, pp. 108-132, (2000); Feng Z., Prentice R., Srivastava S., Research issues and strategies for genomic and proteomic biomarker discovery and validation: A statistical perspective, Pharmacogenomics, 5, pp. 709-719, (2004); Multi-center genetic study of hypertension: The family blood pressure program (FBPP), Hypertension, 39, pp. 3-9, (2002); FBPP Database; Melton III L.J., History of the rochester epidemiology project, Mayo Clin Proc, 71, pp. 266-274, (1996); Proprietary Concepts. Master Drug Data Base Documentation Manual, (1996); NCBI Database; Celera Database; Liang K.Y., Zeger S.L., Longitudinal data analysis using generalized estimating equations, Biometrika, 73, pp. 13-22, (1986); Mushiroda T., Saito S., Tanaka Y., Takasaki J., Kamatani N., Beck Y., Tahara H., Nakamura Y., Ohnishi Y., A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms, J Hum Genet, 50, pp. 442-447, (2005); Kannel W.B., Belanger A.J., Epidemiology of heart failure, Am Heart J, 121, pp. 951-957, (1991); Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., Shulman N.B., Stamler J., Blood pressure and end-stage renal disease in men, N Engl J Med, 334, pp. 13-18, (1996); MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J., Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias, Lancet, 335, pp. 765-774, (1990); Stamler J., Stamler R., Neaton J.D., Blood pressure, systolic and diastolic, and cardiovascular risks. US population data, Arch Intern Med, 153, pp. 598-615, (1993); Collins R., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O., Hennekens C.H., Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990); Hebert P.R., Moser M., Mayer J., Glynn R.J., Hennekens C.H., Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease, Arch Intern Med, 153, pp. 578-581, (1993); Williams B., Evolution of hypertensive disease: A revolution in guidelines, Lancet, 368, pp. 6-8, (2006); Psaty B.M., Weiss N.S., Furberg C.D., Recent trials in hypertension: Compelling science or commercial speech?, JAMA, 295, pp. 1704-1706, (2006); Drug reactions enzymes, and biochemical genetics, J Am Med Assoc, 165, pp. 835-837, (1957); Weber W.W., Pharmacogenetics, (1997); Laragh J.H., Lamport B., Sealey J., Alderman M.H., Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001); Turner S.T., Boerwinkle E., Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses, Pharmacogenomics, 4, pp. 53-65, (2003); Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, pp. 1602-1609, (1995); Sasaki M., Oki T., Iuchi A., Tabata T., Yamada H., Manabe K., Fukuda K., Abe M., Ito S., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies, J Hypertens, 14, pp. 1403-1408, (1996); Cusi D., Barlassina C., Azzani T., Casari G., Citterio L., Devoto M., Glorioso N., Lanzani C., Manunta P., Righetti M., Rivera R., Stella P., Troffa C., Zagato L., Bianchi G., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Turner S.T., Chapman A.B., Schwartz G.L., Boerwinkle E., Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide, Am J Hypertens, 16, pp. 834-839, (2003); Jia H., Hingorani A.D., Sharma P., Hopper R., Dickerson C., Trutwein D., Lloyd D.D., Brown M.J., Association of the G(s)alpha gene with essential hypertension and response to beta-blockade, Hypertension, 34, pp. 8-14, (1999); Ferrandi M., Tripodi G., Salardi S., Florio M., Modica R., Barassi P., Parenti P., Shainskaya A., Karlish S., Bianchi G., Ferrari P., Renal na, K-ATPase in genetic hypertension, Hypertension, 28, pp. 1018-1025, (1996); Tikhonoff V., Kuznetsova T., Stolarz K., Bianchi G., Casiglia E., Kawecka-Jaszcz K., Nikitin Y., Tizzone L., Wang J.G., Staessen J.A., Beta-adducin polymorphisms, blood pressure, and sodium excretion in three european populations, Am J Hypertens, 16, pp. 840-846, (2003); Wang J.G., Staessen J.A., Barlassina C., Fagard R., Kuznetsova T., Struijker-Boudier H.A., Zagato L., Citterio L., Messaggio E., Bianchi G., Association between hypertension and variation in the alpha- and beta-adducin genes in a white population, Kidney Int, 62, pp. 2152-2159, (2002); Manly K.F., Reliability of statistical associations between genes and disease, Immunogenetics, 57, pp. 549-558, (2005); Stone M., Cross-validatory choice and assessment of statistical predictions, Journal of the Royal Statistical Society. Series B (Methodological), 36, pp. 111-147, (1974); Zhu J., Hastie T., Classification of gene microarrays by penalized logistic regression, Biostatistics, 5, pp. 427-443, (2004); Ritchie M.D., Motsinger A.A., Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies, Pharmacogenomics, 6, pp. 823-834, (2005); Gong R., Liu Z., Li L., Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: Interaction with environmental/clinical factors, Arthritis Rheum, 56, pp. 1608-1617, (2007); Larsen J.E., Pavey S.J., Passmore L.H., Bowman R.V., Hayward N.K., Fong K.M., Gene expression signature predicts recurrence in lung adenocarcinoma, Clin Cancer Res, 13, pp. 2946-2954, (2007); Pohjanen E., Thysell E., Jonsson P., Eklund C., Silfver A., Carlsson I.B., Lundgren K., Moritz T., Svensson M.B., Antti H., A multivariate screening strategy for investigating metabolic effects of strenuous physical exercise in human serum, J Proteome Res; Agranoff D., Fernandez-Reyes D., Papadopoulos M.C., Rojas S.A., Herbster M., Loosemore A., Tarelli E., Sheldon J., Schwenk A., Pollok R., Rayner C.F., Krishna S., Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum, Lancet, 368, pp. 1012-1021, (2006); Mertens B.J., De Noo M.E., Tollenaar R.A., Deelder A.M., Mass spectrometry proteomic diagnosis: Enacting the double cross-validatory paradigm, J Comput Biol, 13, pp. 1591-1605, (2006); Wood I.A., Visscher P.M., Mengersen K.L., Classification based upon gene expression data: Bias and precision of error rates, Bioinformatics, 27, 11, pp. 1363-1370, (2007); Lanzani C., Citterio L., Jankaricova M., Sciarrone M.T., Barlassina C., Fattori S., Messaggio E., Serio C.D., Zagato L., Cusi D., Hamlyn J.M., Stella A., Bianchi G., Manunta P., Role of the adducin family genes in human essential hypertension, J Hypertens, 23, pp. 543-549, (2005); Richart T., Thijs L., Kuznetsova T., Tikhonoff V., Zagato L., Lijnen P., Fagard R., Wang J., Bianchi G., Staessen J.A., Intra-erythrocyte cation concentrations in relation to the C1797T beta-adducin polymorphism in a general population, J Hum Hypertens, 21, pp. 387-392, (2007)","S.L.R. Kardia; Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States; email: skardia@umich.edu","","","","","","","","14712350","","BMGMA","17854487","English","BMC Med. Genet.","Article","Final","All Open Access; Gold Open Access","Scopus","2-s2.0-35848964570"
"Schelleman H.; Stricker B.H.Ch.; De Boer A.; Kroon A.A.; Verschuren M.W.M.; Van Duijn C.M.; Psaty B.M.; Klungel O.H.","Schelleman, Hedi (8786514900); Stricker, Bruno H. Ch. (35380220500); De Boer, Anthonius (56489803600); Kroon, Abraham A. (35452655900); Verschuren, Monique W.M. (7003301273); Van Duijn, Cornelia M. (36037246700); Psaty, Bruce M. (35374213400); Klungel, Olaf H. (7006204390)","8786514900; 35380220500; 56489803600; 35452655900; 7003301273; 36037246700; 35374213400; 7006204390","Drug-gene interactions between genetic polymorphisms and antihypertensive therapy","2004","Drugs","64","16","","1801","1816","15","37","10.2165/00003495-200464160-00006","https://www.scopus.com/inward/record.uri?eid=2-s2.0-4544246587&doi=10.2165%2f00003495-200464160-00006&partnerID=40&md5=58e22061db7cc5ca4980cc9b8ad940ab","Dept. of Epidemiol. and Biostatist., Erasmus MC, Rotterdam, Netherlands; Dept. Pharmacoepidemiology P., Utrecht Inst. of Pharmaceutical Sci., Utrecht University, Utrecht, Netherlands; Department of Internal Medicine, University Hospital of Maastricht, Cardiovasc. Res. Inst. Maastricht, Maastricht, Netherlands; Ctr. for Prev. and Hlth. Serv. Res., Natl. Inst. Pub. Hlth. the Environ., Bilthoven, Netherlands; Cardiovascular Health Research Unit, Depts. Med., Epidemiol., Hlth. Serv., University of Washington, Seattle, WA, United States; Dept. of Epidemiol. and Biostatist., Erasmus MC, 3000 DR Rotterdam, PO Box 1738, Netherlands","Schelleman H., Dept. of Epidemiol. and Biostatist., Erasmus MC, Rotterdam, Netherlands, Dept. Pharmacoepidemiology P., Utrecht Inst. of Pharmaceutical Sci., Utrecht University, Utrecht, Netherlands; Stricker B.H.Ch., Dept. of Epidemiol. and Biostatist., Erasmus MC, Rotterdam, Netherlands, Dept. of Epidemiol. and Biostatist., Erasmus MC, 3000 DR Rotterdam, PO Box 1738, Netherlands; De Boer A., Dept. Pharmacoepidemiology P., Utrecht Inst. of Pharmaceutical Sci., Utrecht University, Utrecht, Netherlands; Kroon A.A., Department of Internal Medicine, University Hospital of Maastricht, Cardiovasc. Res. Inst. Maastricht, Maastricht, Netherlands; Verschuren M.W.M., Ctr. for Prev. and Hlth. Serv. Res., Natl. Inst. Pub. Hlth. the Environ., Bilthoven, Netherlands; Van Duijn C.M., Dept. of Epidemiol. and Biostatist., Erasmus MC, Rotterdam, Netherlands; Psaty B.M., Cardiovascular Health Research Unit, Depts. Med., Epidemiol., Hlth. Serv., University of Washington, Seattle, WA, United States; Klungel O.H., Dept. Pharmacoepidemiology P., Utrecht Inst. of Pharmaceutical Sci., Utrecht University, Utrecht, Netherlands","Genetic factors may influence the response to antihypertensive medication. A number of studies have investigated genetic polymorphisms as determinants of cardiovascular response to antihypertensive drug therapy. In most candidate gene studies, no such drug-gene interactions were found. However, there is observational evidence that hypertensive patients with the 460W allele of the α-adducin gene have a lower risk of myocardial infarction and stroke when treated with diuretics compared with other antihypertensive therapies. With regard to blood pressure response, interactions were found between genetic polymorphisms for endothelial nitric oxide synthase and diuretics, the α-adducin gene and diuretics, the α-subunit of G protein and β-adrenoceptor antagonists, and the ACE gene and angiotensin II type 1 (AT1) receptor antagonists. Other studies found an interaction between ACE inhibitors and the ACE insertion/deletion (I/D) polymorphism, which resulted in differences in AT1 receptor mRNA expression, left ventricular hypertrophy and arterial stiffness between different genetic variants. Also, drug-gene interactions between calcium channel antagonists and ACE I/D polymorphism regarding arterial stiffness have been reported. Unfortunately, the quality of these studies is quite variable. Given the methodological problems, the results from the candidate gene studies are still inconclusive and further research is necessary.","","Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials; Diuretics; Humans; Hypertension; Pharmacogenetics; Polymorphism, Genetic; Research Design; insertion sequences; adducin; alpha adducin; angiotensin 2 receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; endothelial nitric oxide synthase; guanine nucleotide binding protein; guanine nucleotide binding protein alpha; thiazide diuretic agent; unclassified drug; antihypertensive therapy; blood pressure; cardiovascular response; cardiovascular risk; drug response; essential hypertension; genetic polymorphism; genetic variability; heart infarction; heart left ventricle hypertrophy; hemodynamics; human; pharmacogenetics; protein expression; review; rigidity; stroke","","dipeptidyl carboxypeptidase, 9015-82-1; endothelial nitric oxide synthase, 503473-02-7; Adrenergic beta-Antagonists, ; Angiotensin II Type 1 Receptor Blockers, ; Angiotensin-Converting Enzyme Inhibitors, ; Antihypertensive Agents, ; Calcium Channel Blockers, ; Diuretics, ","","","","","Brown M.J., Haydock S., Pathoaetiology, epidemiology and diagnosis of hypertension, Drugs, 59, 2 SUPPL., pp. 1-12, (2000); Kaplan R.C., Psaty B.M., Heckbert S.R., Et al., Blood pressure level and incidence of myocardial infarction among patients treated for hypertension, Am J Public Health, 89, 9, pp. 1414-1417, (1999); Klungel O.H., Kaplan R.C., Heckbert S.R., Et al., Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients, Stroke, 31, 2, pp. 420-424, (2000); Klungel O.H., Stricker B.Hc.H., Paes A.H.P., Et al., Excess stroke among hypertensive men and women attributable to under-treatment of hypertension, Stroke, 30, 7, pp. 1312-1318, (1999); Materson B.J., Reda D.J., Preston R.A., Et al., Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug: Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, Arch Intern Med, 155, 16, pp. 1757-1762, (1995); Sander C., Genomic medicine and the future of health care, Science, 287, 5460, pp. 1977-1978, (2000); Vesell E.S., Therapeutic lessons from pharmacogenetics, Ann Intern Med, 126, 8, pp. 653-655, (1997); Harrap S.B., Hypertension: Genes versus environment, Lancet, 344, 8916, pp. 169-171, (1994); O'Shaughnessy K.M., The genetics of essential hypertension, Clin Pharmacol, 51, 1, pp. 5-11, (2001); Wilson F.H., Disse-Nicodeme S., Choate K.A., Et al., Human hypertension caused by mutations in WNK kinases, Science, 293, 5532, pp. 1107-1112, (2001); Doris P.A., Hypertension genetics, single nucleotide polymorphisms, and the common disease: Common variant hypothesis, Hypertension, 2, pp. 323-331, (2002); Weber W.W., The legacy of pharmacogenetics and potential applications, Mutat Res, 479, 1-2, pp. 1-18, (2001); Inazu A., Jiang X.C., Haraki T., Et al., Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol, J Clin Invest, 94, 5, pp. 1872-1882, (1994); Philips K.A., Veenstra V.L., Oren E., Et al., Potential role of pharmacogenomics in reducing adverse drug reactions, JAMA, 14, 286, pp. 2270-2279, (2001); Flockhart D.A., Tanus-Santos J.E., Implications of cytochrome P450 interactions when prescribing medication for hypertension, Arch Intern Med, 162, 4, pp. 405-412, (2002); Levy G., Ebling W.F., Forrest A., Concentration- or effect-controlled clinical trails with sparse data, Clin Pharmacol Ther, 56, 1, pp. 1-8, (1994); Turner S.T., Schwartz G.L., Chapman A.B., Et al., Antihypertensive pharmacogenetics: Getting the right drug into the right patient, J Hypertens, 19, 1, pp. 1-11, (2001); Cadman P.E., O'Connor D.T., Pharmacogenetics of hypertension, Curr Opin Nephrol Hypertens, 12, 1, pp. 61-70, (2003); Turner S.T., Boerwinkle E., Genetics of blood pressure, hypertensive complications, and antihypertensive responses, Pharmacogenetics, 4, 1, pp. 53-65, (2003); Bianchi G., Staessen J.A., Patrizia F., Pharmacogenomics of primary hypertension: The lessons from the past to look towards the future, Pharmacogenomics, 4, 3, pp. 279-296, (2003); Cusi D., Barlassina C., Azzani T., Et al., Adducin polymorphism in primary hypertension: Linkage and association study; relationship to salt sensitivity, Lancet, 349, 9062, pp. 1353-1357, (1997); Glorioso N., Manunta P., Filigheddu F., Et al., The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by negative association study, Hypertension, 34, 4 PART 1, pp. 649-654, (1999); Psaty B.M., Smith N.L., Heckbert S.R., Et al., Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, 13, pp. 1680-1689, (2002); Sciarrone M.T., Stella P., Barlassina C., Et al., ACE and α-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Turner S.T., Chapman A.B., Schwartz G.L., Et al., Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide, Am J Hypertens, 16, pp. 834-839, (2003); Schwartz G.L., Turner S.T., Chapman A.B., Et al., Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide, Kidney Int, 62, pp. 1718-1723, (2002); Turner S.T., Schwartz G.L., Chapman A.B., Et al., C825T polymorphism of the G protein B3-subunit and antihypertensive response to a thiazide diuretic, J Hypertens, 37, 2 PART 2, pp. 739-743, (2001); Dudley C., Keavney B., Casadei B., Et al., Prediction of patient responses to antihyertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J Hypertens, 14, 2, pp. 259-262, (1996); Kurland L., Melhus H., Karlsson J., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients, J Hypertens, 19, 10, pp. 1783-1787, (2001); Kurland L., Melhus H., Karlsson J., Et al., Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, J Hypertens, 20, 4, pp. 657-663, (2002); Dieguez-Lucena J.L., Aranda-Lara P., Ruiz-Galdon M., Et al., Angiotensin I-converting enzyme genotypes and angiotensin II receptors: Response to therapy, Hypertension, 28, 1, pp. 98-103, (1996); O'Shaughnessy K.M., Fu B., Dickerson C., Et al., The gain-of-function G389R variant of the betal-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects, Clin Sci, 99, pp. 233-238, (2000); Johnson J.A., Zineh I., Puckett B.J., Et al., Betal-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin Pharmacol, 74, 1, pp. 44-52, (2003); Kurland L., Melhus H., Karlsson J., Et al., Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response, Am J Hypertens, 15, 5, pp. 389-393, (2002); Liljedahl U., Karlsson J., Melhus H., Et al., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenomics, 13, 1, pp. 7-17, (2003); Hallberg P., Lind L., Michaelsson K., Et al., B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, J Hypertens, 21, pp. 621-624, (2003); Jia H., Hingorani A.D., Sharma P., Et al., Association of the G<sub>s</sub>α gene with essential hypertension and response to β-blockade, Hypertension, 34, 1, pp. 8-14, (1999); Hingorani A.D., Jia H., Stevens P.A., Et al., Renin-angiotensin system gene polymorphisms influences blood pressure and the response to angiotensin converting enzyme inhibition, J Hypertens, 13, 12 PART 2, pp. 1602-1609, (1995); Stavroulakis G.A., Makris T.K., Krespi P.G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc Drugs Ther, 14, 4, pp. 427-432, (2000); Kohno M., Yokokawa K., Minami M., Et al., Association between angiotensin converting-enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors, Am J Med, 106, 5, pp. 544-549, (1999); Iwai N., Ohmichi N., Uchida Y., Et al., Does the angiotensin converting enzyme gene polymorphism affect patients response to ACE inhibitor?, Circulation, 98, 1 SUPPL., (1998); Sasaki M., Oki T., Iuchi A., Et al., Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiograhic studies, J Hypertens, 14, 12, pp. 1403-1408, (1996); Ochmichi N., Iwai N., Uchedia Y., Et al., Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype, Am J Hypertens, 10, pp. 951-955, (1997); Parving H.H., Jacobsen P., Tarnow L., Et al., Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study, BMJ, 313, 7057, pp. 591-594, (1996); Hallberg P., Karlsson J., Kurland L., Et al., The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular hypertrophy investigations vs Atenolol (SILVA) trial, J Hypertens, 20, 10, pp. 2089-2093, (2002); Benetos A., Cambien F., Gautier S., Et al., Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals, Hypertension, 28, 6, pp. 1081-1084, (1996); Van Essen G.G., Rensma P.L., De Zeeuw D., Et al., Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy, Lancet, 347, 8994, pp. 94-95, (1996); McNamara D.M., Holubkov R., Janosko K., Et al., Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, Circulation, 103, 12, pp. 1644-1648, (2001); Moriyama T., Kitamura H., Ochi S., Et al., Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin converting enzyme inhibitors in patients with proteinuria, J Am Soc Nephrol, 6, 6, pp. 1676-1678, (1995); O'Toole L., Stewart M., Padfield P., Et al., Effect of the insertion/deletion polymorphism of the angiotensin- converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure, J Cardiovasc Pharmacol, 32, 6, pp. 427-432, (1998); Okamura A., Ohishi M., Rakugi H., Et al., Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty, Angiology, 50, 10, pp. 811-822, (1999); Van Der Kleij F.G., Schmidt A., Navis G.J., Et al., Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status, Kidney Int Suppl, 63, (1997); Meurice T., Bauters C., Hermant X., Et al., Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial, Lancet, 357, 9265, pp. 1321-1324, (2001); Harrap S.B., Tzourio C., Cambien F., Et al., The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition, Hypertension, 42, 3, pp. 297-303, (2003); Manunta P., Cusi D., Barlassina C., Et al., Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients, Kidney Int, 53, 6, pp. 1471-1478, (1998); Manunta P., Burnier M., D'Amico M., Et al., Adducin polymorphism affects renal proximal tubule reabsorption in hypertension, Hypertension, 33, 2, pp. 694-697, (1999); Ferrandi M., Salardi S., Tripodi G., Et al., Evidence for interaction between adducin and Na,K-ATPase: Differential effect of hypertension related human and rat adducin polymorphisms, Am J Physiol, 277, 4 PART 2, pp. 1338-1349, (1999); Tripodi G., Valtorta F., Torielli L., Et al., Hypertension associated-mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport, J Clin Invest, 97, 12, pp. 2815-2822, (1996); Neer E.J., Heterotrimeric G proteins: Organizers of transmembrane signals, Cell, 80, 2, pp. 249-257, (1995); Siffert W., Rosskopf D., Siffert G., Et al., Association of a human G-protein beta3 subunit variant with hypertension, Nat Genet, 18, 1, pp. 45-48, (1998); Rosskopf D., Mantley I., Habich C., Et al., Identification and characterization of Gβ3S2, a novel splice variant of the G-protein β3 subunit, Biochem J, 371, 1 PART, pp. 223-232, (2003); Schorr U., Blaschke K., Beige J., Et al., G-protein beta3 subunit 825T allele and the response to dietary salt in normotensive men, J Hypertens, 18, 7, pp. 855-859, (2000); Pamies-Andrue E., Ramirez-Lorca R., Stiefel Garcia-Junco P., Et al., Renin-angiotensin-aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension, J Hum Hypertens, 17, 3, pp. 187-191, (2003); Ciechanowicz A., Widecka K., Drozd R., Et al., Lack of association between Gly460Trp polymorphism of alpha-adducin gene and salt sensitivity of blood pressure in Polish hypertensives, Kidney Blood Press Res, 24, 3, pp. 201-206, (2001); Nickenig G., Strehlow K., Roeling J., Et al., Salt induces vascular AT<sub>1</sub> receptor overexpression in vitro and vivo, Hypertension, 31, 6, pp. 1272-1277, (1998); Poch E., Gonzalez D., De La Sierra A., Et al., Genetic variation of the gamma subunit of the epithelial Na<sup>+</sup> channel and essential hypertension: Relationship with salt sensitivity, Am J Hypertens, 13, 6 PART 1, pp. 648-653, (2000); Giner V., Poch E., Bragulat E., Et al., Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension, Hypertension, 35, 1 PART 2, pp. 512-517, (2000); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin II type-1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, 1, pp. 63-69, (1994); Spiering W., Kroon A.A., Fuss-Lejeune M.M.J.J., Et al., Angiotensin II sensitivity is associated with the angiotensin type I receptor A1166C polymorphism in essential hypertensives on a high sodium diet, Hypertension, 36, 3, pp. 411-416, (2000); Takami S., Imai Y., Katsuya T., Et al., Gene polymorphism of the renin-angiotensin system associates with risk for lucanar intfarctions: The Ohasama study, Am J Hypertens, 13, 2, pp. 121-127, (2000); Buraczynska M., Pijanowski Z., Spasiewicz D., Et al., Renin-angiotensin system gene polymorphisms: Assessment of the risk of coronary heart disease, Kardiol Pol, 58, 1, pp. 1-9, (2003); Tiret L., Bonnardeaux A., Poirier O., Et al., Synergistic effects on angiotensin-converting enzyme and the angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction, Lancet, 344, 8927, pp. 910-913, (1994); Tomino Y., Makita Y., Shike T., Et al., Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or the angiotensin II receptor and renal progress in Japanese NIDDM patients, Nephron, 82, 2, pp. 139-144, (1999); Van Der Kleij F.G., Rensma P.L., De Zeeuw D., Et al., Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status, Kidney Int Suppl, 63, 4, pp. 23-26, (1997); Davies E., Holloway C.D., Ingramm M.C., Et al., Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2, Hypertension, 33, 2, pp. 703-707, (1999); Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Et al., Molecular basis of hypertension: Role of human hypertension: Role of angiotensinogen, Cell, 71, 1, pp. 169-180, (1992); Caulfield M., Lavender P., Farrall M., Et al., Linkage of the angiotensinogen gene to essential hypertension, N Engl J Med, 330, 23, pp. 1629-1633, (1994); Brand E., Chatelain N., Keavney B., Et al., Evaluation of the angiotensinogen locus in human essential hypertension: A European study, Hypertension, 31, 3, pp. 725-729, (1998); Kunz R., Kreutz R., Beige J., Et al., Association between the angiotensinogen 235T-variant and essential hypertension in whites: A systematic review and methodological appraisal, Hypertension, 30, 6, pp. 1331-1337, (1997); Luan J.A., Wong W.Y., Day N.E., Et al., Sample size determination for studies of gene-environment interaction, Int J Epidemiol, 30, pp. 1035-1040, (2001); Wong M.Y., Day N.E., Luan J.A., Et al., The detection of gene-environment interaction for continuous traits: Should we deal with measurement error by bigger studies or better measurements?, Int J Epidemiol, 32, 1, pp. 51-57, (2003); Jeunemaitre X., Inoue I., Williams C., Et al., Haplotypes of angiotensinogen in essential hypertension, Am J Hum Genet, 96, 6, pp. 295-300, (1997); Inoue I., Nakajima T., Williams C.S., Et al., A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and effects basal transcription in vitro, J Clin Invest, 99, 7, pp. 1786-1797, (1997); Hunt S.C., Cook N.R., Oberman A., Et al., Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II, Hypertension, 32, 3, pp. 393-401, (1998); Rigat B., Hubert C., Alhenc Gelas F., Et al., An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels, J Clin Invest, 86, 4, pp. 1343-1346, (1990); Tiret L., Rigat B., Visvikis S., Et al., Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels, Am J Hum Genet, 51, 1, pp. 197-205, (1992); Danser A.H., Schalekamp M.A., Bax W.A., Et al., Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism, Circulation, 92, 6, pp. 1387-1388, (1995); McKenzie C.A., Julier C., Forrester T., Et al., Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: Evidence for two quantitative-trait loci, Am J Hum Genet, 57, 6, pp. 1426-1435, (1995); Villard E., Tiret L., Visvikis S., Et al., Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis, Am J Hum Genet, 58, 6, pp. 1268-1278, (1996); Risch N., Merikangas K., The future of genetic studies of complex human diseases, Science, 273, 5281, pp. 1516-1517, (1996); Thomas D.C., Witte J.C., Point: Population stratification: A problem for case-control studies of candidate-gene associations?, Cancer Epidemiol Biomark, 11, 6, pp. 505-512, (2002); Materson B.J., Reda D.J., Cushman W.C., Et al., Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo, N Engl J Med, 328, pp. 914-921, (1993); Preston R.A., Materson B.J., Reda D.J., Et al., Age-race subgroups compared with renin profile as predictors of blood pressure response to antihypertensive therapy: Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, JAMA, 280, pp. 1168-1172, (1998); Chapman A.B., Schwartz G.L., Boerwinkle E., Et al., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int, 61, pp. 1047-1055, (2002); Marino M.R., Vachharajani N.N., Pharmacogenetics of irbesartan are not altered in special populations, J Cardiovasc Pharmacol, 40, 1, pp. 112-122, (2002); Wacholder S., Rothman N., Caporaso N., Counterpoint: Bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer, Cancer Epidemiol Biomark Prev, 11, 6, pp. 513-520, (2002); Pritchard J.K., Rosenberg N.A., Use of unlinked genetic markers to detect population stratification in association studies, Am J Hum Genet, 65, 1, pp. 220-228, (1999); Rosenberg N.A., Pritchard J.K., Weber J.L., Et al., Genetic structure of human populations, Science, 298, pp. 2381-2385, (2002)","B.H.Ch. Stricker; Dept. of Epidemiol. and Biostatist., Erasmus MC, 3000 DR Rotterdam, PO Box 1738, Netherlands; email: b.stricker@erasmusmc.nl","","","","","","","","00126667","","DRUGA","15301563","English","Drugs","Review","Final","","Scopus","2-s2.0-4544246587"
"Kreutz R.","Kreutz, Reinhold (7005487816)","7005487816","Pharmacogenetics of antihypertensive drug response","2004","Current Hypertension Reports","6","1","","15","20","5","9","10.1007/s11906-004-0005-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-5444220883&doi=10.1007%2fs11906-004-0005-9&partnerID=40&md5=0c1143d32c08a4cf056a4461bfd09692","Department of Clinical Pharmacology, Charité, Universitätsmedizin Berlin, 12203 Berlin, Hindenburgdamm 30, Germany","Kreutz R., Department of Clinical Pharmacology, Charité, Universitätsmedizin Berlin, 12203 Berlin, Hindenburgdamm 30, Germany","Pharmacogenetics is a discipline of molecular medicine that investigates the genetic basis of individual variation of drug responses. Before the era of the human genome project and the subsequent progress in genomic research, this field was primarily restricted to the invesirigation of the genetics of drug-metabolizing enzymes as they account for individual differences in pharmacokinetics and tolerability of drugs. In the current genomic era, pharmacogenetic research is applied to all fields of drug treatment in clinical medicine, including hypertension research. In contrast to the traditional approach, however, the influence of individual genetic variation on the efficacy of a drug (ie, the pharmacodynamic response) is the major focus of pharmacogenetic: research and its clinical applicability. Therefore, the identification of individual genetic variation influencing the blood pressure - lowering effect of an antihypertensive compound and the implementation of this knowledge into clinical practice is the major goal of pharmacogenetic research in the field of hypertension. In this article, some important, recent research work and progress on the pharmacogenetics of antihypertensive drug responses are reviewed and evaluated. Copyright © 2004 by Current Science Inc.","","adducin; aldosterone synthase; alpha adrenergic receptor; angiotensin 1 receptor; angiotensin 1 receptor antagonist; antihypertensive agent; atenolol; beta 2 adrenergic receptor; beta adrenergic receptor; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase; diuretic agent; hydrochlorothiazide; irbesartan; adrenergic receptor blocking; antihypertensive activity; blood pressure monitoring; blood pressure regulation; cardiovascular risk; clinical trial; drug efficacy; drug response; essential hypertension; gene deletion; gene expression; gene expression profiling; gene insertion; genetic polymorphism; genetic variability; human; nonhuman; pharmacogenetics; pilot study; renin angiotensin aldosterone system; review; single nucleotide polymorphism; sodium absorption","","aldosterone synthase, 122933-89-5; atenolol, 29122-68-7, 93379-54-5; dipeptidyl carboxypeptidase, 9015-82-1; hydrochlorothiazide, 58-93-5; irbesartan, 138402-11-6","","","","","Bianchi G., Staessen J.A., Patrizia F., Pharmacogenomics of primary hypertension: The lessons from the past to look toward the future, Pharmacogenomics, 4, pp. 279-296, (2003); Cadman P.E., O'Connor D.T., Pharmacogenomics of hypertension, Curr. Opin. Nephrol. Hypertens., 12, pp. 61-70, (2003); Laragh J.H., Lamport B., Sealey J., Alderman M.H., Diagnosis ex juvantibus: Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment, Hypertension, 12, pp. 223-226, (1988); Barlassina C., Lanzani C., Manunta P., Bianchi G., Genetics of essential hypertension: From families to genes, J. Am. Soc. Nephrol., 13, SUPPL. 3, (2002); Lindpaintner K., Pharmacogenetics and the future of medical practice, J. Mol. Med., 81, pp. 141-153, (2003); Lifton R.P., Wilson F.H., Choate K.A., Geller D.S., Salt and blood pressure: New insight from human genetic studies, Cold Spring Harb. Symp. Quant. Biol., 67, pp. 445-450, (2002); Siragy H.M., ALLHAT: Do we have all the answers yet?, Curr. Hypertens. Rep., 5, pp. 293-294, (2003); Chapman A.B., Schwartz G.L., Boerwinkle E., Turner S.T., Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension, Kidney Int., 61, pp. 1047-1055, (2002); Sciarrone M.T., Stella P., Barlassina C., Et al., ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, pp. 398-403, (2003); Bianchi G., Tripodi G., Genetics of hypertension: The adducin paradigm, Ann. N Y Acad. Sci., 986, pp. 660-668, (2003); Rigat B., Hubert C., Alhenc-Gelas F., Et al., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J. Clin. Invest., 86, pp. 1343-1346, (1990); Lindpaintner K., Pfeffer M.A., Kreutz R., Et al., A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease, N. Engl. J. Med., 332, pp. 706-711, (1995); Singer D.R., Missouris C.G., Jeffery S., Angiotensin-converting enzyme gene polymorphism: What to do about all the confusion, Circulation, 94, pp. 236-239, (1996); Costerousse O., Allegrini J., Huang W., Alhenc-Gelas F., Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases, Biol. Res., 31, pp. 161-167, (1998); Barlassina C., Schork N.J., Manunta P., Et al., Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion, Kidney Int., 57, pp. 1083-1090, (2000); Swart S., Bing R.F., Swales J.D., Thurston H., Plasma renin in long-term diuretic treatment of hypertension: Effect of discontinuation and restarting therapy, Clin. Sci. (Lond.), 63, pp. 121-125, (1982); Cusi D., Barlassina C., Azzani T., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, pp. 1353-1357, (1997); Schwartz G.L., Turner S.T., Chapman A.B., Boerwinkle E., Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide, Kidney Int., 62, pp. 1718-1723, (2002); Psaty B.M., Smith N.L., Heckbert S.R., Et al., Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, pp. 1680-1689, (2002); Malmqvist K., Kahan T., Edner M., Et al., Regression of left ventricular hypertrophy in human hypertension with irbesartan, J. Hypertens., 19, pp. 1167-1176, (2001); Kurland L., Melhus H., Karlsson J., Et al., Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type I antagonist treatment in hypertensive patients, J. Hypertens., 19, pp. 1783-1787, (2001); Kurland L., Melhus H., Karlsson J., Et al., Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, Am. J. Hypertens., 15, pp. 389-393, (2002); Bassett M.H., Zhang Y., Clyne C., Et al., Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1, J. Mol. Endocrinol., 28, pp. 125-135, (2002); Kurland L., Melhus H., Karlsson J., Et al., Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, J. Hypertens., 20, pp. 657-663, (2002); Klingbeil A.U., Schneider M., Martus P., Et al., A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension, Am. J. Med., 115, pp. 41-46, (2003); Schmieder R.E., Erdmann J., Delles C., Et al., Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans, J. Am. Coll. Cardiol., 37, pp. 175-182, (2001); Siegel A.K., Planert M., Rademacher S., Et al., Genetic loci contribute to the progression of vascular and cardiac hypertrophy in salt-sensitive spontaneous hypertension, Arterioscler. Thromb. Vasc. Biol., 23, pp. 1211-1217, (2003); Liljedahl U., Karlsson J., Melhus H., Et al., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response, Pharmacogenetics, 13, pp. 7-17, (2003); Singh B.M., Mehta J.L., Interactions between the renin-angiotensin system and dyslipidemia: Relevance in the therapy of hypertension and coronary heart disease, Arch. Intern. Med., 163, pp. 1296-1304, (2003); Terwilliger J.D., Haghighi F., Hiekkalinna T.S., Goring H.H., A biased assessment of the use of SNPs in human complex traits, Curr. Opin. Genet. Dev., 12, pp. 726-734, (2002)","R. Kreutz; Department of Clinical Pharmacology, Charité, Universitätsmedizin Berlin, 12203 Berlin, Hindenburgdamm 30, Germany; email: Kreutz@medizin.fu-berlin.de","","Current Science Ltd","","","","","","15226417","","CHRUC","14972084","English","Curr. Hypertens. Rep.","Review","Final","","Scopus","2-s2.0-5444220883"
"Baudin B.","Baudin, Bruno (55257056200)","55257056200","Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations","2002","Pharmacogenomics","3","1","","65","73","8","40","10.1517/14622416.3.1.65","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036208543&doi=10.1517%2f14622416.3.1.65&partnerID=40&md5=34e34d4d9b7fab9b9518d136a93539ae","Service de Biochimie A, Hôpital Saint-Antoine, 75571 Paris Cedex 12, France","Baudin B., Service de Biochimie A, Hôpital Saint-Antoine, 75571 Paris Cedex 12, France","Molecular variants of individual components of the renin-angiotensin system (RAS) are thought to contribute to inherited predisposition towards essential hypertension. Polymorphisms in genes of angiotensinogen (AGT), angiotensin I-converting enzyme (ACE) and angiotensin II type 1 receptor (AT-1) have been related to differential responses to antihypertensive drugs. AT-1 receptor mediates the major pressor and trophic actions of angiotensin II (Ang II). At least 14 AT-1 polymorphisms have been described in the gene (AGT1R); in particular the +1166 A/C polymorphism has been associated with the severe form of essential hypertension. A relationship was suggested between this polymorphism and the humoral and renal hemodynamic responses to losartan, an antihypertensive drug acting as anAT-1 blocker. Variability in the individual response to AT-1 antagonists could also be due to variations in the pharmacokinetics of the drugs. This review presents current knowledge on Ang II-receptors and polymorphisms in AGT1R related to cardiovascular disease and antihypertensive therapy.","Angiotensin II receptor; Angiotensin II receptor antagonists; Antihypertensive therapy; Cardiovascular disease; Renin-angiotensin system; SNP","Antihypertensive Agents; Genetic Predisposition to Disease; Humans; Hypertension; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin-Angiotensin System; Variation (Genetics); adenine; adenylate cyclase; aldosterone; angiotensin; angiotensin 2 receptor; angiotensin 2 receptor antagonist; angiotensinogen; antihypertensive agent; atrial natriuretic factor; beta adrenergic receptor blocking agent; bradykinin; calcium channel blocking agent; calcium ion; catecholamine; cyclic GMP; cytosine; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; endothelin; guanine nucleotide binding protein; losartan; nitric oxide; phosphatidylinositide; phospholipase A2; phospholipase C; phospholipase D; sodium; unindexed drug; vasopressin; cardiovascular disease; controlled study; disease severity; DNA polymorphism; drug metabolism; drug response; essential hypertension; genetic predisposition; genetic variability; heredity; human; humoral immunity; kidney blood flow; pharmacogenetics; pressor response; receptor blocking; renin angiotensin aldosterone system; review","","Antihypertensive Agents, ; Losartan, 114798-26-4; Receptor, Angiotensin, Type 1, ; Receptors, Angiotensin, ","","","","","Burnier M., Brunner H.R., Angiotensin II receptor antagonists, Lancet, 335, pp. 637-645, (2000); Lindpainter K., Ganten D., The cardiac renin angiotensin system: An appraisal of present experimental and clinical evidence, Cir. Res, 68, pp. 905-921, (1991); Dzau V.J., Circulating versus local renin-angiotensin system in cardiovascular homeostasis, Circulation, 77, SUPPL. 1, pp. 14-113, (1988); Degasparo M., Catt K.J., Inagami T., Wright J.W., Unger T., The angiotensin II receptors, Pharmacol. Rev, 52, pp. 415-472, (2000); Lucius R., Gallinat S., Busche S., Rosentiel P., Unger T., Beyond blood pressure: New role for angiotensin II, Cell. Mol. Life Sci, 56, pp. 1008-1019, (1999); Carey R.M., Wang Z.Q., Siragy H.M., Role of the angiotensin Type 2 receptor in the regulation of blood pressure and renal function, Hypertension, 35, PART 2, pp. 155-163, (2000); Gradman A.H., Long-term benefits of angiotensin II blockade: Is the consensus changing?, Am. J. Cardiol, 84, (1999); Gallinat S., Busche S., Raizada M.K., Summers C., The angiotensin II Type 2 receptor: An enigma with multiple variations, Am. J. Physiol. Endocrinol. Metab, 278, (2000); Bonnardeaux A., Davies E., Jeunemaitre X., Et al., Angiotensin II Type 1 receptor gene polymorphisms in human essential hypertension, Hypertension, 24, pp. 63-69, (1994); Erdmann J., Riedel K., Rohde K., Et al., Characterization of polymorphisms in the promoter of the human angiotensin II subtype 1 (AT1) receptor gene, Ann. Hum. Genet, 63, pp. 369-374, (1999); Takahashi N., Murakami H., Kodama K., Et al., Association of a polymorphism at the 5′-region of the angiotensin II Type 1 receptor with hypertension, Ann. Hum. Genet, 64, pp. 197-205, (2000); Nakagawa K., Ishizaki T., Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine, Pharmacol. Therap, 86, pp. 1-28, (2000); Schmidt S., Sharma A.M., Zilch O., Et al., Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset, Nephrol. Dial. Transplant, 10, pp. 1145-1148, (1995); Hata A., Namikawa C., Sasaki A., Et al., Angiotensinogen as a risk factor for essential hypertension in Japan, J. Clin. Invest, 93, pp. 1285-1287, (1994); Tiret L., Ricard S., Poirier O., Et al., Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction: The ECTIM study, J. Hypertens, 13, pp. 311-317, (1995); Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the evidence of serum levels, J. Clin. Invest, 86, pp. 1343-1346, (1990); Villard E., Tiret L., Visvikis S., Rakotovao R., Cambien F., Soubrier F., Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene and study of their relationship to plasma ACE levels by two-QTL, segregation-linkage analysis, Am. J. Hum. Genet, 58, pp. 1268-1278, (1996); Faure-Delanef L., Baudin B., Beneteau-Burnat B., Beaudoin J.C., Giboudeau J., Cohen D., Plasma concentration, kinetic constants and gene polymorphism of angiotensin I-converting enzyme in centenarians, Clin. Chem, 44, pp. 2083-2087, (1998); Baudin B., Angiotensin I-converting enzyme gene polymorphism and drug response, Clin. Chem. Lab. Med, 38, pp. 853-856, (2000); Kainulainen K., Perola M., Terwilliger J., Et al., Evidence for involvement of the Type 1 angiotensin II receptor locus in essential hypertension, Hypertension, 33, pp. 844-849, (1999); Wang J.G., Staessen J.A., Genetic polymorphisms in the renin-angiotensin system: Relevance for susceptibility to cardiovascular disease, Eur. J. Pharmacol, 410, pp. 289-302, (2000); Castellano M., Muiesan M.L., Beschi M., Et al., Angiotensin II Type 1 receptor A/C<sup>1166</sup> polymorphism. Relationships with blood pressure and cardiovascular structure, Hypertension, 28, pp. 1076-1080, (1996); Benetos A., Gautier S., Ricard S., Et al., Influence of angiotensin-converting enzyme and angiotensin II Type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients, Circulation, 94, pp. 698-703, (1996); Takami S., Katsuya T., Rakugi H., Et al., Angiotensin II Type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension, Am. J. Hypertens, 11, pp. 316-321, (1998); Morisawa T., Kishimoto Y., Kitano M., Kawasaki H., Hasega W.A.J., Influence of angiotensin II type 1 receptor polymorphism on hypertension in patients with hypercholesterolemia, Clin. Chim. Acta, 304, pp. 91-97, (2001); Szombathy T., Szalai C., Katalin B., Palicz T., Romics L., Csaszar A., Association of angiotensin II Type 1 receptor polymorphism in resistant hypertension, Clin. Chim. Acta, 269, pp. 91-100, (1998); Ishanow A., Okamoto H., Watanabe M., Et al., Angiotensin II Type 1 receptor gene polymorphisms in patients with cardiac hypertrophy, Jap. Heart J, 39, pp. 87-96, (1998); Zhang X., Erdmann J., Regitz-Zagrosek V., Kurzinger S., Hense H.W., Schunker T.H., Evaluation of three polymorphisms in the promoter region of the angiotensin II Type 1 receptor gene, J. Hypertension, 18, pp. 267-272, (2000); Cambien F., Poirier O., Lecerf L., Et al., Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction, Nature, 359, pp. 641-644, (1992); Samani N.J., Thompson J.R., O'Toole L., Channer K., Woods K.L., A meta-analysis of the angiotensin-converting enzyme gene with myocardial infarction, Circulation, 94, pp. 708-712, (1996); Swales J.D., ACE gene: The plot thickens, Lancet, 342, pp. 1065-1066, (1993); Lindpainter K., Pfeffer M.A., Kreutz R., Et al., A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease, N. Engl. J. Med, 332, pp. 706-711, (1995); Tiret L., Bonnardeaux A., Poirier O., Et al., Synergistic effects of angiotensin-converting enzyme and angiotensin II Type 1 receptor gene polymorphisms on risk of myocardial infarction, Lancet, 344, pp. 910-913, (1994); Nakauchi Y., Suchiro T., Yamamoto M., Et al., Significance of angiotensin 1-converting enzyme and angiotensin II Type 1 receptor gene polymorphisms as risk factors for coronary heart disease, Atherosclerosis, 125, pp. 161-169, (1996); Danser A.H., Schunkert H., Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases, Eur. J. Pharmacol, 410, pp. 303-316, (2000); Gardemann A., Nguyen Q.D., Humme J., Et al., Angiotensin II Type 1 receptor A1116C gene polymorphism: Absence of an association with the risk of coronary artery disease and myocardial gene polymorphism on the risk of these diseases, Eur. Heart J, 19, pp. 1657-1665, (1998); Steeds R.P., Wardle A., Smith P.D., Martin D., Channer K.S., Samani N.J., Analysis of the postulated interaction between the angiotensin II sub-type 1 receptor gene A1166C polymorphism and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on risk of myocardial infarction, Atherosclerosis, 154, pp. 123-128, (2001); Kee F., Morrison C., Poirier O., Et al., Angiotensin II type-1 receptor and ACE polymorphism as risk of myocardial infarction in men and women, Eur. J. Clin. Invest, 30, pp. 1076-1082, (2000); Van Geel P.P., Pinto Y.M., Voors A.A., Et al., Angiotensin II Type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries, Hypertension, 35, pp. 717-721, (2000); Amant C., Hamon M., Bauters C., Et al., The angiotensin II Type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction, J. Am. Cell. Cardiol, 29, pp. 486-490, (1997); Steeds R.P., Toole L.O., Channer K.S., Morice A.H., Human vascular reactivity and polymorphisms of the angiotensin-converting enzyme and the angiotensin Type 1 receptor genes, J. Vasc. Res, 36, pp. 445-455, (1999); Vuagnat A., Giacche M., Hopkins P.N., Et al., Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II Type 1 receptor gene in hypertensive sibling pairs, J. Mol. Med, 79, pp. 175-183, (2001); Stangl K., Cascorbi I., Stangl V., Et al., A1166C polymorphism of the angiotensin II Type 1 receptor gene and risk of adverse events after coronary catheter interventions, Am. Heart J, 140, pp. 170-175, (2000); Brscic E., Bergerone S., Gagnor A., Et al., Acute myocardial infarction in young adults: Prognostic value of angiotensin-converting enzyme, angiotensin II Type 1 receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and genetic polymorphisms at medium-term follow-up, Am. Heart J, 139, pp. 979-984, (2000); Hamon M., Amant C., Bauters C., Et al., Dual determination of angiotensin-converting enzyme and angiotensin II Type 1 receptor genotypes as predictors of restenosis after coronary angioplasty, Am. J. Cardiol, 81, pp. 79-81, (1998); Chowdhury T.A., Dyer P.H., Kumars S., Et al., Lack of association of angiotensin II Type 1 receptor gene polymorphism with diabetic nephropathy in insulin-dependent diabetes mellitus, Diabet. Med, 14, pp. 837-840, (1997); Savage D.A., Feeney S.A., Fogarty D.G., Maxwell A.P., Risk of developing diabetic nephropathy is not associated with synergism between the angiotensin II (type 1) receptor C1166 allele and poor glycaemic control, Nephrol. Dial. Transplant, 14, pp. 891-894, (1999); Marre M., Jeunemaitre X., Gallois Y., Et al., Contribution of genetic polymorphism in the renin angiotensin system to the development of renal complication in insulin-dependent diabetes, J. Clin. Invest, 99, pp. 1585-1595, (1997); Tarnow L., Kjeld T., Knudsen E., Major-Pedersen A., Parving H.H., Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin-angiotensin system on risk of developing diabetic nephropathy in Type 1 diabetic patients, Diabetologia, 43, pp. 794-799, (2000); Frimat I., Philippe C., Maghakian M.N., Et al., Polymorphism of angiotensin-converting enzyme, angiotensinogen, and angiotensin II Type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS-a study of 274 men, J. Am. Soc. Nephrol, 11, pp. 2062-2067, (2000); Harden P.N., Geddes C., Rowe P.A., Et al., Polymorphism in angiotensin-converting enzyme gene and progression of IgA nephropathy, Lancet, 345, pp. 1540-1542, (1995); Yoshida H., Mitarai T., Kawamura, Et al., Role of the deletion polymorphism of the angiotensin-converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy, J. Clin. Invest, 96, pp. 2162-2169, (1995); Miller J.A., Thai K., Scholey J.W., Angiotensin II Type 1 receptor gene polymorphism predicts response to losartan and angiotensin II, Kidney Inter, 56, pp. 2173-2180, (1999); Spiering W., Kroon A.A., Fuss-Lejeune M., Daemen M., De Leeuw P., Angiotensin II sensitivity is associated with the angiotensin II Type 1 receptor A<sup>1166</sup>C polymorphism in essential hypertensives on a high sodium diet, Hypertension, 36, pp. 411-416, (2000); Kurland L., Melhus H., Sarabi M., Millgard J., Ljunghall S., Lind L., Polymorphisms in the renin-angiotensin system and endothelium dependent vasodilation in normotensive subjects, Clin. Physiol, 21, pp. 343-349, (2001); Dieguez-Lucena J.L., Aranda-Lara P., Ruiz-Galdon M., Garcia-Villanova J., Morell-Ocana M., Reyes-Engel A., Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy, Hypertension, 28, pp. 98-103, (1996); Benetos A., Cambien F., Gautier S., Et al., Influence of the angiotensin II Type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive patients, Hypertension, 28, pp. 1081-1084, (1996); Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E.C., Brown M.J., Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin-converting enzyme inhibition, J. Hypertens, 13, pp. 1602-1609, (1995); Dudley C., Keavney B., Casadei B., Conway J., Bird R., Ratcliffe P., Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes, J. Hypertens, 14, pp. 259-262, (1996); Delles C., Erdmann J., Jacobi J., Fleck E., Regitz-Zagrosek V., Schmieder R.E., Lack of association between polymorphisms of angiotensin II receptor genes and response to short-term angiotensin II infusion, J. Hypertens, 18, pp. 1573-1578, (2000); Schmieder R.E., Erdmann J., Delles C., Et al., Effect of the angiotensin II Type 2-receptor gene (+1675G/A) on left ventricular structure in humans, J. Am. Coll. Cardiol, 37, pp. 175-182, (2001); Ortlepp J.R., Breithardt O., Ohme F., Hanrath P., Hoffmann R., Lack of association among five genetic polymorphisms on the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis, Am. Heart J, 141, pp. 671-676, (2001); Unger T., Björn Fokow Award Lecture: The angiotensin Type 2 receptor, variations on an enigmatic theme, J. Hypertens, 17, pp. 1775-1786, (1999); Stearns R.A., Chakravarty P.K., Chen R., Chiu S.H., Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P450 2C and 3A subfamily members, Drug Metab. Dispos, 23, pp. 207-215, (1995)","B. Baudin; Service de Biochimie A, Hôpital Saint-Antoine, 75571 Paris Cedex 12, France; email: bruno.baudin@sat.aphop-paris.fr","","","","","","","","14622416","","PARMF","11966404","English","Pharmacogenomics","Review","Final","","Scopus","2-s2.0-0036208543"
"Sun B.; Williams J.S.; Svetkey L.P.; Kolatkar N.S.; Conlin P.R.","Sun, Bei (57208888814); Williams, Jonathan S. (55499948300); Svetkey, Laura P. (7005517676); Kolatkar, Nikheel S. (15042597600); Conlin, Paul R. (7005696632)","57208888814; 55499948300; 7005517676; 15042597600; 7005696632","β2-Adrenergic receptor genotype affects the renin-angiotensin-aldosterone system response to the Dietary Approaches to Stop Hypertension (DASH) dietary pattern","2010","American Journal of Clinical Nutrition","92","2","","444","449","5","35","10.3945/ajcn.2009.28924","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955507703&doi=10.3945%2fajcn.2009.28924&partnerID=40&md5=d8685633d1780227cbf1fda620578317","Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Duke Hypertension Center, Duke University Medical Center, Durham, NC, United States; Cardiovascular Metabolic Medicines Development Centre, GlaxoSmithKline Research and Development, King of Prussia, PA, United States; Philadelphia Veterans Affairs (VA) Medical Center, University of Pennsylvania School of Medicine, Philadelphia, PA, United States; VA Boston Healthcare System, Boston, MA, United States","Sun B., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Williams J.S., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Svetkey L.P., Duke Hypertension Center, Duke University Medical Center, Durham, NC, United States; Kolatkar N.S., Cardiovascular Metabolic Medicines Development Centre, GlaxoSmithKline Research and Development, King of Prussia, PA, United States, Philadelphia Veterans Affairs (VA) Medical Center, University of Pennsylvania School of Medicine, Philadelphia, PA, United States; Conlin P.R., Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States, VA Boston Healthcare System, Boston, MA, United States","Background: β2-Adrenergic receptor (β2-AR) is a susceptibility locus for hypertension, and polymorphisms at this site relate to salt sensitivity and low plasma renin activity (PRA). The Dietary Approaches to Stop Hypertension (DASH) dietary pattern lowers blood pressure and appears to interact with the renin-angiotensin-aldosterone system (RAAS). Objective: We hypothesized that the DASH diet associates with increased RAAS activity, and genotype status at β2-AR G46A modifies this response. Design: We genotyped participants in the DASH-Sodium study (n = 372) at β2-AR G46A to determine the association with blood pressure, RAAS components, and consumption of the DASH diet. We used 2-way mixed linear regression and an additive model for all primary analyses. Results: Mean (±SEM) PRAwas significantly higher in participants in the DASH group than in participants in the control group (0.68 ± 0.03 compared with 0.54 ± 0.03 ng · mL-1 · h-1, P = 0.002). Serum aldosterone, urinary aldosterone, and urinary potassium concentrations were also significantly higher in the DASH group (P < 0.01 for all). We observed significant gene-diet interactions for changes in systolic blood pressure (SBP) and concentrations of aldosterone and urinary potassium (P for interaction = 0.048, 0.017, and 0.001 for SBP and aldosterone and urinary potassium concentrations, respectively). There was an association between the A allele of β2-AR G46A and greater blood pressure reduction and blunted aldosterone and PRA responses to the DASH diet. Conclusions: Our results indicate that the DASH diet lowers blood pressure and increases PRA and aldosterone concentrations. There is an association between the G46A polymorphism of β2-AR and blood pressure and RAAS responses to the DASH diet, which suggests that β2-AR may be a genetic modifier of DASH-diet responsiveness. This trial was registered at clinicaltrials.gov as NCT00000608. © 2010 American Society for Nutrition.","","Aldosterone; Alleles; Blood Pressure; Diet; Female; Genotype; Humans; Hypertension; Male; Middle Aged; Nutrigenomics; Polymorphism, Single Nucleotide; Potassium; Receptors, Adrenergic, beta-2; Regression Analysis; Renin; Renin-Angiotensin System; aldosterone; beta 2 adrenergic receptor; potassium; aldosterone; beta 2 adrenergic receptor; potassium; renin; adult; aldosterone blood level; aldosterone urine level; article; clinical trial; controlled study; diet therapy; DNA polymorphism; female; genotype environment interaction; human; hypertension; major clinical study; male; plasma renin activity; potassium urine level; renin angiotensin aldosterone system; systolic blood pressure; treatment response; allele; blood; blood pressure; controlled clinical trial; diet; diet therapy; genetics; genotype; hypertension; middle aged; nutrigenomics; randomized controlled trial; regression analysis; single nucleotide polymorphism; urine","","aldosterone, 52-39-1, 6251-69-0; potassium, 7440-09-7; renin, 61506-93-2, 9015-94-5; Aldosterone, 52-39-1; Potassium, 7440-09-7; Receptors, Adrenergic, beta-2, ; Renin, 3.4.23.15","","","National Heart, Lung, and Blood Institute, NHLBI, (T32HL007609)","","Svetkey L.P., Chen Y.-T., McKeown S.P., Preis L., Wilson A.F., Preliminary evidence of linkage of salt sensitivity in black Americans at the beta<sub>2</sub>-adrenergic receptor locus, Hypertension, 29, 4, pp. 918-922, (1997); Caulfield M., Munroe P., Pembroke J., Et al., Genome-wide mapping of human loci for essential hypertension, Lancet, 361, pp. 2118-2123, (2003); Insel P.A., Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors-evolving concepts and clinical implications, N Engl J Med, 334, pp. 580-585, (1996); Naslund T., Silberstein D.J., Merrell W.J., Nadeau J.H., Wood A.J.J., Low sodium intake corrects abnormality in beta-receptor-mediated arterial vasodilation in patients with hypertension: Correlation with beta-receptor function in vitro, Clinical Pharmacology and Therapeutics, 48, 1, pp. 87-95, (1990); Stein C.M., Nelson R., Deegan R., He H., Wood M., Wood A.J., Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension, J Clin Invest, 96, pp. 579-585, (1995); Lang C.C., Stein C.M., Brown R.M., Et al., Attenuation of isoproterenol-mediated vasodilatation in blacks, N Engl J Med, 333, pp. 155-160, (1995); Kopp U.C.D.G., Interaction between epinephrine and renal nerves in control of renin secretion rate, Am J Physiol, 250, (1986); DiBona G.F., Neural control of the kidney: Functionally specific renal sympathetic nerve fibers, Am J Physiol Regul Integr Comp Physiol, 279, (2000); Kim S.M.C.L., Faulhaber-Walter R., Oppermann M., Et al., Regulation of renin secretion and expression in mice deficient in beta1- And beta2-adrenergic receptors, Hypertension, 50, pp. 103-109, (2007); Dishy V., Sofowora G.G., Xie H.G., Et al., The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization, N Engl J Med, 345, pp. 1030-1035, (2001); Green S.A., Turki J., Innis M., Liggett S.B., Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties, Biochemistry, 33, pp. 9414-9419, (1994); Timmermann B., Mo R., Luft F.C., Et al., Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study, Kidney Int, 53, pp. 1455-1460, (1998); Lanfear D.E., Jones P.G., Marsh S., Cresci S., McLeod H.L., Spertus J.A., Beta<sub>2</sub>-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome, Journal of the American Medical Association, 294, 12, pp. 1526-1533, (2005); Pojoga L., Kolatkar N.S., Williams J.S., Et al., Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension, Hypertension, 48, pp. 892-900, (2006); Appel L.J., Moore T.J., Obarzanek E., Et al., A clinical trial of the effects of dietary patterns on blood pressure, N Engl J Med, 336, pp. 1117-1124, (1997); Sacks F.M., Svetkey L.P., Vollmer W.M., Et al., Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet, N Engl J Med, 344, pp. 3-10, (2001); Conlin P.R., Erlinger T.P., Bohannon A., Et al., The DASH diet enhances the blood pressure response to losartan in hypertensive patients, Am J Hypertens, 16, pp. 337-342, (2003); Akita S., Sacks F.M., Svetkey L.P., Conlin P.R., Kimura G., Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship, Hypertension, 42, pp. 8-13, (2003); Emanuel R.L., Cain J.P., Williams G.H., Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma, J Lab Clin Med, 81, pp. 632-640, (1973); Svetkey L.P., Simons-Morton D., Vollmer W.M., Et al., Effects of dietary patterns on blood pressure: Subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial, Arch Intern Med, 159, pp. 285-293, (1999); Bao X., Mills P.J., Rana B.K., Dimsdale J.E., Schork N.J., Smith D.W., Rao F., Milic M., O'Connor D.T., Ziegler M.G., Interactive effects of common beta<sub>2</sub>-adrenoceptor haplotypes and age on susceptibility to hypertension and receptor function, Hypertension, 46, 2, pp. 301-307, (2005); Conlin P.R., Chow D., Miller III E.R., Et al., The effect of dietary patterns on blood pressure control in hypertensive patients: Results from the Dietary Approaches to Stop Hypertension (DASH) trial, Am J Hypertens, 13, pp. 949-955, (2000); Svetkey L.P., Moore T.J., Simons-Morton D.G., Et al., Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study, J Hypertens, 19, pp. 1949-1956, (2001); Bray M.S., Krushkal J., Li L., Et al., Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension, Circulation, 101, pp. 2877-2882, (2000); Krushkal J., Xiong M., Ferrell R., Sing C.F., Turner S.T., Boerwinkle E., Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation, Hum Mol Genet, 7, pp. 1379-1383, (1998); Tomaszewski M., Brain N.J., Charchar F.J., Et al., Essential hypertension and beta2-adrenergic receptor gene: Linkage and association analysis, Hypertension, 40, pp. 286-291, (2002); Cockcroft J.R., Gazis A.G., Cross D.J., Wheatley A., Dewar J., Hall I.P., Noon J.P., Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans, Hypertension, 36, pp. 371-375, (2000); Garovic V.D., Joyner M.J., Dietz N.M., Boerwinkle E., Turner S.T., Beta (2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans, J Physiol, 546, pp. 583-589, (2003); Eisenach J.H., Schroeder D.R., Pike T.L., Et al., Dietary sodium restriction and beta2-adrenergic receptor polymorphism modulate cardiovascular function in humans, J Physiol, 574, pp. 955-965, (2006)","J. S. Williams; Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; email: jwilliams5@partners.org","","","","","","","","19383207","","AJCNA","20519561","English","Am. J. Clin. Nutr.","Article","Final","All Open Access; Bronze Open Access","Scopus","2-s2.0-77955507703"
"Wenzel R.R.; Siffert W.; Bruck H.; Philipp T.; Schäfers R.F.","Wenzel, René R. (57205911873); Siffert, Winfried (7005096601); Bruck, H. (7006378961); Philipp, Thomas (15136745600); Schäfers, Rafael F. (7003538215)","57205911873; 7005096601; 7006378961; 15136745600; 7003538215","Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation","2002","Pharmacogenetics","12","6","","489","495","6","48","10.1097/00008571-200208000-00010","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036667959&doi=10.1097%2f00008571-200208000-00010&partnerID=40&md5=7a732e300aaae90708afb363a9f615e7","Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany","Wenzel R.R., Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany; Siffert W., Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany; Bruck H., Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany; Philipp T., Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany; Schäfers R.F., Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany","Hypertension is associated with enhanced peripheral vascular resistance, which may be mediated by enhanced vasoconstriction. The impact of the recently detected G-protein β3-subunit gene C825T polymorphism on the response to the major pressor mediators has been studied in vivo in the human microcirculation. We assessed the effects of endothelin-1 (ET-1), angiotensin II (AT), endothelin-antagonists (BQ-123 and BQ-788) and noradrenaline (NA, each 10-16-10-8 mol) on vasoconstriction in the human skin microcirculation in vivo in 25 healthy male volunteers (13 with CC genotype, 12 TC/TT genotype) using laser Doppler flowmetry. The effects of endothelium-derived vasodilation on NA-induced effects were studied using the NO-synthase inhibitor L-nitro-monomethyl-arginine (L-NMMA) and the α2-adrenoceptor-antagonist yohimbine (YO). ET-1, AT and NA caused a dose-dependent vasoconstriction (P < 0.001). In carriers of the 825T allele the response to ET-1, AT and NA was significantly enhanced leading to a shift to the left of the dose-response curve of up to two log units (ET-1: P < 0.001 vs. CC; AT: P < 0.01 vs. CC; NA: P < 0.05 vs. CC). After pretreatment with L-NMMA or YO, NA induced vasoconstriction was no longer different between subjects with the CC- and CT/TT genotypes. However, following combined pretreatment with both L-NMMA and YO, vasoconstriction to NA was significantly potentiated in carriers of the T-allele. Vasodilatation to an ETA-antagonist (BQ-123) was more pronounced in the CT/TT genotype, while ETB-antagonism (BQ-788) led to a more pronounced vasoconstriction in the CT/TT genotype (not significant vs. CC). Healthy, normotensive carriers of the 825T-allele have enhanced vasoconstriction to ET-1, AT and NA in the skin microcirculation. This enhanced vasoconstriction appears to be partially antagonized by an enhanced release of endothelium derived vasodilators mediated by the stimulation of endothelial α2-adrenoceptors. The GNB3 C825T polymorphism is potentially an attractive pharmacogenetic marker to predict hormone-mediated responses in humans. © 2002 Lippincott Williams & Wilkins.","Angiotensin II; Endothelin-1; G protein; L-NMMA; Laser Doppler flowmetry; Nitric oxide; Noradrenaline; Skin microcirculation","Adrenergic alpha-Antagonists; Adult; Alleles; Angiotensin II; Drug Synergism; Endothelin-1; Enzyme Inhibitors; Heterotrimeric GTP-Binding Proteins; Heterozygote; Human; Laser-Doppler Flowmetry; Male; Microcirculation; Nitric-Oxide Synthase; Norepinephrine; Oligopeptides; omega-N-Methylarginine; Peptides, Cyclic; Piperidines; Protein Subunits; Receptors, Endothelin; Skin; Support, Non-U.S. Gov't; Vasoconstriction; Vasoconstrictor Agents; Yohimbine; Adrenergic alpha-Antagonists; Adult; Alleles; Drug Synergism; Enzyme Inhibitors; Heterozygote; Humans; Laser-Doppler Flowmetry; Male; Microcirculation; Nitric Oxide Synthase; Oligopeptides; omega-N-Methylarginine; Peptides, Cyclic; Piperidines; Protein Subunits; Receptors, Endothelin; Yohimbine; angiotensin; cyclo(dextro tryptophyl dextro aspartylprolyl dextro valylleucyl); endothelin 1; guanine nucleotide binding protein; n (2,6 dimethylpiperidinocarbonyl) 4 methylleucyl dextro (1 methoxycarbonyltryptophanyl) dextro norleucine; n(g) methylarginine; noradrenalin; yohimbine; alpha adrenergic receptor blocking agent; angiotensin II; cyclo(Trp Asp Pro Val Leu); cyclo(Trp-Asp-Pro-Val-Leu); cyclopeptide; endothelin 1; endothelin receptor; enzyme inhibitor; G protein beta3 subunit; G-protein beta3 subunit; heterotrimeric guanine nucleotide binding protein; n (2,6 dimethylpiperidinocarbonyl) 4 methylleucyl dextro (1 methoxycarbonyltryptophanyl) dextro norleucine; n(g) methylarginine; nitric oxide synthase; noradrenalin; oligopeptide; piperidine derivative; protein subunit; vasoconstrictor agent; yohimbine; adult; allele; article; clinical trial; controlled clinical trial; controlled study; DNA polymorphism; Doppler flowmeter; dose response; double blind procedure; drug sensitivity; genetic marker; genotype; heterozygote; human; hypertension; male; priority journal; randomized controlled trial; skin blood flow; vascular resistance; vasoconstriction; vasodilatation; allele; drug antagonism; drug effect; drug potentiation; genetics; heterozygote; laser Doppler flowmetry; metabolism; microcirculation; skin; vascularization","","Adrenergic alpha-Antagonists, ; Angiotensin II, 11128-99-7; BQ 788, ; cyclo(Trp-Asp-Pro-Val-Leu), 136553-81-6; Endothelin-1, ; Enzyme Inhibitors, ; G-protein beta3 subunit, ; Heterotrimeric GTP-Binding Proteins, EC 3.6.1.-; Nitric-Oxide Synthase, EC 1.14.13.39; Norepinephrine, 51-41-2; Oligopeptides, ; omega-N-Methylarginine, 17035-90-4; Peptides, Cyclic, ; Piperidines, ; Protein Subunits, ; Receptors, Endothelin, ; Vasoconstrictor Agents, ; Yohimbine, 146-48-5; Heterotrimeric GTP-Binding Proteins, EC 3.6.1.46; Nitric Oxide Synthase, EC 1.14.13.39","bq 123, Clinalfa, Switzerland; bq 788, Clinalfa, Switzerland","Clinalfa, Switzerland; Clinalfa, Switzerland","","","Luscher T.F., Wenzel R.R., Noll G., Local regulation of the coronary circulation in health and disease: Role of nitric oxide and endothelin, Eur Heart J, 16, pp. 51-58, (1995); Wenzel R.R., Czyborra P., Luscher T.F., Philipp T., Endothelin in cardiovascular control: The role of endothelin antagonists, Curr Hypertension Rep, 1, pp. 79-87, (1999); Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Et al., A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, 332, pp. 411-415, (1988); Siffert W., Rosskopf D., Siffert G., Busch S., Moritz A., Erbel R., Et al., Association of a human G-protein beta3 subunit variant with hypertension, Nat Genet, 18, pp. 45-48, (1998); Beige J., Hohenbleicher H., Distler A., Sharma A.M., G-protein beta3 subunit C825T variant and ambulatory blood pressure in essential hypertension, Hypertension, 33, pp. 1049-1051, (1999); Benjafield A.V., Jeyasingam C.L., Nyholt D.R., Griffiths L.R., Morris B.J., G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension, Hypertension, 32, pp. 1094-1097, (1998); Siffert W., Forster P., Jockel K.H., Mvere D.A., Brinkmann B., Naber C., Et al., Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals, J Am Soc Nephrol, 10, pp. 1921-1930, (1999); Siffert W., Naber C., Walla M., Ritz E., G protein beta3 subunit 825T allele and its potential association with obesity in hypertensive individuals, J Hypertens, 17, pp. 1095-1098, (1999); Gutersohn A., Naber C., Muller N., Erbel R., Siffert W., G protein beta3 subunit 825 TT genotype and post-pregnancy weight retention, Lancet, 355, pp. 1240-1241, (2000); Baumgart D., Naber C., Haude M., Oldenburg O., Erbel R., Heusch G., Et al., G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation, Circ Res, 85, pp. 965-969, (1999); Meirhaeghe A., Bauters C., Helbecque N., Hamon M., McFadden E., Lablanche J.M., Et al., The human G-protein beta3 subunit C825T polymorphism is associated with coronary artery vasoconstriction, Eur Heart J, 22, pp. 845-848, (2001); Schafers R.F., Nurnberger J., Rutz A., Siffert W., Wenzel R.R., Mitchell A., Et al., Haemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein beta3 subunit, Pharmacogenetics, 11, pp. 461-470, (2001); Macrez N., Morel J.L., Mironneau J., Specific Gα<sub>11</sub>β<sub>3</sub>γ<sub>5</sub> protein involvement in endothelin receptor-induced phosphatidylinositol hydrolysis and Ca<sup>2+</sup> release in rat portal vein myocytes, Mol Pharmacol, 55, pp. 684-692, (1999); Macrez-Lepretre N., Kalkbrenner F., Schultz G., Mironneau J., Distinct functions of Gq and G11 proteins in coupling alpha1-adrenoreceptors to Ca<sup>2+</sup> release and Ca<sup>2+</sup> entry in rat portal vein myocytes, J Biol Chem, 272, pp. 5261-5268, (1997); Bruck H., Gossl M., Spitthover R., Schafers R.F., Kohnle M., Philipp T., Et al., The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: Effects of the alpha2-receptor antagonist yohimbine, J Hypertens, 19, pp. 907-911, (2001); Stern M.D., In vivo evaluation of microcirculation by coherent light scattering, Nature, 254, pp. 56-58, (1975); Nilsson G.E., Tenland T., Oberg P.A., A new instrument for continuous measurement of tissue blood flow by light beating spectroscopy, IEEE Trans Biom Eng, 27, pp. 12-19, (1980); Wenzel R.R., Noll G., Luscher T.F., Endothelin receptor antagonists inhibit endothelin in human skin microcirculation, Hypertension, 23, pp. 581-586, (1994); Wenzel R.R., Duthiers N., Noll G., Bucher J., Kaufmann U., Luscher T.F., Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease, Circulation, 94, pp. 316-322, (1996); Wenzel R.R., Minimal invasive in vivo pharmacology: News from a new method holding promise in nephrology-related research, Nephrol Dial Transplant, 12, pp. 649-651, (1997); Wenzel R.R., Ruthemann J., Bruck H., Schafers R.F., Michel M.C., Philipp T., Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man, Br J Clin Pharmacol, 52, pp. 151-157, (2001); Wenzel R.R., Zbinden S., Noll G., Meier B., Luscher T.F., Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide, Br J Clin Pharmacol, 45, pp. 441-446, (1998); Schunkert H., Hense H.W., Doring A., Riegger G.A., Siffert W., Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels, Hypertension, 32, pp. 510-513, (1998); Wenzel R.R., Bruck H., Noll G., Schafers R.F., Daul A.E., Philipp T., Antihypertensive drugs and the sympathetic nervous system, J Cardiovasc Pharmacol, 35, pp. 43-52, (2000); Luscher T.F., Vanhoutte P.M., The endothelium: modulator of cardiovascular function, (1990); Garcia-Villalon A.L., Monge L., Fernandez N., Sanchez M.A., Martinez M.A., Gomez B., Et al., Basal inhibitory action of endogenous endothelin on the sympathetic contraction in the isolated rat tail artery, Eur J Pharmacol, 384, pp. 163-167, (1999); Chen H.I., Li H.T., Chen C.C., Physical conditioning decreases norepinephrine-induced vasoconstriction in rabbits. Possible roles of norepinephrine-evoked endothelium-derived relaxing factor, Circulation, 90, pp. 970-975, (1994); Snapir A., Heinonen P., Tuomainen T.P., Lakka T.A., Kauhanen J., Salonen J.T., Et al., G-protein beta3 subunit C825T polymorphism: No association with risk for hypertension and obesity, J Hypertens, 19, pp. 2149-2155, (2001); Larson N., Hutchinson R., Boerwinkle E., Lack of association of 3 functional gene variants with hypertension in African Americans, Hypertension, 35, pp. 1297-1300, (2000); Tsai C.H., Yeh H.I., Chou Y., Liu H.F., Yang T.Y., Wang J.C., Et al., G protein beta3 subunit variant and essential hypertension in Taiwan - A case-control study, Int J Cardiol, 73, pp. 191-195, (2000); Grossmann M., Dobrev D., Siffert W., Kirch W., Heterogeneity in hand veins responses to acetylcholine is not associated with polymorphisms in the G-protein beta3-subunit (C825T) and endothelial nitric oxide synthase (G894T) genes but with serum low density lipopretein cholesterol, Pharmacogeneties, 11, pp. 307-316, (2001); Virchow S., Ansorge N., Rubben H., Siffert G., Siffert W., Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein beta3 subunit 825 T-allele, FEBS Lett, 436, pp. 155-158, (1998); Virchow S., Ansorge N., Rosskopf D., Rubben H., Siffert W., The G protein beta3 subunit splice variant Gbeta3-s causes enhanced chemotaxis of human neutrophils in response to interleukin-8, Naunyn Schmiedebergs Arch Pharmacol, 360, pp. 27-32, (1999); Lindemann M., Virchow S., Ramann F., Barsegian V., Kreuzfelder E., Siffert W., Et al., The G protein beta3 subunit 825T allele is a genetic marker for enhanced T cell response, FEBS Lett, 495, pp. 82-86, (2001); Naber C., Hermann B.L., Vietzke D., Altmann C., Haude M., Mann K., Et al., Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele, FEBS Lett, 484, pp. 199-201, (2000); Turner S.T., Schwartz G.L., Chapman A.B., Boerwinkle E., C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic, Hypertension, 37, pp. 739-743, (2001)","R.R. Wenzel; Division of Nephrology, University Hospital, D-4b122 Essen, Hutelanastr. 45, Germany; email: rene@rrwenzel.de","","","","","","","","0960314X","","PHMCE","12172218","English","Pharmacogenetics","Article","Final","","Scopus","2-s2.0-0036667959"
"Zineh I.; Johnson J.A.","Zineh, Issam (6603220471); Johnson, Julie A. (55439192600)","6603220471; 55439192600","Pharmacogenetics of chronic cardiovascular drugs: Applications and implications","2006","Expert Opinion on Pharmacotherapy","7","11","","1417","1427","10","17","10.1517/14656566.7.11.1417","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746806364&doi=10.1517%2f14656566.7.11.1417&partnerID=40&md5=7c4ef76e0278a60968a790c1ce336567","University of Florida College of Pharmacy, Department of Pharmacy Practice, Center for Pharmacogenomics, Gainesville, FL 32610, 1600 SW Archer Rd., United States","Zineh I., University of Florida College of Pharmacy, Department of Pharmacy Practice, Center for Pharmacogenomics, Gainesville, FL 32610, 1600 SW Archer Rd., United States; Johnson J.A., University of Florida College of Pharmacy, Department of Pharmacy Practice, Center for Pharmacogenomics, Gainesville, FL 32610, 1600 SW Archer Rd., United States","Cardiovascular disease continues to be a tremendous worldwide problem, and drug therapy is a major modality to attenuate its burden. At present, conditions such as hypertension, dyslipidaemia and heart failure are pharmacologically managed with an empirical trial-and-error approach. However, it has been suggested that this approach fails to adequately address the therapeutic needs of many patients, and pharmacogenetics has been offered as a tool to enhance patient-specific drug therapy. This review outlines pharmacogenetic studies of common cardiovascular drugs, such as diuretics, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins and warfarin, ultimately highlighting considerations for future research and practice. © 2006 Informa UK Ltd.","Cardiovascular disease; Dislipidaemia; Heart failure; Hypertension; Pharmacogenetics; Pharmacogenomics; Warfarin","Anticoagulants; Cardiovascular Agents; Cardiovascular Diseases; Chronic Disease; Humans; Hypertension; Pharmacogenetics; adducin; angiotensin receptor antagonist; apolipoprotein B; apolipoprotein E; atorvastatin; beta 1 adrenergic receptor; beta 2 adrenergic receptor; beta adrenergic receptor blocking agent; bucindolol; cardiovascular agent; carvedilol; cholesterol ester transfer protein; cytochrome P450 2C9; cytochrome P450 2D6; cytochrome P450 3A4; cytochrome P450 3A5; dipeptidyl carboxypeptidase; dipeptidyl carboxypeptidase inhibitor; diuretic agent; hydroxymethylglutaryl coenzyme A reductase; hydroxymethylglutaryl coenzyme A reductase inhibitor; loop diuretic agent; low density lipoprotein receptor; metoprolol; pravastatin; reduced nicotinamide adenine dinucleotide (phosphate) dehydrogenase (quinone); spironolactone; thiazide diuretic agent; unindexed drug; warfarin; amino acid substitution; bleeding; cardiovascular disease; clinical trial; drug blood level; drug efficacy; drug mechanism; drug metabolism; drug response; drug safety; drug targeting; drug tolerability; dyslipidemia; gene expression; heart failure; heart transplantation; human; hypertension; low drug dose; mortality; pharmacogenetics; review; single nucleotide polymorphism; thromboembolism; treatment outcome","","atorvastatin, 134523-00-5, 134523-03-8; bucindolol, 71119-11-4; carvedilol, 72956-09-3; cytochrome P450 3A4, 329736-03-0; cytochrome P450 3A5, 336874-97-6; dipeptidyl carboxypeptidase, 9015-82-1; hydroxymethylglutaryl coenzyme A reductase, 37250-24-1; metoprolol, 37350-58-6; pravastatin, 81131-74-0; reduced nicotinamide adenine dinucleotide (phosphate) dehydrogenase (quinone), 9032-20-6; spironolactone, 52-01-7; warfarin, 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2; Anticoagulants, ; Cardiovascular Agents, ","","","American Heart Association Florida/Puerto Rico SDG, (0435278B); National Institutes of Health, NIH, (HL68834, HL74730); National Institutes of Health, NIH; National Institute of General Medical Sciences, NIGMS, (U01GM074492); National Institute of General Medical Sciences, NIGMS","The authors wish to thank CL Aquilante and AL Beitelshees for their valuable input regarding this review. This work was supported in part by American Heart Association Florida/Puerto Rico SDG Grant 0435278B (to I Zineh) and NIH grants GM74492 (to JA Johnson and I Zineh), and HL74730 and HL68834 (to JA Johnson).","HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches, J. Card. Fail., 5, 4, pp. 357-382, (1999); Chobanian A.V., Bakris G.L., Black H.R., Et al., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, pp. 1206-1252, (2003); Grundy S.M., Cleeman J.I., Merz C.N., Et al., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 2, pp. 227-239, (2004); Hunt S.A., Baker D.W., Chin M.H., Et al., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 104, 24, pp. 2996-3007, (2001); Materson B.J., Variability in response to antihypertensive drug treatment, Hypertension, 43, 6, pp. 1166-1167, (2004); Materson B.J., Reda D.J., Cushman W.C., Et al., Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo, N. Engl. J. Med., 328, 13, pp. 914-921, (1993); Pedro-botet J., Schaefer E.J., Bakker-arkema R.G., Et al., Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner, Atherosclerosis, 158, 1, pp. 183-193, (2001); Dang M.T., Hambleton J., Kayser S.R., The influence of ethnicity on warfarin dosage requirement, Ann. Pharmacother., 39, 6, pp. 1008-1012, (2005); Szczeklik A., Musial J., Undas A., Sanak M., Aspirin resistance, J. Thromb. Haemost., 3, 8, pp. 1655-1662, (2005); Johnson J.A., Zineh I., Puckett B.J., Et al., Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol, Clin. Pharmacol. Ther., 74, 1, pp. 44-52, (2003); Johnson J.A., Cavallari L.H., Cardiovascular pharmacogenomics, Exp. Physiol., 90, 3, pp. 283-289, (2005); Johnson J.A., Zineh I., Pharmacogenetics and personalized medicine, Cardiovascular Genetics and Genomics for the Cardiologist; Mason D.A., Moore J.D., Green S.A., Liggett S.B., A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor, J. Biol. Chem., 274, 18, pp. 12670-12674, (1999); Levin M.C., Marullo S., Muntaner O., Andersson B., Magnusson Y., The myocardium-protective g]y-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation, J. Biol. Chem., 277, 34, pp. 30429-30435, (2002); Rathz D.A., Brown K.M., Kramer L.A., Liggett S.B., Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking, J. Cardiovasc. Pharmacol., 39, 2, pp. 155-160, (2002); Karlsson J., Lind L., Hallberg P., Et al., Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension, Clin. Cardiol., 27, 6, pp. 347-350, (2004); Liu J., Liu Z.Q., Tan Z.R., Et al., Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol, Clin. Pharmacol. Ther., 74, 4, pp. 372-379, (2003); O'Shaughnessy K.M., Fu B., Dickerson C., Thurston D., Brown M.J., The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects, Clin. Sci., 99, 3, pp. 233-238, (2000); Sofowora C.C., Dishy V., Muszkat M., Et al., A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade, Clin. Pharmacol. Ther., 73, 4, pp. 366-371, (2003); Mialet Perez J., Rathz D.A., Petrashevskaya N.N., Et al., Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure, Nat. Med, 9, 10, pp. 1300-1305, (2003); Terra S.G., Hamilton K.K., Pauly D.F., Et al., Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy, Pharmacogene Genomics, 15, 4, pp. 227-234, (2005); Kaye D.M., Smirk B., Williams C., Et al., Beta2-adrenoceptor genotype influences the responses to carvedilol in patients with congestive heart failure, Pharmacogenetics, 13, 7, pp. 379-382, (2003); De Groote P., Helbecque N., Lamblin N., Et al., Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure, Pharmacogenet. Genomics, 15, 3, pp. 137-142, (2005); Terra S.G., Pauly D.F., Lee C.R., Et al., Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure, Clin. Pharmacol. Ther., 77, 3, pp. 127-137, (2005); Borjesson M., Magnusson Y., Hjalmarson A., Andersson B., A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure, Eur. Heart J., 21, 22, pp. 1853-1858, (2000); Magnusson Y., Levin M.C., Eggertsen R., Et al., Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy, Clin. Pharmacol. Ther., 78, 3, pp. 221-231, (2005); White H.L., De Boer R.A., Maqbool A., Et al., An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: A MERIT-HF sub-study, Eur. J. Heart Fail., 5, 4, pp. 463-468, (2003); Liggett S.B., Mailet-Perez J., Thaneemit-Chen S., Et al., A polymorphism within a conserved beta-1 adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure, Proc. Natl. Acad. Sci.; Lanfear D.E., Jones P.G., Marsh S., Et al., Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome, JAMA, 294, 12, pp. 1526-1533, (2005); Zineh I., Beitelshees A.L., Gaedigk A., Et al., Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension, Clin. Pharmacol. Ther., 76, 6, pp. 536-544, (2004); Cambien F., Alhenc-Gelas F., Herbeth B., Et al., Familial resemblance of plasma angiotensin-converting enzyme level: The Nancy Study, Am. J. Hum. Genet., 43, 5, pp. 774-780, (1988); Tiret L., Rigat B., Visvikis S., Et al., Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels, Am. J. Hum. Genet., 51, 1, pp. 197-205, (1992); Rigat B., Hubert C., Alhenc-Gelas F., Et al., An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J. Clin. Invest., 86, 4, pp. 1343-1346, (1990); Ohmichi N., Iwai N., Uchida Y., Et al., Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype, Am. J. Hypertens., 10, 8, pp. 951-955, (1997); Stavroulakis G.A., Makris T.K., Krespi P.G., Et al., Predicting response to chronic antihypertensive treatment with fosinopril: The role of angiotensin-converting enzyme gene polymorphism, Cardiovasc. Drugs Ther., 14, 4, pp. 427-432, (2000); Harrap S.B., Tzourio C., Cambien F., Et al., The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition, Hypertension, 42, 3, pp. 297-303, (2003); Kurland L., Melhus H., Karlsson J., Et al., Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial, Am. J. Hypertens., 15, 5, pp. 389-393, (2002); Li X., Du Y., Huang X., Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor, J. Cardiovasc. Pharmacol. Ther, 8, 1, pp. 25-30, (2003); Ortlepp J.R., Hanrath P., Mevissen V., Et al., Variants of the CYP11B2 gene predict response to therapy with candesartan, Eur. J. Pharmacol., 445, 1-2, pp. 151-152, (2002); Yu H., Zhang Y., Liu G., Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients, Hypertens. Res., 26, 11, pp. 881-886, (2003); Arnett D.K., Davis B.R., Ford C.E., Et al., Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study, Circulation, 111, 25, pp. 3374-3383, (2005); Mcnamara D.M., Holubkov R., Postava L., Et al., Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, J. Am. Coll. Cardiol., 44, 10, pp. 2019-2026, (2004); Cusi D., Barlassina C., Azzani T., Et al., Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension, Lancet, 349, 9062, pp. 1353-1357, (1997); Glorioso N., Manunta P., Filigheddu F., Et al., The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study, Hypertension, 34, 4 PART 1, pp. 649-654, (1999); Sciarrone M.T., Stella P., Barlassina C., Et al., ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy, Hypertension, 41, 3, pp. 398-403, (2003); Psaty B.M., Smith N.L., Heckbert S.R., Et al., Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, 13, pp. 1680-1689, (2002); Gerhard T., Gong Y., Beitelshees A.L., Et al., Cardiovascular outcomes, diuretic therapy and the alpha-adducin polymorphism: Results for the International Verapamil SR-Trandolapril Study Genetic Substudy (INVEST-GENES) (Abstract), Circulation, 112, (2005); Cicoira M., Rossi A., Bonapace S., Et al., Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure, Am. J. Med., 116, 10, pp. 657-661, (2004); Libby P., The forgotten majority: Unfinished business in cardiovascular risk reduction, J. Am. Coll. Cardiol., 46, 7, pp. 1225-1228, (2005); Zineh I., HMG-CoA reductase inhibitor pharmacogenomics: Overview and implications for practice, Future Cardiol., 1, 2, pp. 191-206, (2005); Mangravite L.M., Thorn C.F., Krauss R.M., Clinical implications of pharmacogenomics of statin treatment, Pharmacogenomics J., (2006); Chasman D.I., Posada D., Subrahmanyan L., Et al., Pharmacogenetic study of statin therapy and cholesterol reduction, JAMA, 291, 23, pp. 2821-2827, (2004); Zineh I., Genetic polymorphisms and statin therapy, JAMA, 292, 11, pp. 1302-1303, (2004); Thompson J.F., Man M., Johnson K.J., Et al., An association study of 43 SNPs in 16 candidate genes with atorvastatin response, Pharmacogenomics J., 5, 6, pp. 352-358, (2005); Ballantyne C.M., Herd J.A., Stein E.A., Et al., Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy, J. Am. Coll. Cardiol. 2000, 36, 5, pp. 1572-1578; Nestel P., Simons L., Barter P., Et al., A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin, Atherosclerosis, 129, 2, pp. 231-239, (1997); Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., Et al., Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy, Atherosclerosis, 113, 2, pp. 157-166, (1995); Gerdes L.U., Gerdes C., Kervinen K., Et al., The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study, Circulation, 101, 12, pp. 1366-1371, (2000); Garcia-Otin A.L., Civeira F., Aristegui R., Et al., Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment, Eur. J. Clin. Invest., 32, 6, pp. 421-428, (2002); Ojala J.P., Helve E., Ehnholm C., Et al., Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia, J. Intern. Med., 230, 5, pp. 397-405, (1991); Pena R., Lahoz C., Mostaza J.M., Et al., Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting, J. Intern. Med., 251, 6, pp. 518-525, (2002); Carmena R., Roederer G., Mailloux H., Lussier-Cacan S., Davignon J., The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism, Metabolism, 42, 7, pp. 895-901, (1993); Maitland-Van Der Zee A.H., Stricker B.H., Klungel O.H., Et al., Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes, Pharmacogenetics, 13, 4, pp. 219-223, (2003); Lee C.R., Goldstein J.A., Pieper J.A., Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data, Pharmacogenetics, 12, 3, pp. 251-263, (2002); Takahashi H., Echizen H., Pharmacogenetics of warfarin elimination and its clinical implications, Clin. Pharmacokinet., 40, 8, pp. 587-603, (2001); Takahashi H., Kashima T., Nomizo Y., Et al., Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes, Clin. Pharmacol. Ther., 63, 5, pp. 519-528, (1998); Daly A.K., Aithal G.P., Genetic regulation of warfarin metabolism and response, Semin. Vasc. Med., 3, 3, pp. 231-238, (2003); Daly A.K., Day C.P., Aithal G.P., CYP2C9 polymorphism and warfarin dose requirements, Br. J. Clin. Pharmacol., 53, 4, pp. 408-409, (2002); Daly A.K., King B.P., Pharmacogenetics of oral anticoagulants, Pharmacogenetics, 13, 5, pp. 247-252, (2003); Furuya H., Fernandez-Salguero P., Gregory W., Et al., Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy, Pharmacogenetics, 5, 6, pp. 389-392, (1995); Aithal G.P., Day C.P., Kesteven P.J., Daly A.K., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, 353, 9154, pp. 717-719, (1999); Voora D., Eby C., Linder M.W., Et al., Prospective dosing of warfarin based on cytochrome P450 2C9 genotype, Thromb. Haemost., 93, 4, pp. 700-705, (2005); Li T., Chang C.Y., Jin D.Y., Et al., Identification of the gene for vitamin K epoxide reductase, Nature, 427, 6974, pp. 541-544, (2004); Rost S., Fregin A., Ivaskevicius V., Et al., Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2, Nature, 427, 6974, pp. 537-541, (2004); Rieder M.J., Reiner A.P., Gage B.F., Et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N. Engl. J. Med., 352, 22, pp. 2285-2293, (2005); Sconce E.A., Khan T.I., Wynne H.A., Et al., The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen, Blood, 106, 7, pp. 2329-2333, (2005); D'Andrea G., D'Ambrosio R.L., Di Perna P., Et al., A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin, Blood, 105, 2, pp. 645-649, (2005); Harrington D.J., Underwood S., Morse C., Et al., Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1, Thromb. Haemost., 93, 1, pp. 23-26, (2005); Pelz H.J., Rost S., Hunerberg M., Et al., The genetic basis of resistance to anticoagulants in rodents, Genetics, 170, 4, pp. 1839-1847, (2005); Wadelius M., Chen L.Y., Downes K., Et al., Common VKORC1 and GGCX polymorphisms associated with warfarin dose, Pharmacogenomics J., 5, 4, pp. 262-270, (2005); Yuan H.Y., Chen J.J., Lee M.T., Et al., A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity, Hum. Mol. Genet., 14, 13, pp. 1745-1751, (2005); Veenstra D.L., You J.H., Rieder M.J., Et al., Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population, Pharmacogenet. Genomics, 15, 10, pp. 687-691, (2005); Aquilante C.L., Langaee T.Y., Lopez L.M., Et al., Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements, Clin. Pharmacol. Ther., 79, 4, pp. 291-302, (2006); Zineh I., Gerhard T., Aquilante C.L., Et al., Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs, Pharmacogenomics J., 4, 6, pp. 354-358, (2004); Webster A., Martin P., Lewis G., Smart A., Integrating pharmacogenetics into society: In search of a model, Nat. Rev. Genet., 5, 9, pp. 663-669, (2004); Zineh I., Pebanco G.D., Aquilante C.L., Et al., Discordance between availability of pharmacogenetic studies and pharmacogenetics-based prescribing information for the top 200 drugs, Ann. Pharmacother., 40, 4, pp. 639-644, (2006); Salerno R.A., Lesko L.J., Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: A commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop, Pharmacogenomics J., 6, 2, pp. 78-81, (2006); Beitelshees A.L., Zineh I., Yarandi H.N., Pauly D.F., Johnson J.A., Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics, Pharmacogenomics J., 6, pp. 174-178, (2006); Padmanabhan S., Wallace C., Munroe P.B., Et al., Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension study, Hypertension, 47, 3, pp. 603-608, (2006); Schelleman H., Stricker B.H., Verschuren W.M., Et al., Interactions between five candidate genes and antihypertensive drug therapy on blood pressure, Pharmacogenomics J., 6, 1, pp. 22-26, (2006)","I. Zineh; University of Florida College of Pharmacy, Department of Pharmacy Practice, Center for Pharmacogenomics, Gainesville, FL 32610, 1600 SW Archer Rd., United States; email: zineh@cop.ufl.edu","","","","","","","","14656566","","EOPHF","16859425","English","Expert Opin. Pharmacother.","Review","Final","","Scopus","2-s2.0-33746806364"
"Arsenault J.; Lehoux J.; Lanthier L.; Cabana J.; Guillemette G.; Lavigne P.; Leduc R.; Escher E.","Arsenault, Jason (26640162500); Lehoux, Julie (7005480668); Lanthier, Luc (8907383300); Cabana, Jérôme (35104500100); Guillemette, Gaëtan (7005608522); Lavigne, Pierre (19334958900); Leduc, Richard (56251814800); Escher, Emanuel (7005259199)","26640162500; 7005480668; 8907383300; 35104500100; 7005608522; 19334958900; 56251814800; 7005259199","A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity","2010","Pharmacogenetics and Genomics","20","6","","377","388","11","26","10.1097/FPC.0b013e32833a6d4a","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952420727&doi=10.1097%2fFPC.0b013e32833a6d4a&partnerID=40&md5=56f7fd8926a0e6a3e4cf32658e7378e4","Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Département de Médecine, Centre Hospitalier de L, Universitéde Sherbrooke, Sherbrooke, QC, Canada","Arsenault J., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Lehoux J., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Lanthier L., Département de Médecine, Centre Hospitalier de L, Universitéde Sherbrooke, Sherbrooke, QC, Canada; Cabana J., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Guillemette G., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Lavigne P., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Leduc R., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; Escher E., Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada","BACKGROUND AND Objective: AT1 is the principal receptor for angiotensin II (AngII), which regulates blood pressure and osmotic homeostasis. Earlier studies have shown that position 163 interacts with the antihypertensive nonpeptide antagonist, Losartan. A recently discovered polymorphism found in humans (rs12721226) coding for residue 163 led us to determine whether this polymorphism would affect Losartan antihypertensive therapies. The pharmacological properties of the A163T hAT1 variant are described. METHOD AND RESULTS: The A163T hAT1 mutation was evaluated by testing its affinity by dose displacement of AngII analogs in COS-7 cells expressing either wild-type hAT1 or the A163T hAT1. The expressions of the receptors were evaluated by saturation binding and the efficacies were assessed by measuring the H-inositol phosphate production. The results showed that the A163T hAT1 receptor is comparable with the affinity, expression, and efficacy of native hAT1 towards peptide ligands. The affinities were also tested with nonpeptide antagonists Losartan, L-158-809, valsartan, telmisartan, irbesartan, candesartan, and EXP3174. Losartan and EXP3174 displayed a 7-fold loss in affinity towards A163T hAT1. The ability of Losartan to inhibit AngII-induced inositol triphosphate production also confirmed a loss in efficacy. Molecular modeling showed a higher steric and hydrophilic hindrance of the A163T hAT1-Losartan complex. Conclusion: The polymorphism that codes for the A163T hAT1 variant results in a receptor with normal physiological properties toward the endogenous hormone. However, the significant reduction in affinity to Losartan and its active metabolite, EXP3174, could significantly impair the clinical effectiveness of an antihypertensive therapy using Losartan with patients bearing the A163T polymorphism. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.","Angiotensin II; EXP3174; HAT1; Hypertension; Losartan; Single-nucleotide polymorphism","2 butyl 4 chloro 1 [[2' (1h tetrazol 5 yl) 4 biphenylyl]methyl] 5 imidazolecarboxylic acid; 2 ethyl 5,7 dimethyl 3 [4 [2 (2h tetrazol 5 yl)phenyl]benzyl]imidazo[4,5 b]pyridine; alanine; angiotensin 1 receptor; candesartan; exp 3171; irbesartan; losartan; telmisartan; threonine; unclassified drug; valsartan; animal cell; article; concentration response; controlled study; drug efficacy; drug receptor binding; drug structure; drug treatment failure; gene expression; gene mutation; genetic variability; human; IC 50; nonhuman; photoaffinity labeling; priority journal; receptor affinity; single nucleotide polymorphism","","2 butyl 4 chloro 1 [[2' (1h tetrazol 5 yl) 4 biphenylyl]methyl] 5 imidazolecarboxylic acid, 124750-92-1; 2 ethyl 5,7 dimethyl 3 [4 [2 (2h tetrazol 5 yl)phenyl]benzyl]imidazo[4,5 b]pyridine, 133240-46-7; alanine, 56-41-7, 6898-94-8; candesartan, 139481-59-7; irbesartan, 138402-11-6; losartan, 114798-26-4; telmisartan, 144701-48-4; threonine, 36676-50-3, 72-19-5; valsartan, 137862-53-4","exp 3171, DuPont Merck, United States; l 158809, Merck Frosst, Canada","DuPont Merck, United States; Merck Frosst, Canada","","","De Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T., International union of pharmacology. XIII. the angiotensin II receptors, Pharmacol Rev, 52, pp. 415-472, (2000); Su X., Lee L., Li X., Lv J., Hu Y., Zhan S., Et al., Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor, Circulation, 115, pp. 725-732, (2007); Auger-Messier M., Arguin G., Chaloux B., Leduc R., Escher E., Guillemette G., Down-regulation of inositol 1,4,5-trisphosphate receptor in cells stably expressing the constitutively active angiotensin II N111G-AT(1) receptor, Mol Endocrinol, 18, pp. 2967-2980, (2004); Arsenault J., Renaud M.P., Clement M., Fillion D., Guillemette G., Leduc R., Et al., Temperature-dependent variations of ligand-receptor contact points in hAT(1), J Pept Sci, 13, pp. 575-580, (2007); Oro C., Qian H., Thomas W.G., Type 1 angiotensin receptor pharmacology: Signaling beyond G proteins, Pharmacol Ther, 113, pp. 210-226, (2007); Yan C., Zhan J., Feng W., Gene polymorphisms of angiotensin II type 1 receptor and angiotensin-converting enzyme in two ethnic groups living in Zhejiang Province, China, J Renin Angiotensin Aldosterone Syst, 6, pp. 132-137, (2005); Elton T.S., Martin M.M., Alternative splicing: A novel mechanism to fine-tune the expression and function of the human AT<sub>1</sub> receptor, Trends Endocrinol Metab, 14, pp. 66-71, (2003); Ismail M.A., Barker S., Abou el-Ella DA, Abouzid KA, Toubar RA, Todd MH. Design and synthesis of new tetrazolyl-and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT<sub>1</sub> receptor antagonists, J Med Chem, 49, pp. 1526-1535, (2006); Israili Z.H., Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension, J Hum Hypertens, 14, SUPPL. 1, (2000); Association C.P., Compendium of Pharmaceuticals and Specialties, (2005); Lo M.W., Goldberg M.R., McCrea J.B., Lu H., Furtek C.I., Bjornsson T.D., Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans, Clin Pharmacol Ther, 58, pp. 641-649, (1995); Zoumpoulakis P., Grdadolnik S.G., Matsoukas J., Mavromoustakos T., Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT<sub>1</sub> antagonist, J Pharm Biomed Anal, 28, pp. 125-135, (2002); Cappelli A., Nannicini C., Gallelli A., Giuliani G., Valenti S., Mohr G.P., Et al., Design, synthesis, and biological evaluation of AT<sub>1</sub> angiotensin II receptor antagonists based on the pyrazolo(3,4-b)pyridine and related heteroaromatic bicyclic systems, J Med Chem, 51, pp. 2137-2146, (2008); Clement M., Martin S.S., Beaulieu M.E., Chamberland C., Lavigne P., Leduc R., Et al., Determining the environment of the ligand binding pocket of the human angiotensin II type i (hAT1) receptor using the methionine proximity assay, J Biol Chem, 280, pp. 27121-27129, (2005); Rihakova L., Deraet M., Auger-Messier M., Perodin J., Boucard A.A., Guillemette G., Et al., Methionine proximity assay, a novel method for exploring peptide ligand-receptor interaction, J Recept Signal Transduct Res, 22, pp. 297-313, (2002); Ji H., Leung M., Zhang Y., Catt K.J., Sandberg K., Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT<sub>1</sub> angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan, J Biol Chem, 269, pp. 16533-16536, (1994); Noda K., Saad Y., Kinoshita A., Boyle T.P., Graham R.M., Husain A., Et al., Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms, J Biol Chem, 270, pp. 2284-2289, (1995); Antonellis A., Rogus J.J., Canani L.H., Makita Y., Pezzolesi M.G., Nam M., Et al., A method for developing high-density SNP maps and its application at the type 1 angiotensin II receptor (AGTR1) locus, Genomics, 79, pp. 326-332, (2002); Crawford D.C., Carlson C.S., Rieder M.J., Carrington D.P., Yi Q., Smith J.D., Et al., Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations, Am J Hum Genet, 74, pp. 610-622, (2004); Hansen J.L., Haunso S., Brann M.R., Sheikh S.P., Weiner D.M., Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor, Mol Pharmacol, 65, pp. 770-777, (2004); Gosselin M.J., Leclerc P.C., Auger-Messier M., Guillemette G., Escher E., Leduc R., Molecular cloning of a ferret angiotensin II AT(1) receptor reveals the importance of position 163 for Losartan binding, Biochim Biophys Acta, 1497, pp. 94-102, (2000); De Gasparo M., Whitebread S., Binding of valsartan to mammalian angiotensin AT<sub>1</sub> receptors, Regul Pept, 59, pp. 303-311, (1995); Inoue Y., Nakamura N., Inagami T., A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism, J Hypertens, 15, pp. 703-714, (1997); Lim J., Kim Y.J., Yoon Y., Kim S.O., Kang H., Park J., Et al., Comparative study of the linkage disequilibrium of an ENCODE region, chromosome 7p15, in Korean, Japanese, and Han Chinese samples, Genomics, 87, pp. 392-398, (2006); Bosse R., Servant G., Zhou L.M., Boulay G., Guillemette G., Escher E., Sar1-p-benzoylphenylalanine-angiotensin, a new photoaffinity probe for selective labeling of the type 2 angiotensin receptor, Regul Pept, 44, pp. 215-223, (1993); Fraker P.J., Speck Jr. J.C., Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril, Biochem Biophys Res Commun, 80, pp. 849-857, (1978); Perodin J., Deraet M., Auger-Messier M., Boucard A.A., Rihakova L., Beaulieu M.E., Et al., Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor, Biochemistry, 41, pp. 14348-14356, (2002); Laemmli U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, pp. 680-685, (1970); Blanton M.P., Cohen J.B., Identifying the lipid-protein interface of the Torpedo nicotinic acetylcholine receptor: Secondary structure implications, Biochemistry, 33, pp. 2859-2872, (1994); Tuccinardi T., Calderone V., Rapposelli S., Martinelli A., Proposal of a new binding orientation for non-peptide AT<sub>1</sub> antagonists: Homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis, J Med Chem, 49, pp. 4305-4316, (2006); Hunyady L., Catt K.J., Pleiotropic AT<sub>1</sub> receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II, Mol Endocrinol, 20, pp. 953-970, (2006); Integrating ethics and science in the International HapMap Project, Nat Rev Genet, 5, pp. 467-475, (2004); Giacomini K.M., Brett C.M., Altman R.B., Benowitz N.L., Dolan M.E., Flockhart D.A., Et al., The pharmacogenetics research network: From SNP discovery to clinical drug response, Clin Pharmacol Ther, 81, pp. 328-345, (2007); Schmidt B., Schieffer B., Angiotensin II AT<sub>1</sub> receptor antagonists. Clinical implications of active metabolites, J Med Chem, 46, pp. 2261-2270, (2003); Burnier M., Angiotensin II type 1 receptor blockers, Circulation, 103, pp. 904-912, (2001); Lee C.R., Pieper J.A., Hinderliter A.L., Blaisdell J.A., Goldstein J.A., Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, * 1/*2, and *1/*3 individuals, Pharmacotherapy, 23, pp. 720-725, (2003); Maekawa K., Fukushima-Uesaka H., Tohkin M., Hasegawa R., Kajio H., Kuzuya N., Et al., Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese, Pharmacogenet Genomics, 16, pp. 497-514, (2006); Schwarz U.I., Clinical relevance of genetic polymorphisms in the human CYP2C9 gene, Eur J Clin Invest, 33, SUPPL. 2, pp. 23-30, (2003); Yin T., Maekawa K., Kamide K., Saito Y., Hanada H., Miyashita K., Et al., Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan, Hypertens Res, 31, pp. 1549-1557, (2008); Yasar U., Forslund-Bergengren C., Tybring G., Dorado P., Llerena A., Sjoqvist F., Et al., Pharmacokinetics of Losartan and its metabolite E-3174 in relation to the CYP2C9 genotype, Clin Pharmacol Ther, 71, pp. 89-98, (2002)","E. Escher; Département de Pharmacologie, Facultéde Médecine et des Sciences de la Santé, Universitéde Sherbrooke, Sherbrooke, QC, 3001 12e avenue Nord, Canada; email: Emanuel.Escher@usherbrooke.ca","","Lippincott Williams and Wilkins","","","","","","17446872","","","20436376","English","Pharmacogenet. Genomics","Article","Final","","Scopus","2-s2.0-77952420727"
